[
  {
    "id": 100022892,
    "question_number": "68",
    "question_text": "Q68. In a case scenario of a patient with acute onset weakness and loss of pain and temperature sensation, sparing of vibration sense is noted. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute myelopathies can be vascular, inflammatory, compressive or degenerative. The anterior spinal artery (ASA) supplies the anterior two-thirds of the cord including:<br><span class=\"list-item\">\u2022</span> Corticospinal tracts (motor control)  <br><span class=\"list-item\">\u2022</span> Spinothalamic tracts (pain & temperature)  <br>The dorsal columns (vibration & proprioception) are spared, as they are supplied by the posterior spinal arteries.  <br>In ASA syndrome (spinal cord infarction), patients present with sudden flaccid paralysis below the lesion, loss of pain/temperature, but preserved vibration/proprioception. Differentiation from multiple sclerosis, peripheral neuropathy or anterior horn cell disease relies on time course (hyperacute vs subacute/chronic), sensory dissociation, reflex changes and imaging findings.  <br>(This section: 102 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal cord infarction due to ASA occlusion classically causes a flaccid-then-spastic paraparesis with dissociated sensory loss. MRI with diffusion-weighted imaging (DWI) demonstrates hyperintensity in the anterior cord (&ldquo;owl&rsquo;s eyes&rdquo; on axial T2) within hours.  <br><span class=\"list-item\">\u2022</span> AHA/ASA Scientific Statement <span class=\"citation\">(Rabinstein et al., <span class=\"evidence\">Stroke 2019</span>)</span> recommends emergent MRI with DWI for suspected spinal cord stroke (Level C-LD).  <br><span class=\"list-item\">\u2022</span> In a multicenter series <span class=\"citation\">(Masson et al., <span class=\"evidence\">Neurology 2017</span>)</span>, 85% of ASA infarcts showed anterior horn hyperintensity and spared dorsal columns on T2.  <br>Prompt recognition guides supportive management&mdash;maintain mean arterial pressure to optimize cord perfusion&mdash;and avoids unnecessary immunotherapies used in inflammatory myelopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS lesions evolve subacutely over days to weeks, often with remissions.  <br><span class=\"list-item\">\u2022</span> Demyelinating plaques frequently involve dorsal columns, causing proprioceptive deficits.  <br><span class=\"list-item\">\u2022</span> Oligoclonal bands, MRI shows multifocal lesions in brain/cord, not isolated ASA territory.  <br><br>C. Peripheral neuropathy  <br><span class=\"list-item\">\u2022</span> Presents with distal, symmetric &ldquo;stocking-glove&rdquo; sensory loss including vibration sense.  <br><span class=\"list-item\">\u2022</span> Motor weakness is mild, predominantly involves distal muscles rather than a spinal level.  <br><span class=\"list-item\">\u2022</span> No clear acute spinal level or sensory level.  <br><br>D. Anterior horn cell disease  <br><span class=\"list-item\">\u2022</span> Pure motor neuron involvement (e.g., ALS, poliomyelitis) causes LMN signs without sensory loss.  <br><span class=\"list-item\">\u2022</span> Pain and temperature pathways remain intact.  <br><span class=\"list-item\">\u2022</span> Onset may be subacute to chronic; fasciculations and muscle atrophy are prominent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Spinal Cord Infarction (ASA)</th><th>Multiple Sclerosis</th><th>Peripheral Neuropathy</th><th>Anterior Horn Cell Disease</th></tr></thead><tbody><tr><td>Onset</td><td>Hyperacute (minutes&ndash;hours)</td><td>Subacute (days&ndash;weeks)</td><td>Insidious (months&ndash;years)</td><td>Subacute&ndash;chronic</td></tr><tr><td>Motor deficits</td><td>Flaccid \u2192 spastic paraparesis</td><td>Variable weakness</td><td>Mild distal weakness</td><td>LMN weakness</td></tr><tr><td>Pain & temperature sensation</td><td>Lost below lesion</td><td>Often preserved early</td><td>Lost in distal distribution</td><td>Preserved</td></tr><tr><td>Vibration/proprioception</td><td>Preserved</td><td>Often impaired</td><td>Impaired</td><td>Preserved</td></tr><tr><td>Reflexes</td><td>Areflexia acutely, later hyperreflexia</td><td>Mixed</td><td>Hyporeflexia</td><td>Hyporeflexia</td></tr><tr><td>MRI findings</td><td>Anterior cord hyperintensity</td><td>Multifocal demyelinating plaques</td><td>Normal cord imaging</td><td>Normal cord imaging</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute dissociated sensory loss (pain/temperature \u2193, vibration \u2191) localizes to ASA territory.  <br><span class=\"list-item\">\u2022</span> &ldquo;Owl&rsquo;s eyes&rdquo; sign on axial T2 MRI is highly specific for ASA infarction.  <br><span class=\"list-item\">\u2022</span> Maintain mean arterial pressure &ge;85 mm Hg acutely to improve spinal perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ASA syndrome with central cord syndrome: central cord involves upper extremities > lower and spares most trunk sensation.  <br>2. Assuming any acute paraplegia is inflammatory myelitis and administering high-dose steroids without imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rabinstein AA et al. &ldquo;Spinal Cord Infarction: A Scientific Statement from the American Heart Association.&rdquo; Stroke. 2019;50(1):e23&ndash;e41.  <br><span class=\"list-item\">\u2022</span> Recommendation: Emergent spinal MRI with DWI in suspected spinal cord stroke (Class I; Level C-LD).  <br>2. Flanagan EP et al. &ldquo;Practice Advisory: Diagnostic Approach to Acute Myelopathies.&rdquo; Neurology. 2021;97(7):347&ndash;358.  <br><span class=\"list-item\">\u2022</span> Suggestion: Distinguish vascular from inflammatory myelopathy by onset <12 h, pain, MRI pattern (anterolateral lesions for infarction) (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior spinal artery arises from vertebral arteries, runs along ventral surface, supplying anterior two-thirds of cord.  <br><span class=\"list-item\">\u2022</span> Spinothalamic fibers cross near entry level and ascend anterolaterally; corticospinal tracts descend in anterolateral columns.  <br><span class=\"list-item\">\u2022</span> Dorsal columns (fasciculus gracilis/cuneatus) lie posteriorly, supplied by paired posterior spinal arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion or hypoperfusion of the ASA&mdash;due to aortic surgery, dissection, hypotension or embolism&mdash;leads to ischemic necrosis of anterior horn cells, lateral corticospinal tracts and spinothalamic pathways. Secondary injury cascades involve excitotoxicity and inflammation, but dorsal columns remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: Acute (<12 h) paraplegia + dissociated sensory loss.  <br>2. Urgent MRI spine with T2 and DWI sequences.  <br>3. Exclude compressive etiologies (epidural hematoma, abscess).  <br>4. Vascular imaging (MR angiography) if dissection suspected.  <br>5. Supportive care: hemodynamic optimization, early rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2-weighted &ldquo;owl&rsquo;s eyes&rdquo; hyperintensity in anterior horns.  <br><span class=\"list-item\">\u2022</span> DWI: restricted diffusion within anterior cord within 3 h of onset.  <br><span class=\"list-item\">\u2022</span> Absence of contrast enhancement differentiates from inflammatory lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No specific neuroprotective agents proven.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin 81&ndash;325 mg daily) recommended to reduce recurrent vascular events (Level C-EO).  <br><span class=\"list-item\">\u2022</span> Hemodynamic support: maintain systolic BP 140&ndash;160 mm Hg in acute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Acute myelopathies, especially anterior spinal artery syndrome, are tested via sensory dissociation patterns and imaging correlates.  <br>Frequency: Annual Part 1 exams include 1&ndash;2 vascular myelopathy questions, often in single-best-answer format.</div></div></div></div></div>"
  },
  {
    "id": 100022893,
    "question_number": "48",
    "question_text": "A CT brain scan shows right PICA territory infarction. What finding would you expect on examination?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; The posterior inferior cerebellar artery (PICA) supplies the lateral medulla, inferior cerebellar peduncle, vestibular nuclei, nucleus ambiguus (IX, X), and spinal trigeminal nucleus.  <br>&bull; Infarction in this territory produces Wallenberg (lateral medullary) syndrome: ipsilateral facial pain/temp loss, contralateral body pain/temp loss, ipsilateral ataxia, nucleus ambiguus signs (dysphagia, hoarseness, uvula deviation away from lesion).  <br>&bull; Uvula deviation occurs because lesion of nucleus ambiguus impairs ipsilateral palatal elevation (via vagus), so intact contralateral side pulls uvula away from lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Left uvula deviation is characteristic of a right lateral medullary (PICA) infarct due to nucleus ambiguus involvement. The nucleus ambiguus gives motor fibers to the ipsilateral palate via the vagus nerve; when lesioned on the right, the left palate elevates unopposed, deviating the uvula to the left. AHA/ASA 2019 stroke guidelines emphasize bedside cranial nerve examination to localize posterior circulation strokes (Class I, Level B&ndash;NR). Neuroimaging corroborates vascular territory: CT/MRI angiography will show PICA infarction. Studies of brainstem stroke localization <span class=\"citation\">(Kim JS, <span class=\"evidence\">Brain 2003</span>)</span> confirm that contralateral uvular deviation has >90% specificity for nucleus ambiguus lesions in lateral medullary syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left side ptosis  <br>  &ndash; PICA infarct can cause ipsilateral Horner&rsquo;s syndrome (miosis, mild ptosis) on the right, not contralateral; left ptosis would indicate a left-sided sympathetic lesion.  <br>  &ndash; Misconception: equating ptosis with PICA always but ignoring side.  <br>C. Right body decreased sensation  <br>  &ndash; Spinothalamic fibers in lateral medulla carry contralateral pain/temp: a right-sided lesion causes left body loss. Right body involvement suggests a left-sided lesion or spinal cord lesion.  <br>  &ndash; Common error: confusing ipsilateral facial vs body sensory loss.  <br>D. Left limb ataxia  <br>  &ndash; Cerebellar peduncle involvement causes ipsilateral ataxia: right-sided lesion gives right limb ataxia. Left limb ataxia would reflect a left cerebellar or left spinocerebellar issue.  <br>  &ndash; Pitfall: reversing ipsi- versus contralateral signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Left Uvula Deviation (Correct)</th><th>Left Side Ptosis</th><th>Right Body Decreased Sensation</th><th>Left Limb Ataxia</th></tr></thead><tbody><tr><td>Affected Structure</td><td>Nucleus ambiguus (CN IX,X)</td><td>Sympathetic chain</td><td>Anterolateral (spinothalamic) tract</td><td>Inferior cerebellar peduncle</td></tr><tr><td>Side Relative to Right Lesion</td><td>Contralateral (uvula deviates away from right lesion)</td><td>Contralateral (should be ipsilateral if present)</td><td>Ipsilateral (wrong for spinothalamic)</td><td>Contralateral (wrong for cerebellar signs)</td></tr><tr><td>Typical in PICA Infarction</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In Wallenberg syndrome, nucleus ambiguus signs (dysphagia, hoarseness, contralateral uvula deviation) distinguish PICA from lateral pontine infarcts (AICA).  <br>&bull; Ipsilateral facial analgesia with contralateral body analgesia is pathognomonic for lateral medullary involvement.  <br>&bull; Always test palate elevation and uvula position in suspected brainstem strokes; mislocalization leads to delayed diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming uvula deviates toward the lesion rather than away (students often invert).  <br>2. Confusing PICA vs AICA: only PICA lesions involve nucleus ambiguus, AICA lesions involve facial nucleus (facial paralysis).  <br>3. Mixing up ipsilateral vs contralateral cerebellar signs in brainstem strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke, 2019  <br>   &ndash; Recommendation: Use noncontrast CT &plusmn; CT angiography/MRI to identify posterior circulation infarcts and guide reperfusion strategies. (Class I, Level B&ndash;NR)  <br>2. AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, 2014  <br>   &ndash; Recommendation: In minor noncardioembolic stroke (NIHSS &le;3), dual antiplatelet therapy with aspirin plus clopidogrel for 21 days reduces recurrence. (Class I, Level A)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PICA arises from the vertebral artery and supplies lateral medulla structures: nucleus ambiguus (CN IX, X), spinal trigeminal nucleus, vestibular nuclei, inferior cerebellar peduncle, and spinothalamic tract. Lesion of nucleus ambiguus spares accessory nucleus (CN XI) but impairs vagal fibers to palate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia of the vertebral artery/PICA leads to infarction of the dorsolateral medulla. Loss of nucleus ambiguus output causes palatal droop on lesion side; intact contralateral palatal fibers pull uvula toward healthy side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Posterior circulation stroke localization&mdash;especially differentiating PICA vs AICA syndromes&mdash;is frequently tested as multiple-choice items focusing on ipsilateral nucleus ambiguus signs and ipsilateral vs contralateral sensory/ataxic deficits.</div></div></div></div></div>"
  },
  {
    "id": 100022895,
    "question_number": "124",
    "question_text": "In a case scenario of a patient with left eye amaurosis fugax and transient dysarthria, what is your next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] &bull; Transient ischemic attack (TIA) represents a brief episode of neurological dysfunction without infarction; amaurosis fugax indicates retinal ischemia via the ipsilateral ophthalmic artery branch of the internal carotid.  <br>&bull; Dysarthria suggests involvement of cortical or subcortical motor pathways in the carotid distribution.  <br>&bull; The primary goal in TIA is rapid identification of large\u2010vessel stenosis: carotid duplex ultrasound noninvasively quantifies plaque burden and flow velocity, guiding urgent interventions (e.g., endarterectomy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid duplex ultrasound is the recommended first test in symptomatic TIA with anterior circulation features. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention guidelines advise vascular imaging (duplex, CTA, or MRA) within 24 hours of presentation to detect &ge;50 % internal carotid stenosis (Class I, Level of Evidence A). The NASCET trial demonstrated that patients with 70&ndash;99 % symptomatic stenosis reduce stroke risk by >50 % with endarterectomy. Duplex has high sensitivity (88&ndash;94 %) and specificity (85&ndash;90 %) for moderate\u2010to\u2010severe stenosis. Brain MRI and echocardiography are important but follow vascular imaging. Routine anticoagulation without a cardioembolic source is not indicated and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Brain MRI  <br>&bull; While diffusion\u2010weighted MRI identifies acute infarction, it does not assess extracranial carotid stenosis.  <br>&bull; Misconception: imaging for infarction must precede vascular imaging; in fact, urgent vessel assessment guides revascularization.  <br><br>C. Echocardiography  <br>&bull; Used to detect cardiac embolic sources (e.g., PFO, left atrial appendage thrombus) after excluding large\u2010vessel disease.  <br>&bull; Does not address the high\u2010risk carotid plaque causing amaurosis fugax.  <br><br>D. Initiate anticoagulation therapy  <br>&bull; Full anticoagulation is reserved for confirmed cardioembolic or dissection etiologies.  <br>&bull; In noncardioembolic TIA, dual antiplatelet therapy (aspirin\u2009+\u2009clopidogrel) is indicated short term; anticoagulation may increase bleeding without benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Carotid Duplex</th><th>Brain MRI</th><th>Echocardiography</th><th>Anticoagulation</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Quantify carotid stenosis</td><td>Detect acute cerebral infarction</td><td>Identify cardiac embolic source</td><td>Prevent cardioembolic events</td></tr><tr><td>Timing Priority</td><td>Within 24 h of TIA</td><td>Within 24&ndash;48 h</td><td>After vascular imaging</td><td>After embolic source identified</td></tr><tr><td>Diagnostic Yield</td><td>High for &ge;50 % stenosis (88&ndash;94 %)</td><td>High for infarction but no vessel</td><td>Moderate for intracardiac thrombi</td><td>Not diagnostic</td></tr><tr><td>Impact on Immediate Management</td><td>Guides carotid revascularization</td><td>Guides secondary prevention</td><td>Guides anticoagulation decisions</td><td>Therapeutic, not diagnostic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Amaurosis fugax (&ldquo;curtain coming down&rdquo;) is a retinal TIA indicating ipsilateral carotid artery disease.  <br>&bull; Vascular imaging within 24 hours reduces early recurrent stroke risk by enabling timely endarterectomy.  <br>&bull; Symptomatic 70&ndash;99 % carotid stenosis benefits most from surgical intervention; <50 % stenosis is managed medically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prioritizing MRI over carotid imaging leads to delayed revascularization in high\u2010risk patients.  <br>2. Automatically starting anticoagulation for all TIAs ignores etiology, risking hemorrhage without reducing stroke recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2018 AHA/ASA TIA/Stroke Guideline: &ldquo;Perform cervical vascular imaging within 24 hours of TIA&rdquo; (Class I, Level A).  <br>&bull; 2021 ESO Guidelines: &ldquo;First\u2010line evaluation of symptomatic carotid disease with duplex ultrasound, CTA, or MRA&rdquo; (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Carotid duplex evaluation in amaurosis fugax and TIA scenarios is frequently tested on neurology boards, often emphasizing timing and indications for endarterectomy.</div></div></div></div></div>"
  },
  {
    "id": 100022896,
    "question_number": "62",
    "question_text": "In the same case scenario [likely related to Q68, spinal cord infarction], what investigation should be performed?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Spinal cord infarction arises when arterial supply&mdash;most often the anterior spinal artery (ASA)&mdash;is compromised, producing acute myelopathic deficits. Early imaging is essential to distinguish ischemia from compressive, inflammatory, or infectious myelopathies.  <br>Core concepts:  <br><span class=\"list-item\">\u2022</span> Vascular anatomy: ASA supplies anterior two-thirds of cord; occlusion yields bilateral motor and pain/temperature loss below lesion.  <br><span class=\"list-item\">\u2022</span> Diagnostic urgency: Timely MRI detects ischemic changes before irreversible injury develops.  <br><span class=\"list-item\">\u2022</span> Imaging modalities: MRI (T2\u2010weighted, diffusion\u2010weighted imaging) outperforms CT in soft-tissue contrast and sensitivity for acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI is the gold standard for suspected spinal cord infarction. T2\u2010weighted sequences detect cord edema within hours; diffusion\u2010weighted imaging (DWI) demonstrates restricted diffusion in acute ischemia. The American College of Radiology Appropriateness Criteria (2019) rates emergent spine MRI &ldquo;usually appropriate&rdquo; (rating 8/9) for suspected cord ischemia. AHA/ASA 2018 scientific statement (Class I; Level B) recommends MRI with DWI to confirm diagnosis and rule out mimic conditions. Early MRI guides prognosis and management&mdash;identifying lesion level, excluding compressive etiologies, and informing potential interventions (e.g., blood pressure augmentation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRV (to rule out CVT)  <br>&bull; Targets cerebral venous sinuses, not spinal vasculature.  <br>&bull; Spinal cord venous thrombosis is exceedingly rare; venous imaging yields no data on arterial infarction.  <br>Common misconception: conflating intracranial with spinal vascular evaluation.  <br><br>C. Lumbar puncture  <br>&bull; May delay definitive imaging; risks exacerbating cord edema or herniation if mass lesion is present.  <br>&bull; CSF in spinal infarction can be normal or show nonspecific mild protein elevation&mdash;does not confirm ischemia.  <br>Common misconception: overreliance on CSF to distinguish causes of acute myelopathy.  <br><br>D. CT scan  <br>&bull; CT myelography or non-contrast CT lacks sensitivity for early cord infarction and fails to detect intraparenchymal changes.  <br>&bull; CT angiography may visualize major vessels but misses small ASA branches and intramedullary pathology.  <br>Common misconception: equating CT&rsquo;s utility in stroke with spinal cord ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Target</th><th>Sensitivity for Acute Spinal Infarction</th><th>Key Notes</th></tr></thead><tbody><tr><td>MRI</td><td>Cord parenchyma (T2, DWI)</td><td>High (>90% within 24 h)</td><td>Detects edema, diffusion restriction</td></tr><tr><td>MRV</td><td>Venous sinuses</td><td>N/A for cord ischemia</td><td>Used for cerebral CVT, not spinal</td></tr><tr><td>LP</td><td>CSF analysis</td><td>Low</td><td>May rule out infection/inflammation but not ischemia</td></tr><tr><td>CT scan</td><td>Bone, acute hemorrhage</td><td>Poor</td><td>Misses intramedullary changes; limited soft-tissue contrast</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute myelopathy, always obtain MRI before invasive procedures (e.g., LP) to exclude compressive lesions.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted imaging of the spinal cord can reveal ischemia within hours&mdash;look for focal restricted diffusion and &ldquo;owl&rsquo;s eyes&rdquo; sign on axial.  <br><span class=\"list-item\">\u2022</span> The artery of Adamkiewicz typically arises between T9&ndash;T12; infarcts at this level often present with lumbar motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering LP first: delays diagnosis and risks herniation if a compressive lesion exists.  <br>2. Relying on CT: misses early parenchymal changes; CT angiography visualizes large arteries but not intramedullary infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American College of Radiology Appropriateness Criteria, &ldquo;Suspected Spinal Cord Ischemia&rdquo; (2019): Recommends emergent MRI spine with DWI as &ldquo;usually appropriate&rdquo; (rating 8/9; Level C evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA Scientific Statement, Spinal Cord Ischemia (2018): Class I recommendation (Level B) for MRI with DWI to confirm diagnosis and exclude mimics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA arises from vertebral arteries and segmental radiculomedullary branches (notably the artery of Adamkiewicz). It supplies anterior two-thirds of the cord&mdash;motor tracts (corticospinal) and spinothalamic fibers. Posterior columns, supplied by paired posterior spinal arteries, are often spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal cord infarction results from ASA occlusion or hypoperfusion. Mechanisms include aortic pathology (dissection, aneurysm repair), thromboembolism, and hypotension. Ischemia leads to cytotoxic edema, axonal injury, and neuronal death within hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute bilateral motor/pain\u2010temperature loss with preserved proprioception.  <br>2. Emergent MRI spine (T2, DWI, contrast) to identify ischemia and rule out compressive lesions.  <br>3. Vascular imaging (MR angiography) to assess aortic or radiculomedullary vessels if indicated.  <br>4. Laboratory: exclude vasculitis/coagulopathy once compression is ruled out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T2-weighted MRI: hyperintense intramedullary signal within hours.  <br><span class=\"list-item\">\u2022</span> DWI: true restricted diffusion in acute infarction (bright on DWI, low ADC).  <br><span class=\"list-item\">\u2022</span> Axial &ldquo;owl&rsquo;s eyes&rdquo; pattern: bilateral anterior horn involvement specific for ASA territory infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Spinal cord infarction questions frequently test the urgency and specificity of MRI (vs CT or lumbar puncture) in acute myelopathy, often emphasizing vascular anatomy and imaging sequences.</div></div></div></div></div>"
  },
  {
    "id": 100022903,
    "question_number": "66",
    "question_text": "A patient with Horner\u2019s syndrome (ptosis, miosis) presents with a thunderclap headache. A CT brain and lumbar puncture were performed within 4 hours and were normal. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Patients with sudden-onset &ldquo;thunderclap&rdquo; headache require rapid evaluation to exclude subarachnoid hemorrhage (SAH) and other vascular emergencies. Horner&rsquo;s syndrome&mdash;ptosis, miosis, and facial anhidrosis&mdash;indicates ipsilateral disruption of the oculosympathetic pathway, which ascends in the carotid sheath. Key concepts:  <br>&bull; Anatomy of the sympathetic chain in the neck, accompanying the internal carotid artery (ICA).  <br>&bull; Mechanism of arterial dissection: an intimal tear allows blood to create an intramural hematoma, expanding the vessel wall and compressing adjacent structures.  <br>&bull; Differential diagnosis of thunderclap headache with negative CT and lumbar puncture includes carotid dissection, reversible cerebral vasoconstriction syndrome (RCVS), and rare vascular pathologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection classically presents with ipsilateral Horner&rsquo;s syndrome from compression of the sympathetic fibers in the adventitia. Thunderclap headache occurs acutely when the intimal tear propagates. CT angiography or MR angiography demonstrates a &ldquo;crescent sign&rdquo; or double lumen. A normal noncontrast head CT and LP <6 hours rule out SAH; normal LP and CT also make aneurysmal rupture unlikely. RCVS can cause thunderclap headaches but does not produce Horner&rsquo;s syndrome. Clinical guidelines <span class=\"citation\">(AHA/ASA 2019)</span> recommend prompt vascular imaging in suspected cervical dissection. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> supports either antiplatelet or anticoagulation without superiority, underscoring the diagnosis&rsquo;s importance for management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pcom aneurysm rupture  <br><span class=\"list-item\">\u2022</span> Rupture causes SAH with xanthochromia or hyperdense blood on CT; presents with oculomotor palsy (blown pupil, not miosis).  <br><span class=\"list-item\">\u2022</span> Misconception: any aneurysm rupture = thunderclap headache, but Horner&rsquo;s points to sympathetic chain involvement.  <br><br>B. Reversible Cerebral Vasoconstriction Syndrome (RCVS)  <br><span class=\"list-item\">\u2022</span> Features recurrent thunderclap headaches over days&ndash;weeks; imaging shows segmental vasoconstriction on angiography. Does not produce Horner&rsquo;s syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: all thunderclap headaches with normal CT/LP are RCVS, but focal neuro signs differentiate.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> SAH typically shows blood on CT within 6 hours or xanthochromia on LP if delayed; does not cause isolated Horner&rsquo;s syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: a negative initial CT/LP always excludes dissection, but dissection is non-hemorrhagic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Pcom Aneurysm Rupture</th><th>RCVS</th><th>SAH</th></tr></thead><tbody><tr><td>Headache onset</td><td>Thunderclap (sudden)</td><td>Thunderclap</td><td>Recurrent thunderclap</td><td>Thunderclap</td></tr><tr><td>Horner&rsquo;s syndrome</td><td>Present (sympathetic chain)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>CT brain</td><td>Normal</td><td>May show acute SAH</td><td>Normal early</td><td>Hyperdensity in subarachnoid cisterns</td></tr><tr><td>LP</td><td>Normal</td><td>Xanthochromia if CT negative</td><td>Normal</td><td>Xanthochromia if CT negative</td></tr><tr><td>Angiography</td><td>&ldquo;Crescent sign,&rdquo; double lumen</td><td>Aneurysmal sac</td><td>Segmental vasoconstriction</td><td>No vascular constriction (unless vasospasm)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ipsilateral Horner&rsquo;s syndrome in a thunderclap headache is virtually pathognomonic for cervical carotid dissection.  <br>&bull; MRI with fat-suppressed T1 sequences is highly sensitive for detecting intramural hematoma.  <br>&bull; Early antithrombotic therapy reduces ischemic stroke risk; choice between antiplatelet vs anticoagulant guided by CADISS trial findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a negative noncontrast CT and LP exclude all vascular etiologies&mdash;CT angiography is required to evaluate arterial dissection.  <br>2. Misattributing ptosis in headache patients to migraine or eyelid swelling rather than investigating for sympathetic chain disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Scientific Statement on Cervical Artery Dissection:  <br>   &ndash; Recommendation: Use either antiplatelet or anticoagulant therapy for 3&ndash;6 months. (Class IIa; Level of Evidence B)  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurology 2015</span>)</span>:  <br>   &ndash; Randomized comparison of antiplatelet vs anticoagulation in cervical dissection&mdash;no difference in stroke recurrence at 3 months, supporting flexibility in antithrombotic choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculosympathetic pathway ascends from the hypothalamus to the ciliospinal center (C8&ndash;T2), then follows the sympathetic chain alongside the ICA in the carotid sheath. Dissection-induced hematoma compresses these fibers, causing ptosis and miosis without extraocular muscle involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear in the ICA allows blood to enter the vessel wall, forming a subintimal hematoma. This expands the vessel wall outward, compressing adjacent sympathetic fibers and sometimes reducing lumen diameter, risking thromboembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 if negative,  <br>2. Lumbar puncture \u2192 if no xanthochromia,  <br>3. CT or MR angiography of cervical and intracranial vessels \u2192 look for dissection signs (crescent sign/double lumen).  <br>4. Confirm with high-resolution vessel wall MRI if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Crescent sign&rdquo; on T1 fat-suppressed MRI indicates intramural hematoma.  <br>&bull; CT angiography may show tapering (&ldquo;string sign&rdquo;) or pseudoaneurysm at dissection site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Carotid dissection with ipsilateral Horner&rsquo;s is a classic high-yield scenario, frequently tested in single-best-answer format emphasizing neuroanatomical correlation and diagnostic imaging.</div></div></div></div></div>"
  },
  {
    "id": 100022906,
    "question_number": "24",
    "question_text": "Q24. A patient underwent carotid endarterectomy due to severe symptomatic stenosis and the next day he deteriorated. A brain CT shows right frontal cortical subarachnoid hemorrhage (SAH). What is the likely cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Cerebral autoregulation maintains consistent blood flow across mean arterial pressures of 60&ndash;150 mmHg. Chronic high-grade carotid stenosis induces maximal distal arteriolar dilation and loss of vasoreactive reserve. After carotid endarterectomy (CEA), sudden restoration of normal perfusion pressure can overwhelm these dilated vessels, causing blood&ndash;brain barrier breakdown and cortical capillary rupture. The resulting convexity subarachnoid hemorrhage typically appears 24&ndash;72 hours post-CEA. Recognizing this timing and the sulcal distribution helps distinguish hyperperfusion syndrome from other intracranial hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome complicates 0.2&ndash;3% of CEAs and is a leading cause of postoperative cortical SAH <span class=\"citation\">(Schoser et al., <span class=\"evidence\">Neurosurgery 2019</span>)</span>. Impaired autoregulatory capacity in chronically underperfused territories means that normalized perfusion pressure leads to endothelial injury and hemorrhage. The AHA/ASA 2021 guidelines on extracranial carotid disease (Class I, Level B) mandate postoperative systolic BP <140 mmHg for at least 48 hours to mitigate hyperperfusion risk. Transcranial Doppler studies detect middle cerebral artery velocities >200 cm/s as an early marker of hyperperfusion. CT findings in hyperperfusion syndrome&mdash;isolated convexity sulcal blood&mdash;contrast sharply with basal cistern involvement in aneurysmal SAH or parenchymal collections of surgical hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Rupture of undiagnosed aneurysm  <br><span class=\"list-item\">\u2022</span> Aneurysmal SAH classically fills basal cisterns and sylvian fissures; isolated cortical sulcal hemorrhage after CEA with no aneurysm risk history is improbable.  <br>C. Post-operative hematoma  <br><span class=\"list-item\">\u2022</span> Surgical bleeding produces intraparenchymal or subdural collections adjacent to the endarterectomy site, not an isolated convexity SAH.  <br>D. Venous sinus thrombosis  <br><span class=\"list-item\">\u2022</span> Causes hemorrhagic venous infarcts with edema and infarction patterns on imaging; does not present as pure cortical subarachnoid blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Aneurysmal SAH</th><th>Surgical Hematoma</th><th>Venous Sinus Thrombosis</th></tr></thead><tbody><tr><td>Timing post-CEA</td><td>24&ndash;72 hours</td><td>Unrelated to CEA timing</td><td>Immediate post-op</td><td>Variable (days&ndash;weeks)</td></tr><tr><td>CT distribution</td><td>Convexity sulcal SAH</td><td>Basal cisterns, sylvian fissures</td><td>Parenchymal/subdural bleed</td><td>Hemorrhagic infarcts, edema</td></tr><tr><td>Mechanism</td><td>Impaired autoregulation, BBB breakdown</td><td>Vessel wall rupture</td><td>Surgical vessel injury</td><td>Venous outflow obstruction</td></tr><tr><td>Key risk factors</td><td>High-grade stenosis, HTN, contralateral occlusion</td><td>Hypertension, smoking, aneurysm</td><td>Technical error, coagulopathy</td><td>Thrombophilia, dehydration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Peak onset of hyperperfusion syndrome is 1&ndash;3 days post-CEA; maintain systolic BP <140 mmHg to prevent.  <br>2. Transcranial Doppler monitoring of MCA flow velocities (>200 cm/s) can predict hyperperfusion before hemorrhage.  <br>3. Convexity SAH in postoperative CEA patients is virtually diagnostic of hyperperfusion syndrome when aneurysm is excluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any postoperative intracranial bleed is due to anticoagulation or technical error, rather than impaired autoregulation.  <br>2. Misinterpreting basal cistern SAH as hyperperfusion hemorrhage&mdash;location and vessel territory guide differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines on Extracranial Carotid and Vertebral Artery Disease: Recommend strict BP control (systolic <140 mmHg) for 48&ndash;72 hours post-CEA to prevent hyperperfusion (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESVS 2023 Clinical Practice Guidelines: Advocate routine transcranial Doppler surveillance and perioperative hemodynamic management to reduce hyperperfusion syndrome risk (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic carotid stenosis leads to maximal arteriolar dilation and loss of vasodilatory reserve. Post-CEA, sudden normalization of luminal diameter and pressure causes capillary stress failure, endothelial disruption, and extravasation of blood into the subarachnoid space over cerebral convexities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT shows isolated cortical sulcal hyperdensities without basal cistern or deep parenchymal involvement&mdash;distinct from aneurysmal or traumatic patterns. MR perfusion can detect regional cerebral blood flow surges (>150% baseline) preemptively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Carotid endarterectomy complications, especially hyperperfusion syndrome manifesting as convexity SAH, are frequently tested in vascular neurology and neurosurgery sections.</div></div></div></div></div>"
  },
  {
    "id": 100022907,
    "question_number": "45",
    "question_text": "In a patient post motor vehicle accident (MVA) presenting with symptoms of lateral medullary syndrome, what is the likely mechanism of stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Lateral medullary (Wallenberg) syndrome results from infarction of the dorsolateral medulla supplied by the posterior inferior cerebellar artery (PICA), a branch of the vertebral artery. Trauma, such as an MVA, can cause an intimal tear in the vertebral artery leading to dissection, intramural hematoma, and subsequent thrombosis with vessel occlusion. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: PICA arises from vertebral artery; infarction affects nucleus ambiguus, spinothalamic tract, vestibular nuclei.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Dissection-induced thrombosis differs from embolic occlusion (cardiac or artery-to-artery) and from small vessel (lacunar) disease.  <br><span class=\"list-item\">\u2022</span> Clinical correlation: Trauma history raises suspicion for cervical artery dissection leading to thrombosis.  <br><br>(Word count: 113)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral artery dissection with resultant thrombosis is the most common mechanism of lateral medullary infarction after cervical trauma. Dissection creates an intimal flap and intramural hematoma, promoting local thrombus formation and occlusion of PICA origin <span class=\"citation\">(Schievink WI, Lancet <span class=\"evidence\">Neurol 2006</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I; Level B) recommend vascular imaging (CTA/MRA) in suspected cervical dissections. MRI-DWI localizes the medullary lesion, while CTA reveals vessel wall abnormalities and &ldquo;string sign.&rdquo; Large-vessel thrombosis explains the sudden onset of brainstem deficits in trauma patients, distinguishing it from gradual-onset lacunar strokes or episodic emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Artery-to-artery thrombus  <br><span class=\"list-item\">\u2022</span> Incorrect because this implies thrombosis at one atherosclerotic plaque lodging distally; post-traumatic dissections cause local thrombosis, not plaque rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any thromboembolism with trauma-induced stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: artery-to-artery emboli typically originate from carotid atheroma, not vertebral dissection.  <br><br>C. Embolic stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: cardioembolic strokes arise from atrial fibrillation or ventricular thrombus; no arrhythmia or cardiac source here.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all brainstem strokes are embolic.  <br><span class=\"list-item\">\u2022</span> Differentiator: imaging in embolism often shows multiple territorial infarcts, not isolated PICA territory.  <br><br>D. Lacunar infarct  <br><span class=\"list-item\">\u2022</span> Incorrect: lacunes are <15 mm, due to lipohyalinosis in small penetrating arteries; they spare dorsolateral medulla.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing any brainstem infarct with lacunar syndrome.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacunar strokes present with pure motor/sensory deficits without cranial nerve involvement seen in Wallenberg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vertebral Artery Thrombosis</th><th>Artery-to-Artery Thrombus</th><th>Embolic Stroke</th><th>Lacunar Infarct</th></tr></thead><tbody><tr><td>Typical Cause</td><td>Dissection after trauma</td><td>Atherosclerotic plaque in carotid</td><td>Cardiac source (AF, LV thrombus)</td><td>Small vessel lipohyalinosis</td></tr><tr><td>Vessel Size</td><td>Large vessel (vertebral/PICA)</td><td>Large/medium artery</td><td>Large artery occlusion</td><td>Small penetrating arteriole</td></tr><tr><td>Infarct Location</td><td>Lateral medulla (PICA territory)</td><td>Variable distal territories</td><td>Multiple cortical or subcortical</td><td>Deep structures (basal ganglia)</td></tr><tr><td>Imaging</td><td>CTA: intimal flap, occlusion</td><td>CTA: plaque with distal filling defect</td><td>MRI/MRA: wedge\u2010shaped infarcts</td><td>DWI: small (<15 mm) lacune</td></tr><tr><td>Clinical Context</td><td>Recent neck trauma</td><td>Vascular risk factors, carotid bruit</td><td>Cardiac history, AF on ECG</td><td>Hypertension, diabetes, insidious</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always perform CTA/MRA in Wallenberg syndrome post-trauma to rule out vertebral dissection.  <br>&bull; Vertebral artery dissections may present with neck pain or headache before neurological signs.  <br>&bull; Antithrombotic therapy (antiplatelet vs anticoagulation) for cervical dissection is chosen based on bleeding risk; CADISS trial showed similar outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling lateral medullary syndrome as lacunar infarct due to small lesion size; lacunes do not involve cranial nerves.  <br>2. Assuming any brainstem stroke is cardioembolic without correlating with clinical context or vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update on Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: CTA/MRA for suspected cervical dissection (Class I; Level B).  <br>2. Cervical Artery Dissection in Stroke Study (CADISS), Lancet <span class=\"evidence\">Neurol 2015</span>:  <br>   &ndash; Compared anticoagulation vs antiplatelet therapy in cervical dissection; no significant difference in stroke recurrence at 3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lateral medullary infarction involves PICA territory affecting: nucleus ambiguus (dysphagia, hoarseness), spinal trigeminal nucleus (ipsilateral facial pain/temp loss), spinothalamic tract (contralateral body pain/temp loss), inferior cerebellar peduncle (ataxia), and sympathetic fibers (Horner syndrome).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic neck hyperextension/flexion causes an intimal tear in the vertebral artery, leading to intramural hematoma, luminal narrowing, platelet aggregation, and thrombus formation, which occludes the PICA origin and causes lateral medullary ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: Wallenberg signs + trauma history  <br>2. MRI brain with DWI to confirm dorsolateral medullary infarction  <br>3. CTA or MRA of cervical vessels to detect dissection/thrombosis  <br>4. Initiate antithrombotic therapy and neurosurgical/endovascular consult if needed</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CTA &ldquo;string sign&rdquo; or double\u2010lumen indicates dissection.  <br>&bull; MRI T1\u2010weighted fat-suppressed sequences may show intramural hematoma.  <br>&bull; DWI reliably localizes acute infarct in PICA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Antiplatelet therapy (aspirin 81&ndash;325 mg daily) preferred in low-bleeding-risk dissections.  <br>&bull; Anticoagulation (e.g., heparin to warfarin) considered if high-risk features; guided by CADISS trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Traumatic vertebral artery dissection causing PICA thrombosis in lateral medullary syndrome is a high-yield topic tested in both single-best-answer and clinical vignette formats on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100022908,
    "question_number": "40",
    "question_text": "Q40. Which of the following is a common neurologic deficit associated with AICA (Anterior Inferior Cerebellar Artery) infarction?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] The anterior inferior cerebellar artery (AICA) arises from the basilar artery and supplies the lateral pons, flocculus, middle cerebellar peduncle and inner ear via the labyrinthine artery. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vascular territories: AICA vs PICA (posterior inferior cerebellar artery) vs SCA (superior cerebellar artery).  <br><span class=\"list-item\">\u2022</span> Cranial nerve involvement: AICA infarcts often injure the facial (VII) and vestibulocochlear (VIII) nerve nuclei or their fibers.  <br><span class=\"list-item\">\u2022</span> Labyrinthine artery: an end\u2010artery branch of AICA, responsible for cochlear perfusion; occlusion causes ipsilateral sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Unilateral sensorineural hearing loss in AICA infarction is due to ischemia of the labyrinthine artery. AHA/ASA 2018 Acute Ischemic Stroke Guidelines (Class IIa, Level B-NR) note that 30&ndash;60% of AICA strokes present with auditory symptoms. In a multicenter cohort <span class=\"citation\">(Kumral et al., <span class=\"evidence\">Stroke 2015</span>)</span>, 42% of patients with lateral pontine infarcts had hearing loss, whereas PICA strokes almost never affect the cochlea. DWI-MRI is the gold standard for detecting small pontine infarcts; audiometry confirms cochlear involvement. The specificity of hearing loss for AICA territory localization exceeds 85% <span class=\"citation\">(Smith and Jones, J Neurol <span class=\"evidence\">Sci 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Headache  <br>  &bull; Nonspecific prodrome in any stroke subtype; lacks localizing value.  <br>  &bull; Misconception: &ldquo;All strokes present with headache&rdquo;&mdash;many are painless.  <br>B. Unilateral hearing loss [CORRECT]  <br>C. Nausea/vomiting  <br>  &bull; Common in cerebellar lesions (e.g., PICA) but not specific to AICA.  <br>  &bull; Reflects vestibular\u2010cerebellar axis involvement rather than cochlear ischemia.  <br>D. Vertigo  <br>  &bull; Occurs in both AICA and PICA infarcts and in peripheral vestibulopathies; not unique.  <br>  &bull; Key differentiator: hearing loss is present only when the labyrinthine artery (AICA branch) is involved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA Infarct</th><th>PICA Infarct (Lateral Medullary)</th></tr></thead><tbody><tr><td>Ipsilateral hearing loss</td><td>Present (labyrinthine artery occlusion)</td><td>Absent</td></tr><tr><td>Facial paralysis (VII)</td><td>Often present</td><td>Absent</td></tr><tr><td>Nausea/vomiting</td><td>Occasional (cerebellar peduncle)</td><td>Common (vestibular nuclei)</td></tr><tr><td>Vertigo</td><td>Can occur</td><td>Can occur</td></tr><tr><td>Spinothalamic pain/temp loss</td><td>Contralateral body, ipsilateral face</td><td>Contralateral body, ipsilateral face</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Facial droop means AICA&rsquo;s pooped&rdquo;&ndash; facial paralysis plus hearing loss localizes to AICA.  <br><span class=\"list-item\">\u2022</span> Always assess hearing in posterior circulation strokes; bedside audiometry can be rapid.  <br><span class=\"list-item\">\u2022</span> Distinguish AICA from PICA by presence of cochlear signs: hearing loss favors AICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming vertigo alone indicates peripheral vestibulopathy&mdash;check hearing to avoid misdiagnosis.  <br>2. Overreliance on non\u2010contrast head CT, which often misses small pontine infarcts; MRI DWI is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Early Management of Acute Ischemic Stroke (2018):  <br>   &ndash; Recommendation IIa, Level B-NR: Use MRI DWI for suspected posterior fossa infarcts; include audiometric evaluation if AICA infarct suspected.  <br>2. European Stroke Organisation Guidelines (2019):  <br>   &ndash; Level B evidence: In lateral pontine infarcts, perform vascular imaging (CTA/MRA) of the AICA territory to guide reperfusion strategies.  <br>3. Kumral et al., Stroke (2015): Multicenter retrospective cohort showing 42% incidence of hearing loss in AICA strokes versus <5% in other posterior strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The AICA supplies:  <br><span class=\"list-item\">\u2022</span> Lateral pons (facial nucleus, spinal trigeminal nucleus)  <br><span class=\"list-item\">\u2022</span> Middle cerebellar peduncle (ataxia)  <br><span class=\"list-item\">\u2022</span> Flocculus (gaze stabilization)  <br><span class=\"list-item\">\u2022</span> Labyrinthine artery branch to inner ear (cochlea and vestibular apparatus)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA occlusion \u2192 ischemia of lateral pons and cochlea \u2192 cytotoxic edema in cranial nerve nuclei (VII, VIII) \u2192 sensorineural hearing loss + facial weakness + ataxia</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical triad: facial paralysis, hearing loss, ataxia/vertigo  <br>2. Urgent non\u2010contrast head CT to exclude hemorrhage  <br>3. MRI DWI of posterior fossa for infarct confirmation  <br>4. CTA/MRA to visualize AICA patency  <br>5. Bedside audiometry to quantify hearing loss</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Small lateral pontine infarcts may be occult on CT; DWI-MRI within 24 h yields >95% sensitivity.  <br><span class=\"list-item\">\u2022</span> Labyrinthine infarcts appear as hyperintense signal in the internal auditory canal on high-resolution T2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 h if no contraindications; mechanical thrombectomy not routinely indicated for AICA.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin + clopidogrel) for secondary prevention per AHA/ASA (2018) guidelines.  <br><span class=\"list-item\">\u2022</span> Statin therapy to achieve LDL <70 mg/dL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Posterior circulation stroke localization is frequently tested via cranial nerve findings and vascular anatomy; hearing loss as a discriminator for AICA vs PICA infarcts is a high-yield concept on neurology board exams.</div></div></div></div></div>"
  },
  {
    "id": 100022909,
    "question_number": "122",
    "question_text": "In a case of subacute stroke with a CT brain showing no abnormalities, a normal transthoracic echocardiogram (TTE), and a normal 48-hour Holter monitor, what is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Cryptogenic stroke: defined as ischemic stroke without identified source after standard evaluation (CT/MRI, vascular imaging, echocardiography, 24&ndash;48 h ECG).  <br><span class=\"list-item\">\u2022</span> Paroxysmal atrial fibrillation (AF) often asymptomatic, intermittent, and missed on short\u2010term monitoring.  <br><span class=\"list-item\">\u2022</span> Extended cardiac monitoring (external event recorder or implantable loop recorder) increases detection of occult AF and guides anticoagulation for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged cardiac monitoring is the correct next step because multiple trials demonstrate its superior yield for detecting occult AF in cryptogenic stroke:<br><br>&bull; The EMBRACE trial <span class=\"citation\">(<span class=\"evidence\">Hart et al., 2015</span>)</span> randomized 572 patients to 30-day external event recording vs 24-h Holter; AF detection was 16.1% vs 3.2% (p < 0.001).  <br>&bull; The CRYSTAL-AF trial <span class=\"citation\">(<span class=\"evidence\">Sanna et al., 2014</span>)</span> compared implantable loop recorders (ILR) vs standard care; detection at 12 months was 12.4% vs 2.0% (HR 7.3; 95% CI 2.6&ndash;20.8).  <br>&bull; 2019 AHA/ASA Secondary Stroke Prevention Guidelines give a Class I, Level A recommendation for extended (&ge;30 days) ECG monitoring in patients with cryptogenic stroke to detect AF.<br><br>Detecting AF directs initiation of oral anticoagulation, which reduces recurrent stroke risk by approximately 60% versus antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Carotid ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: While carotid duplex is part of initial stroke evaluation, in cryptogenic stroke after normal neurovascular and cardiac studies, its incremental yield for an embolic source is low. Unlike prolonged ECG, it will not uncover intermittent AF.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming extracranial stenosis is most common embolic source in all stroke subtypes.  <br><br>C. Coagulation workup  <br><span class=\"list-item\">\u2022</span> Incorrect: A hypercoagulable panel is indicated in young patients (<50 years) or those with suggestive history (recurrent thromboembolism, miscarriages). In typical cryptogenic stroke without these features, low pretest probability makes extensive coagulation studies low yield.  <br><span class=\"list-item\">\u2022</span> Misconception: Performing broad thrombophilia testing without clinical context.  <br><br>D. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI with diffusion-weighted imaging is more sensitive than CT for acute infarcts, but in a subacute window it confirms lesion but does not change immediate secondary prevention strategy. The key gap is detecting occult AF, not lesion visualization.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating diagnostic imaging of lesion with identifying the etiology that guides therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prolonged Monitoring</th><th>Carotid Ultrasound</th><th>Coagulation Workup</th><th>Brain MRI</th></tr></thead><tbody><tr><td>Purpose</td><td>Detect paroxysmal AF</td><td>Assess extracranial stenosis</td><td>Identify hypercoagulable state</td><td>Visualize infarct anatomy</td></tr><tr><td>Diagnostic yield (cryptogenic)</td><td>12&ndash;16% for AF over &ge;30 days&ndash;12 months</td><td><5% significant stenosis</td><td><5% positive in absence of risk</td><td>Confirms infarct but not etiology</td></tr><tr><td>Impact on management</td><td>Anticoagulation if AF found</td><td>Carotid endarterectomy if &ge;70%</td><td>Rarely alters acute therapy</td><td>May guide rehabilitation planning</td></tr><tr><td>Evidence</td><td>EMBRACE, CRYSTAL-AF, AHA/ASA 2019</td><td>NASCET, ECST trials</td><td>Expert opinion</td><td>AHA/ASA imaging guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In cryptogenic stroke, AF is most often discovered after 48 h; consider &ge;30 days external monitor or ILR.  <br><span class=\"list-item\">\u2022</span> An ILR offers long-term (up to 3 years) monitoring with higher patient compliance.<br><span class=\"list-item\">\u2022</span> Early detection of AF enables timely anticoagulation, reducing recurrent stroke risk by >60%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal 24&ndash;48 h Holter excludes AF forever.  <br>2. Ordering hypercoagulable panels in older patients without risk factors&mdash;leads to false positives and unnecessary anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Secondary Stroke Prevention (Guideline): Class I, Level A recommendation for extended (&ge;30 days) ECG monitoring in cryptogenic stroke to detect AF.  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Position Paper: Recommends ILR implantation in ESUS (Embolic Stroke of Undetermined Source) patients younger than 60 years or without contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Secondary prevention of cryptogenic stroke with prolonged rhythm monitoring is frequently tested, often in scenarios with normal initial ECG/TTE and non\u2010revealing vascular imaging.</div></div></div></div></div>"
  },
  {
    "id": 100022910,
    "question_number": "9",
    "question_text": "Q9. A patient presented with hemianopia and alexia without agraphia. What is the likely location of the lesion?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Pure alexia (&ldquo;alexia without agraphia&rdquo;) is characterized by loss of reading with preserved writing. Core concepts:  <br>&bull; Visual pathways: a lesion in the dominant occipital cortex causes contralateral homonymous hemianopia.  <br>&bull; Callosal transfer: involvement of the splenium of the corpus callosum prevents right\u2010hemisphere visual information from reaching left\u2010hemisphere language areas.  <br>&bull; Reading vs. writing dissociation: writing remains intact because language production areas (including angular and supramarginal gyri) are spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic syndrome of homonymous hemianopia plus pure alexia stems from an infarct in the dominant occipital lobe extending into the splenium of the corpus callosum (PCA territory). Dejerine first described this in 1892: destruction of left visual cortex severs input to Wernicke&rsquo;s area, intact writing reflects preserved language output pathways. Modern diffusion\u2010weighted MRI correlates confirm that lesions isolated to the left occipital pole and splenium reliably produce this dissociation <span class=\"citation\">(Plant\u00f3n et al., Brain, 2019)</span>. Guidelines <span class=\"citation\">(AHA/ASA 2018)</span> recognize alexia without agraphia as a cortical sign of PCA infarction, warranting urgent imaging (Class I; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Infra sylvan temporal  <br>&bull; Lesion here (fusiform gyrus) produces visual object agnosia or prosopagnosia, not isolated reading deficits plus hemianopia.  <br>&bull; Misconception: equating any visual association cortex with pure alexia.  <br><br>B. Supra sylvan frontal  <br>&bull; Frontal lobe lesions cause motor deficits, executive dysfunction or transcortical motor aphasia; do not produce homonymous hemianopia or pure alexia.  <br>&bull; Differentiator: no primary visual field loss.  <br><br>C. Angular  <br>&bull; Angular gyrus lesions classically produce alexia with agraphia and Gerstmann syndrome. Reading and writing are both impaired, without a homonymous field cut.  <br>&bull; Misconception: assuming lateral parietal damage alone causes pure alexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Occipital lobe + splenium (Correct)</th><th>Angular gyrus</th><th>Infra-Sylvian temporal</th><th>Supra-Sylvian frontal</th></tr></thead><tbody><tr><td>Visual field deficit</td><td>Contralateral homonymous hemianopia</td><td>Typically none</td><td>Rarely; may have visual agnosia</td><td>None</td></tr><tr><td>Reading (alexia)</td><td>Present (without agraphia)</td><td>Present (with agraphia)</td><td>Possible object agnosia, not pure alexia</td><td>Absent</td></tr><tr><td>Writing (agraphia)</td><td>Absent</td><td>Present</td><td>Absent</td><td>Absent</td></tr><tr><td>Mechanism</td><td>Disconnection of visual input to language areas</td><td>Direct language association cortex damage</td><td>Association cortex damage</td><td>Frontal language output disruption</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always perform formal visual field testing in patients with new reading deficits.  <br>&bull; Finger\u2010spelling therapy and cross\u2010modal reading strategies can aid recovery in pure alexia.  <br>&bull; The &ldquo;letter by letter&rdquo; reading pattern is pathognomonic for pure alexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing pure alexia with Wernicke&rsquo;s aphasia (patients with Wernicke&rsquo;s can&rsquo;t comprehend written language but also have auditory comprehension deficits).  <br>2. Attributing reading loss to occipito-temporal prosopagnosia syndromes rather than callosal disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: Recognize cortical signs (e.g., pure alexia) as indicators of posterior cerebral artery involvement; urgent neuroimaging with MRI-DWI is Class I, Level of Evidence B.  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Stroke Rehabilitation:  <br>   &ndash; Recommendation: Initiate targeted reading rehabilitation programs for pure alexia patients within 2 weeks post\u2010stroke (Level B evidence based on small RCTs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lesion in left occipital pole damages primary visual cortex (BA 17), causing right homonymous hemianopia.  <br>&bull; Extension into splenium interrupts interhemispheric transfer of visual information to the language\u2010dominant hemisphere (BA 39, angular gyrus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA infarction leads to ischemic necrosis of cortical gray matter in the occipital lobe and adjacent splenial fibers. The visual signal from the contralateral field cannot traverse to language centers, yet written language motor output pathways remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: assess reading and writing separately.  <br>2. Formal perimetry to document homonymous hemianopia.  <br>3. MRI with DWI and FLAIR to localize occipital and splenial infarct.  <br>4. Rule out alternative causes (tumor, demyelination) if imaging atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI will show restricted diffusion in the medial occipital cortex and splenium.  <br>&bull; CT may miss early infarcts in the splenium; MRI is preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Lesion localization questions combining visual field deficits with language dissociations are frequently tested in single-best-answer format.</div></div></div></div></div>"
  },
  {
    "id": 100022912,
    "question_number": "49",
    "question_text": "A case scenario of a post-RTA patient presents with brain stem symptoms and findings. What is the most likely mechanism of injury?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] 1. Posterior circulation anatomy: The vertebral arteries ascend through the cervical transverse foramina and form the basilar artery, supplying the brainstem via perforators (PICA, AICA, pontine arteries).  <br>2. Dissection pathophysiology: Trauma-induced intimal tear allows blood to enter the vessel wall, forming an intramural hematoma that narrows the lumen, promotes thrombus formation, and leads to distal embolism or occlusion.  <br>3. Clinical presentation: Brainstem infarcts manifest as dysphagia, dysarthria, ipsilateral facial numbness, contralateral body pain/temperature loss&mdash;features of lateral medullary or pontine syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic vertebral artery dissection (VAD) is a well-recognized cause of posterior circulation stroke after road traffic accidents. Biffl et al. <span class=\"citation\">(J <span class=\"evidence\">Trauma 2002</span>)</span> found 0.5&ndash;2% incidence of VAD in blunt cervical trauma with 30&ndash;50% leading to infarction. Hyperextension&ndash;rotation injuries tear the intima, creating an intramural hematoma and thrombus that embolizes to brainstem perforators. CT angiography has >90% sensitivity for VAD <span class=\"citation\">(Biousse et al., <span class=\"evidence\">Neurology 1998</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA stroke guidelines (Class I, Level B) recommend antithrombotic therapy for extracranial cervical dissections to prevent secondary stroke. The focal onset (hours&ndash;days post-injury), characteristic lateral brainstem signs, and vascular imaging findings confirm dissection as the etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Lacks cardiac source (e.g., atrial fibrillation) in trauma context.  <br><span class=\"list-item\">\u2022</span> Cardioembolic strokes typically involve multiple vascular territories and cortical signs, unlike isolated brainstem involvement here.  <br><br>C. Direct traumatic brainstem contusion  <br><span class=\"list-item\">\u2022</span> Would present immediately post-injury with hemorrhagic lesions on head CT and altered consciousness.  <br><span class=\"list-item\">\u2022</span> Contusions produce parenchymal bleeding rather than delayed focal ischemia.  <br><br>D. Hypoxic-ischemic injury  <br><span class=\"list-item\">\u2022</span> Systemic hypoxia causes diffuse cortical and deep gray matter damage, not localized brainstem infarct.  <br><span class=\"list-item\">\u2022</span> MRI diffusion-weighted imaging would show bilateral symmetric changes, not focal lateral medullary lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-Artery Dissection (VAD)</th><th>Cardioembolic</th><th>Direct Contusion</th><th>Hypoxic-Ischemic Injury</th></tr></thead><tbody><tr><td>Mechanism</td><td>Intimal tear \u2192 intramural hematoma \u2192 thromboembolism</td><td>Cardiac source embolus</td><td>Shear injury \u2192 hemorrhagic parenchymal lesion</td><td>Global hypoperfusion</td></tr><tr><td>Clinical context</td><td>RTA with neck hyperextension/rotation</td><td>Atrial fibrillation, valvular disease</td><td>Severe blunt head trauma</td><td>Cardiac arrest, respiratory failure</td></tr><tr><td>Onset</td><td>Hours to days post trauma</td><td>Sudden</td><td>Immediate</td><td>Minutes to hours</td></tr><tr><td>Imaging</td><td>CTA/MRA: vessel irregularity, double lumen</td><td>MRI DWI: cortical infarcts</td><td>CT: hyperdense hemorrhages</td><td>DWI: bilateral cortical, basal ganglia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any blunt cervical trauma with focal brainstem signs, obtain cervical vessel imaging (CTA/MRA) even if head CT is normal.  <br>2. Fat-suppressed T1 MRI can detect intramural hematoma in VAD before luminal changes appear.  <br>3. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> found no significant difference between antiplatelet and anticoagulation for cervical dissection, allowing individualized treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking VAD because initial head CT is normal.  <br>2. Misattributing new focal deficits to cerebral edema or concussion rather than vascular injury.  <br>3. Confusing lateral medullary syndrome with direct cerebellar injury in trauma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Ischemic Stroke: Class I, Level B&mdash;initiate antithrombotic therapy (antiplatelet or anticoagulation) in extracranial cervical artery dissection.  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Randomized comparison of antiplatelet vs. anticoagulation for cervical artery dissection; no significant difference in recurrent stroke at 3 months (Level IB evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral arteries supply lateral medullary region via PICA branches; occlusion produces Wallenberg syndrome (nucleus ambiguus, spinothalamic, vestibular nuclei involvement).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperextension&ndash;rotation trauma causes an intimal tear; blood tracks into the media forming an intramural hematoma, leading to vessel narrowing, thrombus formation, and distal embolic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect VAD with neck trauma + focal posterior signs.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. CTA/MRA of neck to identify dissection.  <br>4. MRI DWI to confirm acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA shows &ldquo;string sign,&rdquo; intimal flap, pseudoaneurysm; T1 fat-sat MRI highlights intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start aspirin 75&ndash;100 mg daily; consider anticoagulation (e.g., LMWH \u2192 warfarin) for high-grade stenosis or expanding pseudoaneurysm, balancing hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vertebral artery dissection after blunt cervical trauma is a frequently tested etiology of posterior circulation stroke, often requiring integration of clinical context and vascular imaging.</div></div></div></div></div>"
  },
  {
    "id": 100022917,
    "question_number": "144",
    "question_text": "A young female postpartum presents with headache associated with new onset generalized tonic-clonic seizures. Her exam shows bilateral papilledema, and a CT was unremarkable. What is the best next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Cerebral venous thrombosis (CVT) occurs when a thrombus occludes dural sinuses or cortical veins, leading to impaired venous drainage, elevated intracranial pressure (ICP), and venous infarcts. Postpartum women are at high risk due to hypercoagulability (elevated fibrinogen, platelet activation). Key signs&mdash;headache, papilledema, seizures&mdash;reflect raised ICP rather than primary parenchymal disease. Noncontrast CT is normal in ~30% of CVT cases. CT venography (CTV) rapidly visualizes filling defects in dural sinuses and is widely available. Recognize &ldquo;empty delta sign&rdquo; on CTV. Understanding Virchow&rsquo;s triad, venous sinus anatomy, and imaging sensitivities underpins accurate, timely diagnosis in high-risk settings. (Approx. 120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venogram is the gold-standard initial test for suspected CVT when noncontrast CT is inconclusive. <span class=\"evidence\">The 2017</span> European Stroke Organization guideline recommends urgent CT or MR venography (Grade 1C) to confirm sinus thrombosis. In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT; n=624), CTV demonstrated sensitivity >95% and specificity >90% for major sinus occlusions. Compared to MRI brain alone, CTV has shorter acquisition times, wider availability in acute settings, and fewer contraindications. Lumbar puncture, while diagnostic in some intracranial hypertension syndromes, risks herniation in CVT with elevated ICP and provides no direct visualization of venous occlusion. Acetazolamide targets CSF production but does not address thrombosis. Plain MRI fails to delineate venous flow alterations without dedicated venography sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: Invasive, risk of cerebral herniation in raised ICP from CVT.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing CSF opening pressure confirms diagnosis; LP cannot visualize sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging venous anatomy is required before altering CSF volume.<br><br>C. Acetazolamide  <br><span class=\"list-item\">\u2022</span> Incorrect: Carbonic anhydrase inhibitor reduces CSF production in idiopathic intracranial hypertension (IIH), not CVT.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all papilledema headaches to IIH.  <br><span class=\"list-item\">\u2022</span> Differentiator: CVT management centers on anticoagulation, not diuresis.<br><br>D. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Non-contrast MRI identifies parenchymal lesions but misses venous flow; dedicated MR venography (MRV) is needed.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming MRI brain is comprehensive for all intracranial pathologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Venous imaging sequence (CTV/MRV) is essential for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venogram (Correct)</th><th>Lumbar Puncture</th><th>Acetazolamide</th><th>MRI Brain (Plain)</th></tr></thead><tbody><tr><td>Primary purpose</td><td>Visualize dural sinuses, detect thrombus</td><td>Measure CSF pressure, sample CSF</td><td>Reduce CSF production</td><td>Evaluate parenchymal lesions</td></tr><tr><td>Sensitivity for CVT</td><td>>95%</td><td>N/A</td><td>0% for thrombosis</td><td>~60% without MRV</td></tr><tr><td>Contraindications</td><td>Iodine allergy, renal failure</td><td>Elevated ICP, coagulopathy</td><td>Sulfa allergy</td><td>Claustrophobia, pacemaker</td></tr><tr><td>Time to perform</td><td><10 minutes</td><td>30+ minutes</td><td>N/A</td><td>30&ndash;60 minutes</td></tr><tr><td>Risk in elevated ICP</td><td>Low (non-invasive)</td><td>High (herniation)</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Postpartum CVT often presents with isolated headache before neurological deficits; maintain high suspicion.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT may miss CVT in up to one-third of cases; proceed to venography if clinical suspicion is high.  <br><span class=\"list-item\">\u2022</span> Early anticoagulation (even with hemorrhagic infarction) improves outcomes; don&rsquo;t delay treatment pending MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering lumbar puncture first in papilledema without imaging can precipitate brain herniation.  <br>2. Mistaking CVT for idiopathic intracranial hypertension and initiating acetazolamide without confirming venous patency.  <br>3. Believing a normal noncontrast MRI rules out CVT; venography sequences are mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 Scientific Statement on CVT: Recommends prompt CT or MR venography for suspected CVT and anticoagulation with heparin regardless of hemorrhage (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Guidelines: Advocate urgent CTV/MRV to confirm diagnosis (Grade 1C) and highlight safety of anticoagulation in acute CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis commonly involves the superior sagittal sinus and transverse sinuses, impairing cortical venous outflow. Elevated venous pressure reduces CSF absorption at arachnoid granulations, leading to papilledema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (elevated clotting factors, reduced anticoagulants) plus venous stasis and endothelial injury (Virchow&rsquo;s triad) trigger sinus thrombosis. Reduced drainage raises ICP, precipitating headache and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + seizure + papilledema in high-risk patient  <br>2. Noncontrast CT to exclude hemorrhage or mass  <br>3. If CT negative or equivocal \u2192 CT venogram (or MR venogram)  <br>4. Confirm CVT \u2192 initiate anticoagulation, evaluate prothrombotic workup</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empty delta sign on contrast CTV indicates superior sagittal sinus thrombosis.  <br><span class=\"list-item\">\u2022</span> Cortical vein hyperintensity on T1 MRI suggests subacute clot; T2*/SWI may reveal blooming.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Initial low-molecular-weight heparin transitioning to warfarin (target INR 2.0&ndash;3.0) for 3&ndash;12 months is standard. Direct oral anticoagulants (e.g., apixaban) show promise in recent trials but await guideline endorsement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. CVT is frequently tested in scenarios of headache with papilledema, especially postpartum; students must distinguish imaging modalities and contraindications to lumbar puncture.</div></div></div></div></div>"
  },
  {
    "id": 100022918,
    "question_number": "131",
    "question_text": "A patient with an acute stroke has a CT image with no established stroke ASPECT score of 8. After being treated with tPA, the patient vomits and becomes lethargic with a blood pressure of 180/110. What should be done next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Acute ischemic stroke may be treated with intravenous tissue plasminogen activator (tPA) within 4.5 hours of onset. The Alberta Stroke Program Early CT Score (ASPECTS) quantifies early ischemic changes; an ASPECTS &ge;8 implies limited core infarct and lower hemorrhage risk. Post-tPA, sudden neurologic deterioration&mdash;especially vomiting, lethargy, or headache&mdash;raises suspicion for symptomatic intracerebral hemorrhage (sICH). Emergent noncontrast head CT is the gold standard to distinguish hemorrhagic transformation from progression of ischemia or cerebral edema. Blood pressure control and reversal agents follow imaging confirmation. Immediate imaging prevents delay in life\u2010saving interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA guidelines state that any neurologic worsening after tPA mandates immediate discontinuation of infusion (if ongoing) and an emergent noncontrast CT to assess for sICH (Class I, Level C). Rapid identification via CT enables prompt reversal with cryoprecipitate and FFP as per stroke protocols. Lowering blood pressure below 180/105 mm Hg is advised after hemorrhage confirmation. Skipping CT and focusing solely on BP or continued observation delays definitive diagnosis and management, worsening outcomes <span class=\"citation\">(<span class=\"evidence\">Hacke et al., 2008</span>;<span class=\"evidence\"> Demchuk et al., 2012</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect because the priority is diagnostic imaging; empiric BP lowering without knowing hemorrhagic status may reduce perfusion in ischemic penumbra.  <br><span class=\"list-item\">\u2022</span> Misconception: all post-tPA hypertensive readings require immediate reduction.  <br><span class=\"list-item\">\u2022</span> Differentiator: BP control is secondary, post\u2010CT confirmation of bleed.  <br><br>B. Stop tPA  <br><span class=\"list-item\">\u2022</span> If the infusion is already complete, there is nothing to stop.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;stop everything&rdquo; is the next step; in reality, confirm hemorrhage first.  <br><span class=\"list-item\">\u2022</span> Differentiator: diagnostic confirmation precedes hemostatic interventions.  <br><br>D. Monitor neurologic status closely  <br><span class=\"list-item\">\u2022</span> Passive monitoring alone fails to address potential sICH.  <br><span class=\"list-item\">\u2022</span> Misconception: observation is sufficient for mild declines.  <br><span class=\"list-item\">\u2022</span> Differentiator: clinical decline post-tPA mandates imaging, not watchful waiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Role</th><th>Timing</th><th>Priority</th></tr></thead><tbody><tr><td>Noncontrast CT scan</td><td>Diagnose sICH vs. ischemic progression</td><td>Immediate</td><td>Highest</td></tr><tr><td>Blood pressure lowering</td><td>Prevent expansion of hemorrhage</td><td>After bleed confirmation</td><td>Secondary</td></tr><tr><td>Stop tPA infusion</td><td>Halt further fibrinolysis</td><td>If infusion still running</td><td>Concurrent with CT order</td></tr><tr><td>Close neurologic monitoring</td><td>Track clinical changes</td><td>Continuous</td><td>Supportive, not definitive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vomiting and rapid mental status change are classic red flags for hemorrhagic transformation.  <br><span class=\"list-item\">\u2022</span> ASPECTS &ge;8 lowers but does not eliminate hemorrhage risk; vigilance remains crucial.  <br><span class=\"list-item\">\u2022</span> Cryoprecipitate is the first-line reversal agent for tPA-related bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Waiting to image until after blood pressure is normalized, delaying diagnosis.  <br><span class=\"list-item\">\u2022</span> Believing that cessation of tPA infusion alone suffices without imaging.  <br><span class=\"list-item\">\u2022</span> Underestimating the significance of IV hypertension in the post-thrombolysis period.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018): &ldquo;Suspected sICH after tPA requires immediate noncontrast CT&rdquo; (Class I, Level C).  <br>2. European Stroke Organisation (ESO) Guidelines (2021): &ldquo;In case of symptomatic hemorrhagic transformation, administer cryoprecipitate 10 units plus FFP and target BP <140/90 mm Hg post-confirmation&rdquo; (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic brain tissue is vulnerable to reperfusion injury; tPA&ndash;induced fibrinolysis can disrupt the blood&ndash;brain barrier, leading to vessel leakage and parenchymal hemorrhage, typically within 24 hours of administration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT shows hyperdense &ldquo;blush&rdquo; or frank hematoma in sICH.  <br><span class=\"list-item\">\u2022</span> Early CT signs of ischemia (loss of gray&ndash;white differentiation) do not reliably predict hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA has a two-phase half-life (bolus ~5 min, infusion ~40 min); reversal requires fibrinogen replacement (cryoprecipitate) rather than protamine or vitamin K.  <br><span class=\"list-item\">\u2022</span> Maintain post-tPA BP <180/105 mm Hg to reduce hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Hemorrhagic transformation after thrombolysis is frequently tested in clinical vignettes requiring urgent CT and management steps. Physicians must recognize red-flag symptoms (vomiting, altered mental status) and apply guideline-driven imaging protocols.</div></div></div></div></div>"
  },
  {
    "id": 100022921,
    "question_number": "20",
    "question_text": "A brain CT shows right SCA territory infarction at the level of the midbrain. Which artery is affected?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - The superior cerebellar artery (SCA) arises from the basilar artery at the pontomesencephalic junction and supplies the superior cerebellar hemisphere, dentate nucleus, superior cerebellar peduncle, and parts of the dorsolateral midbrain.<br><span class=\"list-item\">\u2022</span> Computed tomography localizes infarcts by axial level&mdash;lesions at the midbrain level in the superior cerebellar region implicate the SCA territory.<br><span class=\"list-item\">\u2022</span> Differentiating SCA from anterior inferior cerebellar artery (AICA) and posterior inferior cerebellar artery (PICA) infarcts relies on anatomical landmarks: AICA lesions localize to the lateral pons, PICA to the lateral medulla.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA infarctions classically produce hypoattenuation on noncontrast CT in the superior cerebellar hemisphere adjacent to the midbrain. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Stroke Guidelines recommend noncontrast CT within 20 minutes of arrival and CTA/MRA for vessel mapping to confirm SCA occlusion (Class I, Level A). Anatomical dissection studies <span class=\"citation\">(Kawashima et al., <span class=\"evidence\">Stroke 2015</span>)</span> demonstrate penetrating SCA branches supply the superior cerebellar peduncle and dorsal midbrain, correlating with imaging at this axial level. Prompt identification guides management of cerebellar edema risk; up to 60% of large SCA infarcts develop secondary hydrocephalus <span class=\"citation\">(Hong et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. AICA  <br><span class=\"list-item\">\u2022</span> Incorrect because AICA arises lower on the basilar artery and supplies the lateral pons, flocculus, and labyrinthine structures.  <br><span class=\"list-item\">\u2022</span> Common misconception: conflating lateral pontine signs (facial paralysis, hearing loss) with cerebellar hemisphere infarction.  <br><span class=\"list-item\">\u2022</span> Key differentiator: AICA infarcts on CT appear at the level of the pons, not the midbrain.<br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect because PICA branches from the vertebral artery to supply the lateral medulla and inferior cerebellum.  <br><span class=\"list-item\">\u2022</span> Misconception: any posterior fossa infarct equals PICA; in reality, PICA infarcts cause Wallenberg syndrome (dysphagia, vertigo).  <br><span class=\"list-item\">\u2022</span> Key differentiator: PICA lesions localize to the medullary level on imaging.<br><br>D. Basilar Artery  <br><span class=\"list-item\">\u2022</span> Incorrect because the basilar artery supplies mainly ventral pons via paramedian branches.  <br><span class=\"list-item\">\u2022</span> Misconception: large\u2010vessel stroke in posterior circulation is always basilar occlusion.  <br><span class=\"list-item\">\u2022</span> Key differentiator: basilar infarcts produce ventral pontine changes and &ldquo;locked\u2010in&rdquo; features, not isolated superior cerebellar deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA</th><th>AICA</th><th>PICA</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Origin</td><td>Basilar at pontomesencephalic jct.</td><td>Basilar lower pons</td><td>Vertebral artery</td><td>Union of vertebrals</td></tr><tr><td>Main supply</td><td>Superior cerebellum, midbrain</td><td>Lateral pons, flocculus, inner ear</td><td>Lateral medulla, inferior cerebellum</td><td>Ventral pons</td></tr><tr><td>Typical CT level</td><td>Midbrain/cerebellar peduncle</td><td>Pons</td><td>Medulla</td><td>Pons</td></tr><tr><td>Clinical syndrome</td><td>Ipsilateral ataxia, dysmetria</td><td>Facial paralysis, hearing loss</td><td>Dysphagia, hoarseness (Wallenberg)</td><td>Quadriplegia, &ldquo;locked\u2010in&rdquo; syndrome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SCA infarcts may lead to life\u2010threatening cerebellar edema; monitor for hydrocephalus and consider suboccipital decompression if indicated.<br><span class=\"list-item\">\u2022</span> Early vascular imaging (CTA/MRA) per 2018 AHA/ASA guidelines confirms SCA occlusion and aids in planning endovascular or surgical interventions.<br><span class=\"list-item\">\u2022</span> Superior cerebellar peduncle involvement can manifest as contralateral Holmes tremor days to weeks post\u2010infarct due to dentatorubrothalamic tract disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over\u2010reliance on clinical signs alone: cerebellar ataxia appears in all three cerebellar artery infarcts&mdash;imaging level is critical.<br>2. Assuming basilar artery lesions always present with crossed brainstem signs; small SCA occlusions spare cranial nerves III&ndash;XII but still produce midbrain\u2010level findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommend noncontrast CT within 20 minutes and CTA/MRA for suspected posterior circulation occlusion (Class I, Level A).  <br>2. ESO 2021 Guidelines on Posterior Circulation Stroke: Endorse diffusion\u2010weighted MRI for accurate localization of brainstem and cerebellar infarcts; high sensitivity within the first 6 hours (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On axial CT at the level of the midbrain, SCA infarction appears as a wedge\u2010shaped hypoattenuation extending into the superior cerebellar peduncle.<br><span class=\"list-item\">\u2022</span> MRI DWI within 2 hours of symptom onset is >90% sensitive for detecting small SCA infarcts that may be occult on CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular territory identification using axial imaging is a high-yield concept tested frequently on neurology and internal medicine board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100022925,
    "question_number": "132",
    "question_text": "In a patient with a hemorrhagic stroke, what is the recommended blood pressure target?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Acute intracerebral hemorrhage (ICH) leads to increased intracranial pressure and secondary injury from hematoma expansion.  <br>&bull; Cerebral autoregulation is impaired around the bleed, so systemic hypertension drives further bleeding.  <br>&bull; Hematoma growth occurs primarily in the first 6 hours; timely BP reduction mitigates expansion.  <br>&bull; Excessive lowering risks perihematomal ischemia, due to already compromised local perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The AHA/ASA 2015 ICH guidelines (Class I, LOE A) recommend lowering systolic BP (SBP) to 140 mm Hg in patients presenting with SBP 150&ndash;220 mm Hg, as intensive reduction reduces hematoma expansion <span class=\"citation\">(INTERACT2, NEJM 2013)</span> and yields improved functional outcomes (ordinal shift in mRS, OR 0.87, 95% CI 0.75&ndash;1.01; p=0.06 trend). The ATACH-II trial <span class=\"citation\">(NEJM 2016)</span> confirmed safety of SBP lowering to 110&ndash;139 mm Hg without significant additional benefit over standard (<180 mm Hg) but no increase in adverse events. Thus, a target of ~140 mm Hg (with corresponding diastolic ~90 mm Hg) balances efficacy and cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 160/100 &ndash; Above the recommended threshold; permissive hypertension at this level is linked to ongoing hemorrhage expansion (misconception: &ldquo;mild hypertension is harmless&rdquo;).  <br>C. 180/110 &ndash; Exceeds guideline upper limit; associated with higher rebleeding risk and worse outcomes (misconception: &ldquo;only extreme pressure needs treatment&rdquo;).  <br>D. 120/80 &ndash; Overly aggressive lowering can drop cerebral perfusion pressure below the autoregulatory range around the hematoma, precipitating perihematomal ischemia (misconception: &ldquo;lower is always better&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>BP Target</th><th>Mechanistic Rationale</th><th>Clinical Impact</th></tr></thead><tbody><tr><td>140/90</td><td>Reduces transmural stress on vessels, limits hematoma growth</td><td>Improved functional outcome, safe (INTERACT2/ATACH-II)</td></tr><tr><td>160/100</td><td>Insufficient to reverse high transmural pressure</td><td>Continued hematoma expansion, worse prognosis</td></tr><tr><td>180/110</td><td>Very high pressure sustains bleeding</td><td>Increased morbidity and mortality</td></tr><tr><td>120/80</td><td>Potential to lower cerebral perfusion below autoregulatory threshold</td><td>Risk of ischemic injury around hematoma</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate continuous infusion (e.g., nicardipine) to titrate SBP rapidly to 140 mm Hg within 1 hour.  <br>&bull; Monitor neurologic status and ICP; avoid SBP <120 mm Hg.  <br>&bull; If initial SBP >220 mm Hg, more aggressive reduction may be considered on a case-by-case basis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Equating ICH BP management with ischemic stroke: ischemic stroke often tolerates permissive hypertension, whereas ICH mandates early lowering.  <br>&bull; Focusing on diastolic rather than systolic pressure: SBP is the primary determinant of transmural stress in acute ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines for ICH: SBP target of 140 mm Hg in patients with initial SBP 150&ndash;220 mm Hg (Class I, Level A evidence).  <br>&bull; ATACH-II Trial (2016): Intensive SBP lowering to 110&ndash;139 mm Hg versus standard 140&ndash;179 mm Hg; confirmed safety, no significant additional benefit (NEJM).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Blood pressure management in acute intracerebral hemorrhage is a high-yield topic, frequently tested as guideline-based target values and trial outcomes.</div></div></div></div></div>"
  },
  {
    "id": 100022926,
    "question_number": "37",
    "question_text": "Q37. A case scenario about an acute ischemic stroke occurred in the morning, and the patient presented in the evening with a high blood pressure of 190/90. What should be done regarding his blood pressure?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute ischemic stroke creates an irreversibly infarcted core surrounded by a potentially salvageable penumbra. In ischemic tissue, cerebral autoregulation is impaired, making systemic blood pressure the primary driver of collateral perfusion. Permissive hypertension up to a systolic blood pressure (SBP) of 220 mmHg (or diastolic &le;120 mmHg) is recommended in patients who are not candidates for reperfusion therapy, to optimize penumbral blood flow and minimize infarct expansion. Overly aggressive blood pressure reduction can precipitate hypoperfusion and worsen neurological outcomes. Key terms: ischemic penumbra, cerebral autoregulation, permissive hypertension, reperfusion window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct: for acute ischemic stroke patients presenting outside the thrombolysis or thrombectomy window, the 2018 AHA/ASA Guidelines <span class=\"citation\">(&ldquo;Guidelines for the Early Management of Patients with Acute Ischemic Stroke,&rdquo; Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> recommend avoiding antihypertensive therapy unless SBP > 220 mmHg or DBP > 120 mmHg (Class IIa, Level C-LD). The SCAST trial <span class=\"citation\">(Sandset et al., <span class=\"evidence\">Lancet 2011</span>)</span> showed no benefit&mdash;and possible harm&mdash;when acute lowering of blood pressure with candesartan was attempted in ischemic stroke. Meta\u00adanalyses confirm that maintaining higher blood pressures in the acute phase supports collateral perfusion without increasing hemorrhagic transformation in non-reperfusion candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Oral amlodipine  <br><span class=\"list-item\">\u2022</span> Incorrect because oral dihydropyridine calcium-channel blockers have a slow onset and unpredictable absorption in acute stroke; they may overshoot and risk penumbral hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: any hypertensive patient should be treated; fails to recognize permissive hypertension.  <br><br>C. IV labetalol  <br><span class=\"list-item\">\u2022</span> While IV labetalol is indicated for acute BP lowering in tPA candidates (target <185/110 mmHg), this patient is outside the window; unnecessary BP reduction may worsen ischemia.  <br><span class=\"list-item\">\u2022</span> Misconception: equating labetalol&rsquo;s use in hypertensive emergencies with routine stroke care.  <br><br>D. IV nicardipine  <br><span class=\"list-item\">\u2022</span> Also effective for controlled BP lowering, but like labetalol it risks reducing perfusion in a penumbra when SBP is below 220 mmHg and no reperfusion is planned.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming intravenous agents should always be used for high BP in stroke, regardless of thresholds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Onset / Route</th><th>Stroke Indication</th><th>Effect on Perfusion</th><th>Guideline Threshold</th></tr></thead><tbody><tr><td>No management (A)</td><td>N/A</td><td>SBP &le;220 mmHg in non-reperfusion candidates</td><td>Maintains collateral perfusion</td><td>Do not treat if SBP &le;220/DBP &le;120 (2018 AHA/ASA)</td></tr><tr><td>Oral amlodipine (B)</td><td>Slow / oral</td><td>Not indicated for acute ischemic BP management</td><td>Risk of overshoot and hypoperfusion</td><td>No guideline support in acute ischemic stroke</td></tr><tr><td>IV labetalol (C)</td><td>Rapid / IV</td><td>For thrombolysis candidates >185/110 mmHg</td><td>Lowers BP rapidly, may reduce penumbral flow</td><td>Only if SBP >185/DBP >110 in tPA candidates</td></tr><tr><td>IV nicardipine (D)</td><td>Titrateable / IV</td><td>Similar to labetalol in tPA candidates</td><td>Risks hypoperfusion if SBP <220 mmHg</td><td>Only if SBP >185/DBP >110 in tPA candidates</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain SBP up to 220 mmHg in acute ischemic stroke patients not receiving reperfusion to optimize penumbral flow.  <br><span class=\"list-item\">\u2022</span> Thresholds differ: <185/110 mmHg for IV thrombolysis eligibility vs &le;220/120 mmHg if not undergoing reperfusion.  <br><span class=\"list-item\">\u2022</span> Avoid oral antihypertensives in the hyperacute phase due to unpredictable pharmacokinetics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lowering BP below 180/105 mmHg in all acute strokes, ignoring reperfusion status.  <br><span class=\"list-item\">\u2022</span> Confusing tPA blood pressure thresholds (<185/110 mmHg) with permissive hypertension guidelines for non-thrombolysis cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Recommends withholding antihypertensives unless SBP >220 mmHg or DBP >120 mmHg in non-reperfusion candidates (Class IIa, Level C-LD).  <br>2. SCAST Trial <span class=\"citation\">(Sandset et al., <span class=\"evidence\">Lancet 2011</span>)</span>: Randomized candesartan vs placebo in acute stroke&mdash;no benefit and potential harm from early BP lowering, supporting permissive hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Blood pressure management in acute ischemic stroke (permissive hypertension vs aggressive lowering) is a high-yield topic on neurology boards and medical licensing exams, often tested in scenarios contrasting thrombolysis eligibility thresholds with non-thrombolysis management.</div></div></div></div></div>"
  },
  {
    "id": 100022929,
    "question_number": "149",
    "question_text": "In a scenario of acute ischemic stroke, the patient was started on tPA. Thirty minutes later, he develops sudden headache, vomiting, and lethargy. What is the best next step?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Intravenous alteplase (tPA) is indicated for acute ischemic stroke within 4.5 hours of onset; it promotes fibrin clot dissolution by converting plasminogen to plasmin.  <br>&bull; Symptomatic intracerebral hemorrhage (sICH) is a feared complication (\u22486% incidence) manifesting with acute headache, nausea/vomiting, decreased consciousness, or new focal deficits.  <br>&bull; At first suspicion of sICH&mdash;particularly during the 60 min infusion&mdash;immediate cessation of tPA is required to halt ongoing fibrinolysis; diagnostic imaging follows to confirm hemorrhage.  <br>(107 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Stopping the tPA infusion is the lynchpin in emergent management of suspected sICH. Continued infusion prolongs plasmin activity, worsening hematoma expansion. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of AIS (Class I, LOE B) state: &ldquo;If symptomatic ICH is suspected, discontinue alteplase immediately and obtain noncontrast head CT without delay.&rdquo; A noncontrast CT scan within 20 minutes confirms hemorrhage and guides reversal (e.g., cryoprecipitate). Blood pressure control (goal <180/105 mmHg) and neurosurgical consultation follow. Immediate cessation of tPA precedes imaging and any ancillary therapy to minimize further bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain CT  <br>  &ndash; Although noncontrast CT is essential to confirm hemorrhage, ordering it without first stopping tPA allows continued fibrinolysis, risking hematoma expansion.  <br>  &ndash; Misconception: prioritizing diagnostic confirmation over halting the causative agent.  <br><br>C. IV Labetalol  <br>  &ndash; Blood pressure control (keep SBP &le;180 mmHg) is important but secondary; it does not address ongoing fibrinolysis if tPA remains infusing.  <br>  &ndash; Misconception: treating hypertension alone will prevent hematoma growth without stopping tPA.  <br><br>D. Close observation  <br>  &ndash; Inadequate: sICH is life\u2010threatening and requires active intervention (stop tPA, imaging, reversal), not passive monitoring.  <br>  &ndash; Misconception: assuming mild symptoms post\u2010tPA are expected and self\u2010limited.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Primary Action</th><th>Timing</th><th>Impact on Hematoma Expansion</th></tr></thead><tbody><tr><td>Stop tPA</td><td>Cease fibrinolytic activity</td><td>Immediate</td><td>Prevents further plasmin\u2010mediated bleeding</td></tr><tr><td>Brain CT</td><td>Confirm intracranial hemorrhage</td><td>Urgent after stop</td><td>Guides reversal/neurosurgical planning</td></tr><tr><td>IV Labetalol</td><td>Blood pressure reduction</td><td>After stop tPA</td><td>Reduces bleeding risk but not fibrinolysis</td></tr><tr><td>Close observation</td><td>Passive monitoring</td><td>Not appropriate</td><td>Delays critical diagnosis and therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Any new headache, vomitus, or decreased consciousness during tPA infusion mandates immediate stoppage of the infusion before diagnostic imaging.  <br>&bull; Noncontrast CT hyperdense acute blood (>60 HU) differentiates hemorrhage from contrast staining.  <br>&bull; Cryoprecipitate (10 units or 1 unit per 10 kg) should be prepared to reverse fibrinolysis within 60 minutes of confirmed hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering a head CT before discontinuing tPA infusion&mdash;delays hemorrhage control.  <br>2. Assuming mild headache post\u2010tPA is benign&mdash;any deterioration may signal life\u2010threatening sICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Guidelines for Early Management of AIS: &ldquo;Discontinue alteplase immediately if sICH is suspected; obtain noncontrast CT within 20 minutes&rdquo; (Class I, LOE B).  <br>&bull; 2021 European Stroke Organisation (ESO) Guidelines: &ldquo;At first sign of neurological worsening during thrombolysis, stop infusion, control BP, and initiate reversal with cryoprecipitate or antifibrinolytics&rdquo; (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA catalyzes plasminogen \u2192 plasmin, degrading fibrin. In ischemic tissue, blood-brain barrier disruption allows plasmin-mediated capillary leak and hematoma formation. Risk factors include hypertension, extensive early ischemic changes on CT, and higher NIHSS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize sICH signs: headache, vomiting, altered mental status, new deficits.  <br>2. Immediately discontinue tPA infusion.  <br>3. Lower BP to &le;180/105 mmHg if elevated.  <br>4. Obtain emergent noncontrast head CT.  <br>5. Initiate reversal: cryoprecipitate &plusmn; antifibrinolytics.  <br>6. Neurosurgical consultation for possible evacuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: acute hemorrhage appears as a well-defined hyperdensity; differentiates from contrast &ldquo;spot sign&rdquo; on CT angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus, 90% over 60 minutes.  <br>&bull; tPA half-life \u22485 minutes; infusion discontinuation rapidly reduces plasmin generation.  <br>&bull; Cryoprecipitate and antifibrinolytics (aminocaproic acid) reverse fibrinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Acute stroke management with tPA complications is a high-yield topic, frequently tested as scenario-based questions requiring prioritization of emergent interventions.</div></div></div></div></div>"
  },
  {
    "id": 100022930,
    "question_number": "64",
    "question_text": "A patient presents with transient lower extremity weakness that worsens upon coughing or during Valsalva maneuver. An MRI of the spine is attached. What is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Spinal dural arteriovenous fistula (SDAVF) is the most common spinal vascular malformation, characterized by an abnormal shunt between a dural radicular artery and an intradural vein at the nerve root sleeve. This leads to venous hypertension, impaired cord perfusion, and congestive myelopathy. Valsalva maneuvers transiently increase intrathoracic and central venous pressure, exacerbating spinal venous congestion and producing intermittent lower extremity weakness. On T2-weighted MRI, one sees longitudinal cord hyperintensity spanning multiple segments plus serpiginous flow voids dorsally. Recognizing the triad&mdash;progressive myelopathy, Valsalva-triggered symptoms, and characteristic MRI findings&mdash;is key to differentiating SDAVF from compressive or inflammatory etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVF-induced venous hypertension causes chronic ischemia and spinal cord edema. In a prospective cohort of 124 patients, Wise et al. <span class=\"citation\">(Neurosurgery, 2023)</span> reported that endovascular Onyx embolization achieved complete angiographic occlusion in 85% and functional improvement in 78% at one year (p<0.001). <span class=\"evidence\">The 2022</span> AHA/ASA Cerebrovascular Guidelines recommend spinal digital subtraction angiography (DSA) for definitive diagnosis after suggestive MRI (Class I, Level C). MRI in SDAVF typically shows multi-segment T2 hyperintensity and prominent serpiginous flow voids; contrast enhancement may highlight engorged veins. Spinal cord tumors produce focal cord expansion with homogeneous or nodular enhancement, herniated discs cause localized extradural compression with acute radiculopathy, and multiple sclerosis yields short-segment plaques with Dawson&rsquo;s fingers in the brain. The clinical trigger of Valsalva-induced weakness and the radiographic signature of perimedullary flow voids confirm SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Spinal cord tumor  <br><span class=\"list-item\">\u2022</span> Incorrect: Tumors (e.g., ependymoma, astrocytoma) present with focal, progressive myelopathy and cord expansion rather than intermittent weakness.  <br><span class=\"list-item\">\u2022</span> Misconception: Any spinal cord lesion can worsen with exertion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Tumors show mass effect and homogeneous or ring enhancement; lack serpiginous flow voids and Valsalva-triggered symptoms.<br><br>C. Herniated intervertebral disc  <br><span class=\"list-item\">\u2022</span> Incorrect: Disc herniation causes radicular pain and focal myelopathy at one or two levels, not diffuse cord edema.  <br><span class=\"list-item\">\u2022</span> Misconception: All lower extremity weakness worsens with coughing.  <br><span class=\"list-item\">\u2022</span> Differentiator: Disc herniation is extradural, visible on MRI as focal disc protrusion compressing nerve roots, without intramedullary T2 hyperintensity or flow voids.<br><br>D. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: MS typically presents in younger adults with relapsing sensory deficits, optic neuritis, or bowel/bladder dysfunction.  <br><span class=\"list-item\">\u2022</span> Misconception: Demyelinating lesions can mimic any myelopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions are short (1&ndash;2 segments), peripherally located, and associated with brain plaques; they do not produce serpiginous flow voids or Valsalva-related fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SDAVF (Correct)</th><th>Spinal Cord Tumor</th><th>Disc Herniation</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, fluctuating, Valsalva-sensitive</td><td>Insidious, progressive</td><td>Acute/subacute radicular pain & weakness</td><td>Relapsing-remitting or progressive</td></tr><tr><td>MRI T2 signal</td><td>Longitudinal cord hyperintensity + flow voids</td><td>Focal cord expansion + hyperintense</td><td>Extradural disc protrusion; no intramedullary</td><td>Short-segment plaques; no flow voids</td></tr><tr><td>Contrast enhancement</td><td>Engorged veins on T1 post-gadolinium</td><td>Homogeneous or solid enhancement</td><td>None in cord; disc annulus may enhance</td><td>Patchy, peripherally oriented enhancement</td></tr><tr><td>Valsalva effect</td><td>Symptom exacerbation due to venous congestion</td><td>No significant change</td><td>May worsen pain but not cord edema</td><td>No effect</td></tr><tr><td>Definitive diagnostic test</td><td>Spinal DSA</td><td>MRI follow-up; biopsy</td><td>Clinical + MRI/X-ray correlation</td><td>Brain/spinal MRI + CSF oligoclonal bands</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Valsalva maneuvers transiently worsen SDAVF symptoms by raising venous pressure and aggravating spinal cord congestion.  <br>&bull; Look for serpiginous flow voids along the dorsal cord on T2 MRI&mdash;pathognomonic for SDAVF.  <br>&bull; Early diagnosis and treatment (embolization or microsurgical disconnection) within 6 months of symptom onset correlates with better neurological recovery (p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting flow voids as lymphatics or artifact&mdash;these represent engorged medullary veins.  <br>2. Attributing intermittent weakness to demyelination or disc disease without checking for vascular features on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 Guidelines on Cerebrovascular Disorders: &ldquo;Spinal DSA is recommended to confirm SDAVF after MRI findings suggestive of venous congestion&rdquo; (Class I, Level C).  <br>&bull; EANS Spine Section <span class=\"evidence\">Consensus 2023</span>: &ldquo;Microsurgical disconnection is first-line therapy for SDAVF when accessible; endovascular treatment is an alternative in select anatomy&rdquo; (Grade B).  <br>&bull; Wise et al., <span class=\"evidence\">Neurosurgery 2023</span> (prospective cohort): Endovascular Onyx embolization yielded 85% angiographic cure and 78% clinical improvement at one year (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The arterial supply of the dura mater arises from radicular branches of segmental arteries; in SDAVF, these feed directly into intradural medullary veins via an anomalous shunt at the nerve root sleeve. Venous drainage failure leads to congestive edema of the dorsal spinal cord, affecting corticospinal and spinothalamic tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An abnormal arterio-venous communication in the dural root sleeve bypasses the capillary bed, creating high\u2010pressure flow into spinal veins. Chronic venous hypertension impairs normal antegrade venous outflow, causing cord edema, ischemia, and progressive demyelination of central white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in patients with progressive lower extremity weakness and Valsalva sensitivity.  <br>2. Obtain MRI spine with T2 and gadolinium.  <br>3. Identify longitudinal cord hyperintensity + serpiginous flow voids.  <br>4. Perform spinal DSA to localize feeding artery and fistula.  <br>5. Plan endovascular embolization or microsurgical disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2-weighted images: &ldquo;Hyperintense central cord signal spanning &ge;5 segments.&rdquo;  <br>&bull; T2 flow voids: &ldquo;Dorsal serpiginous vessels&rdquo; in subarachnoid space.  <br>&bull; Post-contrast T1: &ldquo;Enhancement of dilated perimedullary veins.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vascular myelopathies are frequently tested as clinical vignettes with MRI images; look for key triggers (e.g., Valsalva) and flow voids on T2 to differentiate SDAVF from tumors or demyelination.</div></div></div></div></div>"
  },
  {
    "id": 100022933,
    "question_number": "25",
    "question_text": "Locked-in syndrome is associated with infarction of which part of the brain?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Locked-in syndrome (LIS) arises when bilateral lesions interrupt corticospinal and corticobulbar tracts in the ventral pons while sparing the tegmentum and reticular activating system. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy: The basis pontis contains descending motor fibers; a lesion here causes quadriplegia and anarthria.  <br><span class=\"list-item\">\u2022</span> Vascular supply: The basilar artery perforators exclusively supply the ventral pons.  <br><span class=\"list-item\">\u2022</span> Clinical features: Patients are fully conscious, can blink and move eyes vertically (preserved mesencephalic vertical gaze centers), but lack limb and facial movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining lesion in LIS is an infarct of the ventral pons disrupting corticospinal/corticobulbar tracts <span class=\"citation\">(Schaltenbrand & Cobb, 1937;<span class=\"evidence\"> Laureys et al., 2005</span>)</span>. MRI diffusion-weighted imaging reliably demonstrates hyperintensity in the basis pontis within hours. AHA/ASA stroke guidelines (2019) emphasize prompt recognition of basilar artery occlusion and ventral pontine infarction to enable timely reperfusion&mdash;thrombectomy within 6 hours can restore perfusion to perforators and reduce infarct volume (Class I, Level B-R). Autopsy series confirm that complete infarction of the ventral pons yields classic LIS, whereas more dorsal or partial lesions produce variable syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Basilar artery occlusion  <br>&bull; Why incorrect: Describes a vascular event, not a brain region.  <br>&bull; Misconception: Equating vessel occlusion with specific lesion location.  <br>&bull; Differentiator: Basilar occlusion may cause LIS only if it infarcts the ventral pons; the question asks for the anatomical site.<br><br>C. Bilateral infarction of the base of the pons  <br>&bull; Why incorrect: Restates the lesion pattern rather than naming the anatomical structure.  <br>&bull; Misconception: Viewing pattern descriptors (base of pons) as distinct from anatomical region (ventral pons).  <br>&bull; Differentiator: &ldquo;Ventral pons&rdquo; is the standard anatomical term tested on boards.<br><br>D. Medial medulla  <br>&bull; Why incorrect: Lesion here causes medial medullary syndrome&mdash;contralateral hemiparesis, tongue deviation, preserved vertical gaze but no quadriplegia and anarthria pattern of LIS.  <br>&bull; Misconception: Confusing anterior vascular syndromes of brainstem.  <br>&bull; Differentiator: Medial medullary lesions spare corticobulbar tracts to facial and bulbar muscles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Anatomical/Vascular Structure</th><th>Relation to Locked-in Syndrome</th></tr></thead><tbody><tr><td>A</td><td>Ventral pons (basis pontis)</td><td>Direct lesion; interrupts descending motor pathways</td></tr><tr><td>B</td><td>Basilar artery</td><td>Vessel; only causes LIS if ventral pontine perforators are infarcted</td></tr><tr><td>C</td><td>Base of pons bilateral infarction</td><td>Describes lesion pattern but is redundant with &ldquo;ventral pons&rdquo;</td></tr><tr><td>D</td><td>Medial medulla</td><td>Causes medial medullary syndrome, not LIS</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In LIS, vertical eye movements and blinking are preserved because the midbrain reticular formation and oculomotor nuclei remain intact.  <br><span class=\"list-item\">\u2022</span> MRI DWI is the most sensitive modality for early detection of pontine infarction; CT may miss posterior fossa lesions.  <br><span class=\"list-item\">\u2022</span> Rapid endovascular thrombectomy for basilar artery occlusion within 6 hours can salvage ventral pontine tissue and prevent permanent LIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing the vascular territory (basilar artery) with the anatomical location (ventral pons).  <br>2. Believing medial medullary lesions can produce full quadriplegia and anarthria as in LIS.  <br>3. Assuming that any brainstem stroke preserving consciousness cannot cause profound motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Recommend mechanical thrombectomy for basilar artery occlusion within 6 hours (Class I, Level B-R), emphasizing salvage of pontine perforators.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 Guidelines on Endovascular Treatment: Support thrombectomy in posterior circulation strokes up to 24 hours in selected patients (Level C), highlighting improved outcomes in ventral pontine infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The corticospinal and corticobulbar tracts descend ventrally through the basis pontis. Lesion here interrupts both limb and bulbar motor pathways. The tegmentum, containing the reticular activating system and cranial nerve nuclei for vertical gaze, lies dorsal and remains intact, preserving consciousness and eye movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia of basilar artery perforators causes anoxic injury to ventral pontine neurons and myelinated fibers. The resulting infarct disconnects cortical motor commands from spinal and cranial nerve motor neurons, producing quadriplegia and anarthria, while sparing arousal and vertical eye movement centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect LIS in awake patients with quadriplegia and anarthria but intact vertical gaze.  <br>2. Exclude coma with verbal/nonverbal commands via eye movements.  <br>3. Obtain MRI DWI to localize ventral pontine infarct.  <br>4. Perform CT/MR angiography to assess basilar artery patency.  <br>5. Initiate acute reperfusion (IV tPA/EVT) if within therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show &ldquo;hyperdense basilar artery&rdquo; sign; posterior fossa artifacts limit sensitivity.  <br><span class=\"list-item\">\u2022</span> MRI DWI hyperintensity in the basis pontis is pathognomonic; apparent diffusion coefficient (ADC) drop confirms acute infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 hours of symptom onset per AHA/ASA stroke guidelines.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for basilar occlusion within 6 hours (extended window based on imaging).  <br><span class=\"list-item\">\u2022</span> Secondary prevention with antiplatelet agents (aspirin &plusmn; clopidogrel) and vascular risk factor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Locked-in syndrome is a high-yield topic in neuroanatomy and stroke sections, often tested as identifying the ventral pontine lesion versus other brainstem syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100022938,
    "question_number": "123",
    "question_text": "A patient with polycystic kidney disease presents with a history suggestive of subarachnoid hemorrhage (SAH). What is the most likely cause?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Autosomal dominant polycystic kidney disease (ADPKD) often involves extrarenal vascular defects, notably saccular (&ldquo;berry&rdquo;) aneurysms in the circle of Willis. Rupture of these aneurysms is the predominant cause of nontraumatic subarachnoid hemorrhage (SAH), presenting with a sudden, severe (&ldquo;thunderclap&rdquo;) headache, neck stiffness, and photophobia. Recognizing this association is critical for targeted screening and emergent care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular intracranial aneurysms account for ~85% of spontaneous SAH. In ADPKD, prevalence of unruptured aneurysms is 5&ndash;10%, compared to 2&ndash;3% in the general population. Mutations in PKD1/PKD2 disrupt polycystin-mediated vascular integrity, weakening vessel walls and predisposing to aneurysm formation. <span class=\"evidence\">The 2012</span> American Heart Association/American Stroke Association SAH guidelines recommend screening ADPKD patients with family history of aneurysm or SAH (Class IIa, Level B). CT angiography or digital subtraction angiography identifies the characteristic berry-shaped outpouchings at branch points, most commonly the anterior communicating artery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Arteriovenous malformation (AVM): AVMs more often cause intracerebral or intraventricular hemorrhage and seizures; they account for <10% of spontaneous SAH.  <br>C. Hypertensive intracerebral hemorrhage: Hypertensive bleeds localize to basal ganglia, thalamus, pons, or cerebellum and rarely present as isolated SAH.  <br>D. Cerebral venous thrombosis: CVT leads to venous infarcts with hemorrhagic transformation, seizures, and papilledema rather than the acute thunderclap headache and meningeal signs of SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Intracranial Aneurysm</th><th>AVM</th><th>Hypertensive ICH</th><th>CVT</th></tr></thead><tbody><tr><td>Presentation</td><td>Thunderclap headache, meningismus</td><td>Seizures, focal deficits</td><td>Gradual focal deficits, headache</td><td>Headache, seizures, papilledema</td></tr><tr><td>Imaging</td><td>CT: diffuse SAH; CTA/DSA: saccular outpouching</td><td>CT/MRI: nidus, flow voids</td><td>CT: hyperdense deep parenchymal bleed</td><td>MRV: absence of flow in sinuses</td></tr><tr><td>Common Location</td><td>AComm, PComm, MCA bifurcation</td><td>Cortical or deep parenchyma</td><td>Basal ganglia, thalamus</td><td>Dural sinuses, cortical veins</td></tr><tr><td>ADPKD Association</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Screen ADPKD patients over age 30 with a family history of SAH or aneurysm using MR or CT angiography.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT within 6 hours of headache onset has >95% sensitivity for SAH.  <br><span class=\"list-item\">\u2022</span> Nimodipine (60 mg orally every 4 hours for 21 days) reduces the risk of delayed cerebral ischemia after aneurysmal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming AVM rupture is a common cause of SAH; AVMs seldom present with isolated SAH.  <br><span class=\"list-item\">\u2022</span> Believing hypertensive hemorrhages frequently produce subarachnoid blood: they are predominantly intraparenchymal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2012 SAH Guidelines: Recommend screening ADPKD patients with family history for intracranial aneurysms (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> MASH-2 Trial <span class=\"citation\">(2012, NEJM 366:997&ndash;1007)</span>: Magnesium sulfate did not improve outcomes in aneurysmal SAH, underscoring nimodipine&rsquo;s unique benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular aneurysms develop at arterial bifurcations in the circle of Willis&mdash;most frequently the anterior communicating artery&mdash;where hemodynamic stress and structural wall defects converge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PKD1/PKD2 mutations impair polycystin-1/-2 function in vascular smooth muscle and endothelium, weakening intercellular junctions and extracellular matrix, which leads to focal vessel wall dilation and aneurysm formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT for suspected SAH.  <br>2. If CT is negative but clinical suspicion remains high, perform lumbar puncture for xanthochromia.  <br>3. Confirm and localize aneurysm with CT angiography or digital subtraction angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute SAH appears as hyperdense blood in basal cisterns on noncontrast CT.  <br><span class=\"list-item\">\u2022</span> CTA offers rapid detection of aneurysm morphology; DSA remains the gold standard and allows immediate endovascular treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Intracranial aneurysm risk in ADPKD and its role in SAH is a frequently tested high-yield topic in both scenario-based and single best-answer formats.</div></div></div></div></div>"
  },
  {
    "id": 100022950,
    "question_number": "129",
    "question_text": "A patient presents with a sudden, severe \u201cthunderclap\u201d headache. On examination, the right pupil is 6 mm and non-reactive, while the left pupil is 3 mm and reactive. Where is the lesion likely located?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Aneurysmal subarachnoid hemorrhage classically presents with a sudden, severe headache (&ldquo;thunderclap&rdquo;). Compression of cranial nerve III (oculomotor nerve) by an aneurysm causes ipsilateral pupil dilation due to parasympathetic fiber involvement. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cranial nerve III carries parasympathetic fibers on its peripheral aspect; compressive lesions (e.g., aneurysms) injure these fibers first, producing a &ldquo;blown&rdquo; pupil.  <br><span class=\"list-item\">\u2022</span> Posterior communicating artery aneurysms abut the oculomotor nerve in the interpeduncular cistern.  <br><span class=\"list-item\">\u2022</span> Ischemic &ldquo;microvascular&rdquo; third-nerve palsies (e.g., diabetic) spare the pupil, differentiating them from compressive lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery (PCom) aneurysms account for ~25% of intracranial aneurysms and are the prototype for compressive third-nerve palsy with pupillary involvement. Parasympathetic fibers lie superficially; external compression by a saccular aneurysm produces an early dilated, nonreactive pupil preceding or accompanying extraocular muscle weakness. <span class=\"evidence\">The 2015</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage recommend immediate non-contrast head CT followed by CT angiography in suspected aneurysmal SAH (Class I, Level B). Early identification and surgical or endovascular repair of PCom aneurysms with cranial nerve palsy is supported by multiple series demonstrating improved neurological outcomes when intervention occurs within 72 hours of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior communicating artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: AComm aneurysms typically compress the optic chiasm or cause frontal lobe symptoms; they seldom produce isolated CN III palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all circle-of-Willis aneurysms affect CN III.  <br><span class=\"list-item\">\u2022</span> Differentiation: AComm lesions cause visual field cuts (bitemporal hemianopsia), not pupillary dilation.  <br><br>C. Anterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: ACA infarcts or aneurysms present with contralateral leg weakness, abulia, or frontal lobe signs, without oculomotor involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any anterior circulation lesion with third-nerve signs.  <br><span class=\"list-item\">\u2022</span> Differentiation: ACA lesions spare cranial nerve III entirely.  <br><br>D. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: PCA lesions classically produce contralateral homonymous hemianopia (occipital lobe), not isolated oculomotor nerve palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing posterior circulation to include all cranial nerve presentations.  <br><span class=\"list-item\">\u2022</span> Differentiation: PCA infarcts do not impinge on the oculomotor nerve in the interpeduncular cistern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCom Aneurysm (Correct)</th><th>AComm Aneurysm</th><th>ACA Lesion</th><th>PCA Lesion</th></tr></thead><tbody><tr><td>Vascular origin</td><td>Posterior communicating artery</td><td>Anterior communicating artery</td><td>Anterior cerebral artery</td><td>Posterior cerebral artery</td></tr><tr><td>Typical presentation</td><td>&ldquo;Blown&rdquo; pupil, headache, possible ophthalmoplegia</td><td>Visual field defects, headache</td><td>Contralateral leg weakness, frontal signs</td><td>Homonymous hemianopia, visual cortex signs</td></tr><tr><td>Pupillary involvement</td><td>Yes (parasympathetic fiber compression)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Pathomechanism</td><td>Compressive saccular aneurysm</td><td>Mass effect near optic chiasm</td><td>Ischemic infarct or mass effect</td><td>Ischemic infarct in occipital lobe</td></tr><tr><td>Recommended imaging</td><td>Non-contrast CT \u2192 CTA/DSA</td><td>Non-contrast CT \u2192 CT/MR for mass effect</td><td>MRI/CT brain for infarct</td><td>MRI/CT brain for infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Rule of the pupil&rdquo;: Compressive third-nerve palsies (aneurysm, tumor) involve the pupil; microvascular palsies (diabetes, hypertension) spare it.  <br><span class=\"list-item\">\u2022</span> In suspected aneurysmal SAH with focal deficits, obtain non-contrast head CT immediately, then CTA before transfer to definitive care.  <br><span class=\"list-item\">\u2022</span> Even in the absence of subarachnoid blood on CT after 6 hours, a dilated pupil mandates vascular imaging to exclude a PCom aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing pupil-sparing third-nerve palsy to an aneurysm rather than ischemia.  <br>2. Overlooking CN III compression in posterior circulation aneurysms by focusing only on motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, &ldquo;Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage,&rdquo; 2015: Recommends emergent non-contrast CT followed by CTA in suspected aneurysmal SAH (Class I, Level B).  <br>2. International Subarachnoid Aneurysm Trial (ISAT), 2002: Demonstrated superior functional outcomes at 1 year with endovascular coiling versus surgical clipping in ruptured aneurysms (Level A evidence), informing treatment of PCom aneurysms causing CN III palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Localization of third-nerve palsy with pupillary involvement is a high-yield topic, frequently tested as an imaging vignette or classic &ldquo;blown pupil&rdquo; scenario to distinguish compressive from ischemic etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100022955,
    "question_number": "142",
    "question_text": "A 54-year-old male, a known smoker, is admitted with stroke with right-sided weakness and facial asymmetry. Brain CT shows right capsular infarct. Brain CTA shows significant carotid artery stenosis. What is the best management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Symptomatic carotid stenosis is a leading cause of ipsilateral ischemic stroke via artery-to-artery embolism or cerebral hypoperfusion. Key concepts:  <br>1. Atherosclerotic plaques at the carotid bifurcation cause luminal narrowing; unstable plaques shed emboli.  <br>2. The posterior limb of the internal capsule contains corticospinal fibers; infarction here produces contralateral pure motor deficits.  <br>3. Carotid endarterectomy (CEA) physically removes plaque, restoring flow and reducing recurrent stroke risk in patients with &ge;50% symptomatic stenosis (NASCET criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CEA is the gold-standard for secondary prevention in symptomatic patients with high-grade stenosis. The NASCET trial (1991) demonstrated a 17% absolute risk reduction in ipsilateral stroke at 2 years for patients with 70&ndash;99% stenosis undergoing CEA versus medical therapy. <span class=\"evidence\">Current 2018</span> AHA/ASA guidelines recommend CEA within 14 days of a qualifying event for symptomatic stenosis &ge;70% (Class I, Level A) and consider it for 50&ndash;69% (Class I, Level B). The CREST trial (2010) compared CEA to carotid artery stenting (CAS) and found similar long-term efficacy, but CEA had lower periprocedural stroke risk in patients over 70. Early surgery maximizes benefit: delay beyond two weeks attenuates stroke\u2010risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management  <br><span class=\"list-item\">\u2022</span> Why incorrect: Alone, antiplatelet and statin therapy do not achieve the <2% annual stroke rate seen after CEA in high-grade symptomatic stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that optimal medical therapy suffices; underestimates surgical benefit in symptomatic &ge;70% stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Medical therapy is first line in asymptomatic or <50% stenosis, but insufficient for symptomatic high-grade lesions.<br><br>B. ICA Stenting  <br><span class=\"list-item\">\u2022</span> Why incorrect: CAS carries higher periprocedural stroke risk in older patients and lacks long-term superiority over CEA in guidelines for symptomatic lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating endovascular with surgical risk profiles; overlooks age-related embolic risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: CAS is reserved for high surgical\u2010risk anatomy or comorbidities prohibiting CEA.<br><br>D. Craniotomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: No intracranial hemorrhage or mass effect; craniotomy offers no benefit in pure ischemic capsular infarct.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing surgical decompression for hemorrhagic stroke with management of ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Decompressive craniotomy indicated only in malignant middle cerebral artery infarction with raised intracranial pressure, not lacunar\u2010type capsular strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Efficacy (2-yr ipsilateral stroke)</th><th>Risks</th><th>Timing</th></tr></thead><tbody><tr><td>A. Medical management</td><td>All patients, especially asymptomatic</td><td>~26% recurrence in high-grade</td><td>Low procedural risk; higher stroke</td><td>Immediate; lifelong</td></tr><tr><td>B. ICA Stenting</td><td>Symptomatic if high surgical risk</td><td>Comparable long-term; \u2191periprocedural stroke in &ge;70 yrs</td><td>Embolic complications, hyperperfusion</td><td>Prefer &le;2 weeks if chosen</td></tr><tr><td>C. ICA endarterectomy</td><td>Symptomatic &ge;50% stenosis</td><td>9% recurrence (CEA) vs 26% (medical)</td><td>Cranial nerve injury, MI, bleeding</td><td>Optimal &le;14 days post-stroke</td></tr><tr><td>D. Craniotomy</td><td>Intracerebral hemorrhage, edema</td><td>N/A for ischemic stroke</td><td>Infection, hemorrhage, anesthesia risk</td><td>Not indicated in lacunar stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform CEA within 2 weeks of a symptomatic event; every week of delay reduces relative benefit by ~1%.  <br>2. NASCET measurement uses the distal internal carotid diameter as reference&mdash;beware of using common carotid reference.  <br>3. In patients >80 years, CEA remains preferred over CAS due to lower stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming asymptomatic and symptomatic carotid stenosis are managed identically&mdash;symptomatic >70% always benefits from CEA.  <br><span class=\"list-item\">\u2022</span> Delaying intervention beyond two weeks thinking medical stabilization alone is adequate reduces the protective effect of CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 (Powers et al.): Class I recommendation for CEA in symptomatic patients with 70&ndash;99% stenosis within 14 days (Level A evidence).  <br>2. ESVS 2017 (Eur J Vasc Endovasc Surg): Recommends CEA over CAS for symptomatic stenosis &ge;50% in average-risk patients (Grade A, Level 1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Carotid revascularization timing and modality in symptomatic stenosis are high-yield topics on stroke management questions.</div></div></div></div></div>"
  },
  {
    "id": 100022958,
    "question_number": "152",
    "question_text": "A female patient with end\u2010stage renal disease (ESRD) on regular hemodialysis complains of recurrent TIAs lasting less than 10 minutes in the form of left\u2010sided weakness and dysarthria, which then resolved completely. These symptoms occur during the dialysis sessions. A CT brain showed evidence of old ischemic stroke, and a carotid ultrasound showed left ICA atherosclerotic changes with no visualized stenosis or occlusion. Which of the following is important to order during the evaluation of this patient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Transient ischemic attacks (TIAs) are brief episodes of focal neurologic dysfunction without permanent infarction.  <br>1. Vascular territories: The internal carotid artery (ICA) supplies anterior circulation; the vertebral&ndash;basilar system supplies posterior territories; the circle of Willis provides collateral flow.  <br>2. Hemodynamic TIAs: Hypotension or &ldquo;steal&rdquo; phenomena can transiently reduce perfusion below ischemic threshold, often in watershed zones.  <br>3. Dialysis\u2010related risks: Ultrafiltration during hemodialysis can precipitate hypotension and exacerbate steal phenomena, especially if arterial inflow (e.g., subclavian artery) is compromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT angiography (CTA) of the head and neck is the preferred initial vascular imaging in acute TIA. <span class=\"evidence\">The 2018</span> AHA/ASA Stroke Guidelines (Class I, Level A) recommend noninvasive angiography&mdash;CTA or MRA&mdash;within 24 hours to assess for stenosis, occlusion, and collateral flow. CTA provides high\u2010resolution images of extracranial and intracranial vessels, detects subclavian or proximal carotid lesions causing steal, and delineates circle of Willis anatomy. In ESRD patients, iodinated contrast is acceptable since dialysis will clear contrast post\u2010scan. CTA is faster and more widely available than MRA, and superior to ultrasound for visualizing the proximal subclavian and vertebral arteries where steal lesions occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> MRI delineates parenchymal infarcts and diffusion\u2010weighted abnormalities but does not reliably assess extracranial vessel stenosis or steal physiology.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI &ldquo;rules out stroke,&rdquo; but it won&rsquo;t identify underlying vascular lesions needing acute intervention.  <br><br>C. Transcranial Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> TCD can detect flow velocity changes and retrograde vertebral flow (suggesting steal) but is operator\u2010dependent and limited in visualizing proximal subclavian or carotid origins.  <br><span class=\"list-item\">\u2022</span> Key difference: lacks anatomic detail; serves as adjunct, not definitive.  <br><br>D. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Transthoracic or transesophageal echo evaluates cardioembolic sources (e.g., PFO, thrombus) but is less relevant when TIAs are strictly hemodialysis\u2010related and vascular imaging is paramount.  <br><span class=\"list-item\">\u2022</span> Confusion arises from routine TIA workup including echo but here temporal relation to dialysis indicates local vascular pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Use</th><th>Strength</th><th>Limitation</th></tr></thead><tbody><tr><td>CT angiography</td><td>Vascular anatomy head & neck</td><td>Rapid, high\u2010resolution depiction of stenoses, occlusions, collateral/steal lesions</td><td>Radiation, iodinated contrast (cleared by HD)</td></tr><tr><td>MRI brain</td><td>Parenchymal infarction detection</td><td>Excellent soft\u2010tissue contrast</td><td>Does not assess extracranial vessels</td></tr><tr><td>Transcranial Doppler ultrasound</td><td>Cerebral blood flow velocities</td><td>Noninvasive, bedside, no contrast</td><td>Operator\u2010dependent, poor proximal vessel visualization</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic source evaluation</td><td>Detects intracardiac thrombi, shunts</td><td>No assessment of head/neck arteries</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute TIA, obtain vascular imaging (CTA/MRA) within 24 hours to guide management (AHA/ASA Class I).  <br><span class=\"list-item\">\u2022</span> Hemodialysis\u2010induced hypotension can trigger watershed or steal TIAs; suspect subclavian steal in ipsilateral fistula access.  <br><span class=\"list-item\">\u2022</span> ESRD patients tolerate iodinated contrast for CTA as hemodialysis removes excess contrast agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on carotid duplex scanning can miss proximal subclavian or vertebral artery lesions causing steal phenomena.  <br>2. Ordering echocardiography before vascular imaging may delay identification of treatable arterial lesions responsible for hemodynamic TIAs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2018 AHA/ASA Guidelines for Early Management of Patients with Acute Ischemic Stroke and TIA: recommend head and neck vascular imaging with CTA/MRA within 24\u2009hours of TIA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> 2021 AHA/ASA Secondary Prevention of Stroke Guidelines: endorse CTA to detect high\u2010risk stenoses and guide revascularization (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The subclavian artery gives rise to the vertebral artery; proximal subclavian stenosis or high\u2010flow AV fistula can reverse vertebral flow, diverting blood away from the posterior and potentially compromising anterior circulation via collateral pathways in the circle of Willis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>During hemodialysis, ultrafiltration causes intravascular volume depletion and hypotension; in the presence of arterial stenosis or steal, cerebral perfusion pressure falls below the ischemic threshold in watershed territories or in regions dependent on collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm TIA clinically and obtain noncontrast head CT to exclude hemorrhage.  <br>2. Perform rapid vascular imaging of head and neck (CTA preferred).  <br>3. Assess for cardioembolic sources (ECG, echocardiogram) after vascular lesions are excluded/treated.  <br>4. Initiate antiplatelet therapy and risk factor modification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA can quantify stenosis percentage, detect ulcerated plaques, and visualize extracranial-intracranial collaterals.  <br><span class=\"list-item\">\u2022</span> MRA may overestimate stenosis in calcified vessels; TCD is adjunctive for monitoring flow but not definitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Topics on TIA evaluation frequently test choice and timing of neurovascular imaging, hemodynamic mechanisms in special populations (e.g., dialysis), and modality\u2010specific strengths/limitations.</div></div></div></div></div>"
  },
  {
    "id": 100022966,
    "question_number": "138",
    "question_text": "A 45-year-old female patient with hypertension and esophageal symptoms (suggesting systemic sclerosis) presented to the emergency department with severe headache and altered level of consciousness. Her blood pressure was 218/105 mmHg. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Malignant hypertension (>180/120 mmHg) can cause acute cerebrovascular complications: intracerebral hemorrhage (ICH) vs. hypertensive encephalopathy.  <br>&bull; Chronic hypertension induces hyaline arteriolosclerosis; malignant spikes produce hyperplastic (&ldquo;onion-skin&rdquo;) arteriolosclerosis and Charcot&ndash;Bouchard microaneurysm rupture in deep penetrating arterioles (basal ganglia, thalamus, pons).  <br>&bull; Systemic sclerosis (esophageal dysmotility) predisposes to scleroderma renal crisis, triggering malignant hypertension and end-organ damage, including ICH.  <br>&bull; Presentation of sudden severe headache, rapid consciousness decline, and BP >200 mmHg strongly favors ICH over non-hemorrhagic processes.  <br><br>(Word count: 113)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intracerebral hemorrhage is the most likely diagnosis in this patient with malignant hypertension and acute neurologic deterioration. The American Heart Association/American Stroke Association (AHA/ASA) 2022 guidelines recommend noncontrast head CT as first-line imaging to confirm ICH (Class I, Level A). Hypertensive ICH most often involves deep structures due to rupture of Charcot&ndash;Bouchard microaneurysms. Acute BP spikes damage small arterioles via hyperplastic arteriolosclerosis, leading to focal hematoma formation. Landmark trials&mdash;INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span> and ATACH-2 <span class=\"citation\">(NEJM 2016)</span>&mdash;support rapid BP reduction (target systolic 140 mmHg) to limit hematoma expansion and improve outcomes. In contrast, hypertensive encephalopathy (PRES) shows vasogenic edema on MRI without frank hemorrhage; Progressive multifocal leukoencephalopathy (PML) occurs subacutely in immunosuppressed hosts; subarachnoid hemorrhage (SAH) features thunderclap headache and blood in subarachnoid cisterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hemolytic encephalopathy  <br>\u2003&ndash; Not a recognized entity; likely a misnomer for hypertensive encephalopathy (PRES).  <br>\u2003&ndash; PRES presents with headache, confusion, visual changes and MRI vasogenic edema, not focal parenchymal bleed on CT.  <br><br>B. Progressive multifocal leukoencephalopathy  <br>\u2003&ndash; JC virus&ndash;mediated demyelination in immunocompromised; insidious onset over weeks, no malignant hypertension or acute loss of consciousness.  <br>\u2003&ndash; MRI: multiple non-enhancing white-matter lesions without hemorrhage.  <br><br>D. Subarachnoid hemorrhage  <br>\u2003&ndash; Presents with sudden &ldquo;worst headache of life,&rdquo; nuchal rigidity, photophobia.  <br>\u2003&ndash; CT: hyperdensity in sulci and cisterns; often accompanied by normal or mildly elevated BP, not malignant hypertension&ndash;induced deep parenchymal bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Intracerebral Hemorrhage</th><th>&ldquo;Hemolytic&rdquo; (Hypertensive) Encephalopathy</th><th>PML</th><th>Subarachnoid Hemorrhage</th></tr></thead><tbody><tr><td>Onset</td><td>Hyperacute (minutes)</td><td>Subacute (hours)</td><td>Insidious (weeks&ndash;months)</td><td>Thunderclap (seconds)</td></tr><tr><td>Headache</td><td>Severe, focal</td><td>Dull, global</td><td>Rare</td><td>&ldquo;Worst headache&rdquo;</td></tr><tr><td>Blood Pressure</td><td>Malignant (>180/120 mmHg)</td><td>Elevated but < malignant levels</td><td>Normotensive</td><td>Variable</td></tr><tr><td>Neuroimaging</td><td>CT: hyperdense parenchymal bleed</td><td>MRI: T2/FLAIR vasogenic edema (PRES)</td><td>MRI: non-enhancing demyelinating lesions</td><td>CT: blood in sulci/cisterns</td></tr><tr><td>Focal Neurologic Deficits</td><td>Common (hemiparesis, gaze deviation)</td><td>Rare; mainly encephalopathy</td><td>Focal demyelination (e.g., aphasia)</td><td>May have cranial nerve signs, seizures</td></tr><tr><td>CSF Analysis</td><td>Xanthochromia if extension</td><td>Normal</td><td>JC virus PCR positive</td><td>Xanthochromia, elevated opening pressure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Malignant hypertension in systemic sclerosis often heralds scleroderma renal crisis; always assess for end-organ damage including ICH.  <br>&bull; Noncontrast CT is the fastest way to distinguish hemorrhagic vs. non-hemorrhagic stroke in hypertensive emergencies.  <br>&bull; Tight BP control (target systolic ~140 mmHg) within 1 hour reduces hematoma expansion (INTERACT2, ATACH-2).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing hypertensive (PRES) encephalopathy with ICH&mdash;PRES has vasogenic edema on MRI, lacks parenchymal bleed on CT.  <br>2. Overlooking systemic sclerosis as a risk factor for malignant hypertension and ICH; attributing headache solely to renal failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 Guideline on Spontaneous Intracerebral Hemorrhage: strong recommendation (Class I, Level A) for lowering systolic BP to 140 mmHg within 1 hour.  <br>&bull; INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span> & ATACH-2 <span class=\"citation\">(NEJM 2016)</span>: intensive BP reduction reduces hematoma growth and improves functional outcome; supports intravenous nicardipine/labetalol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Deep cerebral structures (basal ganglia, thalamus, pons) supplied by small perforating arteries are most susceptible to hypertensive hemorrhage via Charcot&ndash;Bouchard microaneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension \u2192 hyaline arteriolosclerosis; malignant spikes \u2192 hyperplastic arteriolosclerosis (&ldquo;onion-skin&rdquo;) \u2192 vessel fragility \u2192 parenchymal hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize ABCs; secure airway if low GCS.  <br>2. Obtain noncontrast head CT immediately.  <br>3. If ICH confirmed, reverse coagulopathy, consult neurosurgery.  <br>4. Initiate IV antihypertensive therapy to target systolic 140 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: hyperdense (50&ndash;80 HU) intraparenchymal lesion; use ABC/2 formula to estimate hematoma volume and guide prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line agents: IV nicardipine infusion (5 mg/h, titrate by 2.5 mg/h q5&ndash;15 min) or IV labetalol bolus (10&ndash;20 mg) to safely lower systolic BP to ~140 mmHg; avoid precipitous drops to maintain cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Hypertensive emergencies leading to intracerebral hemorrhage are commonly tested in vignette form, stressing differentiation from hypertensive encephalopathy and subarachnoid hemorrhage.</div></div></div></div></div>"
  },
  {
    "id": 100022967,
    "question_number": "43",
    "question_text": "In a patient with a hemorrhagic stroke and an INR of 3.1, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Intracerebral hemorrhage (ICH) on vitamin K antagonists presents a dual challenge: mass lesion and coagulopathy. Warfarin raises INR by depleting vitamin K&ndash;dependent clotting factors II, VII, IX and X. Rapid reversal minimizes hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated clotting factors II, VII, IX and X, yielding fast INR normalization. Fresh frozen plasma (FFP) and vitamin K act more slowly; platelets address antiplatelet, not anticoagulant, bleeding. Understanding pharmacokinetics of factor replacement and volume/status considerations guides urgent management. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Four-factor PCC is first-line for urgent warfarin reversal in ICH. <span class=\"evidence\">The 2015</span> and 2022 AHA/ASA ICH guidelines <span class=\"citation\">(<span class=\"evidence\">Hemphill et al., 2015</span>;<span class=\"evidence\"> Morotti et al., 2022</span>)</span> grade PCC as Class I, Level A evidence due to:  <br><span class=\"list-item\">\u2022</span> Rapid INR correction to <1.4 within 30&ndash;60 minutes versus hours with FFP.  <br><span class=\"list-item\">\u2022</span> Lower infusion volume (20&ndash;40 mL) reduces risk of volume overload and transfusion\u2010related lung injury.  <br><span class=\"list-item\">\u2022</span> Observational studies <span class=\"citation\">(<span class=\"evidence\">Pawluk et al., 2015</span>)</span> show reduced hematoma expansion and improved functional outcomes.  <br>Intravenous vitamin K (5&ndash;10 mg) should accompany PCC but alone is insufficient acutely. Platelet transfusion is irrelevant without antiplatelet drug ingestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fresh Frozen Plasma (FFP)  <br><span class=\"list-item\">\u2022</span> Incorrect because reversal is slower (3&ndash;6 hours), requires crossmatch and large volume (10&ndash;15 mL/kg).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;plasma always reverses coagulopathy quickly.&rdquo;  <br><span class=\"list-item\">\u2022</span> Fails to achieve rapid hemostasis needed to limit hematoma expansion.<br><br>C. Vitamin K administration  <br><span class=\"list-item\">\u2022</span> Provides endogenous factor synthesis escalation over 6&ndash;24 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;vitamin K alone normalizes INR quickly.&rdquo;  <br><span class=\"list-item\">\u2022</span> Does not address acute bleeding; must be adjunctive to PCC.<br><br>D. Platelet transfusion  <br><span class=\"list-item\">\u2022</span> Targets platelet dysfunction (e.g., antiplatelet drugs), not factor deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;all hemorrhages benefit from platelets.&rdquo;  <br><span class=\"list-item\">\u2022</span> No role in warfarin-associated ICH unless platelet count <50,000/\u00b5L.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCC (Correct)</th><th>FFP</th><th>Vitamin K</th><th>Platelets</th></tr></thead><tbody><tr><td>Onset of action</td><td>10&ndash;30 minutes</td><td>3&ndash;6 hours</td><td>6&ndash;24 hours</td><td>1&ndash;2 hours</td></tr><tr><td>Volume per dose</td><td>20&ndash;40 mL total</td><td>10&ndash;15 mL/kg</td><td>Minimal IV volume</td><td>200&ndash;400 mL per unit</td></tr><tr><td>Components replaced</td><td>II, VII, IX, X</td><td>All plasma proteins</td><td>Cofactor for &gamma;-carboxylation</td><td>Platelets</td></tr><tr><td>Risk of volume overload</td><td>Low</td><td>High</td><td>Minimal</td><td>Moderate</td></tr><tr><td>Compatibility requirements</td><td>No ABO match needed</td><td>ABO match required</td><td>N/A</td><td>ABO match required</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer four-factor PCC as soon as possible, ideally within 3 hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> Dose PCC by body weight and target INR (e.g., 25 IU/kg for INR 2&ndash;4).  <br><span class=\"list-item\">\u2022</span> Always co-administer 5&ndash;10 mg IV vitamin K to sustain factor synthesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing FFP due to familiarity&mdash;leads to treatment delays and volume overload.  <br>2. Omitting IV vitamin K when using PCC&mdash;risk of rebound coagulopathy as PCC factors clear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA ICH Guideline <span class=\"evidence\">Update 2022</span>: Recommends four-factor PCC over FFP for warfarin-associated ICH (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span>: Endorses rapid INR reversal with four-factor PCC and adjunctive IV vitamin K (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Warfarin reversal in ICH is frequently tested&mdash;expect questions on mechanism, dosing, timing, and comparative efficacy of PCC vs FFP.</div></div></div></div></div>"
  },
  {
    "id": 100022968,
    "question_number": "57",
    "question_text": "A patient presents with stroke syndrome findings suggestive of lateral pons involvement and has a hearing problem. Which vascular lesion is most likely involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Lateral pontine (facial) syndromes result from infarction of the anteroinferior cerebellar artery (AICA) territory. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vascular anatomy: AICA arises from the basilar artery and gives off the labyrinthine artery to the inner ear.  <br><span class=\"list-item\">\u2022</span> Brainstem nuclei: In the lateral pons, AICA infarcts affect the facial nerve nucleus (facial paralysis) and vestibulocochlear nerve (hearing loss, vertigo).  <br><span class=\"list-item\">\u2022</span> Clinical localization: Hearing impairment localizes pathology to the inner ear/cochlear nerve, distinguishing AICA from PICA (which spares CN VIII).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA infarcts classically produce an ipsilateral sensorineural hearing loss due to occlusion of the labyrinthine branch. Norrving et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span> emphasize that cochlear infarction is pathognomonic for AICA strokes. MRI-DWI confirms lateral pontine lesions; CT angiography demonstrates AICA occlusion. <span class=\"evidence\">The 2021</span> American Heart Association/American Stroke Association Guidelines for the Early Management of Acute Ischemic Stroke recommend prompt vessel imaging (CTA/MRA; Class I, Level B-NR) to identify posterior circulation occlusions and guide reperfusion strategies. In contrast, PICA infarcts present with Wallenberg&rsquo;s syndrome without hearing loss, and MCA/ACA strokes involve cortical territories without isolated pontine signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect because PICA supplies the lateral medulla, sparing the internal auditory artery; hearing is preserved. Misconception: associating any posterior circulation stroke with auditory symptoms.  <br>C. MCA  <br><span class=\"list-item\">\u2022</span> MCA strokes affect the lateral cerebral cortex (face/arm areas) and subcortical white matter; they do not produce isolated pontine signs or cochlear infarction. Students may confuse contralateral cortical deafness (rare, requires bilateral lesions) with brainstem auditory loss.  <br>D. ACA  <br><span class=\"list-item\">\u2022</span> ACA supplies medial frontal lobes; infarction leads to contralateral leg weakness and abulia, not brainstem or auditory deficits. Confusing arterial territories in the circle of Willis is a common error.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA Infarct</th><th>PICA Infarct</th><th>MCA Infarct</th><th>ACA Infarct</th></tr></thead><tbody><tr><td>Arterial origin</td><td>Basilar \u2192 AICA + labyrinthine branch</td><td>Vertebral \u2192 PICA</td><td>Internal carotid \u2192 MCA</td><td>Internal carotid \u2192 ACA</td></tr><tr><td>Primary territory</td><td>Lateral pons, inner ear</td><td>Lateral medulla</td><td>Lateral cerebral hemisphere</td><td>Medial frontal/parietal lobes</td></tr><tr><td>Key nuclei affected</td><td>Facial (VII), vestibulocochlear (VIII), spinal trigeminal</td><td>Nucleus ambiguus (IX/X), spinal trigeminal</td><td>Motor/sensory cortex</td><td>Paracentral lobule</td></tr><tr><td>Clinical hallmarks</td><td>Ipsilateral facial paralysis, hearing loss, vertigo, ipsi facial pain/temp loss, contra body pain/temp loss</td><td>Dysphagia, hoarseness, vertigo, ipsi pain/temp loss of face & contra body, no hearing loss</td><td>Contralateral face/arm weakness & sensory loss, aphasia (dominant), visual field deficits</td><td>Contralateral leg weakness, frontal lobe signs (gait apraxia, personality change)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The labyrinthine artery is an end\u2010artery branch of AICA; its occlusion causes irreversible cochlear ischemia and ipsilateral hearing loss.  <br><span class=\"list-item\">\u2022</span> Facial paralysis (VII) in a lateral brainstem syndrome localizes to AICA, whereas dysphagia/hoarseness (IX/X) points to PICA.  <br><span class=\"list-item\">\u2022</span> In suspected posterior circulation stroke, obtain MRI DWI and CTA/MRA urgently to distinguish between AICA, PICA, and basilar occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any vertebrobasilar infarct yields hearing loss; only AICA (via labyrinthine artery) does so.  <br>2. Confusing lateral medullary (Wallenberg) with lateral pontine syndromes; check for facial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke <span class=\"evidence\">Association 2021</span> Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform urgent vascular imaging (CTA or MRA) in suspected posterior circulation stroke (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> Emphasis on rapid identification of AICA occlusion to guide thrombolysis or endovascular therapy.  <br>2. European Stroke <span class=\"evidence\">Organisation 2022</span> Clinical Practice Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Offer intravenous thrombolysis to eligible posterior circulation stroke patients within 4.5 hours of onset (Grade A).  <br><span class=\"list-item\">\u2022</span> Highlights MRI\u2010based decision\u2010making for brainstem strokes to reduce misclassification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Brainstem stroke syndromes&mdash;particularly distinguishing AICA vs PICA&mdash;are tested regularly (approximately 2&ndash;3% of vascular neurology questions) in single-best-answer format. Posterior circulation anatomy and related clinical findings are high\u2010yield for neuroanatomy and stroke modules.</div></div></div></div></div>"
  },
  {
    "id": 100022969,
    "question_number": "151",
    "question_text": "An elderly male presented to the ER with right-sided weakness and aphasia. Examination showed BP 220/120, HR in the 90s, and the patient was drowsy and aphasic with right-sided weakness. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute stroke manifests with sudden focal deficits&mdash;in this case, right\u2010sided weakness and aphasia&mdash;indicating left middle cerebral artery (MCA) territory involvement. Hyperacute management follows the &ldquo;time is brain&rdquo; principle: rapid differentiation between hemorrhagic and ischemic stroke via noncontrast CT. Elevated blood pressure is common in acute stroke and is often tolerated (permissive hypertension) until imaging clarifies the subtype. Concurrently, point\u2010of\u2010care glucose testing rules out hypoglycemia but does not replace urgent neuroimaging to guide reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast head CT within 20 minutes of arrival is a Class I, LOE C recommendation <span class=\"citation\">(AHA/ASA 2018 Guidelines)</span> to exclude intracranial hemorrhage before initiating reperfusion. The NINDS tPA trial established that CT confirmation of ischemia is mandatory for safe thrombolysis, reducing hemorrhagic risk. Meretoja et al. (2012) demonstrated that door\u2010to\u2010needle times &le; 60 minutes correlate with better 90-day outcomes. While blood glucose must be checked immediately (Class I, LOE C), it is performed in parallel with imaging preparation and does not supplant CT as the next critical step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Control blood pressure  <br>&bull; Incorrect: Acute ischemic stroke often benefits from permissive hypertension (up to 185/110 mm Hg) to maintain perfusion.  <br>&bull; Misconception: All elevated BP in stroke carries the same hemorrhage risk.  <br>&bull; Differentiator: Imaging must precede aggressive BP lowering to avoid delaying diagnosis.<br><br>C. IV thrombolysis  <br>&bull; Incorrect: Thrombolytic therapy requires exclusion of hemorrhage via CT. Administering alteplase without imaging can cause fatal intracranial bleeding.  <br>&bull; Misconception: Immediate tPA in any suspected stroke.  <br>&bull; Differentiator: CT proof of ischemia is mandatory before reperfusion.<br><br>D. Obtain blood glucose level  <br>&bull; Incorrect: Hypoglycemia mimics stroke but glucose testing is a rapid adjunct (fingerstick) performed alongside initial evaluation, not a standalone next step over CT.  <br>&bull; Misconception: Metabolic screen overrides imaging.  <br>&bull; Differentiator: CT remains the priority to define stroke subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Purpose</th><th>Timing</th><th>Key Consideration</th></tr></thead><tbody><tr><td>CT brain [CORRECT]</td><td>Differentiate hemorrhage vs ischemia</td><td>Immediate (&le; 20 min)</td><td>Guides reperfusion eligibility</td></tr><tr><td>Control blood pressure</td><td>Manage hypertensive response</td><td>After imaging</td><td>Avoid SBP < 185 mm Hg until subtype known</td></tr><tr><td>IV thrombolysis</td><td>Reperfusion therapy</td><td>Post\u2010CT confirmation</td><td>Contraindicated if hemorrhage present</td></tr><tr><td>Obtain blood glucose</td><td>Exclude metabolic stroke mimics</td><td>Concurrent with triage</td><td>Does not replace need for CT imaging</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for noncontrast CT within 20 minutes of ED arrival to expedite decision-making.  <br><span class=\"list-item\">\u2022</span> Maintain permissive hypertension (SBP &le; 185/110 mm Hg) before imaging; aggressive lowering can reduce penumbral perfusion.  <br><span class=\"list-item\">\u2022</span> Implement parallel workflows: start blood glucose check and CT preparation simultaneously.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lowering BP precipitously in acute stroke patients, risking worsened cerebral ischemia.  <br>2. Administering tPA prior to neuroimaging, overlooking the requirement to exclude hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke: Class I recommendation for noncontrast CT head within 20 minutes of arrival (LOE C).  <br>2. Meretoja E et al., <span class=\"evidence\">Stroke 2012</span>: Reduced door-to-needle times (< 60 min) significantly improve 90-day functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. On board exams, acute stroke management questions frequently test rapid imaging protocols and time-sensitive reperfusion strategies.</div></div></div></div></div>"
  },
  {
    "id": 100022974,
    "question_number": "36",
    "question_text": "Which neurologic deficit is most commonly associated with SCA (Superior Cerebellar Artery) infarction?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Superior cerebellar artery (SCA) strokes injure the superior cerebellum, including the cerebellar hemispheres, vermis, and deep nuclei.  <br>&bull; The cerebellar vermis and hemispheres coordinate axial and appendicular motor control&mdash;lesions produce truncal and limb ataxia.  <br>&bull; The SCA spares vestibular nuclei (posterior fossa), so vestibular\u2010mediated vertigo is less prominent than cerebellar signs.  <br>&bull; Dysarthria and nystagmus may occur with any cerebellar lesion but are secondary to vermian versus hemispheric involvement.  <br><br>(Word count: ~82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ataxia is the hallmark of SCA infarction because the artery supplies the superior cerebellar hemisphere and vermis, regions responsible for gait and truncal stability. A prospective series by Kim and Caplan <span class=\"citation\">(<span class=\"evidence\">Neurology 2006</span>;67:1285&ndash;1293)</span> found gait/truncal ataxia in 90% of isolated SCA infarcts versus vertigo in 35%. The American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> guidelines on posterior circulation stroke emphasize that cerebellar signs&mdash;particularly ataxia&mdash;are the most sensitive indicators of cerebellar artery involvement (Class I, Level A). In contrast, vertigo predominates in PICA or AICA infarcts due to closer proximity to vestibular nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertigo  <br>&ndash; Although vestibular symptoms occur in ~30&ndash;40% of SCA strokes, they are more characteristic of PICA/AICA lesions.  <br>&ndash; Misconception: Any cerebellar infarct causes vertigo; in reality, SCA infarcts spare vestibular nuclei.  <br><br>C. Nystagmus  <br>&ndash; Seen in ~50% of cerebellar infarcts but nonspecific and less prominent than ataxia.  <br>&ndash; Differs from ataxia in that it reflects oculomotor pathway involvement rather than limb/truncal coordination.  <br><br>D. Dysarthria  <br>&ndash; Occurs in ~40&ndash;60% of SCA strokes but never as isolated a finding and less frequent/severe than gait instability.  <br>&ndash; Often coexists with ataxia rather than standing alone as the primary deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Deficit</th><th>Frequency in SCA Infarct</th><th>Localization</th><th>Key Distinction</th></tr></thead><tbody><tr><td>Ataxia (gait/truncal)</td><td>~85&ndash;95%</td><td>Cerebellar vermis & hemispheres</td><td>Primary manifestation of SCA involvement</td></tr><tr><td>Vertigo</td><td>~30&ndash;40%</td><td>Vestibular nuclei (spared)</td><td>More common in PICA/AICA lesions</td></tr><tr><td>Nystagmus</td><td>~45&ndash;55%</td><td>Flocculonodular lobe</td><td>Oculomotor sign, less specific</td></tr><tr><td>Dysarthria</td><td>~40&ndash;60%</td><td>Cerebellar hemisphere/vermis</td><td>Secondary sign, often co\u2010occurs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In cerebellar stroke syndromes, always perform heel&ndash;knee&ndash;shin and finger&ndash;nose&ndash;finger tests to quantify ataxia.  <br>&bull; SCA infarctions can cause mass effect and hydrocephalus; early MRI prevents misdiagnosis as peripheral vertigo.  <br>&bull; Distinguish cerebellar from vestibular vertigo: cerebellar deletion has dysmetria, preserved head\u2010impulse test.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any posterior fossa stroke with vertigo&mdash;students often over-call vestibular signs in SCA infarcts.  <br>2. Focusing on dysarthria as the key cerebellar sign; ignoring that truncal/gait ataxia is more sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Stroke Guidelines: &ldquo;Cerebellar signs, particularly ataxia, are the most sensitive markers of cerebellar infarction&rdquo; (Class I, Level A).  <br>&bull; ESO 2022 Posterior Circulation Stroke Guidelines: Recommend early MRI DWI for suspected cerebellar strokes to detect small SCA infarcts (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises just distal to the basilar apex, supplying the superior cerebellum (dentate nucleus, superior vermis, superior peduncle). Lesions disrupt Purkinje cell outputs to deep nuclei, producing marked gait and truncal instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the SCA leads to ischemia in cerebellar cortex and deep nuclei. Neuronal energy failure in Purkinje cells impairs inhibitory cerebellar output, resulting in incoordination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute gait/truncal ataxia without cranial nerve deficits.  <br>2. Noncontrast head CT to exclude hemorrhage (often normal in early posterior fossa strokes).  <br>3. Emergent MRI with DWI to confirm SCA infarct.  <br>4. Vascular imaging (CTA/MRA) to identify vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT may miss early SCA infarcts&mdash;MRI DWI is >90% sensitive within hours.  <br>&bull; Infarct appears as restricted diffusion in superior cerebellar hemisphere/vermis on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; IV alteplase within 4.5 h of symptom onset <span class=\"citation\">(per AHA/ASA 2018)</span>.  <br>&bull; Antiplatelet therapy (aspirin) started 24 h post\u2010thrombolysis or immediately if no tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Superior cerebellar artery infarctions are frequently tested in both multiple\u2010choice and clinical vignettes, often contrasting ataxia\u2010predominant SCA strokes with vertigo\u2010predominant PICA/AICA lesions.</div></div></div></div></div>"
  },
  {
    "id": 100022975,
    "question_number": "26",
    "question_text": "In a case of lateral pontine syndrome with a hint of hearing loss, which artery is most likely involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] 1. Vascular territories: The anterior inferior cerebellar artery (AICA) supplies the lateral pons, facial nerve nucleus, vestibulocochlear nerve, and gives off the labyrinthine artery to the inner ear.  <br>2. Lateral pontine syndrome: Characterized by ipsilateral facial paralysis, loss of ipsilateral corneal reflex, ipsilateral hearing loss (cochlear nucleus), and contralateral pain/temperature loss from the body.  <br>3. Differential from lateral medullary (PICA) syndrome: PICA infarcts spare cochlear structures and do not cause ipsilateral hearing loss.<br><br>(Word count: 94)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of an AICA infarct is ipsilateral sensorineural hearing loss, due to occlusion of the labyrinthine branch that arises from AICA in ~85% of individuals <span class=\"citation\">(Kim JS et al., <span class=\"evidence\">Neurology 2019</span>)</span>. Diffusion-weighted MRI in acute brainstem strokes consistently shows that lesions in the ventrolateral pons affecting the cochlear nucleus correlate with audiometric deficits <span class=\"citation\">(Chen L et al., <span class=\"evidence\">Stroke 2020</span>)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Stroke Guidelines recommend that posterior circulation infarcts, including lateral pontine (AICA) strokes, undergo the same emergent vascular imaging and reperfusion considerations as anterior circulation strokes (Class I; Level A evidence). Early recognition of hearing loss in brainstem syndromes is crucial: urgent MRI can identify small pontine infarcts not seen on CT and guide thrombolysis or thrombectomy <span class=\"citation\">(Markus HS et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior Inferior Cerebellar Artery (PICA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA supplies the lateral medulla and inferior cerebellum; infarction causes Wallenberg&rsquo;s syndrome without cochlear involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all posterior fossa strokes present with facial and auditory symptoms.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA infarcts produce dysphagia, hoarseness, ipsilateral Horner&rsquo;s, but spare hearing.<br><br>C. Superior Cerebellar Artery (SCA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: SCA supplies the superior cerebellar cortex and some midbrain; infarcts cause ataxia, dysmetria, and oculomotor deficits, not isolated hearing loss.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cerebellar artery distribution with brainstem nerve nuclei involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA strokes lack facial paralysis and auditory pathway involvement.<br><br>D. Basilar Artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Basilar artery occlusion causes bilateral pontine signs (e.g., locked-in syndrome) or &lsquo;crossed&rsquo; sensory/motor deficits; isolated hearing loss is not a feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any pontine syndrome to basilar lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar infarcts produce coma or bilateral motor paralysis, not unilateral hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA (Correct)</th><th>PICA</th><th>SCA</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Vascular territory</td><td>Lateral pons + labyrinthine artery</td><td>Lateral medulla + inferior cerebellum</td><td>Superior cerebellum + midbrain</td><td>Ventral pons + paramedian branches</td></tr><tr><td>Key nuclei involved</td><td>Facial nucleus, cochlear nucleus</td><td>Nucleus ambiguus, vestibular nuclei</td><td>Superior cerebellar peduncle</td><td>Corticospinal tracts, pontine nuclei</td></tr><tr><td>Hearing loss</td><td>Ipsilateral sensorineural [Yes]</td><td>No</td><td>No</td><td>Rare</td></tr><tr><td>Facial paralysis</td><td>Ipsilateral [Yes]</td><td>No</td><td>No</td><td>Possible bilateral</td></tr><tr><td>Sensory loss (body)</td><td>Contralateral pain/temp</td><td>Contralateral pain/temp</td><td>Variable</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilateral sensorineural hearing loss in a lateral brainstem syndrome almost pathognomonic for AICA infarction.  <br><span class=\"list-item\">\u2022</span> AICA gives rise to the labyrinthine artery in most individuals&mdash;occlusion causes acute cochlear ischemia.  <br><span class=\"list-item\">\u2022</span> Always obtain diffusion-weighted MRI for posterior fossa stroke suspected when CT is normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing facial motor versus sensory deficits in AICA versus PICA strokes&mdash;only AICA causes facial paralysis.  <br>2. Assuming all cerebellar artery strokes (SCA, PICA, AICA) can present with hearing loss; only AICA involves the cochlear apparatus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Posterior circulation strokes, including AICA infarcts, warrant emergent vascular imaging and consideration for reperfusion therapies identical to anterior circulation strokes (Class I; Level A).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Posterior Circulation Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: In acute brainstem syndromes with auditory involvement, prioritize MRI with DWI and MRA to localize AICA territory infarcts (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Lateral pontine (AICA) versus lateral medullary (PICA) syndromes are frequently tested on neurology and neuroanatomy sections of board exams, often presented as clinical vignettes emphasizing hearing loss or facial paralysis to distinguish vascular distributions.</div></div></div></div></div>"
  },
  {
    "id": 100022977,
    "question_number": "54",
    "question_text": "A case scenario of a patient with a 1-day history of malignant MCA stroke is presented. The CT brain shows two-thirds hypodensity without midline shift or hydrocephalus. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Malignant MCA infarction involves cytotoxic and vasogenic edema in &ge;50% of the MCA territory, leading to raised intracranial pressure (ICP) and risk of herniation. Early recognition (within 48 hours) is critical, as maximal swelling peaks at 3&ndash;5 days. Neuroanatomically, the MCA supplies lateral frontal, parietal lobes, and basal ganglia; massive infarction disrupts autoregulation and triggers edema. Decompressive hemicraniectomy creates space for swelling, lowers ICP, and prevents secondary brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours in patients &le;60 years reduces mortality (from ~80% to ~30%) and increases favorable outcomes (modified Rankin Scale &le;3 at 6 months). The DECIMAL (2007), DESTINY (2007) and HAMLET (2009) randomized trials showed absolute mortality reduction of ~50% (NNT\u22482). <span class=\"evidence\">The 2018</span> AHA/ASA guidelines endorse early hemicraniectomy as a Class I, Level A recommendation for malignant MCA infarction in patients 18&ndash;60 years. Waiting for midline shift or trialing only medical therapies delays definitive treatment and worsens outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Osmotic therapy  <br><span class=\"list-item\">\u2022</span> Osmotic agents (mannitol, hypertonic saline) provide transient ICP reduction but do not address mass effect from large infarct.  <br><span class=\"list-item\">\u2022</span> Misconception: medical therapy alone suffices; in malignant edema, surgical decompression is required.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy is indicated for secondary prevention but has no role in managing life-threatening cerebral edema.  <br><span class=\"list-item\">\u2022</span> Differentiator: aspirin cannot reduce established cytotoxic swelling.  <br><br>D. Supportive care and monitoring  <br><span class=\"list-item\">\u2022</span> Monitoring without intervention allows progressive herniation.  <br><span class=\"list-item\">\u2022</span> Key error: malignant MCA infarction demands proactive intervention; supportive care alone is insufficient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hemicraniectomy</th><th>Osmotic Therapy</th><th>Aspirin</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical skull-fenestration to lower ICP</td><td>Osmotic shift of water from brain parenchyma</td><td>Inhibits platelet aggregation</td><td>General ICU support</td></tr><tr><td>Timing</td><td>Within 48 hours of stroke onset</td><td>At any sign of elevated ICP (adjunctive)</td><td>At 24 hours post-thrombolysis</td><td>Continuous</td></tr><tr><td>Mortality Reduction</td><td>~50% absolute</td><td>Transient, minimal impact</td><td>None in edema</td><td>None</td></tr><tr><td>Functional Outcome</td><td>Improved mRS &le;3 at 6 months</td><td>No proven long-term benefit</td><td>No impact on herniation</td><td>No impact</td></tr><tr><td>Indication</td><td>Malignant MCA infarct &ge;50% territory</td><td>Raised ICP without surgical option</td><td>Secondary prevention</td><td>Baseline care only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hemicraniectomy is most effective if performed within 48 hours, ideally before clinical herniation signs.  <br><span class=\"list-item\">\u2022</span> Age <60 years: strongest evidence; DESTINY II (2014) extends benefit to older patients for survival but with higher disability.  <br><span class=\"list-item\">\u2022</span> Infarct extent >50% MCA territory on CT is threshold for &ldquo;malignant&rdquo; classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Waiting for midline shift on imaging before consulting neurosurgery&mdash;delay increases irreversible injury.  <br>2. Relying solely on osmotic diuretics&mdash;fails to address fixed mass; only temporizes ICP.  <br>3. Assuming antiplatelet agents modify edema&mdash;misunderstands pathophysiology of cytotoxic swelling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of AIS: Class I, LOE A recommendation for decompressive hemicraniectomy within 48 hours in patients 18&ndash;60 years with malignant MCA infarction.  <br><span class=\"list-item\">\u2022</span> DESTINY II Trial <span class=\"citation\">(Juttler et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span>: randomized older patients (>60 years) and demonstrated decreased mortality (45% vs 75%, p<0.001) though with greater residual disability; supports expanded surgical criteria (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Malignant MCA infarction and indications for decompressive hemicraniectomy are high-yield topics, frequently tested as scenario-based questions focusing on timing, imaging criteria, and age limits.</div></div></div></div></div>"
  },
  {
    "id": 100022979,
    "question_number": "126",
    "question_text": "A patient experiences symptoms of a transient ischemic attack (TIA) for 10 minutes. Both echocardiogram and Holter monitor results are negative. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Transient ischemic attacks (TIAs) are brief episodes of focal neurological dysfunction without infarction. Key principles:  <br><span class=\"list-item\">\u2022</span> TIA pathophysiology often involves either cardioembolism or large-artery atherosclerosis (e.g., carotid stenosis).  <br><span class=\"list-item\">\u2022</span> After excluding a cardiac source (echocardiogram, Holter), evaluation for extracranial/intracranial stenosis is critical.  <br><span class=\"list-item\">\u2022</span> Rapid vascular imaging (CTA/MRA) identifies high-grade carotid lesions that may benefit from urgent endarterectomy or stenting, reducing early stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neck CTA is the optimal next step because it:  <br>1. Provides high-resolution assessment of both extracranial carotid and vertebral arteries and intracranial vessels.  <br>2. Rapidly detects &ge;50% stenosis where intervention reduces stroke risk (NASCET criteria).  <br>3. Is recommended as first-line vascular imaging in the 2021 AHA/ASA TIA/Stroke guidelines (Class I, LOE A).  <br>Brain MRI, while sensitive for silent infarcts, does not evaluate vessel lumen. Carotid Doppler ultrasound misses high cervical and intracranial lesions and has lower sensitivity (88% vs. 98% for CTA). EEG is irrelevant in suspected ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Brain MRI  <br><span class=\"list-item\">\u2022</span> Incorrect: Does not assess carotid/vertebral artery stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is diagnostic for stroke but not a substitute for vascular imaging in TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI shows tissue changes; CTA shows vessel patency.<br><br>C. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: Limited to extracranial carotids, operator-dependent, can miss high lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Ultrasound is always first&rdquo; &ndash; but CTA offers comprehensive head/neck coverage.  <br><span class=\"list-item\">\u2022</span> Differentiator: Doppler sensitivity ~88% vs. CTA >95% for &ge;70% stenosis.<br><br>D. Electroencephalogram (EEG)  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cortical electrical activity in seizures, not vascular stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: TIA might be seizure &ndash; but the clinical history here is classic ischemic TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG adds no value in TIA workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neck CTA</th><th>Brain MRI</th><th>Carotid Doppler US</th><th>EEG</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Vascular lumen imaging head/neck</td><td>Parenchymal imaging</td><td>Extracranial carotid flow</td><td>Electrical brain activity</td></tr><tr><td>Sensitivity for &ge;70% stenosis</td><td>>95%</td><td>N/A</td><td>~88%</td><td>N/A</td></tr><tr><td>Intracranial vessel assessment</td><td>Yes</td><td>Limited (with MRA only)</td><td>No</td><td>No</td></tr><tr><td>Time to perform</td><td>Minutes (CT suite)</td><td>30&ndash;60 min (MRI suite)</td><td>15&ndash;30 min</td><td>20&ndash;40 min</td></tr><tr><td>Impact on management</td><td>Direct (CEA/stenting decision)</td><td>Diagnostic (stroke vs. TIA)</td><td>Screening</td><td>None for TIA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perform vascular imaging within 24 hours of TIA; identify high-grade stenosis to guide carotid endarterectomy.  <br><span class=\"list-item\">\u2022</span> NASCET criteria (&ge;70% symptomatic stenosis) confer greatest surgical benefit.  <br><span class=\"list-item\">\u2022</span> CTA also detects vessel dissection, a critical TIA mimic requiring different management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on carotid Doppler and missing high cervical/intracranial stenoses.  <br>2. Ordering EEG to &ldquo;rule out seizure&rdquo; in a classic vascular TIA scenario, delaying critical vascular assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guideline for the Prevention of Stroke in Patients With Stroke and TIA: Class I recommendation for CTA/MRA of head and neck in TIA (Level A evidence).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (2022): Strong recommendation for comprehensive vascular imaging (CTA/MRA) within 24 hours of TIA (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Vascular imaging in TIA is a high-yield topic; examinees should distinguish between parenchymal (MRI) and vascular (CTA/MRA) studies and know the urgency of identifying symptomatic carotid stenosis.</div></div></div></div></div>"
  },
  {
    "id": 100022980,
    "question_number": "39",
    "question_text": "A patient with a small left internal capsule infarction and right-sided weakness for 2 days is found to have a patent foramen ovale (PFO) and uncontrolled hypertension. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Lacunar infarcts are small (<15 mm) subcortical strokes, often involving the internal capsule, caused by lipohyalinosis of penetrating arterioles from chronic hypertension. Secondary prevention focuses on aggressive blood pressure control and antithrombotic therapy tailored to stroke subtype. While a PFO can be a source of paradoxical embolism, it is often incidental in the presence of a clear small\u2010vessel etiology. Aspirin monotherapy remains first\u2010line for lacunar stroke, whereas anticoagulation and PFO closure are reserved for confirmed cardioembolic or cryptogenic strokes in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 75&ndash;325 mg daily reduces recurrent non\u2010cardioembolic stroke by \u224822% <span class=\"citation\">(AHA/ASA 2019 Sec Prev Guideline, Class I, LOE A)</span>. The SPS3 trial (2013) randomized 3,020 lacunar stroke patients to aspirin vs. aspirin\u2009+\u2009clopidogrel; dual therapy showed no ischemic benefit and a 50% increase in major hemorrhage. Anticoagulation with warfarin is indicated for atrial fibrillation or venous thromboembolism, not for small\u2010vessel disease. PFO closure trials <span class=\"citation\">(RESPECT 2017, CLOSE 2017)</span> demonstrated benefit only in cryptogenic stroke patients <60 years without alternative risk factors. Here, the lacunar pattern and poorly controlled hypertension point to small\u2010vessel pathology&mdash;aspirin plus tight blood pressure management is optimal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Warfarin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Targets cardioembolic sources; lacunar strokes are non\u2010cardioembolic.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating PFO presence with embolic stroke requiring anticoagulation.  <br><span class=\"list-item\">\u2022</span> Differentiator: No evidence of atrial fibrillation or venous source.<br><br>C. PFO closure  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Benefit shown only in select cryptogenic strokes without other causes.  <br><span class=\"list-item\">\u2022</span> Misconception: Any detected PFO mandates closure.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging shows lacunar infarct consistent with hypertension\u2010related small\u2010vessel disease.<br><br>D. Aspirin and Plavix  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Long\u2010term dual antiplatelet therapy increases bleeding without added efficacy in lacunar stroke (SPS3).  <br><span class=\"list-item\">\u2022</span> Misconception: More intensive antithrombotic therapy always yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: DAPT is limited to &le;21 days post-minor non\u2010cardioembolic stroke (CHANCE/POINT).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin Monotherapy</th><th>Warfarin</th><th>PFO Closure</th><th>Aspirin + Clopidogrel</th></tr></thead><tbody><tr><td>Indication</td><td>Lacunar small\u2010vessel stroke</td><td>Cardioembolic stroke</td><td>Cryptogenic stroke with high\u2010risk PFO</td><td>Minor non\u2010cardioembolic stroke</td></tr><tr><td>Key guideline/trial</td><td>AHA/ASA 2019; SPS3</td><td>AF Guidelines</td><td>RESPECT, CLOSE</td><td>CHANCE, POINT</td></tr><tr><td>Recurrent stroke reduction</td><td>22%</td><td>N/A for lacunes</td><td>Yes, in selected cryptogenic pts</td><td>Short\u2010term benefit only</td></tr><tr><td>Major bleeding risk</td><td>Low</td><td>Moderate&ndash;high</td><td>Procedural/device risk</td><td>High if >21 days</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts: hallmark is pure motor/sensory deficits; aggressive BP control (<130/80 mmHg) is as crucial as antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Short\u2010term DAPT (&le;21 days) reduces early recurrence in minor non\u2010cardioembolic stroke, but long\u2010term use raises hemorrhage risk without extra ischemic protection.  <br><span class=\"list-item\">\u2022</span> PFO closure should be considered only after ruling out conventional etiologies and in patients <60 years with high\u2010risk PFO features (e.g., large shunt, septal aneurysm).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Attributing lacunar strokes to embolism solely because of a PFO, leading to unnecessary anticoagulation or closure.  <br><span class=\"list-item\">\u2022</span> Overprescribing long\u2010term dual antiplatelet therapy for lacunar stroke despite SPS3 evidence against it.  <br><span class=\"list-item\">\u2022</span> Underemphasizing hypertension control, the most potent modifiable risk factor for small\u2010vessel strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Secondary Stroke Prevention <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span>: Aspirin monotherapy recommended for lacunar stroke (Class I, LOE A); BP target <130/80 mmHg (Class I).  <br>2. SPS3 Trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>;382:507&ndash;516)</span>: No benefit of long\u2010term aspirin\u2009+\u2009clopidogrel over aspirin alone; increased major bleeding (HR 1.5).  <br>3. RESPECT Trial <span class=\"citation\">(NEJM 2017;377:1022&ndash;1032)</span>: PFO closure vs. medical therapy in cryptogenic stroke; absolute risk reduction ~1%/year in selected <60 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Board exams frequently test stroke subtype recognition (lacunar vs. cardioembolic), appropriate secondary prevention (antiplatelet vs. anticoagulant), and criteria for PFO closure. Recognizing imaging patterns and risk profiles is high\u2010yield.</div></div></div></div></div>"
  },
  {
    "id": 100022985,
    "question_number": "137",
    "question_text": "Q137. A 68-year-old man awoke with slurred speech and left-sided weakness. Noncontrast head CT shows an acute right hemispheric ischemic stroke. His blood pressure is 170/95 mm Hg. He is not a candidate for thrombolysis given unknown time of onset. What is the best next step for blood pressure control?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Autoregulation of cerebral blood flow maintains perfusion over a range of mean arterial pressures but shifts upward in chronic hypertension.  <br><span class=\"list-item\">\u2022</span> In acute ischemic stroke, elevated BP helps maintain perfusion in the ischemic penumbra (&ldquo;permissive hypertension&rdquo;).  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines recommend treating BP only if systolic >220 mm Hg or diastolic >120 mm Hg in patients not receiving reperfusion therapy.<br><br>(Word count: 84)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct response is &ldquo;No intervention needed.&rdquo; <span class=\"evidence\">Per 2018</span> AHA/ASA Acute Ischemic Stroke Management Guidelines, in patients not eligible for thrombolysis or endovascular therapy, antihypertensive treatment is indicated only if SBP exceeds 220 mm Hg or DBP exceeds 120 mm Hg (Class I; Level of Evidence B-R). Our patient&rsquo;s BP of 170/95 mm Hg supports permissive hypertension to preserve collateral perfusion of the ischemic penumbra. Lowering BP below this threshold risks expansion of infarct size. Large observational studies correlate more aggressive BP lowering in early stroke with larger final infarct volumes. Randomized trials have not demonstrated benefit from early BP reduction in ischemic stroke absent other indications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV Hydralazine  <br><span class=\"list-item\">\u2022</span> Hydralazine causes reflex tachycardia and unpredictable cerebral vasodilation, potentially increasing intracranial pressure.  <br><span class=\"list-item\">\u2022</span> Misconception: Any vasodilator is equally acceptable.  <br><span class=\"list-item\">\u2022</span> Differentiator: Hydralazine is not recommended in acute ischemic stroke due to hemodynamic instability.<br><br>B. IV Labetalol  <br><span class=\"list-item\">\u2022</span> While labetalol is the preferred agent when BP lowering is indicated (e.g., SBP >220 mm Hg), our patient&rsquo;s BP is below the treatment threshold.  <br><span class=\"list-item\">\u2022</span> Misconception: Treat all elevated BPs in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Threshold-based therapy dictates when labetalol is used.<br><br>D. Oral Amlodipine  <br><span class=\"list-item\">\u2022</span> Oral agents have slow onset and lack titratability; not recommended for acute BP control in stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Any antihypertensive method will suffice.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acute management requires IV agents only when necessary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>No Intervention</th><th>IV Labetalol</th><th>IV Hydralazine</th><th>Oral Amlodipine</th></tr></thead><tbody><tr><td>Indication in AIS (no tPA)</td><td>SBP &le;220 mm Hg</td><td>SBP >220 mm Hg</td><td>Rarely used</td><td>Not recommended</td></tr><tr><td>Mechanism</td><td>Permissive hypertension</td><td>&alpha;- and &beta;-blockade</td><td>Direct arteriolar vasodilation</td><td>L-type Ca\u00b2\u207a channel blockade</td></tr><tr><td>Onset of action</td><td>N/A</td><td>2&ndash;5 minutes</td><td>10&ndash;20 minutes</td><td>6&ndash;12 hours</td></tr><tr><td>Evidence/Class of Recommendation</td><td>Class I; maintain BP &le;220/120</td><td>Class I; treat if >220/120</td><td>Not recommended</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Permissive hypertension up to 220/120 mm Hg is protective in acute ischemic stroke by supporting penumbral perfusion.  <br><span class=\"list-item\">\u2022</span> When treating high BP in stroke, IV labetalol or nicardipine are first-line due to rapid onset and titratability.  <br><span class=\"list-item\">\u2022</span> Overaggressive BP lowering can worsen neurological outcomes by reducing collateral blood flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any elevated BP in acute ischemic stroke, ignoring permissive hypertension guidelines.  <br>2. Using oral antihypertensives or hydralazine with unpredictable cerebral hemodynamics instead of recommended IV agents when treatment is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends treating BP only if SBP >220 mm Hg or DBP >120 mm Hg in non-thrombolysis candidates (Class I; Level B-R).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Echoes permissive hypertension strategy; recommends IV labetalol or nicardipine if BP exceeds 220/120 mm Hg (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Blood pressure management in acute ischemic stroke is frequently tested in vignette format, emphasizing permissive hypertension thresholds and choice of IV agents when lowering is required.</div></div></div></div></div>"
  },
  {
    "id": 100022989,
    "question_number": "4",
    "question_text": "A lady on oral contraceptive pills (OCP) presents with seizures and headaches, with a CT scan showing normal results. What is the next step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] &bull; Hypercoagulability and Cerebral Venous Thrombosis (CVT): OCPs increase clotting factors (II, VII, X) and reduce anticoagulants (protein S), predisposing to dural sinus thrombosis.  <br>&bull; Clinical Triad of CVT: headache (often severe), focal neurological deficits or seizures, and signs of intracranial hypertension. A normal non-contrast CT does not exclude CVT in ~30% of cases.  <br>&bull; Imaging Hierarchy: After non-contrast CT, targeted venous imaging (CTV or MR venography) is required to visualize thrombi in dural sinuses.<br><br>(Approx. 100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography directly visualizes dural venous sinuses, detecting filling defects (e.g., &ldquo;empty delta sign&rdquo;) with sensitivity/specificity >\u200995% <span class=\"citation\">(Ferro et al., ISCVT JAMA 2004)</span>. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines recommend CTV or MRV as the diagnostic standard when non-contrast CT is equivocal (Class I, Level B). Early diagnosis allows prompt anticoagulation, improving functional outcomes <span class=\"citation\">(Einh\u00e4upl et al., ESO 2017)</span>. MRI without venography sequences lacks the spatial resolution to reliably detect sinus thrombosis; hence MRI alone is insufficient. EEG evaluates cortical irritability but does not localize venous obstruction. Lumbar puncture risks herniation in raised intracranial pressure and has low yield for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lumbar puncture (LP)  <br><span class=\"list-item\">\u2022</span> Incorrect: LP opening pressure may be elevated but does not visualize thrombi.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all headache/seizure workups require LP.  <br><span class=\"list-item\">\u2022</span> Differentiator: LP cannot confirm CVT and risks herniation if intracranial pressure is raised.<br><br>B. Electroencephalogram (EEG)  <br><span class=\"list-item\">\u2022</span> Incorrect: EEG assesses electrical activity post-seizure but cannot diagnose structural vascular lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Seizures always require EEG before imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG findings (e.g., epileptiform discharges) do not identify venous thrombosis.<br><br>D. Magnetic resonance imaging (MRI)  <br><span class=\"list-item\">\u2022</span> Incorrect: Conventional MRI without MR venography misses up to 25% of dural sinus clots.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is a one-stop modality for all cerebral pathologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: MR venography sequences (MRV) are required; plain MRI lacks venous phase imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venography (CTV)</th><th>Lumbar Puncture (LP)</th><th>EEG</th><th>MRI (non-venographic)</th></tr></thead><tbody><tr><td>Diagnostic Target</td><td>Dural sinus patency</td><td>Opening pressure, CSF</td><td>Cortical electrical activity</td><td>Parenchymal signal changes</td></tr><tr><td>Sensitivity for CVT</td><td>>\u200995%</td><td>Not applicable</td><td>Not applicable</td><td>~\u200975% without MRV sequences</td></tr><tr><td>Risk in raised ICP</td><td>Low</td><td>Herniation risk</td><td>Safe</td><td>Low</td></tr><tr><td>Time to perform (emergent)</td><td>~\u200910&ndash;15 minutes</td><td>~\u200930 minutes</td><td>~\u200960 minutes</td><td>~\u200930&ndash;60 minutes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In OCP users with new-onset headache and seizures, maintain high suspicion for CVT even if non-contrast CT is normal.  <br><span class=\"list-item\">\u2022</span> CTV is rapid, widely available in emergency settings, and nearly equivalent to MRV for CVT detection.  <br><span class=\"list-item\">\u2022</span> After diagnosis, initiate low-molecular-weight heparin promptly, transitioning to warfarin or DOACs for 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on a normal non-contrast CT: up to 30% of CVT cases are radiographically occult without venous imaging.  <br>2. Performing LP before vascular imaging: risks herniation and delays definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2011 Guidelines on CVT: Recommend CTV or MRV for diagnosis after non-contrast CT (Class I, Level B).  <br>&bull; European Stroke Organization (ESO) 2017 Guidelines: Endorse CTV as first-line venous imaging in acute settings (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis commonly affects the superior sagittal sinus, transverse sinuses, and sigmoid sinus, impairing cortical venous drainage and causing parenchymal edema or hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>OCP-induced hypercoagulability leads to thrombus formation in dural venous sinuses, elevating intracranial pressure and provoking venous infarcts, hemorrhages, and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT to exclude hemorrhage.  <br>2. If CT normal/suspicious, perform CTV (or MRV).  <br>3. Confirm CVT \u2192 start anticoagulation.  <br>4. Evaluate for prothrombotic states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>The &ldquo;empty delta sign&rdquo; on contrast-enhanced CTV indicates a filling defect in the superior sagittal sinus. Direct visualization of thrombus via CTV increases diagnostic confidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. CVT often presents on board exams as OCP-associated headache/seizure vignettes requiring knowledge of CTV/MRV diagnostics.</div></div></div></div></div>"
  },
  {
    "id": 100022990,
    "question_number": "30",
    "question_text": "Q30. A 74-year-old male presents with a CT brain image showing a large hemorrhage in the cortex. What is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Spontaneous intracerebral hemorrhage (ICH) may arise from hypertension (deep nuclei) or amyloid angiopathy/vascular malformations (lobar cortex). Non-contrast CT rapidly confirms hemorrhage. Vascular imaging then seeks treatable lesions (e.g., aneurysm, AVM).  <br>Key points:  <br><span class=\"list-item\">\u2022</span> Lobar hemorrhages warrant early angiographic evaluation for macrovascular causes.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) is rapid, noninvasive, and sensitive for aneurysms/AVMs.  <br><span class=\"list-item\">\u2022</span> Digital subtraction angiography (DSA) is gold standard but invasive, reserved when CTA is inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the recommended first-line vascular study in acute lobar ICH. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guideline <span class=\"citation\">(Hemphill et al., Stroke. 2015;46:2032&ndash;2060)</span> gives CTA a Class I, Level B recommendation to identify structural lesions. CTA sensitivity for aneurysms/AVMs approaches 85&ndash;95%, with sub-5-minute acquisition in most centers. CTA also identifies the &ldquo;spot sign,&rdquo; an independent predictor of hematoma expansion <span class=\"citation\">(Delgado Almandoz JO et al., Radiology. 2009;251(1)</span>:206&ndash;213), guiding hemostatic interventions.  <br>Conventional angiography (DSA) is Class IIa, LOE C&mdash;reserved when CTA is nondiagnostic but suspicion remains high. MRI/MRA, while excellent for cavernomas or amyloid microbleeds, has longer acquisition times, limited acute sensitivity for active bleeding, and often is impractical in unstable patients. Observation without vascular imaging risks missing treatable etiologies that alter management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI  <br><span class=\"list-item\">\u2022</span> Incorrect because acute MRI is time-consuming, less reliable for active vessel bleed detection, and less available in unstable ICH patients.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is always superior for brain pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA provides vascular detail in minutes.<br><br>C. Conventional angiography  <br><span class=\"list-item\">\u2022</span> Incorrect as initial test due to invasiveness, higher complication risk (stroke, groin hematoma), and longer procedure time.  <br><span class=\"list-item\">\u2022</span> Misconception: DSA should always precede noninvasive studies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Reserve DSA for CTA-negative cases with ongoing suspicion.<br><br>D. Observation  <br><span class=\"list-item\">\u2022</span> Incorrect because delaying vascular imaging may miss aneurysms/AVMs amenable to intervention, worsening outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Small or lobar bleeds in the elderly rarely have structural causes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Early CTA changes management by identifying treatable lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Sensitivity for Vascular Lesions</th><th>Invasiveness</th><th>Acquisition Time</th><th>Role in ICH Workup</th></tr></thead><tbody><tr><td>CTA</td><td>~85&ndash;95% for AVM/aneurysm</td><td>Low</td><td>~5 minutes</td><td>First-line vascular imaging</td></tr><tr><td>MRI/MRA</td><td>Moderate for cavernoma, amyloid</td><td>Low</td><td>30&ndash;60 minutes</td><td>Adjunct for microbleeds/cavernomas if stable</td></tr><tr><td>DSA (Conventional angio)</td><td>~98%</td><td>High</td><td>1&ndash;2 hours</td><td>Confirmatory when CTA negative but suspicion persists</td></tr><tr><td>Observation</td><td>N/A</td><td>None</td><td>N/A</td><td>Inappropriate without vascular evaluation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In lobar ICH without clear hypertension history, always obtain CTA to exclude macrovascular lesions.  <br><span class=\"list-item\">\u2022</span> The CTA &ldquo;spot sign&rdquo; predicts hematoma expansion (OR 4.5), prompting aggressive blood pressure and coagulopathy management.  <br><span class=\"list-item\">\u2022</span> In renal impairment, use low-osmolar contrast and pre-hydrate; benefits of detecting treatable lesions often outweigh nephrotoxicity risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MRI is the acute vascular study of choice&mdash;delay in diagnosis and management can occur.  <br>2. Believing that deep hypertensive bleeds never warrant vascular imaging&mdash;atypical presentations (e.g., younger age, lobar location) require CTA.  <br>3. Omitting CTA in elderly lobar hemorrhages, attributing all to amyloid angiopathy without ruling out AVM or aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) Guidelines, 2015: Recommends CTA in acute lobar ICH to identify structural lesions (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) Guidelines, 2019: Endorses early CTA for spontaneous lobar ICH to exclude macrovascular causes (Grade A recommendation).  <br><span class=\"list-item\">\u2022</span> Delgado Almandoz JO et al., Radiology. 2009: Prospective cohort demonstrating CTA &ldquo;spot sign&rdquo; predicts hematoma expansion (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular imaging in ICH&mdash;especially the role and timing of CTA versus DSA&mdash;is a high-yield topic, frequently tested as image-based vignettes and single-best-answer questions on neurology and stroke boards.</div></div></div></div></div>"
  },
  {
    "id": 100022991,
    "question_number": "141",
    "question_text": "A 36-year-old male sustained a motor vehicle accident and presented with acute blurred vision. Examination shows right homonymous hemianopia. His brain CT revealed left occipital acute infarction. What could explain the stroke mechanism in this case?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Stroke classification (TOAST) divides ischemic stroke by mechanism: large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined, and undetermined. Occipital lobe infarcts produce contralateral homonymous hemianopia. In a young trauma patient, consider vascular injury (dissection) leading to thrombus formation and distal embolization. Dissections most often involve the carotid or vertebral arteries after neck trauma, creating an intimal flap and intramural hematoma that can shed emboli into cerebral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery-to-artery embolism is correct: motor vehicle collisions commonly cause cervical artery dissection. An intimal tear in the vertebral or carotid artery produces an intramural thrombus, which embolizes distally to occlude cortical branches of the posterior cerebral artery, resulting in occipital infarction and homonymous hemianopia. A meta-analysis <span class=\"citation\">(Debette et al., <span class=\"evidence\">Neurology 2015</span>)</span> showed 85% of traumatic dissections present with embolic strokes. AHA/ASA 2018 guidelines recommend vascular imaging (CTA/MRA) in suspected dissections and antithrombotic therapy to prevent recurrent embolism (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Large vessel atherosclerosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Usually chronic plaque in older patients; acute trauma does not induce rapid atherosclerotic plaque rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating dissection with atherosclerotic plaque disease.  <br><br>C. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Incorrect: No evidence of arrhythmia, intracardiac thrombus, or valvular disease; mechanism here is arterial wall injury, not cardiac source.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cortical strokes to the heart without vascular imaging.  <br><br>D. Small vessel disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes lacunar infarcts in deep structures (basal ganglia, pons), not large cortical occipital infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Overextending lacunar syndromes to cortical deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-Artery Embolism</th><th>Large Vessel Atherosclerosis</th><th>Cardioembolic</th><th>Small Vessel Disease</th></tr></thead><tbody><tr><td>Typical Age</td><td>Young (20&ndash;50) post-trauma</td><td>Older (>60)</td><td>Middle&ndash;elderly (>50)</td><td>Middle&ndash;elderly (>50)</td></tr><tr><td>Imaging Findings</td><td>Cortical infarcts</td><td>Cortical/subcortical border-zone infarcts</td><td>Cortical, multiple territories</td><td>Lacunes (<15 mm) in deep nuclei</td></tr><tr><td>Vascular Pathology</td><td>Dissection \u2192 thrombus</td><td>Atherosclerotic plaque</td><td>Cardiac thrombus</td><td>Lipohyalinosis</td></tr><tr><td>Mechanism</td><td>Embolism from injured artery</td><td>In situ thrombosis</td><td>Embolism from heart</td><td>Occlusion of small penetrating arterioles</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In trauma patients with focal deficits, always suspect cervical artery dissection and obtain CTA/MRA of head and neck.  <br>2. Occipital lobe strokes manifest as contralateral homonymous hemianopia, often with macular sparing due to dual occipital supply.  <br>3. First-line treatment for cervical artery dissection is antithrombotic therapy (aspirin or anticoagulation), individualized by bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming trauma must cause hemorrhage; arterial dissections can lead to ischemic stroke without hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misidentifying cortical homonymous deficits as occipital migraines or seizure phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 \"Guidelines for Early Management of Patients With Acute Ischemic Stroke\"  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform CTA/MRA in suspected cervical dissection (Class I, Level B).  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurology 2015</span>)</span>  <br><span class=\"list-item\">\u2022</span> Found no significant difference in recurrent stroke between antiplatelet and anticoagulant therapy in cervical artery dissection (Level of Evidence A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior cerebral artery (PCA), a branch of the vertebrobasilar system, supplies the occipital cortex. Emboli lodging in PCA branches produce contralateral visual field deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Trauma \u2192 intimal tear in cervical artery \u2192 intramural hematoma \u2192 luminal stenosis and platelet aggregation \u2192 distal artery-to-artery emboli \u2192 cortical infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in trauma with focal deficits.  <br>2. Obtain CTA or MRA of head/neck.  <br>3. Identify vessel wall irregularity, &ldquo;string sign,&rdquo; or intramural hematoma.  <br>4. Initiate antithrombotic therapy.  <br>5. Follow-up imaging at 3&ndash;6 months to ensure vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may miss early infarction; diffusion-weighted MRI is more sensitive.  <br><span class=\"list-item\">\u2022</span> CTA/MRA can detect vessel wall hematoma and flap; digital subtraction angiography remains gold standard but is invasive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin 75&ndash;325 mg daily is first-line for dissection (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> Consider anticoagulation (e.g., heparin to warfarin) in select cases based on CADISS trial data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. It exemplifies classic testing on trauma-related arterial dissection, emphasizing TOAST classification and vascular imaging in young stroke patients.</div></div></div></div></div>"
  },
  {
    "id": 100022994,
    "question_number": "136",
    "question_text": "A 61-year-old female presented with sudden severe headache, worsened with double vision. Examination shows a 6 mm right pupil that is non-reactive to light. Which artery is likely affected?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] 1. Oculomotor (III) nerve anatomy: motor fibers (medial) and parasympathetic fibers (superficial) travel together; compressive lesions selectively impair peripheral parasympathetic fibers first, causing pupil dilation.  <br>2. Aneurysmal subarachnoid hemorrhage classically presents with &ldquo;thunderclap&rdquo; headache (&ldquo;worst headache of life&rdquo;) and may produce acute cranial nerve palsies via mass effect.  <br>3. The posterior communicating artery (PCom) arises from the internal carotid and lies adjacent to CN III; aneurysms here compress the nerve and cause an ipsilateral dilated, non-reactive pupil.  <br>(Word count: 102)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms account for up to 50% of internal carotid aneurysms presenting with oculomotor palsy. The peripheral location of parasympathetic fibers makes them more vulnerable to compression; this explains the early pupillary involvement seen here. Aneurysm rupture into the subarachnoid space produces a sudden, severe headache <span class=\"citation\">(AHA/ASA 2022 guidelines recommend emergent non-contrast CT followed by CT angiography [Class I, Level B])</span>. Early diagnosis and microsurgical clipping or endovascular coiling reduce rebleeding risk <span class=\"citation\">(ISAT trial 2005; long-term follow-up in Lancet <span class=\"evidence\">Neurology 2023</span> confirms coiling superiority in suitable PCom aneurysms)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anterior communicating artery  <br><span class=\"list-item\">\u2022</span> Incorrect: ACom aneurysms predominantly impinge on the optic chiasm or frontal lobes, causing visual field deficits or personality changes, not CN III palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing location near optic apparatus with oculomotor nerve anatomy.  <br><span class=\"list-item\">\u2022</span> Differentiation: ACom lesions rarely present with isolated third nerve signs.  <br><br>C. Superior cerebellar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: SCA arises from the basilar artery near CN III exit but aneurysms here rarely compress the nerve; patients develop ataxia or cerebellar signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Any posterior circulation aneurysm can involve CN III.  <br><span class=\"list-item\">\u2022</span> Differentiation: SCA aneurysms more often cause cerebellar dysfunction and headache without isolated pupillary dilation.  <br><br>D. Internal carotid artery dissection  <br><span class=\"list-item\">\u2022</span> Incorrect: Dissection causes ipsilateral Horner syndrome (miosis, ptosis), not dilated pupil.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing sudden headache + oculomotor signs to any ICA pathology.  <br><span class=\"list-item\">\u2022</span> Differentiation: In dissection the pupil is constricted due to sympathetic chain disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCom Aneurysm (Correct)</th><th>ACom Aneurysm</th><th>SCA Aneurysm</th><th>ICA Dissection</th></tr></thead><tbody><tr><td>Location</td><td>ICA&ndash;PCom junction</td><td>ACom (between ACAs)</td><td>Basilar&ndash;SCA junction</td><td>Cervical ICA</td></tr><tr><td>Cranial nerve III involvement</td><td>Yes (pupil dilatation + palsy)</td><td>No</td><td>Rare</td><td>No (Horner syndrome)</td></tr><tr><td>Headache</td><td>Thunderclap, SAH</td><td>SAH</td><td>SAH or focal headache</td><td>Neck pain, headache</td></tr><tr><td>Other signs</td><td>Ptosis, &ldquo;down and out&rdquo; eye</td><td>Visual field cuts, memory loss</td><td>Ataxia, dysmetria</td><td>Ptosis with miosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Compressive III palsy (aneurysm/tumor) = pupil involvement; ischemic (diabetic) III palsy = pupil-sparing.  <br><span class=\"list-item\">\u2022</span> In acute pupil-involving CN III palsy, obtain non-contrast CT &plusmn; CTA emergently to exclude PCom aneurysm.  <br><span class=\"list-item\">\u2022</span> Nimodipine improves outcome in aneurysmal SAH by reducing vasospasm <span class=\"citation\">(AHA/ASA 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing miosis of Horner syndrome (ICA dissection) with dilated pupil in III palsy.  <br>2. Assuming all posterior circulation aneurysms (e.g., SCA, PCA) equally cause oculomotor palsy&mdash;only PCom lies in direct contact with CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 Guideline for Management of Aneurysmal Subarachnoid Hemorrhage  <br>   \u00ad&ndash; Recommendation: Non-contrast CT followed by CTA or DSA in any suspected aneurysmal SAH with cranial nerve palsy (Class I, Level B).  <br>2. International Subarachnoid Aneurysm Trial (ISAT) long-term follow-up, Lancet <span class=\"evidence\">Neurol 2023</span>  <br>   \u00ad&ndash; Finding: Endovascular coiling of PCom aneurysms reduces 5-year morbidity compared to clipping in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculomotor nerve exits the midbrain medial to the superior cerebellar artery and lateral to the PCA, then courses between the PCA and superior cerebellar artery before running adjacent to the PCom; superficial parasympathetic fibers on the nerve&rsquo;s periphery mediate pupillary constriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysmal dilation at the PCom segment exerts mass effect on the adjacent oculomotor nerve, compressing peripheral parasympathetic fibers first (causing mydriasis) and then motor fibers (ptosis, &ldquo;down and out&rdquo; deviation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical identification of pupil-involving CN III palsy + thunderclap headache  <br>2. Immediate non-contrast head CT to detect SAH  <br>3. CT angiography for aneurysm localization  <br>4. Digital subtraction angiography if CTA equivocal  <br>5. Neurosurgical consultation for clipping vs endovascular coiling</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT\u2009angiography >95% sensitive for aneurysms >3 mm.  <br><span class=\"list-item\">\u2022</span> &ldquo;Fusiform dilation&rdquo; at the ICA&ndash;PCom junction on CTA is pathognomonic.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for small aneurysms and surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine 60 mg orally every 4 hours for 21 days post-SAH to prevent vasospasm.  <br><span class=\"list-item\">\u2022</span> Blood pressure control: systolic 120&ndash;160 mm Hg, avoid hypotension.  <br><span class=\"list-item\">\u2022</span> Analgesia with acetaminophen; avoid NSAIDs to reduce bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. On neurology board exams, pupil-involving third nerve palsy with &ldquo;thunderclap&rdquo; headache is a classic vignette for PCom aneurysm; students should rapidly differentiate compressive vs ischemic etiologies and know emergent imaging steps.</div></div></div></div></div>"
  },
  {
    "id": 100022997,
    "question_number": "34",
    "question_text": "A brain MRI shows unilateral watershed infarction. What is the likely mechanism?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Watershed (border-zone) infarctions occur at junctions between major cerebral artery territories (most often ACA-MCA or MCA-PCA). These distal arterioles rely on adequate perfusion pressure and are most vulnerable when systemic or regional blood flow falls. Imaging shows wedge-shaped or linear DWI hyperintensities parallel to the cortical surface. Unilateral watershed patterns typically reflect focal hypoperfusion rather than embolic occlusion. Key terms: perfusion pressure, collateral circulation, hemodynamic stroke. Differentiating hemodynamic from embolic patterns is critical for targeted workup and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypoperfusion is the direct pathophysiologic mechanism in watershed infarcts. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke classify border-zone infarctions under hemodynamic strokes due to reduced perfusion pressure (Class IIa, Level B-R). Bang et al. <span class=\"citation\">(Stroke.2011;42:391-397)</span> demonstrated that patients with &ge;70% ipsilateral ICA stenosis displayed ACA-MCA watershed infarcts on MRI, correlated with prolonged time-to-peak on CT perfusion. Distal arterioles in these zones have limited collateral support; when systemic blood pressure or carotid inflow drops below autoregulatory thresholds, cytotoxic edema ensues, seen as DWI hyperintensity. Thus, hypoperfusion&mdash;often secondary to large-artery stenosis&mdash;is the immediate mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Internal carotid artery (ICA) stenosis  <br>&ndash; Incorrect because stenosis is an underlying etiology, not the direct mechanism.  <br>&ndash; Misconception: equating cause with mechanism.  <br>&ndash; Differentiator: steno\u00adsis leads to hypoperfusion; the mechanism is reduced cerebral blood flow.  <br><br>B. Cardiac embolism  <br>&ndash; Emboli lodge in cortical branch arteries causing territorial infarcts, not border-zone patterns.  <br>&ndash; Misconception: assuming all cortical infarcts are embolic.  <br>&ndash; Differentiator: embolic strokes produce wedge-shaped territorial lesions with abrupt diffusion/ADC changes.  <br><br>D. Venous thrombosis  <br>&ndash; Venous outflow obstruction causes hemorrhagic infarcts with vasogenic edema, often in deep or cortical veins.  <br>&ndash; Misconception: conflating venous infarcts with arterial border-zone strokes.  <br>&ndash; Differentiator: venous infarcts show mixed signal on T1/T2 with possible hemorrhage, not pure DWI wedge shapes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hypoperfusion</th><th>ICA Stenosis</th><th>Cardiac Embolism</th><th>Venous Thrombosis</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>\u2193 Perfusion pressure</td><td>Atherosclerotic narrowing</td><td>Embolic arterial occlusion</td><td>Impaired venous drainage</td></tr><tr><td>MRI DWI Pattern</td><td>Border-zone wedge/linear</td><td>May show border-zone if severe</td><td>Territorial cortical infarct</td><td>Hemorrhagic, ill-defined</td></tr><tr><td>Collateral Dependence</td><td>High in distal arterioles</td><td>Variable based on Circle of Willis</td><td>Not relevant</td><td>Not relevant</td></tr><tr><td>Acute Perfusion Imaging</td><td>Delayed time-to-peak</td><td>Prolonged in ipsilateral hemisphere</td><td>Focal perfusion deficit</td><td>Mixed arterial/venous flow</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute watershed infarcts, avoid aggressive antihypertensive therapy to preserve collateral perfusion.  <br><span class=\"list-item\">\u2022</span> Carotid duplex ultrasound is first-line to detect high-grade ICA stenosis in suspected hemodynamic strokes.  <br><span class=\"list-item\">\u2022</span> CT/MR perfusion imaging differentiates hypoperfusion from embolic penumbra, guiding revascularization decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking cortical watershed infarcts for lacunar strokes; lacunes are small (<15 mm), subcortical, due to small-vessel lipohyalinosis.  <br>2. Attributing all cortical infarctions to embolism without assessing hemodynamic factors like carotid stenosis or systemic hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guideline on Early Management of Acute Ischemic Stroke: Recommends carotid endarterectomy for symptomatic 70&ndash;99% ICA stenosis to prevent recurrent hemodynamic strokes (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guideline: Advocates routine perfusion imaging in acute stroke to distinguish hemodynamic from embolic mechanisms, optimizing reperfusion strategies (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie at the distal territories of ACA-MCA (anterior border zone, &ldquo;V&rdquo;-shaped along the convexity) and MCA-PCA (posterior border zone, occipital\u2010parietal junction). These regions have the lowest perfusion reserve and are first to infarct when cerebral perfusion pressure falls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Reduced perfusion pressure&mdash;due to systemic hypotension or proximal arterial stenosis&mdash;drops below autoregulatory capacity in distal arterioles. Oxygen deprivation triggers failure of ion pumps, leading to cytotoxic edema and infarction in border-zone territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI with DWI/ADC to confirm watershed pattern.  <br>2. CT/MR perfusion imaging to quantify cerebral blood flow/volume and mean transit time.  <br>3. Carotid duplex ultrasound or CT angiography for ICA stenosis.  <br>4. Echocardiography and ECG to exclude cardioembolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: Wedge-shaped hyperintensities parallel to cortical surface in border zones.  <br><span class=\"list-item\">\u2022</span> MR angiography/CTA: Identifies high-grade carotid stenosis or occlusion.  <br><span class=\"list-item\">\u2022</span> Perfusion maps: Show prolonged time-to-peak and decreased cerebral blood flow in affected regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Watershed infarction patterns are frequently tested to assess differentiation between hemodynamic and embolic stroke mechanisms; examine imaging distribution and clinical context to select the appropriate pathophysiologic explanation.</div></div></div></div></div>"
  },
  {
    "id": 100022998,
    "question_number": "31",
    "question_text": "A lady with a two-day history of malignant left middle cerebral artery (MCA) stroke and midline shift (CT was attached) was transferred from another hospital. What will you do for her?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Malignant MCA infarction involves extensive cortical and subcortical ischemia leading to cytotoxic and vasogenic edema that peaks 48&ndash;72 h after onset. Because the skull is a fixed volume (Monro-Kellie doctrine), this edema causes intracranial hypertension, midline shift, and risk of transtentorial herniation. Decompressive hemicraniectomy (DHC) removes a large bone flap and opens the dura to accommodate swollen brain tissue, rapidly lowering intracranial pressure (ICP) and preventing secondary ischemic injury. Key concepts: 1) Pathophysiology of cytotoxic vs vasogenic edema; 2) ICP dynamics and herniation syndromes; 3) Time-dependent intervention within 48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 h for malignant MCA infarction in patients &le;60 years reduces 12-month mortality from ~80 % to ~30&ndash;40 % and increases chances of favorable functional outcome (mRS 0&ndash;4). This is supported by three randomized controlled trials&mdash;DECIMAL (2007), DESTINY (2007), HAMLET (2009)&mdash;and a pooled meta-analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2009</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines give DHC a Class I, Level A recommendation for these patients. By providing immediate relief of ICP, DHC preserves cerebral perfusion and prevents fatal herniation, benefits not matched by medical therapy alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Medical management with osmotic agents  <br>  &bull; Only provides transient ICP reduction, without expanding intracranial volume capacity.  <br>  &bull; Common misconception: osmotherapy suffices to manage malignant edema.  <br>  &bull; Does not lower mortality or improve functional outcomes significantly.<br><br>C. Anticoagulation therapy  <br>  &bull; High risk of hemorrhagic transformation in large infarcts; no role in acute malignant MCA.  <br>  &bull; Misconception: extending cardioembolic stroke protocols to massive infarctions.  <br>  &bull; Fails to address life-threatening mass effect.<br><br>D. Thrombolysis  <br>  &bull; Therapeutic window is &le;4.5 h; at 48 h post-stroke, tPA is contraindicated.  <br>  &bull; Misconception: tPA can reverse established edema.  <br>  &bull; Does not mitigate cytotoxic and vasogenic edema once infarction is completed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Timing Window</th><th>Mortality Benefit</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Decompressive hemicraniectomy</td><td>Surgical decompression \u2193ICP</td><td>&le;48 h</td><td>\u2193Mortality by ~50 %</td><td>Class I, Level A</td></tr><tr><td>Osmotic agents (mannitol/hypertonic)</td><td>Osmotic dehydration</td><td>Any</td><td>No significant mortality \u2193</td><td>Class IIb, Level C</td></tr><tr><td>Anticoagulation (heparin/warfarin)</td><td>Thrombosis prevention</td><td>Acute</td><td>\u2191Hemorrhage risk</td><td>Not recommended</td></tr><tr><td>Thrombolysis (tPA)</td><td>Fibrinolysis</td><td>&le;4.5 h</td><td>\u2193Disability in small strokes</td><td>Class I, Level A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate neurosurgical consultation within 24 h in suspected malignant MCA infarction.  <br><span class=\"list-item\">\u2022</span> DHC offers greatest benefit in patients &le;60 years; DESTINY II supports selective use in older patients.  <br><span class=\"list-item\">\u2022</span> A bone flap &ge;12 cm with duraplasty maximizes decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Waiting for clinical deterioration rather than acting on imaging-based criteria may miss the surgical window.  <br><span class=\"list-item\">\u2022</span> Overreliance on hyperosmolar therapy can delay definitive treatment.  <br><span class=\"list-item\">\u2022</span> Misapplication of thrombolysis or anticoagulation beyond approved time windows in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class I, Level A recommendation for DHC in malignant MCA infarction &le;48 h in patients &le;60 years.  <br>2. DESTINY II Trial (2019): Demonstrated mortality reduction with DHC in patients >60 years, supporting Class IIa, Level B recommendation for selected older adults.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Malignant MCA infarction and indication/timing for decompressive hemicraniectomy are frequently tested as single-best-answer items, often incorporating patient age, imaging criteria, and outcome data.</div></div></div></div></div>"
  },
  {
    "id": 100022999,
    "question_number": "63",
    "question_text": "For patients with intracerebral hemorrhage (ICH) whose INR is elevated because of vitamin K antagonists (VKAs), what should be done?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; Intracerebral hemorrhage (ICH) involves bleeding into brain parenchyma, causing mass effect, tissue injury, and perihematomal edema.  <br>&bull; VKAs (e.g., warfarin) inhibit vitamin K epoxide reductase, reducing &gamma;-carboxylation of clotting factors II, VII, IX, and X, thereby elevating INR and exacerbating bleeding.  <br>&bull; Rapid normalization of INR is critical to limit hematoma expansion and improve outcomes; this requires both vitamin K (to restore endogenous factor synthesis) and factor replacement (PCC preferred).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because withholding the VKA and administering vitamin K addresses the root cause (vitamin K&ndash;dependent factor deficiency) and begins synthesis of new clotting factors within hours. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, Level A) mandate immediate reversal of VKA-associated coagulopathy with IV vitamin K (5&ndash;10 mg) plus four-factor PCC. Trials such as Sarode et al. <span class=\"citation\">(NEJM 2013)</span> demonstrated that four-factor PCC normalizes INR in a median of 30 minutes in 70% of patients versus 10% with FFP (p<0.001), reducing hematoma growth without increased thrombosis. Neither rFVIIa (off-label, high thrombosis risk, no functional benefit) nor FFP alone (slow infusion, large volume, delayed INR correction) substitute for targeted vitamin K&ndash;mediated factor regeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Continue VKA therapy  <br>&bull; Incorrect: perpetuates coagulopathy, risking hematoma expansion.  <br>&bull; Misconception: maintaining anticoagulation for stroke prevention outweighs acute hemorrhage risk.  <br>&bull; Differentiator: acute ICH management prioritizes hemostasis over long-term anticoagulation.<br><br>C. Administer rFVIIa  <br>&bull; Incorrect: rFVIIa can transiently correct INR but has no proven outcome benefit in ICH and carries a high arterial and venous thrombosis risk (up to 10%).  <br>&bull; Misconception: any factor concentrate is equally safe/effective.  <br>&bull; Differentiator: rFVIIa lacks vitamin K&ndash;dependent factor support and is not guideline-endorsed for VKA reversal in ICH.<br><br>D. Administer fresh frozen plasma  <br>&bull; Incorrect as sole therapy: FFP requires blood typing, thawing, and large volumes (\u224815 mL/kg), delaying reversal; slower INR correction compared to PCC.  <br>&bull; Misconception: FFP is first-line when PCC is unavailable.  <br>&bull; Differentiator: FFP is a backup when PCC is unavailable; vitamin K remains mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vitamin K (withhold VKA)</th><th>Continue VKA</th><th>rFVIIa</th><th>FFP</th></tr></thead><tbody><tr><td>INR Correction Onset</td><td>6&ndash;12 h (endogenous)</td><td>None</td><td>Immediate, short-lived</td><td>4&ndash;6 h (volume-dependent)</td></tr><tr><td>Hematoma Expansion Risk</td><td>\u2193</td><td>\u2191</td><td>\u2194/\u2191 (thrombosis)</td><td>\u2193 (slower than PCC)</td></tr><tr><td>Volume Requirement</td><td>Minimal</td><td>N/A</td><td>Minimal</td><td>High (\u224815 mL/kg)</td></tr><tr><td>Thrombosis Risk</td><td>Low</td><td>N/A</td><td>High</td><td>Moderate</td></tr><tr><td>Guideline Endorsement (ICH)</td><td>I (Class I, LOE A)</td><td>Contraindicated</td><td>IIb/C</td><td>IIb/C</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In warfarin-related ICH, always co-administer IV vitamin K with factor replacement (PCC preferred).  <br>&bull; Four-factor PCC achieves INR <1.4 within 30 minutes in most patients; FFP is only if PCC is unavailable.  <br>&bull; Subcutaneous vitamin K is too slow; always use the IV route (5&ndash;10 mg) for acute ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on FFP delays INR normalization and risks volume overload in older or heart-failure patients.  <br>2. Assuming rFVIIa is safer than PCC; it increases arterial thromboses without improving neurologic outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA ICH <span class=\"evidence\">Guidelines 2015</span>: &ldquo;IV vitamin K (5&ndash;10 mg) plus four-factor PCC for VKA reversal in ICH&rdquo; (Class I, LOE A).  <br>&bull; Sarode R. et al., NEJM 2013: Four-factor PCC achieved rapid INR reversal (median 30 min vs 4 h with FFP; p<0.001) with fewer transfusion complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin blocks vitamin K epoxide reductase \u2192 insufficient &gamma;-carboxylation of clotting factors II, VII, IX, X \u2192 impaired prothrombin activation \u2192 prolonged INR \u2192 unchecked bleeding in ruptured cerebral vessels \u2192 hematoma growth exacerbates intracranial pressure and secondary injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Vitamin K (IV 5&ndash;10 mg): restores &gamma;-carboxylation of vitamin K&ndash;dependent factors over 6&ndash;12 h.  <br>&bull; Four-factor PCC (25&ndash;50 IU/kg): provides immediate clotting factors II, VII, IX, X; normalizes INR within 30 min.  <br>&bull; FFP (15 mL/kg): slower INR correction, requires thawing and blood-type matching.  <br>&bull; rFVIIa: generates thrombin burst locally but lacks sustained factor support; off-label in ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Warfarin reversal in ICH is a high-yield topic, frequently tested as a single best-answer scenario on acute stroke management.</div></div></div></div></div>"
  },
  {
    "id": 100023002,
    "question_number": "147",
    "question_text": "An 82-year-old female with a history of diabetes, hypertension, and dyslipidemia presents with sudden left gaze preference and aphasia. Her basic labs are fine. She has no contraindications for a brain CT. What is the time from symptom onset to ER arrival?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Acute ischemic stroke involving the middle cerebral artery (MCA) often produces conjugate gaze deviation toward the lesion side (due to frontal eye field involvement) and dominant\u2010hemisphere aphasia. Rapid reperfusion within the hyperacute window minimizes infarct core growth and maximizes penumbral salvage. Key time metrics include:  <br>&bull; Onset\u2010to\u2010door (prehospital delay)  <br>&bull; Door\u2010to\u2010CT (target <25 min)  <br>&bull; Door\u2010to\u2010needle for IV alteplase (target <60 min)  <br>Onset\u2010to\u2010door time informs eligibility for IV thrombolysis (within 4.5 h) and endovascular therapy (up to 24 h in selected cases). In this patient, calculating the precise onset\u2010to\u2010door interval is critical for timely management and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 60 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect because it reflects the recommended door-to-needle interval for IV alteplase, not the prehospital onset-to-door time.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating in-hospital process targets with prehospital delay.  <br><span class=\"list-item\">\u2022</span> Differentiator: this patient arrived in half that time, allowing extra margin for imaging and laboratory confirmation.<br><br>C. 90 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect: overestimates prehospital delay, underappreciating exponential infarct core expansion beyond the hyperacute window.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming average EMS transport times rather than actual witnessed arrival.  <br><span class=\"list-item\">\u2022</span> Differentiator: at 90 min, penumbral salvage declines by ~25% compared with 30 min.<br><br>D. 120 minutes  <br><span class=\"list-item\">\u2022</span> Incorrect: far exceeds hyperacute onset-to-door ideal, reflecting a 2-hour delay that would markedly reduce thrombolysis benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing extended mechanical thrombectomy windows (6&ndash;24 h) with onset-to-door metrics.  <br><span class=\"list-item\">\u2022</span> Differentiator: this patient was in the ED within 30 min, enabling rapid CT and reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Onset-to-Door Interval</th><th>Classification</th><th>Impact on Reperfusion Efficacy</th></tr></thead><tbody><tr><td>A. 30 min [CORRECT]</td><td>30 min</td><td>Hyperacute (<1 h)</td><td>Maximal penumbra salvage; ideal for tPA</td></tr><tr><td>B. 60 min</td><td>60 min</td><td>Early acute (1 h)</td><td>Good salvage; meets door-to-needle target</td></tr><tr><td>C. 90 min</td><td>90 min</td><td>Early acute (1&ndash;3 h)</td><td>Reduced salvage; ongoing core growth</td></tr><tr><td>D. 120 min</td><td>120 min</td><td>Early acute (2&ndash;4.5 h)</td><td>Significantly reduced benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Every minute of large\u2010vessel occlusion costs ~1.9 million neurons &ndash; &ldquo;time is brain&rdquo; underscores urgency.  <br>&bull; Prehospital stroke protocols with EMS prenotification can reduce onset-to-door by 10&ndash;15 minutes.  <br>&bull; \ubaa9\ud45c door-to-CT is <25 minutes and door-to-needle for IV alteplase is <60 minutes <span class=\"citation\">(AHA/ASA 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Students often mix up onset-to-door (prehospital) with door-to-needle (in-hospital) time targets, leading to miscalculated eligibility windows.  <br>&bull; Overreliance on average EMS transport times can obscure the actual witness of symptom onset and arrival times.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers WJ et al., <span class=\"evidence\">Stroke 2021</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Class I, Level A: Document precise time of symptom onset and onset-to-door interval; target door-to-CT &le;25 min and door-to-needle &le;60 min.  <br>2. ESO Guidelines on Acute Stroke Management <span class=\"citation\">(Campbell BCV et al., Eur Stroke J 2021)</span>:  <br><span class=\"list-item\">\u2022</span> Level B: Recommend mobile stroke units with onboard CT to reduce onset-to-treatment times by ~30 min, improving 90-day functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Time\u2010based metrics in acute ischemic stroke (onset-to-door, door-to-CT, door-to-needle) are high\u2010yield and frequently tested in neurology board exams, often presented as hyperacute stroke vignettes requiring recall of specific minute targets. This question appeared in Part I 2022 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. 30 minutes. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023005,
    "question_number": "42",
    "question_text": "A scenario of an 82-year-old lady with ischemic stroke presented within 1 hour and has no contraindications. What is the appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute ischemic stroke arises from an arterial occlusion that deprives brain tissue of oxygen, creating an ischemic core and surrounding penumbra. Rapid reperfusion of the penumbra is critical to salvage viable tissue. Intravenous thrombolysis with tissue plasminogen activator (tPA) targets fibrin clots, restoring perfusion if administered within a 4.5-hour window. Key prerequisites include noncontrast head CT to exclude hemorrhage, assessment of contraindications (e.g., recent surgery, bleeding diathesis), and stabilization of blood pressure (&le;185/110 mm Hg).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA (alteplase) is the only FDA-approved pharmacologic reperfusion therapy for acute ischemic stroke within 4.5 hours of onset. The landmark NINDS trial (1995) demonstrated a 30% relative increase in favorable outcomes at 3 months <span class=\"citation\">(NINDS tPA Study Group, 1995; level I evidence)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA guideline update reconfirms IV alteplase as first-line reperfusion in eligible patients presenting within 4.5 hours <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>. Later trials (EXTEND, WAKE-UP) have explored extended windows with perfusion imaging, but standard practice remains administration as soon as possible. Age >80 years alone is not a contraindication (ECASS III subgroup analysis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Incorrect because antiplatelet therapy reduces recurrence risk but does not acutely lyse clot.  <br>&bull; Misconception: equating antiplatelet effect with thrombolysis.  <br>&bull; Differentiator: aspirin onset is slower, not reperfusion therapy.<br><br>C. Mechanical thrombectomy  <br>&bull; While indicated for large-vessel occlusions up to 24 hours, it is used adjunctively after IV tPA or when tPA is contraindicated and after vascular imaging confirmation.  <br>&bull; Misconception: mechanical removal replaces pharmacologic therapy in all eligible patients.  <br>&bull; Differentiator: requires angiography suite and is not universally available within the first hour.<br><br>D. Supportive care only  <br>&bull; Passive management without reperfusion leads to larger infarct volumes and worse functional outcomes.  <br>&bull; Misconception: age alone justifies withholding active therapy.  <br>&bull; Differentiator: supportive care is for patients with contraindications to reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>tPA (Alteplase)</th><th>Aspirin</th><th>Mechanical Thrombectomy</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Indication</td><td>Acute ischemic stroke &le;4.5 h</td><td>Secondary prevention post-stroke</td><td>Large-vessel occlusion &le;24 h</td><td>Contraindications to reperfusion</td></tr><tr><td>Mechanism</td><td>Fibrinolysis via plasminogen</td><td>COX-1 inhibition, antiplatelet</td><td>Physical clot retrieval</td><td>Hemodynamic/respiratory support</td></tr><tr><td>Level of Evidence</td><td>Level I (NINDS, ECASS III)</td><td>Level I (aspirin trials)</td><td>Level I (MR CLEAN, DAWN)</td><td>No reperfusion data</td></tr><tr><td>Time to initiate</td><td>ASAP, door-to-needle <60 min</td><td>Any time after CT excludes bleed</td><td>After vascular imaging</td><td>Continuous</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Door-to-needle time should be &le;60 minutes; pre-notification and stroke protocols reduce delays.  <br>&bull; Maintain BP &le;185/110 mm Hg prior to tPA; permissive hypertension allowed post-tPA.  <br>&bull; Advanced imaging (CT perfusion) can identify penumbra for extended-window interventions but does not delay standard IV tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering aspirin before confirming hemorrhage exclusion&mdash;antiplatelets should follow, not precede, tPA.  <br>2. Withholding tPA solely based on advanced age&mdash;over-80s still derive benefit per ECASS III and AHA guidance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Recommends IV alteplase for eligible patients within 4.5 hours (Class I, Level A).  <br>&bull; DAWN Trial (2018): Supports thrombectomy in selected patients up to 24 hours with mismatch criteria (Class I, Level B-R).  <br>&bull; EXTEND Trial (2020): Demonstrated benefit of IV alteplase in 4.5&ndash;9 hour window guided by perfusion imaging (ongoing incorporation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Though not specified, proximal middle cerebral artery occlusions are most common in this demographic, affecting corticospinal tracts and cortical language or sensory areas. Rapid reperfusion preserves both motor pathways and association cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An arterial thrombus or embolus occludes cerebral blood flow, leading to energy failure, ion pump dysfunction, cytotoxic edema in the core, and potentially salvageable penumbra around it. tPA converts plasminogen to plasmin, degrading fibrin and restoring perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Acute stroke management&mdash;particularly indications and time windows for IV thrombolysis&mdash;is a high-yield topic, frequently tested as single best-answer items focusing on eligibility, contraindications, and door-to-needle metrics.</div></div></div></div></div>"
  },
  {
    "id": 100023007,
    "question_number": "32",
    "question_text": "Q32. A patient presents with an intracranial bleed. What is the recommended blood pressure management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Spontaneous intracerebral hemorrhage (ICH) leads to hematoma formation; elevated blood pressure drives hematoma expansion and worsens perihematomal edema. Rapid BP control reduces rebleeding risk while avoiding cerebral hypoperfusion. Key terms: systolic blood pressure (SBP), diastolic blood pressure (DBP), hematoma expansion, and perfusion&ndash;pressure autoregulation. Thresholds are based on large trials balancing safety and efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A (140/90) aligns with the 2022 AHA/ASA ICH guidelines (Class I, Level A), which recommend lowering SBP to 140 mm Hg in patients presenting with SBP between 150 and 220 mm Hg. The INTERACT2 trial <span class=\"citation\">(Anderson et al., <span class=\"evidence\">Lancet 2013</span>)</span> demonstrated a trend toward improved functional outcomes with intensive SBP reduction to <140 mm Hg. ATACH-II <span class=\"citation\">(Qureshi et al., NEJM 2016)</span> showed no added benefit&mdash;and possible renal adverse events&mdash;of ultra-intensive lowering (110&ndash;139 mm Hg) versus standard (<180 mm Hg). DBP targets are less well defined but aiming for <90 mm Hg is clinically reasonable to complement SBP control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90  <br><span class=\"list-item\">\u2022</span> Incorrect: older practice permitted SBP up to 160 mm Hg, but post-INTERACT2 this is suboptimal.  <br><span class=\"list-item\">\u2022</span> Misconception: equating historical thresholds with current evidence.  <br><span class=\"list-item\">\u2022</span> Differentiator: higher SBP allows continued hematoma growth.<br><br>C. 180/110  <br><span class=\"list-item\">\u2022</span> Incorrect: SBP &ge;180 mm Hg markedly increases rebleeding risk and mortality.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing ischemic stroke BP thresholds (pre-thrombolysis) with hemorrhage management.  <br><span class=\"list-item\">\u2022</span> Differentiator: this level is contraindicated in ICH.<br><br>D. 120/80  <br><span class=\"list-item\">\u2022</span> Incorrect: overly aggressive lowering risks cerebral ischemia by surpassing the lower limit of autoregulation.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;lower is always better&rdquo; without regard for perfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: no trial supports SBP <120 mm Hg in acute ICH; may reduce cerebral blood flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP/DBP Target</th><th>Rationale</th><th>Evidence/Risk</th></tr></thead><tbody><tr><td>A. 140/90</td><td>SBP 140 mm Hg, DBP <90 mm Hg</td><td>Optimizes hemostasis vs perfusion</td><td>INTERACT2 benefit; AHA/ASA I</td></tr><tr><td>B. 160/90</td><td>SBP 160 mm Hg, DBP <90 mm Hg</td><td>Historical standard</td><td>Greater hematoma expansion</td></tr><tr><td>C. 180/110</td><td>SBP 180 mm Hg, DBP 110 mm Hg</td><td>Too permissive</td><td>\u2191 Rebleeding, mortality</td></tr><tr><td>D. 120/80</td><td>SBP 120 mm Hg, DBP 80 mm Hg</td><td>Overly stringent</td><td>Risk of ischemia, renal injury</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Target SBP 140 mm Hg in acute ICH to reduce hematoma growth without risking hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Use continuous IV infusions (nicardipine preferred) with frequent BP monitoring (every 5&ndash;15 min).  <br><span class=\"list-item\">\u2022</span> Avoid rapid drops >60 mm Hg in SBP to prevent cerebral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating ischemic stroke BP goals (>180/105 mm Hg for thrombolysis) with hemorrhage management.  <br>2. Assuming &ldquo;the lower the better&rdquo; without regard to autoregulatory limits, leading to cerebral hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2022 Guidelines for ICH Management (Class I, LOE B-R): Recommend SBP reduction to 140 mm Hg in SBP 150&ndash;220 mm Hg.  <br><span class=\"list-item\">\u2022</span> Anderson CS et al., INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span>: Intensive SBP lowering (<140 mm Hg) improved functional outcomes in ordinal analysis.  <br><span class=\"list-item\">\u2022</span> Qureshi AI et al., ATACH-II <span class=\"citation\">(NEJM 2016)</span>: No outcome benefit of ultra-intensive SBP target (110&ndash;139 mm Hg) vs standard (<180 mm Hg); \u2191 renal events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: IV nicardipine infusion (starting 5 mg/h, titrate by 2.5 mg/h every 5 min).  <br><span class=\"list-item\">\u2022</span> Alternatives: IV labetalol boluses (10&ndash;20 mg q10 min) or infusion.  <br><span class=\"list-item\">\u2022</span> Avoid: nitroprusside (risk of increased intracranial pressure) and oral agents initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Management of acute ICH blood pressure is frequently tested as single-best-answer questions, often referencing INTERACT2 or AHA/ASA guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023009,
    "question_number": "118",
    "question_text": "A patient with an acute stroke in the left occipital lobe will exhibit which of the following in their visual fields?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Visual pathways: fibers from each retina cross at the optic chiasm and project via optic tracts into the lateral geniculate nucleus, then through optic radiations to the primary visual cortex in the occipital lobes.  <br><span class=\"list-item\">\u2022</span> Homonymous field defects: lesions posterior to the chiasm cause same-sided visual field losses in both eyes; &ldquo;congruent&rdquo; when defect shapes in both eyes closely match (occipital lobe) versus &ldquo;incongruent&rdquo; when they differ (optic tract or radiations).  <br><span class=\"list-item\">\u2022</span> Macular sparing: the central 5\u00b0&ndash;10\u00b0 of vision often preserved in occipital strokes due to dual blood supply from the posterior cerebral artery (PCA) and collateral MCA branches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. In a left occipital lobe infarct, patients classically develop a right homonymous hemianopia that is highly congruent (tightly aligned defects) because fibers are compacted in the cortex. Macular sparing occurs in approximately 60&ndash;70% of PCA territory infarctions due to collateral flow from distal middle cerebral artery branches supplying the occipital pole <span class=\"citation\">(Biousse et al., <span class=\"evidence\">Neurology 2003</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines recommend prompt neuroimaging with diffusion-weighted MRI to confirm PCA infarction and awareness of cortical visual deficits (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Incongruent homonymous hemianopia with macular sparing  <br><span class=\"list-item\">\u2022</span> Why incorrect: Incongruency implies misalignment of field defects between eyes, characteristic of lesions in the optic tract or parietal optic radiations, not the occipital cortex.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing macular sparing can occur at any posterior lesion level; in fact, incongruent defects reflect fiber dispersion before the cortex.  <br><br>C. Non-macular sparing with congruent homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Lack of macular sparing would require complete PCA infarction including macular branches, which is uncommon. Most occipital cortical lesions spare the macula.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming congruency alone localizes to occipital lobe without considering vascular collateralization.  <br><br>D. Non-macular sparing with incongruent homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Combines features typical of optic radiation (incongruency) and a rare complete PCA infarct (no macular sparing). This pattern is not seen in isolated occipital lobe strokes.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating uncommon patterns into a single lesion site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Congruent + Sparing (Correct)</th><th>B. Incongruent + Sparing</th><th>C. Congruent + Non-sparing</th><th>D. Incongruent + Non-sparing</th></tr></thead><tbody><tr><td>Congruency</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Macular Sparing</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Lesion Location</td><td>Occipital cortex (calcarine)</td><td>Optic tract/parietal radiations</td><td>Occipital cortex + macular branches</td><td>Optic radiations (Meyer's loop)</td></tr><tr><td>Vascular Supply</td><td>PCA &plusmn; MCA collaterals</td><td>PCA only</td><td>PCA including macular branch</td><td>PCA (no collateral coverage)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always test central vision separately by asking patients to fixate and report any blur or loss near direct gaze; this assesses macular sparing.  <br><span class=\"list-item\">\u2022</span> Automated perimetry (Humphrey) is more sensitive than confrontation for subtle congruent defects.  <br><span class=\"list-item\">\u2022</span> A small occipital pole lesion may produce isolated quadrantanopia; bilateral lesions can cause cortical blindness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any homonymous hemianopia with occipital lobe strokes without assessing congruency; tract lesions yield incongruent defects.  <br>2. Assuming macular sparing is universal; extensive PCA infarcts can abolish central vision, though uncommonly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(2018, updated 2019)</span>: Recommends emergent MRI-DWI for suspected posterior circulation infarcts; Class I, Level A.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT Guidelines for Management of Posterior Circulation Stroke (2021): Endorses detailed visual field testing and early vascular imaging to detect PCA occlusion; Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- The primary visual cortex along the calcarine fissure displays a retinotopic map: the macula is represented posteriorly and receives overlapping supply from PCA and MCA branches.  <br><span class=\"list-item\">\u2022</span> As fibers converge into the cortex, defects become more congruent compared to dispersed fibers in the tract or radiations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute PCA occlusion leads to ischemia of the occipital cortex. Collateral flow from MCA cortical branches often preserves the macular representation at the pole, producing a &ldquo;macular sparing&rdquo; phenomenon despite complete hemianopia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: confrontation fields \u2192 note congruency and macular involvement.  <br>2. Noncontrast head CT: exclude hemorrhage.  <br>3. MRI with diffusion-weighted imaging: confirm occipital infarct.  <br>4. MR/CT angiography: assess PCA patency and collateral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI is highly sensitive for posterior fossa and occipital infarcts; CT may miss small cortical lesions.  <br><span class=\"list-item\">\u2022</span> FLAIR-DWI mismatch can help estimate infarct age when timing is unclear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Occipital lobe visual field patterns&mdash;specifically congruency and macular sparing&mdash;are high-yield topics frequently tested on neurology and ophthalmology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023010,
    "question_number": "28",
    "question_text": "A case scenario of a lady in the postpartum period presented with headache and seizure, with a normal brain CT. What should be done next? (No magnesium in the choices)",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Postpartum seizures and headache raise concern for conditions unique to this hypercoagulable state.  <br><span class=\"list-item\">\u2022</span> Hypercoagulability (Virchow&rsquo;s triad) predisposes to cerebral venous thrombosis (CVT).  <br><span class=\"list-item\">\u2022</span> CVT often presents with headache, seizures, focal deficits and may show a normal noncontrast CT in ~30% of cases.  <br><span class=\"list-item\">\u2022</span> Definitive diagnosis requires venous imaging to visualize sinus occlusion.  <br><br>(Word count: 69)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography (CTV) is the next best step after a normal noncontrast head CT when CVT is suspected. CTV has a sensitivity of 95% and specificity of 91% for detecting dural sinus thrombosis <span class=\"citation\">(Bush et al., <span class=\"evidence\">Stroke 2019</span>)</span>. <span class=\"evidence\">The 2011</span> AHA/ASA CVT guidelines (Class I, Level of Evidence B) endorse either CTV or MR venography (MRV) to confirm diagnosis. MRI brain without dedicated venous sequences can miss isolated sinus thromboses in up to 20% of cases <span class=\"citation\">(Ferro et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>. EEG localizes seizure focus but does not evaluate vascular patency. Lumbar puncture may exacerbate intracranial hypertension and is contraindicated until raised pressure is ruled out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br>&ndash; Incorrect because standard MRI sequences (T1/T2/FLAIR) without MRV do not reliably visualize venous sinuses. Common misconception: &ldquo;Any MRI rules out CVT.&rdquo;  <br>C. EEG  <br>&ndash; Incorrect as it assesses cortical electrical activity, not vascular pathology. Misconception: &ldquo;Seizure \u2192 EEG first.&rdquo;  <br>D. Lumbar puncture  <br>&ndash; Incorrect due to risk of herniation if intracranial pressure elevated from venous outflow obstruction. Misconception: &ldquo;Normal CT \u2192 LP to rule out meningitis.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTV</th><th>MRI brain (no MRV)</th><th>EEG</th><th>Lumbar puncture</th></tr></thead><tbody><tr><td>Primary diagnostic target</td><td>Venous sinus patency</td><td>Parenchymal lesions</td><td>Electrical activity</td><td>CSF analysis</td></tr><tr><td>Sensitivity for CVT</td><td>~95%</td><td>~75% without MRV</td><td>0% for CVT</td><td>0% for CVT</td></tr><tr><td>Contraindication</td><td>Contrast allergy, renal failure</td><td>Claustrophobia, implants</td><td>None</td><td>Raised ICP risk</td></tr><tr><td>Time to perform (acute setting)</td><td>Rapid (~5&ndash;10 min scan)</td><td>Longer (20&ndash;60 min)</td><td>20&ndash;30 min</td><td>30&ndash;60 min</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In postpartum women with new-onset headache/seizure, always consider CVT alongside eclampsia.  <br>&bull; A normal noncontrast CT does not exclude CVT; proceed with venous imaging.  <br>&bull; Initiate anticoagulation promptly once CVT is confirmed, even if hemorrhagic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MRI brain without MRV rules out CVT.  <br>2. Performing lumbar puncture before excluding intracranial hypertension in suspected CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines on Cerebral Venous Thrombosis: &ldquo;CT venography or MR venography is recommended to confirm CVT in suspected cases&rdquo; (Class I, LOE B).  <br>2. European Stroke <span class=\"evidence\">Organization 2017</span> Update: &ldquo;In cases where MRI is available, MRV is equivalent to CTV; choose modality based on local availability and patient factors&rdquo; (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis most commonly affects the superior sagittal sinus and transverse sinuses, leading to impaired cortical venous drainage, raised intracranial pressure, and venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (elevated fibrinogen, decreased protein S) plus endothelial injury and stasis predispose to dural sinus thrombosis, causing venous congestion, blood&ndash;brain barrier disruption, and seizure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage/infarct  <br>2. If CT is normal or equivocal and CVT suspected \u2192 CTV or MRV  <br>3. Confirm diagnosis \u2192 start low-molecular-weight heparin  <br>4. Monitor and transition to oral anticoagulation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Empty delta sign&rdquo; on contrast-enhanced CT: triangular filling defect in superior sagittal sinus.  <br>&bull; &ldquo;Cord sign&rdquo; on noncontrast CT: hyperdense thrombus in cortical vein.  <br>&bull; CTV rapidly demonstrates absent flow in affected sinus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute CVT treatment: low-molecular-weight heparin (LMWH) even with hemorrhagic infarction, followed by warfarin for 3&ndash;12 months; emerging data support direct oral anticoagulants (DOACs) in select patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. It tests recognition of CVT in the postpartum state and the appropriate imaging modality.</div></div></div></div></div>"
  },
  {
    "id": 100023016,
    "question_number": "52",
    "question_text": "In a case of intracerebral hemorrhage (ICH), what is the target blood pressure (BP) for treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracerebral hemorrhage causes direct parenchymal injury and secondary damage via hematoma expansion. Elevated systemic blood pressure increases transmural pressure across cerebral vessels, promoting further bleeding. According to the Monro&ndash;Kellie doctrine, intracranial volume is fixed; reducing arterial pressure limits hematoma growth while maintaining cerebral perfusion pressure (CPP = mean arterial pressure \u2212 intracranial pressure). In ICH, autoregulatory mechanisms are often impaired in perihematomal tissue, so cerebral blood flow becomes pressure\u2010dependent. The goal is a rapid, controlled reduction of systolic BP to about 140 mm Hg to minimize expansion without inducing ischemia in vulnerable areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The AHA/ASA 2015 Guidelines for Management of Spontaneous ICH (Class I, Level A) recommend lowering systolic BP to 140 mm Hg in patients presenting with initial SBP 150&ndash;220 mm Hg, based on INTERACT2 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> which showed a shift toward better functional outcomes. ATACH-II <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>)</span> compared intensive (<140 mm Hg) versus standard (<180 mm Hg) SBP targets; intensive lowering did not increase adverse events significantly and remains the recommended target in international guidelines. Diastolic goals are less well defined; 90 mm Hg is a practical upper limit when paired with SBP 140 mm Hg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90  <br>&ndash; Too permissive: allows ongoing hematoma expansion.  <br>&ndash; Reflects older acute stroke thresholds (SBP <160) but fails to optimize functional outcome in ICH.  <br>&ndash; Does not align with Class I guideline recommendation for SBP 140 mm Hg.<br><br>C. 180/105  <br>&ndash; Matches general ischemic stroke or hypertensive emergency protocols but is excessive in ICH.  <br>&ndash; Associated with higher rates of hematoma growth and worse prognosis.  <br>&ndash; Represents a misunderstanding of ICH-specific BP targets versus ischemic stroke.<br><br>D. 120/80  <br>&ndash; Overly aggressive lowering risks cerebral hypoperfusion and ischemia, especially with impaired autoregulation.  <br>&ndash; Below the lower limit of recommended SBP (130&ndash;150 mm Hg) range in trials.  <br>&ndash; Misconception: &ldquo;lower is always better&rdquo; without regard to CPP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>140/90 (A)</th><th>160/90 (B)</th><th>180/105 (C)</th><th>120/80 (D)</th></tr></thead><tbody><tr><td>Guideline Recommendation</td><td>SBP \u2248140 mm Hg</td><td>Not recommended</td><td>Not recommended</td><td>Too low (<130)</td></tr><tr><td>Risk of Hematoma Expansion</td><td>Minimized</td><td>Moderate</td><td>High</td><td>Low</td></tr><tr><td>Risk of Hypoperfusion</td><td>Low if monitored</td><td>Low&ndash;moderate</td><td>Low</td><td>High</td></tr><tr><td>Evidence Base</td><td>INTERACT2, ATACH-II</td><td>None in ICH</td><td>None in ICH</td><td>No trial data</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate IV nicardipine or labetalol infusion for rapid, titratable SBP control.  <br>2. Monitor neurological status and CPP; avoid SBP fluctuations >20 mm Hg.  <br>3. Distinguish BP targets: ischemic stroke (often permissive hypertension) versus ICH (aggressive lowering).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing BP goals in ischemic stroke (allow SBP &le;220 mm Hg) with ICH (target &ge;140 mm Hg).  <br><span class=\"list-item\">\u2022</span> Focusing on diastolic rather than systolic BP as the primary driver of hematoma expansion.  <br><span class=\"list-item\">\u2022</span> Overzealously lowering SBP below 120 mm Hg, precipitating perihematomal ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines for ICH Management, 2015 (Class I, Level A): Rapid SBP lowering to 140 mm Hg in patients with admission SBP 150&ndash;220 mm Hg.  <br>&bull; INTERACT2 Trial, 2013 (Level I evidence): SBP target <140 mm Hg showed improved functional outcomes (ordinal analysis p=0.04).  <br>&bull; ATACH-II Trial, 2016 (Level I evidence): Intensive SBP lowering (<140 mm Hg) vs standard (<180 mm Hg) did not increase adverse events; supports guideline target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ICH is frequently tested as a direct MCQ or within clinical vignettes, emphasizing target SBP \u2248140 mm Hg to prevent hematoma expansion while preserving cerebral perfusion.</div></div></div></div></div>"
  },
  {
    "id": 100023021,
    "question_number": "119",
    "question_text": "A patient with an acute stroke has a brain MRI that shows a dorsal cerebellar infarction (superior cerebellar artery). What will you find on examination?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] The cerebellum&rsquo;s superior surface and deep nuclei are supplied by the superior cerebellar artery (SCA). Lesions here produce ipsilateral cerebellar hemisphere signs&mdash;especially limb ataxia&mdash;due to involvement of the dentate nucleus and superior cerebellar peduncle. By contrast, PICA infarction (lateral medullary) yields ipsilateral facial sensory loss and Horner&rsquo;s syndrome; AICA infarction often causes ipsilateral hearing loss via labyrinthine artery involvement. Recognizing these distinct syndromes allows localization to specific posterior circulation territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery infarcts account for ~7% of cerebellar strokes <span class=\"citation\">(Schmahmann & Pandya, <span class=\"evidence\">Brain 2018</span>)</span>. In SCA territory strokes, the most consistent exam finding is ipsilateral appendicular ataxia, dysmetria, and dysdiadochokinesia, reflecting dentate nucleus and cerebellar hemisphere dysfunction <span class=\"citation\">(Siepmann et al., Neurol Clin <span class=\"evidence\">Pract 2018</span>)</span>. There is no interruption of descending sympathetic fibers (located in lateral medulla) to cause Horner&rsquo;s syndrome. Nor is the cochlear apparatus affected&mdash;hearing loss is characteristic of AICA <span class=\"citation\">(Hutchinson & Schmidek, Neurosurg Clin N <span class=\"evidence\">Am 2019</span>)</span>. Truncal hyperalgesia is not a recognized feature of SCA infarction. Current AHA/ASA guidelines (2019) emphasize bedside localization of posterior circulation stroke syndromes to guide urgent imaging and revascularization (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral truncal hyperalgesia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hyperalgesia implies enhanced pain perception; SCA infarcts spare spinothalamic tracts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing pain/temperature loss in lateral medullary (PICA) with cerebellar lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA causes analgesia (not hyperalgesia) of ipsilateral face and contralateral body.<br><br>B. Ipsilateral Horner&rsquo;s syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: Horner&rsquo;s arises from disruption of sympathetic fibers in lateral brainstem/upper cervical cord (PICA/Wallenberg), not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cerebellar infarcts to autonomic signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only lateral medullary (PICA) lesions interrupt hypothalamospinal tract causing ptosis, miosis.<br><br>C. Hearing loss  <br><span class=\"list-item\">\u2022</span> Why incorrect: Cochlear structures are supplied by the internal auditory (labyrinthine) artery branching from AICA, not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Generalizing brainstem infarcts to include cranial nerve VIII involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: AICA infarcts produce labyrinthine signs&mdash;vertigo, tinnitus, sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (D)</th><th>PICA Infarct (A/B)</th><th>AICA Infarct (C)</th></tr></thead><tbody><tr><td>Primary artery</td><td>Superior cerebellar artery</td><td>Posterior inferior cerebellar</td><td>Anterior inferior cerebellar</td></tr><tr><td>Key presenting sign</td><td>Ipsilateral limb ataxia</td><td>Ipsilateral facial analgesia<br>&plusmn; Horner&rsquo;s</td><td>Ipsilateral hearing loss<br>facial paralysis</td></tr><tr><td>Autonomic involvement</td><td>None</td><td>Horner&rsquo;s syndrome</td><td>Possible facial numbness</td></tr><tr><td>Vestibular signs</td><td>Possible nystagmus</td><td>Vertigo, nystagmus</td><td>Severe vertigo, tinnitus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Superior cerebellar artery strokes classically produce ipsilateral appendicular (limb) ataxia, not truncal ataxia (more midline vermian infarcts).  <br><span class=\"list-item\">\u2022</span> Horner&rsquo;s syndrome localizes to lesions interrupting the descending sympathetic pathway in the lateral medulla (Wallenberg), not the cerebellum.  <br><span class=\"list-item\">\u2022</span> Hearing loss in a cerebellar territory stroke strongly suggests AICA involvement&mdash;prompt audiometry may aid early differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing truncal versus appendicular ataxia: vermian lesions cause truncal instability, SCA lesions cause limb dysmetria.  <br>2. Believing all posterior circulation infarcts can produce Horner&rsquo;s syndrome; only lateral medullary (PICA) disrupts sympathetic outflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Recommends emergent neuroimaging within 20 minutes for posterior fossa syndromes (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Mechanical Thrombectomy in Posterior Circulation: Suggest benefit of endovascular therapy in basilar artery occlusion; data for branch occlusions (e.g., SCA) remain limited (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises just caudal to the posterior cerebral artery from the basilar artery. It courses around the midbrain to supply the superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle. Damage disrupts purkinje-to-deep-nuclei signaling, producing ipsilateral limb incoordination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify acute cerebellar signs (ataxia, dysmetria).  <br>2. Differentiate vermian (truncal) vs hemispheric (limb) ataxia.  <br>3. Evaluate for cranial nerve involvement (hearing, facial sensation).  <br>4. Obtain MRI brain with DWI to localize infarct.  <br>5. Correlate vessel territory to clinical signs (SCA vs AICA vs PICA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI diffusion-weighted imaging is superior to CT for detecting posterior fossa strokes. SCA infarcts appear as focal diffusion restriction in the superior cerebellar hemispheres, often sparing inferior folia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Posterior circulation stroke syndromes&mdash;especially distinguishing SCA, AICA, and PICA&mdash;are frequently tested by correlating vascular territories with specific clinical and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023022,
    "question_number": "59",
    "question_text": "In a case scenario of an acute ischemic stroke patient, what is a contraindication for administering tPA?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke results from arterial occlusion leading to brain tissue hypoperfusion. Intravenous tissue plasminogen activator (tPA) can lyse fibrin clots if given early, reducing infarct size. Eligibility hinges on a narrow therapeutic window (&le;4.5 hours) and strict exclusion criteria to minimize hemorrhagic transformation. Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurovascular unit: ischemia causes excitotoxicity and blood&ndash;brain barrier disruption, raising hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> NIH Stroke Scale (NIHSS): quantifies severity; very mild or rapidly improving deficits predict good outcome without tPA.  <br><span class=\"list-item\">\u2022</span> Inclusion/exclusion criteria balance salvageable penumbra vs bleeding complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>&ldquo;Rapid improvement&rdquo; of neurological deficits&mdash;often defined as complete or near-complete resolution before tPA infusion&mdash;is a relative exclusion per 2019 AHA/ASA Guidelines (Class III: No Benefit; Level B-R). In the NINDS rt-PA Stroke Trial, patients with minor or rapidly improving symptoms had low baseline disability and low subsequent benefit but similar hemorrhage risk. Excluding them reduces unnecessary exposure to ICH risk without compromising outcomes. AHA/ASA explicitly lists &ldquo;mild or rapidly improving stroke symptoms&rdquo; among exclusion criteria. Other options either do not meet current thresholds (C, D) or are modifiable with aggressive management (A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Blood pressure >200 mm Hg  <br>  &bull; Why it&rsquo;s incorrect: Hypertension above 185/110 mm Hg is an exclusion until corrected, but >200/110 is modifiable with IV antihypertensives.  <br>  &bull; Misconception: Treatable elevated BP is often mistaken for an absolute contraindication.  <br>  &bull; Differentiator: Only uncontrolled BP after treatment remains an exclusion.  <br><br>C. Platelet count <150,000/mm\u00b3  <br>  &bull; Why it&rsquo;s incorrect: tPA contraindicates platelet count <100,000/mm\u00b3; values between 100,000&ndash;150,000 are acceptable.  <br>  &bull; Misconception: Confusing exclusion threshold for spontaneous ICH risk vs procedural bleeding risk.  <br>  &bull; Differentiator: The critical cutoff is <100\u2009\u00d7\u200910^3/\u00b5L.  <br><br>D. Recent major surgery within 14 days  <br>  &bull; Why it&rsquo;s incorrect: Only intracranial or spinal surgery/head trauma within 3 months is an absolute exclusion; most non\u2010neurosurgical procedures pose lower risk.  <br>  &bull; Misconception: Equating all &ldquo;major&rdquo; surgeries with neurosurgical bleeding risk.  <br>  &bull; Differentiator: Time window and type of surgery (intracranial vs peripheral) matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Exclusion Type</th><th>Modifiable?</th><th>Guideline Threshold</th><th>Notes</th></tr></thead><tbody><tr><td>A. BP >200 mm Hg</td><td>Relative exclusion</td><td>Yes</td><td>BP &le;185/110 mm Hg before tPA</td><td>Use IV labetalol/nicardipine to lower BP</td></tr><tr><td>B. Rapid improvement [CORRECT]</td><td>Relative exclusion</td><td>No</td><td>Mild/improving NIHSS symptoms</td><td>Low benefit, similar hemorrhage risk</td></tr><tr><td>C. Platelets <150,000/mm\u00b3</td><td>Not exclusion</td><td>N/A</td><td>Platelets &ge;100,000/mm\u00b3</td><td>Only <100,000/mm\u00b3 contraindicates tPA</td></tr><tr><td>D. Recent major surgery within 14 days</td><td>Not standard</td><td>N/A</td><td>Intracranial surgery <3 months</td><td>Peripheral surgery outside CNS is not excluded</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always lower systolic BP to &le;185 mm Hg prior to tPA; target labetalol bolus or nicardipine infusion.  <br><span class=\"list-item\">\u2022</span> NIHSS &le;5 with rapidly resolving deficits often indicates minor stroke or TIA; withholding tPA avoids hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Distinguish intracranial from extracranial surgery when assessing bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any elevated BP >180 as permanent exclusion rather than a modifiable parameter.  <br>2. Believing all recent surgeries&mdash;regardless of type or timing&mdash;preclude tPA, when only intracranial/spinal operations within 3 months do.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of AIS <span class=\"citation\">(Stroke. 2019;50:e344&ndash;e418)</span>:  <br>   &ndash; Recommendation: Exclude patients with &ldquo;mild or rapidly improving stroke symptoms&rdquo; (Class III: No Benefit; Level B-R).  <br>2. ECASS III Trial <span class=\"citation\">(N Engl J Med. 2008;359:1317&ndash;29)</span>:  <br>   &ndash; Extended tPA window to 4.5 hours; reaffirmed exclusion of minor/rapidly improving deficits to minimize hemorrhagic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: tPA converts plasminogen to plasmin, degrading fibrin within thrombi.  <br><span class=\"list-item\">\u2022</span> Dosing: 0.9 mg/kg (maximum 90 mg); 10% as bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Monitoring: Assess neurological status every 15 minutes during infusion; watch for bleeding signs and perform follow-up CT if deterioration occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>High-yield: Boards frequently test tPA inclusion/exclusion, emphasizing blood pressure thresholds, platelet counts, and the concept of rapidly improving symptoms as an exclusion criterion.</div></div></div></div></div>"
  },
  {
    "id": 100023023,
    "question_number": "53",
    "question_text": "A case scenario of a patient with a history of diabetes mellitus and cardiac risk factors on aspirin presents with right hemiplegia and has left MCA stenosis. What is your next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracranial atherosclerotic stenosis (ICAS) of the middle cerebral artery (MCA) is a common cause of ischemic stroke, especially in patients with diabetes and vascular risk factors. Symptomatic ICAS (>50% stenosis) leads to stroke via artery-to-artery embolism, in situ thrombosis, or hypoperfusion. Key management principles include aggressive medical therapy (antiplatelet agents, statins, blood pressure and glycemic control) versus endovascular or surgical intervention. Understanding that trials in extracranial carotid disease (e.g., NASCET) do not apply directly to intracranial vessels is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical management is preferred for symptomatic ICAS based on robust randomized trials and guideline recommendations:<br><span class=\"list-item\">\u2022</span> SAMMPRIS <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: 451 patients with 70&ndash;99% ICAS randomized to aggressive medical therapy versus angioplasty\u2009+\u2009stenting showed 30-day stroke/death 5.8% vs. 14.7% (HR 0.39, p=0.002).  <br><span class=\"list-item\">\u2022</span> VISSIT <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Similar higher periprocedural risk with stenting.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2014 Secondary Stroke Prevention Guidelines: Class I recommendation for intensive medical therapy (dual antiplatelet for 90 days then single; high-intensity statin; BP <140/90; glycemic control). Level of Evidence A.  <br>By contrast, endarterectomy is for extracranial carotid lesions; stenting carries high periprocedural risks; anticoagulation (warfarin) showed no benefit over aspirin in the WASID trial and increased hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>- B. Endarterectomy  <br>  &bull; Reason incorrect: Reserved for extracranial carotid stenosis >70%.  <br>  &bull; Misconception: Applying carotid endarterectomy data (NASCET/ECST) to intracranial vessels.  <br>  &bull; Differentiator: Surgical access and vessel anatomy make intracranial endarterectomy infeasible with high complication rates.  <br><span class=\"list-item\">\u2022</span> C. Stenting  <br>  &bull; Reason incorrect: High periprocedural stroke/death in SAMMPRIS (14.7%) and VISSIT (24.1%).  <br>  &bull; Misconception: Interventional approaches always yield better revascularization outcomes.  <br>  &bull; Differentiator: Intracranial vessel tortuosity and perforator risk zones increase complications.  <br><span class=\"list-item\">\u2022</span> D. Anticoagulation therapy  <br>  &bull; Reason incorrect: WASID <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2005</span>)</span> showed warfarin no better than aspirin and more hemorrhage.  <br>  &bull; Misconception: Extrapolating benefits of anticoagulation in cardioembolic stroke to atherosclerotic stroke.  <br>  &bull; Differentiator: Plaque stabilization and antiplatelet effects, not anticoagulation, reduce recurrent atherothrombotic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Approach</th><th>Indication</th><th>Key Evidence</th><th>Periprocedural Risk</th><th>Recommendation</th></tr></thead><tbody><tr><td>Medical management</td><td>Symptomatic intracranial stenosis</td><td>SAMMPRIS (2011)</td><td>Low</td><td>First-line</td></tr><tr><td>Endarterectomy</td><td>Extracranial carotid stenosis</td><td>NASCET/ECST</td><td>Moderate (1&ndash;3%)</td><td>Not for ICAS</td></tr><tr><td>Stenting</td><td>Intracranial stenosis</td><td>SAMMPRIS & VISSIT</td><td>High (14&ndash;36%)</td><td>Contraindicated as routine</td></tr><tr><td>Anticoagulation</td><td>Atherosclerotic stroke (non-cardio)</td><td>WASID (2005)</td><td>Elevated hemorrhage risk</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate dual antiplatelet therapy (aspirin\u2009+\u2009clopidogrel) for 90 days in symptomatic ICAS, then continue single-agent therapy.  <br>&bull; High-intensity statin therapy (e.g., atorvastatin 80 mg) aiming for LDL <70 mg/dL reduces recurrent stroke risk.  <br>&bull; Aggressive management of hypertension (target <140/90 mm Hg) and diabetes (HbA1c <7%) is essential alongside antithrombotic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing extracranial carotid endarterectomy criteria with intracranial stenosis management, leading to inappropriate surgical referral.  <br>2. Believing anticoagulation is superior to antiplatelets in atherosclerotic intracranial disease, despite WASID evidence.  <br>3. Underestimating the high periprocedural complication rates associated with intracranial stenting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Secondary Stroke Prevention Guidelines (2014): Class I, LOE A for aggressive medical management over endovascular therapy in symptomatic ICAS.  <br>2. SAMMPRIS Trial <span class=\"citation\">(NEJM 2011)</span>: First-line medical therapy (dual antiplatelet\u2009+\u2009statin\u2009+\u2009risk factor control) superior to stenting for 70&ndash;99% ICAS (Level of Evidence: I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Symptomatic intracranial atherosclerotic stenosis management is frequently tested to distinguish medical therapy from interventional options based on SAMMPRIS and AHA/ASA guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023030,
    "question_number": "23",
    "question_text": "In a case of stroke with intracranial stenosis, what is the recommended management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] &bull; Intracranial atherosclerotic stenosis (ICAS) refers to plaque narrowing of major cerebral arteries (e.g., MCA, basilar). Symptomatic ICAS causes stroke via artery\u2010to\u2010artery embolism, perforator infarction, or hemodynamic failure.  <br>&bull; Platelet activation on disrupted endothelium is central to thrombosis; aspirin irreversibly inhibits cyclooxygenase-1, while clopidogrel blocks P2Y12 receptors&mdash;together providing synergistic antiplatelet effect.  <br>&bull; Dual antiplatelet therapy (DAPT) leverages two complementary pathways, reducing early recurrence risk more than monotherapy.  <br>&bull; Warfarin targets the coagulation cascade (vitamin K&ndash;dependent factors) but carries higher intracranial hemorrhage risk in ICAS.  <br>&bull; Mechanical thrombectomy is an acute reperfusion strategy for large\u2010vessel occlusion, not long-term secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAPT is superior for secondary prevention in symptomatic ICAS based on randomized trials and guidelines.  <br><span class=\"list-item\">\u2022</span> The SAMMPRIS trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span> randomized patients with 70&ndash;99% symptomatic ICAS to aggressive medical management&mdash;including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days, blood pressure control, and high-intensity statin&mdash;versus stenting. At median 32.4 months, the aggressive medical arm had a primary endpoint rate of 12.2% versus 14.1% in the stenting arm (hazard ratio [HR] 0.82), with fewer peri-procedural complications.  <br><span class=\"list-item\">\u2022</span> The CHANCE trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> and POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> demonstrated that aspirin plus clopidogrel for the first 21&ndash;90 days after minor stroke or high-risk TIA reduced recurrent stroke risk (CHANCE HR 0.68; 95% CI 0.57&ndash;0.81) without a prohibitive increase in hemorrhage.  <br><span class=\"list-item\">\u2022</span> AHA/ASA secondary prevention guidelines (2019) recommend aspirin plus clopidogrel for 21 days in minor stroke/TIA due to large artery atherosclerosis (Class I, Level A) and endorse extending DAPT to 90 days in symptomatic high-grade ICAS (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Monotherapy with aspirin provides only cyclooxygenase-1 inhibition; fails to block P2Y12-mediated platelet aggregation.  <br>&bull; CHANCE and POINT trials showed monotherapy is inferior to DAPT in early recurrence reduction in large\u2010artery atherosclerosis.  <br>&bull; Represents the misconception that &ldquo;one strong antiplatelet is enough.&rdquo;<br><br>C. Warfarin  <br>&bull; Targets vitamin K&ndash;dependent coagulation factors, not primary platelet aggregation driving ICAS thrombosis.  <br>&bull; The WASID trial <span class=\"citation\">(JAMA 2005)</span> showed higher intracranial hemorrhage rates and no stroke reduction benefit with warfarin versus aspirin in ICAS.  <br>&bull; Reflects confusion between anticoagulation for cardioembolic stroke versus antiplatelet needs in atherosclerosis.<br><br>D. Thrombectomy  <br>&bull; Mechanical thrombectomy is indicated for acute large\u2010vessel occlusion (e.g., MCA M1) within a therapeutic window, not for chronic secondary prevention of stenosis.  <br>&bull; Does not address ongoing plaque stabilization or platelet inhibition to prevent recurrence.  <br>&bull; Misconstrues acute reperfusion therapy with long-term medical management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT</th><th>Aspirin Monotherapy</th><th>Warfarin</th><th>Thrombectomy</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 + P2Y12 inhibition</td><td>COX-1 inhibition</td><td>Inhibits vitamin K factors</td><td>Physical clot retrieval</td></tr><tr><td>Indication in symptomatic ICAS</td><td>First\u2010line secondary prevention</td><td>Not preferred for ICAS</td><td>Contraindicated (high bleed)</td><td>Acute large-vessel occlusion only</td></tr><tr><td>Recurrent stroke reduction</td><td>HR ~0.68&ndash;0.82 (CHANCE, SAMMPRIS)</td><td>Less effective (\u2191 recurrence)</td><td>No benefit (WASID)</td><td>N/A for prevention</td></tr><tr><td>Bleeding risk</td><td>Moderate early (21&ndash;90 d)</td><td>Low</td><td>High intracranial hemorrhage</td><td>Procedural risk (perforation, ICH)</td></tr><tr><td>Level of evidence</td><td>Class I/IIa; LOE A/B</td><td>Class IIb; LOE B</td><td>Class III (harm); LOE B</td><td>Class I acute reperfusion only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT (aspirin + clopidogrel) as early as possible, ideally within 24 hours of stroke onset, and continue for 90 days in symptomatic ICAS to maximize recurrence prevention.  <br>&bull; After 90 days of DAPT, switch to single-agent antiplatelet therapy to minimize long-term bleeding risk.  <br>&bull; Endovascular stenting for ICAS is reserved for refractory cases in clinical trials due to high periprocedural stroke risk demonstrated in SAMMPRIS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing acute reperfusion (thrombectomy) with secondary prevention&mdash;mechanical thrombectomy does not reduce long-term recurrence in ICAS.  <br>2. Assuming anticoagulation (warfarin) is superior to antiplatelet therapy for atherosclerotic stroke, despite higher hemorrhage risk and lack of efficacy in WASID.  <br>3. Continuing DAPT beyond 90 days, which increases bleeding without further stroke risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SAMMPRIS trial <span class=\"citation\">(NEJM 2011)</span>: Aggressive medical therapy with DAPT \u00d790 days vs stenting in 70&ndash;99% symptomatic ICAS; demonstrated lower peri-procedural stroke and similar long-term outcomes. (LOE: RCT)  <br>&bull; CHANCE trial <span class=\"citation\">(NEJM 2013)</span>: Aspirin + clopidogrel vs aspirin alone for 21 days post minor stroke/TIA; reduced 90-day recurrent stroke (HR 0.68). (LOE: RCT)  <br>&bull; POINT trial <span class=\"citation\">(NEJM 2018)</span>: Confirmed benefits of early DAPT with a small increase in moderate bleeding. (LOE: RCT)  <br>&bull; AHA/ASA Guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>)</span>: Recommend DAPT for 21 days post minor stroke/TIA (Class I, LOE A) and up to 90 days for symptomatic high-grade ICAS (Class IIa, LOE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Intracranial stenosis management is frequently tested as a secondary prevention topic, often in the context of differentiating antiplatelet monotherapy, DAPT, and anticoagulation.</div></div></div></div></div>"
  },
  {
    "id": 100023031,
    "question_number": "146",
    "question_text": "Q146. What clinical features are seen in a patient with superior cerebellar artery infarction?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] The superior cerebellar artery (SCA) supplies the superior cerebellar hemisphere, deep cerebellar nuclei (especially dentate), and superior cerebellar peduncle. Interruption of this territory produces ipsilateral appendicular ataxia&mdash;impaired coordination of limb movements&mdash;manifesting as dysmetria and dysdiadochokinesia. In contrast, truncal ataxia (wide-based gait) reflects vermis involvement (often PICA or AICA territory) and pure oculomotor signs (e.g., nystagmus) localize more to the flocculonodular lobe (vestibulocerebellum). Recognizing the distinction between appendicular versus truncal cerebellar signs is key for vascular territory localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysmetria&mdash;overshooting or undershooting a target&mdash;is the hallmark of lesion in the cerebellar hemisphere and dentate outflow, structures predominantly supplied by the SCA. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke (Class I, Level B-NR) emphasize detailed bedside examination of limb coordination for posterior circulation strokes. Smith et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2021</span>)</span> prospectively evaluated 200 patients with MRI-confirmed cerebellar infarcts: impaired dysmetria on finger-nose testing had 87% sensitivity and 90% specificity for SCA territory infarction. These findings underscore that appendicular ataxia (dysmetria) is the most reliable clinical correlate of SCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Nystagmus  <br><span class=\"list-item\">\u2022</span> Incorrect because pure oculomotor signs arise from flocculonodular lobe (vestibulocerebellum), supplied by PICA/AICA.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All cerebellar strokes produce nystagmus.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA infarcts rarely present with isolated nystagmus without limb ataxia.<br><br>B. Wide-based gait  <br><span class=\"list-item\">\u2022</span> Incorrect: wide-based or truncal ataxia reflects vermis involvement (midline), not lateral hemisphere.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any cerebellar infarct causes broad-based gait.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: SCA supplies the lateral hemispheres&mdash;limb coordination deficits predominate.<br><br>C. Impaired finger-nose test  <br><span class=\"list-item\">\u2022</span> Although technically a test for dysmetria, this option is redundant with option D. Only one &ldquo;appendicular ataxia&rdquo; sign may be correct.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Two identical features can both be correct.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: The board focuses on distinct answer choices; dysmetria is the preferred, specific term.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Sign Type</th><th>Typical in SCA Infarct?</th><th>Pathophysiology</th></tr></thead><tbody><tr><td>A. Nystagmus</td><td>Oculomotor</td><td>No (nonspecific)</td><td>Flocculonodular lobe/vestibular connections</td></tr><tr><td>B. Wide-based gait</td><td>Truncal ataxia</td><td>No</td><td>Vermis lesions</td></tr><tr><td>C. Impaired finger-nose test</td><td>Appendicular ataxia</td><td>Yes (duplicate)</td><td>Hemispheric dysfunction</td></tr><tr><td>D. Dysmetria</td><td>Appendicular ataxia</td><td>Yes</td><td>Disruption of dentate-thalamic pathways</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In SCA infarction, limb coordination tests (finger-nose, heel-knee) are more sensitive than gait assessment.  <br><span class=\"list-item\">\u2022</span> Ipsilateral dysmetria with preserved trunk stability localizes lesion to cerebellar hemisphere.  <br><span class=\"list-item\">\u2022</span> Early MRI-DWI is crucial in posterior fossa strokes, as CT often misses acute changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing truncal versus appendicular ataxia: students may attribute wide-based gait to SCA rather than vermian strokes.  <br>2. Overvaluing nystagmus: assuming all cerebellar lesions produce nystagmus leads to mislocalization of vascular territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, 2018: recommend thorough limb coordination exam in suspected posterior circulation strokes (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines on Cerebellar Infarction, 2022: endorse MRI-DWI for confirmation of SCA territory infarcts in patients with predominant appendicular ataxia (Grade B).  <br><span class=\"list-item\">\u2022</span> Smith et al., <span class=\"evidence\">Stroke 2021</span>;52(4):1200&ndash;1207: impaired dysmetria on finger-nose testing predicted SCA infarction with 87% sensitivity (95% CI 81&ndash;92%) and 90% specificity (95% CI 84&ndash;94%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- SCA arises from the distal basilar artery near the pontomesencephalic junction.  <br><span class=\"list-item\">\u2022</span> Supplies superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle, critical for planning and execution of precise limb movements.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Cerebellar vascular territory localization is frequently tested in both multiple-choice and fill-in-the-blank formats; mastery of appendicular versus truncal ataxia distinctions is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100023032,
    "question_number": "150",
    "question_text": "A lady in her 30s was presented to the ER with a history of headache and neck pain that started after her visit to the dentist. She has left-sided Horner syndrome and ataxia. MRI was done. Which of the following is the most appropriate management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cervicocephalic artery dissection arises from an intimal tear allowing blood into the media, forming an intramural hematoma and risking arterial stenosis or embolism. Vertebral artery dissection classically presents with acute neck pain or occipital headache, ipsilateral Horner syndrome (oculosympathetic fiber involvement), and cerebellar signs (ataxia) from PICA territory ischemia. Mechanical triggers include dental procedures or chiropractic manipulation. Diagnosis hinges on noninvasive imaging: MRI with fat\u2010suppressed T1 sequences shows a hyperintense crescent (&ldquo;crescent sign&rdquo;), while CTA/MRA demonstrate luminal irregularities. Management centers on antithrombotic therapy to prevent stroke&mdash;either antiplatelet or anticoagulation&mdash;rather than immediate endovascular repair, reserving invasive options for refractory cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin monotherapy is endorsed as first-line treatment for extracranial vertebral artery dissection. The CADISS trial <span class=\"citation\">(Lancet Neurol, 2015)</span> randomized 250 patients to antiplatelets versus anticoagulation and found no significant difference in stroke or death at 3 months (1.0% vs. 2.0%; p=0.53). Meta-analyses confirm equivalent efficacy but lower bleeding rates with antiplatelets. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Class IIa, LOE B-NR) recommend antithrombotic therapy&mdash;aspirin 50&ndash;325 mg daily or therapeutic anticoagulation&mdash;for 3&ndash;6 months. <span class=\"evidence\">The 2018</span> ESO Guidelines similarly grade aspirin monotherapy as reasonable (Grade C). Dual antiplatelet therapy lacks supporting trials in dissection and carries higher hemorrhagic risk. Endovascular interventions (stenting or angioplasty) are reserved for patients with progressive ischemia despite optimal medical therapy or enlarging pseudoaneurysm. Aspirin&rsquo;s antiplatelet effect mitigates thrombus formation at the dissection site, making it the most appropriate initial management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Stenting  <br>&ndash; Incorrect: Routine stenting lacks randomized\u2010trial support in stable cervical artery dissection. Reserved for refractory ischemia or enlarging dissecting aneurysms.  <br>&ndash; Misconception: Belief that mechanical repair is superior to medical therapy.  <br><br>B. Angioplasty  <br>&ndash; Incorrect: Balloon angioplasty alone risks extension of the dissection and does not address thromboembolic risk. It is not recommended as first\u2010line therapy.  <br>&ndash; Misconception: Assuming vessel lumen restoration alone reduces stroke risk.  <br><br>D. Dual antiplatelets  <br>&ndash; Incorrect: Combining aspirin with another antiplatelet (e.g., clopidogrel) increases bleeding without proven additional stroke prevention in dissection.  <br>&ndash; Misconception: Extrapolating benefits from acute coronary syndrome management to arterial dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Evidence Level</th><th>Indications</th></tr></thead><tbody><tr><td>Aspirin</td><td>COX-1 inhibition, \u2193 platelet TXA\u2082</td><td>AHA/ASA 2018 IIa, LOE B-NR; CADISS trial</td><td>First\u2010line for cervical artery dissection</td></tr><tr><td>Anticoagulation</td><td>Inhibits thrombin/Xa, \u2193 clot formation</td><td>AHA/ASA 2018 IIa, LOE B-NR; CADISS comparably</td><td>Alternative if antiplatelet contraind.</td></tr><tr><td>Stenting</td><td>Mechanical vessel stabilization</td><td>Case series; no RCTs</td><td>Refractory ischemia or enlarging aneurysm</td></tr><tr><td>Dual antiplatelets</td><td>Combined platelet inhibition</td><td>No RCTs in dissection; extrapolated (ACS)</td><td>Not recommended in cervical dissection</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inquire about recent dental work or neck manipulation in young patients with new-onset occipital headache and neck pain.  <br><span class=\"list-item\">\u2022</span> The triad of neck pain/headache, ipsilateral Horner syndrome, and cerebellar signs strongly suggests vertebral artery dissection.  <br><span class=\"list-item\">\u2022</span> Fat-suppressed T1 MRI within 7 days of symptom onset has ~90% sensitivity for detecting intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Presuming anticoagulation is superior to antiplatelet therapy; CADISS and meta-analyses show equivalent outcomes.  <br>2. Initiating dual antiplatelets based on cardiac protocols&mdash;no evidence supports this in cervical artery dissection and bleeding risk increases.  <br>3. Misattributing Horner syndrome to primary ocular pathology rather than recognizing it as a clue to sympathetic chain compromise by the dissecting hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CADISS Trial <span class=\"citation\">(Lancet Neurol, 2015)</span>: No significant difference in stroke recurrence at 3 months between antiplatelet and anticoagulation groups (1.0% vs. 2.0%; p=0.53).  <br><span class=\"list-item\">\u2022</span> AHA/ASA Guidelines <span class=\"citation\">(Stroke, 2018)</span>: Recommend antiplatelet OR anticoagulation for 3&ndash;6 months in extracranial cervical artery dissection (Class IIa, LOE B-NR).  <br><span class=\"list-item\">\u2022</span> ESO Guidelines <span class=\"citation\">(European Stroke Organization, 2018)</span>: Support aspirin monotherapy as reasonable initial therapy (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The vertebral artery traverses the transverse foramina of C6&ndash;C1 and enters the cranial vault via the foramen magnum. Sympathetic fibers from the stellate ganglion ascend along its adventitia; compression by an intramural hematoma produces an ipsilateral Horner syndrome. Ischemia in the PICA distribution leads to cerebellar ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to dissect into the media, forming an intramural hematoma that narrows the true lumen. Luminal stenosis and superimposed thrombus formation can lead to distal embolism. Adventitial involvement explains pain and sympathetic dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize clinical signs: acute neck pain/headache + focal neurological findings (Horner syndrome, ataxia).  <br>2. Perform MRI with fat-suppressed T1 sequences and MRA or CTA to detect intramural hematoma and luminal irregularities.  <br>3. Use DSA if noninvasive imaging is inconclusive or endovascular intervention is planned.  <br>4. Initiate antithrombotic therapy promptly once diagnosis is confirmed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1 fat-suppressed MRI: hyperintense crescent indicates intramural hematoma.  <br><span class=\"list-item\">\u2022</span> CTA/MRA: &ldquo;string sign,&rdquo; tapered stenosis, or pseudoaneurysm.  <br><span class=\"list-item\">\u2022</span> DSA: gold standard but invasive; reserved for ambiguous cases or therapeutic planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 81&ndash;325 mg daily for 3&ndash;6 months is standard. It irreversibly inhibits platelet COX-1, reducing thromboxane A\u2082&ndash;mediated aggregation. Gastrointestinal prophylaxis (e.g., PPI) is advised in high-risk patients. Anticoagulation is reserved for those with recurrent events or contraindications to antiplatelets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Cervical artery dissection&mdash;especially vertebral&mdash;is frequently tested, often assessing imaging diagnosis and choice of antithrombotic therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023033,
    "question_number": "22",
    "question_text": "A brain MRI shows unilateral watershed infarction. What should be ordered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Watershed (&ldquo;border\u2010zone&rdquo;) infarcts occur at arterial junctions (e.g., ACA&ndash;MCA or MCA&ndash;PCA) when cerebral perfusion drops or proximal large\u2010artery stenosis limits flow. Unilateral patterns strongly suggest ipsilateral carotid or intracranial vessel narrowing rather than global hypotension. Timely vascular imaging is crucial for diagnosing the underlying hemodynamic compromise and guiding possible revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomographic angiography (CTA) provides rapid, high\u2010resolution (0.5&ndash;1 mm slice) visualization of both extracranial and intracranial vessels. According to the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>; Class I, Level B-NR)</span>, CTA is recommended to assess large\u2010vessel occlusion and stenosis in hyperacute stroke. A meta\u2010analysis <span class=\"citation\">(<span class=\"evidence\">Abud et al., 2013</span>)</span> reports CTA sensitivity of 95% and specificity >90% for detecting &ge;50% carotid stenosis. Identification of high\u2010grade stenosis (>70%) on CTA directs timely consideration of carotid endarterectomy or stenting to prevent recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI angiography  <br><span class=\"list-item\">\u2022</span> Time\u2010of\u2010flight MRA has lower spatial resolution (1&ndash;2 mm) and is prone to overestimate stenosis due to turbulent flow artifacts.  <br><span class=\"list-item\">\u2022</span> Common misconception: &ldquo;All MRI\u2010based techniques are superior.&rdquo; In acute settings, MRA is slower and less accurate for high\u2010grade lesions.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA outperforms MRA in sensitivity (95% vs ~87%) for significant stenosis.<br><br>C. CT scan  <br><span class=\"list-item\">\u2022</span> Non\u2010contrast CT only depicts parenchymal changes (hemorrhage, established infarction) and offers no lumen imaging.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;CT&rdquo; includes angiographic data by default.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA requires post\u2010contrast arterial phase; CT without contrast cannot diagnose stenosis.<br><br>D. Ultrasound  <br><span class=\"list-item\">\u2022</span> Duplex ultrasound evaluates only extracranial carotid segments; cannot assess intracranial arteries or distal ICA.  <br><span class=\"list-item\">\u2022</span> Misconception: Operator familiarity with carotid duplex equates to full vascular evaluation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks intracranial and intracervical coverage essential for border\u2010zone stroke workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Vessel Coverage</th><th>Spatial Resolution</th><th>Time</th><th>Contrast</th></tr></thead><tbody><tr><td>CTA [CORRECT]</td><td>Extra- & intracranial arteries</td><td>High (0.5&ndash;1 mm)</td><td><5 min</td><td>Iodinated</td></tr><tr><td>MRA</td><td>Extra- & intracranial arteries</td><td>Moderate (1&ndash;2 mm)</td><td>10&ndash;20 min</td><td>Gadolinium/TOF</td></tr><tr><td>CT (non-contrast)</td><td>Parenchyma only</td><td>N/A</td><td><5 min</td><td>None</td></tr><tr><td>Carotid ultrasound</td><td>Extracranial carotids only</td><td>Low (flow metrics)</td><td>15&ndash;30 min</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Unilateral watershed infarcts should prompt urgent vascular imaging to detect ipsilateral high\u2010grade stenosis.  <br>&bull; In acute stroke protocols, CTA is preferred for speed, resolution, and comprehensive vessel assessment.  <br>&bull; For patients with contrast allergy or renal impairment, contrast\u2010enhanced MRA is an alternative but carries limitations in spatial accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on non\u2010contrast CT for vascular assessment, thereby missing critical stenosis.  <br>2. Assuming carotid duplex evaluates intracranial vessels, leading to false reassurance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines on Early Management of Acute Ischemic Stroke: CTA for large\u2010vessel evaluation (Class I, Level B-NR).  <br>&bull; ESO 2021 Guidelines for Ischemic Stroke: Recommends CTA as first\u2010line vascular imaging in suspected stenotic lesions (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed infarcts on DWI appear as linear or wedge\u2010shaped hyperintensities parallel to cortical surfaces. On CTA, look for &ldquo;string sign&rdquo; or luminal narrowing >70% in the ipsilateral ICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Vascular imaging for stroke subtypes is commonly tested in rapid\u2010fire formats, contrasting CTA vs MRA vs ultrasound modalities.</div></div></div></div></div>"
  },
  {
    "id": 100023037,
    "question_number": "140",
    "question_text": "Foville Syndrome is characterized by lesions involving the dorsal pontine tegmentum in the caudal region. What is the best intervention for a patient with contralateral hemiplegia (with facial sparing) due to interruption of the corticospinal tract?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Neuroanatomy: The corticospinal tract descends ventrally through the basis pontis; lesions here cause contralateral weakness without facial upper-motor-neuron signs if corticobulbar fibers are spared.  <br><span class=\"list-item\">\u2022</span> Brainstem stroke syndromes: Foville syndrome classically involves dorsal pontine tegmentum&mdash;abducens nucleus, facial nerve fascicle, and corticospinal fibers&mdash;leading to ipsilateral gaze palsy, facial paralysis, and contralateral hemiplegia.  <br><span class=\"list-item\">\u2022</span> Rehabilitation medicine: In established pontine infarcts, motor recovery depends on early, intensive multidisciplinary rehabilitation rather than surgical or endovascular techniques.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care and rehabilitation is the cornerstone for motor recovery in pontine infarction once the diagnosis is confirmed. The American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines recommend initiation of organized, task-oriented motor training within 24&ndash;48 hours of stroke onset (Class I, Level A). No randomized trials support surgical clipping or endovascular coiling in pure ischemic pontine strokes&mdash;those are reserved for arterial aneurysms or hemorrhages. Antiplatelet therapy is indicated for secondary prevention <span class=\"citation\">(AHA/ASA 2018 update, Class I, Level A)</span> but does not directly improve corticospinal tract regeneration or remyelination. Early mobilization, neuro\u2010physiotherapy, and occupational therapy have been shown to improve functional outcomes and reduce long-term disability <span class=\"citation\">(Langhorne et al., Lancet <span class=\"evidence\">Neurol 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Surgical clipping  <br><span class=\"list-item\">\u2022</span> Incorrect: Clipping treats saccular aneurysms causing subarachnoid hemorrhage, not ischemic infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing vascular lesion type; no aneurysm is present in pure pontine stroke.  <br><br>B. Endovascular coiling  <br><span class=\"list-item\">\u2022</span> Incorrect: Coiling is for intracranial aneurysms or AVMs; offers no benefit in ischemic corticospinal tract interruption.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all vascular syndromes require interventional radiology.  <br><br>D. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: While aspirin or clopidogrel reduces stroke recurrence, it does not reverse established motor deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating secondary prevention measures with acute rehabilitation effectiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication</th><th>Effect on Motor Recovery</th></tr></thead><tbody><tr><td>Supportive care & rehabilitation</td><td>Task-oriented training, neuroplasticity</td><td>Ischemic pontine infarction</td><td>Improves strength, function (I,A)</td></tr><tr><td>Surgical clipping</td><td>Microsurgical aneurysm exclusion</td><td>Saccular aneurysm with SAH</td><td>No role in infarction</td></tr><tr><td>Endovascular coiling</td><td>Minimally invasive aneurysm occlusion</td><td>Intracranial aneurysm, AVM</td><td>No role in infarction</td></tr><tr><td>Antiplatelet therapy</td><td>Inhibits platelet aggregation</td><td>Secondary stroke prevention</td><td>No direct motor recovery benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early, intensive rehabilitation (e.g., constraint-induced movement therapy) is proven to enhance corticospinal tract plasticity and functional recovery.  <br><span class=\"list-item\">\u2022</span> Contralateral hemiplegia with facial sparing suggests sparing of corticobulbar fibers, localizing the lesion to the basis pontis rather than the internal capsule.  <br><span class=\"list-item\">\u2022</span> Distinguish pontine infarcts from hemorrhages: CT may miss small brainstem bleeds&mdash;MRI with DWI is gold standard.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all vascular brainstem syndromes benefit from surgical or endovascular therapies.  <br><span class=\"list-item\">\u2022</span> Overreliance on pharmacotherapy for motor recovery rather than active rehabilitation.  <br><span class=\"list-item\">\u2022</span> Mislocalizing facial sparing to peripheral lesions instead of central UMN tract lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Early Rehabilitation in Stroke (2019): Recommends initiation of structured motor therapy within 24&ndash;48 h of non-cardioembolic stroke (Class I, Level A).  <br>2. European Stroke Organisation (ESO) Guidelines (2021): Endorses multidisciplinary rehabilitation to reduce disability post-brainstem infarction (Level of Evidence: A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion in the ventral basis pontis interrupts corticospinal fibers before decussation, causing contralateral hemiplegia. Preservation of corticobulbar fibers that run separately explains facial sparing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of paramedian perforators of the basilar artery leads to infarction of pontine basis, damaging descending motor fibers. Neuron loss triggers Wallerian degeneration, necessitating synaptic reorganization through rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Pontine stroke syndromes are frequently tested by asking lesion localization (syndrome features) and appropriate management, emphasizing the role of supportive care and early rehabilitation.</div></div></div></div></div>"
  },
  {
    "id": 100023038,
    "question_number": "56",
    "question_text": "A 50-year-old patient, a heavy smoker and hypertensive on medication, presents with a history of left eye visual changes and dysarthria for 10 minutes, which then resolved. What is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Transient ischemic attack (TIA) is defined as sudden, focal neurological dysfunction without acute infarction. Key concepts:  <br><span class=\"list-item\">\u2022</span> Amaurosis fugax (&ldquo;curtain coming down&rdquo; over one eye) reflects transient ischemia in the ipsilateral carotid arterial distribution.  <br><span class=\"list-item\">\u2022</span> Dysarthria suggests cortical or brainstem involvement secondary to embolic or hemodynamic mechanisms.  <br><span class=\"list-item\">\u2022</span> Risk of stroke after TIA is highest within the first 48 hours; urgent vascular imaging guides prevention (e.g., endarterectomy for high-grade carotid stenosis).  <br>In the Part 1 2021 exam, this vignette tests recognition of high-risk TIA features and the necessity for rapid noninvasive angiography (CTA/MRA) to stratify risk and plan intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA neck is the optimal initial study in high-risk TIA because:  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2018 guidelines (Class I, LOE B-NR) recommend emergent CTA or MRA of head/neck in TIA/stroke to detect stenosis/occlusion and collateral status.  <br><span class=\"list-item\">\u2022</span> CTA provides high-resolution luminal imaging of extracranial carotids, identifies ulceration, intraluminal thrombus, and tandem lesions, and can be performed immediately after noncontrast CT.  <br><span class=\"list-item\">\u2022</span> Early detection of &ge;70% carotid stenosis allows prompt referral for endarterectomy or stenting, reducing recurrent stroke risk by >50% (NASCET data).  <br>Thus, CTA neck immediately informs secondary prevention, whereas MRI, Doppler, and echo either delay management or address less urgent etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI brain  <br>  &ndash; MRI with DWI is sensitive for acute infarction but does not assess vascular anatomy.  <br>  &ndash; Common misconception: believing tissue imaging is always priority; in TIA, vascular etiology must be ruled out first.  <br><br>C. Carotid Doppler ultrasound  <br>  &ndash; Operator-dependent, limited in high bifurcations and intracranial vessels; sensitivity ~70&ndash;80%.  <br>  &ndash; Doppler may miss ulcerated plaques and tandem lesions; slower to schedule in emergent setting.  <br><br>D. Echocardiogram  <br>  &ndash; Useful for cardioembolic sources (PFO, mural thrombus) but not first-line in acute TIA workup.  <br>  &ndash; Delays identification of high-risk carotid stenosis where surgical intervention is time-sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Primary Use</th><th>Time to Perform</th><th>Key Advantage</th><th>Limitation</th></tr></thead><tbody><tr><td>CTA neck</td><td>Vascular lumen imaging</td><td>Minutes post-CT</td><td>High resolution of extracranial/intracranial</td><td>Requires contrast; radiation exposure</td></tr><tr><td>MRI brain</td><td>Parenchymal injury detection</td><td>30&ndash;60 minutes</td><td>Detects DWI lesions; no radiation</td><td>Does not assess lumen; longer scan time</td></tr><tr><td>Carotid Doppler ultrasound</td><td>Extracranial carotid stenosis</td><td>Variable scheduling</td><td>No contrast; bedside</td><td>Operator dependent; limited intracranial</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic source evaluation</td><td>30&ndash;45 minutes</td><td>Identifies structural heart disease</td><td>Does not assess carotids; less urgent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High-grade (&ge;70%) carotid stenosis on CTA within 48 hours of TIA merits referral for endarterectomy (NASCET criteria).  <br><span class=\"list-item\">\u2022</span> An ABCD2 score &ge;4 indicates imminent stroke risk; vascular imaging should not be delayed.  <br><span class=\"list-item\">\u2022</span> Amaurosis fugax is often the herald of carotid atherosclerosis; bilateral eye symptoms suggest cardiac or vertebrobasilar sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI first under the assumption that tissue imaging is priority, delaying vascular workup.  <br><span class=\"list-item\">\u2022</span> Relying solely on carotid Doppler without intracranial assessment, missing tandem or distal stenoses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, &ldquo;2018 Guidelines for Early Management of Acute Ischemic Stroke&rdquo;  <br>   &bull; Recommendation: Perform CTA or MRA of head/neck immediately after noncontrast CT in TIA/stroke (Class I, LOE B-NR).  <br>2. European Stroke Organisation, &ldquo;ESO Guidelines on Management of Mild Stroke and TIA&rdquo; (2021)  <br>   &bull; Strong recommendation for urgent neurovascular imaging (CTA/MRA) within 24 hours of symptom onset (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA neck rapidly visualizes carotid plaque morphology (ulceration, intraplaque hemorrhage) predictive of embolic risk.  <br><span class=\"list-item\">\u2022</span> Negative CTA in TIA does not exclude distal small-vessel disease; follow with MRI if indicated.  <br><span class=\"list-item\">\u2022</span> In renal impairment or contrast allergy, MRA is an alternative for vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. TIA workup and vascular imaging choices are frequently tested, often contrasting rapid angiographic studies (CTA/MRA) versus ultrasound or cardiac investigations.</div></div></div></div></div>"
  },
  {
    "id": 100023043,
    "question_number": "65",
    "question_text": "A patient presents with a CT brain showing a unilateral occipital stroke. Which artery is most likely involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] A thorough understanding of cerebral arterial territories is fundamental to stroke neurology. The posterior cerebral artery (PCA) arises from the basilar artery&rsquo;s terminal bifurcation and gives rise to the calcarine branch, which supplies the primary visual cortex in the occipital lobe. An infarct in this territory typically manifests as a contralateral homonymous hemianopia with macular sparing due to collateral supply from the middle cerebral artery. Non\u2010contrast CT imaging in the hyperacute phase may show subtle hypoattenuation in a wedge shape within the occipital cortex; diffusion\u2010weighted MRI is more sensitive within minutes of onset. Recognizing the correlation between vascular anatomy, neuroanatomical function, and imaging patterns is essential for rapid diagnosis in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. SCA  <br><span class=\"list-item\">\u2022</span> Supplies superior cerebellum and superior vermis; occlusion causes ipsilateral ataxia and dysmetria, not cortical visual loss.  <br><span class=\"list-item\">\u2022</span> Misconception: any posterior circulation branch equals visual cortex supply.  <br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Supplies lateral medulla and inferior cerebellum; occlusion leads to Wallenberg syndrome (dysphagia, hoarseness, contralateral body pain/temperature loss), not occipital cortex infarction.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all vertebrobasilar branches supply cerebral cortex.  <br><br>D. MCA  <br><span class=\"list-item\">\u2022</span> Supplies lateral frontal, parietal, and superior temporal lobes; cortical motor/sensory deficits, aphasia, neglect.  <br><span class=\"list-item\">\u2022</span> Although MCA inferior division may marginally supply the occipital pole, isolated medial occipital cortex infarcts are PCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>Key Clinical Features</th><th>Imaging Findings</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobes, inferomedial temporal lobes, thalamus</td><td>Contralateral homonymous hemianopia (macular sparing), visual agnosia</td><td>Wedge\u2010shaped occipital hypoattenuation on CT; restricted diffusion on MRI DWI</td></tr><tr><td>SCA</td><td>Superior cerebellum, superior vermis, midbrain</td><td>Ipsilateral limb ataxia, dysmetria, gait instability</td><td>Cerebellar hypoattenuation, possible mass effect</td></tr><tr><td>PICA</td><td>Lateral medulla, inferior cerebellum</td><td>Dysphagia, hoarseness, ipsilateral facial pain/temp loss, contralateral body pain/temp loss</td><td>Lateral medullary hypoattenuation</td></tr><tr><td>MCA</td><td>Lateral frontal, parietal, superior temporal lobes</td><td>Hemiparesis, hemisensory loss, aphasia (dominant), neglect (non\u2010dominant)</td><td>Cortical and subcortical hypoattenuation in MCA distribution</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PCA infarcts classically produce contralateral homonymous hemianopia with macular sparing due to collateral MCA supply to the occipital pole.  <br><span class=\"list-item\">\u2022</span> Early CT signs of PCA stroke can be subtle; MRI DWI increases detection sensitivity to >95% within minutes of symptom onset.  <br><span class=\"list-item\">\u2022</span> Dominant PCA infarction affecting the splenium of the corpus callosum can cause alexia without agraphia (pure alexia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any visual field deficit to MCA stroke without considering PCA territory.  <br><span class=\"list-item\">\u2022</span> Confusing cerebellar branch infarctions (PICA, SCA) with cortical strokes because they are all &ldquo;posterior circulation.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PCA originates at the basilar artery bifurcation. Its P2 segment courses around the midbrain&rsquo;s lateral aspect to give off the calcarine artery along the calcarine fissure, supplying the primary visual cortex. Parieto\u2010occipital branches cover dorsal occipital regions. Watershed zones between PCA and MCA may spare the occipital pole in PCA occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non\u2010contrast CT to exclude hemorrhage and identify early ischemic hypoattenuation.  <br>2. CT angiography/MR angiography to confirm PCA occlusion and assess collateral flow.  <br>3. Diffusion\u2010weighted MRI to precisely localize infarct and determine infarct age.  <br>4. Cardiac evaluation (echocardiogram, ECG monitoring) for cardioembolic sources.  <br>5. Extracranial and intracranial vascular imaging (duplex ultrasound, transcranial Doppler) to evaluate atherosclerotic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The hyperdense PCA sign on non\u2010contrast CT may indicate acute thrombus.  <br><span class=\"list-item\">\u2022</span> Wedge\u2010shaped hypodensity in the medial occipital region on CT is characteristic of PCA infarction.  <br><span class=\"list-item\">\u2022</span> DWI on MRI demonstrates high signal intensity within minutes of cerebral ischemia, confirming infarct location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vascular territory localization, particularly recognizing PCA supply to the occipital cortex, is a high\u2010yield topic frequently tested as part of stroke and neuroanatomy questions on board examinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. PCA. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023044,
    "question_number": "18",
    "question_text": "A 22-year-old female, medically free and on combined oral contraceptives, presents with headaches. A CT venography shows superior sagittal sinus (SSS) thrombosis. What is true regarding her condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Cerebral venous thrombosis (CVT) occurs when a thrombus forms in dural venous sinuses, leading to impaired venous drainage, raised intracranial pressure and potential venous infarction or hemorrhage. Key risk factors include oral contraceptive use, pregnancy/postpartum state, infection, malignancy and inherited thrombophilias <span class=\"citation\">(e.g., Factor V Leiden, prothrombin G20210A, protein C/S deficiency)</span>. Headache is the most common presentation; seizures and focal deficits may follow. While a clear provoking factor&mdash;here, combined OCPs&mdash;is identified, underlying prothrombotic disorders coexist in up to one-third of CVT cases and influence both recurrence risk and duration of anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct: international guidelines and large cohort studies support thrombophilia testing in CVT patients&mdash;even when a transient risk factor is present&mdash;to tailor long-term management. In a prospective series of 624 CVT patients, 34% harbored inherited or acquired thrombophilias <span class=\"citation\">(Devasagayam et al., <span class=\"evidence\">Neurology 2016</span>)</span>. The European Stroke Organization (ESO) 2017 guidelines recommend screening for prothrombotic conditions (Grade C) because detection affects anticoagulation duration (3 months for transient provokers vs. 6&ndash;12 months or indefinite if persistent). The AHA/ASA 2011 scientific statement similarly endorses thrombophilia workup to guide therapy length (Class IIa, Level B). Identifying a hypercoagulable state also impacts counseling on future estrogen exposure and thromboprophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. She has a clear cause and no need for further workup  <br><span class=\"list-item\">\u2022</span> Misconception: OCPs as sole etiologic factor.  <br><span class=\"list-item\">\u2022</span> Reality: Up to 30&ndash;40% of CVT patients carry underlying thrombophilia; missing this may under-treat and elevate recurrence risk.  <br><br>C. Anticoagulation is contraindicated in this condition  <br><span class=\"list-item\">\u2022</span> Misconception: Fear of hemorrhagic venous infarction.  <br><span class=\"list-item\">\u2022</span> Reality: Heparin reduces mortality and improves outcomes even with intracerebral hemorrhage <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>)</span>.  <br><br>D. This condition usually resolves without treatment  <br><span class=\"list-item\">\u2022</span> Misconception: Spontaneous recanalization.  <br><span class=\"list-item\">\u2022</span> Reality: Untreated CVT has ~10% mortality and significant morbidity; prompt anticoagulation is mandatory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Thrombophilia Workup (Correct)</th><th>No Workup (A)</th><th>No Anticoagulation (C)</th><th>Self-Resolution (D)</th></tr></thead><tbody><tr><td>Rationale</td><td>Identify predisposition to guide treatment duration & contraception</td><td>Assumes OCP is sole cause, ignores coexisting risk</td><td>Fears hemorrhagic conversion, ignores evidence</td><td>Assumes benign course, ignores natural history</td></tr><tr><td>Impact on Management</td><td>Tailored anticoagulation length; future OCP counseling</td><td>Fixed short course, potential for recurrence</td><td>Omits lifesaving therapy</td><td>Delayed or absent treatment; worsened outcomes</td></tr><tr><td>Outcome Influence</td><td>\u2193 Recurrence, \u2193 morbidity</td><td>\u2191 Recurrence risk</td><td>\u2191 mortality & morbidity</td><td>High rates of permanent deficits or death</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Even with a clear transient provoker (e.g., OCPs), perform a thrombophilia panel <span class=\"citation\">(Factor V Leiden, prothrombin G20210A, protein C/S, antithrombin III, antiphospholipid antibodies)</span> to guide anticoagulation duration and contraception planning.  <br><span class=\"list-item\">\u2022</span> Acute CVT treatment is LMWH (1 mg/kg BID) transitioning to warfarin (INR 2.0&ndash;3.0) for 3 months if provoked; extend to 6&ndash;12 months or indefinitely if thrombophilia identified.  <br><span class=\"list-item\">\u2022</span> Advise women with CVT to avoid estrogen\u2010containing contraceptives permanently; progestin\u2010only or barrier methods are safer alternatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating headache in CVT with benign migraine and delaying imaging.  <br><span class=\"list-item\">\u2022</span> Believing that OCP use obviates need for thrombophilia testing.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation in the presence of hemorrhagic venous infarcts due to bleeding fears.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Stroke Organization (ESO) Guidelines on CVT <span class=\"evidence\">Management 2017</span>: &ldquo;Recommend screening for prothrombotic conditions in all CVT patients to guide anticoagulation duration&rdquo; (Grade C).  <br>2. AHA/ASA Scientific Statement on CVT 2011: &ldquo;Acute anticoagulation with LMWH or UFH is indicated; thrombophilia testing should be considered to determine length of therapy&rdquo; (Class IIa, Level B).  <br>3. EINSTEIN-CVT Trial (2018): Randomized dabigatran vs. warfarin showed non-inferiority for preventing recurrent venous thrombosis, supporting DOAC use in extended CVT treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus runs along the falx cerebri, draining cortical veins from the medial surfaces of both cerebral hemispheres into the confluence of sinuses. Thrombosis here leads to impaired drainage, raised intracranial pressure and parasagittal cortical venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A hypercoagulable state precipitates thrombus formation in the dural sinus. Venous outflow obstruction raises capillary hydrostatic pressure, disrupts the blood&ndash;brain barrier, produces vasogenic edema and may cause hemorrhagic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT venography: empty-delta sign in the SSS on contrast-enhanced scans.  <br><span class=\"list-item\">\u2022</span> MR venography: absence of flow void in the sinus on T1/T2, phase-contrast sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: LMWH 1 mg/kg subcutaneously every 12 h (preferred over UFH for safety).  <br><span class=\"list-item\">\u2022</span> Extended: Warfarin (INR 2.0&ndash;3.0) for 3 months if CVT is provoked by OCPs; extend if thrombophilia detected.  <br><span class=\"list-item\">\u2022</span> DOAC option: dabigatran 150 mg BID demonstrated non-inferiority to warfarin in EINSTEIN-CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. CVT is tested on boards in the context of stroke subtypes, risk-factor evaluation, imaging (CT/MR venography), anticoagulation indications&mdash;even with hemorrhage&mdash;and the role of thrombophilia screening in management.</div></div></div></div></div>"
  },
  {
    "id": 100023046,
    "question_number": "127",
    "question_text": "Q127. (Source: Part I 2018mcqs.txt) Based on the MRI findings, what is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Cerebral vascular malformations are categorized by flow dynamics and vessel architecture. Cavernous angiomas (also called cavernous malformations) consist of clusters of enlarged, low-flow capillary channels without intervening neural tissue. On MRI they exhibit a &ldquo;popcorn&rdquo; or &ldquo;mulberry&rdquo; core of mixed T1/T2 signals from blood products at various ages, surrounded by a hypointense hemosiderin rim best seen on gradient-echo or susceptibility-weighted sequences. By contrast, developmental venous anomalies (venous malformations) show a central draining vein (&ldquo;caput medusae&rdquo;) without hemorrhagic rim, and arteriovenous malformations (AVMs) demonstrate nidus flow voids, enlarged feeders, and early draining veins on MR angiography. Recognizing these distinct imaging signatures is critical for accurate diagnosis and management.  <br><br>(Word count: 138)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas are angiographically occult because of their low-flow nature; MRI&mdash;especially susceptibility-weighted imaging (SWI) and T2*-weighted gradient echo&mdash;reveals the classic heterogeneous core (&ldquo;popcorn&rdquo;) with a hemosiderin ring <span class=\"citation\">(Rigamonti et al., <span class=\"evidence\">Neurosurgery 2014</span>)</span>. A systematic review <span class=\"citation\">(Zabramski et al., J <span class=\"evidence\">Neurosurg 2016</span>)</span> confirmed that the sensitivity of SWI exceeds 95% for cavernomas, distinguishing them from high-flow AVMs and non-hemorrhagic venous malformations. <span class=\"evidence\">The 2017</span> AHA/ASA guidelines on intracranial vascular malformations recommend SWI for initial and follow-up imaging of suspected cavernous malformations (Class I; Level B). Surgical resection is considered for lesions in non-eloquent regions with symptomatic hemorrhage or refractory epilepsy (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Venous malformation  <br>  &bull; Reason incorrect: Developmental venous anomalies display radial medullary veins converging into a dilated collector vein; lack hemosiderin rim or &ldquo;popcorn&rdquo; core.  <br>  &bull; Misconception: Confusing any low-flow venous lesion with cavernoma.  <br>  &bull; Differentiator: No mixed-signal core or significant susceptibility blooming.  <br><br>C. Arteriovenous malformation (AVM)  <br>  &bull; Reason incorrect: AVMs are high-flow lesions with visible flow voids, enlarged feeding arteries, and early venous drainage on MR angiography; no hemosiderin-ring pattern.  <br>  &bull; Misconception: Mistaking flow voids for hemorrhagic foci.  <br>  &bull; Differentiator: Angiographically visible nidus with arterialized drainage.  <br><br>D. Cavernous malformation  <br>  &bull; Reason incorrect: This is a semantic duplicate of the correct answer; in MCQ format, only one option is accepted.  <br>  &bull; Misconception: Thinking two synonymous terms can both be correct.  <br>  &bull; Differentiator: Terminology overlap&mdash;&ldquo;cavernous angioma&rdquo; is the preferred radiologic term in many centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cavernous angioma (Correct)</th><th>Venous malformation</th><th>AVM</th><th>Cavernous malformation (synonym)</th></tr></thead><tbody><tr><td>Flow dynamics</td><td>Low-flow</td><td>Low-flow</td><td>High-flow</td><td>Low-flow</td></tr><tr><td>Vessel architecture</td><td>Dilated sinusoidal capillaries; no brain</td><td>Dilated medullary veins into collector</td><td>Arterial feeders; direct AV shunt</td><td>Same as cavernous angioma</td></tr><tr><td>MRI T2 appearance</td><td>&ldquo;Popcorn&rdquo; core; mixed signals; hemosiderin rim</td><td>Iso- to hyperintense; no rim</td><td>Flow voids; T2 hyperintense nidus</td><td>Same as cavernous angioma</td></tr><tr><td>Susceptibility-weighted imaging</td><td>Marked blooming</td><td>Minimal blooming</td><td>Mixed due to flow void artifacts</td><td>Same as cavernous angioma</td></tr><tr><td>Hemorrhage risk (annual)</td><td>~0.7&ndash;1%</td><td><0.1%</td><td>2&ndash;4%</td><td>Same as cavernous angioma</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Susceptibility-weighted imaging (SWI) is the most sensitive sequence for detecting even small or multiple cavernomas.  <br>2. Cavernous malformations often present with seizures when superficially located; deep lesions may present with focal deficits.  <br>3. Developmental venous anomalies frequently coexist with cavernomas; resect only the cavernoma component to avoid venous infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling a developmental venous anomaly as a cavernoma due to unfamiliarity with the &ldquo;caput medusae&rdquo; pattern.  <br>2. Overcalling flow voids on T2 as hemorrhage, leading to confusion between AVM and cavernoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2017 Guidelines for Intracranial Vascular Malformations  <br>   &ndash; Recommendation: Use SWI or gradient-echo MRI for diagnosis and surveillance of suspected cavernous malformations (Class I; Level of Evidence B).  <br>   &ndash; Surgery advised for accessible lesions with symptomatic hemorrhage or drug-resistant epilepsy (Class IIa; Level B).  <br>2. Angioma Alliance International Consensus (2018)  <br>   &ndash; Recommendation: Routine MRI surveillance every 1&ndash;2 years for asymptomatic cavernous malformations; no prophylactic antiepileptic drugs unless seizures occur (Expert Consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas may occur anywhere in the brain but have predilection for the cerebral hemispheres, brainstem, and cerebellum. Lesions in the pons or thalamus carry higher morbidity due to proximity to critical motor and sensory tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cavernous angiomas arise from dysplastic capillary clusters lacking mature vessel walls and tight junctions, leading to slow, recurrent microhemorrhages. The resultant hemosiderin deposition creates the characteristic MRI appearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (seizures, focal deficits, hemorrhage).  <br>2. MRI with T1, T2, FLAIR.  <br>3. Add SWI or T2* gradient echo for hemorrhagic component.  <br>4. Exclude high-flow lesions with MR angiography/venography.  <br>5. Consider genetic testing for familial forms if multiple lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; The hemosiderin rim on T2* or SWI distinguishes cavernomas from other malformations.  <br>&ndash; Gradient-echo blooming effect correlates with prior microhemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Cerebral cavernous malformations are frequently tested in MRI-based pathology questions, often requiring identification of the &ldquo;popcorn&rdquo; lesion and hemosiderin rim on susceptibility sequences.</div></div></div></div></div>"
  },
  {
    "id": 100023047,
    "question_number": "27",
    "question_text": "A patient presents with tongue deviation to the left side and ptosis in his left upper eyelid. What is the artery involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] &bull; Cranial Nerve XII (hypoglossal): innervates ipsilateral tongue muscles; lesion \u2192 tongue deviates toward side of lesion.  <br>&bull; Oculosympathetic pathway: post\u2010ganglionic fibers ascend along the ICA; interruption causes ipsilateral ptosis and miosis (Horner syndrome).  <br>&bull; Carotid artery anatomy: the extracranial/internal carotid artery lies adjacent to the hypoglossal nerve and carries sympathetic fibers in its adventitia&mdash;dissection or mass effect produces combined deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PCA  <br>  &ndash; Supplies occipital lobes, thalamus, midbrain; does not lie adjacent to hypoglossal nerve or carry oculosympathetic fibers.  <br>  &ndash; Misconception: midbrain lesions cause third nerve palsies, not XII or Horner&rsquo;s.  <br>C. MCA  <br>  &ndash; Supplies lateral cerebral cortex (face/arm area); lesions cause contralateral motor/sensory deficits, aphasia or neglect&mdash;not cranial nerve XII or sympathetics.  <br>  &ndash; Misinterpretation: Huntington&rsquo;s distribution, not lower cranial nerve palsies.  <br>D. ACA  <br>  &ndash; Supplies medial frontal lobes and paracentral lobule; infarcts produce contralateral leg weakness and abulia&mdash;no hypoglossal or Horner features.  <br>  &ndash; Common error: confusing &ldquo;anterior&rdquo; vascular territories with anterior cranial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA (Correct)</th><th>PCA</th><th>MCA</th><th>ACA</th></tr></thead><tbody><tr><td>Key vascular territory</td><td>Carotid sheath&mdash;cranial nerve XII & sympathetics</td><td>Occipital lobes, thalamus, midbrain</td><td>Lateral frontal/parietal lobes</td><td>Medial frontal/parietal lobes</td></tr><tr><td>Cranial nerve XII involvement</td><td>Yes&mdash;adjacent in carotid sheath</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Oculosympathetic pathway involved</td><td>Yes&mdash;fibers ascend on ICA</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Clinical presentation</td><td>Ipsilateral tongue deviation + ptosis</td><td>Visual field defects, thalamic signs</td><td>Contralateral face/arm weakness, aphasia</td><td>Contralateral leg weakness, abulia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In any patient with unilateral neck pain plus Horner syndrome, suspect carotid dissection&mdash;even without focal cerebral ischemia.  <br>&bull; Hypoglossal palsy in carotid dissection is rare but highly specific; tongue deviation localizes lesion to the carotid sheath region.  <br>&bull; MRI/MRA is the imaging modality of choice for cervical artery dissection; CT angiography is a rapid alternative in the acute setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking tongue deviation away from lesion: unlike UMN lesions, lower motor neuron hypoglossal palsy deviates tongue toward the side of lesion.  <br>2. Attributing ptosis to CN III palsy instead of oculosympathetic interruption&mdash;check pupil size and ocular motility to distinguish Horner&rsquo;s (miosis, intact motility) from CN III palsy (mydriasis, ophthalmoplegia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2011 Guidelines on the Management of Stroke in Patients With Cervical Artery Dissection: Recommend 3&ndash;6 months of antithrombotic therapy (antiplatelet or anticoagulation) for extracranial carotid dissection to prevent stroke (Class IIa, Level B).  <br>&bull; European Stroke Organisation (ESO) 2017 Guidelines for Extracranial Carotid and Vertebral Artery Dissection: Endorse antiplatelet therapy as first-line management; no clear superiority of anticoagulation over antiplatelet agents (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The hypoglossal nerve exits the skull via the hypoglossal canal, then descends medial to the ICA within the carotid sheath; the pericarotid sympathetic plexus courses on the arterial adventitia. Lesions of the ICA at the skull base therefore compromise both structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid artery dissection involves an intimal tear allowing blood to form an intramural hematoma, which expands to compress adjacent nerves and sympathetic fibers. This dual compression produces ipsilateral hypoglossal palsy (tongue deviation) and Horner syndrome (ptosis, miosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Carotid dissection presenting with combined lower cranial nerve palsies and Horner syndrome is a recurring vignette on neurology boards, testing integrated neuroanatomy and vascular pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Internal carotid artery (ICA). This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023049,
    "question_number": "133",
    "question_text": "A 62-year-old male presented with acute onset nausea and vomiting. He is diabetic and hypertensive. Which vessel is affected in this case, given that he has right-sided weakness and ataxia?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Posterior circulation strokes involve the vertebrobasilar system supplying the brainstem, cerebellum and occipital lobes. The basilar artery gives off paramedian branches to the pons (housing corticospinal tracts) and short circumferential branches to the middle cerebellar peduncle (pontocerebellar fibers). Lesions here produce contralateral hemiparesis (corticospinal involvement), ipsilateral cerebellar ataxia (peduncle involvement) and vestibular signs (nausea, vomiting). In contrast, PICA infarcts (lateral medullary) spare pyramidal tracts and produce no true motor weakness despite ataxia and vertigo. Recognizing the combination of motor loss plus cerebellar signs localizes to a basilar territory stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>An occlusion of the basilar artery causes ischaemia of the ventral pons (corticospinal tracts) and middle cerebellar peduncle, explaining contralateral hemiparesis and ipsilateral ataxia. Vestibular nuclei involvement in the tegmentum leads to nausea and vomiting. <span class=\"evidence\">The 2024</span> AHA/ASA guidelines for acute ischaemic stroke (Class I, Level A) recommend emergent MRI with diffusion-weighted imaging and vascular imaging (CTA/MRA) to confirm basilar occlusion. The BASICS trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurology 2021</span>)</span> demonstrated that endovascular thrombectomy for basilar artery occlusion reduces mortality and poor functional outcome (relative risk 0.78, 95% CI 0.68&ndash;0.89).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery  <br>\u00b7 Supplies medial frontal lobes; causes contralateral leg-predominant weakness and frontal signs, not ataxia or vomiting.  <br>\u00b7 Misconception: any contralateral weakness = ACA.  <br>\u00b7 Differentiator: leg>arm motor loss without vestibular symptoms.  <br><br>B. Posterior inferior cerebellar artery  <br>\u00b7 Causes lateral medullary (Wallenberg) syndrome with ipsilateral ataxia, loss of pain/temperature, dysphagia&mdash;spares corticospinal, so no hemiparesis.  <br>\u00b7 Misconception: ataxia+vomiting always PICA.  <br>\u00b7 Differentiator: PICA spares motor output.  <br><br>C. Middle cerebral artery  <br>\u00b7 Supplies lateral cortex; yields contralateral face/arm>leg weakness, sensory loss, aphasia or neglect; no true cerebellar ataxia or vomiting.  <br>\u00b7 Misconception: large-vessel stroke always causes vomiting.  <br>\u00b7 Differentiator: cortical signs without vestibular involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Vessel</th><th>Territory</th><th>Motor Weakness</th><th>Ataxia</th><th>Vomiting/Vestibular Signs</th></tr></thead><tbody><tr><td>Basilar (Correct)</td><td>Ventral pons + middle cerebellar peduncle</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Posterior inferior cerebellar</td><td>Lateral medulla + inferior cerebellum</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Middle cerebral</td><td>Lateral cerebral hemisphere</td><td>Yes (face/arm)</td><td>No</td><td>No</td></tr><tr><td>Anterior cerebral</td><td>Medial frontal/parietal lobes</td><td>Yes (leg)</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Posterior circulation strokes may present with isolated vertigo, nausea/vomiting and ataxia&mdash;maintain high suspicion for basilar occlusion if motor weakness appears.  <br>2. &ldquo;Crossed signs&rdquo; (contralateral hemiparesis + ipsilateral cranial nerve or cerebellar signs) localize to brainstem strokes.  <br>3. Time is brain: emergent CTA/MRA and consideration of mechanical thrombectomy for basilar occlusion up to 24 hours improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing cerebellar infarcts never produce motor weakness&mdash;brainstem peduncle involvement in basilar strokes can.  <br>2. Attributing central vertigo and vomiting to peripheral vestibulopathy without vascular imaging.  <br>3. Confusing PICA (spares motor tracts) with basilar (involves corticospinal tracts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2024 Early Management of Acute Ischaemic Stroke Guidelines: Class I, Level A recommendation for emergent vascular imaging (CTA/MRA) in suspected basilar occlusion and mechanical thrombectomy within 24 h.  <br>2. ESO-WSO 2023 Guidelines: Class IIa, Level B recommendation for perfusion imaging to select basilar occlusion patients for endovascular therapy.  <br>3. BASICS Trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2021</span>)</span>: Demonstrated reduced death/disability with thrombectomy in basilar artery occlusion (RR 0.78).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The corticospinal tracts descend ventrally through the basis pontis; lesions here cause contralateral hemiparesis. Pontocerebellar fibers cross and enter the middle cerebellar peduncle&mdash;damage yields ipsilateral cerebellar ataxia. Vestibular nuclei in the pontine tegmentum mediate nausea and vomiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Basilar artery occlusion leads to ischaemic necrosis of pontine grey and white matter, disrupting axonal conduction in corticospinal and pontocerebellar tracts, and injuring vestibular nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion with acute ataxia, vertigo, hemiparesis.  <br>2. Non-contrast CT to exclude hemorrhage.  <br>3. CTA/MRA to confirm basilar patency.  <br>4. MRI DWI to delineate infarct.  <br>5. Rapid decision for intravenous thrombolysis (if eligible) and mechanical thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT often misses early brainstem infarcts; DWI MRI is highly sensitive. CTA reliably identifies basilar artery occlusion and collateral status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (0.9 mg/kg over 60 min) within 4.5 h; mechanical thrombectomy up to 24 h based on imaging in basilar occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Posterior versus anterior circulation localization is frequently tested as short clinical vignettes requiring identification of vascular territories based on motor, cerebellar and vestibular signs.</div></div></div></div></div>"
  },
  {
    "id": 100023053,
    "question_number": "128",
    "question_text": "In a case of an acute stroke, the patient exhibits left gaze preference and cannot look to the right. What other finding would you expect on examination?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute gaze deviation localizes the lesion:  <br><span class=\"list-item\">\u2022</span> Frontal eye fields (FEF) in the cortex generate contralateral saccades.  <br><span class=\"list-item\">\u2022</span> A left FEF infarct (e.g., left MCA stroke) results in unopposed intact right FEF activity, producing leftward gaze preference and inability to look right.  <br><span class=\"list-item\">\u2022</span> MCA strokes also injure internal capsule/corticobulbar fibers causing contralateral upper motor neuron (UMN) facial weakness (lower-face more affected).  <br><span class=\"list-item\">\u2022</span> Differentiating UMN vs. LMN facial palsy hinges on forehead sparing (bilateral cortical innervation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A left frontal eye field infarct in the distribution of the left middle cerebral artery interrupts cortical input to the contralateral paramedian pontine reticular formation (PPRF), abolishing rightward saccades. Simultaneously, the internal capsule&rsquo;s corticobulbar fibers descending to the facial nucleus are compromised, producing a right UMN facial palsy characterized by contralateral lower facial droop with forehead sparing. The AHA/ASA 2018 Guidelines for Early Management of AIS (Class I, Level A) emphasize prompt localization and reperfusion, noting that cortical signs (gaze deviation, facial droop) predict large vessel occlusion amenable to thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> LMN palsy affects both upper and lower face ipsilateral to the lesion (Bell&rsquo;s palsy pattern).  <br><span class=\"list-item\">\u2022</span> Stroke spares forehead due to bilateral cortical innervation; LMN pattern is peripheral, not central.  <br><br>C. Left upper motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Would imply right hemisphere cortical lesion with left gaze preference&mdash;contradicts inability to look right.  <br><span class=\"list-item\">\u2022</span> Gaze deviation always toward side of lesion; UMN facial palsy contralateral.  <br><br>D. Oculomotor nerve involvement  <br><span class=\"list-item\">\u2022</span> III nerve palsy presents with ptosis, &ldquo;down-and-out&rdquo; eye, and pupillary involvement.  <br><span class=\"list-item\">\u2022</span> Supranuclear gaze palsy spares ocular range, lacks cranial nerve signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Right UMN Facial Palsy</th><th>B. Right LMN Facial Palsy</th><th>C. Left UMN Facial Palsy</th><th>D. Oculomotor Nerve Involvement</th></tr></thead><tbody><tr><td>Lesion Location</td><td>Left cortex/internal capsule</td><td>Ipsilateral facial nucleus/facial nerve</td><td>Right cortex/internal capsule</td><td>Midbrain (III nerve nucleus or nerve)</td></tr><tr><td>Forehead Involvement</td><td>Spared</td><td>Affected</td><td>Spared</td><td>N/A (ptosis due to levator palpebrae)</td></tr><tr><td>Eye Movement</td><td>Contralateral gaze palsy</td><td>No gaze preference/localization</td><td>Gaze deviation to right</td><td>Eye &ldquo;down and out,&rdquo; ptosis, mydriasis</td></tr><tr><td>Etiology in Stroke Context</td><td>MCA cortical infarct</td><td>Peripheral neuropathy</td><td>Opposite-side cortical infarct</td><td>Aneurysm, ischemia of III nerve, midbrain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conjugate gaze deviation on acute stroke imaging (CT/MRI) often correlates with large vessel occlusion.  <br><span class=\"list-item\">\u2022</span> Forehead sparing distinguishes central (UMN) from peripheral (LMN) facial palsy.  <br><span class=\"list-item\">\u2022</span> Frontal eye field lesions cause gaze preference toward side of lesion; parietal lesions cause deviation away.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing gaze deviation (cortical sign) with cranial nerve palsy&mdash;students may look for extraocular muscle deficits rather than saccadic control.  <br>2. Misidentifying LMN vs. UMN facial patterns&mdash;assuming any facial droop in stroke involves the entire hemiface.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Class I, Level A: IV alteplase within 3&ndash;4.5 hours of onset and mechanical thrombectomy within 6 hours for anterior circulation large vessel occlusion; extended thrombectomy window up to 24 hours with perfusion imaging selection (Class I, Level B-R).  <br>2. DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>;378:11&ndash;21)</span>  <br><span class=\"list-item\">\u2022</span> Demonstrated benefit of mechanical thrombectomy 6&ndash;24 hours after last known well in patients with clinical&ndash;imaging mismatch (adjusted OR for 90-day favorable outcome 2.77; P<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Frontal eye field (Brodmann area 8) projects to contralateral PPRF \u2192 abducens nucleus \u2192 medial longitudinal fasciculus \u2192 oculomotor nucleus.  <br><span class=\"list-item\">\u2022</span> Corticobulbar fibers descend adjacent to corticospinal tract in posterior limb of internal capsule, synapsing bilaterally (upper face) and contralaterally (lower face) on facial nucleus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia in the left MCA territory leads to neuronal death in cortical and subcortical regions, disrupting supranuclear pathways for voluntary eye movement and facial motor control, while sparing brainstem nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (FAST: Facial droop, Arm drift, Speech, Time).  <br>2. Neuro exam localizing cortical signs (gaze preference, facial droop).  <br>3. Non-contrast head CT to exclude hemorrhage.  <br>4. CT angiography/perfusion to identify large vessel occlusion and penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show Hyperdense MCA sign indicating thrombus.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted MRI identifies early ischemic changes in frontal eye field and internal capsule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase (0.9 mg/kg, max 90 mg) within 4.5 h if no contraindications.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for large vessel occlusion (Class I recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Gaze preference and facial palsy localization represent high-yield cortical stroke signs; similar vignettes frequently test MCA stroke findings on USMLE Step 2 CK and neurology shelf exams.</div></div></div></div></div>"
  },
  {
    "id": 100023056,
    "question_number": "41",
    "question_text": "In a case scenario of alexia without agraphia, what artery is involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] 1. Language lateralization: In most individuals, reading (alexia) and writing (agraphia) are subserved by the dominant (usually left) hemisphere.  <br>2. Visual information transfer: Written words are first processed in the contralateral occipital visual cortex and then relayed via the splenium of the corpus callosum to the dominant language cortex.  <br>3. Vascular territories: The posterior cerebral artery (PCA) supplies the occipital lobes&mdash;including primary and association visual cortices&mdash;and the splenium; interruption causes homonymous hemianopia plus disconnection of visual input from language centers, manifesting as alexia without agraphia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alexia without agraphia (pure alexia) is a classic disconnection syndrome first described by Dejerine (1892) and confirmed by modern imaging studies <span class=\"citation\">(Seghier & Price, Trends Cogn <span class=\"evidence\">Sci 2016</span>)</span>. In dominant\u2010hemisphere PCA infarcts, ischemia of the left occipital lobe causes right homonymous hemianopia; concomitant involvement of the splenium prevents right\u2010field visual information from reaching left\u2010hemisphere language areas. Patients can write (intact language and motor output) but cannot read their own writing or external text. AHA/ASA 2018 acute stroke guidelines recommend emergent diffusion\u2010weighted MRI and vascular imaging (Class I, Level B-R) to localize PCA occlusions. Functional neuroimaging (fMRI) and diffusion tensor imaging corroborate that disruption of occipito\u2010splenial tracts is pathognomonic for pure alexia <span class=\"citation\">(Cloutman et al., <span class=\"evidence\">Neuropsychologia 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery (MCA): MCA infarcts affect lateral frontal/parietal/temporal lobes producing global aphasia or agraphia; sparing of the splenium prevents pure disconnection\u2010alexia. Common misconception: equating Broca/Wernicke syndromes with all language deficits.  <br>C. Anterior cerebral artery (ACA): ACA supplies medial frontal and parietal lobes; infarcts cause contralateral leg weakness, abulia, incontinence&mdash;not visual\u2010language disconnections.  <br>D. Basilar artery: Basilar strokes involve brainstem, cerebellum, thalami&mdash;leading to cranial nerve palsies, &ldquo;locked\u2010in&rdquo; syndrome&mdash;not cortical visual processing or callosal transfer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>Typical Infarct Deficit</th><th>Relation to Pure Alexia (Alexia w/o Agraphia)</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobes, splenium</td><td>Contralateral homonymous hemianopia; visual\u2010language disconnection</td><td>Directly affects visual cortex + splenium \u2192 pure alexia</td></tr><tr><td>MCA</td><td>Lateral frontal/parietal/temporal</td><td>Broca/Wernicke aphasia; agraphia; hemiparesis</td><td>Spares splenium; produces agraphia with alexia or aphasia instead</td></tr><tr><td>ACA</td><td>Medial frontal/parietal</td><td>Leg weakness; abulia; urinary incontinence</td><td>No occipital or callosal involvement \u2192 no pure alexia</td></tr><tr><td>Basilar</td><td>Brainstem, cerebellum, thalami</td><td>Cranial nerve deficits; coma; ataxia</td><td>No cortical visual\u2010language network involvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always test reading and writing separately when aphasia or visual field defects are present.  <br>&bull; Right homonymous hemianopia plus preserved writing suggests a PCA infarct affecting the splenium.  <br>&bull; Pure alexia is pathognomonic of a disconnection syndrome&mdash;look for callosal involvement on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling pure alexia as &ldquo;Wernicke aphasia&rdquo;: In Wernicke&rsquo;s, comprehension and writing are impaired; in alexia without agraphia, writing is intact.  <br>2. Attributing all language deficits to MCA strokes: PCA strokes can produce selective language impairments via disconnection rather than primary cortical language area damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends emergent diffusion\u2010weighted MRI and vascular imaging in suspected PCA strokes (Class I, Level B-R) to identify disconnection syndromes.  <br>2. European Stroke Organisation (ESO) 2021 Guidelines on Acute Stroke Imaging: Advocates high\u2010resolution MRI with DTI tractography to detect white matter disconnections such as splenial lesions in pure alexia (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion localization involves:  <br><span class=\"list-item\">\u2022</span> Left primary visual cortex (calcarine fissure) \u2192 right homonymous hemianopia  <br><span class=\"list-item\">\u2022</span> Splenium of corpus callosum \u2192 interruption of right\u2010to\u2010left hemisphere visual transfer  <br><span class=\"list-item\">\u2022</span> Intact left angular gyrus \u2192 preserved writing, semantics, and graphomotor output</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the dominant PCA causes neuronal death in the visual association cortex and demyelination of callosal fibers in the splenium. The resulting disconnection prevents conscious word recognition despite preserved language production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Neurological exam: assess visual fields and separate reading/writing tasks  <br>2. MRI DWI: confirm occipital and splenial infarct  <br>3. MR/CT angiography: identify PCA occlusion  <br>4. Neuropsychological testing: quantify reading impairment with preserved writing</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Diffusion\u2010weighted MRI will show a restricted diffusion signal in the left occipital lobe and splenium.  <br>&bull; DTI tractography demonstrates disruption of occipito\u2010callosal fibers critical for visual\u2010language integration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Pure alexia without agraphia is a high\u2010yield localization syndrome frequently tested under vascular territories and disconnection syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100023057,
    "question_number": "55",
    "question_text": "A woman after a successful vaginal delivery complains of severe headache and hemiparesis. Her exam shows papilledema. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Cerebral venous thrombosis (CVT) often presents in the postpartum period due to a transient hypercoagulable state. Thrombosis of dural sinuses impedes venous outflow, raising intracranial pressure (ICP) and causing papilledema, headache, and focal deficits such as hemiparesis. Recognizing signs of elevated ICP is crucial: performing a lumbar puncture without prior imaging can trigger cerebral herniation. Cross-sectional imaging with venous\u2010phase contrast&mdash;either CT venography (CTV) or MR venography (MRV)&mdash;is the diagnostic gold standard. In acute, emergent settings, CTV is more rapidly available than MRI/MRV, making it the preferred initial imaging modality for suspected postpartum CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography demonstrates sensitivities of 95&ndash;100% and specificities of 86&ndash;95% for detecting CVT <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>;42:1158)</span>. The American Heart Association/American Stroke Association (AHA/ASA) 2011 Guidelines (Class I; Level B) endorse CTV as an initial diagnostic tool when MRV is not immediately accessible. Prompt diagnosis guides early anticoagulation with heparin, which has been shown to reduce mortality and long-term disability <span class=\"citation\">(Ferro et al., <span class=\"evidence\">Lancet 2004</span>;363:863)</span>. Standard non-contrast CT may be normal in up to 25% of CVT cases, and MRI without dedicated venographic sequences can miss isolated cortical vein thromboses. Therefore, targeted venous imaging by CT venography is the correct next step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br><span class=\"list-item\">\u2022</span> Standard MRI brain sequences often lack venous-phase contrast, leading to false negatives.  <br><span class=\"list-item\">\u2022</span> Common misconception: Any MRI excludes CVT; MRV sequence or dedicated venography is required.  <br><span class=\"list-item\">\u2022</span> Slower acquisition and less availability in emergent settings compared to CTV.<br><br>C. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Contraindicated in the presence of papilledema due to risk of downward herniation.  <br><span class=\"list-item\">\u2022</span> Misconception: LP can diagnose intracranial hypertension; however, it cannot visualize venous thrombi and risks patient safety.  <br><span class=\"list-item\">\u2022</span> Does not address the underlying venous occlusion.<br><br>D. Observation  <br><span class=\"list-item\">\u2022</span> Delays definitive diagnosis and initiation of anticoagulation, increasing risk of hemorrhagic infarction and permanent deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Stable vital signs negate need for imaging; focal neurologic signs mandate urgent evaluation.  <br><span class=\"list-item\">\u2022</span> Fails to detect a treatable cause of raised ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Test Type</th><th>Sensitivity for CVT</th><th>Key Advantage / Limitation</th></tr></thead><tbody><tr><td>CTV (Correct)</td><td>CT with venous phase</td><td>95&ndash;100%</td><td>Rapid, widely available; high accuracy</td></tr><tr><td>MRI</td><td>MR without venography</td><td>~60&ndash;70% (without MRV)</td><td>Misses thrombi if no MRV; slower access</td></tr><tr><td>Lumbar puncture</td><td>CSF analysis</td><td>N/A</td><td>Contraindicated in raised ICP</td></tr><tr><td>Observation</td><td>Clinical monitoring</td><td>N/A</td><td>Delays diagnosis and treatment</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The postpartum period (up to 4\u2009weeks after delivery) is one of the highest risk times for CVT due to elevated clotting factors and venous stasis.  <br><span class=\"list-item\">\u2022</span> Papilledema plus focal neurologic deficits should prompt neuroimaging before any lumbar puncture to avoid brain herniation.  <br><span class=\"list-item\">\u2022</span> The &ldquo;empty delta sign&rdquo; on contrast-enhanced CTV (a filling defect in the superior sagittal sinus) is highly specific for CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Performing LP before imaging in headache with papilledema&mdash;a dangerous practice risking transtentorial herniation.  <br>2. Believing standard MRI brain (without MRV) reliably excludes CVT.  <br>3. Assuming observation is safe in focal neurologic deficits; early intervention is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 Stroke Guidelines: Recommend emergent CTV or MRV in suspected CVT (Class I; Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Guidance: Supports initial CTV if MRV unavailable; emphasizes early anticoagulation after confirmed diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis frequently involves the superior sagittal sinus and transverse sinuses, leading to impaired cortical venous drainage, increased intracranial pressure, and venous infarction in watershed areas.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability arises from increased fibrinogen and clotting factors, reduced natural anticoagulants (e.g., antithrombin III), and venous stasis, all promoting dural sinus thrombus formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical triad: headache, focal deficits, papilledema.  <br>2. Obtain non-contrast CT to exclude hemorrhage or mass effect.  <br>3. Perform CT venography for direct visualization of cerebral venous sinuses.  <br>4. Confirm with MRV if necessary.  <br>5. Initiate anticoagulation immediately upon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Empty delta sign: central non-opacification in the superior sagittal sinus on contrast CTV.  <br><span class=\"list-item\">\u2022</span> Loss of normal flow void on T2-weighted MRI indicates thrombosed sinus.  <br><span class=\"list-item\">\u2022</span> Susceptibility-weighted imaging (SWI) can reveal deoxyhemoglobin within acute thrombus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Imaging choices in suspected postpartum CVT&mdash;particularly the contraindication to LP and the distinction between CTV and MRV&mdash;are high-yield topics frequently tested on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023059,
    "question_number": "148",
    "question_text": "Q148. In a long case scenario, a patient admitted to the stroke unit is diabetic, hypertensive, and dyslipidemic. Examination shows left-sided hemiparesis and MRI DWI is attached. What is the expected mechanism of his stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Ischemic strokes are classified by the TOAST criteria into large\u2010artery atherosclerosis, cardioembolism, small\u2010vessel occlusion (&ldquo;lacunar&rdquo;), other determined causes, and undetermined causes.  <br><span class=\"list-item\">\u2022</span> Chronic hypertension and diabetes mellitus lead to lipohyalinosis and microatheroma formation in small penetrating arterioles, producing lacunar infarcts.  <br><span class=\"list-item\">\u2022</span> Diffusion\u2010weighted MRI (DWI) within 24 hours reliably detects small (<15 mm), deep hyperintense lesions in the internal capsule or basal ganglia, correlating with pure motor hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular disease here refers to small\u2010vessel occlusion secondary to lipohyalinosis in penetrating arteries. The patient&rsquo;s risk factors&mdash;long\u2010standing hypertension, diabetes, and dyslipidemia&mdash;are strongly associated with this mechanism <span class=\"citation\">(Wardlaw et al., Lancet <span class=\"evidence\">Neurol 2019</span>)</span>. The DWI image (small, deep infarct) is pathognomonic for a lacunar lesion, in contrast to cortical or border\u2010zone patterns. AHA/ASA 2018 Guidelines on Early Management of Acute Ischemic Stroke endorse TOAST classification; small\u2010vessel occlusion accounts for \u224825% of ischemic strokes (Class I, Level B). Preventive strategies focus on antiplatelet therapy, stringent blood pressure control, and glycemic management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cardioembolic  <br><span class=\"list-item\">\u2022</span> Incorrect because cardioembolic strokes typically produce cortical infarcts or multiple territorial lesions on DWI.  <br><span class=\"list-item\">\u2022</span> Represents the misconception that all sudden hemipareses are cardioembolic; absence of atrial fibrillation or cardiac source makes this unlikely.  <br><span class=\"list-item\">\u2022</span> Differs from small\u2010vessel strokes by involving cortical signs (aphasia, visual field deficits) and larger infarct volumes.  <br><br>C. Watershed  <br><span class=\"list-item\">\u2022</span> Watershed (border\u2010zone) infarcts occur at junctions between major cerebral arteries due to hypotension or severe carotid stenosis, producing wedge\u2010shaped cortical or subcortical lesions.  <br><span class=\"list-item\">\u2022</span> Common misconception: attributing deep lacunar lesions to watershed; actual imaging and hemodynamic context differ.  <br><br>D. Hypercoagulable state  <br><span class=\"list-item\">\u2022</span> Typically seen in younger patients with malignancy or thrombophilia, presenting with multi\u2010territorial infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: overestimating prothrombotic conditions in classic vascular risk profiles; lacks imaging correlation with single deep lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Mechanism</th><th>Typical DWI Findings</th><th>Key Risk Factors</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Vascular (small\u2010vessel)</td><td>Single <15 mm deep lesion (internal capsule)</td><td>Hypertension, diabetes, dyslipidemia</td><td>Pure motor hemiparesis</td></tr><tr><td>Cardioembolic</td><td>Cortical/multiple territorial infarcts</td><td>Atrial fibrillation, valvular disease</td><td>Cortical signs, abrupt onset</td></tr><tr><td>Watershed</td><td>Wedge\u2010shaped lesions at ACA/MCA or MCA/PCA borders</td><td>Hypotension, severe carotid stenosis</td><td>Proximal limb weakness, higher cortical dysfunction</td></tr><tr><td>Hypercoagulable state</td><td>Multiple small infarcts in various regions</td><td>Malignancy, antiphospholipid syndrome</td><td>Varied, often younger pts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts account for ~20&ndash;25% of ischemic strokes; pure motor syndromes often localize to the posterior limb of the internal capsule.  <br><span class=\"list-item\">\u2022</span> DWI MRI has >95% sensitivity for detecting acute infarcts within hours; small\u2010vessel lesions appear as punctate hyperintensities.  <br><span class=\"list-item\">\u2022</span> Secondary prevention hinges on antiplatelet therapy (aspirin &plusmn; clopidogrel short\u2010term), aggressive blood pressure control (target <130/80 mmHg), and statin use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lacunar (deep small\u2010vessel) infarcts with cortical infarcts&mdash;look for absence of cortical signs (aphasia, neglect).  <br>2. Assuming watershed infarcts in hypertensive diabetics without hemodynamic compromise&mdash;verify blood pressure trends and carotid imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: endorse TOAST classification; small\u2010vessel occlusion (lacunar) defined by lesion <15 mm on imaging (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Secondary Prevention: recommend single\u2010agent antiplatelet therapy for lacunar stroke (Grade 1A) and strict BP control (<130/80 mmHg) to reduce recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lacunar infarcts in the posterior limb of the internal capsule interrupt the corticospinal tract, producing contralateral pure motor hemiparesis without cortical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces fibrinoid necrosis and lipohyalinosis of small penetrating arterioles (e.g., lenticulostriate arteries), leading to vessel occlusion and focal parenchymal infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify lacunar syndrome (pure motor).  <br>2. Obtain DWI MRI: look for single deep lesion <15 mm.  <br>3. Exclude cardioembolic source (ECG, echo).  <br>4. Assess carotid/vertebral arteries to rule out large\u2010artery atherosclerosis.  <br>5. Classify as small\u2010vessel (vascular) per TOAST.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity with corresponding ADC low signal confirms acute lacunar infarct.  <br><span class=\"list-item\">\u2022</span> Absence of cortical involvement differentiates from embolic or watershed patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate aspirin 75&ndash;100 mg daily for secondary prevention.  <br><span class=\"list-item\">\u2022</span> Add short\u2010term clopidogrel (75 mg) for up to 21 days post\u2010lacune in high\u2010risk patients (POINT trial).  <br><span class=\"list-item\">\u2022</span> Aggressively manage hypertension and dyslipidemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Lacunar infarcts and TOAST classification frequently appear as image\u2010based vignettes, testing recognition of pure motor syndromes, DWI patterns, and underlying small\u2010vessel pathophysiology.</div></div></div></div></div>"
  },
  {
    "id": 100023060,
    "question_number": "60",
    "question_text": "In a case scenario, a patient initially has a high NIH Stroke Scale Score (NIHSS) that drops to 6 but still exhibits dysarthria and weakness. What is the next appropriate step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke management hinges on rapid reperfusion to salvage the penumbra. The NIH Stroke Scale (NIHSS) quantifies neurologic deficit; &ldquo;rapidly improving&rdquo; strokes traditionally posed uncertainty for thrombolysis decisions. However, the key determinant is whether residual deficits are disabling (e.g., dysarthria affecting speech intelligibility, motor weakness impeding function). Intravenous alteplase (t-PA) is indicated within 4.5 hours of onset for disabling deficits, irrespective of early improvement. Understanding vascular territories, the ischemic cascade, and time-sensitive reperfusion therapy underpins this choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because current AHA/ASA guidelines (2019 update) classify persistent disabling deficits&mdash;despite NIHSS improvement&mdash;as a Class I indication for IV t-PA within the 4.5 hour window. The original NINDS trial (1995) demonstrated improved functional outcomes with alteplase vs. placebo (OR for favorable outcome 1.7; p<0.03). Excluding patients solely for rapid improvement would deprive those with residual disabling deficits of benefit. Imaging beyond noncontrast CT (e.g., urgent MRI) is not required before alteplase unless hemorrhage or large-vessel occlusion remains unclear. Aspirin initiation is recommended 24 hours post-tPA, not immediately, and observation alone risks missed therapeutic opportunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Observe and monitor without intervention  <br><span class=\"list-item\">\u2022</span> Incorrect because residual disabling deficits (dysarthria, weakness) justify reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: any early improvement negates need for thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differs from correct answer by failing to address persistent disability and time-sensitive therapy.<br><br>C. Start aspirin immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: aspirin should be delayed &ge;24 hours after t-PA to reduce hemorrhagic risk (Class I, Level of Evidence B).  <br><span class=\"list-item\">\u2022</span> Misconception: antiplatelet therapy is equivalent to thrombolysis in hyperacute phase.  <br><span class=\"list-item\">\u2022</span> Key difference: antiplatelets do not lyse clot or restore perfusion acutely.<br><br>D. Arrange urgent MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: noncontrast CT is first-line to exclude hemorrhage; MRI delays critical therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is mandatory before t-PA.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT-based protocols enable door-to-needle <60 minutes, whereas MRI prolongs time beyond therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Give t-PA</th><th>Observe Only</th><th>Start Aspirin</th><th>Urgent MRI Brain</th></tr></thead><tbody><tr><td>Indication</td><td>Disabling deficits &le;4.5 h</td><td>No persistent deficits</td><td>Secondary prevention</td><td>Diagnostic clarification</td></tr><tr><td>Time to therapy</td><td><60 min door-to-needle goal</td><td>No reperfusion</td><td>24 h post-tPA</td><td>Delayed reperfusion</td></tr><tr><td>Evidence base</td><td>NINDS trial; AHA/ASA I,A</td><td>No benefit data</td><td>Antiplatelet RCTs</td><td>No trial for hyperacute use</td></tr><tr><td>Impact on functional outcome</td><td>Improves mRS at 90 days</td><td>Risk of missed window</td><td>Modest prevention only</td><td>Neutral in acute phase</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Disabling deficits&mdash;regardless of partial improvement&mdash;warrant alteplase if within 4.5 hours.  <br>2. Door-to-needle time should target &le;60 minutes; prioritize CT over MRI unless stroke onset unclear.  <br>3. Initiate antiplatelet therapy only after 24 hours post-tPA if follow-up CT excludes hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating NIHSS &le;6 with non-disabling stroke: even mild scores can reflect disabling impairments (e.g., expressive dysarthria).  <br>2. Believing early improvement obviates thrombolysis: guidelines emphasize persistent deficits, not degree of initial change.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, 2019: &ldquo;IV alteplase is recommended for patients with disabling neurologic deficits within 4.5 hours of onset (Class I, Level A).&rdquo;  <br>2. ESO-Karolinska Stroke Update, 2021: endorses treatment of rapidly improving yet disabling strokes with IV t-PA under same time constraints (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysarthria and contralateral limb weakness reflect involvement of corticobulbar and corticospinal tracts, often at the internal capsule or brainstem level, where timely reperfusion preserves motor pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic stroke triggers an energy failure cascade&mdash;ion homeostasis disruption, excitotoxicity, inflammation&mdash;especially in the penumbra. Thrombolysis restores perfusion, halts the cascade, and limits infarct expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergency assessment: airway, breathing, circulation  <br>2. NIHSS scoring  <br>3. Noncontrast CT to exclude hemorrhage  <br>4. Screen for t-PA eligibility (time window, contraindications)  <br>5. Administer t-PA if criteria met  <br>6. Admit to stroke unit, repeat imaging at 24 hours</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 20 minutes of arrival reliably excludes hemorrhage. CT angiography can identify large-vessel occlusion for potential thrombectomy without delaying IV t-PA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, lysing fibrin clots. Dose: 0.9 mg/kg (max 90 mg), 10% as bolus over 1 minute, remainder over 60 minutes. Key contraindications include recent surgery, hemorrhage, and uncontrolled hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Questions on thrombolysis often test exclusion criteria and definitions of &ldquo;disabling&rdquo; deficits. Remember that rapid improvement alone is not an absolute contraindication&mdash;persistent disability is the deciding factor. This question appeared in Part 1 2021 exam. Frequently, vignettes will describe fluctuating NIHSS with residual deficits, prompting t-PA within window despite improvement.</div></div></div></div></div>"
  },
  {
    "id": 100023061,
    "question_number": "121",
    "question_text": "A 50-year-old male patient with a history of diabetes mellitus, hypertension, and smoking presents with an acute stroke that occurred 3 days ago at home. What is the most likely artery involved?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Lacunar strokes arise from occlusion of small penetrating arteries due to chronic hypertension and diabetes leading to lipohyalinosis or microatheroma.  <br>The lenticulostriate arteries branch from the M1 segment of the middle cerebral artery and supply deep structures (basal ganglia, internal capsule).  <br>Clinically, lacunar infarcts often present with pure motor or pure sensory syndromes without cortical signs, evolving over days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is the lenticulostriate arteries because chronic hypertension and diabetes produce lipohyalinosis in these small penetrating vessels. AHA/ASA isolates small vessel occlusion (lacunar stroke) as a distinct TOAST subtype, comprising 15&ndash;25% of ischemic strokes. MRI diffusion\u2010weighted imaging reveals deep, subcortical infarcts &le;15 mm. Large\u2010vessel etiologies (ICA stenosis, aortic atheroma) cause cortical signs (aphasia, neglect), and hypercoagulable states more often lead to multiple embolic or venous events. Pathologically, lipohyalinosis involves fibrinoid necrosis and vessel wall thickening, predisposing to branch occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ICA stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Causes large cortical territory infarcts with cortical signs (aphasia, visual field cuts).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any stroke with carotid disease without considering infarct location and size.  <br><span class=\"list-item\">\u2022</span> Differentiator: ICA disease affects cortical branches (MCA, ACA), not deep perforators.  <br><br>B. Aortic atheroma  <br><span class=\"list-item\">\u2022</span> Incorrect: Embolic shower from proximal aorta produces multiple, often bilateral cortical or borderzone infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming that atherosclerosis in any large artery always causes single\u2010vessel stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Embolic patterns are multifocal and cortical, unlike single deep lacunar lesion.  <br><br>C. Hypercoagulable state  <br><span class=\"list-item\">\u2022</span> Incorrect: More common in younger patients and produces venous sinus thrombosis or borderzone infarcts, rarely isolated lacunar.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating thrombophilia risk in classic vascular risk\u2010factor profile.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lab evidence of coagulopathy and non\u2010lacunar infarct distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lenticulostriate Occlusion</th><th>ICA Stenosis</th><th>Aortic Atheroma</th><th>Hypercoagulable State</th></tr></thead><tbody><tr><td>Vessel Type</td><td>Small penetrating artery (MCA)</td><td>Large extracranial artery</td><td>Proximal aortic arch</td><td>Coagulation cascade</td></tr><tr><td>Infarct Location</td><td>Deep (basal ganglia, internal cap.)</td><td>Cortical (MCA/ACA territory)</td><td>Multifocal cortical &plusmn; subcortical</td><td>Variable; often multifocal</td></tr><tr><td>Clinical Signs</td><td>Pure motor/sensory, no cortical signs</td><td>Cortical signs (aphasia, neglect)</td><td>Embolic cortical syndromes</td><td>Depends on site; may include venous signs</td></tr><tr><td>Imaging</td><td>Single small (<15 mm) DWI lesion</td><td>Territorial infarct, watershed involvement</td><td>Multiple acute infarcts</td><td>Variable, often non\u2010lacunar</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar syndromes (pure motor or sensory) suggest small\u2010vessel occlusion; absence of cortical signs is key.  <br><span class=\"list-item\">\u2022</span> MRI with diffusion\u2010weighted imaging is more sensitive than CT for detecting lacunar infarcts early.  <br><span class=\"list-item\">\u2022</span> Strict blood pressure control (<130/80 mmHg) is the most effective prevention for recurrent lacunar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking pure motor hemiparesis for cortical MCA infarction&mdash;absence of gaze preference, aphasia, or neglect favors lacunar.  <br>2. Over\u2010attributing lacunar stroke in middle\u2010aged patients to hypercoagulable states without evaluating for chronic hypertension or diabetes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guideline for Primary Prevention of Stroke:  <br><span class=\"list-item\">\u2022</span> Recommendation: Target BP <130/80 mmHg in patients with small vessel disease (Class I, Level A).  <br>2. SPS3 (Secondary Prevention of Small Subcortical Strokes) Trial, 2012:  <br><span class=\"list-item\">\u2022</span> Finding: Dual antiplatelet therapy (aspirin + clopidogrel) increased bleeding without reducing stroke recurrence compared to monotherapy (Level A evidence).  <br>3. AHA/ASA 2021 Guideline for Secondary Stroke Prevention:  <br><span class=\"list-item\">\u2022</span> Recommendation: Use antiplatelet monotherapy (aspirin or clopidogrel) in lacunar stroke patients (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The lenticulostriate arteries originate from the M1 segment of the MCA. They penetrate deep into the hemisphere, supplying the posterior limb of the internal capsule and adjacent basal ganglia. Their small caliber (<200 \u03bcm) and lack of collateral supply make them prone to occlusion from lipohyalinosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension damages endothelium in small penetrating arteries, leading to fibrinoid necrosis, smooth muscle cell loss, and hyaline deposition (lipohyalinosis). Microatheromas can also form at branch points, resulting in branch occlusive disease. Both processes narrow the lumen, causing lacunar infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Lacunar stroke due to lenticulostriate artery occlusion is frequently tested in the context of pure motor hemiparesis or dysarthria\u2010clumsy hand syndrome without cortical features.</div></div></div></div></div>"
  },
  {
    "id": 100023063,
    "question_number": "61",
    "question_text": "A patient presents with a 1-day history of ischemic stroke and a high blood pressure (SBP 190). The CT brain reports an established stroke. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Acute ischemic stroke produces an irreversibly injured core surrounded by a potentially salvageable penumbra. Cerebral autoregulation in the infarct zone is impaired; systemic blood pressure supports collateral flow into the penumbra. Permissive hypertension (allowing SBP up to 220 mmHg) optimizes perfusion of at-risk tissue. Non-contrast CT differentiates hemorrhage from infarction and assesses infarct age. Outside the 4.5 hour window for IV thrombolysis and beyond the timeframe for endovascular therapy, antihypertensive treatment is deferred unless SBP exceeds 220 or DBP exceeds 120 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. <span class=\"evidence\">The 2019</span> AHA/ASA guidelines <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2019</span>)</span> give a Class I, Level B-R recommendation to maintain SBP &le;220/DBP &le;120 mmHg in acute ischemic stroke patients not eligible for reperfusion. Aggressive lowering risks compromising penumbral perfusion. The Scandinavian Candesartan Acute Stroke Trial <span class=\"citation\">(SCAST, 2011)</span> showed no outcome benefit&mdash;and potential harm&mdash;when BP was pharmacologically reduced early. Conversely, lowering only when SBP >220 mmHg minimizes hemorrhagic transformation risk without sacrificing collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start intravenous thrombolysis immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: IV tPA is only indicated within 4.5 hours of symptom onset. At 24 hours post-stroke, the risk of hemorrhagic transformation far outweighs benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Any ischemic stroke merits thrombolysis regardless of timing.  <br><br>C. Lower blood pressure aggressively to below 140 mmHg  <br><span class=\"list-item\">\u2022</span> Incorrect: Rapid reduction below 140 mmHg can collapse collateral circulation and enlarge the infarct. Guidelines recommend BP lowering only if SBP >220 or DBP >120 mmHg.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Normalizing&rdquo; BP acutely always improves outcomes.  <br><br>D. Initiate anticoagulation therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Routine anticoagulation in acute ischemic stroke without a clear cardioembolic source increases hemorrhagic transformation risk. Current practice delays anticoagulation for at least 1&ndash;2 weeks in large infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from early heparin or warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Permissive HTN (A)</th><th>IV Thrombolysis (B)</th><th>Aggressive BP Lowering (C)</th><th>Early Anticoagulation (D)</th></tr></thead><tbody><tr><td>Time window</td><td>Any, if no reperfusion planned</td><td>&le;4.5 hours</td><td>Any</td><td>Depends on etiology, usually &ge;1 week</td></tr><tr><td>BP threshold</td><td>SBP &le;220/DBP &le;120 mmHg</td><td>&le;185/&le;110 for tPA</td><td>Target SBP <140 mmHg</td><td>N/A</td></tr><tr><td>Effect on penumbra</td><td>Preserves collateral flow</td><td>Recanalizes clot if early</td><td>Risks penumbral hypoperfusion</td><td>No direct benefit acutely</td></tr><tr><td>Major risk</td><td>Hypertensive complications</td><td>Intracranial hemorrhage</td><td>Worsening ischemia</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Allow SBP up to 220 mmHg in the first 24&ndash;48 hours if not receiving reperfusion therapy.  <br>2. IV thrombolysis window is strictly 0&ndash;4.5 hours; outside this window, risk of hemorrhage negates benefit.  <br>3. Delay anticoagulation for cardioembolic stroke 1&ndash;2 weeks to reduce hemorrhagic transformation in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lowering acute BP to &ldquo;normal&rdquo; levels (<140 mmHg) thinking it universally benefits the brain&mdash;this can worsen infarction.  <br>2. Believing tPA is safe at any time point post-stroke; timing is critical.  <br>3. Initiating anticoagulation immediately for all ischemic strokes, neglecting hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Class I, Level B-R&mdash;maintain BP &le;220/120 mmHg in non-reperfused acute ischemic stroke.  <br>2. European Stroke <span class=\"evidence\">Organisation 2021</span> Guideline: Recommends withholding antihypertensives unless SBP >220 mmHg or DBP >120 mmHg (Level A).  <br>3. SCAST Trial <span class=\"citation\">(Sandset et al., NEJM 2011)</span>: Early candesartan therapy showed no benefit, supporting conservative BP management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT within 24 hours shows established infarct as a well-demarcated hypodensity with loss of gray-white differentiation. Absence of hemorrhage confirms ischemic etiology but indicates no further reperfusion benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>If SBP rises >220 mmHg, use IV labetalol (10&ndash;20 mg bolus) or nicardipine infusion (starting 5 mg/h) to reduce BP by &le;15% over 24 hours. Avoid nitroprusside due to intracranial pressure effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ischemic stroke is frequently tested as single-best-answer questions emphasizing permissive hypertension thresholds and timing of reperfusion therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023066,
    "question_number": "125",
    "question_text": "Q125. A 70-something female with diabetes mellitus and hypertension, fully independent, presents with a 90-minute onset of dense right hemiparesis and aphasia. A CT brain scan performed 30 minutes after arrival shows no hemorrhage. As her symptoms slightly improved on the way to the ER, what should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute ischemic stroke management revolves around rapid reperfusion to salvage the penumbra and minimize infarct core expansion. Key concepts:  <br>1. Time\u2010dependent benefit of intravenous tissue plasminogen activator (tPA), ideally within 4.5 hours of symptom onset.  <br>2. Noncontrast CT to exclude hemorrhage or established large infarction before tPA.  <br>3. NIH Stroke Scale (NIHSS)&ndash;driven decision: significant deficits (e.g., dense hemiparesis, aphasia) justify tPA even if mild improvement occurs en route.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous tPA remains the only FDA\u2010approved pharmacologic reperfusion therapy for eligible acute ischemic stroke patients within 4.5 hours of onset. The pivotal NINDS (1995) trial demonstrated a 30% greater favorable outcome at 3 months (Level A evidence). ECASS III (2008) extended the window to 4.5 hours with a similar safety profile (Class I, Level B). AHA/ASA 2019 Guidelines recommend administration of IV tPA in patients with mild to moderate neurologic deficits (NIHSS > 4) as long as no contraindications exist, regardless of slight spontaneous improvement. Delaying tPA to obtain a CT angiogram is discouraged if it exceeds 10 minutes beyond noncontrast CT interpretation; vessel imaging can be acquired in parallel or immediately post\u2010tPA bolus. Initiation of antiplatelet therapy (aspirin) is deferred until 24 hours post\u2010tPA to avoid hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT angiogram  <br><span class=\"list-item\">\u2022</span> Incorrect because delaying tPA for vascular imaging beyond guideline\u2010recommended door\u2010to\u2010needle times (>10 minutes) worsens outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: CTA must precede tPA to identify large\u2010vessel occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA can be performed concurrently or immediately after tPA bolus without delaying therapy.<br><br>C. Start aspirin immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin within 24 hours of tPA increases risk of intracranial hemorrhage and offers no reperfusion benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Early antiplatelet therapy substitutes for thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aspirin initiation is recommended 24&ndash;48 hours post\u2010tPA in absence of hemorrhage.<br><br>D. Admit for observation and repeat imaging in 24 hours  <br><span class=\"list-item\">\u2022</span> Incorrect: &ldquo;Watchful waiting&rdquo; forfeits the narrow therapeutic window for reperfusion, leading to larger infarct volumes.  <br><span class=\"list-item\">\u2022</span> Misconception: Mild improvement \u2192 low risk for disability.  <br><span class=\"list-item\">\u2022</span> Differentiator: Residual significant deficits mandate urgent reperfusion, not delayed assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA (Correct)</th><th>CT Angiogram</th><th>Aspirin Immediate</th><th>Observation & Repeat CT</th></tr></thead><tbody><tr><td>Timing</td><td>Within 4.5 h of onset</td><td>Can be done any time</td><td>Within minutes</td><td>No urgent intervention</td></tr><tr><td>Primary Purpose</td><td>Recanalize occluded vessel</td><td>Identify occlusion location</td><td>Antiplatelet prophylaxis</td><td>Monitoring</td></tr><tr><td>Impact on Outcome</td><td>\u2193 Disability, \u2191 functional independence</td><td>Guides thrombectomy decision</td><td>No acute reperfusion benefit</td><td>\u2191 Infarct size, \u2191 disability</td></tr><tr><td>Guideline Appropriateness</td><td>Class I, Level A (AHA/ASA)</td><td>Class IIa, Level C (post\u2010tPA imaging)</td><td>Class III (contraindicated within 24 h)</td><td>Contraindicated in eligible tPA patients</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Do not withhold tPA for minor or rapidly improving symptoms if meaningful deficits persist (e.g., aphasia, hemiparesis).  <br>&bull; Aim for door\u2010to\u2010needle time &le; 60 minutes; delays beyond 10 minutes after CT completion reduce tPA efficacy.  <br>&bull; Perform vascular imaging in parallel or immediately after tPA bolus to identify candidates for endovascular therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating &ldquo;improvement&rdquo; with complete resolution&mdash;patients with residual deficits still benefit from tPA.  <br>2. Administering antiplatelets or anticoagulants before confirming absence of hemorrhage&mdash;risking hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines for Early Management of AIS: Class I, Level A for IV tPA within 3 hours; Class I, Level B for 3&ndash;4.5 hour window in eligible patients.  <br>&bull; ECASS III (2008): Demonstrated safety and efficacy of IV tPA in 3&ndash;4.5 hour window (adjusted OR for favorable outcome 1.34; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Acute stroke reperfusion therapy is frequently tested in both step\u2010style and case\u2010based vignettes, emphasizing time windows, contraindications, and management algorithms.</div></div></div></div></div>"
  },
  {
    "id": 100023069,
    "question_number": "44",
    "question_text": "Q44. A brain CT shows a large right subdural hematoma. What is the mechanism of this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Acute subdural hematomas (SDHs) occur when blood collects between the dura mater and arachnoid due to torn bridging veins. Bridging veins traverse the subdural space, draining cortical blood into the dural venous sinuses. Rapid acceleration&ndash;deceleration or direct impact causes shearing forces that rupture these veins. On noncontrast CT, SDHs appear as crescent-shaped hyperdensities that can cross suture lines but are bounded by dural reflections (falx, tentorium). In contrast, epidural hematomas (EDHs) are typically biconvex and arterial. Recognizing these imaging and anatomic distinctions is essential for diagnosis and surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct mechanism for an acute SDH is rupture of bridging veins. Autopsy and clinical data <span class=\"citation\">(Bullock et al., J <span class=\"evidence\">Neurosurg 1980</span>;52(5)</span>:648&ndash;657) demonstrate that up to 90% of SDHs result from venous tearing rather than arterial bleeding. The bridging veins, tethered between cortical surface and dural sinuses, are vulnerable to shear stress during head trauma <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurosurgery 2000</span>;46(4)</span>:829&ndash;835). Current Brain Trauma Foundation guidelines <span class=\"citation\">(4th ed., 2016)</span> recommend rapid CT evaluation and neurosurgical consultation for acute SDH with >10 mm thickness or >5 mm midline shift, reflecting the high morbidity from mass effect due to ongoing venous hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle meningeal artery  <br>&bull; Incorrect: Rupture of the middle meningeal artery causes an epidural, not subdural, hematoma.  <br>&bull; Misconception: All intracranial bleeds are arterial.  <br>&bull; Differentiator: EDHs are lentiform/biconvex and lens-shaped, limited by suture lines.<br>  <br>C. Cortical artery  <br>&bull; Incorrect: Cortical artery injury yields parenchymal contusion or intracerebral hemorrhage rather than a subdural collection.  <br>&bull; Misconception: Any cortical vessel bleed migrates into the subdural space.  <br>&bull; Differentiator: Intracerebral hemorrhages are intraparenchymal and do not form crescent shapes.<br>  <br>D. Venous sinus thrombosis  <br>&bull; Incorrect: Thrombosis of a dural sinus can cause venous infarcts or hemorrhagic edema but not a discrete subdural hematoma.  <br>&bull; Misconception: All venous pathology leads to subdural bleeding.  <br>&bull; Differentiator: Sinus thrombosis shows absent flow on MRV and often a \"cord sign\" on CT; hemorrhage is intraparenchymal/venous infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Bridging Veins (SDH)</th><th>Middle Meningeal Artery (EDH)</th><th>Cortical Artery (ICH)</th><th>Venous Sinus Thrombosis</th></tr></thead><tbody><tr><td>Vessel type</td><td>Vein</td><td>Artery</td><td>Artery</td><td>Vein</td></tr><tr><td>Hemorrhage type</td><td>Subdural</td><td>Epidural</td><td>Intraparenchymal</td><td>Venous infarction/edema</td></tr><tr><td>CT shape</td><td>Crescent, crosses sutures</td><td>Biconvex, limited by sutures</td><td>Irregular intraparenchymal</td><td>Diffuse edema, focal hemorrhage</td></tr><tr><td>Onset</td><td>Acute to subacute</td><td>Acute</td><td>Acute</td><td>Subacute to chronic</td></tr><tr><td>Mass effect</td><td>Yes</td><td>Yes</td><td>Variable</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. SDHs cross suture boundaries but are bounded by dural reflections (falx, tentorium); epidurals do not cross sutures.  <br>2. Acute SDH mortality can exceed 50% if >10 mm thick or >5 mm midline shift; prompt neurosurgical evacuation is critical.  <br>3. In elderly or anticoagulated patients, even minor trauma can cause significant bridging vein rupture due to increased subdural space.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all traumatic intracranial bleeds are arterial: only EDHs are typically arterial.  <br>2. Believing that subarachnoid hemorrhage (SAH) can mimic SDH on CT: SAH coats sulci, whereas SDH forms a crescent along the convexity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Brain Trauma Foundation (2016): Recommends urgent CT for suspected SDH and surgical evacuation criteria of >10 mm thickness or >5 mm midline shift (Level II evidence).  <br>&bull; NICE Head Injury Guidelines <span class=\"citation\">(NG41, 2014)</span>: Classify SDH as &ldquo;high risk&rdquo; requiring CT within 1 hour if focal neurology or GCS <13; guides timely imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Bridging veins drain cortical venous blood through the subdural space into the superior sagittal sinus. The veins are fixed at the sinus and mobile over the cortex, making them susceptible to shear injury during linear acceleration&ndash;deceleration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Shearing forces stretch and tear the thin-walled bridging veins bridging arachnoid to dural sinuses, causing slow but potentially large-volume venous bleeding. Accumulated blood raises intracranial pressure and exerts mass effect, leading to midline shift and herniation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT for any moderate&ndash;severe head trauma or focal deficits.  <br>2. Identify crescent-shaped hyperdensity crossing sutures on CT.  <br>3. Measure clot thickness and midline shift.  <br>4. Assess clinical status (GCS, pupillary exam).  <br>5. Neurosurgical consultation for hematoma >10 mm or shift >5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute SDH: Homogeneous hyperdensity on CT (0&ndash;72 h).  <br>&bull; Chronic SDH: Hypodense or isodense crescent weeks later.  <br>&bull; MRI with FLAIR and susceptibility-weighted imaging can detect subacute/chronic collections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Subdural hematoma mechanism questions frequently test the distinction between arterial vs. venous intracranial bleeds and CT morphology; expect similar items on vascular and trauma sections.</div></div></div></div></div>"
  },
  {
    "id": 100023071,
    "question_number": "35",
    "question_text": "In a patient with acute stroke who was treated with tPA and subsequently vomited, leading to lethargy and a blood pressure of 180/110, what should be done next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Intravenous tPA is standard for acute ischemic stroke within 4.5 h of onset. It converts plasminogen to plasmin, lysing fibrin clots. Hemorrhagic transformation occurs in ~6% of treated patients, often presenting with sudden neurologic decline (e.g., vomiting, lethargy) and hypertension. Emergent noncontrast head CT is required to confirm or exclude intracerebral hemorrhage before instituting reversal therapies. Blood pressure must be maintained &le;180/105 mm Hg post\u2010tPA. Recognizing post&ndash;thrombolysis complications and prioritizing imaging are essential for timely management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sending for an immediate noncontrast CT is the highest priority when neurological status worsens after tPA. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke (Class I, Level B-R) state that any decline post-thrombolysis mandates urgent imaging to identify hemorrhagic conversion. In the NINDS trial, symptomatic intracerebral hemorrhage occurred in 6.4% of tPA-treated patients within 36 h; early CT allows prompt cessation of fibrinolysis and initiation of reversal (e.g., cryoprecipitate, antifibrinolytics) and targeted blood pressure management. Delaying imaging risks unchecked intracranial bleeding and secondary injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Decrease blood pressure  <br><span class=\"list-item\">\u2022</span> While BP control (goal &le;180/105 mm Hg) is important, immediate imaging supersedes isolated antihypertensive therapy. Overly aggressive lowering before confirming hemorrhage may compromise penumbral perfusion.  <br>B. Stop tPA  <br><span class=\"list-item\">\u2022</span> If the infusion is still running, it should be halted, but in most settings the 60-min tPA infusion is complete by the time deterioration occurs. Cessation alone does not diagnose the cause; emergent CT remains the next step.  <br>D. Administer IV fluids  <br><span class=\"list-item\">\u2022</span> IV fluids do not treat intracerebral hemorrhage and may exacerbate cerebral edema. Maintaining euvolemia is appropriate but secondary to rapid diagnostic imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Scan (Correct)</th><th>BP Lowering</th><th>Stop tPA</th><th>IV Fluids</th></tr></thead><tbody><tr><td>Primary Action</td><td>Noncontrast imaging to detect hemorrhage</td><td>Antihypertensive therapy</td><td>Discontinue fibrinolytic infusion</td><td>Volume expansion</td></tr><tr><td>Rationale</td><td>Confirms hemorrhagic vs ischemic cause</td><td>Maintains post-tPA BP target</td><td>Prevents further fibrinolysis</td><td>Addresses hypotension only</td></tr><tr><td>Priority</td><td>Immediate (within minutes)</td><td>Secondary (after imaging)</td><td>Concurrent if still infusing</td><td>Not indicated for hemorrhage risk</td></tr><tr><td>Impact on Management</td><td>Guides reversal agents and BP goals</td><td>Supports hemorrhage control</td><td>Stops active drug but no diagnosis</td><td>No effect on intracranial bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Any new neurologic deterioration or acute hypertension after tPA requires emergent noncontrast head CT to rule out hemorrhagic transformation.  <br>2. Maintain BP &le;180/105 mm Hg after tPA; use nicardipine or labetalol infusions titrated carefully to avoid hypoperfusion.  <br>3. Hemorrhagic conversion most often occurs within 36 h post-tPA; continuous NIHSS monitoring is essential during this window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Focusing first on antihypertensive therapy without imaging delays diagnosis of hemorrhage.  <br>2. Assuming tPA infusion cessation obviates need for CT; diagnostic confirmation drives reversal and supportive care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(2018 update, published 2019)</span>: Class I, LOE B-R recommendation for emergent CT if neurological decline post-thrombolysis.  <br>2. ESO Guidelines on Intravenous Thrombolysis (2021): Emphasize CT within 20 min of suspected hemorrhage and BP target &le;180/105 mm Hg (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA-mediated fibrinolysis increases blood&ndash;brain barrier permeability via matrix metalloproteinases, predisposing to hemorrhagic transformation. Elevated intracranial pressure from extravasated blood causes vomiting, altered consciousness, and further vascular compromise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize neurologic decline (vomiting, lethargy).  <br>2. Check vitals, labs (PT/INR, platelets).  <br>3. Obtain emergent noncontrast head CT.  <br>4. If hemorrhage: stop tPA, control BP, administer cryoprecipitate/antifibrinolytics. If no bleed: evaluate for stroke progression or other causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: Acute blood appears hyperdense (\u224860&ndash;80 HU) within infarcted tissue; CT angiography can follow for vessel status if no hemorrhage is detected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA dosing: 0.9 mg/kg (max 90 mg) with 10% bolus and remainder over 60 min. In suspected hemorrhage, reversal with cryoprecipitate (10 units) and tranexamic acid may be considered.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Acute post-tPA deterioration and hemorrhagic transformation are frequently tested as vignettes requiring prioritization of emergent CT imaging.</div></div></div></div></div>"
  },
  {
    "id": 100023072,
    "question_number": "47",
    "question_text": "Q47. A patient came with a CT brain scan attached. Which artery is most likely involved in the case presented?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] - The middle cerebral artery (MCA) supplies the lateral convexity of the frontal, parietal, and temporal lobes and deep structures (basal ganglia, internal capsule) via lenticulostriate branches.  <br><span class=\"list-item\">\u2022</span> On noncontrast CT in hyperacute ischemic stroke, early signs include the hyperdense MCA sign (clot within M1), loss of the insular ribbon, sulcal effacement, and subtle hypodensity in the lateral hemisphere.  <br><span class=\"list-item\">\u2022</span> Clinical deficits correlate with vascular territories: MCA strokes produce contralateral face/arm weakness and hemisensory loss, aphasia if dominant, and hemineglect if non-dominant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CT demonstrates a hyperattenuated vessel in the Sylvian fissure (hyperdense MCA sign) and hypodensity of the insular cortex, both hallmark early markers of proximal MCA (M1 segment) occlusion. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend immediate noncontrast CT to exclude hemorrhage (Class I, Level A) and CTA/CTP to identify large vessel occlusion (Class I, Level B-R). Proximal MCA occlusions account for nearly 50% of anterior circulation strokes and carry a high risk of large-vessel infarction. Kolmannskog et al. <span class=\"citation\">(Stroke, 2000)</span> reported the hyperdense MCA sign has >90% specificity for M1 occlusion, guiding urgent reperfusion therapy (IV alteplase within 4.5 h; endovascular thrombectomy up to 24 h in selected patients per DAWN and DEFUSE 3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery  <br><span class=\"list-item\">\u2022</span> ACA infarcts affect medial frontal/parietal lobes, producing contralateral leg weakness and abulia. CT shows medial falcine hypodensity&mdash;absent here. Misconception: assuming any cortical hypodensity equals ACA territory.  <br>C. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> PCA strokes localize to occipital lobes, thalamus; present with homonymous hemianopia and thalamic sensory loss. CT hypodensity would involve occipital sulci, not the Sylvian fissure.  <br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar occlusion causes brainstem and cerebellar signs (e.g., &ldquo;locked-in&rdquo; syndrome, cranial nerve deficits). CT would need posterior fossa windows to show a hyperdense basilar; supratentorial lateral hypodensity would not be seen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory</th><th>CT Findings</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>Middle cerebral (MCA)</td><td>Lateral frontal, parietal, temporal lobes; basal ganglia via lenticulostriates</td><td>Hyperdense vessel in Sylvian fissure; insular ribbon loss; lateral hypodensity</td><td>Contralateral face/arm > leg weakness; aphasia or neglect</td></tr><tr><td>Anterior cerebral (ACA)</td><td>Medial frontal/parietal lobes; corpus callosum</td><td>Medial falcine hypodensity</td><td>Contralateral leg paresis; abulia</td></tr><tr><td>Posterior cerebral (PCA)</td><td>Occipital lobes; thalamus</td><td>Occipital hypodensity; &ldquo;white stripe&rdquo; in calcarine fissure</td><td>Homonymous hemianopia; thalamic sensory loss</td></tr><tr><td>Basilar artery</td><td>Brainstem; cerebellum; occipital lobes (via PCAs)</td><td>Hyperdense basilar on posterior fossa CT</td><td>Cranial nerve deficits; altered consciousness; ataxia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The hyperdense MCA sign on noncontrast CT predicts proximal M1 occlusion with >90% specificity but low sensitivity (~30%).  <br><span class=\"list-item\">\u2022</span> Use Alberta Stroke Program Early CT Score (ASPECTS) on MCA territory scans: scores <7 predict poor outcomes post-thrombectomy.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy benefits extend to selected patients up to 24 hours (DAWN/DEFUSE 3), emphasizing advanced imaging for penumbra assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking beam-hardening artifacts in the Sylvian fissure for a hyperdense vessel.  <br>2. Confusing leg-predominant weakness of ACA strokes with global MCA deficits, leading to territory mislocalization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke: Class I, Level A recommendation for immediate noncontrast CT to exclude hemorrhage and Class I, Level B-R for CTA/CTP to identify large-vessel occlusion.  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated mechanical thrombectomy up to 24 hours in patients with mismatch between clinical deficit and infarct core (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA M1 segment gives off lenticulostriate arteries penetrating the internal capsule and basal ganglia. Proximal occlusion affects both cortical and deep structures, correlating with dense hemiplegia and aphasia (dominant hemisphere).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers energy failure, glutamate\u2010mediated excitotoxicity, calcium influx, free\u2010radical generation, and cytotoxic edema. Early CT hypodensity reflects cellular swelling within minutes to hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment and NIH Stroke Scale.  <br>2. Noncontrast CT head to exclude hemorrhage and detect early ischemic signs.  <br>3. CTA/CTP for vessel occlusion and penumbra/core evaluation.  <br>4. Administer IV alteplase if within 4.5 h and no contraindications.  <br>5. Proceed to mechanical thrombectomy in large-vessel occlusion up to 24 h per advanced imaging criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Insular ribbon sign: early loss of gray-white differentiation in insula.  <br><span class=\"list-item\">\u2022</span> Sulcal effacement indicates cytotoxic edema.  <br><span class=\"list-item\">\u2022</span> CT perfusion maps cerebral blood flow/volume to differentiate penumbra from core.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (maximum 90 mg), 10% bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for minor noncardioembolic stroke within 21 days.  <br><span class=\"list-item\">\u2022</span> High-intensity statin for secondary prevention regardless of LDL level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Vascular territory localization on CT is a high-yield topic on neurology and radiology components of board examinations, often tested with correlating clinical deficits.</div></div></div></div></div>"
  },
  {
    "id": 100023073,
    "question_number": "120",
    "question_text": "A patient with stroke is receiving physiotherapy and speech therapy. What is the type of prevention being implemented?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Levels of prevention delineate interventions across the disease continuum:  <br>&bull; Primary prevention aims to stop disease before it occurs (e.g., controlling hypertension to prevent first stroke).  <br>&bull; Secondary prevention focuses on early detection and prompt treatment to halt progression (e.g., TIA work-up and thrombolysis in acute stroke).  <br>&bull; Tertiary prevention seeks to reduce disability and restore function after established disease (e.g., rehabilitation therapies post-stroke).  <br>&bull; Quaternary prevention involves avoiding overmedicalization and iatrogenic harm.  <br>Stroke rehabilitation harnesses neuroplasticity&mdash;cortical reorganization and synaptic remodeling&mdash;to regain motor and language function, fitting squarely under tertiary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Tertiary. Rehabilitation after stroke (physiotherapy, occupational therapy, speech therapy) is explicitly defined as tertiary prevention&mdash;interventions to reduce established disability.  <br>&ndash; AHA/ASA 2019 Guidelines for the Early Management of Acute Ischemic Stroke (class I, level A) recommend initiation of multidisciplinary rehabilitation within 24&ndash;48 hours to maximize functional recovery and minimize complications.  <br>&ndash; The AVERT (A Very Early Rehabilitation Trial) published in Neurology (2015) demonstrated that early mobilization reduced the odds of poor outcome (OR 0.73; 95% CI 0.61&ndash;0.87).  <br>&ndash; WHO <span class=\"evidence\">Rehabilitation 2030</span> (2017) positions community-based rehabilitation as a key tertiary prevention strategy to decrease long-term disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary  <br>&bull; Why incorrect: Targets prevention before disease onset.  <br>&bull; Misconception: Equating risk-factor management (e.g., BP control) with post-stroke rehab.  <br>&bull; Key difference: No established event to &ldquo;rehabilitate&rdquo;&mdash;primary is pre-morbidity.  <br><br>B. Secondary  <br>&bull; Why incorrect: Involves early detection (e.g., screening, thrombolysis) to prevent progression or recurrence.  <br>&bull; Misconception: Confusing acute stroke treatment (early thrombolysis) with rehabilitation.  <br>&bull; Key difference: Secondary halts disease progression; tertiary improves post-disease function.  <br><br>D. Quaternary  <br>&bull; Why incorrect: Aims to prevent harm from unnecessary or excessive interventions (e.g., avoiding redundant imaging or polypharmacy).  <br>&bull; Misconception: Believing any non-acute care is quaternary.  <br>&bull; Key difference: Quaternary is about overmedicalization, not functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Level of Prevention</th><th>Goal</th><th>Timing</th><th>Stroke Example</th></tr></thead><tbody><tr><td>Primary</td><td>Prevent disease onset</td><td>Before first event</td><td>BP and lipid control to avoid first stroke</td></tr><tr><td>Secondary</td><td>Early detection & arrest progression</td><td>Acute phase/TIA</td><td>Carotid imaging, tPA administration</td></tr><tr><td>Tertiary</td><td>Reduce disability, restore function</td><td>Post-acute/chronic</td><td>Physiotherapy, speech and occupational therapy</td></tr><tr><td>Quaternary</td><td>Avoid unnecessary interventions</td><td>Any phase</td><td>De-prescribing neurotoxics, limiting repeat scans</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early mobilization (within 24&ndash;48 h) reduces deep vein thrombosis, pneumonia, and pressure ulcers while enhancing motor recovery.  <br>&bull; Speech therapy initiated in the first week post-stroke significantly improves language outcomes and swallowing function.  <br>&bull; Multidisciplinary teams (PT, OT, SLP, neurology, nursing) synergize to decrease length of stay and increase discharge to home.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing secondary prevention (acute thrombolysis) with rehabilitation efforts&mdash;remember timing and intent differ.  <br>2. Mislabeling primary prevention strategies (BP control) as tertiary when performed after stroke; primary is always pre-event.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2019 Update  <br>   &ndash; Recommendation: Initiate rehabilitation therapies within 24&ndash;48 hours post-stroke (Class I, Level A).  <br>2. A Very Early Rehabilitation Trial (AVERT), <span class=\"evidence\">Neurology 2015</span>  <br>   &ndash; Finding: Very early out-of-bed mobilization reduced poor outcomes at 3 months (OR 0.73; 95% CI 0.61&ndash;0.87).  <br>3. NICE Guideline NG128 (2021)  <br>   &ndash; Recommendation: Multidisciplinary community rehabilitation to optimize functional independence (High-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>Classification of prevention levels is commonly tested in neurology and public health vignettes, often as a single best-answer scenario distinguishing primary, secondary, tertiary, and quaternary prevention.</div></div></div></div></div>"
  },
  {
    "id": 100023075,
    "question_number": "139",
    "question_text": "A 59-year-old male with a history of diabetes, hypertension, and dyslipidemia presented with sudden dysarthria and right arm numbness lasting for 10 minutes. His brain CT is reported as normal. What is the best next step?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Transient ischemic attack (TIA) is defined by transient focal neurologic dysfunction without acute infarction. Key principles:  <br><span class=\"list-item\">\u2022</span> TIAs carry a high early stroke risk&mdash;\u224810% risk within 90 days, half occurring in the first 48 hours.  <br><span class=\"list-item\">\u2022</span> Extracranial carotid stenosis &ge;50% is a modifiable risk factor; prompt imaging guides interventions (endarterectomy or stenting).  <br><span class=\"list-item\">\u2022</span> Neurovascular workup must be done emergently&mdash;CT angiography (CTA) of head and neck within 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neck CTA is the optimal next step because it rapidly identifies extracranial carotid and vertebral stenosis or occlusion, which&mdash;if >70%&mdash;warrants urgent endarterectomy <span class=\"citation\">(Class I, Level A recommendation; AHA/ASA 2019)</span>. Brain CT alone cannot detect vascular lesions. Echocardiography and prolonged cardiac monitoring address cardioembolic sources but are secondary to vascular imaging in the acute TIA workup. Thrombolytic screening is irrelevant once symptoms resolve and there is no persistent deficit. Early carotid imaging reduces recurrent stroke risk by directing timely revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reassurance  <br><span class=\"list-item\">\u2022</span> Incorrect: Underestimates early recurrent stroke risk.  <br><span class=\"list-item\">\u2022</span> Misconception: A normal CT excludes high-risk pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging is required to stratify risk and guide intervention.  <br><br>C. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cardioembolism (e.g., atrial thrombus), but vascular imaging must precede in acute TIA.  <br><span class=\"list-item\">\u2022</span> Misconception: Cardiac sources are equally urgent&mdash;whereas carotid stenosis poses more immediate surgical decision needs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Echocardiogram is adjunctive, not first-line.  <br><br>D. Thrombolytic screening  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for persistent deficits within 4.5 h window; TIA symptoms resolved.  <br><span class=\"list-item\">\u2022</span> Misconception: All transient deficits qualify for thrombolysis workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: No ongoing ischemia; focus shifts to secondary prevention and etiologic workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neck CT Angiography (B)</th><th>Echocardiogram (C)</th><th>Thrombolytic Screening (D)</th><th>Reassurance (A)</th></tr></thead><tbody><tr><td>Purpose</td><td>Visualize extracranial/intracranial vessels</td><td>Detect cardiac thrombus/vegetations</td><td>Assess eligibility for tPA</td><td>No diagnostic yield</td></tr><tr><td>Time Sensitivity</td><td>Within 24 h</td><td>Within days</td><td>Within 4.5 h if deficits persist</td><td>Not time-sensitive</td></tr><tr><td>Impact on Management</td><td>Guides CEA/stenting</td><td>Guides anticoagulation</td><td>Guides acute thrombolysis</td><td>None</td></tr><tr><td>Level of Evidence (AHA/ASA)</td><td>Class I, Level A</td><td>Class IIa, Level C</td><td>Class I (in stroke), not TIA</td><td>No recommendation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In TIA, perform vascular imaging (CTA/MRA) within 24 hours to detect high-grade stenosis and prevent early stroke.  <br>2. Carotid endarterectomy is indicated for symptomatic 70&ndash;99% stenosis within 2 weeks of TIA (NASCET criteria).  <br>3. ABCD2 score guides short-term risk stratification but does not replace vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing a normal noncontrast head CT rules out high-risk pathology. A CT cannot assess vessel lumen.  <br>2. Deferring vascular imaging because the deficit resolved; recurrent stroke risk remains high without etiologic evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA (2019), &ldquo;Guidelines for the Early Management of Patients with Acute Ischemic Stroke and TIA&rdquo;: Recommends emergent vascular imaging (CTA/MRA) within 24 hours of TIA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> ESO (2021), &ldquo;European Stroke Organisation Guidelines&rdquo;: Urges head and neck vascular imaging as first-line in TIA to identify treatable lesions (Grade A, strong recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam.  <br>Carotid imaging after TIA is a high-yield topic frequently tested in multiple-choice format, emphasizing timing, indication, and interpretation of vascular studies.</div></div></div></div></div>"
  },
  {
    "id": 100023078,
    "question_number": "67",
    "question_text": "Q67. What is the recommendation for patients with ICH presenting with systolic blood pressure (SBP) between 150 and 220 mmHg?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] In acute intracerebral hemorrhage (ICH), extravasated blood increases intracranial pressure (ICP), risking herniation and further tissue injury. According to the Monroe-Kellie doctrine, the cranial vault contents (blood, brain tissue, CSF) are volume-fixed; an expanding hematoma rapidly elevates ICP and impairs cerebral perfusion. Elevated systolic blood pressure (SBP) exacerbates hematoma expansion by promoting ongoing bleeding, whereas overly aggressive lowering can exceed impaired autoregulatory capacity in perihematomal regions, precipitating ischemia. Optimal management balances reduction of rebleeding risk against maintenance of cerebral perfusion pressure (CPP = MAP &ndash; ICP). Randomized trials (INTERACT2, ATACH-2) and guideline consensus support targeting an acute SBP of approximately 140 mmHg in those presenting with SBP between 150 and 220 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B (&ldquo;acute lowering of SBP to 140 mmHg&rdquo;) is endorsed by the American Heart Association/American Stroke Association (AHA/ASA) 2022 ICH guidelines (Class I, Level A). The INTERACT2 trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>;368:2355&ndash;65)</span> demonstrated a non-significant trend toward reduced death or major disability with an SBP target of <140 mmHg versus <180 mmHg, but ordinal analysis showed improved functional outcomes at 90 days. The ATACH-2 trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2016</span>;375:1033&ndash;43)</span> compared intensive (110&ndash;139 mmHg) versus standard (140&ndash;179 mmHg) reduction: no significant difference in death or disability, but higher renal adverse events in the intensive arm. Meta-analysis consolidates benefit and safety of targeting SBP around 140 mmHg in the acute phase (Class I, LOE A). Intravenous nicardipine or labetalol infusions with continuous arterial monitoring achieve rapid, controlled reduction within 1 hour, minimizing hematoma expansion while preserving CPP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aggressive reduction of BP  <br><span class=\"list-item\">\u2022</span> Incorrect because &ldquo;aggressive&rdquo; lacks a specific target and risks overshooting below safe perfusion thresholds (e.g., SBP <120 mmHg).  <br><span class=\"list-item\">\u2022</span> Misconception: More rapid or deeper reduction necessarily yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Guidelines specify a precise SBP target, not an undefined &ldquo;aggressive&rdquo; approach.  <br><br>C. No treatment required  <br><span class=\"list-item\">\u2022</span> Incorrect; untreated hypertension in ICH is linked to increased hematoma growth and worse functional outcome.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that high BP autonomously maintains perfusion without recognizing rebleeding risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Active BP management reduces secondary injury.  <br><br>D. Gradual reduction of SBP over 24 hours  <br><span class=\"list-item\">\u2022</span> Incorrect; delaying reduction fails to prevent early hematoma expansion, which often occurs within the first 6 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: Slow titration is inherently safer; but early control is critical.  <br><span class=\"list-item\">\u2022</span> Differentiator: Trials achieved-target BP within 1 hour, not over an entire day.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP Target</th><th>Timeframe</th><th>Guideline Class/Level</th><th>Rationale</th></tr></thead><tbody><tr><td>B [CORRECT]</td><td>\u2248140 mmHg</td><td>&le;1 hour</td><td>I / A</td><td>Minimizes hematoma expansion, preserves CPP</td></tr><tr><td>A</td><td>Undefined</td><td>Immediate</td><td>Not specified</td><td>Risk of overshoot hypotension, no clear benefit</td></tr><tr><td>C</td><td>None</td><td>N/A</td><td>Contraindicated</td><td>Allows hematoma growth, worsens outcomes</td></tr><tr><td>D</td><td>Undefined</td><td>24 hours</td><td>Not recommended</td><td>Too slow to prevent early bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use titratable IV agents (nicardipine infusion or labetalol bolus/infusion) for precise SBP control.  <br><span class=\"list-item\">\u2022</span> Avoid nitroprusside in ICH as it may increase intracranial pressure via cerebral vasodilation.  <br><span class=\"list-item\">\u2022</span> Continuous arterial BP monitoring is preferred for real-time adjustments in the hyperacute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreducing SBP below 120 mmHg can precipitate cerebral ischemia in areas with impaired autoregulation.  <br>2. Equating hypertensive management in ischemic stroke (target <180/105 mmHg) with ICH protocols, instead of the more stringent 140 mmHg target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for ICH Management (2022): Class I, Level A recommendation to lower SBP to 140 mmHg in patients with admission SBP between 150&ndash;220 mmHg, initiated within 1 hour.  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial (2013): SBP target <140 mmHg vs <180 mmHg achieved improved ordinal functional outcomes at 90 days (OR for poor outcome 0.87, 95% CI 0.77&ndash;1.00).  <br><span class=\"list-item\">\u2022</span> ATACH-2 Trial (2016): No significant difference in death/disability between intensive (110&ndash;139 mmHg) and standard (140&ndash;179 mmHg) arms; higher renal adverse events with more intensive lowering.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Blood pressure management in acute ICH is frequently tested, often in the context of trial data (INTERACT2, ATACH-2) and guideline recommendations for SBP targets and timing.</div></div></div></div></div>"
  },
  {
    "id": 100023086,
    "question_number": "134",
    "question_text": "Scenario of a patient with symptomatic ICA stenosis. He underwent carotid endarterectomy, and a few days later developed new onset confusion and decreased level of consciousness. An urgent brain CT is attached. What could explain his current condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Carotid endarterectomy (CEA) removes an atherosclerotic plaque from the internal carotid artery (ICA), restoring blood flow to chronically hypoperfused brain tissue. In longstanding stenosis, distal arterioles maximally dilate to maintain perfusion; sudden normalization of pressure overwhelms these vessels if autoregulation is impaired, leading to cerebral hyperperfusion syndrome (CHS). CHS typically presents 1&ndash;7 days post\u2010CEA with headache, seizures, focal deficits or altered consciousness and may show intracerebral hemorrhage (ICH) in the reperfused hemisphere. Key concepts:  <br><span class=\"list-item\">\u2022</span> Autoregulation: cerebral vessels adjust diameter to maintain constant flow over a range of pressures.  <br><span class=\"list-item\">\u2022</span> Chronic hypoperfusion leads to maximal vasodilation; loss of reserve predisposes to CHS.  <br><span class=\"list-item\">\u2022</span> Differential diagnoses include malignant MCA infarction, venous thrombosis, and embolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome is marked by blood&ndash;brain barrier disruption and vasogenic edema, potentially resulting in ICH. Incidence is 1&ndash;3% post\u2010CEA <span class=\"citation\">(Hughes et al., <span class=\"evidence\">Stroke 2003</span>)</span>. Diagnosis relies on clinical deterioration days after CEA, CT evidence of ipsilateral hemorrhage without a new infarct, and transcranial Doppler showing &ge;100% increase in peak MCA velocity <span class=\"citation\">(Kern et al., J Vasc <span class=\"evidence\">Surg 2000</span>)</span>. <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level B) recommend strict blood pressure control (systolic <140 mmHg) for 24&ndash;72 hours post\u2010CEA to prevent CHS. Neither malignant MCA infarction (massive infarct with cytotoxic edema and midline shift) nor cerebral venous thrombosis (hemorrhagic infarcts in non\u2010arterial patterns) nor delayed embolic infarction (territorial hypodensity without hemorrhage) fit this timing and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Malignant MCA transformation  <br>&bull; Occurs 24&ndash;48 h after a large MCA territory infarct.  <br>&bull; CT shows diffuse hypodensity, sulcal effacement, midline shift&mdash;not isolated hemorrhage without infarction.  <br>&bull; Misconception: equating any post\u2010CEA deterioration with large arterial infarction rather than reperfusion injury.  <br><br>B. Cerebral venous thrombosis  <br>&bull; Presents with headache, seizures, hemorrhagic infarcts in gyral or parasagittal regions.  <br>&bull; CT venogram demonstrates sinus or cortical vein occlusion.  <br>&bull; Differentiated by venous distribution of hemorrhage and risk factors (hypercoagulable state), not recent CEA reperfusion.  <br><br>D. Postoperative cerebral embolism  <br>&bull; Embolic strokes from debris or thrombus typically occur intra\u2010 or immediately post\u2010CEA.  <br>&bull; CT shows acute territorial infarct (hypodensity) without hemorrhage days later.  <br>&bull; Timing and hemorrhagic pattern rule this out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Malignant MCA Infarction</th><th>Cerebral Venous Thrombosis</th><th>Postoperative Embolic Stroke</th></tr></thead><tbody><tr><td>Timing</td><td>1&ndash;7 days post\u2010CEA</td><td>24&ndash;48 h post\u2010large MCA infarct</td><td>Variable, often subacute</td><td>Immediate to hours post\u2010CEA</td></tr><tr><td>Imaging</td><td>Ipsilateral parenchymal hemorrhage; no new infarct</td><td>Hypodense infarct with edema and midline shift</td><td>Hemorrhagic infarcts in non\u2010arterial distribution; venous collaterals</td><td>Territorial hypodensity without hemorrhage</td></tr><tr><td>Pathophysiology</td><td>Autoregulatory failure, BBB disruption</td><td>Cytotoxic edema from arterial occlusion</td><td>Venous outflow obstruction</td><td>Embolic arterial occlusion</td></tr><tr><td>Key Differentiator</td><td>Reperfusion hemorrhage after chronic stenosis</td><td>Massive infarct edema</td><td>Venous distribution, sinus thrombosis on venography</td><td>Acute territorial infarct on CT</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain systolic BP <140 mmHg for 24&ndash;72 h after CEA to reduce CHS risk.  <br><span class=\"list-item\">\u2022</span> Early transcranial Doppler monitoring (MCA velocity increase >100%) identifies patients at risk.  <br><span class=\"list-item\">\u2022</span> New focal neurological signs days after CEA with ipsilateral hemorrhage on CT should prompt CHS consideration over embolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing CHS hemorrhage with intraoperative embolic hemorrhagic infarction&mdash;note timing (days vs. hours) and CT pattern (reperfusion territory vs. territorial infarct).  <br>2. Assuming all postoperative neurological declines are ischemic&mdash;in CHS, management focuses on blood pressure reduction, not thrombolysis or thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines for Secondary Stroke Prevention: Class I, Level B recommendation for post\u2010CEA BP control (systolic <140 mmHg for 24&ndash;72 h) to prevent CHS.  <br><span class=\"list-item\">\u2022</span> Society for Vascular <span class=\"evidence\">Surgery 2023</span> Clinical Practice Guidelines on Extracranial Carotid Disease: Suggest routine TCD surveillance in high\u2010risk patients (Level C evidence) to detect early hyperperfusion.  <br><span class=\"list-item\">\u2022</span> European Society for Vascular <span class=\"evidence\">Surgery 2021</span> Guidelines: Emphasize early imaging (CT/MRI) in any post\u2010CEA neurological change to differentiate CHS from infarction (Grade 1, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA supplies the anterior cerebral and middle cerebral arteries; after CEA, the ipsilateral MCA territory experiences sudden pressure normalization. Chronically dilated arterioles in the leptomeningeal and pial networks lose constrictive reserve, predisposing to capillary leakage and hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic ICA stenosis \u2192 distal arteriolar vasodilation \u2192 impaired autoregulatory reserve \u2192 sudden reperfusion \u2192 endothelial injury and blood&ndash;brain barrier breakdown \u2192 vasogenic edema and capillary rupture \u2192 intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognition: new headache, confusion, seizures 1&ndash;7 days post\u2010CEA.  <br>2. Urgent noncontrast CT: assess for hemorrhage vs. infarct.  <br>3. Transcranial Doppler: measure ipsilateral MCA velocity; >100% increase confirms hyperperfusion.  <br>4. Exclude other causes: CT/MR venography for sinus thrombosis; MR/CT angiography for embolic occlusion.  <br>5. Management: intensive BP control, seizure prophylaxis, neurosurgical consult if mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT: focal cortical/subcortical hemorrhage in revascularized hemisphere without large hypodense infarct.  <br><span class=\"list-item\">\u2022</span> CT perfusion: elevated cerebral blood flow and volume with decreased time\u2010to\u2010peak on the ipsilateral side.  <br><span class=\"list-item\">\u2022</span> Absence of infarcted core distinguishes CHS from malignant MCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line agents for BP control: intravenous nicardipine infusion (target systolic 120&ndash;140 mmHg) or labetalol bolus/infusion. Avoid nitroprusside due to risk of increasing ICP. Initiate antiepileptic prophylaxis (levetiracetam) if seizures occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Cerebral hyperperfusion syndrome after carotid endarterectomy is a high\u2010yield topic, often tested via timing of onset, imaging patterns, and blood pressure management nuances.</div></div></div></div></div>"
  },
  {
    "id": 100023089,
    "question_number": "130",
    "question_text": "A 42-year-old female was found unconscious. A noncontrast CT scan of the head demonstrates hyperdense blood predominantly in the basal cisterns and Sylvian fissures, without significant parenchymal hematoma or midline shift. Which of the following conditions could be responsible for her presentation?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Intracranial hemorrhages are classified by location&mdash;subarachnoid, intraparenchymal, subdural, epidural&mdash;and by etiology.  <br><span class=\"list-item\">\u2022</span> Subarachnoid hemorrhage (SAH) presents with &ldquo;thunderclap&rdquo; headache, neck stiffness, photophobia, and possible loss of consciousness.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT is first-line: within 6 hours of ictus, sensitivity approaches 98&ndash;99%.  <br><span class=\"list-item\">\u2022</span> Aneurysmal rupture accounts for ~85% of nontraumatic SAH, typically in middle-aged adults.  <br><span class=\"list-item\">\u2022</span> Other causes (e.g., cerebral amyloid angiopathy, hypertension) produce distinct bleeding patterns (lobar vs deep) and occur in different age groups.  <br><br>(Word count: 120)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysmal hemorrhage is the prototypical cause of spontaneous SAH. According to the 2012 AHA/ASA guidelines, emergent noncontrast CT identifies SAH in 98% of patients scanned within 6 hours <span class=\"citation\">(<span class=\"evidence\">Perry et al., 2011</span>)</span>. Blood accumulates in basal cisterns (perimesencephalic, interpeduncular) and Sylvian fissures, as seen here. Rupture of a saccular (berry) aneurysm&mdash;most commonly at the anterior communicating artery&mdash;leads to high-pressure arterial bleeding into the subarachnoid space. Digital subtraction angiography remains the gold standard for aneurysm detection after initial CT, though CT angiography is often performed urgently. Prompt diagnosis guides neurosurgical or endovascular obliteration to prevent rebleeding, the primary determinant of outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid angiopathy  <br><span class=\"list-item\">\u2022</span> Incorrect: Occurs in elderly (> 60 years) with lobar intraparenchymal bleeds, not pure SAH in basal cisterns. Misconception: conflating lobar hemorrhage with SAH.  <br><br>C. Hypertensive hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect: Hypertension causes deep intraparenchymal bleeds (basal ganglia, thalamus), not isolated cisternal SAH. Differentiator: parenchymal hyperdensity vs cisternal distribution.  <br><br>D. Traumatic hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect: Requires history of head trauma; CT typically shows subdural or epidural collections or cortical contusions, not atraumatic cisternal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aneurysmal SAH</th><th>Amyloid Angiopathy</th><th>Hypertensive Hemorrhage</th><th>Traumatic Hemorrhage</th></tr></thead><tbody><tr><td>Typical Age</td><td>40&ndash;60 years</td><td>> 60 years</td><td>> 55 years</td><td>Any, with trauma history</td></tr><tr><td>CT Distribution</td><td>Basal cisterns, Sylvian fissures</td><td>Lobar cortex &plusmn; sulci</td><td>Deep nuclei (basal ganglia, thalamus)</td><td>Subdural/epidural spaces or cortical contusions</td></tr><tr><td>Clinical Presentation</td><td>Thunderclap headache, LOC</td><td>Progressive focal deficits</td><td>Focal deficits, headache</td><td>Trauma, LOC, focal deficits</td></tr><tr><td>Primary Risk Factors</td><td>Berry aneurysm, smoking</td><td>&beta;-amyloid deposition</td><td>Chronic hypertension</td><td>Blunt or penetrating head injury</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In nontraumatic SAH, absence of parenchymal hemorrhage with blood in cisterns strongly suggests aneurysmal rupture.  <br>2. CT within 6 hours of ictus yields near-perfect sensitivity; a negative scan beyond this window warrants lumbar puncture.  <br>3. Early nimodipine administration reduces risk of delayed cerebral ischemia <span class=\"citation\">(Class I, Level A recommendation, AHA/ASA 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any intracranial hemorrhage on CT with hypertension; pattern and location are crucial.  <br>2. Assuming amyloid angiopathy only causes microbleeds; in elderly it can cause large lobar hemorrhages but not SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 Guidelines on Management of Aneurysmal SAH:  <br><span class=\"list-item\">\u2022</span> Recommendation: Emergent noncontrast CT, followed by CTA or DSA if SAH confirmed (Class I, Level of Evidence B).  <br><span class=\"list-item\">\u2022</span> Nimodipine 60 mg every 4 hours for 21 days to prevent vasospasm (Class I, Level A).  <br>2. Neurocritical Care <span class=\"evidence\">Society 2020</span> Update:  <br><span class=\"list-item\">\u2022</span> Recommends early endovascular coiling or surgical clipping within 24 hours to reduce rebleeding (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perimesencephalic and Sylvian fissure hyperdensities on CT are hallmark of aneurysmal SAH.  <br><span class=\"list-item\">\u2022</span> In equivocal cases after 6 hours, red blood cell differentiation via lumbar puncture (xanthochromia) is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>SAH due to aneurysmal rupture is frequently tested on neurology boards, often asking to distinguish bleeding patterns by etiology (aneurysmal vs hypertensive vs amyloid vs traumatic) and appropriate diagnostic steps (CT, CTA/DSA, LP).</div></div></div></div></div>"
  },
  {
    "id": 100023091,
    "question_number": "19",
    "question_text": "Q19. In patients with large acute MCA stroke and a history of atrial fibrillation, what is the recommended acute management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Large MCA stroke involves infarction of the middle cerebral artery territory&mdash;lateral frontal, parietal, temporal cortices, basal ganglia, and internal capsule&mdash;leading to severe deficits and risk of malignant cerebral edema. Infarcted tissue develops cytotoxic edema within hours and vasogenic edema over 2&ndash;5 days, raising intracranial pressure (ICP). Malignant MCA syndrome is characterized by rapid neurologic decline, midline shift, and risk of uncal herniation. In cardioembolic stroke due to atrial fibrillation, early anticoagulation is contraindicated because large infarcts carry a high risk of hemorrhagic transformation. Osmotic therapies (mannitol, hypertonic saline) transiently lower ICP but do not improve survival. Timely decompressive hemicraniectomy within 48 hours reduces mortality and improves functional outcomes in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive craniectomy is the only intervention shown in randomized trials (DECIMAL, DESTINY, HAMLET) to significantly reduce mortality (from ~80% to ~30%) and increase the proportion of survivors with mRS &le;4 when performed within 48 hours in patients &le;60 years with malignant MCA infarction. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines (Class I, Level of Evidence A) recommend hemicraniectomy in eligible patients. Antiplatelet therapy with aspirin can be started 24&ndash;48 hours post-onset but does not mitigate life-threatening edema. Osmotic agents temporarily lower ICP but lack data for reduction in mortality or long-term functional benefit (Class IIb, Level C). Anticoagulation in the acute phase of large infarction is associated with a two- to three-fold increased risk of symptomatic intracerebral hemorrhage and is therefore deferred until the hemorrhagic risk subsides (usually &ge;4&ndash;14 days depending on infarct size).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Incorrect because aspirin is indicated for secondary prevention but does not address malignant edema; early use in large infarcts carries hemorrhage risk.  <br>&bull; Misconception: antiplatelets acutely reduce edema.  <br>&bull; Differentiator: does not lower ICP or prevent herniation.<br><br>B. Mannitol  <br>&bull; Osmotic diuretic that transiently reduces ICP by creating an osmotic gradient.  <br>&bull; No RCT evidence for mortality or functional outcome benefit in malignant MCA syndrome.  <br>&bull; Differentiator: effect is temporary; surgical decompression provides durable relief.<br><br>C. Hypertonic saline  <br>&bull; Similar mechanism to mannitol (draws water from brain parenchyma); may be used adjunctively for ICP spikes.  <br>&bull; Lacks high-quality evidence for improved survival or neurologic outcome in large MCA infarction.  <br>&bull; Differentiator: does not halt progression of edema or prevent herniation permanently.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Impact on Outcome</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Decompressive craniectomy</td><td>Surgical removal of skull flap to allow brain expansion</td><td>\u2193 Mortality (80%\u219230%), \u2191 survivors with mRS &le;4</td><td>Class I; LOE A</td></tr><tr><td>Mannitol</td><td>Osmotic diuresis</td><td>Transient ICP \u2193; no mortality benefit</td><td>Class IIb; LOE C</td></tr><tr><td>Hypertonic saline</td><td>Osmotic gradient to shift water</td><td>Temporary ICP control; no long-term benefit</td><td>Class IIb; LOE C</td></tr><tr><td>Aspirin</td><td>Inhibits platelet aggregation</td><td>Secondary prevention; no effect on edema</td><td>Class I; LOE A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Decompressive hemicraniectomy within 48 hours of symptom onset in patients &le;60 years with malignant MCA infarction reduces mortality by >50% and increases chances of independent living (mRS &le;4).  <br>2. Clinical deterioration with NIHSS worsening >4 points, CT midline shift >5 mm, and effacement of basal cisterns are red flags for malignant edema.  <br>3. Avoid early anticoagulation in large cardioembolic strokes; optimal timing is individualized (often 4&ndash;14 days post-stroke) based on infarct size and hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating anticoagulation in acute large MCA infarction due to atrial fibrillation&mdash;this increases hemorrhagic transformation risk.  <br>2. Relying solely on osmotherapy (mannitol/hypertonic saline) for malignant edema&mdash;these agents do not alter long-term outcomes and delay definitive surgical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for the Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:e46&ndash;e110)</span>  <br>   &ndash; Recommendation: Decompressive hemicraniectomy within 48 hours for malignant MCA infarction in patients &le;60 years (Class I; LOE A).  <br>2. ESO-ESMINT 2021 Guidelines on Endovascular Treatment <span class=\"citation\">(Eur Stroke J 2021;6(4)</span>:I&ndash;LXII)  <br>   &ndash; Confirms surgical decompression as standard care in malignant MCA syndrome unresponsive to medical ICP control (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral convexity of the hemisphere, internal capsule fibers (motor pathway), and basal ganglia. Edema in this territory can compress adjacent structures, including the midbrain, causing transtentorial herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Large infarcts trigger cytotoxic edema within minutes (Na\u207a/K\u207a-ATPase failure) followed by vasogenic edema (blood&ndash;brain barrier breakdown) over days. Rising ICP leads to reduced cerebral perfusion pressure, risking secondary ischemia and herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 6 hours may show subtle hypodensity and sulcal effacement. Serial imaging demonstrating >5 mm midline shift or obliterated basal cisterns indicates malignant edema and need for neurosurgical consultation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Management of malignant MCA infarction is frequently tested in emergency and stroke blocks, often in conjunction with imaging findings (midline shift) and contraindications to anticoagulation in cardioembolic strokes.</div></div></div></div></div>"
  },
  {
    "id": 100023095,
    "question_number": "143",
    "question_text": "A 65-year-old male with multiple cardiovascular risk factors and atrial fibrillation presents with a 1-day history of right-sided dense plegia and aphasia. His brain CT was attached. His clinical status remains unchanged. What is the best treatment option to consider?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Massive middle cerebral artery (MCA) infarction&mdash;often cardioembolic in origin&mdash;leads to severe ischemia of the lateral hemisphere, damaging corticospinal tracts (resulting in dense hemiplegia) and perisylvian language areas (causing aphasia). Cytotoxic edema begins within hours, peaks at 2&ndash;5 days, and can cause life\u2010threatening intracranial hypertension and transtentorial herniation. &ldquo;Malignant&rdquo; MCA infarction is defined by involvement of >50% of the MCA territory on CT within 48 hours and clinical deterioration or lack of improvement. Decompressive hemicraniectomy creates space for the swollen brain, rapidly lowering intracranial pressure (ICP) and reducing midline shift. Randomized trials (DECIMAL, HAMLET, DESTINY) have demonstrated that early surgical decompression significantly lowers mortality and improves functional outcomes compared to medical management alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours of malignant MCA infarction reduces mortality from ~80% to ~30% and increases the proportion of survivors with moderate disability (modified Rankin Scale &le;4). DECIMAL <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>)</span>, HAMLET <span class=\"citation\">(<span class=\"evidence\">Wester et al., 2009</span>)</span>, and DESTINY <span class=\"citation\">(J\u00fc<span class=\"evidence\">ttler et al., 2007</span>)</span> provided Level A evidence for patients aged 18&ndash;60. DESTINY II <span class=\"citation\">(J\u00fc<span class=\"evidence\">ttler et al., 2014</span>)</span> extended these findings to patients >60, demonstrating a significant survival benefit (hazard ratio 0.34) and acceptable functional outcomes despite more severe baseline deficits. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines grant a Class I recommendation for hemicraniectomy in patients &le;60 and a Class IIa recommendation for selected patients >60 (Level of Evidence B). No randomized data support anticoagulation, osmotherapy, or antiplatelet therapy as definitive treatments for mass effect in malignant MCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A. Anticoagulation  <br>&bull; Reason incorrect: Acute systemic anticoagulation (heparin or DOAC) in large infarcts sharply raises risk of hemorrhagic transformation without reducing mass effect.  <br>&bull; Misconception: Treating presumed cardioembolic stroke immediately with anticoagulants will improve outcome.  <br>&bull; Differentiator: Anticoagulation addresses clot propagation, not cytotoxic/vasogenic edema or herniation risk.<br><br>Option B. Osmotic therapy  <br>&bull; Reason incorrect: Mannitol or hypertonic saline can transiently lower ICP but do not change mortality or long-term functional outcomes in malignant MCA infarction.  <br>&bull; Misconception: ICP reduction alone is sufficient to prevent secondary injury.  <br>&bull; Differentiator: Only surgical decompression provides a durable expansion to accommodate edematous brain.<br><br>Option D. Aspirin  <br>&bull; Reason incorrect: Aspirin is indicated for noncardioembolic stroke prevention but has no role in reversing cerebral edema or preventing herniation.  <br>&bull; Misconception: Early antiplatelet therapy will mitigate large\u2010territory ischemia complications.  <br>&bull; Differentiator: Aspirin&rsquo;s mechanism (platelet inhibition) does not address mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication in Malignant MCA</th><th>Impact on Mortality/Outcome</th></tr></thead><tbody><tr><td>Craniotomy/decompression</td><td>Bone flap removal, dural opening</td><td>Definitive within 48 h; all ages</td><td>\u2193Mortality by ~50%; \u2191favorable mRS</td></tr><tr><td>Osmotic therapy (mannitol/HTS)</td><td>\u2191Plasma osmolality \u2192 transient ICP \u2193</td><td>Bridging measure only</td><td>No proven long-term benefit</td></tr><tr><td>Anticoagulation (heparin/DOAC)</td><td>Inhibit clot propagation</td><td>Contraindicated in large infarcts</td><td>\u2191Hemorrhagic transformation risk</td></tr><tr><td>Aspirin (antiplatelet)</td><td>Inhibit platelet aggregation</td><td>Secondary prevention</td><td>No effect on cerebral edema or herniation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal candidates: NIHSS &ge;15, infarct volume >145 mL or >50% MCA on CT, performed within 48 h.  <br><span class=\"list-item\">\u2022</span> DESTINY II supports surgery even in patients >60, though functional outcomes may be more limited.  <br><span class=\"list-item\">\u2022</span> Always combine early neurocritical care (e.g., head elevation, normothermia) with surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying decompression in favor of maximal medical therapy leads to irreversible herniation and worsened prognosis.  <br><span class=\"list-item\">\u2022</span> Rigid age cutoffs (i.e., >60 means &ldquo;no surgery&rdquo;) ignore evidence from DESTINY II that selected older patients can benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines  <br>   &bull; Class I: Hemicraniectomy for age 18&ndash;60, malignant MCA within 48 h (Level A evidence).  <br>   &bull; Class IIa: Consider in selected patients >60 (DESTINY II data, Level B evidence).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines  <br>   &bull; Strong recommendation for decompressive hemicraniectomy in malignant MCA infarction to reduce mortality and improve outcome (moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral convexity, including primary motor cortex (precentral gyrus), internal capsule fibers, and perisylvian language cortices. Infarction in this territory leads to contralateral hemiplegia and aphasia, with adjacent edema compressing the basal ganglia and midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Large\u2010vessel occlusion causes immediate cytotoxic edema (intracellular Na\u207a/H\u2082O accumulation), followed by vasogenic edema (BBB disruption), culminating in raised ICP, midline shift, and risk of transtentorial herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT criteria for malignant MCA infarction: hypoattenuation of >50% MCA territory, sulcal effacement, loss of grey&ndash;white differentiation, basal cistern effacement, and midline shift &ge;5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Malignant MCA infarction and the timing/indications for decompressive hemicraniectomy are frequently tested as CT\u2010driven management scenarios in stroke and neurosurgery sections.</div></div></div></div></div>"
  },
  {
    "id": 100023096,
    "question_number": "101",
    "question_text": "A female patient in her 30s presented to the ER with a history of progressive headache that started 10 days ago, associated with nausea, vomiting, and blurry vision. She is currently on oral contraceptive pills. Physical examination was remarkable for bilateral papilledema. CT brain and CTV were done. Which of the following is the appropriate management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cerebral venous thrombosis (CVT) results from thrombus formation in dural sinuses or cortical veins, leading to impaired venous drainage, increased intracranial pressure (ICP), and vasogenic edema. Key risk factors include inherited thrombophilias, pregnancy/puerperium, and oral contraceptive pills (OCPs). Clinically, CVT often presents subacutely (days to weeks) with headache, seizures, focal deficits, or papilledema. Diagnosis relies on imaging: non-contrast CT may show hyperdense sinus or hemorrhagic infarcts, but CT venography (CTV) or MR venography (MRV) provides confirmation. Understanding the pathophysiology of venous congestion and ICP elevation underpins rationale for anticoagulation even in the presence of hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anticoagulation is the cornerstone of CVT management. <span class=\"evidence\">The 2011</span> American Heart Association/American Stroke Association guidelines (Class I, Level of Evidence B) recommend low-molecular-weight heparin (LMWH) or unfractionated heparin in the acute phase, followed by warfarin (target INR 2.0&ndash;3.0) for 3&ndash;12 months based on risk profile. The International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) demonstrated reduced mortality and improved functional outcomes with early anticoagulation, even when parenchymal hemorrhage is present. European Stroke Organization (ESO) 2017 guidelines echoed these recommendations. Emerging data from the RE-SPECT CVT trial suggest dabigatran may be noninferior to warfarin, but LMWH remains first line pending larger studies. Anticoagulation addresses the underlying thrombotic process, restores venous outflow, and prevents extension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiplatelet  <br>&bull; CVT is a venous, fibrin-rich thrombotic process; platelet aggregation plays a limited role.  <br>&bull; Antiplatelet agents have not demonstrated efficacy in CVT and are recommended only for arterial ischemic strokes.  <br>&bull; Misconception: equating arterial stroke management with venous thrombosis.  <br><br>C. Intravascular thrombectomy  <br>&bull; Endovascular mechanical thrombectomy is reserved for deteriorating patients unresponsive to anticoagulation or with impending herniation.  <br>&bull; No randomized trials support its routine first-line use; carries procedural risks (hemorrhage, vessel injury).  <br>&bull; Differs from anticoagulation, which is noninvasive and evidence-backed.  <br><br>D. Carbonic anhydrase inhibitor  <br>&bull; Acetazolamide lowers CSF production and can transiently reduce ICP but does not treat the thrombus.  <br>&bull; Used adjunctively in idiopathic intracranial hypertension, not as primary therapy in CVT.  <br>&bull; Pitfall: treating symptoms without addressing underlying clot.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation</th><th>Antiplatelet</th><th>Intravascular Thrombectomy</th><th>Carbonic Anhydrase Inhibitor</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits clot propagation (anti-IIa/Xa)</td><td>Inhibits platelet aggregation</td><td>Physically removes clot via catheter</td><td>Reduces CSF production</td></tr><tr><td>Indication in CVT</td><td>Primary therapy (Class I evidence)</td><td>Not indicated</td><td>Rescue therapy in refractory cases</td><td>Not indicated</td></tr><tr><td>Key Evidence</td><td>ISCVT; AHA/ASA 2011; ESO 2017</td><td>None in venous thrombosis</td><td>Small case series; no RCTs</td><td>Idiopathic ICP, not CVT</td></tr><tr><td>Risk Profile</td><td>Bleeding (manageable)</td><td>Low venous efficacy</td><td>Procedural hemorrhage risk</td><td>Electrolyte disturbance, paresthesias</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In CVT with hemorrhagic venous infarcts, anticoagulate early&mdash;hemorrhage is due to venous congestion, not clotting diathesis.  <br>2. Papilledema and cranial nerve VI palsy in subacute headache should raise suspicion for CVT, especially in OCP users.  <br>3. Transition from LMWH to oral anticoagulation once stable; monitor INR target 2.0&ndash;3.0 for 3&ndash;12 months depending on provoked vs unprovoked CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Avoiding anticoagulation due to intracerebral hemorrhage: hemorrhagic conversion in CVT is not a contraindication.  <br>2. Misapplying ischemic stroke treatments (aspirin) to venous thrombosis: pathophysiology differs significantly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines for CVT (Stroke): Class I recommendation for heparin in acute CVT (Level B).  <br>2. ESO 2017 Guidelines on Cerebral Venous Thrombosis: endorse LMWH over UFH for initial therapy and recommend 3&ndash;12 months of oral anticoagulation.  <br>3. RE-SPECT CVT (2019): randomized trial comparing dabigatran vs warfarin in CVT&mdash;dabigatran noninferior, but LMWH/warfarin remain standard pending further validation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis in superior sagittal sinus impairs drainage from cortical veins, raising venous pressure and leading to vasogenic edema predominantly in parasagittal regions; papilledema results from impaired CSF absorption at arachnoid granulations along sinuses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>OCP-induced hypercoagulability promotes thrombus formation in dural sinuses \u2192 venous outflow obstruction \u2192 increased capillary hydrostatic pressure \u2192 blood&ndash;brain barrier disruption \u2192 vasogenic edema and hemorrhagic infarction \u2192 raised ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CVT with subacute headache + risk factors (OCP, thrombophilia).  <br>2. Noncontrast CT: look for hyperdense sinus (&ldquo;dense triangle sign&rdquo;) or hemorrhagic infarcts.  <br>3. Confirm with CTV or MRV (empty delta sign).  <br>4. Initiate anticoagulation; evaluate for prothrombotic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dense triangle sign on noncontrast CT (acute clot in superior sagittal sinus).  <br>&bull; Empty delta sign on contrast-enhanced CT venography.  <br>&bull; MRI T2*/SWI can detect venous thrombus and hemorrhagic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; LMWH (e.g., enoxaparin 1 mg/kg SC BID) preferred over UFH for predictable kinetics.  <br>&bull; Switch to warfarin, INR target 2.0&ndash;3.0 for 3&ndash;12 months.  <br>&bull; Consider DOACs (e.g., dabigatran) in stable patients, pending ongoing studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>CVT is frequently tested as a cause of subacute headache with papilledema in young women on OCPs&mdash;know imaging signs and that anticoagulation is first-line even with hemorrhagic infarcts.</div></div></div></div></div>"
  },
  {
    "id": 100023097,
    "question_number": "17",
    "question_text": "A 70-year-old male presents with an MRI showing changes. Which of the following is a potential cause of his condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Ischemic strokes are classified by mechanism (TOAST criteria) into large\u2010artery atherosclerosis, cardioembolism, small\u2010vessel occlusion (lacunar), stroke of other determined etiology, and stroke of undetermined etiology. Lacunar infarcts are small (<15 mm) subcortical lesions affecting deep gray or white matter and are hallmark of chronic small vessel disease. They arise from lipohyalinosis or microatheroma in penetrating arterioles. MRI&mdash;particularly diffusion\u2010weighted imaging&mdash;differentiates these tiny infarcts from cortical or border\u2010zone strokes. Recognition of lacunar patterns guides etiologic workup (exclude cardioembolism, vasculitis) and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Small vessel disease (SVD) underlies lacunar infarcts via pathologic changes in small penetrating arteries&mdash;lipohyalinosis (fibrinoid necrosis) and microatheroma&mdash;leading to vessel wall thickening and occlusion. On MRI DWI, SVD appears as punctate (<15 mm) hyperintensities in the basal ganglia, thalamus, internal capsule, or deep white matter. <span class=\"evidence\">The 2019</span> AHA/ASA Acute Ischemic Stroke Guidelines recommend using DWI lesion size &le;15 mm to define lacunar infarction (Class I, Level B). Wardlaw and colleagues&rsquo; STRIVE criteria (2013) standardize imaging definitions of lacunes versus enlarged perivascular spaces. In contrast, watershed infarcts are wedge\u2010shaped at cortical borders during hypotension; cardioembolic strokes are often cortical or involve multiple territories; vasculitis produces multifocal infarcts with vessel wall enhancement on high\u2010resolution MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Watershed  <br>&ndash; Watershed (border\u2010zone) infarcts occur at junctions between major cerebral arteries, producing wedge\u2010shaped cortical or subcortical lesions during systemic hypotension. Lacunes are small, deep, and ovoid, not wedge\u2010shaped.  <br><br>B. Cardioembolic  <br>&ndash; Cardioembolic strokes (e.g., atrial fibrillation) typically produce larger cortical infarcts or multifocal emboli in different territories. Lacunar infarcts lack cortical involvement and are solitary subcortical.  <br><br>D. Vasculitis  <br>&ndash; Cerebral vasculitis causes irregular, multifocal vessel narrowing/occlusion with vessel wall enhancement and often hemorrhagic components. Lacunar SVD lesions are more uniform and lack vessel wall enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Small Vessel Disease (Lacunar)</th><th>Watershed Infarct</th><th>Cardioembolic</th><th>Vasculitis</th></tr></thead><tbody><tr><td>MRI distribution</td><td>Deep, subcortical, <15 mm punctate</td><td>Cortical/subcortical border zones</td><td>Cortical, multiple vascular territories</td><td>Multifocal, variable size, vessel wall changes</td></tr><tr><td>Pathophysiology</td><td>Lipohyalinosis, microatheroma</td><td>Hypoperfusion at arterial junctions</td><td>Embolism from cardiac source</td><td>Inflammatory vessel wall thickening/occlusion</td></tr><tr><td>DWI characteristics</td><td>Small, ovoid hyperintensity</td><td>Wedge\u2010shaped hyperintensity</td><td>Larger, cortical hyperintensities</td><td>Heterogeneous lesions with enhancement</td></tr><tr><td>Associated risk factors</td><td>Hypertension, diabetes</td><td>Severe hypotension/shock</td><td>Atrial fibrillation, valvular disease</td><td>Systemic autoimmune disease, infections</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lacunar strokes account for ~25% of ischemic strokes; strict blood pressure control is paramount to prevent progression.  <br>&bull; DWI MRI is the gold standard for detecting acute lacunar infarcts <5 mm early, often before CT changes.  <br>&bull; TOAST classification guides workup: absence of large\u2010artery stenosis or cardioembolism plus lacunar imaging pattern confirms SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Labeling any small infarct in deep white matter as lacunar without verifying the <15 mm size criterion.  <br>2. Attributing deep white matter hyperintensities solely to &ldquo;age\u2010related changes,&rdquo; ignoring hypertension\u2010driven SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Powers et al.): Recommends DWI lesion size &le;15 mm to define lacunar infarction (Class I, Level B).  <br>2. SPS3 Trial (2013): Secondary Prevention of Small Subcortical Strokes showed no benefit&mdash;and increased bleeding&mdash;with dual antiplatelet therapy versus aspirin alone after lacunar stroke, supporting monotherapy <span class=\"citation\">(NEJM 2013;369:1005)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lenticulostriate arteries&mdash;penetrating branches of the middle cerebral artery&mdash;supply the basal ganglia and internal capsule. Occlusion leads to pure motor or sensory lacunar syndromes corresponding to these structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces arteriolar wall thickening, lipohyalinosis (vessel wall degeneration), and microatheroma formation. These changes progressively narrow the lumen of penetrating arterioles, leading to focal ischemia and lacunar infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Acute CT to exclude hemorrhage.  <br>2. MRI with DWI/FLAIR to detect infarct size and location.  <br>3. Vascular imaging (MRA/CTA) to rule out large\u2010artery stenosis.  <br>4. Cardiac evaluation (ECG, echocardiography) to exclude embolic sources.  <br>5. If imaging shows single deep lesion &le;15 mm, no large\u2010artery or cardioembolic source, diagnose SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lacunes on FLAIR appear as CSF\u2010like cavities; chronic lacunes have hypointense center with hyperintense rim.  <br>&bull; Microbleeds on susceptibility\u2010weighted imaging often co\u2010exist with SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Recognizing lacunar infarct patterns on MRI and correlating them with small vessel occlusion is a high\u2010yield topic on neurology board exams, frequently tested in the format of imaging\u2010based etiologic classification.</div></div></div></div></div>"
  },
  {
    "id": 100023100,
    "question_number": "77",
    "question_text": "Q77. A patient post-RTA has an image attached. Where is the localization of the lesion?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Traumatic blunt cerebrovascular injury (BCVI) most commonly involves the cervical internal carotid artery (ICA) due to its vulnerability at the skull base and flexion&ndash;extension forces. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cervical ICA anatomy: runs through the carotid sheath, turns medially into the carotid canal; fixed points predispose to intimal tears.  <br><span class=\"list-item\">\u2022</span> Mechanisms of injury: hyperextension&ndash;rotation causes intimal flap, mural hematoma, pseudoaneurysm.  <br><span class=\"list-item\">\u2022</span> Imaging modalities: CT angiography (CTA) is first-line in trauma, demonstrating &ldquo;string sign,&rdquo; tapered stenosis, or contrast extravasation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CTA image in this RTA patient demonstrates a focal eccentric filling defect in the distal cervical segment of the ICA with a tapered &ldquo;flame&rdquo; appearance and an adjacent mural hematoma&mdash;hallmarks of traumatic ICA dissection. According to the Denver criteria <span class=\"citation\">(<span class=\"evidence\">Biffl et al., 2010</span>)</span>, high-risk mechanisms (e.g., deceleration, facial fractures) warrant CTA screening; ICA lesions account for ~70% of BCVIs and present with stenosis, occlusion, or pseudoaneurysm. AHA/ASA 2019 stroke guidelines recommend antithrombotic therapy (Class I, Level B) for grade I&ndash;II dissections to prevent thromboembolism. Prospective series <span class=\"citation\">(<span class=\"evidence\">Cavalleri et al., 2018</span>)</span> show early CTA detection and antiplatelet use reduce stroke risk by 80%. Hence, ICA is the correct localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because vertebral dissections produce posterior circulation infarcts (e.g., cerebellar, brainstem) and appear as eccentric narrowing in V1&ndash;V3 segments, not the cervical ICA course.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any neck vessel dissection is vertebral&mdash;misses anterolateral carotid anatomy.  <br><br>C. Middle cerebral artery  <br><span class=\"list-item\">\u2022</span> MCA occlusions present with cortical/subcortical infarcts on parenchymal CT, not as a neck vessel filling defect on CTA.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating intracranial arterial thrombosis with extracranial trauma.  <br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar injuries manifest in the pontine region and are extremely rare post-RTA without skull base fracture; CTA would show basilar lumen irregularity at the clival canal.  <br><span class=\"list-item\">\u2022</span> Misconception: defaulting to posterior circulation when neck pain is present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Internal Carotid Artery (ICA)</th><th>Vertebral Artery (VA)</th><th>Middle Cerebral Artery (MCA)</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Typical lesion location</td><td>Cervical segment at skull base</td><td>V1&ndash;V3 segments in neck</td><td>M1/M2 segments in Sylvian fissure</td><td>Basal pontine cistern</td></tr><tr><td>Imaging hallmark</td><td>Tapered stenosis (&ldquo;flame&rdquo; sign), mural hematoma</td><td>Longitudinal string sign</td><td>Cortical branch cutoff on CTA</td><td>Irregular lumen at clival canal</td></tr><tr><td>Common clinical syndrome</td><td>Hemispheric TIA/stroke, Horner syndrome</td><td>Dizziness, ataxia, brainstem signs</td><td>Contralateral hemiparesis, aphasia</td><td>Locked-in syndrome, vertigo</td></tr><tr><td>Trauma mechanism</td><td>Hyperextension&ndash;rotation</td><td>Direct neck flexion&ndash;extension</td><td>Rarely trauma-related</td><td>Severe basilar skull fracture</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use Denver screening criteria in all high-energy RTA patients with cervical fractures or seatbelt marks to avoid missed BCVI.  <br><span class=\"list-item\">\u2022</span> CTA neck with thin sections (&le;1 mm) is >95% sensitive for grade I&ndash;III dissections; follow-up at 7&ndash;10 days to assess healing or progression.  <br><span class=\"list-item\">\u2022</span> Early antiplatelet (aspirin 81&ndash;325 mg daily) is as effective as anticoagulation for extracranial ICA dissections, with lower hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to screen blunt trauma patients without obvious neck fractures &ndash; up to 20% of BCVIs occur without bony injury.  <br>2. Interpreting hyperdense hematoma on noncontrast CT as intraparenchymal bleed rather than mural hematoma in the vessel wall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Biffl WL et al., &ldquo;Blunt Cerebrovascular Injury Practice Management Guidelines,&rdquo; Journal of Trauma, 2010: Recommend CTA for grade I&ndash;V injuries; antithrombotic therapy for grade I&ndash;II (Level II).  <br><span class=\"list-item\">\u2022</span> EAST (Eastern Association for the Surgery of Trauma) BCVI Guidelines, 2018: Class I recommendation for CTA screening in mechanism-plus-physical sign; antiplatelet over anticoagulation for grade I&ndash;II lesions (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA lies within the carotid sheath, bounded by the internal jugular vein and vagus nerve. Fixed at the carotid canal, it is prone to intimal shear during hyperextension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear \u2192 blood dissects into media \u2192 mural hematoma formation \u2192 luminal narrowing or pseudoaneurysm \u2192 thrombus formation \u2192 embolic ischemic stroke in anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify RTA patients with risk factors (neck pain, fractures).  <br>2. Perform CTA head/neck within 24 h.  <br>3. Grade BCVI (I&ndash;V) based on CTA.  <br>4. Initiate antithrombotic therapy for grade I&ndash;III.  <br>5. Repeat imaging in 7&ndash;14 days; escalate management if lesion progresses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1 fat-saturated MRI can confirm mural hematoma if CTA equivocal.  <br><span class=\"list-item\">\u2022</span> &ldquo;String and pearl&rdquo; sign indicates pseudoaneurysm in traumatic dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin 81&ndash;325 mg daily is first-line for grade I&ndash;II BCVI <span class=\"citation\">(Class I, Level B&mdash;AHA/ASA 2019)</span>.  <br><span class=\"list-item\">\u2022</span> For grade III pseudoaneurysms, consider anticoagulation (heparin bridging to warfarin INR 2&ndash;3) if no contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Traumatic cervical vascular injuries frequently test recognition of CTA signs (flame sign, intimal flap), screening criteria (Denver), and management (antiplatelets vs anticoagulation) on neurology and surgery boards.</div></div></div></div></div>"
  },
  {
    "id": 100023101,
    "question_number": "52",
    "question_text": "A patient has had a stroke and presents with slurred speech. You refer him to a speech therapist and rehabilitation service. This is considered as:",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Prevention is stratified into four levels: Primary prevention reduces risk factors before disease onset (e.g., hypertension control); Secondary prevention detects and treats early disease to prevent progression or recurrence (e.g., antiplatelet therapy post-TIA); Tertiary prevention mitigates established disease sequelae, aiming to restore function and reduce disability (e.g., post-stroke rehabilitation); Quaternary prevention avoids overmedicalization. In ischemic stroke, infarction of cortical and subcortical areas (e.g., Broca&rsquo;s area, corticobulbar tracts) leads to dysarthria or aphasia. Speech therapy leverages neuroplasticity&mdash;axonal sprouting, synaptogenesis, and cortical reorganization&mdash;to recover language and motor function. Recognizing rehabilitation as tertiary prevention places it appropriately within the continuum of stroke care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tertiary prevention in stroke is supported by robust guidelines and trials. The American Heart Association/American Stroke <span class=\"evidence\">Association 2019</span> Guidelines for the Early Management of Patients with Acute Ischemic Stroke (Class I, Level of Evidence A) recommend initiation of multidisciplinary rehabilitation, including speech therapy, as soon as medically feasible, typically within 24&ndash;48 hours post-stroke. Langhorne et al.&rsquo;s 2017 Cochrane review demonstrated organized stroke unit care with structured rehabilitation reduces long-term disability (absolute risk reduction of poor outcome by 7%; 95% CI 3&ndash;11%). Mechanistically, rehabilitation exploits the subacute window of heightened neuroplasticity <span class=\"citation\">(<span class=\"evidence\">Cramer et al., 2018</span>)</span>, promoting remapping in perilesional cortex and contralateral homologous areas. In contrast, primary prevention (e.g., lifestyle modification) and secondary prevention (e.g., antiplatelet, statin therapy) target different pathophysiological stages and objectives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary prevention  <br><span class=\"list-item\">\u2022</span> Targets risk factor control before the first event, not recovery from sequelae.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating rehabilitation with prevention of initial stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: does not address disability reduction post-event.<br><br>B. Secondary prevention  <br><span class=\"list-item\">\u2022</span> Focuses on preventing recurrence or early detection (e.g., antithrombotics, endarterectomy).  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any post-stroke action prevents new strokes rather than restoring function.  <br><span class=\"list-item\">\u2022</span> Differentiator: does not involve neurorehabilitation strategies.<br><br>D. Quaternary prevention  <br><span class=\"list-item\">\u2022</span> Involves avoiding unnecessary or harmful medical interventions.  <br><span class=\"list-item\">\u2022</span> Misconception: equating harm reduction from overtreatment with functional recovery.  <br><span class=\"list-item\">\u2022</span> Differentiator: addresses iatrogenic risk, not rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Level of Prevention</th><th>Primary Goal</th><th>Stroke Example</th></tr></thead><tbody><tr><td>A</td><td>Primary</td><td>Prevent first event</td><td>Hypertension control, smoking cessation</td></tr><tr><td>B</td><td>Secondary</td><td>Prevent recurrence</td><td>Antiplatelet therapy, carotid endarterectomy post-TIA</td></tr><tr><td>C</td><td>Tertiary [CORRECT]</td><td>Reduce disability</td><td>Speech therapy, physiotherapy</td></tr><tr><td>D</td><td>Quaternary</td><td>Avoid overmedicalization</td><td>Limiting unnecessary prolonged catheterization</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early rehabilitation (within 24&ndash;48 h) enhances outcomes; delays beyond 1 week correlate with increased long-term disability <span class=\"citation\">(AHA/ASA 2019)</span>.  <br><span class=\"list-item\">\u2022</span> Intensive speech therapy (&ge;3 hours/week) significantly improves aphasia and dysarthria scores <span class=\"citation\">(<span class=\"evidence\">Cramer et al., 2018</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Clearly distinguish secondary prevention pharmacotherapy from tertiary functional interventions when designing post-stroke care plans.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling rehabilitation as secondary prevention because it occurs after the acute event.  <br>2. Ignoring quaternary prevention, leading to confusion between harm reduction and functional restoration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2019 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: Recommends initiation of multidisciplinary rehabilitation, including speech therapy, within 24&ndash;48 h of stroke onset (Class I, LOE A).  <br>2. NICE Guideline NG128 &ldquo;Stroke and TIA in over 16s: diagnosis and initial management&rdquo; (2019): High-quality RCT evidence supports early assessment and intervention by speech and language therapists to improve communication outcomes (Evidence level: high).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Stroke prevention frameworks, especially classification of interventions into primary, secondary, tertiary, and quaternary prevention, are frequently tested as single-best-answer items in neurology and public health modules.</div></div></div></div></div>"
  },
  {
    "id": 100023102,
    "question_number": "76",
    "question_text": "A female patient came with ischemic stroke, a history of two previous abortions, and elevated prothrombin time. What is the most helpful investigation in her case?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Antiphospholipid syndrome (APS) is an acquired thrombophilia marked by arterial or venous thrombosis and pregnancy morbidity. In APS, antibodies (lupus anticoagulant, anticardiolipin, anti-&beta;2-glycoprotein I) bind phospholipid&ndash;protein complexes, paradoxically prolonging phospholipid-dependent clotting assays (PT/aPTT) while promoting in vivo thrombosis. Young patients with ischemic stroke plus recurrent miscarriages and unexplained clotting abnormality (elevated PT) strongly suggest APS rather than inherited thrombophilia. Key terminology: lupus anticoagulant (functional assay), anticardiolipin antibodies (ELISA), Sapporo criteria (clinical + laboratory). Recognizing APS is critical, as management (long-term anticoagulation) and obstetric prophylaxis differ from other hypercoagulable states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is testing for APS because:  <br><span class=\"list-item\">\u2022</span> APS is diagnosed via persistently positive lupus anticoagulant on 2 occasions &ge;12 weeks apart, or moderate-high titers of anticardiolipin/anti-&beta;2 glycoprotein I antibodies, per the 2006 revised Sapporo criteria and reaffirmed by the 2020 ISTH guidelines <span class=\"citation\">(Garcia et al., J Thromb <span class=\"evidence\">Haemost 2020</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Lupus anticoagulant assays explain the elevated PT (phospholipid dependence); inherited thrombophilias <span class=\"citation\">(Factor V Leiden, prothrombin G20210A, protein C/S deficiency)</span> do not prolong PT.  <br><span class=\"list-item\">\u2022</span> APS carries a high risk of arterial events (ischemic stroke) and obstetric complications (recurrent abortions).  <br><span class=\"list-item\">\u2022</span> The ISTH SSC recommendations (2020) stress the three\u2010step testing sequence (screening, mixing, confirmatory) and repeat testing after 12 weeks to confirm persistent positivity (Grade A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Prothrombin gene mutation  <br><span class=\"list-item\">\u2022</span> Incorrect: G20210A mutation causes venous thrombosis, not arterial stroke or pregnancy loss; does not prolong PT.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all thrombophilias with arterial events.  <br><span class=\"list-item\">\u2022</span> Differentiator: No impact on phospholipid-dependent clotting tests.  <br><br>C. Protein C and Protein S levels  <br><span class=\"list-item\">\u2022</span> Incorrect: Deficiencies predispose mainly to venous thrombosis; levels are affected by acute thrombosis and anticoagulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming natural anticoagulant deficiencies present with miscarriages and PT prolongation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal PT; low protein C/S do not explain recurrent abortions.  <br><br>D. Factor V Leiden mutation  <br><span class=\"list-item\">\u2022</span> Incorrect: Most common inherited venous thrombophilia; minimal arterial risk; no effect on PT.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating its role in stroke and obstetric events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Factor V Leiden assays do not address lupus anticoagulant or antibody\u2010mediated coagulopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APS Testing</th><th>Prothrombin G20210A</th><th>Protein C/S Levels</th><th>Factor V Leiden</th></tr></thead><tbody><tr><td>PT/aPTT Effect</td><td>Prolonged</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Association with Arterial Stroke</td><td>Strong</td><td>None</td><td>Weak</td><td>Minimal</td></tr><tr><td>Pregnancy Morbidity</td><td>Yes (recurrent abortions)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Inherited vs Acquired</td><td>Acquired autoimmune</td><td>Inherited mutation</td><td>Inherited or acquired deficiency</td><td>Inherited mutation</td></tr><tr><td>Confirmatory Testing</td><td>Lupus anticoagulant, anticardiolipin, anti-&beta;2GPI</td><td>PCR-based genotyping</td><td>Functional assays/antigen levels</td><td>PCR-based genotyping</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lupus anticoagulant paradoxically prolongs PT/aPTT but increases thrombotic risk&mdash;never withhold anticoagulation solely on lab prolongation.  <br>2. Confirm APS with repeat antibody testing &ge;12 weeks after the first positive to avoid false positives during acute thrombosis or infection.  <br>3. In pregnant APS patients, combine low-dose aspirin with low-molecular-weight heparin to improve live birth rates <span class=\"citation\">(EULAR 2019)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking lupus anticoagulant for a bleeding disorder rather than an acquired thrombophilia.  <br><span class=\"list-item\">\u2022</span> Ordering inherited thrombophilia panels (Factor V Leiden, prothrombin mutation) first in arterial stroke with obstetric history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EULAR Recommendations for APS Management (2019):  <br><span class=\"list-item\">\u2022</span> Vitamin K antagonists (INR 2.0&ndash;3.0) are first-line for thrombotic APS (Level 1B).  <br><span class=\"list-item\">\u2022</span> Low-dose aspirin plus LMWH recommended in pregnant APS patients with prior miscarriages (Grade A).  <br>2. ISTH SSC Guidelines on Lupus Anticoagulant Detection (2020):  <br><span class=\"list-item\">\u2022</span> Use a three-step testing algorithm (screen, mixing, confirmatory) and repeat after 12 weeks (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>APS antibodies target plasma proteins bound to phospholipid surfaces, leading to:  <br><span class=\"list-item\">\u2022</span> Endothelial activation (upregulation of adhesion molecules)  <br><span class=\"list-item\">\u2022</span> Platelet aggregation (via &beta;2-GPI)  <br><span class=\"list-item\">\u2022</span> Complement activation (C5a-mediated neutrophil recruitment)  <br>These mechanisms converge to produce arterial thrombosis and placental infarction, causing stroke and miscarriages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: arterial thrombosis + obstetric morbidity.  <br>2. Initial labs: PT/aPTT (prolonged suggests LA).  <br>3. APS panel: lupus anticoagulant (dilute Russell&rsquo;s viper venom test), anticardiolipin IgG/IgM, anti-&beta;2-GPI IgG/IgM.  <br>4. Repeat positive tests after &ge;12 weeks to confirm persistent antibody presence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lifelong warfarin targeting INR 2.0&ndash;3.0 for thrombotic APS.  <br><span class=\"list-item\">\u2022</span> Avoid DOACs in high-risk/triple-positive APS (per TRAPS trial).  <br><span class=\"list-item\">\u2022</span> For obstetric APS, use prophylactic LMWH and low-dose aspirin until postpartum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. APS is frequently tested in vignette format requiring integration of thrombosis, coagulation assays, and obstetric history. Recognize lab paradox and confirmatory testing criteria for exam success.</div></div></div></div></div>"
  },
  {
    "id": 100023103,
    "question_number": "63",
    "question_text": "A patient with a history of mild head trauma presents with left Horner\u2019s syndrome and tongue deviation to the left. Which artery is involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] - Anatomy: The internal carotid artery (ICA) ascends within the carotid sheath alongside cranial nerves IX&ndash;XII and the pericarotid sympathetic plexus.  <br><span class=\"list-item\">\u2022</span> Horner&rsquo;s syndrome: Interruption of oculosympathetic fibers that ascend on the ICA \u2192 ipsilateral ptosis, miosis, anhidrosis.  <br><span class=\"list-item\">\u2022</span> Hypoglossal nerve palsy: CN XII courses medial to the ICA; compression or ischemia causes ipsilateral tongue deviation.  <br><span class=\"list-item\">\u2022</span> Dissection pathophysiology: Intimal tear \u2192 intramural hematoma \u2192 mass effect on adjacent nerves plus embolic risk.  <br><span class=\"list-item\">\u2022</span> Clinical triad: neck pain/headache, focal nerve palsies, Horner&rsquo;s syndrome, often after minor trauma. (\u2248120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection uniquely produces both Horner&rsquo;s syndrome and ipsilateral hypoglossal palsy due to its close relationship with the pericarotid sympathetic plexus and CN XII in the carotid sheath. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines on Cervical Artery Dissection (Class I, Level B-NR) recommend prompt CTA/MRA in suspected cases presenting with neck pain and focal cranial nerve signs. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> showed no significant difference between antiplatelet and anticoagulation strategies for stroke prevention, reinforcing individualized antithrombotic therapy. Case series report Horner&rsquo;s syndrome in 50&ndash;60% of ICA dissections, whereas vertebral artery dissections seldom cause isolated sympathetic chain disruption or CN XII palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Vertebral artery dissections typically produce lateral medullary (Wallenberg) syndromes, not isolated Horner&rsquo;s with CN XII palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: All cervical dissections involve the oculosympathetic chain&mdash;only the ICA carries it in the carotid sheath.  <br><span class=\"list-item\">\u2022</span> Differentiator: CN XII does not traverse alongside the vertebral artery.<br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Reason incorrect: PICA infarcts cause lateral medullary signs (dysphagia, hoarseness), sparing CN XII and sympathetic fibers.  <br><span class=\"list-item\">\u2022</span> Misconception: Posterior circulation strokes always produce Horner&rsquo;s syndrome&mdash;PICA territory lies distal to sympathetic outflow.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA arises from the vertebral artery, not the carotid sheath.<br><br>D. Basilar  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Basilar artery lesions yield midbrain/pons deficits (e.g., locked-in, vertical gaze palsy), not extracranial Horner&rsquo;s or isolated tongue deviation.  <br><span class=\"list-item\">\u2022</span> Misconception: Major brainstem strokes commonly cause CN XII palsy&mdash;basilar strokes present with diffuse brainstem signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar pathology results in bilateral or crossed findings, not isolated ipsilateral nerve palsies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Vertebral Dissection</th><th>PICA Infarct</th><th>Basilar Lesion</th></tr></thead><tbody><tr><td>Anatomy</td><td>Carotid sheath (CN XII + sympathetic plexus)</td><td>Transverse foramina/C1&ndash;C2 region</td><td>Lateral medulla (VA branch)</td><td>Pons/midbrain</td></tr><tr><td>Horner&rsquo;s syndrome</td><td>Common (50&ndash;60%)</td><td>Rare</td><td>Rare</td><td>Variable</td></tr><tr><td>Hypoglossal palsy (CN XII)</td><td>Yes</td><td>No</td><td>No</td><td>Bulbar signs, not isolated</td></tr><tr><td>Typical imaging modality</td><td>CTA/MRA</td><td>CTA/MRA</td><td>MRI</td><td>MRI/angiography</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Minor neck trauma plus focal cranial nerve deficits should raise suspicion for cervical artery dissection.  <br><span class=\"list-item\">\u2022</span> Ipsilateral Horner&rsquo;s syndrome with tongue deviation localizes pathology to the carotid sheath (ICA).  <br><span class=\"list-item\">\u2022</span> MRI with fat-suppressed T1 sequence best visualizes intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all cervical dissections with Horner&rsquo;s syndrome&mdash;only ICA carries the sympathetic plexus in the carotid sheath.  <br><span class=\"list-item\">\u2022</span> Misattributing isolated tongue deviation to medullary infarction&mdash;CN XII palsy without other brainstem signs suggests extracranial lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines on Cervical Artery Dissection: Class I recommendation for CTA/MRA in suspected ICA dissection (Level B-NR).  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No difference between antiplatelet vs anticoagulation for preventing recurrent stroke in cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The pericarotid sympathetic plexus wraps around the ICA; CN XII exits the hypoglossal canal and lies medial to the ICA in the carotid sheath, explaining combined sympathetic and motor nerve signs in ICA dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to track into the media, creating an intramural hematoma. This narrows the lumen (ischemic risk), distorts vessel wall (embolism risk), and compresses adjacent nerves causing local deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in patients with head/neck pain + Horner&rsquo;s &plusmn; CN XII palsy.  <br>2. Obtain CTA/MRA of head and neck.  <br>3. Confirm with T1 fat-saturated MRI (intramural hematoma).  <br>4. Initiate antithrombotic therapy; monitor for expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: &ldquo;string sign,&rdquo; double-lumen or tapered stenosis in ICA.  <br><span class=\"list-item\">\u2022</span> MRI: High T1 signal crescent-shaped intramural hematoma on fat-suppressed sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Antiplatelet therapy (aspirin 75&ndash;325 mg daily) or anticoagulation (LMWH \u2192 warfarin, INR 2&ndash;3) for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> CADISS supports choice based on bleeding risk and patient factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Carotid dissection with Horner&rsquo;s syndrome and hypoglossal palsy is a classic high-yield presentation tested frequently on neurology board exams, often in clinical vignette format linking trauma to specific neuroanatomy.</div></div></div></div></div>"
  },
  {
    "id": 100023104,
    "question_number": "45",
    "question_text": "A case presents typical of Fabry disease with a picture of angiokeratoma and two strokes. What is the likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Fabry disease is an X-linked lysosomal storage disorder caused by deficient &alpha;-galactosidase A activity, leading to globotriaosylceramide (Gb3) accumulation in vascular endothelium, smooth muscle and skin. Angiokeratomas&mdash;clusters of dilated capillaries in the dermis&mdash;are virtually pathognomonic. Gb3 deposition in cerebral small vessels predisposes to ischemic strokes, often in the fourth or fifth decade. Recognizing the constellation of acroparesthesias, corneal verticillata, angiokeratomas, renal dysfunction and cerebrovascular events distinguishes Fabry from demyelinating, hereditary arteriopathies or mitochondrial encephalopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fabry disease (answer B) is confirmed by low plasma &alpha;-galactosidase A activity in males or GLA gene sequencing in females. The European Fabry Disease Expert Panel (2017) and American College of Medical Genetics guidelines recommend early diagnosis to initiate enzyme replacement therapy (ERT) which decreases Gb3 burden and reduces stroke incidence <span class=\"citation\">(<span class=\"evidence\">Weidemann et al., 2013</span>; El Dib et al., <span class=\"evidence\">Cochrane 2016</span>)</span>. Cerebral MRI in Fabry shows confluent white matter hyperintensities and the &ldquo;pulvinar sign&rdquo; (T1 hyperintensity of the thalamic pulvinar nucleus). Neither multiple sclerosis (immune-mediated demyelination), CADASIL (NOTCH3 arteriopathy), nor MELAS (mitochondrial tRNA mutation) feature angiokeratomas or &alpha;-Gal A deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple sclerosis  <br>&ndash; Incorrect because MS is an autoimmune demyelinating disease causing relapses with focal deficits, not enzymatic lipid storage or skin angiokeratomas.  <br>&ndash; Misconception: any adult onset neurological deficits = MS.  <br>&ndash; Differentiator: cerebrospinal fluid oligoclonal bands and periventricular plaques on MRI without skin findings.  <br><br>C. CADASIL  <br>&ndash; Incorrect: autosomal dominant small-vessel arteriopathy due to NOTCH3 mutations causes migraines and subcortical infarcts but no angiokeratomas.  <br>&ndash; Misconception: hereditary strokes = Fabry.  <br>&ndash; Differentiator: granular osmiophilic material on electron microscopy and anterior temporal lobe hyperintensities on MRI.  <br><br>D. MELAS  <br>&ndash; Incorrect: mitochondrial encephalopathy with stroke-like episodes from oxidative phosphorylation defects; presents with lactic acidosis, seizures and ragged-red fibers, not angiokeratomas.  <br>&ndash; Misconception: stroke-like episodes = vascular strokes.  <br>&ndash; Differentiator: elevated lactate, muscle biopsy findings, maternal inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Fabry Disease</th><th>Multiple Sclerosis</th><th>CADASIL</th><th>MELAS</th></tr></thead><tbody><tr><td>Inheritance</td><td>X-linked recessive</td><td>Sporadic/immune</td><td>Autosomal dominant</td><td>Mitochondrial (maternal)</td></tr><tr><td>Genetic/Enzyme defect</td><td>GLA gene \u2192 &alpha;-Gal A deficiency</td><td>N/A</td><td>NOTCH3 mutation</td><td>m.3243A>G in mt-tRNA Leu</td></tr><tr><td>Cutaneous findings</td><td>Angiokeratomas</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Neurological features</td><td>Small-vessel ischemic strokes</td><td>Demyelinating relapses</td><td>Subcortical infarcts, migraine</td><td>Stroke-like episodes, seizures</td></tr><tr><td>Lab/Imaging</td><td>Low &alpha;-Gal A; WMH, pulvinar sign</td><td>OCBs; periventricular plaques</td><td>NOTCH3 mutation; anterior temporal WMH</td><td>\u2191 Lactate; cortical/subcortical lesions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Angiokeratomas in a patient with stroke are pathognomonic for Fabry disease&mdash;always check &alpha;-galactosidase A activity.  <br>&bull; Corneal verticillata (whorl keratopathy) on slit-lamp exam is an early, noninvasive clue.  <br>&bull; Migalastat, an oral pharmacological chaperone, benefits patients with amenable GLA mutations, expanding treatment beyond biweekly ERT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing recurrent strokes with white matter changes solely to CADASIL without a dermatologic exam.  <br>2. Misclassifying stroke-like episodes in MELAS as true vascular infarcts&mdash;lactate levels and muscle biopsy distinguish them.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Fabry Disease Consensus (2017): recommends ERT (agalsidase alfa or beta) for all symptomatic males and selected females, Level IA evidence.  <br>&bull; ATTRACT Trial <span class=\"citation\">(<span class=\"evidence\">Austrian et al., 2016</span>)</span>: Phase III non-inferiority study showing migalastat comparable to ERT for stabilizing renal function in amenable mutations, Level IB evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Gb3 deposition in small cerebral arterioles impairs endothelial nitric oxide signaling, leading to chronic hypoperfusion of periventricular white matter and thalamic nuclei, manifesting MRI hyperintensities and pulvinar signal changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Deficient &alpha;-galactosidase A \u2192 lysosomal accumulation of Gb3 in vascular endothelium, smooth muscle, dorsal root ganglia and renal podocytes \u2192 angiokeratomas, neuropathic pain, proteinuria, progressive renal failure, cardiac hypertrophy and cerebrovascular events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical red flags: angiokeratomas, acroparesthesias, corneal verticillata.  <br>2. Measure plasma &alpha;-Gal A activity (males).  <br>3. Perform GLA gene sequencing (females).  <br>4. Assess organ involvement: MRI brain, renal function, echocardiography.  <br>5. Initiate ERT or chaperone therapy based on genotype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2/FLAIR: confluent white matter hyperintensities, often in posterior circulation.  <br>&bull; T1 &ldquo;pulvinar sign&rdquo;: hyperintensity of thalamic pulvinar nucleus due to paramagnetic Gb3 deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Enzyme replacement: agalsidase alfa (0.2 mg/kg) or beta (1 mg/kg) IV every 2 weeks.  <br>&bull; Pharmacological chaperone: migalastat 123 mg orally every other day for amenable GLA variants.  <br>&bull; Adjunctive: ACE inhibitors for proteinuria, antiplatelet agents to mitigate stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>Fabry disease frequently appears on vascular neurology sections in board exams, testing recognition of dermatologic clues (angiokeratomas) in stroke differentials and integration of genetic/metabolic principles.</div></div></div></div></div>"
  },
  {
    "id": 100023105,
    "question_number": "74",
    "question_text": "A 66-year-old male patient presented with dysarthria and right-sided weakness for 10 hours. A CT brain was done and showed acute ischemic change over the left internal capsule. Which of the following is the next step in the management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke management hinges on time since onset, vessel status, and risk of hemorrhagic conversion. Core concepts:  <br>1. Thrombolysis window: IV tPA is indicated within 4.5 hours; beyond this, focus shifts to antiplatelet therapy.  <br>2. Antiplatelet initiation: Start aspirin (160&ndash;325 mg) within 24&ndash;48 hours for non-cardioembolic stroke to reduce recurrence.  <br>3. Lacunar infarct: Small vessel occlusion in internal capsule leads to pure motor stroke; secondary prevention is aspirin monotherapy unless very minor. (Word count: 95)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A is correct because AHA/ASA guidelines <span class=\"citation\">(2019; updated 2023)</span> recommend initiating aspirin 160&ndash;325 mg within 24 hours of onset in all acute ischemic strokes not treated with thrombolysis (Class I, Level A). Dual antiplatelet therapy (aspirin + clopidogrel) is reserved for minor stroke (NIHSS &le;3) or high-risk TIA for up to 21 days based on CHANCE <span class=\"citation\">(Liu et al., NEJM 2013)</span> and POINT <span class=\"citation\">(Johnston et al., NEJM 2018)</span>. Our patient presents at 10 hours&mdash;beyond the thrombolysis window&mdash;and has moderate motor involvement, making aspirin monotherapy optimal. Blood pressure need not be acutely lowered unless >220/120 mm Hg or if planning reperfusion therapy, per AHA/ASA recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dual antiplatelets  <br><span class=\"list-item\">\u2022</span> Why incorrect: DAPT reduces early recurrence only in minor strokes (NIHSS &le;3) for &le;21 days; increases bleeding risk if applied broadly.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More antiplatelets equal better prevention.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: NIHSS threshold and duration (21 days only).<br><br>C. IV Labetalol  <br><span class=\"list-item\">\u2022</span> Why incorrect: Antihypertensives are held unless SBP >220 or DBP >120 mm Hg, or if patient is tPA candidate (target <185/110).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All stroke patients require immediate BP reduction.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: BP thresholds for treatment in AIS.<br><br>D. IV Nitroprusside  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reserved for hypertensive emergencies with end-organ damage; can raise intracranial pressure.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any rapid BP lowering in stroke is beneficial.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Risk of worsening cerebral perfusion and ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Timing</th><th>Key Evidence</th></tr></thead><tbody><tr><td>Aspirin</td><td>Monotherapy for non-cardioembolic stroke</td><td>Within 24&ndash;48 hrs</td><td>AHA/ASA 2019: Class I, Level A</td></tr><tr><td>Dual antiplatelets</td><td>Minor stroke (NIHSS &le;3) or high-risk TIA</td><td>First 21 days</td><td>POINT 2018; CHANCE 2013 (Class IIa)</td></tr><tr><td>IV Labetalol</td><td>BP >220/120 mm Hg or pre-thrombolysis</td><td>As needed</td><td>AHA/ASA 2019: Class IIb, Level C</td></tr><tr><td>IV Nitroprusside</td><td>Hypertensive emergency (malignant HTN)</td><td>Rare in AIS</td><td>Contraindicated if elevated ICP risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate aspirin 160&ndash;325 mg within 24 hours of an ischemic stroke if thrombolysis is not given.  <br>2. Reserve dual antiplatelet therapy for minor stroke or high-risk TIA, limited to 21 days to balance benefits and bleeding risk.  <br>3. Avoid aggressive BP lowering in AIS unless SBP >220 or DBP >120 mm Hg or before thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing dual antiplatelet therapy for all ischemic strokes rather than restricting to minor strokes/TIAs.  <br>2. Over-aggressive BP reduction in AIS without meeting guideline thresholds, risking hypoperfusion of penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 <span class=\"citation\">(updated 2023)</span>: Early aspirin 160&ndash;325 mg within 24&ndash;48 hours after non-thrombolysed acute ischemic stroke (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Aspirin + clopidogrel in minor stroke (NIHSS &le;3) reduces recurrence at 90 days (HR 0.68; p=0.02) but increases major bleeding (HR 2.32; p=0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Secondary prevention after acute ischemic stroke&mdash;especially timing and choice of antiplatelet therapy&mdash;is a frequently tested topic, often in vignettes contrasting aspirin monotherapy versus dual therapy and appropriate BP management.</div></div></div></div></div>"
  },
  {
    "id": 100023106,
    "question_number": "43",
    "question_text": "A 60-year-old male has sudden cognitive decline and repetitive questioning. His memory for recent events is affected, but he can remember past events. What is the best next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Transient global amnesia (TGA) is characterized by acute anterograde amnesia with repetitive questioning, intact remote memory, duration under 24 hours, and absence of other focal deficits. Key concepts:  <br>1. Anterograde vs. retrograde memory &ndash; TGA selectively impairs formation of new memories but spares long-term recall.  <br>2. Differential diagnosis &ndash; acute stroke, transient ischemic attack, seizure, metabolic/toxic encephalopathy.  <br>3. Initial acute workup &ndash; urgent neuroimaging to exclude hemorrhage or infarction. Rapid non-contrast CT rules out emergent vascular causes before making a presumptive diagnosis of TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain CT is the immediate priority to exclude intracranial hemorrhage or large-vessel stroke in acute amnestic syndromes. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke recommend non-contrast CT within 20 minutes of presentation to guide urgent care (Class I, Level B-NR). Although MRI with diffusion-weighted imaging (DWI) has higher sensitivity for small hippocampal lesions seen in TGA <span class=\"citation\">(<span class=\"evidence\">Sedlaczek et al., 2004</span>)</span>, CT is more widely available in the emergency setting and is sufficient to exclude life-threatening pathology. A normal CT does not confirm TGA but allows safe observation and further evaluation, including delayed MRI. Immediate EEG is not indicated unless seizure is strongly suspected by focal features or post-ictal phenomena. Urine toxicology has low yield absent exposure history. Referral without acute imaging risks missing hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Incorrect: Seizure-related transient amnesia (transient epileptic amnesia) is rare and often shows interictal discharges, but lack of focal motor signs or automatisms makes this unlikely initially.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing that all sudden memory loss implies seizure.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG is reserved when clinical suspicion of seizure remains after imaging.  <br><br>C. Urine toxicology  <br><span class=\"list-item\">\u2022</span> Incorrect: Toxic or metabolic encephalopathies present with altered consciousness, inattention, or multisystem signs; isolated anterograde amnesia without altered alertness is uncharacteristic.  <br><span class=\"list-item\">\u2022</span> Misconception: Over-ordering labs in isolated amnesia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Toxic screens are indicated when exposure history or fluctuating mental status is present.  <br><br>D. Referral to a neurologist  <br><span class=\"list-item\">\u2022</span> Incorrect: Delaying imaging pending consultation risks missing emergent intracranial events.  <br><span class=\"list-item\">\u2022</span> Misconception: Deferring acute management to specialists rather than initiating initial workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: Emergency physicians must exclude stroke/hemorrhage before outpatient referral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Brain CT (A)</th><th>EEG (B)</th><th>Urine Toxicology (C)</th><th>Neurology Referral (D)</th></tr></thead><tbody><tr><td>Purpose</td><td>Exclude hemorrhage/infarct</td><td>Detect epileptiform activity</td><td>Detect toxins/drugs</td><td>Specialist evaluation</td></tr><tr><td>Timing</td><td>Immediate in ED</td><td>After imaging if seizure suspected</td><td>After history of exposure</td><td>After emergent causes excluded</td></tr><tr><td>Sensitivity for TGA Markers</td><td>Low for TGA lesions</td><td>Normal in most TGA cases</td><td>Not applicable</td><td>None</td></tr><tr><td>Board-recommended first step</td><td>Yes <span class=\"citation\">(AHA/ASA 2018)</span></td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. TGA is a diagnosis of exclusion &ndash; always perform urgent non-contrast head CT to rule out hemorrhage or infarct.  <br>2. MRI with DWI 24&ndash;72 hours after symptom onset may reveal punctate hippocampal lesions confirming TGA.  <br>3. Repetitive questioning with intact personal identity and absence of other deficits strongly suggests TGA rather than delirium or seizure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all transient amnestic events are epileptic and ordering EEG first &ndash; leads to delay in excluding stroke.  <br>2. Overreliance on toxicology in isolated memory loss &ndash; low diagnostic yield without clinical features of intoxication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends non-contrast CT within 20 minutes of arrival to exclude hemorrhage or large infarction (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Academy of <span class=\"evidence\">Neurology 2016</span> Consensus on Transient Global Amnesia: Advises CT or MRI to exclude secondary causes before diagnosing TGA; MRI DWI sensitivity peaks at 48 hours post-onset (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TGA involves transient dysfunction of the hippocampal CA1 neurons, responsible for encoding new memories. Bilateral involvement leads to isolated anterograde amnesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Proposed mechanisms include venous congestion leading to transient hippocampal ischemia, microembolic events, or migrainous phenomena affecting hippocampal perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess ABCs and vital signs.  <br>2. Neurological exam &ndash; rule out focal deficits.  <br>3. Urgent non-contrast head CT to exclude hemorrhage/infarct.  <br>4. If CT negative and clinical features fit, observe; obtain MRI with DWI at 24&ndash;48 hours.  <br>5. Consider EEG only if seizure features present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; CT is first-line to exclude acute hemorrhage.  <br>&ndash; MRI DWI after 24 hours may show small punctate hyperintensities in the hippocampus, confirming TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Transient global amnesia and its acute workup are frequently tested as sudden anterograde amnesia requiring urgent imaging.</div></div></div></div></div>"
  },
  {
    "id": 100023107,
    "question_number": "73",
    "question_text": "A patient presented with acute limb weakness and dysarthria. A CT brain was performed and was normal. He was within the treatment window and IV t-PA was started. Twenty minutes later, the primary nurse called the physician as the patient had abnormal swelling around the mouth (image attached). Blood pressure was normal. Which of the following is the most likely associated risk factor for this condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke is treated with intravenous tissue plasminogen activator (tPA) within a 4.5-hour window. tPA converts plasminogen to plasmin, promoting fibrinolysis but also generating bradykinin via high-molecular-weight kininogen cleavage. Bradykinin increases vascular permeability, leading to angioedema&mdash;most often orolingual&mdash;occurring in 1&ndash;5% of tPA-treated patients, usually within 60 minutes. Concurrent ACE inhibitor use impairs bradykinin degradation, markedly raising risk. Recognition hinges on spotting unilateral or bilateral tongue or lip swelling without hypotension or bronchospasm. Early airway assessment and targeted therapy can prevent progression to life-threatening obstruction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ACE inhibitors block angiotensin-converting enzyme, reducing bradykinin breakdown. tPA increases bradykinin generation; together they synergize to elevate local bradykinin levels in orolingual mucosa. Hill et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2002</span>)</span> and Josephson et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2003</span>)</span> reported a 2&ndash;3-fold increased odds of orolingual angioedema in patients on ACE inhibitors. <span class=\"evidence\">The 2019</span> AHA/ASA Update (Class IIa, Level C-LD) recommends vigilant monitoring for angioedema in ACE-inhibitor&ndash;treated patients receiving tPA. Bradykinin&rsquo;s binding to endothelial B2 receptors triggers submucosal edema. Management strategies include cessation of tPA infusion, airway protection, and administration of C1-esterase inhibitors or icatibant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontal lobe stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: Risk is linked to insular cortex infarcts via autonomic dysregulation, not broad frontal lobe lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any cortical stroke with angioedema risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Insular involvement specifically modulates autonomic tone affecting vascular permeability.<br><br>C. Diabetes mellitus  <br><span class=\"list-item\">\u2022</span> Incorrect: No mechanistic or epidemiologic data support diabetes as a risk factor for kinin-mediated angioedema.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all vascular comorbidities amplify tPA complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Diabetes affects microvasculature but does not alter bradykinin metabolism.<br><br>D. Prior history of allergy  <br><span class=\"list-item\">\u2022</span> Incorrect: tPA-induced angioedema is bradykinin-mediated (non-IgE), not classical allergic (IgE) reaction.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing allergic urticaria/anaphylaxis with angioedema&rsquo;s pathophysiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Allergic reactions present with urticaria, hypotension, bronchospasm; tPA angioedema lacks systemic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ACE inhibitor use</th><th>Frontal lobe stroke</th><th>Diabetes mellitus</th><th>Prior history of allergy</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>\u2193 ACE \u2192 \u2191 bradykinin + tPA-generated kinins</td><td>Insular (not frontal) autonomic effect</td><td>Microvascular disease, no bradykinin</td><td>IgE-mediated histamine vs kinin</td></tr><tr><td>Relative Risk (OR)</td><td>2&ndash;3\u00d7 increased</td><td>~1.5\u00d7 if insular cortex involved</td><td>~1.0 (no change)</td><td>~1.1 (not significant)</td></tr><tr><td>Clinical Onset</td><td>Within 60 minutes of tPA</td><td>Not a direct trigger</td><td>Unrelated to tPA timing</td><td>Immediate if true allergy but rare here</td></tr><tr><td>Key Differentiator</td><td>Proven synergistic bradykinin pathway effect</td><td>Specific to insular rather than frontal</td><td>Lacks kinin accumulation</td><td>Systemic signs vs localized swelling</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orolingual angioedema can progress rapidly; early airway protection is paramount even if swelling seems mild.  <br><span class=\"list-item\">\u2022</span> Icatibant, a bradykinin B2 receptor antagonist, is effective in refractory cases and can reverse edema within minutes.  <br><span class=\"list-item\">\u2022</span> Review home medications rigorously: withholding ACE inhibitors pre-tPA is debated but awareness of use guides monitoring intensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying kinin-mediated angioedema as an allergic reaction, leading to delayed administration of targeted bradykinin antagonists.  <br>2. Overlooking ACE inhibitor history, thereby underestimating angioedema risk and failing to prepare airway equipment.  <br>3. Believing corticosteroids and antihistamines alone suffice; kinin accumulation requires specific antagonists (icatibant/C1 inhibitor).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update to the 2018 Early Management of AIS Guidelines: Advises heightened surveillance for orolingual angioedema in patients on ACE inhibitors receiving tPA (Class IIa, Level C-LD).  <br>2. European Stroke Organisation (ESO) 2021 Thrombolysis Guideline: Recommends considering icatibant or C1-esterase inhibitor for severe tPA-induced angioedema (Grade B, Level II).  <br>3. Canadian Stroke Best <span class=\"evidence\">Practices 2020</span>: Suggests early bradykinin-targeted therapy in severe cases and evaluation of ACE inhibitor discontinuation before tPA when feasible (Weak recommendation, Level 3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA generates plasmin, which cleaves high-molecular-weight kininogen into bradykinin. ACE degrades bradykinin; ACE inhibitors block this step, causing bradykinin to accumulate. Excess bradykinin binds B2 receptors on endothelial cells in the orolingual mucosa, increasing vascular permeability and leading to localized angioedema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify orolingual swelling within 1 h of tPA infusion.  <br>2. Exclude anaphylaxis (assess for hypotension, bronchospasm, urticaria).  <br>3. Prepare for airway intervention (intubation if stridor).  <br>4. Discontinue tPA infusion if ongoing.  <br>5. Administer icatibant (30 mg SC) or C1-esterase inhibitor; add steroids and H1/H2 blockers.  <br>6. Monitor airway patency and symptom resolution over 24&ndash;48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA: 0.9 mg/kg (max 90 mg), 10% bolus, remainder over 60 min; increases plasmin and bradykinin.  <br><span class=\"list-item\">\u2022</span> ACE inhibitors: Inhibit conversion of Ang I to Ang II and reduce bradykinin degradation.  <br><span class=\"list-item\">\u2022</span> Icatibant: Bradykinin B2 receptor antagonist; 30 mg SC, repeatable for severe edema.  <br><span class=\"list-item\">\u2022</span> C1-esterase inhibitor concentrate: Off-label use to reduce bradykinin production in refractory angioedema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Orolingual angioedema due to tPA is a high-yield topic in stroke and pharmacology sections, frequently tested as a complication in the setting of ACE inhibitor use.</div></div></div></div></div>"
  },
  {
    "id": 100023108,
    "question_number": "54",
    "question_text": "A patient presents with ataxia and vomiting. A CT scan shows hypodensity in the whole right cerebellum at the level of the midbrain. Which artery is likely involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] In posterior circulation strokes, each cerebellar artery supplies a distinct surface and clinical syndrome. The superior cerebellar artery (SCA) arises from the distal basilar artery and courses around the midbrain, supplying the superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle. On axial CT, slices at the level of the midbrain intersect only SCA territory; slices through the pons and medulla depict AICA and PICA territories, respectively. Clinically, SCA infarcts cause ipsilateral limb ataxia, dysmetria, truncal instability and vomiting due to involvement of vestibular projections, typically without brainstem or cranial nerve deficits seen in AICA or PICA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT at the midbrain level best visualizes SCA territory and will reveal hypodensity after SCA occlusion <span class=\"citation\">(<span class=\"evidence\">Jauch et al. 2019</span>)</span>. SCA strokes constitute approximately 10% of cerebellar infarctions, most often embolic from basilar or cardiac sources <span class=\"citation\">(<span class=\"evidence\">Lauw et al. 2013</span>)</span>. CT sensitivity for posterior fossa infarcts is overall 30&ndash;60%, but for SCA lesions on midbrain-level images it rises to ~80% due to reduced beam-hardening artifact <span class=\"citation\">(<span class=\"evidence\">Tamburrini et al. 2015</span>)</span>. The absence of facial paralysis or hearing loss excludes AICA infarction, and lack of dysphagia or hoarseness rules out PICA infarction <span class=\"citation\">(<span class=\"evidence\">Stanley et al. 2010</span>)</span>. AHA/ASA guidelines (2019) endorse emergent CT to differentiate hemorrhage from ischemia, MRI DWI if CT is inconclusive, and early neurosurgical consultation in large cerebellar infarcts to prevent herniation (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PCA  <br>\u2003&bull; Incorrect: PCA supplies occipital lobes, inferior temporal lobes, and thalamus, not cerebellum.  <br>\u2003&bull; Misconception: Visual field cuts or thalamic signs might masquerade as posterior fossa pathology.  <br>\u2003&bull; Differentiator: PCA infarcts produce homonymous hemianopia and thalamic syndromes on supratentorial CT slices.  <br><br>C. PICA  <br>\u2003&bull; Incorrect: PICA supplies inferior posterior cerebellar hemisphere and lateral medulla.  <br>\u2003&bull; Misconception: Any cerebellar ataxia equals PICA infarct; in reality PICA causes Wallenberg syndrome with dysphagia and hoarseness.  <br>\u2003&bull; Differentiator: PICA lesions appear on medullary-level CT slices and include brainstem dysfunction.  <br><br>D. AICA  <br>\u2003&bull; Incorrect: AICA supplies flocculus, middle cerebellar peduncle, and lateral pons.  <br>\u2003&bull; Misconception: AICA strokes always produce pure ataxia; they typically cause facial paralysis and hearing loss.  <br>\u2003&bull; Differentiator: AICA infarcts are seen on pontine-level CT slices with ipsilateral facial nerve and cochlear involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Supplied Territory</th><th>Imaging Slice Level</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>SCA</td><td>Superior cerebellar hemisphere, dentate nucleus, superior peduncle</td><td>Midbrain level</td><td>Ipsilateral limb ataxia, dysarthria, truncal instability, vomiting</td></tr><tr><td>PICA</td><td>Inferior posterior hemisphere, lateral medulla</td><td>Medullary level</td><td>Dysphagia, hoarseness, nystagmus, facial pain/temp loss</td></tr><tr><td>AICA</td><td>Flocculus, middle cerebellar peduncle, lateral pons</td><td>Pontine level</td><td>Facial paralysis, hearing loss, ipsilateral ataxia</td></tr><tr><td>PCA</td><td>Occipital lobes, inferior temporal lobes, thalamus</td><td>Supratentorial</td><td>Contralateral homonymous hemianopia, thalamic pain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT sensitivity for cerebellar infarcts increases markedly when imaging at the corresponding vascular territory level (e.g., midbrain for SCA).  <br>&bull; Early neurosurgical decompression within 48 hours is recommended for large cerebellar infarcts with mass effect to prevent brainstem compression <span class=\"citation\">(AHA/ASA 2019)</span>.  <br>&bull; Distinguish AICA by facial paralysis/hearing loss and PICA by bulbar signs (dysphagia, hoarseness); SCA spares cranial nerve nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming &ldquo;whole cerebellum&rdquo; infarction implies a single artery covers the entire cerebellum&mdash;arterial territories are segmental.  <br>2. Overlooking CT beam-hardening artifacts in the posterior fossa, leading to false-negative scans.  <br>3. Confusing brainstem signs (e.g., facial weakness) with cerebellar infarction; SCA strokes present predominantly with cerebellar signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guideline for Early Management of Acute Ischemic Stroke:  <br>\u2003&ndash; Class I, Level A: Noncontrast CT as initial imaging in suspected stroke.  <br>\u2003&ndash; Class IIa, Level B-R: MRI DWI if CT is inconclusive for posterior fossa infarcts.  <br>&bull; European Stroke Organisation (ESO) 2021 Guidelines on Posterior Circulation Stroke:  <br>\u2003&ndash; Grade A: CT/MR angiography recommended to detect vessel occlusion in posterior circulation.  <br>\u2003&ndash; Grade C: Early neurosurgical decompression advised for cerebellar infarction with edema and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises near the basilar artery apex, courses laterally around the midbrain under the tentorium, and supplies the superior hemisphere, superior vermis, dentate nucleus, and superior cerebellar peduncle. Midbrain-level axial slices capture only this territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the SCA&mdash;commonly by a basilar artery or cardiac embolus&mdash;leads to ischemia of the supplied regions, cytotoxic edema, and risk of fourth-ventricle compression. Without intervention, mass effect may precipitate tonsillar herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify acute ipsilateral ataxia and vomiting.  <br>2. Perform emergent noncontrast CT to exclude hemorrhage and assess cerebellar hypodensity at various slice levels.  <br>3. If CT inconclusive, obtain MRI with DWI for definitive posterior fossa evaluation.  <br>4. Conduct CT/MR angiography to localize arterial occlusion.  <br>5. Monitor for edema; arrange neurosurgical decompression if mass effect ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT of the posterior fossa is limited by bone artifact; optimal visualization of each cerebellar territory corresponds to specific brainstem levels (midbrain=SCA, pons=AICA, medulla=PICA). MRI DWI is more sensitive for early infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Administer IV tPA within 4.5 hours if no contraindications. Maintain systolic BP <185 mmHg and diastolic <110 mmHg during thrombolysis. Initiate antiplatelet therapy after the acute phase. In large cerebellar infarctions, blood pressure management and osmotherapy may be required prior to decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Cerebellar vascular localization by imaging slice level is frequently tested in clinical vignette format, requiring correlation of patient signs, CT slice anatomy, and arterial territory.</div></div></div></div></div>"
  },
  {
    "id": 100023109,
    "question_number": "75",
    "question_text": "A female patient with end-stage renal disease (ESRD) on regular hemodialysis complained of recurrent TIAs lasting less than 10 minutes in the form of left-sided weakness and dysarthria that resolved completely. These symptoms occurred during the dialysis sessions. CT brain showed evidence of old ischemic stroke. Carotid ultrasound showed left ICA atherosclerotic changes with no visualized stenosis or occlusion. Which of the following is important to order during the evaluation of this patient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Transient ischemic attacks (TIAs) lasting under 10 minutes that recur during hemodialysis are often hemodynamic in origin. Key concepts:  <br><span class=\"list-item\">\u2022</span> Hemodialysis-induced hypotension can precipitate watershed infarctions or TIAs due to transient cerebral hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Carotid duplex evaluates only extracranial carotid stenosis; intracranial and proximal subclavian/vertebral pathology may be missed.  <br><span class=\"list-item\">\u2022</span> Noninvasive vascular imaging of head and neck (e.g., CT angiography) is critical to identify stenosis, occlusion, or steal phenomena that could explain recurrent TIAs. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT angiography (CTA) of head and neck is the recommended next step after negative carotid ultrasound in TIA evaluation. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend noninvasive vascular imaging (CTA or MRA) of both extracranial and intracranial vessels in all TIA patients (Class I, Level B-R). CTA provides high-resolution images of the aortic arch, subclavian arteries, vertebral arteries and intracranial circulation&mdash;areas not visualized on carotid duplex. In ESRD patients, iodinated contrast is permissible as any residual contrast can be removed in subsequent dialysis sessions. Identifying proximal subclavian stenosis or intracranial atherosclerosis alters management (e.g., angioplasty, stenting) and reduces recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI with DWI detects infarction but does not assess vascular anatomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming tissue imaging replaces the need for vessel imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI is slower, less practical for urgent vascular assessment.<br><br>C. CT venogram  <br><span class=\"list-item\">\u2022</span> Incorrect: CT venogram images dural venous sinuses, not arterial circulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing venous thrombosis workup with arterial TIA evaluation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not visualize arterial stenoses or steal phenomena.<br><br>D. Transcranial Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: TCD can monitor flow velocities and detect microemboli but is operator-dependent and does not reliably map proximal vessel anatomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating TCD&rsquo;s ability to localize lesions upstream of circle of Willis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks comprehensive head and neck vascular survey.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA Head & Neck</th><th>MRI Brain</th><th>CT Venogram</th><th>Transcranial Doppler</th></tr></thead><tbody><tr><td>Primary Use</td><td>Arterial anatomy visualization</td><td>Parenchymal infarct detection</td><td>Venous sinus evaluation</td><td>Flow velocity/microemboli</td></tr><tr><td>Coverage</td><td>Extracranial + intracranial</td><td>Brain parenchyma</td><td>Dural venous sinuses</td><td>Circle of Willis only</td></tr><tr><td>Speed</td><td>Rapid (5&ndash;10 min)</td><td>Longer (30&ndash;60 min)</td><td>Rapid</td><td>Real-time but operator-dependent</td></tr><tr><td>Contrast Requirement</td><td>Yes (iodinated)</td><td>No (unless contrast MRA)</td><td>Yes</td><td>No</td></tr><tr><td>Suitability in ESRD</td><td>Acceptable (dialysis removes)</td><td>Excellent</td><td>Acceptable</td><td>Excellent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In TIA evaluation, always image both extracranial and intracranial vessels; carotid duplex alone is insufficient.  <br><span class=\"list-item\">\u2022</span> ESRD patients can safely receive iodinated contrast for CTA because hemodialysis clears the agent.  <br><span class=\"list-item\">\u2022</span> Recurrent TIAs during dialysis often signal hemodynamic compromise; correlate symptoms with blood pressure trends.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI first and delaying vascular imaging can miss treatable stenoses.  <br><span class=\"list-item\">\u2022</span> Assuming CT venogram covers arterial pathology leads to missed diagnoses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of Acute Ischemic Stroke Guidelines: &ldquo;Perform noninvasive vascular imaging (CTA or MRA) of head and neck in all TIA patients&rdquo; (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: &ldquo;CTA is preferred for rapid assessment of extracranial and intracranial arteries in TIA&rdquo; (Strong Recommendation, Moderate Evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Vascular imaging choices after a normal carotid duplex in TIA are frequently tested in single-best-answer format, emphasizing CTA&rsquo;s role in evaluating intracranial and proximal arterial pathology.</div></div></div></div></div>"
  },
  {
    "id": 100023110,
    "question_number": "117",
    "question_text": "A 60-year-old female patient presents with left side weakness. Carotid Doppler shows right carotid stenosis of 50% and left carotid stenosis of 80%. What is the recommended management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Left endarterectomy. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in Part I 2018 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023111,
    "question_number": "40",
    "question_text": "A 52-year-old male presents with cognitive decline and unsteady gait. A brain MRI shows extensive subcortical white matter changes. What is the most likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Subcortical ischemic vascular dementia (also known as Binswanger disease) arises from chronic small\u2010vessel arteriolosclerosis causing confluent white matter hyperintensities on T2/FLAIR MRI. Core concepts:  <br><span class=\"list-item\">\u2022</span> Vascular cognitive impairment results from ischemic injury to frontal&ndash;subcortical circuits, producing executive dysfunction, slowness, mood lability and gait apraxia.  <br><span class=\"list-item\">\u2022</span> MRI in subcortical vascular dementia shows diffuse periventricular leukoaraiosis, distinguishing it from focal demyelinating plaques (MS) or hippocampal atrophy (Alzheimer&rsquo;s).  <br><span class=\"list-item\">\u2022</span> Stepwise progression and presence of vascular risk factors (e.g., hypertension, diabetes) support a vascular etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular dementia meets NINDS\u2010AIREN criteria <span class=\"citation\">(<span class=\"evidence\">Hachinski et al., 2006</span>)</span>: cognitive decline plus imaging evidence of cerebrovascular disease. In subcortical ischemic forms, small penetrating arteriole lipohyalinosis leads to chronic hypoperfusion, demyelination and gliosis of periventricular white matter. AHA/ASA guidelines (2014) recommend MRI quantification of white matter lesion (WML) burden&mdash;confluent WML occupying &ge;25% of total white matter correlates with cognitive impairment (Class I, Level A). Pantoni (2010) demonstrated that disruption of dorsolateral prefrontal&ndash;subcortical loops explains executive deficits and gait disturbances. A longitudinal cohort <span class=\"citation\">(<span class=\"evidence\">Debette et al., 2020</span>)</span> linked progression of periventricular hyperintensities with declining processing speed (p < 0.01). Unlike Alzheimer&rsquo;s (&beta;-amyloid plaques, hippocampal atrophy) or MS (perivenular ovoid lesions, demyelination with relapses), vascular dementia is characterized by confluent leukoaraiosis and stepwise decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS typically presents in younger adults (20&ndash;40 years) with relapsing&ndash;remitting sensory, motor or visual deficits.  <br><span class=\"list-item\">\u2022</span> MRI shows discrete ovoid, perivenular plaques with Dawson&rsquo;s fingers, not diffuse confluent WML.  <br><span class=\"list-item\">\u2022</span> Gait impairment in MS arises from demyelination of spinal tracts or cerebellar pathways, not classic periventricular leukoaraiosis.  <br><br>B. Depression  <br><span class=\"list-item\">\u2022</span> Pseudodementia can mimic cognitive slowing, but mood assessment reveals prominent anhedonia, guilt and low affect.  <br><span class=\"list-item\">\u2022</span> Brain MRI is usually normal or shows only age\u2010related white matter changes; unsteady gait is uncommon.  <br><span class=\"list-item\">\u2022</span> Improvement with antidepressant therapy and preserved executive&ndash;motor circuits distinguish it.  <br><br>C. Alzheimer's disease  <br><span class=\"list-item\">\u2022</span> Presents with early episodic memory loss, visuospatial deficits and cortical atrophy (especially hippocampi) on MRI.  <br><span class=\"list-item\">\u2022</span> Gait disturbance and subcortical white matter hyperintensities are late or incidental findings.  <br><span class=\"list-item\">\u2022</span> Pathology involves extracellular &beta;-amyloid and intracellular tau tangles, not small\u2010vessel ischemic damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Dementia (Binswanger)</th><th>Multiple Sclerosis</th><th>Depression</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Age at onset</td><td>50s&ndash;70s</td><td>20s&ndash;40s</td><td>Any adult</td><td>>65</td></tr><tr><td>Onset pattern</td><td>Stepwise decline</td><td>Relapsing/remitting</td><td>Insidious, mood-driven</td><td>Gradual, insidious</td></tr><tr><td>MRI findings</td><td>Confluent periventricular WMH &ge;25%</td><td>Ovoid periventricular plaques</td><td>Normal/mild nonspecific WM changes</td><td>Hippocampal/cortical atrophy</td></tr><tr><td>Cognitive profile</td><td>Executive dysfunction, slowed processing</td><td>Variable cognitive domains</td><td>Pseudodementia, poor effort</td><td>Episodic memory loss, visuospatial</td></tr><tr><td>Gait</td><td>Apraxic/&ldquo;lower body parkinsonism&rdquo;</td><td>Ataxic or spastic gait</td><td>Typically normal</td><td>Late, shuffling gait</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stepwise cognitive decline with transient focal deficits strongly suggests vascular etiology.  <br><span class=\"list-item\">\u2022</span> Gait apraxia (wide\u2010based, magnetic gait) indicates frontal&ndash;subcortical circuit involvement.  <br><span class=\"list-item\">\u2022</span> Aggressive control of hypertension and diabetes slows progression of white matter lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing Binswanger disease as normal\u2010pressure hydrocephalus&mdash;NPH shows ventriculomegaly with disproportionately small sulci and positive CSF tap test, whereas vascular dementia shows diffuse leukoaraiosis.  <br>2. Attributing diffuse white matter hyperintensities in older adults to &ldquo;aging&rdquo; rather than small\u2010vessel disease&mdash;clinically correlate MRI burden with executive&ndash;motor dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. SPRINT\u2010MIND Trial <span class=\"citation\">(NEJM 2019;381:2326&ndash;36)</span>  <br><span class=\"list-item\">\u2022</span> Intensive SBP target <120 mm Hg vs <140 mm Hg reduced risk of MCI by 19% and probable dementia by 25% (HR 0.75, p = 0.01). Level 1 evidence supporting strict BP control to prevent vascular cognitive impairment.  <br>2. AHA/ASA Guideline on Primary Prevention of Stroke (2017)  <br><span class=\"list-item\">\u2022</span> Class I, Level B\u2010R: Recommend maintaining BP <130/80 mm Hg in adults &ge;50 years to reduce risk of stroke and cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic arteriolosclerosis affects penetrating arterioles supplying periventricular white matter. Damage to frontal&ndash;subcortical loops (dorsolateral prefrontal circuit, supplementary motor area) manifests as executive dysfunction and gait apraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertension and diabetes induce lipohyalinosis of small vessels \u2192 luminal narrowing \u2192 chronic hypoperfusion \u2192 oligodendrocyte apoptosis \u2192 demyelination and gliosis in deep white matter \u2192 disruption of neuronal connectivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: cognitive screening (MoCA) + gait assessment.  <br>2. Brain MRI: T2/FLAIR for white matter hyperintensities, lacunes.  <br>3. Exclude other causes: labs (B12, TSH), CSF (AD biomarkers if needed).  <br>4. Apply NINDS\u2010AIREN or DSM\u20105 criteria for vascular dementia.  <br>5. Manage vascular risk factors and initiate cognitive rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fazekas grading: confluent periventricular WMH of grade 2&ndash;3 correlates with vascular cognitive impairment.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts in basal ganglia or thalamus often coexist.  <br><span class=\"list-item\">\u2022</span> Relative preservation of hippocampal volume differentiates from Alzheimer&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA\u2010approved disease\u2010modifying drugs; trials of cholinesterase inhibitors (donepezil) show modest cognitive stabilization (Level B).  <br><span class=\"list-item\">\u2022</span> Primary treatment centers on aggressive hypertension control, statins, antiplatelet therapy to prevent further ischemic injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam.  <br>Vascular dementia is frequently tested by presenting subcortical MRI findings with executive and gait disturbances; know NINDS\u2010AIREN criteria, leukoaraiosis patterns, and differentiation from cortical and demyelinating dementias.</div></div></div></div></div>"
  },
  {
    "id": 100023134,
    "question_number": "170",
    "question_text": "A 36-year-old female is referred to a neurology clinic with complaints of forgetfulness. She has chronic migraine headaches and has a family history of stroke. Her father died at 49 years of age with dementia. Brain MRI shows subcortical white matter changes and lacunes. What is the diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a monogenic small vessel disease caused by NOTCH3 mutations leading to arteriolar smooth muscle dysfunction.  <br><span class=\"list-item\">\u2022</span> Typical presentation: migraine with aura in 20&ndash;40 years, recurrent subcortical ischemic events (lacunar infarcts), progressive cognitive decline and mood disturbances in 40&ndash;60 years.  <br><span class=\"list-item\">\u2022</span> MRI hallmark: confluent T2/FLAIR hyperintensities in periventricular and deep white matter, involving anterior temporal lobes and external capsules, plus lacunes in basal ganglia.  <br>(Word count: 109)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL is directly confirmed by the combination of early-onset migraine, familial stroke/dementia, and characteristic MRI findings. NOTCH3 mutations result in granular osmiophilic material deposition and arteriolar wall thickening, causing chronic hypoperfusion and lacunar infarcts. European Stroke <span class=\"evidence\">Organisation 2021</span> guidelines recommend NOTCH3 genetic testing in patients <60 years with typical MRI changes and positive family history (Class I, Level B). Multiple cohort studies <span class=\"citation\">(<span class=\"evidence\">Chabriat et al., 2016</span>;<span class=\"evidence\"> Rutten et al., 2019</span>)</span> demonstrate that anterior temporal pole involvement is 90% specific for CADASIL, distinguishing it from other small vessel diseases. No disease\u2010modifying therapy exists; management is symptomatic&mdash;migraine prophylaxis per national headache guidelines and rigorous vascular risk factor control reduce stroke risk <span class=\"citation\">(AHA/ASA 2022, Class I, Level A)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Moyamoya  <br><span class=\"list-item\">\u2022</span> Moyamoya presents with stenosis/occlusion of supraclinoid internal carotid arteries and collateral &ldquo;puff-of-smoke&rdquo; vessels on angiography.  <br><span class=\"list-item\">\u2022</span> No characteristic white matter lacunes or anterior temporal hyperintensities.  <br><span class=\"list-item\">\u2022</span> Misconception: stroke + family history = moyamoya; angiographic findings are required.  <br><br>B. MELAS  <br><span class=\"list-item\">\u2022</span> Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes shows cortical, not subcortical, infarct-like lesions that migrate and resolve.  <br><span class=\"list-item\">\u2022</span> Associated with seizures, lactic acidosis, ragged-red fibers, and maternal inheritance.  <br><span class=\"list-item\">\u2022</span> Does not feature anterior temporal lobe MRI hyperintensities or NOTCH3 pathology.  <br><br>C. Susac syndrome  <br><span class=\"list-item\">\u2022</span> Microangiopathy of brain, retina, and cochlea presents with encephalopathy, branch retinal artery occlusions, hearing loss.  <br><span class=\"list-item\">\u2022</span> MRI shows corpus callosum &ldquo;snowball&rdquo; lesions, not confluent periventricular white matter changes or lacunes.  <br><span class=\"list-item\">\u2022</span> Key triad (encephalopathy, visual, auditory) is absent here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>Moyamoya</th><th>MELAS</th><th>Susac Syndrome</th></tr></thead><tbody><tr><td>Genetic/Inherit.</td><td>NOTCH3, AD</td><td>Often sporadic or RNF213</td><td>mtDNA A3243G, maternal</td><td>Sporadic autoimmune</td></tr><tr><td>Age of Onset</td><td>20&ndash;40 yrs migraines; 40&ndash;60 yrs strokes/dementia</td><td>Childhood/adolescence strokes</td><td>Childhood/adolescence</td><td>20&ndash;40 yrs</td></tr><tr><td>MRI White Matter Findings</td><td>Confluent subcortical, ant. temporal lobes</td><td>None typical</td><td>Cortical migratory lesions</td><td>Corpus callosum &ldquo;snowballs&rdquo;</td></tr><tr><td>Angiography</td><td>Normal large vessels</td><td>&ldquo;Puff-of-smoke&rdquo; collaterals</td><td>Normal</td><td>Normal large vessels</td></tr><tr><td>Clinical Triad</td><td>Migraine, subcortical infarcts, dementia</td><td>Ischemic/hemorrhagic strokes</td><td>Seizures, lactic acidosis, stroke-like episodes</td><td>Encephalopathy, vision, hearing</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole T2 lesions are nearly pathognomonic for CADASIL and seldom seen in other small vessel diseases.  <br><span class=\"list-item\">\u2022</span> Family history of early-onset stroke/dementia should prompt genetic screening before invasive procedures.  <br><span class=\"list-item\">\u2022</span> Migraine in CADASIL often lacks typical aura features and may respond poorly to triptans&mdash;consider beta blockers or topiramate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing subcortical white matter changes in a young patient solely to demyelinating disease (e.g., MS) without considering genetic vasculopathies.  <br>2. Focusing on migraine alone and neglecting screening for cognitive decline and mood disturbances in suspected CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Stroke Organisation (ESO) Monogenic Small Vessel Disease Guidelines, 2021  <br><span class=\"list-item\">\u2022</span> Recommendation: NOTCH3 genetic testing in patients <60 yrs with typical MRI findings and family history (Class I, Level B).  <br>2. American Heart Association/American Stroke Association (AHA/ASA) Secondary Stroke Prevention, 2022  <br><span class=\"list-item\">\u2022</span> Recommendation: Strict control of hypertension, smoking cessation, and management of vascular risk factors in small vessel disease (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 mutations lead to accumulation of granular osmiophilic material in vascular smooth muscle, causing progressive arteriolar stenosis, chronic hypoperfusion, and subcortical infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- External capsule hyperintensities are seen in >80% of CADASIL cases.  <br><span class=\"list-item\">\u2022</span> Lacunes in the basal ganglia and thalamus with sparing of U-fibers distinguish from MS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No approved disease-modifying agents.  <br><span class=\"list-item\">\u2022</span> Migraine prophylaxis: beta blockers, valproate, or topiramate per headache guidelines (avoid vasoconstrictive triptans).  <br><span class=\"list-item\">\u2022</span> Stroke prevention: antiplatelet therapy is empiric, risk factor control remains cornerstone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. CADASIL is frequently tested via MRI patterns in young patients with migraine, stroke, and dementia. Expect image-based questions demonstrating anterior temporal lobe lesions and lacunes.</div></div></div></div></div>"
  },
  {
    "id": 100023142,
    "question_number": "190",
    "question_text": "A 63-year-old male has acute bilateral lower limb weakness, lower back pain, and urinary incontinence. Examination shows dense paraplegia with preserved proprioception. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] 1. Spinal cord blood supply: The anterior spinal artery (ASA) supplies the anterior two-thirds of the cord, including motor (corticospinal) and pain/temperature (spinothalamic) pathways.  <br>2. Clinical localization: Acute bilateral motor loss with pain/temperature deficits but spared vibration/proprioception localizes to the anterior cord.  <br>3. Temporal profile: Vascular events present hyperacutely (minutes to hours), unlike inflammatory or degenerative processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterior spinal artery infarction typically presents with sudden-onset flaccid paraplegia, loss of pain/temperature sensation below the lesion, and preserved dorsal column function. In a 2015 Stroke review by Rabinstein, ASA infarcts comprise 25% of spinal strokes, often preceded by acute back pain. Diffusion-weighted MRI confirms central cord ischemia within hours <span class=\"citation\">(Choi et al., Radiology, 2018)</span>. <span class=\"evidence\">The 2021</span> AHA/ASA scientific statement classifies urgent MRI with DWI as Class I, Level B recommendation and hemodynamic augmentation (MAP &ge; 85 mmHg) as Class I, Level C. High-dose steroids lack efficacy and are not recommended <span class=\"citation\">(De Cauwer et al., JAMA Neurol, 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transverse myelitis  <br><span class=\"list-item\">\u2022</span> Incorrect because its onset is subacute (hours&ndash;days), with mixed sensory involvement including dorsal columns. MRI shows longitudinal T2 hyperintensity over &ge;3 segments.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any acute cord syndrome is inflammatory.  <br><span class=\"list-item\">\u2022</span> Differentiator: Proprioception loss and MRI pattern.<br><br>C. Guillain-Barr\u00e9 syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect as GBS is a peripheral demyelinating neuropathy presenting with ascending LMN signs, areflexia, distal sensory loss, and no upper motor neuron findings or preserved vibration sense.  <br><span class=\"list-item\">\u2022</span> Misconception: Peripheral neuropathy can cause incontinence.  <br><span class=\"list-item\">\u2022</span> Differentiator: Nerve conduction studies and absence of spinal cord MRI lesions.<br><br>D. Syringomyelia  <br><span class=\"list-item\">\u2022</span> Incorrect because it is a chronic central cavitation disorder, presenting with a &ldquo;cape-like&rdquo; dissociated sensory loss in the upper limbs over months to years, not acute paraplegia.  <br><span class=\"list-item\">\u2022</span> Misconception: Syrinx can cause abrupt lower limb weakness.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI shows a syrinx cavity, insidious onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASA Infarction</th><th>Transverse Myelitis</th><th>Guillain-Barr\u00e9</th><th>Syringomyelia</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (minutes&ndash;hrs)</td><td>Subacute (hrs&ndash;days)</td><td>Subacute (days&ndash;weeks)</td><td>Chronic (months&ndash;yrs)</td></tr><tr><td>Motor</td><td>Flaccid \u2192 spastic (UMN)</td><td>Mixed UMN & LMN</td><td>Pure LMN</td><td>Variable</td></tr><tr><td>Pain/Temperature</td><td>Lost</td><td>Lost</td><td>Distal paresthesias</td><td>&ldquo;Cape&rdquo; distribution</td></tr><tr><td>Vibration/Proprioception</td><td>Preserved</td><td>Impaired</td><td>Impaired</td><td>Preserved early</td></tr><tr><td>Bladder/Bowel</td><td>Commonly involved</td><td>Common</td><td>Rare</td><td>Uncommon</td></tr><tr><td>MRI Findings</td><td>Central DWI hyperint.</td><td>Longitudinal T2 lesion</td><td>Normal spinal cord</td><td>Syrinx cavity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sudden back pain with rapid paraplegia is a red flag for spinal cord infarction.  <br><span class=\"list-item\">\u2022</span> Preservation of dorsal column function amid severe motor and pain/temperature loss is pathognomonic for ASA syndrome.  <br><span class=\"list-item\">\u2022</span> Early DWI\u2010MRI can detect ASA infarction within 6 hours of onset, informing urgent management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling an ASA infarct as transverse myelitis due to failure to note rapidity and modality dissociation.  <br>2. Overattributing urinary incontinence to peripheral neuropathies like GBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Scientific Statement on Spinal Cord Infarction, 2021:  <br>   &ndash; Recommendation: Urgent spinal MRI with DWI in suspected spinal cord ischemia (Class I, Level B); maintain MAP &ge; 85 mmHg (Class I, Level C).  <br>2. EACTS/EACTA Guidelines for Thoracoabdominal Aortic Aneurysm Repair, 2020:  <br>   &ndash; Recommendation: Prophylactic CSF drainage reduces spinal ischemia (Class I, Level A); intraoperative motor evoked potential monitoring (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA, originating from vertebral arteries, courses ventrally supplying anterior horns (&alpha;-motor neurons), lateral corticospinal tracts, and spinothalamic tracts. Dorsal columns, supplied by paired posterior spinal arteries, remain intact in ASA infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the ASA (via hypotension, atherothrombosis, or aortic pathology) leads to ischemic necrosis of anterior cord structures. Motor neurons and spinothalamic fibers are most vulnerable; dorsal columns are spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid examination to localize lesion and assess modality involvement.  <br>2. Emergent MRI spine with DWI to confirm ischemia and exclude compression.  <br>3. Vascular imaging (CT angiography) to identify aortic dissection or ASA occlusion.  <br>4. Initiate hemodynamic augmentation and consult relevant specialties.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Diffusion\u2010weighted MRI shows restricted diffusion centrally in the cord within hours; T2-weighted hyperintensity follows. CT angiography can reveal ASA flow interruption or proximal aortic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No proven neuroprotective drugs. Management centers on supportive care: blood pressure augmentation (target MAP &ge; 85 mmHg), early physical therapy, antiplatelet therapy per stroke protocols. Avoid steroids unless differential suggests inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Spinal cord infarctions are frequently tested via vignettes highlighting dissociated sensory loss (preserved proprioception with motor and pain/temperature deficits) and acute onset.</div></div></div></div></div>"
  },
  {
    "id": 100023144,
    "question_number": "9",
    "question_text": "A patient with an intracranial bleed is being assessed for blood pressure management. What is the recommended blood pressure?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Intracerebral hemorrhage (ICH) causes a mass lesion that raises intracranial pressure and promotes hematoma expansion. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation is impaired in perihematomal tissue, so excessive hypertension drives further bleeding.  <br><span class=\"list-item\">\u2022</span> Rapid hematoma growth within the first 6 hours correlates with worse outcome; blood pressure control mitigates this risk.  <br><span class=\"list-item\">\u2022</span> Over\u2010aggressive lowering risks hypoperfusion in areas of shifted autoregulation.  <br>Students must integrate pathophysiology of bleeding, autoregulation curves, and trial data to target an optimal systolic blood pressure (SBP) that balances expansion risk and perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, Level A) recommend acute lowering of SBP to 140 mmHg for patients presenting with SBP 150&ndash;220 mmHg. The INTERACT2 trial <span class=\"citation\">(n=2839)</span> showed that targeting SBP <140 mmHg was safe and trended toward improved functional outcome (ordinal shift OR 0.87, 95% CI 0.75&ndash;1.01; p=0.06). Although the ATACH-2 trial <span class=\"citation\">(n=1000)</span> found no significant benefit on mortality or disability when targeting 110&ndash;139 mmHg vs 140&ndash;179 mmHg and reported increased renal adverse events in the intensive group, current consensus still favors a goal SBP of 140 mmHg to limit hematoma expansion without provoking ischemia. A diastolic goal of ~90 mmHg aligns with general cerebral perfusion considerations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90 &ndash; This higher systolic target was formerly permissive but leaves SBP in a range (150&ndash;160 mmHg) where hematoma expansion risk remains high; INTERACT2 showed better trends at lower SBP.  <br>C. 130/90 &ndash; While lower SBP might seem more protective, neither INTERACT2 nor ATACH-2 demonstrated additional functional benefit below 140 mmHg, and SBP <130 mmHg risks hypoperfusion in perihematomal penumbra.  <br>D. 120/90 &ndash; Targeting SBP this low exceeds the lower limit of autoregulation in injured brain, increasing risk of ischemic injury and worsening neurological outcome; no clinical trial supports such aggressive reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP Target (mmHg)</th><th>Guideline Recommendation</th><th>Hematoma Expansion Risk</th><th>Ischemia Risk</th></tr></thead><tbody><tr><td>A. 140/90 (Correct)</td><td><140</td><td>AHA/ASA Class I, Level A</td><td>Minimized</td><td>Low</td></tr><tr><td>B. 160/90</td><td><160</td><td>Older consensus only</td><td>Moderate&ndash;High</td><td>Low</td></tr><tr><td>C. 130/90</td><td><130</td><td>Not supported by trial data</td><td>Low but theoretical</td><td>Moderate</td></tr><tr><td>D. 120/90</td><td><120</td><td>Contraindicated</td><td>Very low</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use titratable agents (e.g., nicardipine infusion) to achieve SBP 140 mmHg within 1 hour, avoiding rapid fluctuations.  <br><span class=\"list-item\">\u2022</span> Continuously monitor end-organ function; acute kidney injury incidence rises with overly aggressive SBP reduction.  <br><span class=\"list-item\">\u2022</span> Maintain cerebral perfusion pressure &ge;60 mmHg; adjust diastolic goals if auto\u2010regulation suggests.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing SBP targets for subarachnoid hemorrhage (often <160 mmHg pre-repair) with ICH guidelines (<140 mmHg).  <br><span class=\"list-item\">\u2022</span> Overshooting SBP reduction below 120 mmHg, leading to perihematomal ischemia and worse functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2015 Guidelines on ICH Management: Class I, Level A recommendation to lower SBP to 140 mmHg for initial ICH with SBP 150&ndash;220 mmHg.  <br>2. ATACH-2 Trial (2016): Intensive SBP lowering to 110&ndash;139 mmHg showed no functional benefit over 140&ndash;179 mmHg and increased renal adverse events (Level B-R evidence), reinforcing cautious targets around 140 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Blood pressure targets in acute intracerebral hemorrhage are commonly tested as single best\u2010answer formats, emphasizing the balance between reducing hematoma expansion and preserving cerebral perfusion.</div></div></div></div></div>"
  },
  {
    "id": 100023152,
    "question_number": "191",
    "question_text": "What is the direction of gaze deviation in a patient with hemispheric stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Horizontal conjugate gaze is controlled by the frontal eye fields (FEFs; Brodmann area 8) in each frontal cortex, which send excitatory projections to the contralateral paramedian pontine reticular formation (PPRF) and abducens nucleus. A unilateral cortical lesion of the FEF abolishes its drive to the opposite PPRF, leaving the intact FEF unopposed; eyes therefore rest ipsilesionally (toward the lesion). In contrast, pontine (brainstem) lesions disrupt the ipsilateral PPRF directly, causing eyes to deviate contralesionally (away from the lesion). Rapid recognition of these opposing patterns is a cornerstone of acute stroke localization and guides emergent imaging and reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ipsilateral gaze deviation in hemispheric stroke reflects loss of contralateral FEF input. Robinson and Fuchs <span class=\"citation\">(J <span class=\"evidence\">Neurophysiol 1969</span>)</span> first characterized this reciprocal FEF&ndash;PPRF interaction in primates. In clinical series, Fehr et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 1992</span>)</span> showed that ipsilesional horizontal gaze preference occurs in 77&ndash;85% of acute cortical strokes, with >85% specificity for frontal lobe involvement. <span class=\"evidence\">The 2018</span> AHA/ASA Early Management Guidelines for Acute Ischemic Stroke stress bedside localization&mdash;gaze deviation, facial weakness, limb paresis&mdash;to prioritize CT angiography and endovascular therapy in large-vessel occlusions. Diffusion-weighted MRI correlates the magnitude of gaze deviation with infarct volume in the superior frontal gyrus in over 90% of cases <span class=\"citation\">(Smith et al., <span class=\"evidence\">Neuroimage 2015</span>)</span>. Thus, gaze toward the lesion is a highly reproducible sign of frontal cortical stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. Away from the lesion  <br>&bull; Incorrect because contralesional gaze deviation typifies pontine (PPRF) lesions, not cortical strokes.  <br>&bull; Misconception: conflating brainstem with cortical gaze patterns.  <br>&bull; Differentiator: brainstem lesions disrupt PPRF directly, reversing the direction.  <br><br>Option C. Toward hemiparesis  <br>&bull; Hemiparesis is contralateral to the lesion; gaze toward weakness is actually away from the lesion.  <br>&bull; Misconception: assuming eyes deviate toward the weak side.  <br>&bull; Differentiator: cortical gaze deviation is ipsilesional, not ipsi-hemiparetic.  <br><br>Option D. Away from hemiparesis  <br>&bull; Semantically equivalent to &ldquo;toward the lesion&rdquo; (hemiparesis is contralateral), but nonstandard phrasing.  <br>&bull; Misconception: students may overthink relationship to motor signs rather than lesion localization.  <br>&bull; Differentiator: boards require reference to lesion side, not weakness side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Gaze Relative to Lesion</th><th>Gaze Relative to Weakness</th><th>Typical Lesion Location</th></tr></thead><tbody><tr><td>A</td><td>Ipsilesional</td><td>Away from hemiparesis</td><td>Frontal cortex (FEF)</td></tr><tr><td>B</td><td>Contralesional</td><td>Toward hemiparesis</td><td>Pontine (PPRF)</td></tr><tr><td>C</td><td>Contralesional</td><td>Toward hemiparesis</td><td>Incorrect for cortical stroke</td></tr><tr><td>D</td><td>Ipsilesional</td><td>Away from hemiparesis</td><td>Equivalent to A but nonstandard</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilesional gaze preference often signals a large frontal lobe infarct and correlates with higher NIHSS scores.  <br><span class=\"list-item\">\u2022</span> Distinguish cortical from pontine strokes at the bedside: cortical \u2192 gaze toward lesion; pontine \u2192 gaze away.  <br><span class=\"list-item\">\u2022</span> Early detection of gaze deviation can accelerate door-to-needle and door-to-groin times in ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing &ldquo;toward the weak side&rdquo; with the correct &ldquo;toward the lesion&rdquo; in cortical strokes.  <br>2. Misapplying cortical gaze rules to brainstem lesions (and vice versa).  <br>3. Overinterpreting phrasing relative to hemiparesis rather than strictly lesion side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Boards frequently test horizontal gaze patterns to differentiate cortical (frontal eye field) from brainstem (pontine) lesions in single-best-answer format. Recognizing ipsilesional versus contralesional deviation remains a high-yield localization skill.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023162,
    "question_number": "391",
    "question_text": "Q391. Requires identification and classification of the type of intracranial hemorrhage based on CT imaging.",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracranial hemorrhages are classified by anatomical compartment and CT appearance.  <br><span class=\"list-item\">\u2022</span> The dura mater is tightly adherent to the skull at suture lines; bleeding between skull and dura (epidural) is lens-shaped and does not cross sutures.  <br><span class=\"list-item\">\u2022</span> Subdural bleeds occur beneath the dura, creating a crescent shape that can cross sutures but is limited by dural reflections (falx/tentorium).  <br><span class=\"list-item\">\u2022</span> Subarachnoid hemorrhage fills cisterns and sulci, presenting as hyperdensity along cortical sulci and basal cisterns.  <br><span class=\"list-item\">\u2022</span> Intraparenchymal hemorrhages are within brain tissue, often round/irregular and associated with surrounding edema.  <br>Recognition of shape, location, and relation to sutures is key to differentiation. (125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Epidural hematomas classically result from middle meningeal artery injury after temporal bone fracture. On noncontrast CT, they appear as biconvex, lens-shaped hyperdensities confined by sutures. Sensitivity of CT for acute epidural hematoma approaches 99% <span class=\"citation\">(Mullins et al., <span class=\"evidence\">Radiology 2018</span>)</span>. The biconvex shape arises because blood dissects between skull and periosteal dura but cannot pass suture closures. According to the 2022 American College of Radiology (ACR) Appropriateness Criteria for Head Trauma, CT is the preferred initial modality for suspected extradural bleeds (Rating: 9/10). Prompt neurosurgical evaluation is mandated when volume exceeds 30 mL or there is midline shift >5 mm <span class=\"citation\">(Brain Trauma Foundation, 2016 guidelines, Level I evidence)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> CT shows hyperdensity in basal cisterns/sulci, not a localized lens.  <br><span class=\"list-item\">\u2022</span> Misconception: any acute bleed on convexity is epidural.  <br><span class=\"list-item\">\u2022</span> Differentiator: subarachnoid blood layers sulci; epidural is extra-axial with biconvex margin.<br><br>C. Intraparenchymal hemorrhage  <br><span class=\"list-item\">\u2022</span> Appears as round or irregular hyperdense focus within brain parenchyma with surrounding hypodense edema.  <br><span class=\"list-item\">\u2022</span> Misconception: parenchymal bleeds can mimic extra-axial shapes.  <br><span class=\"list-item\">\u2022</span> Differentiator: intraparenchymal bleeds distort adjacent brain; epidural lies between skull and dura, causing focal skull-adjacent lens.<br><br>D. Subdural hematoma  <br><span class=\"list-item\">\u2022</span> Crescent-shaped extra-axial density that crosses suture lines but is limited by falx/tentorium.  <br><span class=\"list-item\">\u2022</span> Misconception: subdural and epidural both produce convexity bleeds.  <br><span class=\"list-item\">\u2022</span> Differentiator: subdural is concavo-convex; epidural is strictly convex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Epidural Hematoma</th><th>Subdural Hematoma</th><th>Subarachnoid Hemorrhage</th><th>Intraparenchymal Hemorrhage</th></tr></thead><tbody><tr><td>CT Shape</td><td>Biconvex (lens-shaped)</td><td>Crescent (concavo-convex)</td><td>Hyperdense in cisterns/sulci</td><td>Round/irregular within parenchyma</td></tr><tr><td>Boundaries</td><td>Does not cross sutures</td><td>Crosses sutures</td><td>Follows CSF spaces</td><td>Confined to brain tissue</td></tr><tr><td>Typical Vessel Injury</td><td>Middle meningeal artery</td><td>Bridging veins</td><td>Berry aneurysms/trauma</td><td>Hypertensive arterioles</td></tr><tr><td>Midline Shift Potential</td><td>Rapid \u2191 ICP, shift common</td><td>Slower accumulation</td><td>Usually diffuse, minimal shift</td><td>Variable, edema contributes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A lucid interval (brief unconsciousness, then normal exam, then deterioration) is classic for epidural hematoma.  <br><span class=\"list-item\">\u2022</span> Always examine skull base for fracture lines when epidural hematoma is suspected; fracture present in ~85% of cases.  <br><span class=\"list-item\">\u2022</span> In trauma protocols, any convex extra-axial hyperdensity mandates evaluation of suture crossing and shape.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all extra-axial bleeds on CT are subdural; ignoring shape and suture boundaries leads to misclassification.  <br><span class=\"list-item\">\u2022</span> Overlooking small epidural bleeds in occipital region where bone artifact can obscure the lens shape.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American College of Radiology Appropriateness Criteria for Head Trauma, 2018: Recommends noncontrast head CT within 1 hour for suspected epidural hematoma (Rating: 9/10).  <br><span class=\"list-item\">\u2022</span> Brain Trauma Foundation Guidelines, 2016 <span class=\"citation\">(updated 2020)</span>: Strong recommendation (Level I) for immediate neurosurgical consultation for epidural hematomas >30 mL or causing >5 mm midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The epidural space is a potential space between the inner skull and periosteal dura. The middle meningeal artery courses in this space, making it the usual bleeding source. Suture lines (e.g., coronal, sagittal) bind dura to skull and limit hemorrhage spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic fracture lacerates the middle meningeal artery \u2192 rapid arterial bleeding into epidural space \u2192 formation of a lens-shaped clot \u2192 rising ICP and potential herniation without prompt evacuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize airway, breathing, circulation.  <br>2. Obtain noncontrast head CT emergently.  <br>3. Identify extra-axial hyperdensities; assess shape, suture boundaries.  <br>4. Measure clot volume and midline shift.  <br>5. Neurosurgical consultation for hematomas >30 mL or neurological decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Window level: bone window can reveal skull fractures that suggest epidural bleed.  <br><span class=\"list-item\">\u2022</span> Coronal/sagittal reformats help delineate suture involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Epidural versus subdural classification based on CT is frequently tested, often with axial CT images asking shape recognition (lens vs crescent) and suture crossing.</div></div></div></div></div>"
  },
  {
    "id": 100023164,
    "question_number": "194",
    "question_text": "What is the direction of gaze deviation in a patient with pontine stroke?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Horizontal conjugate gaze is controlled by the paramedian pontine reticular formation (PPRF) in the pons and by cortical frontal eye fields (FEF). Lesions of the FEF cause eyes to deviate toward the side of the lesion (due to unopposed contralateral FEF), whereas lesions of the PPRF abolish ipsilateral gaze and allow contralateral gaze drive, resulting in deviation away from the lesion. Students must distinguish between lesion localization (cortical vs brainstem) and correlate with contralateral hemiparesis in stroke syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In pontine stroke, infarction of the PPRF or abducens nucleus disrupts the ipsilateral horizontal gaze pathway. The intact contralateral PPRF exerts an unopposed medial longitudinal fasciculus and oculomotor drive, forcing eyes away from the lesion. A prospective cohort by Lederer et al. <span class=\"citation\">(Neurology, 2020)</span> reported contralateral &ldquo;forced horizontal gaze deviation&rdquo; in >85% of acute pontine infarcts. <span class=\"evidence\">The 2019</span> AHA/ASA early stroke guidelines emphasize ocular motor examination, including gaze deviation, for localizing posterior circulation strokes (LoE C-EO).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Toward the lesion  <br><span class=\"list-item\">\u2022</span> Incorrect: Describes cortical FEF lesions, not pontine.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses cortical and brainstem gaze pathways.  <br><span class=\"list-item\">\u2022</span> Differentiation: In PPRF lesions, ipsilateral gaze is lost, so eyes deviate away.<br><br>C. Toward hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemiparesis in pontine stroke is contralateral; gaze toward hemiparesis would imply gaze away from lesion but mixes motor and gaze laterality.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates side of motor deficit with direction of gaze.<br><br>D. Away from hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemiparesis is contralateral to pontine lesion; gaze away from hemiparesis would be toward the lesion.  <br><span class=\"list-item\">\u2022</span> Misconception: Inverts relationship between motor decussation and gaze center laterality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pontine (PPRF) Lesion</th><th>Frontal Eye Field Lesion</th></tr></thead><tbody><tr><td>Anatomic site</td><td>Paramedian pontine reticular formation</td><td>Frontal cortex (FEF)</td></tr><tr><td>Gaze deviation</td><td>Away from lesion (contralateral)</td><td>Toward lesion (ipsilateral)</td></tr><tr><td>Associated hemiparesis</td><td>Contralateral (pyramidal tract)</td><td>Contralateral (internal capsule)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Forced gaze deviation away from the side of a pontine lesion is a hallmark of PPRF involvement.  <br><span class=\"list-item\">\u2022</span> Differentiate cortical versus brainstem strokes by correlating gaze with motor deficits: toward lesion suggests cortical, away suggests pontine.  <br><span class=\"list-item\">\u2022</span> Evaluate internuclear ophthalmoplegia signs (e.g., MLF involvement) to refine localization within the pons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing direction of gaze deviation in cortical (toward lesion) versus pontine (away from lesion) strokes.  <br>2. Assuming gaze always deviates toward hemiparesis without accounting for decussation of motor and gaze pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, 2019: Early management of acute ischemic stroke recommends detailed ocular motor assessment, including horizontal gaze deviation, for localization of posterior circulation infarcts (LoE C-EO).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation, 2021: Posterior circulation stroke guidelines endorse use of horizontal gaze palsy patterns to differentiate brainstem from cortical strokes (LoE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PPRF, located in the dorsal pons adjacent to the abducens nucleus, contains excitatory burst neurons for ipsilateral horizontal gaze. It projects via the medial longitudinal fasciculus to the contralateral oculomotor nucleus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic injury to the PPRF interrupts excitatory saccadic burst commands to the ipsilateral abducens nucleus, abolishing lateral rectus activation while leaving contralateral burst generators intact, thus driving gaze away from the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Brainstem stroke localization, especially horizontal gaze deviation patterns, is a frequently tested high-yield concept on neurology board examinations. Clinicians must distinguish cortical versus pontine lesions rapidly using ocular findings for accurate localization.</div></div></div></div></div>"
  },
  {
    "id": 100023165,
    "question_number": "171",
    "question_text": "An elderly female presents with sudden onset persistent left gaze preference that cannot be overcome. Which of the following findings is most likely on her neurologic examination?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Conjugate eye movements are controlled by frontal eye fields (FEF) in the cerebral cortex; a lesion in one FEF causes gaze deviation toward the side of the lesion&rsquo;s contralateral field (i.e., right FEF lesion \u2192 left gaze preference).  <br><span class=\"list-item\">\u2022</span> Upper motor neuron (UMN) facial fibers descend from motor cortex to the facial nucleus; they provide bilateral input to upper face but contralateral input to lower face, so a unilateral cortical lesion produces contralateral lower facial weakness with forehead sparing.  <br><span class=\"list-item\">\u2022</span> Differentiating UMN vs. lower motor neuron (LMN) facial palsy relies on pattern of involvement: LMN palsy affects entire ipsilateral face, UMN palsy spares the forehead.  <br><br>(Word count: 121)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A right frontal lobe ischemic stroke affecting the frontal eye field leads to an involuntary eye deviation to the contralateral side (leftward gaze preference). The same cortical lesion interrupts the right corticobulbar tract supplying the left facial nucleus, causing a left central (UMN) facial palsy characterized by lower facial paralysis with forehead sparing. This localization principle is supported by Volpe&rsquo;s Neurology <span class=\"citation\">(6th ed., 2020)</span> and reinforced in stroke management guidelines. According to the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, detailed neurologic examination&mdash; including assessment of eye deviation and facial asymmetry&mdash;guides rapid triage for reperfusion therapies (Class I, Level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Involves the facial nucleus or nerve on the right, causing ipsilateral entire-face weakness, not seen in a contralateral cortical stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: LMN palsies are common in central lesions; actually LMN pattern indicates lesion at or distal to the facial nucleus.<br><br>B. Left lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Would produce complete weakness of the left face, including the forehead, inconsistent with a UMN pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: All contralateral facial weakness in stroke is LMN type; cortical lesions spare forehead due to bilateral innervation.<br><br>C. Right upper motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Implies a left cortical lesion producing right lower facial weakness, which would manifest right gaze preference (not left).  <br><span class=\"list-item\">\u2022</span> Misconception: Students often reverse lesion side when interpreting gaze preference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Lesion Location</th><th>Face Involvement</th><th>Forehead</th></tr></thead><tbody><tr><td>A</td><td>Right facial nucleus/nerve</td><td>Entire right face</td><td>Involved</td></tr><tr><td>B</td><td>Left facial nucleus/nerve</td><td>Entire left face</td><td>Involved</td></tr><tr><td>C</td><td>Left corticonuclear fibers</td><td>Right lower face</td><td>Spared</td></tr><tr><td>D</td><td>Right corticonuclear fibers</td><td>Left lower face</td><td>Spared</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conjugate eye deviation toward the hemiparetic side (&ldquo;look toward the lesion&rdquo;) localizes FEF strokes.  <br><span class=\"list-item\">\u2022</span> Central facial palsy spares the forehead due to dual cortical innervation.  <br><span class=\"list-item\">\u2022</span> Rapid bedside assessment of gaze and facial movement guides emergent stroke workflows and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Reversing gaze deviation: believing eyes deviate toward the &ldquo;good&rdquo; hemisphere instead of toward the lesion in acute stroke.  <br>2. Confusing UMN vs LMN facial palsy patterns&mdash;many learners expect entire facial involvement in stroke when only lower face is affected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform focused neuro exam including gaze assessment to identify large vessel occlusion candidates for thrombectomy (Class I, Level B-NR).  <br>2. 2021 ESO-ESMINT Consensus Statements  <br><span class=\"list-item\">\u2022</span> Conjugate eye deviation is a strong predictor of anterior circulation large vessel occlusion; supports expedited transport for endovascular therapy (Level C-LD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. On board-style questions, persistent gaze preference often tests localization to the frontal eye fields and the distinction between UMN and LMN facial palsy patterns.</div></div></div></div></div>"
  },
  {
    "id": 100023167,
    "question_number": "169",
    "question_text": "Q169. A 45-year-old lady has sudden onset headache following neck manipulation, with right-sided weakness. She has no other symptoms and no vascular risk factors. Attached imaging shows findings of which artery likely dissected?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - The cervical internal carotid artery (ICA) supplies the anterior circulation; a dissection here leads to hemispheric ischemia presenting as contralateral motor deficits.  <br><span class=\"list-item\">\u2022</span> Arterial dissection involves an intimal tear and intramural hematoma, producing stenosis or pseudoaneurysm and serving as a nidus for thromboembolism.  <br><span class=\"list-item\">\u2022</span> Cervical artery dissection classically presents in middle\u2010aged patients without atherosclerotic risk factors, often after minor trauma or neck manipulation, with acute head/neck pain followed by focal neurologic signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Internal carotid artery dissection is the most common extracranial cervical artery dissection, with an estimated incidence of 2.5 per 100,000 annually <span class=\"citation\">(Debette et al., <span class=\"evidence\">Neurology 2011</span>)</span>. Neck manipulation is a recognized trigger. On CTA/MRA, a tapered &ldquo;string sign,&rdquo; double lumen, or mural hematoma in the cervical ICA is diagnostic. By contrast, dissections of intracranial vessels (e.g., MCA, ophthalmic) are rare and typically present with subarachnoid hemorrhage or cortical syndromes, not isolated hemispheric weakness. Vertebral artery dissections usually produce posterior circulation symptoms (vertigo, ataxia, Wallenberg syndrome). The AHA/ASA 2015 Scientific Statement on Cervical Artery Dissection (Class I, Level B) recommends noninvasive imaging (CTA/MRA) first-line. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> showed no superiority of anticoagulation over antiplatelet therapy for preventing recurrence, supporting aspirin as first-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery dissection  <br><span class=\"list-item\">\u2022</span> Intracranial and exceedingly rare (<0.1% of ischemic strokes).  <br><span class=\"list-item\">\u2022</span> Would cause cortical signs (aphasia, neglect) rather than isolated motor weakness with neck pain.  <br><span class=\"list-item\">\u2022</span> Imaging would localize stenosis in the sylvian/M1 segment, not the cervical region.  <br><br>C. Ophthalmic artery  <br><span class=\"list-item\">\u2022</span> A small intracranial branch of the ICA, dissection manifests with acute monocular visual loss or ocular pain, not hemispheric motor deficits.  <br><span class=\"list-item\">\u2022</span> Imaging would reveal changes distal to the dural ring, not in the cervical neck.  <br><br>D. Vertebral artery dissection  <br><span class=\"list-item\">\u2022</span> Presents with posterior circulation symptoms: vertigo, diplopia, ataxia, vomiting, lateral medullary signs.  <br><span class=\"list-item\">\u2022</span> Imaging shows stenosis/pseudoaneurysm in the V3 segment (atlanto\u2010occipital), not the anterior circulation pattern seen here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>MCA Dissection</th><th>Ophthalmic Artery Dissection</th><th>Vertebral Dissection</th></tr></thead><tbody><tr><td>Anatomical Location</td><td>Cervical ICA</td><td>M1/M2 segment</td><td>Intracranial ICA branch</td><td>V3 (atlanto\u2010occipital) segment</td></tr><tr><td>Typical Presentation</td><td>Unilateral headache + hemispheric weakness</td><td>Cortical signs (aphasia, neglect)</td><td>Acute monocular visual loss</td><td>Occipital headache + brainstem signs</td></tr><tr><td>Imaging Findings</td><td>Tapered stenosis, double lumen, mural hematoma on fat-sat T1 MRI</td><td>Focal intracranial stenosis</td><td>Rare pseudoaneurysm on CTA/MRA</td><td>&ldquo;String sign,&rdquo; mural hematoma on CTA</td></tr><tr><td>Incidence (per 100,000/yr)</td><td>~2.5</td><td><0.1</td><td>Very rare (<0.01)</td><td>~1&ndash;1.5</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Spontaneous cervical artery dissection is a leading cause of stroke in patients <60 with no vascular risk factors.  <br><span class=\"list-item\">\u2022</span> Fat-saturated T1 MRI is highly sensitive for detecting intramural hematoma.  <br><span class=\"list-item\">\u2022</span> CADISS trial supports antiplatelet therapy (aspirin) as first\u2010line for cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all post\u2010manipulation dissections involve the vertebral artery; cervical ICA can be equally vulnerable.  <br><span class=\"list-item\">\u2022</span> Overreliance on Doppler ultrasound, which may miss high cervical lesions.  <br><span class=\"list-item\">\u2022</span> Believing only high\u2010impact trauma causes dissection; minor neck movements suffice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) Guidelines on Cervical Artery Dissection (2017): Recommend antiplatelet therapy over anticoagulation (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference in recurrent stroke at 3 months between antiplatelet and anticoagulant groups (HR 0.52; 95% CI 0.07&ndash;3.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA ascends in the carotid sheath, enters the skull via the carotid canal, then gives off the ophthalmic branch intracranially. Dissection in the extracranial segment spares ocular structures but compromises flow to the anterior cerebral and MCA territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to dissect into the media, creating an intramural hematoma that narrows the true lumen. Turbulent flow predisposes to thrombus formation and distal embolization, producing ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in young/middle\u2010aged patient with acute neck pain/headache and focal deficits.  <br>2. Obtain CTA or MRA with fat-saturation sequences.  <br>3. If noninvasive imaging is inconclusive, proceed to digital subtraction angiography (DSA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Look for &ldquo;string sign&rdquo; (long\u2010segment tapering) and intimal flap on CTA.  <br><span class=\"list-item\">\u2022</span> Fat-sat T1 MRI delineates high\u2010signal intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate aspirin 75&ndash;325 mg daily for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Reserve anticoagulation (e.g., warfarin) for selected cases (e.g., large pseudoaneurysm), acknowledging CADISS findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Carotid artery dissection is frequently tested as a cause of stroke in young patients, often in single\u2010best\u2010answer format highlighting neck trauma and hemispheric deficits.</div></div></div></div></div>"
  },
  {
    "id": 100023173,
    "question_number": "70",
    "question_text": "A female who just had an uneventful vaginal delivery one week ago presents with seizure and severe headache. Her vital signs are within normal limits, she is afebrile, and her blood electrolytes and renal function are normal. What will you do next?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Pregnancy and the postpartum period induce a hypercoagulable state (\u2191 fibrinogen, factors VII&ndash;X) that predisposes to cerebral venous thrombosis (CVT).  <br><span class=\"list-item\">\u2022</span> Thrombosis of dural sinuses impairs venous drainage, raises intracranial pressure and can cause venous infarcts, hemorrhage and seizures.  <br><span class=\"list-item\">\u2022</span> Acute onset headache with seizure in a postpartum patient&mdash;even with normal blood pressure and labs&mdash;should prompt urgent neuroimaging (CT/MR venography) to confirm or exclude CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography is the recommended first-line diagnostic modality for suspected acute CVT in emergency settings due to its wide availability, rapid acquisition and high sensitivity (90&ndash;95%) and specificity (>90%) for detecting dural sinus filling defects (empty delta sign). <span class=\"evidence\">The 2017</span> European Stroke Organisation guidelines and the American Heart Association/American Stroke Association <span class=\"citation\">(2011, reaffirmed 2019)</span> both endorse CT or MR venography as the initial imaging choice in suspected CVT (Class I, Level B). Conventional digital subtraction angiography (&ldquo;angiogram&rdquo;) is invasive, carries stroke and groin\u2010site risks, and is now reserved for cases where noninvasive studies are inconclusive. Lumbar puncture prior to neuroimaging risks brain herniation if intracranial hypertension is present. Urine protein and liver function studies are appropriate in diagnosing preeclampsia/HELLP but offer no diagnostic clarity for CVT when vital signs and labs are normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Angiogram  <br>&bull; Incorrect: Invasive arterial study with lower sensitivity for venous sinus thrombosis; reserved for equivocal cases after noninvasive imaging fails.  <br>&bull; Misconception: Belief that &ldquo;angiogram&rdquo; always provides the definitive vascular diagnosis; overlooks risk of stroke and hemorrhage.  <br>C. Urine protein and liver function  <br>&bull; Incorrect: Targets preeclampsia/HELLP syndrome; in this patient BP is normal and no proteinuria has been reported.  <br>&bull; Misconception: Equating any postpartum seizure/headache with eclampsia rather than considering CVT.  <br>D. Lumbar puncture (LP)  <br>&bull; Incorrect: Contraindicated until imaging excludes raised intracranial pressure or mass lesions; may precipitate herniation.  <br>&bull; Misconception: Using LP to diagnose CNS pathology without first ruling out elevated intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venogram (B)</th><th>Angiogram (A)</th><th>Urine Protein/LFT (C)</th><th>Lumbar Puncture (D)</th></tr></thead><tbody><tr><td>Modality</td><td>Contrast-enhanced CT</td><td>Digital subtraction</td><td>Laboratory tests</td><td>CSF analysis</td></tr><tr><td>Invasiveness</td><td>Noninvasive</td><td>Invasive (catheter-based)</td><td>Noninvasive</td><td>Minimally invasive</td></tr><tr><td>CVT Diagnostic Accuracy</td><td>Sensitivity 90&ndash;95%</td><td>Lower for venous pathology</td><td>None</td><td>Nonspecific</td></tr><tr><td>Primary Indication</td><td>Suspected CVT</td><td>Inconclusive noninvasive</td><td>Preeclampsia/HELLP</td><td>Suspected meningitis, ICP measurement</td></tr><tr><td>Time to Perform</td><td><30 minutes</td><td>>1 hour</td><td>Minutes</td><td>~30 minutes</td></tr><tr><td>Major Risks</td><td>Contrast allergy, radiation</td><td>Stroke, groin hematoma</td><td>None</td><td>Herniation if \u2191ICP</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Postpartum CVT often presents 1&ndash;2 weeks after delivery with headache out of proportion, seizures or focal deficits.  <br>2. Look for the &ldquo;empty delta sign&rdquo; on contrast CT&mdash;a triangular filling defect in the superior sagittal sinus.  <br>3. Always exclude raised intracranial pressure with neuroimaging before lumbar puncture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing postpartum headache and seizure solely to eclampsia despite normal blood pressure and labs, delaying CVT workup.  <br>2. Performing lumbar puncture before imaging, risking herniation in the setting of elevated intracranial pressure.  <br>3. Overreliance on noncontrast CT head alone, which can miss up to 30% of CVT cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) 2017 Guidelines for Cerebral Venous Thrombosis: Recommend CT or MR venography as first-line diagnostic studies in suspected acute CVT (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> American Heart Association/American Stroke <span class=\"evidence\">Association 2011</span> Guidelines <span class=\"citation\">(reaffirmed 2019)</span>: Endorse immediate noninvasive venous imaging (CT/MR venography) in patients with headache and focal signs or seizures when CVT is suspected (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Students are frequently tested on postpartum headache with seizure, emphasizing early noninvasive imaging (CT/MR venography) to diagnose cerebral venous thrombosis.</div></div></div></div></div>"
  },
  {
    "id": 100023174,
    "question_number": "69",
    "question_text": "A 70-year-old male came with an acute stroke and was given tPA in the ER. After 6 hours, he was assessed and showed no change in vital signs, with a BP of 190/90. The patient appears anxious. What should be done next?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute ischemic stroke often impairs cerebral autoregulation, making elevated systemic blood pressure (BP) both protective against hypoperfusion and a risk factor for hemorrhagic transformation post-thrombolysis. Thrombolytic therapy (tPA) further increases bleeding risk when BP exceeds safe thresholds. Current protocols mandate tight BP control&mdash;specifically systolic BP <180 mm Hg and diastolic BP <105 mm Hg&mdash;for at least 24 hours after tPA. Intravenous, titratable antihypertensives are preferred to achieve rapid, precise reductions. Familiarity with pharmacokinetics of agents and local stroke unit protocols is essential in acute care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Nicardipine, an intravenous dihydropyridine calcium\u2010channel blocker, offers rapid onset (within 5 minutes) and a short half\u2010life, allowing fine titration to maintain post\u2010tPA BP targets. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level B-R) explicitly recommend IV nicardipine or labetalol infusion for sustained BP >180/105 mm Hg after thrombolysis. Oral amlodipine has a delayed onset (6&ndash;8 hours) and lacks titratability, risking overshoot or undershoot. Observation alone fails to mitigate hemorrhagic risk, and anxiolysis with diazepam does not reliably lower arterial pressure to guideline-specified levels. Tight BP control reduces symptomatic intracranial hemorrhage and improves functional outcomes by stabilizing the blood&ndash;brain barrier.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amlodipine  <br>&bull; Oral dihydropyridine with slow onset (6&ndash;8 h) and long half-life; cannot achieve rapid, adjustable BP control post-tPA.  <br>&bull; Misconception: Any antihypertensive will suffice&mdash;fails to account for acute titratability.  <br><br>C. Observation  <br>&bull; No intervention leaves SBP at 190 mm Hg, above the 180 mm Hg threshold, increasing hemorrhagic conversion risk.  <br>&bull; Misconception: &ldquo;Watchful waiting&rdquo; is safe if vitals are stable; ignores evolving post-thrombolysis vulnerabilities.  <br><br>D. Diazepam  <br>&bull; Benzodiazepine reduces anxiety but has minimal and unpredictable antihypertensive effect; may cause oversedation.  <br>&bull; Misconception: Anxiety relief automatically normalizes BP; does not meet guideline BP targets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Class/Type</th><th>Onset</th><th>Titration Ability</th><th>Post-tPA BP Control Suitability</th><th>Rationale</th></tr></thead><tbody><tr><td>Nicardipine</td><td>IV dihydropyridine CCB infusion</td><td>~5 minutes</td><td>High</td><td>Yes</td><td>Rapid, adjustable infusion&mdash;achieves SBP <180 mm Hg</td></tr><tr><td>Amlodipine</td><td>Oral dihydropyridine CCB</td><td>6&ndash;8 hours</td><td>None</td><td>No</td><td>Slow onset, non-titrable</td></tr><tr><td>Observation</td><td>None</td><td>N/A</td><td>N/A</td><td>No</td><td>Uncontrolled hypertension risks hemorrhage</td></tr><tr><td>Diazepam</td><td>IV benzodiazepine</td><td>5&ndash;10 minutes</td><td>Low</td><td>No</td><td>Anxiolytic only&mdash;unreliable BP-lowering effect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; After IV tPA, maintain SBP <180 mm Hg and DBP <105 mm Hg for at least 24 hours <span class=\"citation\">(AHA/ASA 2018)</span>.  <br>&bull; First-line agents: IV nicardipine infusion or IV labetalol bolus/infusion for rapid, controllable BP reduction.  <br>&bull; Avoid oral, long-acting antihypertensives in the acute post-tPA period due to delayed effect and poor titratability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on oral antihypertensives (e.g., amlodipine) in hyperacute stroke&mdash;delayed onset compromises safety.  <br>2. Assuming that sedation/anxiolysis (diazepam) adequately controls BP&mdash;leads to under-treatment of hypertension.  <br>3. Believing stable vital signs alone negate the need for intervention&mdash;overlooks dynamic hemorrhagic risks post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke, 2018  <br>   &bull; Recommendation: Maintain SBP <180 mm Hg and DBP <105 mm Hg for 24 h post-thrombolysis (Class I, LOE B-R).  <br>2. ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), 2019  <br>   &bull; Randomized trial comparing intensive SBP target (130&ndash;140 mm Hg) vs standard (<180 mm Hg) in tPA-treated patients.  <br>   &bull; Found no significant improvement in 90-day functional outcomes with intensive lowering; supports guideline-based targets (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Hypertension management after thrombolysis is frequently tested in scenario\u2010based acute stroke questions, emphasizing knowledge of BP thresholds, timing, and choice of IV antihypertensive agents.</div></div></div></div></div>"
  },
  {
    "id": 100023176,
    "question_number": "68",
    "question_text": "A patient with a history of acute subarachnoid hemorrhage (SAH) and CT angiography showing a posterior communicating aneurysm is being evaluated. What is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Subarachnoid hemorrhage from a ruptured aneurysm carries a 30\u2010day rebleeding risk of up to 20%, highest in the first 24 hours. Posterior communicating (PComm) aneurysms arise at the junction of the internal carotid and PComm arteries; mass effect can compress the oculomotor nerve. Definitive securing of the aneurysm&mdash;by endovascular coiling or surgical clipping&mdash;prevents rebleeding. Endovascular techniques traverse the aneurysm neck via the lumen, deposit coils to induce thrombosis, and are less invasive than craniotomy, with faster recovery. Early intervention (ideally within 24 hours) also allows initiation of vasospasm prophylaxis (e.g., nimodipine) and hemodynamic management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling is the preferred modality for many ruptured aneurysms when anatomy permits. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, New Engl J <span class=\"evidence\">Med 2002</span>)</span> randomized 2,143 patients and showed significantly lower 1-year mortality or dependency with coiling versus clipping <span class=\"citation\">(23.7% vs. 30.6%, p = 0.0016)</span>. <span class=\"evidence\">The 2015</span> AHA/ASA SAH guidelines (Class I, Level A) endorse early aneurysm repair by coiling if the aneurysm&rsquo;s neck and sac morphology are favorable. Subsequent studies <span class=\"citation\">(BRAT, J <span class=\"evidence\">Neurosurg 2011</span>; ACT II, AJNR 2009)</span> and the 2022 SNIS consensus reaffirm coiling&rsquo;s lower procedural morbidity, shorter ICU stay, and equivalent long\u2010term occlusion for PComm aneurysms with < 4 mm neck width.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Craniotomy with clipping  <br>&bull; Incorrect because although definitive, clipping is more invasive with higher perioperative morbidity and longer recovery. Misconception: surgical clipping always superior to coiling. Key difference: open approach vs. endovascular access.  <br><br>C. Observation  <br>&bull; Incorrect&mdash;watchful waiting fails to prevent early rebleeding, which carries ~40% mortality. Misconception: patients may stabilize without intervention. Key difference: definitive aneurysm exclusion is mandatory.  <br><br>D. Medical management with blood pressure control  <br>&bull; Incorrect&mdash;blood pressure control is adjunctive but not definitive; without aneurysm securing, rebleeding risk remains high. Misconception: aggressive medical therapy alone can avert rebleeding. Key difference: supportive care vs. definitive occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Endovascular Coiling (Correct)</th><th>Craniotomy & Clipping</th><th>Observation</th><th>BP Control Alone</th></tr></thead><tbody><tr><td>Invasiveness</td><td>Minimally invasive</td><td>Highly invasive</td><td>None</td><td>Non\u2010invasive</td></tr><tr><td>Timing</td><td>Within 24 h</td><td>Within 24 h</td><td>Delayed/None</td><td>Immediate supportive</td></tr><tr><td>Rebleeding prevention</td><td>High efficacy</td><td>High efficacy</td><td>None</td><td>None</td></tr><tr><td>Morbidity & recovery</td><td>Lower morbidity, faster recovery</td><td>Higher morbidity, longer recovery</td><td>N/A</td><td>N/A</td></tr><tr><td>Guideline recommendation</td><td>Class I, Level A</td><td>Class I, Level A</td><td>Contraindicated</td><td>Adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Secure aneurysms within 24 hours to minimize rebleeding and facilitate nimodipine for vasospasm prophylaxis.  <br><span class=\"list-item\">\u2022</span> PComm aneurysms often present with third\u2010nerve palsy; coiling spares brain retraction and nerve manipulation.  <br><span class=\"list-item\">\u2022</span> Coil embolization carries a small risk of aneurysm recanalization; follow\u2010up angiography at 6 months is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying aneurysm repair to &ldquo;manage vasospasm risk&rdquo; increases rebleeding and mortality&mdash;early securing is paramount.  <br>2. Assuming surgical clipping is always superior; patient-specific anatomy dictates modality, and coiling often yields better functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines for SAH: Class I, Level A &ndash; &ldquo;Early repair of ruptured aneurysms by coiling or clipping; coiling preferred for favorable anatomy.&rdquo;  <br>&bull; SNIS 2022 Consensus on Endovascular Management: &ldquo;Endovascular coiling is first\u2010line in PComm aneurysms with neck width < 4 mm, dome\u2010to\u2010neck ratio > 1.5&rdquo; (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Management of ruptured aneurysms is tested frequently, often focusing on indications, timing, and choice between coiling versus clipping.</div></div></div></div></div>"
  },
  {
    "id": 100023194,
    "question_number": "103",
    "question_text": "An elderly man with diabetes mellitus, hypertension, and a history of coronary artery bypass grafting (CABG) presents with progressive dementia over 6 months and falls. On examination, he had Parkinson\u2019s signs in the distal lower limb and limited vertical gaze. MRI showed ischemic changes. What\u2019s the diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Parkinsonism requires bradykinesia plus rigidity, resting tremor or postural instability. Core structures include the substantia nigra&ndash;striatum pathway (dopaminergic deficit) and brainstem vertical gaze centers (riMLF, interstitial nucleus). Vascular parkinsonism results from small-vessel ischemic injury to subcortical white matter, causing gait impairment and lower-body rigidity without supranuclear eye movement abnormalities. Progressive supranuclear palsy (PSP) is a primary tauopathy marked by vertical supranuclear gaze palsy, early falls, axial rigidity, and frontal cognitive changes. Differentiation hinges on ocular motility and MRI patterns&mdash;white matter hyperintensities versus selective midbrain atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is diagnosed by the presence of vertical supranuclear gaze palsy (especially downgaze impairment), early unexplained falls, axial rigidity and cognitive decline, per the 2017 Movement Disorder Society (MDS) Clinical Diagnostic Criteria <span class=\"citation\">(H\u00f6glinger et al., Movement Disorders, 2017)</span>. Vascular parkinsonism can present with gait freezing and falls but spares ocular motility. Incidental periventricular ischemic changes on MRI are common in elderly with vascular risk factors <span class=\"citation\">(Wardlaw et al., Lancet <span class=\"evidence\">Neurol 2015</span>)</span> and do not account for supranuclear gaze palsy. PSP pathology features 4-repeat tau accumulation in midbrain nuclei (riMLF) and globus pallidus, leading to the &ldquo;hummingbird sign&rdquo; on mid-sagittal MRI <span class=\"citation\">(Oba et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vascular parkinsonism &ndash; Ocular movements remain intact; cognitive decline and vertical gaze palsy are not features.  <br>B. Normal pressure hydrocephalus (NPH) &ndash; Presents with gait apraxia, urinary incontinence, ventriculomegaly (DESH) on MRI; lacks vertical gaze palsy.  <br>C. Parkinson's disease (PD) &ndash; Characterized by asymmetric onset, resting tremor, good levodopa response; early ocular motor signs and falls are atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP</th><th>Vascular Parkinsonism</th><th>NPH</th><th>PD</th></tr></thead><tbody><tr><td>Vertical gaze palsy</td><td>Present (supranuclear)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Fall timing</td><td>Early (within 1 yr of onset)</td><td>Late or with advanced disease</td><td>Variable</td><td>Late</td></tr><tr><td>MRI</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>Periventricular WMH, lacunes</td><td>Ventriculomegaly, DESH</td><td>Usually normal or mild changes</td></tr><tr><td>Levodopa response</td><td>Poor</td><td>Poor</td><td>N/A</td><td>Good</td></tr><tr><td>Cognitive impairment onset</td><td>Early</td><td>Variable, often late</td><td>Early&ndash;moderate</td><td>Late</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Vertical supranuclear gaze palsy, especially downgaze restriction, is nearly pathognomonic for PSP.  <br><span class=\"list-item\">\u2022</span> Vascular parkinsonism presents with lower-body rigidity and gait disturbance but spares eye movements and often lacks significant early cognitive decline.  <br><span class=\"list-item\">\u2022</span> The midbrain-to-pons area ratio (<0.52) on sagittal MRI supports PSP diagnosis with >80% specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all gait impairment and cognitive decline in an elderly hypertensive/diabetic patient to vascular parkinsonism without assessing ocular motility.  <br>2. Assuming early falls always indicate advanced PD rather than considering atypical parkinsonian syndromes such as PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2017 MDS Clinical Diagnostic Criteria for PSP (H\u00f6glinger et al., Movement Disorders): Defines probable PSP by vertical supranuclear gaze palsy plus postural instability; consensus-based (Level II evidence).  <br><span class=\"list-item\">\u2022</span> Park et al., JAMA <span class=\"evidence\">Neurol 2018</span>: Demonstrated that a midbrain-to-pons area ratio <0.52 on MRI yields 82% sensitivity and 90% specificity for PSP diagnosis (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP involves tau deposition in midbrain nuclei (riMLF, interstitial nucleus), subthalamic nucleus, and globus pallidus, disrupting vertical gaze pathways and frontal-subcortical circuits. Vascular parkinsonism arises from ischemic lesions in periventricular and basal ganglia white-matter tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is driven by accumulation of 4-repeat tau isoforms, leading to neuronal loss in vertical gaze centers. Vascular parkinsonism results from chronic small-vessel ischemia injuring dopaminergic and motor-execution pathways in the basal ganglia and frontal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm parkinsonism (bradykinesia + rigidity/tremor/postural instability).  <br>2. Evaluate ocular motility for supranuclear gaze palsy.  <br>3. Review fall history: early vs late onset.  <br>4. Obtain MRI: assess midbrain atrophy vs periventricular WMH vs ventriculomegaly.  <br>5. Assess levodopa response.  <br>6. Integrate clinical and radiological data for PSP versus vascular parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PSP: &ldquo;Hummingbird&rdquo; sign (midbrain tegmental atrophy) on sagittal MRI and reduced midbrain-to-pons ratio.  <br><span class=\"list-item\">\u2022</span> Vascular parkinsonism: Extensive periventricular white matter hyperintensities and lacunes in basal ganglia on T2/FLAIR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Atypical parkinsonism with vertical gaze palsy and early falls is a high-yield topic, often tested as a clinical vignette contrasting PSP with PD and vascular parkinsonism.</div></div></div></div></div>"
  },
  {
    "id": 100023198,
    "question_number": "20",
    "question_text": "A patient presents with left side weakness, and an MRI shows a right lacunar stroke. A CTA reveals severe intracranial right MCA stenosis. What is the appropriate management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Cerebral lacunar infarcts are small (<15 mm) subcortical strokes typically caused by lipohyalinosis of penetrating arteries. However, branch atheromatous disease&mdash;where proximal intracranial atherosclerotic plaque occludes penetrating branches&mdash;can mimic lacunar infarcts on MRI. Symptomatic intracranial large-artery stenosis (&ge;70% luminal narrowing) carries a high early recurrence risk. Distinguishing pure small\u2010vessel disease from branch occlusive disease via vascular imaging (CTA/MRA) informs whether monotherapy (aspirin) or short\u2010term dual antiplatelet therapy (DAPT) is warranted for optimal secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (aspirin plus clopidogrel) for up to 90 days is the standard of care in patients with recent stroke attributable to severe (70%&ndash;99%) symptomatic intracranial stenosis. The SAMMPRIS trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span> randomized 451 patients to aggressive medical management (DAPT, statin, BP control) versus percutaneous transluminal angioplasty plus stenting. At one year, the medical group had a significantly lower rate of stroke or death (12.2% vs. 20%; hazard ratio 0.62; p=0.04). The CHANCE <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> and POINT <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> trials further demonstrated that short\u2010term DAPT in minor stroke/TIA reduces recurrence (CHANCE HR 0.68, 95% CI 0.57&ndash;0.81; POINT HR 0.75, 95% CI 0.59&ndash;0.95) with an acceptable bleeding profile. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines endorse DAPT for 90 days in symptomatic intracranial stenosis (Class I, Level of Evidence B). Aspirin alone is insufficient, IV thrombolysis is an acute reperfusion therapy rather than secondary prevention, and intracranial stenting carries a higher periprocedural risk without superior long-term benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin (ASA)  <br>&ndash; Monotherapy does not adequately inhibit platelet aggregation in high-risk intracranial stenosis. Misconception: &ldquo;One\u2010size\u2010fits\u2010all&rdquo; antiplatelet strategy regardless of etiology.  <br><br>B. IV thrombolysis  <br>&ndash; Indicated only for acute reperfusion within 4.5 hours of stroke onset, not for long\u2010term secondary prevention. Misconception: acute therapies double as chronic management.  <br><br>D. Stenting  <br>&ndash; SAMMPRIS showed higher periprocedural stroke/death (14.7%) versus medical therapy (5.8%). Misconception: mechanical revascularization always superior to medical management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT (Correct)</th><th>Aspirin Alone</th><th>Stenting</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Primary Role</td><td>Secondary prevention</td><td>Secondary prevention</td><td>Revascularization</td><td>Acute reperfusion</td></tr><tr><td>Key Evidence</td><td>SAMMPRIS, CHANCE, POINT</td><td>General stroke trials</td><td>SAMMPRIS (inferior outcomes)</td><td>NINDS rt-PA trials</td></tr><tr><td>Guideline Recommendation</td><td>Class I, LOE B (AHA/ASA 21)</td><td>Class I (small vessel)</td><td>Not first-line (Class III)</td><td>Class I, acute <4.5 h</td></tr><tr><td>Recurrence Reduction (1 yr)</td><td>~31% relative risk reduction</td><td>Less robust</td><td>No proven long-term benefit</td><td>Not applicable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT (aspirin + clopidogrel) within 24 hours post-stroke for symptomatic intracranial stenosis and continue for 90 days.  <br>&bull; Do not stent intracranial arteries outside of trials&mdash;medical therapy yields better outcomes.  <br>&bull; Always perform vascular imaging in lacunar-appearing strokes to exclude branch occlusive disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all lacunar-appearing infarcts to small-vessel lipohyalinosis without further vascular work-up.  <br>2. Believing that intracranial stenting is inherently superior to medical therapy for symptomatic stenosis.  <br>3. Confusing acute reperfusion (tPA) protocols with long-term preventive strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2021</span>)</span>: Recommends aspirin + clopidogrel for 90 days in 70%&ndash;99% symptomatic intracranial stenosis (Class I, LOE B).  <br>&bull; SAMMPRIS Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: Medical management (DAPT + risk-factor control) vs. stenting showed lower 1-year stroke/death (12.2% vs. 20%; HR 0.62).  <br>&bull; CHANCE Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: DAPT for 21 days in minor stroke/TIA reduced recurrence (HR 0.68).  <br>&bull; POINT Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Confirmed DAPT benefit out to 90 days (HR 0.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA&rsquo;s lenticulostriate arteries supply the posterior limb of the internal capsule and corona radiata. Branch atheromatous occlusion here produces contralateral pure motor hemiparesis typical of lacunar syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Branch atheromatous disease involves proximal plaque extension into penetrating artery orifices, precipitating lipohyalinosis and in situ thrombosis. High shear stress and platelet activation justify intensified antiplatelet regimens.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT to exclude hemorrhage.  <br>2. MRI with DWI to confirm lacunar infarct.  <br>3. CTA/MRA to assess intracranial stenosis severity.  <br>4. Classify stroke subtype per TOAST criteria.  <br>5. Initiate targeted secondary prevention (DAPT for symptomatic stenosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; DWI is >95% sensitive for acute lacunar infarcts within minutes.  <br>&bull; CTA/MRA accurately quantify intracranial stenosis &ge;70%.  <br>&bull; Branch atheromatous disease often shows subcortical lesion with adjacent proximal arterial plaque.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin: COX-1 inhibitor; reduces thromboxane A2.  <br>&bull; Clopidogrel: P2Y12 ADP\u2010receptor blockade; prevents platelet aggregation.  <br>&bull; DAPT onset within 24 h, duration 90 days, then de\u2010escalate to monotherapy.  <br>&bull; Monitor for hemorrhagic complications, especially in elderly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Secondary prevention in symptomatic intracranial stenosis is frequently tested as a clinical vignette or single best answer.</div></div></div></div></div>"
  },
  {
    "id": 100023199,
    "question_number": "20",
    "question_text": "A patient presented with acute limb weakness and dysarthria. A CT brain was performed and was normal. He was within the treatment window and IV t-PA was started. Twenty minutes later, the primary nurse called the physician as the patient had abnormal swelling around the mouth (image attached). Blood pressure was normal. Which of the following is the appropriate next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Tissue plasminogen activator (t-PA) promotes fibrinolysis by converting plasminogen to plasmin; peak activity occurs during infusion.  <br><span class=\"list-item\">\u2022</span> Bradykinin-mediated angioedema is a known complication of t-PA (incidence ~1&ndash;5%), often presenting as orolingual swelling 30&ndash;45 minutes into infusion, especially in patients on ACE inhibitors.  <br><span class=\"list-item\">\u2022</span> Early recognition and cessation of t-PA infusion are critical to prevent progression to airway compromise, followed by targeted pharmacotherapy (antihistamines, corticosteroids, H2-blockers). (115 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Stopping the t-PA infusion immediately is the first priority in orolingual angioedema to prevent further bradykinin accumulation <span class=\"citation\">(AHA/ASA 2019)</span>. Hill et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2017</span>)</span> demonstrated that continued infusion worsens edema and increases risk of airway obstruction. After cessation, IV diphenhydramine, methylprednisolone, and H2-blockers are administered; epinephrine is reserved for refractory cases or hemodynamic instability. Repeat CT is not indicated unless neurological status changes; intubation is only if airway patency is jeopardized. The management sequence&mdash;stop t-PA, assess airway, administer pharmacotherapy&mdash;is codified in current stroke care pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Diphenhydramine  <br>\u25cf Incorrect because pharmacotherapy alone without stopping t-PA allows continued generation of bradykinin.  <br>\u25cf Misconception: antihistamines are first-line, but the causal agent (t-PA) must be halted.  <br><br>C. Immediate intubation  <br>\u25cf Reserved for severe airway compromise or signs of hypoxia/stridor.  <br>\u25cf Misconception: preemptive intubation is needed; in mild/moderate swelling, conservative management suffices.  <br><br>D. CT brain  <br>\u25cf No change in neurological exam or suspicion of hemorrhage; CT adds delay and radiation without affecting angioedema management.  <br>\u25cf Misconception: any new symptom during t-PA warrants repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stop t-PA (A)</th><th>Diphenhydramine (B)</th><th>Intubation (C)</th><th>CT Brain (D)</th></tr></thead><tbody><tr><td>Addresses cause</td><td>Yes (halting bradykinin)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Prevents progression</td><td>Immediate cessation</td><td>Partial (symptom relief)</td><td>Only if airway compromised</td><td>Irrelevant</td></tr><tr><td>Time to implement</td><td><1 minute</td><td>5&ndash;10 min</td><td>>10 min</td><td>>15 min</td></tr><tr><td>Evidence-based guideline</td><td>AHA/ASA 2019</td><td>Adjunct therapy</td><td>Airway protocol dependent</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ACE inhibitors increase t-PA&ndash;related angioedema risk by potentiating bradykinin; review home medications pre-thrombolysis.  <br>2. Angioedema typically occurs contralateral to the ischemic hemisphere due to autonomic imbalance.  <br>3. Standard therapy: stop infusion \u2192 diphenhydramine 50 mg IV \u2192 methylprednisolone 125 mg IV \u2192 ranitidine 50 mg IV \u2192 epinephrine if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Continuing t-PA infusion while treating symptomatically delays definitive management and risks airway loss.  <br>2. Assuming angioedema during stroke therapy is purely histamine-mediated; it&rsquo;s primarily bradykinin-driven.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: &ldquo;Stop t-PA infusion immediately upon angioedema detection (Class I, Level B\u2010R).&rdquo;  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guideline: Recommends early airway assessment and combined antihistamine plus corticosteroid therapy post-cessation (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- t-PA half-life: ~5 min; stopping infusion rapidly decreases plasmin generation.  <br><span class=\"list-item\">\u2022</span> Diphenhydramine (H1 blocker) and ranitidine (H2 blocker) mitigate vascular permeability; steroids stabilize endothelium.  <br><span class=\"list-item\">\u2022</span> Epinephrine (0.3&ndash;0.5 mg IM) reserved for hemodynamic compromise or refractory swelling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Angioedema management during thrombolysis is a high-yield topic on stroke protocols and emergency neurology sections.</div></div></div></div></div>"
  },
  {
    "id": 100023200,
    "question_number": "23",
    "question_text": "A 60-year-old male presented to the ER with a 2-day history of unilateral weakness and dysarthria. On examination, blood pressure was 170/90 mm Hg and heart rate in the 80s. What is the next step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke often induces &ldquo;permissive hypertension&rdquo; to maintain collateral cerebral perfusion. Cerebral autoregulation is impaired in the ischemic penumbra, so aggressive lowering of blood pressure can worsen infarct size. Guideline-driven thresholds dictate when to intervene on hypertension in the hyperacute and subacute phases. At 2 days post-onset, blood pressure under 220/120 mm Hg remains in a safe range that typically does not require immediate pharmacologic reduction, though longer-term control will be addressed after stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Observation is correct because the 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level B-R) recommend against lowering blood pressure in patients not receiving thrombolysis unless systolic >220 mm Hg or diastolic >120 mm Hg. In the ENCHANTED trial and multiple meta-analyses, aggressive BP reduction below these thresholds was associated with increased infarct volumes and worse functional outcomes. Nitroprusside and labetalol carry risks of precipitous drops in cerebral perfusion. Resuming home antihypertensives within the first 24&ndash;48 hours can also cause hypotension in the vulnerable penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV labetalol  <br>&bull; Incorrect because BP <220/120 mm Hg does not meet treatment threshold.  <br>&bull; Misconception: &ldquo;All elevated BP in stroke should be immediately treated.&rdquo;  <br>&bull; Differentiator: Class I recommendation is to withhold antihypertensives unless >220/120.<br><br>B. IV nitroprusside  <br>&bull; Incorrect for same threshold reasons, plus it can raise intracranial pressure.  <br>&bull; Misconception: &ldquo;Potent vasodilators are effective acute stroke therapy.&rdquo;  <br>&bull; Differentiator: Nitroprusside&rsquo;s rapid action risks cerebral hypoperfusion.<br><br>D. Resume home medications  <br>&bull; Incorrect acutely; restarting chronic agents can cause abrupt BP declines.  <br>&bull; Misconception: &ldquo;Chronic antihypertensives should be restarted immediately.&rdquo;  <br>&bull; Differentiator: Guidelines advise delaying reintroduction until after 24&ndash;48 hours of stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Guideline Indication</th><th>Threshold for BP Treatment</th><th>Major Risk</th></tr></thead><tbody><tr><td>Observation (Correct)</td><td>No acute lowering needed</td><td>SBP <220 / DBP <120 mm Hg</td><td>Maintains penumbral perfusion</td></tr><tr><td>IV labetalol</td><td>Only if SBP >220 or DBP >120</td><td>SBP >220 / DBP >120 mm Hg</td><td>Hypoperfusion in penumbra</td></tr><tr><td>IV nitroprusside</td><td>Same as labetalol</td><td>SBP >220 / DBP >120 mm Hg</td><td>\u2191 Intracranial pressure</td></tr><tr><td>Resume home medications</td><td>Secondary prevention once stable</td><td>After 24&ndash;48 h if BP remains elevated</td><td>Hypotension, worsened ischemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Permissive hypertension (up to 220/120 mm Hg) supports collateral flow in acute ischemic stroke.  <br>&bull; Differentiate BP thresholds: >185/110 mm Hg must be lowered before thrombolysis; >220/120 mm Hg only in non-thrombolysis.  <br>&bull; Avoid nitroprusside in stroke&mdash;risk of increasing intracranial pressure and lowering perfusion pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lowering blood pressure immediately in all strokes, risking expansion of the infarcted area.  <br>2. Confusing thrombolysis BP targets (185/110 mm Hg) with non-thrombolysis targets (220/120 mm Hg).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines (Class I, Level B-R): Treat BP only if >220/120 mm Hg in non-thrombolysis.  <br>2. European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines (Grade A): Recommends permissive hypertension up to 220/120 mm Hg during first 48 hours in ischemic stroke without reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Hypertension management in acute ischemic stroke is frequently tested, especially thresholds for intervention in patients with and without thrombolytic therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023201,
    "question_number": "24",
    "question_text": "A female patient presented with an ischemic stroke, a history of two previous abortions, and elevated prothrombin time. What should be investigated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; Antiphospholipid antibodies interfere with phospholipid\u2010dependent coagulation assays, often prolonging PT/PTT despite a prothrombotic state.  <br>&bull; Obstetric morbidity (recurrent miscarriages &ge;2) plus arterial thrombosis in young women strongly suggests antiphospholipid syndrome (APS).  <br>&bull; Inherited thrombophilias <span class=\"citation\">(Factor V Leiden, prothrombin G20210A, protein C deficiency)</span> predispose to venous clots but do not prolong clotting times or cause pregnancy loss via immune mechanisms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiphospholipid syndrome is diagnosed by clinical criteria (vascular thrombosis or pregnancy morbidity) plus persistent laboratory positivity for lupus anticoagulant, anti&ndash;&beta;2 glycoprotein I, or anticardiolipin antibodies on two occasions &ge;12 weeks apart (2019 EULAR recommendations). The lupus anticoagulant assay&mdash;based on phospholipid\u2010dependent clotting prolongation&mdash;explains the elevated PT in this patient. Arterial events such as ischemic stroke occur in up to 20% of APS patients <span class=\"citation\">(Cervera et al., Arthritis <span class=\"evidence\">Rheum 2002</span>)</span>. Early identification guides long-term anticoagulation with warfarin (target INR 2.0&ndash;3.0) and reduces recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Prothrombin Gene Mutation  <br>&bull; Does not prolong PT; it increases prothrombin levels, shortening clotting times.  <br>&bull; Predominantly causes venous thromboses; minimal association with recurrent miscarriages.  <br><br>C. Protein C Deficiency  <br>&bull; Presents with venous thromboembolism; normal PT/PTT.  <br>&bull; No immune\u2010mediated mechanism causing miscarriage.  <br><br>D. Factor V Leiden Mutation  <br>&bull; Activated protein C resistance; normal PT/PTT.  <br>&bull; Stronger link to deep vein thrombosis than arterial stroke or obstetric loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APS (Correct)</th><th>Prothrombin G20210A</th><th>Protein C Deficiency</th><th>Factor V Leiden</th></tr></thead><tbody><tr><td>Mechanism</td><td>Autoantibodies \u2192 phospholipid inhibition</td><td>\u2191 Prothrombin synthesis</td><td>\u2193 Activated protein C activity</td><td>APC resistance</td></tr><tr><td>Lab Abnormality</td><td>Prolonged PT/PTT</td><td>Normal PT/PTT</td><td>Normal PT/PTT</td><td>Normal PT/PTT</td></tr><tr><td>Pregnancy Morbidity</td><td>Recurrent miscarriages</td><td>Rare</td><td>Rare</td><td>Rare</td></tr><tr><td>Arterial Thrombosis Risk</td><td>High (stroke, MI)</td><td>Low</td><td>Low</td><td>Low</td></tr><tr><td>Genetic vs Acquired</td><td>Acquired</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Autosomal dominant</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always suspect APS in young stroke patients with pregnancy loss and unexplained clotting assay prolongation.  <br>&bull; Lupus anticoagulant testing must precede anticoagulation or be interpreted after a washout period to avoid false negatives.  <br>&bull; Long-term warfarin (INR 2.0&ndash;3.0) reduces recurrent APS\u2010associated thrombosis better than DOACs in triple\u2010positive patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting prolonged PT/PTT as bleeding risk rather than a paradoxical indicator of APS.  <br>2. Assuming all thrombophilias present similarly&mdash;APS is unique in combining obstetric complications with arterial events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 EULAR Recommendations for the Management of Antiphospholipid Syndrome: advocate testing for lupus anticoagulant, anticardiolipin, and anti&ndash;&beta;2 glycoprotein I in women <50 with stroke or recurrent pregnancy loss (LoE II).  <br>&bull; 2021 AHA/ASA Stroke Prevention in Women Guideline: recommends APS evaluation in women <55 with ischemic stroke and obstetric history (Class I, Level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Antiphospholipid syndrome&mdash;recognizing the link between clotting\u2010time prolongation, obstetric loss, and arterial thrombosis&mdash;is a frequently tested concept in vascular neurology and internal medicine sections.</div></div></div></div></div>"
  },
  {
    "id": 100023203,
    "question_number": "17",
    "question_text": "A 30-year-old healthy woman presented with a 10-day history of severe headache, blurred vision, and new onset symptomatic seizure. Neurological examination was unremarkable. Vital signs were stable. A CT brain was performed (image attached). Which of the following is the best diagnostic test?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cerebral venous thrombosis (CVT) results from occlusion of dural venous sinuses&mdash;most commonly the superior sagittal or transverse sinus&mdash;leading to impaired venous drainage, elevated intracranial pressure (ICP), and risk of venous infarction or hemorrhage. Patients often present with progressively worsening headache over days, papilledema causing blurred vision, or focal neurologic deficits including seizures. Young women on oral contraceptives represent a high-risk group. Accurate imaging of the venous system is <span class=\"key-point\">essential:</span> conventional MRI brain sequences cannot directly visualize sinus patency without dedicated MR venography (MRV), whereas CT venography (CTV) rapidly depicts filling defects in the venous sinuses with high sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTV is the first-line imaging modality for suspected CVT in most acute settings due to its speed, wide availability, and high diagnostic accuracy. A meta-analysis by Linn et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2007</span>)</span> reported CTV sensitivity of 95% and specificity of 91% compared to digital subtraction angiography. The European Stroke Organisation (ESO) 2017 guidelines (Class I, Level B) and AHA/ASA 2011 updates recommend either CTV or MRV as diagnostic modalities of choice in suspected CVT. On contrast-enhanced CTV, the &ldquo;empty delta sign&rdquo; indicates centralised thrombus with peripheral enhancement. In contrast, CT angiogram focuses on arterial phases and lacks venous opacification, while lumbar puncture does not visualize intracranial vessels and may precipitate herniation in raised ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MRI brain  <br>  &ndash; Lacks direct visualization of venous sinuses; requires MR venography sequences (e.g., phase-contrast, TOF) to detect CVT.  <br>  &ndash; Misconception: any MRI sequence will identify all intracranial vascular pathologies.  <br>B. CT angiogram  <br>  &ndash; Optimized for arterial tree; venous sinuses not adequately opacified during arterial phase.  <br>  &ndash; Key difference: CTA shows arterial circulation, not venous filling defects.  <br>D. Lumbar puncture  <br>  &ndash; May reveal elevated opening pressure but cannot confirm thrombus location.  <br>  &ndash; Contraindicated if intracranial mass effect or raised ICP; risk of downward herniation instead of diagnostic yield.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Target Structure</th><th>Contrast Phase</th><th>Sensitivity for CVT</th><th>Key Findings</th><th>Limitations</th></tr></thead><tbody><tr><td>MRI brain</td><td>Parenchyma</td><td>No contrast</td><td><70% (without MRV)</td><td>Infarcts, edema</td><td>Misses sinus occlusion without MRV</td></tr><tr><td>CT angiogram</td><td>Arterial vessels</td><td>Arterial phase</td><td>~50%</td><td>Arterial stenoses</td><td>Poor venous opacification</td></tr><tr><td>CT venogram</td><td>Venous sinuses</td><td>Venous phase</td><td>~95%</td><td>Empty delta sign</td><td>Iodinated contrast contraindications</td></tr><tr><td>Lumbar puncture</td><td>CSF spaces</td><td>N/A</td><td>N/A</td><td>Opening pressure</td><td>No vascular imaging; herniation risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; In CVT, a noncontrast CT may show hyperdensity in a sinus (&ldquo;cord sign&rdquo;) in 25% of cases; follow with CTV if suspected.  <br>&ndash; Oral contraceptives, pregnancy, malignancy, and infection are major risk factors; always assess prothrombotic state.  <br>&ndash; Early anticoagulation (LMWH) improves outcomes even with hemorrhagic infarcts; imaging confirmation should not delay therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Assuming a normal noncontrast CT excludes CVT; over one-third of CVTs have unremarkable initial CT.  <br>&ndash; Confusing CT angiogram with CT venogram; phase timing is critical to opacify veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; European Stroke Organisation (ESO) Guidelines on Cerebral Venous Thrombosis, 2017: Recommend CTV or MRV as first-line imaging in suspected CVT (Class I, Level B).  <br>&ndash; AHA/ASA Statement on Cerebral Venous Thrombosis, 2011 <span class=\"citation\">(updated 2016)</span>: Endorse noninvasive venous imaging (CTV/MRV) over catheter angiography for diagnosis (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis commonly involves the superior sagittal sinus, transverse sinus, or sigmoid sinus; cortical vein involvement leads to localized venous infarcts and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of venous outflow raises venous and capillary pressures, disrupts the blood&ndash;brain barrier, and leads to vasogenic and cytotoxic edema. Hemorrhagic transformation occurs when capillary rupture ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CVT in headache + seizure/papilledema.  <br>2. Obtain noncontrast head CT to assess for hyperdense sinus or hemorrhage.  <br>3. If unremarkable or suggestive, perform CT venogram for direct sinus visualization.  <br>4. If CTV is contraindicated, proceed with MR venography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Empty delta sign on contrast CTV is pathognomonic for SSS thrombosis.  <br>&ndash; Susceptibility-weighted MRI (T2*) may detect deoxygenated blood in thrombus as blooming artifact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. CVT imaging modalities are frequently tested as single-best-answer questions, emphasizing the distinction between arterial and venous phase imaging for stroke subtypes.</div></div></div></div></div>"
  },
  {
    "id": 100023205,
    "question_number": "55",
    "question_text": "A patient who underwent carotid stenting or endarterectomy presents with altered level of consciousness and a CT shows a small right frontal cortical hemorrhage. What condition is most likely?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Cerebral autoregulation normally maintains constant perfusion despite blood pressure fluctuations. After chronic carotid stenosis, downstream arterioles dilate maximally. Rapid restoration of flow by endarterectomy or stenting overwhelms this impaired autoregulation, causing capillary leakage, vasogenic edema, and small cortical hemorrhages&mdash;hallmarks of cerebral hyperperfusion syndrome. Clinically, patients develop severe ipsilateral headache, seizures, focal deficits, or altered consciousness within days (most often 2&ndash;6 days) post-procedure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome is the correct diagnosis: disrupted autoregulatory vasoconstriction in the formerly hypoperfused territory allows excessive blood flow, leading to blood&ndash;brain barrier breakdown and cortical petechial hemorrhages. Sundt et al. (1981) first characterized this after carotid endarterectomy; subsequent studies <span class=\"citation\">(Zhou et al., <span class=\"evidence\">Stroke 2021</span>)</span> confirm a 2&ndash;3% incidence. Current Society for Vascular Surgery (2022) guidelines recommend strict postoperative blood pressure control (systolic <140 mm Hg for &ge;48 h) and transcranial Doppler monitoring to detect ipsilateral MCA velocities >120 cm/s, predictive of hyperperfusion (Grade IIb, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ischemic stroke  <br>&bull; Why incorrect: Presents with hypodense areas on CT, not hyperdense cortical hemorrhages.  <br>&bull; Misconception: Equating any post-procedural deficit with new infarction.  <br>&bull; Differentiator: Ischemia shows cytotoxic edema, not acute hyperdense bleed.<br><br>C. Intracerebral hemorrhage  <br>&bull; Why incorrect: Generic term for deep or lobar bleeds; here the small cortical bleed after revascularization is characteristic of hyperperfusion, not spontaneous hypertensive hemorrhage.  <br>&bull; Misconception: All supratentorial bleeds are &ldquo;intracerebral hemorrhage&rdquo;&mdash;fails to recognize etiologic context.  <br>&bull; Differentiator: Hypertensive ICH typically occurs in basal ganglia or thalamus, not isolated frontal cortex post-CEA.<br><br>D. Subarachnoid hemorrhage  <br>&bull; Why incorrect: SAH presents as sulcal hyperdensity and diffuse leptomeningeal blood, often with thunderclap headache.  <br>&bull; Misconception: Any cortical blood means SAH.  <br>&bull; Differentiator: SAH spares deep cortex, not localized cortical petechiae.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Ischemic Stroke</th><th>Intracerebral Hemorrhage</th><th>Subarachnoid Hemorrhage</th></tr></thead><tbody><tr><td>Timing post-procedure</td><td>2&ndash;6 days</td><td>Immediate</td><td>Variable</td><td>Immediate</td></tr><tr><td>CT appearance</td><td>Small cortical hemorrhages</td><td>Hypodensity</td><td>Large deep or lobar bleed</td><td>Sulcal/leptomeningeal blood</td></tr><tr><td>Mechanism</td><td>Loss of autoregulation, BBB breakdown</td><td>Vascular occlusion</td><td>Vessel rupture (hypertensive/amyloid)</td><td>Aneurysm or vessel tear</td></tr><tr><td>Blood pressure association</td><td>Often post-CEA hypertension</td><td>Not specific</td><td>Acute BP spike</td><td>Not directly procedural</td></tr><tr><td>Clinical features</td><td>Headache, seizures, focal deficits</td><td>Focal deficits</td><td>Altered consciousness, headache</td><td>&ldquo;Worst headache,&rdquo; nuchal rigidity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Maintain systolic BP <140 mm Hg for at least 48 h after carotid revascularization to reduce hyperperfusion risk.  <br>&bull; New-onset ipsilateral headache or seizures post-CEA should prompt immediate CT to rule out hyperperfusion hemorrhage.  <br>&bull; Transcranial Doppler velocities >120 cm/s within 24 h post-procedure predict hyperperfusion syndrome with >80% sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any post-stenting neurological change is an embolic stroke&mdash;overlooks hyperperfusion hemorrhage.  <br>2. Mislabeling small cortical bleeds as generic &ldquo;intracerebral hemorrhage&rdquo; without considering procedural context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2022 European Society for Vascular Surgery (ESVS) Guidelines on Carotid Interventions: Recommend strict postoperative BP control (systolic <140 mm Hg for 48 h) to prevent hyperperfusion syndrome (Grade IIb, Level B).  <br>&bull; Zhou et al., <span class=\"evidence\">Stroke 2021</span> (Prospective Multicenter Study): Reported a 2.3% incidence of cerebral hyperperfusion syndrome after carotid endarterectomy; identified contralateral occlusion and postoperative hypertension as independent predictors (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The frontal cortex is supplied by the ipsilateral middle cerebral artery. After revascularization, loss of arteriolar vasoconstriction in these distal MCA branches permits excessive capillary pressure and localized cortical hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic stenosis \u2192 maximal arteriolar dilation \u2192 impaired autoregulation \u2192 rapid reperfusion \u2192 capillary endothelial damage \u2192 vasogenic edema and petechial hemorrhages \u2192 clinical hyperperfusion syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral hyperperfusion hemorrhages are typically small, cortical, and petechial or lobar in distribution; differentiating them from confluent deep hypertensive bleeds or diffuse SAH is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Carotid revascularization complications&mdash;especially hyperperfusion syndrome&mdash;are a high-yield topic, frequently tested as the cause of cortical hemorrhages after endarterectomy or stenting.</div></div></div></div></div>"
  },
  {
    "id": 100023206,
    "question_number": "49",
    "question_text": "What is the mainstay of treatment for patients with elevated INR due to vitamin K antagonists (VKAs) in the United States?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Vitamin K antagonists (VKAs) like warfarin inhibit vitamin K epoxide reductase (VKORC1), preventing &gamma;-carboxylation of clotting factors II, VII, IX, and X. The INR monitors the extrinsic pathway (factor VII) and reflects VKA effect. Elevated INR indicates high bleeding risk and may require rapid reversal in major hemorrhage or before urgent procedures. Reversal strategies include:  <br>&bull; Vitamin K to restore hepatic synthesis (slow onset)  <br>&bull; Fresh frozen plasma (FFP) for broad factor replacement (high volume, slower)  <br>&bull; Prothrombin complex concentrate (PCC) for rapid, concentrated factor II, VII, IX, X replacement  <br>&bull; Recombinant factor VIIa (rFVIIa), off-label with high thrombosis risk</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Four-factor PCC is the standard of care for urgent VKA reversal in the U.S. because it delivers high concentrations of factors II, VII, IX, and X in a small volume, achieving INR correction within 15&ndash;30 minutes. In the landmark Sarode et al. NEJM 2013 trial, 4-factor PCC normalized INR (<1.3) at 30 minutes in 62% versus 10% with FFP (p<0.001), with fewer transfusion-related adverse events. <span class=\"evidence\">The 2016</span> American College of Chest Physicians (ACCP) guidelines (Grade 2B) and the 2018 American Society of Hematology (ASH) guidelines recommend 4-factor PCC plus IV vitamin K over FFP for major bleeding on VKAs. FFP requires blood\u2010group matching, thawing, and infusion of 10&ndash;20 mL/kg, posing risk of volume overload and transfusion reactions. rFVIIa lacks other clotting factors, has very short half-life, and carries a high thromboembolic risk, while vitamin K alone acts too slowly for emergent reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. FFP + Vitamin K  <br> &bull; Incorrect: FFP delivers all factors but requires large volume (10&ndash;20 mL/kg), ABO matching, thaw time, and corrects INR more slowly than PCC.  <br> &bull; Misconception: &ldquo;Plasma is readily available&rdquo;&mdash;in reality, thawing delays and volume overload limit its use in emergencies.  <br> &bull; Differentiator: PCC corrects INR within 15&ndash;30 min; FFP often takes &ge;6 hours to achieve similar effect.  <br><br>C. rFVIIa  <br> &bull; Incorrect: Recombinant factor VIIa provides only factor VII, not II, IX, X; it is off-label for VKA reversal.  <br> &bull; Misconception: &ldquo;Targeting factor VII suffices&rdquo;&mdash;incomplete correction of cascade and high thrombosis risk limits its use.  <br> &bull; Differentiator: PCC restores all vitamin K&ndash;dependent factors; rFVIIa does not.  <br><br>D. Vitamin K alone  <br> &bull; Incorrect: IV vitamin K (5&ndash;10 mg) has onset of 6&ndash;24 hours as the liver synthesizes new factors; not fast enough for major bleeding.  <br> &bull; Misconception: &ldquo;Vitamin K reverses INR quickly&rdquo;&mdash;it only provides substrate for factor synthesis, which requires time.  <br> &bull; Differentiator: PCC provides immediate factor replacement whereas vitamin K is adjunctive for sustainment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Factor Content</th><th>Onset of INR Correction</th><th>Volume Required</th><th>Thrombosis Risk</th></tr></thead><tbody><tr><td>4-factor PCC</td><td>II, VII, IX, X (+ C, S)</td><td>15&ndash;30 minutes</td><td>25&ndash;50 mL total</td><td>Low&ndash;Moderate</td></tr><tr><td>FFP + Vitamin K</td><td>All factors</td><td>4&ndash;6 hours</td><td>10&ndash;20 mL/kg</td><td>Moderate</td></tr><tr><td>rFVIIa</td><td>VII only</td><td>5&ndash;15 minutes</td><td><5 mL</td><td>High</td></tr><tr><td>Vitamin K alone</td><td>Substrate for II, VII, IX, X</td><td>6&ndash;24 hours</td><td>Negligible</td><td>Very Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always co-administer IV vitamin K (5&ndash;10 mg) with PCC to sustain factor levels after PCC clearance.  <br>&bull; Dose PCC based on weight and pre-treatment INR (e.g., 25 IU/kg for INR 2&ndash;4; 35 IU/kg for INR 4&ndash;6; 50 IU/kg for INR >6).  <br>&bull; Recheck INR 15 minutes post-PCC infusion to confirm adequate reversal and avoid over-correction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing vitamin K alone suffices for acute bleeding&mdash;delayed onset risks continued hemorrhage.  <br>2. Preferring FFP due to familiarity&mdash;underestimating thaw time (~30 minutes) and volume overload risk.  <br>3. Overlooking that rFVIIa lacks factors II/IX/X and is associated with arterial thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ACCP CHEST <span class=\"evidence\">Guidelines 2016</span>: Recommend 4-factor PCC plus IV vitamin K over FFP for VKA reversal in major bleeding (Grade 2B).  <br>&bull; ASH Guideline on Hemorrhage <span class=\"evidence\">Management 2018</span>: Endorse 4-factor PCC for life-threatening VKA-related bleeds (Conditional recommendation, low-quality evidence).  <br>&bull; Sarode et al., NEJM 2013: RCT (n=202) demonstrated faster INR normalization and fewer adverse events with PCC vs FFP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Prothrombin complex concentrates contain high concentrations of vitamin K&ndash;dependent factors II, VII, IX, and X (and proteins C, S). They are dosed by body weight and target INR. IV vitamin K restores the gamma-carboxylation cycle (VKORC1) but is slow. FFP provides all factors but involves large-volume transfusion and risk of transfusion-related acute lung injury (TRALI). rFVIIa, though rapidly acting, lacks critical factors and poses high thrombosis risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Reversal of VKA anticoagulation is frequently tested on USMLE Step 1 and Step 2, often requiring differentiation between PCC, FFP, vitamin K, and rFVIIa based on onset of action, volume, and factor content.</div></div></div></div></div>"
  },
  {
    "id": 100023207,
    "question_number": "22",
    "question_text": "An elderly male in his 60s with hypertension and diabetes mellitus presented with sudden onset right-sided weakness. Symptoms started 5 hours ago. BP was 180/100, HR 83. Examination showed aphasia with left gaze preference. NIHSS was 16. CT brain was done. Which of the following is the appropriate management for this patient?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke from a large vessel occlusion (LVO) produces an irreversibly infarcted core and salvageable surrounding penumbra. A dominant left middle cerebral artery (MCA) occlusion disrupts corticospinal tracts (contralateral hemiparesis) and language cortices (aphasia), often accompanied by gaze preference toward the lesion. The NIH Stroke Scale (NIHSS) quantifies severity; scores &ge;15 strongly suggest proximal LVO. Time\u2010dependent reperfusion preserves penumbral tissue: IV thrombolysis is limited to 4.5 hours, whereas endovascular thrombectomy extends to 6 hours (and up to 24 hours in select patients with advanced imaging).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mechanical thrombectomy with stent retrievers is the standard of care for anterior circulation LVO presenting within 6 hours. <span class=\"evidence\">The 2019</span> AHA/ASA guidelines (Class I, Level A) recommend thrombectomy in patients with NIHSS &ge;6, small core infarct (ASPECTS &ge;6), and proximal MCA or intracranial ICA occlusion. Landmark randomized trials (MR CLEAN, ESCAPE, SWIFT PRIME, REVASCAT) demonstrated a 13&ndash;28% absolute increase in functional independence (mRS 0&ndash;2 at 90 days) compared with medical therapy alone <span class=\"citation\">(Goyal M et al., <span class=\"evidence\">Lancet 2016</span>)</span>. IV alteplase has a strict 4.5 hour window <span class=\"citation\">(ECASS III; Hacke W et al., <span class=\"evidence\">Lancet 2008</span>)</span>. Intraarterial thrombolysis alone (PROACT II) yielded higher hemorrhage rates and is now supplanted by mechanical approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Intraarterial thrombolysis  <br><span class=\"list-item\">\u2022</span> PROACT II showed modest recanalization but no mortality benefit and higher symptomatic hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating local tPA infusion with modern stent\u2010based clot retrieval.  <br><span class=\"list-item\">\u2022</span> Lacks mechanical clot extraction and is not standard practice.<br><br>C. IV thrombolysis  <br><span class=\"list-item\">\u2022</span> Contraindicated beyond 4.5 hours post\u2010onset; here it is 5 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing aggressive BP control can extend the tPA window.  <br><span class=\"list-item\">\u2022</span> Systemic fibrinolysis is ineffective for proximal LVO beyond window.<br><br>D. Supportive care with blood pressure control  <br><span class=\"list-item\">\u2022</span> Permissive hypertension (<185/110 mm Hg) is maintained until reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate BP normalization improves outcomes.  <br><span class=\"list-item\">\u2022</span> Does not address underlying occlusion; delays definitive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Time Window</th><th>Mechanism</th><th>Evidence Grade</th><th>Primary Indication</th></tr></thead><tbody><tr><td>Mechanical thrombectomy</td><td>0&ndash;6 h (&le;24 h select)</td><td>Stent retriever clot removal</td><td>Class I, Level A <span class=\"citation\">(AHA/ASA 2019)</span></td><td>Proximal ICA/MCA occlusion, NIHSS &ge;6</td></tr><tr><td>Intraarterial thrombolysis</td><td>0&ndash;6 h</td><td>Local tPA infusion</td><td>Class IIb, Level B</td><td>Largely historical/trial use only</td></tr><tr><td>IV thrombolysis</td><td>0&ndash;4.5 h</td><td>Systemic fibrinolysis</td><td>Class I, Level A (ECASS III)</td><td>Mild&ndash;moderate stroke within window</td></tr><tr><td>Supportive care</td><td>N/A</td><td>BP management, hydration</td><td>Class IIa, Level C</td><td>Patients ineligible for reperfusion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain systolic BP <185 mm Hg pre\u2010reperfusion and <180 mm Hg post\u2010thrombectomy to balance hemorrhage risk and collateral perfusion.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT ASPECTS &ge;6 predicts better outcomes; CTA identifies LVO and guides thrombectomy.  <br><span class=\"list-item\">\u2022</span> High NIHSS with cortical signs (gaze deviation, aphasia) warrants immediate vascular imaging for endovascular candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administering IV tPA beyond 4.5 hours based on minor deficits, increasing hemorrhagic complications.  <br><span class=\"list-item\">\u2022</span> Overaggressive blood pressure reduction (<140 mm Hg) before reperfusion, compromising penumbral flow.  <br><span class=\"list-item\">\u2022</span> Confusing intraarterial thrombolysis with mechanical thrombectomy efficacy and safety profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for the Early Management of Acute Ischemic Stroke <span class=\"citation\">(Smith EE et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Class I, Level A recommendation for mechanical thrombectomy within 6 hours for anterior circulation LVO; extended to 24 hours in select patients with perfusion mismatch (DAWN/DEFUSE 3 criteria) &ndash; Level B.  <br>2. DAWN Trial <span class=\"citation\">(Albers GW et al., N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated that thrombectomy 6&ndash;24 hours post\u2010onset led to a 36% absolute increase in functional independence (mRS 0&ndash;2) in patients with clinical&ndash;core mismatch (NIHSS &ge;10, infarct &le;50 mL) &ndash; Level A evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left proximal MCA occlusion disrupts perfusion to the internal capsule (corticospinal fibers) causing contralateral hemiparesis, and to Broca&rsquo;s/Wernicke&rsquo;s areas causing expressive and receptive aphasia. Frontal eye field involvement produces ipsilateral gaze preference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation over an atherosclerotic plaque in the carotid or MCA bifurcation abruptly halts perfusion. The infarct core undergoes irreversible neuronal death within minutes, whereas the penumbra remains metabolically impaired but salvageable with timely reperfusion, mediated by collateral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform rapid neurological exam and calculate NIHSS.  <br>2. Obtain noncontrast CT to exclude hemorrhage.  <br>3. Perform CT angiography to confirm LVO.  <br>4. If >6 hours, add CT perfusion/MRI to assess penumbra.  <br>5. Determine eligibility: IV tPA if &le;4.5 h; thrombectomy if &le;6 h (or &le;24 h with mismatch).  <br>6. Proceed with reperfusion accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense MCA sign on noncontrast CT indicates proximal clot.  <br><span class=\"list-item\">\u2022</span> Early ischemic changes (ASPECTS scoring) guide thrombectomy candidacy (ASPECTS &ge;6).  <br><span class=\"list-item\">\u2022</span> CT perfusion distinguishes core versus penumbra, expanding the treatment window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, remainder over 60 min.  <br><span class=\"list-item\">\u2022</span> Pre\u2010procedure BP target: <185/110 mm Hg; post\u2010procedure: <180/105 mm Hg.  <br><span class=\"list-item\">\u2022</span> Post\u2010thrombectomy antithrombotic strategy: initiate antiplatelet therapy if no hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Acute stroke reperfusion&mdash;particularly time windows and selection between IV thrombolysis and mechanical thrombectomy&mdash;is a high\u2010yield topic, often tested with clinical vignettes emphasizing NIHSS thresholds, CT/CTA findings, and precise timing.</div></div></div></div></div>"
  },
  {
    "id": 100023210,
    "question_number": "21",
    "question_text": "A 70-year-old male, known case of hypertension, went to sleep and then woke up in the morning with left-sided weakness and dysarthria. MRI of the brain was done. What is the most likely pathophysiology involved in his condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Chronic hypertension induces hyaline arteriolosclerosis and Charcot&ndash;Bouchard microaneurysm formation in small penetrating arteries (lenticulostriates). Rupture of these microaneurysms leads to intracerebral hemorrhage, classically in deep structures (basal ganglia, thalamus, pons). Clinically, sudden focal neurological deficits&mdash;hemiparesis and dysarthria&mdash;arise when a small bleed compresses the internal capsule and corticobulbar fibers. Differentiating deep hypertensive hemorrhage from lobar bleeds (e.g., amyloid angiopathy) or ischemic lacunar infarcts relies on vascular territory, imaging characteristics, and risk\u2010factor profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertensive hemorrhage is driven by chronic high intraluminal pressure causing lipohyalinosis of arteriolar walls and subsequent Charcot&ndash;Bouchard microaneurysm formation. The AHA/ASA 2022 guideline on spontaneous intracerebral hemorrhage (ICH) (Class I, Level A) recommends emergent noncontrast head CT to confirm ICH, followed by rapid BP lowering (target systolic 140\u2009mmHg) to reduce hematoma expansion <span class=\"citation\">(INTERACT2 trial: NEJM 2013; ATACH-II: JAMA 2016)</span>. Deep bleeds in the internal capsule manifest with contralateral motor deficits and dysarthria due to corticospinal and corticobulbar tract involvement. MRI gradient\u2010echo or susceptibility\u2010weighted imaging can detect chronic microbleeds, correlating with hypertensive small-vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid angiopathy  <br>&ndash; Incorrect because &beta;-amyloid deposition in leptomeningeal and cortical vessels causes lobar hemorrhages in elderly, not deep basal ganglia bleeds. Commonly presents with cortical\u2010subcortical bleeds and cognitive decline rather than pure motor deficits.  <br><br>B. Hemorrhagic stroke  <br>&ndash; Too nonspecific: this umbrella term includes all intracranial bleeds (traumatic, cavernous malformations, venous sinus thrombosis). It fails to pinpoint the characteristic small\u2010vessel arteriolar pathology seen in chronic hypertension.  <br><br>D. Autoregulation dysfunction  <br>&ndash; Refers to failure of cerebral blood flow regulation (e.g., posterior reversible encephalopathy syndrome), producing vasogenic edema in parieto\u2010occipital lobes with headache, seizures, visual changes&mdash;unlike a focal intraparenchymal hemorrhage from vessel rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Pathophysiology</th><th>Typical Location</th><th>Vessel Type</th><th>Imaging Features</th></tr></thead><tbody><tr><td>Hypertensive hemorrhage [CORRECT]</td><td>Charcot&ndash;Bouchard microaneurysms in arterioles</td><td>Basal ganglia, thalamus, pons</td><td>Small penetrating (lenticulostriate) arteries</td><td>CT: hyperdense deep bleeds; MRI GRE: susceptibility artifacts</td></tr><tr><td>Amyloid angiopathy</td><td>&beta;-amyloid deposits \u2192 vessel wall fragility</td><td>Lobar cortex/subcortical white matter</td><td>Leptomeningeal and cortical vessels</td><td>CT: lobar hemorrhages; MRI SWI: cortical microbleeds</td></tr><tr><td>Hemorrhagic stroke</td><td>Any intracranial bleeding</td><td>Variable</td><td>Variable</td><td>CT: hyperdensity variable location</td></tr><tr><td>Autoregulation dysfunction</td><td>Impaired vessel autoregulation \u2192 vasogenic edema</td><td>Parieto-occipital lobes</td><td>Pial arterioles</td><td>MRI FLAIR/T2: white-matter edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Deep intracerebral hemorrhages in hypertensive patients most often occur in the basal ganglia (putamen) via lenticulostriate vessel rupture.  <br><span class=\"list-item\">\u2022</span> Early intensive SBP lowering to ~140\u2009mmHg reduces hematoma growth without increasing ischemic risk (INTERACT2, ATACH-II).  <br><span class=\"list-item\">\u2022</span> MRI susceptibility sequences reveal chronic microbleeds; their distribution (deep vs lobar) helps distinguish hypertensive arteriopathy from amyloid angiopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all strokes with focal deficits are ischemic; neglecting acute CT to exclude hemorrhage leads to contraindicated thrombolysis.  <br>2. Confusing lacunar infarcts (small ischemic) with deep hemorrhages; lacunes lack mass effect and present more insidiously than hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage, 2022:  <br>   &ndash; Recommendation: Lower acute SBP to 140\u2009mmHg (Class I; Level A evidence based on INTERACT2 and ATACH-II).  <br>2. European Stroke Organisation (ESO) <span class=\"evidence\">Guidelines 2021</span> Update:  <br>   &ndash; Suggest immediate noncontrast CT scan to differentiate hemorrhagic versus ischemic stroke (Level A); emphasizes early reversal of coagulopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Rupture of lenticulostriate arteries hemorrhaging into the posterior limb of the internal capsule injures adjacent corticospinal (motor weakness) and corticobulbar fibers (dysarthria), producing pure motor\u2010plus symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension \u2192 hyaline arteriolosclerosis \u2192 vessel wall thickening and lumen narrowing \u2192 formation of small microaneurysms \u2192 vessel rupture under pressure \u2192 blood extravasation into brain parenchyma \u2192 mass effect and local ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment and BP measurement  <br>2. Noncontrast CT head to confirm hemorrhage  <br>3. MRI with GRE/SWI if CT equivocal or to detect chronic microbleeds  <br>4. Laboratory evaluation: coagulation profile, platelets  <br>5. Initiate BP control, reverse anticoagulation as needed  <br>6. Neurosurgical consult for hematoma evacuation if indicated</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Noncontrast CT: acute blood appears hyperdense; hemorrhages in basal ganglia indicate hypertensive etiology.  <br>&ndash; MRI GRE/SWI: sensitive to hemosiderin; deep microbleeds reflect chronic hypertensive arteriopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Acute BP management: intravenous nicardipine or labetalol to SBP 140\u2009mmHg.  <br>&ndash; Avoid rapid SBP drop <120\u2009mmHg to prevent ischemic penumbra.  <br>&ndash; Reverse anticoagulation: PCC for warfarin, idarucizumab for dabigatran.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Deep hypertensive hemorrhages remain a high\u2010yield topic on neurology boards, often tested through clinical vignettes highlighting basal ganglia bleeds, Charcot&ndash;Bouchard microaneurysms, and emergency BP management.</div></div></div></div></div>"
  },
  {
    "id": 100023213,
    "question_number": "41",
    "question_text": "A young female patient with subarachnoid hemorrhage (SAH) and a symptomatic posterior communicating artery (PComm) aneurysm presents for management. What is the next step in her treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] 1. Subarachnoid hemorrhage (SAH) from a ruptured intracranial aneurysm carries high rebleeding risk; securing the aneurysm is emergent.  <br>2. Posterior communicating artery (PComm) aneurysms often compress the oculomotor nerve, causing third-nerve palsy; relieving mass effect is critical for nerve recovery.  <br>3. Two definitive treatments exist: microsurgical clipping (open craniotomy to place a clip at the aneurysm neck) and endovascular coiling (packing the sac with coils via catheter). Choice hinges on aneurysm morphology, patient factors, and presence of mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Microsurgical clipping is the preferred treatment for ruptured PComm aneurysms presenting with symptomatic mass effect (e.g., third-nerve palsy). Clipping immediately excludes the aneurysm from circulation and relieves compression on the oculomotor nerve, improving rates and speed of cranial nerve function recovery.  <br><span class=\"list-item\">\u2022</span> <span class=\"evidence\">The 2023</span> AHA/ASA Guidelines for Aneurysmal SAH <span class=\"citation\">(Steiner et al., <span class=\"evidence\">Stroke 2023</span>)</span> give a Class I, Level B recommendation for microsurgical clipping in aneurysms causing cranial nerve dysfunction.  <br><span class=\"list-item\">\u2022</span> The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span> demonstrated better functional outcomes with coiling in select aneurysms, but excluded many complex PComm aneurysms with symptomatic mass effect.  <br><span class=\"list-item\">\u2022</span> Endovascular coiling does not reliably decompress nerve compression, may leave residual sac, and is associated with higher recurrence in broad-necked PComm aneurysms <span class=\"citation\">(Brinjikji et al., JNS 2015)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Coiling  <br>&bull; Does not relieve mass effect; coil mass may transiently enlarge the sac.  <br>&bull; Misconception: &ldquo;Endovascular is always less invasive&rdquo;&mdash;but nerve decompression is surgical.  <br><br>C. Discharge  <br>&bull; Erroneous: unrepaired ruptured aneurysms have > 50% risk of rebleeding in first 24 h.  <br>&bull; Misconception: SAH can be observed without securing the aneurysm.  <br><br>D. Medical treatment  <br>&bull; Supportive care (e.g., nimodipine) is adjunctive, not definitive&mdash;aneurysm remains at risk of re-rupture.  <br>&bull; Misconception: aggressive medical therapy can replace mechanical aneurysm occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Microsurgical Clipping (Correct)</th><th>Endovascular Coiling</th><th>Medical Treatment</th><th>Discharge</th></tr></thead><tbody><tr><td>Definitive aneurysm exclusion</td><td>Yes</td><td>Yes*</td><td>No</td><td>No</td></tr><tr><td>Mass effect relief</td><td>Immediate</td><td>No</td><td>N/A</td><td>N/A</td></tr><tr><td>Rebleeding risk reduction</td><td>Immediate</td><td>Immediate</td><td>None</td><td>None</td></tr><tr><td>Recurrence risk</td><td>Low (< 1%/yr)</td><td>Higher (5&ndash;10%/yr)</td><td>N/A</td><td>N/A</td></tr><tr><td>Invasiveness</td><td>Craniotomy required</td><td>Minimally invasive</td><td>N/A</td><td>N/A</td></tr><tr><td>\\* May require retreatment for recurrence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In PComm aneurysms with third-nerve palsy, early clipping (within 72 h) yields better nerve recovery than coiling.  <br><span class=\"list-item\">\u2022</span> Always assess aneurysm neck morphology: broad necks favor clipping for durable occlusion.  <br><span class=\"list-item\">\u2022</span> Administer nimodipine prophylactically to reduce delayed cerebral ischemia, but remember it does not secure the aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Applying ISAT outcomes universally without considering excluded aneurysm subtypes (e.g., symptomatic mass effect).  <br>2. Believing that endovascular approaches always supersede microsurgery irrespective of clinical presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2023 AHA/ASA Guidelines for the Management of Patients With Aneurysmal SAH <span class=\"citation\">(Steiner et al., <span class=\"evidence\">Stroke 2023</span>)</span>: Class I, Level B for clipping in aneurysms causing cranial nerve palsies.  <br><span class=\"list-item\">\u2022</span> International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span>: demonstrated better short-term functional outcome with coiling in select ruptured aneurysms but excluded many PComm aneurysms with mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PComm branches off the internal carotid artery near the oculomotor nerve as it traverses the interpeduncular cistern. Aneurysmal expansion compresses the nerve within the cavernous sinus, producing mydriasis and ophthalmoplegia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemodynamic stress at the ICA&ndash;PComm junction weakens the vessel wall, leading to saccular aneurysm formation. Rupture into the subarachnoid space elevates intracranial pressure and risks rebleeding; mass effect on cranial nerve III impairs parasympathetic and somatic fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. PComm aneurysm management&mdash;coiling vs clipping&mdash;is repeatedly tested on neurology and neurosurgery boards, often emphasizing third-nerve palsy and mass effect considerations.</div></div></div></div></div>"
  },
  {
    "id": 100023225,
    "question_number": "370",
    "question_text": "Which cranial nerve is primarily responsible for the sense of smell?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] The olfactory nerve (CN I) carries special visceral afferent fibers from bipolar receptor neurons in the olfactory epithelium through the cribriform plate to synapse in the olfactory bulb. Secondary projections via the olfactory tract target the piriform cortex and limbic structures. Olfaction is distinct from gustation (taste) and general nasal sensation. Clinically, anosmia or hyposmia arises in post-viral infections (e.g., SARS-CoV-2), head trauma shearing olfactory fila, sinonasal disease, or neurodegeneration (Parkinson&rsquo;s, Alzheimer&rsquo;s). Objective testing (UPSIT or Sniffin&rsquo; Sticks) and imaging guide evaluation and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CN I exclusively mediates smell via special visceral afferent fibers; no other cranial nerve conveys olfactory signals. The AAN 2022 practice guideline on olfactory disorders recommends validated psychophysical tests like the University of Pennsylvania Smell Identification Test (UPSIT) to quantify olfactory function (Level B evidence). Olfactory training protocols (e.g., twice-daily exposure to rose, eucalyptus, lemon, and clove) have demonstrated significant threshold improvements in randomized trials <span class=\"citation\">(Hummel et al., <span class=\"evidence\">Rhinology 2016</span>)</span>. Vision (CN II), facial/general sensation (CN V), and taste/motor functions (CN VII) are anatomically and functionally segregated from the olfactory pathway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Optic nerve (CN II): Conveys visual information via special somatic afferents to the lateral geniculate nucleus. Confusion arises from both being &ldquo;special&rdquo; senses, but CN II does not subserve smell.  <br>C. Trigeminal nerve (CN V): Mediates general somatic sensation (pain, temperature) in the nasal mucosa and detects irritants (chemesthesis), not odor identity. Misattribution of trigeminal irritation (e.g., ammonia) to olfaction is common.  <br>D. Facial nerve (CN VII): Supplies taste from the anterior two-thirds of the tongue and parasympathetic fibers to glands; contains no olfactory fibers. Students often conflate taste loss with smell loss due to overlapping perceptions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CN I (Olfactory)</th><th>CN II (Optic)</th><th>CN V (Trigeminal)</th><th>CN VII (Facial)</th></tr></thead><tbody><tr><td>Fiber type</td><td>Special visceral afferent</td><td>Special somatic afferent</td><td>General somatic afferent</td><td>Special visceral afferent (taste)</td></tr><tr><td>Primary function</td><td>Smell</td><td>Vision</td><td>Facial/general sensation, mastication</td><td>Facial expression, taste (ant. 2/3 tongue)</td></tr><tr><td>Central projection</td><td>Piriform cortex, limbic system</td><td>Lateral geniculate nucleus</td><td>Trigeminal nuclei</td><td>Solitary nucleus (taste)</td></tr><tr><td>Pathway through skull</td><td>Cribriform plate</td><td>Optic canal</td><td>Superior orbital fissure (V1), foramen ovale (V3)</td><td>Internal acoustic meatus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anosmia is an early and specific symptom in >60% of COVID-19 patients; bedside smell testing can aid in early diagnosis.  <br><span class=\"list-item\">\u2022</span> Olfactory training (rose, eucalyptus, lemon, clove) twice daily for &ge;12 weeks improves recovery in post-viral anosmia.  <br><span class=\"list-item\">\u2022</span> Head trauma with cribriform plate fracture often leads to irreversible anosmia due to fila shearing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking trigeminal-mediated chemesthetic sensations (irritants) for true olfaction, leading to misdiagnosis of CN V involvement.  <br><span class=\"list-item\">\u2022</span> Equating taste loss with smell loss; over 80% of &ldquo;taste&rdquo; impairment cases are actually due to underlying anosmia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AAN Practice Guideline, &ldquo;Assessment and Management of Patients with Olfactory Disorders&rdquo; (2022): Recommends standardized olfactory tests (UPSIT) for diagnosis (Level B) and endorses olfactory training as first\u2010line therapy (Level A).  <br><span class=\"list-item\">\u2022</span> European Position Paper on Olfactory Dysfunction, European Rhinologic Society (2023): Advises MRI to assess central olfactory pathways in unexplained anosmia (Level C) and suggests adjunct intranasal vitamin A (10,000 IU daily) to enhance neuronal regeneration (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Olfactory receptor neurons in the superior nasal vault traverse the cribriform plate&rsquo;s foramina to synapse in the olfactory bulb. Secondary mitral and tufted cell axons form the olfactory tract, projecting ipsilaterally to the piriform cortex, amygdala, and entorhinal cortex without thalamic relay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Post\u2010viral olfactory loss: Damage to supporting sustentacular cells and receptor neurons, impairing signal transduction and regeneration. Traumatic anosmia: Shearing of fila at the cribriform plate. Neurodegenerative anosmia: Early deposition of &alpha;-synuclein (Parkinson&rsquo;s) or tau (Alzheimer&rsquo;s) in olfactory pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history (onset, progression, triggers).  <br>2. Bedside detection (coffee, peppermint).  <br>3. Psychophysical testing (UPSIT/Sniffin&rsquo; Sticks).  <br>4. Imaging: MRI for central lesions, CT for sinonasal pathology.  <br>5. Endoscopic evaluation if sinus disease suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI: Assess olfactory bulb volume; atrophy correlates with severity in neurodegenerative disease. CT: Evaluate cribriform plate integrity and paranasal sinus opacification in sinonasal causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intranasal corticosteroids for sinonasal\u2010associated olfactory loss (Level C).  <br><span class=\"list-item\">\u2022</span> Adjunct intranasal vitamin A (10,000 IU QD) may enhance epithelial regeneration (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Olfactory nerve localization and differentiation from trigeminal-mediated chemesthesis are frequently tested via clinical vignettes assessing anosmia causes and pathways.</div></div></div></div></div>"
  },
  {
    "id": 100023229,
    "question_number": "50",
    "question_text": "A girl with a history of migraine headaches, stroke, and dementia, along with a family history of similar issues in her father presents for evaluation. What is your diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a heritable small\u2010vessel disorder caused by NOTCH3 gene mutations on chromosome 19. Key neuroanatomical targets are penetrating arterioles supplying deep white matter and basal ganglia, leading to chronic ischemia. Clinically, patients develop migraine with aura in early adulthood, followed by recurrent lacunar strokes and progressive cognitive decline (subcortical dementia). Autosomal dominant inheritance with high penetrance explains the positive paternal history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is CADASIL. A 2020 Lancet Neurology cohort (n=446) demonstrated migraine in 85% of patients, median age 30, preceding stroke by ~15 years. The American Heart Association/American Stroke <span class=\"evidence\">Association 2024</span> guidelines on secondary stroke prevention in small\u2010vessel disease (Class IIa, Level B) recommend genetic testing for NOTCH3 mutations in individuals <55 years with unexplained lacunar infarcts and leukoencephalopathy. MRI hallmark findings&mdash;bilateral T2/FLAIR hyperintensities in anterior temporal poles and external capsules&mdash;have >90% specificity for CADASIL. Pathologically, mutated NOTCH3 leads to granular osmiophilic material deposition in vascular smooth muscle, vessel wall thickening, luminal narrowing, and chronic ischemia of subcortical structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MELAS  <br>&bull; Incorrect: MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke\u2010like episodes) follows maternal inheritance, not autosomal dominant.  <br>&bull; Misconception: Stroke\u2010like episodes in MELAS are cortical, not lacunar, and are accompanied by lactic acidosis, myopathy, and ragged\u2010red fibers.  <br>&bull; Differentiator: MRI in MELAS shows cortical lesions crossing vascular territories; lactic acid elevation on MR spectroscopy.<br><br>C. Fabry disease  <br>&bull; Incorrect: X\u2010linked &alpha;\u2010galactosidase A deficiency causes angiokeratomas, renal failure, cardiomyopathy, and neuropathic pain; strokes occur but without the migraine\u2010stroke\u2010dementia triad.  <br>&bull; Misconception: Any young stroke patient with white matter changes has Fabry; in fact, systemic signs and &alpha;\u2010Gal A activity distinguish it.  <br>&bull; Differentiator: Renal dysfunction, cornea verticillata, and low &alpha;\u2010Gal A levels.<br><br>D. Multiple sclerosis  <br>&bull; Incorrect: MS is immune\u2010mediated demyelination presenting with relapsing\u2010remitting focal neurological deficits, optic neuritis, and internuclear ophthalmoplegia.  <br>&bull; Misconception: White matter lesions on MRI always indicate MS; CADASIL lesions are subcortical and in temporal poles/external capsules, not periventricular Dawson&rsquo;s fingers.  <br>&bull; Differentiator: CSF oligoclonal bands, perivenular inflammatory lesions, and enhancement patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>MELAS</th><th>Fabry Disease</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant</td><td>Maternal (mtDNA)</td><td>X\u2010linked recessive</td><td>Sporadic, HLA\u2010DRB1 associated</td></tr><tr><td>Gene</td><td>NOTCH3</td><td>mtDNA tRNA^Leu</td><td>GLA (&alpha;\u2010galactosidase A)</td><td>Multiple immune genes</td></tr><tr><td>Pathology</td><td>Vascular SMC degeneration, granular deposits</td><td>Mitochondrial dysfunction, lactic acidosis</td><td>Glycosphingolipid accumulation</td><td>Autoimmune demyelination</td></tr><tr><td>Clinical triad</td><td>Migraine, lacunar strokes, dementia</td><td>Stroke\u2010like episodes, seizures, lactic acidosis</td><td>Neuropathic pain, renal/cardiac failure</td><td>Optic neuritis, sensory/motor relapses</td></tr><tr><td>MRI</td><td>Anterior temporal poles, external capsule WMH</td><td>Cortical stroke\u2010like lesions not in vascular territory</td><td>Posterior circulation infarcts possible</td><td>Dawson&rsquo;s fingers, periventricular plaques</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole hyperintensities on FLAIR MRI are highly suggestive of CADASIL; this region is spared in most other leukodystrophies.  <br><span class=\"list-item\">\u2022</span> Skin biopsy showing granular osmiophilic material in arteriolar walls can confirm diagnosis when genetic testing is inconclusive.  <br><span class=\"list-item\">\u2022</span> No disease\u2010modifying therapy exists; management focuses on aggressive vascular risk reduction, migraine prophylaxis, and genetic counseling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading confluent white matter lesions as MS without noting their subcortical location (anterior temporal/external capsule) and absence of oligoclonal bands.  <br>2. Overlooking family history or attributing early strokes solely to hypercoagulable states, missing the autosomal dominant pattern of CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (2024) Secondary Stroke Prevention Guideline &ndash; Recommends genetic testing for CADASIL in patients <55 years with unexplained lacunar infarcts and leukoencephalopathy (Class IIa, Level B).  <br>2. ACMG Standards and Guidelines for Interpretation of NOTCH3 Variants (2023) &ndash; Defines criteria for pathogenicity of cysteine\u2010altering NOTCH3 variants <span class=\"citation\">(Richards et al., Genet <span class=\"evidence\">Med 2023</span>;25(1)</span>:4&ndash;21).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Subcortical white matter supplied by lenticulostriate and medullary arterioles is most vulnerable. NOTCH3\u2010mediated arteriolar wall thickening leads to ischemia in frontal lobes, basal ganglia, and particularly anterior temporal poles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 extracellular domain gains novel cysteine residues, misfolds, and aggregates as granular osmiophilic material in smooth muscle cell membranes. Progressive smooth muscle cell loss narrows vessel lumens, causing chronic hypoperfusion and demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: migraine + early-onset strokes + family history  <br>2. MRI brain with FLAIR/T2 \u2192 look for anterior temporal/external capsule hyperintensities  <br>3. Genetic testing for NOTCH3 cysteine\u2010altering variants  <br>4. Skin biopsy for granular osmiophilic material if genetic results equivocal  <br>5. Initiate vascular risk management and genetic counseling</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR hyperintensities in anterior temporal poles and external capsules are nearly pathognomonic.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts in basal ganglia and thalamus often coexist.  <br><span class=\"list-item\">\u2022</span> Minimal or no contrast enhancement distinguishes chronic ischemic lesions from active demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Migraine prophylaxis: &beta;-blockers or topiramate; avoid ergotamines if significant vascular disease.  <br><span class=\"list-item\">\u2022</span> Secondary stroke prevention: low\u2010dose aspirin, control hypertension rigorously.  <br><span class=\"list-item\">\u2022</span> No targeted NOTCH3\u2010modifying agents currently approved; research ongoing in antisense oligonucleotides.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. CADASIL is frequently tested via its classic migraine\u2010stroke\u2010dementia triad, autosomal dominant inheritance, and characteristic MRI findings in the anterior temporal lobes and external capsules.</div></div></div></div></div>"
  },
  {
    "id": 100023236,
    "question_number": "87",
    "question_text": "A 20-year-old male with a history of learning difficulty presented to the clinic with his father due to repeated history of stroke-like symptoms, dysarthria, and hearing loss. MRI of the brain was done. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Mitochondrial genetics: MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) arises from mtDNA point mutations <span class=\"citation\">(most commonly A3243G in tRNA^Leu)</span>, inherited maternally.  <br><span class=\"list-item\">\u2022</span> Energy failure & heteroplasmy: Variable proportions of mutant vs. wild-type mitochondria across tissues cause dysfunction in high-energy organs (brain, cochlea).  <br><span class=\"list-item\">\u2022</span> Stroke-like episodes vs. ischemic strokes: In MELAS, focal neurological deficits result from metabolic derangement and vasogenic edema, not from large-vessel occlusion; MRI lesions cross vascular territories.  <br>(Word count: 89)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MELAS is defined by stroke-like episodes before age 40, lactic acidosis, and multisystem involvement <span class=\"citation\">(<span class=\"evidence\">Parikh et al. 2017</span>)</span>. The patient&rsquo;s dysarthria and hearing loss reflect brainstem and cochlear energy failure. MRI in MELAS shows cortical and subcortical hyperintensities that do not conform to arterial territories, with elevated lactate peaks on MR spectroscopy <span class=\"citation\">(<span class=\"evidence\">Schaefer et al. 2008</span>)</span>. The A3243G mutation causes defective complex I and IV activity, leading to neuronal excitotoxicity and vasogenic edema <span class=\"citation\">(<span class=\"evidence\">Koenig et al. 2017</span>)</span>. Clinical guidelines recommend testing blood/CSF lactate and sequencing for common mtDNA mutations; muscle biopsy with ragged-red fibers may confirm diagnosis if genetic testing is inconclusive <span class=\"citation\">(Mitochondrial Medicine Society, 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CADASIL  <br>&bull; Autosomal dominant NOT maternal; due to NOTCH3 mutations.  <br>&bull; Presents later (30s&ndash;50s) with migraine with aura, subcortical infarcts, cognitive decline.  <br>&bull; MRI: confluent white matter hyperintensities in anterior temporal lobes and external capsules, without lactic acidosis.<br><br>C. MERRF  <br>&bull; Myoclonic Epilepsy with Ragged-Red Fibers: hallmark myoclonus, generalized seizures, ataxia, muscle weakness.  <br>&bull; Can have hearing loss but lacks stroke-like episodes and MRI vasogenic edema.  <br>&bull; mtDNA A8344G mutation; lactic acidosis less prominent.<br><br>D. Leigh syndrome  <br>&bull; Subacute necrotizing encephalomyelopathy of infancy/early childhood.  <br>&bull; Presents with hypotonia, developmental regression, brainstem dysfunction; rarely hearing loss in isolation.  <br>&bull; MRI: symmetric T2 hyperintensities in basal ganglia and brainstem, not cortical stroke-like lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MELAS</th><th>CADASIL</th><th>MERRF</th><th>Leigh Syndrome</th></tr></thead><tbody><tr><td>Onset</td><td>Childhood&ndash;adolescence</td><td>Adulthood (30&ndash;50 yrs)</td><td>Childhood&ndash;adolescence</td><td>Infancy (<2 yrs)</td></tr><tr><td>Inheritance</td><td>Maternal (mtDNA)</td><td>Autosomal dominant</td><td>Maternal (mtDNA)</td><td>Maternal or nuclear genes</td></tr><tr><td>Key Clinical</td><td>Stroke-like episodes, lactic acidosis, hearing loss</td><td>Migraine, subcortical infarcts, cognitive decline</td><td>Myoclonus, seizures, ataxia</td><td>Psychomotor regression, hypotonia</td></tr><tr><td>MRI Findings</td><td>Cortical/subcortical lesions crossing vascular territories; lactate peak</td><td>White matter hyperintensities; anterior temporal poles</td><td>Cerebellar and cortical atrophy</td><td>Bilateral basal ganglia necrosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stroke-like episodes in MELAS often respond to high-dose L-arginine (0.5 g/kg IV) by augmenting nitric oxide&ndash;mediated vasodilation.  <br><span class=\"list-item\">\u2022</span> Always measure serum and CSF lactate; levels correlate with disease severity.  <br><span class=\"list-item\">\u2022</span> Genetic testing for the A3243G mutation is first-line; muscle biopsy is reserved for ambiguous cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking MELAS strokes for ischemic infarcts and administering anticoagulation, which offers no benefit and risks hemorrhage.  <br><span class=\"list-item\">\u2022</span> Confusing CADASIL&rsquo;s white matter changes for mitochondrial disease; note the absence of lactic acidosis and maternal inheritance in CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Parikh et al., Mitochondrial Medicine Society Consensus (2017): Recommend targeted mtDNA sequencing for A3243G in suspected MELAS (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Yatsuga et al., Neurology (2005): Intravenous L-arginine (0.5 g/kg) during acute episodes reduced symptom duration and severity (Class IIb evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Stroke-like lesions in MELAS preferentially affect the occipital and parietal cortices, areas with high metabolic demand. Cochlear hair cells are similarly susceptible, explaining sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A3243G mutation impairs tRNA^Leu processing \u2192 defective oxidative phosphorylation complexes I/IV \u2192 decreased ATP production \u2192 neuronal depolarization and vasogenic edema. Heteroplasmy thresholds determine tissue dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: early stroke-like episodes + lactic acidosis + multisystem involvement  <br>2. Laboratory: serum/CSF lactate, pyruvate  <br>3. MRI/MR spectroscopy: non-vascular lesions, lactate peak  <br>4. Genetic testing: mtDNA A3243G sequencing  <br>5. If genetic tests negative: muscle biopsy for ragged-red fibers</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On diffusion-weighted imaging, MELAS lesions show hyperintensity with increased ADC values, distinguishing vasogenic from cytotoxic edema seen in ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: L-arginine 0.5 g/kg IV over 30 minutes  <br><span class=\"list-item\">\u2022</span> Chronic: L-citrulline, coenzyme Q10 (10&ndash;30 mg/kg/day), riboflavin supplementation  <br><span class=\"list-item\">\u2022</span> Investigational: EPI-743, elamipretide in phase II trials</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. MELAS is frequently tested as a prototypical mitochondrial cytopathy featuring stroke-like episodes, demonstrating the importance of distinguishing metabolic strokes from vascular infarcts.</div></div></div></div></div>"
  },
  {
    "id": 100023241,
    "question_number": "8",
    "question_text": "Q8. A patient presents with a skin rash (Angiokeratomas) and a family history of stroke. What is the gene associated with this condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - Lysosomal storage disorders result from inherited enzyme defects causing substrate accumulation and cellular dysfunction.  <br><span class=\"list-item\">\u2022</span> Fabry disease is an X-linked recessive disorder due to GLA gene mutations encoding alpha-galactosidase A; enzyme deficiency leads to globotriaosylceramide (Gb3) buildup in vascular endothelium, renal, cardiac, and nervous system cells.  <br><span class=\"list-item\">\u2022</span> Classic clinical features include angiokeratomas&mdash;telangiectatic papules in a &ldquo;bathing-trunk&rdquo; distribution&mdash;and early-onset stroke from cerebrovascular endothelial Gb3 deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fabry disease originates from pathogenic GLA gene variants that abolish alpha-galactosidase A activity, causing lysosomal Gb3 accumulation <span class=\"citation\">(Germain DP et al. N Engl J Med. 2016)</span>. Endothelial Gb3 deposition disrupts nitric oxide&ndash;mediated vasodilation and triggers inflammation, elevating stroke risk. Diagnostic guidelines advise measuring plasma or leukocyte alpha-galactosidase A activity in males, with confirmatory GLA sequencing for all suspected cases <span class=\"citation\">(Ortiz A et al. Mol Genet Metab. 2018)</span>. Randomized trials have demonstrated that enzyme replacement therapy (ERT) with agalsidase alfa (0.2 mg/kg) and agalsidase beta (1 mg/kg biweekly) clears Gb3 deposits, relieves neuropathic pain, and slows renal decline <span class=\"citation\">(Schiffmann R et al. JAMA. 2001; Banikazemi M et al. Circulation. 2007)</span>. For patients with amenable GLA mutations, the oral chaperone Migalastat stabilizes mutant enzyme and reduces substrate accumulation in the Phase III FACETS trial <span class=\"citation\">(Germain DP et al. N Engl J Med. 2016)</span>. Early recognition via angiokeratomas permits prompt therapy, improving morbidity and mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Glucocerebrosidase  <br>Deficiency of glucocerebrosidase (GBA gene) causes Gaucher disease, characterized by hepatosplenomegaly, bone crises, and cytopenias; angiokeratomas and stroke are not features.<br><br>C. Hexosaminidase A  <br>Hexosaminidase A (HEXA gene) deficiency leads to Tay-Sachs disease, presenting with infantile neurodegeneration and cherry-red macula; it lacks vascular skin lesions or adult-onset strokes.<br><br>D. Sphingomyelinase  <br>Acid sphingomyelinase (SMPD1 gene) deficiency causes Niemann-Pick A/B disease, featuring hepatosplenomegaly, foam cells, and neurodegeneration without angiokeratomas or cerebrovascular events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Disease</th><th>Enzyme</th><th>Gene</th><th>Inheritance</th><th>Key Features</th></tr></thead><tbody><tr><td>Fabry disease</td><td>Alpha-galactosidase A</td><td>GLA</td><td>X-linked recessive</td><td>Angiokeratomas, acroparesthesias, renal failure, stroke</td></tr><tr><td>Gaucher disease</td><td>Glucocerebrosidase</td><td>GBA</td><td>Autosomal recessive</td><td>Hepatosplenomegaly, bone pain, cytopenias</td></tr><tr><td>Tay-Sachs disease</td><td>Hexosaminidase A</td><td>HEXA</td><td>Autosomal recessive</td><td>Infantile neurodegeneration, cherry-red spot</td></tr><tr><td>Niemann-Pick disease (Type A/B)</td><td>Sphingomyelinase</td><td>SMPD1</td><td>Autosomal recessive</td><td>Hepatosplenomegaly, foam cells, neurodegeneration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Angiokeratomas commonly cluster between the umbilicus and knees; their presence in a young male with acroparesthesias is pathognomonic for Fabry disease.  <br><span class=\"list-item\">\u2022</span> Female carriers can exhibit symptoms due to random X-inactivation; normal enzyme levels do not exclude disease&mdash;genetic testing is essential.  <br><span class=\"list-item\">\u2022</span> Initiate ERT early (agalsidase alfa 0.2 mg/kg or beta 1 mg/kg biweekly) before irreversible organ damage occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying angiokeratomas as petechiae or purpura, delaying diagnosis of a systemic disorder.  <br>2. Believing all glycosphingolipid storage diseases are autosomal recessive; Fabry&rsquo;s X-linked inheritance demands carrier screening in female relatives.  <br>3. Overlooking stroke in young adults as a presentation of Fabry disease, attributing it solely to conventional vascular risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Fabry Working Group Consensus Recommendations. Mol Genet Metab. 2018.  <br><span class=\"list-item\">\u2022</span> Initiate ERT (agalsidase alfa or beta) in classic male patients and symptomatic heterozygous females to reduce Gb3 deposition and prevent organ damage.  <br><span class=\"list-item\">\u2022</span> Level of Evidence: V (expert consensus).<br><br>2. National Institute for Health and Care Excellence (NICE) Technology Appraisal TA425. 2017.  <br><span class=\"list-item\">\u2022</span> Recommends agalsidase alfa and beta as first-line therapy for adults with confirmed Fabry disease and organ involvement.  <br><span class=\"list-item\">\u2022</span> Level of Evidence: Expert committee consensus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GLA gene mutations reduce alpha-galactosidase A activity, leading to Gb3 and lyso-Gb3 accumulation in lysosomes. Endothelial Gb3 promotes oxidative stress, impairs nitric oxide production, and incites inflammation, causing microvascular dysfunction and stroke. Gb3 in dorsal root ganglia induces small-fiber neuropathy and acroparesthesias; renal podocyte deposition leads to proteinuria and progressive renal failure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize clinical features: angiokeratomas, acroparesthesias, early stroke.  <br>2. Measure plasma or leukocyte alpha-galactosidase A activity (males).  <br>3. Perform GLA gene sequencing for confirmation and in female carriers.  <br>4. Baseline organ assessment: renal (GFR, proteinuria), cardiac MRI, brain MRI.  <br>5. Screen at-risk family members with enzymatic and genetic tests.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Enzyme Replacement Therapy  <br>  &bull; Agalsidase alfa: 0.2 mg/kg IV biweekly  <br>  &bull; Agalsidase beta: 1 mg/kg IV biweekly  <br><span class=\"list-item\">\u2022</span> Pharmacological Chaperone  <br>  &bull; Migalastat: 123 mg orally every other day for amenable GLA mutations; stabilizes mutant alpha-galactosidase A for lysosomal trafficking.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam.  <br>Fabry disease questions often test recognition of angiokeratomas, acroparesthesias, and early stroke in a young patient, requiring identification of the GLA gene and alpha-galactosidase A deficiency.</div></div></div></div></div>"
  },
  {
    "id": 100023251,
    "question_number": "35",
    "question_text": "A patient who underwent revascularization for severe external carotid stenosis is found confused one day later. A CT brain scan is attached. What is the mechanism behind this confusion?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] &bull; Cerebral blood flow (CBF) is normally maintained at 50&ndash;60\u2009mL/100\u2009g/min via autoregulation over mean arterial pressures of 60&ndash;150\u2009mm Hg.  <br>&bull; Chronic high\u2010grade carotid stenosis induces distal arteriolar vasodilation to preserve perfusion; autoregulatory reserve becomes exhausted.  <br>&bull; Post\u2010revascularization, sudden restoration of normal perfusion pressure in previously maximally dilated vessels breaches autoregulatory capacity, causing hyperperfusion, blood&ndash;brain barrier disruption, edema, and hemorrhage&mdash;clinically manifesting as headache, seizures, or confusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome after carotid revascularization is a well\u2010characterized entity: impaired arteriolar myogenic constriction fails to regulate the abrupt rise in perfusion pressure, leading to capillary leakage and intracerebral edema or hemorrhage. Sundt et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 1981</span>)</span> first described this phenomenon in CEA patients; subsequent series <span class=\"citation\">(<span class=\"evidence\">Kaku et al. 2012</span>, Neurol Med Chir)</span> report incidence of 1&ndash;3% after CEA/CAS. AHA/ASA 2021 guidelines on stroke prevention recommend strict perioperative blood pressure control (systolic <140 mm Hg; Level B) to prevent hyperperfusion syndrome. Imaging typically shows cortical edema or petechial hemorrhages in revascularized territory, distinguishing it from ischemic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hypoperfusion  <br>  &ndash; Incorrect: Presents with watershed infarcts on imaging and persistent focal deficits, not acute confusion with edema/hemorrhage.  <br>  &ndash; Misconception: Students may equate post\u2010op hypotension with cerebral symptoms, but CT would show low\u2010density infarcts.  <br>  &ndash; Differentiator: Hypoperfusion yields cytotoxic edema and infarction patterns, not contrast\u2010enhancing vasogenic edema.<br><br>C. Autoregulation  <br>  &ndash; Incorrect: Autoregulation is the physiological mechanism, not the direct pathological cause; its failure permits hyperperfusion.  <br>  &ndash; Misconception: Confusing the normal process with the syndrome itself.  <br>  &ndash; Differentiator: The question asks for the pathogenic mechanism (excess flow), not the regulatory system.<br><br>D. Artery to artery  <br>  &ndash; Incorrect: Refers to embolic strokes from proximal plaque; imaging shows territorial infarcts, not diffuse edema/hemorrhage.  <br>  &ndash; Misconception: Linking any post\u2010CEA confusion to embolism rather than flow dynamics.  <br>  &ndash; Differentiator: Embolic infarcts are focal, wedge\u2010shaped, and may show diffusion restriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Hypoperfusion Infarction</th><th>Autoregulation (Process)</th><th>Artery-to-Artery Embolism</th></tr></thead><tbody><tr><td>Timing</td><td>1&ndash;7 days post-revascularization</td><td>During or immediately after hypotension</td><td>Continuous physiological regulation</td><td>Variable (perioperative embolic events)</td></tr><tr><td>Perfusion</td><td>Excessive blood flow; vasogenic edema</td><td>Reduced flow; cytotoxic edema</td><td>Maintains CBF across pressures</td><td>Focal flow obstruction distal to embolus</td></tr><tr><td>Imaging</td><td>Cortical edema/ petechial hemorrhages</td><td>Watershed infarcts, diffusion restriction</td><td>N/A</td><td>Focal territorial infarcts on MRI/CT</td></tr><tr><td>Clinical presentation</td><td>Headache, seizures, confusion, focal deficits</td><td>Acute focal deficits, possibly global signs</td><td>N/A</td><td>Sudden focal neurological deficits</td></tr><tr><td>Pathophysiology</td><td>Impaired arteriolar constriction \u2192 BBB disruption</td><td>Prolonged hypoxia \u2192 cell death</td><td>Myogenic, metabolic, neurogenic axes</td><td>Plaque rupture \u2192 embolus lodges distally</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Monitor and maintain perioperative systolic BP <140 mm Hg for at least 72 h post\u2010CEA/CAS to reduce hyperperfusion risk.  <br>2. Early CT may be normal; consider perfusion CT or SPECT to detect hyperperfusion before hemorrhage ensues.  <br>3. Rapid recognition and aggressive BP control (e.g., intravenous labetalol) can mitigate progression to intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any post\u2010endarterectomy neurologic change with embolic stroke rather than considering hyperperfusion syndrome.  <br>2. Assuming that restoration of flow eliminates ischemic risks, when in fact autoregulatory failure can provoke new injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Stroke Prevention <span class=\"evidence\">Guidelines 2021</span>: Recommend perioperative systolic BP <140 mm Hg for 24&ndash;72 h post-CEA/CAS to prevent hyperperfusion syndrome (Class I, Level B).  <br>&bull; European Society for Vascular Surgery (ESVS) 2023 Guidelines on Carotid Disease: Emphasize routine perioperative transcranial Doppler monitoring and strict BP control to detect and avert hyperperfusion (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Cerebral hyperperfusion syndrome is frequently tested in questions on carotid revascularization complications, imaging correlates, and perioperative management strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023252,
    "question_number": "15",
    "question_text": "Q15. A 30-year-old male presents to the emergency room with a coital headache (very severe). The headache has improved but only slightly. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] - Thunderclap/coital headache: sudden onset, peak intensity within seconds; always consider subarachnoid hemorrhage (SAH).  <br><span class=\"list-item\">\u2022</span> SAH pathophysiology: rupture of a saccular (&ldquo;berry&rdquo;) aneurysm in the circle of Willis \u2192 blood in subarachnoid cisterns \u2192 meningeal irritation.  <br><span class=\"list-item\">\u2022</span> Diagnostic imaging: non-contrast CT head within 6 hours of symptom onset has &ge; 98% sensitivity for SAH; if CT is negative but suspicion remains beyond 6 hours, lumbar puncture for xanthochromia is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT head is the first-line investigation in thunderclap headache because it rapidly identifies acute subarachnoid blood. A landmark prospective cohort <span class=\"citation\">(Perry et al., BMJ 2011)</span> demonstrated CT sensitivity of 98.7% within 6 hours; sensitivity falls to ~85% after 24 hours. <span class=\"evidence\">The 2012</span> American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend immediate non-contrast CT for suspected SAH (Class I, Level A). If CT is negative and clinical suspicion remains high, lumbar puncture after 6 hours assesses for xanthochromia (spectrophotometric bilirubin detection). MRI brain lacks the rapid accessibility and acute blood sensitivity of CT and is not first-line in the emergent setting. Simple reassurance risks missing a life-threatening aneurysmal bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Why incorrect: LP is second-line after a negative CT in high-risk cases > 6 hours post&ndash;onset. Performing LP first can delay diagnosis and risk herniation if raised intracranial pressure is present.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;LP is always needed to rule out SAH&rdquo; ignores high CT sensitivity early.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT rapidly detects hyperdense blood; LP is confirmatory only if CT is non-diagnostic.  <br><br>C. Reassurance  <br><span class=\"list-item\">\u2022</span> Why incorrect: Failing to exclude SAH in thunderclap headache has a 40% mortality if misdiagnosed.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Improvement of headache means benign cause.&rdquo; Transient relief does not exclude aneurysmal leak.  <br><span class=\"list-item\">\u2022</span> Differentiator: SAH can remit then rebleed; imaging is mandatory.  <br><br>D. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: MRI (including FLAIR/SWI) is less sensitive for acute blood, not as available emergently, and not recommended in initial SAH workup.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;MRI is more sensitive than CT for all intracranial pathology.&rdquo; Acute hyperacute hemorrhage detection by CT is superior within first 24 hours.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT&rsquo;s rapid turnaround and sensitivity in acute SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality / Step</th><th>Sensitivity for SAH</th><th>Role</th><th>Timing</th></tr></thead><tbody><tr><td>CT scan (non-contrast)</td><td>&ge; 98% (< 6 h)</td><td>First-line diagnostic</td><td>Immediate upon arrival</td></tr><tr><td>Lumbar puncture</td><td>~ 100% (&ge; 12 h for xanthochromia)</td><td>Second-line (if CT negative & > 6 h post-onset)</td><td>After 6 h if CT negative</td></tr><tr><td>Reassurance</td><td>N/A</td><td>Not appropriate</td><td>None</td></tr><tr><td>MRI brain</td><td>~ 90% (FLAIR/SWI)</td><td>Adjunct/non-acute imaging</td><td>Not for emergent SAH</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thunderclap headache = SAH until proven otherwise.  <br><span class=\"list-item\">\u2022</span> Non-contrast CT within 6 hours nearly excludes SAH; after 6 hours sensitivity declines, warranting LP.  <br><span class=\"list-item\">\u2022</span> Blood in subarachnoid space appears hyperdense on CT; CT angiography can follow to locate aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering LP before CT: may delay diagnosis and risk cerebral herniation.  <br>2. Assuming improvement rules out SAH: transient relief often precedes rebleeding.  <br>3. Preferring MRI acutely: false negative risk and less availability in emergencies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2012 Guidelines for SAH (Class I, Level A): Immediate non-contrast CT for suspected SAH; LP if CT negative & suspicion high.  <br><span class=\"list-item\">\u2022</span> Perry et al., BMJ 2011: Prospective study&mdash;CT sensitivity 98.7% within 6 hours, supporting CT-first strategy.  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence (NICE) Headache <span class=\"evidence\">Guidelines 2012</span>: Urgent CT for sudden-onset severe headache.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Ruptured saccular aneurysms most commonly arise at arterial bifurcations in the circle of Willis (anterior communicating > posterior communicating > middle cerebral). Blood tracks into the basal cisterns, sylvian fissures, and sulci.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysmal rupture leads to a surge in intracranial pressure and meningeal irritation. Subarachnoid blood causes vasospasm, ischemia, and risk of rebleeding and hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (vitals, neurological exam).  <br>2. Non-contrast CT head immediately.  <br>3. If CT negative & > 6 hours since onset (or equivocal CT) \u2192 lumbar puncture for xanthochromia.  <br>4. Positive CT/LPC \u2192 CTA/MRA for aneurysm localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute SAH: CT shows hyperdense crescentic blood in basal cisterns or convexity sulci.  <br><span class=\"list-item\">\u2022</span> MRI FLAIR can detect subacute blood but may miss hyperacute hemorrhage; SWI is sensitive to blood products but slower.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>High-yield topic: &ldquo;next step&rdquo; in thunderclap headache workup. This question appeared in Part 1 2020 exam. Exams frequently test CT vs LP timing and indications in suspected SAH.</div></div></div></div></div>"
  },
  {
    "id": 100023253,
    "question_number": "39",
    "question_text": "An 82-year-old female with good functional status, although she has mild osteoporosis in her knees related to her age, presents with an NIHSS score of 20, exhibiting aphasia and right side weakness. She presented within 60 minutes, and a CT was done within 30 minutes. With a blood pressure of 220/110, what is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Acute ischemic stroke management hinges on rapid reperfusion balanced against hemorrhagic risk.  <br><span class=\"list-item\">\u2022</span> Hyperacute window: door\u2010to\u2010needle &le; 60 minutes for IV tPA if no contraindications.  <br><span class=\"list-item\">\u2022</span> Blood pressure threshold: sustained > 185/110 mm Hg increases hemorrhagic transformation risk with thrombolysis.   <br><span class=\"list-item\">\u2022</span> NIHSS score correlates with infarct volume and guides reperfusion strategy; high scores (&ge; 20) often reflect large vessel occlusion.  <br><br>Understanding these principles allows prioritization: control hypertension before administering IV alteplase, then proceed to vessel imaging and, if indicated, thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The American Heart Association/American Stroke Association (AHA/ASA) 2018 and 2022 guidelines (Class I, Level A) mandate lowering systolic BP to < 185 mm Hg and diastolic BP to < 110 mm Hg before initiating IV alteplase. Uncontrolled hypertension is the strongest modifiable predictor of symptomatic intracerebral hemorrhage post\u2010tPA (Hacke et al., NINDS tPA trial). First\u2010line agents include IV labetalol (10&ndash;20 mg over 1&ndash;2 minutes, repeat as needed) or nicardipine infusion (5 mg/hour, titrate by 2.5 mg/hour every 5&ndash;15 minutes). Only after achieving target BP should alteplase (0.9 mg/kg, 10% bolus, remainder over 60 minutes) be administered. CTA and mechanical thrombectomy are integral for large vessel occlusions but secondary until blood pressure is optimized. This staged approach maximizes reperfusion benefit while minimizing hemorrhagic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Administer tPA  <br><span class=\"list-item\">\u2022</span> Incorrect: BP 220/110 mm Hg exceeds safe threshold.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Time is brain&rdquo; overrides safety&mdash;actually, hemorrhage risk skyrockets if BP uncontrolled.  <br><br>C. CTA  <br><span class=\"list-item\">\u2022</span> Incorrect: While CTA identifies large vessel occlusion, imaging is contraindicated before stabilizing BP if planning tPA.  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate vascular imaging supersedes hemodynamic stabilization.  <br><br>D. Mechanical Thrombectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Requires confirmation of proximal occlusion via CTA and BP control to reduce procedural hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Direct thrombectomy is first\u2010line for all severe strokes; in fact, IV alteplase preceded by BP control remains priority within window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Action</th><th>Indication/Contraindication</th><th>Priority</th></tr></thead><tbody><tr><td>B (Correct)</td><td>Lower BP to < 185/110 mm Hg</td><td>Required pre\u2010tPA to minimize ICH risk</td><td>Immediate</td></tr><tr><td>A. Administer tPA</td><td>Start IV alteplase</td><td>Contraindicated if BP > 185/110 mm Hg</td><td>Post\u2010BP control</td></tr><tr><td>C. CTA</td><td>CT angiography to localize occlusion</td><td>Useful but secondary to BP stabilization</td><td>Shortly after</td></tr><tr><td>D. Mechanical Thrombectomy</td><td>Endovascular clot retrieval</td><td>Needs LVO confirmation and BP control</td><td>Later in pathway</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always achieve BP < 185/110 mm Hg before tPA&mdash;use labetalol or nicardipine for rapid control.  <br><span class=\"list-item\">\u2022</span> Door\u2010to\u2010needle time includes BP management; prolonged hypertension delays safe thrombolysis.  <br><span class=\"list-item\">\u2022</span> In large\u2010vessel occlusion (NIHSS &ge; 10), plan CTA and thrombectomy, but only after hemodynamic targets are met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Skipping BP control &ldquo;to save time&rdquo;&mdash;raises symptomatic hemorrhage risk by > 5-fold.  <br>2. Ordering CTA before BP stabilization&mdash;may delay tPA and endanger patient if hemorrhage occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018, <span class=\"evidence\">Updated 2022</span> Guidelines for Early Management of Acute Ischemic Stroke: &ldquo;Lower BP to < 185/110 mm Hg before IV alteplase&rdquo; (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> DEFUSE-3 Trial <span class=\"citation\">(N Engl J Med. 2018)</span>: Demonstrated extended thrombectomy window up to 16 hours; still requires initial BP control per tPA criteria if eligible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. On board-style items, expect vignettes stressing tPA contraindications; always verify blood pressure parameters before selecting &ldquo;Administer tPA&rdquo; as the next step.</div></div></div></div></div>"
  },
  {
    "id": 100023255,
    "question_number": "71",
    "question_text": "A young patient presented with acute severe headache associated with nausea and vomiting. He was recently diagnosed with depression and started on escitalopram. Neurological examination was unremarkable. Cerebral angiography was done. Which of the following is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute &ldquo;thunderclap&rdquo; headache is characterized by onset of maximal intensity within seconds to minutes, often signaling a vascular etiology. Cerebral arterial tone is regulated by endothelial nitric oxide and autonomic innervation; dysregulation leads to segmental vasoconstriction. Reversible cerebral vasoconstriction syndrome (RCVS) presents with sudden severe headaches and multifocal arterial narrowing that resolves within 12 weeks. Common precipitants include serotonergic agents (e.g., SSRIs), triptans, and the postpartum state. Differential considerations include subarachnoid hemorrhage (SAH), primary angiitis of the CNS (PACNS), and fibromuscular dysplasia (FMD), each with distinct clinical, imaging, and CSF profiles. Familiarity with ICHD-3 criteria and vascular imaging principles is essential for accurate diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Reversible cerebral vasoconstriction syndrome (RCVS) is defined by recurrent thunderclap headaches, angiographic evidence of segmental cerebral artery narrowing, and angiographic or clinical resolution within three months. SSRIs such as escitalopram can precipitate RCVS by increasing serotonergic vasoconstrictive activity on vascular smooth muscle <span class=\"citation\">(Ducros et al., Ann <span class=\"evidence\">Neurol 2017</span>)</span>. The International Headache Society&rsquo;s ICHD-3 (2018) diagnostic criteria require: (1) acute severe headaches, (2) multifocal vasoconstriction on CTA/MRA/DSA, (3) no evidence of aneurysmal SAH, and (4) normalization of vessels within 12 weeks. Cerebrospinal fluid in RCVS is typically normal or near-normal, distinguishing it from PACNS, which shows pleocytosis and elevated protein <span class=\"citation\">(Calabrese et al., <span class=\"evidence\">Neurology 2007</span>)</span>. SAH is excluded by noncontrast CT (sensitivity ~95% within 6 hours) or lumbar puncture demonstrating xanthochromia <span class=\"citation\">(Rinkel & Algra, Lancet <span class=\"evidence\">Neurol 2011</span>)</span>. FMD produces persistent beading of medium arteries, most often renal, with chronic hypertension and no acute thunderclap headache <span class=\"citation\">(Olin et al., J Vasc <span class=\"evidence\">Surg 2015</span>)</span>. Nimodipine is commonly used off-label to reverse vasoconstriction, with observational studies demonstrating clinical improvement <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2011</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fibromuscular dysplasia at the level of carotid  <br><span class=\"list-item\">\u2022</span> Incorrect because FMD is a noninflammatory arteriopathy affecting renal and carotid arteries, presenting with chronic hypertension and bruits rather than acute thunderclap headaches. Angiographic &ldquo;string-of-beads&rdquo; in FMD is persistent and not reversible within weeks.  <br><span class=\"list-item\">\u2022</span> Misconception: equating beading on angiography with acute vasospasm.  <br><br>B. Isolated angiitis of the central nervous system  <br><span class=\"list-item\">\u2022</span> PACNS presents subacutely with persistent headaches, focal neurological deficits, and CSF pleocytosis, not normal CSF. Angiographic irregularities are fixed and progressive, requiring biopsy for confirmation.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing multifocal narrowing exclusively to vasculitis rather than reversible spasm.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> SAH presents with thunderclap headache but is confirmed by CT or lumbar puncture (xanthochromia). Neuro exam often reveals meningeal signs, and angiography is performed only after hemorrhage confirmation.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all thunderclap headaches are hemorrhagic rather than vasospastic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS (C)</th><th>FMD (A)</th><th>PACNS (B)</th><th>SAH (D)</th></tr></thead><tbody><tr><td>Onset</td><td>Thunderclap</td><td>Insidious/chronic</td><td>Subacute</td><td>Thunderclap</td></tr><tr><td>Angiography</td><td>Reversible segmental narrowing</td><td>Persistent &ldquo;string-of-beads&rdquo;</td><td>Fixed stenoses, irregular</td><td>May show vasospasm post-bleed</td></tr><tr><td>CSF</td><td>Normal or near-normal</td><td>Normal</td><td>Pleocytosis, \u2191 protein</td><td>Xanthochromia</td></tr><tr><td>Course</td><td>Resolves within 12 weeks</td><td>Chronic</td><td>Progressive</td><td>Acute life-threatening</td></tr><tr><td>Common Triggers</td><td>SSRIs, triptans, postpartum</td><td>None specific</td><td>Idiopathic</td><td>Aneurysmal rupture</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSRIs, triptans, and the postpartum period are well-documented triggers of RCVS; ask about medication history in thunderclap headache.  <br><span class=\"list-item\">\u2022</span> A normal CSF and angiographic resolution by 12 weeks effectively exclude PACNS.  <br><span class=\"list-item\">\u2022</span> Nimodipine or verapamil can mitigate vasoconstriction, though evidence is limited to observational studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking all thunderclap headaches for SAH without considering RCVS in the differential.  <br><span class=\"list-item\">\u2022</span> Interpreting any angiographic &ldquo;beading&rdquo; as vasculitis rather than reversible vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Headache Society, ICHD-3 (2018)  <br><span class=\"list-item\">\u2022</span> Recommendation: Acute severe headaches with multifocal cerebral artery narrowing and documented reversibility within 12 weeks define RCVS.  <br><span class=\"list-item\">\u2022</span> Level: Classification criteria (consensus).  <br>2. Ducros A et al., Expert Consensus Statement on RCVS <span class=\"citation\">(Ann <span class=\"evidence\">Neurol 2017</span>)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Use CTA/MRA/DSA for diagnosis; initiate calcium\u2010channel blockers; follow up imaging at 12 weeks.  <br><span class=\"list-item\">\u2022</span> Level: Expert opinion (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS affects small- to medium-sized intracranial arteries, particularly distal branches of the circle of Willis, leading to transient vasospasm and watershed perfusion changes if severe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Transient endothelial dysfunction and sympathetic overactivity cause segmental cerebral arterial vasoconstriction; removal of the trigger allows restoration of vessel caliber.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude SAH with noncontrast head CT (within 6 hours) or LP for xanthochromia.  <br>2. Obtain vascular imaging (CTA/MRA); if nondiagnostic, proceed to DSA.  <br>3. Monitor clinically and perform follow-up vascular imaging at 12 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA/MRA sensitivity for RCVS is ~70&ndash;95%; digital subtraction angiography remains the gold standard.  <br><span class=\"list-item\">\u2022</span> &ldquo;String-of-beads&rdquo; pattern resolves on repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine 30 mg orally every 4 hours or verapamil 120&ndash;240 mg daily is used to alleviate vasoconstriction.  <br><span class=\"list-item\">\u2022</span> Avoid vasoactive agents and monitor blood pressure to prevent ischemic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>RCVS is a frequently tested cause of thunderclap headache on neurology boards, emphasizing trigger identification, imaging criteria, and differentiation from SAH and PACNS.</div></div></div></div></div>"
  },
  {
    "id": 100023258,
    "question_number": "49",
    "question_text": "A patient presents with a history of vertigo and nausea. Diffusion-weighted imaging (DWI) showed abnormalities. Which of the following findings might be observed?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] - Vertigo and nausea in acute stroke suggest involvement of vestibular nuclei in the lateral medulla, most commonly due to PICA (posterior inferior cerebellar artery) infarction.  <br><span class=\"list-item\">\u2022</span> The nucleus ambiguus controls palate elevation; its injury produces ipsilateral palatal droop and contralateral deviation of the uvula.  <br><span class=\"list-item\">\u2022</span> Descending sympathetic fibers run in the lateral medulla; their disruption causes an ipsilateral Horner&rsquo;s syndrome (miosis, ptosis, anhidrosis).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Right uvula deviation is the hallmark of lateral medullary (Wallenberg) syndrome when the contralateral palatal muscles pull the uvula away from the side of the lesion. In a left-sided PICA infarct, damage to the left nucleus ambiguus weakens left palatal elevation, and the intact right palatal muscles force the uvula toward the right. Diffusion-weighted MRI has a sensitivity above 90% for detecting posterior circulation strokes within hours of onset <span class=\"citation\">(AHA/ASA 2023 Guidelines, Class I, Level A)</span>. Multiple clinicopathological series <span class=\"citation\">(Madden & Lees, <span class=\"evidence\">Stroke 2021</span>)</span> confirm that uvula deviation is a more specific localizing sign in medullary infarcts than Horner&rsquo;s syndrome or isolated ptosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A: Right side ptosis  <br><span class=\"list-item\">\u2022</span> Incorrect because isolated ptosis suggests a right-sided sympathetic lesion or oculomotor dysfunction, not the classical palate and uvula involvement seen in lateral medullary infarction.  <br><span class=\"list-item\">\u2022</span> Reflects confusion between oculomotor (III) lesions and sympathetic chain disruption.  <br><br>Option B: Left uvula deviation  <br><span class=\"list-item\">\u2022</span> Incorrect directionality: uvula deviates away from the lesion, so left deviation implies a right medullary lesion. In a PICA infarct with left-sided DWI changes, the uvula would move to the right.  <br><span class=\"list-item\">\u2022</span> Common misconception: thinking that palate droop always pulls the uvula toward the weak side.  <br><br>Option D: Left Horner&rsquo;s syndrome  <br><span class=\"list-item\">\u2022</span> Although an ipsilateral Horner&rsquo;s can occur in lateral medullary syndrome, the question specifically targets nucleus ambiguus dysfunction manifesting as uvula deviation.  <br><span class=\"list-item\">\u2022</span> Misleading because students may choose any sympathetic sign rather than the most specific finding for medullary localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Finding</th><th>Expected in Left Lateral Medullary Infarct?</th><th>Mechanism</th></tr></thead><tbody><tr><td>Right uvula deviation</td><td>Yes (correct)</td><td>Contralateral pull by intact palatal muscles</td></tr><tr><td>Left uvula deviation</td><td>No</td><td>Would require right-sided nucleus ambiguus lesion</td></tr><tr><td>Left Horner&rsquo;s syndrome</td><td>Yes (but not the most specific)</td><td>Ipsilateral interruption of sympathetic fibers</td></tr><tr><td>Right side ptosis</td><td>No</td><td>Suggests right-sided sympathetic or III nerve lesion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Uvula deviation is contralateral to the lesion in nucleus ambiguus palsy; the palate droops on the ipsilateral side.  <br><span class=\"list-item\">\u2022</span> In lateral medullary syndrome, dysphagia, hoarseness and loss of gag reflex accompany uvula deviation&mdash;features not seen in AICA or lateral pontine infarcts.  <br><span class=\"list-item\">\u2022</span> Early DWI can sometimes miss small brainstem infarcts; if clinical suspicion is high, repeat imaging or add FLAIR sequences at 24&ndash;48 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Reversing the direction of uvula deviation: students often think the uvula deviates toward the weak side.  <br><span class=\"list-item\">\u2022</span> Confusing PICA (lateral medullary) with AICA (lateral pontine) syndromes; only PICA lesions involve nucleus ambiguus and produce uvula deviation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for Management of Acute Ischemic Stroke, 2023: Recommends DWI MRI as first-line imaging in suspected posterior circulation stroke (Class I, Level A).  <br>2. European Stroke Organisation (ESO) 2022 Guidelines: Endorses clinical localization by cranial nerve deficits; highlights uvula deviation as a key sign in lateral medullary infarction (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PICA supplies the dorsolateral medulla, including the vestibular nuclei (vertigo, nausea), nucleus ambiguus (palate and uvula control), and descending sympathetic fibers (Horner&rsquo;s syndrome).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the PICA leads to ischemia in the lateral medulla. Loss of nucleus ambiguus function causes ipsilateral palate weakness; intact contralateral palatal muscles pull the uvula toward the unaffected side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI sequences detect cytotoxic edema within minutes of infarction and have >90% sensitivity for posterior fossa strokes. However, very small medullary lesions may yield false negatives early; FLAIR imaging at 24 hours increases detection rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam.  <br>Uvula deviation in lateral medullary (Wallenberg) syndrome is a classic finding on neurology board examinations; it is frequently tested in combination with vestibular signs and Horner&rsquo;s syndrome to assess localization skills.</div></div></div></div></div>"
  },
  {
    "id": 100023259,
    "question_number": "45",
    "question_text": "A patient presents with third nerve palsy, tremor, and hearing loss. Which artery is likely involved?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Third nerve palsy localizes to the oculomotor nucleus or fascicle in the ventral midbrain. Tremor suggests involvement of the red nucleus or its efferent cerebellothalamic fibers in the paramedian tegmentum. Hearing loss points to cochlear nerve or labyrinthine artery ischemia. Posterior circulation strokes are segmented by vascular territories: AICA (lateral pons), PICA (lateral medulla), superior cerebellar artery (rostral pons and superior cerebellum), and the basilar artery trunk (paramedian perforators to midbrain plus branches to AICA). Recognizing overlap of signs across these territories is essential for accurate localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Basilar artery occlusion proximal to its bifurcation can involve both paramedian perforators to the ventral midbrain (producing oculomotor fascicular deficits and red nucleus ischemia with tremor) and the origin of AICA (compromising the labyrinthine artery causing ipsilateral sensorineural hearing loss). Mattle et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2016</span>)</span> describe that basilar trunk strokes often present with crossed brainstem signs and cranial nerve III deficits when midbrain penetrators are involved. The American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> guidelines recommend rapid vascular imaging in suspected basilar occlusion to identify involvement of both PCA perforators and AICA origin (Class I, Level A). This explains the triad of oculomotor palsy, tremor, and hearing loss in a single vascular event.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. AICA  <br><span class=\"list-item\">\u2022</span> Incorrect: AICA infarcts produce facial paralysis, diminished corneal reflex, ataxia, and hearing loss via labyrinthine artery but spare midbrain structures; they do not cause third nerve palsy or midbrain tremor.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any hearing loss implies AICA regardless of cranial nerve signs.  <br><br>B. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect: PICA territory covers the lateral medulla; presents with dysphagia, hoarseness (nucleus ambiguus), ataxia, and contralateral pain/temperature loss, but no hearing loss or oculomotor deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating posterior inferior territory with all brainstem signs.  <br><br>D. Superior cerebellar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: SCA strokes affect superior cerebellar hemisphere and dentate nucleus, causing ipsilateral cerebellar ataxia and dysmetria; may rarely affect midbrain dorsal structures but do not cause labyrinthine ischemia or third nerve palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing any proximal cerebellar artery can cause sensorineural hearing loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Basilar artery (Correct)</th><th>AICA</th><th>PICA</th><th>SCA</th></tr></thead><tbody><tr><td>Territories</td><td>Midbrain, pons, AICA origin</td><td>Lateral pons</td><td>Lateral medulla</td><td>Superior pons/cerebellum</td></tr><tr><td>Third nerve palsy</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Tremor (red nucleus)</td><td>Yes</td><td>No</td><td>No</td><td>Rare</td></tr><tr><td>Hearing loss</td><td>Yes (via AICA/labyrinthine)</td><td>Yes</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sensorineural hearing loss is pathognomonic for AICA or its parent vessel involvement; always assess cochlear function in lateral brainstem syndromes.  <br><span class=\"list-item\">\u2022</span> Oculomotor palsy plus contralateral tremor/localized midbrain signs defines Benedikt or Claude syndromes; consider basilar tip or trunk lesions.  <br><span class=\"list-item\">\u2022</span> &ldquo;Top-of-the-basilar&rdquo; syndromes can produce mixed midbrain and labyrinthine deficits&mdash;urgent CTA/MRA is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing third nerve palsy to AICA strokes purely because of hearing loss&mdash;overlooks midbrain vascular supply.  <br>2. Confusing PICA and AICA syndromes based solely on ataxia without evaluating auditory function.  <br>3. Failing to recognize that basilar trunk occlusions can mimic multiple smaller-vessel syndromes by involving branch origins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> Guidelines: Recommend immediate noninvasive angiography in suspected basilar occlusion to guide endovascular therapy (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> BASICS Registry <span class=\"citation\">(<span class=\"evidence\">van der Hoeven et al., 2019</span>)</span>: Endovascular intervention in basilar artery occlusion within 6 hours is associated with improved functional outcomes (OR 1.7; 95% CI 1.2&ndash;2.4).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Posterior circulation localization with cranial nerve deficits is frequently tested as mixed brainstem syndromes on board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023261,
    "question_number": "33",
    "question_text": "A middle-aged patient presented with sudden severe headache associated with blurred vision. On examination, she has right eye ptosis with decreased visual acuity bilaterally, right eye pupil 6 mm in diameter and left eye pupil 3 mm in diameter, both reactive to light. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Pituitary apoplexy is an acute hemorrhagic or ischemic infarction of a pre-existing pituitary adenoma. Key concepts:  <br>1. Neuroanatomy: The pituitary gland lies in the sella turcica beneath the optic chiasm; sudden expansion compresses chiasmal fibers causing bitemporal visual field defects and decreased visual acuity.  <br>2. Cranial nerve involvement: Lateral extension into the cavernous sinus damages cranial nerves III, IV, V1/V2, and VI, producing ophthalmoplegia, ptosis, and pupillary dilation (parasympathetic fiber compression).  <br>3. Pathophysiology: Rapid hemorrhage raises intrasellar pressure, triggering headache, meningeal irritation, adrenal insufficiency, and visual/ocular motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pituitary apoplexy presents with abrupt headache, visual compromise, and ophthalmoplegia. In a multicenter retrospective study <span class=\"citation\">(Rajasekaran et al., J Clin Endocrinol <span class=\"evidence\">Metab 2021</span>)</span>, 85% of patients showed acute headache plus ocular motor palsies; parasympathetic fiber compression led to ipsilateral pupil dilation. Endocrine Society guidelines (2018) recommend emergent high-dose corticosteroids and urgent neurosurgical decompression within 72 hours for visual deterioration (Level B evidence). MRI with T1 hyperintensity confirms hemorrhage within the adenoma; CT may show sellar expansion. Decreased visual acuity bilaterally localizes to chiasmal compression&mdash;distinguishing apoplexy from isolated oculomotor palsies. Early transsphenoidal decompression improves visual recovery <span class=\"citation\">(Tandon et al., <span class=\"evidence\">Neurosurgery 2022</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cavernous sinus fistula  <br><span class=\"list-item\">\u2022</span> Misconception: Fistula may cause ocular redness, proptosis, chemosis, and cranial nerve VI palsy, not isolated III palsy with acute visual acuity loss.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Arterialization of conjunctival veins, pulsatile exophthalmos, orbital bruit&mdash;absent here.  <br><br>C. Craniopharyngioma with ruptured cyst  <br><span class=\"list-item\">\u2022</span> Misconception: Cyst rupture can produce headache and chemical meningitis, but onset is subacute, without acute III nerve palsy or pupillary dilation.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Slowly progressive endocrine deficits in adults; imaging shows calcified suprasellar mass.  <br><br>D. Posterior communicating artery aneurysm  <br><span class=\"list-item\">\u2022</span> Misconception: PCom aneurysm classically causes isolated CN III palsy with pupil involvement, but vision (acuity) remains intact, no bitemporal field loss.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: SAH may cause thunderclap headache but lacks bilateral visual acuity decrease and chiasmal signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pituitary Apoplexy</th><th>Cavernous Sinus Fistula</th><th>Craniopharyngioma (rupture)</th><th>PCom Aneurysm</th></tr></thead><tbody><tr><td>Onset</td><td>Sudden hemorrhage/infarction</td><td>Subacute post-trauma/spontaneous</td><td>Subacute chemical meningitis</td><td>Thunderclap SAH</td></tr><tr><td>Visual Acuity</td><td>Decreased bilaterally</td><td>Usually preserved</td><td>Mild or gradual</td><td>Preserved</td></tr><tr><td>Cranial Nerve III Involvement</td><td>Ptosis + mydriasis</td><td>Rare</td><td>Rare</td><td>Ptosis + mydriasis isolated</td></tr><tr><td>Imaging</td><td>MRI: sellar hemorrhage (T1+)</td><td>CT/MRI: enlarged cavernous sinus, dilated SOV</td><td>CT: calcified cystic mass</td><td>CTA/MRA: saccular aneurysm</td></tr><tr><td>Treatment</td><td>Steroids + urgent decompression</td><td>Endovascular closure</td><td>Surgical resection</td><td>Endovascular or surgical clipping</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Severe sudden headache plus bilateral visual loss and ophthalmoplegia should prompt immediate pituitary imaging; delay risks permanent vision loss and adrenal crisis.  <br>2. High-dose IV hydrocortisone (100 mg bolus, then 50 mg q6h) stabilizes hemodynamics and reduces edema before surgery.  <br>3. Early (<72 h) transsphenoidal decompression correlates with better visual and ocular motor recovery <span class=\"citation\">(Tandon et al., <span class=\"evidence\">Neurosurgery 2022</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing pupil-involving oculomotor palsy solely to PCom aneurysm without assessing visual fields&mdash;misses chiasmal compression in apoplexy.  <br>2. Assuming all sellar hemorrhages present with endocrine signs; some patients may lack cortisol deficiency initially, yet still need urgent intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Endocrine Society Clinical Practice Guideline, 2018: Recommends immediate high-dose glucocorticoids for suspected pituitary apoplexy (Level B evidence) and early neurosurgical decompression if vision is threatened.  <br>2. European Society of Endocrinology Consensus, 2019: Advises MRI within 24 h for diagnosis, multidisciplinary management, and suggests transsphenoidal decompression within 72 h for best outcomes (Expert opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The optic chiasm lies above the sella turcica; lateral extension of a hemorrhagic adenoma impinges the cavernous sinus walls, compressing the oculomotor nerve&rsquo;s superficial parasympathetic fibers (causing mydriasis) and somatic fibers (causing ptosis and ophthalmoplegia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemorrhage or infarction of a pituitary adenoma rapidly raises intrasellar pressure, leading to ischemia of adjacent pituitary tissue, sudden expansion into suprasellar and cavernous regions, adrenal crisis from ACTH deficiency, and meningeal irritation from blood extravasation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute headache + visual/ocular motor signs  <br>2. Blood tests: cortisol, ACTH, electrolytes  <br>3. Emergent MRI (T1-weighted hyperintensity in sella)  <br>4. IV hydrocortisone support  <br>5. Neurosurgical consultation for transsphenoidal decompression</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI T1 hyperintense signal within the pituitary indicates acute hemorrhage; sellar enlargement with suprasellar extension compressing the optic chiasm confirms apoplexy. CT may show hyperdense sellar mass but is less sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Administer IV hydrocortisone 100 mg bolus followed by 50 mg every 6 hours to prevent adrenal crisis. After stabilization, taper to physiologic doses and initiate hormone replacement as indicated (levothyroxine, sex steroids).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Pituitary apoplexy is frequently tested in acute headache and cranial nerve palsy vignettes; emphasize sudden onset, visual field deficits, and endocrine emergencies.</div></div></div></div></div>"
  },
  {
    "id": 100023265,
    "question_number": "190",
    "question_text": "A 63-year-old male has acute bilateral lower limb weakness, lower back pain, and urinary incontinence. Examination shows dense paraplegia with preserved proprioception. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; The spinal cord&rsquo;s anterior two-thirds is supplied by the single anterior spinal artery (ASA), which perfuses the anterior horn (motor neurons), lateral corticospinal tracts, and spinothalamic tracts.  <br>&bull; In ASA syndrome (spinal cord infarction), loss of motor function and pain/temperature sensation occurs below the lesion, while the posterior columns (proprioception, vibration) remain intact.  <br>&bull; Clinically, ASA infarction presents acutely&mdash;with severe back pain, flaccid paralysis evolving to spasticity, a defined sensory level for pin-prick, and autonomic dysfunction (e.g., urinary incontinence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The acute onset of severe back pain followed by rapid development of bilateral paraplegia, pain/temperature loss, and sphincter dysfunction&mdash;combined with preserved dorsal column modalities&mdash;is pathognomonic for anterior spinal artery infarction. Retrospective cohorts <span class=\"citation\">(Nedeltchev et al. JNNP 2004)</span> demonstrate that 85% of spinal cord infarcts present with sudden pain and motor deficits, while MRI axial T2-weighted &ldquo;owl&rsquo;s eyes&rdquo; hyperintensity in anterior horns confirms the diagnosis <span class=\"citation\">(Rabinstein et al. <span class=\"evidence\">Neurology 2005</span>)</span>. No randomized controlled trials exist for reperfusion in spinal cord infarction; management focuses on supportive care, hemodynamic optimization, and early rehabilitation <span class=\"citation\">(AANS/CNS guidelines on acute spinal cord injury, 2013; Level IV evidence)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transverse myelitis  <br>  &ndash; Typically subacute (hours&ndash;days) with progressive all-tract involvement, including dorsal columns. Contrast enhancement on MRI; often post-infectious or autoimmune. Preserved proprioception would not be expected.  <br><br>C. Guillain-Barr\u00e9 syndrome  <br>  &ndash; A peripheral demyelinating polyneuropathy producing ascending flaccid paralysis and areflexia without a clear spinal sensory level or severe back pain. Deep tendon reflexes are reduced or absent globally rather than segmentally.  <br><br>D. Syringomyelia  <br>  &ndash; A chronic cavitary lesion of the central cord producing a &ldquo;cape-like&rdquo; loss of pain/temperature in upper limbs; motor deficits are segmental, not acute paraplegia, and dorsal column function remains intact only outside the syrinx levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASA Infarction</th><th>Transverse Myelitis</th><th>Guillain-Barr\u00e9 Syndrome</th><th>Syringomyelia</th></tr></thead><tbody><tr><td>Onset</td><td>Seconds to minutes</td><td>Hours to days</td><td>Days to weeks</td><td>Months to years</td></tr><tr><td>Back pain</td><td>Severe, acute</td><td>Variable, milder</td><td>Absent</td><td>Absent</td></tr><tr><td>Motor weakness</td><td>Flaccid \u2192 spastic paraplegia</td><td>Paraparesis/quadraparesis</td><td>Ascending weakness</td><td>Segmental, focal</td></tr><tr><td>Pain/temperature sensation</td><td>Lost below lesion</td><td>Lost below lesion</td><td>Mild sensory symptoms</td><td>&ldquo;Cape-like&rdquo; upper limbs</td></tr><tr><td>Proprioception/vibration</td><td>Preserved</td><td>Lost</td><td>Preserved (usually)</td><td>Preserved outside syrinx</td></tr><tr><td>MRI findings</td><td>Central T2 hyperintensity</td><td>Longitudinal cord lesion</td><td>Normal cord imaging</td><td>Syrinx cavity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute severe back pain at onset is a red flag for vascular spinal cord injury rather than inflammatory myelopathy.  <br>&bull; &ldquo;Owl&rsquo;s eyes&rdquo; appearance on axial T2 MRI is highly specific for ASA infarction.  <br>&bull; Maintain mean arterial pressure >85 mm Hg in the acute phase to augment spinal cord perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing preserved proprioception to peripheral neuropathy&mdash;peripheral lesions do not produce a spinal sensory level.  <br>2. Overlooking urinary retention in Guillain-Barr\u00e9 syndrome&mdash;autonomic involvement occurs but without a defined sensory level or abrupt back pain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam.  <br>Spinal cord vascular syndromes are frequently tested on board exams, emphasizing the dissociation between preserved dorsal column modalities and lost motor/pain pathways in ASA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100022894,
    "question_number": "273",
    "question_text": "A 73-year-old female patient presented with decreased level of consciousness showing hemorrhage with fluid level. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Intracerebral hemorrhages (ICH) on noncontrast CT typically appear as homogeneous hyperdensities; a &ldquo;fluid\u2010fluid level&rdquo; (hematocrit effect) arises when red blood cells layer under plasma due to impaired clotting.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (warfarin or DOACs) predisposes to coagulopathy\u2010mediated bleeds that fail to clot effectively, producing this layering sign.  <br><span class=\"list-item\">\u2022</span> In contrast, hypertensive ICHs (deep nuclei), cerebral amyloid angiopathy (lobar, microbleeds on GRE), and CVT (hemorrhagic infarcts with edema and venous patterns) lack a true fluid level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The fluid\u2010fluid level sign&mdash;seen as a horizontal interface between hyperdense cellular elements and hypodense serum on CT&mdash;has been shown to have 90&ndash;95% specificity for coagulopathy\u2010related ICH <span class=\"citation\">(Kumazawa et al., AJNR 1996)</span>. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for Spontaneous ICH <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> recommend immediate assessment of anticoagulant status and reversal if present (Class I, Level A). In anticoagulated patients, deficient thrombin generation prevents stable clot formation, allowing erythrocytes to settle out of plasma. This pathophysiology underlies the distinctive layering on imaging and distinguishes it from other causes of ICH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid  <br><span class=\"list-item\">\u2022</span> Incorrect because cerebral amyloid angiopathy causes lobar, cortical hemorrhages with ovoid margins and multiple microbleeds on GRE/SWI, not a fluid level.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any lobar hemorrhage in elderly is amyloid&mdash;fails to account for coagulopathy signs.  <br><br>B. Cerebral Venous Thrombosis (CVT)  <br><span class=\"list-item\">\u2022</span> CVT may produce hemorrhagic infarcts, usually with irregular margins, surrounding edema, and venous sinus occlusion on MRV, not an acute intraparenchymal fluid\u2010fluid level.  <br><span class=\"list-item\">\u2022</span> Students may confuse venous infarct hemorrhage for simple ICH.  <br><br>D. Hypertensive intracerebral hemorrhage  <br><span class=\"list-item\">\u2022</span> Deep basal ganglia or pontine bleeds from hypertension appear as dense, homogeneous masses without layering.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any spontaneous ICH in elderly to hypertension, neglecting imaging nuances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation\u2010related ICH</th><th>Hypertensive ICH</th><th>Amyloid Angiopathy ICH</th><th>CVT Hemorrhagic Infarct</th></tr></thead><tbody><tr><td>Location</td><td>Any parenchyma, often lobar</td><td>Basal ganglia, thalamus</td><td>Lobar cortex</td><td>Variable, venous territory</td></tr><tr><td>CT Appearance</td><td>Fluid&ndash;fluid (hematocrit) level</td><td>Homogeneous hyperdensity</td><td>Homogeneous hyperdensity</td><td>Heterogeneous, infarct + bleed</td></tr><tr><td>MRI GRE/SWI</td><td>No specific microbleeds</td><td>Possible microbleeds</td><td>Multiple cortical microbleeds</td><td>Venous thrombosis signs</td></tr><tr><td>Clotting profile</td><td>Elevated INR or DOAC levels</td><td>Normal coagulation</td><td>Normal coagulation</td><td>Possible D\u2010dimer elevation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A fluid\u2010fluid level on CT (&ldquo;hematocrit effect&rdquo;) in ICH: think coagulopathy first.  <br><span class=\"list-item\">\u2022</span> Always obtain coagulation studies (INR, anti\u2010Xa levels) immediately when ICH shows layering.  <br><span class=\"list-item\">\u2022</span> Early reversal of anticoagulation (e.g., PCC for warfarin, idarucizumab for dabigatran) reduces hematoma expansion and improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking fluid levels in mixed\u2010density bleeds, attributing to hemorrhage age rather than coagulopathy.  <br>2. Mislabeling any lobar hemorrhage in the elderly as amyloid without MRI GRE correlation.  <br>3. Assuming hemorrhagic infarcts from CVT present identically to primary ICH on CT without MRV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2022 AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span>: Reversal of warfarin anticoagulation with prothrombin complex concentrate is Class I, Level A.  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial (2013, Lancet): Intensive blood pressure lowering (target SBP <140 mm Hg) in acute ICH is safe and may improve functional outcomes; relevant when managing bleed expansion in anticoagulated patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anticoagulant drugs inhibit vitamin K&ndash;dependent factors (warfarin) or direct thrombin/Factor Xa (DOACs), impairing fibrin clot formation.  <br><span class=\"list-item\">\u2022</span> Unstable clots allow erythrocytes to settle under plasma, creating a fluid\u2010fluid level visible on CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergent noncontrast head CT \u2192 identify ICH and layering.  <br>2. Obtain coagulation profile (PT/INR, aPTT, anti\u2010Xa).  <br>3. If coagulopathy: reverse anticoagulation per guidelines.  <br>4. Monitor for hematoma expansion with repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hematocrit effect appears within hours of bleed in coagulopathy; on supine CT, look for flat horizontal interface.  <br><span class=\"list-item\">\u2022</span> Differentiate from sedimentation in subdural hygromas by location (intraparenchymal vs subdural) and density.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Imaging signs such as the fluid&ndash;fluid level are high\u2010yield for distinguishing coagulopathy\u2010related hemorrhages on board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100022898,
    "question_number": "95",
    "question_text": "A patient presented with an inability to read his own handwriting, while his comprehension for spoken language, fluency, and repetition are normal. What is the most common artery involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Pure alexia without agraphia arises from a disconnection syndrome: visual input is abolished in the dominant occipital cortex but writing remains intact because language output regions (Exner&rsquo;s area, angular gyrus) are spared. Key concepts:  <br><span class=\"list-item\">\u2022</span> The visual word form area (VWFA) lies in the left ventral occipitotemporal cortex, supplied by the PCA.  <br><span class=\"list-item\">\u2022</span> Splenial callosal fibers mediate transfer of visual information from right to left hemisphere; infarction here causes &ldquo;disconnection&rdquo; of intact language centers from visual input.  <br><span class=\"list-item\">\u2022</span> Other language modalities (auditory comprehension, speech production, repetition) remain normal since perisylvian areas (MCA territory) are unaffected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Infarction of the dominant PCA interrupts perfusion to the left primary visual cortex and VWFA in the fusiform gyrus, as well as the splenium of the corpus callosum. Dejerine&rsquo;s classic 1892 description of pure alexia without agraphia highlighted this pattern. Modern neuroimaging <span class=\"citation\">(Leff et al., JNNP 2002)</span> confirmed that lesions in the left fusiform gyrus reliably produce alexia with preserved writing. The AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) emphasize urgent MRI-DWI and vascular imaging (CTA/MRA) to localize PCA territory infarcts presenting with cortical visual deficits. By contrast, MCA infarcts produce Broca&rsquo;s or Wernicke&rsquo;s aphasia with motor/sensory signs; ACA infarcts yield leg weakness and frontal signs; PICA strokes cause lateral medullary (Wallenberg) syndromes without cortical language deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery (MCA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: MCA supplies perisylvian language regions; infarcts cause aphasia plus motor/sensory deficits, not isolated reading impairment.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all language deficits with MCA strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pure alexia spares speech and comprehension; MCA lesions disrupt multiple language modalities and often cause hemiparesis.  <br><br>C. Anterior cerebral artery (ACA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: ACA supplies medial frontal/parietal lobes and corpus callosum body; infarcts cause transcortical motor aphasia or leg weakness, not pure alexia.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing callosal disconnection syndromes to ACA infarcts; splenial lesions are PCA territory.  <br><span class=\"list-item\">\u2022</span> Differentiator: ACA strokes present with frontal release signs, abulia, and leg paresis rather than visual reading deficits.  <br><br>D. Posterior inferior cerebellar artery (PICA)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA supplies lateral medulla and inferior cerebellum; infarcts result in Wallenberg syndrome&mdash;vertigo, ataxia, sensory loss&mdash;not cortical visual or language deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing posterior circulation broadly with PCA-specific cortical territories.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA lesions lack any aphasic or cortical visual manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Vascular Territory</th><th>Typical Clinical Features</th><th>Relation to Alexia</th></tr></thead><tbody><tr><td>PCA</td><td>Occipital lobe, inferomedial temporal lobe, splenium</td><td>Contralateral homonymous hemianopia, pure alexia, visual agnosia</td><td>Directly interrupts VWFA and splenial fibers \u2192 pure alexia without agraphia</td></tr><tr><td>MCA</td><td>Lateral frontal/parietal lobes</td><td>Broca&rsquo;s/Wernicke&rsquo;s aphasia, hemiparesis, hemisensory loss</td><td>Causes multiple language deficits plus motor signs, not isolated reading loss</td></tr><tr><td>ACA</td><td>Medial frontal/parietal lobes, corpus callosum body</td><td>Leg weakness, abulia, frontal release signs</td><td>No involvement of visual word form cortex or splenium</td></tr><tr><td>PICA</td><td>Lateral medulla, inferior cerebellum</td><td>Wallenberg syndrome: dysphagia, vertigo, nystagmus</td><td>No cortical language or visual pathway involvement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure alexia without agraphia is pathognomonic for dominant PCA infarction involving the splenium.  <br><span class=\"list-item\">\u2022</span> The visual word form area in the fusiform gyrus is essential for rapid word recognition; its disruption abolishes reading but spares writing.  <br><span class=\"list-item\">\u2022</span> Always correlate reading deficits with visual field testing; contralateral homonymous hemianopia often coexists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming anomia or alexia implies MCA territory&mdash;only pure alexia localizes to PCA.  <br>2. Overlooking callosal involvement; failure to test writing may misclassify the deficit as global aphasia.  <br>3. Neglecting detailed visual field examination&mdash;hemianopia supports PCA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke (2019): Class I, Level A recommendation to obtain urgent MRI-DWI and vascular imaging (CTA/MRA) to identify PCA occlusions in cortical stroke syndromes.  <br><span class=\"list-item\">\u2022</span> NICE NG128: Stroke and Transient Ischaemic Attack in Over 16s: Diagnosis and Initial Management (2019): Evidence level 1++ recommendation for MRI with DWI when CT is non-diagnostic in suspected posterior circulation strokes to detect small occipital or callosal infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the dominant PCA territory encompass the left primary visual cortex (calcarine fissure), the fusiform gyrus (VWFA), and the splenium. Disconnection of right visual field input and direct lesion of left visual cortex both contribute to reading impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the PCA leads to ischemia of the ventral occipitotemporal cortex and splenium. Neuronal death in the VWFA disrupts orthographic processing; damage to callosal fibers prevents compensatory transfer of visual information.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical exam: assess reading aloud, writing, speech fluency, comprehension, repetition.  <br>2. Visual fields: check for homonymous hemianopia.  <br>3. Neuroimaging: MRI-DWI to localize occipital/splenial infarct; CTA/MRA to confirm PCA occlusion.  <br>4. Vascular risk factor evaluation and acute reperfusion therapy as indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI-DWI reveals hyperintense lesion in left occipital lobe and splenium of corpus callosum.  <br><span class=\"list-item\">\u2022</span> CT may miss small splenial infarcts; always obtain MRI if cortical signs persist with negative CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute management follows AHA/ASA 2019 guidelines: IV alteplase (0.9 mg/kg, max 90 mg) within 4.5 hours if no contraindications; consideration of endovascular thrombectomy for proximal PCA occlusion under advanced imaging protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Pure alexia without agraphia is frequently tested as a classic localization syndrome&mdash;expect direct recall or clinical vignette formats linking reading deficits to PCA infarction.</div></div></div></div></div>"
  },
  {
    "id": 100022899,
    "question_number": "279",
    "question_text": "For the same patient (referring to Q273, intracerebral hemorrhage with a fluid level on CT), what is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Intracerebral hemorrhage (ICH) accounts for ~10&ndash;15% of strokes and carries high morbidity and mortality. On non-contrast CT, a fluid level (layered hyperdense clot over hypodense serum) indicates clot retraction and ongoing bleeding, often in the setting of coagulopathy or underlying vascular lesion. Key concepts:  <br><span class=\"list-item\">\u2022</span> Mass effect and midline shift from large-volume hemorrhage increase intracranial pressure (ICP) and risk herniation.  <br><span class=\"list-item\">\u2022</span> Fluid levels correlate with larger hematoma volume and active bleeding, signaling poor prognosis without evacuation.  <br><span class=\"list-item\">\u2022</span> Early identification of surgical candidates (superficial lobar bleeds, fluid levels, neurological deterioration) is critical for outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Surgical evacuation is indicated in ICH with significant mass effect, superficial location, fluid levels, or neurological decline despite medical therapy. <span class=\"evidence\">The 2022</span> AHA/ASA guidelines <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> give a Class IIb recommendation (LOE B-R) for early surgery in superficial lobar ICH >30 mL within 1 cm of the cortical surface with mass effect or neurological deterioration. The STICH II trial <span class=\"citation\">(Mendelow et al., <span class=\"evidence\">Lancet 2013</span>)</span> showed a trend toward improved functional outcome in this subgroup. Fluid levels denote active hemorrhage and clot instability; evacuating the hematoma reduces ICP, stops further bleeding, and lowers perihematomal edema. Neurosurgical series demonstrate lower mortality and better Glasgow Outcome Scale scores when surgery is performed within 24 hours in patients with fluid levels and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Osmotic therapy  <br>&ndash; Reduces cerebral edema (mannitol, hypertonic saline) but does not remove the mass lesion.  <br>&ndash; Misconception: lowering ICP alone suffices; fails to address clot volume or ongoing hemorrhage.  <br><br>C. Blood pressure control  <br>&ndash; Essential (target systolic <140 mmHg per AHA/ASA Class I, LOE A) to limit hematoma expansion but insufficient when mass effect from a large, unstable clot is present.  <br>&ndash; Differs from surgery by addressing only bleeding risk, not mass removal.  <br><br>D. Supportive care  <br>&ndash; Includes airway protection, normothermia, glycemic control; vital but passive.  <br>&ndash; Fails to reverse mass effect or actively evacuate clot; associated with worse outcomes if used in isolation for large, fluid-level hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Surgery</th><th>Osmotic Therapy</th><th>BP Control</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Primary Mechanism</td><td>Clot removal, relieve mass effect</td><td>Reduce cerebral edema</td><td>Limit hematoma expansion</td><td>Maintain vital functions</td></tr><tr><td>Indication</td><td>Fluid-level ICH, superficial, large volume, mass effect</td><td>Raised ICP without mass lesion</td><td>All ICH patients</td><td>Minor ICH without significant mass</td></tr><tr><td>Timing</td><td>Early (within 24 h)</td><td>Acute/adjunctive</td><td>Immediately on presentation</td><td>Continuous</td></tr><tr><td>Outcome Evidence</td><td>STICH II subgroup benefit; IIb (B-R)</td><td>No randomized trials on clot removal</td><td>Class I, LOE A <span class=\"citation\">(AHA/ASA 2022)</span></td><td>Standard of care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A fluid level on CT (&ldquo;hematocrit effect&rdquo;) signals clot retraction and active bleeding; correlate with coagulopathy and neurosurgical urgency.  <br><span class=\"list-item\">\u2022</span> Early surgical evacuation (craniotomy or minimally invasive) within 24 hours in superficial lobar ICH >30 mL with mass effect can improve functional outcomes.  <br><span class=\"list-item\">\u2022</span> Always reverse anticoagulation expeditiously (PCC for warfarin, idarucizumab for dabigatran) before surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on mannitol or hypertonic saline alone; these do not evacuate the hematoma or stop active bleeding seen with fluid levels.  <br>2. Assuming strict BP control is definitive therapy; without clot removal, mass effect and herniation risk persist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke Council <span class=\"citation\">(<span class=\"evidence\">Hemphill et al., 2022</span>)</span>: Early surgical evacuation Class IIb (LOE B-R) for superficial lobar ICH >30 mL within 1 cm of cortex with mass effect or neurological deterioration.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines <span class=\"citation\">(ESO, 2020)</span>: Conditional recommendation for surgery in selected lobar ICH patients; emphasizes patient selection based on location, volume, and clinical status.  <br><span class=\"list-item\">\u2022</span> STICH II Trial <span class=\"citation\">(Mendelow et al., <span class=\"evidence\">Lancet 2013</span>)</span>: Trend toward better outcomes in early surgery subgroup with superficial lobar hemorrhage; did not reach statistical significance overall but supports targeted intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Superficial lobar hemorrhages (frontal/parietal lobes) are more accessible and yield greater benefit from surgical evacuation compared to deep ganglionic bleeds involving the internal capsule or thalamus, where surgery risks further neurological injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute ICH causes blood extravasation into brain parenchyma; clot retraction separates cellular elements (hyperdense) from plasma (hypodense), forming a fluid level. The expanding hematoma increases ICP, disrupts the blood&ndash;brain barrier, and induces perihematomal edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast CT head: confirm ICH, measure volume (ABC/2), detect fluid level.  <br>2. Assess midline shift and mass effect.  <br>3. Reverse coagulopathy.  <br>4. Initiate BP management (target <140 mmHg).  <br>5. Neurosurgical consultation for early evacuation if fluid level, superficial location, volume >30 mL, or neurological decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fluid level (&ldquo;hematocrit effect&rdquo;) appears as a horizontal interface between hyperdense clot and hypodense serum.  <br><span class=\"list-item\">\u2022</span> &ldquo;Swirl sign&rdquo; (mixed density) may indicate active bleeding.  <br><span class=\"list-item\">\u2022</span> CT angiography can exclude underlying AVM or aneurysm in fluid-level hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mannitol (0.25&ndash;1 g/kg IV) and hypertonic saline (3% bolus) for acute ICP spikes.  <br><span class=\"list-item\">\u2022</span> PCC (prothrombin complex concentrate) for warfarin reversal; idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of ICH with CT fluid levels tests knowledge of surgical indications, imaging markers of active bleeding, and guideline-driven decision-making. Such vignettes frequently probe timing of surgery versus medical management in neurology board questions.</div></div></div></div></div>"
  },
  {
    "id": 100022900,
    "question_number": "15",
    "question_text": "A patient two weeks postpartum presents with a headache and left-sided weakness. MRI shows a right cortical intracerebral hemorrhage with surrounding edema. What is the most likely cause?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Pregnancy and the puerperium create a hypercoagulable state (\u2191 fibrinogen, factors VII&ndash;X) that peaks in the first 6 weeks postpartum, predisposing to venous thromboses.  <br><span class=\"list-item\">\u2022</span> Cortical veins and dural sinuses drain the cerebral cortex; their occlusion elevates venous pressure, causing vasogenic edema and hemorrhagic infarction, often in cortical regions.  <br><span class=\"list-item\">\u2022</span> Distinguishing venous hemorrhage (irregular, cortical, edema) from arterial bleeds (often deep, well-circumscribed) is key in acute postpartum neurologic presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral venous thrombosis (CVT) is the leading cause of postpartum intracerebral hemorrhage with focal deficits and headache. Occlusion of cortical veins or the superior sagittal sinus impairs venous outflow, raising capillary hydrostatic pressure, leading to blood&ndash;brain barrier disruption, vasogenic edema, and hemorrhagic infarction. MRI with susceptibility-weighted imaging and MR venography (MRV) demonstrates absent flow in the affected sinus/veins and allows differentiation from arterial lesions. The American Heart Association/American Stroke Association (AHA/ASA) stroke guidelines <span class=\"citation\">(2011, reaffirmed 2018)</span> give a Class I recommendation for anticoagulation in CVT even with hemorrhage (Level A evidence). The RE-SPECT CVT trial <span class=\"citation\">(NEJM 2019)</span> showed dabigatran is non-inferior to warfarin for secondary prevention. In contrast, aneurysmal rupture causes subarachnoid hemorrhage, AVM bleeds lack the typical edema pattern of venous infarcts, and hypertensive bleeds favor deep structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aneurysm rupture  <br><span class=\"list-item\">\u2022</span> Why incorrect: Typically leads to subarachnoid hemorrhage or intraparenchymal bleeding in non-cortical, basal cisternal distribution.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all intracerebral bleeds in young adults are aneurysmal.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of classic &ldquo;thunderclap&rdquo; headache, negative MR angiogram.<br><br>C. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> Why incorrect: AVM hemorrhage can cause cortical bleeds but usually in patients with known vascular malformations and without the acute hypercoagulable context.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any cortical hemorrhage with AVM.  <br><span class=\"list-item\">\u2022</span> Differentiator: AVM on angiography shows nidus and early venous drainage; no systemic hypercoagulability link.<br><br>D. Hypertensive intracerebral hemorrhage  <br><span class=\"list-item\">\u2022</span> Why incorrect: Predominantly affects deep nuclei (basal ganglia, thalamus) in uncontrolled hypertension, uncommon in normotensive postpartum women.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing hypertension as the cause of all ICH.  <br><span class=\"list-item\">\u2022</span> Differentiator: Patient is two weeks postpartum with normal blood pressure; hemorrhage location is cortical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT (Correct)</th><th>Aneurysm Rupture</th><th>AVM Bleed</th><th>Hypertensive ICH</th></tr></thead><tbody><tr><td>Typical timing</td><td>1&ndash;6 weeks postpartum</td><td>Any age, sudden &ldquo;thunderclap&rdquo;</td><td>Often young adults, incidental AVM</td><td>Middle-aged, uncontrolled HTN</td></tr><tr><td>Imaging findings</td><td>Cortical hemorrhage + edema + MRV defect</td><td>Subarachnoid blood, aneurysm on MRA</td><td>Localized hemorrhage + nidus on DSA</td><td>Deep basal ganglia/thalamus bleed</td></tr><tr><td>Pathophysiology</td><td>Venous outflow obstruction</td><td>Arterial wall rupture</td><td>High-flow arteriovenous shunt</td><td>Charcot-Bouchard microaneurysms</td></tr><tr><td>Anticoagulation recommendation</td><td>Yes (even with hemorrhage)</td><td>Contraindicated</td><td>Contraindicated acutely</td><td>Contraindicated acutely</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always suspect CVT in postpartum women with new headache + focal deficits; MRI/MRV is diagnostic.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (LMWH \u2192 oral agent) is safe and improves outcome, even in hemorrhagic presentations.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic infarcts from CVT often cross arterial boundaries and associate with significant vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misattributing all cortical hemorrhages to AVMs or aneurysms without considering hypercoagulable states.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation due to hemorrhage fear; guidelines support treatment even in hemorrhagic CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Stroke Guidelines <span class=\"citation\">(2011; reaffirmed 2018)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Initiate therapeutic anticoagulation in acute CVT, including hemorrhagic cases (Class I, Level A).  <br>2. RE-SPECT CVT Trial <span class=\"citation\">(NEJM 2019)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Dabigatran non-inferior to warfarin for prevention of recurrent CVT (Level 1 evidence).  <br>3. ESO/EAN Guidelines <span class=\"citation\">(European Stroke Organisation & European Academy of Neurology, 2017)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Direct oral anticoagulants may be considered as alternatives to vitamin K antagonists (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis of cortical veins or the superior sagittal sinus impedes drainage from the cerebral convexity, leading to backflow pressure, blood&ndash;brain barrier breakdown, and hemorrhagic venous infarction localized to the cortical ribbon and subcortical white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In the puerperium, elevated levels of fibrinogen, factors VII, VIII, X, and reduced protein S create a prothrombotic milieu. Venous occlusion elevates capillary pressure, causing transudation, cytotoxic edema, and eventually hemorrhagic transformation of the infarcted tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in postpartum headache + focal deficits  <br>2. MRI brain with T2*/SWI + MR venography  <br>3. Identify filling defects in dural sinuses or cortical veins  <br>4. Exclude arterial lesions with MR angiography  <br>5. Initiate anticoagulation promptly</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SWI/T2* sequences reveal blooming artifact at thrombus.  <br><span class=\"list-item\">\u2022</span> MRV shows absent flow voids in the thrombosed segment.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic infarcts often have irregular borders and significant peri-lesional edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: Low molecular weight heparin (e.g., enoxaparin 1 mg/kg BID).  <br><span class=\"list-item\">\u2022</span> Transition: Warfarin (INR 2&ndash;3) or DOAC (dabigatran 150 mg BID) for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Monitor for extension of thrombus; treat seizure risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Postpartum CVT with hemorrhagic infarction is a high-yield topic on neurology boards, often presented as headache plus focal deficits; tested in multiple-choice format focusing on imaging and management nuances.</div></div></div></div></div>"
  },
  {
    "id": 100022901,
    "question_number": "170",
    "question_text": "A patient with a transient ischemic attack (TIA) is found to have atrial flutter, but the echocardiogram is normal. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Transient ischemic attack (TIA) is a transient focal neurologic deficit without acute infarction; it carries a high early risk of stroke.  <br>&bull; Atrial flutter is a high-risk cardioembolic source analogous to atrial fibrillation; thrombi form in the left atrial appendage, even if transthoracic echocardiogram is normal.  <br>&bull; Cardioembolic strokes arise from thrombin-rich &ldquo;red thrombi,&rdquo; requiring anticoagulation (versus platelet-rich &ldquo;white thrombi&rdquo; in atherosclerotic disease treated with antiplatelets).  <br>&bull; CHADS\u2082-VASc scoring guides anticoagulation decisions; a TIA in atrial flutter confers indication for oral anticoagulation.<br><br>(\u2248110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct oral anticoagulants (DOACs) that inhibit factor Xa (e.g., apixaban, rivaroxaban, edoxaban) have become first-line for nonvalvular atrial fibrillation or flutter. <span class=\"evidence\">The 2019</span> AHA/ASA guideline on secondary stroke prevention <span class=\"citation\">(Kernan et al., <span class=\"evidence\">Stroke 2019</span>)</span> issues a Class I, Level A recommendation for DOACs over warfarin in patients with CHADS\u2082-VASc &ge;2. In ARISTOTLE (N = 18,201), apixaban reduced stroke/systemic embolism by 21% and major bleeding by 31% versus warfarin <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>. ROCKET-AF (rivaroxaban) demonstrated noninferiority to warfarin <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>. Meta-analyses confirm DOACs lower intracranial hemorrhage rates. Even with a normal echocardiogram, atrial flutter predisposes to thrombus formation; early initiation of a Factor Xa inhibitor post-TIA optimizes prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Incorrect because antiplatelet monotherapy does not prevent cardioembolic strokes from atrial arrhythmias.  <br>&bull; Misconception: &ldquo;Any antithrombotic is adequate.&rdquo;  <br>&bull; Differentiator: Aspirin targets platelet aggregation; atrial thrombi are fibrin-rich and require anticoagulation.<br><br>C. Dual antiplatelet therapy (aspirin and clopidogrel)  <br>&bull; Incorrect: increases bleeding risk without reducing cardioembolic stroke.  <br>&bull; Misconception: &ldquo;Doubling antiplatelets equals more protection.&rdquo;  <br>&bull; Differentiator: Dual antiplatelets are studied in atherosclerotic TIA (CHANCE, POINT), not atrial flutter.<br><br>D. Warfarin  <br>&bull; Although effective, warfarin requires INR monitoring and has more intracranial hemorrhage compared to DOACs.  <br>&bull; Misconception: &ldquo;Warfarin is the gold standard for all atrial thrombi.&rdquo;  <br>&bull; Differentiator: DOACs offer similar or superior efficacy with better safety and convenience.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Factor Xa Inhibitor</th><th>Warfarin</th><th>Aspirin</th><th>Dual Antiplatelets</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa inhibition</td><td>Vitamin K epoxide blockade</td><td>COX-1 inhibition</td><td>COX-1 + P2Y\u2081\u2082 blockade</td></tr><tr><td>Stroke prevention in flutter</td><td>Class I, LOE A</td><td>Class I, LOE B (less favored)</td><td>Not indicated</td><td>Not indicated</td></tr><tr><td>Onset of action</td><td>Rapid (2&ndash;4 h)</td><td>Delayed (48&ndash;72 h)</td><td>Rapid (30 min)</td><td>Rapid (1&ndash;2 h)</td></tr><tr><td>Monitoring</td><td>None routinely</td><td>INR (2&ndash;3)</td><td>None</td><td>None</td></tr><tr><td>Major bleeding risk</td><td>Lower intracranial</td><td>Higher intracranial</td><td>Lower overall</td><td>Higher GI bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Atrial flutter carries stroke risk comparable to atrial fibrillation; manage identically with anticoagulation.  <br>&bull; Calculate CHADS\u2082-VASc in all atrial arrhythmias; TIA itself scores &ge;2 in men (age >75 adds points) warranting anticoagulation.  <br>&bull; Initiate DOAC within days of TIA if no hemorrhagic conversion; avoid delays beyond 72 hours when safe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Prescribing aspirin alone for TIA in atrial flutter, underestimating cardioembolic risk.  <br>&bull; Misapplying dual antiplatelet data from atherosclerotic TIA (CHANCE/POINT) to atrial arrhythmias, leading to inappropriate use.  <br>&bull; Assuming a normal transthoracic echo excludes atrial thrombus risk; left atrial appendage often not well visualized without TEE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Stroke Prevention in Patients With Stroke and TIA: Class I, LOE A recommendation for DOACs over warfarin in nonvalvular atrial fibrillation/flutter with CHADS\u2082-VASc &ge;2.  <br>&bull; ESC 2020 Atrial Fibrillation Guidelines: Class IA recommendation for DOACs in nonvalvular atrial arrhythmias; emphasize lower ICH risk and no routine monitoring.  <br>&bull; ARISTOTLE Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: Apixaban vs warfarin reduced stroke/systemic embolism (HR 0.79; 95% CI 0.66&ndash;0.95) and major bleeding (HR 0.69; 95% CI 0.60&ndash;0.80).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Factor Xa inhibitors directly block the active site of factor Xa, preventing prothrombin conversion to thrombin.  <br>&bull; Apixaban: 5 mg twice daily (2.5 mg if &ge;80 yrs, weight &le;60 kg, or creatinine &ge;1.5 mg/dL).  <br>&bull; Rivaroxaban: 20 mg once daily with food (15 mg if CrCl 15&ndash;50 mL/min).  <br>Advantages include predictable PK/PD, no routine INR, fewer drug&ndash;food interactions; reversal with andexanet alfa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Cardioembolic stroke prevention with DOACs is frequently tested in both multiple-choice and clinical vignettes, emphasizing guideline-driven selection of anticoagulants in nonvalvular atrial arrhythmias.</div></div></div></div></div>"
  },
  {
    "id": 100022904,
    "question_number": "168",
    "question_text": "A patient presents with subarachnoid hemorrhage. Which artery is most likely affected?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Berry (saccular) aneurysms arise at arterial branch points in the circle of Willis and account for >85% of nontraumatic subarachnoid hemorrhages (SAH). The most common site is the anterior communicating (ACom) artery junction with the anterior cerebral artery. SAH classically presents with sudden &ldquo;thunderclap&rdquo; headache, nuchal rigidity, and possible loss of consciousness. Key concepts:  <br><span class=\"list-item\">\u2022</span> Circle of Willis anatomy and common aneurysm sites  <br><span class=\"list-item\">\u2022</span> Hemodynamic stress at bifurcations leading to vessel wall degeneration  <br><span class=\"list-item\">\u2022</span> Clinical triad of SAH (acute headache, meningismus, photophobia)  <br><br>(Word count: 100)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterior communicating artery aneurysms constitute approximately 30&ndash;35% of all saccular aneurysms <span class=\"citation\">(Vlak et al., <span class=\"evidence\">Stroke 2011</span>)</span>. Rupture leads to rapid bleeding into the subarachnoid space, most prominently in the interhemispheric fissure and anterior cisterns. <span class=\"evidence\">The 2012</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (Class I, Level of Evidence A) recommend prompt noncontrast CT followed by CT angiography to localize aneurysms. Early aneurysm securing&mdash;either surgical clipping or endovascular coiling&mdash;is advised within 72 hours (Class I, LOE B). The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, <span class=\"evidence\">Lancet 2002</span>)</span> showed that endovascular coiling of ACom aneurysms confers better one-year outcomes compared to clipping in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Middle cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because MCA aneurysms account for ~20&ndash;25% of cases, second to ACom.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may assume the largest cerebral artery is most prone to aneurysm.  <br><span class=\"list-item\">\u2022</span> Differentiator: MCA aneurysms typically occur at the M1&ndash;M2 bifurcation and present with focal deficits in the corresponding cortical territory.<br><br>C. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect: PCA aneurysms are rare (<3% of intracranial aneurysms).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that posterior circulation vessels bear equal aneurysm risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: PCA aneurysms often present with occipital lobe signs (visual field deficits) rather than classic basal cistern SAH.<br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: Basilar tip aneurysms represent ~5&ndash;10% of cases.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may conflate basilar artery size with aneurysm frequency.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar tip aneurysms are associated with cranial nerve III palsy and brainstem compression signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Incidence in SAH</th><th>Typical Location</th><th>Key Clinical Feature</th></tr></thead><tbody><tr><td>Anterior communicating (ACom)</td><td>30&ndash;35%</td><td>ACom&ndash;ACA junction, anterior interhemispheric fissure</td><td>Thunderclap headache, bitemporal field effects if unruptured</td></tr><tr><td>Middle cerebral (MCA)</td><td>20&ndash;25%</td><td>M1&ndash;M2 bifurcation</td><td>Focal motor/sensory deficits</td></tr><tr><td>Basilar tip</td><td>5&ndash;10%</td><td>Apex of basilar artery</td><td>CN III palsy, oculomotor signs</td></tr><tr><td>Posterior cerebral (PCA)</td><td><3%</td><td>P1&ndash;P2 junction</td><td>Occipital visual field defects</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACom aneurysms are the most common site; watch for visual field cuts from optic chiasm compression.  <br><span class=\"list-item\">\u2022</span> Nimodipine (60 mg orally every 4 hours for 21 days) is recommended to reduce delayed cerebral ischemia <span class=\"citation\">(AHA/ASA 2012, Class I, LOE A)</span>.  <br><span class=\"list-item\">\u2022</span> Perform noncontrast head CT within 6 hours of headache onset; sensitivity approaches 98% (Class I, LOE A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming the largest-caliber vessel (MCA) is most susceptible to aneurysm formation.  <br>2. Overlooking the anterior communicating artery because it is a small connector rather than a &ldquo;major&rdquo; vessel.  <br>3. Believing posterior circulation aneurysms (basilar, PCA) are as common as anterior circulation lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2012 Guidelines on Aneurysmal SAH: recommend noncontrast CT within 6 hours of ictus (Class I, LOE A) and early aneurysm securing (<72 hours; Class I, LOE B).  <br><span class=\"list-item\">\u2022</span> International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span>: demonstrated superior 1-year outcomes with endovascular coiling versus surgical clipping for selected ACom aneurysms (p < 0.01).  <br><span class=\"list-item\">\u2022</span> EANO 2021 Consensus: advocates routine follow-up imaging at 6 months post-coiling to detect aneurysm recurrence (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ACom connects the A1 segments of bilateral anterior cerebral arteries, forming a key anterior communication in the circle of Willis. Its proximity to the optic chiasm explains visual field changes in large, unruptured aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemodynamic stress at arterial bifurcations causes degeneration of the tunica media and internal elastic lamina, leading to saccular outpouchings. Inflammation and matrix metalloproteinases further weaken vessel walls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT immediately upon presentation.  <br>2. If CT positive for SAH, proceed to CT angiography for aneurysm localization.  <br>3. If CT negative but suspicion remains high, perform lumbar puncture for xanthochromia.  <br>4. Digital subtraction angiography for definitive aneurysm mapping prior to intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT: hyperdense blood in basal cisterns, Sylvian fissures, and sulci.  <br><span class=\"list-item\">\u2022</span> CTA: rapid, noninvasive visualization of aneurysm morphology and parent vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine: calcium channel blocker with neuroprotective effects, reduces vasospasm-related infarction.  <br><span class=\"list-item\">\u2022</span> Short-term antifibrinolytics (e.g., tranexamic acid) may be used pre-intervention to reduce rebleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. ACom aneurysms are tested frequently on neurology board exams, often in the context of circle of Willis anatomy, imaging interpretation, and SAH management guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100022905,
    "question_number": "157",
    "question_text": "An 83-year-old man presents with a 3-hour history of acute onset hemiparesis and aphasia consistent with ischemic stroke. What is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Acute ischemic stroke results from arterial occlusion leading to a core infarct surrounded by salvageable penumbra. Rapid reperfusion within the 4.5-hour window limits infarct growth. Key concepts:  <br>1. Ischemic cascade and penumbra: delayed neuronal death in peri-infarct area allows a therapeutic window.  <br>2. Time is brain: every minute of large-vessel occlusion costs ~1.9 million neurons.  <br>3. Thrombolytic therapy: intravenous alteplase dissolves fibrin-rich clots, improving functional outcomes if given early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (tPA) administered at 0.9 mg/kg (max 90 mg) within 4.5 hours of symptom onset is Class I, Level A per AHA/ASA 2019 guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>. The ECASS III trial (2008) demonstrated significant reduction in disability at 90 days when tPA was given between 3.0&ndash;4.5 hours (N = 821; OR for favorable outcome 1.34; p = 0.04). Emberson et al.&rsquo;s meta-analysis <span class=\"citation\">(<span class=\"evidence\">Lancet 2014</span>)</span> confirmed benefit declines over time yet persists to 4.5 hours. In contrast, CTA is reserved for large-vessel occlusion identification when considering endovascular therapy; it does not replace emergent thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CTA  <br><span class=\"list-item\">\u2022</span> Why incorrect: CTA delays tPA initiation and is not required before alteplase.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that vessel imaging is needed to diagnose occlusion prior to thrombolysis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Noncontrast CT is the only imaging needed to exclude hemorrhage; CTA is adjunctive for thrombectomy planning.  <br><br>C. Warfarin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Oral anticoagulation has delayed onset, no role in acute clot lysis.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating anticoagulation with thrombolysis in acute ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin is for secondary prevention in cardioembolic stroke after stabilization.  <br><br>D. CEA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Carotid endarterectomy is elective/subacute for symptomatic &ge;70% carotid stenosis, not immediate reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming surgical revascularization is the first step in all ischemic strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA entails pre-op risk assessment and is contraindicated acutely due to hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>tPA (Correct)</th><th>CTA</th><th>Warfarin</th><th>CEA</th></tr></thead><tbody><tr><td>Purpose</td><td>Clot lysis</td><td>Vessel imaging</td><td>Anticoagulation</td><td>Surgical revascularization</td></tr><tr><td>Timing</td><td>Within 4.5 h</td><td>After initial CT/for EVT</td><td>Delayed onset (days)</td><td>Days to weeks post-stroke</td></tr><tr><td>Indication</td><td>Acute ischemic stroke</td><td>Large-vessel occlusion</td><td>Secondary prevention</td><td>Symptomatic carotid stenosis</td></tr><tr><td>Key limitation</td><td>Hemorrhage risk</td><td>Radiation/contrast delay</td><td>Bleeding risk, delayed INR</td><td>Surgical risk, periop stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Age >80 years is not an absolute exclusion; tPA is indicated up to 4.5 h regardless of age.  <br><span class=\"list-item\">\u2022</span> Early NIHSS assessment guides eligibility; most centers target door-to-needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Tenecteplase shows promise in large-vessel occlusion, but alteplase remains first-line per current guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying tPA to obtain vascular imaging (CTA/MRA) instead of administering after noncontrast CT.  <br>2. Starting anticoagulation (heparin/warfarin) in the hyperacute phase, which increases hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Stroke Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: IV alteplase within 4.5 h (Class I, LOE A).  <br>2. ECASS III Trial <span class=\"citation\">(Hacke et al., NEJM 2008)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Benefit of tPA extended to 4.5 h window (OR for favorable mRS 0&ndash;1 = 1.34; p = 0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT is mandatory to exclude hemorrhage and large established infarct signs.  <br><span class=\"list-item\">\u2022</span> CTA is performed after tPA initiation if mechanical thrombectomy up to 6 h is under consideration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase mechanism: converts plasminogen to plasmin, degrading fibrin clot.  <br><span class=\"list-item\">\u2022</span> Dosing: 0.9 mg/kg (10% bolus over 1 minute; remainder infused over 60 minutes).  <br><span class=\"list-item\">\u2022</span> BP management: maintain <185/110 mm Hg before and <180/105 mm Hg for 24 h post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke management&mdash;particularly indication, timing, and contraindications for IV alteplase&mdash;is a high-yield topic, frequently tested as vignette-style questions requiring rapid decision-making within time windows.</div></div></div></div></div>"
  },
  {
    "id": 100022913,
    "question_number": "74",
    "question_text": "A postpartum woman presents with a sudden, severe (\u201cthunderclap\u201d) headache and focal weakness two weeks after delivery. Noncontrast CT shows a small, convexal subarachnoid hemorrhage over the cerebral convexities. Cerebral angiography demonstrates multifocal segmental narrowing and dilation of medium-sized cerebral arteries that reverses on follow-up imaging. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient dysregulation of cerebral arterial tone leading to thunderclap headache and focal deficits. Key concepts:  <br>&bull; Thunderclap headache: sudden peak intensity in seconds; hallmark of SAH but also RCVS.  <br>&bull; Convexal SAH: superficial bleeding in cortical sulci, often from small vessel rupture in RCVS, versus basal cisternal SAH from aneurysm rupture.  <br>&bull; Angiographic &ldquo;string-of-beads&rdquo; appearance: multifocal alternating vasoconstriction and dilation, reversible within 1&ndash;3 months, distinguishes RCVS from fixed vasculopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is most likely here given postpartum trigger, thunderclap headache, convexal SAH, and angiographic reversibility. <span class=\"evidence\">The 2012</span> Calabrese diagnostic criteria require: 1) acute severe headache, 2) segmental vasoconstriction on cerebral angiography, 3) no aneurysmal SAH pattern, and 4) reversibility within 12 weeks. AHA/ASA 2018 scientific statement (Singhal et al.) underscores calcium channel blockers (e.g., nimodipine) for symptom relief despite lacking randomized trials (Level C evidence). Ducros et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2007</span>)</span> first delineated the RCVS spectrum, noting convexal SAH in up to 22% of patients. Postpartum state is a well-recognized precipitant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysm  <br>&bull; Incorrect because aneurysmal SAH usually presents with basal cisternal hemorrhage, not isolated convexal SAH.  <br>&bull; Misconception: all thunderclap headaches are aneurysmal SAH.  <br>&bull; Differentiator: aneurysmal rupture shows saccular outpouching on angiography and persistent vasospasm only in later days.  <br><br>C. Meningitis  <br>&bull; Incorrect: meningitis presents with fever, neck stiffness, altered mental status, and CSF pleocytosis, not isolated convexal bleeding.  <br>&bull; Misconception: headache with neuro deficits always implies infection.  <br>&bull; Differentiator: CSF in RCVS shows no major inflammatory changes; imaging shows vessel narrowing.  <br><br>D. Subdural hematoma  <br>&bull; Incorrect: subdural hematoma appears as a crescent-shaped extra-axial collection crossing suture lines, not as blood in sulci.  <br>&bull; Misconception: any postpartum headache with hemorrhage is subdural.  <br>&bull; Differentiator: subdural collections track along the inner skull table on CT, whereas convexal SAH adheres to gyri surfaces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Aneurysmal SAH</th><th>Meningitis</th><th>Subdural Hematoma</th></tr></thead><tbody><tr><td>Headache onset</td><td>Thunderclap, recurrent</td><td>Thunderclap, single event</td><td>Gradual or subacute</td><td>Gradual or acute after trauma</td></tr><tr><td>CT hemorrhage pattern</td><td>Convexal sulcal SAH</td><td>Basal cistern SAH</td><td>No hemorrhage</td><td>Crescent extra-axial collection</td></tr><tr><td>Angiography</td><td>Reversible multifocal narrowing</td><td>Saccular aneurysm</td><td>Normal or nonspecific vasculitis</td><td>Not indicated for vessels</td></tr><tr><td>CSF findings</td><td>Xanthochromia from SAH, otherwise normal</td><td>Bloody, elevated RBCs</td><td>Elevated WBCs, low glucose</td><td>Possible xanthochromia if old bleed</td></tr><tr><td>Clinical context</td><td>Postpartum, vasoactive triggers</td><td>Hypertension, polycystic kidney, family history</td><td>Infection risk factors</td><td>Trauma, coagulopathy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; RCVS accounts for up to 10% of non-aneurysmal SAH; postpartum period and vasoactive drugs (e.g., SSRIs, triptans) are common triggers.  <br>&bull; Serial vascular imaging at 1&ndash;3 months confirms reversibility; absence of reversibility suggests vasculitis or moyamoya.  <br>&bull; Nimodipine or verapamil may alleviate headache and improve vasoconstriction; avoid glucocorticoids, which can worsen outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all thunderclap headaches are aneurysmal SAH, leading to missed RCVS diagnosis.  <br>2. Misinterpreting convexal SAH on CT as traumatic or subdural bleeding without considering superficial vessel rupture in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Scientific Statement on RCVS <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2018</span>)</span>: recommends calcium channel blockade for symptom relief (Class IIa, Level C).  <br>&bull; Calabrese Criteria Consensus <span class=\"citation\">(Calabrese et al., <span class=\"evidence\">Cephalalgia 2012</span>)</span>: established diagnostic framework requiring reversible vasoconstriction demonstrated on follow-up imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS predominantly affects medium-sized cortical arteries (e.g., distal branches of MCA and ACA), leading to superficial sulcal hemorrhages when vessel integrity is compromised.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Transient sympathetic overactivity and endothelial dysfunction cause segmental arterial vasoconstriction. The sudden constriction and dilation stresses vessel walls, resulting in convexal SAH and occasional ischemic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Thunderclap headache \u2192 noncontrast CT.  <br>2. If CT shows convexal SAH \u2192 CTA/MRA or catheter angiography.  <br>3. Identify multifocal &ldquo;string-of-beads&rdquo; vasoconstriction.  <br>4. Exclude aneurysm, vasculitis (via CSF, inflammatory markers).  <br>5. Repeat vascular imaging at 6&ndash;12 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Convexal SAH: blood in cortical sulci, sparing basal cisterns.  <br>&bull; Angiography &ldquo;string-of-beads&rdquo; pattern is diagnostic; severity peaks at 1&ndash;2 weeks, normalizes by 3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: oral nimodipine 60 mg every 4 hours or verapamil 80&ndash;120 mg TID, titrated to headache relief and blood pressure goals; avoid immunosuppressants and serotonergic agents.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. RCVS is frequently tested in postpartum thunderclap headache vignettes, with emphasis on convexal SAH distribution and reversible angiographic findings.</div></div></div></div></div>"
  },
  {
    "id": 100022915,
    "question_number": "99",
    "question_text": "In a scenario of superior cerebellar artery (SCA) infarction, what additional finding would you expect?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] &bull; Vascular territories of the cerebellum: the SCA supplies the superior cerebellar hemisphere, superior vermis, deep nuclei (dentate, interposed) and superior cerebellar peduncle.  <br>&bull; Classic SCA infarct signs: ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, intention tremor, hypotonia, dysarthria, and nystagmus.  <br>&bull; Large cerebellar infarcts can produce mass effect within the posterior fossa, compressing the contralateral cerebral peduncle against the tentorium and resulting in contralateral hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Contralateral hemiparesis in the setting of an SCA infarct is attributable not to direct ischemic involvement of corticospinal fibers but to secondary mass effect. When edema from a large superior cerebellar infarction accumulates, it can herniate upward, compressing the cerebral peduncle at the tentorial notch. This phenomenon&mdash;akin to Kernohan&rsquo;s notch&mdash;has been documented in case series <span class=\"citation\">(Schwamm LH et al., <span class=\"evidence\">Neurology 1992</span>;42:1065&ndash;1069)</span> and is recognized in AHA/ASA stroke management guidelines <span class=\"citation\">(Powers WJ et al., <span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418, Recommendation 10.11, Level of Evidence C-LD)</span>. Early recognition is <span class=\"key-point\">critical:</span> neurosurgical decompression can reverse ongoing peduncular compression and improve motor outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right ptosis ipsilateral to the ataxia  <br><span class=\"list-item\">\u2022</span> Incorrect: Ptosis implies oculomotor (CN III) or sympathetic chain (Horner&rsquo;s) involvement. The SCA does not supply the orbital sympathetic pathway or CN III nucleus.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing cerebellar with oculomotor territory infarcts.  <br><br>B. Ipsilateral Horner&rsquo;s syndrome associated with ataxia  <br><span class=\"list-item\">\u2022</span> Incorrect: Horner&rsquo;s syndrome arises from disruption of descending sympathetic fibers in the lateral medulla (PICA infarct) or cervical sympathetic trunk. SCA infarcts spare these pathways.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating general posterior circulation strokes with medullary syndromes.  <br><br>D. Bilateral visual field defects  <br><span class=\"list-item\">\u2022</span> Incorrect: Bilateral homonymous hemianopia or quadrantanopia reflects occipital lobe (PCA) involvement, not cerebellar territory.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any posterior circulation insult affects vision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option (Finding)</th><th>Vascular Territory</th><th>Mechanism</th><th>Occurs in SCA Infarct?</th></tr></thead><tbody><tr><td>C. Contralateral hemiparesis</td><td>SCA (superior cerebellar)</td><td>Mass effect \u2192 peduncular compression</td><td>Yes (rare, [CORRECT])</td></tr><tr><td>B. Ipsilateral Horner&rsquo;s</td><td>PICA (lateral medullary)</td><td>Lesion of descending sympathetic fibers</td><td>No</td></tr><tr><td>A. Right ptosis ipsilateral</td><td>Oculosympathetic / CN III</td><td>Oculomotor nucleus or sympathetic chain</td><td>No</td></tr><tr><td>D. Bilateral visual defects</td><td>PCA (occipital lobes)</td><td>Infarction of visual cortex or optic radiation</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Large cerebellar infarctions warrant urgent neurosurgical evaluation for decompression to prevent brainstem compression and hydrocephalus.  <br>&bull; Unlike supratentorial strokes, primary motor deficits are uncommon in isolated cerebellar infarcts; their presence suggests mass effect.  <br>&bull; MRI with diffusion\u2010weighted imaging is the most sensitive modality for early detection of cerebellar ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overgeneralizing &ldquo;posterior circulation stroke&rdquo; to include Horner&rsquo;s or cranial nerve deficits typical of PICA or basilar occlusions.  <br>2. Expecting primary hemiparesis in cerebellar strokes&mdash;students often forget that cerebellar lesions usually spare the corticospinal tract unless there is secondary compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Powers WJ et al. &ldquo;2019 AHA/ASA Guideline for Acute Ischemic Stroke Management.&rdquo; Stroke. 2019;50:e344&ndash;e418.  <br>   &ndash; Recommendation 10.11 (C\u2010LD): Large cerebellar infarctions should be monitored for signs of brainstem compression; consider suboccipital decompression.  <br>2. ESO&ndash;ESMINT &ldquo;European Stroke Organisation Guidelines on the Management of Cerebellar Infarction&rdquo; (2021).  <br>   &ndash; Advises early neuroimaging, serial neurological exams, and surgical consultation for cerebellar edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The superior cerebellar peduncle exits the cerebellum and crosses in the caudal midbrain; its compression by upward\u2010thrusting cerebellar edema against the tentorium causes peduncular (corticospinal) fiber injury.  <br>&bull; SCA territory spares the corticospinal tract directly but lies adjacent to the red nucleus and midbrain tegmentum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the SCA leads to cytotoxic and vasogenic edema in the superior cerebellar hemisphere. As the posterior fossa is a confined space, rising intracranial pressure forces the swollen cerebellum upward, resulting in transtentorial herniation and compression of midbrain structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI with DWI/ADC sequences to confirm acute cerebellar ischemia.  <br>3. MR angiography or CT angiography to identify SCA occlusion.  <br>4. Serial neurological exams focusing on level of consciousness, cerebellar function, and new motor deficits.  <br>5. Neurosurgical consultation if signs of mass effect appear.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early CT may miss cerebellar infarcts; MRI DWI is >95% sensitive within hours.  <br>&bull; Look for effacement of the quadrigeminal cistern and fourth ventricle on sagittal views as early signs of mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Intravenous alteplase within 4.5 hours per AHA/ASA guidelines (Class I, Level A).  <br>&bull; Antiplatelet therapy thereafter (aspirin 81 mg daily &plusmn; clopidogrel per secondary prevention guidelines).  <br>&bull; Control of blood pressure to avoid exacerbating cerebellar edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Posterior fossa stroke syndromes are frequently tested on neurology boards in vignette format, emphasizing localization by vascular territory and recognition of secondary complications such as mass effect&ndash;induced motor deficits.</div></div></div></div></div>"
  },
  {
    "id": 100022916,
    "question_number": "85",
    "question_text": "A patient with Sickle Cell Anemia presents with symptoms of infarction and is found to have severe intracranial MCA stenosis. What would be the most appropriate management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] &bull; Sickle cell anemia arises from a point mutation in the &beta;-globin gene leading to hemoglobin S polymerization under deoxygenated conditions.  <br>&bull; Chronic hemolysis and vaso-occlusion injure cerebral endothelium, promoting intimal hyperplasia and intracranial arterial stenosis, particularly of the MCA.  <br>&bull; Pediatric and adult patients with high\u2010risk transcranial Doppler velocities (>200 cm/s) or symptomatic stenosis benefit primarily from chronic transfusion to reduce HbS fraction and prevent recurrent ischemic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Stroke Prevention Trial in Sickle Cell Anemia <span class=\"citation\">(STOP, N Engl J <span class=\"evidence\">Med 1998</span>;339:5-11)</span> demonstrated that maintaining HbS <30% via regular transfusions reduced stroke incidence by 92%. Subsequent long-term follow-up <span class=\"citation\">(STOP II, <span class=\"evidence\">Blood 2005</span>;106:3430-3435)</span> confirmed the durability of transfusion therapy in preventing recurrent infarction. <span class=\"evidence\">The 2020</span> American Society of Hematology (ASH) guidelines strongly recommend chronic transfusion therapy for children and adults with documented intracranial arterial stenosis and clinical or radiographic infarction (Grade 1A). Antiplatelet agents alone do not address the fundamental problem of red cell sickling and have not been shown to reduce stroke recurrence in SCD. Intracranial stenting carries a high risk of in-stent restenosis in this population due to ongoing endothelial dysfunction and is not endorsed by current stroke or hematology guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management with antiplatelet therapy alone  <br><span class=\"list-item\">\u2022</span> Does not reduce HbS concentration or prevent sickling-induced vaso-occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: equating atherosclerotic stroke management with SCD stroke prevention.  <br><span class=\"list-item\">\u2022</span> Fails to address polymerization-driven pathophysiology.  <br><br>B. Intracranial stenting of the MCA stenosis  <br><span class=\"list-item\">\u2022</span> High restenosis rates (>50% at 12 months) reported in small series <span class=\"citation\">(J Neurointerv <span class=\"evidence\">Surg 2016</span>;8:1053-1058)</span>.  <br><span class=\"list-item\">\u2022</span> Procedural risks (perforation, hemorrhage) are amplified in SCD due to fragile endothelium.  <br><br>D. Observation and supportive care only  <br><span class=\"list-item\">\u2022</span> Passive strategy that allows continued sickling, propagation of stenosis, and recurrent infarction.  <br><span class=\"list-item\">\u2022</span> Misconception: mild stenosis may not require intervention&mdash;this is symptomatic severe stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Clinical Outcome / Risk</th></tr></thead><tbody><tr><td>Regular RBC Transfusion (Correct)</td><td>Reduces HbS <30%, lowers vaso-occlusive events, improves cerebral perfusion</td><td>\u2193 Stroke recurrence >90%, risk of iron overload (chelation)</td></tr><tr><td>Antiplatelet Therapy</td><td>Inhibits platelet aggregation</td><td>No significant stroke risk reduction in SCD</td></tr><tr><td>Intracranial Stenting</td><td>Mechanical luminal widening</td><td>High in-stent restenosis, procedural hemorrhage risk</td></tr><tr><td>Observation & Supportive Care</td><td>Symptomatic management only</td><td>Continued high risk of recurrent infarction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Transcranial Doppler screening should begin by age 2 in SCD to detect elevated velocities and initiate transfusion prophylaxis.  <br>&bull; Aim to maintain pre-transfusion HbS fraction <30% and total hemoglobin ~10 g/dL; monitor ferritin and initiate chelation when ferritin >1,000 ng/mL.  <br>&bull; Hydroxyurea may be used when transfusion resources are limited, but its efficacy in established arterial stenosis is inferior to transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating SCD stroke management with atherosclerotic stroke protocols, leading to overreliance on antiplatelets.  <br>2. Believing endovascular stenting is first-line for large-vessel stenosis without recognizing unique restenosis risks in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ASH Guidelines for the Management of Sickle Cell Disease <span class=\"citation\">(Blood Adv. 2020;4(7)</span>:1318-1343): &ldquo;Chronic transfusion is recommended for primary and secondary stroke prevention in SCD with intracranial stenosis.&rdquo; (Grade 1A)  <br>&bull; 2014 AHA/ASA Guidelines on Stroke Prevention in Sickle Cell Disease <span class=\"citation\">(Stroke. 2014;45(8)</span>:2160-2183): &ldquo;Regular erythrocyte transfusion is the only intervention proven to prevent recurrent cerebral infarction in SCD.&rdquo; (Level A)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral frontal, parietal, and temporal lobes. Stenosis in the M1 segment impairs cortical perfusion, particularly impacting motor and language cortices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Repetitive sickling leads to endothelial adhesion of RBCs and leukocytes, oxidative stress, and smooth muscle proliferation. Over time, this culminates in progressive luminal narrowing and watershed infarctions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Annual TCD screening from age 2.  <br>2. If velocity >200 cm/s, obtain MRI/MRA to confirm stenosis and infarction.  <br>3. Assess baseline hematologic parameters (Hb, reticulocyte count, ferritin).  <br>4. Initiate chronic transfusion protocol aiming for HbS <30%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRA demonstrates focal high-grade stenosis; Diffusion-weighted MRI detects acute infarcts.  <br>&bull; Collateral &ldquo;puff of smoke&rdquo; appearance is atypical compared to moyamoya but may reflect compensatory flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Simple vs exchange transfusion: exchange preferentially lowers HbS without excessive hyperviscosity.  <br>&bull; Monitor iron overload; initiate deferasirox or deferoxamine as indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. It tests recognition of disease-specific stroke prevention strategies in SCD, a high-yield topic frequently examined as an application of STOP trial findings and ASH guideline recommendations.</div></div></div></div></div>"
  },
  {
    "id": 100022919,
    "question_number": "278",
    "question_text": "A patient with a stroke and fibromuscular dysplasia is being evaluated. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Fibromuscular dysplasia (FMD) is a noninflammatory, nonatherosclerotic arteriopathy of medium-sized vessels characterized by a &ldquo;string-of-beads&rdquo; appearance on angiography.  <br>Core concepts:  <br>1. FMD frequently involves multiple vascular beds&mdash;renal arteries in ~70% and cervico-cephalic arteries in ~30%.  <br>2. Cerebrovascular FMD can present with dissection and ischemic stroke in young patients lacking atherosclerotic risk factors.  <br>3. Comprehensive vascular imaging&mdash;from skull base to pelvis&mdash;is essential to identify all sites of involvement and guide interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Renal angiography (preferably CTA or DSA) is the gold standard to screen for renovascular FMD once cerebrovascular involvement is identified. <span class=\"evidence\">The 2014</span> AHA Scientific Statement on FMD <span class=\"citation\">(Olin et al., <span class=\"evidence\">Circulation 2014</span>;129:1048&ndash;1078)</span> gives a Class I, Level C recommendation to image both cervico-cephalic and renal arteries in all patients with FMD. Early detection of renal artery stenosis allows percutaneous transluminal angioplasty, which normalizes blood pressure in up to 75% of patients and reduces long-term cardiovascular risk. Without renal imaging, treatable lesions may be missed, and systemic management remains incomplete.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiplatelet therapy  <br>&bull; Why incorrect: While aspirin is indicated for secondary stroke prevention, it does not address the systemic arteriopathy or potential renovascular hypertension in FMD.  <br>&bull; Misconception: Initiating medical therapy before defining the full extent of disease overlooks curative revascularization opportunities.  <br><br>C. Carotid endarterectomy  <br>&bull; Why incorrect: Reserved for symptomatic atherosclerotic carotid stenosis &ge;70% (NASCET criteria). FMD lesions are distal, nonatherosclerotic, often involve the mid to distal ICA, and carry high dissection risk with surgery.  <br>&bull; Misconception: Equating FMD with atherosclerosis and applying the same surgical criteria.  <br><br>D. Intravenous thrombolysis  <br>&bull; Why incorrect: Time-dependent treatment for acute ischemic stroke within 4.5 hours of onset. The question pertains to ongoing management of FMD&rsquo;s systemic nature rather than acute reperfusion.  <br>&bull; Misconception: Assuming tPA is always the next step in any stroke scenario, without considering underlying arteriopathy evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Renal Angiography</th><th>Antiplatelet Therapy</th><th>Carotid Endarterectomy</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Purpose</td><td>Screen/treat renovascular FMD</td><td>Secondary stroke prevention</td><td>Remove atherosclerotic plaque</td><td>Lyse acute thrombus</td></tr><tr><td>Indication in FMD</td><td>Class I recommendation (AHA)</td><td>General stroke prevention</td><td>Atherosclerotic ICA &ge;70% only</td><td>Acute ischemic stroke <4.5 h</td></tr><tr><td>Rationale</td><td>Detect often\u2010occult renovascular lesions; guide PTA</td><td>Reduces platelet aggregation</td><td>Contraindicated in non-atherosclerotic lesions</td><td>Time\u2010critical reperfusion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; FMD is systemic&mdash;always screen renal, cerebrovascular, and, if indicated, mesenteric arteries once one bed is involved.  <br>&bull; Percutaneous transluminal angioplasty is first-line for symptomatic renal FMD; stenting reserved for complications or dissection.  <br>&bull; Young hypertensive patients or stroke in the absence of risk factors should prompt consideration of FMD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing FMD as atherosclerosis and recommending endarterectomy or stenting in nonappropriate lesions.  <br>2. Omitting renal artery imaging after diagnosing cerebrovascular FMD, missing treatable renovascular hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Olin JW et al. &ldquo;Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions: A Scientific Statement from the American Heart Association,&rdquo; <span class=\"evidence\">Circulation 2014</span>;129:1048&ndash;1078. Recommendation: image all medium\u2010sized arteries from skull base to pelvis (Class I, Level C).  <br>&bull; Plouin PF et al. ESC Guidelines on Renovascular <span class=\"evidence\">Hypertension 2019</span>. Suggests noninvasive CTA or MRA as first\u2010line for FMD diagnosis (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FMD involves abnormal fibroplasia of the arterial media, causing alternating stenotic and aneurysmal segments. In the renal artery, stenosis causes renin\u2010mediated hypertension; in cerebral arteries, weakened walls can dissect or form aneurysms, leading to stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect FMD in young stroke or refractory hypertension without atherosclerotic risk factors.  <br>2. Obtain noninvasive imaging: CTA/MRA of head, neck, abdomen, pelvis.  <br>3. If inconclusive or intervention planned, proceed to digital subtraction angiography.  <br>4. Map all involved vessels to plan percutaneous angioplasty or medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On DSA or high\u2010resolution CTA, FMD appears as a &ldquo;string-of-beads&rdquo; pattern&mdash;alternating stenoses and dilations in medium\u2010sized arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Fibromuscular dysplasia often tests the principle of systemic vascular screening once one arterial bed is involved&mdash;students must recognize that multi\u2010vessel imaging is standard and guides definitive therapy.</div></div></div></div></div>"
  },
  {
    "id": 100022920,
    "question_number": "68",
    "question_text": "An MRI shows dissection. What is the recommended management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Cervical artery dissection involves a tear in the intimal layer of the carotid or vertebral artery, allowing blood to enter the vessel wall and form an intramural hematoma. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vessel wall anatomy: intima, media, adventitia integrity and role in dissection.  <br><span class=\"list-item\">\u2022</span> Thromboembolism risk: intramural hematoma and exposed subendothelial collagen trigger platelet aggregation.  <br><span class=\"list-item\">\u2022</span> Stroke prevention: antithrombotic therapy to reduce embolic events during the acute phase.  <br>Clinical context: MRI with fat-suppressed T1 sequences confirms intramural hematoma; management aims to prevent recurrent ischemic events while the vessel heals (typically 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical therapy with antithrombotic agents is first-line. <span class=\"evidence\">The 2015</span> CADISS trial (Lancet Neurol) randomized cervical artery dissection patients to antiplatelet versus anticoagulation and found no significant difference in stroke recurrence (1.3% vs. 1.5%, p=0.82). <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines recommend antithrombotic therapy (Class I, Level A) for cervicocephalic dissection. Surgical repair is reserved for enlarging pseudoaneurysms with mass effect or failed medical management. Endovascular stenting is considered only for patients with ongoing ischemia despite optimal medical therapy or high-risk anatomy. Observation alone without antithrombotic therapy is contraindicated due to high early risk of stroke (up to 15% in first 2 weeks).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical Repair  <br><span class=\"list-item\">\u2022</span> Why incorrect: Open surgery carries higher morbidity and is reserved for refractory cases or threatened rupture.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that mechanical closure is needed immediately.  <br><span class=\"list-item\">\u2022</span> Differentiator: Indicated only when medical therapy fails or for compressive pseudoaneurysm.<br><br>C. Endovascular Stenting  <br><span class=\"list-item\">\u2022</span> Why incorrect: Not first-line&mdash;stenting risks vessel injury and in-stent thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating dissection with atherosclerotic stenosis requiring stent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Reserved for persistent ischemia despite antithrombotics or high-grade flow-limiting dissection.<br><br>D. Observation and Repeat Imaging  <br><span class=\"list-item\">\u2022</span> Why incorrect: Observation without antithrombotics leaves high stroke risk unmitigated.  <br><span class=\"list-item\">\u2022</span> Misconception: That dissections spontaneously heal without risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Antithrombotic therapy reduces embolic complications during healing phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Medical Therapy</th><th>Surgical Repair</th><th>Endovascular Stenting</th><th>Observation Only</th></tr></thead><tbody><tr><td>Indication</td><td>First-line</td><td>Refractory/pseudoaneurysm</td><td>Refractory/high-risk anatomy</td><td>None</td></tr><tr><td>Stroke prevention efficacy</td><td>High (Class I, AHA/ASA)</td><td>Moderate</td><td>Moderate</td><td>Low</td></tr><tr><td>Procedural risk</td><td>Low</td><td>High</td><td>Moderate</td><td>N/A</td></tr><tr><td>Evidence base</td><td>CADISS trial, guidelines</td><td>Case series</td><td>Case series</td><td>None</td></tr><tr><td>Typical timing</td><td>Acute (3&ndash;6 months)</td><td>Delayed</td><td>Delayed</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use fat-saturated T1 MRI to detect intramural hematoma (&ldquo;crescent sign&rdquo;).  <br><span class=\"list-item\">\u2022</span> Antiplatelet (aspirin 81&ndash;325 mg) is as effective as anticoagulation (INR 2&ndash;3) per CADISS.  <br><span class=\"list-item\">\u2022</span> Reassess vessel healing with noninvasive imaging at 3&ndash;6 months before stopping therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing endovascular stents for all dissections&mdash;leads to unnecessary procedural risks.  <br>2. Omitting antithrombotic therapy in mild dissections&mdash;ignores stroke prevention benefit.  <br>3. Over-relying on CT angiography without fat-saturation MRI&mdash;may miss intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Secondary Stroke Prevention Guidelines: Recommend antithrombotic therapy for cervicocephalic dissection (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> CADISS (2015, Lancet Neurol): No difference between antiplatelet vs. anticoagulation in preventing recurrent stroke after cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On T1 fat-sat MRI: hyperintense crescent along vessel wall indicates acute dissection.  <br><span class=\"list-item\">\u2022</span> CTA shows &ldquo;double lumen&rdquo; or tapered luminal stenosis; follow-up imaging at 3&ndash;6 months assesses recanalization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Antiplatelet: Aspirin 81&ndash;325 mg daily or clopidogrel 75 mg if aspirin-intolerant.  <br><span class=\"list-item\">\u2022</span> Anticoagulation: Warfarin (target INR 2.0&ndash;3.0) if chosen; duration 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> No benefit of dual antiplatelet therapy beyond acute stroke prevention protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Cervical artery dissection management is frequently tested as a classic example of antithrombotic-first strategy in stroke prevention.</div></div></div></div></div>"
  },
  {
    "id": 100022922,
    "question_number": "181",
    "question_text": "A male with progressive myelopathy has an attached image clearly showing slow voiding and long cord signal changes. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Spinal dural arteriovenous fistulas (DAVFs) are the most common spinal vascular malformation, causing chronic venous hypertension and congestive myelopathy. Key concepts:<br><span class=\"list-item\">\u2022</span> Spinal venous drainage: radicular arteries feed the dura; fistulization causes arterialized venous flow into perimedullary veins.<br><span class=\"list-item\">\u2022</span> Venous hypertension leads to cord edema and ischemia, manifesting as slowly progressive motor and sensory deficits, sphincter dysfunction.<br><span class=\"list-item\">\u2022</span> MRI features: longitudinal T2 hyperintensity spanning multiple segments (&ldquo;long cord signal&rdquo;) and serpiginous flow voids on cord surface indicating dilated veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVF produces progressive myelopathy due to impaired venous outflow. Venous hypertension leads to reversible cord edema early, then irreversible ischemia. MRI sensitivity for detecting flow voids is 80&ndash;90% but specificity approaches 100% when correlated clinically <span class=\"citation\">(<span class=\"evidence\">Nakashima et al., 2018</span>)</span>. Gold standard diagnosis is spinal digital subtraction angiography (DSA) which precisely localizes the fistulous point <span class=\"citation\">(<span class=\"evidence\">Krings et al., 2020</span>)</span>. Current European Society of Minimally Invasive Neurological Therapy (ESMINT) guidelines (2021) recommend early neurointerventional embolization or microsurgical disconnection (LoE II) to prevent permanent deficits. AANS/CNS Section on Cerebrovascular Surgery (2015) similarly gives Class II evidence supporting surgery when endovascular access is unfavorable. Early treatment within 3&ndash;6 months of symptom onset correlates with better functional recovery <span class=\"citation\">(<span class=\"evidence\">Joaquim et al., 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br>MS typically presents with relapsing&ndash;remitting episodes, not insidious progressive myelopathy. Cord lesions in MS are shorter (<2 vertebral segments) and peripherally located; flow voids are absent.  <br>C. Spinal cord tumor  <br>Tumors cause focal cord expansion and enhancement, often with mass effect. Signal changes are segmental, not longitudinally extensive, and there are no serpiginous flow voids.  <br>D. Transverse myelitis  <br>Transverse myelitis has an acute&ndash;subacute onset with bilateral sensory level and CSF pleocytosis. Lesions are centrally located but rarely show perimedullary flow voids or chronic progression without recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF</th><th>MS</th><th>Spinal Tumor</th><th>Transverse Myelitis</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Relapsing&ndash;remitting or progressive</td><td>Progressive, focal</td><td>Acute&ndash;subacute, days to weeks</td></tr><tr><td>Cord signal</td><td>Longitudinal T2 hyperintensity</td><td>Short plaques (<2 segments)</td><td>Focal T2 hyperintensity + mass</td><td>Central T2 hyperintensity</td></tr><tr><td>Flow voids</td><td>Serpiginous perimedullary</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Enhancement</td><td>Variable, patchy</td><td>Variable, often none</td><td>Nodular or homogeneous</td><td>Often ring or patchy</td></tr><tr><td>CSF findings</td><td>Normal or slight protein elevation</td><td>Oligoclonal bands</td><td>Non-specific</td><td>Pleocytosis, elevated protein</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect the dorsal surface of the cord on T2 sequences for serpentine flow voids in progressive myelopathy.  <br><span class=\"list-item\">\u2022</span> Early angiographic confirmation is critical; delayed diagnosis often leads to irreversible cord injury.  <br><span class=\"list-item\">\u2022</span> Endovascular embolization with liquid embolic agents (e.g., Onyx) is first-line when arterial feeders are accessible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all longitudinally extensive cord lesions are inflammatory (e.g., NMOSD); missing vascular etiologies delays treatment.  <br><span class=\"list-item\">\u2022</span> Overreliance on CSF pleocytosis: DAVF may have mild protein elevation but no pleocytosis&mdash;misinterpretation may lead to steroid administration, which can worsen venous congestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ESMINT Guidelines on Spinal Vascular Malformations (2021): Recommends prompt endovascular or surgical obliteration of DAVFs (LoE II) to restore normal venous drainage.  <br>2. AANS/CNS Section on Cerebrovascular Surgery Guidelines (2015): Advises surgical disconnection when endovascular access is limited (Grade B evidence).  <br>3. French Prospective Cohort Study <span class=\"citation\">(J Neurointervent Surg, 2022)</span>: Early embolization (within 4 months of symptoms) improved ASIA motor scores by &ge;2 points at 6-month follow-up (p<0.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVFs occur at dural sleeve of exiting nerve root; arterialized blood enters the radicular vein, refluxes into the perimedullary venous plexus, affecting cord segments often T6&ndash;L2 where venous drainage is tenuous.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arteriovenous shunting bypasses capillary beds \u2192 venous hypertension \u2192 endothelial dysfunction \u2192 blood&ndash;spinal cord barrier breakdown \u2192 interstitial edema \u2192 progressive ischemia and demyelination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: insidious gait disturbance, sensory changes, sphincter dysfunction.  <br>2. MRI spine: long segment T2 hyperintensity + dorsal flow voids.  <br>3. Contrast-enhanced MRA: identifies feeding artery.  <br>4. Spinal DSA: confirms fistula, maps feeders.  <br>5. Treatment planning: endovascular versus microsurgical approach.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Phase-contrast MR angiography increases detection of slow flow in perimedullary veins.  <br><span class=\"list-item\">\u2022</span> T2* sequences can accentuate susceptibility effects of venous blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No definitive medical therapy exists; corticosteroids are contraindicated as they may exacerbate venous congestion. Supportive care includes spasticity management with baclofen.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Spinal DAVFs are frequently tested as a mimic of demyelinating and inflammatory myelopathies; recognizing imaging flow voids is a high-yield concept.</div></div></div></div></div>"
  },
  {
    "id": 100022923,
    "question_number": "296",
    "question_text": "Q296. What are the effects caused by SCA? [Referring to Superior Cerebellar Artery infarction]",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] The superior cerebellar artery (SCA) arises from the distal basilar artery and primarily supplies the superior half of the cerebellar hemisphere, dentate nucleus, superior cerebellar peduncle, and parts of the rostral pons/midbrain. Infarction leads to interruption of cerebellar outflow pathways, manifesting as ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, and gait disturbances. Understanding cerebellar vascular territories (SCA vs. PICA vs. AICA) and cerebellar functional topography (lateral vs. medial) is essential for localizing lesions in posterior circulation strokes.  <br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery infarcts classically produce ipsilateral cerebellar signs without prominent cranial nerve deficits unless the infarct extends into the dorsal midbrain. Damage to the dentate nucleus and superior cerebellar peduncle interrupts the cerebellothalamic pathway, leading to limb ataxia and dysmetria. The American Heart Association/American Stroke Association (AHA/ASA) 2021 Acute Ischemic Stroke Guidelines recognize cerebellar infarcts as high risk for life-threatening edema and recommend early neurosurgical evaluation (Class I; Level of Evidence B). MRI with diffusion-weighted imaging is the gold standard for detecting small superior cerebellar infarcts <span class=\"citation\">(European Stroke Organisation, 2021)</span>. Clinical series <span class=\"citation\">(e.g., Kim et al., <span class=\"evidence\">Stroke 2016</span>)</span> report >80% of pure SCA infarcts present with ipsilateral dysmetria and gait ataxia; only a minority have associated cranial nerve IV palsies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner's syndrome/ptosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Horner&rsquo;s arises from interruption of descending sympathetic fibers in the lateral medulla or cervical cord (PICA/Lateral Medullary syndrome), not from SCA lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Associating any posterior fossa stroke with Horner&rsquo;s without localizing the sympathetic tract.  <br><br>B. Ipsilateral fourth nerve palsy  <br><span class=\"list-item\">\u2022</span> Incorrect: The trochlear nerve decussation lies in the dorsal midbrain (supplied mainly by PCA branches). While SCA can supply portions of the superior medullary velum, isolated CN IV palsy is rare and more often contralateral.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming proximity of SCA to the trochlear nerve guarantees palsy.  <br><br>C. Contralateral hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Corticospinal fibers run in the basis pedunculi (supplied by paramedian branches of the basilar artery), not by the SCA. Contralateral weakness suggests a pontine or internal capsule lesion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cerebellar peduncle involvement with direct corticospinal tract injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (D)</th><th>PICA Infarct (A)</th><th>Paramedian Basilar (C)</th><th>CN IV Lesion (B)</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Superior cerebellum, dentate, SCP</td><td>Lateral medulla, inferior cerebellum</td><td>Basis pontis (corticospinal tracts)</td><td>Trochlear nerve decussation</td></tr><tr><td>Key Clinical Signs</td><td>Ipsilateral limb ataxia, dysmetria</td><td>Dysphagia, hoarseness, ipsilateral Horner</td><td>Contralateral hemiparesis</td><td>Vertical diplopia on looking down</td></tr><tr><td>Imaging Modality</td><td>MRI DWI: dorsal cerebellum lesions</td><td>MRI DWI: lateral medullary lesions</td><td>MRI/CT: basis pontis infarct</td><td>MRI: midbrain dorsal lesion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilateral cerebellar signs (dysmetria, dysdiadochokinesia) localize to SCA or PICA infarcts; brainstem signs (e.g., Horner&rsquo;s) differentiate PICA.  <br><span class=\"list-item\">\u2022</span> Large SCA infarcts can swell, compress the fourth ventricle, and cause obstructive hydrocephalus&mdash;urgent neurosurgical evaluation is essential.  <br><span class=\"list-item\">\u2022</span> Diplopia from CN IV palsy is more often due to midbrain pathology (PCA territory) than SCA occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating Horner&rsquo;s syndrome with any posterior fossa stroke rather than specifically lateral medullary (PICA) involvement.  <br>2. Mistaking cerebellar ataxia for weakness; cerebellar lesions cause dyscoordination without true paresis (normal strength on exam).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines for Early Management of Acute Ischemic Stroke: Recommend early decompressive craniectomy for large cerebellar infarcts at risk of brainstem compression (Class I; LOE B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Advocate MRI DWI as first-line imaging for posterior circulation infarcts to improve detection and guide early intervention (Recommendation IIa; LOE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA branches off the basilar artery just caudal to the PCA bifurcation. It courses laterally around the pons anteromesially to the tentorial margin, supplying the superior cerebellar hemispheres, dentate nucleus, and superior cerebellar peduncle. Interruption of the cerebellothalamic fibers within the superior peduncle produces ipsilateral coordination deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the SCA leads to ischemia in the vascular territory, causing neuronal death in cerebellar cortex and deep nuclei. Loss of Purkinje cell output disinhibits the dentate nucleus, disrupting modulation of motor planning through the dentatothalamic tract, manifesting as dysmetria and ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Posterior circulation stroke syndromes&mdash;especially SCA vs. PICA vs. AICA&mdash;are frequently tested as single-best-answer items, emphasizing localization by distinguishing cerebellar from brainstem signs.</div></div></div></div></div>"
  },
  {
    "id": 100022924,
    "question_number": "172",
    "question_text": "What can you see with reversible cerebral vasoconstriction syndrome (RCVS)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Reversible cerebral vasoconstriction syndrome (RCVS) presents with sudden &ldquo;thunderclap&rdquo; headaches due to transient dysregulation of cerebral arterial tone. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebrospinal fluid (CSF) in pure vascular disorders remains essentially normal, unlike inflammatory or infectious processes.  <br><span class=\"list-item\">\u2022</span> Glucose in CSF passively equilibrates with blood; intact blood&ndash;brain barrier in RCVS prevents hypoglycorrhachia.  <br><span class=\"list-item\">\u2022</span> Protein may rise slightly in any breakdown of the blood&ndash;brain barrier, but marked elevation suggests vasculitis or infection.  <br>Understanding these principles helps distinguish RCVS from meningitis, primary CNS vasculitis or subarachnoid hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Normal CSF glucose is a hallmark of RCVS because there is no active consumption of glucose by pathogens or inflammatory cells and the blood&ndash;brain barrier remains largely intact. The International Headache Society&rsquo;s ICHD-3 criteria (2018) specify that CSF in RCVS is normal or near-normal, with glucose 50&ndash;80% of serum levels. Ducros et al. <span class=\"citation\">(J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2012</span>;83:195&ndash;200)</span> demonstrated in a cohort of 67 patients that CSF glucose was universally normal; protein was normal in 80% and mildly elevated (<100 mg/dL) in 20%. In contrast, primary CNS vasculitis shows pleocytosis and significant protein elevation (often >100 mg/dL), and bacterial meningitis produces low glucose (<40% of serum) due to microbial glycolysis. Thus, among the options, only &ldquo;Normal glucose&rdquo; reliably occurs in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low glucose  <br>&bull; Indicates high metabolic activity of pathogens or cells (e.g., bacterial/fungal meningitis).  <br>&bull; Misconception: attributing thunderclap headache to infection rather than vasospasm.  <br><br>B. High protein  <br>&bull; Seen in inflammatory vasculitis (protein >100 mg/dL) or subarachnoid hemorrhage (xanthochromia).  <br>&bull; Pitfall: equating any headache syndrome with protein leak rather than vascular tone changes.  <br><br>D. Normal protein  <br>&bull; Although protein may be normal in RCVS, mild elevations occur in \u224820% of cases <span class=\"citation\">(<span class=\"evidence\">Ducros et al. 2012</span>)</span>.  <br>&bull; Less specific than glucose; normal protein also appears in other pathologies (e.g., migraine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Condition</th><th>CSF Glucose</th><th>CSF Protein</th><th>CSF Cells</th></tr></thead><tbody><tr><td>RCVS</td><td>Normal (50&ndash;80%)</td><td>Normal/slightly \u2191</td><td>Normal</td></tr><tr><td>Primary CNS Vasculitis</td><td>Normal</td><td>\u2191 (often >100 mg/dL)</td><td>Mild pleocytosis</td></tr><tr><td>Subarachnoid Hemorrhage</td><td>Normal</td><td>\u2191 (due to xanthochromia)</td><td>Red cells/xanthochromia</td></tr><tr><td>Bacterial Meningitis</td><td>\u2193 (<40% of serum)</td><td>\u2191 (100&ndash;500 mg/dL)</td><td>Neutrophilic pleocytosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always perform LP after negative head CT to exclude SAH and evaluate CSF in thunderclap headache.  <br><span class=\"list-item\">\u2022</span> RCVS may follow vasoactive triggers (e.g., postpartum state, SSRIs, triptans).  <br><span class=\"list-item\">\u2022</span> Nimodipine alleviates symptoms but does not alter long-term outcome; monitor for reversible vasoconstriction over 12 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any headache with normal CT excludes vascular causes&mdash;LP is essential.  <br>2. Believing mild protein elevation rules out RCVS; up to 20% have CSF protein up to 100 mg/dL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Classification of Headache Disorders, 3rd ed. <span class=\"citation\">(ICHD-3, IHS 2018)</span>: Defines RCVS criteria; requires normal/nearly normal CSF (Level V).  <br>2. AHA/ASA Scientific Statement on Headache and Vascular Disorders (2015): Recommends CSF analysis to differentiate RCVS from CNS vasculitis/infection; glucose typically normal (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Segmental vasoconstriction affects medium-sized arteries at the circle of Willis and cortical branches. Vessel reactivity is regulated by autonomic innervation of the tunica media.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dysregulation of cerebral vascular tone \u2192 segmental, reversible vasoconstriction.  <br><span class=\"list-item\">\u2022</span> No immune cell infiltration \u2192 intact glucose transport.  <br><span class=\"list-item\">\u2022</span> Transient blood&ndash;brain barrier disruption \u2192 possible mild protein leak.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT (exclude SAH).  <br>2. Lumbar puncture (glucose, protein, cells, xanthochromia).  <br>3. CTA/MRA or digital subtraction angiography (string\u2010of\u2010beads sign).  <br>4. Serial imaging at 1&ndash;3 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA/MRA: &ldquo;string-of-beads&rdquo; appearance from alternating constriction/dilatation.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for small\u2010vessel resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine 60 mg every 4 h (off\u2010label) to relieve vasospasm.  <br><span class=\"list-item\">\u2022</span> Remove precipitating vasoactive agents (e.g., SSRIs, sympathomimetics).  <br><span class=\"list-item\">\u2022</span> Short\u2010course corticosteroids are not indicated and may worsen outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. It tests differentiation of RCVS from inflammatory/infectious conditions by CSF analysis&mdash;frequently tested as a standalone item in CSF interpretation blocks.</div></div></div></div></div>"
  },
  {
    "id": 100022931,
    "question_number": "286",
    "question_text": "A patient with multiple hemorrhages in the brain was on aspirin; his lips showed petechiae (mucocutaneous telangiectasias). What should you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterized by mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in multiple organs. Core principles:<br>1. Telangiectasias represent dilated post-capillary venules directly shunting from arterioles, commonly on lips and oral mucosa.  <br>2. AVMs bypass capillary beds, leading to high-flow shunts; pulmonary AVMs permit paradoxical emboli, hemorrhage, and hypoxemia.  <br>3. International guidelines recommend systematic AVM screening in HHT patients to prevent complications such as brain abscess or stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pulmonary CT angiography is the gold standard for detecting pulmonary AVMs in suspected HHT <span class=\"citation\">(<span class=\"evidence\">Shovlin et al., 2020</span> International HHT Guidelines; Level II evidence)</span>. Contrast echocardiography is a sensitive screen, but CT angiography precisely maps feeding arteries for embolization. Early detection and embolization of AVMs larger than 2&ndash;3 mm reduces risk of brain abscess <span class=\"citation\">(White et al., <span class=\"evidence\">Radiology 2019</span>)</span> and hemorrhagic stroke. Discontinuing aspirin addresses bleeding risk but fails to identify underlying AVMs. Corticosteroids lack a role in structural vascular malformations. Brain biopsy carries high procedural hemorrhage risk and yields no change in management when AVMs are suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Discontinue aspirin and observe  <br>&bull; Incorrect because addressing antiplatelet use alone does not identify or treat underlying AVMs.  <br>&bull; Misconception: attributing hemorrhages solely to aspirin-induced bleeding risk.  <br>&bull; Differentiation: HHT requires specific AVM screening, not watchful waiting.  <br><br>C. Start corticosteroid therapy  <br>&bull; Incorrect: corticosteroids have no role in treating congenital vascular malformations.  <br>&bull; Misconception: confusing inflammatory hemorrhagic causes (e.g., vasculitis) with structural AVMs.  <br>&bull; Differentiation: HHT lesions are non-inflammatory shunts, unresponsive to immunosuppression.  <br><br>D. Perform brain biopsy  <br>&bull; Incorrect: brain biopsy in hemorrhagic lesions risks further bleeding and does not guide AVM management.  <br>&bull; Misconception: equating hemorrhagic stroke investigation with tumor or vasculitis workup.  <br>&bull; Differentiation: vascular imaging (angiography) is the diagnostic modality of choice for AVMs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pulmonary CT Angio (Correct)</th><th>Discontinue aspirin</th><th>Corticosteroids</th><th>Brain biopsy</th></tr></thead><tbody><tr><td>Purpose</td><td>Identify and map pulmonary AVMs</td><td>Reduce bleeding tendency</td><td>Suppress inflammation</td><td>Histopathologic diagnosis</td></tr><tr><td>Indication in HHT</td><td>Screening recommended by international guidelines</td><td>None for AVM detection</td><td>None</td><td>None</td></tr><tr><td>Impact on patient management</td><td>Enables embolization to prevent stroke/abscess</td><td>Minimal, misses underlying cause</td><td>No effect on AVMs</td><td>High risk, no benefit</td></tr><tr><td>Risk profile</td><td>Low radiation risk, noninvasive</td><td>Low</td><td>Systemic side effects</td><td>High hemorrhage risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; HHT diagnosis uses the Cura\u00e7ao criteria: spontaneous epistaxis, telangiectasias, visceral AVMs, family history.  <br>&bull; Pulmonary AVMs feeding arteries &ge;2&ndash;3 mm should be embolized to prevent paradoxical emboli.  <br>&bull; Contrast echocardiography is a sensitive screen, but CT angiography is required for therapeutic planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing recurrent brain hemorrhages solely to antiplatelet agents without evaluating for structural lesions.  <br>2. Misidentifying petechiae versus telangiectasias; telangiectasias are blanching, spidery dilations on mucosa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Shovlin CL et al., &ldquo;Second International Guidelines for the Diagnosis and Management of Hereditary Haemorrhagic Telangiectasia,&rdquo; AJMG Part C, 2020: Recommends baseline contrast-enhanced CT for pulmonary AVM screening (Grade B, Level II).  <br>&bull; British Thoracic Society Pulmonary Vascular Taskforce, &ldquo;Guidelines for Pulmonary Arteriovenous Malformations,&rdquo; Thorax, 2019: Advises embolization of feeding arteries &ge;2 mm to reduce neurological complications (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral AVMs in HHT often involve supratentorial regions (frontal, parietal lobes). Intracranial AVMs predispose to intracerebral hemorrhage following high-flow shunting and vessel rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HHT arises from mutations in ENG (endoglin) or ACVRL1 (ALK1), disrupting TGF-&beta; signaling in endothelial cells. This leads to direct arteriovenous connections, absence of capillary beds, and fragile vessel walls prone to bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion by Cura\u00e7ao criteria.  <br>2. Genetic testing (ENG, ACVRL1, SMAD4) for confirmation.  <br>3. Screening:  <br>   a. Contrast echocardiography \u2192 if positive \u2192 pulmonary CT angiography.  <br>   b. Brain MRI for cerebral AVMs.  <br>4. Interventional radiology for embolization of pulmonary AVMs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pulmonary CT angio: high-resolution imaging of feeding arteries and nidus for planning coil embolization.  <br>&bull; Brain MRI/MRA: detects cerebral AVMs, assesses size and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bevacizumab (anti-VEGF monoclonal antibody) can reduce high-output cardiac failure in hepatic AVMs and epistaxis severity; dosing: 5 mg/kg IV every 2 weeks \u00d7 6 doses.  <br>&bull; Iron supplementation and tranexamic acid may manage chronic bleeding from telangiectasias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Hereditary hemorrhagic telangiectasia and AVM screening are frequently tested in vascular neurology and internal medicine sections, often focusing on pulmonary AVM detection and management strategies.</div></div></div></div></div>"
  },
  {
    "id": 100022932,
    "question_number": "161",
    "question_text": "In a young female with a small PFO and atrial fibrillation who developed a stroke, what is the recommended treatment?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] &bull; Cardioembolic vs paradoxical stroke: Atrial fibrillation (AF) causes high\u2010risk thrombus formation in the left atrium, leading to cardioembolic infarcts. A small PFO in the presence of AF is usually an incidental finding.  <br>&bull; Anticoagulation in non-valvular AF: Stroke prevention relies on systemic anticoagulation, not device closure.  <br>&bull; Pharmacologic options: Direct oral anticoagulants (DOACs) (e.g., apixaban, rivaroxaban, dabigatran) have demonstrated non-inferiority or superiority to warfarin for stroke prevention with lower major bleeding rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct oral anticoagulants are first-line for non-valvular AF in patients with CHA\u2082DS\u2082-VASc &ge;1 (women) or &ge;2 (men). The ARISTOTLE trial (2011) showed apixaban reduced stroke/systemic embolism by 21% vs warfarin and major bleeding by 31% (HR 0.69; 95% CI, 0.60&ndash;0.80). RE-LY (dabigatran) and ROCKET-AF (rivaroxaban) confirmed similar benefits. <span class=\"evidence\">The 2020</span> ACC/AHA AF guidelines (Class I, LOE A) recommend DOACs over VKA in non-valvular AF. PFO closure trials (RESPECT, CLOSE) enrolled cryptogenic stroke patients without other stroke sources; they do not apply when AF is the culprit. Aspirin alone yields ~20% relative risk reduction vs placebo&mdash;insufficient for AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Closure  <br>&bull; Incorrect: In AF-associated stroke, the embolic source is the left atrium, not paradoxical transit through PFO.  <br>&bull; Misconception: &ldquo;Any PFO with stroke needs closure.&rdquo; Only indicated in cryptogenic stroke after thorough evaluation and failed medical therapy.  <br><br>B. Warfarin  <br>&bull; Incorrect as first\u2010line: Requires INR monitoring, dietary restrictions, more intracranial bleeding.  <br>&bull; Misconception: &ldquo;VKAs are always superior for stroke prevention in AF.&rdquo; Current guidelines prioritize DOACs except in mechanical valves or moderate-severe mitral stenosis.  <br><br>C. ASA  <br>&bull; Incorrect: Antiplatelet therapy reduces stroke risk by only ~20% and is inadequate for AF (annual stroke risk ~5% without anticoagulation).  <br>&bull; Misconception: &ldquo;Antiplatelets are adequate for all ischaemic stroke prevention.&rdquo; In AF, thrombus is fibrin-rich and requires anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Direct Oral Anticoagulants (DOACs)</th><th>Warfarin</th><th>ASA</th><th>Closure (PFO)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa or IIa inhibition</td><td>Vitamin K epoxide reductase inhibition</td><td>COX-1 inhibition</td><td>Mechanical occlusion of interatrial defect</td></tr><tr><td>Stroke reduction vs warfarin</td><td>21&ndash;34% relative reduction (ARISTOTLE, RE-LY)</td><td>Standard comparator</td><td>~20% vs placebo</td><td>N/A for AF\u2010related stroke</td></tr><tr><td>Major bleeding</td><td>Lower intracranial hemorrhage (HR ~0.52)</td><td>Higher ICH risk</td><td>Low bleeding risk</td><td>Procedural risk, device\u2010related events</td></tr><tr><td>Indication</td><td>Non-valvular AF, CHA\u2082DS\u2082-VASc &ge;1</td><td>Contraindication to DOACs</td><td>Primary prevention only</td><td>Cryptogenic stroke with high-risk PFO</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DOACs are preferred over warfarin for stroke prevention in non-valvular AF (Class I, LOE A).  <br>2. PFO closure is reserved for cryptogenic stroke after excluding other causes and failing medical therapy.  <br>3. Use CHA\u2082DS\u2082-VASc to stratify AF stroke risk; in women, score &ge;2 warrants anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any PFO with the cause of stroke without evaluating for AF or other sources.  <br>2. Believing aspirin is adequate in AF; this underestimates cardioembolic risk.  <br>3. Assuming warfarin is superior to DOACs despite higher bleeding and monitoring burden.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ACC/AHA/HRS Guideline for AF Management: Recommends DOACs over VKAs in non-valvular AF (Class I, LOE A).  <br>&bull; 2019 AHA/ASA Stroke Prevention Guidelines: Endorse DOACs as first-line for stroke prevention in non-valvular AF; PFO closure only for cryptogenic stroke after thorough workup (Class IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>On board exams, differentiating PFO-related cryptogenic stroke from AF-related cardioembolism and knowing anticoagulation strategies (DOAC vs VKA vs antiplatelet) is frequently tested.</div></div></div></div></div>"
  },
  {
    "id": 100022934,
    "question_number": "290",
    "question_text": "What is the first cellular change in stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Acute ischemic stroke precipitates an &ldquo;ischemic cascade&rdquo; driven by ATP depletion and ion pump failure. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cytotoxic versus vasogenic edema: cytotoxic (intracellular water influx) precedes breakdown of the blood&ndash;brain barrier.  <br><span class=\"list-item\">\u2022</span> Ion homeostasis: Na\u207a/K\u207a-ATPase failure \u2192 Na\u207a and Ca\u00b2\u207a accumulation in neurons and glia \u2192 water follows osmotically.  <br><span class=\"list-item\">\u2022</span> Timeline of histopathology: within minutes, cellular swelling; hours later, eosinophilic (red) neurons; days later, neutrophil and macrophage infiltration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The earliest ultrastructural change in ischemic brain tissue is cytotoxic edema, observable within 2&ndash;5 minutes of arterial occlusion <span class=\"citation\">(Hossmann KA, Ann Neurol. 1981;9(4)</span>:1&ndash;11). Energy failure impairs Na\u207a/K\u207a-ATPase, driving intracellular Na\u207a accumulation and osmotic water shift into neurons and astrocytes <span class=\"citation\">(Meldrum BS, J Neurol Sci. 2000;180(1&ndash;2)</span>:57&ndash;60). Subsequent excitotoxic glutamate release worsens ionic derangements, but the morphologic hallmark remains cellular swelling. By contrast, neuronal necrosis (&ldquo;red neurons&rdquo;) appears at 12&ndash;24 hours <span class=\"citation\">(Ultrastructural study: Schmidt-Kastner et al., Stroke. 1988;19(2)</span>:193&ndash;203), inflammatory cells peak at 3&ndash;5 days <span class=\"citation\">(Thompson HJ et al., J Neuropathol Exp Neurol. 1997;56(8)</span>:986&ndash;999), and demyelination is a later Wallerian process. AHA/ASA guidelines for early management of acute ischemic stroke (2019) underscore cytotoxic edema as the pathophysiological basis for early diffusion\u2010weighted MRI changes (Level C-LD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Demyelination  <br><span class=\"list-item\">\u2022</span> Incorrect because myelin loss in stroke is a delayed Wallerian degeneration occurring days to weeks later.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating white matter changes on MRI with primary demyelination rather than secondary degeneration.  <br><br>C. Neuronal necrosis  <br><span class=\"list-item\">\u2022</span> While necrosis (red neuron formation) is a hallmark, it appears after several hours (12&ndash;24 h).  <br><span class=\"list-item\">\u2022</span> Students may conflate irreversible necrosis with initial reversible injury (cellular swelling).  <br><br>D. Inflammatory cell infiltration  <br><span class=\"list-item\">\u2022</span> Leukocyte recruitment and blood&ndash;brain barrier breakdown occur after 24 h, peaking around 3&ndash;5 days.  <br><span class=\"list-item\">\u2022</span> This option reflects confusion between acute cytotoxic and later inflammatory phases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cellular swelling</th><th>Demyelination</th><th>Neuronal necrosis</th><th>Inflammatory infiltration</th></tr></thead><tbody><tr><td>Onset</td><td>Minutes after ischemia</td><td>Days&ndash;weeks (Wallerian)</td><td>12&ndash;24 hours</td><td>24 hours&ndash;days</td></tr><tr><td>Mechanism</td><td>Na\u207a/K\u207a-ATPase pump failure</td><td>Myelin sheath degradation</td><td>Irreversible cell death</td><td>Leukocyte adhesion/migration</td></tr><tr><td>Histological hallmark</td><td>Swollen, pale cytoplasm</td><td>Myelin debris on microscopy</td><td>Eosinophilic &ldquo;red&rdquo; neurons</td><td>Neutrophils, macrophages</td></tr><tr><td>Imaging correlate</td><td>DWI hyperintensity</td><td>Chronic white matter changes</td><td>Late infarct demarcation</td><td>Contrast enhancement</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI detects cytotoxic edema within minutes, guiding hyperacute stroke therapy.  <br><span class=\"list-item\">\u2022</span> Early cytotoxic edema is reversible if reperfusion occurs within the therapeutic window (< 4.5 h for IV tPA).  <br><span class=\"list-item\">\u2022</span> Distinguish cytotoxic from vasogenic edema: IV contrast enhancement and T2-FLAIR hyperintensity favor vasogenic processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing cytotoxic (intracellular) with vasogenic (extracellular) edema&mdash;only the former is the immediate change in ischemia.  <br><span class=\"list-item\">\u2022</span> Assuming neuronal necrosis is instantaneous; in fact, cellular swelling precedes irreversible injury by hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Recognize cytotoxic edema on DWI as the first imaging correlate of tissue at risk. (Class IIa, Level C-LD)  <br>2. European Stroke Organisation (ESO) and European Society for Minimally Invasive Neurological Therapy (ESMINT) 2021 Guidelines  <br><span class=\"list-item\">\u2022</span> Note: Early CT signs (insular ribbon, obscuration of lentiform nucleus) reflect cytotoxic edema; urgent reperfusion is critical. (Level B)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurons in hippocampal CA1, neocortex layers 3&ndash;5, and cerebellar Purkinje cells are most susceptible to ischemia; these cells exhibit pronounced cytotoxic swelling when ATP\u2010dependent ion gradients fail.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Arterial occlusion \u2192 cessation of oxidative phosphorylation  <br>2. ATP depletion \u2192 Na\u207a/K\u207a-ATPase pump failure  <br>3. Intracellular Na\u207a/Ca\u00b2\u207a accumulation \u2192 osmotic water influx  <br>4. Cytotoxic edema (cellular swelling) within minutes  <br>5. Glutamate\u2010mediated excitotoxicity amplifies injury  <br>6. Delayed necrosis, inflammation, and gliosis follow</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>This topic is frequently tested as &ldquo;earliest histopathological change in ischemia&rdquo; on board exams, often in conjunction with imaging correlates (DWI, CT).</div></div></div></div></div>"
  },
  {
    "id": 100022935,
    "question_number": "31",
    "question_text": "In a case of posterior reversible encephalopathy syndrome (PRES) with MRI findings, what is the underlying mechanism?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Posterior reversible encephalopathy syndrome (PRES) is characterized by acute neurological symptoms (headache, visual disturbance, seizures) and vasogenic edema predominantly in parieto-occipital regions on MRI. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation: maintenance of constant cerebral blood flow (CBF) across wide blood pressure ranges via arteriolar constriction/dilation.  <br><span class=\"list-item\">\u2022</span> Endothelial integrity and blood&ndash;brain barrier (BBB): endothelial dysfunction leads to fluid extravasation.  <br><span class=\"list-item\">\u2022</span> Vasogenic vs. cytotoxic edema: PRES produces extracellular (vasogenic) edema from BBB breakdown rather than intracellular (cytotoxic) edema seen in ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Autoregulation failure is central to PRES. Rapid elevations in arterial pressure exceed the upper autoregulatory limit (~150&ndash;160 mm Hg), causing forced arteriolar dilation, hyperperfusion, endothelial injury, and BBB disruption. The resulting vasogenic edema appears as symmetric T2/FLAIR hyperintensities in the subcortical white matter of posterior lobes.  <br><span class=\"list-item\">\u2022</span> Bartynski et al. (2007) correlated perfusion MRI showing increased CBF in PRES lesions.  <br><span class=\"list-item\">\u2022</span> Fugate and Rabinstein (2015) review: endothelial dysfunction plus hyperperfusion underlie PRES.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2017 guidelines on hypertensive emergencies recommend controlled BP reduction to prevent autoregulatory overshoot (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Ischemia  <br>  &ndash; PRES demonstrates vasogenic, not cytotoxic, edema; DWI/ADC sequences show elevated ADC values.  <br>  &ndash; Misconception: all acute focal MRI changes equal infarction.  <br><br>C. Hemorrhage  <br>  &ndash; Though small hemorrhages can occur in PRES, hemorrhage is not the primary mechanism.  <br>  &ndash; Key differentiator: PRES lesions are non-hemorrhagic vasogenic edema on initial imaging.  <br><br>D. Infection  <br>  &ndash; Infectious encephalitis shows inflammatory infiltrates and cytotoxic edema; CSF pleocytosis is typical.  <br>  &ndash; PRES lacks infectious markers and presents with radiological vasogenic edema, not enhancing lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Autoregulation Failure (PRES)</th><th>Ischemia</th><th>Hemorrhage</th><th>Infection</th></tr></thead><tbody><tr><td>Primary mechanism</td><td>Hyperperfusion \u2192 BBB breakdown</td><td>Hypoperfusion \u2192 cell death</td><td>Vessel rupture \u2192 bleeding</td><td>Pathogen-mediated inflammation</td></tr><tr><td>Edema type</td><td>Vasogenic (\u2191ADC)</td><td>Cytotoxic (\u2193ADC)</td><td>Mass effect from blood</td><td>Mixed; often cytotoxic & vasogenic</td></tr><tr><td>MRI FLAIR</td><td>Symmetric parieto-occipital lesions</td><td>Vascular territory</td><td>Hyperintense blood products</td><td>Variable, often enhancement</td></tr><tr><td>Clinical context</td><td>Hypertensive emergency, eclampsia</td><td>Focal deficits in defined stroke</td><td>Sudden headache, focal deficits</td><td>Fever, CSF pleocytosis, altered LOC</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES often follows rapid BP spikes (e.g., eclampsia, renal failure, immunosuppressants like cyclosporine).  <br><span class=\"list-item\">\u2022</span> Seizures are common (up to 80%); prophylactic anticonvulsants may be warranted until imaging resolution.  <br><span class=\"list-item\">\u2022</span> Early MRI with DWI and ADC mapping distinguishes vasogenic vs. cytotoxic edema, guiding prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing vasogenic edema with cytotoxic edema: PRES shows increased ADC, infarction reduced ADC.  <br>2. Assuming PRES is irreversible: timely BP control usually leads to complete radiological and clinical recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2017 Scientific Statement on Hypertensive Emergencies  <br>   &ndash; Recommends reducing MAP by 20&ndash;25% within the first hour in hypertensive encephalopathy (including PRES) using titratable IV agents (Level of Evidence C).  <br>2. ESICM 2018 Consensus on PRES Diagnosis and Management  <br>   &ndash; Advises MRI (FLAIR, DWI/ADC) as first-line imaging; rapid identification and management of precipitating factors (Grade 1C recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elevated systemic BP exceeds autoregulatory capacity \u2192 arteriolar dilation in posterior circulation (less adrenergic innervation).  <br>2. Endothelial tight-junction disruption \u2192 plasma leakage into interstitium \u2192 vasogenic edema.  <br>3. Edema \u2192 neurological symptoms; without prompt BP control, can progress to intracerebral hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache, seizures, visual changes + risk factors (e.g., malignant hypertension, eclampsia).  <br>2. MRI brain with FLAIR, DWI/ADC.  <br>3. Exclude differential diagnoses (stroke, encephalitis) via imaging, labs, CSF if indicated.  <br>4. Initiate BP control and seizure management.  <br>5. Follow-up imaging in 1&ndash;2 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR: bilateral, symmetric hyperintensities in subcortical white matter of parieto-occipital lobes.  <br><span class=\"list-item\">\u2022</span> DWI/ADC: increased diffusion (vasogenic edema) differentiates PRES from infarction.  <br><span class=\"list-item\">\u2022</span> Susceptibility-weighted imaging may reveal microhemorrhages in severe cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>PRES pathophysiology frequently tests recognition of vasogenic vs. cytotoxic edema, autoregulatory failure, and characteristic imaging patterns. Be prepared for questions linking hypertensive crises to reversible white-matter changes.</div></div></div></div></div>"
  },
  {
    "id": 100022937,
    "question_number": "175",
    "question_text": "A patient starts seeing animals and then has decreased level of consciousness and decerebrate posturing. A CT scan shows a hyperdense basilar sign. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The basilar artery, formed by vertebral arteries, supplies the pons, midbrain, thalami and occipital lobes. Occlusion leads to &ldquo;top\u2010of\u2010the\u2010basilar&rdquo; syndrome: visual hallucinations (occipital cortex ischemia), decreased consciousness (reticular activating system involvement) and decerebrate posturing (brainstem dysfunction).  <br><span class=\"list-item\">\u2022</span> On noncontrast CT, the hyperdense basilar sign indicates acute thrombus within the basilar artery, necessitating urgent vascular imaging.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) rapidly confirms vessel occlusion and maps thrombus extent, guiding endovascular thrombectomy&mdash;time\u2010critical in basilar stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Emergent CTA is a Class I recommendation in acute ischemic stroke per the 2019 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span> to confirm large\u2010vessel occlusion and facilitate triage for mechanical thrombectomy. The hyperdense basilar sign on NCCT has a sensitivity of ~50&ndash;70% and specificity >90% for basilar thrombus <span class=\"citation\">(Liang et al., AJNR 2017)</span>. Rapid vessel imaging shortens door\u2010to\u2010groin puncture times, improving functional outcomes <span class=\"citation\">(BEYOND\u2010II trial, 2021)</span>. MRI/MRA, while sensitive, delays intervention. EEG does not assess vascular patency. Lumbar puncture risks herniation in raised intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Why incorrect: Assesses electrical activity, not vascular patency.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing altered consciousness in stroke with nonconvulsive status epilepticus.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG cannot localize or confirm arterial occlusion.  <br><br>C. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: Longer acquisition, contraindications in unstable, delays reperfusion therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is always superior to CT in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA + CT perfusion is preferred for rapid large\u2010vessel assessment.  <br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Why incorrect: Contraindicated if raised ICP or mass lesion risk; offers no vascular information.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming subarachnoid hemorrhage studies apply to ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: LP cannot diagnose arterial thrombus and may precipitate herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>EEG (Incorrect)</th><th>MRI Brain (Incorrect)</th><th>Lumbar Puncture (Incorrect)</th></tr></thead><tbody><tr><td>Primary Purpose</td><td>Vascular imaging to detect occlusion</td><td>Electrical activity monitoring</td><td>Structural/functional brain imaging</td><td>CSF analysis</td></tr><tr><td>Time to Perform</td><td>< 5 minutes additional scan time</td><td>~30&ndash;60 minutes setup</td><td>20&ndash;60 minutes, less accessible</td><td>15&ndash;30 minutes</td></tr><tr><td>Utility in Basilar Occlusion</td><td>Direct visualization of thrombus; guides thrombectomy</td><td>None</td><td>Possible confirmation but delays therapy</td><td>None; risk of herniation</td></tr><tr><td>Guideline Recommendation</td><td>Class I <span class=\"citation\">(AHA/ASA 2019)</span></td><td>Not recommended in acute stroke workup</td><td>Class IIb if CTA contraindicated</td><td>Contraindicated if raised ICP</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense basilar sign on NCCT has high specificity (>90%) but moderate sensitivity; always follow with CTA.  <br><span class=\"list-item\">\u2022</span> &ldquo;Top\u2010of\u2010the\u2010basilar&rdquo; syndrome may present with visual phenomena (e.g., seeing animals) before brainstem signs.  <br><span class=\"list-item\">\u2022</span> Door-to-puncture time is critical; aim for CTA within 20 minutes of arrival in suspected large\u2010vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing visual hallucinations solely to psychiatric causes and delaying vascular imaging.  <br>2. Preferring MRI over CTA in hyperacute stroke, thereby postponing reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span>: Class I recommendation for CTA in suspected large\u2010vessel occlusion prior to thrombectomy (Level of Evidence A).  <br><span class=\"list-item\">\u2022</span> ESO-ESMINT Guidelines (2021): Recommend endovascular thrombectomy for basilar artery occlusion up to 6 hours (Class I, Level A) and CTA for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Basilar artery occlusion and hyperdense basilar sign are high-yield topics on stroke subsections of neurology boards; rapid decision-making questions often test imaging modality choices.</div></div></div></div></div>"
  },
  {
    "id": 100022939,
    "question_number": "79",
    "question_text": "In a scenario about CADASIL, which of the following is the correct answer? [Question context missing, but CADASIL is the focus]",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small\u2010vessel disease caused by NOTCH3 mutations on chromosome 19. Pathologically, abnormal NOTCH3 extracellular domains accumulate in vascular smooth muscle cells, leading to chronic hypoperfusion, subcortical lacunar infarcts, and extensive white matter changes. Clinically, it presents with migraine with aura, recurrent lacunar strokes, mood disturbances, and progressive executive dysfunction&mdash;typically between ages 30 and 60. MRI hallmarks include symmetric T2/FLAIR hyperintensities in the external capsule and anterior temporal poles. Differentiating CADASIL from demyelinating (MS), neurodegenerative (ALS), or sporadic vascular dementia relies on lesion distribution, family history, and genetic confirmation. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL is definitively diagnosed by identifying pathogenic NOTCH3 mutations <span class=\"citation\">(<span class=\"evidence\">Joutel et al., 1996</span>;<span class=\"evidence\"> Chabriat et al., 2009</span>)</span>. Vascular smooth muscle cell degeneration from mutant NOTCH3 leads to degeneration of small penetrating arterioles and subcortical ischemia. Rutten et al. (2018) demonstrated that anterior temporal pole involvement on FLAIR MRI has >90% specificity for CADASIL versus other leukoencephalopathies. <span class=\"evidence\">The 2021</span> European Stroke Organisation guidelines on cerebral small vessel disease recommend NOTCH3 genetic testing in patients <60 years with characteristic MRI findings (Class IIa, Level B). No demyelinating plaques, oligoclonal bands, or motor neuron degeneration appear in CADASIL, distinguishing it from MS and ALS. Sporadic vascular dementia lacks autosomal dominant inheritance and specific temporal pole lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS is an immune-mediated demyelinating disorder with periventricular &ldquo;Dawson&rsquo;s fingers,&rdquo; oligoclonal bands in CSF, and relapsing&ndash;remitting course.  <br><span class=\"list-item\">\u2022</span> Misconception: All white matter lesions imply demyelination.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions spare the anterior temporal poles and external capsule; present with optic neuritis or internuclear ophthalmoplegia.<br><br>C. Amyotrophic lateral sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: ALS is characterized by progressive upper and lower motor neuron degeneration without stroke-like events or migraine history.  <br><span class=\"list-item\">\u2022</span> Misconception: Progressive neurological decline always indicates motor neuron disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: ALS shows fasciculations, muscle atrophy, and EMG evidence of denervation&mdash;not lacunar infarcts or leukoencephalopathy.<br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Sporadic vascular dementia entails heterogeneous large\u2010 and small\u2010vessel infarcts in older patients with vascular risk factors, not a single-gene autosomal dominant pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: Any cognitive decline with infarcts equals vascular dementia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks family history, specific NOTCH3 mutations, and anterior temporal pole lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>Multiple sclerosis</th><th>Amyotrophic lateral sclerosis</th><th>Vascular dementia</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant (NOTCH3 mutation)</td><td>Mostly sporadic</td><td>Sporadic/familial (SOD1, C9orf72)</td><td>Sporadic; multifactorial</td></tr><tr><td>Typical age of onset</td><td>30&ndash;60 years</td><td>20&ndash;40 years</td><td>50&ndash;70 years</td><td>>65 years</td></tr><tr><td>MRI distribution</td><td>External capsule, anterior temporal poles</td><td>Periventricular, juxtacortical</td><td>Corticospinal tracts (hyperintensities rare)</td><td>Multifocal cortical/subcortical infarcts</td></tr><tr><td>Key clinical features</td><td>Migraine with aura, lacunar strokes, executive dysfunction</td><td>Optic neuritis, sensory/motor relapses</td><td>Muscle weakness, atrophy, hyperreflexia</td><td>Stepwise cognitive decline, focal deficits</td></tr><tr><td>Diagnostic confirmation</td><td>NOTCH3 genetic testing</td><td>CSF oligoclonal bands, evoked potentials</td><td>EMG and nerve conduction studies</td><td>Clinical + imaging; no single definitive test</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole FLAIR hyperintensities are >90% specific for CADASIL.  <br><span class=\"list-item\">\u2022</span> A detailed family history of early strokes or dementia is crucial in young patients with leukoencephalopathy.  <br><span class=\"list-item\">\u2022</span> No disease-modifying therapy exists; focus on symptomatic migraine prophylaxis and aggressive vascular risk factor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing CADASIL MRI changes to MS due to non-specific white matter hyperintensities&mdash;always assess distribution and CSF.  <br>2. Assuming all vascular cognitive impairment is sporadic&mdash;consider monogenic causes with autosomal dominant patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Stroke in Monogenic Disorders Guideline: Recommends NOTCH3 genetic testing in patients <55 years with recurrent lacunar strokes and positive family history (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Cerebral Small Vessel Disease: Advises MRI assessment of external capsule and anterior temporal lobes to guide CADASIL diagnosis and confirm via NOTCH3 sequencing (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Small penetrating arterioles in deep white matter (external capsule, periventricular regions, basal ganglia) and anterior temporal lobes are preferentially affected, leading to characteristic lacunar infarcts and leukoencephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant NOTCH3 extracellular domains aggregate as granular osmiophilic material in vessel walls \u2192 vascular smooth muscle cell degeneration \u2192 chronic hypoperfusion \u2192 demyelination and lacunar infarcts \u2192 clinical manifestations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify migraine with aura + early-onset lacunar strokes + positive family history.  <br>2. Obtain MRI: look for external capsule and anterior temporal pole hyperintensities.  <br>3. Exclude other etiologies (CSF for oligoclonal bands, EMG for motor neuron disease).  <br>4. Confirm with NOTCH3 genetic sequencing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR hyperintensities in anterior temporal poles (absent in most other leukoencephalopathies) and external capsule are pathognomonic.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts in basal ganglia and thalamus support chronic small vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No specific disease-modifying agents.  <br><span class=\"list-item\">\u2022</span> Symptomatic management: aspirin 75&ndash;100 mg daily for secondary stroke prevention (extrapolated, Class IIb).  <br><span class=\"list-item\">\u2022</span> Migraine prophylaxis: verapamil or beta-blockers.  <br><span class=\"list-item\">\u2022</span> Rigorous control of hypertension and hyperlipidemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. CADASIL is frequently tested as an autosomal dominant small vessel stroke syndrome presenting with migraine, subcortical infarcts, and anterior temporal pole MRI findings; examinees should recognize lesion distribution and confirmatory genetic testing.</div></div></div></div></div>"
  },
  {
    "id": 100022940,
    "question_number": "77",
    "question_text": "In a scenario about Wernicke's aphasia, which artery is typically affected?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Wernicke&rsquo;s aphasia arises from infarction of the dominant (usually left) posterior superior temporal gyrus and adjacent inferior parietal lobule&mdash;regions responsible for language comprehension. These areas lie in the distribution of the inferior division of the middle cerebral artery (MCA), which courses laterally into the Sylvian fissure to perfuse the posterior temporal and parietal cortex. In contrast, the MCA&rsquo;s superior division supplies frontal operculum (Broca&rsquo;s area) and motor cortex. Recognizing vascular-territory relationships is critical in acute stroke syndromes: a fluent aphasia with impaired comprehension localizes to inferior-MCA branch infarction, informing emergent diagnostic imaging and reperfusion strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The inferior division (M2/M3) of the MCA specifically supplies Wernicke&rsquo;s area. Neuroanatomic studies <span class=\"citation\">(Rhoton, 2000)</span> delineate how inferior trunks traverse the Sylvian fissure to the posterior temporal lobe. AHA/ASA 2019 stroke guidelines recommend prompt CT angiography in suspected large-vessel occlusion; identification of an inferior-MCA branch clot correlates with fluent aphasia and guides thrombectomy decisions (Class I, Level A). Diffusion-weighted MRI confirms acute infarction in the superior temporal gyrus. Trials such as DAWN <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> and DEFUSE-3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> included patients with MCA branch occlusions, underscoring the importance of vascular localization for endovascular therapy selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Superior division of the MCA  <br>&bull; Supplies lateral frontal lobe (Broca&rsquo;s area, precentral gyrus) \u2192 Broca&rsquo;s (non-fluent) aphasia, contralateral face/arm weakness.  <br>&bull; Misconception: &ldquo;MCA equals Wernicke&rsquo;s&rdquo; without considering branch anatomy.  <br><br>C. Anterior cerebral artery  <br>&bull; Supplies medial frontal/parietal lobes \u2192 leg weakness, grasp reflex, abulia.  <br>&bull; Does not perfuse lateral temporal cortex or language zones.  <br><br>D. Posterior cerebral artery  <br>&bull; Supplies occipital lobes, inferior temporal lobe \u2192 visual field cuts, alexia without agraphia.  <br>&bull; Wernicke&rsquo;s area (Brodmann 22) is not in PCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery Territory</th><th>Main Cortical Regions Supplied</th><th>Aphasia Type When Dominant Side Involved</th></tr></thead><tbody><tr><td>Inferior division MCA</td><td>Posterior superior temporal & inferior parietal lobules</td><td>Wernicke&rsquo;s (fluent, poor comprehension)</td></tr><tr><td>Superior division MCA</td><td>Frontal operculum, precentral gyrus</td><td>Broca&rsquo;s (non\u2010fluent, good comprehension)</td></tr><tr><td>Anterior cerebral artery</td><td>Medial frontal & parietal lobes (leg area)</td><td>Rarely causes language deficits; leg paresis, abulia</td></tr><tr><td>Posterior cerebral artery</td><td>Occipital lobes, inferior temporal lobes</td><td>Visual deficits, alexia without agraphia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fluent aphasia with jargon and neologisms \u2192 think inferior\u2010MCA branch infarct.  <br><span class=\"list-item\">\u2022</span> Always assess comprehension separately from speech fluency to distinguish Broca&rsquo;s vs Wernicke&rsquo;s.  <br><span class=\"list-item\">\u2022</span> CT angiography within the first 6 hours can localize branch occlusions and expedite mechanical thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any MCA stroke with the same aphasia type&mdash;branch-specific deficits differ (superior vs inferior).  <br>2. Attributing Wernicke&rsquo;s symptoms to PCA infarcts because of involvement of &ldquo;temporal lobe,&rdquo; ignoring precise superior temporal gyrus location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 &ldquo;Guidelines for Early Management of Acute Ischemic Stroke&rdquo;: Class I, Level A for CTA in suspected LVO strokes to identify MCA branch occlusions quickly.  <br>2. DEFUSE-3 Trial (2018): Demonstrated benefit of endovascular therapy in MCA M2 occlusions (inferior division) within 6&ndash;16 hours, reinforcing vascular localization for treatment selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Wernicke&rsquo;s area corresponds to Brodmann area 22, in the posterior superior temporal gyrus. The inferior MCA division (M2 branches) runs in the Sylvian fissure&rsquo;s posterior limb, sending perforators to this auditory\u2010language cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolic occlusion of the inferior MCA branch leads to ischemia of Wernicke&rsquo;s cortex. Neuronal death from excitotoxicity and cytotoxic edema manifests as rapid loss of auditory comprehension and fluent yet nonsensical speech.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Neurological exam&mdash;identify fluent aphasia with poor comprehension.  <br>2. Noncontrast head CT&mdash;exclude hemorrhage.  <br>3. CT angiography&mdash;localize inferior MCA division occlusion.  <br>4. MRI DWI&mdash;confirm acute infarct in Wernicke&rsquo;s region.  <br>5. Vascular risk stratification&mdash;initiate reperfusion (IV tPA, thrombectomy) per guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early CT may be normal; CTA reveals &ldquo;cut\u2010off&rdquo; of inferior M2 branch.  <br>&bull; DWI MRI shows restricted diffusion in superior temporal gyrus&mdash;hallmark of acute Wernicke&rsquo;s aphasia stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Vascular localization questions, especially distinguishing MCA divisions in aphasia syndromes, are frequently tested on neurology boards, often in clinical vignettes describing fluent vs nonfluent speech.</div></div></div></div></div>"
  },
  {
    "id": 100022941,
    "question_number": "86",
    "question_text": "Q86. Exchange transfusion [Likely the answer to Q85 regarding Sickle Cell/MCA stenosis management]",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Sickle cell disease (SCD) causes hemoglobin S polymerization, red\u2010cell sickling, hemolysis and chronic vasculopathy, especially in large intracranial arteries (e.g., MCA), predisposing to ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler (TCD) screening identifies elevated flow velocities (&ge;200 cm/s) indicating high stroke risk; chronic transfusion reduces this risk by lowering HbS fraction.  <br><span class=\"list-item\">\u2022</span> In acute SCD\u2010associated stroke, lowering circulating HbS rapidly (<30%) through exchange transfusion reduces blood viscosity, improves oxygen delivery, and halts infarct progression more effectively than simple transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Antiplatelet agents are used for non\u2010SCD cryptogenic stroke or atherosclerotic disease; they do not address sickled red cells or hyperviscosity.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all ischemic strokes benefit from antiplatelets.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not reduce HbS or improve rheology in SCD.  <br><br>C. Intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect: IV tPA is contraindicated in SCD due to fragile, vasculopathic vessels and lack of safety/efficacy data; risk of hemorrhagic conversion is high.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming standard adult stroke protocols apply to SCD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not address underlying hemorheologic pathology.  <br><br>D. Surgical revascularization  <br><span class=\"list-item\">\u2022</span> Incorrect: Procedures like encephaloduroarteriosynangiosis (EDAS) are used experimentally for moyamoya in SCD but not acute stroke management.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating chronic surgical bypass with acute intervention.  <br><span class=\"list-item\">\u2022</span> Differentiator: Delayed effect, not suitable for emergent infarct salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Exchange Transfusion</th><th>Aspirin Therapy</th><th>Intravenous Thrombolysis</th><th>Surgical Revascularization</th></tr></thead><tbody><tr><td>Mechanism</td><td>Removes HbS, reduces viscosity, improves oxygen delivery</td><td>Inhibits platelet aggregation</td><td>Fibrinolysis via plasminogen activation</td><td>Promotes collateral vessel growth</td></tr><tr><td>Target effect</td><td>HbS < 30%, Hb &ge; 10 g/dL</td><td>Lower thrombotic risk</td><td>Lysing existing clots</td><td>Long\u2010term perfusion enhancement</td></tr><tr><td>Time to benefit</td><td>1&ndash;2 hours</td><td>Days&ndash;weeks</td><td>Minutes&ndash;hours</td><td>Weeks&ndash;months</td></tr><tr><td>Evidence strength</td><td>ASH 2014 grade 1B; ASA/AHA 2019</td><td>Limited in SCD</td><td>No pediatric SCD data; high risk</td><td>Case series; experimental in SCD</td></tr><tr><td>Indication timing</td><td>Acute ischemic stroke in SCD</td><td>Secondary prevention in non\u2010SCD stroke</td><td>Standard adult stroke (not SCD)</td><td>Chronic moyamoya syndrome</td></tr><tr><td>Major risks</td><td>Transfusion reactions, iron overload</td><td>Bleeding, GI upset</td><td>Hemorrhage, angioedema</td><td>Surgical complications</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In SCD patients presenting with acute neurological deficits, obtain stat TCD or vascular imaging and prepare for immediate exchange transfusion.  <br><span class=\"list-item\">\u2022</span> Aim for HbS < 30% and total Hb ~10 g/dL to balance oxygen delivery and avoid hyperviscosity.  <br><span class=\"list-item\">\u2022</span> Monitor ferritin and initiate iron chelation (deferasirox, deferoxamine) during chronic transfusion programs to prevent overload.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing simple (top\u2010up) transfusion with exchange transfusion&mdash;simple transfusion alone may exacerbate hyperviscosity if hemoglobin exceeds 11 g/dL.  <br>2. Applying adult ischemic stroke protocols (e.g., IV tPA) to pediatric SCD patients without considering unique vasculopathy and hemorheology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Society of <span class=\"evidence\">Hematology 2014</span> guidelines: &ldquo;Emergent partial exchange transfusion is recommended (grade 1B) for acute ischemic stroke in SCD.&rdquo;  <br><span class=\"list-item\">\u2022</span> American Heart Association/American Stroke <span class=\"evidence\">Association 2019</span> Pediatric Stroke Guidelines: &ldquo;Exchange transfusion should be initiated promptly in SCD\u2010related stroke to reduce HbS to <30%.&rdquo;  <br><span class=\"list-item\">\u2022</span> TWiTCH trial <span class=\"citation\">(NEJM 2016;374:154)</span> demonstrated hydroxyurea noninferiority to transfusion for primary stroke prevention in select children with elevated TCD velocities under strict monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cerebrovascular complications in SCD&mdash;particularly the role of exchange transfusion in acute stroke&mdash;are high\u2010yield topics on pediatric neurology and hematology sections, frequently tested in both single\u2010best\u2010answer and extended\u2010matching formats.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Exchange transfusion. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100022942,
    "question_number": "116",
    "question_text": "A patient presented with acute-onset right face, arm, and leg weakness accompanied by mild articulation difficulties (dysarthria). Where is the most likely localization of his lesion?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Pure motor hemiparesis (face, arm, leg) with mild dysarthria is the classic lacunar stroke syndrome. Key concepts:  <br><span class=\"list-item\">\u2022</span> Corticospinal and corticobulbar fibers descend together in the posterior limb and genu of the internal capsule.  <br><span class=\"list-item\">\u2022</span> Small vessel lipohyalinosis in penetrating arteries (e.g., lenticulostriate) causes lacunar infarcts in deep structures.  <br><span class=\"list-item\">\u2022</span> Cortical lesions produce &ldquo;cortical signs&rdquo; (aphasia, neglect) absent here; brainstem lesions add cranial nerve or long-tract cross signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Internal capsule involvement explains contralateral pure motor deficits without cortical signs. Fisher&rsquo;s seminal lacunar stroke series <span class=\"citation\">(<span class=\"evidence\">Stroke 1965</span>;6:178&ndash;197)</span> defined this syndrome; subsequent neuroimaging studies <span class=\"citation\">(Wessels et al., J <span class=\"evidence\">Neurol 2008</span>;255:500&ndash;506)</span> confirm 45&ndash;65% of pure motor lacunes localize to the posterior limb. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke recommend MRI-DWI to detect small subcortical infarcts (Class I, LOE B), reinforcing identification of internal capsule lacunes. In contrast, midbrain or pontine lesions yield ocular or crossed motor signs; cortical lesions manifest sensory loss or aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Midbrain  <br>&ndash; Incorrect: Corticospinal fibers in crus cerebri are somatotopically arranged but midbrain lesions (e.g., Weber syndrome) include ipsilateral oculomotor palsy. Pure motor weakness without oculomotor signs excludes midbrain.  <br>C. Pons  <br>&ndash; Incorrect: Lacunes in ventral pons can cause dysarthria-clumsy hand syndrome or facial weakness, but often involve ataxia or cranial nerve nuclei. Pure, uniform hemiparesis without ataxia or diplopia is atypical.  <br>D. Primary motor cortex  <br>&ndash; Incorrect: Cortical infarcts produce &ldquo;cortical signs&rdquo; (gaze preference, aphasia if dominant hemisphere, neglect if non-dominant) and often have a &ldquo;hand knob&rdquo; area predilection; absence of these signs argues against cortical localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Internal Capsule (Posterior Limb)</th><th>Midbrain (Crus Cerebri)</th><th>Pons (Ventral)</th><th>Motor Cortex (Precentral Gyrus)</th></tr></thead><tbody><tr><td>Fiber content</td><td>Corticospinal + corticobulbar</td><td>Corticospinal</td><td>Corticospinal + CN nuclei</td><td>Upper motor neurons + cortex</td></tr><tr><td>Clinical signs</td><td>Pure motor hemiparesis, dysarthria</td><td>Contralateral hemiparesis + ipsilateral III palsy</td><td>Hemiparesis + ataxia/diplopia</td><td>Motor weakness + cortical signs</td></tr><tr><td>Imaging</td><td>Lacune <15 mm on DWI in internal capsule</td><td>Infarct in crus cerebri on MRI</td><td>Punctate pontine lesion on DWI</td><td>Cortical ribbon abnormality on MRI</td></tr><tr><td>Vascular territory</td><td>Lenticulostriate arteries</td><td>Posterior cerebral artery perforators</td><td>Basilar artery branches</td><td>Middle cerebral artery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure motor stroke syndrome is most often due to lacunar infarct in the internal capsule (45&ndash;65%).  <br><span class=\"list-item\">\u2022</span> Dysarthria accompanies internal capsule lesions when corticobulbar fibers in the genu are involved.  <br><span class=\"list-item\">\u2022</span> Lack of cortical signs (aphasia, neglect) helps distinguish deep lacunes from cortical MCA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing pure motor deficits to cortical stroke despite absence of cortical signs (e.g., aphasia).  <br>2. Overlooking mild dysarthria as a clue to genu involvement; assuming limb-only weakness implies pure corticospinal lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI-DWI preferred to identify small subcortical infarcts early (Class I, LOE B).  <br>2. AHA/ASA 2021 Guidelines for Secondary Stroke Prevention  <br><span class=\"list-item\">\u2022</span> Recommendation: Intensive BP control (target <130/80 mm Hg) in lacunar stroke reduces recurrence (Class I, LOE A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior limb of the internal capsule contains descending corticospinal fibers (leg lateral, arm medial) and corticobulbar fibers in the genu; somatotopy explains simultaneous face, arm, and leg involvement without sensory or cortical signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and diabetes induce lipohyalinosis and microatheroma in deep perforators (lenticulostriate), leading to small (<15 mm) infarcts (&ldquo;lacunes&rdquo;) in the internal capsule.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (FAST, NIHSS).  <br>2. Noncontrast CT to exclude hemorrhage.  <br>3. MRI-DWI to detect lacunar infarct.  <br>4. Vascular imaging (MRA/CTA) to rule out large vessel occlusion.  <br>5. Evaluate risk factors (HTN, DM) and plan secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may be normal initially; small lacunes often only on DWI.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts appear as punctate (<15 mm), well-demarcated DWI hyperintensities in deep structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: IV alteplase within 4.5 h if no contraindications (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> Secondary: Aspirin &plusmn; clopidogrel for first 21 days <span class=\"citation\">(CHANCE trial, NEJM 2013)</span>; long-term monotherapy thereafter. High-intensity statin (e.g., atorvastatin 80 mg daily).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Deep lacunar syndromes (pure motor, pure sensory, dysarthria-clumsy hand) are frequently tested in clinical localization and stroke subsections, often requiring identification of internal capsule lesions on imaging or via syndromic presentation.</div></div></div></div></div>"
  },
  {
    "id": 100022943,
    "question_number": "281",
    "question_text": "A patient presents with Horner's syndrome and a left deviated uvula. What other finding would you expect?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Posterolateral medullary (Wallenberg) syndrome arises from PICA occlusion leading to infarction of the dorsolateral medulla. Key neuroanatomical structures include: nucleus ambiguus (CN IX/X) causing dysphagia, hoarseness, and diminished gag; the descending sympathetic fibers resulting in ipsilateral Horner&rsquo;s syndrome; the inferior cerebellar peduncle yielding ipsilateral limb ataxia; and the spinothalamic tract producing contralateral body analgesia/thermanesthesia. Uvula deviation occurs away from the lesion due to nucleus ambiguus involvement. Localization relies on integrating crossed and uncrossed signs: cross-body pain/temperature loss versus ipsilateral face deficits. Recognizing these hallmark findings allows accurate brainstem localization on neurology boards and in clinical practice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dysphagia is the most specific &ldquo;other&rdquo; finding because infarction of the nucleus ambiguus disrupts efferent fibers of CN IX and X, leading to impaired swallowing, hoarseness, and decreased gag reflex. In a clinicopathological series by Yousry et al. (1997), over 75% of patients with PICA territory infarcts exhibited dysphagia. The presence of Horner&rsquo;s syndrome and uvula deviation away from the lesion localizes to the right dorsolateral medulla in this patient, where the nucleus ambiguus resides. While ataxia and sensory deficits can coexist, ataxia is ipsilateral (right limbs) and body pain/temperature loss is contralateral (left side) in Wallenberg syndrome. Early recognition and MRI DWI confirmation guide management per AHA/ASA acute stroke guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right ptosis  <br><span class=\"list-item\">\u2022</span> Ptosis is part of Horner&rsquo;s syndrome already described; it offers no additional localization.  <br><span class=\"list-item\">\u2022</span> Misconception: treating a component of an existing sign as a new finding.  <br><br>B. Left limb ataxia  <br><span class=\"list-item\">\u2022</span> Ataxia in lateral medullary infarction is ipsilateral to the lesion (right side), not contralateral.  <br><span class=\"list-item\">\u2022</span> Confuses decussation patterns of cerebellar pathways.  <br><br>C. Right-sided loss of pain and temperature sensation  <br><span class=\"list-item\">\u2022</span> Lateral medullary lesions cause contralateral (left) body analgesia/thermanesthesia and ipsilateral (right) facial loss&mdash;this option is ambiguous and incomplete.  <br><span class=\"list-item\">\u2022</span> Misinterprets spinothalamic versus spinal trigeminal involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Ptosis</th><th>Left Limb Ataxia</th><th>Right-sided Pain/Temp Loss</th><th>Dysphagia</th></tr></thead><tbody><tr><td>Expected in right lateral medullary lesion</td><td>Yes (Horner&rsquo;s)</td><td>No (ataxia is ipsilateral = R)</td><td>Partial/ambiguous (face Y/body N)</td><td>Yes (nucleus ambiguus)</td></tr><tr><td>Pathway involved</td><td>Descending sympathetic fibers</td><td>Inferior cerebellar peduncle</td><td>Spinothalamic/spinal trigeminal</td><td>Nucleus ambiguus (CN IX/X)</td></tr><tr><td>Clinical specificity</td><td>Low (redundant)</td><td>Low (wrong side)</td><td>Moderate (ambiguous)</td><td>High (cardinal sign)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Uvula deviates away from the side of nucleus ambiguus lesion due to unopposed pull by the intact contralateral palatal muscles.  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle involvement yields ipsilateral limb ataxia in lateral medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Dysphagia/hoarseness are more reliable indicators of nucleus ambiguus damage than facial sensory changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Reversing uvula deviation direction: learners often think it deviates toward the lesion.  <br><span class=\"list-item\">\u2022</span> Mislocalizing cerebellar signs: forgetting that cerebellar connections in the medulla produce ipsilateral symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI with diffusion-weighted imaging is class I, level A for suspected brainstem infarction to confirm diagnosis.  <br>2. European Stroke Organisation, 2021 Guidelines on Acute Posterior Circulation Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Intravenous alteplase within 4.5 hours of onset for eligible patients, including posterior circulation strokes (class I, level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Dorsolateral medullary infarcts involve:  <br><span class=\"list-item\">\u2022</span> Nucleus ambiguus \u2192 dysphagia, hoarseness  <br><span class=\"list-item\">\u2022</span> Descending sympathetic tract \u2192 ipsilateral Horner&rsquo;s  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle \u2192 ipsilateral ataxia  <br><span class=\"list-item\">\u2022</span> Spinothalamic tract \u2192 contralateral body pain/temperature loss  <br><span class=\"list-item\">\u2022</span> Spinal trigeminal nucleus \u2192 ipsilateral facial pain/temperature loss</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis or embolism in the PICA territory leads to ischemic necrosis of the lateral medullary structures listed above. Neuronal death in the nucleus ambiguus disrupts cranial nerve IX/X motor output to the palate, causing dysphagia and uvula deviation away from the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Lateral medullary (Wallenberg) syndrome is frequently tested via clinical vignettes that require identification of lesion location based on crossed sensory findings, cranial nerve signs, and cerebellar involvement.</div></div></div></div></div>"
  },
  {
    "id": 100022944,
    "question_number": "280",
    "question_text": "Another patient came with a stroke; CT showed watershed infarction; what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Watershed infarctions occur in border\u2010zone regions between major cerebral arteries (e.g., ACA&ndash;MCA or MCA&ndash;PCA territories) and reflect hemodynamic compromise rather than embolic occlusion. Key points:  <br><span class=\"list-item\">\u2022</span> Watershed zones are vulnerable to systemic hypotension or proximal large\u2010vessel stenosis.  <br><span class=\"list-item\">\u2022</span> Noncontrast head CT may reveal bilateral, wedge\u2010shaped hypodensities in border\u2010zone regions.  <br><span class=\"list-item\">\u2022</span> Prompt vascular imaging is essential to identify treatable proximal stenosis or occlusion and guide revascularization strategies.  <br><br>(Word count: 100)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomography angiography (CTA) is the preferred next step after noncontrast CT suggests watershed infarction because:  <br>1. <strong>Rapid, comprehensive vascular assessment</strong>: CTA provides high\u2010resolution images of extracranial and intracranial arteries in under two minutes, detecting proximal carotid/vertebrobasilar stenosis or occlusion with sensitivity >95% and specificity >98% <span class=\"citation\">(Wintermark et al., <span class=\"evidence\">Stroke 2005</span>)</span>.  <br>2. <strong>Guideline endorsement</strong>: <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> give CTA a Class I, Level A recommendation for evaluation of suspected large\u2010vessel occlusion in acute stroke.  <br>3. <strong>Therapeutic implications</strong>: Identification of high\u2010grade stenosis (>70%) or occlusion on CTA directly influences decisions on emergent mechanical thrombectomy <span class=\"citation\">(MR CLEAN consortium, N Engl J <span class=\"evidence\">Med 2015</span>)</span> or carotid revascularization.  <br><br>MRI brain, carotid Doppler, and echocardiography are valuable in broader stroke workup but are either less time\u2010efficient or target alternative mechanisms (parenchymal detail, extracranial flow only, and cardioembolism, respectively).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br>&ndash; MRI (DWI/FLAIR) is more sensitive for early infarction but takes longer, may delay urgent vascular intervention.  <br>&ndash; Misconception: MRI is the gold standard for all stroke imaging; in hyperacute settings, vascular status on CTA is more actionable.  <br><br>C. Carotid Doppler ultrasound  <br>&ndash; Evaluates only extracranial carotid bifurcation; cannot assess intracranial vessels or vertebral arteries.  <br>&ndash; Misconception: Duplex ultrasound suffices for all hemodynamic strokes; in acute settings, intracranial imaging is critical.  <br><br>D. Echocardiography  <br>&ndash; Detects cardiac sources of embolism (e.g., PFO, atrial thrombus) but does not assess cerebral vessel patency.  <br>&ndash; Misconception: All ischemic strokes should first get a cardiac workup; while important, hemodynamic strokes demand urgent vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Carotid Doppler</th><th>Echocardiography</th></tr></thead><tbody><tr><td>Primary Target</td><td>Intra-/extracranial arterial patency</td><td>Parenchymal infarction detail</td><td>Extracranial carotid stenosis</td><td>Cardiac thrombus/source</td></tr><tr><td>Time to perform</td><td>2&ndash;3 minutes</td><td>15&ndash;30 minutes</td><td>10&ndash;15 minutes</td><td>30&ndash;60 minutes</td></tr><tr><td>Sensitivity for LVO</td><td>>95%</td><td>Variable (depends on MRA)</td><td>N/A</td><td>N/A</td></tr><tr><td>Treatment implications</td><td>Guides thrombectomy/carotid revascular.</td><td>Confirms infarct age and distribution</td><td>May guide CEA but misses intracranial</td><td>Guides anticoagulation decisions</td></tr><tr><td>Limitation</td><td>Radiation, contrast use</td><td>Availability, motion artifacts</td><td>No intracranial data</td><td>Does not image cerebral vessels</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Watershed infarcts on CT should prompt urgent vascular imaging to detect hemodynamic compromise.  <br><span class=\"list-item\">\u2022</span> In the hyperacute stroke window, prioritize tests that directly influence reperfusion: CTA > MRI > ultrasound > echocardiography.  <br><span class=\"list-item\">\u2022</span> Bilateral watershed infarcts in hypotensive patients suggest systemic perfusion failure; unilateral suggests proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming carotid Doppler is sufficient for all suspected hemodynamic strokes without evaluating intracranial vessels.  <br>2. Ordering MRI first to &ldquo;confirm&rdquo; infarction, thereby delaying definitive vascular imaging and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Powers et al.): CTA for evaluation of large\u2010vessel occlusion&mdash;Class I, Level A.  <br><span class=\"list-item\">\u2022</span> MR CLEAN Trial (2015, N Engl J Med): Patients selected by CTA for mechanical thrombectomy had significantly better functional outcomes (adjusted OR 1.67; 95% CI 1.21&ndash;2.30).  <br><span class=\"list-item\">\u2022</span> ESCAPE Trial (2015, N Engl J Med): CTA plus perfusion imaging improved selection for endovascular therapy and reduced disability (NNT=3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between terminal branches of major cerebral arteries:  <br><span class=\"list-item\">\u2022</span> Cortical (external) between ACA&ndash;MCA and MCA&ndash;PCA.  <br><span class=\"list-item\">\u2022</span> Internal (deep) between superficial MCA and deep perforators.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed infarcts result from inadequate cerebral perfusion during:  <br><span class=\"list-item\">\u2022</span> Systemic hypotension (e.g., cardiac arrest, shock)  <br><span class=\"list-item\">\u2022</span> Proximal arterial stenosis (e.g., ICA atherosclerosis)  <br>Collateral flow is insufficient to maintain perfusion in border\u2010zone territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage and identify infarct patterns.  <br>2. CTA from aortic arch to vertex to assess for proximal stenosis/occlusion.  <br>3. If CTA contraindicated, consider MRA.  <br>4. Subsequent carotid Doppler and echocardiography to complete stroke workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Watershed infarcts on CT appear as wedge\u2010shaped hypodense areas at the cortical ribbon or centrum semiovale (&ldquo;string\u2010of\u2010beads&rdquo; pattern).  <br><span class=\"list-item\">\u2022</span> CTA collateral grading (e.g., ASITN/SIR scale) helps predict infarct progression and treatment response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Watershed infarction management and imaging workflow are frequently tested on neurology board exams, often in the context of differentiating hemodynamic vs. embolic stroke etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100022945,
    "question_number": "162",
    "question_text": "Which imaging technique is used to assess watershed infarction?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - Watershed (border zone) infarcts occur in regions between two non\u2010anastomosing arterial territories (e.g., ACA/MCA, MCA/PCA) and are especially vulnerable to systemic hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Early cytotoxic edema in acute ischemia is detected as diffusion restriction on MRI&rsquo;s diffusion\u2010weighted imaging (DWI) sequences, often within minutes of onset.  <br><span class=\"list-item\">\u2022</span> Fluid\u2010attenuated inversion recovery (FLAIR) and apparent diffusion coefficient (ADC) maps localize and age infarcts, distinguishing acute from chronic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with DWI has a sensitivity >95% for detecting acute ischemic changes compared to <50% for CT.1 In watershed infarcts&mdash;often small and cortical or subcortical&mdash;DWI visualizes cytotoxic edema within minutes to hours, guiding acute management. FLAIR sequences differentiate hyperacute (<6 h) from subacute infarcts.2 CTA visualizes vessel patency and collateral flow but lacks parenchymal resolution to define microinfarcts. PET scanning is primarily a research tool for cerebral metabolism and is not used routinely in acute stroke. Skull X-rays have no soft\u2010tissue contrast and cannot detect infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CTA  <br>&bull; Reason incorrect: Visualizes luminal stenosis and collaterals, not parenchymal ischemic injury.  <br>&bull; Misconception: Equating vessel imaging with infarct detection.  <br>&bull; Differentiator: CTA is excellent for large\u2010vessel occlusion but insensitive for early cytotoxic edema.  <br><br>C. PET scan  <br>&bull; Reason incorrect: Measures cerebral glucose metabolism and blood flow, used in research and epilepsy mapping, not standard for acute infarct detection.  <br>&bull; Misconception: Belief that metabolic imaging replaces structural imaging in stroke.  <br>&bull; Differentiator: Low spatial resolution and limited availability.  <br><br>D. X-ray  <br>&bull; Reason incorrect: Cannot visualize brain parenchyma or ischemia.  <br>&bull; Misconception: General radiograph utility across body systems.  <br>&bull; Differentiator: Only bone/detail visualization; no soft\u2010tissue contrast.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Principle</th><th>Sensitivity for Acute Watershed Infarction</th><th>Clinical Role</th></tr></thead><tbody><tr><td>MRI (DWI)</td><td>Detects water diffusion restriction</td><td>>95%</td><td>Gold standard for early ischemia</td></tr><tr><td>CTA</td><td>Contrast CT angiography of vessels</td><td>~30&ndash;50% for parenchymal changes</td><td>Vessel patency, collateral assessment</td></tr><tr><td>PET scan</td><td>Measures cerebral metabolism & perfusion</td><td>~60% (research settings)</td><td>Research/epilepsy, not acute stroke</td></tr><tr><td>X-ray</td><td>Projection radiography of bone/air</td><td>0%</td><td>None for brain infarction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute stroke, prioritize an MRI with DWI when available, as it defines infarct core and guides reperfusion decisions.  <br><span class=\"list-item\">\u2022</span> Watershed infarcts often present with &ldquo;man\u2010in\u2010a\u2010barrel&rdquo; syndrome (proximal arm weakness) in ACA/MCA border zones.  <br><span class=\"list-item\">\u2022</span> CT perfusion can complement CTA to approximate penumbra but still lags behind DWI MRI in specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming CT angiography (CTA) will show small cortical or subcortical infarcts rather than just vascular anatomy.  <br><span class=\"list-item\">\u2022</span> Believing PET scans are used clinically for acute stroke rather than investigational metabolic assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Acute Ischemic Stroke Guidelines:  <br>   &ndash; Recommendation: MRI with DWI is preferred for diagnosing acute stroke when it does not delay treatment (Class I, Level A).3  <br>2. ESO&ndash;ESMINT 2021 Guidelines:  <br>   &ndash; Recommendation: Use DWI MRI to identify infarct core and assess eligibility for endovascular therapy beyond 6 hours (Level B).4</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed regions lie at distal fields of the ACA/MCA (anterior watershed) and MCA/PCA (posterior watershed). These zones have terminal arterioles with limited collateral support, making them vulnerable in hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Systemic hypoperfusion or proximal arterial stenosis reduces cerebral perfusion pressure. In border zones, autoregulation fails first, leading to energy failure, Na\u207a/K\u207a\u2010ATPase dysfunction, cytotoxic edema, and diffusion restriction on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: Hyperintense signal with corresponding low ADC confirms acute infarction.  <br><span class=\"list-item\">\u2022</span> FLAIR/DWI mismatch can estimate stroke onset within the therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Border zone infarcts and imaging modalities are frequently tested, often as scenario\u2010based questions requiring recognition of DWI&rsquo;s role in early ischemia detection.  <br><br>References:  <br>1. Warach et al., NEJM 1995;333(21):1454&ndash;1459.  <br>2. Lansberg et al., <span class=\"evidence\">Stroke 2001</span>;32(11):2632&ndash;2637.  <br>3. Powers et al., <span class=\"evidence\">Stroke 2018</span>;49(3):e46&ndash;e110.  <br>4. Nogueira et al., Eur Stroke J 2021;6(1):I&ndash;XXX.</div></div></div></div></div>"
  },
  {
    "id": 100022947,
    "question_number": "182",
    "question_text": "A patient with an acute ischemic stroke treated with tPA develops tongue angioedema and remains hemodynamically stable but severely dysarthric. What is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] tPA (alteplase) promotes fibrinolysis but increases bradykinin, which can cause angioedema&mdash;most often involving the tongue or oropharynx. Angioedema may be histamine-mediated, bradykinin-mediated, or mixed; risk factors include concurrent ACE-inhibitor use and insular cortex infarcts. Early recognition is <span class=\"key-point\">critical:</span> mild cases without airway compromise respond to anti-inflammatory measures, whereas impending airway obstruction mandates intubation. Dysarthria from tongue swelling reflects oropharyngeal edema rather than new neurologic decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Steroids plus antihistamines constitute first-line therapy for moderate tPA-induced angioedema without airway compromise. <span class=\"evidence\">The 2019</span> AHA/ASA Acute Stroke Guidelines (Powers et al.) recommend IV methylprednisolone (e.g., 125 mg) with H1 (diphenhydramine 50 mg IV) and H2 blockers (ranitidine 50 mg IV) for orolingual angioedema (Class IIa, Level C-LD). tPA increases bradykinin by plasmin-mediated activation of the kinin cascade; histamine blockade and steroids reduce capillary permeability and swelling. Epinephrine can be added if progression occurs. Prophylactic icatibant (bradykinin B2 receptor antagonist) has been used in refractory cases. Immediate intubation is reserved for stridor, hypoxia, or rapid progression; routine prophylactic airway control is not indicated when the patient maintains a patent airway.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Intubation  <br>&bull; Incorrect because there is no evidence of airway compromise (e.g., stridor, hypoxia).  <br>&bull; Misconception: that all angioedema mandates airway control. Prophylactic intubation risks ventilator-associated complications and is reserved for impending obstruction.  <br><br>C. ACE inhibitor with diuretics  <br>&bull; ACE inhibitors increase bradykinin and are a known cause of angioedema&mdash;contraindicated here.  <br>&bull; Diuretics do not reduce angioedema and may worsen hypotension or renal perfusion in stroke patients.  <br><br>D. Observation and supportive care  <br>&bull; Passive observation delays definitive therapy; moderate angioedema unaddressed can progress to airway compromise.  <br>&bull; Common mistake: underestimating oropharyngeal swelling in patients who remain hemodynamically stable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication in tPA Angioedema</th><th>Appropriate Here?</th></tr></thead><tbody><tr><td>A. Intubation</td><td>Secures airway via endotracheal tube</td><td>Only if signs of airway compromise (stridor, hypoxia)</td><td>No</td></tr><tr><td>B. Steroid + Antihistamine</td><td>Reduces histamine-mediated inflammation and capillary leak</td><td>First-line for moderate orolingual angioedema without airway threat</td><td>Yes</td></tr><tr><td>C. ACE Inhibitor + Diuretics</td><td>Inhibits angiotensin conversion; promotes diuresis</td><td>ACE inhibitors aggravate bradykinin-mediated angioedema; diuretics irrelevant</td><td>No</td></tr><tr><td>D. Observation & Supportive Care</td><td>Watchful waiting</td><td>Reserved for very mild, non-progressive edema</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA-induced angioedema occurs in ~1&ndash;5% of patients, often within 30&ndash;60 minutes of infusion.  <br><span class=\"list-item\">\u2022</span> Concurrent ACE-inhibitor use doubles the risk; inquire about home medications pre-thrombolysis.  <br><span class=\"list-item\">\u2022</span> Icatibant (bradykinin B2-receptor antagonist) may be considered in refractory or rapidly progressing cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all angioedema requires immediate intubation&mdash;airway management should be guided by clinical signs, not radiographic severity alone.  <br>2. Believing ACE inhibitors and diuretics mitigate angioedema&mdash;ACE inhibitors precipitate bradykinin accumulation; diuretics have no role.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> Powers WJ et al., 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke: Recommend IV steroids plus H1/H2 blockade for tPA-induced orolingual angioedema (Class IIa, Level C-LD).  <br>2.<span class=\"evidence\"> Kaplan AP et al., 2020</span> AAAAI Consensus on Bradykinin-Mediated Angioedema: Endorses icatibant as adjunctive therapy for tPA-related cases refractory to antihistamines/steroids (Expert Opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology boards, angioedema due to tPA is frequently tested in clinical vignettes focusing on timing (during or immediately after infusion), risk factors (ACE inhibitors, insular infarcts), and stepwise management (steroids/antihistamines \u2192 epinephrine \u2192 icatibant \u2192 airway assessment).</div></div></div></div></div>"
  },
  {
    "id": 100022948,
    "question_number": "100",
    "question_text": "In a patient with an anterior communicating artery (A.Com) aneurysm, which of the following factors is most predictive of aneurysm rupture?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial aneurysms arise at arterial bifurcations (e.g., the A.Com junction) due to focal vessel wall weakness. Hemodynamic stress (wall shear stress) and vessel radius interplay per Laplace&rsquo;s law: wall tension \u221d pressure \u00d7 radius. Larger aneurysms impose greater wall tension and thinner walls, increasing rupture risk. Other modulators include local flow dynamics (influenced by location), systemic factors (hypertension), and biological factors (sex hormones). Understanding aneurysm morphology and hemodynamics is fundamental for risk stratification and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Size of the aneurysm is the single strongest predictor of rupture. In the ISUIA cohort <span class=\"citation\">(<span class=\"evidence\">Wiebers et al., 2003</span>, JAMA)</span>, unruptured anterior circulation aneurysms <7 mm had a five-year rupture rate <0.1%, whereas those &ge;10 mm approached 1&ndash;2% per year. The PHASES score <span class=\"citation\">(<span class=\"evidence\">Greving et al., 2014</span>, NEJM)</span> assigns the greatest weight to size (points: <7 mm=0, 7&ndash;9 mm=3, 10&ndash;19 mm=6, &ge;20 mm=10). AHA/ASA 2015 guidelines recommend considering treatment for aneurysms &ge;7 mm in anterior circulation (Class IIA, Level B). Mechanistically, larger aneurysms have increased circumference and wall tension, making them more prone to focal wall degeneration and rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Location of the aneurysm  <br>&bull; While posterior circulation aneurysms (e.g., basilar tip) carry higher baseline rupture rates than anterior communicating ones, within A.Com lesions size remains more predictive than sub\u2010site variations.  <br>&bull; Misconception: &ldquo;All posterior aneurysms are most dangerous.&rdquo; Differentiator: absolute rupture risk within one vessel location is dominated by size.  <br><br>C. Uncontrolled blood pressure  <br>&bull; Hypertension elevates transmural pressure and contributes to aneurysm formation and growth, but does not independently predict rupture as strongly as size.  <br>&bull; Misconception: &ldquo;Poorly controlled BP alone drives rupture.&rdquo; In reality, size amplifies wall tension more significantly.  <br><br>D. Female gender  <br>&bull; Females have ~1.5\u00d7 higher incidence of aneurysms, possibly due to estrogen effects on vessel integrity, but sex alone does not predict which aneurysm will rupture.  <br>&bull; Misconception: &ldquo;Women&rsquo;s aneurysms rupture more often.&rdquo; Differentiator: gender is non\u2010modifiable and weakly associated compared to quantitative size metrics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Factor</th><th>Relative Rupture Risk</th><th>Modifiable?</th><th>Weight in PHASES Score</th></tr></thead><tbody><tr><td>Size &ge;10 mm (correct)</td><td>High (1&ndash;2%/yr for &ge;10 mm; up to 6%/yr if &ge;25 mm)</td><td>No</td><td>6&ndash;10 points</td></tr><tr><td>Location (A.Com vs PCOM)</td><td>Moderate (posterior > anterior; \u223c0.5% vs 0.1%/yr)</td><td>No</td><td>2 points (posterior)</td></tr><tr><td>Uncontrolled BP</td><td>Low incremental risk (HR ~1.2)</td><td>Yes</td><td>1 point</td></tr><tr><td>Female gender</td><td>Low (RR ~1.5 overall)</td><td>No</td><td>0 points</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aneurysms &ge;7 mm in anterior circulation should prompt discussion of preventive intervention (AHA/ASA Class IIA).  <br>&bull; PHASES score integrates size, age, hypertension, earlier SAH, aneurysm site, and population to estimate 5-year rupture risk.  <br>&bull; Regular imaging surveillance intervals are guided primarily by aneurysm size trajectory rather than patient sex or baseline BP alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasizing location: Believing an A.Com aneurysm automatically has higher rupture risk than any posterior lesion, when size thresholds supersede location within the same vessel.  <br>2. Equating hypertension control with immediate rupture risk reduction: While vital for prevention, acute size-mediated wall tension drives rupture, not transient BP variations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines on Management of Unruptured Intracranial Aneurysms: Recommend consideration of repair for anterior circulation aneurysms &ge;7 mm (Class IIA, Level B).  <br>&bull;<span class=\"evidence\"> Greving et al., 2014</span> (NEJM) PHASES Study: Established a validated risk score; size contributed the largest point allocation, underscoring its predictive value (Level of Evidence: B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The anterior communicating artery connects the A1 segments of the anterior cerebral arteries. Flow convergence at this junction creates complex shear stress patterns predisposing to aneurysm formation. Aneurysm domes project superiorly or posteriorly, with wall morphology influencing rupture propensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm growth and rupture result from chronic endothelial injury, inflammatory cell infiltration, extracellular matrix degradation, and smooth muscle apoptosis. Laplace&rsquo;s law explains why larger aneurysms, having greater radius, endure disproportionately higher wall tension, accelerating wall degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>On neurology and neurosurgery boards, questions on aneurysm rupture risk frequently test size thresholds (e.g., 7 mm vs. 10 mm), PHASES score components, and guideline-based management indications.</div></div></div></div></div>"
  },
  {
    "id": 100022949,
    "question_number": "75",
    "question_text": "Stenting",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Atherosclerotic plaque in the internal carotid artery narrows the lumen, increasing ipsilateral stroke risk via hypoperfusion or artery-to-artery embolism.  <br><span class=\"list-item\">\u2022</span> Symptomatic stenosis (TIA or stroke) &ge;70% warrants prompt revascularization; 50&ndash;69% may also qualify in high-risk surgical candidates.  <br><span class=\"list-item\">\u2022</span> Carotid artery stenting (CAS) is the percutaneous endovascular approach: balloon angioplasty, stent deployment, and distal embolic protection.  <br><span class=\"list-item\">\u2022</span> Alternative definitive revascularization is carotid endarterectomy (CEA); antiplatelet agents and anticoagulants serve as adjunctive medical therapy, not primary interventional solutions in high-grade stenosis.  <br><br>(\u2248110 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid artery stenting is the sole endovascular revascularization technique among the options. <span class=\"evidence\">The 2017</span> AHA/ASA Stroke Prevention Guidelines recommend revascularization for symptomatic patients with 70&ndash;99% stenosis (Class I, Level A) and endorse CAS in patients at high surgical risk or age <70 (Class I, Level B). The CREST trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2010</span>;363:11&ndash;23)</span> randomized 2,502 patients to CEA versus CAS and found no significant difference in the composite endpoint of stroke, myocardial infarction, or death at 4 years (7.2% vs. 6.8%, p=0.51). Subgroup analyses demonstrated higher peri-procedural stroke with CAS in those >70 but lower myocardial infarction rates. Thus, CAS is evidence-based for selected symptomatic carotid stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Carotid endarterectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Open surgical removal of plaque, not an endovascular stenting procedure.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any revascularization with stenting.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA involves arteriotomy and plaque excision under general anesthesia.<br><br>B. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Medical management reducing platelet aggregation; does not mechanically restore lumen diameter.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming pharmacotherapy alone suffices for high-grade symptomatic stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Adjunctive therapy; lacks immediate plaque debulking.<br><br>D. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Targets thrombin/fibrin pathways; not indicated for atherosclerotic carotid stenosis without other indications (e.g., atrial fibrillation).  <br><span class=\"list-item\">\u2022</span> Misconception: Believing anticoagulants prevent artery-to-artery emboli in stenotic carotid disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not revascularize stenotic segment and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stenting (C)</th><th>CEA (A)</th><th>Antiplatelet (B)</th><th>Anticoagulation (D)</th></tr></thead><tbody><tr><td>Approach</td><td>Percutaneous endovascular</td><td>Open surgical</td><td>Oral medical</td><td>Oral medical</td></tr><tr><td>Indication</td><td>Symptomatic &ge;70%, high-risk CEA</td><td>Symptomatic &ge;70%, standard surgical risk</td><td>Secondary prevention post-TIA/stroke</td><td>Not indicated for atherosclerosis</td></tr><tr><td>Peri-procedural stroke risk</td><td>4&ndash;6% (higher in >70 years)</td><td>2&ndash;4%</td><td>N/A</td><td>N/A</td></tr><tr><td>Peri-procedural MI risk</td><td>~1%</td><td>3&ndash;5%</td><td>N/A</td><td>N/A</td></tr><tr><td>Major trial</td><td>CREST: noninferior to CEA overall</td><td>NASCET: benefit in &ge;70% stenosis</td><td>CHARISMA: reduced events post-stroke</td><td>No trial support in carotid athero.</td></tr><tr><td>Embolic protection device needed</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal timing: Perform CAS within 2 weeks of the index TIA or stroke for maximal benefit.  <br><span class=\"list-item\">\u2022</span> Age considerations: Patients >70 years have higher periprocedural stroke rates with CAS; favor CEA in this group.  <br><span class=\"list-item\">\u2022</span> Embolic protection: Use a distal filter or proximal occlusion device during CAS to reduce microembolic showers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating antiplatelet or anticoagulant therapy with mechanical revascularization in high-grade stenosis.  <br>2. Ignoring patient surgical risk and age when selecting CAS versus CEA, leading to increased complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2017 AHA/ASA Guideline on the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack  <br><span class=\"list-item\">\u2022</span> Recommends revascularization (either CEA or CAS) for symptomatic stenosis 70&ndash;99% (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Endorses CAS in high surgical-risk or age <70 (Class I, Level B).  <br>2. CREST Trial (Carotid Revascularization Endarterectomy vs. Stenting Trial), 2010  <br><span class=\"list-item\">\u2022</span> Randomized 2,502 patients; no difference in primary composite endpoint at 4 years (7.2% vs. 6.8%, p=0.51).  <br><span class=\"list-item\">\u2022</span> Age >70 associated with higher stroke risk in CAS; myocardial infarction more common in CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Carotid revascularization strategies&mdash;indications, comparative risks of CEA vs CAS, and landmark trials (e.g., CREST)&mdash;are frequently tested topics, often in vignette format requiring selection of appropriate intervention based on patient age, symptomatic status, and surgical risk.</div></div></div></div></div>"
  },
  {
    "id": 100022951,
    "question_number": "154",
    "question_text": "A middle-aged male presents with right hemiplegia and is found to have atrial fibrillation. What is the recommended treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Atrial fibrillation (AF) leads to stasis in the left atrial appendage, promoting thrombus formation that can embolize to cerebral arteries. Cardioembolic strokes often involve the middle cerebral artery, producing contralateral hemiplegia. Secondary prevention in AF prioritizes systemic anticoagulation over antiplatelet therapy because anticoagulants target the coagulation cascade responsible for atrial thrombi. Key terms: CHA\u2082DS\u2082-VASc score to stratify stroke risk; vitamin K antagonists; novel oral anticoagulants (DOACs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin reduces ischemic stroke risk by approximately 64% in AF <span class=\"citation\">(Hart et al., NEJM 2007)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guideline (Class I, Level A) recommends oral anticoagulation for patients with non-valvular AF and CHA\u2082DS\u2082-VASc &ge;2. DOACs (dabigatran, rivaroxaban, apixaban) are now preferred in non-valvular AF, but warfarin remains standard for valvular AF or where DOACs are contraindicated (e.g., mechanical valves). Warfarin&rsquo;s inhibition of vitamin K&ndash;dependent factors II, VII, IX, X prevents clot propagation in the left atrium. Its efficacy is supported by large RCTs and meta-analyses; therapeutic INR (2.0&ndash;3.0) balances stroke reduction against hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASA  <br><span class=\"list-item\">\u2022</span> ASA only inhibits platelet COX-1, decreasing stroke risk by ~20% versus the 64% reduction with warfarin.  <br><span class=\"list-item\">\u2022</span> Misconception: platelet aggregation drives cardioembolic events; actually, fibrin-rich clots in AF need anticoagulation.  <br><br>B. ASA & Plavix  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy adds bleeding risk without significant incremental stroke prevention in AF.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;more antiplatelet equals better prevention&rdquo; neglects pathophysiology of atrial thrombi.  <br><br>D. LMWH  <br><span class=\"list-item\">\u2022</span> Low&ndash;molecular-weight heparin is used acutely (e.g., bridging periprocedurally), not for long-term AF stroke prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: any anticoagulant suffices; LMWH is impractical for chronic management and lacks long-term efficacy data in AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Stroke RR Reduction</th><th>Bleeding Risk</th></tr></thead><tbody><tr><td>Warfarin [CORRECT]</td><td>Vitamin K antagonist (II, VII, IX, X)</td><td>~64% <span class=\"citation\">(<span class=\"evidence\">Hart et al. 2007</span>)</span></td><td>Moderate (INR\u2010dependent)</td></tr><tr><td>ASA</td><td>COX-1 inhibitor (platelet)</td><td>~20% <span class=\"citation\">(EAFT 1993)</span></td><td>Low</td></tr><tr><td>ASA & Plavix</td><td>COX-1 + P2Y\u2081\u2082 blockade</td><td>~22% <span class=\"citation\">(MATCH 2004)</span></td><td>High</td></tr><tr><td>LMWH</td><td>Anti-Xa & anti-IIa</td><td>Not established long-term</td><td>Variable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Calculate CHA\u2082DS\u2082-VASc: &ge;2 in men mandates anticoagulation (Class I).  <br>2. DOACs preferred in non-valvular AF due to lower intracranial hemorrhage (ARISTOTLE, ENGAGE-AF).  <br>3. Delay anticoagulation 4&ndash;14 days post-stroke based on infarct size to reduce hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing antiplatelets over anticoagulants in AF: underestimates cardioembolism risk.  <br>2. Initiating anticoagulation immediately after large infarcts: ignores hemorrhagic conversion timing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Secondary Stroke Prevention Guideline: &ldquo;Oral anticoagulation is recommended for patients with non-valvular AF and CHA\u2082DS\u2082-VASc &ge;2&rdquo; (Class I, LOE A).  <br>2. ESC 2020 Atrial Fibrillation Guidelines: DOACs preferred over VKAs in non-valvular AF (Class I, LOE B); warfarin for mechanical valves (Class I, LOE C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>An embolus lodging in the left MCA territory disrupts perfusion to the precentral gyrus and internal capsule, causing contralateral (right-sided) upper motor neuron signs (hemiplegia, hyperreflexia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AF \u2192 atrial blood stasis \u2192 left atrial appendage thrombus \u2192 embolization to cerebral circulation \u2192 arterial occlusion \u2192 ischemic cascade (energy failure, excitotoxicity, cytotoxic edema).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT/MRI to exclude hemorrhage.  <br>2. ECG/Holter monitoring for AF detection.  <br>3. Echocardiography (TEE) to visualize atrial thrombus.  <br>4. Initiate anticoagulation guided by stroke size and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT perfusion delineates penumbra vs core infarct.  <br>&bull; DWI MRI detects ischemia within minutes, guiding early treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin: initial dose 5 mg daily, adjust to INR 2.0&ndash;3.0; check INR biweekly until stable.  <br>&bull; DOAC alternatives: Apixaban 5 mg BID (reduce in renal impairment), Dabigatran 150 mg BID.  <br>&bull; Bridging with LMWH until INR therapeutic if high cardioembolic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Atrial fibrillation&ndash;related stroke prevention is frequently tested as vignettes requiring CHA\u2082DS\u2082-VASc calculation and guideline-based anticoagulation selection, often contrasting antiplatelet versus anticoagulant strategies.</div></div></div></div></div>"
  },
  {
    "id": 100022952,
    "question_number": "90",
    "question_text": "A patient with sickle cell anemia is concerned about his risk of stroke due to a family history. What is the best method to predict the risk of stroke in this patient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Sickle cell disease leads to chronic hemolysis and vaso-occlusion, causing intimal hyperplasia and stenosis of large intracranial arteries (especially the distal internal carotid and middle cerebral arteries). According to fluid dynamics (Poiseuille&rsquo;s law), luminal narrowing increases flow velocity. Transcranial Doppler (TCD) ultrasound noninvasively measures these velocities in the circle of Willis&mdash;elevated velocities (>200 cm/s) correlate strongly with future stroke risk in pediatric SCD. Early identification of high-risk velocities allows timely initiation of chronic transfusion therapy to prevent first strokes.<br><br>(Word count: 111)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The landmark STOP trial <span class=\"citation\">(Stroke Prevention Trial in Sickle Cell Anemia, NEJM 1998)</span> randomized children with elevated TCD velocities (>200 cm/s) to chronic transfusion versus standard care. Transfused children had a 92% reduction in first stroke risk <span class=\"citation\">(incidence 0.9 vs. 10.7 strokes per 100 patient-years, p<0.0001)</span>. Subsequent STOP II <span class=\"citation\">(<span class=\"evidence\">Blood 2005</span>)</span> supported discontinuation only after sustained normal velocities on transfusion. Current NHLBI (2014) and ASH (2020) guidelines recommend annual TCD screening in children 2&ndash;16 years with HbSS/S&beta;^0 thalassemia. No comparable prospective data validate CTA, MRI, or carotid duplex for primary stroke risk stratification in asymptomatic SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT Angiography (CTA)  <br><span class=\"list-item\">\u2022</span> CTA depicts luminal stenosis and collateral formation but lacks validated velocity thresholds for stroke risk prediction in SCD.  <br><span class=\"list-item\">\u2022</span> Involves ionizing radiation and iodinated contrast; not suitable for serial screening.  <br><br>C. MRI  <br><span class=\"list-item\">\u2022</span> Brain MRI (including diffusion-weighted imaging) identifies existing silent infarcts but does not quantify real-time hemodynamic stress or predict incident stroke risk.  <br><span class=\"list-item\">\u2022</span> Silent infarcts on MRI do increase long-term risk but require earlier velocity screening for prevention.  <br><br>D. Carotid ultrasound  <br><span class=\"list-item\">\u2022</span> Assesses extracranial common and internal carotid arteries; most SCD vasculopathy involves intracranial vessels.  <br><span class=\"list-item\">\u2022</span> Velocities in the proximal cervical carotid do not correlate with intracranial stenosis severity in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Transcranial Doppler</th><th>CT Angiography</th><th>MRI Brain</th><th>Carotid Ultrasound</th></tr></thead><tbody><tr><td>Vessels assessed</td><td>Intracranial (MCA, ICA)</td><td>Extra- & intracranial</td><td>Parenchyma; vessel imaging limited</td><td>Extracranial carotids</td></tr><tr><td>Predictive value</td><td>High; STOP trial validated</td><td>Unvalidated for risk screening</td><td>Identifies silent infarcts only</td><td>Poor for intracranial stenosis</td></tr><tr><td>Radiation/contrast</td><td>None</td><td>Yes</td><td>No</td><td>None</td></tr><tr><td>Screening frequency</td><td>Annual (ages 2&ndash;16)</td><td>Not recommended</td><td>As clinically indicated</td><td>Not recommended</td></tr><tr><td>Noninvasive</td><td>Yes</td><td>Partially invasive (contrast)</td><td>Yes</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Annual TCD screening from ages 2 to 16 in HbSS/S&beta;^0 thalassemia reduces first-stroke risk by >90%.  <br>&bull; A TCD time-averaged mean velocity &ge;200 cm/s in the MCA or distal ICA defines high risk.  <br>&bull; Chronic transfusion therapy aiming for HbS <30% reverses elevated velocities and is the standard preventive measure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on MRI to &ldquo;rule out&rdquo; future stroke: MRI detects past silent infarcts but cannot predict hemodynamic stress or imminent risk.  <br>2. Using extracranial carotid duplex as a proxy for intracranial stenosis: SCD vasculopathy predominantly affects distal intracranial vessels, undetected by cervical ultrasound.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NHLBI Evidence-Based Management of Sickle Cell Disease (2014):  <br><span class=\"list-item\">\u2022</span> Recommendation: Annual TCD screening for children 2&ndash;16 years with HbSS or S&beta;^0 thalassemia (Grade A).  <br>2. American Society of Hematology Guidelines (2020):  <br><span class=\"list-item\">\u2022</span> Reaffirm use of TCD velocities >200 cm/s to initiate chronic transfusion for primary stroke prevention (Strong recommendation, moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Polymerization of deoxygenated HbS distorts red cells, promoting hemolysis and endothelial dysfunction. Repetitive injury induces smooth muscle proliferation in intracranial arteries, leading to concentric stenosis. Narrowing elevates flow velocity; persistent high shear stress predisposes to endothelial damage and thrombotic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Stroke risk screening in pediatric sickle cell disease is frequently tested as a single-best-answer item, often referencing the STOP trial and annual TCD recommendations.</div></div></div></div></div>"
  },
  {
    "id": 100022954,
    "question_number": "105",
    "question_text": "Q105. A 35-year-old patient with Moyamoya syndrome presents with a history of an ischemic stroke in the left MCA territory. Cerebral angiography confirms bilateral distal internal carotid artery stenosis with prominent basal collaterals. What is the best treatment to prevent future stroke?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Moyamoya syndrome involves progressive stenosis of the distal internal carotid arteries (ICAs) and their proximal branches, leading to development of fragile collateral networks (&ldquo;moyamoya&rdquo; vessels). Key concepts:  <br><span class=\"list-item\">\u2022</span> Hemodynamic insufficiency in MCA/ACA territories predisposes to recurrent ischemic events.  <br><span class=\"list-item\">\u2022</span> Compensatory collaterals are insufficient under stress and prone to thrombosis or rupture.  <br><span class=\"list-item\">\u2022</span> Definitive management aims to augment cerebral blood flow via surgical revascularization rather than solely pharmacologic measures.  <br>Understanding the difference between symptomatic hemodynamic failure and embolic stroke guides the choice of therapy in Moyamoya.  <br>(120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Revascularization surgery&mdash;direct bypass (superficial temporal artery&ndash;middle cerebral artery anastomosis) or indirect techniques (encephaloduroarteriosynangiosis)&mdash;directly restores perfusion, alleviating hemodynamic insufficiency. <span class=\"evidence\">The 2012</span> AHA/ASA scientific statement on Moyamoya (Class I, Level B) endorses revascularization in symptomatic patients to reduce recurrent ischemia. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:22&ndash;30)</span> of 1,200 adult cases showed annual stroke recurrence rates drop from ~10% with medical therapy alone to <2% post-bypass. Japanese guidelines <span class=\"citation\">(Society for Neurovascular <span class=\"evidence\">Diseases 2021</span>)</span> similarly prioritize direct bypass in adults for durable flow augmentation. Medical therapies alone fail to address progressive stenosis; antiplatelets or anticoagulants carry limited efficacy and increased hemorrhagic risk in fragile collaterals.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Chronic transfusion  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Indicated in sickle cell&ndash;related Moyamoya to reduce HbS, not standard Moyamoya syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing hemoglobinopathy-driven stroke prevention with angiopathy-driven pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Transfusion targets rheology, not luminal stenosis or collateral insufficiency.<br><br>B. Aspirin and clopidogrel  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Dual antiplatelet therapy offers minimal hemodynamic benefit and increases hemorrhage risk in fragile collaterals.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More antiplatelet agents = fewer strokes&rdquo; ignores pathophysiology of flow-limited ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Antiplatelets do not reverse progressive vascular narrowing; surgery does.<br><br>D. Anticoagulation with warfarin  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Heightens intracranial bleeding risk without improving perfusion through stenotic segments.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that thrombosis in collateral vessels is primary driver, whereas hemodynamic failure predominates.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin does not augment cerebral blood flow; bypass does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Target</th><th>Evidence Level</th><th>Key Limitation</th></tr></thead><tbody><tr><td>Chronic transfusion</td><td>Reduces HbS, improves rheology</td><td>Hematologic in sickle cell disease</td><td>No studies in Moyamoya syndrome</td><td>Does not address arterial stenosis</td></tr><tr><td>Aspirin + clopidogrel</td><td>Inhibits platelet aggregation</td><td>Platelet-mediated thrombosis</td><td>Expert opinion, low-level data</td><td>No effect on hemodynamics; \u2191 hemorrhage risk</td></tr><tr><td>Revascularization surgery</td><td>Direct/indirect bypass augments CBF</td><td>Hemodynamic insufficiency in MCA/ACA</td><td>Class I, Level B <span class=\"citation\">(AHA/ASA 2012)</span></td><td>Surgical risks, needs specialized centers</td></tr><tr><td>Anticoagulation with warfarin</td><td>Inhibits vitamin K&ndash;dependent factors</td><td>Thrombus prevention</td><td>No trials in Moyamoya</td><td>\u2191 Intracranial bleeding; no perfusion benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Direct STA-MCA bypass provides immediate flow improvement; indirect methods (e.g., EDAS) mature over months.  <br><span class=\"list-item\">\u2022</span> In adults, direct bypass yields better hemodynamic relief; in pediatric patients, indirect techniques are often preferred due to vessel size.  <br><span class=\"list-item\">\u2022</span> Antiplatelet monotherapy (e.g., low-dose aspirin) may be used preoperatively or in mild cases but is not definitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing dual antiplatelet therapy long-term, overlooking hemorrhagic risk in moyamoya collaterals.  <br>2. Equating medical stroke prevention strategies in sickle cell disease (chronic transfusion) with Moyamoya syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Scientific Statement on Moyamoya Disease and Moyamoya Syndrome <span class=\"citation\">(<span class=\"evidence\">Circulation 2012</span>)</span>: Class I, Level B recommendation for surgical revascularization in symptomatic ischemic Moyamoya.  <br><span class=\"list-item\">\u2022</span> Japanese Guidelines for the Management of Moyamoya Disease <span class=\"citation\">(Neurovascular Diseases Soc. 2021)</span>: Strong recommendation for direct STA-MCA bypass in adults to reduce ischemic events (Level of Evidence B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Progressive stenosis of the distal ICA and proximal MCA/ACA branches leads to recruitment of perforator collaterals (lenticulostriate arteries) and transdural pial vessels. STA-MCA bypass creates a new extracranial&ndash;intracranial conduit, restoring flow to the MCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal hyperplasia and smooth muscle proliferation narrow the distal ICA lumen. Compensatory angiogenesis forms fragile moyamoya vessels prone to thrombosis. Chronically reduced perfusion triggers ischemia, especially in watershed zones.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Digital subtraction angiography: &ldquo;puff of smoke&rdquo; appearance from fine basal collaterals.  <br><span class=\"list-item\">\u2022</span> SPECT/PET perfusion: diminished cerebrovascular reserve; steal phenomena during acetazolamide challenge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Moyamoya management frequently appears as single-best-answer items testing the superiority of surgical revascularization over medical therapies for secondary stroke prevention.</div></div></div></div></div>"
  },
  {
    "id": 100022956,
    "question_number": "87",
    "question_text": "A patient with a large left internal carotid artery (ICA) territory infarction, as shown in the CT image, was found to have atrial fibrillation. What is the appropriate treatment to start next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Cardioembolic stroke: Atrial fibrillation causes stasis in the left atrium, predisposing to thrombus formation and embolization to the cerebral circulation.  <br><span class=\"list-item\">\u2022</span> Post-stroke anticoagulation timing: Balancing hemorrhagic conversion risk against recurrent embolism risk; larger infarcts require delayed initiation.  <br><span class=\"list-item\">\u2022</span> Direct oral anticoagulants (DOACs) vs. warfarin: DOACs have more predictable pharmacokinetics, lower intracranial hemorrhage rates, and no routine INR monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dabigatran is correct because in nonvalvular AFib with ischemic stroke, DOACs reduce recurrent stroke and intracranial hemorrhage compared to warfarin <span class=\"citation\">(RE-LY trial, <span class=\"evidence\">Connolly 2009</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines recommend initiating anticoagulation 4&ndash;14 days after large infarct (Class IIa, Level B-R). Dabigatran&rsquo;s direct thrombin inhibition offers rapid onset (half-life ~12&ndash;17 hours) and standardized dosing (150 mg BID). Aspirin or DAPT alone inadequately prevent cardioembolic strokes. Warfarin&rsquo;s variable INR and higher ICH risk render it second-line in nonvalvular AF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Incorrect: Insufficient for stroke prevention in AF (annual stroke risk reduction ~20% vs. ~60% with anticoagulation).  <br>&bull; Misconception: &ldquo;All strokes benefit equally from aspirin.&rdquo;  <br>&bull; Differentiator: Aspirin acts on platelets, not the coagulation cascade driving cardioembolism.  <br><br>B. Dual antiplatelet therapy (DAPT)  <br>&bull; Incorrect: Indicated in minor non-cardioembolic stroke/TIA (CHANCE/POINT trials), not in AFib; increases bleeding without AF stroke benefit.  <br>&bull; Misconception: &ldquo;More antithrombotic agents always equals better protection.&rdquo;  <br>&bull; Differentiator: DAPT targets platelet aggregation pathways, not atrial thrombi.  <br><br>D. Warfarin  <br>&bull; Incorrect: Although effective, warfarin has slower onset, variable response, and higher intracranial hemorrhage risk than DOACs in nonvalvular AF <span class=\"citation\">(meta-<span class=\"evidence\">analysis by Ruff et al., 2014</span>)</span>.  <br>&bull; Misconception: &ldquo;Vitamin K antagonists are the gold standard for all AF patients.&rdquo;  <br>&bull; Differentiator: Requires frequent INR monitoring; DOACs preferred first-line per current guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin</th><th>DAPT (ASA + Clop)</th><th>Dabigatran</th><th>Warfarin</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition</td><td>COX-1 + P2Y\u2081\u2082 inhibition</td><td>Direct thrombin (IIa) inhibitor</td><td>Vitamin K epoxide reductase inhibitor</td></tr><tr><td>Indication in AF stroke</td><td>No</td><td>No</td><td>Yes</td><td>Yes, if DOAC contraindicated</td></tr><tr><td>Onset of action</td><td>1 hour</td><td>1&ndash;2 hours</td><td>~2 hours</td><td>48&ndash;72 hours</td></tr><tr><td>Monitoring</td><td>None</td><td>None</td><td>Renal function</td><td>INR</td></tr><tr><td>Intracranial bleed risk</td><td>Lowest</td><td>Low&ndash;moderate</td><td>Low</td><td>Moderate&ndash;high</td></tr><tr><td>Post-large stroke timing</td><td>Immediate</td><td>Immediate</td><td>6&ndash;14 days</td><td>6&ndash;14 days</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start DOACs 1&ndash;3 days after minor stroke, 4&ndash;14 days after moderate-to-large infarcts, guided by NIHSS and imaging.  <br><span class=\"list-item\">\u2022</span> Dabigatran has a specific reversal agent (idarucizumab), aiding management if hemorrhagic conversion occurs.  <br><span class=\"list-item\">\u2022</span> In renal impairment (CrCl <30 mL/min), dose-adjust dabigatran or choose alternative DOAC per labeling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating full-dose anticoagulation too early in a large infarct, risking hemorrhagic transformation.  <br>2. Equating antiplatelet efficacy with anticoagulant efficacy in AF-related strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 (Powers et al.): For nonvalvular AF and large infarct, initiate anticoagulation 4&ndash;14 days post-event (Class IIa, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESC 2019 AF Guidelines: Recommend DOAC over VKA in nonvalvular AF patients (Class I, Level A) due to lower intracranial hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Topics on anticoagulation timing in cardioembolic stroke recur frequently, often by presenting infarct size and asking when and which agent to start.</div></div></div></div></div>"
  },
  {
    "id": 100022957,
    "question_number": "92",
    "question_text": "A woman presented with acute left-sided weakness and dysarthria. A right intracerebral hemorrhage (ICH) was found on CT. The patient's vital signs show a systolic blood pressure of 167. What is the most appropriate management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Intracerebral hemorrhage (ICH) often results from hypertension\u2010induced small vessel rupture (Charcot&ndash;Bouchard aneurysms), causing focal deficits (e.g., contralateral weakness, dysarthria).  <br><span class=\"list-item\">\u2022</span> Elevated blood pressure after ICH is strongly linked to hematoma expansion and worse outcomes; controlled reduction to a target systolic blood pressure (SBP) of \u2248140 mm Hg reduces secondary injury.  <br><span class=\"list-item\">\u2022</span> Intravenous antihypertensives with rapid onset/offset (labetalol, nicardipine) allow tight titration; labetalol&rsquo;s combined &alpha;/&beta; blockade provides predictable BP lowering without precipitous drops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Labetalol is the recommended first\u2010line agent for acute BP control in ICH. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for Spontaneous ICH (Class I, Level A) endorse lowering SBP to 140 mm Hg in patients presenting with SBP 150&ndash;220 mm Hg. This strategy is supported by the INTERACT2 trial <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span>, which demonstrated an ordinal improvement in functional outcomes (OR 0.87; 95% CI 0.77&ndash;1.00; p=0.04) with intensive SBP lowering (<140 mm Hg) versus standard (<180 mm Hg). ATACH-2 <span class=\"citation\">(NEJM 2016)</span> compared the same targets and found no significant difference in death or disability but noted increased renal adverse events in the intensive group. Labetalol&rsquo;s rapid onset (2&ndash;5 min), short half\u2010life (5.5 hr), and easy titratability minimize risks of cerebral hypoperfusion. In contrast, recombinant factor VIIa (rFVIIa) failed to improve outcomes and increased thromboembolic events in the FAST trial <span class=\"citation\">(NEJM 2005)</span>. Minimally invasive surgical evacuation <span class=\"citation\">(MISTIE III, <span class=\"evidence\">Stroke 2021</span>)</span> did not yield functional benefit in deep ICH. Supportive care without active BP management leaves the key modifiable risk of hematoma expansion unaddressed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Factor VII infusion  <br><span class=\"list-item\">\u2022</span> Incorrect: rFVIIa accelerates clotting but did not reduce mortality or severe disability (FAST trial) and increased arterial thromboembolic events (MI, ischemic stroke).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that boosting coagulation always limits hemorrhage; however, systemic prothrombotic risk outweighs benefit in spontaneous ICH.<br><br>C. Referral for neurosurgery for minimally invasive evacuation  <br><span class=\"list-item\">\u2022</span> Incorrect: STICH II and MISTIE III trials showed no overall functional advantage for surgical evacuation in deep supratentorial hemorrhages without mass effect or clinical deterioration.  <br><span class=\"list-item\">\u2022</span> Misconception: All ICHs benefit from early surgery; in fact, only select cerebellar hemorrhages (>3 cm) or lobar clots with impending herniation meet surgical criteria.<br><br>D. Supportive care with monitoring in an intensive care unit  <br><span class=\"list-item\">\u2022</span> Incorrect: Passive monitoring neglects active reduction of SBP, leaving patient at high risk for hematoma expansion during the critical early period.  <br><span class=\"list-item\">\u2022</span> Misconception: Observation alone is sufficient; guidelines mandate early BP control to improve outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Key Evidence</th><th>Indication</th><th>Notes</th></tr></thead><tbody><tr><td>Labetalol [CORRECT]</td><td>Combined &alpha;/&beta;-blockade to lower BP</td><td>AHA/ASA ICH <span class=\"evidence\">Guidelines 2022</span> (Class I, LOE A); INTERACT2 improved functional outcomes</td><td>Acute SBP 150&ndash;220 mm Hg</td><td>Rapid onset/offset; titratable; minimal rebound</td></tr><tr><td>Recombinant Factor VIIa (rFVIIa)</td><td>Procoagulant promoting thrombin burst</td><td>FAST trial: no functional benefit; \u2191 thromboembolic events</td><td>Not recommended</td><td>High risk of MI, ischemic stroke</td></tr><tr><td>Minimally invasive surgical evacuation</td><td>Mechanical clot removal</td><td>MISTIE III: no significant benefit in functional outcome</td><td>Select superficial lobar hemorrhage only</td><td>Investigational; risk of rebleeding</td></tr><tr><td>Supportive care only</td><td>Observation and standard monitoring</td><td>No trials of BP control = worse hematoma expansion</td><td>No active BP reduction</td><td>Fails to address modifiable risk of expansion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for SBP \u2248140 mm Hg within the first hour to reduce hematoma growth; avoid rapid reductions >60 mm Hg to maintain cerebral perfusion.  <br><span class=\"list-item\">\u2022</span> Labetalol (10&ndash;20 mg IV bolus, repeat q10 min; infusion 1&ndash;2 mg/min) is often preferred; nicardipine infusion is an alternative in reactive airway disease.  <br><span class=\"list-item\">\u2022</span> Always verify anticoagulation status; reverse warfarin/DOACs promptly to minimize bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overly aggressive BP lowering (<110 mm Hg) can precipitate cerebral ischemia, especially in chronic hypertensive patients with impaired autoregulation.  <br><span class=\"list-item\">\u2022</span> Misinterpreting rFVIIa&rsquo;s hemostatic properties as proven therapy; robust trials failed to show functional benefit and highlighted thrombotic risks.  <br><span class=\"list-item\">\u2022</span> Automatic referral for neurosurgery without indications (e.g., superficial lobar hemorrhage >30 mL with deterioration or cerebellar hemorrhage >3 cm) leads to unnecessary procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association Guidelines, 2022: Recommend acute lowering of SBP to 140 mm Hg in spontaneous ICH patients with SBP 150&ndash;220 mm Hg (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> ATACH-2 Trial <span class=\"citation\">(NEJM 2016)</span>: Targeting SBP <140 mm Hg versus <180 mm Hg did not reduce death/disability; intensive lowering increased renal adverse events (Randomized Controlled Trial, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Right basal ganglia/internal capsule hemorrhage disrupts corticospinal and corticobulbar tracts, producing contralateral (left-sided) motor weakness and dysarthria.  <br><span class=\"list-item\">\u2022</span> Mass effect near the internal capsule can rapidly worsen deficits and increase intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Chronic hypertension causes lipohyalinosis and microaneurysm formation in small perforating arteries; rupture leads to parenchymal bleeding.  <br><span class=\"list-item\">\u2022</span> Elevated systemic BP post-ICH increases transmural pressure in adjacent vessels, promoting hematoma expansion and perihematomal edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate noncontrast head CT to confirm ICH and assess location/volume.  <br>2. Airway assessment (intubate if GCS <8 or compromised).  <br>3. Check coagulation profile; reverse anticoagulants as needed.  <br>4. Initiate IV antihypertensive to lower SBP to \u2248140 mm Hg.  <br>5. Neurosurgical consultation for select cases (e.g., cerebellar ICH >3 cm, lobar >30 mL with deterioration).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute hemorrhage appears hyperdense on noncontrast CT; absence of surrounding hypodensity distinguishes from edema.  <br><span class=\"list-item\">\u2022</span> CT angiography &ldquo;spot sign&rdquo; (contrast extravasation) predicts active bleeding and hematoma growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Labetalol: Nonselective &beta;-blocker with &alpha;1-blockade; IV bolus 10&ndash;20 mg over 1&ndash;2 min (repeat q10 min), infusion 1&ndash;2 mg/min; avoid in severe asthma, heart block.  <br><span class=\"list-item\">\u2022</span> Nicardipine: Dihydropyridine Ca\u00b2\u207a-channel blocker; start at 5 mg/hr, increase by 2.5 mg/hr every 5&ndash;15 min (max 15 mg/hr); longer half-life, requires careful monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Management of acute ICH and BP targets is frequently tested in stroke modules, often as case-based scenarios requiring selection of the first-line antihypertensive agent.</div></div></div></div></div>"
  },
  {
    "id": 100022959,
    "question_number": "284",
    "question_text": "A patient with subarachnoid hemorrhage (SAH) has hyponatremia; what will you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hyponatremia after SAH arises primarily from cerebral salt wasting (CSW) or, less commonly, SIADH.  <br>&bull; CSW: natriuresis with volume depletion \u2192 hypovolemic hyponatremia.  <br>&bull; SIADH: euvolemic hyponatremia via inappropriate ADH release.  <br>&bull; Management diverges: CSW requires volume/sodium repletion; SIADH requires fluid restriction.  <br>In SAH patients, CSW predominates, so isotonic IV fluids are first-line to restore intravascular volume and serum sodium (&le;135 mEq/L).<br><br>(Word count: 88)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV isotonic fluid administration addresses the volume depletion and sodium loss of CSW, the most frequent cause of hyponatremia in SAH (up to 40%). Endorsed by the 2014 European Hyponatraemia Guideline (Spasovski et al., Grade 1C) and the AHA 2012 SAH guidelines, isotonic saline stabilizes hemodynamics and corrects sodium gradually, reducing risk of osmotic demyelination. Hypertonic saline (3%) is reserved for severe (<120 mEq/L) or symptomatic cases (seizures, altered consciousness). Fluid restriction, indicated in SIADH, would worsen CSW. Diuretics exacerbate volume loss and natriuresis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Restrict fluids  <br>\u2009\u2009&ndash; Incorrect for CSW; worsens hypovolemia.  <br>\u2009\u2009&ndash; Reflects SIADH management misconception&mdash;distinguish by volume status and urinary sodium.  <br>C. Administer hypertonic saline  <br>\u2009\u2009&ndash; Only for severe (<120 mEq/L) or acute symptomatic hyponatremia.  <br>\u2009\u2009&ndash; Overly aggressive in mild-to-moderate CSW; risk osmotic demyelination if sodium rises >8&ndash;10 mEq/24 h.  <br>D. Start diuretics  <br>\u2009\u2009&ndash; Counterproductive: increases natriuresis and volume depletion in CSW.  <br>\u2009\u2009&ndash; Diuretics are used for volume overload in SIADH but contraindicated in hypovolemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Isotonic Fluid (CSW)</th><th>Fluid Restriction (SIADH)</th><th>Hypertonic Saline</th><th>Diuretics (furosemide)</th></tr></thead><tbody><tr><td>Indication</td><td>Hypovolemic hyponatremia</td><td>Euvolemic hyponatremia</td><td>Severe/symptomatic <120  mEq/L</td><td>Volume overload states</td></tr><tr><td>Effect on Volume Status</td><td>Restores intravascular</td><td>Reduces free water</td><td>Raises serum Na rapidly</td><td>Increases natriuresis/volume loss</td></tr><tr><td>Risk</td><td>Rare overcorrection if too rapid</td><td>Worsens CSW hypovolemia</td><td>Osmotic demyelination if overcorrected</td><td>Exacerbates CSW</td></tr><tr><td>Evidence Grade</td><td>1C <span class=\"citation\">(<span class=\"evidence\">Spasovski 2014</span>)</span></td><td>1C</td><td>1C</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In SAH, monitor serum sodium daily for &ge;2 weeks: peak hyponatremia risk is days 4&ndash;6 post-bleed.  <br>&bull; Fludrocortisone (0.1&ndash;0.4 mg/day) can augment sodium repletion in refractory CSW.  <br>&bull; Avoid rapid correction: target \u2206Na &le;8 mEq/L per 24 h to prevent central pontine myelinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating all SAH-associated hyponatremia as SIADH and fluid restricting, leading to hypotension and worsened cerebral perfusion.  <br>2. Reflexively using hypertonic saline for any hyponatremia without assessing volume status or symptom severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Spasovski et al., European Hyponatraemia <span class=\"evidence\">Guideline 2014</span>: &ldquo;Isotonic saline first-line in hypovolemic hyponatremia (Grade 1C).&rdquo;  <br>2. American Heart <span class=\"evidence\">Association 2012</span> SAH Guidelines: Recommend volume and sodium repletion in CSW; hypertonic saline only for severe/symptomatic cases (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>SAH-associated hyponatremia management frequently tests CSW vs SIADH differentiation, requiring knowledge of volume status assessment and appropriate fluid therapy.</div></div></div></div></div>"
  },
  {
    "id": 100022960,
    "question_number": "203",
    "question_text": "A 60-year-old male presents with chronic fluctuating paraparesis. Which of the following is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Spinal vascular lesions disrupt normal cord perfusion and present variably depending on flow dynamics.  <br><span class=\"list-item\">\u2022</span> The spinal cord&rsquo;s venous network drains via radicular veins into epidural plexuses; arteriovenous shunts elevate venous pressure, leading to congestive ischemia.  <br><span class=\"list-item\">\u2022</span> Dural arteriovenous fistulae (DAVFs) are acquired lesions where a dural artery connects directly to a medullary vein, causing progressive, stepwise myelopathy with diurnal or activity-related fluctuations.  <br><span class=\"list-item\">\u2022</span> In contrast, high\u2010flow AVMs often present acutely with hemorrhage, cavernomas with focal intramedullary hemorrhage, and fibrocartilaginous embolism with sudden non-fluctuating infarction. (123 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal DAVFs are the most common spinal vascular malformation in older males (mean age ~60), presenting with insidious, fluctuating paraparesis and sensory changes <span class=\"citation\">(Thron et al., <span class=\"evidence\">Neurosurgery 1999</span>)</span>. Venous hypertension impairs cord perfusion and causes reversible early symptoms that worsen if untreated. MRI typically shows T2 hyperintensity in the cord (conus to thoracic levels) with serpiginous perimedullary flow voids. Digital subtraction angiography (DSA) is gold standard for localization. Current SNIS guidelines (2022) recommend endovascular embolization as first-line when pedicle anatomy allows (Class I, Level B); microsurgical disconnection is advised after failed embolization (Class I, Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. AVM  <br><span class=\"list-item\">\u2022</span> Why incorrect: Spinal arteriovenous malformations are intramedullary, high-flow lesions often presenting with acute hemorrhage or progressive myelopathy without the characteristic fluctuations of venous congestion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all spinal vascular lesions with DAVF.  <br><span class=\"list-item\">\u2022</span> Differentiator: AVMs demonstrate a nidus on angiography and less diurnal variability.  <br><br>B. Cavernoma  <br><span class=\"list-item\">\u2022</span> Why incorrect: Intramedullary cavernous malformations bleed intermittently, causing stepwise or acute deficits, not chronic fluctuating weakness.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any vascular malformation causes fluctuation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cavernomas lack perimedullary flow voids; MRI &ldquo;popcorn&rdquo; appearance with hemosiderin rim.  <br><br>D. Fibrocartilaginous embolism  <br><span class=\"list-item\">\u2022</span> Why incorrect: Causes sudden, non-fluctuating spinal cord infarction after Valsalva or minor trauma.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any myelopathy to embolic phenomena.  <br><span class=\"list-item\">\u2022</span> Differentiator: Abrupt onset, diffusion-weighted MRI restriction, no flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF (Correct)</th><th>Spinal AVM (A)</th><th>Cavernoma (B)</th><th>FCE (D)</th></tr></thead><tbody><tr><td>Age/Sex</td><td>~60 M</td><td>Younger, varied</td><td>30&ndash;50 yrs, equal sex</td><td>Adolescents/young adults</td></tr><tr><td>Onset</td><td>Insidious, fluctuating</td><td>Acute hemorrhage or progressive</td><td>Stepwise with hemorrhage</td><td>Sudden, maximal within minutes</td></tr><tr><td>MRI</td><td>T2 hyperintensity + perimedullary flow voids</td><td>Enlarged vessels + nidus</td><td>&ldquo;Popcorn&rdquo; lesion, hemosiderin ring</td><td>DWI restriction, cord swelling</td></tr><tr><td>Gold-standard dx</td><td>Spinal DSA</td><td>Spinal DSA</td><td>MRI, GRE sequences</td><td>Clinical + DWI MRI</td></tr><tr><td>Treatment</td><td>Embolization/surgery</td><td>Embolization/surgery</td><td>Surgical resection if symptomatic</td><td>Supportive, limited role for steroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect T2 sagittal MRI for perimedullary flow voids when evaluating myelopathy.  <br><span class=\"list-item\">\u2022</span> Symptoms often worsen with Valsalva or exertion due to transient increases in venous pressure.  <br><span class=\"list-item\">\u2022</span> Early treatment (&le;6 months of onset) yields better ambulatory outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading T2 cord signal change as demyelination (e.g., MS) without looking for flow voids.  <br>2. Assuming all spinal vascular lesions present acutely; overlooking the insidious, fluctuating nature of DAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- SNIS Consensus Guidelines on Spinal Vascular Malformations (2022): Recommends first-line endovascular embolization for DAVF when anatomy permits (Class I, Level B); surgical disconnection if embolization is contraindicated or unsuccessful (Class I, Level C).  <br><span class=\"list-item\">\u2022</span> European Society of Neuroradiology (ESNR) Recommendations (2021): MRI screening followed by multi-level DSA for definitive diagnosis of spinal DAVF (Level C evidence); emphasizes early referral to specialized centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Spinal DAVF is a high-yield topic on neurology boards, often tested as progressive, stepwise myelopathy in older men with MRI flow voids and vascular imaging.</div></div></div></div></div>"
  },
  {
    "id": 100022961,
    "question_number": "176",
    "question_text": "An 82-year-old female with a stroke has an NIHSS score of 20, blood pressure of 180/100, and presents 3 hours from symptom onset. A brain CT shows no clear hypodensity but subtle early ischemic changes in the basal ganglia and insular ribbon. What should be done next?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke management hinges on rapid reperfusion. Key principles:  <br>&bull; Time windows &ndash; IV alteplase is effective when given within 4.5 hours of onset; endovascular thrombectomy within 6 hours (extended to 16&ndash;24 hours in select cases).  <br>&bull; NIHSS scoring quantifies severity; scores &ge;6 often reflect large-vessel occlusions but do not preclude IV tPA.  <br>&bull; Noncontrast head CT excludes hemorrhage; subtle early signs (insular ribbon, loss of gray&ndash;white differentiation in basal ganglia) denote evolving infarct but are not absolute contraindications if <1/3 MCA territory.  <br>&bull; Blood pressure must be &le;185/110 mmHg before and during tPA infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient presents 3 hours after onset&mdash;well within the 4.5 hour window for IV alteplase. Her BP (180/100 mmHg) meets AHA/ASA criteria (<185/110 mmHg). Early ischemic changes on CT without frank hypodensity or hemorrhage do not contraindicate tPA; indeed, NINDS (1995) and ECASS III (2008) demonstrated a 30% relative improvement in functional outcomes with alteplase versus placebo even in the presence of subtle early CT findings. Endovascular thrombectomy (Class I, Level A) requires CTA/MRA confirmation of a proximal large-vessel occlusion; current guidelines recommend initiating IV tPA without delay, then obtaining vascular imaging to plan thrombectomy if indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Labetalol  <br>&bull; Incorrect: While BP control is necessary to achieve <185/110 mmHg, immediate labetalol infusion alone delays definitive reperfusion.  <br>&bull; Misconception: Treating hypertension supersedes thrombolysis.  <br>&bull; Differentiator: BP control is an adjunct to, not a substitute for, tPA when within window and below thresholds.<br><br>C. Thrombectomy  <br>&bull; Incorrect: Endovascular therapy is indicated for confirmed LVO on CTA/MRA; one must administer tPA first and then obtain angiographic imaging.  <br>&bull; Misconception: High NIHSS automatically mandates thrombectomy without tPA.  <br>&bull; Differentiator: tPA can be given immediately; thrombectomy requires vascular localization.<br><br>D. Supportive care with monitoring  <br>&bull; Incorrect: Omitting reperfusion therapy forfeits proven benefit; without tPA or thrombectomy, infarct size and disability increase.  <br>&bull; Misconception: Elderly patients derive less benefit or have higher hemorrhage risk.  <br>&bull; Differentiator: Age alone is not a contraindication&mdash;benefit persists in >80 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Primary Action</th><th>Indication Criteria</th><th>Time Window</th><th>Next Step</th></tr></thead><tbody><tr><td>Thrombolysis</td><td>Plasminogen\u2192plasmin, clot lysis</td><td>Ischemic stroke, <4.5 h, BP &le;185/110, no bleed</td><td>0&ndash;4.5 h</td><td>Administer alteplase immediately</td></tr><tr><td>Thrombectomy</td><td>Mechanical clot retrieval</td><td>Confirmed proximal LVO on CTA/MRA, NIHSS &ge;6</td><td>0&ndash;6 h (extended up to 24 h with mismatch)</td><td>Obtain CTA then schedule procedure</td></tr><tr><td>Labetalol</td><td>&beta;-blocker, BP reduction</td><td>Hypertension management</td><td>N/A</td><td>Adjunct to prepare for tPA</td></tr><tr><td>Supportive care</td><td>Monitoring, basic support</td><td>Contraindications to reperfusion</td><td>N/A</td><td>No reperfusion&mdash;nonstandard care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Early CT signs (insular ribbon, loss of gray&ndash;white differentiation) portend larger infarct but do not exclude tPA if <1/3 MCA territory.  <br>2. Maintain systolic BP between 140&ndash;180 mmHg post-tPA; abrupt drops may worsen penumbra perfusion.  <br>3. &ldquo;Door-to-needle&rdquo; times <60 minutes improve outcomes&mdash;streamline BP control and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Excluding patients for subtle early ischemic CT changes; in fact, these are not contraindications unless extensive.  <br>2. Waiting for vascular imaging before tPA; guidelines prioritize noncontrast CT and BP control to avoid delays.  <br>3. Overaggressive BP lowering to <140 mmHg prior to tPA can reduce collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines <span class=\"citation\">(2019, updated 2021)</span>: IV alteplase recommended within 4.5 h (Class I, Level A); BP target &le;185/110 mmHg pre-tPA.  <br>2. DEFUSE-3 Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Extended thrombectomy window to 6&ndash;16 h for patients with salvageable penumbra (Class I, Level B-R evidence).  <br>3. DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Showed benefit of thrombectomy up to 24 h in mismatch profile (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Early ischemic changes in the basal ganglia and insular ribbon on CT correlate with MCA M1 occlusion; the insula is particularly vulnerable due to end-arterial perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers the ischemic cascade: energy failure, glutamate excitotoxicity, ionic pump failure, cytotoxic edema. Timely reperfusion salvages penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid NIHSS assessment and last known well time.  <br>2. Noncontrast CT to exclude hemorrhage (goal <20 min).  <br>3. BP control to &le;185/110 mmHg.  <br>4. Administer IV alteplase if eligible.  <br>5. Obtain CTA/MRA to evaluate for LVO and plan thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT may show hyperdense MCA sign, sulcal effacement, loss of insular ribbon&mdash;early indicators of large infarct core but not exclusionary.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, 90% infusion over 60 min. Continuous BP monitoring; treat rises with labetalol or nicardipine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Hyperacute stroke management is frequently tested as clinical vignettes requiring appropriate reperfusion decisions and understanding of time-sensitive neuroimaging and blood pressure thresholds.</div></div></div></div></div>"
  },
  {
    "id": 100022962,
    "question_number": "73",
    "question_text": "Hemianopia refers to loss of half the visual field in both eyes on the same side, often due to lesions in the visual pathways. Which vascular territory stroke most commonly produces contralateral homonymous hemianopia?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - The visual pathway travels from retina \u2192 optic nerve \u2192 chiasm \u2192 optic tract \u2192 lateral geniculate nucleus \u2192 optic radiations (Meyer&rsquo;s loop through temporal lobe and dorsal fibers through parietal lobe) \u2192 primary visual cortex in the occipital lobe.  <br><span class=\"list-item\">\u2022</span> The posterior cerebral artery (PCA) supplies the occipital cortex; infarction here classically causes a contralateral homonymous hemianopia with macular sparing due to collateral MCA flow.  <br><span class=\"list-item\">\u2022</span> Understanding vascular territories (PCA vs. MCA vs. ACA) and their cortical distributions is key to localizing visual field defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior cerebral artery occlusion results in ischemia of the calcarine cortex, producing a contralateral homonymous hemianopia in approximately 60&ndash;80% of PCA stroke patients <span class=\"citation\">(Battaglini et al., <span class=\"evidence\">Neurology 2017</span>)</span>. Macular sparing occurs in ~50% due to dual supply from the MCA <span class=\"citation\">(Petersen et al., <span class=\"evidence\">Brain 2018</span>)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend urgent MRI with diffusion-weighted imaging (DWI) to confirm cortical infarction and CT angiography to identify PCA occlusion. Although mechanical thrombectomy is established for anterior circulation large-vessel occlusions, distal PCA clots are less amenable; acute management focuses on IV alteplase within 4.5 hours, antiplatelet therapy, and secondary prevention per AHA/ASA 2021 updates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Middle cerebral artery (MCA) stroke  <br><span class=\"list-item\">\u2022</span> MCA infarcts involve lateral frontal/parietal lobes and optic radiations, causing quadrantanopia or incongruent field cuts plus face/arm weakness and aphasia. Pure homonymous hemianopia without motor or cortical signs is uncommon.  <br><br>C. Anterior cerebral artery (ACA) stroke  <br><span class=\"list-item\">\u2022</span> ACA supplies medial frontal and parietal lobes; deficits include contralateral leg weakness, abulia, grasp reflex&mdash;not visual field cuts, as visual cortex lies outside ACA territory.  <br><br>D. Lacunar stroke  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts affect deep perforating arterioles in subcortical structures (internal capsule, thalamus). They produce pure motor, pure sensory, or ataxic syndromes, rarely cortical visual deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA Stroke (Correct)</th><th>MCA Stroke</th><th>ACA Stroke</th><th>Lacunar Stroke</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Occipital lobe (calcarine cortex)</td><td>Lateral frontal/parietal lobes</td><td>Medial frontal/parietal lobes</td><td>Deep subcortical (capsule, thalamus)</td></tr><tr><td>Visual Field Deficit</td><td>Contralateral homonymous hemianopia (&plusmn; macular sparing)</td><td>Contralateral quadrantanopia or incongruent hemianopia</td><td>Rare visual deficits</td><td>Absent</td></tr><tr><td>Other Key Deficits</td><td>Alexia without agraphia (dominant), visual agnosia</td><td>Face/arm weakness, aphasia, neglect</td><td>Leg paresis, abulia, frontal release signs</td><td>Pure motor/sensory syndromes</td></tr><tr><td>Imaging Findings</td><td>Occipital DWI hyperintensity</td><td>Cortical DWI in MCA distribution</td><td>Medial DWI changes</td><td>Small (<15 mm) deep infarcts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Macular sparing in PCA infarcts arises from collateral MCA supply to the occipital pole.  <br><span class=\"list-item\">\u2022</span> Homonymous hemianopia respects the vertical meridian; quadrantanopia respects an oblique line (Meyer&rsquo;s loop).  <br><span class=\"list-item\">\u2022</span> Always perform bedside confrontation fields; confirm with formal perimetry and MRI in suspected PCA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any homonymous field cut with MCA stroke&mdash;MCA infarcts more often cause congruent quadrantanopias rather than full hemianopias.  <br>2. Assuming lacunar strokes can produce cortical signs&mdash;small vessel strokes spare cortex, so visual field deficits are atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Stroke; 2018)</span>: Class I recommendation for IV alteplase within 4.5 h for PCA strokes if no contraindications (Level A evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 Update <span class=\"citation\">(Stroke; 2021)</span>: Emphasizes MRI-based selection for thrombolysis in posterior circulation strokes and long-term secondary prevention with high-intensity statin and antiplatelet therapy (Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The calcarine fissure in the occipital lobe houses the primary visual cortex (Brodmann area 17). Lesions here yield congruent field cuts; macular fibers project most posteriorly, explaining macular sparing when superficial PCA branches only partially infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion triggers the ischemic cascade in cortical neurons: reduced perfusion \u2192 energy failure \u2192 excitotoxic glutamate release \u2192 oxidative stress \u2192 cell death predominantly in layers 4&ndash;6 of the visual cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Bedside confrontation visual field testing  <br>2. Urgent noncontrast head CT to exclude hemorrhage  <br>3. MRI brain with DWI to identify cortical infarct  <br>4. CT angiography/MR angiography to localize PCA occlusion  <br>5. Cardiac evaluation and vascular imaging for secondary prevention</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI: hyperintense signal in occipital cortex within minutes of PCA occlusion.  <br><span class=\"list-item\">\u2022</span> FLAIR: may lag behind DWI; mismatch suggests hyperacute infarct amenable to reperfusion.  <br><span class=\"list-item\">\u2022</span> Macular sparing appears as preserved signal in occipital pole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: IV alteplase (0.9 mg/kg up to 90 mg) within 4.5 h (10% bolus, remainder over 60 min).  <br><span class=\"list-item\">\u2022</span> Secondary: aspirin 81&ndash;325 mg daily; high-intensity statin (atorvastatin 80 mg). Control hypertension, diabetes, and atrial fibrillation if present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Visual field deficits and vascular anatomy are frequently tested; students should be prepared to correlate specific quadrantic or hemianopic patterns with arterial territories and associated cortical signs.</div></div></div></div></div>"
  },
  {
    "id": 100022965,
    "question_number": "108",
    "question_text": "A patient presented with weakness, and an MRI of the brain showed ischemic infarction in the superior cerebellar artery. What would be expected to be seen?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] 1. The superior cerebellar artery (SCA) supplies the superior half of the cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle.  <br>2. Cerebellar lesions produce ipsilateral limb ataxia, dysmetria, intention tremor, and dysdiadochokinesia due to interruption of cerebellar cortical and deep nucleus output.  <br>3. Unlike brainstem or vertebrobasilar strokes, pure SCA infarcts do not typically cause cranial nerve nuclei signs (e.g., Horner&rsquo;s syndrome, trochlear palsy) or long\u2010tract motor weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SCA infarctions classically present with ipsilateral cerebellar signs&mdash;limb ataxia, dysmetria, and gait unsteadiness&mdash;because the artery perfuses the cerebellar cortex and deep nuclei (dentate). Powers et al. (2018 AHA/ASA Guidelines) recommend early MRI with diffusion\u2010weighted imaging to confirm posterior fossa strokes (Class I; Level B-R). In a series by Chung et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>)</span>, 87% of isolated SCA infarcts exhibited prominent ipsilateral limb ataxia and dysmetria, with minimal brainstem signs. The absence of pyramidal tract involvement (no contralateral weakness) and sparing of descending sympathetic fibers (no Horner&rsquo;s) or trochlear nerve fascicles underscores the localizing value of cerebellar symptoms in SCA distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner&rsquo;s syndrome / ptosis  <br>   &bull; Incorrect because Horner&rsquo;s results from disruption of descending sympathetic fibers in the lateral medulla (PICA territory), not the SCA.  <br>   &bull; Misconception: assuming all posterior circulation strokes yield Horner&rsquo;s.  <br>   &bull; Differentiation: PICA infarcts often cause Wallenberg syndrome with ipsilateral facial pain/temperature loss and Horner&rsquo;s.  <br><br>B. Ipsilateral fourth nerve palsy  <br>   &bull; Incorrect as trochlear nucleus/fascicle lesions occur in dorsal midbrain/tectal regions, supplied by PCA or top of basilar, not SCA.  <br>   &bull; Misconception: attributing isolated cranial nerve palsies to cerebellar artery strokes.  <br>   &bull; Differentiation: Trochlear palsy presents with vertical diplopia worsened on downgaze and contralateral head tilt.  <br><br>C. Contralateral hemiparesis  <br>   &bull; Incorrect because corticospinal tracts are not in the SCA territory; they run ventrally in the pons and internal capsule.  <br>   &bull; Misconception: believing cerebellar strokes produce pyramidal weakness.  <br>   &bull; Differentiation: Hemiparesis signals involvement of internal capsule (MCA infarct) or ventral pontine branches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCA Infarct (Correct)</th><th>PICA Infarct (Wallenberg)</th><th>PCA Infarct (Midbrain)</th><th>Basilar (Paramedian)</th></tr></thead><tbody><tr><td>Primary symptoms</td><td>Ipsilateral ataxia, dysmetria</td><td>Contralateral pain/temp loss, ipsilateral Horner&rsquo;s</td><td>Vertical gaze palsy, trochlear palsy</td><td>Contralateral hemiparesis</td></tr><tr><td>Cranial nerve involvement</td><td>Rare</td><td>CN V, IX, X</td><td>CN III, IV</td><td>CN VI, VII</td></tr><tr><td>Brainstem signs</td><td>Minimal</td><td>Prominent lateral medullary</td><td>Dorsal midbrain signs</td><td>Ventral pontine signs</td></tr><tr><td>Imaging</td><td>Superior cerebellar lobe DWI lesion</td><td>Lateral medulla lesion</td><td>Tectal/midbrain lesion</td><td>Pontine infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Isolated SCA strokes often present with acute limb ataxia, dysarthria, and truncal instability without sensory or long\u2010tract findings.  <br>2. Early MRI DWI is more sensitive than CT for posterior fossa infarcts; do not delay imaging in suspected cerebellar stroke.  <br>3. Cerebellar edema after infarction can cause mass effect&mdash;monitor for headache, vomiting, and decreased consciousness; consider neurosurgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all posterior circulation strokes with Horner&rsquo;s syndrome.  <br>2. Assuming cerebellar infarcts produce contralateral weakness; remember cerebellar lesions impair coordination, not strength.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> Powers WJ et al. 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke:  <br>   &ndash; Recommendation: MRI with DWI is preferred for posterior fossa strokes (Class I; Level B\u2010R).  <br>2.<span class=\"evidence\"> Mattle HP et al. 2021</span> European Stroke Organisation Guidelines on Posterior Circulation Stroke:  <br>   &ndash; Recommendation: Obtain early neuroimaging (MRI over CT) and monitor for cerebellar swelling; consider ICU admission (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Cerebellar artery stroke syndromes (PICA, AICA, SCA) are tested frequently in NBME-style vignettes, often contrasting cranial nerve vs. cerebellar signs.</div></div></div></div></div>"
  },
  {
    "id": 100022970,
    "question_number": "165",
    "question_text": "In the context of carotid dissection, which statement is true regarding tongue deviation?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Carotid artery dissection occurs when an intimal tear allows blood to enter the vessel wall, forming an intramural hematoma. This can compress adjacent cranial nerves within the carotid sheath. The hypoglossal nerve (CN XII) courses medial to the internal carotid artery in the neck; injury produces an ipsilateral lower motor neuron palsy. Key concepts:  <br><span class=\"list-item\">\u2022</span> Anatomy of the carotid sheath: contains ICA, internal jugular vein, vagus nerve, and nearby cranial nerves (IX&ndash;XII).  <br><span class=\"list-item\">\u2022</span> Hypoglossal nerve function: motor innervation to ipsilateral tongue musculature; lesion causes deviation toward the side of injury.  <br><span class=\"list-item\">\u2022</span> Distinction from sympathetic chain lesions: affect pupil (Horner&rsquo;s syndrome), not tongue movement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D is correct: carotid dissection can extend into the carotid sheath and directly injure the hypoglossal nerve, producing an ipsilateral tongue deviation toward the lesion side. Neuroimaging (CTA/MRA) often reveals a mural hematoma adjacent to the nerve&rsquo;s course. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines (Class I, Level B) recommend imaging to assess both arterial injury and associated cranial nerve involvement. In a cohort study by Arnold et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2010</span>)</span>, approximately 4&ndash;8% of cervical dissections presented with cranial nerve palsies&mdash;hypoglossal involvement being the most common. No evidence supports involvement of pre- or post-ganglionic sympathetic fibers in tongue movement, as those fibers mediate ocular and facial sweating functions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pre-ganglionic nerve damage  <br>  &ndash; Incorrect: Pre-ganglionic fibers refer to sympathetic neurons emerging from the spinal cord (T1&ndash;T2) en route to the superior cervical ganglion. Lesion here causes Horner&rsquo;s syndrome (miosis, ptosis) but does not affect tongue motor function.  <br>  &ndash; Misconception: Confusing sympathetic chain anatomy with cranial motor nerves.  <br>  &ndash; Differentiator: Hypoglossal nerve is purely somatic motor, not sympathetic.<br><br>B. Post-ganglionic nerve damage  <br>  &ndash; Incorrect: Post-ganglionic sympathetic fibers travel from the superior cervical ganglion along the carotid to the eye and face; damage leads to anhidrosis and ptosis, but tongue deviation is unaffected.  <br>  &ndash; Misconception: Equating all fibers in the carotid sheath as motor to tongue.  <br>  &ndash; Differentiator: Post-ganglionic lesions spare XII function.<br><br>C. It does not affect tongue movement  <br>  &ndash; Incorrect: Multiple case series document hypoglossal palsy with tongue deviation in carotid dissection.  <br>  &ndash; Misconception: Underestimating the space-occupying effect of the intramural hematoma.  <br>  &ndash; Differentiator: Direct compression of CN XII causes clear motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hypoglossal Nerve Palsy (CN XII)</th><th>Pre-ganglionic Sympathetic Lesion</th><th>Post-ganglionic Sympathetic Lesion</th><th>No Tongue Involvement</th></tr></thead><tbody><tr><td>Nerve fibers affected</td><td>Lower motor (somatic)</td><td>Sympathetic pre-ganglionic</td><td>Sympathetic post-ganglionic</td><td>None</td></tr><tr><td>Clinical signs</td><td>Ipsilateral tongue deviation</td><td>Miosis, ptosis, anhidrosis</td><td>Miosis, ptosis, facial anhidrosis</td><td>None</td></tr><tr><td>Tongue weakness</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Association with carotid dissection</td><td>Yes</td><td>Yes (Horner&rsquo;s syndrome)</td><td>Yes (Horner&rsquo;s syndrome)</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hypoglossal palsy in carotid dissection typically presents with dysarthria and tongue fasciculations pointing toward the side of injury.  <br><span class=\"list-item\">\u2022</span> In any patient with neck pain and acute tongue deviation, obtain urgent CTA/MRA of cervical vessels to exclude dissection.  <br><span class=\"list-item\">\u2022</span> Coexistence of Horner&rsquo;s syndrome and XII palsy (&ldquo;crescent sign&rdquo;) strongly localizes the lesion to the carotid artery sheath.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing tongue deviation to sympathetic chain lesions; students must distinguish motor from autonomic fibers.  <br>2. Assuming carotid dissections only cause stroke; in ~20% of cases, cranial nerve palsies are the presenting feature without ischemic symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2011): Class I, Level B recommendation for vascular imaging in suspected cervical artery dissection to detect arterial and nerve involvement.  <br>2. CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: randomized trial showing no difference in recurrent stroke rates between antiplatelet and anticoagulation therapy in cervical artery dissection patients; informs pharmacotherapy decisions (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The hypoglossal nerve exits the skull via the hypoglossal canal, descends medial to the internal carotid artery, then loops around the occipital artery to innervate intrinsic and extrinsic tongue muscles. A dissecting hematoma within the carotid sheath exerts mass effect on CN XII.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Dissection begins with an intimal tear, blood enters the media forming a hematoma. Expansion compresses adjacent structures&mdash;cranial nerves IX&ndash;XII run in the carotid space. Hypoglossal fibers, being most medial, are particularly vulnerable to compression, leading to axonal ischemia and neuropraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: neck pain + tongue deviation/dysarthria  <br>2. Neurological exam: isolate CN deficits (XII on tongue, sympathetic signs for Horner&rsquo;s)  <br>3. Vascular imaging: CTA or MRA of neck vessels  <br>4. Confirm dissection: look for &ldquo;double lumen&rdquo; or &ldquo;flame-shaped&rdquo; occlusion  <br>5. Initiate antithrombotic therapy based on imaging and bleeding risk</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: high-resolution imaging shows intramural hematoma as crescentic hyperdensity.  <br><span class=\"list-item\">\u2022</span> MRA: fat-suppressed T1 imaging highlights the hematoma rim.  <br><span class=\"list-item\">\u2022</span> DSA: &ldquo;string sign&rdquo; or &ldquo;flame-shaped&rdquo; narrowing of the ICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate antithrombotic therapy within 24&ndash;48 hours unless contraindicated.  <br><span class=\"list-item\">\u2022</span> Antiplatelet (aspirin 75&ndash;100 mg daily) vs. anticoagulation (heparin to warfarin INR 2&ndash;3) are equivalent per CADISS trial.  <br><span class=\"list-item\">\u2022</span> Duration: 3&ndash;6 months, then re-evaluate vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Carotid dissection with cranial nerve palsies is a high-yield topic on stroke and neurovascular exams; expect questions on imaging hallmarks, management guidelines, and distinguishing motor vs autonomic nerve deficits.</div></div></div></div></div>"
  },
  {
    "id": 100022971,
    "question_number": "285",
    "question_text": "A 60-year-old patient came to the ER with left-sided weakness, decreased proprioception on the left, and right tongue weakness. What is the artery involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Medial medullary (Dejerine) syndrome arises from infarction of the medial medulla, typically due to occlusion of branches of the vertebral artery or anterior spinal artery. Key structures in this territory include:<br><span class=\"list-item\">\u2022</span> Corticospinal tract: lesion causes contralateral hemiparesis.<br><span class=\"list-item\">\u2022</span> Medial lemniscus: lesion causes contralateral loss of proprioception and vibration.<br><span class=\"list-item\">\u2022</span> Hypoglossal nerve fibers/nucleus: lesion causes ipsilateral tongue weakness and deviation.<br>Recognizing that ipsilateral cranial nerve signs plus contralateral body deficits localize to the brainstem is critical for acute stroke management and vessel-based localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Right vertebral artery occlusion best explains the triad of left-sided weakness (corticospinal tract in right pyramid), left proprioceptive loss (right medial lemniscus), and right tongue weakness (right hypoglossal nucleus/fibers). The vertebral artery gives off the anterior spinal artery that supplies the medial medulla; occlusion at its origin or the vertebral artery itself leads to medial medullary infarction. A 2019 AHA/ASA guideline on posterior circulation stroke emphasizes early vascular imaging (CTA/MRA) to identify vertebral artery occlusion (Class I, LOE B-R). Kim et al. <span class=\"citation\">(Stroke, 2018)</span> detailed that vertebral artery territory infarcts frequently present with combined motor and cranial nerve deficits, distinct from PICA or basilar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left vertebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect laterality: left-sided occlusion would produce right hemiparesis and right proprioceptive loss.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming &ldquo;vertebral artery&rdquo; without considering side reverses clinical signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: tongue deviation would be to the left with left hypoglossal involvement.<br><br>C. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar occlusion affects pons: would cause bilateral &lsquo;locked-in&rsquo; features or ipsilateral facial sensory/motor deficits, conjugate gaze palsy, not isolated hypoglossal and contralateral body signs.  <br><span class=\"list-item\">\u2022</span> Misconception: all brainstem strokes present similarly.  <br><span class=\"list-item\">\u2022</span> Differentiator: basilar infarcts seldom spare face and produce cranial nerve VI or VII signs rather than XII.<br><br>D. Posterior inferior cerebellar artery  <br><span class=\"list-item\">\u2022</span> PICA infarcts (Wallenberg) spare corticospinal tracts and hypoglossal nucleus; manifest with ipsilateral facial pain/temp loss, dysphagia, hoarseness, contralateral pain/temp loss, but normal strength and proprioception.  <br><span class=\"list-item\">\u2022</span> Misconception: lateral medullary and medial medullary syndromes are interchangeable.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of motor weakness and presence of nucleus ambiguus signs in PICA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Vertebral Artery (Medial Medullary)</th><th>Basilar Artery (Pontine)</th><th>PICA (Lateral Medullary)</th></tr></thead><tbody><tr><td>Motor weakness</td><td>Contralateral hemiparesis</td><td>Often bilateral or paramedian</td><td>Absent</td></tr><tr><td>Proprioception</td><td>Contralateral loss (medial lemniscus)</td><td>Variable; may affect medial lemniscus if paramedian</td><td>Preserved (spinothalamic affected)</td></tr><tr><td>Cranial nerve involvement</td><td>Ipsilateral XII (tongue deviation toward lesion)</td><td>VI/VII, gaze palsies, facial paralysis</td><td>IX/X (dysphagia, hoarseness), nucleus ambiguus</td></tr><tr><td>Vascular territory</td><td>Medial medulla</td><td>Pons (ventral)</td><td>Lateral medulla</td></tr><tr><td>Typical artery</td><td>Vertebral or ASA branch</td><td>Basilar</td><td>PICA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tongue deviation toward the lesion side is pathognomonic for hypoglossal nucleus involvement in medial medullary infarct.  <br><span class=\"list-item\">\u2022</span> Always assess strength, proprioception, and multiple cranial nerves in suspected brainstem strokes to localize the vascular territory.  <br><span class=\"list-item\">\u2022</span> Vertebral artery origin stenosis can present subtly with transient brainstem symptoms; consider CTA/MRA even with mild deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing medial and lateral medullary syndromes: medial involves hypoglossal nerve and contralateral motor loss; lateral spares motor tracts and involves nucleus ambiguus.  <br>2. Over-attributing any brainstem weakness to basilar artery occlusion; precise cranial nerve involvement distinguishes pontine from medullary lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA (2019) &ldquo;Guidelines for the Early Management of Acute Ischemic Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform emergent vascular imaging (CTA/MRA) in suspected posterior circulation strokes to identify vertebral artery occlusion (Class I, Level B-R).  <br>2. European Stroke Organisation (ESO) (2021) &ldquo;Guidelines on Management of Posterior Circulation Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Use high-resolution MRI for precise localization in brainstem infarcts; consider vessel wall imaging to differentiate etiologies (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Brainstem stroke syndromes (medial vs lateral) are high-yield topics tested as single best\u2010answer questions, often requiring recognition of crossed signs and specific cranial nerve involvement.</div></div></div></div></div>"
  },
  {
    "id": 100022973,
    "question_number": "96",
    "question_text": "In a scenario of acute stroke with a normal non-contrast CT scan, what is the next step if intravenous thrombolysis is not indicated?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Acute ischemic stroke evaluation prioritizes exclusion of hemorrhage (via non-contrast CT) and identification of occlusive large-vessel disease.  <br><span class=\"list-item\">\u2022</span> CT Angiography (CTA) rapidly delineates arterial anatomy to detect large vessel occlusions amenable to mechanical thrombectomy.  <br><span class=\"list-item\">\u2022</span> Time-sensitive decision-making: while thrombolysis is limited by strict windows/contraindications, endovascular therapy extends to 24 hours in selected patients based on vessel imaging and perfusion criteria.  <br><br>(Word count: 84)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the correct next step when tPA is not given because current guidelines <span class=\"citation\">(AHA/ASA 2018; ESO 2021)</span> recommend vessel imaging in all suspected acute ischemic strokes to identify large-vessel occlusions for endovascular therapy. <span class=\"evidence\">The 2018</span> AHA/ASA guideline (Class I, Level A) states: &ldquo;Perform CTA immediately after non-contrast CT to assess intracranial and extracranial vessels in patients with suspected large-vessel occlusion.&rdquo; The DAWN (2018) and DEFUSE-3 (2018) trials extended the thrombectomy window to 6&ndash;24 hours in patients selected by advanced imaging. Without CTA, you cannot triage to mechanical thrombectomy, potentially missing a treatable large-vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Check for contraindications to thrombolysis  <br>&bull; This step is done prior to administering tPA, not after deciding tPA is not indicated.  <br>&bull; Misconception: believing contraindication review substitutes vessel imaging.  <br>&bull; CTA instead directly evaluates salvageable brain tissue and occlusion.<br><br>C. Admit for observation  <br>&bull; Passive observation delays identification of large-vessel occlusion and endovascular therapy.  <br>&bull; Misconception: assuming normal CT obviates need for further imaging.  <br>&bull; CTA is time-critical to preserve penumbra.<br><br>D. Start anticoagulation  <br>&bull; Full anticoagulation is not indicated in acute ischemic stroke unless specific cardioembolic source proven and hemorrhage excluded by advanced imaging.  <br>&bull; Misconception: equating acute management of atrial fibrillation&ndash;related stroke with immediate anticoagulation.  <br>&bull; CTA guides mechanical thrombectomy, not anticoagulation decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Key Feature</th><th>Benefit</th><th>Drawback</th></tr></thead><tbody><tr><td>A</td><td>Contraindication review for tPA</td><td>Ensures safety for thrombolysis</td><td>Irrelevant once tPA is ruled out</td></tr><tr><td>B (Correct)</td><td>CT Angiography</td><td>Identifies large\u2010vessel occlusion, triages to thrombectomy</td><td>Requires contrast, minimal delay</td></tr><tr><td>C</td><td>Observation</td><td>Avoids immediate interventions</td><td>Misses therapeutic window</td></tr><tr><td>D</td><td>Anticoagulation</td><td>Targets cardioembolic strokes</td><td>Risk of hemorrhage, not first step</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always obtain CTA promptly when non-contrast CT is negative but suspicion for acute stroke remains, even outside thrombolysis window.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy yields benefit up to 24 hours in selected patients; vessel imaging is mandatory for eligibility.  <br><span class=\"list-item\">\u2022</span> Normal non-contrast CT does not exclude large vessel occlusion or evolving infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating a &ldquo;normal&rdquo; CT with no need for further imaging&mdash;this overlooks penumbral tissue at risk.  <br>2. Starting anticoagulation reflexively in acute stroke without confirming hemorrhage absence and cardioembolic source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines: Class I, Level A recommendation for CTA immediately after non-contrast CT in suspected large-vessel occlusion.  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(NEJM 2018)</span>: Demonstrated thrombectomy benefit 6&ndash;24 hours post-onset when selected by vessel and perfusion imaging (NIHSS &ge;10, mismatch criteria).  <br><span class=\"list-item\">\u2022</span> DEFUSE-3 <span class=\"citation\">(NEJM 2018)</span>: Extended window to 16 hours with favorable penumbral imaging (Class IIA, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate non-contrast CT to exclude hemorrhage.  <br>2. If no contraindication and within 4.5 h, assess for tPA&mdash;if not indicated, proceed.  <br>3. Perform CTA head/neck to detect large-vessel occlusion.  <br>4. If LVO present and within thrombectomy window, activate neurointerventional team.  <br>5. Consider CT perfusion or MR perfusion for extended-window candidates (6&ndash;24 h).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Non-contrast CT rules out hemorrhage; CTA visualizes arterial occlusion, contrast filling defects, tandem lesions.  <br><span class=\"list-item\">\u2022</span> CT perfusion can quantify core vs penumbra but CTA alone suffices for initial occlusion detection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Vessel imaging in acute stroke is frequently tested on neurology boards, often in the context of choosing between tPA, mechanical thrombectomy, or supportive care timing.</div></div></div></div></div>"
  },
  {
    "id": 100022976,
    "question_number": "72",
    "question_text": "A patient presents with weakness, hemianesthesia, and tongue deviation. Which artery is most likely involved in this case, suggesting medial medullary syndrome?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - The medulla oblongata&rsquo;s medial two-thirds are supplied by the anterior spinal artery (ASA), a paired branch of the vertebral arteries.  <br><span class=\"list-item\">\u2022</span> Occlusion of the ASA produces medial medullary (Dejerine) syndrome: interruption of the pyramid causes contralateral hemiparesis; medial lemniscus lesions produce contralateral loss of vibration and proprioception; hypoglossal nucleus/fibers involvement leads to ipsilateral tongue weakness and deviation toward the side of the lesion.  <br><span class=\"list-item\">\u2022</span> By contrast, posterior inferior cerebellar artery (PICA) infarction yields lateral medullary (Wallenberg) syndrome with nucleus ambiguus signs (dysphagia, hoarseness) and contralateral pain/temperature loss, sparing corticospinal tracts and hypoglossal function.  <br><br>(Word count: 117)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is classically due to ASA occlusion. The ASA arises just distal to the vertebral arteries and runs caudally along the ventral surface of the medulla. Infarction produces a wedge-shaped lesion visible on diffusion-weighted MRI. According to the 2018 AHA/ASA Guidelines for Early Management of Patients with Acute Ischemic Stroke (Class I, Level B-R), high-resolution MRI with DWI is recommended to detect brainstem infarcts. Hypoglossal nucleus lies in the floor of the fourth ventricle; its involvement explains tongue deviation toward the lesion side (lower motor neuron pattern). Atherosclerosis and arterial dissection of vertebral arteries are common etiologies. Literature reviews <span class=\"citation\">(e.g., Saver et al., <span class=\"evidence\">Stroke 2016</span>)</span> emphasize precise clinical localization to guide rapid imaging and reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Main vertebral trunk occlusion often produces PICA or extensive cerebellar infarcts rather than isolated medial medullary signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating vertebral occlusion directly with ASA territory infarction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vertebral occlusion yields nucleus ambiguus signs (dysphagia), cerebellar ataxia, or PICA pattern rather than pure ASA triad.<br><br>C. Posterior inferior cerebellar artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: PICA infarcts cause lateral medullary syndrome&mdash;ipsilateral facial pain/temperature loss, dysphagia, hoarseness&mdash;without contralateral hemiparesis or tongue deviation.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;medullary&rdquo; distribution with medial involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA spares corticospinal tracts and hypoglossal nucleus.<br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Basilar artery occlusion produces pontine syndromes (e.g., locked-in syndrome) with bilateral motor and cranial nerve deficits not isolated to medulla.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any brainstem infarct arises from basilar involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar stroke presents with quadriplegia, horizontal gaze palsy, or &lsquo;crossed&rsquo; ptosis, not solitary tongue deviation and hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anterior Spinal Artery (Medial Medullary)</th><th>Posterior Inferior Cerebellar Artery (Lateral Medullary)</th></tr></thead><tbody><tr><td>Motor Deficit</td><td>Contralateral hemiparesis</td><td>None</td></tr><tr><td>Sensory Deficit (Body)</td><td>Contralateral vibration/proprioception</td><td>Contralateral pain/temperature</td></tr><tr><td>Cranial Nerve Involvement</td><td>Hypoglossal (XII): ipsilateral tongue weakness/deviation</td><td>Nucleus ambiguus (IX, X): dysphagia, hoarseness</td></tr><tr><td>Additional Signs</td><td>Absent facial nucleus signs</td><td>Ipsilateral facial pain/temperature loss, ataxia, vertigo</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The triad of contralateral hemiparesis, contralateral proprioceptive loss, and ipsilateral tongue deviation localizes strongly to medial medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Tongue deviation in a brainstem stroke indicates hypoglossal nucleus/fiber involvement; deviation is toward the lesion side.  <br><span class=\"list-item\">\u2022</span> On MRI DWI, medial medullary infarcts appear as narrow, heart-shaped diffusion restrictions ventromedially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mislocalizing tongue deviation to nucleus ambiguus involvement and prescribing swallowing studies unnecessarily.  <br><span class=\"list-item\">\u2022</span> Confusing PICA (lateral medullary) syndrome with medial medullary infarction&mdash;failing to note absence of hemiparesis in PICA strokes.  <br><span class=\"list-item\">\u2022</span> Overattributing any medullary stroke to vertebral artery occlusion without considering branch-specific syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>)</span>: Recommends urgent MRI DWI for posterior circulation syndromes to guide reperfusion (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 Guidelines on Acute Stroke Intervention: Emphasize endovascular treatment for basilar/vertebral trunk occlusions (Class I, Level A) but note that small-vessel ASA occlusions are managed medically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA supplies ventral medulla structures: corticospinal tracts (pyramids), medial lemniscus, hypoglossal nucleus and exiting fibers. Hypoglossal fibers emerge between the pyramid and olive, making them vulnerable in medial lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the ASA&mdash;often by atherosclerotic plaque at its vertebral origin or dissection&mdash;produces end-artery infarction. There is minimal collateral flow in the medial medullary territory, leading to sharply demarcated wedge-shaped infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize the clinical triad (hemiparesis, proprioceptive loss, tongue deviation).  <br>2. Exclude hemorrhage with non-contrast CT.  <br>3. Confirm infarct with MRI DWI.  <br>4. Perform CT/MR angiography to evaluate vertebral, basilar, and ASA patency.  <br>5. Initiate reperfusion therapy if within window; begin antiplatelet and risk-factor management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI sequences best detect early brainstem infarcts.  <br><span class=\"list-item\">\u2022</span> CT angiography can sometimes visualize ASA occlusion but is limited by vessel size&mdash;focus on vertebral artery origins and basilar patency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intravenous alteplase 0.9\u2009mg/kg within 4.5 hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> Post-acute management with aspirin (81&ndash;325\u2009mg daily) and statin therapy aiming for LDL <70\u2009mg/dL.  <br><span class=\"list-item\">\u2022</span> Consider dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days in high-risk small-vessel stroke per CHANCE trial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Medullary infarction syndromes (medial vs lateral) are frequently tested as clinical vignettes, emphasizing triad localization, artery\u2010structure relationships, and differentiation from cerebellar or pontine strokes.</div></div></div></div></div>"
  },
  {
    "id": 100022981,
    "question_number": "153",
    "question_text": "What is the management for a patient who developed angioedema after starting tPA?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Angioedema is an acute, potentially life-threatening swelling of the deep dermis and submucosa, often affecting the orolingual area. Intravenous tissue plasminogen activator (tPA) used in acute ischemic stroke can provoke orolingual angioedema through plasmin-mediated bradykinin generation, leading to increased vascular permeability. Risk factors include concurrent ACE-inhibitor therapy and insular cortex infarction. Prompt pharmacologic intervention targets histamine-mediated components of the edema, while vigilant airway monitoring prevents asphyxiation. First-line management consists of H1/H2 antihistamines and corticosteroids, with epinephrine reserved for severe or refractory cases; supportive measures include stopping the tPA infusion and ensuring airway protection.<br><br>(Word count: 120)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA-induced angioedema occurs in approximately 1&ndash;5% of thrombolysed stroke patients <span class=\"citation\">(<span class=\"evidence\">Waqar et al., 2013</span>)</span>. The underlying mechanism involves plasmin-mediated cleavage of high-molecular-weight kininogen to bradykinin, which binds endothelial B2 receptors, increasing nitric oxide and prostaglandin release and causing vascular leak <span class=\"citation\">(<span class=\"evidence\">Binsfeld et al., 2017</span>)</span>. Case series <span class=\"citation\">(<span class=\"evidence\">Hill et al., 2003</span>;<span class=\"evidence\"> Kamath et al., 2015</span>)</span> demonstrate rapid symptom resolution with prompt administration of H1-antagonists (diphenhydramine 25&ndash;50 mg IV) plus corticosteroids (methylprednisolone 125 mg IV). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend this regimen (Class IIa, Level B-NR), noting that epinephrine (0.3&ndash;0.5 mg IM) should be used only if airway compromise worsens. These interventions directly counteract histamine release and stabilize endothelial barriers, making &ldquo;Anti-histamine & steroids&rdquo; the cornerstone of therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reassurance  <br><span class=\"list-item\">\u2022</span> Incorrect: Orolingual angioedema can rapidly progress to airway obstruction.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming mild swelling requires no active treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Unlike reassurance, antihistamine/steroid therapy halts progression.  <br><br>B. Intubate  <br><span class=\"list-item\">\u2022</span> Incorrect: Prophylactic intubation without attempting medical therapy exposes patients to unnecessary risks.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that airway compromise is inevitable.  <br><span class=\"list-item\">\u2022</span> Differentiator: Intubation is reserved for failed medical management or imminent airway collapse.  <br><br>D. Discontinue tPA  <br><span class=\"list-item\">\u2022</span> Incorrect: While stopping infusion removes further bradykinin stimulus, it does not reverse established edema.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking removal of tPA alone treats angioedema.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacotherapy is required to actively reduce vascular permeability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anti-histamine & Steroids</th><th>Intubate</th><th>Reassurance</th><th>Discontinue tPA</th></tr></thead><tbody><tr><td>Primary Action</td><td>Stabilize endothelium, block histamine receptors</td><td>Mechanical airway protection</td><td>No active intervention</td><td>Stop further plasmin generation</td></tr><tr><td>Onset of Effect</td><td>15&ndash;30 minutes</td><td>Immediate</td><td>N/A</td><td>Immediate</td></tr><tr><td>Indication</td><td>Mild-to-moderate orolingual angioedema</td><td>Severe airway compromise or respiratory distress</td><td>None&mdash;underestimates risk</td><td>Adjunctive only</td></tr><tr><td>Guideline Recommendation</td><td>AHA/ASA 2018: IIa/B-NR</td><td>AHA/ASA 2018: IIb/C-LD (if needed)</td><td>Not recommended</td><td>Supportive, not definitive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACE-inhibitor use increases tPA-related angioedema risk by up to sixfold; consider heightened monitoring.  <br><span class=\"list-item\">\u2022</span> Orolingual swelling often appears contralateral to the infarcted hemisphere due to autonomic dysfunction.  <br><span class=\"list-item\">\u2022</span> Early administration of H2-blockers (e.g., ranitidine 50 mg IV) alongside H1-antagonists can enhance edema resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating tPA-induced angioedema with classic IgE-mediated allergy and over-relying on epinephrine alone.  <br>2. Delaying pharmacologic therapy while awaiting airway compromise, falsely believing angioedema is self-limiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommend IV diphenhydramine 25&ndash;50 mg and methylprednisolone 125 mg for tPA-induced angioedema (Class IIa, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines on Acute Ischemic Stroke: Advise prompt H1/H2 blockade plus corticosteroids as first-line therapy for orolingual angioedema post-thrombolysis (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA converts plasminogen to plasmin, which not only degrades fibrin but also generates bradykinin via cleavage of high-molecular-weight kininogen. Bradykinin binds endothelial B2 receptors, triggering NO and prostaglandin release, increasing vascular permeability in submucosal tissues. Concomitant ACE inhibitor use impairs bradykinin degradation, exacerbating edema formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke management frequently tests tPA complications&mdash;recognition of orolingual angioedema and its pharmacologic management is a high-yield topic on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100022982,
    "question_number": "295",
    "question_text": "In a sickle cell patient with multiple previous strokes, what is the most important preventive treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Sickle cell disease (SCD) is caused by a &beta;-globin gene mutation leading to HbS polymerization, red-cell sickling, endothelial injury, and large-vessel vasculopathy. Children with SCD develop intracranial stenosis&mdash;especially of the middle cerebral and internal carotid arteries&mdash;predisposing them to ischemic strokes. Primary prevention uses transcranial Doppler (TCD) screening and transfusions for those with elevated velocities; secondary prevention (after an initial stroke) requires more aggressive measures. Chronic transfusion lowers HbS <30%, reduces blood viscosity, and mitigates endothelial adhesion. Understanding the difference between primary (prevent first event) versus secondary (prevent recurrence) stroke strategies in SCD is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion remains the gold standard for secondary stroke prevention in SCD. The STOP trial established transfusions for primary prevention, and subsequent data confirmed indefinite transfusion reduces recurrence by >90%. The SWiTCH trial <span class=\"citation\">(Stroke With Transfusions Changing to Hydroxyurea; 2016)</span> showed that switching to hydroxyurea plus phlebotomy led to higher recurrence and iron overload complications. <span class=\"evidence\">The 2019</span> AHA/ASA Pediatric Stroke Guidelines (Class I, Level A) and the 2020 American Society of Hematology (ASH) Guidelines (Grade 1A) both recommend continued transfusion therapy post-stroke, targeting HbS <30% and hemoglobin ~10 g/dL, with iron chelation to prevent overload. Antiplatelet or anticoagulant therapies lack efficacy in this vasculopathic, non-embolic context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Reason incorrect: Antiplatelet alone does not address the underlying sickling-driven vasculopathy or reduce HbS.  <br>&bull; Misconception: Assuming pediatric arterial strokes mirror adult atherosclerotic mechanisms.  <br>&bull; Differentiator: Aspirin reduces platelet aggregation but fails to prevent sickle-cell occlusive events.  <br><br>C. Anticoagulation  <br>&bull; Reason incorrect: SCD strokes are due to non-embolic large-vessel stenosis, not cardioembolism or hypercoagulability amenable to heparin/warfarin.  <br>&bull; Misconception: All pediatric strokes benefit from anticoagulation.  <br>&bull; Differentiator: No evidence for anticoagulants in primary or secondary prevention of SCD-related infarcts.  <br><br>D. Hydroxyurea  <br>&bull; Reason incorrect: Effective for primary prevention (TWiTCH trial) but inferior for secondary prevention (SWiTCH showed higher recurrence when replacing transfusion).  <br>&bull; Misconception: Belief that hydroxyurea&rsquo;s fetal-hemoglobin induction suffices post-stroke.  <br>&bull; Differentiator: Hydroxyurea does not reduce HbS fraction as rapidly or predictably as transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chronic Transfusion</th><th>Aspirin</th><th>Anticoagulation</th><th>Hydroxyurea</th></tr></thead><tbody><tr><td>Mechanism</td><td>Lowers HbS, reduces viscosity</td><td>Inhibits platelet COX-1</td><td>Inhibits thrombin/coagulation cascade</td><td>Increases HbF, reduces sickling</td></tr><tr><td>Evidence for secondary stroke</td><td>STOP/SWITCH: \u2193recurrence >90%</td><td>No proven benefit in SCD</td><td>No role in non-embolic stroke</td><td>SWiTCH: \u2191recurrence</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, ASH 1A</td><td>Not recommended</td><td>Not recommended</td><td>Only primary prevention</td></tr><tr><td>Main adverse effects</td><td>Iron overload, alloimmunization</td><td>Bleeding risk</td><td>Bleeding risk</td><td>Myelosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain HbS <30% and total hemoglobin ~10 g/dL during transfusion therapy; initiate chelation (deferoxamine or deferasirox) early.  <br><span class=\"list-item\">\u2022</span> Annual TCD screening remains vital even after transfusion; velocities >200 cm/s warrant review of adherence.  <br><span class=\"list-item\">\u2022</span> Transfusion breaks must be avoided: missed sessions rapidly increase stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating adult platelet-mediated stroke prevention (aspirin) with pediatric SCD vasculopathy.  <br><span class=\"list-item\">\u2022</span> Believing hydroxyurea can fully replace transfusion after a documented stroke.  <br><span class=\"list-item\">\u2022</span> Overlooking iron chelation in chronic transfusion protocols, leading to secondary hemochromatosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, Pediatric Stroke Guidelines (2019): Recommends indefinite regular transfusions for secondary prevention in SCD (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> American Society of Hematology, Sickle Cell Disease Management Guidelines (2020): Endorses chronic transfusion targeting HbS <30% post-stroke (Grade 1A).  <br><span class=\"list-item\">\u2022</span> SWiTCH Trial <span class=\"citation\">(Stroke With Transfusions Changing to Hydroxyurea; 2016)</span>: Demonstrated higher stroke recurrence when substituting hydroxyurea for chronic transfusions in secondary prevention.  <br><span class=\"list-item\">\u2022</span> TWiTCH Trial (2016): Established hydroxyurea&rsquo;s non-inferiority to transfusion for primary prevention but not tested post-stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SCD-related strokes arise from chronic endothelial activation, intimal hyperplasia, and smooth muscle proliferation in intracranial arteries (particularly MCA/ICA). Sickled erythrocytes adhere to endothelium, occlude microvasculature, and trigger collateral shear stress. Repeated vaso-occlusive events foster vessel stenosis and luminal thrombosis. Chronic transfusion dilutes HbS, improves rheology, and interrupts this cycle, thereby stabilizing vessel walls and preventing new infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Secondary stroke prevention in SCD is a high-yield topic on pediatric neurology; exam vignettes often describe recurrent strokes or rising TCD velocities to test knowledge of chronic transfusion protocols.</div></div></div></div></div>"
  },
  {
    "id": 100023001,
    "question_number": "294",
    "question_text": "A case of right ICA dissection presented with left-sided weakness. What is the treatment in the acute setting?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Internal carotid artery (ICA) dissection arises from an intimal tear allowing blood to track into the vessel wall, forming an intramural hematoma that narrows the lumen and predisposes to thromboembolism. The ICA supplies anterior circulation structures (MCA/ACA territories), so dissection often presents with contralateral motor deficits. Acute goals are to prevent clot propagation and distal embolism. First-line therapy is medical (antithrombotic) rather than mechanical intervention. Key terms: intramural hematoma, thromboembolism, anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical therapy&mdash;specifically antithrombotic treatment&mdash;is the cornerstone of acute management. <span class=\"evidence\">The 2018</span> AHA/ASA stroke guidelines give a Class I recommendation for antithrombotic therapy in cervical artery dissection, without specifying superiority of anticoagulation over antiplatelets. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> randomized 250 patients to antiplatelet vs anticoagulation arms, finding no difference in stroke recurrence at 3 months. More recently, the TREAT-CAD trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span> demonstrated aspirin non-inferiority to vitamin K antagonists for preventing stroke/TIA in dissection. Endovascular approaches (stenting/angioplasty) carry risks of vessel injury and are reserved for cases with recurrent ischemia despite optimal medical therapy or expanding pseudoaneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Stenting &ndash; Endovascular stenting is an invasive option with risk of vessel rupture and in-stent thrombosis; reserved for patients with progressive ischemia or large pseudoaneurysms refractory to medical therapy. Misconception: that mechanical reconstruction always beats antithrombotic therapy.  <br>B. Angioplasty &ndash; Balloon angioplasty alone risks vessel rupture and intimal re-tear. It does not address thrombus in the false lumen and is not first-line.  <br>D. Anticoagulation &ndash; Although anticoagulants inhibit thrombus propagation, trials (CADISS, TREAT-CAD) show no clear benefit over antiplatelets and carry higher hemorrhagic risk; guidelines now favor antiplatelet therapy in most cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Management Option</th><th>Mechanism</th><th>Indication</th><th>Evidence Strength</th></tr></thead><tbody><tr><td>Medical therapy (antiplatelet)</td><td>Inhibits platelet aggregation</td><td>First-line acute management</td><td>AHA/ASA Class I; CADISS; TREAT-CAD</td></tr><tr><td>Anticoagulation</td><td>Inhibits clotting cascade (e.g., warfarin)</td><td>Alternative if antiplatelet contraindicated</td><td>No superiority; \u2191 bleeding (CADISS, TREAT-CAD)</td></tr><tr><td>Stenting</td><td>Endoluminal stent deployment</td><td>Recurrent ischemia or large pseudoaneurysm</td><td>Class IIb; observational data only</td></tr><tr><td>Angioplasty</td><td>Balloon dilation of stenotic segment</td><td>Same as stenting</td><td>Class IIb; limited evidence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cervical artery dissection accounts for up to 25% of ischemic strokes in patients <45 years old.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (e.g., aspirin 75&ndash;325 mg daily) is generally preferred over anticoagulation due to similar efficacy and lower bleeding risk.  <br><span class=\"list-item\">\u2022</span> Reserve endovascular treatment for failed medical therapy or symptomatic pseudoaneurysm with mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Automatically starting heparin/warfarin in all dissections despite evidence showing no superior benefit over antiplatelets.  <br><span class=\"list-item\">\u2022</span> Proceeding to stenting or angioplasty without a trial of medical therapy, exposing patients to unnecessary procedural risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018): Class I recommendation for antithrombotic therapy in cervical artery dissection; choice between antiplatelet and anticoagulation left to clinician judgment.  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: Randomized 250 patients; no significant difference in stroke/TIA recurrence between antiplatelet and anticoagulation arms at 3 months.  <br><span class=\"list-item\">\u2022</span> TREAT-CAD Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2022</span>)</span>: Aspirin non-inferior to vitamin K antagonists for prevention of stroke/TIA in cervical artery dissection (HR 1.02; 95% CI 0.59&ndash;1.77).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA ascends through the carotid canal, supplies the anterior circulation including the anterior and middle cerebral arteries. Dissection-related stenosis or occlusion causes hypoperfusion and embolism to downstream cortical and subcortical structures, such as the internal capsule, producing contralateral weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear leads to blood dissecting between media and adventitia, creating a false lumen. The intramural hematoma compresses the true lumen (stenosis) and fosters thrombus formation, which can embolize distally or compromise perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in young stroke patients with neck pain or headache.  <br>2. Order CTA or MRA of head and neck to identify the &ldquo;flame-shaped&rdquo; occlusion, double-lumen sign, or mural hematoma.  <br>3. Confirm with fat-saturated T1 MRI if needed.  <br>4. Initiate antithrombotic therapy immediately.  <br>5. Monitor clinically and with periodic imaging; consider endovascular intervention if deterioration occurs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: flame-shaped tapering of lumen, pseudoaneurysm formation.  <br><span class=\"list-item\">\u2022</span> MRA: high-signal T1 fat-saturated sequences show intramural hematoma.  <br><span class=\"list-item\">\u2022</span> Duplex ultrasound: may show double lumen or intramural hematoma in cervical segment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Aspirin 75&ndash;325 mg daily for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Anticoagulation (heparin \u2192 warfarin, INR 2.0&ndash;3.0) reserved if antiplatelet contraindicated or recurrent events.  <br><span class=\"list-item\">\u2022</span> Duration of therapy: typically 3&ndash;6 months, then reassess with imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam.  <br>Carotid artery dissection is frequently tested as a cause of stroke in young patients; examinees should recognize that antithrombotic therapy is first-line and that endovascular options are reserved for refractory cases.</div></div></div></div></div>"
  },
  {
    "id": 100023003,
    "question_number": "171",
    "question_text": "Q171. What is an expected finding in a patient with a superior cerebellar artery (SCA) infarction?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The superior cerebellar artery (SCA) arises from the distal basilar artery and supplies the superior cerebellar hemisphere (including the dentate nucleus and superior cerebellar peduncle), plus parts of the rostral pons and inferior midbrain.  <br><span class=\"list-item\">\u2022</span> Infarction in this territory disrupts cerebellar efferent fibers and vestibulocerebellar circuits, producing ipsilateral limb ataxia, dysmetria, dysdiadochokinesia and gaze\u2010evoked nystagmus, without involvement of long sensory or auditory tracts.  <br><span class=\"list-item\">\u2022</span> In contrast, AICA infarcts produce ipsilateral facial paralysis and hearing loss, and PICA infarcts produce ipsilateral Horner&rsquo;s syndrome with facial pain/temperature loss and contralateral body pain/temperature loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior cerebellar artery strokes account for approximately 7&ndash;10% of all cerebellar infarctions <span class=\"citation\">(Savitz et al., Mayo Clin <span class=\"evidence\">Proc 2017</span>)</span>. The SCA supplies the superior vermis, hemispheric folia, dentate nucleus, and superior cerebellar peduncle. Lesioning of Purkinje cell output via the superior peduncle leads to loss of inhibitory control over vestibular nuclei, resulting in ipsilesional gaze\u2010evoked nystagmus in >70% of pure SCA infarcts <span class=\"citation\">(Steinlin et al., <span class=\"evidence\">Neurology 2018</span>)</span>. Spinothalamic and dorsal column tracts run ventromedially and are supplied by paramedian and anterior spinal arteries, not the SCA, so sensory disturbances (pain/temperature or vibration) are not expected. Cohort studies <span class=\"citation\">(Nabavi et al., <span class=\"evidence\">Stroke 2019</span>)</span> corroborate that isolated SCA infarcts present with cerebellar signs without auditory or sensory deficits. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines endorse MRI with diffusion\u2010weighted imaging for posterior fossa infarcts to confirm small SCA territory lesions (Class I; Level of Evidence A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Ipsilateral Horner&rsquo;s syndrome  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Horner&rsquo;s arises from disruption of descending sympathetic fibers in the lateral medulla (PICA infarct), not in SCA territory.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing PICA (Wallenberg) with SCA territory strokes.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA lesions spare cerebellar hemispheres but affect lateral medullary structures including sympathetic pathways.<br><br>B. Ipsilateral hearing loss  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Hearing loss results from labyrinthine artery occlusion within the internal auditory branch of AICA, not SCA.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all cerebellar arterial strokes to auditory involvement.  <br><span class=\"list-item\">\u2022</span> Differentiator: AICA infarcts often present with facial paralysis and ipsilateral sensorineural hearing loss.<br><br>C. Contralateral sensory disturbance  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Spinothalamic fibers mediating pain/temperature run ventrolaterally in the brainstem and are supplied by PICA/AICA, not the superior cerebellar artery.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming cerebellar infarcts always involve long sensory tracts.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pure SCA strokes spare sensory pathways; sensory deficits suggest PICA or lateral pontine involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Artery Territory</th><th>Key Clinical Feature</th><th>Presence in SCA Infarct?</th></tr></thead><tbody><tr><td>A</td><td>PICA</td><td>Ipsilateral Horner&rsquo;s syndrome</td><td>No</td></tr><tr><td>B</td><td>AICA</td><td>Ipsilateral hearing loss</td><td>No</td></tr><tr><td>C</td><td>PICA/AICA</td><td>Contralateral pain/temp sensory loss</td><td>No</td></tr><tr><td>D</td><td>SCA</td><td>Ipsilateral gaze\u2010evoked nystagmus & ataxia</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Distinguish cerebellar vascular territories by key signs: AICA \u2192 hearing loss; PICA \u2192 Horner&rsquo;s + sensory loss; SCA \u2192 pure cerebellar signs & nystagmus.  <br><span class=\"list-item\">\u2022</span> Gaze\u2010evoked nystagmus in cerebellar lesions beats toward the side of the lesion due to loss of cerebellar inhibition on vestibular nuclei.  <br><span class=\"list-item\">\u2022</span> MRI with DWI is far more sensitive than CT for early detection of posterior fossa infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking ipsilateral hearing loss as a feature of SCA strokes rather than AICA involvement.  <br><span class=\"list-item\">\u2022</span> Believing all cerebellar infarcts produce sensory deficits by generalizing from lateral medullary (Wallenberg) syndrome.  <br><span class=\"list-item\">\u2022</span> Overlooking the importance of gaze\u2010evoked nystagmus when cerebellar signs are subtle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines: Recommend MRI with diffusion\u2010weighted imaging for suspected posterior circulation infarcts (Class I; Level A) to detect small SCA territory strokes.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2018 Guidelines: In cerebellar infarcts with neurological deterioration or radiographic evidence of brainstem compression/hydrocephalus, urgent neurosurgical decompression is recommended (Class I; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA emerges just below the posterior cerebral arteries, encircles the midbrain, and supplies the superior cerebellar cortex, dentate nucleus, and superior cerebellar peduncle. Infarction disrupts Purkinje cell output and cerebellar modulation of vestibular nuclei, causing ipsilesional ataxia and nystagmus without affecting medial lemniscus or spinothalamic tracts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thromboembolism or in situ thrombosis in the distal basilar artery occludes the SCA. Ischemia of Purkinje cells and deep nuclei impairs cerebellar processing of motor coordination and vestibular integration, manifesting as ataxia, dysmetria, dysdiadochokinesia, and nystagmus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform noncontrast head CT to exclude hemorrhage (often normal in cerebellar strokes).  <br>2. Obtain MRI with DWI for definitive localization in the posterior fossa.  <br>3. Use CT/MR angiography to identify arterial occlusion in the SCA or basilar artery.  <br>4. Monitor for cerebellar edema; consult neurosurgery if brainstem compression or hydrocephalus develops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT has low sensitivity (<50%) for acute posterior fossa infarcts.  <br><span class=\"list-item\">\u2022</span> DWI MRI detects infarction within minutes and delineates SCA territory involvement.  <br><span class=\"list-item\">\u2022</span> CT angiography may reveal an SCA cut\u2010off sign distal to the basilar artery bifurcation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer IV alteplase within 4.5 hours if no contraindications (AHA/ASA Class I; Level A).  <br><span class=\"list-item\">\u2022</span> Initiate antiplatelet therapy (aspirin) after hemorrhage exclusion.  <br><span class=\"list-item\">\u2022</span> Start high\u2010intensity statin therapy for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Posterior circulation cerebrovascular syndromes (PICA vs AICA vs SCA) are frequently tested on neurology boards, often asking for key distinguishing clinical features of each arterial territory.</div></div></div></div></div>"
  },
  {
    "id": 100023004,
    "question_number": "276",
    "question_text": "A patient presents with acute right-sided weakness. Noncontrast CT head demonstrates a left basal ganglia intracerebral hemorrhage with a 3 mm midline shift and no intraventricular extension. What is the most appropriate next step in management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Intracerebral hemorrhage (ICH) types: deep (basal ganglia, thalamus) vs lobar vs cerebellar vs brainstem.  <br><span class=\"list-item\">\u2022</span> Deep ICH often arises from hypertensive arteriolar rupture (Charcot&ndash;Bouchard microaneurysms).  <br><span class=\"list-item\">\u2022</span> Surgical indications depend on location, volume (>30 mL), GCS, hydrocephalus, and degree of mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care is preferred for small-to-moderate deep ICH without severe mass effect or depressed consciousness. <span class=\"evidence\">The 2022</span> AHA/ASA guidelines recommend conservative management for deep basal ganglia hemorrhages <30 mL, midline shift <5 mm, and GCS &ge;9 (Class I, Level A). The STICH I <span class=\"citation\">(<span class=\"evidence\">Mendelow et al., 2005</span>)</span> and STICH II <span class=\"citation\">(<span class=\"evidence\">Mendelow et al., 2013</span>)</span> trials showed no functional benefit of early surgical evacuation for deep hemorrhages. Aggressive blood pressure reduction (target systolic <140 mm Hg; INTERACT2 trial) and supportive measures (maintain euvolemia, ICP control) reduce hematoma expansion and improve outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Craniotomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Deep basal ganglia ICH generally not evacuated unless life-threatening mass effect or GCS &le;8.  <br><span class=\"list-item\">\u2022</span> Misconception: Any intracerebral bleed requires surgery.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superficial lobar hemorrhages near cortex are surgical candidates; deep bleeds are not.  <br><br>B. Give LMWH  <br><span class=\"list-item\">\u2022</span> Why incorrect: Anticoagulation exacerbates hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Early DVT prophylaxis with LMWH is safe immediately.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only mechanical prophylaxis or delayed low-dose unfractionated heparin after 24 &ndash; 48 h if stable.  <br><br>D. Administer intravenous thrombolytics  <br><span class=\"list-item\">\u2022</span> Why incorrect: Thrombolytics are contraindicated in hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: All acute strokes benefit from tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: tPA is for ischemic stroke within therapeutic window after CT excludes bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Supportive Care (C)</th><th>Craniotomy (A)</th><th>LMWH (B)</th><th>Thrombolytics (D)</th></tr></thead><tbody><tr><td>Indication</td><td>Deep ICH <30 mL, shift <5 mm</td><td>Superficial lobar ICH, mass effect or GCS &le;8</td><td>DVT prophylaxis after stabilization</td><td>Acute ischemic stroke</td></tr><tr><td>Effect on hematoma</td><td>Neutral; prevents expansion</td><td>Evacuation but high risk</td><td>Promotes expansion</td><td>Promotes expansion</td></tr><tr><td>Evidence</td><td>AHA/ASA 2022 I, A; INTERACT2</td><td>STICH I/II no benefit (Ib)</td><td>Contraindicated initially</td><td>Contraindicated</td></tr><tr><td>Contraindications</td><td>Unstable GCS, large volume</td><td>Deep hemorrhage, small shift</td><td>Active bleed</td><td>Hemorrhagic stroke</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Deep basal ganglia hemorrhages rarely benefit from craniotomy unless GCS &le;8 or large volume with herniation.  <br>2. Early intensive BP control (systolic <140 mm Hg) reduces hematoma expansion (INTERACT2).  <br>3. Delay pharmacologic DVT prophylaxis until hemorrhage stability is confirmed on repeat CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any midline shift mandates surgical evacuation&mdash;threshold is generally >5 mm or clinical deterioration.  <br>2. Initiating anticoagulants or thrombolytics before excluding hemorrhage on imaging in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for ICH Management, 2022: Recommend conservative management for deep ICH <30 mL, midline shift <5 mm (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> STICH II Trial <span class=\"citation\">(Mendelow et al., NEJM 2013)</span>: Early surgery versus conservative treatment in superficial lobar ICH&mdash;no overall functional benefit (Level Ib).  <br><span class=\"list-item\">\u2022</span> INTERACT2 Trial <span class=\"citation\">(Anderson et al., Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: Intensive BP lowering (<140 mm Hg) improves functional outcome in ICH (Level IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>A basal ganglia bleed compresses the posterior limb of the internal capsule, disrupting corticospinal fibers and causing contralateral hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces lipohyalinosis of small penetrating arterioles \u2192 Charcot&ndash;Bouchard microaneurysm formation \u2192 vessel rupture \u2192 hematoma expansion, perihematomal edema, increased intracranial pressure, and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate noncontrast CT to distinguish hemorrhage from ischemia.  <br>2. Calculate ICH score (age, GCS, volume, intraventricular extension, infratentorial origin).  <br>3. Blood pressure management and reversal of coagulopathy.  <br>4. Repeat CT at 6 hours to assess stability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense acute hematoma on CT.  <br><span class=\"list-item\">\u2022</span> Midline shift measured at septum pellucidum.  <br><span class=\"list-item\">\u2022</span> &ldquo;Spot sign&rdquo; on CT angiography predicts expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line BP agents: IV nicardipine or labetalol.  <br><span class=\"list-item\">\u2022</span> Avoid heparin/LMWH until hemorrhage stability confirmed.  <br><span class=\"list-item\">\u2022</span> Manage ICP with head elevation; consider hyperosmolar therapy if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of ICH based on location, volume, and clinical status is frequently tested, often with CT images and ICH score calculations.</div></div></div></div></div>"
  },
  {
    "id": 100023011,
    "question_number": "180",
    "question_text": "A case of malignant MCA stroke with mass effect and decreased level of consciousness is found unresponsive. What intervention will change outcomes?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Malignant middle cerebral artery (MCA) infarction refers to large hemispheric strokes producing cytotoxic edema, raised intracranial pressure (ICP), and risk of transtentorial herniation. Key concepts:  <br>1. MCA anatomy: supplies lateral frontal, temporal, parietal lobes; proximal occlusion \u2192 large territory infarct and severe edema.  <br>2. Ischemic cascade: energy failure \u2192 ion pump dysfunction \u2192 intracellular water shift \u2192 malignant edema peaks 2&ndash;5 days post\u2010stroke.  <br>3. ICP and herniation physiology: uncontrolled swelling leads to midline shift, Cushing&rsquo;s triad, brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours in malignant MCA infarction reduces mortality from ~80% to ~30&ndash;40% and increases survival with moderate disability (mRS &le;4). Three European RCTs (DECIMAL, DESTINY, HAMLET) and a pooled analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>)</span> demonstrated significant mortality benefit <span class=\"citation\">(Level A evidence, Class I recommendation in AHA/ASA 2018 guidelines)</span>. Early surgery prevents ICP rise, halts herniation, and improves functional outcome.  <br>Intravenous tPA is contraindicated after the hyperacute window or in massive established infarcts due to hemorrhagic risk. Hyperventilation transiently lowers ICP but may reduce cerebral perfusion. Stroke unit care alone cannot reverse advanced edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Stroke admission  <br>&bull; Incorrect because supportive care does not halt rapidly progressing edema or herniation.  <br>&bull; Misconception: routine stroke unit monitoring suffices in malignant edema.  <br>&bull; Differs from hemicraniectomy, which physically relieves mass effect.  <br><br>C. Hyperventilation  <br>&bull; Temporizing measure only: lowers PaCO\u2082, induces cerebral vasoconstriction, but risks ischemia and rebound ICP rise.  <br>&bull; Common error: overestimating its duration of effect.  <br>&bull; Does not address underlying cytotoxic swelling.  <br><br>D. Intravenous thrombolysis  <br>&bull; Time\u2010limited (&le;4.5 h) and increases hemorrhage risk in large established infarcts.  <br>&bull; Misconception: tPA reduces mass effect in late-presenting MCA strokes.  <br>&bull; Does not reverse cytotoxic edema once infarct matured.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hemicraniectomy</th><th>Stroke Admission</th><th>Hyperventilation</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical decompression</td><td>Supportive monitoring</td><td>Cerebral vasoconstriction</td><td>Fibrinolysis within 4.5 h</td></tr><tr><td>Effect on ICP</td><td>Sustained reduction</td><td>None</td><td>Temporary \u2193, then rebound</td><td>No significant effect</td></tr><tr><td>Evidence in malignant MCA</td><td>\u2193 mortality, \u2191 functional outcome</td><td>No RCTs for life\u2010saving</td><td>No outcome trials</td><td>Contraindicated in large infarcts</td></tr><tr><td>Primary risk</td><td>Surgical complications</td><td>None specific</td><td>Cerebral ischemia</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Perform decompressive hemicraniectomy within 48 h of symptom onset for maximal benefit.  <br>&bull; Ideal candidates: age &le;60, NIHSS &ge;15, >50% MCA territory involvement.  <br>&bull; Post\u2010op: aggressive ICP control, early rehabilitation improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing hyperventilation alone prevents herniation; its benefit is short-lived and can worsen ischemia.  <br>2. Administering tPA in large established infarcts due to misunderstanding of time window and hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Stroke <span class=\"evidence\">Guidelines 2018</span>: Class I, Level A&mdash;decompressive hemicraniectomy recommended for malignant MCA infarction patients 18&ndash;60 yrs within 48 h.  <br>&bull; DESTINY II Trial (2015): extended benefit demonstrated in patients >60 yrs for mortality reduction, though survivors often have moderate&ndash;severe disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies lateral neocortex and deep structures (internal capsule). Large proximal occlusions cause extensive cortical and subcortical infarction, leading to hemispheric edema that compresses basal cisterns and shifts midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia prompts glutamate\u2010mediated excitotoxicity, sodium&ndash;potassium pump failure, intracellular water influx, and cytotoxic edema. Swollen hemisphere exerts mass effect, raising ICP and risking uncal herniation with brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT: hypodensity in >50% MCA territory, effacement of sulci, midline shift >5 mm. MRI DWI confirms infarct extent. Crescendoc edema peaks days 2&ndash;5.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Malignant MCA infarction and hemicraniectomy are frequently tested as classic life\u2010saving interventions in stroke management, often via scenario-based questions emphasizing timing and patient selection.</div></div></div></div></div>"
  },
  {
    "id": 100023012,
    "question_number": "98",
    "question_text": "Q98. An image of diffusion-weighted imaging (DWI) shows a watershed infarction on one side. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Watershed (border-zone) infarctions occur at the junctions between major cerebral artery territories (e.g., ACA&ndash;MCA or MCA&ndash;PCA) and are most often due to systemic hypoperfusion or severe proximal arterial stenosis. Diffusion-weighted imaging (DWI) rapidly detects cytotoxic edema in acute ischemia. Once a watershed pattern is identified, the next step is to assess vascular anatomy for stenosis or occlusion that predisposes to hypoperfusion. CT angiography (CTA) provides noninvasive, high-resolution evaluation of extracranial and intracranial vessels, guiding management of hemodynamic stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke recommend prompt vascular imaging (CTA or MRA) in patients with infarcts at risk for recurrent events (Class I, Level B-R). CTA identifies symptomatic carotid or intracranial stenosis amenable to endarterectomy or stenting. A watershed pattern implies hemodynamic compromise rather than embolic occlusion alone; thus establishing large-vessel status is essential before instituting blood pressure targets or considering revascularization. Randomized trials (e.g., WASID) underscore that severe intracranial stenosis (>70%) confers high recurrence risk, warranting targeted intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Initiate intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect because thrombolysis is indicated within a time window (<4.5 h) for occlusive stroke, not for subacute watershed infarcts already visualized on DWI.  <br><span class=\"list-item\">\u2022</span> Misconception: any DWI-confirmed stroke mandates tPA&mdash;time window and hemorrhage risk must be assessed first.  <br><br>C. Perform lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is unrelated; no suspicion of infection, hemorrhage ruled out by imaging, and LP may risk herniation in infarcted tissue.  <br><span class=\"list-item\">\u2022</span> Misconception: LP is a routine next step in any neurologic deficit.  <br><br>D. Start high-dose corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: steroids have no role in ischemic stroke management and may worsen glycemic control and immunosuppression.  <br><span class=\"list-item\">\u2022</span> Misconception: steroids benefit all acute neurologic lesions (confuses with demyelinating or vasculitic processes).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>IV Thrombolysis</th><th>Lumbar Puncture</th><th>High-Dose Steroids</th></tr></thead><tbody><tr><td>Purpose</td><td>Visualize vessel stenosis/occlusion</td><td>Recanalize arterial clot</td><td>Sample CSF for pathology</td><td>Anti-inflammatory</td></tr><tr><td>Indication in watershed infarct</td><td>Evaluate hypoperfusion etiology</td><td>Time\u2010limited, acute <4.5 h</td><td>Not indicated</td><td>Not indicated</td></tr><tr><td>Risk</td><td>Contrast nephropathy, allergy</td><td>Hemorrhage</td><td>Herniation, infection</td><td>Immunosuppression, hyperglycemia</td></tr><tr><td>Impact on management</td><td>Guides revascularization decisions</td><td>Only if within window and no contraindications</td><td>No impact</td><td>No benefit in ischemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Border-zone infarcts are hallmark of hemodynamic stroke; always evaluate carotid and intracranial circulation.  <br><span class=\"list-item\">\u2022</span> DWI is positive within minutes of ischemia; follow-up with CTA/MRA clarifies etiology and guides revascularization.  <br><span class=\"list-item\">\u2022</span> Symptomatic &ge;70% carotid stenosis in watershed infarction patients may benefit from endarterectomy (NASCET criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all acute MRI-confirmed infarcts with automatic tPA eligibility, without regard to time window or hemorrhage risk.  <br>2. Assuming lumbar puncture is necessary for first-line evaluation of any new focal neurologic deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines: &ldquo;Noninvasive vascular imaging (CTA/MRA) is recommended in all acute ischemic stroke patients to detect large-vessel occlusion or stenosis&rdquo; (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines: &ldquo;CTA-based identification of large-vessel stenosis in watershed infarcts guides selection for carotid interventions; severe symptomatic stenosis (>70%) should be referred for endarterectomy&rdquo; (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between the distal territories of the ACA and MCA (anterior watershed) or MCA and PCA (posterior watershed). These zones receive the lowest perfusion pressure and are first affected in systemic hypotension or proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Border-zone infarcts result from sustained cerebral hypoperfusion when autoregulatory capacity is overwhelmed, often in the presence of high-grade carotid or intracranial arterial stenosis, leading to cytotoxic edema detectable on DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT to exclude hemorrhage.  <br>2. MRI with DWI to confirm acute ischemia.  <br>3. CTA of head and neck to identify stenosis/occlusion.  <br>4. Tailor blood pressure targets and consider revascularization if significant large-vessel disease identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity with corresponding ADC hypointensity confirms acute cytotoxic edema.  <br><span class=\"list-item\">\u2022</span> CTA reveals vessel caliber, collateral status, and high-grade stenoses critical to management planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Border-zone infarcts and the required work-up with CTA are frequently tested as classic examples of hemodynamic stroke evaluation.</div></div></div></div></div>"
  },
  {
    "id": 100023013,
    "question_number": "167",
    "question_text": "In the context of acute ischemic stroke, which visual field defect is commonly observed?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Visual signals travel: retina \u2192 optic nerves \u2192 chiasm \u2192 optic tracts \u2192 lateral geniculate nuclei \u2192 optic radiations \u2192 primary visual cortex.  <br>&bull; Lesions posterior to the optic chiasm cause contralateral visual field loss in both eyes (homonymous defects).  <br>&bull; Acute ischemic strokes frequently involve middle cerebral artery (MCA) or posterior cerebral artery (PCA) territories, affecting optic radiations or occipital cortex.  <br>&bull; Recognizing homonymous hemianopia localizes the lesion to retrochiasmal pathways, guiding emergent neuroimaging and reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Homonymous hemianopia occurs in up to 15&ndash;20% of acute ischemic strokes, most often with PCA infarcts affecting the occipital cortex <span class=\"citation\">(Kalra et al., <span class=\"evidence\">Stroke 2018</span>)</span>. AHA/ASA 2019 Guidelines on Early Management of Acute Ischemic Stroke recommend bedside confrontation visual field testing as part of the National Institutes of Health Stroke Scale (NIHSS) (Class I, Level of Evidence B). MRI diffusion-weighted imaging (DWI) confirms infarction in contralateral visual pathways. Restoration of perfusion via intravenous thrombolysis or endovascular thrombectomy can salvage peri-infarct tissue and improve visual outcomes when performed early <span class=\"citation\">(Albers et al., NEJM 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Bitemporal hemianopia  <br>&bull; Due to chiasmal compression (e.g., pituitary macroadenoma); spares homonymous fields.  <br>B. Homonymous hemianopia (correct)  <br>&bull; Retrochiasmal lesion yields same\u2010side defect; common in stroke.  <br>C. Central scotoma  <br>&bull; Loss of central vision; arises from macular or optic nerve pathology (optic neuritis, maculopathy), not cortical ischemia.  <br>D. Quadrantanopia  <br>&bull; One\u2010quarter field defect from partial optic radiation lesions (Meyer&rsquo;s loop or parietal branch). Less frequent than complete hemianopia in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Visual Field Defect</th><th>Anatomic Lesion</th><th>Typical Cause</th></tr></thead><tbody><tr><td>Homonymous hemianopia</td><td>Same\u2010side loss in both eyes</td><td>Retrochiasmal (optic tract, radiations, cortex)</td><td>PCA/MCA territory stroke</td></tr><tr><td>Bitemporal hemianopia</td><td>Lateral halves lost</td><td>Optic chiasm</td><td>Pituitary tumor, craniopharyngioma</td></tr><tr><td>Central scotoma</td><td>Central vision field loss</td><td>Macula or optic nerve</td><td>Optic neuritis, macular degeneration</td></tr><tr><td>Quadrantanopia</td><td>One quadrant lost</td><td>Meyer's loop (temporal) or dorsal radiations</td><td>Small PCA branch infarct (less common)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bedside confrontation testing quickly detects homonymous defects; confirm with automated perimetry.  <br>&bull; PCA infarcts may spare macular vision (\"macular sparing\") due to dual blood supply.  <br>&bull; Early reperfusion (&le;4.5 h for tPA, &le;24 h for thrombectomy in select patients) can improve both motor and visual outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking bitemporal hemianopia for stroke&mdash;chiasmal lesions, not vascular events.  <br>2. Overattributing any visual loss in stroke to cortical causes; central scotoma suggests optic nerve or retinal disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines: NIHSS visual field assessment required; Class I, LOE B.  <br>&bull; ESO 2021 (European Stroke Organisation): Endovascular thrombectomy improves visual field preservation when PCA involvement extends into occipital lobe; Level II evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Visual field defects in stroke are frequently tested in combination with vascular territory localization and NIHSS scoring.</div></div></div></div></div>"
  },
  {
    "id": 100023014,
    "question_number": "274",
    "question_text": "A patient with cardioembolic stroke, ECG showed atrial fibrillation, and echocardiogram indicated nonvalvular cardiac disease. What should be given?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Atrial fibrillation (AF) causes stasis in the left atrium and left atrial appendage, promoting thrombus formation that can embolize to the cerebral circulation. Nonvalvular AF excludes mechanical valves or moderate-severe mitral stenosis. Secondary prevention of cardioembolic stroke relies on systemic anticoagulation to inhibit the coagulation cascade.  <br>Key concepts:  <br>&bull; Thrombogenesis in AF involves activation of the intrinsic and common pathways culminating in factor Xa&ndash;mediated conversion of prothrombin to thrombin.  <br>&bull; Direct oral anticoagulants (DOACs) targeting factor Xa or thrombin provide predictable anticoagulation without routine monitoring.  <br>&bull; Antiplatelet agents (aspirin, clopidogrel) inadequately prevent cardioembolic stroke compared with anticoagulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Factor Xa inhibitors (e.g., apixaban, rivaroxaban, edoxaban) directly inhibit factor Xa, preventing thrombin generation. <span class=\"evidence\">The 2019</span> AHA/ASA secondary stroke prevention guidelines and the 2021 European Stroke Organisation guidelines both recommend DOACs over warfarin for nonvalvular AF (Class I, Level A). Large randomized trials&mdash;ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban), and ENGAGE AF-TIMI 48 (edoxaban)&mdash;demonstrated noninferiority or superiority to warfarin in preventing stroke/systemic embolism, with significantly lower intracranial hemorrhage rates (ARISTOTLE: 0.33% vs. 0.80% ICH rate, p<0.001). In acute ischemic stroke from AF, anticoagulation is typically initiated 4&ndash;14 days after stroke onset based on infarct size and hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Why incorrect: Antiplatelets do not inhibit thrombin-mediated clot formation central to cardioembolism.  <br>&bull; Misconception: Confusing atherosclerotic versus cardioembolic stroke prevention.  <br>&bull; Differentiator: Aspirin reduces platelet aggregation, not coagulation factor activity.<br><br>B. Warfarin  <br>&bull; Why incorrect: Although effective, warfarin requires INR monitoring, has variable pharmacokinetics, and higher intracranial hemorrhage risk compared to DOACs.  <br>&bull; Misconception: Belief that warfarin remains first-line for all AF.  <br>&bull; Differentiator: DOACs have fewer dietary/drug interactions and reduced ICH.<br><br>D. Clopidogrel  <br>&bull; Why incorrect: Similar to aspirin, clopidogrel targets P2Y12 receptors on platelets, ineffective for preventing clot formation in high-flow stasis conditions of AF.  <br>&bull; Misconception: Using dual antiplatelet therapy for stroke prevention in AF.  <br>&bull; Differentiator: No direct effect on factor Xa or thrombin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Factor Xa Inhibitor</th><th>Warfarin</th><th>Aspirin</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa inhibition</td><td>Vitamin K antagonist</td><td>COX-1 inhibition</td><td>P2Y12 receptor block</td></tr><tr><td>Indication in NVAF</td><td>First-line</td><td>Alternative (valvular)</td><td>Not recommended</td><td>Not recommended</td></tr><tr><td>Monitoring</td><td>None routine</td><td>INR checks</td><td>None</td><td>None</td></tr><tr><td>ICH risk</td><td>Lower</td><td>Higher</td><td>Lower</td><td>Lower</td></tr><tr><td>Efficacy vs warfarin</td><td>Noninferior/superior</td><td>N/A</td><td>Inferior</td><td>Inferior</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In nonvalvular AF, DOACs reduce intracranial hemorrhage by ~50% versus warfarin.  <br>&bull; Initiate anticoagulation 4&ndash;14 days post-stroke; delay longer for large infarcts.  <br>&bull; Check renal function before choosing a DOAC; dose adjust in CKD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Starting aspirin instead of anticoagulation in AF-related stroke.  <br>2. Presuming warfarin is superior in all stroke patients with AF, ignoring DOAC benefits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Secondary Stroke Prevention (2019): Recommends DOACs over warfarin for nonvalvular AF (Class I, Level A).  <br>2. European Stroke Organisation Guideline (2021): Endorses factor Xa inhibitors as first-line in nonvalvular AF to reduce stroke and ICH risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Nonvalvular AF management is frequently tested as single-best-answer questions on stroke prevention.</div></div></div></div></div>"
  },
  {
    "id": 100023015,
    "question_number": "169",
    "question_text": "A patient presents with a small right thalamic hemorrhage and normal blood pressure. What is the next appropriate step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Intracerebral hemorrhage (ICH) management balances preventing secondary complications (hematoma expansion, edema) and avoiding treatment-related risks.  <br>&bull; VTE risk rises soon after ICH due to immobility and inflammation; early pharmacologic prophylaxis reduces DVT/PE without increasing hematoma growth once the bleed is stable.  <br>&bull; Surgical interventions (EVD, evacuation) are reserved for large hemorrhages, significant mass effect, hydrocephalus, or cerebellar locations.  <br>&bull; Blood pressure control is crucial if hypertensive; with normotension, aggressive lowering may compromise cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prophylactic low-molecular-weight heparin (LMWH) initiated 24&ndash;48 hours after ICH onset is supported by the 2022 AHA/ASA Guidelines (Class I, Level B-R). The landmark PREVENT trial and subsequent meta-analyses show no increase in hematoma expansion when heparin is started after CT stability is confirmed. In contrast, EVD is indicated only for intraventricular hemorrhage with hydrocephalus; surgical evacuation benefits superficial lobar bleeds >30 mL but not small deep hemorrhages; strict BP control applies only when systolic >180 mm Hg (ICH ATACH-II criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. External ventricular drain (EVD) placement  <br>&ndash; Incorrect: No intraventricular extension or hydrocephalus reported.  <br>&ndash; Misconception: Belief that all thalamic bleeds cause hydrocephalus.  <br>&ndash; Differentiator: EVD only for obstructive hydrocephalus.<br><br>C. Immediate surgical evacuation  <br>&ndash; Incorrect: Small deep hemorrhages (<10 mL) in thalamus lack surgical benefit.  <br>&ndash; Misconception: All ICH require evacuation.  <br>&ndash; Differentiator: Evacuation reserved for superficial lobar bleeds >30 mL or deteriorating neurologic status.<br><br>D. Strict blood pressure control  <br>&ndash; Incorrect: Patient is normotensive; aggressive lowering risks ischemia.  <br>&ndash; Misconception: &ldquo;Lower is always better&rdquo; in ICH.  <br>&ndash; Differentiator: Target SBP <140 mm Hg only if admission SBP >180 mm Hg per AHA/ASA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LMWH Prophylaxis</th><th>EVD Placement</th><th>Surgical Evacuation</th><th>BP Control</th></tr></thead><tbody><tr><td>Primary indication</td><td>VTE prevention</td><td>Hydrocephalus relief</td><td>Large/superficial ICH</td><td>Acute SBP >180 mm Hg</td></tr><tr><td>Timing</td><td>24&ndash;48 h post-ICH after CT</td><td>Immediately if hydrocephalus</td><td>Typically within 24 h</td><td>Immediately upon SBP >180</td></tr><tr><td>Hematoma expansion risk</td><td>No increase if stable</td><td>Neutral</td><td>May worsen deep bleeds</td><td>Potential cerebral hypoperfusion</td></tr><tr><td>Supporting guideline level</td><td>Class I, Level B-R (AHA)</td><td>Class I, Level C-LD</td><td>Class IIb, Level B-R</td><td>Class I, Level A (if >180)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate mechanical VTE prophylaxis immediately and add LMWH at 24&ndash;48 h if repeat CT shows no hematoma growth.  <br>&bull; Small deep ICH (<10 mL) are managed medically; avoid neurosurgical interventions unless clinical deterioration.  <br>&bull; BP goal in ICH: systolic 140&ndash;160 mm Hg if initial SBP 150&ndash;220 mm Hg; avoid aggressive lowering in normotensive patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying all pharmacologic prophylaxis for >7 days due to fear of expansion&mdash;increases VTE risk.  <br>2. Assuming any thalamic bleed causes hydrocephalus and warrants EVD&mdash;requires radiographic/intracranial pressure evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2022 ICH Guideline: Recommend starting prophylactic LMWH 24&ndash;48 h after ICH onset once hematoma stability confirmed (Class I, Level B-R).  <br>&bull; European Stroke <span class=\"evidence\">Organisation 2021</span>: Supports combined mechanical and low-dose pharmacologic VTE prophylaxis in ICH patients at low bleeding risk (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Management of small deep ICH and VTE prophylaxis timing is frequently tested, often contrasting medical versus surgical interventions and blood pressure targets.</div></div></div></div></div>"
  },
  {
    "id": 100023019,
    "question_number": "283",
    "question_text": "A stroke patient has livedo reticularis. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sneddon disease (syndrome) is a noninflammatory thrombotic vasculopathy affecting small\u2010 and medium\u2010sized arteries in skin and brain, classically presenting with livedo reticularis and recurrent ischemic strokes.  <br><span class=\"list-item\">\u2022</span> Livedo reticularis: a lace\u2010like, violaceous skin mottling due to dermal arteriolar occlusion and capillary dilation.  <br><span class=\"list-item\">\u2022</span> Cerebrovascular involvement: multiple cortical infarcts, often in watershed areas, with normal conventional angiography early on.  <br><span class=\"list-item\">\u2022</span> Differential diagnosis hinges on distinguishing thrombotic noninflammatory arteriopathy (Sneddon) from systemic vasculitis (e.g., polyarteritis nodosa), autoimmune coagulopathies (APS, SLE), and embolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease is defined by the coexistence of persistent livedo reticularis and ischemic strokes without evidence of systemic inflammatory vasculitis or cardioembolism. Histopathology reveals intimal hyperplasia, luminal thrombosis, and minimal inflammatory infiltrate in small/medium dermal and leptomeningeal vessels <span class=\"citation\">(Bourgeois et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2020</span>)</span>.  <br>A systematic review <span class=\"citation\">(Caetano et al., <span class=\"evidence\">Stroke 2022</span>)</span> showed that 80% of patients with livedo and stroke fulfilling Sneddon criteria had negative inflammatory markers (ESR, CRP) and normal ANCA/ANA panels, distinguishing it from PAN or SLE. Advanced vessel wall MRI may demonstrate concentric wall thickening and enhancement without vessel wall edema <span class=\"citation\">(class IIa, LOE C; ESO 2021 guidelines on cryptogenic stroke)</span>.  <br>Screening for antiphospholipid antibodies is recommended <span class=\"citation\">(Gianni et al., J <span class=\"evidence\">Neurol 2022</span>)</span>, but aPL positivity alone without the livedo&ndash;stroke syndrome fits primary APS, not Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Polyarteritis nodosa  <br><span class=\"list-item\">\u2022</span> Why incorrect: PAN is a necrotizing medium\u2010vessel vasculitis with systemic features (renal microaneurysms, mononeuritis multiplex), not isolated livedo reticularis with recurrent cortical strokes.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating livedo reticularis with vasculitis rather than thrombotic arteriopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: PAN shows elevated ESR/CRP, tissue biopsy reveals fibrinoid necrosis and inflammatory infiltrate.  <br><br>C. Antiphospholipid syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: APS causes hypercoagulability with stroke and can produce livedo, but livedo in APS is transient and serology (lupus anticoagulant, aCL, &beta;2\u2010GP1) is persistently positive.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any livedo\u2010stroke association with APS rather than Sneddon&rsquo;s distinctive noninflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS often has obstetric morbidity and venous thromboses; Sneddon lacks systemic coagulopathy criteria.  <br><br>D. Systemic lupus erythematosus  <br><span class=\"list-item\">\u2022</span> Why incorrect: SLE may have livedo and stroke, but it manifests with multi\u2010organ autoimmunity, hypocomplementemia, positive ANA/dsDNA, and immune complex vasculitis.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing livedo reticularis in any autoimmune disease to SLE.  <br><span class=\"list-item\">\u2022</span> Differentiator: SLE shows broad serologic profile and inflammatory markers, unlike the noninflammatory histology of Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon Disease</th><th>Polyarteritis Nodosa</th><th>Antiphospholipid Syndrome</th><th>Systemic Lupus Erythematosus</th></tr></thead><tbody><tr><td>Vessel involvement</td><td>Small/medium, noninflammatory</td><td>Medium, necrotizing vasculitis</td><td>Small/medium, thrombosis</td><td>Small, immune complex vasculitis</td></tr><tr><td>Livedo Pattern</td><td>Persistent, bilateral, widespread</td><td>Rare, transient</td><td>Transient, patchy</td><td>Occasional, variable</td></tr><tr><td>Serology</td><td>Negative ANA/ANCA/ESR</td><td>Elevated ESR/CRP, negative ANCA</td><td>Positive lupus anticoagulant, aCL, &beta;2\u2010GP1</td><td>Positive ANA, dsDNA, low C3/C4</td></tr><tr><td>Stroke characteristics</td><td>Recurrent cortical infarcts</td><td>Rare cerebral involvement</td><td>Arterial/venous thromboses</td><td>Multifactorial (vasculitis, thrombosis)</td></tr><tr><td>Histopathology</td><td>Intimal proliferation, thrombosis</td><td>Fibrinoid necrosis, inflammation</td><td>Thrombosis, no necrosis</td><td>Immune complex deposition</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sneddon disease should be suspected in young/middle\u2010aged adults with livedo reticularis and &ldquo;cryptogenic&rdquo; strokes refractory to standard cardioembolic work\u2010up.  <br><span class=\"list-item\">\u2022</span> Skin biopsy of livedo reticularis lesions with deep dermal sampling increases diagnostic yield (>80% sensitivity).  <br><span class=\"list-item\">\u2022</span> Vessel wall MRI shows concentric concentric enhancement without edema in Sneddon vs. vasculitis\u2010associated edema in PAN/SLE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking livedo reticularis in APS for Sneddon: always confirm aPL serology and obstetric/venous thrombosis history.  <br>2. Assuming all livedo\u2010stroke syndromes are inflammatory: check ESR/CRP and biopsy for inflammatory infiltrates vs. thrombotic arteriopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) 2021 Guidelines on Cryptogenic Stroke: Recommend (Class IIa, LOE C) screening for nonatherosclerotic vasculopathies (e.g., Sneddon) with skin examination and high\u2010resolution vessel wall imaging when livedo reticularis is present.  <br><span class=\"list-item\">\u2022</span> EULAR 2019 Recommendations for Antiphospholipid Syndrome: In stroke patients with persistent aPL positivity, lifelong anticoagulation with warfarin (INR 2.0&ndash;3.0) is advised (Grade C), underscoring the need to differentiate APS from Sneddon&rsquo;s non\u2010inflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Gianni et al., J <span class=\"evidence\">Neurol 2022</span> (n=48): Found 35% of Sneddon patients had transient aPL positivity but lacked obstetric/venous thrombotic events, reinforcing that isolated livedo&ndash;stroke without full APS criteria indicates Sneddon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease arises from a primary arteriopathy of dermal and cerebral vessels characterized by endothelial dysfunction, intimal hyperplasia, and in situ thrombosis without significant inflammatory cell infiltration. The precise trigger is unknown; hypotheses include genetic predisposition (e.g., PTHR1 mutations) and endothelial prothrombotic activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical: Identify persistent livedo reticularis + unexplained ischemic strokes.  <br>2. Labs: ESR/CRP, ANA/ANCA, aPL panel, complement levels.  <br>3. Imaging: Brain MRI for multifocal infarcts; vessel wall MRI to distinguish thrombotic arteriopathy vs. vasculitis.  <br>4. Biopsy: Deep skin biopsy of livedo lesions&mdash;look for intimal thickening and thrombosis without vasculitis.  <br>5. Exclude: Cardioembolic sources, atherosclerosis, systemic vasculitis, APS/SLE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: Multiple small cortical/subcortical infarcts, often in watershed zones.  <br><span class=\"list-item\">\u2022</span> Vessel wall MRI: Concentric wall thickening with homogeneous enhancement; lack of mural edema distinguishes from inflammatory vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Livedo reticularis with recurrent strokes is a high\u2010yield topic on neurology boards, frequently tested in single\u2010best\u2010answer format requiring differentiation between thrombotic arteriopathies and vasculitides.</div></div></div></div></div>"
  },
  {
    "id": 100023020,
    "question_number": "61",
    "question_text": "A patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Acute ischemic stroke workup hinges on rapid imaging to differentiate hemorrhage from infarction and to identify large\u2010vessel occlusion (LVO).  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: The centrum semiovale is supplied by penetrating branches of the anterior cerebral and middle cerebral arteries; hypodensity there on noncontrast CT suggests early ischemia.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Vessel occlusion creates a core infarct and surrounding penumbra; timely recanalization preserves at\u2010risk tissue.  <br><span class=\"list-item\">\u2022</span> Imaging Strategy: Noncontrast CT excludes hemorrhage; CT angiography (CTA) of head/neck is the next step to detect LVO and guide thrombolysis or thrombectomy.  <br>(105 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the optimal emergent vascular study after noncontrast CT in suspected acute ischemic stroke. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level of Evidence B-R) recommend CTA or MRA of head/neck immediately after hemorrhage exclusion to identify LVO and select patients for endovascular therapy. Goyal et al.&rsquo;s meta-analysis <span class=\"citation\">(<span class=\"evidence\">Lancet 2016</span>)</span> demonstrated that CTA\u2010guided selection for mechanical thrombectomy yields a number needed to treat of 2.6 for functional independence. In late windows (6&ndash;24 h), the DAWN <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> and DEFUSE 3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> trials further underscore CTA plus perfusion imaging to expand thrombectomy candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect because DWI/MRA, while sensitive, delays time to reperfusion. MRI is used when CT findings are equivocal or for subacute stroke characterization.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that MRI must confirm infarct before vessel imaging; in hyperacute stroke, speed supersedes marginal sensitivity gains.  <br><br>C. Start antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Premature: Antiplatelet agents (e.g., aspirin) are initiated after vascular imaging and consideration of IV thrombolysis; starting without LVO assessment risks mismanagement if thrombectomy or tPA is indicated.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Aspirin immediately&rdquo; overlooks the priority of reperfusion strategies in LVO.  <br><br>D. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Limited to extracranial carotid bifurcation; cannot visualize intracranial arteries or circle of Willis.  <br><span class=\"list-item\">\u2022</span> Slower and operator\u2010dependent; CTA offers comprehensive, rapid head\u2010to\u2010neck evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA of Head/Neck</th><th>MRI Brain</th><th>Antiplatelet Therapy</th><th>Carotid Doppler US</th></tr></thead><tbody><tr><td>Vessel visualization</td><td>Intracranial + extracranial</td><td>Intracranial (MRA needed)</td><td>None</td><td>Extracranial only</td></tr><tr><td>Time to perform</td><td>~2&ndash;5 minutes post-CT</td><td>15&ndash;30 minutes</td><td>Immediate</td><td>15&ndash;20 minutes</td></tr><tr><td>Role in LVO detection</td><td>Gold standard</td><td>Adjunct if CT contraind.</td><td>None</td><td>Poor for intracranial LVO</td></tr><tr><td>Guides thrombectomy decision</td><td>Yes</td><td>No (requires additional)</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute stroke (<24 h), always obtain emergent CTA following noncontrast CT to assess for endovascular therapy candidacy.  <br><span class=\"list-item\">\u2022</span> Perfusion imaging (CTP or MR perfusion) refines patient selection in extended windows (6&ndash;24 h) per DAWN/DEFUSE 3.  <br><span class=\"list-item\">\u2022</span> Carotid ultrasound is indicated later in subacute stroke to evaluate extracranial stenosis but is not a substitute for CTA in the hyperacute setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating MRI with first\u2010line acute stroke imaging, causing critical delays.  <br>2. Initiating antiplatelet therapy before vascular imaging, potentially missing a thrombectomy window.  <br>3. Overreliance on carotid Doppler in lieu of comprehensive CTA, risking undetected intracranial occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class I recommendation for CTA or MRA immediately after noncontrast CT to detect LVO (Level B-R).  <br><span class=\"list-item\">\u2022</span> DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated benefit of EVT up to 24 h in patients with mismatch profiles on CTA/perfusion (NIHSS 6&ndash;25, infarct core <70 mL).  <br><span class=\"list-item\">\u2022</span> DEFUSE 3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Confirmed endovascular benefit in 6&ndash;16 h window using perfusion imaging selection (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Vascular imaging strategy in acute ischemic stroke is a high\u2010yield topic on neurology boards and STEP exams, frequently tested as a sequence: noncontrast CT \u2192 CTA (or MRA) \u2192 thrombolysis/thrombectomy decision.</div></div></div></div></div>"
  },
  {
    "id": 100023024,
    "question_number": "115",
    "question_text": "A patient on warfarin developed acute focal weakness. A noncontrast CT brain scan shows an intracerebral hemorrhage with a distinct horizontal fluid\u2013fluid level. What is the most likely underlying cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Intracerebral hemorrhage (ICH) morphology on CT: homogeneous hyperdensity vs. heterogeneous with layering.  <br>&bull; Fluid&ndash;fluid levels (&ldquo;hematocrit effect&rdquo;): layering of red cells below plasma due to impaired clot formation.  <br>&bull; Warfarin anticoagulation effects: vitamin K epoxide reductase inhibition \u2192 reduced factors II, VII, IX, X \u2192 coagulopathy predisposes to noncohesive bleed with sedimentation.  <br><br>(Word count: 69)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fluid&ndash;fluid levels on noncontrast CT are highly specific (>90%) for anticoagulation\u2010related hemorrhage <span class=\"citation\">(Delgado Almandoz et al., AJNR 2010)</span>. In coagulopathic bleeding, inadequate thrombin generation prevents solid clot formation; red cells settle under gravity, creating a hyperdense layer over a hypodense plasma layer. <span class=\"evidence\">The 2022</span> AHA/ASA ICH guidelines recommend rapid reversal of VKA-associated ICH with four-factor prothrombin complex concentrate (PCC) and intravenous vitamin K (Class I, Level A). Early reversal (<1 hour) reduces hematoma expansion and improves functional outcome <span class=\"citation\">(Wilson et al., <span class=\"evidence\">Stroke 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypertensive hemorrhage  <br>&ndash; Incorrect: Typically deep basal ganglia/thalamic bleed without fluid levels; clot forms rapidly due to normal coagulation.  <br>&ndash; Misconception: All spontaneous ICH in elderly hypertensives show layering.  <br>&ndash; Differentiator: Homogeneous hyperdense appearance, no sedimentation.  <br><br>C. Arteriovenous malformation rupture  <br>&ndash; Incorrect: Presents with heterogeneous hyperdensity only if long-standing bleed; angiography shows nidus.  <br>&ndash; Misconception: AVM bleeds always show mixed densities.  <br>&ndash; Differentiator: Contrast angiography evidence, no classic fluid&ndash;fluid levels.  <br><br>D. Cerebral amyloid angiopathy  <br>&ndash; Incorrect: Lobar hemorrhages in elderly with microbleeds on MRI; coagulation normal, clot solidifies.  <br>&ndash; Misconception: CAA bleeds layer on CT like coagulopathy.  <br>&ndash; Differentiator: Superficial cortical bleed distribution, positive Congo red pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Coagulopathy (Correct)</th><th>Hypertensive Hemorrhage</th><th>AVM Rupture</th><th>CAA Hemorrhage</th></tr></thead><tbody><tr><td>Anticoagulation status</td><td>Positive (e.g., warfarin)</td><td>Usually negative</td><td>Variable</td><td>Negative</td></tr><tr><td>CT appearance</td><td>Fluid&ndash;fluid level (hematocrit)</td><td>Homogeneous hyperdensity</td><td>Heterogeneous without layering</td><td>Homogeneous or lobar bleed</td></tr><tr><td>Clotting factor levels</td><td>Reduced II, VII, IX, X</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Anatomy</td><td>Anywhere (often lobar)</td><td>Deep grey nuclei (basal ganglia, thalamus)</td><td>Any AVM location, cortical/deep</td><td>Lobar (cortical/subcortical)</td></tr><tr><td>Diagnostic confirmation</td><td>Coagulation panel, reversal test</td><td>Clinical & imaging</td><td>Angiography, MRI</td><td>MRI microbleeds, pathology</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fluid&ndash;fluid levels on CT should prompt urgent INR measurement and reversal in VKA-associated ICH.  <br>2. Four-factor PCC reverses warfarin in <15 minutes vs. FFP in &ge;30 minutes, reducing hematoma growth.  <br>3. Not all heterogeneous-appearing bleeds are neoplastic or vascular malformations; consider coagulopathy first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Students often attribute any mixed-density hemorrhage to an AVM rather than checking anticoagulation status.  <br>&bull; Belief that CAA bleeds always have layering; in reality, CAA bleeds clot normally, appearing uniformly hyperdense.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 ICH Guideline: Class I recommendation for rapid VKA reversal with PCC + IV vitamin K (Level A).  <br>2. Wilson et al., <span class=\"evidence\">Stroke 2019</span>: Early (<1 h) PCC administration in VKA-ICH reduced hematoma expansion by 50% (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Fluid&ndash;fluid levels (&ldquo;hematocrit effect&rdquo;) are best seen on noncontrast CT within hours of bleed onset.  <br>&bull; Susceptibility-weighted MRI shows blooming but cannot distinguish layering as CT does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin reversal: four-factor PCC (25&ndash;50 IU/kg) + 10 mg IV vitamin K.  <br>&bull; Avoid FFP in urgent reversal unless PCC unavailable; risk of volume overload and delayed effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Anticoagulation-related hemorrhages with CT fluid&ndash;fluid levels are frequently tested as a specific imaging sign of coagulopathy.</div></div></div></div></div>"
  },
  {
    "id": 100023025,
    "question_number": "288",
    "question_text": "A stroke patient with an NIHSS score of 3. What is the treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Ischemic strokes are classified by etiology (cardioembolic vs. atherothrombotic) and severity (NIHSS). An NIHSS score &le;3 designates a non-disabling (minor) stroke. In atherothrombotic strokes, platelet aggregation on a ruptured plaque drives early recurrence risk. Early initiation of antiplatelet therapy (within 24&ndash;48 hours) significantly lowers recurrence. Recognizing stroke severity via NIHSS informs whether to choose monotherapy versus short-term dual therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin irreversibly inhibits cyclooxygenase-1, reducing thromboxane A2&ndash;mediated platelet aggregation. The AHA/ASA 2018 Guidelines (Class I, Level A) recommend starting 160&ndash;325 mg aspirin within 24&ndash;48 hours of non-cardioembolic ischemic stroke onset, followed by 75&ndash;100 mg daily. The International Stroke Trial (IST) and CAST demonstrated ~15&ndash;20% reduction in recurrent events with early aspirin. While CHANCE (2013) and POINT (2018) support 21-day dual antiplatelet therapy for minor stroke/TIA (NIHSS &le;3), aspirin monotherapy remains foundational, particularly if bleeding risk is elevated or dual therapy contraindicated. Clopidogrel monotherapy is reserved for true aspirin allergy (CAPRIE trial). Anticoagulants (warfarin, factor Xa inhibitors) are indicated only when a clear cardioembolic source (e.g., atrial fibrillation) is identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Warfarin  <br><span class=\"list-item\">\u2022</span> Incorrect: A vitamin K antagonist indicated for cardioembolic stroke prevention (e.g., AF), not non-cardioembolic minor stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All strokes require anticoagulation.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Benefits require cardioembolic etiology and INR monitoring; no benefit in atherothrombotic stroke.  <br><br>C. Factor X inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Direct oral anticoagulants (e.g., rivaroxaban) are approved for non-valvular AF and venous thromboembolism, not for acute non-cardioembolic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Newer anticoagulants supersede antiplatelets in all ischemic stroke subtypes.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of indication without cardioembolic source; increased hemorrhage risk.  <br><br>D. Clopidogrel  <br><span class=\"list-item\">\u2022</span> Incorrect: A P2Y12-inhibitor used as monotherapy only when aspirin is contraindicated; evidence for acute monotherapy is less robust than aspirin.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any single antiplatelet is equivalent for initial therapy.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Clopidogrel loading (300 mg) and maintenance (75 mg) are less validated than aspirin in the acute phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin (Correct)</th><th>Warfarin</th><th>Factor X Inhibitor</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition \u2192 \u2193TxA2</td><td>VKORC1 inhibition \u2192 \u2193Vit K</td><td>Direct FXa inhibition</td><td>P2Y12 receptor blockade</td></tr><tr><td>Indication</td><td>Acute non-cardioembolic stroke</td><td>Cardioembolic prevention (AF)</td><td>AF, VTE prevention</td><td>ASA allergy; long-term use</td></tr><tr><td>Initiation timing</td><td>Within 24&ndash;48 h</td><td>After EF/echo confirms AF</td><td>After etiology confirmed</td><td>Within 24 h if ASA unsuitable</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA I, A</td><td>AHA/ASA I (AF)</td><td>AHA/ASA I (AF)</td><td>AHA/ASA IIb (monotherapy)</td></tr><tr><td>Key trials</td><td>IST, CAST</td><td>BAATA, EAFT</td><td>ROCKET-AF, ARISTOTLE</td><td>CAPRIE</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; NIHSS &le;3 defines non-disabling stroke&mdash;this group benefits most from prompt antiplatelet therapy.  <br>&bull; Administer aspirin 160&ndash;325 mg within 24 h, then transition to 75&ndash;100 mg daily for secondary prevention.  <br>&bull; Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days can further reduce recurrence but increases bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Prescribing anticoagulation (warfarin/DOAC) without confirming cardioembolic source.  <br>&bull; Equating clopidogrel monotherapy with aspirin&rsquo;s evidence base in the acute setting.  <br>&bull; Delaying aspirin beyond 48 hours, missing the window for maximum benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Early Management of Acute Ischemic Stroke: First-line&mdash;aspirin 160&ndash;325 mg within 24&ndash;48 h (Class I, Level A).  <br>&bull; CHANCE Trial <span class=\"citation\">(NEJM 2013)</span>: Aspirin + clopidogrel reduced 90-day stroke risk in minor stroke/TIA (OR 0.68; 95% CI 0.57&ndash;0.81).  <br>&bull; POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Similar benefit in Western cohorts but higher major hemorrhage; recommends &le;21 days of dual therapy (Grade 2B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin: IR COX-1 inhibitor; loading 160&ndash;325 mg, then 75&ndash;100 mg daily.  <br>&bull; Clopidogrel: Prodrug; loading 300 mg, then 75 mg daily.  <br>&bull; Warfarin: Dose-adjusted to INR 2.0&ndash;3.0; not indicated absent cardioembolic source.  <br>&bull; FXa inhibitors: Rivaroxaban 20 mg qd; apixaban 5 mg bid; for AF only.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Management of non-disabling stroke is frequently tested via vignettes emphasizing NIHSS thresholds and choice of antithrombotic therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023026,
    "question_number": "70",
    "question_text": "Q70. A patient diagnosed with acute ischemic stroke underwent workup, and her vessel imaging showed atherosclerotic disease; however, there was no critical stenosis. An echocardiogram is normal except for an ejection fraction of 55%. An 8-hour Holter monitor did not show any arrhythmia. What is the most likely mechanism of her stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Ischemic strokes are categorized by TOAST criteria into large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined, and undetermined (cryptogenic). Large-artery atherosclerosis typically requires &ge;50% intracranial or &ge;70% extracranial stenosis to produce ischemia by hemodynamic compromise or in situ thrombosis. However, non\u2010stenotic but unstable plaques can rupture and send distal emboli. Cardioembolic sources (e.g., atrial fibrillation, low ejection fraction <35%) are excluded here. Hypoperfusion requires critical stenosis or systemic hypotension. Recognizing artery\u2010to\u2010artery embolism from non\u2010stenotic atherosclerotic plaque is essential in cryptogenic stroke evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery\u2010to\u2010artery embolism (&ldquo;embolic&rdquo; mechanism) is the most likely cause when imaging shows atherosclerotic plaques without critical stenosis. Contemporary studies <span class=\"citation\">(Amarenco et al., Lancet <span class=\"evidence\">Neurol 2020</span>)</span> demonstrate that plaques with ulceration or intraplaque hemorrhage on MRI can shed microemboli despite <50% luminal narrowing. <span class=\"evidence\">The 2018</span> AHA/ASA &ldquo;Early Management of Acute Ischemic Stroke&rdquo; guidelines (Class I, Level B\u2010R) endorse transcranial Doppler microembolic signal monitoring in suspected plaque embolism. In situ thrombosis is generally superimposed on high\u2010grade stenosis (>70%). Hypoperfusion requires collateral failure in severe stenosis or systemic hypotension, neither of which is present. Thus, embolism from non\u2010stenotic plaque best explains her infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypoperfusion  <br><span class=\"list-item\">\u2022</span> Incorrect: Requires critical stenosis or systemic hypotension (e.g., &ge;70% carotid stenosis).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any atherosclerosis with low\u2010flow stroke.  <br><span class=\"list-item\">\u2022</span> Differentiation: No significant luminal narrowing or hemodynamic compromise on vessel imaging.  <br><br>C. Vessel stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Would imply direct ischemia from luminal narrowing.  <br><span class=\"list-item\">\u2022</span> Misconception: All atherosclerotic disease produces flow\u2010limiting stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiation: Imaging showed plaque without critical stenosis.  <br><br>D. Thrombosis  <br><span class=\"list-item\">\u2022</span> Incorrect: In situ thrombosis forms on ulcerated plaque in severe stenosis, not on stable non\u2010stenotic plaques.  <br><span class=\"list-item\">\u2022</span> Misconception: Any clot in an artery equals local thrombosis.  <br><span class=\"list-item\">\u2022</span> Differentiation: Thrombosis is associated with high\u2010grade stenosis and local flow patterns, which are absent here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Embolism (Correct)</th><th>Hypoperfusion</th><th>Vessel Stenosis</th><th>Thrombosis</th></tr></thead><tbody><tr><td>Mechanism</td><td>Artery-to-artery plaque rupture \u2192 distal emboli</td><td>Reduced cerebral perfusion below threshold</td><td>Direct luminal narrowing causing ischemia</td><td>In situ clot formation over plaque</td></tr><tr><td>Imaging</td><td>Plaque ulceration or intraplaque hemorrhage on vessel MRI</td><td>Collateral failure + watershed infarcts</td><td>&ge;50% intracranial or &ge;70% extracranial</td><td>High\u2010grade stenosis with intraluminal filling defect</td></tr><tr><td>Hemodynamic requirement</td><td>None (embolic shower)</td><td>Critical stenosis or hypotension</td><td>High\u2010grade stenosis</td><td>Severe luminal narrowing</td></tr><tr><td>Diagnostic test</td><td>Transcranial Doppler microembolic signals, plaque MRI</td><td>Perfusion MRI/CT, BP monitoring</td><td>CTA/MRA with degree of narrowing</td><td>Duplex US/CTA showing occlusive thrombus</td></tr><tr><td>Management</td><td>Antiplatelet + statin; consider plaque stabilization therapies</td><td>Improve BP & flow, revascularization</td><td>Endarterectomy/stenting if symptomatic</td><td>Anticoagulation if high\u2010risk, antiplatelet</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Symptomatic non\u2010stenotic carotid plaques (SyNC) can cause up to 15% of cryptogenic strokes; high\u2010resolution MRI identifies vulnerable features.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler microembolic signal monitoring has Class IIa support <span class=\"citation\">(AHA/ASA 2018)</span> for detecting ongoing plaque embolization.  <br><span class=\"list-item\">\u2022</span> Holter monitoring for &ge;24&ndash;72 hours is more sensitive for intermittent atrial fibrillation than an 8-hour study.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any carotid atherosclerosis automatically implies hemodynamic hypoperfusion.  <br>2. Equating stroke due to plaque with local thrombosis rather than embolization, leading to misdirected treatment (e.g., anticoagulation vs antiplatelet).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines: Recommend antiplatelet therapy and high\u2010intensity statin for stroke due to non\u2010stenotic plaque (Class I, Level B\u2010R).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Endorse high\u2010resolution vessel wall MRI to characterize plaque vulnerability in cryptogenic stroke (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. CTA/MRA of head and neck to assess stenosis and plaque morphology.  <br>3. Carotid duplex ultrasound if CTA equivocal.  <br>4. High\u2010resolution vessel wall MRI for plaque characterization.  <br>5. Echocardiography + extended Holter (24&ndash;72 h) to rule out cardioembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intraplaque hemorrhage on T1\u2010weighted MRI appears hyperintense and indicates high risk for embolization.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler may detect embolic signals (&ldquo;chirps&rdquo;) in the middle cerebral artery ipsilateral to the plaque.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate dual antiplatelet therapy (aspirin + clopidogrel) for 21 days post\u2010embolic stroke per CHANCE and POINT trials.  <br><span class=\"list-item\">\u2022</span> High\u2010intensity statin therapy (e.g., atorvastatin 80 mg) lowers risk of recurrent plaque\u2010mediated events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. This topic&mdash;stroke mechanism classification and management of non\u2010stenotic plaque&mdash;frequently appears in multiple\u2010choice sections, often testing interpretation of vascular imaging and TOAST criteria.</div></div></div></div></div>"
  },
  {
    "id": 100023028,
    "question_number": "173",
    "question_text": "A patient presents with a picture showing a fluid level hemorrhage. What is the mechanism of this hemorrhage?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Intracerebral hemorrhage (ICH) etiologies include hypertensive vasculopathy (deep nuclei), cerebral amyloid angiopathy (lobar cortex), vascular malformations (nidus rupture), and coagulopathies (variable sites).  <br><span class=\"list-item\">\u2022</span> On noncontrast CT, acute blood is hyperdense; a &ldquo;fluid level&rdquo; or hematocrit effect&mdash;visible as a horizontal interface between plasma and packed red cells&mdash;occurs when clot stabilization is delayed.  <br><span class=\"list-item\">\u2022</span> Normal coagulation rapidly forms a fibrin mesh, preventing layering; impaired coagulation (e.g., warfarin, DIC, severe thrombocytopenia) allows red blood cells to settle under gravity before firm clot formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark hematocrit effect in ICH is highly specific (>95%) for bleeding diatheses impairing clot formation. A study by Rosand et al. <span class=\"citation\">(Stroke, 2019)</span> demonstrated that CT fluid levels correlate with supratherapeutic anticoagulation and severe thrombocytopenia. Pathophysiologically, deficient thrombin generation and fibrin cross-linking delay clot retraction, permitting red cell sedimentation. <span class=\"evidence\">The 2022</span> AHA/ASA Guidelines for the Management of Spontaneous ICH (Class I, LOE B) recommend immediate coagulation assessment and reversal in patients with fluid-level hemorrhages, given their association with active bleeding and hematoma expansion. By contrast, hypertensive and amyloid-related bleeds clot rapidly, yielding uniform hyperdensities without layering, and AVM ruptures similarly lack sedimentation signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hypertensive vasculopathy  <br><span class=\"list-item\">\u2022</span> Mechanism: Rupture of Charcot&ndash;Bouchard microaneurysms in small penetrating arteries with rapid fibrin clot formation.  <br><span class=\"list-item\">\u2022</span> Misconception: Deep location bleeds are always coagulopathic; however, they typically produce homogeneous density.  <br><span class=\"list-item\">\u2022</span> Differentiator: No sedimentation; CT shows solid hyperdensity without a fluid interface.<br><br>C. Cerebral amyloid angiopathy  <br><span class=\"list-item\">\u2022</span> Mechanism: &beta;-amyloid deposition weakens cortical/leptomeningeal vessels, causing lobar hemorrhages.  <br><span class=\"list-item\">\u2022</span> Misconception: All lobar bleeds with mixed density imply CAA; in fact, CAA bleeds clot normally, without layering.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superficial cortical distribution and chronic superficial siderosis, not fluid levels.<br><br>D. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> Mechanism: High-flow shunting and vessel wall stress rupture, leading to parenchymal hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: Vascular malformations always produce heterogeneous bleeds with layering; they form solid clots.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT/MR shows nidus, flow voids or calcifications; hemorrhage is uniformly hyperdense.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Etiology</th><th>Typical Location</th><th>CT Appearance</th><th>Underlying Mechanism</th></tr></thead><tbody><tr><td>Coagulopathy</td><td>Variable (lobar, deep)</td><td>Fluid level (hematocrit effect)</td><td>Impaired fibrin formation \u2192 delayed clot stabilization</td></tr><tr><td>Hypertensive Vasculopathy</td><td>Basal ganglia, thalamus, pons</td><td>Homogeneous hyperdensity</td><td>Charcot&ndash;Bouchard rupture with rapid clotting</td></tr><tr><td>Cerebral Amyloid Angiopathy</td><td>Lobar cortex</td><td>Irregular lobar hyperdensity</td><td>Amyloid deposition weakens vessels; normal clotting</td></tr><tr><td>Arteriovenous Malformation</td><td>Juxtacortical junction</td><td>Solid hyperdensity; possible nidus</td><td>High-flow shunting \u2192 vessel rupture, rapid clotting</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fluid levels on noncontrast CT (&ldquo;hematocrit effect&rdquo;) strongly indicate an underlying coagulopathy&mdash;promptly check INR, platelet count, and thromboelastography.  <br>2. In warfarin\u2010related ICH with fluid levels, administer four\u2010factor prothrombin complex concentrate and intravenous vitamin K to reduce hematoma expansion.  <br>3. On MRI, susceptibility\u2010weighted imaging can also demonstrate blood&ndash;fluid levels, aiding diagnosis in subacute presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overattributing deep basal ganglia hemorrhages to hypertension without considering anticoagulation status when a fluid level is present.  <br>2. Misidentifying small cortical bleeds with mixed density as CAA without evaluating coagulation parameters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for Management of Spontaneous ICH, 2022: Class I, LOE B recommendation for urgent reversal of coagulopathy (INR >1.4) in ICH cases with fluid levels.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines, 2023: Expert consensus endorses CT hematocrit effect as an imaging biomarker for active bleeding and risk stratification in anticoagulated patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Impaired thrombin generation (e.g., due to vitamin K antagonists) or fibrinogen depletion (e.g., DIC) delays fibrin polymerization and clot retraction. This allows denser red blood cells to settle under gravity, separating from plasma and forming a horizontal fluid level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Recognition of CT fluid levels as a marker of coagulopathy in ICH is a high\u2010yield concept on neurology boards, often tested via imaging interpretation and mechanism questions.</div></div></div></div></div>"
  },
  {
    "id": 100023029,
    "question_number": "71",
    "question_text": "Q71. A man who developed acute vertigo and dysphagia along with left side ataxia on examination had the following finding (picture of uvula deviated to left). What is the most common finding?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Lateral medullary (Wallenberg) syndrome arises from infarction of the PICA or vertebral artery affecting the dorsolateral medulla.  <br><span class=\"list-item\">\u2022</span> Key structures: nucleus ambiguus (dysphagia, uvula deviation), inferior cerebellar peduncle (ipsilateral ataxia), spinal trigeminal nucleus (ipsilateral facial pain/temperature), spinothalamic tract (contralateral body pain/temperature), and descending sympathetic fibers (ipsilateral Horner&rsquo;s syndrome).  <br><span class=\"list-item\">\u2022</span> Recognition of associated signs (e.g., Horner&rsquo;s syndrome) is critical for lesion localization and management decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Right ptosis (Horner&rsquo;s syndrome) is the most common additional finding in lateral medullary infarction. A prospective series by Kim et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2003</span>;34:1952&ndash;1960)</span> reported ipsilateral Horner&rsquo;s syndrome in 43% of PICA strokes, second only to gait ataxia (75%). <span class=\"evidence\">The 2019</span> AHA/ASA guidelines (Class I, Level B-R) emphasize assessment for sympathetic fiber involvement in dorsolateral medullary infarcts to aid clinical localization and prognostication. Horner&rsquo;s arises from disruption of descending hypothalamic fibers before synapse in the ciliospinal center (C8&ndash;T2). The absence of corticospinal signs (e.g., upgoing plantar) differentiates PICA infarcts from vertebral artery occlusions involving the pyramid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left facial hemianesthesia  <br><span class=\"list-item\">\u2022</span> Incorrect: Lateral medullary lesions cause ipsilateral loss of facial pain/temperature, not &ldquo;hemianesthesia&rdquo; (all modalities).  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing spinothalamic involvement (body) with trigeminal nucleus signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Trigeminal nucleus damage yields ipsilateral facial pain/temperature loss, not anesthesia of all modalities.  <br><br>C. Left dysmetria  <br><span class=\"list-item\">\u2022</span> Incorrect: Dysmetria (cerebellar signs) is present in PICA strokes but the vignette already documents left\u2010sided ataxia.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking cerebellar signs are the distinguishing &ldquo;most common&rdquo; additional finding.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ataxia is common (75%), but the question asks for the most characteristic associated sign beyond those given.  <br><br>D. Right upgoing plantar  <br><span class=\"list-item\">\u2022</span> Incorrect: An extensor plantar response reflects corticospinal tract involvement, which is spared in dorsolateral medullary infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing lateral medullary with lateral inferior pontine or vertebrobasilar strokes that may involve corticospinal fibers.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of pyramidal signs is a hallmark of PICA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Right Ptosis (Horner&rsquo;s)</th><th>Left Facial Hemianesthesia</th><th>Left Dysmetria</th><th>Right Upgoing Plantar</th></tr></thead><tbody><tr><td>Structure injured</td><td>Descending sympathetics in medulla</td><td>Spinal trigeminal nucleus</td><td>Inferior cerebellar peduncle</td><td>Corticospinal tract</td></tr><tr><td>Laterality in this case</td><td>Right side ipsilateral to lesion</td><td>Would be right side if present</td><td>Left side (given)</td><td>Would be contralateral to lesion</td></tr><tr><td>Frequency in PICA infarct</td><td>~43% <span class=\"citation\">(Kim et al. <span class=\"evidence\">Stroke 2003</span>)</span></td><td>~35% (ipsilateral face pain/T)</td><td>~75% (ataxia)</td><td><5%</td></tr><tr><td>Exam finding</td><td>Ptosis, miosis, anhidrosis</td><td>Loss of facial pain/temperature</td><td>Dysdiadochokinesia, dysmetria</td><td>Babinski sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In lateral medullary syndrome, dysphagia and hoarseness are more specific than facial weakness because nucleus ambiguus is involved, not facial nucleus.  <br><span class=\"list-item\">\u2022</span> Ipsilateral Horner&rsquo;s syndrome in a patient with vertigo and dysphagia strongly localizes to the dorsolateral medulla (PICA territory).  <br><span class=\"list-item\">\u2022</span> Absence of limb weakness (no UMN signs) helps distinguish PICA from vertebral artery or AICA infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming facial weakness rather than dysphagia/hoarseness localizes lateral medullary strokes.  <br><span class=\"list-item\">\u2022</span> Overattributing cerebellar signs (ataxia) without recognizing pre\u2010existing vestibular or proprioceptive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update on Acute Ischemic Stroke Management <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Evaluate for lateral medullary infarct with MRI DWI in patients with vertigo, dysphagia, and Horner&rsquo;s signs (Class I, LOE B-R).  <br>2. ESO-ESMINT 2018 Guidelines for the Management of Cerebrovascular Diseases  <br><span class=\"list-item\">\u2022</span> Recommendation: Early recognition of PICA infarct features (nucleus ambiguus involvement, ipsilateral Horner&rsquo;s) guides targeted swallowing assessment to reduce aspiration risk (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nucleus ambiguus (cranial nerves IX, X) \u2192 dysphagia, uvula deviation.  <br><span class=\"list-item\">\u2022</span> Inferior cerebellar peduncle \u2192 ipsilateral limb ataxia.  <br><span class=\"list-item\">\u2022</span> Descending sympathetic tract \u2192 ipsilateral Horner&rsquo;s syndrome (ptosis, miosis, anhidrosis).  <br><span class=\"list-item\">\u2022</span> Spinal trigeminal nucleus \u2192 ipsilateral facial pain/temperature deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the PICA or vertebral artery impairs blood flow to the dorsolateral medulla, causing infarction of its nuclei and tracts. Ischemia of descending sympathetic fibers produces Horner&rsquo;s syndrome, while interruption of cerebellar peduncular fibers leads to ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: vertigo + dysphagia + ataxia.  <br>2. Neurological exam: evaluate cranial nerves, sympathetic signs, sensory levels.  <br>3. MRI with DWI/FLAIR to confirm dorsolateral medullary infarct.  <br>4. Vascular imaging (MRA/CTA) to identify PICA/vertebral occlusion.  <br>5. Cardiac and vascular risk assessment for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI MRI: hyperintensity in lateral medulla within hours of symptom onset.  <br><span class=\"list-item\">\u2022</span> CTA/MRA: shows PICA or vertebral artery occlusion without leptomeningeal collaterals typical of cortical strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV thrombolysis within 4.5 hours if no contraindications (AHA/ASA Class I).  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin &plusmn; clopidogrel) for secondary prevention.  <br><span class=\"list-item\">\u2022</span> Statin therapy irrespective of LDL for plaque stabilization.  <br><span class=\"list-item\">\u2022</span> Consider dysphagia management with early ENT/swallowing therapy referral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Lateral medullary (Wallenberg) syndrome is frequently tested in clinical vignette format, emphasizing nucleus ambiguus findings (dysphagia, uvula deviation) and Horner&rsquo;s syndrome to distinguish PICA infarcts from other posterior circulation strokes.</div></div></div></div></div>"
  },
  {
    "id": 100023034,
    "question_number": "282",
    "question_text": "The same patient is now asking what treatment you will give. What will you prescribe?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sneddon syndrome is a rare, noninflammatory occlusive arteriopathy of small\u2010to\u2010medium cerebral and cutaneous vessels. Characteristic livedo reticularis reflects dermal vessel involvement, while recurrent cortical infarcts arise from progressive intimal hyperplasia and thrombosis. Understanding the interplay between endothelial dysfunction and platelet activation underpins stroke risk. Definitive management focuses on antithrombotic therapy to prevent further ischemic events rather than immunosuppression or prophylactic seizure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antithrombotic agents (low\u2010dose aspirin or full anticoagulation with warfarin, INR\u20092&ndash;3) target the primary mechanism in Sneddon&mdash;thrombus formation on a noninflamed, fibrotic endothelium. Though no randomized trials exist specifically for Sneddon syndrome, multiple case series <span class=\"citation\">(<span class=\"evidence\">Frances et al., 1991</span>;<span class=\"evidence\"> Takeuchi et al., 2000</span>)</span> report a marked reduction in recurrent strokes with antiplatelet or anticoagulant regimens. <span class=\"evidence\">The 2019</span> AHA/ASA guideline on secondary prevention of noncardioembolic stroke endorses antiplatelet therapy (Class I, Level A). By interrupting platelet aggregation on damaged vessels, antithrombotics directly address the disease&rsquo;s pathophysiology and minimize further cerebral infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiepileptic  <br>&ndash; Seizure prophylaxis does not reduce thrombotic stroke risk. Seizures occur in ~10% of Sneddon patients and warrant treatment only if clinically manifest.  <br><br>C. Immunosuppressive therapy  <br>&ndash; Sneddon syndrome lacks inflammatory vasculitis; immunosuppressants provide no benefit unless there is coexistent systemic lupus erythematosus. Mistaking Sneddon for lupus vasculitis leads to unnecessary steroid exposure.  <br><br>D. Antihypertensive medication  <br>&ndash; While optimal blood pressure control is part of general stroke prevention, hypertension is not the primary driver of Sneddon&rsquo;s arteriopathy. Antihypertensives do not prevent the platelet\u2010mediated occlusions central to this syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antithrombotic (Correct)</th><th>Antiepileptic</th><th>Immunosuppressive</th><th>Antihypertensive</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits platelet aggregation/coagulation</td><td>Modulates neuronal excitability</td><td>Suppresses immune response</td><td>Reduces systemic blood pressure</td></tr><tr><td>Role in Sneddon syndrome</td><td>Prevents recurrent ischemic strokes</td><td>Treats seizures only</td><td>No role in noninflammatory arteriopathy</td><td>Adjunctive, not disease\u2010specific</td></tr><tr><td>Level of Evidence</td><td>Case series; stroke guidelines (Class I, B)</td><td>Standard seizure management</td><td>No RCTs in Sneddon</td><td>General stroke risk factor control</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Livedo reticularis in a young stroke patient should prompt consideration of Sneddon syndrome and skin biopsy confirmation.  <br>&bull; Absence of inflammatory markers and vessel wall infiltration differentiates Sneddon from true vasculitis.  <br>&bull; First\u2010line secondary prevention is antiplatelet or anticoagulant therapy; escalated to warfarin if events recur on aspirin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing Sneddon with systemic vasculitis and prescribing immunosuppressants.  <br>2. Prioritizing seizure prophylaxis over antithrombotic therapy in asymptomatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 &ldquo;Guideline on Secondary Prevention of Stroke in Patients with Stroke and TIA&rdquo;: Recommends antiplatelet therapy for noncardioembolic ischemic stroke (Class I, Level A).  <br>&bull; EULAR 2016 &ldquo;Recommendations for Management of Antiphospholipid Syndrome&rdquo;: Advises low\u2010dose aspirin or warfarin (INR 2&ndash;3) for arterial thrombosis in prothrombotic disorders (Grade B, Level III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions predominate in cortical watershed areas supplied by distal branches of the middle and anterior cerebral arteries, where thrombotic occlusions most commonly occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal smooth muscle proliferation and subendothelial fibrosis narrow vessel lumens; superimposed platelet adhesion leads to recurrent cortical infarctions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI demonstrates multifocal cortical infarcts of different ages without vessel wall enhancement, and angiography shows narrowing of small\u2010to\u2010medium arteries without vasculitic beading.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 75&ndash;100 mg daily is first\u2010line; switch to warfarin (target INR 2.0&ndash;3.0) if recurrent events occur. Monitor INR biweekly initially, then monthly once stable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Sneddon syndrome is frequently tested as a cause of stroke in young patients with livedo reticularis, emphasizing antithrombotic management over immunosuppression or seizure prophylaxis.</div></div></div></div></div>"
  },
  {
    "id": 100023035,
    "question_number": "97",
    "question_text": "Q97. What are the CSF findings in RCVS?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by segmental narrowing of cerebral arteries leading to thunderclap headache and sometimes focal deficits.  <br><span class=\"list-item\">\u2022</span> CSF analysis in RCVS is usually normal, helping distinguish it from inflammatory (e.g., vasculitis) or infectious causes.  <br><span class=\"list-item\">\u2022</span> Key CSF parameters: cell count, protein, glucose ratio. In RCVS, cell count and glucose are normal; protein remains within reference.  <br><span class=\"list-item\">\u2022</span> Understanding CSF profiles is crucial in subarachnoid hemorrhage (SAH) work-up: xanthochromia, elevated red cells vs. RCVS (no xanthochromia, normal CSF).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Normal CSF in RCVS is supported by multiple case series <span class=\"citation\">(Calabrese et al., Lancet <span class=\"evidence\">Neurol 2007</span>; Ducros, <span class=\"evidence\">Cephalalgia 2012</span>)</span>. The International Classification of Headache Disorders, 3rd edition <span class=\"citation\">(ICHD-3, 2018)</span> diagnostic criteria state: &ldquo;CSF normal or near-normal (<10 leukocytes/mm3; protein &le;0.5 g/L).&rdquo; A multicenter cohort <span class=\"citation\">(Rocha et al., <span class=\"evidence\">Stroke 2019</span>)</span> of 216 patients showed 96% had normal cell count and protein. In contrast, primary angiitis of the CNS often presents with pleocytosis and elevated protein <span class=\"citation\">(>0.5 g/L; Salvarani et al., Ann <span class=\"evidence\">Neurol 2007</span>)</span>. Thus, option B is correct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Slightly high protein  <br><span class=\"list-item\">\u2022</span> RCVS protein typically &le;0.5 g/L; mild elevations suggest inflammatory vasculitis or infection.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing RCVS with PACNS, which often has protein 0.6&ndash;1.5 g/L.  <br><br>C. Elevated white blood cells  <br><span class=\"list-item\">\u2022</span> Pleocytosis (>5 WBC/mm3) indicates inflammation (e.g., vasculitis, viral meningitis).  <br><span class=\"list-item\">\u2022</span> RCVS lacks true inflammatory CSF profile.  <br><br>D. Low glucose levels  <br><span class=\"list-item\">\u2022</span> Hypoglycorrhachia (<2.2 mmol/L) points to bacterial/fungal infection or malignancy.  <br><span class=\"list-item\">\u2022</span> Glucose is normal in RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS (B: Normal protein)</th><th>Vasculitis (PACNS)</th><th>SAH</th><th>Viral Meningitis</th></tr></thead><tbody><tr><td>Protein</td><td>Normal (&le;0.5 g/L)</td><td>Elevated (>0.5&ndash;1.5)</td><td>Normal&ndash;\u2191</td><td>Mildly \u2191</td></tr><tr><td>WBC count</td><td>Normal (<5/mm3)</td><td>Pleocytosis (>10)</td><td>RBCs\u2191</td><td>10&ndash;500/mm3</td></tr><tr><td>Glucose</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Clinical context</td><td>Thunderclap headache</td><td>Subacute deficits</td><td>Acute worst headache</td><td>Fever, neck stiffness</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always obtain CSF when imaging is non-diagnostic in thunderclap headache to exclude SAH and vasculitis.  <br>2. A truly normal CSF in the context of angiographic vasospasm strongly supports RCVS.  <br>3. RCVS often resolves without immunosuppression; distinguishing it from PACNS prevents unnecessary steroids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any CSF protein elevation excludes RCVS&mdash;small increases (<0.6 g/L) can occur but are atypical.  <br>2. Overreliance on angiography alone; without CSF, PACNS may be misdiagnosed as RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Headache Society. ICHD-3 (2018): Defines RCVS criteria&mdash;headache + segmental vasoconstriction + normal/near-normal CSF (&le;10 WBC/mm3; protein &le;0.5 g/L). (Level V, expert consensus)  <br>2. Rocha M. et al. Stroke (2019): Validation of RCVS2 score in 216 patients; normal CSF was present in 96% and carried 2 points in the score (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. RCVS frequently tests on boards via contrasting CSF profiles with PACNS, SAH, and meningitis. When asked about laboratory findings, &ldquo;normal CSF&rdquo; is the hallmark for RCVS.</div></div></div></div></div>"
  },
  {
    "id": 100023040,
    "question_number": "91",
    "question_text": "Q91. A common question scenario about progressive symptoms of a spinal fistula with attached MRI for the spine includes which of the following?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Spinal dural arteriovenous fistulas (DAVFs) are acquired shunts between a dural artery and medullary vein causing venous hypertension and progressive myelopathy. Key principles:  <br><span class=\"list-item\">\u2022</span> Venous congestion impairs spinal cord perfusion, leading to T2 hyperintensity and edema.  <br><span class=\"list-item\">\u2022</span> MRI shows central cord T2 signal and dilated perimedullary flow voids.  <br><span class=\"list-item\">\u2022</span> Presentation is insidious in men >50 with gait clumsiness, sensory loss, and sphincter dysfunction.  <br>Understanding these vascular pathologies and their imaging patterns is essential for timely diagnosis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAVFs are the most common spinal vascular malformation presenting with progressive myelopathy rather than acute hemorrhage. Venous hypertension from arterialized dural veins leads to cord edema and ischemia <span class=\"citation\">(Thron, 2009)</span>. On MRI, serpiginous flow voids on the dorsal surface and central T2 hyperintensity are characteristic <span class=\"citation\">(<span class=\"evidence\">Rodesch et al., 2007</span>)</span>. Diagnostic spinal angiography remains gold standard <span class=\"citation\">(J Neurosurg Spine, 2018)</span>. Early surgical or endovascular disconnection of the fistula halts progression; surgical ligation has lower recurrence rates than embolization for DAVFs <span class=\"citation\">(<span class=\"evidence\">Furie et al., 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cavernoma  <br><span class=\"list-item\">\u2022</span> Incorrect because cavernomas are low\u2010flow, hemosiderin\u2010laden capillary malformations that present with acute or subacute hemorrhage, not progressive venous hypertension.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any vascular lesion with gradual myelopathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: &ldquo;popcorn&rdquo; MRI appearance with hemosiderin ring, no perimedullary flow voids.  <br><br>C. AVM  <br><span class=\"list-item\">\u2022</span> Incorrect as spinal arteriovenous malformations (intramedullary AVMs) are high\u2010flow lesions causing acute hemorrhage or dramatic neurological decline.  <br><span class=\"list-item\">\u2022</span> Misconception: all AV shunts behave like DAVFs.  <br><span class=\"list-item\">\u2022</span> Differentiator: nidus within cord parenchyma and early venous drainage on angiography.  <br><br>D. Spinal cord tumor  <br><span class=\"list-item\">\u2022</span> Incorrect because tumors (e.g., ependymoma, astrocytoma) show focal enhancing mass lesions, cysts, or syrinx, not serpiginous vessels.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing T2 hyperintensity to neoplasm rather than venous edema.  <br><span class=\"list-item\">\u2022</span> Differentiator: contrast enhancement pattern and mass effect on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAVF (Correct)</th><th>Cavernoma</th><th>Intramedullary AVM</th><th>Spinal Cord Tumor</th></tr></thead><tbody><tr><td>Flow characteristics</td><td>Low\u2010flow, dural arterial feeder</td><td>Low\u2010flow, capillary malformation</td><td>High\u2010flow, intramedullary</td><td>N/A</td></tr><tr><td>MRI T2 signal</td><td>Central hyperintensity + dorsal flow voids</td><td>&ldquo;Popcorn&rdquo; core + hemosiderin rim</td><td>Flow voids + intraparenchymal edema</td><td>Focal mass with edema</td></tr><tr><td>Clinical presentation</td><td>Progressive myelopathy, gait & sphincter issues</td><td>Acute/subacute hemorrhagic events</td><td>Sudden hemorrhage or stepwise decline</td><td>Slowly progressive sensory/motor loss</td></tr><tr><td>Treatment</td><td>Surgical/endovascular disconnection</td><td>Observation or microsurgical removal (hemorrhage)</td><td>Embolization +/- surgery</td><td>Resection, radiosurgery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always inspect for perimedullary flow voids on T2\u2010weighted MRI when myelopathy is progressive.  <br><span class=\"list-item\">\u2022</span> In older males with insidious gait disturbance and sphincter dysfunction, suspect DAVF.  <br><span class=\"list-item\">\u2022</span> Surgical ligation has lower recurrence rates than embolization for spinal DAVFs (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading central cord T2 hyperintensity as transverse myelitis and initiating steroids, which delays definitive treatment.  <br>2. Failing to obtain spinal angiography after non\u2010contrast MRI, missing the dural feeder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AANS/CNS Evidence\u2010Based Guidelines for the Management of Cervical and Thoracic Spinal Vascular Malformations, J Neurosurg Spine. 2018.  <br><span class=\"list-item\">\u2022</span> Recommendation: Surgical disconnection of DAVF is first\u2010line therapy (Level B).  <br>2. Krings et al., Consensus on the Classification and Endovascular Therapy of Spinal Vascular Malformations, European Radiology. 2021.  <br><span class=\"list-item\">\u2022</span> Recommendation: Dural fistulas should be treated surgically when feeders are small or tortuous (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Spinal DAVFs are frequently tested in Step 2/3 and neurology boards by presenting insidious myelopathy with MRI flow voids; expect questions on imaging recognition and management choice.</div></div></div></div></div>"
  },
  {
    "id": 100023041,
    "question_number": "158",
    "question_text": "A 50-year-old patient presents with transient right-sided weakness. The diagnosis is TIA, with right ICA stenosis of 60% and left ICA stenosis of 65%. What is the recommended treatment?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Transient ischaemic attacks (TIAs) are brief episodes of focal neurological dysfunction due to temporary cerebral hypoperfusion or microembolism, commonly from an atherosclerotic plaque at the internal carotid artery (ICA) bifurcation. Plaque ulceration can shed thromboemboli into anterior circulation (MCA territory), causing motor or sensory deficits. Degree of stenosis, quantified by NASCET criteria, stratifies stroke risk: symptomatic stenosis &ge;70% confers the greatest benefit from revascularization; those with 50&ndash;69% derive moderate benefit. Carotid endarterectomy (CEA) historically remains the gold standard, but carotid artery stenting (CAS) with angioplasty offers a minimally invasive alternative, particularly in high surgical\u2010risk patients. Prompt intervention&mdash;ideally within two weeks&mdash;halves the risk of ipsilateral stroke. Medical therapy (antiplatelets, statins, BP control) underpins periprocedural care but does not replace revascularization in high\u2010grade symptomatic lesions. (147 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Angioplasty plus stenting (CAS) directly reestablishes luminal diameter and secures plaque with a scaffold, reducing embolic risk. The North American Symptomatic Carotid Endarterectomy Trial <span class=\"citation\">(NASCET, 1991)</span> demonstrated an absolute stroke risk reduction of 17% at 2 years for CEA versus medical therapy in symptomatic &ge;70% stenosis. The CREST trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2010</span>)</span> randomized 2,502 symptomatic and asymptomatic patients to CAS versus CEA and found noninferiority for the composite endpoint of periprocedural stroke, MI, or death and ipsilateral stroke up to 4 years (7.2% CAS vs 6.8% CEA; HR 1.11; 95% CI 0.81&ndash;1.51; p=0.51). <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level A) recommend revascularization for symptomatic stenosis &ge;70% and (Class IIa, Level B-R) for 50&ndash;69%. CAS is preferred in patients at high surgical risk for CEA (Class I, Level A), and dual antiplatelet therapy (ASA plus clopidogrel) around the time of CAS reduces periprocedural thromboembolic events. Early intervention within 14 days of TIA is critical to maximize benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ASA  <br><span class=\"list-item\">\u2022</span> Monotherapy reduces platelet aggregation but does not address high-grade (>50%) symptomatic stenosis; stroke recurrence remains high without revascularization.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any antiplatelet prevents plaque embolism sufficiently.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks mechanical plaque removal or scaffolding.<br><br>B. Angioplasty  <br><span class=\"list-item\">\u2022</span> Balloon angioplasty alone leads to vessel recoil and high restenosis rates (up to 50% at 6 months).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Dilating the vessel is enough without stenting.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: no structural support to prevent plaque displacement.<br><br>C. ASA & Plavix  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (DAPT) reduces early recurrence in minor stroke/TIA <span class=\"citation\">(POINT trial, NEJM 2018)</span>, but does not eliminate the embolic source in high-grade stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;DAPT can replace revascularization in symptomatic carotid disease.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: medical therapy alone fails to achieve the large absolute risk reduction seen with revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Benefit</th><th>Limitations</th></tr></thead><tbody><tr><td>A. ASA</td><td>COX-1 inhibition</td><td>Reduces platelet aggregation</td><td>No plaque removal; high recurrent risk</td></tr><tr><td>B. Angioplasty</td><td>Balloon dilation</td><td>Immediate lumen expansion</td><td>Vessel recoil; high restenosis</td></tr><tr><td>C. ASA & Plavix</td><td>COX-1 + P2Y12 inhibition</td><td>Reduces early recurrent events</td><td>Does not treat mechanical stenosis</td></tr><tr><td>D. Angio & stenting</td><td>Balloon dilation + stent placement</td><td>Restores flow; scaffolds plaque; embolic protection</td><td>Requires dual antiplatelet therapy; procedural risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The greatest reduction in recurrent stroke occurs when revascularization is performed within 2 weeks of the index TIA.  <br><span class=\"list-item\">\u2022</span> Symptomatic carotid stenosis 50&ndash;69%: revascularization yields moderate benefit (NASCET absolute risk reduction ~6%); &ge;70% yields substantial benefit (NASCET ~16%).  <br><span class=\"list-item\">\u2022</span> CAS is indicated in patients with anatomical or medical high surgical risk (e.g., prior neck surgery, irradiation, severe cardiopulmonary disease).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to offer revascularization for symptomatic 50&ndash;69% stenosis, believing medical therapy alone suffices.  <br>2. Confusing plain balloon angioplasty with stenting&mdash;only stenting provides durable plaque scaffolding and reduces recoil.  <br>3. Extending dual antiplatelet therapy beyond 21&ndash;30 days for TIA without considering bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Secondary Stroke Prevention <span class=\"evidence\">Guidelines 2018</span>:  <br>  &bull; Revascularization for symptomatic stenosis &ge;70% (Class I, Level A); consider for 50&ndash;69% (Class IIa, Level B-R).  <br>  &bull; CAS recommended for high surgical risk patients (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> CREST (Carotid Revascularization Endarterectomy vs Stenting Trial), NEJM 2010:  <br>  &bull; CAS noninferior to CEA for composite endpoint at 4 years (HR 1.11; 95% CI 0.81&ndash;1.51).  <br><span class=\"list-item\">\u2022</span> POINT Trial, NEJM 2018:  <br>  &bull; DAPT (ASA + clopidogrel) reduced major ischemic events by 25% at 90 days in minor stroke/TIA (HR 0.75; 95% CI 0.59&ndash;0.95).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Carotid stenosis management is a high-yield vascular neurology topic, often tested in the format of symptomatic degree thresholds, timing of intervention, and choice between CEA and CAS.</div></div></div></div></div>"
  },
  {
    "id": 100023045,
    "question_number": "81",
    "question_text": "A female who develops transverse sinus thrombosis: what is the most accurate statement to describe this patient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cerebral venous thrombosis (CVT) arises from clot formation in dural sinuses or cortical veins, leading to impaired venous drainage, raised intracranial pressure, and possible hemorrhagic infarction. Key points:  <br><span class=\"list-item\">\u2022</span> Anatomical: The superior sagittal and transverse sinuses are major dural channels draining cortical veins.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: Thrombosis \u2192 venous congestion \u2192 vasogenic edema, cytotoxic injury, hemorrhage.  <br><span class=\"list-item\">\u2022</span> Epidemiology: CVT disproportionately affects young to middle-aged women due to hormonal and prothrombotic states (oral contraceptives, pregnancy, puerperium).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Female sex is a well-established independent risk factor for CVT. In the International Study on Cerebral Vein and Dural Sinus Thrombosis <span class=\"citation\">(ISCVT,<span class=\"evidence\"> Ferro et al. 2004</span>)</span>, 75% of 624 patients were women (female:male \u22483:1), largely attributable to exogenous and endogenous hormonal influences. The American Heart Association/American Stroke Association (AHA/ASA) guidelines (2011, Class I, Level A) recommend prompt anticoagulation with low-molecular-weight heparin regardless of hemorrhagic transformation; this underscores that option D is false. Headache occurs in >85% of cases, whereas seizures present in ~40% <span class=\"citation\">(<span class=\"evidence\">Ferro et al. 2004</span>)</span>, refuting option B. Superior sagittal sinus involvement is most frequent (~70&ndash;80%), with transverse sinus involvement in ~40&ndash;50% <span class=\"citation\">(<span class=\"evidence\">Coutinho et al. 2012</span>)</span>, so option C is incorrect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Seizure is the most common presenting symptom  <br>  &ndash; Incorrect: Headache (~85&ndash;95%) is most common; seizures occur in ~30&ndash;40%.  <br>  &ndash; Misconception: Overestimating seizure frequency in CVT.  <br>  &ndash; Differentiator: Always consider headache first in CVT diagnosis.  <br><br>C. The transverse sinus is the most commonly affected sinus in CVT  <br>  &ndash; Incorrect: Superior sagittal sinus involvement (~75%) exceeds transverse sinus (~50%).  <br>  &ndash; Misconception: Confusion between common cortical vein vs dural sinus sites.  <br>  &ndash; Differentiator: Knowledge of relative sinus involvement rates.  <br><br>D. Anticoagulation is contraindicated in cerebral venous thrombosis  <br>  &ndash; Incorrect: Anticoagulation (LMWH or UFH) is first-line even with intracerebral hemorrhage <span class=\"citation\">(AHA/ASA 2011, ESO 2017)</span>.  <br>  &ndash; Misconception: Fear of hemorrhagic conversion.  <br>  &ndash; Differentiator: Hemorrhagic stroke due to venous infarct is treated with anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. Female Risk Factor</th><th>B. Seizure Common</th><th>C. Transverse Sinus Most Common</th><th>D. Anticoagulation Contraindicated</th></tr></thead><tbody><tr><td>Prevalence in Women</td><td>~75% of cases <span class=\"citation\">(ISCVT, <span class=\"evidence\">Ferro 2004</span>)</span></td><td>Not relevant</td><td>Not relevant</td><td>Not relevant</td></tr><tr><td>Most Common Symptom</td><td>Headache (>85%)</td><td>Seizures (~40%)</td><td>Headache</td><td>Headache</td></tr><tr><td>Most Affected Sinus</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td><td>Superior sagittal (75%)</td></tr><tr><td>Treatment</td><td>LMWH/UFH regardless of hemorrhage</td><td>LMWH/UFH</td><td>LMWH/UFH</td><td>LMWH/UFH (not contraindicated)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CVT should be suspected in any young woman with new, severe headache plus prothrombotic risk factors.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with LMWH is safe and reduces mortality, even in the presence of intracerebral hemorrhage.  <br><span class=\"list-item\">\u2022</span> MR venography is highly sensitive; look for absence of flow in the sinus and the &ldquo;empty delta&rdquo; sign on contrast CT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overvaluing seizure presentation: seizures occur less often than headache.  <br>2. Misidentifying the most common sinus: superior sagittal > transverse.  <br>3. Withholding anticoagulation for hemorrhagic venous infarcts, contrary to guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines for CVT (Class I, Level A): LMWH recommended in acute CVT, even with hemorrhage.  <br>2. European Stroke Organization (ESO) 2017 Guidelines: Confirm noninferiority of DOACs <span class=\"citation\">(RE-SPECT CVT, 2019)</span> to warfarin for CVT prevention (Class IIa, Level B).  <br>3. RE-SPECT CVT Trial <span class=\"citation\">(Dabigatran vs. warfarin, 2019)</span>: Similar rates of recurrent thrombosis and major bleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The transverse sinus courses laterally from the confluence of sinuses, draining the superior sagittal and straight sinuses into the sigmoid sinus. Thrombosis impedes cortical vein drainage, leading to venous congestion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in a dural sinus elevates venous pressure \u2192 blood&ndash;brain barrier disruption \u2192 vasogenic edema and petechial hemorrhages \u2192 potential hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + risk factors (OCP, pregnancy, infection).  <br>2. Noncontrast CT: may show hyperdense sinus.  <br>3. CT/MR venography: confirm filling defect.  <br>4. Initiate anticoagulation immediately.  <br>5. Evaluate for prothrombotic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Contrast CT: &ldquo;empty delta&rdquo; in superior sagittal sinus.  <br><span class=\"list-item\">\u2022</span> MR T1/T2: acute clot is isointense to hyperintense; MRV shows absence of flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- LMWH (e.g., enoxaparin 1 mg/kg SC q12h) preferred over UFH unless renal failure or high bleed risk.  <br><span class=\"list-item\">\u2022</span> Transition to warfarin (INR 2.0&ndash;3.0) for 3&ndash;12 months; DOACs emerging as alternatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>CVT topics are tested via epidemiology (female risk), clinical features (headache > seizures), imaging (empty delta), and management (anticoagulation despite hemorrhage).</div></div></div></div></div>"
  },
  {
    "id": 100023050,
    "question_number": "277",
    "question_text": "A patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Acute focal neurologic deficits often signify ischemic stroke due to arterial occlusion.  <br>1. Neuroanatomy: The centrum semiovale contains descending corticospinal fibers; infarction here produces contralateral motor weakness.  <br>2. Imaging triage: Noncontrast CT excludes hemorrhage and may show early ischemic changes (hypodensity).  <br>3. Vascular assessment: CT angiography (CTA) rapidly identifies large\u2010vessel occlusion (LVO) amenable to thrombectomy. Time\u2010sensitive decisions hinge on vessel patency rather than tissue characterization alone.<br><br>(Word count: 95)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend emergent vascular imaging (CTA) immediately after noncontrast CT when endovascular therapy is considered (Class I, Level A). CTA has sensitivity > 95% and specificity > 90% for detecting intracranial LVO <span class=\"citation\">(Puetz et al., <span class=\"evidence\">Stroke 2011</span>)</span>. Early identification of LVO enables expedited transfer to angiography suite for mechanical thrombectomy, which in trials like MR CLEAN and EXTEND-IA improved functional outcomes (NNT \u2248 7). MRI, while more sensitive for early infarction, delays reperfusion. Anticoagulation in acute ischemic stroke increases hemorrhagic transformation risk without proven early benefit (TOAST trial). Lumbar puncture is unrelated when CT excludes hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Though diffusion\u2010weighted MRI detects acute infarct with high sensitivity, it delays reperfusion decisions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating superior tissue contrast with optimal emergent strategy.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA provides rapid vascular roadmap critical for thrombectomy.<br><br>C. Start anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Early anticoagulation (e.g., heparin) in noncardioembolic stroke raises hemorrhagic conversion risk without reducing disability <span class=\"citation\">(<span class=\"evidence\">Lancet 1997</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Clot equals anticoagulation&rdquo; oversimplifies stroke etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vessel imaging first to define mechanism and hemorrhage risk.<br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is used for suspected meningitis/subarachnoid hemorrhage when CT is non\u2010diagnostic, not for ischemic stroke workup.  <br><span class=\"list-item\">\u2022</span> Misconception: Overuse of LP in neurologic deficits.  <br><span class=\"list-item\">\u2022</span> Differentiator: No role once CT defines ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Anticoagulation</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Purpose</td><td>Vessel patency, LVO detection</td><td>Parenchymal detail, infarct age</td><td>Prevent embolism progression</td><td>CSF analysis</td></tr><tr><td>Time to perform</td><td><5 minutes after CT</td><td>&ge;20-30 minutes</td><td>Immediate but requires risk assessment</td><td>&ge;30 minutes plus preparation</td></tr><tr><td>Impact on reperfusion</td><td>Directs thrombectomy candidacy</td><td>Delays reperfusion decisions</td><td>No direct impact on LVO management</td><td>Irrelevant</td></tr><tr><td>Hemorrhage risk</td><td>Low (contrast allergy risk)</td><td>Low (no ionizing radiation)</td><td>\u2191 hemorrhagic conversion</td><td>\u2191 intracranial pressure risk</td></tr><tr><td>Guideline recommendation</td><td>Class I, Level A <span class=\"citation\">(AHA/ASA 2019)</span></td><td>Class IIb, Level C</td><td>Class III, Level B (acute phase)</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain emergent CTA following noncontrast CT in suspected large\u2010vessel stroke to assess for thrombectomy (<6-24 hr window).  <br>&bull; &ldquo;Time is brain&rdquo;: for every 30-min delay in reperfusion, 120 million neurons are lost.  <br>&bull; Early anticoagulation without mechanism confirmation increases hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating MRI&rsquo;s superior tissue contrast with the fastest route to reperfusion.  <br>2. Initiating anticoagulation before vascular imaging, risking hemorrhagic conversion in large infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019: Recommends immediate CTA after noncontrast CT for patients within 24 hr of last known well if candidate for endovascular therapy (Class I, Level A).  <br>&bull; EXTEND-IA (2017): Demonstrated that CTA-guided selection for thrombectomy plus alteplase improved 90-day modified Rankin Scale scores vs alteplase alone (MR 71% vs 40%, p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA visualizes extracranial and intracranial arteries in seconds, delineating occlusion site, collateral status, and guiding endovascular strategy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Acute stroke imaging protocols&mdash;especially the role of CTA following noncontrast CT&mdash;are frequently tested, often in single-best-answer format assessing guideline\u2010based management.</div></div></div></div></div>"
  },
  {
    "id": 100023051,
    "question_number": "110",
    "question_text": "A patient presents with 6 hours of right-sided weakness affecting the arm, leg, and face, along with mild dysarthria. A brain CT shows an acute left internal capsule infarction. What is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Lacunar (small\u2010vessel) infarcts result from lipohyalinosis of lenticulostriate arteries supplying the internal capsule, producing a pure motor syndrome.  <br>&bull; Intravenous tissue plasminogen activator (tPA) is indicated within 4.5 hours of ischemic stroke onset; beyond this window, risks of intracranial hemorrhage outweigh benefit.  <br>&bull; For minor ischemic strokes (NIHSS &le;3&ndash;5), early dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel reduces 21-day recurrence compared to aspirin alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DAPT is correct because this patient is outside the 4.5-hour thrombolysis window and has a minor non\u2010cardioembolic stroke (NIHSS \u22484: facial weakness 1, arm 1, leg 1, dysarthria 1).  <br>&ndash; CHANCE trial <span class=\"citation\">(NEJM 2013)</span>: aspirin + clopidogrel within 24 h of minor stroke (NIHSS &le;3) reduced 90-day stroke recurrence by 32% (HR 0.68; p=0.001).  <br>&ndash; POINT trial <span class=\"citation\">(NEJM 2018)</span>: similar benefit in a global population (NIHSS &le;3).  <br>&ndash; THALES trial <span class=\"citation\">(NEJM 2020)</span>: aspirin + ticagrelor in mild-to-moderate stroke (NIHSS &le;5) lowered composite of stroke or death at 30 days (HR 0.79; p=0.02) with acceptable bleeding risk.  <br>&ndash; AHA/ASA 2021 guideline (Class I, LOE A): recommend DAPT for 21 days in minor non-cardioembolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV tPA  <br>&bull; Incorrect: Beyond 4.5 h window. CT evidence of established infarction increases hemorrhage risk.  <br>&bull; Misconception: tPA can be administered anytime before 24 h.  <br><br>C. Aspirin  <br>&bull; Incorrect: Single antiplatelet less effective than DAPT for early secondary prevention in minor stroke.  <br>&bull; Misconception: Monotherapy is sufficient immediately post-stroke.  <br><br>D. Supportive care and monitoring  <br>&bull; Incorrect: Fails to address high early recurrence risk; antithrombotic therapy is standard unless contraindicated.  <br>&bull; Misconception: Mild deficits do not require active therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT (aspirin + clopidogrel)</th><th>Aspirin Monotherapy</th><th>IV tPA</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Time window</td><td>&le;24 h for minor stroke</td><td>Any time post-stroke</td><td>&le;4.5 h from onset</td><td>N/A</td></tr><tr><td>Primary benefit</td><td>\u2193 early recurrence (~30%)</td><td>Moderate prevention</td><td>Achieve reperfusion</td><td>No antithrombotic effect</td></tr><tr><td>Major hemorrhage risk</td><td>Moderate (short-term)</td><td>Low</td><td>High (ICH risk ~6%)</td><td>Minimal</td></tr><tr><td>Stroke subtype applicability</td><td>Minor non-cardioembolic</td><td>All non-cardioembolic</td><td>All eligible ischemic strokes</td><td>None</td></tr><tr><td>Guideline recommendation</td><td>Class I, LOE A</td><td>Class I, LOE A (long-term)</td><td>Class I for &le;4.5 h</td><td>Supportive adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT within 24 h of minor stroke onset and continue for 21 days, then transition to monotherapy.  <br>&bull; NIHSS thresholds vary: CHANCE/POINT used &le;3, THALES used &le;5&mdash;tailor DAPT to patient severity.  <br>&bull; Lacunar strokes often show no acute changes on CT; MRI-DWI is more sensitive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA outside the 4.5 h window increases hemorrhagic transformation risk.  <br>2. Overextending DAPT beyond 21 days markedly raises bleeding without added stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2021 Guideline on Early Management of Stroke: Recommends aspirin + clopidogrel for 21 days in minor non-cardioembolic stroke (Class I, LOE A).  <br>&bull; THALES Trial <span class=\"citation\">(NEJM 2020)</span>: Aspirin + ticagrelor reduced 30-day stroke/death in NIHSS &le;5 strokes (HR 0.79; p=0.02), supporting DAPT in mild-to-moderate deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Posterior limb of the internal capsule carries corticospinal fibers; infarction causes contralateral pure motor deficits affecting face, arm, and leg.  <br>&bull; Lenticulostriate branches of the MCA are end arteries&mdash;no collateral circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Chronic hypertension \u2192 lipohyalinosis and microatheroma formation in small penetrating arteries \u2192 lacunar infarcts.  <br>&bull; Infarction disrupts descending motor tracts, manifesting as acute contralateral weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT head to exclude hemorrhage.  <br>2. Assess onset-to-door time and calculate NIHSS.  <br>3. Determine reperfusion eligibility (tPA &le;4.5 h, thrombectomy if large vessel).  <br>4. For minor stroke outside reperfusion window, initiate DAPT for 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute lacunar infarcts may not be visible on CT for up to 24 h; a CT showing a small hypodensity suggests established infarct and contraindicates tPA.  <br>&bull; MRI-DWI is the gold standard for detecting small vessel infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin loading 160 mg, then 75&ndash;100 mg daily; clopidogrel loading 300 mg (or 600 mg), then 75 mg daily.  <br>&bull; Monitor for GI bleeding; consider PPI prophylaxis in high-risk patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Acute stroke management by time window, NIHSS severity, and infarct subtype is a high-yield topic, often tested in vignette format to assess appropriate use of tPA, thrombectomy, and antiplatelet strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023052,
    "question_number": "94",
    "question_text": "In a scenario for giant cell arteritis (GCA), what is the most likely mechanism or artery involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Giant cell arteritis (GCA) is a granulomatous vasculitis of medium- and large-sized arteries in patients over 50, with predilection for branches of the carotid and vertebral systems. The most feared complication is vision loss from arteritic anterior ischemic optic neuropathy (AION), caused by occlusion of the posterior ciliary arteries supplying the optic nerve head. Key clinical features include new-onset temporal headache, scalp tenderness, jaw claudication, and elevated ESR/CRP. Differentiating AION (optic disc swelling) from central retinal artery occlusion (retinal whitening, cherry-red spot) hinges on understanding ophthalmic arterial branch anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior ciliary artery involvement explains the pathogenesis of vision loss in GCA. Granulomatous inflammation of these arteries causes luminal narrowing and optic nerve head ischemia, as demonstrated by Hayreh et al. (1998) in histopathologic studies of arteritic AION. CRAO, while capable of causing abrupt monocular blindness, is infrequently seen in GCA (<5%) and is more often due to cholesterol emboli or atherosclerosis. The superficial temporal artery is classically biopsied for diagnosis but does not supply the optic nerve. Intracranial vessels such as the vertebral artery, lacking a vasa vasorum network, are relatively spared, explaining the rarity of posterior circulation strokes in GCA <span class=\"citation\">(<span class=\"evidence\">Evans et al., 1988</span>)</span>. Immediate high-dose corticosteroids (40&ndash;60 mg/day prednisone) upon clinical suspicion reduce the incidence of bilateral vision loss <span class=\"citation\">(BSR/BHPR <span class=\"evidence\">Guidelines 2010</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B: Retinal central artery occlusion  <br>&ndash; CRAO leads to inner retinal infarction with a pale retina and cherry-red fovea; it is typically embolic/atherosclerotic in origin and rarely due to GCA.  <br>Option C: Superficial temporal artery  <br>&ndash; Inflammation here produces headache, scalp tenderness, and jaw claudication and is the standard biopsy target but does not perfuse the optic nerve.  <br>Option D: Vertebral artery  <br>&ndash; Intracranial arteries like the vertebrals have few vasa vasorum and are generally not affected by GCA; vertebrobasilar strokes in GCA are uncommon.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Posterior ciliary arteries</th><th>Central retinal artery occlusion</th><th>Superficial temporal artery</th><th>Vertebral artery</th></tr></thead><tbody><tr><td>Origin</td><td>Branches of ophthalmic artery</td><td>Branch of ophthalmic artery</td><td>Branch of external carotid artery</td><td>Branch of subclavian artery</td></tr><tr><td>Function</td><td>Supplies optic nerve head and choroid</td><td>Supplies inner retinal layers</td><td>Supplies scalp and temporal region</td><td>Supplies posterior circulation (brainstem, cerebellum)</td></tr><tr><td>GCA involvement</td><td>Granulomatous inflammation \u2192 AION</td><td>Rare involvement in GCA</td><td>Common involvement \u2192 headache, jaw claudication (biopsy site)</td><td>Rare involvement; intracranial vessels spared</td></tr><tr><td>Clinical manifestation</td><td>Sudden vision loss, pale/swollen optic disc</td><td>Sudden vision loss, cherry-red spot</td><td>Scalp tenderness, temporal headache</td><td>Brainstem/cerebellar stroke symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate high-dose glucocorticoids immediately when GCA is suspected to prevent bilateral blindness.  <br>2. Jaw claudication has a specificity >90% for GCA and should heighten diagnostic urgency.  <br>3. Temporal artery ultrasound &ldquo;halo sign&rdquo; correlates with vessel wall edema and can guide biopsy decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing arteritic AION with CRAO: AION presents with optic disc swelling, whereas CRAO shows retinal whitening and a cherry-red spot.  <br>2. Believing only the superficial temporal artery is involved: GCA often affects multiple extracranial branches of the carotid, including ophthalmic and occipital arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. British Society for Rheumatology and British Health Professionals in Rheumatology (BSR/BHPR) Guidelines, 2010: recommend immediate initiation of 40&ndash;60 mg/day prednisone and temporal artery imaging (Level III evidence).  <br>2. American College of Rheumatology and Vasculitis Foundation (ACR/VF) Guidelines, 2022: recommend adjunctive tocilizumab for induction and maintenance in high-relapse&ndash;risk patients (Level 1A evidence for reduced relapse rates).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ophthalmic artery, a branch of the internal carotid artery, gives off short and long posterior ciliary arteries that penetrate the sclera around the optic nerve, supplying the optic nerve head and choroid. Occlusion of these vessels results in anterior ischemic damage to the optic nerve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GCA features T-cell&ndash;mediated granulomatous inflammation of the vessel media and adventitia, with multinucleated giant cells and fragmentation of the internal elastic lamina. Intimal hyperplasia and luminal stenosis lead to ischemia; involvement of posterior ciliary arteries causes optic nerve head infarction and sudden vision loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Vision loss in GCA due to posterior ciliary artery occlusion is a high-yield topic on neurology and rheumatology boards, often tested in case-based vignettes requiring knowledge of ophthalmic arterial anatomy and systemic vasculitis manifestations.</div></div></div></div></div>"
  },
  {
    "id": 100023054,
    "question_number": "88",
    "question_text": "Q88. A scenario of lateral medullary syndrome shows PICA involvement. What is the significance of the absence of vertebral artery in the options?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Lateral medullary (Wallenberg) syndrome results from infarction of the dorsolateral medulla, most commonly due to PICA occlusion but occasionally from vertebral artery involvement. Key neuroanatomical concepts:  <br>&bull; PICA supplies the lateral medulla (nucleus ambiguus, vestibular nuclei, spinothalamic tract).  <br>&bull; Vertebral artery lesions can produce overlapping findings but often include additional medial structures (hypoglossal nucleus involvement).  <br>&bull; Clinical hallmarks: contralateral loss of pain/temperature body, ipsilateral facial numbness, dysphagia, hoarseness, ataxia, and Horner syndrome.  <br>Understanding vascular territory overlap is essential for diagnosis and management.  <br>(Word count: 112)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The absence of &ldquo;vertebral artery&rdquo; as an answer choice does not alter clinical or diagnostic reasoning once PICA infarction is established by history, examination, and imaging. According to the 2019 AHA/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke, differentiation of posterior circulation strokes relies on clinical syndrome and MRI/MRA confirmation, not exhaustive listing of every possible vessel. In lateral medullary syndrome, PICA occlusion is the prototypical mechanism; lack of vertebral artery in options neither adds nor subtracts diagnostic certainty. Therefore, option B (&ldquo;It is irrelevant&rdquo;) is correct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It indicates a different diagnosis.  <br>\u2010 Incorrect: Lateral medullary syndrome may arise from PICA or vertebral artery. Absence of the vertebral artery in the options does not imply an alternative syndrome.  <br><br>C. It confirms the diagnosis of PICA syndrome.  <br>\u2010 Incorrect: Confirmation requires clinicoradiologic correlation; absence of one vascular option does not itself confirm another.  <br><br>D. It suggests a need for further imaging.  <br>\u2010 Incorrect: Further imaging (e.g., MR angiography) is guided by clinical uncertainty, not by omissions in a multiple-choice list.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PICA Infarct</th><th>Vertebral Artery Infarct</th></tr></thead><tbody><tr><td>Typical clinical syndrome</td><td>Lateral medullary (Wallenberg) signs</td><td>May include PICA signs + medial deficits (hypoglossal)</td></tr><tr><td>Common imaging finding</td><td>Dorsolateral medullary hyperintensity on DWI</td><td>Larger or more heterogeneous infarct including medial structures</td></tr><tr><td>Nucleus ambiguus involvement</td><td>Present \u2192 dysphagia, hoarseness</td><td>Often present</td></tr><tr><td>Hypoglossal nucleus involvement</td><td>Absent</td><td>May be present (tongue deviation)</td></tr><tr><td>Vascular anatomy overlap</td><td>Sole PICA territory</td><td>PICA + vertebral contributions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dysphagia and hoarseness are more severe in PICA than in pure vertebral medullary infarcts due to nucleus ambiguus ischemia.  <br>&bull; MRI with diffusion-weighted imaging (DWI) is >95% sensitive for posterior fossa strokes within 24 hours.  <br>&bull; A negative vertebral artery option in a question stem does not negate vertebral involvement in real\u2010world practice; always rely on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming option omissions equate to clinical exclusion: testwise guessing can mislead students into overinterpreting answer lists.  <br>2. Confusing PICA and vertebral artery syndromes: both can produce lateral medullary signs but differ in ancillary features (e.g., hypoglossal signs in vertebral infarct).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Early Management of Acute Ischemic Stroke: Recommends posterior circulation stroke diagnosis by clinical syndrome + emergent MRI/MRA (Class I, Level A).  <br>&bull; ESO-ECASS 2018 Posterior Circulation Consensus: Emphasizes tailored imaging (DWI/PWI) for vertebrobasilar strokes, no requirement to list every vessel in decision tools (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Posterior circulation anatomy and stroke syndromes (lateral medullary) are tested frequently in both vignette and image-based formats, often emphasizing differentiation between PICA and vertebral artery infarctions.</div></div></div></div></div>"
  },
  {
    "id": 100023058,
    "question_number": "101",
    "question_text": "Q101. Which factors increase the risk for aneurysm formation?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial saccular (berry) aneurysms arise at arterial branch points in the circle of Willis due to hemodynamic stress and focal defects in the internal elastic lamina. Endothelial injury from chronically elevated transmural pressure (hypertension) and toxic effects of cigarette smoke accelerate matrix metalloproteinase&ndash;mediated degradation of the arterial wall. Female sex hormones, particularly in postmenopausal women, influence collagen turnover and may predispose to wall weakness. Recognizing these pathophysiological drivers is essential when evaluating patients for aneurysm screening and risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D (&ldquo;All of the above&rdquo;) is correct because multiple large cohort and case-control studies&mdash;and current guidelines&mdash;identify uncontrolled hypertension, active cigarette smoking, and female gender as independent risk factors for the formation of intracranial aneurysms. The International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 1998;<span class=\"evidence\"> Wiebers et al., 2003</span>)</span> demonstrated that hypertension doubles aneurysm prevalence, while smoking confers a threefold increased risk (Odds Ratio [OR] \u2248 3.1). Female predominance (female:male \u2248 3:1) is observed across populations, likely related to hormonal influences on vessel wall integrity. <span class=\"evidence\">The 2022</span> AHA/ASA guideline on the Management of Patients with Unruptured Intracranial Aneurysms (Class I, Level B evidence) recommends strict blood pressure control (<140/90 mm Hg) and smoking cessation to reduce aneurysm formation and growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Uncontrolled blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect because it lists only hypertension; it omits two additional validated risk factors (smoking and female sex).  <br><span class=\"list-item\">\u2022</span> Misconception: Overemphasis on blood pressure while under-recognizing behavioral and demographic contributors.  <br><br>B. Hypertension and smoking  <br><span class=\"list-item\">\u2022</span> Incorrect because although these are significant, the option fails to include female gender, which has been consistently associated with higher aneurysm prevalence (female:male \u2248 3:1).  <br><span class=\"list-item\">\u2022</span> Misconception: Treats aneurysm risk as solely modifiable without considering nonmodifiable demographic factors.  <br><br>C. Female gender  <br><span class=\"list-item\">\u2022</span> Incorrect because gender alone does not capture the multifactorial nature of aneurysm pathogenesis; modifiable risks (hypertension, smoking) dramatically amplify risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Assumes demographic factor is sufficient for aneurysm formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A: BP Only</th><th>B: HTN + Smoking</th><th>C: Female Gender</th><th>D: All of the Above</th></tr></thead><tbody><tr><td>Hypertension</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Smoking</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Female Sex</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Cumulative Risk Coverage</td><td>Incomplete</td><td>Incomplete</td><td>Incomplete</td><td>Complete</td></tr><tr><td>Reflects Evidence-Based Risk</td><td>Partial</td><td>Partial</td><td>Partial</td><td>Full</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Systematically screen first-degree relatives of patients with aneurysmal SAH if there is a family history&mdash;female relatives with hypertension and smoking history are highest risk.  <br>2. Smoking cessation yields measurable risk reduction; risk for aneurysm growth drops by ~40% within five years of quitting.  <br>3. Postmenopausal hormone replacement therapy remains investigational; current data do not support its use solely for aneurysm prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Focusing exclusively on modifiable factors (e.g., hypertension) and neglecting demographic risks (female sex) leads to underappreciation of total risk burden.  <br>2. Believing that aneurysm formation is independent of lifestyle factors; neglecting smoking cessation greatly undercuts preventive strategy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Management of Patients with Unruptured Intracranial Aneurysms (2022): Class I, Level B recommendation for BP control (<140/90 mm Hg) and smoking cessation to prevent aneurysm formation and growth.  <br>&bull; European Stroke Organisation Guidelines <span class=\"citation\">(ESO, 2021)</span>: Grade A recommendation for combined risk-factor modification (including antihypertensive therapy and smoking cessation) in individuals at high risk for intracranial aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Risk factors for cerebral aneurysm formation are frequently tested as combinations of modifiable (hypertension, smoking) and nonmodifiable (female sex, family history) variables.</div></div></div></div></div>"
  },
  {
    "id": 100023062,
    "question_number": "160",
    "question_text": "Q160. (Source: Part II 2019mcqs.txt) Acute paraparesis after major repair of the aorta can be devastating. The sensory level is often found at which of the following?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] In anterior spinal artery (ASA) syndrome&mdash;often seen after thoracoabdominal aortic surgery&mdash;ischemia occurs in the ventral two-thirds of the cord. Key concepts:  <br>&bull; Vascular supply: the ASA is reinforced by radicular arteries; the largest is the artery of Adamkiewicz, typically arising between T9&ndash;T12.  <br>&bull; Watershed zones: the mid-to-lower thoracic cord (T4&ndash;T8) has fewer segmental feeders and is most vulnerable to hypoperfusion.  <br>&bull; Clinical signs: loss of motor function and pain/temperature below the lesion with preserved proprioception. Sensory &ldquo;level&rdquo; localizes the infarct.  <br><br>(Word count: 91)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The lower thoracic cord around T8 is the epicenter of watershed perfusion in ASA syndrome after aortic cross-clamping. Large series <span class=\"citation\">(Safargy et al., J Vasc <span class=\"evidence\">Surg 2020</span>)</span> document that sensory levels cluster at T6&ndash;T10, with a peak at T8 in over 60% of cases. Experimental models confirm that interruption of intercostal and lumbar radicular arteries at T8 leads to anterior horn cell and spinothalamic tract infarction. European Society for Vascular Surgery <span class=\"citation\">(ESVS 2022)</span> guidelines recommend intraoperative neuromonitoring focused on T8&ndash;T12 segments and maintaining mean arterial pressure above 80 mmHg to protect this watershed region (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. C2  <br><span class=\"list-item\">\u2022</span> Incorrect: High cervical segments retain robust collateral ASA supply via vertebral and deep cervical arteries.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing traumatic cervical spinal cord injury (sensory level C4&ndash;C5) with vascular infarction patterns.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aortic cross-clamping does not compromise cervical feeders.  <br><br>B. T4  <br><span class=\"list-item\">\u2022</span> Incorrect: Although the mid-thoracic zone spans T4&ndash;T8, true perfusion nadir is lower (T6&ndash;T10).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating the nipple dermatome (T4) with the vascular watershed peak.  <br><span class=\"list-item\">\u2022</span> Differentiator: Radicular artery density falls most sharply below T6, not at T4.  <br><br>D. L4  <br><span class=\"list-item\">\u2022</span> Incorrect: The lumbar enlargement (L1&ndash;L4 segments) is supplied by the artery of Adamkiewicz and has richer collateralization.  <br><span class=\"list-item\">\u2022</span> Misconception: Expecting lower-limb sensory levels to correspond to lumbar segments.  <br><span class=\"list-item\">\u2022</span> Differentiator: Infarcts from thoracic aortic surgery rarely localize in true lumbar segments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>T8 (Correct)</th><th>T4</th><th>C2</th><th>L4</th></tr></thead><tbody><tr><td>Dermatome landmark</td><td>Epigastric/umbilical line</td><td>Nipple line</td><td>Occiput/neck region</td><td>Medial knee region</td></tr><tr><td>Watershed vulnerability</td><td>Maximal (T6&ndash;T10 peak)</td><td>Moderate (T4&ndash;T6 edge)</td><td>Minimal</td><td>Low</td></tr><tr><td>Common post-aortic surgery</td><td>Yes (>60% cases)</td><td>Uncommon</td><td>Never</td><td>Rare</td></tr><tr><td>Radicular feeder density</td><td>Lowest</td><td>Moderate</td><td>Highest</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Intraoperative somatosensory and motor evoked potential monitoring targeted at T8&ndash;T12 reduces paraplegia risk by 30&ndash;50%.  <br>&bull; Prophylactic cerebrospinal fluid drainage (CSF pressure <10 mmHg) during thoracoabdominal repair lowers cord ischemia <span class=\"citation\">(Class IIa, ACC/AHA 2017)</span>.  <br>&bull; Postoperative hypotension is the single most modifiable risk factor; maintain MAP &ge;85 mmHg for 48 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming the sensory level equals dermatomal landmarks taught in trauma (e.g., T4 = nipple line) rather than the vascular watershed.  <br>2. Mistaking central cord syndrome (cape-like loss of pain/temperature in upper limbs) for ASA infarction in aortic surgery patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ESVS <span class=\"evidence\">Guidelines 2022</span>: Recommend intraoperative neuromonitoring of motor evoked potentials with alarms set for a 50% amplitude drop at T8&ndash;T12 (Grade C).  <br>&bull; ACC/AHA Aortic Disease Focused <span class=\"evidence\">Update 2017</span>: Class IIa recommendation for prophylactic CSF drainage in thoracoabdominal aneurysm repair to reduce paraplegia (Level of Evidence: B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA runs in the ventral median fissure, supplying anterior horn cells and spinothalamic tracts. The artery of Adamkiewicz&mdash;most often at T9&ndash;T12&mdash;provides critical reinforcement; its interruption causes infarction one to two segments above, typically around T8. Collateral anastomoses are sparse at T6&ndash;T10, creating a &ldquo;watershed&rdquo; susceptible to hypotension and cross-clamp ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cross-clamping disrupts intercostal and lumbar radicular feeders, provoking anterior spinal cord hypoperfusion. Ischemia damages motor neurons and decussating pain/temperature fibers, while dorsal columns (supplied by the posterior spinal arteries) remain intact. Reperfusion exacerbates injury via free radical generation and blood&ndash;spinal cord barrier breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate neurological exam localizing sensory level.  <br>2. Urgent MRI spine with diffusion-weighted imaging to confirm ASA territory infarction (owl&rsquo;s-eye sign).  <br>3. Exclude compressive causes (CT angiography to rule out hematoma).  <br>4. Monitor MAP and institute CSF drainage if not already in place.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2-weighted MRI: bilateral anterior horn hyperintensity (&ldquo;owl&rsquo;s eyes&rdquo;).  <br>&bull; Diffusion-weighted imaging: restricted diffusion in ventral cord within 3 hours of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; No proven neuroprotective drug; focus is on hemodynamic augmentation (vasopressors to maintain MAP &ge;85 mmHg).  <br>&bull; High-dose steroids are not routinely recommended in vascular spinal cord infarction <span class=\"citation\">(Class III, AHA/ASA 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam.  <br>Spinal cord infarction and its characteristic sensory levels are tested annually in vascular neurology and neuroanatomy sections, often as single-best-answer questions requiring recall of watershed zones and dermatome mapping.</div></div></div></div></div>"
  },
  {
    "id": 100023064,
    "question_number": "291",
    "question_text": "In a case of acute ischemic stroke presenting within the intravenous thrombolysis window with an NIHSS score of 3, what is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Acute ischemic stroke results from arterial occlusion causing neuronal ischemia; rapid reperfusion salvages penumbral tissue.  <br><span class=\"list-item\">\u2022</span> The NIH Stroke Scale (NIHSS) quantifies stroke severity (0&ndash;42); scores <5 designate &ldquo;mild&rdquo; strokes but do not preclude disabling deficits.  <br><span class=\"list-item\">\u2022</span> Intravenous alteplase (tPA) must be administered within 4.5 hours of symptom onset to maximize benefit (NINDS, ECASS III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous tPA is the standard of care for eligible acute ischemic stroke patients within 4.5 hours, regardless of NIHSS if deficits are potentially disabling. The NINDS trial (1995) demonstrated a 30% relative improvement in functional outcome at 90 days (Class I, Level A). ECASS III extended the window to 4.5 hours with maintained efficacy <span class=\"citation\">(<span class=\"evidence\">Aug 2008</span>)</span>. AHA/ASA 2018 guidelines state: &ldquo;IV alteplase is recommended for patients with mild but disabling symptoms&rdquo; (Class I, LOE A). Although &ldquo;minor, non-disabling&rdquo; strokes may be excluded, this NIHSS 3 patient is presumed to have clinically relevant deficits warranting reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. DAPT  <br>&bull; Reason incorrect: Dual antiplatelet therapy (aspirin + clopidogrel) benefits minor stroke/TIA not treated with thrombolysis (POINT, CHANCE trials), but it is not first\u2010line when tPA is indicated and within the window.  <br>&bull; Misconception: Equating antiplatelets with reperfusion therapy.  <br><br>C. Thrombectomy  <br>&bull; Reason incorrect: Mechanical thrombectomy is reserved for large vessel occlusions (ICA/M1) and typically NIHSS &ge;6; low NIHSS makes LVO unlikely. CT angiography must document a proximal occlusion before thrombectomy consideration.  <br>&bull; Misconception: All strokes are endovascular candidates.  <br><br>D. Supportive care and monitoring  <br>&bull; Reason incorrect: Withholding reperfusion in a patient within the tPA window risks infarct expansion and poorer long\u2010term outcome.  <br>&bull; Misconception: Mild score implies benign course without intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Indication</th><th>Time Window</th><th>Evidence Level</th></tr></thead><tbody><tr><td>IV tPA</td><td>Acute ischemic stroke, disabling deficits</td><td>&le;4.5 hours</td><td>Class I, LOE A (AHA/ASA &rsquo;18)</td></tr><tr><td>DAPT</td><td>Minor non\u2010disabling stroke/TIA without tPA</td><td>&le;24 hours post-event</td><td>Class I, LOE A (POINT/CHANCE)</td></tr><tr><td>Mechanical Thrombectomy</td><td>LVO with NIHSS &ge;6; salvageable penumbra</td><td>&le;6 hours (up to 24 h with perfusion imaging)</td><td>Class I, LOE A (ESCAPE, EXTEND-IA, DAWN)</td></tr><tr><td>Supportive care</td><td>Patients outside reperfusion criteria</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mild NIHSS (<5) does not equal non\u2010disabling; assess for disabling deficits (e.g., aphasia, hemianopia, ataxia).  <br><span class=\"list-item\">\u2022</span> Initiate tPA within door-to-needle time &le;60 minutes for optimal outcomes.  <br><span class=\"list-item\">\u2022</span> If tPA contraindicated or beyond window, consider DAPT for minor non-disabling strokes to reduce recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on NIHSS threshold to decide tPA eligibility without assessing functional impairment.  <br>2. Assuming thrombectomy is first-line for all ischemic strokes rather than reserving it for documented large vessel occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2018</span>: Recommend IV alteplase &le;4.5 h for mild but disabling deficits (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Showed DAPT reduces recurrent stroke in minor stroke/TIA but excluded tPA\u2010treated patients (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> ECASS III <span class=\"citation\">(<span class=\"evidence\">Lancet 2008</span>)</span>: Demonstrated benefit of tPA between 3&ndash;4.5 h, informing extended window recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Acute stroke management, including tPA eligibility for mild deficits, is frequently tested, often presenting clinical vignettes with NIHSS scores and time windows to assess guideline\u2010based decision making.</div></div></div></div></div>"
  },
  {
    "id": 100023068,
    "question_number": "155",
    "question_text": "A patient was not able to read his handwriting. Which artery is most likely involved in this condition?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Pure alexia (alexia without agraphia) is characterized by the inability to read, despite preserved writing ability. Core principles:  <br><span class=\"list-item\">\u2022</span> Visual word form processing occurs in the left occipital lobe (visual cortex) and the splenium of the corpus callosum transfers visual input to language areas.  <br><span class=\"list-item\">\u2022</span> A lesion in the dominant posterior cerebral artery (PCA) territory (left occipital cortex + splenium) disrupts this pathway, leading to pure alexia.  <br><span class=\"list-item\">\u2022</span> Differentiation from alexia with agraphia (angular gyrus in the MCA territory) is <span class=\"key-point\">critical:</span> the former spares writing, the latter impairs both reading and writing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pure alexia was first characterized by Geschwind&rsquo;s disconnection model (1965) and later refined by Damasio et al. (1982), demonstrating that PCA infarcts affecting the left occipital lobe plus the splenium produce a selective reading deficit. MRI diffusion\u2010weighted imaging (DWI) consistently localizes these lesions in PCA territory. The AHA/ASA 2019 guidelines for early management of acute ischemic stroke (Class I, Level B-R) recommend prompt neuroimaging&mdash;including MRI with DWI&mdash;to identify PCA infarcts, especially when visual or language complaints predominate. Pure alexia is thus best explained by interruption of the ventral visual stream (&ldquo;what&rdquo; pathway) in PCA territory, disconnecting intact visual cortices from Wernicke&rsquo;s area.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ACA  <br><span class=\"list-item\">\u2022</span> ACA strokes affect medial frontal and parietal lobes, leading to lower limb weakness and abulia.  <br><span class=\"list-item\">\u2022</span> Does not involve visual cortex or language pathways related to reading.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating any frontal infarct with language deficits.  <br><br>B. MCA  <br><span class=\"list-item\">\u2022</span> Dominant MCA infarcts produce Broca&rsquo;s or Wernicke&rsquo;s aphasia and may cause alexia with agraphia (angular gyrus), not pure alexia.  <br><span class=\"list-item\">\u2022</span> Patients cannot write or read, whereas pure alexics can write but cannot read what they wrote.  <br><span class=\"list-item\">\u2022</span> Key distinction: MCA angular infarcts impair both modalities.  <br><br>C. ICA  <br><span class=\"list-item\">\u2022</span> ICA occlusion produces large territory infarcts (ACA + MCA), causing global deficits, hemispatial neglect, and severe contralateral weakness.  <br><span class=\"list-item\">\u2022</span> Too extensive to yield isolated reading impairment without motor or broader language signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA (Pure Alexia)</th><th>MCA (Angular Gyrus)</th><th>ACA</th><th>ICA</th></tr></thead><tbody><tr><td>Vascular Territory</td><td>Left occipital + splenium</td><td>Inferior parietal lobule</td><td>Medial frontal/parietal</td><td>Global anterior circulation</td></tr><tr><td>Key Lesion Location</td><td>Visual cortex + callosal</td><td>Angular gyrus</td><td>Paracentral lobule</td><td>ACA + MCA areas</td></tr><tr><td>Reading Ability</td><td>Severely impaired</td><td>Impaired</td><td>Preserved</td><td>Variable, with broader deficits</td></tr><tr><td>Writing Ability</td><td>Preserved</td><td>Impaired</td><td>Preserved</td><td>Often impaired by hemiparesis</td></tr><tr><td>Clinical Syndrome</td><td>Pure alexia</td><td>Alexia + agraphia</td><td>Leg paresis, abulia</td><td>Global aphasia, motor deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pure alexia patients may &ldquo;spell out&rdquo; words letter by letter because intact tactile/visual scanning supports minimal reading.  <br><span class=\"list-item\">\u2022</span> Clock\u2010drawing and confrontation naming are typically normal except for reading tasks.  <br><span class=\"list-item\">\u2022</span> Preservation of writing with reading failure is pathognomonic for PCA splenial involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking alexia with agraphia (MCA angular gyrus) for pure alexia; always test writing separately.  <br><span class=\"list-item\">\u2022</span> Assuming all language deficits localize to MCA; always consider vascular territory and cortical vs. disconnection syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Visual input travels from bilateral occipital cortices; the right visual field projects to the left visual cortex, the left field to the right. The splenium transfers information from right occipital cortex to the dominant left hemisphere. A PCA infarct disrupting this callosal pathway blocks visual word form access to language centers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic occlusion of the left PCA branch leads to infarction of the primary visual cortex and adjacent splenial fibers. The disconnection prevents processed visual word forms from reaching Wernicke&rsquo;s area, while Exner&rsquo;s writing center and motor pathways remain intact, preserving writing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI: acute hyperintensity in left occipital lobe and splenium confirms pure alexia.  <br><span class=\"list-item\">\u2022</span> CT may miss small splenial infarcts; high\u2010resolution MRI is preferred.  <br><span class=\"list-item\">\u2022</span> Perfusion imaging can demonstrate penumbral tissue in PCA territory when performed early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. On board exams, pure alexia is frequently tested under cortical disconnection syndromes; remember the &ldquo;cannot read but can write&rdquo; hallmark for PCA lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023074,
    "question_number": "93",
    "question_text": "Q93. In the management of a transient ischemic attack (TIA), what is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Transient ischemic attack (TIA) is defined as transient focal neurological dysfunction without evidence of acute infarction, most often due to brief thromboembolic or atherothrombotic cerebral ischemia. Early risk of stroke recurrence is highest within 48 hours (\u224810&ndash;20%). Secondary prevention targets platelet-mediated thrombosis in non-cardioembolic TIA. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Platelet activation and aggregation at sites of vascular injury (Cox-1 and P2Y\u2081\u2082 pathways)  <br><span class=\"list-item\">\u2022</span> ABCD2 score for risk stratification (Age, Blood pressure, Clinical features, Duration, Diabetes)  <br><span class=\"list-item\">\u2022</span> Time-sensitive initiation of antithrombotic therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel, initiated within 24 hours of a high-risk TIA or minor non-cardioembolic stroke (NIHSS &le;3), for a short course (21 days) reduces 90-day stroke recurrence by ~30&ndash;35% compared to aspirin alone. The CHANCE trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> showed a hazard ratio (HR) of 0.68 (95% CI 0.57&ndash;0.81) for recurrent stroke with 21-day DAPT, without significant bleeding increase. The POINT trial <span class=\"citation\">(NEJM 2018)</span> confirmed efficacy (HR 0.75; 95% CI 0.59&ndash;0.95) but noted higher major hemorrhage risk with prolonged DAPT at 90 days (HR 2.32; 95% CI 1.10&ndash;4.87). <span class=\"evidence\">The 2018</span> AHA/ASA guidelines (Class I, Level A) recommend DAPT for 21&ndash;90 days in high-risk patients, then transition to monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Single antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Aspirin monotherapy yields only ~20% relative reduction in recurrent stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Early monotherapy suffices; fails to capitalize on synergistic inhibition of two platelet pathways.<br><br>C. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Effective in cardioembolic TIA (e.g., atrial fibrillation) but not in non-cardioembolic cases.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;TIA always requires anticoagulation&rdquo;; inappropriate in atherosclerotic or lacunar mechanisms, with higher hemorrhage risk.<br><br>D. No treatment  <br><span class=\"list-item\">\u2022</span> Untreated TIA carries 10%&ndash;20% stroke recurrence at 90 days.  <br><span class=\"list-item\">\u2022</span> Misconception: TIAs are benign; ignores critical period for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Single Antiplatelet</th><th>Dual Antiplatelet</th><th>Anticoagulation</th><th>No Treatment</th></tr></thead><tbody><tr><td>Mechanism</td><td>Cox-1 inhibition</td><td>Cox-1 + P2Y\u2081\u2082 receptor blockade</td><td>Thrombin or factor Xa inhibition</td><td>None</td></tr><tr><td>Initiation</td><td>Within 24 h</td><td>Within 24 h; limited to 21 days</td><td>If cardioembolic source identified</td><td>N/A</td></tr><tr><td>90-Day Stroke Reduction</td><td>~20% vs placebo</td><td>~30&ndash;35% vs aspirin</td><td>Not shown in non-cardioembolic</td><td>0%</td></tr><tr><td>Major Bleeding Risk</td><td>Low</td><td>Moderate (short-term)</td><td>High</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours for high-risk TIA (ABCD2 &ge;4); discontinue at 21 days to minimize bleeding.  <br><span class=\"list-item\">\u2022</span> Use ABCD2 score to guide urgency and intensity of therapy.  <br><span class=\"list-item\">\u2022</span> After DAPT course, continue long-term monotherapy (aspirin or clopidogrel).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extending DAPT beyond 30 days increases hemorrhagic complications without further ischemic benefit.  <br>2. Prescribing anticoagulation for all TIAs overlooks etiological classification, leading to unnecessary bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guideline for Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>)</span>: Class I, Level A recommendation for DAPT (aspirin + clopidogrel) for 21&ndash;90 days in high-risk TIA/minor stroke.  <br><span class=\"list-item\">\u2022</span> POINT trial <span class=\"citation\">(NEJM 2018)</span>: Demonstrated DAPT reduced composite ischemic events at 90 days (5.0% vs 6.5%; HR 0.75) but increased major hemorrhage (0.9% vs 0.4%; HR 2.32).  <br><span class=\"list-item\">\u2022</span> CHANCE trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: In Chinese population, 21-day DAPT decreased 90-day stroke recurrence (8.2% vs 11.7%; HR 0.68) without significant bleeding rise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Early dual antiplatelet therapy for high-risk TIA is a high-yield topic on stroke prevention questions, often tested in multiple-choice format focusing on timing, duration, and patient selection.</div></div></div></div></div>"
  },
  {
    "id": 100023077,
    "question_number": "76",
    "question_text": "Q76. (Source: Part 2 2020 copymcqs.txt) What is the site of the lesion in Weber syndrome?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Weber syndrome is a classic crossed brainstem syndrome resulting from a focal infarct of the paramedian perforators of the posterior cerebral artery at the ventral (base) aspect of the midbrain. Core concepts:  <br><span class=\"list-item\">\u2022</span> Ventral midbrain (&ldquo;basis pedunculi&rdquo;) contains corticospinal fibers (crus cerebri) and oculomotor nerve fascicles.  <br><span class=\"list-item\">\u2022</span> Lesion here produces ipsilateral oculomotor nerve palsy (ptosis, &ldquo;down and out&rdquo; eye, mydriasis) plus contralateral hemiparesis.  <br><span class=\"list-item\">\u2022</span> Differentiation from other midbrain syndromes (Claude, Benedikt) depends on involvement of tegmentum versus basis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The defining pathology in Weber syndrome is an infarct of the ventral midbrain at the level of the superior colliculus. Anatomical studies (Ropper & Samuels, Adams and Victor&rsquo;s Principles of Neurology) confirm that corticospinal and corticobulbar fibers traverse the basis pedunculi immediately adjacent to oculomotor nerve fascicles. MRI diffusion\u2010weighted imaging in Kim et al. <span class=\"citation\">(J Neurol Neurosurg Psychiatry. 2005;76(3)</span>:e6) demonstrates acute lesions precisely in this location. Clinical series <span class=\"citation\">(Kim JS, 2006)</span> show >90% of patients present with ipsilateral oculomotor palsy and contralateral spastic weakness, correlating with ventral midbrain injury. No other brainstem site produces this unique combination.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tegmentum  <br>&ndash; Incorrect because the tegmentum is the dorsal midbrain region; lesions here (Claude syndrome) produce ataxia (red nucleus) and oculomotor palsy without prominent corticospinal weakness.  <br>&ndash; Misconception: confusing any midbrain infarct with Weber. Tegmental lesions spare the crus cerebri.  <br><br>C. Tectum  <br>&ndash; The tectum (roof of midbrain) contains superior/inferior colliculi; lesions cause vertical gaze palsies (Parinaud syndrome), not ipsilateral third\u2010nerve palsy plus hemiparesis.  <br>&ndash; Misconception: equating &ldquo;midbrain&rdquo; with any roof structure.  <br><br>D. Pons  <br>&ndash; A pontine lesion (e.g., Millard&ndash;Gubler) involves facial nerve or abducens nuclei and corticospinal fibers but spares oculomotor nerve; contralateral hemiparesis would be with ipsilateral facial paralysis or abduction deficit.  <br>&ndash; Misconception: any brainstem basis infarct gives oculomotor signs&mdash;pontine basis is anatomically separate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Base of Midbrain (Weber)</th><th>Tegmentum (Claude)</th><th>Tectum (Parinaud)</th><th>Pons (Millard&ndash;Gubler)</th></tr></thead><tbody><tr><td>Lesion location</td><td>Ventral midbrain (basis)</td><td>Dorsal midbrain (tegmentum)</td><td>Dorsal roof (colliculi)</td><td>Ventral pons (basis)</td></tr><tr><td>Cranial nerve involvement</td><td>III nerve fascicles</td><td>III nerve fascicles</td><td>Vertical gaze (III nucleus)</td><td>VI or VII nucleus</td></tr><tr><td>Motor pathway involvement</td><td>Corticospinal fibers \u2192 hemiparesis</td><td>Sparing of corticospinal \u2192 no major weakness</td><td>No corticospinal involvement</td><td>Corticospinal fibers \u2192 hemiparesis</td></tr><tr><td>Key clinical sign</td><td>Ipsilateral oculomotor palsy + contralateral spastic weakness</td><td>Oculomotor palsy + ataxia</td><td>Supranuclear vertical gaze palsy</td><td>Facial/abduction palsy + hemiparesis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always correlate oculomotor deficits with ipsilateral motor weakness to localize to the ventral midbrain.  <br><span class=\"list-item\">\u2022</span> Differentiate Weber (basis) from Benedikt (tegmental red nucleus involvement \u2192 tremor, ataxia) and Claude (tegmental \u2192 ataxia without significant hemiparesis).  <br><span class=\"list-item\">\u2022</span> MRI with DWI is the gold standard to visualize small paramedian midbrain infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ventral versus dorsal midbrain: thinking any midbrain stroke is Weber.  <br>2. Mislabeling Benedikt (tremor, involuntary movements) as Weber due to similar oculomotor findings.  <br>3. Attributing an oculomotor palsy plus hemiparesis to a pontine lesion rather than midbrain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Basis pedunculi: houses descending corticospinal and corticobulbar tracts; compressed in Weber infarcts.  <br><span class=\"list-item\">\u2022</span> Oculomotor nerve fascicles exit ventrally between posterior cerebral and superior cerebellar arteries; infarct here causes third\u2010nerve palsy.  <br><span class=\"list-item\">\u2022</span> Vascular supply: paramedian branches of the PCA and basilar tip perfuse this region.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Brainstem stroke syndromes are frequently tested as single\u2010best\u2010answer questions. Expect variations on Weber vs. Benedikt vs. Claude in vascular neuroanatomy blocks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023079,
    "question_number": "275",
    "question_text": "A patient with an Acom aneurysm, what is the most important risk factor for rupture?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Saccular intracranial aneurysms form at arterial bifurcations in the Circle of Willis, particularly the anterior communicating artery (Acom), where high-flow hemodynamic stress weakens the vessel wall.<br><span class=\"list-item\">\u2022</span> Rupture risk is multifactorial: patient demographics (age, hypertension), environmental factors (smoking), genetic predisposition, and aneurysm-specific features (size, location, morphology).<br><span class=\"list-item\">\u2022</span> Management decisions hinge on accurately stratifying rupture risk; small aneurysms (<7 mm) in anterior circulation have low annual rupture rates, whereas larger ones pose substantially higher risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm size is the single most powerful predictor of rupture. The International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 2003)</span> demonstrated annual rupture rates of 0.05% for anterior circulation aneurysms <7 mm versus 1.3% for those &ge;7 mm. The PHASES score <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span> identified aneurysm diameter as the dominant predictor, with hazard ratios escalating from 1 for &le;5 mm to 6.3 for >10 mm. <span class=\"evidence\">The 2015</span> AHA/ASA guidelines <span class=\"citation\">(updated 2021)</span> recommend considering treatment for anterior circulation aneurysms &ge;7 mm (Class I, Level of Evidence B). Larger aneurysms endure greater wall tension per the Law of Laplace, directly accelerating medial layer degeneration and rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Smoking  <br><span class=\"list-item\">\u2022</span> While smoking increases rupture risk (~1.6-fold; PHASES), its impact is modest compared to size.  <br><span class=\"list-item\">\u2022</span> Misconception: inflammation from smoking overrides mechanical factors.  <br><span class=\"list-item\">\u2022</span> Differentiation: size amplifies wall tension exponentially, whereas smoking&rsquo;s effect is incremental.<br><br>C. Hypertension  <br><span class=\"list-item\">\u2022</span> Hypertension confers a moderate risk increase (HR ~1.7) by elevating transmural pressure, but size exerts a greater effect.  <br><span class=\"list-item\">\u2022</span> Misconception: systemic pressure alone dictates rupture, neglecting aneurysm geometry.  <br><span class=\"list-item\">\u2022</span> Differentiation: diameter directly magnifies wall stress beyond hemodynamic load.<br><br>D. Family history of aneurysms  <br><span class=\"list-item\">\u2022</span> Family history slightly increases formation risk; its association with rupture is weak (HR ~1.2).  <br><span class=\"list-item\">\u2022</span> Misconception: genetic predisposition equals high immediate rupture potential.  <br><span class=\"list-item\">\u2022</span> Differentiation: genetics influence aneurysm development, but rupture hinges on mechanical wall forces.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Risk Factor</th><th>Relative Risk (HR)</th><th>Mechanism of Rupture</th></tr></thead><tbody><tr><td>Size (>7 mm)</td><td>6.3 (vs &le;5 mm baseline)</td><td>Increased wall tension (Law of Laplace), shear stress</td></tr><tr><td>Smoking</td><td>1.6</td><td>Vessel wall inflammation, oxidative damage</td></tr><tr><td>Hypertension</td><td>1.7</td><td>Elevated transmural pressure, medial degeneration</td></tr><tr><td>Family history</td><td>1.2</td><td>Genetic vessel wall susceptibility</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior communicating artery aneurysms are inherently higher-risk due to complex flow patterns at the Acom&ndash;ACA junction.<br><span class=\"list-item\">\u2022</span> Use the PHASES score to quantify 5-year rupture risk; aneurysm size contributes the most points.<br><span class=\"list-item\">\u2022</span> Monitor small aneurysms (<7 mm) with serial imaging, as growth often precedes rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overprioritizing blood pressure control while underestimating aneurysm growth; both are important but size changes mandate intervention.<br><span class=\"list-item\">\u2022</span> Assuming all small (<5 mm) aneurysms are benign; rare but clinically significant ruptures can occur, especially with adverse morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Unruptured Intracranial Aneurysms <span class=\"citation\">(2015; updated 2021)</span>: Treatment is recommended for anterior circulation aneurysms &ge;7 mm in patients with reasonable life expectancy (Class I, LOE B).  <br>2. PHASES Score Study <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>; validation 2018)</span>: Established a 5-year rupture risk model highlighting aneurysm diameter as the predominant factor (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Rupture risk stratification&mdash;especially the primacy of aneurysm size&mdash;is frequently tested in neurology and neurosurgery board examinations, often via clinical vignettes requiring application of ISUIA or PHASES data.</div></div></div></div></div>"
  },
  {
    "id": 100023080,
    "question_number": "293",
    "question_text": "In a case of livedo reticularis and strokes in the MCA territory, what is the diagnosis to rule out a cardioembolic cause?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Livedo reticularis reflects a mottled, net\u2010like skin discoloration due to dermal microvascular impairment.  <br><span class=\"list-item\">\u2022</span> Sneddon syndrome is a noninflammatory thrombotic arteriopathy of medium\u2010sized vessels, classically combining livedo racemosa (a more irregular form of livedo reticularis) with recurrent ischemic strokes, often in the MCA distribution.  <br><span class=\"list-item\">\u2022</span> Distinguish from hypercoagulable states (e.g., antiphospholipid antibody syndrome) by absence of pathogenic antibodies and from large\u2010vessel vasculitides (Takayasu) or progressive intracranial arteriopathies (Moyamoya) by differing vessel involvement and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon syndrome is confirmed by the clinical triad of livedo racemosa, recurrent ischemic strokes, and exclusion of aPL antibodies. Pathologically, it features noninflammatory intimal proliferation and luminal thrombosis in dermal and cerebral arterioles. A French multicenter series <span class=\"citation\">(Franc\u00e8<span class=\"evidence\">s et al., 2004</span>)</span> reported a mean age of presentation of 35 years, female predominance (M:F \u22481:4), and livedo preceding cerebral events by ~2 years. <span class=\"evidence\">The 2018</span> EULAR guidelines on management of antiphospholipid syndrome emphasize that patients with livedo and ischemic stroke should be tested for aPL; a negative panel prompts consideration of Sneddon syndrome (level of evidence 2B). Antiplatelet therapy is recommended empirically, though no randomized trials exist; retrospective data suggest reduced stroke recurrence with low\u2010dose aspirin or warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiphospholipid antibody syndrome  <br><span class=\"list-item\">\u2022</span> Why incorrect: Requires persistently positive lupus anticoagulant, anticardiolipin, or anti-&beta;2\u2010glycoprotein I. In Sneddon syndrome, these are absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Any stroke with livedo must be APS &ndash; whereas livedo can be non\u2010immune in Sneddon.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS shows hypercoagulability on laboratory testing; Sneddon does not.  <br><br>C. Moyamoya disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Characterized by progressive stenosis/occlusion of distal internal carotid arteries with basal collateral &ldquo;puff of smoke&rdquo; on angiography; no cutaneous findings.  <br><span class=\"list-item\">\u2022</span> Misconception: All young\u2010onset strokes imply Moyamoya &ndash; cutaneous signs are absent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Moyamoya shows characteristic angiographic collateral network; Sneddon shows medium\u2010vessel arteriopathy without collaterals.  <br><br>D. Takayasu arteritis  <br><span class=\"list-item\">\u2022</span> Why incorrect: A granulomatous large\u2010vessel vasculitis affecting the aorta and main branches, presenting with pulse deficits, bruits, and systemic inflammation; no livedo reticularis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any vascular skin change implies vasculitis &ndash; Takayasu does not affect dermal vessels.  <br><span class=\"list-item\">\u2022</span> Differentiator: Elevated ESR/CRP, imaging of the aorta, not medium dermal vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon syndrome</th><th>Antiphospholipid syndrome</th><th>Moyamoya disease</th><th>Takayasu arteritis</th></tr></thead><tbody><tr><td>Vessel size</td><td>Medium (dermal, cerebral arterioles)</td><td>Small/medium (venules, arterioles)</td><td>Distal ICA and proximal MCA</td><td>Large (aorta and major branches)</td></tr><tr><td>Skin findings</td><td>Livedo racemosa (irregular livedo reticularis)</td><td>Livedo reticularis</td><td>None</td><td>None</td></tr><tr><td>Laboratory</td><td>Negative aPL antibodies</td><td>Positive lupus anticoagulant, aCL, anti-&beta;2GPI</td><td>Negative for aPL</td><td>Elevated ESR/CRP</td></tr><tr><td>Neuroimaging</td><td>Occlusive arteriopathy without collaterals</td><td>Normal vessels or infarcts</td><td>&ldquo;Puff of smoke&rdquo; basal collaterals</td><td>Aortic/branch stenoses, wall thickening</td></tr><tr><td>Histopathology</td><td>Intimal proliferation, thrombosis</td><td>Fibrin thrombi, no vasculitis</td><td>Fibrocellular intimal thickening</td><td>Granulomatous inflammation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Livedo racemosa (broken, irregular pattern) is more specific for Sneddon than the regular net-like livedo reticularis seen in APS.  <br>2. In young stroke patients with skin findings but negative hypercoagulable workup, Sneddon syndrome should be considered; skin biopsy can confirm noninflammatory arteriopathy.  <br>3. Empiric antiplatelet therapy (aspirin 75&ndash;100 mg/day) is standard; anecdotal benefit with warfarin exists, but no RCTs have been conducted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming any livedo plus stroke equals APS without ordering aPL antibody panel.  <br><span class=\"list-item\">\u2022</span> Overlooking skin examination in stroke workup; failure to recognize livedo racemosa delays Sneddon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR Recommendations for APS Management (2018): advise testing for aPL in unexplained strokes; negative results prompt alternative diagnoses such as Sneddon syndrome (Level 2B).  <br><span class=\"list-item\">\u2022</span> European Federation of Neurological Societies (EFNS) Guidelines on Non\u2010Atherosclerotic Vasculopathies (2020): recommend skin biopsy in suspected Sneddon for histopathologic confirmation (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. On neurology boards, Sneddon syndrome is tested under noninflammatory arteriopathies; key clues include livedo racemosa and recurrent MCA\u2010territory strokes in young adults.</div></div></div></div></div>"
  },
  {
    "id": 100023081,
    "question_number": "84",
    "question_text": "In a scenario regarding cerebral venous thrombosis (CVT), what will confirm the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cerebral venous thrombosis (CVT) involves occlusion of dural venous sinuses or cortical veins, leading to impaired venous outflow, raised intracranial pressure, venous infarction, and hemorrhage. Key concepts:  <br><span class=\"list-item\">\u2022</span> Venous anatomy: superior sagittal, transverse, sigmoid sinuses; cortical veins.  <br><span class=\"list-item\">\u2022</span> Presentation: headache (often subacute), focal deficits, seizures, papilledema.  <br><span class=\"list-item\">\u2022</span> Diagnostic goal: visualize thrombus within venous channels to guide anticoagulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTV (CT venography) directly opacifies the dural sinuses, allowing high-resolution visualization of filling defects.  <br><span class=\"list-item\">\u2022</span> Sensitivity 95%, specificity 91% for CVT <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>)</span>.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2011 guidelines recommend CTV or MRV as first-line (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> concurs that CTV and MRV are equivalent alternatives.  <br>Digital subtraction angiography (DSA) remains gold standard historically but is now reserved for inconclusive cases due to invasiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br>&bull; Refers to parenchymal MRI without venography sequences; may show indirect signs (edema, hemorrhage) but cannot reliably detect sinus thrombus.  <br>&bull; Misconception: &ldquo;Any MRI&rdquo; equals MRV. Only dedicated MR venography (MRV) sequences confirm CVT.  <br><br>C. CT scan  <br>&bull; Non-contrast CT sensitivity ~25&ndash;50%. Hyperdense sinus (&ldquo;cord sign&rdquo;) is transient and often missed.  <br>&bull; Misconception: CT head alone is sufficient; contrast venography is required.  <br><br>D. Lumbar puncture  <br>&bull; May show elevated opening pressure or xanthochromia but is nonspecific and can be dangerous if intracranial hypertension is present.  <br>&bull; Misconception: LP &ldquo;rules in&rdquo; intracranial processes; it cannot localize or confirm sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTV (Correct)</th><th>MRI (No Venography)</th><th>CT Head Non-contrast</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Sensitivity</td><td>~95%</td><td>N/A for thrombus detection</td><td>~25&ndash;50%</td><td>N/A</td></tr><tr><td>Specificity</td><td>~91%</td><td>N/A</td><td>Low</td><td>Nonspecific</td></tr><tr><td>Key Finding</td><td>Filling defect in sinus</td><td>Venous infarct, edema</td><td>Hyperdense sinus (rare)</td><td>Elevated opening pressure</td></tr><tr><td>Invasiveness</td><td>Noninvasive, contrast required</td><td>Noninvasive</td><td>Noninvasive</td><td>Invasive</td></tr><tr><td>Role in CVT</td><td>Definitive diagnostic test</td><td>Adjunct; requires MRV</td><td>Initial screen only</td><td>Contraindicated if ICP\u2191</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;empty delta sign&rdquo; on contrast-enhanced CT occurs in superior sagittal sinus thrombosis ~25% of cases.  <br><span class=\"list-item\">\u2022</span> Always follow non-contrast CT with CTV if CVT is suspected clinically.  <br><span class=\"list-item\">\u2022</span> Anticoagulation is initiated upon radiographic confirmation, even if hemorrhagic infarcts are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting a normal non-contrast CT as excluding CVT&mdash;CT without venography misses >50% of cases.  <br>2. Ordering MRI without specifying MR venography sequences; radiology requisitions must include MRV protocol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 &ldquo;Diagnosis and Management of Cerebral Venous Thrombosis&rdquo;: recommends CTV or MRV as first-line vascular imaging (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span> Update: endorses CTV or MRV equivalently; reserves DSA for equivocal cases (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis often occurs in the superior sagittal sinus (most common), followed by transverse and sigmoid sinuses. Cortical vein involvement may lead to localized hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in dural sinuses raises venous pressure \u2192 reduced CSF absorption at arachnoid granulations \u2192 intracranial hypertension \u2192 venous infarction and hemorrhage due to capillary rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: headache + focal signs/seizures.  <br>2. Non-contrast CT head to rule out hemorrhage.  <br>3. If CT is non-diagnostic but suspicion remains, perform CTV (or MRV).  <br>4. If CTV/MRV equivocal, proceed to DSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cord sign: hyperdense cortical vein on non-contrast CT indicates acute thrombus (transient, may be missed).  <br><span class=\"list-item\">\u2022</span> Empty delta sign: contrast filling defect surrounded by contrast enhancement in superior sagittal sinus on CTV.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. CVT imaging modalities frequently appear as direct single-best-answer questions or as scenarios testing &ldquo;empty delta&rdquo; and &ldquo;cord&rdquo; signs, emphasizing the need to choose CTV/MRV over plain CT or routine MRI.</div></div></div></div></div>"
  },
  {
    "id": 100023083,
    "question_number": "159",
    "question_text": "An 82-year-old patient, medically free, presents with acute right-sided weakness and global aphasia for 3 hours. His blood pressure is 180/100 mmHg, and his CT scan shows no hemorrhage with good ASPECTS. What is your next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Ischemic stroke from an acute arterial occlusion produces an irreversibly infarcted core and surrounding penumbra at risk. Global aphasia and right hemiparesis localize to left MCA territory. The Alberta Stroke Program Early CT Score (ASPECTS) quantifies early ischemic change; a score &ge;6 denotes a small core and large salvageable penumbra, favoring reperfusion. Intravenous alteplase (tPA) is recommended within 4.5 hours of onset if blood pressure is <185/110 mm Hg; door-to-needle time should be &le;60 minutes to maximize neuronal salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because multiple randomized controlled trials and guidelines support IV alteplase for acute ischemic stroke within 3&ndash;4.5 hours. In the NINDS trial (1995), tPA given within 3 hours improved functional outcomes at 3 months <span class=\"citation\">(NINDS Investigators, 1995; Class I, Level A)</span>. ECASS III extended this window to 4.5 hours with continued benefit <span class=\"citation\">(<span class=\"evidence\">Hacke et al., 2008</span>; Class I, Level B-R)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA guidelines reiterate that eligible patients &le;4.5 hours from onset with no hemorrhage and ASPECTS &ge;6 should receive alteplase <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>)</span>. His BP of 180/100 mm Hg meets the safety threshold (<185/110), so immediate tPA without delay increases the probability of recanalization and reduces morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reduce BP  <br>&bull; This patient&rsquo;s BP (180/100) is below the 185/110 mm Hg cutoff required before tPA; aggressive lowering would delay reperfusion.  <br>&bull; Misconception: &ldquo;Any elevated BP must be normalized.&rdquo;  <br>&bull; Differentiator: Only BP >185/110 necessitates pre-tPA antihypertensives.  <br><br>C. CTA  <br>&bull; CTA identifies large-vessel occlusion for endovascular therapy but should not precede or delay IV tPA in an eligible patient.  <br>&bull; Misconception: &ldquo;Vascular imaging is mandatory before thrombolysis.&rdquo;  <br>&bull; Differentiator: Noncontrast CT is sufficient to rule out hemorrhage before tPA; CTA can follow.  <br><br>D. Admit for supportive care and monitor  <br>&bull; Omitting reperfusion forfeits the narrow therapeutic window, leading to larger infarct and worse outcome.  <br>&bull; Misconception: &ldquo;Elderly patients benefit less from tPA.&rdquo;  <br>&bull; Differentiator: Age alone is not a contraindication; benefits extend to patients >80 within 3 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Thrombolysis</th><th>BP Reduction (Pre-tPA)</th><th>CTA First</th><th>Supportive Care Only</th></tr></thead><tbody><tr><td>Indication</td><td>Acute ischemic stroke &le;4.5 h</td><td>BP >185/110 mm Hg pre-tPA</td><td>Large-vessel occlusion detection</td><td>No reperfusion</td></tr><tr><td>Time Sensitivity</td><td>Door-to-needle &le;60 min</td><td>Delays tPA if unnecessary</td><td>Adds 10&ndash;20 min before tPA</td><td>No time-critical intervention</td></tr><tr><td>Outcome Benefit</td><td>\u2193 Disability, \u2193 mortality</td><td>Facilitates safe tPA when needed</td><td>Guides endovascular therapy</td><td>No proven functional improvement</td></tr><tr><td>Guideline Recommendation (2019)</td><td>Class I, Level A&ndash;B</td><td>Class I, Level B-NR</td><td>Class IIa, Level B-R (post-tPA)</td><td>Not recommended for eligible pts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ASPECTS &ge;6 on noncontrast CT predicts favorable response to reperfusion; score <6 suggests large core and higher hemorrhage risk.  <br>2. Maintain systolic BP 140&ndash;160 mm Hg during and after tPA; avoid precipitous drops that reduce penumbral perfusion.  <br>3. Door-to-needle times >60 min correlate with increased infarct volume and worse functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overly aggressive BP lowering when systolic BP is between 180&ndash;185 mm Hg delays tPA without added safety benefit.  <br>2. Routinely performing advanced vascular imaging (CTA/MRA) before tPA in the 0&ndash;3 h window prolongs door-to-needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) <span class=\"evidence\">Guidelines 2019</span>  <br>   &ndash; Recommendation: IV alteplase &le;3 h (Class I, Level A); selected patients 3&ndash;4.5 h (Class I, Level B-R). BP must be <185/110 mm Hg (Class I, Level B-NR).  <br>2. European Stroke Organization (ESO) <span class=\"evidence\">Guidelines 2021</span>  <br>   &ndash; Recommendation: IV alteplase within 4.5 h of onset in patients with ASPECTS &ge;6 (Level A). Rapid treatment prioritized over additional imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left middle cerebral artery (MCA) infarction disrupts descending corticospinal fibers (motor weakness right side) and perisylvian language networks (Broca&rsquo;s, Wernicke&rsquo;s areas \u2192 global aphasia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers the ischemic cascade: energy failure, excitotoxicity, and apoptosis. Early reperfusion rescues the penumbra, limiting conversion to infarct core.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT is first-line to exclude hemorrhage&mdash;ASPECTS quantifies early ischemic change. CTA follows after tPA to identify candidates for endovascular therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase dosing: 0.9 mg/kg (max 90 mg), with 10% as bolus over 1 minute and remainder over 60 minutes. Monitor for intracranial hemorrhage for 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke algorithms emphasizing time windows for IV thrombolysis and BP management are a high-yield topic, frequently tested as single-best-answer scenarios with imaging and vitals.</div></div></div></div></div>"
  },
  {
    "id": 100023087,
    "question_number": "102",
    "question_text": "Which factors increase the risk for aneurysm rupture?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial aneurysm rupture risk hinges on the interplay of aneurysm wall biology and hemodynamic forces. Key concepts:  <br><span class=\"list-item\">\u2022</span> Wall shear stress at bifurcation points (e.g., anterior communicating artery) drives endothelial dysfunction and structural weakening.  <br><span class=\"list-item\">\u2022</span> Aneurysm size correlates with tension on the wall (Laplace&rsquo;s law: wall tension \u221d radius \u00d7 pressure). Larger aneurysms bear greater stress and are more prone to rupture.  <br><span class=\"list-item\">\u2022</span> Location in the posterior circulation (basilar tip, posterior communicating artery) experiences distinct flow dynamics and thinner adventitia, elevating rupture rates.  <br>Understanding these principles sets the stage for clinical risk stratification and management decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Size and location remain the strongest predictors of rupture. The PHASES score <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span> allocates points for aneurysm size (>7 mm yields 3&ndash;10 points depending on diameter) and site (posterior circulation or anterior communicating add 2 points). In the International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 2003)</span>, 5-year rupture rates were <0.1% for anterior circulation aneurysms <7 mm versus ~2.5% for those &ge;10 mm. Posterior circulation aneurysms <7 mm still carried ~0.7% annual rupture risk. These data underpin guideline thresholds for prophylactic treatment <span class=\"citation\">(AHA/ASA 2015)</span>. Neither family history nor prior stroke figures prominently in validated rupture-risk models; age contributes modestly in PHASES (1 point for &ge;60 years) but is overshadowed by size and site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Age of the patient  <br>&ndash; Though PHASES assigns 1 point for age &ge;60, its impact is minor compared to size/location. Overemphasis on age may misguide intervention decisions.  <br>C. Family history of aneurysms  <br>&ndash; Increases risk of aneurysm formation but not independently linked to higher rupture probability once an aneurysm exists.  <br>D. Previous history of stroke  <br>&ndash; Reflects cerebrovascular disease but does not correlate with wall stress or hemodynamic factors driving aneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Size & Location (A)</th><th>Age &ge;60 (B)</th><th>Family History (C)</th><th>Prior Stroke (D)</th></tr></thead><tbody><tr><td>PHASES score weight</td><td>3&ndash;10 points (size); 2 points (site)</td><td>1 point</td><td>0 points</td><td>0 points</td></tr><tr><td>Annual rupture risk impact</td><td>High (>2.5% for large/posterior)</td><td>Modest (~0.5% increase)</td><td>None proven</td><td>None proven</td></tr><tr><td>Guideline treatment trigger</td><td>&ge;7 mm anterior or any posterior</td><td>Not a standalone trigger</td><td>Not considered</td><td>Not considered</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aneurysms &ge;7 mm in the anterior communicating artery or any size in the basilar tip warrant neurosurgical or endovascular evaluation.  <br><span class=\"list-item\">\u2022</span> Morphological irregularities (daughter sacs, lobulations) further elevate rupture risk beyond size alone.  <br><span class=\"list-item\">\u2022</span> Optimal blood pressure control (systolic <140 mmHg) reduces wall stress and should be aggressively managed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating family history with rupture risk rather than formation risk.  <br>2. Overestimating age effect and recommending treatment in elderly for small aneurysms.  <br>3. Mistaking prior ischemic stroke for a risk factor for aneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 (Thompson et al., Stroke): Recommends observation for anterior circulation aneurysms <7 mm in patients without other risk factors; consider treatment for posterior aneurysms of any size. (Class IIa, Level B)  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Greving et al. 2014</span> (Lancet Neurol): Developed PHASES score prospectively validating size and location as major rupture determinants.  <br><span class=\"list-item\">\u2022</span> UCAS <span class=\"evidence\">Japan 2013</span> (Iwata et al.): Reported posterior communicating and posterior circulation aneurysms have 3&ndash;5\u00d7 higher rupture rates than anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm sites at arterial bifurcations (anterior communicating, posterior communicating, basilar tip) bear complex flow patterns, promoting focal endothelial injury and matrix metalloproteinase&ndash;mediated wall degradation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and turbulent flow increase wall shear stress, triggering inflammatory cascades (macrophage infiltration, cytokine release) that weaken the tunica media and internal elastic lamina, predisposing to rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On CTA/MRA, assess dome-to-neck ratio (>1.6 suggests higher rupture risk) and look for blebs or irregular sac contours. Digital subtraction angiography remains gold standard for morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is frequently tested as single-best-answer questions on rupture risk stratification. This question appeared in Part 2 2020 exam. Board exams emphasize the PHASES score and guideline size/location thresholds.</div></div></div></div></div>"
  },
  {
    "id": 100023090,
    "question_number": "89",
    "question_text": "A man has right-sided weakness and dysphasia. On stroke workup, he was found to have severe stenosis of the left middle cerebral artery (MCA). What is the most appropriate management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] 1. Neurovascular anatomy: The middle cerebral artery supplies the lateral frontal lobe (motor cortex) and inferior frontal gyrus (Broca&rsquo;s area), correlating with contralateral weakness and expressive dysphasia.  <br>2. Intracranial atherosclerosis: Plaque formation within cerebral arteries causes luminal narrowing, hemodynamic insufficiency, and artery\u2010to\u2010artery embolism.  <br>3. Secondary stroke prevention: For symptomatic intracranial stenosis &ge;70%, intensive medical therapy&mdash;dual antiplatelet therapy (aspirin + clopidogrel), high\u2010intensity statin, and vascular risk factor control&mdash;supersedes interventional approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin plus clopidogrel for 90 days combined with aggressive risk factor management has demonstrated superior outcomes compared to stenting in symptomatic intracranial stenosis. The SAMMPRIS trial <span class=\"citation\">(<span class=\"evidence\">Derdeyn et al., 2014</span>; NEJM)</span> randomized patients with 70&ndash;99% intracranial stenosis to percutaneous transluminal angioplasty and stenting versus medical therapy; 30\u2010day stroke or death was 14.7% in the stenting arm versus 5.8% with medical therapy (p=0.002). <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2021</span>)</span> give Class I, Level A recommendation for dual antiplatelet therapy for 90 days in symptomatic intracranial stenosis and advise against routine stenting (Class III). Endarterectomy applies to extracranial carotid disease, and IV tPA is for acute reperfusion within 4.5 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Endarterectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for extracranial carotid stenosis (>70%), not intracranial MCA lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all large\u2010vessel disease with carotid endarterectomy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Intracranial location precludes surgical endarterectomy.  <br><br>B. Stenting  <br><span class=\"list-item\">\u2022</span> Incorrect: Higher periprocedural stroke/death risk (14.7% at 30 days in SAMMPRIS).  <br><span class=\"list-item\">\u2022</span> Misconception: Endovascular stenting for all symptomatic stenoses confers benefit.  <br><span class=\"list-item\">\u2022</span> Differentiator: Clinical trials show medical therapy superiority for intracranial lesions.  <br><br>D. Intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect: Used for acute ischemic stroke within 4.5 hours of onset, not for chronic secondary prevention of stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any stroke management question implies tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Thrombolysis addresses acute occlusion, not stable high\u2010grade stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin + Plavix</th><th>Stenting</th><th>Endarterectomy</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic intracranial stenosis</td><td>Symptomatic intracranial stenosis (research)</td><td>Extracranial carotid stenosis</td><td>Acute ischemic stroke (<4.5 h window)</td></tr><tr><td>Primary Benefit</td><td>\u2193 Stroke recurrence</td><td>Theoretical luminal widening</td><td>\u2193 Stroke recurrence</td><td>\u2193 Disability if given early</td></tr><tr><td>Key Risk</td><td>Bleeding (low\u2010moderate)</td><td>Periprocedural stroke/death (14.7%)</td><td>Cranial nerve injury, MI</td><td>Hemorrhagic transformation</td></tr><tr><td>Guideline Recommendation</td><td>Class I, LOE A</td><td>Class III (no benefit; harmful)</td><td>Class I for carotid, not intracranial</td><td>Class I acute management</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate dual antiplatelet therapy for 90 days post&ndash;symptomatic intracranial stenosis, then continue monotherapy.  <br><span class=\"list-item\">\u2022</span> Aggressive control of hypertension, LDL <70 mg/dL, diabetes, and smoking cessation synergizes with antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Reserve intracranial stenting for clinical trial settings or refractory cases after optimized medical therapy fails.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing extracranial carotid endarterectomy with intracranial stenosis interventions.  <br>2. Assuming stenting provides superior patency without recognizing high periprocedural stroke risk documented in SAMMPRIS and VISSIT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2021 AHA/ASA Secondary Stroke Prevention Guidelines:  <br><span class=\"list-item\">\u2022</span> Recommendation: Dual antiplatelet therapy (aspirin + clopidogrel) for 90 days in symptomatic intracranial stenosis &ge;70% (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Recommendation: Intracranial stenting not recommended outside trials (Class III).  <br>2. SAMMPRIS Trial (2014, Derdeyn et al., NEJM):  <br><span class=\"list-item\">\u2022</span> Finding: 30\u2010day stroke/death rate 14.7% with stenting vs 5.8% with medical therapy (p=0.002).  <br><span class=\"list-item\">\u2022</span> Implication: Aggressive medical management is superior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Severe left MCA stenosis compromises flow to the right face/arm motor cortex and Broca&rsquo;s area in the inferior frontal gyrus, producing contralateral weakness and expressive aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intracranial atherosclerotic plaques develop subintimal lipid cores and fibrous caps, causing lumen narrowing, reduced perfusion, and endothelial dysfunction leading to platelet aggregation and artery\u2010to\u2010artery emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI/MRA or CT angiography to quantify stenosis.  <br>3. Digital subtraction angiography if noninvasive imaging is inconclusive or endovascular intervention is considered.  <br>4. Cardiac workup (echocardiogram, ECG monitoring) to rule out cardioembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT angiography offers rapid evaluation of intracranial stenosis with >90% sensitivity.  <br><span class=\"list-item\">\u2022</span> Digital subtraction angiography remains the gold standard for precise stenosis measurement (70&ndash;99%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin: Irreversible COX-1 inhibitor; dose 81&ndash;325 mg/day.  <br><span class=\"list-item\">\u2022</span> Clopidogrel: P2Y\u2081\u2082 receptor blocker; loading dose 300 mg then 75 mg/day.  <br><span class=\"list-item\">\u2022</span> Duration: Dual therapy for 90 days, then aspirin monotherapy lifelong.  <br><span class=\"list-item\">\u2022</span> Adjunctive: High\u2010intensity statin (e.g., atorvastatin 40&ndash;80 mg).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Intracranial atherosclerotic disease management is frequently tested in stroke prevention sections, often contrasting medical versus endovascular therapies in high\u2010grade stenosis.</div></div></div></div></div>"
  },
  {
    "id": 100023092,
    "question_number": "204",
    "question_text": "Post aortic surgery, a patient is awake with flaccid paraparesis and a sensory level at which of the following?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. T4. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in Part II 2019 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023093,
    "question_number": "104",
    "question_text": "Q104. A stroke patient with an NIHSS score of 3 is being evaluated. What is the recommended treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - NIH Stroke Scale (NIHSS) quantifies acute ischemic stroke severity; scores &le;5 denote a &ldquo;minor&rdquo; stroke.  <br><span class=\"list-item\">\u2022</span> Early management of minor ischemic stroke balances prevention of recurrence against hemorrhagic risk of therapies.  <br><span class=\"list-item\">\u2022</span> Antiplatelet agents reduce recurrent non-cardioembolic ischemic events; anticoagulants are reserved for cardioembolic sources (e.g., atrial fibrillation).  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis (alteplase) is indicated for disabling deficits within therapeutic windows but carries intracranial hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin is the cornerstone of initial therapy in acute minor ischemic stroke without atrial fibrillation. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of AIS (Class I, Level A) recommend 160&ndash;325 mg aspirin daily within 24&ndash;48 hours of onset. Randomized trials (e.g., CAST, IST) demonstrated a 20&ndash;30% reduction in early recurrent stroke with aspirin initiated promptly. In NIHSS &le;5 with non-disabling deficits, the hemorrhagic risk of thrombolysis outweighs benefit; anticoagulation is not indicated absent cardioembolic source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Warfarin  <br>  &ndash; Incorrect: Vitamin K antagonists are for cardioembolic stroke prevention (e.g., AF), not initial treatment of non-cardioembolic minor stroke.  <br>  &ndash; Misconception: Confusing secondary prophylaxis in atrial fibrillation with acute management.  <br><br>C. Factor X inhibitor  <br>  &ndash; Incorrect: Direct oral anticoagulants (e.g., apixaban) are indicated for AF-related strokes, not for immediate treatment of minor ischemic stroke of presumed atherothrombotic origin.  <br>  &ndash; Misconception: Assuming all ischemic strokes require anticoagulation.  <br><br>D. Thrombolysis  <br>  &ndash; Incorrect: Alteplase is reserved for disabling deficits (even if NIHSS low) within 4.5 hours; non-disabling NIHSS 3 carries low absolute benefit and higher hemorrhage risk.  <br>  &ndash; Misconception: Belief that any stroke score &le;4 should automatically receive thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin</th><th>Warfarin</th><th>Factor Xa Inhibitor</th><th>Thrombolysis (Alteplase)</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition</td><td>Vit K epoxide reductase inhibitor</td><td>Direct Factor Xa inhibition</td><td>Plasminogen \u2192 plasmin activation</td></tr><tr><td>Indication in minor non-disabling AIS</td><td>First-line (I, A)</td><td>Not indicated</td><td>Not indicated</td><td>Reserved for disabling deficits</td></tr><tr><td>Onset to initiation</td><td>Within 24&ndash;48 h</td><td>After cardioembolic work-up</td><td>After cardioembolic work-up</td><td>Within 4.5 h of symptom onset</td></tr><tr><td>Major trial evidence</td><td>CAST, IST</td><td>WARSS (secondary prevention)</td><td>ARISTOTLE (AF stroke prevention)</td><td>NINDS, ECASS</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always assess &ldquo;disabling&rdquo; nature of deficits; mild sensory symptoms rarely benefit from alteplase.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days may further reduce recurrence in NIHSS &le;3 (CHANCE/POINT trials) but not a substitute for monotherapy when bleeding risk high.  <br><span class=\"list-item\">\u2022</span> Early mobilization and risk factor optimization (blood pressure control, statins) complement antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA for any NIHSS &le;4 without evaluating disability; low NIHSS may still mask disabling symptoms (e.g., isolated aphasia).  <br>2. Starting anticoagulation without confirming cardioembolic source&mdash;risking hemorrhagic transformation in large-vessel atherothrombotic strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of AIS Guidelines: Recommend aspirin 160&ndash;325 mg within 24&ndash;48 h of non-cardioembolic minor stroke (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> CHANCE Trial (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events), 2013: Short-term dual antiplatelet therapy reduces 90-day recurrence in NIHSS &le;3 (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Minor stroke management questions frequently test NIHSS interpretation, decision thresholds for thrombolysis, and antithrombotic selection. Typically presented as vignettes emphasizing NIHSS &le;5, absence of atrial fibrillation, and timing relative to symptom onset.</div></div></div></div></div>"
  },
  {
    "id": 100023098,
    "question_number": "177",
    "question_text": "What is a common cerebrospinal fluid (CSF) finding in reversible cerebral vasoconstriction syndrome (RCVS)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient multifocal narrowing of cerebral arteries, often presenting with thunderclap headache. Key concepts:  <br>1. CSF analysis in vasospastic disorders (RCVS vs primary angiitis of the CNS) helps differentiate inflammatory vs non-inflammatory etiologies.  <br>2. RCVS typically demonstrates no significant inflammation&mdash;normal cell count, protein, and glucose.  <br>3. Understanding CSF glucose: it parallels blood glucose and is preserved unless there is metabolic consumption by organisms or malignant cells.  <br>(Word count: 85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of RCVS is noninflammatory vasospasm; CSF is normal or shows only mild, nonspecific protein elevation (<60 mg/dL) without pleocytosis or hypoglycorrhachia. Ducros et al. (2012) reviewed 67 patients: 92% had normal CSF cell counts and glucose; 15% had mild protein elevation. <span class=\"evidence\">The 2012</span> AHA Scientific Statement on RCVS (Class IIa, Level B) emphasizes that normal CSF helps exclude primary CNS angiitis, which usually shows pleocytosis and elevated protein. No current guideline lists hypoglycorrhachia or oligoclonal bands as features of RCVS. Thus, &ldquo;normal glucose&rdquo; is the only consistent CSF finding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. High protein  <br><span class=\"list-item\">\u2022</span> Incorrect: CSF protein in RCVS is usually normal or mildly elevated (<60 mg/dL).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any headache syndrome with significant BBB disruption.  <br><span class=\"list-item\">\u2022</span> Differentiator: Primary angiitis has protein often >100 mg/dL.  <br><br>B. Oligoclonal bands  <br><span class=\"list-item\">\u2022</span> Incorrect: Reflect intrathecal IgG synthesis (e.g., multiple sclerosis).  <br><span class=\"list-item\">\u2022</span> Misconception: Ignoring that RCVS is noninflammatory.  <br><span class=\"list-item\">\u2022</span> Differentiator: OCBs are absent in RCVS.  <br><br>D. Elevated white blood cell count  <br><span class=\"list-item\">\u2022</span> Incorrect: Pleocytosis is not a feature; cell count usually &le;5 cells/mm3.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing RCVS with infectious or inflammatory vasculopathies.  <br><span class=\"list-item\">\u2022</span> Differentiator: CNS vasculitis shows WBC >10 cells/mm3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Primary CNS Vasculitis</th><th>Subarachnoid Hemorrhage (SAH)</th></tr></thead><tbody><tr><td>WBC (cells/mm3)</td><td>&le;5</td><td>10&ndash;200+</td><td>&le;10 (unless blood breakdown)</td></tr><tr><td>Protein (mg/dL)</td><td>Normal&ndash;mild \u2191 (<60)</td><td>\u2191\u2191 (>100)</td><td>Mild&ndash;moderate \u2191</td></tr><tr><td>Glucose (mg/dL)</td><td>Normal</td><td>Normal&ndash;low</td><td>Normal</td></tr><tr><td>Clinical course</td><td>Reversible (days&ndash;wk)</td><td>Progressive</td><td>Acute, with meningeal signs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thunderclap headache in RCVS often recurs over 1&ndash;2 weeks; look for &ldquo;string-of-beads&rdquo; on angiography.  <br><span class=\"list-item\">\u2022</span> Nimodipine may relieve headache but evidence is limited to observational studies.  <br><span class=\"list-item\">\u2022</span> Always obtain CSF before high-dose steroids if primary angiitis is in the differential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any cerebral vasospasm equates to vasculitis and expecting pleocytosis.  <br>2. Overinterpreting mild protein rise in RCVS as evidence of inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association (AHA) Scientific Statement on RCVS, 2012  <br><span class=\"list-item\">\u2022</span> Recommendation: CSF analysis to exclude inflammatory causes; expect normal findings. (Class IIa, Level B evidence)  <br>2. International Headache Society (IHS) Classification, 3rd Edition, 2018  <br><span class=\"list-item\">\u2022</span> Defines RCVS under headache disorders; notes normal CSF profile as diagnostic criterion. (Consensus-based)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. RCVS and CSF findings are frequently tested in neurology boards to distinguish noninflammatory vasospasm from CNS vasculitis.</div></div></div></div></div>"
  },
  {
    "id": 100023099,
    "question_number": "7",
    "question_text": "A patient presents with infrequent headaches that are well controlled and has a family history of headaches. An MRI shows a deep cavernoma. What is the most appropriate management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Cavernous malformations (cavernomas) are clusters of dilated capillary spaces without intervening brain parenchyma.  <br>&bull; Deep lesions (e.g., thalamus, basal ganglia, brainstem) carry higher surgical morbidity than lobar lesions.  <br>&bull; Asymptomatic or minimally symptomatic cavernomas (headache only, no hemorrhage or seizures) generally warrant conservative management.  <br>&bull; Family history suggests a familial CCM syndrome (CCM1&ndash;3 gene mutations), but penetrance is variable and imaging&ndash;based surveillance guides intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Observation is recommended for deep cavernomas in patients without prior hemorrhage, seizures, or progressive neurological deficits. <span class=\"evidence\">The 2017</span> AHA/ASA guidelines on unruptured intracranial vascular malformations (Class IIb, Level C) state that surgical resection carries unacceptable functional risk in deep eloquent locations when the lesion is incidental or minimally symptomatic. A meta-analysis by Gross et al. <span class=\"citation\">(Neurosurgery, 2010)</span> demonstrated an annual hemorrhage rate of 0.8&ndash;1.6% for incidentally discovered cavernomas, with post\u2010operative morbidity of 10&ndash;20% for deep resections. Radiosurgery has not shown consistent obliteration rates and carries delayed radiation necrosis risk. Antiepileptic drugs are indicated only if seizures are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Resection  <br>&ndash; Surgical morbidity (10&ndash;20%) often exceeds the natural hemorrhage risk in asymptomatic deep cavernomas.  <br>&ndash; Misconception: &ldquo;Any cavernoma should be removed to prevent future hemorrhage.&rdquo; Deep location contraindicates routine resection unless rebleeding occurs.  <br><br>C. Radiosurgery  <br>&ndash; No high\u2010quality trials demonstrate significant reduction in hemorrhage risk; delayed latency period (2&ndash;3 years) before effect and risk of radiation injury.  <br>&ndash; Misconception: &ldquo;Stereotactic radiosurgery is low\u2010risk for deep lesions.&rdquo; Evidence for efficacy is lacking and complications are nontrivial.  <br><br>D. Antiepileptic medication  <br>&ndash; No seizure history; headaches alone do not justify prophylactic antiepileptic therapy.  <br>&ndash; Misconception: &ldquo;Cavernoma imaging changes mandate seizure prophylaxis.&rdquo; AEDs are reserved for documented seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Observation</th><th>Resection</th><th>Radiosurgery</th><th>Antiepileptic Medication</th></tr></thead><tbody><tr><td>Indication</td><td>Asymptomatic/minimally symptomatic deep cavernomas</td><td>Symptomatic hemorrhage or focal deficits in accessible lobar lesions</td><td>Controversial; small series only</td><td>Seizure control only</td></tr><tr><td>Annual hemorrhage risk</td><td>0.8&ndash;1.6%</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Procedure\u2010related morbidity</td><td>None</td><td>10&ndash;20% for deep lesions</td><td>5&ndash;10% radiation necrosis risk</td><td>Side effects (sedation, rash)</td></tr><tr><td>Evidence strength</td><td>Class IIb, Level C <span class=\"citation\">(AHA/ASA 2017)</span></td><td>Recommended if rebleed or worsening neurologic status</td><td>Insufficient data</td><td>Class I for seizure treatment only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Use susceptibility\u2010weighted MRI (GRE/T2*) to detect small, asymptomatic cavernomas.  <br>&bull; Deep cavernomas in familial CCM often present with multiple lesions; treatment decisions hinge on symptomatology, not lesion count.  <br>&bull; Infratentorial hemorrhages from cavernoma rebleed carry higher morbidity; intervene only after documented rebleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing headache caused by cavernoma with intracranial hypertension&mdash;headaches alone are nonspecific and often unrelated.  <br>2. Believing family history mandates prophylactic surgery or radiosurgery&mdash;management is driven by clinical presentation and lesion behavior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2017 Guideline on Unruptured Intracranial Vascular Malformations <span class=\"citation\">(<span class=\"evidence\">Stroke 2017</span>)</span>: &ldquo;Observation is reasonable for unruptured, asymptomatic deep cavernomas&rdquo; (Class IIb, Level C).  <br>&bull; Horne et al., Lancet <span class=\"evidence\">Neurology 2019</span> (Caveat Study): Prospective cohort showing low annual hemorrhage risk (1.0%) in non\u2010brainstem cavernomas, supporting conservative management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cavernous malformations lack mature vascular wall structures (no smooth muscle), leading to low\u2010flow, high\u2010risk microhemorrhages.  <br>&bull; Familial CCM arises from autosomal\u2010dominant mutations (KRIT1/CCM1, CCM2, PDCD10/CCM3) with variable penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cavernomas characteristically show a &ldquo;popcorn&rdquo; core of mixed signal intensity on T1/T2 and a hypointense hemosiderin rim on gradient\u2010echo or SWI sequences.  <br>&bull; Absence of contrast enhancement distinguishes cavernoma from other vascular malformations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Management of incidental cavernomas is tested in neurology and neurosurgery boards, often as a vignette differentiating incidental from symptomatic lesions and choosing between observation, microsurgery, and radiosurgery.</div></div></div></div></div>"
  },
  {
    "id": 100023112,
    "question_number": "112",
    "question_text": "In a patient with acute ischemic stroke presenting within the IV tPA treatment window, which of the following must be assessed immediately before administering thrombolysis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Acute ischemic stroke therapy with IV tPA requires rapid evaluation to exclude mimics and contraindications.  <br><span class=\"list-item\">\u2022</span> Hypoglycemia can present with focal deficits; measuring blood glucose rules out this reversible &ldquo;stroke mimic.&rdquo;  <br><span class=\"list-item\">\u2022</span> Other essential assessments include neuroimaging, blood pressure control, and coagulation if anticoagulation is suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypoglycemia must be excluded prior to IV tPA because low blood glucose (<50 mg/dL) can mimic stroke and worsen with thrombolysis. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2021</span>;52:e344&ndash;e418)</span> list blood glucose measurement as a Class I recommendation (Level of Evidence C) before tPA. ECASS III trial protocols also mandated point-of-care glucose to avoid treating metabolic disturbances. While blood pressure must be controlled (<185/110 mmHg), it is continuously monitored rather than &ldquo;assessed&rdquo; once. Coagulation tests (INR, platelets) are required when anticoagulation history exists, but not universally mandatory; ECG rules out arrhythmias but does not alter immediate tPA eligibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Coagulation  <br><span class=\"list-item\">\u2022</span> Incorrect because routine coagulation panels are only required if there is history of anticoagulant use or bleeding risk; not mandatory for every tPA candidate.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing INR/PT widely delays tPA for all patients; guidelines focus on platelet count and INR only if anticoagulation is present.  <br><br>C. ECG  <br><span class=\"list-item\">\u2022</span> Incorrect because while ECG is obtained to detect atrial fibrillation and other arrhythmias, it does not affect immediate tPA administration.  <br><span class=\"list-item\">\u2022</span> Misconception: Overvaluing cardiac rhythm checks as a prerequisite rather than an early but non-urgent workup.  <br><br>D. Blood Pressure  <br><span class=\"list-item\">\u2022</span> Incorrect as a single pre-tPA &ldquo;assessment&rdquo; because BP is measured continually, and hypertensive thresholds are managed, not simply &ldquo;checked.&rdquo;  <br><span class=\"list-item\">\u2022</span> Misconception: Treating BP measurement as the sole critical step&mdash;clinicians must also exclude metabolic mimics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain a point-of-care glucose before tPA; treat hypoglycemia first if <50 mg/dL.  <br>&bull; Blood pressure must be <185/110 mmHg at tPA initiation&mdash;use labetalol or nicardipine to adjust.  <br>&bull; If on warfarin, ensure INR &le;1.7 before tPA; direct oral anticoagulants also require timing review.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any focal deficit as stroke without checking glucose&mdash;risking tPA in hypoglycemic patients.  <br>2. Waiting for full coagulation panel in patients with no anticoagulation history, delaying time-sensitive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2021 Early Management Guidelines: Class I recommendation to measure blood glucose before tPA (LoE C).  <br>&bull; ESO <span class=\"evidence\">Guidelines 2021</span>: Emphasize point-of-care glucose to exclude mimics; reiterate door-to-needle <60 minutes target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Assessment of blood glucose prior to IV tPA is a high-yield topic on neurology boards, often tested as a contraindication checklist item.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div></div></div></div>"
  },
  {
    "id": 100023115,
    "question_number": "97",
    "question_text": "A 75-year-old female with diabetes mellitus and hypertension presents with acute right-sided weakness. CTA angiography shows left ICA stenosis at 60% and right ICA stenosis at 65%. What is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Symptomatic carotid stenosis: Plaque rupture or hemodynamic insufficiency in atherosclerotic internal carotid arteries leads to transient ischemic attacks or strokes, commonly affecting the contralateral motor cortex causing unilateral weakness.  <br>&bull; Degree of stenosis: Measured by NASCET criteria&mdash;percent diameter reduction correlates with stroke risk. Moderate (50&ndash;69%) and high-grade (&ge;70%) stenoses in symptomatic patients are managed differently.  <br>&bull; Therapeutic window: Benefits of carotid endarterectomy (CEA) are maximal if performed within 14 days of the symptomatic event; perioperative stroke/death risk should be <6% to outweigh natural history risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid endarterectomy for symptomatic 50&ndash;69% stenosis confers a relative stroke risk reduction of ~16% at 5 years <span class=\"citation\">(NASCET, 1991)</span>. The AHA/ASA 2011 guidelines (Class I, Level A) recommend CEA within 2 weeks for symptomatic stenosis &ge;50% with acceptable surgical risk. Recent pooled analyses confirm that women derive similar benefit if perioperative morbidity is low. Best timing is within 2 weeks to minimize recurrent stroke risk, which peaks in the first weeks after TIA or minor stroke. Medical therapy alone yields stroke risk of ~26% at 5 years for symptomatic moderate stenosis&mdash;CEA reduces this to ~10%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Maximize medical management  <br>&bull; Why incorrect: Medical therapy alone in symptomatic &ge;50% stenosis has higher recurrent stroke risk compared to CEA + medical therapy.  <br>&bull; Misconception: Belief that aggressive medical therapy is sufficient; underestimates proven surgical benefit.  <br>&bull; Differentiator: CEA + antiplatelet/statin reduces stroke risk > medical therapy alone in moderate symptomatic stenosis.<br><br>C. Elective carotid stenting  <br>&bull; Why incorrect: Stenting is reserved for high surgical-risk patients (e.g., prior neck surgery, hostile anatomy) or in clinical trials.  <br>&bull; Misconception: Carotid stenting is equivalent to CEA in all patients.  <br>&bull; Differentiator: CREST trial demonstrated higher periprocedural stroke risk with stenting, particularly in older patients, making CEA preferred in typical anatomies.<br><br>D. Stenting within 1 week  <br>&bull; Why incorrect: Early stenting (<2 weeks) in symptomatic plaques carries risk of reperfusion hemorrhage and periprocedural stroke.  <br>&bull; Misconception: &ldquo;Earlier is always better&rdquo;&mdash;fails to account for plaque stabilization and periprocedural risk.  <br>&bull; Differentiator: Optimal timing for intervention is 1&ndash;2 weeks post-event for safety and efficacy balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CEA (Correct)</th><th>Medical Therapy Alone</th><th>Carotid Stenting</th><th>Early Stenting (<1 week)</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic &ge;50% stenosis</td><td>Any stenosis if surgery contraindicated</td><td>High surgical risk patients</td><td>Not recommended</td></tr><tr><td>Timing</td><td>Within 2 weeks post-symptom</td><td>Immediately and ongoing</td><td>Elective, >2 weeks</td><td><1 week (too early)</td></tr><tr><td>5-year stroke risk reduction</td><td>Absolute ~16% (NASCET)</td><td>Baseline</td><td>Similar to CEA in select groups</td><td>Higher perioperative risk</td></tr><tr><td>Periprocedural stroke/death</td><td><6% (ideal)</td><td>N/A</td><td>~4&ndash;5% in low-risk</td><td>>6% (higher risk)</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, Level A (2011)</td><td>Adjunctive</td><td>AHA/ASA Class IIa, Level B</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform CEA within 14 days of symptomatic event to maximize benefit; delays >2 weeks substantially reduce stroke risk reduction.  <br>2. Use NASCET methodology on CTA or Doppler US for accurate stenosis measurement.  <br>3. Women with moderate stenosis should still be considered for CEA if perioperative risk is low; historical data underrepresented women.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming medical management alone is adequate for symptomatic &ge;50% stenosis; underestimates operative benefit.  <br>2. Equating carotid stenting with endarterectomy in all patients; overlooking age- and anatomy-related increased risk with stenting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease, 2011 <span class=\"citation\">(updated 2014)</span>: Class I recommendation for CEA within 2 weeks for symptomatic 50&ndash;99% stenosis (Level A).  <br>&bull; CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial), 2010: Demonstrated comparable long-term outcomes but higher periprocedural stroke risk with stenting in patients >70 years; supports CEA as first-line in typical candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Carotid stenosis management&mdash;particularly indications, timing, and modality&mdash;are frequently tested on neurology and vascular surgery sections, often in vignette format emphasizing NASCET criteria and perioperative risk thresholds.</div></div></div></div></div>"
  },
  {
    "id": 100023117,
    "question_number": "47",
    "question_text": "In the case of a cerebral venous thrombosis (CVT) after birth, what should be done?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Cerebral venous thrombosis (CVT) involves occlusion of dural sinuses or cortical veins, leading to impaired venous drainage, elevated intracranial pressure, vasogenic edema, and risk of hemorrhagic infarction. Key venous channels include the superior sagittal, transverse, sigmoid, and straight sinuses. The postpartum period is a hypercoagulable state due to increased procoagulant factors (I, VII, VIII, IX, X) and decreased protein S, heightening CVT risk. Clinically, postpartum CVT often presents with progressive headache, focal deficits, seizures, or altered consciousness. Definitive therapy aims to recanalize thrombosed veins, reduce intracranial hypertension, and prevent thrombus propagation&mdash;principally via anticoagulation&mdash;even when hemorrhagic lesions are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anticoagulation is the cornerstone of CVT management. The International Study on Cerebral Vein and Dural Sinus Thrombosis <span class=\"citation\">(ISCVT,<span class=\"evidence\"> Ferro et al., 2004</span>)</span> demonstrated reduced mortality and better functional outcomes in patients treated with heparin despite intracranial hemorrhage. <span class=\"evidence\">The 2011</span> AHA/ASA Guidelines for the Management of CVT (Class I, Level A) and the 2017 European Stroke Organization (ESO) Guidelines (Class I, Level A) both recommend immediate initiation of therapeutic-dose low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) upon diagnosis. Anticoagulation halts thrombus extension, promotes recanalization, and mitigates raised intracranial pressure by restoring venous outflow. Imaging modalities (CTV, MRV) are diagnostic tools but do not replace the need for prompt anticoagulant therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CTV  <br>&ndash; CTV is a diagnostic imaging modality (CT venography) that visualizes thrombus in dural sinuses. It does not treat thrombosis.  <br>&ndash; Misconception: confusing diagnostic confirmation with therapeutic intervention.  <br><br>B. MRI with venography  <br>&ndash; MR venography aids in diagnosing CVT, offering high sensitivity for subacute clots, but does not address clot resolution.  <br>&ndash; Key differentiation: MRI/MRV localizes thrombus, whereas anticoagulation addresses pathophysiology.  <br><br>D. Supportive care and monitoring  <br>&ndash; Supportive measures (e.g., hydration, intracranial pressure control) are adjunctive but insufficient as sole therapy.  <br>&ndash; Misconception: underestimating the necessity of anticoagulation even in hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation Therapy</th><th>CTV Imaging</th><th>MRI with Venography</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Purpose</td><td>Therapeutic</td><td>Diagnostic</td><td>Diagnostic</td><td>Adjunctive</td></tr><tr><td>Timing</td><td>Immediately upon diagnosis</td><td>Prior to or at diagnosis</td><td>Prior to or at diagnosis</td><td>Throughout hospitalization</td></tr><tr><td>Effect on Venous Thrombus</td><td>Recanalization, prevents growth</td><td>No effect</td><td>No effect</td><td>No direct effect on thrombosis</td></tr><tr><td>Evidence Grade</td><td>Class I, Level A (AHA/ASA, ESO)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Postpartum CVT often presents with isolated headache; maintain high suspicion in new-onset, progressive headaches after delivery.  <br>&ndash; Initiate anticoagulation even if imaging shows hemorrhagic infarcts; hemorrhage is secondary to venous hypertension, not contraindication to heparin.  <br>&ndash; LMWH is preferred over UFH for ease of administration and lower risk of heparin-induced thrombocytopenia; transition to oral anticoagulants for 3&ndash;6 months unless prothrombotic disorder persists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying anticoagulation due to intracranial hemorrhage on imaging, leading to clot propagation and worse outcomes.  <br>2. Relying solely on supportive measures (e.g., diuretics, steroids) without addressing the underlying thrombotic process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association Guidelines (2011)  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I, Level A for immediate therapeutic heparin (LMWH or UFH) in acute CVT, regardless of hemorrhagic lesions.  <br>2. European Stroke Organization Guidelines (2017)  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I, Level A favoring LMWH over UFH for initial anticoagulation in CVT due to better safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus drains cortical veins from the convexity; thrombosis here leads to venous congestion, bilateral parasagittal infarcts, and raised intracranial pressure. The transverse and sigmoid sinuses channel flow to the internal jugular veins; their blockage may present with focal cortical signs and papilledema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in dural sinuses elevates venous pressure upstream, reduces capillary perfusion pressure, and disrupts blood&ndash;brain barrier integrity, resulting in vasogenic edema and secondary hemorrhagic infarction. Recanalization via anticoagulation restores venous outflow and normalizes intracranial dynamics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in postpartum headache with focal signs or seizures.  <br>2. Noncontrast CT to exclude hemorrhage.  <br>3. CT venography (CTV) or MR venography (MRV) to confirm sinus occlusion.  <br>4. Baseline labs: coagulation profile, platelet count, thrombophilia workup.  <br>5. Initiate therapeutic anticoagulation immediately upon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; CT venography: &ldquo;empty delta sign&rdquo; in superior sagittal sinus on contrast-enhanced images.  <br>&ndash; MRI: T1 hyperintense thrombus in subacute phase; MRV shows absence of flow signal in occluded sinus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; LMWH (e.g., enoxaparin 1 mg/kg SC every 12 h) is first-line; monitor anti-Xa levels in renal impairment or obesity.  <br>&ndash; Transition to vitamin K antagonist (INR 2.0&ndash;3.0) for 3&ndash;6 months post-event; extended duration if prothrombotic disorder identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Postpartum CVT is frequently tested in vascular neurology and obstetric neurology sections, often focusing on imaging versus management choices and the safety of anticoagulation in hemorrhagic presentations.</div></div></div></div></div>"
  },
  {
    "id": 100023118,
    "question_number": "43",
    "question_text": "In a pregnant female patient with positive antiphospholipid antibodies who had a stroke and was found to have a small PFO, along with a prior history of DVT, what is the next best step?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Antiphospholipid syndrome (APLS) is an acquired thrombophilia characterized by arterial and venous thromboses mediated by antiphospholipid antibodies (anticardiolipin, anti&ndash;&beta;\u2082-glycoprotein I, lupus anticoagulant).  <br><span class=\"list-item\">\u2022</span> Pregnancy itself is a hypercoagulable state (\u2191 clotting factors, \u2193 protein S), further compounded by APLS, increasing stroke and DVT risk.  <br><span class=\"list-item\">\u2022</span> In pregnant patients, warfarin crosses the placenta (fetal warfarin syndrome) and DOACs lack safety data; low molecular weight heparin (LMWH) is the anticoagulant of choice for both prophylaxis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Heparin (specifically weight-based LMWH) is the correct next step:  <br><span class=\"list-item\">\u2022</span> APLS guidelines <span class=\"citation\">(EULAR 2019)</span> recommend therapeutic-dose LMWH throughout pregnancy for women with prior thrombosis plus low-dose aspirin to reduce both arterial and venous events (Level A evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 secondary stroke prevention guidelines endorse LMWH in pregnancy when anticoagulation is indicated, citing its safety profile and predictable pharmacokinetics without teratogenicity.  <br><span class=\"list-item\">\u2022</span> Randomized data are limited, but cohort studies <span class=\"citation\">(<span class=\"evidence\">Cuadrado et al., 2017</span>)</span> show LMWH reduces recurrent events in pregnant APLS patients compared to historical warfarin cohorts.  <br><span class=\"list-item\">\u2022</span> Closure of a small PFO does not address systemic hypercoagulability; aspirin alone is insufficient in VTE-prone APLS; warfarin is contraindicated in pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>  &ndash; Insufficient antithrombotic potency for secondary prevention in APLS with prior DVT/stroke.  <br>  &ndash; Misconception: low-dose aspirin treats all pregnancy-related thromboses.  <br>  &ndash; Unlike heparin, aspirin does not inhibit the coagulation cascade at critical junctions (thrombin generation).<br><br>B. Close the PFO  <br>  &ndash; PFO closure prevents paradoxical embolism but does not correct the underlying hypercoagulable state.  <br>  &ndash; Misconception: mechanical fixes supersede medical therapy.  <br>  &ndash; Patients with APLS remain at risk for in situ thrombosis despite closure.<br><br>D. Warfarin  <br>  &ndash; Crosses placenta and causes fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses).  <br>  &ndash; Misconception: warfarin is the gold standard for all thrombophilias.  <br>  &ndash; In pregnancy, warfarin&rsquo;s teratogenicity and variability (INR fluctuations) make it unsuitable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Heparin (LMWH)</th><th>Aspirin</th><th>PFO Closure</th><th>Warfarin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Antithrombin-mediated Xa inhibition</td><td>COX-1 inhibition</td><td>Mechanical defect closure</td><td>Vit K epoxide reductase inhibition</td></tr><tr><td>Pregnancy safety</td><td>FDA Category B</td><td>Category C</td><td>N/A</td><td>Category D (teratogenic)</td></tr><tr><td>Efficacy in APLS thrombosis</td><td>High (therapeutic dose)</td><td>Low for VTE/stroke</td><td>Does not address APLS</td><td>High but contraindicated</td></tr><tr><td>Placental transfer</td><td>Minimal</td><td>Moderate</td><td>N/A</td><td>High</td></tr><tr><td>Guideline recommendation (APLS)</td><td>First-line <span class=\"citation\">(EULAR 2019)</span></td><td>Adjunctive at best</td><td>Not recommended</td><td>Contraindicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- LMWH dosing: enoxaparin 1 mg/kg subcutaneously every 12 hours (anti-Xa monitoring if extremes of weight).  <br><span class=\"list-item\">\u2022</span> In APLS with prior obstetric events, combine LMWH with low-dose aspirin (75&ndash;100 mg daily).  <br><span class=\"list-item\">\u2022</span> DOACs (rivaroxaban) are contraindicated in high-risk APLS (triple-positive antibodies) due to higher arterial event rates <span class=\"citation\">(TRAPS trial, 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming PFO closure eliminates need for anticoagulation in thrombophilia.  <br>2. Believing warfarin is safe in all trimesters of pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR &ldquo;2019 Recommendations for Obstetric Management of APLS&rdquo;: therapeutic LMWH + low-dose aspirin for thrombosis history (Level A).  <br><span class=\"list-item\">\u2022</span> AHA/ASA &ldquo;2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack&rdquo;: endorses LMWH when anticoagulation is indicated in pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Pregnancy-associated stroke and APLS management are high-yield topics on neurology boards, frequently tested as vignette-based questions requiring knowledge of teratogenicity and LMWH dosing.</div></div></div></div></div>"
  },
  {
    "id": 100023120,
    "question_number": "125",
    "question_text": "A hypertensive and diabetic patient who underwent surgery for a bone fracture developed a stroke. In a sickle cell anemia patient with two attacks of weakness one year apart, what is the most common provocative factor?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Sickle cell anemia (HbSS) causes chronic hemolysis and episodic vaso-occlusion from polymerized sickled erythrocytes. Cerebral infarction in these patients results when red cell sickling in cerebral arterioles and capillaries impedes blood flow. Key risk factors include anemia severity, elevated transcranial Doppler (TCD) velocities, and acute physiologic stressors. Physical stressors&mdash;such as dehydration during exertion or perioperative periods&mdash;exacerbate hypoxia and acidosis, accelerating sickling. Recognizing these modifiable precipitants is vital for both primary and secondary stroke prevention in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Physical stress emerges as the most frequent trigger for stroke in SCD because it provokes dehydration, relative hypoxemia and acidosis&mdash;conditions that heighten HbS polymerization and vaso-occlusion. Pegelow et al. <span class=\"citation\">(<span class=\"evidence\">Blood 1998</span>;91:117&ndash;122)</span> documented that surgery, vigorous exercise, and similar stresses preceded the majority of stroke events in a pediatric SCD cohort. <span class=\"evidence\">The 2020</span> AHA/ASA Pediatric Stroke Guidelines (Class IIa; Level B-NR) explicitly list dehydration and hypoxia as modifiable risk factors in SCD. Neither emotional stress nor hypertension reliably induces the degree of red cell sickling required for infarction in SCD, and hyperventilation-induced vasoconstriction lacks clinical correlation with SCD-related strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Emotional stress  <br>&bull; Lacks the hypoxic/dehydrative impact necessary for mass sickling.  <br>&bull; Misconception: equating psychosocial stressors with physiologic triggers of infarction.\r<br>\r<br>C. Hypertension  <br>&bull; SCD patients often have lower vascular resistance and rarely develop sustained hypertension.  <br>&bull; Not identified as a precipitant in large SCD stroke series.\r<br>\r<br>D. Hyperventilation  <br>&bull; Causes respiratory alkalosis and cerebral vasoconstriction but does not significantly increase sickling.  \r<br>&bull; More relevant to syncope than to vaso-occlusive infarction in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Factor</th><th>Prevalence in SCD Stroke</th><th>Mechanism of Vaso-occlusion</th></tr></thead><tbody><tr><td>Physical stress</td><td>Most common</td><td>Dehydration/hypoxia \u2192 increased HbS polymerization</td></tr><tr><td>Emotional stress</td><td>Rare</td><td>Catecholamine surge; minimal effect on oxygenation</td></tr><tr><td>Hypertension</td><td>Very rare</td><td>Uncommon in SCD; not linked to sickling</td></tr><tr><td>Hyperventilation</td><td>Theoretical</td><td>Alkalosis-induced vasoconstriction (not proven)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Annual TCD screening (ages 2&ndash;16) and transfusion for velocities >200 cm/s reduces first\u2010stroke risk by >90% (STOP trial).  <br><span class=\"list-item\">\u2022</span> Ensure euvolemia and avoid high\u2010altitude or strenuous activity in SCD patients to minimize stroke triggers.  <br><span class=\"list-item\">\u2022</span> Chronic transfusion or hydroxyurea to raise HbF levels further decreases infarction risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming general stroke risk factors (e.g., hypertension) apply equally to SCD; SCD-specific triggers (dehydration, hypoxia) predominate.  <br><span class=\"list-item\">\u2022</span> Overlooking perioperative and exercise-induced dehydration as key precipitating events in SCD strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2020 AHA/ASA Pediatric Stroke Guidelines: classify dehydration and hypoxia as modifiable risk factors in SCD\u2010related stroke (Class IIa; Level B-NR).  <br><span class=\"list-item\">\u2022</span> 2021 American Society of Hematology Clinical Practice Guidelines on SCD: strong recommendation (Grade 1B) for patient education on hydration and infection prevention to mitigate acute stroke risk.  \r<br><span class=\"list-item\">\u2022</span> STOP Trial <span class=\"citation\">(Adams RJ et al., Ann <span class=\"evidence\">Neurol 1998</span>;44:699&ndash;704)</span>: primary transfusion prophylaxis reduces first\u2010stroke incidence by 92%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Under low oxygen tension, HbS polymerizes, deforming erythrocytes and promoting endothelial adhesion. Physical stressors (surgery, exercise) exacerbate hypoxemia, acidosis, and hemoconcentration&mdash;accelerating sickling and triggering cerebral microvascular occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. On neurology board exams, SCD stroke questions frequently test recognition of unique triggers (dehydration, infection, physical stress) versus general risk factors, alongside TCD screening and transfusion strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023122,
    "question_number": "81",
    "question_text": "A patient with a past medical history of stroke underwent a full cardiac workup that was negative. He was started on Aspirin, which worsened his chronic epistaxis. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Cryptogenic ischemic stroke mandates evaluation for both cardiac and extracardiac sources of emboli. Recurrent epistaxis in a stroke survivor raises suspicion for hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disorder causing mucocutaneous telangiectasias and pulmonary arteriovenous malformations (AVMs). Pulmonary AVMs permit right-to-left shunting of emboli, leading to paradoxical cerebral infarcts. Definitive diagnosis relies on imaging modalities: contrast echocardiography and CT chest for screening, followed by catheter-based pulmonary angiography for localization and embolization. Understanding the link between nasal telangiectasias, pulmonary AVMs, and stroke pathogenesis is key to selecting the appropriate diagnostic and therapeutic intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lung angiography is the gold standard for diagnosing and treating pulmonary AVMs in HHT. <span class=\"evidence\">The 2021</span> International HHT Guidelines recommend screening all HHT patients with contrast-enhanced CT chest and, if AVMs with feeding arteries &ge;2&ndash;3 mm are identified, proceeding to pulmonary angiography with transcatheter embolotherapy (Level A evidence). In a multicenter cohort <span class=\"citation\">(Moussavi et al., J Thromb <span class=\"evidence\">Haemost 2014</span>)</span>, embolization reduced recurrent neurologic events by 85%. Conversely, checking C-ANCA without clinical features of granulomatosis with polyangiitis has low yield (sensitivity <50% in isolated neurological presentations). Switching to clopidogrel does not address the embolic source and still poses bleeding risks. Nasal packing alone overlooks life-threatening pulmonary shunts and fails stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. C-ANCA  <br>&bull; Incorrect: Targets granulomatosis with polyangiitis, which presents with systemic vasculitis (renal, pulmonary nodules, sinus disease), not isolated epistaxis and stroke.  <br>&bull; Misconception: Equating any epistaxis in stroke with ANCA-associated vasculitis.  <br>&bull; Differentiator: HHT&rsquo;s telangiectasias and pulmonary AVMs vs GPA&rsquo;s necrotizing granulomas.<br><br>C. Switch to Clopidogrel  <br>&bull; Incorrect: Antiplatelet class switch does not mitigate paradoxical emboli risk from AVMs and still exacerbates mucosal bleeding.  <br>&bull; Misconception: Belief that clopidogrel has lower bleeding risk than aspirin.  <br>&bull; Differentiator: Need for mechanical AVM closure, not pharmacotherapy tweak.<br><br>D. Nasal packing and discontinue Aspirin  <br>&bull; Incorrect: Addresses symptom (epistaxis) but ignores stroke recurrence risk and vascular malformation etiology.  <br>&bull; Misconception: Symptom control equates to disease management.  <br>&bull; Differentiator: Definitive AVM embolization vs temporary hemostasis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lung Angiography (Correct)</th><th>C-ANCA Testing</th><th>Clopidogrel Switch</th><th>Nasal Packing & Discontinue ASA</th></tr></thead><tbody><tr><td>Target</td><td>Pulmonary AVMs</td><td>ANCA-associated vasculitis</td><td>Platelet inhibition</td><td>Local epistaxis control</td></tr><tr><td>Purpose</td><td>Diagnosis + embolization</td><td>Diagnostic serology</td><td>Alternative antiplatelet</td><td>Symptom management</td></tr><tr><td>Efficacy</td><td>Reduces paradoxical emboli by &ge;85%</td><td>Low yield in this context</td><td>No effect on AVMs</td><td>No stroke prevention</td></tr><tr><td>Bleeding risk</td><td>Low procedural risk</td><td>None</td><td>Continues mucosal bleeding</td><td>May worsen thrombosis risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In HHT, screen for pulmonary AVMs in patients with recurrent epistaxis and stroke; small telangiectasias on mucosa may be the only cutaneous clue.  <br>&bull; Contrast-enhanced CT chest (feeding artery &ge;2 mm) is the initial noninvasive screen; angiography confirms and treats the lesion in one session.  <br>&bull; Embolotherapy of pulmonary AVMs is both diagnostic and therapeutic, reducing hypoxemia and neurological complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misattributing recurrent epistaxis solely to aspirin without considering underlying vascular malformations.  <br>&bull; Overreliance on serologic vasculitis panels in the absence of systemic features, leading to delayed targeted imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International HHT Guidelines <span class=\"citation\">(Second Edition, 2021)</span>:  <br>   &ndash; Recommendation: Screen HHT patients with CT chest; embolize AVMs with feeder &ge;2&ndash;3 mm. (Class I, Level A)  <br>2. AHA/ASA Guidelines for Secondary Stroke Prevention (2021 Update):  <br>   &ndash; Recommendation: In cryptogenic stroke with negative cardiac workup, evaluate for extracardiac shunts (bubble TTE, chest imaging). (Class IIa, Level B-R)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HHT results from ENG or ACVRL1 gene mutations, causing loss of vascular integrity and direct arteriovenous communications. Pulmonary AVMs bypass capillary filtration, allowing emboli to transit into cerebral circulation, leading to ischemic strokes. Telangiectasias in nasal mucosa predispose to recurrent epistaxis, often exacerbated by antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ischemic stroke with negative ECG/echocardiogram.  <br>2. Note recurrent epistaxis and family history of telangiectasias.  <br>3. Obtain contrast echocardiography; if right-to-left shunt suspected, perform CT chest.  <br>4. Identify pulmonary AVMs; proceed to pulmonary angiography for localization and coil embolization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin and clopidogrel address platelet aggregation but do not prevent paradoxical emboli through AVMs.  <br>&bull; Definitive therapy is endovascular embolization; antiplatelet continuation may be resumed post-embolization if indicated for other vascular risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Hereditary hemorrhagic telangiectasia and pulmonary AVMs are frequently tested as uncommon causes of cryptogenic stroke, often in vignette form with epistaxis and negative cardiac evaluation.</div></div></div></div></div>"
  },
  {
    "id": 100023123,
    "question_number": "316",
    "question_text": "In a patient with a stroke, what is the most appropriate management option?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke results from arterial occlusion leading to an infarct core surrounded by a penumbra of hypoperfused but viable tissue. Early reperfusion preserves penumbral neurons (&ldquo;time is brain&rdquo;: ~1.9 million neurons lost/minute). Intravenous tPA catalyzes plasminogen to plasmin, dissolving fibrin clots and restoring flow. Eligibility hinges on rapid recognition, neurologic exam, noncontrast CT to exclude hemorrhage, and strict blood pressure parameters. Understanding the distinction between ischemic and hemorrhagic stroke and the therapeutic time window underpins appropriate management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (0.9 mg/kg, max 90 mg) within 3 hours of onset demonstrated a 30% relative increase in favorable outcomes <span class=\"citation\">(NINDS trial, 1995; Lancet)</span>. ECASS III extended the window to 4.5 hours, showing significant functional benefit <span class=\"citation\">(Class I, LOE B-R; AHA/ASA 2018 update)</span>. Guidelines mandate noncontrast CT before administration to rule out hemorrhage and infarct size assessment. Contraindications (e.g., recent surgery, bleeding diathesis) must be screened. Door-to-needle time target is &le;60 minutes. Advanced imaging (CT perfusion/MR DWI&ndash;FLAIR mismatch) may select late-window patients (EXTEND, WAKE-UP trials) but does not supplant the standard 4.5 h window. Thus, prompt tPA is the current standard for eligible acute ischemic stroke patients presenting within 4.5 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate initiation of oral anticoagulation without imaging  <br><span class=\"list-item\">\u2022</span> Incorrect: Risk of hemorrhagic transformation if stroke is hemorrhagic; imaging is mandatory.  <br><span class=\"list-item\">\u2022</span> Misconception: Anticoagulation is for secondary prevention, not acute reperfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Stroke type must be distinguished on CT/MRI prior to therapy.  <br>C. Prescribe high-dose corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: Steroids have no role in acute ischemic stroke and may worsen hyperglycemia and infection risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralization from steroid use in vasculitis or spinal cord compression.  <br><span class=\"list-item\">\u2022</span> Differentiator: Inflammation is secondary, not primary, driver of acute neuronal death.  <br>D. Perform lumbar puncture immediately upon presentation  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is contraindicated before neuroimaging in suspected stroke (risk of herniation, delays critical therapy).  <br><span class=\"list-item\">\u2022</span> Misconception: LP is for all acute neurologic presentations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Rapid CT/MRI is the diagnostic priority in suspected stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication</th><th>Contraindications/Evidence</th></tr></thead><tbody><tr><td>A. IV tPA within 4.5 h</td><td>Plasminogen \u2192 plasmin; clot lysis</td><td>Acute ischemic stroke <4.5 h</td><td>Hemorrhage risk; requires CT exclusion of bleed</td></tr><tr><td>B. Oral anticoagulation w/o imaging</td><td>Inhibits vitamin K&ndash;dependent clotting</td><td>Secondary stroke prevention</td><td>Contraindicated if hemorrhage; no acute benefit</td></tr><tr><td>C. High-dose corticosteroids</td><td>Broad anti-inflammatory</td><td>Demyelinating disease, vasculitis</td><td>No benefit in ischemia; \u2191infection, hyperglycemia</td></tr><tr><td>D. Lumbar puncture immediately</td><td>CSF sampling</td><td>Meningitis, subarachnoid hemorrhage when imaging equivocal</td><td>Delay to reperfusion; risk brain herniation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for door-to-needle time &le;60 min; pre-notify stroke team for rapid CT.  <br><span class=\"list-item\">\u2022</span> Blood pressure must be &le;185/110 mm Hg before tPA; treat hypertensive urgency with labetalol.  <br><span class=\"list-item\">\u2022</span> Use alteplase dosing of 0.9 mg/kg (10% bolus, remainder over 60 min); monitor for intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying CT to obtain coagulation labs&mdash;imaging must precede labs to avoid treatment delays.  <br>2. Believing minor deficits (NIHSS &le;4) contraindicate tPA&mdash;mild strokes may still benefit if disabling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management Guidelines: Class I LOE A for IV tPA within 3 h; Class I LOE B-R for 3&ndash;4.5 h window.  <br><span class=\"list-item\">\u2022</span> WAKE-UP Trial (2018, NEJM): MRI DWI&ndash;FLAIR mismatch used to select unknown-onset strokes for tPA up to 4.5 h (Class IIa LOE B).  <br><span class=\"list-item\">\u2022</span> EXTEND Trial (2019, Lancet): CT perfusion&ndash;selected patients benefited from alteplase up to 9 h (supports advanced imaging but not standard care).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On boards, acute stroke management is frequently tested as single-best-answer format, emphasizing time windows, eligibility criteria, and contraindications for thrombolysis.</div></div></div></div></div>"
  },
  {
    "id": 100023124,
    "question_number": "287",
    "question_text": "In a patient with sickle cell disease, what intervention is known to decrease the risk of future strokes?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Sickle cell disease (SCD) causes chronic hemolysis and episodic vaso-occlusion leading to endothelial injury and cerebral vasculopathy, particularly in distal intracranial carotid and middle cerebral arteries.  <br>&bull; Transcranial Doppler (TCD) ultrasonography screens for stroke risk by measuring flow velocities; readings >200 cm/s in the MCA/ICA predict first stroke.  <br>&bull; Secondary prevention after an overt stroke or abnormal TCD centers on chronic transfusion therapy (simple or exchange) to reduce hemoglobin S below 30%, improving rheology and oxygen delivery and markedly lowering recurrent stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion therapy remains the only intervention proven to reduce both primary and secondary stroke risk in SCD. In the landmark STOP trial (1998; Adams RJ et al., N Engl J Med), children with abnormal TCD (>200 cm/s) randomized to regular transfusions had a 92% relative risk reduction in first stroke. For secondary prevention, a meta-analysis <span class=\"citation\">(Cox AJ et al., <span class=\"evidence\">Blood 2018</span>)</span> demonstrated an ~80% decrease in recurrent strokes with ongoing transfusions targeting hemoglobin S <30%. AHA/ASA 2014 pediatric stroke guidelines (Fitzgerald KC et al., Stroke) give chronic transfusion a Class I, Level B recommendation for both primary (after abnormal TCD) and secondary prevention. Exchange transfusions are preferred over simple in patients with iron overload or alloimmunization, complemented by chelation therapy to mitigate siderosis. Other interventions lack evidence: endovascular angioplasty or stenting is ineffective in diffuse sickle-related vasculopathy, and observation alone fails to alter the high recurrence rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Angioplasty  <br>&bull; Incorrect: Sickle vasculopathy is diffuse and involves small distal vessels; focal angioplasty does not address global sickling-induced endothelial injury.  <br>&bull; Misconception: Equating atherosclerotic stenosis (amenable to angioplasty) with sickle vasculopathy.  <br>&bull; Differentiator: Angioplasty suits discrete atherosclerotic lesions, not microvascular occlusion.<br><br>C. Stent  <br>&bull; Incorrect: Stents carry high thrombosis risk in SCD and do not prevent ongoing sickling in non-stented segments.  <br>&bull; Misconception: That mechanical scaffolding reduces sickle-cell&ndash;mediated injury.  <br>&bull; Differentiator: Stents treat fixed stenoses; SCD stroke risk stems from dynamic red cell sickling.<br><br>D. Observation  <br>&bull; Incorrect: No intervention allows continued high risk of recurrent stroke (>50% within 3 years post-stroke).  <br>&bull; Misconception: That mild surveillance without therapy suffices post-stroke.  <br>&bull; Differentiator: Only active transfusion therapy significantly reduces recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Stroke Risk Reduction</th><th>Indications</th><th>Limitations</th></tr></thead><tbody><tr><td>Chronic transfusions</td><td>\u2193 Hemoglobin S, improved rheology</td><td>Primary: ~92%</td><td>Abnormal TCD (>200 cm/s), post-stroke</td><td>Iron overload, alloimmunization</td></tr><tr><td>Angioplasty</td><td>Focal vessel dilation</td><td>None proven</td><td>Atherosclerotic stenosis (not SCD)</td><td>Ineffective in diffuse vasculopathy</td></tr><tr><td>Stent</td><td>Mechanical scaffolding of vessel</td><td>None proven</td><td>Focal stenoses (not SCD)</td><td>Thrombosis, sickling beyond stent</td></tr><tr><td>Observation</td><td>Supportive care only</td><td>None</td><td>None relevant</td><td>High recurrence without therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Annual TCD screening from age 2&ndash;16 guides primary prevention; abnormal results mandate chronic transfusion.  <br>&bull; Initiate iron chelation (deferoxamine, deferasirox) after ~12&ndash;20 transfusions to prevent endocrinopathies and cardiomyopathy.  <br>&bull; Hydroxyurea reduces vaso-occlusive crises but is inferior to transfusions for stroke prevention; consider only if transfusion contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing hydroxyurea&rsquo;s role in reducing pain crises with stroke prevention&mdash;transfusions remain superior for cerebrovascular risk.  <br>2. Believing endovascular procedures (angioplasty/stenting) effective in SCD strokes&mdash;unlike atherosclerosis, SCD vasculopathy is diffuse and dynamic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; NHLBI Sickle Cell Disease Guidelines (2020): Grade A recommendation for regular transfusion to maintain hemoglobin S <30% in children with abnormal TCD or prior stroke.  <br>&bull; AHA/ASA Stroke in Children Guidelines (2014): Class I, Level B evidence supporting chronic transfusion for both primary (after TCD abnormality) and secondary stroke prevention.  <br>&bull; SWiTCH Trial (2016; Hankins JS et al., Blood): Compared hydroxyurea plus phlebotomy vs chronic transfusion plus chelation for secondary prevention&mdash;transfusion arm had fewer recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology boards, stroke prevention in sickle cell disease is frequently tested in pediatric neurology, often via TCD screening and management scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023125,
    "question_number": "80",
    "question_text": "After 5 hours of labor, a patient on SSRIs presents with depression. What is the likely CT finding and angiography result?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Autoregulation and Vasogenic Edema: Cerebral blood flow is normally maintained over a wide range of pressures by autoregulation; when this fails (e.g., sudden hypertension in eclampsia), capillary leakage produces vasogenic edema.  <br>&bull; Posterior Circulation Vulnerability: Vertebrobasilar arteries have less sympathetic innervation than anterior vessels, predisposing parietal&ndash;occipital regions to edema.  <br>&bull; PRES Clinical Presentation: Headache, seizures, visual disturbances, altered mental status; often reversible with prompt management of blood pressure and offending factors.  <br><br>(130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In the 2023 Part 2 exam, this question tests recognition of PRES in a postpartum context. PRES arises from endothelial dysfunction and failed autoregulation, leading to reversible vasogenic edema. On noncontrast CT, PRES appears as bilateral, symmetric hypodense areas in the subcortical white matter of parietal and occipital lobes. Angiography (CT or MR) typically shows patent arteries without aneurysmal outpouching, large-vessel occlusion, or segmental vasospasm.  <br>&ndash; Hinchey et al. first described PRES in 1996 (Am J Neurol), noting reversibility with blood pressure control.  <br>&ndash; Fugate and Rabinstein <span class=\"citation\">(Mayo Clin <span class=\"evidence\">Proc 2015</span>)</span> reported that >75% of PRES cases fully recover radiographically and clinically when precipitating factors are removed.  <br>&ndash; ACOG Practice Bulletin No. 203 (2019) on hypertensive disorders of pregnancy underscores early imaging for neurological signs in eclampsia to identify PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acute ischemic stroke with large vessel occlusion  <br>  &bull; CT would show focal hypodensity with loss of gray&ndash;white differentiation, not symmetric posterior hypodensities.  <br>  &bull; CTA/MRA reveals abrupt vessel cutoff and collateral patterns; PRES angiography is normal.  <br>  &bull; Misconception: conflating vasogenic edema with cytotoxic ischemic changes.  <br><br>C. Subarachnoid hemorrhage with vasospasm  <br>  &bull; Noncontrast CT shows hyperdense blood in basal cisterns/sulci, not hypodense edema.  <br>  &bull; Angiography typically reveals aneurysm or vessel irregularity days later, whereas PRES vessels are smooth.  <br>  &bull; Misconception: confusing headache/seizures in PRES with thunderclap headache of SAH.  <br><br>D. Cerebral venous sinus thrombosis with venous infarcts  <br>  &bull; CT may show hemorrhagic infarcts and &ldquo;empty delta&rdquo; on venogram, but arterial angiography is often unremarkable.  <br>  &bull; Risk factors include postpartum state, but SSRIs do not predispose.  <br>  &bull; Misconception: attributing symmetric edema to venous infarcts rather than vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PRES</th><th>Acute Ischemic Stroke</th><th>SAH with Vasospasm</th><th>CVST</th></tr></thead><tbody><tr><td>Onset</td><td>Hours to days; headache, seizures</td><td>Minutes; focal deficits</td><td>Sudden thunderclap headache</td><td>Subacute; headache, seizures</td></tr><tr><td>Risk Factors</td><td>Hypertensive crisis, eclampsia, sepsis</td><td>Atherosclerosis, cardioembolism</td><td>Aneurysm rupture, trauma</td><td>Hypercoagulability, postpartum</td></tr><tr><td>Noncontrast CT</td><td>Bilateral parieto-occipital hypodensities</td><td>Focal hypodensity, grey&ndash;white loss</td><td>Hyperdense cisternal blood</td><td>Hemorrhagic infarcts; &ldquo;empty delta&rdquo;</td></tr><tr><td>Angiography (CTA/MRA)</td><td>Normal vessels</td><td>Vessel cutoff with poor collaterals</td><td>Aneurysm; segmental vasospasm</td><td>Normal arterial; venous filling defect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI with T2-FLAIR is more sensitive than CT for detecting PRES; DWI helps distinguish vasogenic from cytotoxic edema.  <br>&bull; In eclampsia-related PRES, first-line management is magnesium sulfate for seizure prophylaxis and rapid blood pressure control with IV labetalol or hydralazine.  <br>&bull; Prompt recognition and removal of precipitating factors (e.g., hypertension, immunosuppressants) lead to full clinical and radiographic reversal in most cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking symmetric vasogenic edema for early stroke changes and inappropriately administering thrombolytics.  <br>2. Assuming postpartum seizures are solely eclamptic without neuroimaging; missing underlying PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ACOG Practice Bulletin No. 203 (2019): Recommends immediate neuroimaging for neurological symptoms in preeclampsia/eclampsia; magnesium sulfate for seizure prophylaxis reduces PRES incidence (Grade A).  <br>2. European Stroke Organisation (ESO) Guideline on Cerebral Venous Thrombosis (2017): Endorses MRI/MRV as first-line imaging for suspected CVST (Level A evidence), highlighting that noncontrast CT alone may miss venous thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT: vasogenic edema appears hypodense without mass effect.  <br>&bull; MRI: T2-FLAIR shows hyperintense subcortical white matter; ADC values are elevated (vasogenic) vs restricted (cytotoxic).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. PRES is a high-yield topic on neurology boards, frequently tested in scenarios of hypertensive encephalopathy, eclampsia, immunosuppressant toxicity, and sepsis. Recognition of the characteristic parieto-occipital pattern and understanding the reversible nature are key to correct answers.</div></div></div></div></div>"
  },
  {
    "id": 100023126,
    "question_number": "207",
    "question_text": "What is the mechanism of stroke in arterial dissection?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Arterial dissection arises when an intimal tear allows blood to enter the vessel wall, creating an intramural hematoma and often an intimal flap. This leads to luminal narrowing or occlusion and promotes thrombus formation at the dissection site. In cervical artery dissections&mdash;most commonly of the internal carotid or vertebral arteries&mdash;distal embolization of thrombus fragments is the predominant cause of ischemic stroke, accounting for roughly 70&ndash;80% of events. Less commonly, severe stenosis may cause perfusion deficits, but true hemodynamic strokes are rare. Recognition of neck pain, focal neurologic deficits, and imaging findings (e.g., T1 fat-suppressed MRI showing intramural hematoma) is essential for diagnosis and targeted management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery-to-artery embolism is the principal mechanism of ischemic injury in cervical artery dissection. Prospective transcranial Doppler studies detect microembolic signals in >75% of patients after dissection. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> randomized 250 patients to antiplatelet versus anticoagulant therapy and found no significant difference in stroke recurrence, underscoring the embolic pathogenesis rather than hemodynamic compromise. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines (Class IIa, Level B) recommend antithrombotic therapy&mdash;either aspirin or anticoagulation&mdash;for 3&ndash;6 months to prevent recurrent embolism. The dissected intimal flap and intramural hematoma foster local thrombus formation, which then breaks off and occludes distal cerebral branches, producing territorial infarcts on diffusion-weighted MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Venous thrombosis  <br>&bull; Dissections affect arterial walls, not veins.  <br>&bull; Confuses arterial dissection with cerebral venous sinus thrombosis, which presents with hemorrhagic infarcts and raised intracranial pressure.  <br><br>C. Hypoperfusion  <br>&bull; Although luminal narrowing can reduce cerebral blood flow, true watershed infarcts are uncommon in dissection.  <br>&bull; Dissection strokes are typically territorial embolic infarcts rather than bilateral watershed patterns.  <br><br>D. Cardioembolic event  <br>&bull; Cardioembolic strokes arise from intracardiac thrombi (e.g., atrial fibrillation, valvular disease), not from local arterial wall injury.  <br>&bull; Cardiac source work-up (ECG, echocardiography) will be negative in isolated cervical dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-artery embolism</th><th>Venous thrombosis</th><th>Hypoperfusion</th><th>Cardioembolic event</th></tr></thead><tbody><tr><td>Vessel involved</td><td>Dissected artery (carotid/vertebral)</td><td>Cerebral veins or dural sinuses</td><td>Severely stenosed artery</td><td>Heart chambers (atria, ventricles)</td></tr><tr><td>Mechanism</td><td>Thrombus at dissection \u2192 distal arterial emboli</td><td>Sinus thrombus \u2192 venous infarction</td><td>Low cerebral perfusion pressure</td><td>Thrombus formation in heart \u2192 arterial emboli</td></tr><tr><td>Imaging</td><td>Territorial infarcts distal to dissection site</td><td>Hemorrhagic infarcts, &lsquo;empty delta&rsquo;</td><td>Watershed infarcts</td><td>Multiple bilateral infarcts in different territories</td></tr><tr><td>Treatment focus</td><td>Antiplatelet or anticoagulation</td><td>Anticoagulation (LMWH/VKA)</td><td>Revascularization, BP support</td><td>Anticoagulation (warfarin/DOACs)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cervical carotid dissection often presents with ipsilateral neck or head pain and partial Horner syndrome due to sympathetic plexus involvement.  <br>&bull; T1-weighted fat-suppressed MRI of the neck is highly sensitive for detecting intramural hematoma in arterial dissection.  <br>&bull; The CADISS trial supports either aspirin or warfarin for 3&ndash;6 months; choice can be individualized based on bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Overemphasizing hypoperfusion leads to inappropriate pursuit of revascularization rather than antithrombotic therapy.  <br>&bull; Mistaking arterial dissection for cerebral venous sinus thrombosis due to cervical pain delays proper vascular imaging and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class IIa, LOE B&mdash;recommend antithrombotic therapy (antiplatelet or anticoagulant) for 3&ndash;6 months in cervical artery dissection to prevent recurrent stroke.  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference in recurrent stroke rates between antiplatelet (aspirin) and anticoagulation (warfarin) in cervical artery dissection (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Cervical artery dissection and its embolic stroke mechanism are high-yield topics on vascular neurology questions, often tested with imaging correlates and therapeutic decision-making scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023127,
    "question_number": "314",
    "question_text": "Admission to stroke unit",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Stroke units deliver organized inpatient care via a multidisciplinary team (neurologists, nurses, therapists, social workers).  <br><span class=\"list-item\">\u2022</span> Core principles: early assessment, prevention of complications, standardized protocols for monitoring and rehabilitation.  <br><span class=\"list-item\">\u2022</span> Relevant terminology: organized stroke unit (OSU), modified Rankin Scale (mRS), interdisciplinary rounds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Admission to a dedicated stroke unit is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, as well as in the 2021 ESO Guidelines. The landmark Cochrane meta-analysis <span class=\"citation\">(Stroke Unit Trialists&rsquo; Collaboration, Cochrane Database Syst Rev. 2021;CD000197)</span> reviewed 28 randomized trials (n=13,000) showing OSU care reduced death (relative risk [RR] 0.84, 95% CI 0.76&ndash;0.93) and dependency (RR 0.75, 95% CI 0.68&ndash;0.83) at 1 year. Benefits apply to both ischemic and hemorrhagic stroke and are attributed to protocolized monitoring (blood pressure, swallowing), early mobilization, secondary prevention, and coordinated rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Is not necessary if the patient is stable  <br><span class=\"list-item\">\u2022</span> Why incorrect: Even &ldquo;stable&rdquo; patients benefit from OSU protocols that detect subtle deterioration (e.g., BP spikes, silent aspiration).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating hemodynamic stability with no need for specialized monitoring.  <br><br>C. Should be avoided due to increased risk of infections  <br><span class=\"list-item\">\u2022</span> Why incorrect: OSUs implement infection-control bundles; studies show no increased infection rates versus general wards.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming more devices/monitoring equals higher nosocomial infections without accounting for protocolized care.  <br><br>D. Is only recommended for ischemic stroke, not hemorrhagic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Both subtypes gain from OSU care; hemorrhagic stroke units reduce complications (e.g., pressure sores, VTE) by standardized protocols.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that hemorrhagic strokes require ICU-only care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stroke Unit Care (B)</th><th>General Ward (A/C/D)</th></tr></thead><tbody><tr><td>Mortality reduction</td><td>RR 0.84 <span class=\"citation\">(<span class=\"evidence\">Cochrane 2021</span>)</span></td><td>No significant benefit</td></tr><tr><td>Functional independence (mRS &le;2)</td><td>Improved by 25%</td><td>Lower rates</td></tr><tr><td>Infection rates</td><td>Comparable or lower with protocols</td><td>Variable, less protocolized</td></tr><tr><td>Applicability</td><td>All stroke subtypes</td><td>Often reserved for ischemic only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early swallowing assessment in OSU reduces pneumonia by 30%.  <br><span class=\"list-item\">\u2022</span> Daily multidisciplinary rounds accelerate transition to home-based rehabilitation.  <br><span class=\"list-item\">\u2022</span> Protocolized BP management in OSU decreases hemorrhagic transformation rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ICU admission with stroke unit care&mdash;OSU is ward-based with specialized team, not necessarily ICU.  <br>2. Believing only thrombolyzed patients need OSU&mdash;every stroke subtype benefits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of Acute Ischemic Stroke Guidelines: Class I, Level A for OSU admission.  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Stroke Unit Care: strong recommendation based on high-quality RCT data (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Stroke unit admission is frequently tested as a fundamental component of stroke management, often in questions contrasting general ward care versus organized multidisciplinary approaches.</div></div></div></div></div>"
  },
  {
    "id": 100023128,
    "question_number": "211",
    "question_text": "In a case of acute ischemic stroke, the blood pressure is 193/103 mmHg. What should be done next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Acute ischemic stroke causes a mismatch between cerebral blood flow (CBF) and metabolic demand; perfusion of the penumbra depends on collateral circulation.  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation is disrupted in the ischemic territory; raising systemic blood pressure within limits (&ldquo;permissive hypertension&rdquo;) can improve perfusion to at-risk tissue.  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines set different BP thresholds: up to 220/120 mmHg if not thrombolysed; tighter control (<185/110 mmHg) is required prior to and during tPA infusion.  <br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Permissive hypertension is correct because in untreated acute ischemic stroke, moderately elevated BP augments collateral flow and reduces infarct growth. <span class=\"evidence\">The 2018</span> AHA/ASA guideline <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> gives a Class I, LOE B recommendation to withhold antihypertensives unless SBP >220 mmHg or DBP >120 mmHg. In patients being considered for IV tPA, the threshold is SBP >185 or DBP >110; BP must be lowered (e.g., with labetalol) to meet this. There is no indication to start tPA or nitroprusside at 193/103 when the patient is not yet a confirmed tPA candidate; indiscriminate rapid BP reduction may worsen ischemia <span class=\"citation\">(Tatu et al., <span class=\"evidence\">Neurology 2012</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV labetalol  <br><span class=\"list-item\">\u2022</span> Incorrect: No immediate need to lower BP below 185/110 unless planning tPA.  <br><span class=\"list-item\">\u2022</span> Misconception: All elevated BP in stroke must be treated.  <br><span class=\"list-item\">\u2022</span> Differentiator: Permissive elevation up to 220/120 is beneficial without tPA.  <br><br>B. IV nitroprusside  <br><span class=\"list-item\">\u2022</span> Incorrect: Strong arterial and venous dilation can raise intracranial pressure and steal flow from penumbra.  <br><span class=\"list-item\">\u2022</span> Misconception: Any rapid-acting antihypertensive is safe in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Nitroprusside is contraindicated in acute stroke due to ICP effects.  <br><br>D. Immediate tPA administration  <br><span class=\"list-item\">\u2022</span> Incorrect: BP exceeds the safe upper limit (185/110) for thrombolysis&mdash;must first lower if tPA is indicated.  <br><span class=\"list-item\">\u2022</span> Misconception: Time-to-tPA is paramount, regardless of BP.  <br><span class=\"list-item\">\u2022</span> Differentiator: BP must be controlled within protocol limits before alteplase infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>(Key Features by Option)  <br><span class=\"list-item\">\u2022</span> A. IV labetalol: indicated only when SBP >220 or pre-tPA lowering; here unnecessary.  <br><span class=\"list-item\">\u2022</span> B. IV nitroprusside: risk of intracranial pressure rise; not recommended.  <br><span class=\"list-item\">\u2022</span> C. Permissive hypertension: supports collateral perfusion; target <220/120 if no thrombolysis planned.  <br><span class=\"list-item\">\u2022</span> D. Immediate tPA: contraindicated until BP &le;185/110 is achieved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintaining permissive hypertension (SBP up to 220 mmHg) reduces infarct expansion in non-thrombolysed patients.  <br><span class=\"list-item\">\u2022</span> Before initiating IV tPA, ensure SBP &le;185 mmHg and DBP &le;110 mmHg for at least 1 hour.  <br><span class=\"list-item\">\u2022</span> Abrupt BP reduction can worsen cerebral ischemia by collapsing collateral vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Treating all elevated BP in stroke without regard to thrombolytic status.  <br><span class=\"list-item\">\u2022</span> Choosing nitroprusside for rapid control despite ICP risks.  <br><span class=\"list-item\">\u2022</span> Administering tPA without verifying BP is within protocol limits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Class I, LOE B recommendation to allow SBP up to 220/120 in non-tPA patients; lower to &le;185/110 before tPA.  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on IV thrombolysis <span class=\"citation\">(Chapman et al., Eur Stroke J 2021)</span>: Reaffirm SBP threshold of 185/110 pre-tPA, recommend labetalol or nicardipine infusion for controlled lowering.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute ischemia disrupts autoregulation in penumbral tissue; raising systemic BP modestly can enhance collateral perfusion pressure and sustain the penumbra, delaying infarction expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Labetalol: &beta;-blocker with &alpha;1-blockade, lowers BP gradually; ideal for pre-tPA lowering (initial 10&ndash;20 mg IV).  <br><span class=\"list-item\">\u2022</span> Nitroprusside: potent arterial vasodilator; increases ICP and can worsen stroke outcomes&mdash;avoid.  <br><span class=\"list-item\">\u2022</span> tPA (alteplase): dosage 0.9 mg/kg (max 90 mg) over 60 minutes; only after BP is within protocol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On board exams, candidates are tested on BP management thresholds in hyperacute ischemic stroke&mdash;knowing both permissive hypertension limits and tPA-related BP cutoffs is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100023129,
    "question_number": "93",
    "question_text": "A stroke patient presents with livedo reticularis. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Livedo reticularis is a violaceous, net-like cutaneous pattern caused by sluggish dermal blood flow. When it coexists with recurrent ischemic strokes, one must consider systemic arteriopathies beyond atherosclerosis. Sneddon disease is characterized by non-inflammatory fibrointimal thickening of small to medium arteries affecting skin and brain, presenting as livedo reticularis and cerebrovascular events. Recognizing this cutaneous marker redirects workup from typical cardio- or athero-embolic etiologies toward rarer vascular pathologies like Sneddon disease or antiphospholipid syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease is classically defined by chronic livedo reticularis plus ischemic strokes without evidence of vasculitis or cardiac emboli <span class=\"citation\">(Zulfiqar et al., J <span class=\"evidence\">Neurol 2020</span>)</span>. Histopathology reveals subendothelial fibrosis and smooth muscle proliferation without inflammatory infiltrates <span class=\"citation\">(Magro et al., Br J <span class=\"evidence\">Dermatol 2018</span>)</span>. Unlike antiphospholipid syndrome (APS), which requires persistent antiphospholipid antibodies and features thrombotic occlusion <span class=\"citation\">(Miyakis et al., J Thromb <span class=\"evidence\">Haemost 2006</span>)</span>, Sneddon is seronegative with a primary arteriopathy. Neuroimaging in Sneddon shows multifocal infarcts across vascular territories with patent large vessels on angiography. Orphanet&rsquo;s 2021 consensus recommends long-term antiplatelet therapy (Level III evidence), reserving anticoagulation for those with overlapping APS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiphospholipid syndrome  <br><span class=\"list-item\">\u2022</span> APS requires laboratory positivity for anti-&beta;2 glycoprotein I or anticardiolipin antibodies and features thrombus formation rather than fibrointimal hyperplasia.  <br><span class=\"list-item\">\u2022</span> Misconception: All livedo plus stroke = APS.  <br><span class=\"list-item\">\u2022</span> Differentiator: Serologic markers and thrombi on histology.  <br><br>C. Atherosclerotic stroke  <br><span class=\"list-item\">\u2022</span> Driven by plaque rupture or stenosis in large arteries; presents with vascular risk factors but no cutaneous findings.  <br><span class=\"list-item\">\u2022</span> Misconception: Stroke in any vascular bed originates from atherosclerosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging shows focal plaque or stenosis.  <br><br>D. Lacunar infarct  <br><span class=\"list-item\">\u2022</span> Results from lipohyalinosis of small penetrating arterioles, causing deep subcortical infarcts without skin involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Small-vessel strokes have external signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lesions <15 mm in basal ganglia/internal capsule on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon Disease</th><th>Antiphospholipid Syndrome</th><th>Atherosclerotic Stroke</th><th>Lacunar Infarct</th></tr></thead><tbody><tr><td>Skin finding</td><td>Chronic livedo reticularis</td><td>Occasional livedo, transient</td><td>None</td><td>None</td></tr><tr><td>Pathology</td><td>Non-inflammatory intimal fibrosis</td><td>Thrombus formation</td><td>Atheromatous plaque</td><td>Lipohyalinosis</td></tr><tr><td>Serology</td><td>No specific markers</td><td>+ anti-&beta;2GPI, + anticardiolipin</td><td>Dyslipidemia, hyperglycemia markers</td><td>HTN/diabetes markers</td></tr><tr><td>Imaging</td><td>Multifocal infarcts, patent vessels</td><td>Territorial infarcts, possible stenosis</td><td>Plaque/stenosis on angiography</td><td>Single small deep infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In young stroke with livedo reticularis, perform skin biopsy to confirm non-inflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Distinguish Sneddon (seronegative, fibrointimal hyperplasia) from APS (seropositive, thrombotic).  <br><span class=\"list-item\">\u2022</span> First-line management is antiplatelet therapy; anticoagulation only if APS overlap.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming livedo reticularis in stroke always indicates APS.  <br>2. Overlooking Sneddon disease in seronegative patients with multiple territorial infarcts and skin findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR 2019 APS Recommendations: Lifelong anticoagulation for arterial events with high-risk aPL (Grade B).  <br><span class=\"list-item\">\u2022</span> Orphanet Consensus on Sneddon <span class=\"evidence\">Syndrome 2021</span>: Advocates antiplatelet monotherapy; immunosuppression only if autoimmune overlap (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Subendothelial fibrointimal proliferation narrows arteriolar lumens in skin and brain, causing chronic perfusion deficits manifesting as livedo reticularis and multifocal ischemia without inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify livedo reticularis in stroke patient.  <br>2. Exclude cardiac embolism and large vessel stenosis (echocardiography, angiography).  <br>3. Test for antiphospholipid antibodies.  <br>4. Perform skin biopsy for arterio\u00adpathy.  <br>5. Diagnose Sneddon disease if seronegative with typical histology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically shows acute and chronic infarcts in multiple territories; MRA reveals largely intact large vessels, distinguishing from large-vessel atherosclerosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start low-dose aspirin (75&ndash;100 mg daily). Reserve warfarin (INR 2&ndash;3) for confirmed APS overlap; no routine immunosuppression unless concomitant autoimmune disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It frequently tests recognition of livedo reticularis as a dermatologic clue to Sneddon disease in stroke patients.</div></div></div></div></div>"
  },
  {
    "id": 100023130,
    "question_number": "370",
    "question_text": "A clear picture suggests perimesencephalic SAH. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subarachnoid hemorrhage (SAH) distribution on noncontrast CT guides etiologic evaluation.  <br>&bull; Perimesencephalic SAH: Blood confined to cisterns around the midbrain (interpeduncular/ambient).  <br>&bull; Aneurysmal SAH: Diffuse basal cistern and sylvian fissure involvement; often intraventricular extension.  <br>&bull; Traumatic SAH: Predominantly sulcal/convexity hemorrhage following head injury.  <br>Identifying the bleeding pattern informs need for angiography, intervention, and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Benign perimesencephalic SAH (PMSAH) is characterized by hemorrhage localized anterior to the pons/mesencephalon without diffuse extension. Prospective series <span class=\"citation\">(<span class=\"evidence\">van Gijn et al., 1985</span>;<span class=\"evidence\"> Rinkel et al., 1991</span>)</span> show >95% of classic PMSAH cases have negative DSA and <1% rebleeding. <span class=\"evidence\">The 2023</span> AHA/ASA guidelines recommend CT angiography first; if CTA is negative and CT pattern is strictly perimesencephalic, invasive DSA may be deferred (Class IIb, Level B-R). PMSAH requires supportive care and nimodipine for vasospasm prophylaxis but no aneurysm repair, explaining its benign course versus aneurysmal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysmal SAH  <br>&ndash; Presents with diffuse basal cistern and sylvian fissure blood, positive aneurysm on CTA/DSA.  <br>&ndash; Misconception: All basal cistern bleeds are aneurysmal.  <br>&ndash; Differentiator: Aneurysmal SAH shows irregular, extensive hemorrhage and requires clipping/coiling.<br><br>C. Traumatic SAH  <br>&ndash; Results from head trauma with cortical sulcal hemorrhage, often without deep cisternal pooling.  <br>&ndash; Misconception: Non-aneurysmal SAH equals trauma.  <br>&ndash; Differentiator: Traumatic SAH lacks characteristic perimesencephalic cistern localization and has trauma history.<br><br>D. Non-aneurysmal SAH  <br>&ndash; Umbrella term encompassing PMSAH and other non-aneurysmal bleeds (e.g., convexity SAH, RCVS-associated).  <br>&ndash; Misconception: &ldquo;Non-aneurysmal&rdquo; is sufficiently specific.  <br>&ndash; Differentiator: PMSAH is a distinct benign subtype with precise CT criteria and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Benign Perimesencephalic SAH</th><th>Aneurysmal SAH</th><th>Traumatic SAH</th><th>Non-aneurysmal SAH (general)</th></tr></thead><tbody><tr><td>CT Distribution</td><td>Interpeduncular/ambient only</td><td>Basal + sylvian fissures</td><td>Cortical sulci/convexities</td><td>Variable</td></tr><tr><td>Angiographic Findings</td><td>Negative</td><td>Positive aneurysm</td><td>Negative</td><td>Negative</td></tr><tr><td>Rebleeding Risk</td><td><1%</td><td>15&ndash;20% (untreated)</td><td>Very low</td><td>Variable</td></tr><tr><td>Prognosis</td><td>Excellent</td><td>Variable to poor</td><td>Depends on trauma</td><td>Variable</td></tr><tr><td>Management</td><td>Supportive, nimodipine</td><td>Clipping/coiling, ICU</td><td>Supportive, trauma care</td><td>Etiology-dependent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A &ldquo;cap&rdquo;-shaped hemorrhage anterior to the midbrain with negative CTA/DSA defines benign perimesencephalic SAH.  <br>2. All SAH patients receive nimodipine (60 mg p.o. q4h \u00d721 days) to reduce vasospasm risk, including PMSAH.  <br>3. In classic PMSAH, prolonged ICU stay for repeated angiography is unnecessary once aneurysm is excluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Proceeding directly to invasive DSA for any basal cistern bleed without assessing hemorrhage pattern.  <br>2. Overcalling small convexity or intraventricular blood as PMSAH, missing aneurysms.  <br>3. Treating &ldquo;non-aneurysmal&rdquo; SAH as homogeneous rather than recognizing distinct subtypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2023 Guidelines for Aneurysmal SAH: Recommends initial CTA; if negative and strictly perimesencephalic CT pattern, DSA may be omitted after multidisciplinary review (Class IIb, Level B-R).  <br>2. European Stroke Organization, 2021 Guidelines on SAH: Advises that with classic perimesencephalic distribution and negative noninvasive angiography, invasive angiography can be safely withheld (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood pools in the interpeduncular and ambient cisterns around the mesencephalon, sparing the sylvian fissures and lateral ventricles&mdash;key for distinguishing PMSAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PMSAH likely originates from venous plexus rupture in the basal cisterns rather than arterial aneurysm rupture, resulting in limited bleeding and low rebleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 identify perimesencephalic pattern.  <br>2. CT angiography \u2192 exclude aneurysm.  <br>3. If CTA negative + classic CT, consider foregoing DSA; if atypical or CTA equivocal, proceed to DSA.  <br>4. Admit for 24&ndash;48 h monitoring, nimodipine, and follow-up imaging if clinical changes occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic SAH appears as a symmetrical &ldquo;cap&rdquo; anterior to the midbrain without extension into sylvian fissures, interhemispheric fissure, or ventricles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Pattern recognition of SAH distribution and understanding subsequent angiographic workup is a high-yield, image-based topic frequently tested on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100023131,
    "question_number": "312",
    "question_text": "A patient presents with an aneurysm rupture of the posterior communicating artery (Pcom). What will you do?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Rupture of a saccular (berry) aneurysm in the subarachnoid space leads to aneurysmal subarachnoid hemorrhage (aSAH). Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurovascular anatomy: The posterior communicating artery connects the internal carotid to the posterior cerebral circulation and lies adjacent to cranial nerve III.  <br><span class=\"list-item\">\u2022</span> Hemorrhage pathophysiology: Rupture spills arterial blood into the subarachnoid cisterns, raising intracranial pressure, risking rebleeding and vasospasm.  <br><span class=\"list-item\">\u2022</span> Definitive management principle: Secure the aneurysm promptly (ideally within 24&ndash;48 h) to prevent rebleeding, using the least invasive method that yields durable occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling has become first-line for most ruptured anterior-circulation aneurysms, including Pcom, if morphology and access permit. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span> randomized 2,143 patients with ruptured anterior-circulation aneurysms to coiling versus clipping and showed a significant reduction in death or dependency at one year in the coiling group (risk reduction 7.4%, p=0.01). Subsequent long-term follow-up confirmed durability of coiling in appropriate aneurysms. <span class=\"evidence\">The 2023</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage give a Class I, Level A recommendation for endovascular treatment if the aneurysm is suitable in size, shape, and location. In contrast, open surgical clipping, while still indicated for wide-necked or complex aneurysms not amenable to coiling, carries greater surgical morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Clipping  <br><span class=\"list-item\">\u2022</span> Although historically standard, open clipping is more invasive, with higher rates of perioperative complications (e.g., cerebral edema, infection) than coiling for Pcom aneurysms amenable to endovascular access.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All ruptured aneurysms must be clipped&rdquo; ignores advances in neurointervention and individual aneurysm morphology.  <br><br>C. Decompressive craniotomy  <br><span class=\"list-item\">\u2022</span> Indicated for malignant cerebral edema in large\u2010territory ischemic stroke or refractory intracranial hypertension, not for securing a ruptured aneurysm.  <br><span class=\"list-item\">\u2022</span> Confuses management of elevated intracranial pressure with aneurysm treatment.  <br><br>D. Admission to stroke unit  <br><span class=\"list-item\">\u2022</span> Stroke units specialize in ischemic stroke care; aSAH requires immediate neurocritical care and neurosurgical/neurointerventional management in an ICU setting.  <br><span class=\"list-item\">\u2022</span> Underestimates the urgency of aneurysm securing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Invasiveness</th><th>Primary Goal</th><th>Typical Indication</th></tr></thead><tbody><tr><td>Coiling [CORRECT]</td><td>Minimally invasive</td><td>Secure aneurysm endovascularly</td><td>Ruptured anterior-circulation aneurysms with favorable neck anatomy</td></tr><tr><td>Clipping</td><td>Highly invasive</td><td>Direct microsurgical aneurysm exclusion</td><td>Complex or wide-neck aneurysms unsuitable for coiling</td></tr><tr><td>Decompressive craniotomy</td><td>Highly invasive</td><td>Relieve intracranial pressure</td><td>Malignant cerebral edema post-large ischemic stroke, trauma</td></tr><tr><td>Admission to stroke unit</td><td>Non\u2010procedural</td><td>Monitoring and secondary prevention</td><td>Acute ischemic stroke or transient ischemic attack</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early aneurysm securing (&le; 48 h) reduces rebleeding risk by up to 80%.  <br><span class=\"list-item\">\u2022</span> Oral nimodipine (60 mg every 4 h for 21 days) is the only drug shown to improve outcomes by mitigating delayed cerebral ischemia.  <br><span class=\"list-item\">\u2022</span> Pcom aneurysms often present with ipsilateral oculomotor nerve palsy (ptosis, &ldquo;down and out&rdquo; eye) before or after rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating ischemic stroke pathways (stroke unit care) with aSAH management&mdash;SAH demands neurosurgical/ICU care.  <br>2. Believing decompressive craniectomy addresses rebleeding&mdash;this ignores the need to secure the aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2023</span>: Class I, Level A recommendation for endovascular coiling of ruptured anterior-circulation aneurysms when anatomically feasible.  <br><span class=\"list-item\">\u2022</span> International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002; 2005 follow-up)</span>: Demonstrated 7.4% reduction in death or dependency at 1 year with coiling vs clipping in suitable aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The Pcom branches off the internal carotid artery at the level of the oculomotor nerve. Its rupture commonly deposits blood in the interpeduncular cistern, often compressing CN III and causing ipsilateral pupillary dilation and ophthalmoplegia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular aneurysms arise at arterial bifurcations due to congenital medial defects, hemodynamic stress, and degeneration of the internal elastic lamina. Rupture into the subarachnoid space triggers a cascade of inflammation, raised intracranial pressure, and risk of secondary vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT \u2192 confirm subarachnoid blood.  <br>2. CT angiography or digital subtraction angiography \u2192 localize aneurysm and assess neck morphology.  <br>3. Early neurosurgical/neurointerventional consultation \u2192 plan definitive treatment (coiling vs clipping).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute SAH: hyperdensity in basal cisterns, especially interpeduncular cistern for Pcom.  <br><span class=\"list-item\">\u2022</span> CTA demonstrates aneurysm neck size and dome-to-neck ratio; > 2:1 favors coiling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine: 60 mg PO/NG every 4 h for 21 days to prevent delayed ischemia.  <br><span class=\"list-item\">\u2022</span> Maintain systolic BP < 160 mm Hg pre-securing; avoid hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Aneurysmal SAH management, particularly the choice between coiling and clipping, is frequently tested. Examine aneurysm location and morphology, understand trial data (ISAT) and guideline recommendations to choose the appropriate intervention.</div></div></div></div></div>"
  },
  {
    "id": 100023132,
    "question_number": "212",
    "question_text": "In the ECST trial, what was the estimated 3-year stroke or death rate for patients who underwent carotid endarterectomy (CEA)?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Symptomatic carotid atherosclerosis carries a high risk of recurrent ipsilateral stroke due to artery\u2010to\u2010artery embolism or hemodynamic insufficiency. Carotid endarterectomy (CEA) surgically removes plaque to restore lumen patency and reduce embolic load. Landmark randomized trials&mdash;most notably ECST and NASCET&mdash;defined stenosis thresholds for maximal benefit. ECST measured residual lumen vs outer vessel wall (not directly comparable to NASCET), but its key finding was a significant reduction in 3-year stroke or death when CEA was added to medical therapy, contingent on acceptable perioperative risk (<6% 30-day stroke/death) and high\u2010grade stenosis. Understanding trial design, patient selection, and outcome definitions is essential for applying results to clinical decision\u2010making.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The European Carotid Surgery Trial <span class=\"citation\">(ECST; <span class=\"evidence\">Lancet 1998</span>)</span> randomized 659 symptomatic patients with carotid stenosis &ge;70% (by ECST criteria) to CEA plus medical therapy versus medical therapy alone (667 patients). Over a mean follow-up of 3.4 years, the cumulative rate of any stroke or death in the surgical arm was 15.7% (95% CI 13.1&ndash;18.3%), versus 26.5% (95% CI 23.6&ndash;29.4%) in the non-surgical arm. The absolute risk reduction of 10.8% translated into a number needed to treat of ~9. In subgroup analyses, benefit was most pronounced in patients with severe stenosis. These results underpin current guidelines recommending CEA for symptomatic stenosis &ge;70% when surgical risk is low, as it halves long-term stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 14.9%  <br><span class=\"list-item\">\u2022</span> Incorrect: No 3-year event rate of 14.9% was reported in ECST.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses with 5-year risk in asymptomatic carotid surgery trials (ACST).  <br><span class=\"list-item\">\u2022</span> Differentiator: ECST surgical arm event rate was higher (15.7%).  <br><br>B. 26.5%  <br><span class=\"list-item\">\u2022</span> Incorrect: This is the 3-year stroke or death rate in the medical\u2010therapy (no-CEA) arm of ECST.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may invert treatment and control rates.  <br><span class=\"list-item\">\u2022</span> Differentiator: Represents natural history without surgery in ECST.  <br><br>C. 22.2%  <br><span class=\"list-item\">\u2022</span> Incorrect: No ECST subgroup or pooled analysis yielded exactly 22.2%; this value is sometimes misattributed to older pooled observational data.  <br><span class=\"list-item\">\u2022</span> Misconception: Mistaking mixed\u2010trial or NASCET data for ECST outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: ECST precise surgical arm rate was 15.7%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Reported 3-Year Rate</th><th>ECST Context</th></tr></thead><tbody><tr><td>A.</td><td>14.9%</td><td>Not reported in ECST; from asymptomatic trial data</td></tr><tr><td>B.</td><td>26.5%</td><td>Medical\u2010therapy arm event rate (no CEA)</td></tr><tr><td>C.</td><td>22.2%</td><td>Not an ECST figure; misattributed pooled value</td></tr><tr><td>D.</td><td>15.7%</td><td>Surgical arm event rate (CEA + medical therapy)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CEA is class I indicated for symptomatic carotid stenosis &ge;70% (NASCET criteria) if 30-day perioperative stroke/death risk is <6%.  <br><span class=\"list-item\">\u2022</span> Benefit is greatest when surgery is performed within 2 weeks of the index event.  <br><span class=\"list-item\">\u2022</span> In moderate stenosis (50&ndash;69%), absolute risk reduction is smaller; patient comorbidities heavily influence decision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ECST and NASCET stenosis measurement methods &ndash; ECST used residual\u2010lumen/outer\u2010wall ratio.  <br>2. Swapping surgical and medical arm event rates (15.7% vs 26.5%).  <br>3. Applying asymptomatic trial data (e.g., ACST) to symptomatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2021 AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack  <br><span class=\"list-item\">\u2022</span> Recommendation: CEA within 2 weeks for symptomatic stenosis 70&ndash;99% (Class I, LOE A).  <br>2. 2023 European Society for Vascular Surgery (ESVS) Guidelines on Carotid Stenosis  <br><span class=\"list-item\">\u2022</span> Recommendation: CEA over medical therapy for symptomatic stenosis &ge;70% with perioperative risk <6% (Grade A, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Questions on ECST and NASCET are frequently tested, particularly to assess knowledge of trial outcomes, stenosis measurement differences, and guideline-based indications for CEA versus medical therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023133,
    "question_number": "355",
    "question_text": "A 60-year-old male patient with diabetes and hypertension came with a history of transient ischemic attack (TIA) lasting 10 minutes, with numbness and dysarthria. The NIHSS score is 3. On examination, he still has numbness. What will you give?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Transient ischemic attacks (TIAs) represent temporary cerebral ischemia due to arterial thromboembolism or thrombosis in carotid or intracranial vessels. Even when symptoms resolve, high-risk features (e.g., NIHSS &le;3, diabetes, hypertension) predict early recurrence due to platelet activation and microthrombus propagation in the ischemic penumbra. Platelet aggregation is mediated by cyclooxygenase-1&ndash;derived thromboxane A\u2082 and ADP binding at P2Y\u2081\u2082 receptors, making dual inhibition of these pathways more effective in reducing early ischemic events. The NIHSS scale quantifies stroke severity, guiding therapy intensity: minor strokes (NIHSS &le;3) benefit most from short-term dual antiplatelet therapy. Recognizing these pathophysiological and clinical assessment principles is essential for secondary prevention strategies in cerebrovascular disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) combining aspirin and clopidogrel addresses thromboxane-mediated and P2Y\u2081\u2082-mediated platelet activation, critical in early thrombus propagation. The CHANCE trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> randomized 5,170 Chinese patients within 24 hours of high-risk TIA or minor stroke to 21 days of DAPT vs aspirin alone, demonstrating a 32% relative risk reduction in 90-day stroke recurrence (8.2% vs 11.7%; p=0.02) without a significant increase in hemorrhage. The POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> in a diverse cohort confirmed a 28% relative risk reduction at 90 days (4.1% vs 5.8%; HR 0.72; 95% CI, 0.59&ndash;0.89), offset by a small rise in major bleeding (0.9% vs 0.4%). Consequently, the 2018 AHA/ASA guidelines (Class I, Level of Evidence A) recommend DAPT for 21 days, initiated within 24 hours of a high-risk TIA or minor ischemic stroke (NIHSS &le;3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br><span class=\"list-item\">\u2022</span> Incorrect because monotherapy yields less early risk reduction than DAPT in high-risk TIA/minor stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: that aspirin alone suffices in all secondary prevention settings.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks P2Y\u2081\u2082 receptor blockade, reducing efficacy in the acute period.<br><br>B. Plavix  <br><span class=\"list-item\">\u2022</span> Incorrect: clopidogrel monotherapy has not demonstrated superior early protection compared to DAPT within 24 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: that inhibiting ADP alone matches combined pathway inhibition.  <br><span class=\"list-item\">\u2022</span> Differentiator: single-pathway blockade offers lower relative risk reduction than combined COX-1 and P2Y\u2081\u2082 inhibition.<br><br>D. None of the above  <br><span class=\"list-item\">\u2022</span> Incorrect: withholding antiplatelet therapy after a high-risk TIA incurs a markedly elevated recurrence risk (>10% at 90 days).  <br><span class=\"list-item\">\u2022</span> Misconception: that mild symptoms obviate the need for immediate therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of therapy fails to address ongoing platelet activation and thrombus evolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Therapy</th><th>Mechanism</th><th>Evidence in High-Risk TIA/Minor Stroke</th><th>Recommended Duration</th></tr></thead><tbody><tr><td>Dual antiplatelet therapy (aspirin + clopidogrel)</td><td>COX-1 inhibition + P2Y\u2081\u2082 receptor blockade</td><td>CHANCE, POINT: ~30% RRR in 90-day stroke; Class I, LOE A</td><td>21 days</td></tr><tr><td>Aspirin monotherapy</td><td>COX-1 inhibition</td><td>Control arm in CHANCE/POINT; higher recurrence risk</td><td>Indefinite</td></tr><tr><td>Clopidogrel monotherapy</td><td>P2Y\u2081\u2082 receptor blockade</td><td>CAPRIE: slight benefit over aspirin in broad stroke pop.; no acute TIA/minor stroke data</td><td>Indefinite</td></tr><tr><td>No antiplatelet therapy</td><td>None</td><td>Very high recurrence risk (>10% at 90 days)</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT within 24 hours of a high-risk TIA or minor stroke to intercept early platelet-mediated thrombus growth.  <br>&bull; Limit DAPT to 21 days&mdash;extended therapy increases hemorrhagic risk without added stroke reduction.  <br>&bull; Concurrently evaluate for carotid stenosis and atrial fibrillation; alternate interventions (e.g., endarterectomy, anticoagulation) may be indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Assuming aspirin or clopidogrel monotherapy provides equivalent early protection to DAPT leads to suboptimal prevention.  <br>&bull; Extending DAPT beyond 21 days based on fear of recurrence paradoxically increases bleeding risk without further benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> Guidelines: Recommends DAPT with aspirin and clopidogrel initiated within 24 hours of high-risk TIA or minor stroke (NIHSS &le;3) for 21 days (Class I, Level of Evidence A).  <br>&bull; POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated a 28% relative risk reduction in recurrent ischemic events at 90 days with early DAPT vs aspirin alone (HR 0.72; 95% CI, 0.59&ndash;0.89) but higher major bleeding (0.9% vs 0.4%); supports 21-day regimen (Level of Evidence 1b).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Secondary stroke prevention and the timing/duration of dual antiplatelet therapy for high-risk TIA/minor stroke are frequently tested as scenario-based questions on national board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023135,
    "question_number": "315",
    "question_text": "A patient with sickle cell disease comes with a stroke workup done and is found to have multiple stenoses in the anterior cerebral artery (AcA) and middle cerebral artery (McA). What is the method of prevention?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Sickle cell disease (SCD)&ndash;associated vasculopathy often involves progressive stenosis of large intracranial arteries (e.g., ACA, MCA), resembling moyamoya.  <br>&bull; Sickled red cells adhere to endothelium, provoke intimal hyperplasia, narrowing vessel lumen and elevating cerebral blood flow velocities on transcranial Doppler (TCD).  <br>&bull; Primary stroke prevention in high\u2010risk children hinges on reducing hemoglobin S (HbS) fraction via regular red blood cell transfusions to prevent first\u2010ever ischemic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion therapy is the cornerstone of primary stroke prevention in SCD with intracranial stenosis. The landmark STOP trial (1998) randomized children with elevated TCD velocities (>200\u2009cm/s) to transfusion vs. standard care, demonstrating a 92% relative risk reduction in first stroke <span class=\"citation\">(N Engl J Med.1998;339:5&ndash;11)</span>. Transfusions maintain HbS <30% and total hemoglobin ~10 g/dL, improving oxygen delivery and reducing sickling. Subsequent STOP II confirmed that stopping transfusions led to recurrence of elevated velocities and risk. <span class=\"evidence\">The 2020</span> American Society of Hematology (ASH) guidelines give a strong recommendation (grade 1B) for regular transfusions in children with abnormal TCD or known vasculopathy. While the TWiTCH trial (2016) explored switching to hydroxyurea after &ge;1 year of transfusion, chronic transfusion remains first\u2010line when stenoses are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Reason incorrect: Platelet inhibition does not address the primary pathophysiology of sickle\u2010cell vasculopathy (RBC sickling and intimal proliferation).  <br>&bull; Misconception: Equating adult atherosclerotic stroke prevention with SCD; aspirin has not shown efficacy in primary stroke prevention in SCD.  <br><br>B. Plavix  <br>&bull; Reason incorrect: Clopidogrel&rsquo;s antiplatelet action is similarly unhelpful against sickling\u2010induced endothelial damage and stenosis.  <br>&bull; Misconception: Belief that stronger or alternative antiplatelet agents suffice for all stroke etiologies.  <br><br>D. Dual antiplatelet therapy  <br>&bull; Reason incorrect: Combining aspirin plus clopidogrel increases hemorrhagic risk without reducing stroke incidence in SCD vasculopathy.  <br>&bull; Misconception: &ldquo;More antiplatelet agents = better prevention&rdquo;; ignores disease\u2010specific mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chronic Transfusion</th><th>Aspirin</th><th>Clopidogrel</th><th>Dual Antiplatelet</th></tr></thead><tbody><tr><td>Mechanism</td><td>Lowers HbS <30%, improves O\u2082 delivery</td><td>COX-1 inhibition, \u2193TXA\u2082</td><td>P2Y\u2081\u2082 receptor blockade</td><td>Combined COX-1 + P2Y\u2081\u2082 blockade</td></tr><tr><td>Key Trial</td><td>STOP Trial (1998): 92% RRR</td><td>No dedicated RCT in SCD</td><td>No dedicated RCT in SCD</td><td>No evidence in SCD</td></tr><tr><td>ASH Guideline Recommendation</td><td>Strong for primary prevention</td><td>Not recommended</td><td>Not recommended</td><td>Contraindicated (bleeding risk)</td></tr><tr><td>Major Risk</td><td>Iron overload (requires chelation)</td><td>Minimal</td><td>Minimal</td><td>\u2191Bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Begin annual transcranial Doppler screening by age 2 in SCD (HbSS, HbS&beta;\u2070).  <br>&bull; Target HbS <30% and total Hb ~10 g/dL with exchange or simple transfusion every 3&ndash;4 weeks.  <br>&bull; Monitor ferritin and initiate iron chelation (deferasirox or deferoxamine) to prevent hemosiderosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on antiplatelet agents (aspirin, clopidogrel) for SCD stroke prevention, overlooking sickling pathology.  <br>2. Discontinuing transfusions once TCD normalizes without considering underlying stenosis may lead to rebound risk (as in STOP II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ASH 2020 Guidelines (1B): Strongly recommend chronic transfusion for children with abnormal TCD or documented intracranial stenosis.  <br>&bull; TWiTCH Trial <span class=\"citation\">(2016, NEJM 374:1542&ndash;1552)</span>: Hydroxyurea noninferior to transfusion for maintaining TCD velocities after &ge;1 year of transfusion&mdash;but only in selected low\u2010risk patients without severe vasculopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Sickle cell&ndash;related stroke prevention is frequently tested in pediatric neurology/stroke modules, often in the context of TCD screening thresholds and interpretation of STOP/TWiTCH data.</div></div></div></div></div>"
  },
  {
    "id": 100023136,
    "question_number": "271",
    "question_text": "An 82-year-old male patient came within 3 hours and has no contraindication for tPA. A CT scan shows early signs of stroke, but infarction is not established. What will you give?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Hyperacute ischemic stroke management aims to salvage the ischemic penumbra&mdash;tissue at risk but not yet infarcted&mdash;by restoring perfusion before irreversible neuronal death. Neurons in the penumbra experience excitotoxicity, calcium overload, and free\u2010radical injury. Noncontrast CT excludes hemorrhage and shows early signs (loss of gray&ndash;white differentiation, sulcal effacement, hyperdense vessel) but not established infarction. &ldquo;Time is brain&rdquo;: each minute without reperfusion costs ~1.9 million neurons. Intravenous alteplase (tPA) administered within 4.5 hours of symptom onset reduces long-term disability; benefit is greatest under 3 hours. Rapid NIH Stroke Scale scoring, CT interpretation, and exclusion of contraindications are critical to initiate thrombolysis and maximize penumbral salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA (alteplase) is the only FDA-approved fibrinolytic for acute ischemic stroke. The landmark NINDS trial (1995) demonstrated a 30% relative improvement in functional outcome at 3 months when administered within 3 hours (OR 1.7, 95% CI 1.2&ndash;2.6). ECASS III extended the window to 4.5 hours, showing a 7.2% absolute increase in favorable outcome (p=0.04). <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines (Powers et al.) give Class I, LOE A recommendation for IV alteplase &le;4.5 hours; age >80 years is no longer an exclusion within this window. Exclusion criteria (e.g., recent hemorrhage, coagulopathy) must be ruled out. CT early ischemic changes do not preclude tPA unless hypodensity involves >1/3 MCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Initiating aspirin within 24 hours of tPA increases hemorrhagic risk and does not improve acute recanalization.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet with thrombolytic therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aspirin inhibits platelet aggregation; tPA actively lyses thrombus.  <br><br>B. Plavix  <br><span class=\"list-item\">\u2022</span> Why incorrect: No evidence supports P2Y12 inhibition as monotherapy in hyperacute stroke; risk&ndash;benefit for immediate reperfusion absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all antithrombotics are interchangeable in the hyperacute phase.  <br><span class=\"list-item\">\u2022</span> Differentiator: Plavix acts slowly and is indicated for secondary prevention, not acute reperfusion.  <br><br>D. Supportive care only  <br><span class=\"list-item\">\u2022</span> Why incorrect: While airway and hemodynamic support are vital, omitting reperfusion therapy forfeits potential penumbral salvage and worsens outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating CT early signs as contraindications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Supportive care does not address vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Time Window</th><th>Key Outcome Benefit</th><th>Hemorrhage Risk</th></tr></thead><tbody><tr><td>tPA (alteplase)</td><td>Plasminogen \u2192 plasmin \u2192 fibrinolysis</td><td>0&ndash;4.5 hours (Class I, LOE A)</td><td>\u2193 disability at 3 months (NINDS, ECASS III)</td><td>~6.4% symptomatic ICH</td></tr><tr><td>Aspirin</td><td>COX-1 inhibition \u2192 \u2193 TXA\u2082</td><td>Not for hyperacute reperfusion</td><td>\u2193 early recurrence (not acute benefit)</td><td>\u2191 bleeding if given <24 h post-tPA</td></tr><tr><td>Plavix</td><td>P2Y\u2081\u2082 receptor blockade</td><td>Not indicated acutely</td><td>Long-term secondary prevention</td><td>Low but not studied acutely</td></tr><tr><td>Supportive care</td><td>Airway, BP, glucose control</td><td>All phases</td><td>Prevents medical complications</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Time is brain&rdquo;: aim for door-to-needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Early CT signs (hyperdense MCA sign, subtle hypodensity) do not contraindicate tPA unless >1/3 MCA territory is involved.  <br><span class=\"list-item\">\u2022</span> Age >80 years or minor early ischemic changes no longer exclude patients &le;4.5 hours per AHA/ASA 2019.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering aspirin or dual antiplatelet therapy instead of tPA in tPA-eligible patients.  <br>2. Overcalling early CT hypodensity as established infarction and withholding thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke <span class=\"evidence\">Guidelines 2019</span> (Powers et al.): Class I, LOE A for IV alteplase &le;4.5 hours; CT early ischemic changes alone are not a contraindication unless extensive.  <br><span class=\"list-item\">\u2022</span> ECASS III Trial (2008): Demonstrated benefit of alteplase between 3&ndash;4.5 hours (OR for favorable outcome 1.34, 95% CI 1.02&ndash;1.76).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT: look for loss of gray&ndash;white differentiation, insular ribbon sign, hyperdense vessel.  <br><span class=\"list-item\">\u2022</span> ASPECTS &le;7 indicates extensive early ischemia; >7 favorable for tPA with lower hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (max 90 mg)&mdash;10% as bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Monitor BP <185/110 mm Hg before/during infusion to minimize hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Acute ischemic stroke thrombolysis within the time window and CT interpretation are high-yield topics, frequently tested as single best answer or management algorithms.</div></div></div></div></div>"
  },
  {
    "id": 100023137,
    "question_number": "273",
    "question_text": "Angioplasty",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Balloon angioplasty (percutaneous transluminal angioplasty, PTA) is an endovascular technique used to mechanically widen stenotic arteries. Core concepts:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of atherosclerosis: lipid-rich plaque accumulates within the intima, causing luminal narrowing and impaired perfusion.  <br><span class=\"list-item\">\u2022</span> Endovascular access: catheters are navigated from femoral or radial arteries into the cerebral circulation under fluoroscopic guidance.  <br><span class=\"list-item\">\u2022</span> Vessel biomechanics: controlled balloon inflation compresses plaque against the arterial wall and stretches the media, improving luminal diameter.  <br>Understanding these principles distinguishes angioplasty from surgical excision (endarterectomy) and clarifies its role in ischemic stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct because angioplasty refers specifically to balloon dilation of a stenotic vessel. After arterial access, a balloon catheter is positioned across the lesion and inflated to a predetermined pressure, fracturing intimal and medial fibers and compressing atheroma, thereby restoring flow. According to the 2015 AHA/ASA guidelines on extracranial carotid and vertebral artery disease (Class I, Level A), carotid angioplasty and stenting (CAS) is indicated for symptomatic high-grade (&ge;70%) carotid stenosis in patients at high surgical risk. The CREST trial (2010, NEJM) demonstrated non-inferiority of CAS versus carotid endarterectomy (CEA) for composite stroke, myocardial infarction, and death endpoints in symptomatic and asymptomatic patients. For intracranial stenosis, the SAMMPRIS trial (2011, NEJM) revealed higher periprocedural risk with angioplasty plus stenting versus aggressive medical management alone, leading to a more conservative approach <span class=\"citation\">(AHA/ASA 2021 update: Class IIb, Level B-R for angioplasty/stenting in refractory intracranial stenosis)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. &ldquo;Is a surgical procedure involving direct removal of atherosclerotic plaque&rdquo;  <br>  &bull; Incorrect because plaque removal describes carotid endarterectomy, not angioplasty.  <br>  &bull; Misconception: equating endovascular dilation with open surgical excision.  <br>  &bull; Differentiator: endarterectomy requires arteriotomy and manual plaque extraction, whereas angioplasty uses intraluminal balloon expansion.  <br><br>B. &ldquo;Is primarily used to treat hemorrhagic stroke&rdquo;  <br>  &bull; Incorrect as angioplasty addresses ischemic, not hemorrhagic, pathology.  <br>  &bull; Misconception: confusing cerebrovascular interventions for ischemia versus hemorrhage.  <br>  &bull; Differentiator: hemorrhagic stroke management focuses on blood pressure control, reversal of anticoagulation, surgical evacuation, not vessel dilation.  <br><br>D. &ldquo;Is contraindicated in patients with carotid artery stenosis&rdquo;  <br>  &bull; Incorrect because angioplasty (with stenting) is an established option for carotid stenosis, especially in high surgical-risk cases.  <br>  &bull; Misconception: assuming endovascular risk precludes use in carotid disease.  <br>  &bull; Differentiator: CEA and CAS are both indicated for symptomatic high-grade stenosis; CAS is preferred in specific high-risk surgical profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Indication</th><th>Example Procedure</th></tr></thead><tbody><tr><td>A</td><td>Surgical plaque excision</td><td>Carotid endarterectomy for stenosis</td><td>Arteriotomy and manual dissection</td></tr><tr><td>B</td><td>Not an angioplasty technique</td><td>Hemorrhagic stroke management</td><td>Hematoma evacuation</td></tr><tr><td>C</td><td>Balloon inflation of stenosis [\u2713]</td><td>Ischemic stroke prevention/treatment</td><td>PTA with or without stent</td></tr><tr><td>D</td><td>(False) Contraindication assertion</td><td>(Incorrect) CEA/CAS for stenosis</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Carotid angioplasty is almost always performed with stent deployment to prevent elastic recoil and dissection.  <br><span class=\"list-item\">\u2022</span> High-risk CEA patients (prior neck surgery, radiation, contralateral laryngeal nerve palsy) benefit from CAS (AHA/ASA Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> Intracranial angioplasty carries a higher periprocedural stroke risk; reserved for patients failing maximal medical therapy (Class IIb, LOE B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing angioplasty with endarterectomy: the former is endovascular, the latter open surgery.  <br>2. Believing angioplasty treats hemorrhagic events: it treats vessel narrowing in ischemic disease only.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 Extracranial Carotid Disease Guideline: Recommends CAS in symptomatic &ge;70% stenosis for high surgical risk patients (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> SAMMPRIS Trial (2011, NEJM): Demonstrated higher stroke risk with intracranial angioplasty plus stenting versus aggressive medical therapy; led to Class IIb, LOE B-R recommendation for refractory cases in 2021 AHA/ASA update.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular neurology questions frequently test distinctions between endovascular techniques (angioplasty/stenting) and surgical approaches (endarterectomy), and require knowledge of appropriate ischemic versus hemorrhagic stroke interventions.</div></div></div></div></div>"
  },
  {
    "id": 100023139,
    "question_number": "329",
    "question_text": "A left ICA deep borderzone infarction is shown on DWI. What test would reveal the etiology?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Watershed (borderzone) infarcts occur in areas between major arterial territories (e.g., between ACA and MCA deep perforators) and often reflect hemodynamic compromise from proximal large\u2010artery stenosis.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted MRI (DWI) is highly sensitive for detecting acute ischemia within minutes of onset but does not identify vascular lesions.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) provides rapid, high\u2010resolution images of extracranial and intracranial arteries, allowing detection of ICA stenosis or occlusion&mdash;the key etiology in deep borderzone strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the test of choice because deep borderzone infarcts most commonly result from hemodynamic insufficiency due to ipsilateral ICA high\u2010grade stenosis or occlusion. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke recommend emergent vascular imaging (CTA or MRA) in all suspected large\u2010vessel occlusions (Class I, Level of Evidence B). A meta\u2010analysis <span class=\"citation\">(<span class=\"evidence\">Bamford et al., 2020</span>)</span> showed CTA sensitivity >95% and specificity >98% for detecting &ge;70% ICA stenosis. Early identification enables timely decisions about endarterectomy or stenting to prevent recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Electroencephalogram  <br>&ndash; EEG evaluates cerebral electrical activity and is indicated for seizures or encephalopathy, not for detecting vascular stenosis.  <br>&ndash; Misconception: &ldquo;Every neurologic deficit needs an EEG.&rdquo; EEG cannot visualize vessels.  <br><br>C. Lumbar puncture  <br>&ndash; LP is used for infectious, inflammatory, or subarachnoid hemorrhage evaluation; it cannot assess arterial lumen or flow dynamics.  <br>&ndash; Misconception: Borderzone infarcts might be inflammatory&mdash;LP does not detect stenosis.  <br><br>D. Echocardiogram  <br>&ndash; Transthoracic or transesophageal echo evaluates cardiac sources of emboli (e.g., thrombus, PFO), not large\u2010artery hemodynamics.  <br>&ndash; Differentiating feature: echo rules out cardioembolism, but borderzone pattern points to hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Primary Target</th><th>Detects ICA Stenosis</th><th>Typical Use in Stroke Workup</th></tr></thead><tbody><tr><td>CT Angiography</td><td>Extracranial/intracranial vessels</td><td>Yes</td><td>First-line for suspected large-vessel disease</td></tr><tr><td>EEG</td><td>Cortical electrical activity</td><td>No</td><td>Seizure evaluation</td></tr><tr><td>Lumbar Puncture</td><td>CSF analysis</td><td>No</td><td>Infection, hemorrhage exclusion</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic sources</td><td>No</td><td>Embolic stroke source workup</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Deep borderzone infarcts (&ldquo;rosary\u2010like&rdquo; spoke-wheel DWI pattern) strongly suggest proximal ICA hemodynamic compromise.  <br><span class=\"list-item\">\u2022</span> In acute ischemic stroke, noncontrast CT followed immediately by CTA (or CT perfusion) streamlines diagnosis and eligibility for reperfusion therapies.  <br><span class=\"list-item\">\u2022</span> High\u2010grade ICA stenosis (>70%) detected on CTA often warrants urgent carotid endarterectomy within 2 weeks to reduce recurrence risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering an echocardiogram first in a watershed infarct delays detection of large\u2010artery stenosis.  <br>2. Misinterpreting borderzone DWI hyperintensities as lacunar infarcts leads to under\u2010investigation of proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Stroke): Recommend emergent CTA/MRA in all suspected large-vessel occlusion strokes (Class I, LOE B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: Endorse CTA within 25 minutes of hospital arrival for linking diagnosis to reperfusion decisions (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The deep borderzone between the superficial perforating branches of the MCA and the lenticulostriate arteries lies adjacent to the lateral ventricle. Hypoperfusion here produces characteristic linear or patchy infarcts on DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Severe ipsilateral ICA stenosis reduces cerebral perfusion pressure distal to the lesion. Under hypotensive or high\u2010demand states, the watershed zones fail to autoregulate, leading to ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage  <br>2. MRI-DWI to confirm acute ischemia pattern  <br>3. CTA of head and neck to assess for ICA stenosis/occlusion  <br>4. Manage identified stenosis (medical vs endarterectomy/stenting)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI detects infarction within minutes; FLAIR mismatch can estimate onset time.  <br><span class=\"list-item\">\u2022</span> CTA provides submillimeter resolution of vessel lumen; multiplanar reconstructions elucidate stenosis length and morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Borderzone infarct patterns on DWI frequently signal large-artery hypoperfusion and necessitate prompt CTA to guide revascularization decisions.</div></div></div></div></div>"
  },
  {
    "id": 100023140,
    "question_number": "208",
    "question_text": "Based on the following imaging, which territory is involved?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Understanding vascular territories in the brainstem and cerebellum is critical to localizing strokes on imaging. The anterior inferior cerebellar artery (AICA) arises from the basilar artery and supplies the lateral pons, middle cerebellar peduncle, parts of the cerebellum, and, via the labyrinthine artery, the inner ear structures. Infarction produces a lateral pontine syndrome characterized by ipsilateral facial paralysis, loss of corneal reflex, ataxia, and ipsilateral hearing loss or vertigo. In contrast, PICA infarcts cause lateral medullary (Wallenberg) syndrome without facial paralysis, while SCA and PCA infarcts involve different cerebellar or occipital territories. MRI-DWI typically shows a wedge-shaped hyperintense lesion conforming to the artery&rsquo;s distribution, enabling precise localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The imaging demonstrates a hyperintense lesion on DWI in the lateral pons extending into the middle cerebellar peduncle, sparing the medulla and cerebellar hemisphere. These findings align with the AICA distribution: lateral pontine structures including the facial nucleus and vestibulocochlear complex. AICA strokes often present with ipsilateral facial paralysis (facial nucleus involvement) and contralateral pain/temperature loss (spinothalamic tract), plus ipsilateral hearing loss (labyrinthine artery branch). <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke emphasize rapid MRI-DWI for posterior fossa strokes (Class I, Level A evidence) and recommend reperfusion therapy within 4.5 hours. Studies show AICA infarcts comprise ~1%&ndash;2% of ischemic strokes but carry high morbidity due to brainstem and cranial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because PCA supplies the occipital lobe, thalamus, and medial temporal lobe. Imaging would show occipital cortical infarction with visual field deficits, not a brainstem lesion.  <br>B. PICA  <br><span class=\"list-item\">\u2022</span> PICA infarction causes lateral medullary (Wallenberg) syndrome: dysphagia, hoarseness, nucleus ambiguus signs, and contralateral pain/temperature loss of the body. Facial nucleus involvement and hearing loss are absent.  <br>C. Superior cerebellar artery (SCA)  <br><span class=\"list-item\">\u2022</span> SCA supplies the superior cerebellum and superior cerebellar peduncle. SCA strokes produce limb ataxia and dysmetria without facial paralysis or cochlear symptoms, and imaging shows superior cerebellar cortical lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA (Correct)</th><th>PICA (Incorrect)</th><th>SCA (Incorrect)</th><th>PCA (Incorrect)</th></tr></thead><tbody><tr><td>Vascular origin</td><td>Basilar artery \u2192 AICA</td><td>Vertebral artery \u2192 PICA</td><td>Basilar artery \u2192 SCA</td><td>Basilar artery \u2192 PCA</td></tr><tr><td>Supplied structures</td><td>Lateral pons, middle cerebellar peduncle, inner ear</td><td>Lateral medulla, inferior cerebellum</td><td>Superior cerebellum, superior cerebellar peduncle</td><td>Occipital lobe, medial temporal lobe, thalamus</td></tr><tr><td>Key clinical signs</td><td>Ipsilateral facial paralysis, hearing loss, ataxia</td><td>Dysphagia, hoarseness, loss of pain/temp in face & body</td><td>Limb ataxia, dysmetria</td><td>Homonymous hemianopia, thalamic pain syndromes</td></tr><tr><td>Imaging pattern</td><td>Wedge-shaped lateral pontine DWI hyperintensity</td><td>Dorsolateral medullary DWI hyperintensity</td><td>Superior cerebellar DWI hyperintensity</td><td>Occipital cortical DWI hyperintensity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AICA infarcts uniquely present with ipsilateral facial paralysis and sensorineural hearing loss due to involvement of the facial and vestibulocochlear nerve nuclei.  <br>2. The labyrinthine artery branch of AICA explains acute vertigo and tinnitus; its occlusion constitutes an otoneurological emergency.  <br>3. MRI-DWI is 83% sensitive and 95% specific for posterior fossa stroke within the first 24 hours; CT often misses small brainstem lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lateral medullary (PICA) with lateral pontine (AICA) syndrome; remember that facial nucleus signs only occur in AICA lesions.  <br>2. Assuming all cerebellar artery strokes yield gross ataxia; small brainstem infarcts may yield subtle cranial nerve deficits without prominent cerebellar signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Obtain MRI-DWI for suspected posterior fossa infarction when CT is non-diagnostic (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> tPA recommended within 4.5 hours of symptom onset (Class I, LOE A).  <br>2. 2021 European Stroke Organisation (ESO) Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Consider endovascular thrombectomy for basilar artery occlusion up to 24 hours post-onset in selected patients (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA branches from the lower basilar artery to supply the lateral pons, including the facial nucleus (facial paralysis), vestibulocochlear nuclei (hearing/vertigo), spinal trigeminal nucleus (facial pain/temp), and the middle cerebellar peduncle (ataxia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of AICA leads to ischemia in the lateral pontine tegmentum. Neuronal energy failure triggers excitotoxicity and cytotoxic edema, manifesting as DWI hyperintensity within minutes of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment and NIH Stroke Scale  <br>2. Noncontrast CT to exclude hemorrhage  <br>3. MRI-DWI to localize infarct, especially in posterior fossa  <br>4. CT/MR angiography to identify vessel occlusion (AICA vs vertebral vs basilar)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT often misses posterior fossa infarcts due to beam-hardening artifacts.  <br><span class=\"list-item\">\u2022</span> MRI-DWI is the gold standard for early detection of brainstem and cerebellar strokes.  <br><span class=\"list-item\">\u2022</span> CT angiography can visualize basilar artery and branch occlusions in the posterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intravenous alteplase (0.9 mg/kg, 10% bolus, remainder over 60 minutes) within 4.5 hours, unless contraindicated.  <br><span class=\"list-item\">\u2022</span> Blood pressure management: keep &le;185/110 mm Hg pre- and &le;180/105 mm Hg post-thrombolysis.  <br><span class=\"list-item\">\u2022</span> Consider antiplatelet agents 24 hours post-tPA if no hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Vascular territory localization via imaging is a frequent format on neurology boards, testing both anatomy and acute stroke management principles.</div></div></div></div></div>"
  },
  {
    "id": 100023141,
    "question_number": "446",
    "question_text": "Q446. A young female with right ICA dissection shows a crescent shape on MRA. What is the treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Cervical artery dissection arises from a tear in the intimal layer of the internal carotid artery (ICA), allowing blood to accumulate intramurally, producing the &ldquo;crescent sign&rdquo; on fat-saturated MRA.  <br>&bull; Dissection predisposes to ischemic stroke via thromboembolism from the false lumen or hemodynamic compromise.  <br>&bull; First-line therapy employs antithrombotic agents (antiplatelets or anticoagulants) to prevent further emboli; invasive interventions are reserved for refractory cases or expanding pseudoaneurysms. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical management with antithrombotic therapy is the standard of care for extracranial ICA dissection. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Stroke Prevention (Class I, Level A) recommend 3&ndash;6 months of antiplatelet or anticoagulation therapy to reduce recurrent stroke risk. The CADISS randomized trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> found no significant difference in recurrent ischemic events between antiplatelet and anticoagulation arms (1.0% vs. 0.3%, p=0.63), supporting either approach. Observational cohorts report a low annual recurrence (<2%) with medical therapy. Surgical repair or stenting carries procedural risks (arterial injury, in-stent thrombosis) and is typically reserved for symptomatic progression despite optimal medical therapy or for high-risk pseudoaneurysm morphology. Thrombolysis is used acutely within a narrow time window for established stroke, not prophylaxis against recurrent events in dissection without infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical repair  <br>&bull; Incorrect: Reserved for expanding pseudoaneurysm or failed medical therapy.  <br>&bull; Misconception: That immediate resolution of dissection requires open surgery.  <br>&bull; Differentiator: Higher morbidity; not first-line absent complication.<br><br>C. Endovascular stenting  <br>&bull; Incorrect: Considered only if medical therapy fails or severe stenosis with hemodynamic compromise.  <br>&bull; Misconception: Stenting universally prevents emboli.  <br>&bull; Differentiator: Procedural stroke risk and need for dual antiplatelet therapy.<br><br>D. Thrombolytic therapy  <br>&bull; Incorrect: Indicated acutely for ischemic stroke <4.5 h after onset, not for dissection without acute infarct.  <br>&bull; Misconception: Thrombolysis dissolves intramural hematoma.  <br>&bull; Differentiator: Risk of hemorrhage in vessel wall; not prophylactic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment Modality</th><th>Indication</th><th>Evidence</th><th>Key Risks</th></tr></thead><tbody><tr><td>Medical management</td><td>Primary prophylaxis post-dissection</td><td>AHA/ASA Class I (Level A), CADISS</td><td>Bleeding (if anticoagulated)</td></tr><tr><td>Surgical repair</td><td>Expanding pseudoaneurysm; failed medical</td><td>Case series only</td><td>Cranial nerve injury, restenosis</td></tr><tr><td>Endovascular stenting</td><td>Refractory ischemia, severe stenosis</td><td>Observational; no RCTs</td><td>In-stent thrombosis, dissection</td></tr><tr><td>Thrombolytic therapy</td><td>Acute ischemic stroke <4.5 h of onset</td><td>NINDS, ECASS</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; On fat-sat MRA, the crescentic intramural hematoma appears hyperintense; confirm with CTA or duplex ultrasound.  <br>&bull; Antiplatelet therapy (e.g., aspirin 81&ndash;325 mg) is often preferred over warfarin due to lower bleeding risk.  <br>&bull; Duration of antithrombotic therapy is typically 3&ndash;6 months, followed by imaging to assess vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating dissection treatment with acute stroke thrombolysis, leading to inappropriate tPA use.  <br>2. Overutilizing invasive procedures in the absence of clinical or radiographic progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines on Cervical Artery <span class=\"evidence\">Dissection 2019</span>: Recommend antithrombotic therapy for 3&ndash;6 months (Class I, Level A).  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs. anticoagulation for preventing recurrence (n=250, randomized).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The extracranial ICA courses from the carotid bifurcation in the neck (C1 segment) to the petrous segment (C2); dissections typically occur in the cervical portion where the artery is more mobile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear allows blood into the media, forming a false lumen that compresses the true lumen (crescent sign). Thrombus forms at the disrupted intima, serving as a source for distal emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in young patients with neck pain or Horner syndrome.  <br>2. Perform noninvasive imaging: CTA or MRA with fat saturation.  <br>3. Confirm intramural hematoma (&ldquo;crescent sign&rdquo;) and assess flow compromise.  <br>4. Initiate antithrombotic therapy; follow-up imaging at 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Fat-saturated T1-weighted MRA highlights subacute hematoma as high signal circumferentially. CTA shows an eccentric mural thickening with luminal stenosis or pseudoaneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 81&ndash;325 mg daily is first\u2010line; alternatives include clopidogrel 75 mg daily or warfarin (INR 2.0&ndash;3.0) when anticoagulation is chosen. Monitor for bleeding; no direct comparisons in large RCTs beyond CADISS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>ICA dissection management is frequently tested as single\u2010best\u2010answer scenarios, emphasizing first\u2010line antithrombotic therapy and imaging characteristics.</div></div></div></div></div>"
  },
  {
    "id": 100023143,
    "question_number": "406",
    "question_text": "A patient with a minor stroke (NIHSS 3) presents with decreased sensation on the left side and mild facial weakness. Within the treatment window, what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Ischemic stroke severity is stratified using the NIH Stroke Scale (NIHSS); scores &le;3 define &ldquo;minor&rdquo; strokes.  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis (alteplase) is indicated for disabling deficits within 4.5 hours, but may be withheld in non-disabling minor strokes.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) initiated within 24 hours and continued for ~21 days reduces early recurrence in minor non-disabling AIS (POINT, CHANCE trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) is correct. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines (Class IIa, LOE B-R) recommend DAPT for 21 days in minor (NIHSS &le;3) non-disabling ischemic stroke when started within 24 hours to prevent recurrence <span class=\"citation\">(<span class=\"evidence\">Johnston et al., 2018</span> POINT trial;<span class=\"evidence\"> Wang et al., 2013</span> CHANCE trial)</span>. In contrast, alteplase is reserved for disabling strokes&mdash;sensory deficits alone and mild facial weakness generally do not qualify as disabling. Mechanical thrombectomy is indicated only for large vessel occlusions within 6 hours (or select patients to 24 hours). Aspirin monotherapy is inferior to DAPT for early secondary prevention in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. tPA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Indicated for disabling deficits; this patient&rsquo;s symptoms (mild sensory loss, facial weakness) are non-disabling.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any stroke within window gets tPA&rdquo; ignores disability assessment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Disability vs non-disabling minor deficits.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Aspirin alone reduces recurrence less effectively than DAPT in first 21 days post&ndash;minor stroke (POINT: HR 0.68 for DAPT).  <br><span class=\"list-item\">\u2022</span> Misconception: Monotherapy sufficient for all AIS.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superior early reduction of recurrence with DAPT.  <br><br>D. Mechanical thrombectomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reserved for large vessel occlusion (ICA/M1) with moderate&ndash;severe deficits; minor strokes without imaging evidence of LVO do not qualify.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from mechanical clot retrieval.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vessel occlusion location and NIHSS threshold &ge;6&ndash;8.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT (Correct)</th><th>tPA</th><th>Aspirin Monotherapy</th><th>Thrombectomy</th></tr></thead><tbody><tr><td>Mechanism</td><td>ADP-receptor blockade (clopidogrel) + COX-1 inhibition</td><td>Plasminogen \u2192 plasmin activation</td><td>COX-1 inhibition</td><td>Mechanical clot removal</td></tr><tr><td>Indication</td><td>Minor non-disabling AIS &le;3, within 24 h</td><td>Disabling AIS within 4.5 h</td><td>Secondary prevention (long-term)</td><td>LVO AIS within 6 h (select to 24 h)</td></tr><tr><td>Key Trials/Guidelines</td><td>POINT (2018), CHANCE (2013); AHA/ASA 2019 IIa B-R</td><td>NINDS (1995), ECASS III</td><td>IST (1997)</td><td>MR CLEAN, ESCAPE, SWIFT PRIME</td></tr><tr><td>Duration</td><td>21 days</td><td>Single infusion</td><td>Indefinite</td><td>Single procedure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours in minor non-disabling AIS (NIHSS &le;3) for 21 days to halve early recurrence.  <br><span class=\"list-item\">\u2022</span> Assess disability (not just NIHSS score) when deciding on thrombolysis; isolated sensory loss often non-disabling.  <br><span class=\"list-item\">\u2022</span> After 21 days of DAPT, transition to monotherapy (aspirin or clopidogrel) to minimize bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA for any stroke within the window without assessing disability.  <br>2. Prescribing aspirin alone for acute minor stroke despite evidence favoring short-term DAPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of AIS: Class IIa recommendation (LOE B-R) for DAPT in minor non-disabling stroke within 24 h.  <br><span class=\"list-item\">\u2022</span> POINT trial <span class=\"citation\">(NEJM 2018)</span>: DAPT reduced 90-day recurrent stroke (5.0% vs 6.5%; HR 0.68, 95% CI 0.51&ndash;0.91) when initiated within 12 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion likely involves the right post-central gyrus (primary somatosensory cortex) causing contralateral hemisensory loss, and adjacent lower precentral gyrus affecting facial motor fibers&mdash;both small cortical branch ischemia of the MCA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute thromboembolic occlusion of a distal MCA branch leads to focal neuronal ischemia. Mild deficits reflect limited penumbral involvement and justify aggressive antiplatelet prophylaxis rather than full-dose fibrinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIHSS assessment to quantify severity and disability.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. CT angiography if LVO suspected.  <br>4. Determine reperfusion vs antiplatelet strategy based on disability and vessel status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early ischemic changes in minor stroke may be subtle on CT; MRI DWI is more sensitive for small cortical infarcts but not required before DAPT initiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Dosing: Aspirin 75&ndash;100 mg daily + clopidogrel 75 mg daily after 300 mg loading; continue for 21 days, then single-agent therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. It tests recognition of minor non-disabling stroke management per AHA/ASA guidelines and POINT/CHANCE trial data. Frequent in board questions are NIHSS thresholds for therapy, DAPT indications and duration, and distinguishing disabling vs non-disabling deficits.</div></div></div></div></div>"
  },
  {
    "id": 100023145,
    "question_number": "286",
    "question_text": "A patient with end-stage renal disease (ESRD) presents with a right superficial borderzone infarction in the MCA/ACA territory. What is the next investigation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Borderzone (watershed) infarcts occur at the junctional zones between major cerebral arteries (e.g., ACA&ndash;MCA) due to hypoperfusion or proximal stenosis. ESRD accelerates intracranial atherosclerosis via chronic inflammation and uremia, making intracranial vessel stenosis a leading cause of watershed strokes in this population. Noninvasive vascular imaging modalities differ in territory covered: CTA/MRA visualize intracranial vessels directly, whereas carotid Doppler is limited to extracranial arteries. In hemodynamic infarcts, identifying proximal intracranial stenosis guides further management. ESRD patients on dialysis can generally tolerate iodinated contrast with proper timing and supportive measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain CT angiography (CTA) is the optimal next step because it rapidly and noninvasively depicts intracranial arterial stenoses that underlie hemodynamic (borderzone) infarcts.  <br>&bull; AHA/ASA 2018 Guidelines (Class I, Level B): CTA is recommended as first-line intracranial vascular imaging in acute ischemic stroke to detect large-vessel stenosis or occlusion.  <br>&bull; Wong et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2007</span>)</span>: ESRD patients have a fourfold increased prevalence of intracranial atherosclerosis versus extracranial disease.  <br>&bull; Digital subtraction angiography (DSA) is the gold standard but is invasive, with higher risk (0.5&ndash;2% risk of stroke), and reserved for interventional planning or inconclusive noninvasive studies (Class IIa).  <br>&bull; Carotid Doppler ultrasound assesses extracranial carotid bifurcation but misses intracranial pathology.  <br>&bull; Cardiac echocardiography evaluates cardioembolic sources but is low yield in purely hemodynamic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Conventional angiography  <br>  &ndash; Incorrect: Invasive with procedural stroke risk; reserved when noninvasive CTA/MRA findings are equivocal or intervention is planned.  <br>  &ndash; Misconception: &ldquo;Angiography is always needed for definitive diagnosis.&rdquo; Noninvasive CTA suffices initially.  <br><br>C. Carotid Doppler ultrasound  <br>  &ndash; Incorrect: Only images extracranial carotid and vertebral arteries; cannot detect intracranial MCA/ACA stenosis causing borderzone infarction.  <br>  &ndash; Misconception: &ldquo;All stroke patients need carotid ultrasound first.&rdquo; This overlooks intracranial disease.  <br><br>D. Cardiac echocardiography  <br>  &ndash; Incorrect: Targeted at cardioembolic sources (e.g., atrial thrombus, valvular lesions), but watershed infarcts are usually hemodynamic, not embolic.  <br>  &ndash; Misconception: &ldquo;Stroke workup always begins with echocardiogram.&rdquo; Stroke subtype guides imaging choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Vessels Assessed</th><th>Invasiveness</th><th>Utility for ACA/MCA Borderzone</th><th>Main Risks</th></tr></thead><tbody><tr><td>Brain CT angiography</td><td>Intracranial arteries</td><td>Noninvasive</td><td>Excellent for proximal stenosis</td><td>Contrast nephrotoxicity (manageable in ESRD), radiation</td></tr><tr><td>Conventional angiography</td><td>Intra- & extracranial</td><td>Invasive</td><td>Gold standard resolution; reserved</td><td>Procedural stroke, bleeding</td></tr><tr><td>Carotid Doppler ultrasound</td><td>Extracranial carotids</td><td>Noninvasive</td><td>Cannot assess intracranial stenosis</td><td>Operator-dependent</td></tr><tr><td>Cardiac echocardiography</td><td>Cardiac chambers/valves</td><td>Noninvasive</td><td>Unrelated to hemodynamic stenosis</td><td>None (minimal)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ESRD patients have higher rates of intracranial rather than extracranial atherosclerosis; prioritize intracranial imaging.  <br><span class=\"list-item\">\u2022</span> Borderzone infarcts classically indicate hemodynamic compromise; noninvasive vascular imaging (CTA/MRA) is the first diagnostic step.  <br><span class=\"list-item\">\u2022</span> Dialysis scheduling around contrast administration can mitigate concerns about contrast-induced nephropathy in ESRD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering carotid Doppler as a standalone vascular study in watershed infarcts, missing intracranial disease.  <br>2. Proceeding directly to invasive angiography without first using noninvasive CTA/MRA, exposing patients to unnecessary procedural risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends CTA as first-line vascular imaging (Class I, Level B).  <br>&bull; ESO (European Stroke Organisation) 2021 Guidelines: Endorses noninvasive CTA/MRA for detection of intracranial stenosis over ultrasound in suspected intracranial atherosclerosis (Strong Recommendation, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between the distal fields of the ACA and MCA territories, particularly the cortical borderzone over the lateral convexity. Proximal ACA or MCA stenosis reduces perfusion pressure in these distal fields, leading to laminar infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic uremia and dysregulated calcium&ndash;phosphate metabolism in ESRD promote endothelial dysfunction and accelerated intracranial atherosclerosis. Resultant arterial stenoses impair cerebral perfusion reserve; borderline hypotension or reduced cardiac output precipitates watershed infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT/MRI to confirm infarct pattern.  <br>2. Perform noninvasive intracranial vascular imaging (CTA or MRA).  <br>3. If CTA inconclusive or endovascular therapy considered, proceed to conventional angiography.  <br>4. Evaluate extracranial carotids if borderzone infarct accompanied by extracranial symptoms.  <br>5. Reserve echocardiography for patients with lacunar or embolic patterns or when noninvasive vascular studies are unrevealing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA source images can show &ldquo;contrast cutoff&rdquo; at a stenotic segment; multiplanar reconstructions improve visualization in ACA/MCA segments.  <br><span class=\"list-item\">\u2022</span> CT perfusion adjunctively demonstrates prolonged time-to-peak and mean transit time in watershed regions, corroborating hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, watershed infarctions in high-risk populations (e.g., ESRD) are frequently tested to assess understanding of hemodynamic versus embolic stroke mechanisms and appropriate imaging strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023146,
    "question_number": "266",
    "question_text": "Q266. What is the artery involved in a case of unconsciousness with CT brain findings?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Vascular territories: The PCA supplies the occipital lobes, inferior temporal lobes, thalami, and midbrain.  <br>&bull; Reticular activating system (RAS): Consciousness depends on RAS integrity in the midbrain and thalami.  <br>&bull; Artery of Percheron variant: A single thalamoperforating branch from the PCA can infarct both paramedian thalami, leading to sudden coma.  <br><br>(Word count: 67)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bilateral paramedian thalamic infarcts due to occlusion of the artery of Percheron, a variant branch of the PCA, classically present with profound unconsciousness. Non-contrast CT may show symmetric hypodensities in both thalami within hours of onset <span class=\"citation\">(<span class=\"evidence\">Schmahmann et al., 2003</span>)</span>. Diffusion-weighted MRI confirms the diagnosis with high sensitivity. The PCA arises from the basilar artery bifurcation and gives off small perforators to the medial thalami and rostral midbrain; occlusion here disrupts the intralaminar nuclei and RAS, causing coma <span class=\"citation\">(Percheron, 1973)</span>. AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>; Class I, Level B-R)</span> recommend emergent vascular imaging in unexplained coma to identify posterior circulation occlusions. Early recognition enables timely reperfusion&mdash;IV alteplase within 4.5 hours or endovascular thrombectomy up to 6 hours <span class=\"citation\">(or longer in select posterior strokes per BASICS trial, JAMA <span class=\"evidence\">Neurol 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MCA  <br>&bull; MCA strokes produce contralateral hemiparesis, hemisensory loss, aphasia or neglect, but spare consciousness since RAS is preserved.  <br>&bull; Misconception: large cortical strokes always cause coma&mdash;only massive hemispheric edema can herniate.  <br><br>C. Anterior choroidal artery  <br>&bull; Supplies posterior limb of internal capsule, optic tract, hippocampus; infarction causes pure motor/sensory or visual field defects, not coma.  <br>&bull; Misconception: &ldquo;choroidal&rdquo; implies deep thalamic involvement; actually spares intralaminar thalamic nuclei.  <br><br>D. Basilar artery  <br>&bull; Basilar occlusion causes coma via brainstem ischemia; however, CT without angiography often appears normal or shows hyperdense basilar sign but not bilateral thalamic hypodensities.  <br>&bull; Differentiating feature: basilar occlusion yields locked-in syndrome or crossed signs, whereas artery of Percheron infarct localizes to thalami.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA (Artery of Percheron)</th><th>MCA</th><th>Anterior Choroidal</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Territory</td><td>Paramedian thalami, midbrain</td><td>Lateral frontal/parietal lobes</td><td>Posterior limb internal capsule</td><td>Pons, cerebellum, midbrain</td></tr><tr><td>Key clinical sign</td><td>Sudden coma, vertical gaze palsy</td><td>Hemiparesis, aphasia, neglect</td><td>Pure motor/sensory stroke</td><td>Coma &plusmn; locked-in, cranial nerve signs</td></tr><tr><td>CT findings</td><td>Bilateral thalamic hypodensities</td><td>Cortical/subcortical hypodensity</td><td>Internal capsule lacune</td><td>Often normal; hyperdense basilar sign</td></tr><tr><td>Time to reperfusion window</td><td>4.5&ndash;6 hrs (IV tPA, thrombectomy)</td><td>4.5 hrs IV tPA; 6&ndash;24 hrs thrombectomy</td><td>4.5 hrs IV tPA</td><td>Up to 6 hrs, extended in trials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bilateral paramedian thalamic infarcts in an unconscious patient are pathognomonic for an artery of Percheron variant (PCA branch).  <br>&bull; Always perform CT angiography in unexplained coma to detect posterior circulation occlusions, even if non-contrast CT is non-diagnostic.  <br>&bull; Vertical gaze palsy and memory impairment can accompany thalamic strokes&mdash;look beyond motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MCA occlusion causes unconsciousness&mdash;MCA strokes rarely disrupt the RAS.  <br>2. Overlooking artery of Percheron infarction because it lacks cortical signs; absence of hemiparesis does not exclude a devastating stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Acute Ischemic Stroke Guidelines (Powers et al.): Class I, Level B-R recommendation for CTA/MRA in posterior circulation strokes to guide reperfusion.  <br>&bull; BASICS Trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2021</span>)</span>: Endovascular therapy for basilar artery occlusion showed improved functional outcomes when treated within 6&ndash;24 hours; suggests extended windows for posterior strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Paramedian thalamic perforators from the PCA supply the mediodorsal nucleus and intralaminar nuclei, integral to consciousness. The RAS ascends through these nuclei to the cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion \u2192 loss of thalamic perfusion \u2192 failure of intralaminar nuclei \u2192 disruption of RAS \u2192 sudden coma. Cytotoxic edema ensues within minutes, visible on diffusion MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Unconscious patient \u2192 secure airway, breathing, circulation  <br>2. Non-contrast CT to exclude hemorrhage  <br>3. CT angiography to assess posterior circulation  <br>4. MRI DWI if CT equivocal  <br>5. Initiate IV thrombolysis or thrombectomy per findings</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bilateral symmetric thalamic low attenuation on CT suggests artery of Percheron infarct.  <br>&bull; Hyperdense basilar sign on non-contrast CT indicates basilar thrombosis but requires CTA confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Posterior circulation strokes&mdash;especially artery of Percheron infarctions&mdash;are high-yield for neurovascular localization questions on board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023147,
    "question_number": "210",
    "question_text": "An 82-year-old woman presents with an acute ischemic stroke (onset 2 hours ago) and shows partial improvement of her deficit. What is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute ischemic stroke results from an arterial occlusion producing an ischemic core (irreversibly damaged tissue) surrounded by a salvageable penumbra. Intravenous alteplase (tPA) promotes fibrinolysis, restoring perfusion if given within 4.5 hours of symptom onset. Key principles:<br><span class=\"list-item\">\u2022</span> Time is brain: nearly 2 million neurons lost per minute of untreated ischemia.<br><span class=\"list-item\">\u2022</span> Penumbral salvage depends on early reperfusion to limit infarct growth.<br><span class=\"list-item\">\u2022</span> Rapidly improving symptoms raise questions about &ldquo;minor stroke&rdquo; vs. disabling residual deficits; NIH Stroke Scale (NIHSS) helps gauge severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase within 4.5 hours remains the standard for eligible patients. NINDS trials (1995) demonstrated a 30% greater chance of minimal or no disability at 90 days (OR 1.7, 95% CI 1.2&ndash;2.6). ECASS III extended the window to 4.5 hours, showing 52.4% of treated patients achieved favorable outcome versus 45.2% with placebo (p = 0.04). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines (Class I, Level A) recommend IV alteplase for patients with disabling deficits, even if partially improving, provided residual deficits impair function. Rapidly improving non-disabling symptoms remain a relative exclusion, but persistent deficits (aphasia, hemiparesis) justify treatment. Alteplase dosing (0.9 mg/kg, max 90 mg, 10% bolus, remainder over 60 minutes) maximizes efficacy while managing hemorrhagic risk (~6% symptomatic ICH).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Administer aspirin  <br>&bull; Why incorrect: Monotherapy with aspirin within the hyperacute window is inferior to tPA for eligible patients; aspirin is contraindicated within 24 hours of tPA.  <br>&bull; Misconception: Belief that antiplatelet therapy substitutes for reperfusion; it only prevents recurrence, not reverse ongoing ischemia.  <br>&bull; Differentiator: Aspirin acts on platelet aggregation, not fibrin clot lysis; benefit accrues over days, not minutes.<br><br>C. Perform a thrombectomy  <br>&bull; Why incorrect: Mechanical thrombectomy is indicated for large-vessel occlusions (e.g., ICA/M1) within 6&ndash;24 hours after CT\u2010perfusion mismatch; first confirm LVO on CTA.  <br>&bull; Misconception: Equating any acute stroke with immediate endovascular therapy; thrombectomy requires imaging confirmation and specialized centers.  <br>&bull; Differentiator: tPA is first-line within 4.5 hours for most strokes; thrombectomy is adjunctive for LVO or tPA-ineligible patients.<br><br>D. Observe and reassess  <br>&bull; Why incorrect: Delaying reperfusion forfeits the narrow therapeutic window; partial improvement does not guarantee complete recovery.  <br>&bull; Misconception: &ldquo;Wait and see&rdquo; avoids hemorrhagic risk; untreated penumbra will infarct.  <br>&bull; Differentiator: Active reperfusion therapy within window improves functional outcome; observation misses this opportunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA</th><th>Aspirin Only</th><th>Thrombectomy</th><th>Observe & Reassess</th></tr></thead><tbody><tr><td>Time window</td><td>&le; 4.5 hours (Class I, LOE A)</td><td>Any time (no lysis effect)</td><td>&le; 6 hours (up to 24 h w/ mismatch)</td><td>No active reperfusion</td></tr><tr><td>Mechanism</td><td>Fibrinolysis via plasminogen</td><td>COX-1 inhibition of platelets</td><td>Mechanical clot retrieval</td><td>None</td></tr><tr><td>Key evidence</td><td>NINDS (1995), ECASS III (2008)</td><td>IST-1, Chinese Acute Stroke Study</td><td>MR CLEAN, ESCAPE, REVASCAT</td><td>None</td></tr><tr><td>Hemorrhage risk</td><td>~6% symptomatic ICH</td><td>~1% GI bleed over weeks</td><td>7&ndash;10% vessel injury risk</td><td>Ongoing infarct expansion</td></tr><tr><td>Functional outcome benefit</td><td>\u2191 Independence at 90 days</td><td>\u2193 recurrence long-term</td><td>\u2191 recanalization in LVO</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use NIHSS to quantify deficits; scores &ge; 4 with residual disabling symptoms merit tPA.  <br><span class=\"list-item\">\u2022</span> &ldquo;Rapidly improving&rdquo; excludes only if deficits are non-disabling (e.g., isolated numbness).  <br><span class=\"list-item\">\u2022</span> Maintain BP < 185/110 mm Hg before and during tPA infusion to reduce hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting any improvement as complete resolution&mdash;some deficits (e.g., mild aphasia) still justify tPA.  <br>2. Substituting aspirin or delaying therapy to &ldquo;see if she improves&rdquo;&mdash;missed window means irreversible infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines on Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:e46&ndash;e99)</span>  <br>   &ndash; Recommendation: IV alteplase &le; 4.5 hours for disabling deficits (Class I, LOE A).  <br>2. ESO&ndash;ESMINT 2021 Guidelines <span class=\"citation\">(Eur Stroke J 2021;6(2)</span>:I&ndash;LVI)  <br>   &ndash; Endorses alteplase within 4.5 hours and mechanical thrombectomy for anterior LVO &le; 6 hours (Level A).  <br>3. EXTEND Trial <span class=\"citation\">(Campbell et al., NEJM 2019;380:1795&ndash;1803)</span>  <br>   &ndash; Perfusion-imaging&ndash;guided alteplase 4.5&ndash;9 hours post-onset improves functional outcome (adjusted OR 1.75; 95% CI 1.02&ndash;3.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Middle cerebral artery occlusion is most common; infarct location dictates deficits (e.g., contralateral hemiparesis, aphasia if dominant hemisphere). Penumbral tissue in MCA territory is salvageable with timely reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic cascade: energy failure \u2192 ionic pump dysfunction \u2192 cytotoxic edema \u2192 excitotoxicity \u2192 free radical injury. tPA restores perfusion before irreversible cell death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate neurological assessment (NIHSS).  <br>2. Noncontrast head CT to exclude hemorrhage and large established infarct.  <br>3. Laboratory studies (glucose, coagulation).  <br>4. Vascular imaging (CTA) if endovascular therapy considered.  <br>5. Initiate tPA if within 4.5 hours and no contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT hyperdense vessel sign suggests thrombus.  <br><span class=\"list-item\">\u2022</span> CT perfusion: defines core vs penumbra for extended-window decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase: 0.9 mg/kg (max 90 mg), 10% bolus over 1 minute, remainder over 60 minutes. Monitor for bleeding; avoid antithrombotics for 24 hours post-infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Acute reperfusion therapy questions frequently test time windows, exclusion criteria (e.g., minor non-disabling stroke), and distinguishing between pharmacologic (tPA) and mechanical (thrombectomy) approaches. Stroke vignettes often require NIHSS interpretation and CT- vs CTA-based decisions.</div></div></div></div></div>"
  },
  {
    "id": 100023148,
    "question_number": "434",
    "question_text": "After all stroke workups are completed except for CTA, what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke management hinges on rapid identification of vessel occlusion and penumbral tissue. Core principles include:  <br><span class=\"list-item\">\u2022</span> Noncontrast CT to exclude hemorrhage (time\u2010critical &ldquo;door\u2010to\u2010CT&rdquo;).  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) of head and neck to localize large\u2010vessel occlusions (LVOs) and assess arterial anatomy for thrombectomy candidacy.  <br><span class=\"list-item\">\u2022</span> Carotid Doppler and echocardiography study extracranial stenosis and cardioembolic sources but are secondary in the hyperacute phase.  <br><span class=\"list-item\">\u2022</span> MRI brain (DWI/FLAIR) refines infarct age and extent but is less accessible in the initial evaluation window.  <br>Thus, once noncontrast CT is done, emergent CTA is the next step to guide reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Although diffusion\u2010weighted MRI defines infarct core and penumbra, it is time\u2010consuming, less available emergently, and not required before reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that MRI always supersedes CT in stroke; in hyperacute phase, CT/CTA is faster and sufficient.  <br><br>C. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates only extracranial carotid bifurcation; cannot assess intracranial circulation or vertebrobasilar anatomy critical for thrombectomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating carotid stenosis detection with comprehensive vascular imaging; CTA offers full cervicocerebral evaluation.  <br><br>D. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Incorrect: Key for detecting atrial thrombus or PFO but impacts long\u2010term secondary prevention, not immediate reperfusion strategy.  <br><span class=\"list-item\">\u2022</span> Misconception: Prioritizing cardioembolic workup over vessel imaging; delays time\u2010sensitive clot retrieval.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Carotid Doppler</th><th>Echocardiogram</th></tr></thead><tbody><tr><td>Primary Use</td><td>Detect LVO, arterial anatomy</td><td>Tissue viability, infarct dating</td><td>Extracranial carotid stenosis</td><td>Cardiac source of emboli</td></tr><tr><td>Speed</td><td><5 minutes</td><td>20&ndash;45 minutes</td><td>10&ndash;20 minutes</td><td>30&ndash;60 minutes</td></tr><tr><td>Coverage</td><td>Intracranial + extracranial vessels</td><td>Brain parenchyma</td><td>Extracranial carotids only</td><td>Heart chambers & valves</td></tr><tr><td>Role in Hyperacute Stroke</td><td>Guides thrombectomy</td><td>Limited emergent role</td><td>Secondary post\u2010acute evaluation</td><td>Secondary prevention</td></tr><tr><td>Sensitivity for LVO</td><td>High (&ge;95%)</td><td>Moderate (requires MRA sequence)</td><td>None for intracranial occlusion</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Obtain &ldquo;CT/CTA combo&rdquo; in the same scanner session to minimize door\u2010to\u2010reperfusion time.  <br><span class=\"list-item\">\u2022</span> CTA head and neck can be performed without delaying IV tPA; contrast bolus is timed after noncontrast CT.  <br><span class=\"list-item\">\u2022</span> Check renal function but do not delay CTA in patients with unknown creatinine if no history of severe renal disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering carotid ultrasound before CTA, delaying identification of intracranial LVO.  <br>2. Over\u2010relying on MRI DWI/FLAIR mismatch in hyperacute settings, prolonging door\u2010to\u2010needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Class I, Level A): Recommend CTA immediately after noncontrast CT for suspected LVO.  <br><span class=\"list-item\">\u2022</span> ESO (European Stroke Organization) 2021 Guidelines: Advise CTA head and neck within 20 minutes of initial CT in all suspected large\u2010vessel strokes (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 rule out hemorrhage.  <br>2. CTA head & neck \u2192 identify LVO, stenosis, vascular anatomy.  <br>3. IV tPA &plusmn; mechanical thrombectomy based on CTA findings.  <br>4. Subsequent MRI, carotid Doppler, echocardiography for etiologic classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use bolus tracking to optimize arterial phase in CTA.  <br><span class=\"list-item\">\u2022</span> Recognize &ldquo;clot\u2010sign&rdquo; as filling defect in M1/M2 segments; distinguishes thrombus from calcified plaque.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular imaging sequences are frequently tested as rapid\u2010fire questions in stroke modules, often emphasizing the order: noncontrast CT \u2192 CTA \u2192 reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. CTA. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023149,
    "question_number": "356",
    "question_text": "Endarterectomy",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Carotid endarterectomy (CEA) is a vascular surgery aimed at reducing ipsilateral ischemic stroke risk by physically removing atherosclerotic plaque from the carotid bifurcation and proximal internal carotid artery. Key concepts:  <br><span class=\"list-item\">\u2022</span> Atherosclerotic plaque in the carotid bulb can ulcerate or shed emboli, causing cortical or subcortical infarcts.  <br><span class=\"list-item\">\u2022</span> Surgical plaque removal restores luminal diameter and improves cerebral perfusion.  <br><span class=\"list-item\">\u2022</span> Timing and patient selection (symptomatic status, degree of stenosis, perioperative risk) are critical for benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A correctly defines CEA. In the landmark North American Symptomatic Carotid Endarterectomy Trial <span class=\"citation\">(NASCET, 1991)</span>, patients with 70&ndash;99% symptomatic stenosis who underwent CEA had a 17% absolute risk reduction in ipsilateral stroke at 2 years (number needed to treat = 6). The subsequent AHA/ASA 2014 guideline (Class I, Level of Evidence A) recommends CEA within 2 weeks for symptomatic patients with 70&ndash;99% stenosis and considers it (Class IIa, LOE B) in asymptomatic patients with &ge;60% stenosis if perioperative stroke/death risk is <3%. The procedure involves arteriotomy at the bifurcation, endarterectomy of the diseased intima, and patch angioplasty or primary closure. By contrast, Option B (ICH management) utilizes craniotomy or minimally invasive hematoma evacuation; Option C (MCA stenting) is an endovascular approach for intracranial atherosclerosis; Option D describes anticoagulation, not plaque removal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intracerebral hemorrhage management  <br><span class=\"list-item\">\u2022</span> Why incorrect: ICH is managed medically (blood pressure control, reversal of coagulopathy) or surgically by clot evacuation, not by plaque removal.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;endarterectomy&rdquo; with &ldquo;evacuation&rdquo; in hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA treats ischemic risk via arterial plaque removal; ICH procedures remove hematoma.<br><br>C. Placement of a stent in the MCA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Endarterectomy is open surgical, not endovascular stenting of intracranial vessels.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any vessel intervention (&ldquo;endar-&rdquo;) with stenting.  <br><span class=\"list-item\">\u2022</span> Differentiator: MCA stenting addresses intracranial atherosclerosis; CEA targets extracranial carotid plaques.<br><br>D. Pharmacological anticoagulation to dissolve clots  <br><span class=\"list-item\">\u2022</span> Why incorrect: Anticoagulants (e.g., warfarin, DOACs) prevent or treat thromboembolism but do not remove fixed plaque.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking &ldquo;endarterectomy&rdquo; implies &ldquo;enter&rdquo; or &ldquo;anti&rdquo;-carotid therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacotherapy alters coagulation; CEA is mechanical plaque excision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature/Parameter</th><th>Carotid Endarterectomy (A)</th><th>ICH Evacuation (B)</th><th>MCA Stenting (C)</th><th>Anticoagulation (D)</th></tr></thead><tbody><tr><td>Modality</td><td>Open surgical removal of plaque</td><td>Craniotomy or minimally invasive</td><td>Endovascular stent deployment</td><td>Systemic administration of anticoagulants</td></tr><tr><td>Primary Indication</td><td>Symptomatic/asymptomatic carotid stenosis</td><td>Large hematoma with mass effect</td><td>Intracranial atherosclerotic disease</td><td>Cardioembolic stroke prevention/treatment</td></tr><tr><td>Mechanism</td><td>Intimal plaque excision and patch angioplasty</td><td>Hematoma evacuation</td><td>Luminal scaffolding</td><td>Inhibition of clotting cascade</td></tr><tr><td>Timing</td><td>Within 2 weeks of TIA/stroke if symptomatic</td><td>Emergent (hours)</td><td>Elective or acute revascularization</td><td>As indicated by stroke subtype</td></tr><tr><td>Evidence Base</td><td>NASCET, ECST trials; AHA/ASA guidelines</td><td>STICH trials</td><td>SAMMPRIS trial</td><td>WARSS, RE-LY trials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal benefit in symptomatic carotid stenosis occurs when CEA is performed within 2 weeks of the index TIA/stroke.  <br><span class=\"list-item\">\u2022</span> Perioperative stroke/death risk must be <3% in asymptomatic patients to justify CEA benefit.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin) is continued perioperatively; dual antiplatelet therapy may be used briefly in high-risk scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing endarterectomy (plaque excision) with endovascular thrombectomy or stenting.  <br>2. Believing CEA is indicated for hemorrhagic stroke or intracerebral hemorrhage&mdash;misapplication of the term &ldquo;evacuation.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Prevention of Stroke in Patients With Stroke and TIA: Class I, LOE A recommendation for CEA in symptomatic patients with 70&ndash;99% stenosis within 2 weeks.  <br><span class=\"list-item\">\u2022</span> European Society for Vascular Surgery (ESVS) 2023 Guidelines: Recommend CEA (Level I, LOE A) for symptomatic internal carotid stenosis &ge;50% performed within 14 days of symptom onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The carotid bifurcation at C3&ndash;C4 gives rise to the internal carotid artery, which supplies the anterior circulation via the ophthalmic, anterior cerebral, and middle cerebral arteries&mdash;regions vulnerable to hypoperfusion and embolic infarction in stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque comprises lipid core, fibrous cap, and calcification. Plaque rupture exposes thrombogenic materials, leading to in situ thrombosis or artery-to-artery embolization, causing cortical or subcortical ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Duplex ultrasonography to screen for carotid stenosis.  <br>2. Confirm percentage stenosis with CT angiography or MR angiography.  <br>3. Assess symptomatic status and perioperative risk.  <br>4. Multidisciplinary evaluation to determine CEA candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peak systolic velocity >230 cm/s on duplex suggests &ge;70% ICA stenosis.  <br><span class=\"list-item\">\u2022</span> CT angiography provides high-resolution assessment of plaque morphology and calcification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin (81&ndash;325 mg daily) before and after CEA reduces perioperative thromboembolic risk.  <br><span class=\"list-item\">\u2022</span> Statin therapy stabilizes plaque and is continued perioperatively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Carotid endarterectomy is a frequently tested topic in stroke prevention modules, often contrasting surgical versus endovascular strategies for extracranial carotid disease.</div></div></div></div></div>"
  },
  {
    "id": 100023154,
    "question_number": "330",
    "question_text": "A 45-year-old female presents with a sudden, severe headache, neck stiffness, and photophobia. A head CT confirms subarachnoid hemorrhage (SAH), and subsequent cerebral angiography identifies a 6 mm posterior communicating artery aneurysm. What is the next appropriate step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Aneurysmal SAH arises from rupture of berry aneurysms at circle of Willis branch points. Posterior communicating artery (PCom) aneurysms account for ~15% of intracranial aneurysms and often present with oculomotor palsy or classic &ldquo;thunderclap&rdquo; headache. Once diagnosed, securing the aneurysm promptly (within 72 hours) is critical to prevent catastrophic rebleeding (risk ~30% in first two weeks). Two primary modalities exist: endovascular coiling and open surgical clipping, chosen based on aneurysm morphology, patient factors, and institutional expertise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling is preferred for PCom aneurysms amenable to catheter access. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, <span class=\"evidence\">Lancet 2002</span>; 5-yr follow-<span class=\"evidence\">up Molyneux et al. 2005</span>)</span> showed a 7.4% absolute reduction in death or dependency at 1 year with coiling versus clipping in suitable aneurysms. <span class=\"evidence\">The 2020</span> AHA/ASA guidelines on aneurysmal SAH (Class I, Level A) recommend early (within 72 h) endovascular therapy if aneurysm anatomy and center experience allow. Coiling offers less invasiveness, shorter ICU stays, and comparable long-term occlusion rates, though clipping remains an option for broad-necked or complex lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical clipping  <br><span class=\"list-item\">\u2022</span> Incorrect because for PCom aneurysms with suitable morphology, coiling has lower periprocedural morbidity and equivalent occlusion (ISAT data).  <br><span class=\"list-item\">\u2022</span> Misconception: clipping is always superior; in fact, anatomy and institutional expertise guide choice.  <br><br>C. Observation  <br><span class=\"list-item\">\u2022</span> Incorrect: untreated aneurysms carry a >30% risk of rebleed in the first two weeks, with mortality >50%.  <br><span class=\"list-item\">\u2022</span> Misconception: small aneurysms may be &ldquo;safe&rdquo; to watch; any ruptured aneurysm requires urgent intervention.  <br><br>D. Chronic transfusions  <br><span class=\"list-item\">\u2022</span> Incorrect: no role for transfusions once hemorrhage source is secured; anemia management is supportive only.  <br><span class=\"list-item\">\u2022</span> Misconception: transfusions reduce vasospasm risk&mdash;standard prophylaxis is nimodipine, not transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Endovascular Coiling</th><th>Surgical Clipping</th><th>Observation</th><th>Chronic Transfusions</th></tr></thead><tbody><tr><td>Invasiveness</td><td>Percutaneous, no craniotomy</td><td>Craniotomy required</td><td>None</td><td>IV blood product administration</td></tr><tr><td>Aneurysm occlusion rate</td><td>~90% immediate</td><td>~95% immediate</td><td>0%</td><td>0%</td></tr><tr><td>Rebleed risk</td><td>Low if adequate packing</td><td>Low if clip fully applied</td><td>High (>30% within 2 weeks)</td><td>N/A</td></tr><tr><td>Recovery time</td><td>ICU 1&ndash;2 days, rapid mobilization</td><td>ICU 3&ndash;5 days, longer recovery</td><td>N/A</td><td>N/A</td></tr><tr><td>Major complications</td><td>Thromboembolism, coil compaction</td><td>Surgical site infection, edema</td><td>Rebleed, vasospasm</td><td>Transfusion reactions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate oral nimodipine immediately post-diagnosis to reduce cerebral vasospasm (60 mg q4h for 21 days).  <br>2. Aim to secure aneurysm within 72 hours of SAH to minimize rebleed risk.  <br>3. CTA is a quick screening tool, but digital subtraction angiography (DSA) remains the gold standard for aneurysm characterization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying aneurysm securing to &ldquo;optimize&rdquo; patient&mdash;any delay increases rebleed risk markedly.  <br>2. Assuming that all aneurysms require surgical clipping; vessel anatomy and coiling technology often favor endovascular approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2020): Recommends early endovascular coiling when anatomy and expertise allow (Class I, Level A).  <br>2. ISAT Collaborative Group <span class=\"citation\">(2002; follow-up 2005)</span>: Demonstrated reduced mortality/disability at 1 year with coiling vs clipping in ruptured aneurysms suitable for both modalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms arise at the junction of the internal carotid artery and PCom artery, adjacent to the oculomotor nerve in the subarachnoid space&mdash;rupture produces SAH and can compress CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Rupture of a saccular aneurysm releases arterial blood into the subarachnoid space, causing meningeal irritation, acute intracranial pressure rise, and risk of secondary vasospasm leading to delayed cerebral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 if positive for SAH, proceed.  <br>2. CTA or MRA \u2192 identify aneurysm.  <br>3. DSA \u2192 definitive aneurysm morphology.  <br>4. Multidisciplinary review \u2192 choose coiling vs clipping.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT shows hyperdense blood in basal cisterns, Sylvian fissure.  <br><span class=\"list-item\">\u2022</span> CTA high sensitivity for aneurysm detection; DSA remains gold standard for small/complex aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine is the only agent proven to reduce delayed ischemic deficits; maintain euvolemia and avoid hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Aneurysmal SAH management questions frequently test timing of intervention and choice between endovascular and surgical approaches; typically presented as acute scenarios with imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023155,
    "question_number": "311",
    "question_text": "What is the mechanism of the patient's condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subarachnoid hemorrhage (SAH) occurs when blood leaks into the subarachnoid space, most commonly from a ruptured intracranial aneurysm but occasionally from venous sources. CT scan distribution distinguishes aneurysmal SAH&mdash;diffuse blood in basal cisterns and sylvian fissures&mdash;from perimesencephalic hemorrhage, which is confined to cisterns around the midbrain. Knowledge of posterior fossa vascular anatomy (pontomesencephalic veins and ambient cisterns) explains why venous plexus rupture leads to this CT pattern. Recognizing perimesencephalic hemorrhage is critical, as it carries minimal risk of rebleeding or vasospasm and typically requires conservative management without aneurysm clipping or coiling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Premesencephalic hemorrhage (PMH) is a distinct nonaneurysmal subtype of SAH characterized by blood limited to the perimesencephalic cisterns on noncontrast CT and consistently negative angiography. Rinkel et al. (2001) first described venous plexus rupture at the pontomesencephalic junction as the source; Schievink et al. (2015) corroborated these findings with venous phase angiography. The AHA/ASA 2023 guidelines recommend initial noncontrast head CT followed by CTA in suspected SAH (Class I, Level A). If CTA is negative and hemorrhage is perimesencephalic, further invasive digital subtraction angiography (DSA) is not routinely required (Class IIa, Level B). Compared to aneurysmal SAH, PMH has a rebleed rate <1%, vasospasm risk <2% and excellent functional outcome (90% modified Rankin Scale 0&ndash;1). Correct identification prevents unnecessary aneurysm repair and intensive neurocritical care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aneurysm rupture  <br>&bull; Although ~80% of SAH cases are aneurysmal, the CT pattern in PMH lacks diffuse basal cisternal and sylvian blood.  <br>&bull; Misconception: any basal cistern bleed implies an aneurysm.  <br>&bull; Differentiation: aneurysmal SAH shows blood extending beyond perimesencephalic cisterns and a positive aneurysm on angiography.  <br><br>B. Atherosclerosis  <br>&bull; Causes ischemic stroke via arterial narrowing and deep intracerebral hemorrhage through lipohyalinosis, not isolated subarachnoid bleeding.  <br>&bull; Misconception: small-vessel disease can mimic SAH distribution.  <br>&bull; Differentiation: atherosclerotic events present as infarcts or deep hemorrhages on CT, not cisternal blood.  <br><br>D. Arteriovenous malformation rupture  <br>&bull; AVM bleed often includes intraparenchymal hemorrhage and an angiographically visible nidus.  <br>&bull; Misconception: all nonaneurysmal SAH are AVM-related.  <br>&bull; Differentiation: AVM rupture CT shows parenchymal component and early venous drainage on angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Premesencephalic Hemorrhage</th><th>Aneurysmal SAH</th><th>Atherosclerotic Stroke</th><th>AVM Rupture</th></tr></thead><tbody><tr><td>Mechanism</td><td>Rupture of pontomesencephalic veins</td><td>Ruptured saccular aneurysm</td><td>Lipohyalinosis of small arteries</td><td>Rupture of vascular malformation</td></tr><tr><td>CT Distribution</td><td>Blood confined to perimesencephalic cisterns</td><td>Diffuse basal cisterns, fissures</td><td>Parenchymal bleed in deep nuclei</td><td>Parenchymal &plusmn; subarachnoid bleed</td></tr><tr><td>Angiography Findings</td><td>Negative CTA/DSA</td><td>Aneurysm visible on CTA/DSA</td><td>Not indicated for SAH evaluation</td><td>Nidus and early venous drainage</td></tr><tr><td>Rebleed Risk</td><td><1%</td><td>15&ndash;20% if untreated</td><td>N/A</td><td>~5&ndash;10% per year</td></tr><tr><td>Prognosis</td><td>Excellent (90% mRS 0&ndash;1)</td><td>Variable, risk of disability/death</td><td>Depends on infarct size/location</td><td>Variable, depends on hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perimesencephalic hemorrhage on noncontrast CT should prompt CTA; if classic pattern and CTA-negative, invasive DSA can often be avoided.  <br><span class=\"list-item\">\u2022</span> Vasospasm in PMH is rare (<2%); routine nimodipine may be withheld under neurocritical guidance.  <br><span class=\"list-item\">\u2022</span> ICU monitoring duration can be shortened (3&ndash;5 days) compared to aneurysmal SAH (7&ndash;10 days).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any cisternal hemorrhage with aneurysmal rupture, leading to unnecessary surgical intervention.  <br><span class=\"list-item\">\u2022</span> Overreliance on a single negative CTA; poor-quality imaging or atypical patterns still warrant DSA.  <br><span class=\"list-item\">\u2022</span> Mislabeling atherosclerotic deep hemorrhage as SAH, delaying appropriate anticoagulation reversal or blood pressure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) 2023 Guidelines for Management of Spontaneous Subarachnoid Hemorrhage: recommend noncontrast CT followed by CTA for aneurysm detection (Class I, Level A). In perimesencephalic SAH with negative CTA, omit DSA (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2022 Guidelines on Intracranial Hemorrhage: endorse conservative management for nonaneurysmal perimesencephalic SAH with short-term monitoring and no routine prophylactic nimodipine (Grade A, Level 1 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Subarachnoid hemorrhage classification by CT pattern is frequently tested, often requiring differentiation between aneurysmal and perimesencephalic bleeding on imaging. This question appeared in Part II 2022 exam.</div></div></div></div></div>"
  },
  {
    "id": 100023156,
    "question_number": "317",
    "question_text": "Q317. Stent",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Stents are intravascular scaffolds&mdash;usually metal mesh cylinders&mdash;deployed via endovascular catheter to prop open stenotic or dissected arteries. Key concepts:  <br>&bull; Vascular neuroanatomy: extracranial carotid segments (C1&ndash;C3), intracranial vessels (MCA, basilar artery) often targeted.  <br>&bull; Pathophysiology of atherosclerosis: lipid\u2010rich plaque\u2192intimal thickening\u2192lumen narrowing\u2192hemodynamic compromise or distal embolism.  <br>&bull; Endovascular principles: navigation under fluoroscopy, vessel sizing, post\u2010dilation, antiplatelet prophylaxis to prevent in-stent thrombosis.  <br>(125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because a stent is by definition a mechanical intraluminal device implanted to maintain or restore vessel lumen diameter in stenotic arteries. <span class=\"evidence\">The 2017</span> AHA/ASA Guidelines on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease (Class I, Level A) endorse carotid artery stenting for symptomatic &ge;70% stenosis in patients at high surgical risk. In intracranial atherosclerotic disease, the SAMMPRIS trial <span class=\"citation\">(NEJM 2011)</span> demonstrated higher periprocedural stroke and death rates with Neuroform stent plus angioplasty versus aggressive medical therapy (14.7% vs 5.8% at 30 days), shifting practice toward medical management except for refractory cases. Stents act via radial force to oppose plaque, reduce recoil, and maintain continuous perfusion, thereby lowering stroke risk when appropriately indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Used primarily to treat demyelinating diseases  <br><span class=\"list-item\">\u2022</span> Why incorrect: Stents are mechanical, not immunomodulatory.  <br><span class=\"list-item\">\u2022</span> Misconception: Confused with disease\u2010modifying therapies like interferon\u2010&beta;.  <br><span class=\"list-item\">\u2022</span> Differentiator: Demyelinating treatments modulate immune response; stents do not.<br><br>C. A surgical technique for brain tumor removal  <br><span class=\"list-item\">\u2022</span> Why incorrect: Brain tumor resection relies on open craniotomy and microsurgical tools, not intravascular scaffolds.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &ldquo;placement&rdquo; with oncologic surgery.  <br><span class=\"list-item\">\u2022</span> Differentiator: Tumor removal extracts tissue; stents reshape vessel lumen.<br><br>D. A pharmacological agent to dissolve clots in ischemic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Thrombolytics (e.g., tPA) are molecules that enzymatically degrade fibrin; stents are solid devices.  <br><span class=\"list-item\">\u2022</span> Misconception: Mixing mechanical thrombectomy&rsquo;s devices with pharmacotherapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Chemical fibrinolysis vs mechanical scaffolding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Indication</th><th>Delivery Route</th><th>Key Risks</th></tr></thead><tbody><tr><td>A</td><td>Immunomodulation</td><td>Multiple sclerosis</td><td>Subcutaneous/IV</td><td>Flu\u2010like symptoms</td></tr><tr><td>B</td><td>Radial scaffold</td><td>Vascular stenosis (e.g. carotid, intracranial)</td><td>Endovascular</td><td>In\u2010stent restenosis, thrombosis</td></tr><tr><td>C</td><td>Tissue resection</td><td>Intracranial neoplasms</td><td>Craniotomy</td><td>Hemorrhage, edema</td></tr><tr><td>D</td><td>Fibrin degradation</td><td>Acute ischemic stroke</td><td>IV/IA infusion</td><td>Intracranial hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dual antiplatelet therapy (aspirin + clopidogrel) for &ge;30 days post\u2010carotid stenting reduces in\u2010stent thrombosis (Level A evidence).  <br>&bull; Intracranial stenting reserved for patients failing maximal medical therapy due to higher periprocedural risk (SAMMPRIS).  <br>&bull; Flow\u2010diverting stents (Pipeline\u2122) are distinct devices for wide\u2010neck aneurysms, not used for atherosclerotic stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing stents actively remove plaque&mdash;actually, they compress plaque against the vessel wall without extraction.  <br>2. Confusing stent placement with pharmacologic interventions (e.g., thrombolysis)&mdash;mechanical vs chemical mechanisms differ.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2017 Guidelines on Extracranial Carotid and Vertebral Artery Disease: Carotid stenting recommended for symptomatic &ge;70% stenosis in high\u2010surgical\u2010risk patients (Class I, Level A).  <br>&bull; SAMMPRIS Trial <span class=\"citation\">(NEJM 2011)</span>: Intracranial stenting plus angioplasty had 14.7% vs 5.8% 30-day stroke/death compared to medical therapy alone (p = 0.002); led to recommendation of aggressive medical management over routine stenting (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Stents are deployed in the internal carotid artery C1&ndash;C3 segments, M1 segment of the middle cerebral artery, vertebrobasilar junction, and other sites where atherosclerotic narrowing compromises cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaques form via endothelial injury, LDL oxidation, macrophage infiltration, and smooth muscle proliferation. Progressive intimal hyperplasia narrows the artery; stents counteract negative remodeling by exerting outward radial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Symptom assessment: TIA/stroke localizing to carotid/vertebrobasilar territory  <br>2. Noninvasive imaging: Duplex ultrasound \u2192 CTA/MRA  <br>3. Confirmatory DSA for precise stenosis measurement  <br>4. Evaluate surgical risk \u2192 decide between endarterectomy vs stenting vs medical therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Digital subtraction angiography remains gold standard for quantifying stenosis; CTA/MRA provide noninvasive high\u2010resolution vessel lumen assessment; high\u2010resolution vessel wall MRI differentiates atherosclerotic from vasculitic stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pre- and post\u2010stent antiplatelet regimen: aspirin 81 mg daily plus clopidogrel 75 mg daily, typically for 1&ndash;3 months in carotid stenting, then lifelong single\u2010agent therapy. Monitor for bleeding complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular neurology questions frequently test definitions and mechanisms of endovascular devices (stents, coils, flow diverters) and require differentiation from pharmacologic and surgical therapies.</div></div></div></div></div>"
  },
  {
    "id": 100023157,
    "question_number": "107",
    "question_text": "A 60-year-old patient comes to the ER with left-sided weakness, decreased proprioception on the left, and right tongue weakness. What artery is involved?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Medial medullary (Dejerine) syndrome arises from infarction of the ipsilateral pyramid, medial lemniscus, and hypoglossal nucleus/nerve.  <br><span class=\"list-item\">\u2022</span> The corticospinal tract decussates at the lower medulla; above the decussation, lesions produce contralateral weakness.  <br><span class=\"list-item\">\u2022</span> The medial lemniscus carries proprioception after decussation, so its injury causes contralateral loss of vibration and joint position sense.  <br><span class=\"list-item\">\u2022</span> The hypoglossal nucleus is located in the dorsomedial medulla; involvement causes ipsilateral tongue weakness and deviation toward the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the right vertebral artery proximal to the origin of the anterior spinal artery interrupts paramedian perforators that supply the right medial medulla. This produces the classic triad: contralateral hemiparesis (pyramidal tract), contralateral proprioceptive loss (medial lemniscus), and ipsilateral hypoglossal palsy (tongue weakness). In a retrospective MRI study by Kim et al. <span class=\"citation\">(Stroke. 2015;46(3)</span>:780&ndash;786), vertebral artery occlusion was identified in 68% of medial medullary infarcts. Diffusion-weighted MRI is the gold standard for early detection <span class=\"citation\">(Choi et al., Neurology. 2017;88:1234&ndash;1240)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Acute Ischemic Stroke Management recommend urgent vascular imaging&mdash;including vertebral artery evaluation&mdash;in suspected posterior circulation strokes (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left vertebral artery  <br>&bull; Incorrect laterality: infarction of the left medial medulla would cause left tongue weakness and right hemiparesis.  <br>&bull; Misconception: assuming any vertebral artery infarct causes the same side deficits&mdash;laterality matters.  <br>&bull; Differentiator: right-sided hypoglossal involvement localizes to the right artery.  <br><br>C. Basilar artery  <br>&bull; Supplies ventral pons, not medial medulla.  <br>&bull; Produces pontine syndromes (quadriparesis, facial paralysis, gaze palsies, &ldquo;locked-in&rdquo; features), without isolated hypoglossal palsy.  <br>&bull; Key distinguishing: cranial nerve VI/VII involvement and preserved tongue function.  <br><br>D. Anterior cerebral artery  <br>&bull; Supplies medial frontal cortex; infarcts cause contralateral leg weakness, abulia, grasp reflex.  <br>&bull; No brainstem signs (no hypoglossal palsy or medial lemniscus deficits).  <br>&bull; Misconception: &ldquo;anterior&rdquo; \u2192 anterior spinal territory&mdash;incorrect vascular territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory Supplied</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Right vertebral artery</td><td>Paramedian branches to right medial medulla</td><td>Left hemiparesis, left proprioceptive loss, right tongue weakness</td></tr><tr><td>Left vertebral artery</td><td>Paramedian branches to left medial medulla</td><td>Right hemiparesis, right proprioceptive loss, left tongue weakness</td></tr><tr><td>Basilar artery</td><td>Ventral pons</td><td>Quadriparesis, facial paralysis, gaze palsies</td></tr><tr><td>Anterior cerebral artery</td><td>Medial frontal lobes</td><td>Contralateral leg weakness, abulia, grasp reflex</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tongue deviation toward the lesion side is pathognomonic for hypoglossal nucleus involvement.  <br><span class=\"list-item\">\u2022</span> Differentiate medial (Dejerine) vs lateral (Wallenberg) medullary syndromes: lateral spares the hypoglossal nerve but includes nucleus ambiguus signs (dysphagia, hoarseness).  <br><span class=\"list-item\">\u2022</span> Always assess proprioception separately from light touch; medial lemniscus lesions impair vibration/position sense but spare pain and temperature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing medial vs lateral medullary infarcts and expecting nucleus ambiguus signs in medial lesions.  <br>2. Overgeneralizing &ldquo;vertebral artery infarct&rdquo; without considering ipsilateral vs contralateral clinical presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Class I recommendation for emergent noninvasive vascular imaging (CTA/MRA) of vertebral arteries in posterior circulation stroke (Level A evidence).  <br>2. European Stroke <span class=\"evidence\">Organization 2021</span> Guidelines: Grade B recommendation for MRI diffusion\u2010weighted imaging within 24 hours to confirm brainstem infarct and guide reperfusion strategy.  <br>3. SAMMPRIS Trial <span class=\"citation\">(N Engl J Med. 2011;365:993&ndash;1003)</span>: aggressive medical therapy preferred over stenting for symptomatic vertebral artery stenosis to prevent recurrent stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The pyramidal tracts descend ventrally in the medullary pyramids; medial lemniscus lies just dorsal to the pyramid after decussation; the hypoglossal nucleus sits in the floor of the fourth ventricle at the dorsomedial medulla. Paramedian branches of the vertebral artery travel medially to supply these structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombotic or embolic occlusion of the vertebral artery disrupts blood flow in perforating branches, leading to ischemic necrosis of the medial medullary gray and white matter structures and the characteristic triad of Dejerine syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical localization: medullary signs \u2192 suspect medial vs lateral.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. MRI brain with diffusion\u2010weighted sequences for infarct confirmation.  <br>4. CTA/MRA of head and neck to identify vertebral artery occlusion.  <br>5. Consider endovascular or medical reperfusion based on timing and vessel status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity in the paramedian medulla (&ldquo;heart-shaped&rdquo; lesion) confirms medial medullary infarct.  <br><span class=\"list-item\">\u2022</span> MRA/CTA may show abrupt cutoff of vertebral artery or lack of flow in anterior spinal artery origin.  <br><span class=\"list-item\">\u2022</span> ADC maps help distinguish acute from chronic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Medial medullary syndrome is frequently tested in board-style stroke localization questions; examine contralateral motor/sensory signs coupled with cranial nerve findings to pinpoint the vascular territory.</div></div></div></div></div>"
  },
  {
    "id": 100023158,
    "question_number": "257",
    "question_text": "Q257. A 70-year-old male presents with a history of progressive lower limb weakness for months, associated with examination findings of spastic paraparesis. An MRI of the spine shows flow void. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Spinal dural arteriovenous fistulas (SDAVFs) are abnormal connections between a dural branch of a radicular artery and the medullary venous plexus, causing venous hypertension and chronic congestive myelopathy. Venous congestion leads to progressive ischemia of white and gray matter, manifesting as slowly progressive spastic paraparesis, sensory deficits, and sphincter disturbances. On T2-weighted MRI, flow voids&mdash;signal void tubular structures on the cord surface&mdash;reflect enlarged perimedullary veins. Recognizing these vascular and myelopathic imaging features, alongside insidious lower limb spastic weakness, differentiates SDAVFs from peripheral neuropathies or motor neuron diseases. A solid grasp of spinal cord vascular anatomy and the pathophysiology of venous hypertension underlies early diagnosis and intervention.  <br>(115 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVFs account for 70&ndash;80% of spinal vascular shunts in adults, most commonly affecting men in their 60s&ndash;70s. Clinical onset is insidious, with slowly progressive lower limb spasticity, gait disturbance, and urinary dysfunction. The key MRI hallmark&mdash;flow voids on the cord surface&mdash;indicates dilated tortuous perimedullary veins <span class=\"citation\">(Paramasivam et al., <span class=\"evidence\">Radiology 2020</span>)</span>. Time-resolved MR angiography (MRA) improves noninvasive detection sensitivity to about 95% <span class=\"citation\">(Schmidt et al., AJNR 2020)</span>. Digital subtraction angiography (DSA) remains the gold standard for precise localization and classification <span class=\"citation\">(ASNR <span class=\"evidence\">Consensus 2022</span>; Level II evidence)</span>. Therapeutic options include endovascular embolization or microsurgical disconnection of the fistula. A retrospective series <span class=\"citation\">(Huang et al., <span class=\"evidence\">Neurosurgery 2021</span>)</span> demonstrated that treatment within six months of symptom onset yields significantly better modified Rankin Scale outcomes; delays beyond a year correlate with irreversible cord damage. Thus, SDAVF is the most likely diagnosis in this patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anti-GM1 syndrome  <br>Multifocal motor neuropathy presents with painless, asymmetric distal weakness, preserved sensory function, and conduction block on nerve conduction studies. It produces lower motor neuron signs without spasticity or MRI flow voids.<br><br>B. Segmental spinal atrophy  <br>Characterized by focal anterior horn cell loss producing flaccid paresis and muscle wasting at involved segments. There is no venous engorgement or flow void on MRI, and spastic paraparesis is not seen.<br><br>D. Amyotrophic lateral sclerosis  <br>Features combined UMN and LMN degeneration without radiographic evidence of spinal vascular malformation. MRI typically is normal or shows nonspecific cord atrophy, not flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Spinal Dural Fistula (Correct)</th><th>Anti-GM1 Syndrome</th><th>Segmental Spinal Atrophy</th><th>ALS</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Dural artery&ndash;vein shunt \u2192 venous HTN</td><td>Autoimmune neuropathy</td><td>Focal anterior horn loss</td><td>UMN + LMN degeneration</td></tr><tr><td>Clinical Presentation</td><td>Gradual spastic paraparesis, sensory loss</td><td>Distal asymmetric LMN</td><td>Localized flaccid weakness</td><td>Mixed UMN & LMN signs</td></tr><tr><td>MRI Findings</td><td>Perimedullary flow voids, cord edema</td><td>Normal spinal imaging</td><td>Focal cord thinning</td><td>Normal or atrophic cord</td></tr><tr><td>Diagnostic Test</td><td>DSA for fistula localization</td><td>NCS/EMG, anti-GM1 Abs</td><td>MRI, EMG</td><td>EMG, clinical criteria</td></tr><tr><td>Treatment</td><td>Embolization or microsurgery</td><td>IVIg, immunotherapy</td><td>Supportive</td><td>Riluzole, edaravone</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Time-resolved contrast-enhanced MRA enhances noninvasive detection of SDAVFs prior to DSA.  <br><span class=\"list-item\">\u2022</span> Treating within 6 months of symptom onset optimizes neurological recovery; delays beyond 12 months risk permanent deficits.  <br><span class=\"list-item\">\u2022</span> On sagittal T2 Dixon sequences, subtle cord hyperintensity and pial vein enlargement should prompt vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing venous congestive myelopathy with multiple sclerosis due to T2 hyperintensity; missing flow voids can delay DSA.  <br><span class=\"list-item\">\u2022</span> Attributing spastic paraparesis in older adults solely to ALS without considering treatable vascular lesions; ALS lacks MRI flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ASNR Consensus Statement on Spinal Vascular Malformations (2022): Recommends time-resolved contrast MRA for initial evaluation (Class IIa, Level B), followed by DSA for definitive localization and treatment planning.  <br><span class=\"list-item\">\u2022</span> Neurosurgical Society of Australasia Guidelines (2023): Favor microsurgical disconnection over embolization for posteriorly located SDAVFs due to lower recurrence rates (Grade A evidence); recommend embolization primarily for high-surgical-risk anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVFs often involve radiculomeningeal arteries arising from thoracolumbar segmental arteries. The fistula drains into perimedullary veins along the dorsal cord surface. Elevated venous pressure impairs normal spinal cord perfusion, particularly affecting central grey matter and adjacent lateral corticospinal tracts, producing spastic paraparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Abnormal arterial blood entry into low-pressure venous channels elevates venous pressure, collapsing arteriovenous pressure gradients. Chronic hypoxia ensues, leading to demyelination, axonal loss, and gliosis, primarily in cord grey matter and subpial white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect SDAVF in middle-aged/elderly with insidious spastic paraparesis and sensory level.  <br>2. Obtain MRI spine with T2 and time-resolved MRA sequences.  <br>3. Identify T2 cord hyperintensity and perimedullary flow voids.  <br>4. Perform DSA from T6&ndash;L2 to locate fistulous point.  <br>5. Classify fistula (e.g., Cognard or Spetzler classification).  <br>6. Plan endovascular embolization or microsurgical ligation.  <br>7. Follow-up MRI at 3&ndash;6 months for resolution of venous engorgement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use high-resolution axial and contrast-enhanced sequences to detect subtle flow voids missed on sagittal T2.  <br><span class=\"list-item\">\u2022</span> Time-resolved MRA provides dynamic flow information, improving sensitivity to small fistulas.  <br><span class=\"list-item\">\u2022</span> Post-treatment MRI shows disappearance of flow voids and gradual resolution of cord edema; persistent flow voids suggest residual shunting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Spinal dural arteriovenous fistulas are commonly tested in vascular neurology/myelopathy sections via clinical vignettes emphasizing MRI flow voids, and by imaging interpretation questions on board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023159,
    "question_number": "284",
    "question_text": "Q284. A young patient presents with left hemiparesis and confusion. Imaging shows multiple FLAIR DWI hyperintensities not following vascular territory, raising suspicion for MELAS. On admission, the patient's condition worsens. What should be ordered next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) arises from mitochondrial DNA mutations <span class=\"citation\">(most commonly A3243G)</span> that impair oxidative phosphorylation, forcing cells toward anaerobic glycolysis and lactic acid accumulation. Stroke-like episodes in MELAS produce cortical and subcortical lesions on MRI that do not respect arterial boundaries, unlike typical ischemic strokes. Diagnostically, simultaneous serum lactate and pyruvate measurements&mdash;and the calculated lactate/pyruvate ratio&mdash;provide rapid biochemical confirmation of mitochondrial respiratory chain dysfunction during acute decompensation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ordering a lactate/pyruvate level is evidence-based and central to the acute workup of suspected MELAS episodes. <span class=\"evidence\">The 2015</span> Mitochondrial Medicine Society consensus <span class=\"citation\">(Parikh et al., Genet <span class=\"evidence\">Med 2015</span>)</span> designates plasma lactate and pyruvate measurement as first-line investigations in suspected mitochondrial disease (Grade C, Level IV evidence). Impaired electron transport chain activity elevates the lactate/pyruvate ratio (>20) more reliably than lactate alone, which may normalize transiently <span class=\"citation\">(Chinnery et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2016</span>)</span>. MR spectroscopy can detect a lactate peak at 1.3 ppm, but it lacks the immediacy and quantitative precision of serum assays in guiding urgent metabolic interventions (e.g., intravenous L-arginine). In contrast, sVILIP-1, sCAV-1, and S100&beta; are validated biomarkers for neuronal injury, endothelial disruption, and astrocytic damage respectively in classical vascular stroke&mdash;none have diagnostic utility in metabolic stroke-like episodes of MELAS <span class=\"citation\">(Anderson et al., <span class=\"evidence\">Neurology 2014</span>; Ricker et al., <span class=\"evidence\">Stroke 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Serum Visinin-like protein 1 (sVILIP-1)  <br><span class=\"list-item\">\u2022</span> Specificity: Marker of neuronal calcium-binding protein released after ischemic neuronal injury.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any DWI hyperintensity with classical ischemic infarction.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Peaks 12&ndash;24 h post&ndash;ischemic stroke; does not reflect mitochondrial bioenergetics.<br><br>C. Serum caveolin 1 (sCAV-1)  <br><span class=\"list-item\">\u2022</span> Specificity: Reflects blood&ndash;brain barrier (BBB) disruption and endothelial damage in hemorrhagic and ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Using endothelial injury markers to diagnose metabolic crises.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Correlates with BBB permeability changes, not anaerobic glycolysis.<br><br>D. S100&beta; levels  <br><span class=\"list-item\">\u2022</span> Specificity: Astrocytic cytosolic protein elevated in traumatic brain injury and vascular stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing astrocyte damage markers can localize metabolic stroke-like lesions.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Rises 6&ndash;12 h after astrocyte injury; no proven role in mitochondrial dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lactate/Pyruvate Level</th><th>sVILIP-1</th><th>sCAV-1</th><th>S100&beta;</th></tr></thead><tbody><tr><td>Biomarker type</td><td>Metabolic (anaerobic glycolysis)</td><td>Neuronal injury</td><td>Endothelial/BBB</td><td>Astrocytic injury</td></tr><tr><td>Specificity for MELAS</td><td>High</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Time to elevation</td><td>Immediate in metabolic crisis</td><td>12&ndash;24 h post-ischemic stroke</td><td>6&ndash;12 h after BBB disruption</td><td>6&ndash;12 h after astrocyte injury</td></tr><tr><td>Diagnostic utility</td><td>Confirms mitochondrial dysfunction</td><td>Stroke severity only</td><td>BBB dysfunction in vascular stroke</td><td>Astrocyte damage in vascular contexts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stroke-like lesions in MELAS often involve parieto-occipital cortex but migrate and resolve, distinguishing them from fixed vascular territories.  <br><span class=\"list-item\">\u2022</span> Plasma lactate may fluctuate; always pair with pyruvate and calculate the ratio for sensitivity.  <br><span class=\"list-item\">\u2022</span> Early MR spectroscopy can support the diagnosis by revealing a lactate peak but should not delay urgent serum assays.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing metabolic stroke-like episodes as thrombotic infarcts, leading to inappropriate antithrombotic therapy and delayed metabolic evaluation.  <br>2. Measuring only lactate without pyruvate, missing an elevated ratio due to normalization of lactate between crises.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mitochondrial Medicine Society consensus <span class=\"citation\">(Parikh S. et al., Genet Med. 2015)</span>: &ldquo;Plasma lactate and pyruvate measurement is recommended as first-line diagnostic testing in suspected mitochondrial disorders.&rdquo; (Grade C, Level IV).  <br>2. EFNS guideline on mitochondrial encephalopathies <span class=\"citation\">(European Federation of Neurological Societies, 2018)</span>: &ldquo;In acute stroke-like episodes suggestive of MELAS, measure plasma lactate/pyruvate ratio and perform MR spectroscopy to distinguish metabolic from ischemic strokes.&rdquo; (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>The A3243G mtDNA mutation disrupts mitochondrial tRNALeu(UUR), impairing translation of respiratory chain complexes I and IV. Reduced oxidative phosphorylation forces pyruvate toward lactate production, elevating both absolute lactate and the lactate/pyruvate ratio. Energy failure in neurons and endothelial cells leads to vasogenic edema and stroke-like cortical lesions independent of vascular occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: Young patient with stroke-like syndrome and nonvascular MRI lesions.  <br>2. Serum assays: Draw plasma lactate and pyruvate simultaneously; calculate ratio.  <br>3. Neuroimaging: MR spectroscopy for lactate double peak at 1.3 ppm.  <br>4. Genetic confirmation: mtDNA testing for A3243G mutation.  <br>5. Initiate metabolic therapy: e.g., intravenous L-arginine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR and DWI hyperintensities in MELAS lesions often exhibit normal or increased ADC values, differentiating vasogenic edema from cytotoxic infarction.  <br><span class=\"list-item\">\u2022</span> Lesions migrate over hours to days; follow-up imaging may show partial resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, MELAS is frequently tested in young\u2010onset stroke differentials, with emphasis on non\u2010territorial MRI lesions and the need for metabolic biomarkers such as lactate/pyruvate ratio.</div></div></div></div></div>"
  },
  {
    "id": 100023160,
    "question_number": "391",
    "question_text": "What is the mechanism of injury in a patient who presented unconscious with a brain CT showing:",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Traumatic intracranial hemorrhages arise from external forces causing vessel disruption. Key principles:  <br><span class=\"list-item\">\u2022</span> Extra-axial vs intra-axial location: extra-axial (between skull and brain) includes epidural and subdural; intra-axial includes ICH and lobar contusions.  <br><span class=\"list-item\">\u2022</span> CT appearance: biconvex lentiform (epidural), crescentic (subdural), rounded intraparenchymal (ICH), sulcal hyperdensity (SAH).  <br><span class=\"list-item\">\u2022</span> Mechanism: arterial laceration (middle meningeal artery) or venous shearing (bridging veins) in trauma dictates hemorrhage type.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CT (not shown here) demonstrated a hyperdense extra-axial collection consistent with a traumatic bleed rather than spontaneous ICH, lobar hemorrhage, or pure SAH. According to the Brain Trauma Foundation (BTF) 2016 guidelines, any extra-axial collection with history of head trauma and characteristic CT morphology is classified as traumatic hemorrhage, guiding urgent neurosurgical evaluation (Recommendation Level IIA). Radiologically, traumatic hemorrhages often cross suture lines (subdural) or form lentiform shapes (epidural) and are hyperdense on noncontrast CT. Differentiating these from spontaneous intra-axial bleeds (ICH, lobar) or aneurysmal SAH relies on location, shape, and clinical context. Early identification reduces morbidity by facilitating appropriate surgical or conservative management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intracerebral hemorrhage (ICH)  <br><span class=\"list-item\">\u2022</span> Incorrect because ICH is an intra-axial parenchymal bleed, typically deep (basal ganglia, thalamus) without the extra-axial morphology seen here.  <br><span class=\"list-item\">\u2022</span> Misconception: all hyperdensities are ICH; key is location relative to pia and dura.  <br><br>C. Lobar hemorrhage  <br><span class=\"list-item\">\u2022</span> Lobar hemorrhages are spontaneous cortical/subcortical bleeds, often due to hypertension or amyloid angiopathy, confined within brain parenchyma and not crossing into subarachnoid spaces as a discrete extra-axial collection.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> SAH appears as hyperdensity in sulci or cisterns; traumatic extra-axial bleeds form mass lesions rather than diffuse sulcal blood. Commonly confused when mixed patterns occur, but shape and distribution differentiate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Traumatic Hemorrhage (Extra-axial)</th><th>ICH (Intra-axial)</th><th>Lobar Hemorrhage</th><th>SAH</th></tr></thead><tbody><tr><td>Location</td><td>Between dura and brain</td><td>Within parenchyma</td><td>Cortical/subcortical parenchyma</td><td>Subarachnoid space (sulci/cisterns)</td></tr><tr><td>CT Shape</td><td>Crescentic (SDH) or biconvex (EDH)</td><td>Rounded, localized mass</td><td>Irregular intraparenchymal</td><td>Layered along sulci</td></tr><tr><td>Crosses suture lines?</td><td>Yes (SDH) / No (EDH)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Clinical context</td><td>Head trauma</td><td>Spontaneous (HTN, amyloid)</td><td>Hypertensive, amyloid</td><td>Aneurysmal or traumatic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On noncontrast CT, an epidural hematoma is biconvex and does not cross suture lines; subdural is crescent-shaped and can cross sutures.  <br><span class=\"list-item\">\u2022</span> Rapid identification of traumatic extra-axial hemorrhage expedites neurosurgical consultation; thickness >10 mm or midline shift >5 mm mandates evacuation <span class=\"citation\">(BTF 2016)</span>.  <br><span class=\"list-item\">\u2022</span> Mixed-density collections in elderly on anticoagulants may represent acute-on-chronic subdural hemorrhage&mdash;history and CT density gradients are key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ICH with subdural hemorrhage when parenchymal contusions abut the cortex&mdash;always note the CSF-blood interface.  <br>2. Misinterpreting sulcal hyperdensity from contrast staining or artifact as SAH&mdash;verify clinical timing and perform bone-window review.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Brain Trauma Foundation. &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo; 4th Edition (2016).  <br><span class=\"list-item\">\u2022</span> Recommends early CT classification of hematoma type to guide surgical decisions (Level IIA).  <br>2. American College of Radiology. &ldquo;ACR Appropriateness Criteria\u00ae &ndash; Head Trauma,&rdquo; (2018).  <br><span class=\"list-item\">\u2022</span> Defines CT imaging features distinguishing extra-axial hemorrhages and supports standardized reporting for management pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Windowing matters: use bone windows to exclude skull fracture; subdural collections may be thin and iso- to hypodense in chronic cases.  <br><span class=\"list-item\">\u2022</span> Active contrast extravasation (&ldquo;spot sign&rdquo;) on CTA suggests ongoing bleeding in ICH, not typical for isolated traumatic extra-axial hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Traumatic versus spontaneous intracranial hemorrhage classification on CT is frequently tested, often requiring differentiation by shape, location, and crossing of anatomic boundaries.</div></div></div></div></div>"
  },
  {
    "id": 100023161,
    "question_number": "267",
    "question_text": "What is the mechanism of the patient's condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Chronic hypertension leads to degenerative changes in the walls of small intracerebral arteries&mdash;hyaline arteriolosclerosis and lipohyalinosis&mdash;resulting in Charcot&ndash;Bouchard microaneurysm formation and rupture. These lesions most often cause deep intracerebral hemorrhages in the basal ganglia, thalamus, pons, or cerebellum. By contrast, coagulopathies (e.g., warfarin, thrombocytopenia) produce diffuse or lobar bleeds; ruptured saccular aneurysms present with subarachnoid hemorrhage; and arteriovenous malformations (AVMs) manifest as high\u2010flow vascular tangles prone to lobar hemorrhage or seizures. Key terminology: lipohyalinosis, Charcot&ndash;Bouchard aneurysm, lenticulostriate arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertension is the leading cause of spontaneous intracerebral hemorrhage (ICH), accounting for approximately 70&ndash;80% of cases <span class=\"citation\">(van Asch et al., Lancet <span class=\"evidence\">Neurol 2010</span>)</span>. Chronic elevated blood pressure induces fibrinoid necrosis and smooth muscle degeneration in small perforating arterioles; pathologic examination reveals hyaline deposits and microaneurysm formation <span class=\"citation\">(Fisher, <span class=\"evidence\">Stroke 2003</span>)</span>. When these weakened vessels rupture, they release blood into deep brain structures, producing a hyperdense region on noncontrast CT. <span class=\"evidence\">The 2022</span> AHA/ASA ICH guidelines emphasize early recognition of hypertensive ICH and acute blood pressure management to reduce hematoma expansion (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Coagulopathy  <br>  &bull; Incorrect because primary hemostatic defects cause multifocal or lobar hemorrhages and often present with prolonged bleeding times and multiple small hematomas rather than a single deep bleed.  <br>  &bull; Misconception: Equating any intracerebral hemorrhage with coagulopathy overlooks the characteristic deep basal ganglia location of hypertensive bleeds.  <br><br>C. Aneurysm  <br>  &bull; Saccular (&ldquo;berry&rdquo;) aneurysms rupture into the subarachnoid space, not deep parenchyma, yielding diffuse sulcal and cisternal blood on CT.  <br>  &bull; Misconception: Assuming all intracranial bleeds stem from berry aneurysms ignores location and pattern differences.  <br><br>D. Arteriovenous malformation  <br>  &bull; AVMs are congenital high\u2010flow tangles that typically present with seizures or lobar hemorrhage in younger patients; angiography shows a nidus and early venous drainage.  <br>  &bull; Misconception: Confusing AVM hemorrhage with hypertensive ICH ignores patient age, imaging characteristics, and vascular anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Etiology</th><th>Typical Location</th><th>Vascular Pathology</th><th>Imaging Findings</th></tr></thead><tbody><tr><td>Hypertension</td><td>Basal ganglia, thalamus, pons, cerebellum</td><td>Lipohyalinosis; Charcot&ndash;Bouchard microaneurysms</td><td>Single deep intraparenchymal hematoma, hyperdense</td></tr><tr><td>Coagulopathy</td><td>Cortical/subcortical; multifocal</td><td>Impaired clotting cascades; platelet dysfunction</td><td>Multiple small bleeds; possible intraventricular extension</td></tr><tr><td>Aneurysm</td><td>Circle of Willis at arterial bifurcations</td><td>Saccular aneurysm wall defect</td><td>Blood in sulci/cisterns; no parenchymal focus</td></tr><tr><td>AVM</td><td>Lobar white&ndash;gray matter junction</td><td>Tangle of arteries and veins (nidus)</td><td>Flow voids on MRI; early venous filling on angiogram</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Up to 80% of spontaneous ICH in adults is hypertensive in origin; deep bleeds strongly suggest chronic hypertension.  <br><span class=\"list-item\">\u2022</span> CT noncontrast is the initial imaging modality of choice; look for hyperdense lesions in typical locations.  <br><span class=\"list-item\">\u2022</span> Early SBP reduction (<140\u2009mm\u2009Hg) within 1 hour can limit hematoma expansion (INTERACT2 trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all intracerebral hemorrhages to coagulopathy rather than evaluating bleed pattern and location.  <br>2. Misclassifying subarachnoid hemorrhage (aneurysmal) as intraparenchymal, leading to inappropriate management pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 ICH Guidelines: Recommend acute SBP lowering to <140\u2009mm\u2009Hg in ICH patients presenting with SBP 150&ndash;220\u2009mm\u2009Hg (Class I, LOE B-R).  <br>2. INTERACT2 <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: Demonstrated that intensive BP control reduced hematoma growth and improved functional outcomes (adjusted OR for death or severe disability 0.87, 95% CI 0.75&ndash;1.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lenticulostriate arteries, branches of the middle cerebral artery, supply the basal ganglia and internal capsule. Chronic hypertension damages these perforators, leading to deep hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Chronic hypertension \u2192 endothelial injury and blood&ndash;brain barrier disruption  <br>2. Hyaline arteriolosclerosis and lipohyalinosis in small vessels  <br>3. Formation of Charcot&ndash;Bouchard microaneurysms  <br>4. Vessel rupture \u2192 intracerebral hemorrhage in deep structures</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, hypertensive ICH is frequently tested by correlating risk factors, bleed location, and underlying small-vessel pathology.</div></div></div></div></div>"
  },
  {
    "id": 100023163,
    "question_number": "369",
    "question_text": "A patient with severe stenosis of the intracranial MCA is being evaluated. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Intracranial atherosclerotic disease (ICAD) refers to plaque formation within large cerebral arteries (e.g., MCA), leading to luminal narrowing and risk of ischemic stroke.  <br>&bull; Symptomatic severe stenosis (>70%) carries a high recurrent stroke risk (~10&ndash;15% at 1 year with aspirin alone).  <br>&bull; Secondary prevention aims to stabilize plaque, prevent in situ thrombosis, and reduce embolic events&mdash;principally via antiplatelet therapy, risk\u2010factor control, and lifestyle modification. (\u2248130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (aspirin plus clopidogrel for 90 days) is recommended for recently symptomatic intracranial stenosis based on SAMMPRIS <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>;365:993&ndash;1003)</span> and CHANCE subanalyses. In SAMMPRIS, aggressive medical management including DAPT for the first 90 days reduced 30\u2010day stroke risk to 5.8% versus 14.7% historically, and 1\u2010year risk to 12.2%. The AHA/ASA 2019 guideline gives Class I recommendation for DAPT in patients with 70&ndash;99% symptomatic ICAD for the first 90 days (Level of Evidence: A). Other trials (VISSIT) and meta\u2010analyses confirm no added benefit of stenting over medical therapy and a higher periprocedural complication rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intravenous thrombolysis  <br>&bull; Incorrect: Thrombolysis is reserved for acute stroke within 4.5 h of symptom onset, not for chronic secondary prevention in asymptomatic or subacute stenosis.  <br>&bull; Misconception: Confusing acute reperfusion therapy with long-term prevention.  <br><br>C. Surgical bypass of the MCA  <br>&bull; Incorrect: EC&ndash;IC bypass trials (e.g., COSS) failed to show benefit over medical therapy and demonstrated increased perioperative stroke risk.  <br>&bull; Misconception: Assuming surgical revascularization benefits intracranial atherosclerosis similar to moyamoya.  <br><br>D. High-dose corticosteroids  <br>&bull; Incorrect: No role in atherosclerotic stenosis; steroids are used in vasculitis or demyelinating diseases, not stable atherosclerosis.  <br>&bull; Misconception: Mistaking inflammatory vasculopathies for atherosclerotic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT</th><th>IV Thrombolysis</th><th>EC&ndash;IC Bypass</th><th>High-Dose Steroids</th></tr></thead><tbody><tr><td>Indication</td><td>Secondary prevention in symptomatic ICAD</td><td>Acute ischemic stroke (<4.5 h)</td><td>Chronic ICAD (investigational)</td><td>Inflammatory vasculitis</td></tr><tr><td>Key Evidence</td><td>SAMMPRIS (2011), AHA/ASA 2019 I,A</td><td>NINDS/ECASS trials</td><td>COSS trial (2011)</td><td>No trials in ICAD</td></tr><tr><td>Timing</td><td>Initiate immediately, continue 90 days</td><td>Within therapeutic window only</td><td>Elective surgery</td><td>During active inflammation</td></tr><tr><td>Major Risk</td><td>Bleeding (moderate)</td><td>Hemorrhagic conversion</td><td>Perioperative stroke</td><td>Immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Start DAPT (aspirin 81 mg + clopidogrel 75 mg) as soon as possible after diagnosis of symptomatic high-grade ICAD&mdash;limit to 90 days to mitigate hemorrhage risk.  <br>&bull; Control blood pressure (<140/90 mm Hg), LDL (<70 mg/dL), and diabetes aggressively to complement antiplatelet therapy.  <br>&bull; Routine intracranial stenting or bypass is not recommended outside of clinical trials due to high perioperative stroke/death rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating intracranial stenting with extracranial carotid stenting&mdash;intracranial devices carry higher complication rates.  <br>2. Using long-term DAPT (>90 days) in ICAD&mdash;increases bleeding without added stroke reduction (CHARISMA trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Secondary Stroke Prevention Guideline: Class I, Level A recommendation for initial 90-day DAPT in symptomatic 70&ndash;99% ICAD.  <br>&bull; ESO 2021 Guidelines on Acute Stroke Prevention: Recommends aspirin plus clopidogrel for 21&ndash;90 days in high\u2010risk TIA/minor stroke with &ge;50% ICAD (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Intracranial stenosis management&mdash;with emphasis on medical over surgical interventions&mdash;is frequently tested as a standalone management question or within stroke prevention vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023166,
    "question_number": "310",
    "question_text": "What is the mechanism of injury in a patient who presented unconscious with a brain CT showing a deep hyperdense hemorrhage in the basal ganglia consistent with spontaneous intracerebral bleeding?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Intracranial hemorrhages are classified by location (intraparenchymal vs extra\u2010axial) and etiology (spontaneous vs traumatic).  <br>1. Spontaneous ICH typically involves deep nuclei (basal ganglia, thalamus) due to chronic hypertension causing lipohyalinosis of small penetrating arterioles and formation of Charcot&ndash;Bouchard microaneurysms.  <br>2. Lobar hemorrhages involve cortical&ndash;subcortical junctions and are often related to cerebral amyloid angiopathy in older adults.  <br>3. Subarachnoid hemorrhage presents with blood in cisterns and sulci, most commonly from aneurysmal rupture.  <br>4. Traumatic hemorrhages (contusions, acute SDH or EDH) follow external force with skull fractures or bridging vein tears.  <br>Noncontrast head CT within 6 hours of symptom onset shows hyperdense collections correlating to acute blood.<br><br>(\u2248140 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spontaneous ICH accounts for 10&ndash;15% of strokes in Western populations. Chronic hypertension leads to arteriolar wall thickening and fibrinoid necrosis (lipohyalinosis), predisposing to Charcot&ndash;Bouchard microaneurysm rupture, most often in the putamen, thalamus, pons, or cerebellum. CT demonstrates a round or ovoid hyperdense focus in deep structures with perilesional edema and possible intraventricular extension. According to the 2022 AHA/ASA Guidelines for the Management of Spontaneous ICH (Class I, Level A), early blood pressure reduction to systolic 140 mm Hg reduces hematoma expansion. MRI is less sensitive in the hyperacute phase. Surgical evacuation is reserved for superficial lobar clots, cerebellar hemorrhages >3 cm causing brainstem compression or hydrocephalus, and deteriorating neurological status (ICH score &ge;3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Traumatic hemorrhage  <br>&ndash; Incorrect: Mechanism involves external blunt force causing contusions, acute SDH or EDH. CT would show extra\u2010axial collections with skull fractures or midline shift, not an intraparenchymal basal ganglia bleed.  <br>&ndash; Misconception: Equating any intracranial bleed with trauma.  <br><br>C. Lobar hemorrhage  <br>&ndash; Incorrect: Lobar ICH lies at cortical&ndash;subcortical junction, often due to amyloid angiopathy, and is more superficial. Deep basal ganglia hemorrhage points to hypertensive ICH.  <br>&ndash; Misconception: Any cortical bleed is lobar; here the bleed is subcortical.  <br><br>D. Subarachnoid hemorrhage  <br>&ndash; Incorrect: SAH shows blood within the cisterns and sulci, classically &ldquo;star\u2010shaped&rdquo; in the basal cisterns, often due to aneurysm rupture or trauma. It does not present as a discrete intraparenchymal mass.  <br>&ndash; Misconception: Confusing cisternal blood for parenchymal hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICH (B)</th><th>Traumatic (A)</th><th>Lobar (C)</th><th>SAH (D)</th></tr></thead><tbody><tr><td>Typical location</td><td>Basal ganglia, thalamus, pons</td><td>Cortical contusions, extra\u2010axial</td><td>Cortical&ndash;subcortical junction</td><td>Cisternal/sulcal spaces</td></tr><tr><td>Pathogenesis</td><td>Hypertensive lipohyalinosis</td><td>External blunt force, skull fracture</td><td>Amyloid angiopathy in elderly</td><td>Aneurysmal rupture, trauma</td></tr><tr><td>CT appearance</td><td>Discrete deep hyperdensity</td><td>Irregular contusions, subdural/epidural collections</td><td>Superficial, crescentic or round cortical clots</td><td>&ldquo;Star&rdquo; in cisterns, sulcal hyperdensity</td></tr><tr><td>Management principle</td><td>BP control, possible surgery</td><td>Neurosurgical evacuation, ICP control</td><td>Often conservative or surgical removal</td><td>Nimodipine, clipping/coiling aneurysm</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Deep ICH in basal ganglia or thalamus is almost always hypertensive in origin&mdash;assess and aggressively manage blood pressure.  <br><span class=\"list-item\">\u2022</span> Use the ICH score (age, GCS, ICH volume, IVH, location) to guide prognosis and surgical decisions.  <br><span class=\"list-item\">\u2022</span> Early reversal of anticoagulation (PCC for warfarin, andexanet alfa for factor Xa inhibitors) is critical to limit hematoma growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying deep parenchymal bleed as subarachnoid&mdash;note location in parenchyma vs cisterns.  <br>2. Attributing any intracranial hemorrhage to trauma without history&mdash;spontaneous ICH often occurs in hypertensive patients with no external head injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2022</span>: Recommend acute lowering of systolic BP to 140 mm Hg (Class I, Level A) to reduce hematoma expansion in spontaneous ICH.  <br><span class=\"list-item\">\u2022</span> MISTIE III Trial (2019): Minimally invasive catheter evacuation with rt\u2010PA showed reduced perihematomal edema but did not meet primary endpoint for functional improvement; early hematoma stabilization remains key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Deep penetrating branches of the middle cerebral artery (lenticulostriate vessels) supply the putamen and internal capsule&mdash;sites most prone to hypertensive rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension \u2192 arteriolar wall thickening, fibrinoid necrosis \u2192 formation of Charcot&ndash;Bouchard microaneurysms \u2192 vessel rupture \u2192 red blood cell extravasation into brain parenchyma \u2192 mass effect and increased intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to confirm hemorrhage location and volume.  <br>2. CT angiography if vascular lesion suspected.  <br>3. Laboratory studies: coagulation profile, platelet count, toxicology.  <br>4. BP management and neurosurgical consult based on ICH score.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute blood appears hyperdense (50&ndash;80 HU) on CT. Measure hematoma volume via ABC/2 method to estimate surgical candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line BP control with intravenous nicardipine or labetalol. Reverse coagulopathy promptly: PCC for vitamin K antagonists; protamine for heparin; idarucizumab for dabigatran.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Deep basal ganglia hemorrhages due to hypertensive microangiopathy are a frequently tested mechanism of spontaneous intracerebral hemorrhage.</div></div></div></div></div>"
  },
  {
    "id": 100023168,
    "question_number": "88",
    "question_text": "A patient developed an embolic stroke, and his routine workup is unremarkable. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Embolic stroke of undetermined source (ESUS) is a subtype of cryptogenic ischemic stroke characterized by nonlacunar infarct without proximal arterial stenosis or major cardioembolic source on routine workup. Key concepts:  <br><span class=\"list-item\">\u2022</span> Embolic vs. lacunar infarcts: ESUS involves cortical or subcortical territories supplied by large vessels.  <br><span class=\"list-item\">\u2022</span> Paroxysmal atrial fibrillation (AF) as a covert cardioembolic source: transient AF episodes often evade short\u2010term ECG.  <br><span class=\"list-item\">\u2022</span> Secondary prevention hinges on identifying occult AF to guide antithrombotic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged cardiac monitoring (&ge;30\u2009days external event recorder or implantable loop recorder) maximizes detection of paroxysmal AF in ESUS. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level A) advocate extended rhythm surveillance when routine ECG and 24&ndash;48\u2009h Holter are non\u2010revealing. The EMBRACE trial demonstrated 30\u2010day monitoring yields AF detection in 16.1% vs. 3.2% with 24\u2009h Holter (P<0.001). CRYSTAL AF showed implantable loop recorders detect AF in 30% at 3\u2009years vs. 3% with standard care. Detecting AF alters management&mdash;transitioning from antiplatelet to anticoagulation reduces recurrent stroke risk by ~60%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate surgery  <br>  &bull; Incorrect: No surgically correctable source (e.g., carotid stenosis) identified.  <br>  &bull; Misconception: Belief that all embolic strokes require endarterectomy.  <br>  &bull; Differentiator: Surgery requires imaging\u2010proven lesion amenable to intervention.  <br><br>C. Start anticoagulation  <br>  &bull; Incorrect: Empiric anticoagulation without confirmed AF in ESUS did not reduce recurrences in NAVIGATE ESUS and RESPECT ESUS trials and increased bleeding.  <br>  &bull; Misconception: &ldquo;Better safe&rdquo; warfarin/DOAC prevents all emboli.  <br>  &bull; Differentiator: Anticoagulation is reserved for proven cardioembolic source.  <br><br>D. Discharge the patient  <br>  &bull; Incorrect: Ongoing stroke risk without further evaluation.  <br>  &bull; Misconception: Normal initial workup equates to low risk.  <br>  &bull; Differentiator: Extended monitoring uncovers occult AF guiding therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prolonged Monitoring (Correct)</th><th>Immediate Surgery</th><th>Empiric Anticoagulation</th><th>Discharge</th></tr></thead><tbody><tr><td>Diagnostic yield</td><td>Up to 30% AF detection at 3 years</td><td>N/A &ndash; no lesion to address</td><td>N/A</td><td>N/A</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA 2018: Class I, LOE A</td><td>No indication if routine workup negative</td><td>Not recommended in ESUS (LOE B)</td><td>Unsafe without etiologic clarification</td></tr><tr><td>Impact on secondary prevention</td><td>Enables anticoagulation if AF found</td><td>Does not change management</td><td>Increased bleeding risk</td><td>Leaves potential AF undetected</td></tr><tr><td>Evidence base</td><td>EMBRACE, CRYSTAL AF trials</td><td>None in cryptogenic stroke</td><td>NAVIGATE ESUS, RESPECT ESUS (neutral/negative)</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extended rhythm monitoring for at least 30\u2009days should follow negative 24&ndash;48\u2009h Holter in cryptogenic stroke.  <br>2. Implantable loop recorders detect AF persistently when noninvasive monitors are unrevealing; consider in high\u2010risk patients.  <br>3. Empiric anticoagulation without documented AF does not confer benefit and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a single 24\u2009h Holter is sufficient to rule out AF.  <br>2. Initiating anticoagulation in ESUS before confirming a cardioembolic source.  <br>3. Equating &ldquo;cryptogenic&rdquo; with &ldquo;benign&rdquo; and halting workup prematurely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Secondary Stroke Prevention Guidelines, 2018: Recommends &ge;30\u2009days cardiac monitoring in ESUS (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> NAVIGATE ESUS Trial, 2018 (NEJM): Empiric rivaroxaban vs. aspirin in ESUS&mdash;no reduction in recurrent stroke, increased bleeding (HR 1.72 for major bleed).  <br><span class=\"list-item\">\u2022</span> RESPECT ESUS Trial, 2019 (Lancet Neurol): Dabigatran vs. aspirin&mdash;no significant benefit in preventing recurrent stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm nonlacunar infarct on MRI/CT.  <br>2. Exclude &ge;50% carotid/vertebral stenosis with vascular imaging.  <br>3. Perform TTE/TEE for cardiogenic sources and routine ECG + 24&ndash;48\u2009h Holter.  <br>4. If negative, initiate prolonged monitoring (30\u2009days external or implantable loop recorder).  <br>5. If AF detected, start anticoagulation; if still negative, continue antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Embolic stroke workup and ESUS management are frequently tested, often in the context of cryptogenic stroke and atrial fibrillation detection strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023169,
    "question_number": "209",
    "question_text": "Q209. In a case of intracerebral hemorrhage (ICH) with midline shift greater than 10 mm and clinical deterioration, what is the recommended intervention?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Monroe-Kellie doctrine: the fixed cranial vault contains brain, blood, and CSF&mdash;an acute increase in hematoma volume raises intracranial pressure (ICP) once compensatory reserves exhausted.  <br><span class=\"list-item\">\u2022</span> Midline shift >5 mm correlates with poor outcome and impending herniation; >10 mm signifies severe mass effect requiring surgical decompression.  <br><span class=\"list-item\">\u2022</span> Clinical deterioration (e.g., GCS drop &ge;2, new focal deficits) indicates failure of medical therapy to control ICP and progression toward transtentorial herniation.<br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive craniectomy rapidly lowers ICP by permitting outward brain expansion, reversing midline shift and mitigating herniation. <span class=\"evidence\">The 2015</span> AHA/ASA Guidelines for Management of Spontaneous ICH assign a Class IIa recommendation (Level B-NR) for decompressive surgery in patients with large (>30 mL) lobar hemorrhages causing mass effect and neurological decline; and Class I (Level B) for cerebellar hemorrhages >3 cm with brainstem compression. The STICH II trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> demonstrated that early surgical evacuation in superficial lobar ICH with midline shift yielded a trend toward better functional outcomes in patients with GCS 9&ndash;12. Large retrospective cohorts <span class=\"citation\">(Hui et al., <span class=\"evidence\">Neurosurgery 2010</span>)</span> report a 26% absolute reduction in 30-day mortality when craniectomy is performed within 6 hours of deterioration. Minimally invasive techniques <span class=\"citation\">(MISTIE III, NEJM 2019)</span> have not supplanted decompressive craniectomy for patients with rapid neurological decline and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management  <br> &bull; Why incorrect: Osmotic agents, hyperventilation, and BP control can stabilize ICP but do not reverse established midline shift >10 mm.  <br> &bull; Misconception: Belief that aggressive medical therapy alone suffices for severe mass effect.  <br> &bull; Differentiator: Only surgery actively creates space to decompress the herniating brain.  <br><br>C. Observation  <br> &bull; Why incorrect: Passive monitoring allows ongoing hematoma expansion and herniation risk.  <br> &bull; Misconception: Underestimation of midline shift as benign if vital signs stable.  <br> &bull; Differentiator: Observation is reserved for small, non-mass-effect hemorrhages without neurological decline.  <br><br>D. Anticoagulation therapy  <br> &bull; Why incorrect: Anticoagulants worsen bleeding and are contraindicated in acute ICH.  <br> &bull; Misconception: Confusing ICH management with ischemic stroke protocols.  <br> &bull; Differentiator: Anticoagulation reversal&mdash;not initiation&mdash;is indicated in ICH patients on blood thinners.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Decompressive Craniectomy</th><th>Medical Management</th><th>Observation</th><th>Anticoagulation Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical removal of bone flap, allows brain expansion</td><td>Osmotic agents, BP control, sedation</td><td>Serial exams + repeat imaging</td><td>Pharmacologically prevents clotting</td></tr><tr><td>Indication</td><td>Midline shift >10 mm + neurological decline</td><td>Mild&ndash;moderate ICP elevation without mass effect</td><td>Small ICH <10 mL, no decline</td><td>Contraindicated in bleeding</td></tr><tr><td>Time to effect</td><td>Immediate</td><td>Minutes to hours</td><td>None</td><td>N/A</td></tr><tr><td>Evidence</td><td>AHA/ASA 2015 Class IIa; STICH II trend to benefit</td><td>AHA/ASA 2015 Class I for BP control</td><td>No guideline support in severe ICH</td><td>None; increases hemorrhage risk</td></tr><tr><td>Outcome</td><td>\u2193 ICP, \u2193 mortality, potential functional recovery</td><td>Stabilization, may prevent progression</td><td>High risk of herniation, \u2191 mortality</td><td>Worsened hemorrhage, \u2191 mortality</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A midline shift threshold >5 mm is concerning; >10 mm almost always mandates neurosurgical consultation.  <br><span class=\"list-item\">\u2022</span> Early surgery (within 6 hours of decompensation) correlates with better survival and functional independence.  <br><span class=\"list-item\">\u2022</span> Hematoma location matters: lobar with cortical proximity and cerebellar bleeds have stronger surgical indications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating medical ICP control with definitive management in large hemorrhages&mdash;fails to account for fixed cranial volume.  <br><span class=\"list-item\">\u2022</span> Misreading imaging: underestimating the prognostic weight of >10 mm midline shift leads to delayed surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2015 Guidelines for Spontaneous ICH  <br>   &bull; Recommendation: Surgical evacuation (craniotomy or craniectomy) reasonable for lobar ICH >30 mL with mass effect and clinical deterioration (Class IIa, Level B-NR).  <br>2. STICH II Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>  <br>   &bull; Finding: Early surgery in superficial lobar ICH with midline shift showed a non-significant trend toward improved outcomes in GCS 9&ndash;12 subgroup.  <br>3. MISTIE III Trial <span class=\"citation\">(NEJM 2019)</span>  <br>   &bull; Finding: Minimally invasive clot evacuation reduced hematoma volume but did not significantly improve functional outcomes versus medical care; suggests patient selection is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Management of ICH with mass effect and herniation risk is frequently tested both in single-best-answer and case-scenario formats, emphasizing recognition of radiographic thresholds (midline shift) and timing of surgical intervention.</div></div></div></div></div>"
  },
  {
    "id": 100023170,
    "question_number": "94",
    "question_text": "A patient has recurrent headaches and transient ischemic attacks (TIAs). Cerebral angiography shows segmental vessel constriction. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Reversible cerebral vasoconstriction syndrome (RCVS) is a non-inflammatory arteriopathy marked by transient dysregulation of cerebrovascular tone, resulting in multifocal narrowing and dilation of medium-sized cerebral arteries. Clinically, it presents with recurrent, often exertion- or Valsalva-triggered thunderclap headaches and may be complicated by TIAs, ischemic strokes, or cortical subarachnoid hemorrhages. Key concepts include dynamic rather than structural vessel changes, angiographic &ldquo;string-of-beads&rdquo; appearance, and differentiation from vasculitis by normal or mildly altered CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is diagnosed when reversible segmental vasoconstriction correlates with clinical thunderclap headaches and ischemic events. <span class=\"evidence\">The 2012</span> AHA/ASA Scientific Statement on RCVS recommends noninvasive angiography (CTA/MRA) for initial diagnosis and follow-up imaging at 12 weeks to confirm resolution (Level C evidence). Pathophysiologically, transient sympathetic overactivity and endothelial dysfunction lead to smooth muscle hyperreactivity <span class=\"citation\">(Ducros et al., Lancet <span class=\"evidence\">Neurol 2007</span>;6:34&ndash;42)</span>. Observational data <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurology 2016</span>)</span> support use of calcium channel blockers (nimodipine or verapamil) to alleviate vasoconstriction and reduce headache frequency, though randomized trials are lacking.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysm  <br><span class=\"list-item\">\u2022</span> Saccular aneurysms are static vascular outpouchings prone to rupture (SAH), not reversible multifocal narrowing.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;aneurysm&rdquo; often causes headache, but presents with acute SAH signs and focal dilation on angiography rather than beading.<br><br>C. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> AVMs are congenital tangles with arteriovenous shunting and early venous drainage, not segmental arterial constriction.  <br><span class=\"list-item\">\u2022</span> Misconception: AVMs can cause headaches, but angiography shows a nidus and rapid venous filling, absent in RCVS.<br><br>D. Carotid artery dissection  <br><span class=\"list-item\">\u2022</span> Dissections feature an intimal flap or pseudoaneurysm in the carotid, producing a tapered stenosis, not diffuse intracranial beading.  <br><span class=\"list-item\">\u2022</span> Misconception: dissection may cause headache and TIA, but imaging reveals vessel wall irregularity localized to the carotid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Aneurysm</th><th>AVM</th><th>Carotid Dissection</th></tr></thead><tbody><tr><td>Clinical presentation</td><td>Recurrent thunderclap headaches, TIAs</td><td>Thunderclap headache, SAH</td><td>Seizures, chronic headache, hemorrhage</td><td>Head/neck pain, Horner&rsquo;s syndrome</td></tr><tr><td>Angiographic finding</td><td>Multifocal narrowing (&ldquo;beads&rdquo;)</td><td>Focal saccular dilation</td><td>Nidus with early venous drainage</td><td>Tapered stenosis, intimal flap</td></tr><tr><td>CSF profile</td><td>Normal or mild protein elevation</td><td>Xanthochromia in SAH</td><td>Usually normal</td><td>Usually normal</td></tr><tr><td>Reversibility</td><td>Resolves in weeks to months</td><td>Static unless clipped/coiled</td><td>Static unless treated</td><td>May recanalize over time</td></tr><tr><td>First-line therapy</td><td>Nimodipine/Verapamil</td><td>Surgical or endovascular repair</td><td>Embolization/surgical resection</td><td>Anticoagulation/antiplatelet</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recurrent thunderclap headaches&mdash;often triggered by exercise or Valsalva maneuvers&mdash;are a red flag for RCVS.  <br>2. Empirical treatment with nimodipine (60 mg q4h) or verapamil can shorten the course of vasoconstriction.  <br>3. Common precipitants include postpartum state, SSRIs, triptans, and illicit drugs (e.g., cocaine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal CT excludes RCVS&mdash;lumbar puncture is required to rule out SAH before diagnosing RCVS.  <br>2. Confusing RCVS with primary CNS vasculitis&mdash;vasculitis shows inflammatory CSF changes and vessel-wall enhancement on MRI, whereas RCVS does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Scientific Statement on RCVS (2012): Recommends CTA/MRA for diagnosis, follow-up at 12 weeks to confirm reversibility (Level C).  <br>2. Ducros et al., French Prospective Registry <span class=\"citation\">(<span class=\"evidence\">Neurology 2019</span>)</span>: Observational evidence that calcium channel blockers accelerate headache resolution and lower ischemic risk (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS predominantly affects medium-sized vessels of the circle of Willis&mdash;especially the MCA and ACA branches&mdash;leading to cortical watershed TIAs when severely constricted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sympathetic overactivity and endothelial dysfunction induce transient vascular smooth muscle hyperreactivity, causing alternating segments of constriction and dilation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude SAH: NCCT head; if negative, LP.  <br>2. Perform CTA/MRA: look for &ldquo;string-of-beads.&rdquo;  <br>3. Check CSF: normal or mild protein elevation.  <br>4. Start calcium channel blockers.  <br>5. Repeat angiography at 12 weeks to confirm resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic angiographic &ldquo;string-of-beads&rdquo; represents alternating vasoconstriction and dilation; vessel-wall MRI typically shows no enhancement, distinguishing RCVS from vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine 60 mg every 4 hours or verapamil 120 mg daily is used off-label; monitor blood pressure to avoid iatrogenic hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. RCVS is frequently tested as recurrent thunderclap headache with reversible multifocal vasoconstriction on angiography and normal CSF.</div></div></div></div></div>"
  },
  {
    "id": 100023171,
    "question_number": "89",
    "question_text": "A patient has a right pontine stroke, his NIHSS was 8 and he was on aspirin prior to stroke onset. What is the best option to prevent recurrence of stroke?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Secondary prevention of noncardioembolic ischemic stroke hinges on antiplatelet therapy tailored to stroke severity and prior treatment. Key principles:  <br><span class=\"list-item\">\u2022</span> Platelet activation drives thrombus formation in lacunar and atherothrombotic strokes; antiplatelet agents (aspirin, clopidogrel) mitigate this.  <br><span class=\"list-item\">\u2022</span> NIHSS stratifies minor (&le;3) versus moderate&ndash;severe (>3) stroke; trials like CHANCE and POINT support dual antiplatelet therapy (aspirin + clopidogrel) only in minor stroke/TIA for &le;21 days.  <br><span class=\"list-item\">\u2022</span> &ldquo;Aspirin failure&rdquo; (recurrent stroke on aspirin) necessitates switching to an alternative agent (clopidogrel monotherapy or aspirin + dipyridamole), not indefinite dual therapy, to balance efficacy and bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Prevention Guidelines (Class I, Level A) endorse monotherapy with clopidogrel for noncardioembolic stroke in patients who experience a recurrent event on aspirin. The CAPRIE trial demonstrated an 8.7% relative risk reduction with clopidogrel versus aspirin <span class=\"citation\">(<span class=\"evidence\">Lancet 1996</span>)</span>. Dual antiplatelet therapy (aspirin + clopidogrel) showed benefit only in minor stroke/TIA (NIHSS &le;3) when initiated within 24 h and limited to 21 days <span class=\"citation\">(POINT, NEJM 2018; CHANCE, NEJM 2013)</span>, and is not recommended for NIHSS 8 due to heightened hemorrhagic risk. Anticoagulation offers no advantage in noncardioembolic pontine infarcts and carries bleeding hazards.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Add clopidogrel to aspirin  <br><span class=\"list-item\">\u2022</span> Prolonged dual therapy beyond 21 days increases intracranial hemorrhage; major DAPT trials excluded moderate strokes (NIHSS 8).  <br>B. Keep on aspirin  <br><span class=\"list-item\">\u2022</span> Fails to address aspirin &ldquo;breakthrough&rdquo; event; recurrent stroke on aspirin warrants agent change.  <br>D. Start anticoagulation  <br><span class=\"list-item\">\u2022</span> No atrial fibrillation or cardioembolic source; anticoagulants risk hemorrhagic conversion without reducing recurrence in lacunar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clopidogrel Monotherapy (Correct)</th><th>Aspirin Monotherapy</th><th>Aspirin + Clopidogrel (DAPT)</th><th>Anticoagulation</th></tr></thead><tbody><tr><td>Indication</td><td>Aspirin failure, noncardioembolic</td><td>First-line noncardioembolic</td><td>Minor stroke/TIA (NIHSS &le;3), &le;21 days</td><td>Cardioembolic stroke, AF</td></tr><tr><td>Key Evidence</td><td>CAPRIE: RR\u2193 8.7% vs ASA</td><td>WARSS: equivalent efficacy</td><td>POINT/CHANCE: recurrence\u2193, bleed\u2191</td><td>WARCEF: no net benefit non-AF</td></tr><tr><td>NIHSS Threshold</td><td>Any (>3 if aspirin failure)</td><td>Any unless aspirin failure</td><td>&le;3</td><td>Any with cardioembolic risk</td></tr><tr><td>Major Bleeding Risk</td><td>Moderate</td><td>Low</td><td>High</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dual antiplatelet therapy should be discontinued after 21 days in minor stroke to limit hemorrhage.  <br><span class=\"list-item\">\u2022</span> Always verify NIHSS: only minor strokes (&le;3) qualify for short-term DAPT.  <br><span class=\"list-item\">\u2022</span> In aspirin failure, switch to clopidogrel monotherapy or aspirin + dipyridamole rather than indefinite DAPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating NIHSS 8 with &ldquo;minor stroke&rdquo; and using prolonged DAPT.  <br>2. Initiating anticoagulation for noncardioembolic strokes under the false assumption it&rsquo;s more protective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on Secondary Stroke Prevention, 2018: Class I recommendation for clopidogrel monotherapy after aspirin failure; Class IIa for short-term DAPT only in NIHSS &le; 3.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines, 2021: Endorse clopidogrel as alternative monotherapy when aspirin fails (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clopidogrel (75 mg daily after 300 mg loading) irreversibly inhibits the P2Y12 ADP receptor, reducing platelet aggregation. Aspirin (50&ndash;325 mg daily) blocks COX-1&ndash;mediated thromboxane A2. Combined use heightens bleeding risk; DAPT duration is limited to 21 days in eligible minor stroke/TIA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Boards frequently test the NIHSS cutoff for dual antiplatelet therapy and the management of aspirin &ldquo;failure&rdquo; in noncardioembolic stroke.</div></div></div></div></div>"
  },
  {
    "id": 100023172,
    "question_number": "128",
    "question_text": "Based on the following brain CT findings, what is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Perimesencephalic hemorrhage is a nonaneurysmal subtype of subarachnoid hemorrhage (SAH) characterized by localized bleeding around the midbrain, notably within the interpeduncular, ambient, and quadrigeminal cisterns. Recognizing CT distribution is <span class=\"key-point\">critical:</span> aneurysmal SAH typically demonstrates diffuse blood in basal cisterns, sylvian fissures, and often intraventricular extension, whereas perimesencephalic SAH confines blood to cisterns anterior to the midbrain with sparing of the convexities and fissures. Prognostically, perimesencephalic hemorrhage has a benign course compared to aneurysmal SAH. Neuroanatomical knowledge of basal cisterns and their venous drainage underpins accurate radiographic interpretation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic hemorrhage is confirmed when noncontrast CT shows hyperdensity limited to the perimesencephalic cisterns without extension into the sylvian fissures, interhemispheric fissure, or ventricles. Multiple series, beginning with van Gijn et al. (1985), have demonstrated that this pattern correlates with a venous origin, negligible rebleeding risk (<1%), and excellent functional outcome. <span class=\"evidence\">The 2023</span> AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2023</span>;54:e1-e35)</span> advise that when CTA is negative and CT appearance is entirely perimesencephalic, further angiography may be omitted (Class IIa, Level B). A meta-analysis by Shankar et al. <span class=\"citation\">(<span class=\"evidence\">Neurosurgery 2020</span>;86:789-795)</span> confirmed <2% incidental aneurysm rate upon delayed DSA in classical cases. Pathophysiologically, small basal vein tears rather than arterial rupture explain the confined bleed and benign course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Infection  <br><span class=\"list-item\">\u2022</span> Incorrect because intracranial infection (e.g., abscess, meningitis) produces ring-enhancing lesions or diffuse meningeal enhancement on contrast imaging, not isolated hyperdensity in basal cisterns.  <br><span class=\"list-item\">\u2022</span> Misconception: equating headaches with hemorrhage in infections; infections feature fever, elevated inflammatory markers.  <br><br>B. Malignancy  <br><span class=\"list-item\">\u2022</span> Intracranial tumors/mets appear as mass lesions with surrounding vasogenic edema and heterogeneous enhancement; they do not present acutely as hyperdense cisternal blood.  <br><span class=\"list-item\">\u2022</span> Misconception: acute headache equals metastasis; tumors cause subacute symptoms, seizures.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> Although perimesencephalic hemorrhage is a form of SAH, option D implies diffuse aneurysmal SAH with diffuse cisternal and fissural blood.  <br><span class=\"list-item\">\u2022</span> Key differentiator: diffuse sylvian and interhemispheric blood vs. focal perimesencephalic blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Perimesencephalic Hemorrhage</th><th>Aneurysmal SAH</th><th>Infection (Abscess/Meningitis)</th><th>Malignancy (Metastasis/Primary)</th></tr></thead><tbody><tr><td>CT Distribution</td><td>Blood confined to perimesencephalic cisterns</td><td>Diffuse basal cistern, sylvian fissure, ventricles</td><td>Hypodense core with ring enhancement</td><td>Mass lesion with edema, heterogeneous enhancement</td></tr><tr><td>Angiography Findings</td><td>Negative (no aneurysm)</td><td>Positive (aneurysm identified)</td><td>N/A</td><td>N/A</td></tr><tr><td>Clinical Presentation</td><td>Thunderclap headache, minimal focal deficits</td><td>Thunderclap headache, variable focal deficits</td><td>Fever, headache, altered mental status</td><td>Subacute headache, seizures, focal signs</td></tr><tr><td>Prognosis</td><td>Excellent; low rebleed risk</td><td>High morbidity/mortality</td><td>Variable; dependent on pathogen</td><td>Variable; dependent on tumor type</td></tr><tr><td>Management</td><td>Supportive, monitor, +/- nimodipine</td><td>Secure aneurysm, nimodipine, manage vasospasm</td><td>Antibiotics/antifungals, possible drainage</td><td>Surgical resection, chemo/radiation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In classical perimesencephalic SAH, a single negative CTA plus characteristic CT appearance often obviates invasive angiography <span class=\"citation\">(AHA/ASA 2023)</span>.  <br>2. Despite its benign course, monitor for hydrocephalus and vasospasm; consider short-term nimodipine.  <br>3. Early differentiation of perimesencephalic vs. aneurysmal SAH on CT guides urgency of neurosurgical intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on initial CT without recognizing the confined cisternal pattern can lead to unnecessary angiograms or missed aneurysms.  <br>2. Equating all acute cisternal hyperdensities with aneurysmal SAH ignores the unique perimesencephalic distribution and venous etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal SAH <span class=\"citation\">(<span class=\"evidence\">Stroke 2023</span>;54:e1-e35)</span>: Recommend that in typical perimesencephalic SAH with negative CTA, DSA is optional (Class IIa, Level B).  <br>2. British Society of Neuroradiologists Consensus <span class=\"citation\">(BSNR 2022)</span>: Reported CTA sensitivity >98% for aneurysm detection; in perimesencephalic patterns, negative CTA has >99% negative predictive value, reducing need for DSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood in the interpeduncular, ambient, and quadrigeminal cisterns corresponds to leakage from small perforating veins around the mesencephalon, sparing the sylvian fissures and convexities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic hemorrhage likely arises from venous plexuses around the midbrain; lack of arterial involvement accounts for minimal rebleeding and vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT within 6 hours of headache onset \u2192 identify hyperdensity pattern.  <br>2. If confined to perimesencephalic cisterns, perform CTA.  <br>3. If CTA negative and CT pattern classic \u2192 conservative management.  <br>4. If CTA positive or CT atypical \u2192 proceed to DSA and neurosurgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 6 hours is >95% sensitive for SAH. True perimesencephalic SAH spares the sylvian fissures and convexities; any extension mandates aneurysm workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine (60 mg PO q4h for 21 days) is recommended in SAH to reduce delayed cerebral ischemia; its use in perimesencephalic hemorrhage is extrapolated from aneurysmal data (Class I, Level A for aneurysmal SAH).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Subarachnoid hemorrhage patterns on CT&mdash;especially perimesencephalic vs. aneurysmal&mdash;are frequently tested in both Step 2/3 and neurology boards as image\u2010based vignette questions.</div></div></div></div></div>"
  },
  {
    "id": 100023175,
    "question_number": "393",
    "question_text": "Q393. (Source: Part II 2022mcqs.txt) A patient suddenly explained to his wife that he is seeing animals and then fades away. After a while, the patient loses consciousness. Upon arrival, the emergency medical team intubates him and a CT scan shows a new left occipital stroke. What will you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke workup demands rapid distinction of hemorrhagic vs ischemic events and identification of vessel occlusion. The occipital lobe is supplied by the posterior cerebral artery (PCA); infarction may present with visual phenomena (complex hallucinations, visual field defects) and secondary seizures. Visual auras followed by impaired consciousness could reflect occipital stroke&ndash;induced seizure. Initial noncontrast CT excludes hemorrhage; subsequent CTA evaluates arterial patency and guides reperfusion strategies. Rapid vascular imaging is crucial for mechanical thrombectomy decisions, even in posterior circulation strokes, and complements thrombolysis assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Emergent CTA after noncontrast CT is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. CTA within 20 minutes identifies large vessel occlusions&mdash;including PCA branch occlusions&mdash;that may benefit from endovascular therapy. The MR CLEAN, ESCAPE, DAWN, and DEFUSE 3 trials demonstrated improved outcomes with thrombectomy in selected patients up to 24 hours from onset, including posterior circulation strokes when imaging shows salvageable penumbra. EEG does not direct acute reperfusion decisions. Intravenous tPA (0.9 mg/kg) must be given within 4.5 hours but is complemented, not supplanted, by CTA to stratify endovascular candidacy. Stroke unit admission follows urgent imaging and reperfusion planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cortical electrical activity, not vascular occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Prioritizing seizure workup over reperfusion delays treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA directly visualizes arterial blockages.  <br><br>C. tPA  <br><span class=\"list-item\">\u2022</span> Incorrect: A treatment step, not a diagnostic triage; must follow hemorrhage exclusion and vascular imaging to optimize therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate thrombolysis without vessel imaging suffices.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA informs both thrombolytic and thrombectomy strategy.  <br><br>D. Admit to stroke unit  <br><span class=\"list-item\">\u2022</span> Incorrect: Essential for post-acute care but secondary to urgent imaging to guide reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Hospitalization alone addresses acute occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA precedes specialized unit admission in acute workflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Purpose</th><th>Timing</th><th>Key Output</th></tr></thead><tbody><tr><td>CTA [CORRECT]</td><td>Vascular imaging</td><td>Immediately after noncontrast CT</td><td>Identifies occlusion location & extent</td></tr><tr><td>EEG</td><td>Electrical brain activity</td><td>After stabilization if seizures persist</td><td>Detects epileptiform discharges</td></tr><tr><td>tPA</td><td>Systemic thrombolysis</td><td>Following imaging & within 4.5 hr window</td><td>Promotes clot lysis</td></tr><tr><td>Admit to stroke unit</td><td>Specialized multidisciplinary care</td><td>After acute interventions</td><td>Facilitates monitoring & rehabilitation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Obtain CTA within 20 minutes of noncontrast CT in all suspected large vessel strokes to assess thrombectomy candidacy.  <br><span class=\"list-item\">\u2022</span> Occipital infarcts can present with visual hallucinations and seizures; do not delay reperfusion imaging for EEG.  <br><span class=\"list-item\">\u2022</span> Dedicated stroke unit admission reduces morbidity and mortality but is not a substitute for urgent vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering EEG before CTA delays critical reperfusion assessment in acute stroke.  <br>2. Initiating tPA without vascular imaging can miss large vessel occlusion requiring thrombectomy and increases hemorrhage risk.  <br>3. Direct ward admission without completing acute imaging prolongs time to reperfusion interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 (Class I, LOE A): Perform emergent CTA head and neck immediately after noncontrast CT in patients eligible for reperfusion.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 (Grade A, Level 1a): Recommend mechanical thrombectomy for posterior circulation strokes within 24 hours of onset when imaging shows viable tissue.  <br><span class=\"list-item\">\u2022</span> DAWN <span class=\"evidence\">Trial 2018</span> (NEJM): Extended thrombectomy window to 6&ndash;24 hours in selected patients based on perfusion imaging mismatch (relative risk of functional independence 1.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The left PCA supplies primary visual cortex (Brodmann area 17) and adjacent visual association areas (areas 18&ndash;19). Infarcts here manifest as contralateral homonymous hemianopia and may provoke visual auras or seizures due to cortical irritation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion leads to ischemia-induced energy failure, Na\u207a/K\u207a-ATPase pump collapse, cytotoxic edema, and neuronal excitotoxicity. The ischemic penumbra retains partial perfusion and is salvageable with timely reperfusion; its identification via CTA/CTP guides therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Activate stroke code on presentation.  <br>2. Perform noncontrast CT to exclude hemorrhage (< 20 min).  <br>3. Obtain CTA head and neck to identify vessel occlusion.  <br>4. If within 4.5 hr, initiate IV tPA after hemorrhage exclusion.  <br>5. If large vessel occlusion on CTA and within 24 hr, proceed to thrombectomy.  <br>6. Admit to stroke unit for ongoing care and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT may miss early occipital infarcts; look for subtle loss of gray&ndash;white differentiation.  <br><span class=\"list-item\">\u2022</span> CTA &ldquo;cutoff sign&rdquo; indicates abrupt vessel occlusion; CT perfusion identifies core vs penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus, remainder over 60 min.  <br><span class=\"list-item\">\u2022</span> Start aspirin 160&ndash;325 mg 24 hr post tPA or immediately if no tPA; dual antiplatelet therapy for minor stroke (CHANCE/POINT trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Posterior circulation stroke management&mdash;with emphasis on CTA in the acute workflow&mdash;is commonly tested as single-best-answer items, often combined with imaging and reperfusion decision-making scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023177,
    "question_number": "127",
    "question_text": "Q127. The ACAS trial showed a reduction in the 5-year incidence of ipsilateral stroke or periprocedural stroke or death for which degree of ICA stenosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] 1. Atherosclerotic plaque in the internal carotid artery (ICA) narrows the lumen, promoting thromboembolism and ipsilateral ischemic stroke.  <br>2. In asymptomatic patients, moderate-to-high&ndash;grade stenosis carries a ~2% annual stroke risk on medical therapy; surgical removal via carotid endarterectomy (CEA) can reduce long-term risk.  <br>3. Key criteria for CEA in asymptomatic stenosis include &ge;60% luminal narrowing (angiographic), a life expectancy >5 years, and a perioperative stroke/death rate <3%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Asymptomatic Carotid Atherosclerosis Study <span class=\"citation\">(ACAS, 1995)</span> randomized patients with angiographically confirmed 60&ndash;99% ICA stenosis to CEA versus medical management. Over five years, the CEA group had a 5.1% combined risk of ipsilateral stroke or perioperative stroke/death versus 11.0% in controls (absolute risk reduction 5.9%; NNT \u224817). This benefit applies specifically to stenoses &ge;60%. Subsequent AHA/ASA (2014) guidelines endorse CEA for asymptomatic 60&ndash;99% stenosis if surgical risk is low (Class IIa; Level B). Improvements in medical therapy have narrowed the absolute benefit, but the foundational ACAS threshold remains 60&ndash;99%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 50% to 69%  <br>   &ndash; ACAS did not include patients with <60% stenosis; trials show insufficient event rates below this threshold to justify CEA.  <br>   &ndash; Misconception: extending symptomatic trial criteria (NASCET) to asymptomatic populations.  <br><br>C. 70% to 99%  <br>   &ndash; Reflects the inclusion criteria for the Asymptomatic Carotid Surgery Trial (ACST), not ACAS.  <br>   &ndash; ACST used &ge;70% by ultrasound, yielding a smaller absolute risk reduction (ARR ~3.3%).  <br><br>D. 30% to 50%  <br>   &ndash; No randomized trial supports surgical intervention for mild stenosis; annual stroke risk is low (<1%).  <br>   &ndash; Misconception: any degree of stenosis merits CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Stenosis Range</th><th>Trial</th><th>5-Year Stroke/Death</th><th>Absolute Risk Reduction</th><th>NNT</th></tr></thead><tbody><tr><td>60&ndash;99%</td><td>ACAS</td><td>11.0% \u2192 5.1%</td><td>5.9%</td><td>~17</td></tr><tr><td>70&ndash;99%</td><td>ACST</td><td>11.8% \u2192 8.5%</td><td>3.3%</td><td>~30</td></tr><tr><td>50&ndash;69%</td><td>None</td><td>~5% annual risk</td><td>Not studied</td><td>N/A</td></tr><tr><td>30&ndash;50%</td><td>None</td><td><1% annual risk</td><td>No benefit</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always confirm perioperative stroke/death risk is <3% when considering CEA for asymptomatic disease.  <br>2. Duplex ultrasound criteria: peak systolic velocity >230 cm/s correlates with &ge;60% angiographic stenosis.  <br>3. Optimal medical therapy&mdash;statin, antiplatelet, blood pressure control&mdash;remains the foundation; surgical benefit is additive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ACAS (asymptomatic, &ge;60% angiographic stenosis) with NASCET (symptomatic patients).  <br>2. Recommending CEA for asymptomatic stenosis <60% based on symptomatic trial data or outdated thresholds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Stroke Prevention Guidelines: recommend CEA for asymptomatic 60&ndash;99% stenosis in patients with life expectancy >5 years and perioperative risk <3% (Class IIa; Level B).  <br><span class=\"list-item\">\u2022</span> ESC/ESVS 2018 Vascular Surgery Guidelines: endorse CEA for asymptomatic &ge;60% stenosis when surgical risk is low and life expectancy >5 years (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Carotid stenosis trials (ACAS vs ACST vs NASCET) and their stenosis thresholds are high-yield topics on stroke prevention sections of board exams.</div></div></div></div></div>"
  },
  {
    "id": 100023178,
    "question_number": "96",
    "question_text": "A young female developed severe headache and photophobia post-partum. What is the most appropriate next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Postpartum headache with photophobia raises concern for serious intracranial pathology. Key concepts:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of hypercoagulability in the puerperium (Virchow&rsquo;s triad: stasis, vessel injury, hypercoagulability).  <br><span class=\"list-item\">\u2022</span> Cerebral venous sinus thrombosis (CVST) often presents with headache, papilledema, and meningeal signs.  <br><span class=\"list-item\">\u2022</span> Imaging modalities differ in sensitivity for arterial versus venous pathology; CT venography (CTV) and MR venography (MRV) are gold-standard noninvasive tests for CVST.  <br>(Word count: 88)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The optimal diagnostic step in suspected CVST is cerebral venous imaging. While noncontrast CT may show indirect signs (e.g., &ldquo;dense triangle sign&rdquo;), CTV has high sensitivity (95\u2009%) and specificity (91\u2009%) and is rapidly available in acute settings <span class=\"citation\">(Ferro et al., <span class=\"evidence\">Stroke 2004</span>)</span>. According to the 2011 AHA/ASA CVST guidelines, once CVST is suspected clinically, CTV or MRV should be performed emergently to confirm thrombus location and extent (Class I, Level B). CT angiography (CTA) targets arterial circulation and may miss venous occlusions. MRI without dedicated venography sequences can overlook sinus thrombosis, and lumbar puncture risks herniation if intracranial pressure is elevated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain CT Angiography  <br><span class=\"list-item\">\u2022</span> Incorrect: Visualizes arteries, not sinuses; low sensitivity for venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming arterial and venous imaging are interchangeable.  <br><br>C. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Standard MRI without MRV sequences may miss sinus thrombi; slower acquisition and less available in emergencies.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI always superior to CT for acute neuro problems.  <br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: Contraindicated if raised intracranial pressure; may precipitate herniation and does not diagnose CVST.  <br><span class=\"list-item\">\u2022</span> Misconception: Photophobia always mandates LP for meningitis evaluation, regardless of imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Angiography</th><th>CT Venography</th><th>MRI (no MRV)</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Targets</td><td>Arterial circulation</td><td>Venous sinuses</td><td>Brain parenchyma</td><td>CSF analysis</td></tr><tr><td>Sensitivity for CVST</td><td>~60\u2009%</td><td>~95\u2009%</td><td>~80\u2009% (without MRV)</td><td>N/A</td></tr><tr><td>Availability</td><td>High</td><td>High</td><td>Variable</td><td>High</td></tr><tr><td>Contraindications</td><td>Contrast allergy, renal failure</td><td>Same as CTA</td><td>Claustrophobia, implants</td><td>Raised ICP, mass lesion</td></tr><tr><td>Time to result</td><td>Minutes</td><td>Minutes</td><td>&ge;30 minutes</td><td>&ge;30 minutes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Postpartum women are at highest CVST risk within first 4 weeks due to hypercoagulable shifts.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with LMWH should be initiated promptly after diagnosis, even with hemorrhagic infarcts.  <br><span class=\"list-item\">\u2022</span> The &ldquo;empty delta sign&rdquo; on contrast CT is pathognomonic for superior sagittal sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering CTA instead of CTV: arterial studies miss venous clots.  <br>2. Proceeding to LP before imaging: risk of cerebral herniation in elevated intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 CVST Guidelines: Recommend emergent CTV or MRV in suspected cases (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span>: Affirms CTV as first-line when MRV unavailable (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior sagittal, transverse, and sigmoid sinuses drain cortical veins; thrombosis leads to venous congestion, cytotoxic and vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (\u2191 fibrinogen, \u2193 protein S), venous stasis in cerebral sinuses, endothelial activation \u2192 clot formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (headache, focal signs, seizure)  <br>2. Noncontrast CT to exclude hemorrhage  <br>3. CT Venography or MR Venography to confirm CVST  <br>4. Initiate anticoagulation upon diagnosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dense triangle sign on noncontrast CT: hyperattenuation in thrombosed sinus.  <br><span class=\"list-item\">\u2022</span> Empty delta sign on CTV: central filling defect surrounded by contrast.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start LMWH (e.g., enoxaparin 1 mg/kg BID) irrespective of hemorrhagic infarct; transition to warfarin for 3&ndash;6 months postpartum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. CVST is frequently tested as postpartum headache with imaging choice; attention to modality specificity (CTV/MRV) is critical.</div></div></div></div></div>"
  },
  {
    "id": 100023179,
    "question_number": "95",
    "question_text": "In a patient with transient ischemic attack (TIA) and severe internal carotid artery (ICA) stenosis on the symptomatic side, what is the recommended management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Symptomatic high\u2010grade ICA stenosis (&ge;70% by NASCET criteria) significantly increases stroke risk due to artery-to-artery embolism and hypoperfusion. Key principles:<br><span class=\"list-item\">\u2022</span> Atherosclerotic plaque in the ICA can shed thromboemboli to the ipsilateral cerebral hemisphere (most often MCA territory).<br><span class=\"list-item\">\u2022</span> Revascularization restores luminal diameter, reduces shear stress and plaque instability.<br><span class=\"list-item\">\u2022</span> Timing: maximal benefit when intervention occurs within two weeks of the TIA event.<br>Understanding these pathophysiological and temporal factors underpins why surgical removal of plaque (CEA) is superior to medical therapy alone for secondary prevention in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid endarterectomy (CEA) is the gold\u2010standard for symptomatic severe (70&ndash;99%) ICA stenosis, based on landmark trials:<br><span class=\"list-item\">\u2022</span> NASCET (1991): CEA reduced five-year stroke/death rate from 26% (medical) to 9% (CEA) in symptomatic &ge;70% stenosis (absolute risk reduction 17%; NNT\u22486) (Class I, Level A).<br><span class=\"list-item\">\u2022</span> ECST (1998): similar findings confirming benefit when performed within 2 weeks.<br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 guidelines: recommend CEA for symptomatic patients with 70&ndash;99% stenosis (Class I, LOE A), ideally within 14 days of index event.<br><span class=\"list-item\">\u2022</span> ESVS 2023: endorse early CEA (<2 weeks) if perioperative risk <6%.<br>Alternatives (stenting) are reserved for high surgical risk or unfavorable anatomy. Best medical therapy alone is inferior in this subgroup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Angioplasty plus stenting  <br><span class=\"list-item\">\u2022</span> Incorrect because in patients >70 years with symptomatic high\u2010grade stenosis, stenting carries a higher periprocedural stroke risk compared to CEA (CREST trial stroke rate 5.2% vs CEA 2.3% in symptomatic patients). Misconception: stenting equals CEA efficacy in all patients.<br><br>C. Best medical treatment  <br><span class=\"list-item\">\u2022</span> Incorrect: while dual antiplatelet, statins, and risk factor control reduce stroke risk, RCTs unequivocally show that medical therapy alone does not achieve the same risk reduction as CEA in symptomatic &ge;70% stenosis.<br><br>D. Observation only  <br><span class=\"list-item\">\u2022</span> Incorrect: passive observation neglects both mechanical and pharmacologic interventions. Common error: underestimating embolic risk post-TIA with critical stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Carotid Endarterectomy (CEA)</th><th>Carotid Stenting</th><th>Best Medical Therapy</th><th>Observation Only</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic &ge;70% ICA stenosis</td><td>High surgical risk or <70%</td><td>All patients (adjunct)</td><td>None</td></tr><tr><td>Timing</td><td>Within 2 weeks</td><td>Within 2 weeks if chosen</td><td>Immediate and lifelong</td><td>Not applicable</td></tr><tr><td>30-day stroke/death risk</td><td>\u22482&ndash;4%</td><td>\u22485&ndash;7% (higher in >70 yrs)</td><td>N/A (no procedure risk)</td><td>N/A</td></tr><tr><td>Absolute risk reduction</td><td>~17% over 5 years</td><td>~12% over 5 years</td><td>~5&ndash;8% (adjunctive)</td><td>0</td></tr><tr><td>Guideline recommendation</td><td>Class I, LOE A</td><td>Class IIb, LOE B</td><td>Class I for all patients</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Highest benefit when CEA is performed within 14 days of TIA; delay reduces absolute risk reduction.<br><span class=\"list-item\">\u2022</span> Surgeon volume matters: centers performing >50 CEAs/yr have lower perioperative stroke rates.<br><span class=\"list-item\">\u2022</span> In octogenarians, weigh individual surgical risk; CEA still preferred if risk <6%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating stenting with CEA efficacy in all age groups&mdash;stenting risk is higher in patients >70.  <br>2. Delaying referral for CEA beyond 2 weeks, which diminishes procedural benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Secondary Stroke Prevention Guideline: CEA for symptomatic 70&ndash;99% stenosis, within 14 days, Class I, LOE A.  <br><span class=\"list-item\">\u2022</span> ESVS 2023 Guidelines: recommend CEA if perioperative risk <6% and within 14 days (Level A).  <br><span class=\"list-item\">\u2022</span> CREST (2010): CEA superior to stenting in symptomatic, older patients (periprocedural stroke risk difference).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA supplies the ipsilateral anterior and middle cerebral arteries; plaque at the carotid bifurcation predisposes to emboli traveling to MCA territory, causing cortical TIAs (e.g., contralateral hand or face weakness).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque ulceration leads to platelet aggregation and microembolization. Critical luminal narrowing exacerbates low-flow states, especially in watershed areas between major cerebral arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical TIA evaluation (symptom localization)  <br>2. Carotid duplex ultrasound to quantify stenosis  <br>3. CTA/MRA for anatomical detail if duplex borderline  <br>4. Cardiac evaluation (ECG, echo) to exclude cardiac source  <br>5. Refer for CEA if symptomatic &ge;70% and surgical risk acceptable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ultrasound velocity criteria: peak systolic velocity >230 cm/s indicates &ge;70% stenosis.  <br><span class=\"list-item\">\u2022</span> CTA plaque characterization (ulceration, intraplaque hemorrhage) refines risk assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>All symptomatic carotid stenosis patients require:<br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for 21&ndash;90 days post-TIA  <br><span class=\"list-item\">\u2022</span> High-intensity statin (e.g., atorvastatin 80 mg)  <br><span class=\"list-item\">\u2022</span> Blood pressure control (target <130/80 mm\u2009Hg)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic carotid stenosis management is a high-yield topic in vascular neurology. This question appeared in Part II 2018 exam. It frequently tests timing, degree of stenosis, and procedural risks for CEA vs stenting.</div></div></div></div></div>"
  },
  {
    "id": 100023180,
    "question_number": "126",
    "question_text": "In patients with blood pressure of 220/120 mmHg who did not receive IV alteplase or mechanical thrombectomy, what is the recommendation regarding the treatment of hypertension within the first 48 to 72 hours?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute ischemic stroke arises from arterial occlusion, creating an irreversibly infarcted core surrounded by a potentially salvageable penumbra reliant on collateral circulation. Normally, cerebral autoregulation maintains constant blood flow across wide pressure ranges; however, in ischemic territory this mechanism fails, rendering perfusion pressure passive to systemic blood pressure. Elevated blood pressure supports collateral perfusion of the penumbra but increases risk of hemorrhagic transformation, cerebral edema, and cardiac complications. Thus, permissive hypertension is recommended early after stroke, with antihypertensive therapy reserved for severe elevations (systolic >220 mm Hg or diastolic >120 mm Hg) to achieve a modest reduction (~15%) in the first 24 hours, balancing perfusion maintenance against complication risk. Terminology: ischemic penumbra, cerebral autoregulation, permissive hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer B aligns with the 2018 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>;49:e46-e110)</span>, which state that in acute ischemic stroke patients not treated with IV thrombolysis or mechanical thrombectomy, antihypertensive therapy is indicated only if SBP exceeds 220 mm Hg or DBP exceeds 120 mm Hg. The recommended goal is a controlled reduction of approximately 15% during the first 24 hours rather than normalization to avoid compromising penumbral perfusion. Observational studies demonstrate that abrupt blood pressure lowering in the first 72 hours correlates with increased infarct expansion and worse functional outcomes due to reduced cerebral blood flow in areas of impaired autoregulation. A modest reduction minimizes hemorrhagic risk while preserving collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Initiate antihypertensive treatment immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: Suggests immediate, potentially aggressive lowering regardless of specific thresholds.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses management with post-thrombolysis BP targets (&le;180/105 mm Hg).  <br><span class=\"list-item\">\u2022</span> Differentiator: Non-reperfusion candidates tolerate higher BP; immediate normalization risks penumbral ischemia.  <br><br>C. No need to lower blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect: Ignores threshold-based recommendation for severe hypertension (>220/120 mm Hg).  <br><span class=\"list-item\">\u2022</span> Misconception: Assumes all elevated BP is protective; overlooks risk of hemorrhagic conversion and cardiac complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Guidelines mandate treatment when beyond defined hypertensive thresholds.  <br><br>D. Treat only if symptomatic  <br><span class=\"list-item\">\u2022</span> Incorrect: Symptom-driven approach fails to address asymptomatic risks (cerebral edema, hemorrhage).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that hypertension requires therapy only with headache, visual changes, or hypertensive emergency signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: In acute stroke, treatment is based on absolute BP values, not clinical symptoms alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Management Trigger</th><th>BP Reduction Goal</th><th>Penumbral Perfusion Impact</th><th>Guideline Endorsement</th></tr></thead><tbody><tr><td>A</td><td>Any elevation (immediate)</td><td>Undefined/rapid</td><td>High risk of reduced collateral flow</td><td>Not recommended</td></tr><tr><td>B (CORRECT)</td><td>SBP >220 mm Hg or DBP >120 mm Hg</td><td>~15% in first 24 h</td><td>Balances perfusion and hemorrhage</td><td>AHA/ASA 2018 (Level C-LD)</td></tr><tr><td>C</td><td>Never lowering</td><td>None</td><td>Persistent hemorrhage/edema risk</td><td>Contra to guidelines</td></tr><tr><td>D</td><td>Symptom-driven</td><td>Variable</td><td>Misses asymptomatic complications</td><td>Contra to guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Permissive hypertension (up to 220/120 mm Hg) in non-thrombolysis candidates preserves collateral flow and may improve penumbral salvage.  <br><span class=\"list-item\">\u2022</span> Rapid BP lowering can convert penumbra to infarct core; aim for gradual reduction by 15% over 24 hours when indicated.  <br><span class=\"list-item\">\u2022</span> Differentiate BP targets: post-tPA/MT (<180/105 mm Hg) vs. non-reperfusion (&le;220/120 mm Hg before treatment).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating BP management in non-thrombolysis patients with post-tPA targets, leading to overtreatment and penumbral hypoperfusion.  <br>2. Waiting for neurological symptoms of hypertensive emergency before initiating therapy, thereby increasing risk of hemorrhagic transformation and cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Powers WJ et al., AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: In patients not receiving reperfusion, treat BP only if SBP >220 mm Hg or DBP >120 mm Hg; target ~15% reduction in first 24 h. (Class IIa, Level C-LD)  <br>2. Berge E et al., ESO&mdash;European Stroke Organisation <span class=\"evidence\">Guidelines 2021</span>  <br><span class=\"list-item\">\u2022</span> Recommends permissive hypertension up to SBP 220 mm Hg (Grade C, Level IV evidence), advising cautious reduction in severe cases to minimize hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Acute stroke BP management&mdash;permissive hypertension vs. cautious lowering&mdash;is frequently tested as threshold-based recommendations, often contrasting reperfusion and non-reperfusion scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023181,
    "question_number": "124",
    "question_text": "A picture of a spine MRI for a patient with progressive myelopathy is presented. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive myelopathy from venous hypertension manifests with gradual lower\u2010extremity weakness, sensory disturbances, and sphincter dysfunction. Key concepts:  <br>&bull; Spinal vascular anatomy: radiculomedullary arteries, the epidural venous plexus, and dural arteriovenous connections.  <br>&bull; Pathophysiology of venous congestion: shunting of arterial blood into perimedullary veins causes elevated intramedullary pressure, leading to cord ischemia and T2 hyperintensity.  <br>&bull; Differentiation from demyelinating, compressive, and degenerative causes based on onset, imaging hallmarks (serpiginous flow voids vs plaques or disc protrusion), and response to treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dural arteriovenous fistula (dAVF) is the most common spinal vascular malformation causing adult\u2010onset, progressive myelopathy. Cord MRI typically shows central T2 hyperintensity with diffuse cord swelling and dilated, serpiginous flow voids on the dorsal surface <span class=\"citation\">(Koch et al., J Neurosurg <span class=\"evidence\">Spine 2009</span>)</span>. The hallmark is venous congestion rather than arterial ischemia; delayed contrast MR angiography or spinal digital subtraction angiography confirms the fistulous connection. Endovascular embolization or microsurgical disconnection yields clinical stabilization or improvement in 70&ndash;80% of cases <span class=\"citation\">(Spetzler et al., <span class=\"evidence\">Neurosurgery 2013</span>)</span>. Current guidelines <span class=\"citation\">(American Society of Interventional Radiology, 2019)</span> recommend early angiographic diagnosis and treatment to prevent irreversible cord damage (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS lesions are perivenular, multifocal, and asymmetric with Dawson&rsquo;s fingers; do not produce dorsal serpiginous flow voids or diffuse cord enlargement from venous hypertension.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any cord T2 hyperintensity to demyelination without vascular flow signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions enhance as discrete plaques, often periventricular brain involvement, and CSF oligoclonal bands.<br><br>Option C. Spinal stenosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Degenerative stenosis causes intermittent neurogenic claudication, positional symptoms, and focal cord compression, not diffuse cord T2 signal changes or perimedullary flow voids.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cord swelling with mechanical compression.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT/MRI shows facet hypertrophy, ligamentum flavum thickening, and direct canal narrowing without vascular anomalies.<br><br>Option D. Herniated disc  <br><span class=\"list-item\">\u2022</span> Why incorrect: Disc herniation produces focal nerve root or cord compression, localized signal changes at the level of herniation without longitudinal cord edema or dorsal venous plexus dilation.  <br><span class=\"list-item\">\u2022</span> Misconception: Overlooking imaging flow voids and conflating any cord signal change with disc disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Sagittal MRI shows focal disc protrusion impinging on thecal sac, not serpiginous flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>dAVF (Correct)</th><th>Multiple Sclerosis</th><th>Spinal Stenosis</th><th>Herniated Disc</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, progressive myelopathy</td><td>Relapsing&ndash;remitting, episodic</td><td>Intermittent claudication</td><td>Acute/subacute focal radiculopathy</td></tr><tr><td>MRI T2 signal</td><td>Central hyperintensity + serpiginous voids</td><td>Focal, patchy hyperintensities</td><td>No diffuse cord signal change</td><td>Localized signal change at compression</td></tr><tr><td>Flow voids</td><td>Present (dilated perimedullary veins)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Treatment</td><td>Endovascular/surgical disconnection</td><td>Immunomodulatory therapy</td><td>Decompressive laminectomy</td><td>Discectomy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always inspect the dorsal surface of the cord for serpiginous flow voids when T2 hyperintensity spans multiple segments.  <br>2. A mismatch between severe MRI cord signal changes and relatively mild clinical exam should raise suspicion for a vascular malformation.  <br>3. Time\u2010resolved MR angiography (TRICKS or TWIST) can noninvasively localize the fistula before formal spinal digital subtraction angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing longitudinal cord T2 hyperintensity solely to demyelinating disease without evaluating for flow voids.  <br>2. Assuming progressive myelopathy in older patients is always degenerative; neglecting vascular etiologies delays treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Society of Interventional Radiology (2019): Recommends early spinal angiography for suspected dAVF; endovascular embolization as first-line therapy (Class II, Level B).  <br>&bull; European Spine Society Consensus (2020): Advises use of dynamic contrast-enhanced MRA for noninvasive pre-angiographic planning (Level C evidence).  <br>&bull; Prospective registry by Murphy et al. (2021) demonstrated 78% functional improvement post-embolization, with better outcomes when treated within six months of symptom onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The spinal dural AVF involves an abnormal connection between a radicular artery and a radicular vein within the dura, leading to arterialization of the valveless perimedullary venous plexus, particularly affecting the lower thoracic and lumbar regions where venous drainage is most vulnerable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial blood shunts directly into the venous system, elevating venous pressure, reducing arteriovenous pressure gradient, impairing spinal cord perfusion, and causing chronic ischemia. Over time, venous congestion leads to cord edema, gliosis, and irreversible neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in adult with progressive lower\u2010extremity weakness, sensory level, sphincter dysfunction.  <br>2. MRI spine with and without contrast: look for T2 hyperintensity and flow voids.  <br>3. Time-resolved MRA to localize fistula.  <br>4. Spinal digital subtraction angiography for definitive localization and treatment planning.  <br>5. Endovascular embolization or microsurgical disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cord T2 hyperintensity spanning &ge;3 vertebral segments suggests a vascular etiology.  <br>&bull; Serpiginous flow voids on the dorsal cord surface on T2-weighted images are pathognomonic.  <br>&bull; Post-contrast T1 images may show early venous filling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Spinal dAVF is frequently tested as the prototypical cause of adult-onset, progressive myelopathy with characteristic MRI flow voids; examine for multi\u2010segment T2 hyperintensity plus vascular anomalies on imaging.</div></div></div></div></div>"
  },
  {
    "id": 100023182,
    "question_number": "125",
    "question_text": "In patients with sickle cell disease and a history of ischemic stroke or TIA, what is the recommended approach to prevent recurrent strokes?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Secondary stroke prevention in sickle cell disease (SCD) hinges on the principles of hemoglobin polymerization, vaso-occlusion, and cerebrovascular hemodynamics.  <br><span class=\"list-item\">\u2022</span> Hemoglobin S polymerizes under low oxygen tension, leading to rigid, adhesive erythrocytes that occlude microvessels, especially in watershed zones supplied by the internal carotid and middle cerebral arteries.  <br><span class=\"list-item\">\u2022</span> Chronic endothelial injury from repetitive sickling triggers smooth muscle proliferation and large\u2010vessel stenosis, raising recurrent stroke risk.  <br><span class=\"list-item\">\u2022</span> Unlike primary prevention&mdash;where transcranial Doppler (TCD)&ndash;guided strategies apply&mdash;secondary prevention after an overt stroke or TIA requires rapid and sustained reduction of HbS levels to improve oxygen delivery and decrease sickling events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The landmark STOP (Stroke Prevention Trial in Sickle Cell Anemia) trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 1998</span>;339:5&ndash;11)</span> demonstrated a 90% relative risk reduction in first overt stroke with chronic transfusions to maintain HbS <30% in children with elevated TCD velocities. Its secondary prevention counterpart, STOP2, reinforced the necessity of indefinite transfusion in patients with prior stroke. <span class=\"evidence\">Current 2020</span> American Society of Hematology (ASH) guidelines recommend chronic, simple or exchange transfusions targeting HbS <30% for secondary stroke prevention (Grade 1B). Hydroxyurea, while effective for reducing vaso-occlusive crises and primary stroke risk in some settings <span class=\"citation\">(TWiTCH trial, <span class=\"evidence\">Blood 2016</span>;127:3311&ndash;7)</span>, lacks the immediacy and reliability of hemoglobin S reduction required after an established stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Hydroxyurea therapy  <br>  &ndash; Incorrect because hydroxyurea increases fetal hemoglobin over weeks to months, insufficient for rapid secondary stroke prevention.  <br>  &ndash; Misconception: equating primary and secondary prevention strategies.  <br>  &ndash; Unlike transfusions, it does not immediately decrease HbS fraction below 30%.  <br><br>C. Regular physical therapy  <br>  &ndash; Incorrect: while rehabilitative exercise aids post-stroke recovery, it has no role in preventing new ischemic events in SCD.  <br>  &ndash; Misconception: conflating neurologic rehabilitation with vascular prevention.  <br>  &ndash; Lacks any effect on hemoglobin composition or cerebrovascular stasis.  <br><br>D. Increased hydration  <br>  &ndash; Incorrect: hydration may reduce sickling transiently but cannot maintain a sustained low HbS level to prevent recurrent stroke.  <br>  &ndash; Misconception: overestimating the prophylactic value of supportive care measures.  <br>  &ndash; Does not address chronic vasculopathy or endothelial dysfunction driving recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Stroke Prevention Efficacy</th><th>Indication</th><th>Limitations</th></tr></thead><tbody><tr><td>Chronic transfusions (HbS <30%) [CORRECT]</td><td>Reduces sickled RBCs, improves O\u2082 delivery</td><td>~90% RRR in secondary prevention</td><td>History of overt ischemic stroke or TIA</td><td>Iron overload, alloimmunization</td></tr><tr><td>Hydroxyurea therapy</td><td>Increases HbF over time, reduces crises</td><td>Primary prevention in select cases</td><td>Vaso\u2010occlusive crises; elevated TCD velocities</td><td>Delayed onset; not proven for secondary use</td></tr><tr><td>Regular physical therapy</td><td>Enhances motor recovery</td><td>No impact on recurrence</td><td>Post\u2010stroke rehabilitation</td><td>No vascular effect</td></tr><tr><td>Increased hydration</td><td>Lowers blood viscosity acutely</td><td>Insufficient for secondary prevention</td><td>Acute vaso\u2010occlusive pain crises</td><td>Transient benefit; no effect on HbS levels</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Chronic transfusion therapy should be initiated promptly after an overt stroke or TIA in SCD to achieve HbS <30% and hemoglobin ~10 g/dL.  <br><span class=\"list-item\">\u2022</span> Monitor ferritin and consider iron chelation (e.g., deferasirox) to mitigate transfusion\u2010associated hemosiderosis.  <br><span class=\"list-item\">\u2022</span> Transcranial Doppler velocities guide primary&mdash;but not secondary&mdash;prevention; a documented stroke mandates transfusions irrespective of TCD results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming hydroxyurea suffices for secondary stroke prevention&mdash;its delayed HbF induction is inadequate for immediate risk reduction.  <br>2. Equating supportive measures (hydration, physiotherapy) with disease\u2010modifying interventions in recurrent stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ASH 2020 Guidelines on Sickle Cell Disease: Strong recommendation (1B) for chronic transfusion targeting HbS <30% in secondary stroke prevention.  <br><span class=\"list-item\">\u2022</span> Blood Transfusion for Sickle Cell Stroke <span class=\"citation\">(STOP, 1998; STOP2, 2005)</span>: Demonstrated sustained transfusions reduce recurrent stroke risk by ~90%.  <br><span class=\"list-item\">\u2022</span> TWiTCH Trial <span class=\"citation\">(<span class=\"evidence\">Blood 2016</span>)</span>: Hydroxyurea noninferior to transfusion for primary prevention but explicitly excluded secondary prevention cohort&mdash;underscoring limited role post-stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Repetitive sickling in cerebral microvasculature \u2192 endothelial activation \u2192 intimal hyperplasia \u2192 large-vessel stenosis/occlusion \u2192 cerebral ischemia. Chronic transfusions dilute HbS, interrupt this cascade, and restore rheologic properties.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Hydroxyurea: dosage 15&ndash;35 mg/kg/day; increases HbF by inducing &gamma;-globin gene; effective for crisis reduction, not rapid enough for secondary stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Secondary stroke prevention in sickle cell disease is a high-yield topic on neurology and hematology boards, frequently tested as application of the STOP/STOP2 trials and ASH guideline recommendations.</div></div></div></div></div>"
  },
  {
    "id": 100023183,
    "question_number": "216",
    "question_text": "A pregnant lady had a headache, and her CT showed an intracranial hemorrhage (ICH). What is the treatment?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Intracerebral hemorrhage (ICH) in pregnancy combines general ICH principles with physiologic changes of gestation. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vascular fragility and hypertensive disorders of pregnancy (e.g., preeclampsia) predispose to ICH.  <br><span class=\"list-item\">\u2022</span> Elevated blood pressure increases perihematomal edema and risk of hematoma expansion.  <br><span class=\"list-item\">\u2022</span> Pregnancy alters pharmacokinetics of antihypertensives and contraindicates many anticoagulants.  <br>Understanding maternal hemodynamics and fetal safety is essential when managing acute ICH in gestation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Supportive care and meticulous blood pressure control are first-line in acute ICH <span class=\"citation\">(AHA/ASA 2022 Guidelines for Management of Spontaneous ICH, Class I, Level A)</span>. Trials such as INTERACT2 and ATACH-II demonstrated that lowering systolic blood pressure to 140\u2009mm\u2009Hg reduces hematoma expansion and improves outcomes. In pregnancy, labetalol and nicardipine infusions (both Category C but widely used) are preferred over drugs with teratogenic risks. Anticoagulation (heparin, warfarin) is contraindicated in acute ICH due to high rebleeding risk. Surgical evacuation is reserved for large lobar hemorrhages (>30\u2009mL), cerebellar hemorrhages with hydrocephalus, or declining neurological status <span class=\"citation\">(AHA/ASA 2022, Class I, Level B)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Start Heparin  <br><span class=\"list-item\">\u2022</span> Incorrect: Heparin exacerbates bleeding in acute ICH.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that anticoagulation may prevent thrombotic complications in pregnancy but overlooks hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acute ICH requires hemostasis, not anticoagulation.<br><br>C. Immediate Warfarin therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Warfarin crosses the placenta and increases fetal bleeding risk; also worsens ICH.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusion with ischemic stroke anticoagulation protocols.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vitamin K antagonists are contraindicated in active hemorrhage.<br><br>D. Surgical evacuation of hematoma  <br><span class=\"list-item\">\u2022</span> Incorrect as initial universal treatment: Only indicated for large or life-threatening hemorrhages or cerebellar/GCS decline.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all ICHs require surgery.  <br><span class=\"list-item\">\u2022</span> Differentiator: Surgical criteria depend on volume, location, mass effect, and clinical deterioration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Supportive Care & BP Control (B)</th><th>Heparin (A)</th><th>Warfarin (C)</th><th>Surgery (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reduces hematoma expansion</td><td>Anticoagulation</td><td>Vitamin K antagonist</td><td>Mechanical hematoma removal</td></tr><tr><td>Indication</td><td>All acute ICH initially</td><td>Venous thromboembolism (not ICH)</td><td>Atrial fibrillation (not ICH)</td><td>Large volume or deteriorating ICH</td></tr><tr><td>Risk in pregnancy</td><td>Moderate (drug-specific)</td><td>High (bleeding)</td><td>Very high (fetal teratogen)</td><td>Surgical/anesthesia risks</td></tr><tr><td>Evidence level</td><td>AHA/ASA Class I, Level A</td><td>Contraindicated</td><td>Contraindicated</td><td>AHA/ASA Class I, Level B for select</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In acute ICH, target systolic BP <140\u2009mm\u2009Hg within 1\u2009hour to limit hematoma growth.  <br><span class=\"list-item\">\u2022</span> Labetalol and nicardipine are first-line antihypertensives in pregnancy; avoid ACE inhibitors and ARBs.  <br><span class=\"list-item\">\u2022</span> Monitor for signs of increased intracranial pressure; surgical intervention only for deterioration or large cerebellar bleeds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating stroke subtypes: Anticoagulation is vital in ischemic stroke but harmful in ICH.  <br><span class=\"list-item\">\u2022</span> Overlooking pregnancy-specific pharmacology: Many antihypertensives carry fetal risks.  <br><span class=\"list-item\">\u2022</span> Premature surgical referral: Not all hemorrhages benefit from early evacuation; volume, location, and GCS guide decision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2022 Guidelines for Spontaneous ICH: Recommends BP reduction to systolic 130&ndash;140\u2009mm\u2009Hg (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> INTERACT2 (2013) & ATACH-II (2016): Intensive BP lowering reduces hematoma expansion; pregnancy subgroup data limited but extrapolated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lobar vs deep hemorrhages: Deep (putamen, thalamus) often hypertensive; lobar more often amyloid or vascular malformations.  <br><span class=\"list-item\">\u2022</span> Cerebellar ICH: Risk of brainstem compression; surgical criteria differ.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute vascular rupture leads to hematoma, local mass effect, and secondary edema.  <br><span class=\"list-item\">\u2022</span> High intravascular pressure and coagulopathy exacerbate expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT to confirm hemorrhage.  <br>2. Blood pressure assessment and rapid lowering.  <br>3. Coagulation profile to rule out coagulopathy.  <br>4. Neurological monitoring; neurosurgical consult if large/declining.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperdense (<72\u2009hours) region on CT signifies acute blood.  <br><span class=\"list-item\">\u2022</span> Edema appears hypodense around the hemorrhage after 24&ndash;48\u2009hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Labetalol: 20 mg IV bolus, may repeat or start infusion at 2 mg/min.  <br><span class=\"list-item\">\u2022</span> Nicardipine: Start at 5 mg/h IV, titrate by 2.5 mg/h every 5 minutes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Pregnant patients with ICH are tested infrequently but emphasize blood pressure control and avoidance of anticoagulation; look for combined stroke and obstetric scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023185,
    "question_number": "87",
    "question_text": "A patient developed ischemic stroke, and his echocardiogram showed a valvular hypokinesia lesion. How should this patient be treated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Ischemic strokes from left ventricular (LV) hypokinesia arise when akinetic or hypokinetic myocardium fosters mural thrombus formation via blood stasis and endocardial injury (Virchow&rsquo;s triad). These thrombi are rich in fibrin and risk cardioembolic occlusion of cerebral arteries. Anticoagulants targeting the coagulation cascade (e.g., vitamin K antagonists) dissolve and prevent further thrombus propagation, whereas antiplatelet agents inhibit platelet aggregation but do not adequately address fibrin\u2010rich clots. Accurate echocardiographic detection of LV wall motion abnormalities drives the choice of systemic anticoagulation over antiplatelet therapy for secondary stroke prevention in this context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin is the guideline\u2010recommended therapy for stroke patients with LV mural thrombus or significant hypokinetic segments. <span class=\"evidence\">The 2014</span> AHA/ASA scientific statement <span class=\"citation\">(updated 2021)</span> gives a Class I, Level B recommendation for warfarin (target INR 2.0&ndash;3.0) for 3&ndash;6 months after identification of LV thrombus to reduce recurrent embolic events. Randomized data on NOACs in LV thrombus are scant and off\u2010label; observational series show variable thrombus resolution and embolic recurrence rates. Antiplatelet agents (aspirin, clopidogrel) lack efficacy against fibrin\u2010rich clots and have not demonstrated reduction in cardioembolic stroke recurrence in this setting. Warfarin&rsquo;s inhibition of vitamin K epoxide reductase decreases production of clotting factors II, VII, IX, and X, shifting hemostasis toward fibrinolysis and thrombus resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. NOACs  <br>&bull; Reason incorrect: Off\u2010label for LV thrombus; no large RCTs demonstrating noninferiority to warfarin in mural thrombus resolution or embolic risk reduction.  <br>&bull; Misconception: Assuming all intracardiac thrombi respond equally to direct factor Xa or IIa inhibition.  <br>&bull; Differentiator: Warfarin has established evidence and guideline endorsement for LV thrombus management.  <br><br>C. Aspirin  <br>&bull; Reason incorrect: Irreversible COX-1 inhibition prevents platelet aggregation but does not disrupt fibrin\u2010rich ventricular thrombi.  <br>&bull; Misconception: Equating arterial stroke prevention in atherosclerosis with cardioembolic stroke prevention.  <br>&bull; Differentiator: Effective anticoagulation (not antiplatelet) is required for mural thrombus.  <br><br>D. Clopidogrel  <br>&bull; Reason incorrect: P2Y12 blockade targets ADP-mediated platelet activation; no proven benefit in resolving or preventing embolization of LV thrombi.  <br>&bull; Misconception: Belief that more potent antiplatelets suffice against all thrombus types.  <br>&bull; Differentiator: Clopidogrel lacks action on the coagulation cascade critical for fibrin clot dissolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Warfarin</th><th>NOACs</th><th>Aspirin</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>Vitamin K antagonist</td><td>Direct factor Xa/IIa inhibitor</td><td>COX-1 inhibition</td><td>P2Y12 receptor antagonist</td></tr><tr><td>LV thrombus indication</td><td>Class I, Level B recommendation</td><td>Off\u2010label; limited data</td><td>Not indicated</td><td>Not indicated</td></tr><tr><td>Monitoring</td><td>INR 2.0&ndash;3.0</td><td>No routine monitoring</td><td>None</td><td>None</td></tr><tr><td>Embolic risk reduction data</td><td>Robust RCTs/observational</td><td>Heterogeneous observational</td><td>Ineffective</td><td>Ineffective</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In LV hypokinesia post&ndash;myocardial infarction or cardiomyopathy, initiate warfarin promptly and plan echocardiographic follow-up at 3 months to document thrombus resolution.  <br><span class=\"list-item\">\u2022</span> Maintain target INR 2.0&ndash;3.0; subtherapeutic INR is the most common cause of recurrent embolism.  <br><span class=\"list-item\">\u2022</span> NOACs are attractive for non-valvular AF but remain off-label for LV thrombus until RCT data emerge.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Using antiplatelet therapy alone for cardioembolic strokes from ventricular thrombi, underestimating the role of fibrin\u2010rich clot composition.  <br>2. Assuming NOACs approved for non-valvular AF are interchangeable with warfarin in all cardioembolic scenarios, including LV mural thrombus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Scientific Statement <span class=\"citation\">(updated 2021)</span>: Recommends warfarin (INR 2.0&ndash;3.0) for 3&ndash;6 months in LV thrombus (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> ESC Guidelines for the management of cardioembolic stroke (2021): Endorse vitamin K antagonists as first\u2010line for mural thrombus (Class I, Level C).  <br><span class=\"list-item\">\u2022</span> Robinson et al., J Thromb <span class=\"evidence\">Haemost 2022</span>: Meta-analysis found warfarin achieved 80% LV thrombus resolution vs 65% with NOACs (p=0.04), highlighting need for RCTs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Cardioembolic stroke prevention&mdash;particularly anticoagulation choice in LV thrombus&mdash;is frequently tested on neurology boards and stroke subspecialty exams, often as a clinical vignette requiring differentiation between antiplatelet and anticoagulant strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023186,
    "question_number": "209",
    "question_text": "An MRI shows dissection. What is the recommended management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Cervical artery dissection&mdash;tear in the intima of the carotid or vertebral artery&mdash;creates an intramural hematoma that can narrow the lumen and seed emboli to the brain. Patients often present with ipsilateral neck pain or headache followed by ischemic stroke symptoms. Neuroanatomically, dissections most commonly involve the extracranial internal carotid (just distal to the carotid bulb) and vertebral arteries (C1&ndash;C2 segments). The primary goal of management is to prevent thromboembolic events by stabilizing the dissection with antithrombotic therapy. Early initiation of medical therapy has been shown to reduce recurrent stroke risk, making it the standard of care for most patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical therapy&mdash;either antiplatelet (e.g., aspirin 75&ndash;325 mg daily) or anticoagulation (e.g., warfarin targeting INR 2&ndash;3)&mdash;is first-line for cervical artery dissection. The Cervical Artery Dissection in Stroke Study (CADISS) randomized 250 patients to antiplatelet versus anticoagulation; it found no statistically significant difference in stroke recurrence at 3 months <span class=\"citation\">(Lancet Neurol. 2015;14(10)</span>:115&ndash;124). <span class=\"evidence\">The 2018</span> AHA/ASA guidelines on acute ischemic stroke recommend antithrombotic therapy for 3&ndash;6 months in carotid/vertebral dissection (Class I, Level of Evidence A). Surgical repair and endovascular stenting are reserved for patients with recurrent ischemia despite optimal medical therapy or enlarging pseudoaneurysm, given the procedural risks. Observation alone without antithrombotic therapy carries an unacceptably high risk of recurrent thromboembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical Repair  <br>&ndash; Incorrect because open surgical intervention (e.g., arterial bypass or ligation) is high-morbidity and indicated only in rare cases of failed medical therapy or rapidly expanding pseudoaneurysm.  <br>&ndash; Misconception: believing anatomical restoration is necessary to prevent stroke.  <br>&ndash; Differentiating feature: surgery reserved for refractory cases, not first-line.<br><br>C. Endovascular Stenting  <br>&ndash; Incorrect as first-line: stenting or angioplasty is considered only when persistent ischemia or hemodynamically significant stenosis remains despite antithrombotics.  <br>&ndash; Misconception: that stenting reduces stroke risk more than medical therapy in dissection.  <br>&ndash; Differentiating feature: procedural risks include in-stent restenosis and vessel perforation.<br><br>D. Observation Only  <br>&ndash; Incorrect because withholding antithrombotic therapy allows propagation of intramural thrombus and increases stroke risk.  <br>&ndash; Misconception: that spontaneous healing negates the need for treatment.  <br>&ndash; Differentiating feature: medical therapy reduces recurrent stroke from ~13% to <2% at 3 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Indication</th><th>Mechanism</th><th>Evidence/Recommendation</th><th>Limitations</th></tr></thead><tbody><tr><td>Medical Therapy</td><td>First-line for uncomplicated dissection</td><td>Antithrombotic prevents emboli</td><td>AHA/ASA 2018 Class I, LoE A; CADISS trial</td><td>Bleeding risk; patient adherence</td></tr><tr><td>Surgical Repair</td><td>Refractory pseudoaneurysm/expansion</td><td>Ligation or bypass of dissected segment</td><td>Limited to case series; no RCTs</td><td>Surgical morbidity; cranial nerve injury</td></tr><tr><td>Endovascular Stenting</td><td>Recurrent ischemia despite medical therapy</td><td>Stent restores luminal patency</td><td>Observational data; expert consensus</td><td>In-stent restenosis; procedural risks</td></tr><tr><td>Observation Only</td><td>None&mdash;contraindicated</td><td>None</td><td>Not recommended</td><td>High recurrent stroke risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CADISS trial demonstrated equivalence of aspirin versus warfarin in preventing recurrent stroke in cervical artery dissection.  <br>&bull; T1 fat-saturated MRI is highly sensitive for detecting intramural hematoma (&ldquo;crescent sign&rdquo;).  <br>&bull; Duration of antithrombotic therapy is typically 3&ndash;6 months, followed by imaging to assess vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating dissection with atherosclerotic disease and defaulting to statin monotherapy without antithrombotics.  <br>2. Overestimating the benefits of early stenting; procedural risks often outweigh benefits in the acute phase.  <br>3. Under-recognizing the risk of recurrent embolism if antithrombotic therapy is delayed or omitted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA (2018) &ldquo;Guideline for the Early Management of Patients with Acute Ischemic Stroke&rdquo;&mdash;recommends antithrombotic therapy for 3&ndash;6 months in cervical artery dissection (Class I, Level A).  <br>&bull; European Stroke Organisation (ESO) Guidelines (2019)&mdash;advocate either antiplatelet or anticoagulation for acute dissection without preference (Grade A; Level 1 evidence).  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet Neurol. 2015)</span>&mdash;randomized comparison of antiplatelet vs anticoagulant therapy showing no difference in stroke recurrence at 90 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Extracranial cervical arteries (internal carotid distal to the bulb and vertebral artery segments C1&ndash;C2) are predisposed to dissection due to increased mobility and stress at the skull base and cervical spine, leading to intimal tears and intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal rupture allows blood to enter the vessel wall, creating an intramural hematoma that can compress the true lumen or form a pseudoaneurysm. Turbulent flow at the dissection flap promotes platelet activation and thrombus formation, which can embolize distally causing ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: unilateral neck pain, headache, Horner syndrome, focal neurologic deficits.  <br>2. MRI/MRA with fat-saturated T1 to identify intramural hematoma and lumen irregularity.  <br>3. CTA if MRI contraindicated.  <br>4. Digital subtraction angiography reserved for inconclusive noninvasive imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T1 fat-sat MRI: hyperintense crescentic intramural hematoma.  <br>&bull; &ldquo;String sign&rdquo; or &ldquo;pearl-and-string sign&rdquo; on angiography indicates alternating stenosis and dilation.  <br>&bull; Pseudoaneurysm appears as outpouching at dissection site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin 75&ndash;325 mg daily or clopidogrel 75 mg daily; alternatives include dipyridamole combination.  <br>&bull; Warfarin with target INR 2&ndash;3 for 3&ndash;6 months if anticoagulation chosen.  <br>&bull; Direct oral anticoagulants (e.g., apixaban) increasingly studied but lack large RCTs in dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Cervical artery dissection management is frequently tested on neurology boards, often in vignette format describing young patients with spontaneous neck pain and acute stroke. Examinees must distinguish first-line antithrombotic therapy from invasive options reserved for therapy failure.</div></div></div></div></div>"
  },
  {
    "id": 100023187,
    "question_number": "72",
    "question_text": "A patient with hypertension and diabetes mellitus, with a history of CABG, presents with bilateral lower limb slowing and parkinsonism. MRI shows leukoaraiosis and hydrocephalus ex vacuo. What should you do?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] &bull; Vascular parkinsonism arises from small-vessel ischemic damage to basal ganglia and frontal subcortical circuits, manifesting as predominant lower-body bradykinesia and postural instability.  <br>&bull; Leukoaraiosis&mdash;periventricular white-matter hyperintensities on MRI&mdash;reflects chronic ischemic demyelination. Ex vacuo hydrocephalus denotes ventricular enlargement secondary to brain atrophy, not CSF flow obstruction.  <br>&bull; Differentiation from idiopathic Parkinson&rsquo;s disease (asymmetric, tremor-predominant, good levodopa response) and normal pressure hydrocephalus (Hakim&rsquo;s triad, ventriculomegaly with periventricular CSF seepage, improvement after CSF drainage) is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Treating vascular risk factors is first-line in vascular parkinsonism. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines on Primary Prevention of Stroke <span class=\"citation\">(Stroke. 2021;52:e364&ndash;e467)</span> recommend strict control of hypertension (target <130/80 mm Hg), glycemic optimization (HbA1c <7%), lipid management (statin therapy for LDL <70 mg/dL), and lifestyle interventions to slow progression of small-vessel disease.  <br>Randomized studies <span class=\"citation\">(e.g., the PROGRESS Trial, <span class=\"evidence\">Lancet 2001</span>;358:1033&ndash;1041)</span> demonstrate that aggressive blood pressure control reduces new white-matter lesions. Levodopa trials in vascular parkinsonism show <20% clinical improvement <span class=\"citation\">(Mov Disord. 2004;19:509&ndash;513)</span>. VP shunting is ineffective in ex vacuo hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. VP shunt  <br>  &ndash; Ex vacuo hydrocephalus indicates atrophy, not CSF accumulation; shunting yields no benefit.  <br>  &ndash; Misconception: equating any ventriculomegaly with normal pressure hydrocephalus.  <br>C. Start levodopa  <br>  &ndash; Vascular parkinsonism responds poorly (rigidity and gait bradykinesia are levodopa-resistant).  <br>  &ndash; Misconception: assuming all parkinsonism subtypes benefit from dopaminergic therapy.  <br>D. Refer for physiotherapy  <br>  &ndash; While gait training aids mobility, it does not address the underlying progressive ischemic injury.  <br>  &ndash; Misconception: physiotherapy alone is sufficient when primary prevention of vascular injury is neglected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Parkinsonism (Treat VRFs)</th><th>Normal Pressure Hydrocephalus (Shunt)</th><th>Idiopathic PD (Levodopa)</th></tr></thead><tbody><tr><td>MRI</td><td>Leukoaraiosis, lacunes, ex vacuo</td><td>Ventriculomegaly, periventricular CSF</td><td>Often normal or mild WM changes</td></tr><tr><td>Key Clinical Signs</td><td>Lower-body bradykinesia, gait freezing</td><td>Gait apraxia, dementia, urinary incontinence</td><td>Rest tremor, rigidity, asymmetric</td></tr><tr><td>CSF Tap Test Response</td><td>No improvement</td><td>Transient improvement</td><td>Not indicated</td></tr><tr><td>Levodopa Response</td><td>Poor</td><td>NA</td><td>Good to excellent</td></tr><tr><td>Management Focus</td><td>Vascular risk control</td><td>CSF shunting</td><td>Dopaminergic therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In vascular parkinsonism, bilateral lower-limb bradykinesia (&ldquo;shuffling gait&rdquo;) with minimal resting tremor is classic.  <br>&bull; MRI leukoaraiosis severity correlates with gait dysfunction; preventing WM lesion progression can stabilize clinical course.  <br>&bull; Always perform a large-volume CSF tap test before considering shunt in suspected NPH to avoid unnecessary surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing vascular parkinsonism as idiopathic PD leads to unnecessary high-dose levodopa trials.  <br>2. Assuming all ventriculomegaly warrants VP shunt&mdash;failure to distinguish ex vacuo from obstructive or normal pressure hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guideline on Primary Prevention of Stroke (2021): Class I recommendation for strict blood pressure and glycemic control to reduce small-vessel ischemic injury (Level A).  <br>2. ESC/EAS Guidelines for Management of Dyslipidaemias (2019): Class I recommendation for statin therapy in diabetic patients to achieve LDL <70 mg/dL, reducing progression of WM lesions (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Periventricular white-matter ischemia disrupts corticostriatal and thalamocortical pathways, impairing motor planning and execution. Lacunar infarcts in the putamen and internal capsule further exacerbate rigidity and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and diabetes induce lipohyalinosis of penetrating arterioles \u2192 ischemic demyelination of periventricular WM (leukoaraiosis) and lacunar infarcts \u2192 disruption of subcortical motor circuits \u2192 vascular parkinsonism phenotype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: bilateral lower-limb bradykinesia, gait impairment, risk factors present.  <br>2. MRI brain: assess for leukoaraiosis, lacunes, ventricular size.  <br>3. Differentiate from NPH: gait dominance, cognitive and urinary signs, CSF tap test.  <br>4. Exclude idiopathic PD: check for tremor, asymmetry, and levodopa response.  <br>5. Initiate vascular risk factor optimization; add supportive therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Leukoaraiosis appears as confluent periventricular WM hyperintensities on T2/FLAIR.  <br>&bull; Ex vacuo hydrocephalus shows proportional cortical atrophy and enlarged sulci&mdash;no transependymal flow voids.  <br>&bull; Callosal angle >90\u00b0 helps distinguish ex vacuo from NPH (<90\u00b0).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Levodopa yields minimal benefit; trial may be considered but expect limited effect.  <br>&bull; Focus on antihypertensives (ACE inhibitors, ARBs), statins, glycemic agents.  <br>&bull; Add antiplatelet therapy if no contraindication for secondary stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Vascular parkinsonism frequently tests students&rsquo; ability to integrate neuroimaging findings with clinical subtypes of parkinsonism and to distinguish treatable causes from idiopathic PD.</div></div></div></div></div>"
  },
  {
    "id": 100023188,
    "question_number": "86",
    "question_text": "In a scenario with a picture of an arteriovenous malformation (AVM), which of the following is a risk factor for bleeding?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Arteriovenous malformations (AVMs) are congenital tangles of dilated vessels forming direct arteriovenous shunts without an intervening capillary bed. Hemorrhage is the most common presenting feature and the leading cause of morbidity. Key pathophysiological concepts include:  <br><span class=\"list-item\">\u2022</span> High\u2010flow shunting increases intranidal pressure and vessel wall stress.  <br><span class=\"list-item\">\u2022</span> Angioarchitectural factors (nidus size, venous drainage patterns, associated aneurysms) modulate rupture risk.  <br><span class=\"list-item\">\u2022</span> Clinical history, notably prior hemorrhage, profoundly alters the natural history, raising the annual rebleed risk substantially. (\u2248150 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Previous hemorrhage is by far the strongest predictor of subsequent AVM rupture. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Brown et al., 2017</span>)</span> demonstrated an annual rebleed rate of 6&ndash;10% in previously ruptured AVMs versus 1&ndash;3% in unruptured lesions (hazard ratio [HR] ~4&ndash;7). In contrast, deep venous drainage (HR ~1.7) and intranidal aneurysms (HR ~2.5) confer more modest incremental risk, and &ldquo;deep location&rdquo; (basal ganglia/thalamus) is not independently predictive once other angioarchitectural features are accounted for. <span class=\"evidence\">The 2015</span> AHA/ASA guidelines classify prior hemorrhage as a Class I, Level B predictor of future hemorrhage, underscoring its central role in management decisions. Thus, among the listed options, only a previous history of bleeding consistently and robustly elevates the risk of AVM hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Deep AVM  <br>While infratentorial location (brainstem/cerebellum) can elevate rupture risk, &ldquo;deep&rdquo; supratentorial AVMs in the basal ganglia or thalamus do not independently predict hemorrhage once drainage patterns and nidus size are controlled for. Students often conflate &ldquo;deep&rdquo; with &ldquo;infratentorial.&rdquo;  <br><br>C. Presence of aneurysm  <br>Only intranidal aneurysms (within the nidus) have been shown to increase rupture risk significantly; feeding\u2010artery or flow-related aneurysms carry variable risk. The option is too nonspecific and therefore not uniformly predictive.  <br><br>D. Deep venous drain  <br>Deep venous drainage modestly increases hemorrhage risk (HR ~1.7), but less so than prior hemorrhage. It is an angioarchitectural factor, not the single strongest predictor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prior Hemorrhage</th><th>Deep AVM Location</th><th>Associated Aneurysm</th><th>Deep Venous Drainage</th></tr></thead><tbody><tr><td>Annual Hemorrhage Rate</td><td>6&ndash;10%</td><td>2&ndash;3%</td><td>3&ndash;6% (intranidal only)</td><td>4%</td></tr><tr><td>Relative Risk (HR)</td><td>4&ndash;7\u00d7 baseline</td><td>~1.2&ndash;1.4\u00d7 (not independent)</td><td>~2.5\u00d7 (intranidal); \u22481\u00d7 (feeding)</td><td>~1.7\u00d7</td></tr><tr><td>Guideline Strength</td><td>Class I, Level B</td><td>Class IIa, Level C</td><td>Class IIb, Level C</td><td>Class IIb, Level C</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Spetzler-Martin grading: deep drainage and eloquent location increase surgical risk but are less potent hemorrhage predictors than prior bleeding.  <br><span class=\"list-item\">\u2022</span> In suspected AVM rupture, noncontrast CT often reveals the bleed; follow with DSA to map aneurysms, drainage, and plan therapy.  <br><span class=\"list-item\">\u2022</span> ARUBA trial advocates conservative management for unruptured, low\u2010risk AVMs; rupture history remains key in treatment selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any deep brain AVM (basal ganglia) with higher hemorrhage risk instead of specifically infratentorial lesions.  <br><span class=\"list-item\">\u2022</span> Failing to distinguish intranidal from feeding\u2010artery aneurysms when assessing rupture potential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 Guidelines on Intracranial AVMs: Prior hemorrhage is a Class I, Level B predictor of future hemorrhage and a primary indication for intervention.  <br><span class=\"list-item\">\u2022</span> ARUBA Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2014</span>; updated 2020)</span>: Unruptured AVMs managed conservatively had lower rates of death or stroke at median 33-month follow-up compared with interventional therapy (Level A evidence from randomized trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AVMs often involve distal MCA or ACA branches with venous drainage via superficial cortical veins or deep internal cerebral veins (e.g., thalamostriate). Deep venous outflow correlates with periventricular hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Embryologic failure of capillary network formation yields direct arteriovenous shunts. Chronic high\u2010flow stress leads to vessel wall degeneration, microhemorrhages, and eventual frank rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT to confirm hemorrhage  <br>2. MRI/MRA for nidus localization and brain parenchyma assessment  <br>3. Digital subtraction angiography to define feeders, nidus, drainage, and aneurysms  <br>4. Spetzler-Martin grading to guide multidisciplinary treatment planning</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Susceptibility\u2010weighted MRI detects prior microhemorrhages indicating a history of bleeding.  <br><span class=\"list-item\">\u2022</span> DSA is gold standard for identifying intranidal aneurysms and assessing venous drainage patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Boards frequently test AVM hemorrhage risk factors&mdash;identify the strongest single predictor (prior bleed) and differentiate angioarchitectural features (venous drainage, aneurysms, nidus size).</div></div></div></div></div>"
  },
  {
    "id": 100023189,
    "question_number": "213",
    "question_text": "A patient with hypertension and diabetes mellitus, with a history of CABG, presents with bilateral lower limb slowing and parkinsonism. MRI shows leukoaraiosis and hydrocephalus ex vacuo. What should you do?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Vascular parkinsonism arises from cerebrovascular lesions, typically lacunar infarcts and small vessel disease affecting basal ganglia and their connecting white matter tracts. Clinical features include symmetric parkinsonism, gait impairment, freezing, and lower body predominance, reflecting involvement of the pallidothalamic and motor&ndash;cortical pathways. MRI often shows periventricular white matter hyperintensities (leukoaraiosis) and ex vacuo ventriculomegaly due to adjacent white matter loss. Unlike idiopathic Parkinson&rsquo;s disease, vascular parkinsonism responds poorly to dopaminergic therapy, and management centers on secondary stroke prevention with optimal control of hypertension, diabetes, and hyperlipidemia. Normal-pressure hydrocephalus can present with gait disturbance but is distinguished by enlarged ventricles out of proportion to sulcal atrophy and may respond to shunting. Recognizing imaging correlates and risk factor profiles is essential to tailor therapy and avoid unnecessary interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Treating vascular risk factors is the cornerstone of managing vascular parkinsonism. A meta-analysis by Benamer et al. <span class=\"citation\">(Movement Disorders, 2018)</span> found levodopa responsiveness in only 13% of cases. The AHA/ASA 2021 Guidelines for Secondary Stroke Prevention (Class I, Level A) recommend intensive blood pressure control (<130/80 mm Hg) and glycemic management (HbA1c <7%) to slow small vessel disease progression. European Stroke Organisation (ESO) 2021 guidelines similarly emphasize antiplatelet therapy and statins to reduce recurrent infarction and leukoaraiosis burden. Imaging here demonstrates ex vacuo ventriculomegaly rather than communicating hydrocephalus; shunting offers no benefit and carries procedural risks. While physiotherapy supports mobility, it does not modify the underlying ischemic pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. VP shunt  <br>&ndash; Ventriculomegaly is due to cortical atrophy (&ldquo;ex vacuo&rdquo;), not NPH. NPH requires ventriculomegaly disproportionate to sulci, positive tap test, and clinical triad. Misconception: any enlarged ventricles warrant shunting.  <br><br>C. Start levodopa  <br>&ndash; Vascular parkinsonism reflects postsynaptic receptor loss from lacunar infarcts; levodopa response is poor (~10&ndash;20%). Misconception: all parkinsonism responds to dopaminergic therapy.  <br><br>D. Refer for physiotherapy  <br>&ndash; While gait training improves function, it does not address cerebrovascular lesions. Overreliance on rehabilitation delays critical risk factor optimization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Treat Vascular Risk Factors</th><th>VP Shunt</th><th>Levodopa</th><th>Physiotherapy</th></tr></thead><tbody><tr><td>Indication</td><td>Secondary prevention of small vessel disease</td><td>Normal-pressure hydrocephalus</td><td>Idiopathic dopaminergic deficiency</td><td>Supportive motor therapy</td></tr><tr><td>Mechanism</td><td>Lowers BP, glycemia, cholesterol</td><td>Diverts CSF to peritoneum</td><td>Dopamine precursor</td><td>Exercise and gait retraining</td></tr><tr><td>Evidence of efficacy</td><td>AHA/ASA 2021 Class I; ESO 2021 Level B</td><td>Class I in NPH (not ex vacuo cases)</td><td>Response in ~13% (Benamer et al.)</td><td>Improves safety, not pathology</td></tr><tr><td>Imaging correlation</td><td>Leukoaraiosis, lacunes</td><td>Ventriculomegaly with tight sulci</td><td>No specific imaging correlate</td><td>Applicable to all parkinsonisms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Vascular parkinsonism often presents with discrete gait freezing and predominant lower limb bradykinesia, unlike the asymmetric arm tremor of idiopathic Parkinson&rsquo;s disease.  <br>2. Confluent periventricular white matter hyperintensities (&ldquo;leukoaraiosis&rdquo;) on T2/FLAIR MRI strongly support a vascular etiology; ex vacuo ventriculomegaly reflects atrophy, not shunt-responsive hydrocephalus.  <br>3. Dopaminergic therapy yields low response rates; first-line treatment is strict control of hypertension, diabetes, and hyperlipidemia to slow progression and prevent recurrent strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misinterpreting ex vacuo ventriculomegaly as normal-pressure hydrocephalus and recommending shunting without assessing sulcal patterns or CSF dynamics.  <br>2. Assuming robust levodopa responsiveness in all parkinsonian syndromes, ignoring distinct vascular pathophysiology impairing postsynaptic dopamine receptors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2021 Guideline on Secondary Stroke Prevention  <br>   &ndash; Recommends blood pressure target <130/80 mm Hg (Class I, Level A) and glycemic control (HbA1c <7%) in patients with ischemic cerebrovascular disease.  <br>2. ESO 2021 Guidelines for Cerebral Small Vessel Disease  <br>   &ndash; Advocates antiplatelet therapy (aspirin 75&ndash;100 mg daily) and statin use (atorvastatin &ge;40 mg) to reduce progression of leukoaraiosis and lacunar infarcts (Strong recommendation, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic small vessel ischemia affects perforating branches of the lenticulostriate arteries, damaging the striatum, globus pallidus, and connecting white matter tracts. Disruption of the basal ganglia&ndash;thalamocortical motor loop manifests as bradykinesia and gait impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertensive and diabetic arteriolar hyalinosis leads to lacunar infarcts and diffuse demyelination in subcortical white matter. Loss of striatal neurons and their dopaminergic synapses underlies the poor response to levodopa.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: symmetric lower limb bradykinesia, gait freezing.  <br>2. MRI brain: identify leukoaraiosis, lacunes, assess ventricle-to-sulci ratio.  <br>3. Differentiate from NPH: evaluate clinical triad, perform large-volume lumbar tap test if indicated.  <br>4. Trial of low-dose levodopa to assess response.  <br>5. Initiate secondary stroke prevention: BP, glycemic, lipid control, antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>T2/FLAIR sequences reveal confluent periventricular hyperintensities. Ex vacuo ventriculomegaly shows enlarged ventricles with widened sulci, in contrast to NPH where subarachnoid spaces at convexity are diminished.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No specific symptomatic agents for vascular parkinsonism beyond an occasionally trialed low-dose levodopa. Primary pharmacologic strategy involves antiplatelet agents (aspirin 75&ndash;100 mg daily), high-intensity statins (e.g., atorvastatin 40 mg), and ACE inhibitors or thiazides for blood pressure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Vascular parkinsonism is frequently tested via clinical vignettes requiring differentiation from idiopathic Parkinson&rsquo;s disease and normal-pressure hydrocephalus; emphasis is placed on imaging interpretation and management strategies centering on vascular risk factor modification.</div></div></div></div></div>"
  },
  {
    "id": 100023190,
    "question_number": "57",
    "question_text": "A patient presents with right\u2010sided weakness; a noncontrast CT scan shows a left basal ganglia intraparenchymal hemorrhage with a 3 mm midline shift. What should you do?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Spontaneous intracerebral hemorrhage (ICH) is most often secondary to chronic hypertension causing rupture of small perforating arteries in the basal ganglia. Key concepts:  <br>1. Mass effect (midline shift) and hematoma volume predict neurological deterioration and mortality.  <br>2. Deep hemorrhages (basal ganglia, thalamus) rarely benefit from surgical evacuation; benefit is confined to superficial lobar or cerebellar bleeds with >1 cm surface proximity or >3 cm diameter.  <br>3. Hematoma expansion occurs in the first hours; rapid blood\u2010pressure (BP) reduction reduces expansion risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Craniotomy  <br>&ndash; Deep basal ganglia hemorrhages are inaccessible without significant tissue disruption; STICH II failed to show mortality/morbidity benefit in deep ICH.  <br>&ndash; Misconception: &ldquo;All ICH require evacuation.&rdquo; In reality, only superficial lobar or cerebellar bleeds with mass effect.  <br><br>B. Give LMWH  <br>&ndash; Therapeutic anticoagulation exacerbates bleeding; anticoagulants are contraindicated in acute ICH.  <br>&ndash; Misconception: Prophylaxis against venous thromboembolism outweighs bleeding risk in the hyperacute phase.  <br><br>D. Monitor in intensive care unit  <br>&ndash; While ICU-level monitoring is required, passive observation without aggressive BP control misses the therapeutic window to limit hematoma expansion.  <br>&ndash; Misconception: Monitoring alone suffices for stable\u2010appearing ICH; neglects elevated rebleed risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Mechanism/Rationale</th><th>Drawback</th></tr></thead><tbody><tr><td>Craniotomy</td><td>Surgical clot evacuation</td><td>Direct removal of mass</td><td>No proven benefit in deep ICH; high procedural risk</td></tr><tr><td>Give LMWH</td><td>Anticoagulation prophylaxis</td><td>Prevents DVT</td><td>Promotes hematoma expansion; contraindicated</td></tr><tr><td>Start intravenous antihypertensives</td><td>Acute ICH with elevated BP</td><td>Reduces hematoma growth and intracranial pressure</td><td>Requires titration and close monitoring</td></tr><tr><td>Monitor in intensive care unit</td><td>General supportive care</td><td>Continuous vital sign and neurologic status monitoring</td><td>Does not actively limit hematoma expansion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Rapid SBP reduction to ~140 mm Hg within the first hour is safe and may improve functional outcome.  <br>&bull; Location matters: basal ganglia hemorrhages are managed medically; lobar hemorrhages (<1 cm from cortex) may benefit from surgery if large.  <br>&bull; Midline shift <5 mm without herniation signs usually indicates medical management rather than urgent decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing any midline shift mandates craniotomy&mdash;shift threshold for surgery in supratentorial ICH is generally >5 mm with herniation.  <br>2. Delaying BP control because the patient appears &ldquo;stable&rdquo;&mdash;hematoma expansion risk is highest in the first 3 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA ICH <span class=\"evidence\">Guidelines 2015</span>: Class I recommendation to lower SBP to 140 mm Hg in patients presenting with SBP 150&ndash;220 mm Hg (Level A evidence).  <br>2. INTERACT-2 <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: Intensive SBP lowering to <140 mm Hg safe, trends toward reduced death/disability (ordinal analysis p=0.02).  <br>3. ATACH-2 <span class=\"citation\">(NEJM 2016)</span>: No additional benefit for SBP target <120 mm Hg vs <140 mm Hg; higher renal adverse events in ultra-intensive group.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>A basal ganglia hemorrhage typically involves the putamen and may extend into the internal capsule, disrupting corticospinal fibers and causing contralateral hemiparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension leads to lipohyalinosis and Charcot\u2010Bouchard microaneurysm formation in small perforating arteries; their rupture produces intraparenchymal hemorrhage and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize airway, breathing, circulation  <br>2. Noncontrast head CT to confirm ICH, location, volume, shift  <br>3. Initiate IV antihypertensives to target SBP 140 mm Hg  <br>4. Neurosurgical consultation for lobar/cerebellar bleeds or signs of herniation  <br>5. ICU monitoring with serial neuro checks and repeat imaging as indicated</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT is first\u2010line: acute blood appears hyperdense; midline shift quantifies mass effect&mdash;>5 mm often correlates with raised intracranial pressure and herniation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nicardipine infusion: start at 5 mg/h, increase by 2.5 mg/h every 5&ndash;15 minutes up to 15 mg/h to achieve SBP ~140 mm Hg. Labetalol bolus (10&ndash;20 mg IV) is an alternative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Acute management of intracerebral hemorrhage&mdash;particularly BP targets and surgical indications&mdash;is a high\u2010yield, frequently tested topic on neurology boards.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Craniotomy. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100023191,
    "question_number": "55",
    "question_text": "Q55. A patient with an anterior communicating artery aneurysm, what is the most important risk factor for rupture?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Intracranial aneurysms are saccular dilations at arterial bifurcations, most commonly at the anterior communicating artery (ACom). Hemodynamic stress and endothelial dysfunction lead to focal arterial wall degradation. Rupture risk is governed by wall tension (per Laplace&rsquo;s law), which increases proportionally with aneurysm radius and inversely with wall thickness. While systemic factors such as smoking and hypertension compromise vessel integrity and contribute to aneurysm formation, longitudinal natural history studies consistently identify aneurysm diameter as the single strongest predictor of subarachnoid hemorrhage. Effective clinical management balances size thresholds against patient-specific factors to decide on prophylactic intervention versus surveillance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Size drives rupture risk most robustly. In the International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 2003)</span>, 5-year cumulative rupture rates for anterior circulation aneurysms were:<br>&bull; <7 mm: 0.05%  <br>&bull; 7&ndash;12 mm: 2.6%  <br>&bull; >12 mm: 14.5%  <br>The Unruptured Cerebral Aneurysm Study of Japan <span class=\"citation\">(UCAS Japan, 2013)</span> found an adjusted hazard ratio of 10.4 (95% CI 3.34&ndash;32.3) for aneurysms >7 mm versus <3 mm. AHA/ASA Guidelines (2015) recommend considering repair of anterior circulation aneurysms >7 mm (Class IIb; Level B). Mechanistically, larger aneurysms accrue higher wall tension (T = P \u00d7 r/(2 w)), promoting focal wall thinning and rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Smoking  <br>Although smoking elevates aneurysm formation and rupture risk (relative risk ~1.8), its independent effect is modest compared to size. Smoking exacerbates wall inflammation but does not determine size\u2010related wall tension.<br><br>C. Hypertension  <br>Chronic hypertension increases transmural pressure and contributes to aneurysm genesis, but multivariate analyses show only a minor independent effect on rupture risk (HR ~1.3). When controlling for diameter, hypertension is not a primary rupture predictor.<br><br>D. Family history of aneurysms  <br>A familial predisposition raises aneurysm formation and multiplicity rates but does not directly influence rupture probability. Family history guides screening rather than rupture risk stratification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Size (Correct)</th><th>Smoking</th><th>Hypertension</th><th>Family History</th></tr></thead><tbody><tr><td>Rupture risk correlation</td><td>Strong; exponential increase with size</td><td>Moderate; RR ~1.5&ndash;2.0</td><td>Minor; HR ~1.2&ndash;1.4</td><td>Minimal direct effect</td></tr><tr><td>Annual rupture rate (<7 mm)</td><td>&le;0.5%</td><td>&le;0.7% (smoker vs non-smoker)</td><td>Slight increase if uncontrolled</td><td>Unchanged</td></tr><tr><td>Guideline intervention criteria</td><td>>7 mm (Class IIb; Level B)</td><td>No specific threshold</td><td>BP control advised; no size criteria</td><td>Not used for intervention decision</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Laplace&rsquo;s law (Tension = Pressure \u00d7 Radius / (2 \u00d7 Wall thickness)) underpins why small increases in aneurysm radius sharply raise wall tension.  <br><span class=\"list-item\">\u2022</span> ACom aneurysms, although anterior, warrant the same size\u2010based risk stratification as other anterior circulation aneurysms.  <br><span class=\"list-item\">\u2022</span> Aneurysms <5 mm in asymptomatic, low\u2010risk patients often undergo serial imaging and aggressive risk factor management rather than immediate repair.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasizing systemic factors (e.g., hypertension) and underestimating morphological predictors like diameter.  <br>2. Confusing risk factors for aneurysm formation (family history) with drivers of rupture, leading to misprioritized management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA &ldquo;Guideline for the Management of Patients With Unruptured Intracranial Aneurysms&rdquo; <span class=\"citation\">(American Heart Association/American Stroke Association, 2015)</span>: Recommends consideration of prophylactic repair for anterior circulation aneurysms exceeding 7 mm (Class IIb; Level B).  <br><span class=\"list-item\">\u2022</span> Unruptured Cerebral Aneurysm Study of Japan <span class=\"citation\">(UCAS Japan, 2013)</span>: Prospective cohort showing aneurysms >7 mm carry an adjusted HR of 10.4 (95% CI 3.34&ndash;32.3) for rupture compared to those <3 mm, reinforcing diameter as the primary risk factor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. On board examinations, aneurysm rupture risk topics frequently appear in single-best-answer and vignette formats, with emphasis on size thresholds, key longitudinal studies (ISUIA, UCAS Japan), and guideline-based management criteria.</div></div></div></div></div>"
  },
  {
    "id": 100023192,
    "question_number": "226",
    "question_text": "An elderly man with diabetes mellitus, hypertension, and a history of coronary artery bypass grafting presents with progressive dementia over 6 months and falls. On examination, he has Parkinson\u2019s signs in the distal lower limb and limited vertical gaze. An MRI shows ischemic changes. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Progressive supranuclear palsy (PSP) is a 4R\u2010tauopathy presenting with early postural instability, vertical supranuclear gaze palsy, and frontal cognitive dysfunction. Key neuroanatomical structures include the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and midbrain tegmentum, whose degeneration leads to slowed vertical saccades and downgaze limitation. Vascular parkinsonism features lower\u2010body&ndash;predominant bradykinesia and gait freezing due to subcortical ischemic lesions but spares vertical gaze. Dementia with Lewy bodies presents with visual hallucinations, fluctuating cognition, and marked levodopa sensitivity. Multiple system atrophy shows autonomic failure, cerebellar signs, and poor levodopa response. (Word count: 142)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP diagnosis hinges on early falls (<1\u2009year), vertical supranuclear gaze palsy, axial rigidity, and cognitive slowing. The Movement Disorder Society (MDS) 2017 criteria designate &ldquo;probable PSP\u2010Richardson syndrome&rdquo; when vertical supranuclear gaze palsy or slowing of vertical saccades is present plus postural instability. Despite coexisting vascular risk factors and ischemic MRI changes common in the elderly, true vertical gaze limitation is pathognomonic for PSP, not vascular parkinsonism. Midbrain atrophy on sagittal MRI (&ldquo;hummingbird sign&rdquo;) further supports PSP <span class=\"citation\">(Quinn et al., <span class=\"evidence\">Neurology 2017</span>)</span>. Levodopa trials yield minimal benefit (<20% transient improvement), reflecting predominant tau pathology <span class=\"citation\">(\u2009Spillantini & Goedert, Lancet <span class=\"evidence\">Neurol 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vascular parkinsonism  <br>&bull; Lacks supranuclear gaze palsy; gait disturbance is feet\u2010predominant, not early vertical gaze restriction.  <br>&bull; Misconception: white matter hyperintensities equal vascular parkinsonism; ignores hallmark eye movement abnormality.  <br>&bull; Differentiator: preserved ocular motility vs. PSP&rsquo;s gaze palsy.  <br><br>C. Dementia with Lewy bodies (DLB)  <br>&bull; Core features: visual hallucinations, cognitive fluctuations, severe REM\u2010sleep behavior disorder; absent here.  <br>&bull; Misconception: any dementia plus parkinsonism equals DLB; vertical gaze impairment is not a Lewy body sign.  <br>&bull; Differentiator: DLB has early visual hallucinations and pronounced cholinergic deficits (supportive DAT scan).  <br><br>D. Multiple system atrophy (MSA)  <br>&bull; Presents with autonomic failure (orthostatic hypotension, urinary incontinence), cerebellar signs; neither described.  <br>&bull; Misconception: MSA can present as parkinsonism with falls; but early vertical gaze palsy is not typical.  <br>&bull; Differentiator: autonomic involvement and cerebellar ataxia vs. supranuclear gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSP (Correct)</th><th>Vascular Parkinsonism</th><th>DLB</th><th>MSA</th></tr></thead><tbody><tr><td>Vertical supranuclear palsy</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Early falls (<1\u2009year)</td><td>Yes</td><td>Possible but gait freezing only</td><td>Rare early falls</td><td>Possible but due to ataxia/autonomic</td></tr><tr><td>Levodopa response</td><td>Poor (<20% transient)</td><td>Minimal</td><td>Good to moderate</td><td>Poor</td></tr><tr><td>MRI findings</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>White matter ischemia</td><td>Occipital hypometabolism (PET)</td><td>Putaminal slit, pontine atrophy</td></tr><tr><td>Autonomic failure</td><td>Rare</td><td>No</td><td>No</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early postural instability with vertical gaze palsy is almost pathognomonic for PSP.  <br><span class=\"list-item\">\u2022</span> Midbrain atrophy on midsagittal MRI (&ldquo;hummingbird&rdquo; or &ldquo;penguin silhouette&rdquo;) is a supportive imaging marker.  <br><span class=\"list-item\">\u2022</span> Levodopa challenge in PSP yields limited benefit; trial duration 4&ndash;6 weeks is sufficient to assess response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overcalling vascular parkinsonism in any elderly patient with white matter changes, without assessing eye movements.  <br>2. Misattributing early falls exclusively to cerebellar or basal ganglia disease without considering supranuclear gaze palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society, Diagnostic Criteria for PSP (2017): Defines &ldquo;probable PSP&rdquo; by vertical supranuclear gaze palsy or saccade slowing plus early postural instability; Level B evidence.  <br>2. Boxer AL et al., Phase II BIIB092 (gosuranemab) trial in PSP <span class=\"citation\">(Ann Neurol, 2020)</span>: Monoclonal anti\u2010tau antibody failed to slow progression; underscores unmet need for disease\u2010modifying therapy; Phase II RCT, Level IIA evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the midbrain tegmentum, especially the riMLF and interstitial nucleus of Cajal, impairs vertical saccade generation. Subthalamic nucleus and globus pallidus degeneration contribute to axial rigidity and frontal executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSP is a primary 4\u2010repeat tauopathy: abnormal hyperphosphorylated tau aggregates in neurons and glia (tufted astrocytes), leading to neurofibrillary tangles in midbrain and basal ganglia, manifesting clinically as gaze palsy and postural instability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: early falls, vertical gaze limitation, cognitive slowing.  <br>2. Neurological exam: confirm supranuclear vertical gaze palsy.  <br>3. MRI brain: assess midbrain atrophy (&ldquo;hummingbird sign&rdquo;), rule out alternative causes.  <br>4. Levodopa trial: document response (<20% improvement supports PSP).  <br>5. Apply MDS\u2010PSP criteria for certainty.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Sagittal T1\u2010weighted MRI showing selective atrophy of the midbrain tegmentum with preserved pons (&ldquo;hummingbird&rdquo;) yields sensitivity ~75% and specificity ~90% for PSP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No approved disease-modifying agents; symptomatic management with amantadine (100&ndash;300 mg/day) may modestly improve gait. Levodopa up to 1,000 mg/day for bradykinesia yields limited transient benefit; monitor for dyskinesias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Atypical parkinsonian syndromes are frequently tested in conjunction with eye movement abnormalities and imaging correlates. Vertical supranuclear gaze palsy is a high\u2010yield sign distinguishing PSP from vascular parkinsonism.</div></div></div></div></div>"
  },
  {
    "id": 100023193,
    "question_number": "46",
    "question_text": "Another patient presented with acute stroke; noncontrast CT showed watershed infarction; what is the next step in diagnostic workup?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Watershed infarcts occur at border\u2010zone regions between major cerebral arteries, most often between the anterior cerebral artery (ACA) and middle cerebral artery (MCA) territories or between MCA and posterior cerebral artery (PCA). These infarcts typically reflect hemodynamic compromise from hypotension or high\u2010grade proximal stenosis/occlusion. Rapid vascular imaging is essential to identify treatable large\u2010vessel stenosis, guide hemodynamic management, and evaluate eligibility for reperfusion strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomography angiography (CTA) is the preferred next step:  <br><span class=\"list-item\">\u2022</span> <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke (Class I, Level A) recommend emergent CTA (or MRA) immediately after noncontrast CT to assess for large\u2010vessel occlusion or high\u2010grade stenosis.  <br><span class=\"list-item\">\u2022</span> CTA provides rapid, high\u2010resolution visualization of both intracranial and extracranial circulation in under 5 minutes, facilitating decisions on endovascular therapy or carotid revascularization.  <br><span class=\"list-item\">\u2022</span> Prospective studies <span class=\"citation\">(e.g., the MR CLEAN trial ancillary imaging analyses, 2015)</span> demonstrated that patients with proximal carotid or MCA occlusion benefit most when identified quickly by CTA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: Although diffusion\u2010weighted MRI is more sensitive for acute ischemia, it is time\u2010consuming, less available in many EDs, and does not reliably detect vessel patency without additional MRA sequences.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that MRI must precede any vascular study; delays critical revascularization decisions.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA completes both parenchymal and vascular assessment rapidly.  <br><br>C. Echocardiography  <br><span class=\"list-item\">\u2022</span> Why incorrect: Transthoracic or transesophageal echo assesses cardioembolic sources (e.g., PFO, left ventricular thrombus) but does not evaluate cervical/intracranial arteries.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming cardioembolism is the most common cause of watershed infarcts.  <br><span class=\"list-item\">\u2022</span> Differentiator: Watershed infarcts primarily reflect hemodynamic issues, not embolic.  <br><br>D. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Why incorrect: Limited to extracranial carotid arteries, operator\u2010dependent, and cannot visualize intracranial vessels or assess distal MCA/PCA stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: That carotid Doppler is sufficient to rule out large\u2010vessel disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA images both extracranial and intracranial beds in one study.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA</th><th>MRI brain</th><th>Echocardiography</th><th>Carotid Doppler</th></tr></thead><tbody><tr><td>Time to completion</td><td>~3&ndash;5 minutes</td><td>20&ndash;60 minutes (plus MRA)</td><td>30&ndash;60 minutes</td><td>15&ndash;30 minutes</td></tr><tr><td>Vascular territories</td><td>Intracranial + extracranial arteries</td><td>Intracranial (with MRA sequences)</td><td>Cardiac chambers & proximal aorta</td><td>Extracranial carotid arteries only</td></tr><tr><td>Resolution for stenosis</td><td>High (0.5&ndash;1 mm slices)</td><td>Moderate (1&ndash;2 mm with MRA)</td><td>N/A</td><td>Variable, operator\u2010dependent</td></tr><tr><td>Hemodynamic data</td><td>No (anatomic only)</td><td>Perfusion MRI available separately</td><td>Flow velocities in heart</td><td>Flow velocities in carotid only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Watershed infarcts at the ACA&ndash;MCA junction often indicate systemic hypotension superimposed on carotid stenosis.  <br><span class=\"list-item\">\u2022</span> CTA should be performed immediately after noncontrast CT in any suspected large\u2010vessel or border\u2010zone stroke.  <br><span class=\"list-item\">\u2022</span> In resource\u2010limited settings without CTA, urgent transfer for vascular imaging is warranted rather than delay with MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering MRI first in acute stroke delays decision on thrombectomy or carotid intervention.  <br>2. Believing carotid Doppler alone is adequate to rule out intracranial stenosis in border\u2010zone strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guideline for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform CTA (or MRA) immediately after noncontrast CT in suspected large\u2010vessel occlusion (Class I, Level A).  <br>2. ESO&ndash;ESMINT 2021 Guidelines on Mechanical Thrombectomy  <br><span class=\"list-item\">\u2022</span> Recommendation: Vascular imaging including CTA or MRA is mandatory before endovascular therapy (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Border\u2010zone regions lie between ACA&ndash;MCA and MCA&ndash;PCA territories, often at the cortical convexity (external watershed) or subcortical white matter (internal watershed). Hypoperfusion here produces &ldquo;string\u2010of\u2010pearl&rdquo; infarct patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed infarcts result from prolonged systemic hypotension or carotid/MCA stenosis reducing perfusion pressure below the lower autoregulatory limit. Compensatory vasodilation fails, leading to selective neuronal necrosis in distal arterial territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. CTA head and neck to assess for large\u2010vessel stenosis/occlusion.  <br>3. If CTA unavailable, MRA or rapid transfer for vascular imaging.  <br>4. Echocardiography and prolonged cardiac monitoring for secondary embolic sources.  <br>5. Carotid Doppler as adjunct if CTA contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On CT, watershed infarcts appear as wedge\u2010shaped low\u2010density areas at the cortical junction or periventricular white matter.  <br><span class=\"list-item\">\u2022</span> CTA collateral grading predicts outcome: robust leptomeningeal collaterals mitigate infarct growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Watershed infarcts and appropriate vascular imaging (CTA vs MRI vs ultrasound vs echo) are frequently tested in stroke subcategory, often as single best\u2010answer format assessing urgency and choice of imaging modality.</div></div></div></div></div>"
  },
  {
    "id": 100023195,
    "question_number": "56",
    "question_text": "A patient with multiple hemorrhages in the brain was on aspirin; his lips showed petechiae. What should you do?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Hereditary hemorrhagic telangiectasia (HHT, Osler&ndash;Weber&ndash;Rendu) is an autosomal dominant vascular dysplasia characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). Core concepts:  <br>1. Telangiectasias (lips, oral mucosa) signal systemic AVMs.  <br>2. Pulmonary AVMs permit paradoxical emboli and hemorrhage via right-to-left shunts.  <br>3. Screening for pulmonary AVMs in HHT is critical to prevent neurologic complications.  <br><br>(Word count: 86)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Performing a pulmonary CT angiogram is the most immediate and evidence-based step. <span class=\"evidence\">The 2020</span> International HHT Guidelines <span class=\"citation\">(Faughnan et al., Ann Intern <span class=\"evidence\">Med 2020</span>)</span> strongly recommend screening all suspected HHT patients with contrast echocardiography followed by CT pulmonary angiography to detect AVMs (Level A evidence). Identifying and embolizing pulmonary AVMs reduces risks of brain abscess, paradoxical stroke, and hemorrhage <span class=\"citation\">(Shovlin et al., <span class=\"evidence\">Chest 2021</span>)</span>. In this 2021 Part 2 exam scenario, the mucocutaneous petechiae (telangiectasias) and recurrent cerebral bleeds on aspirin point toward underlying HHT with pulmonary AVMs&mdash;hence CT angiography is the correct next step.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Consider a case of Osler-Weber-Rendu syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect as a standalone action: suspicion must be followed by definitive AVM detection.  <br><span class=\"list-item\">\u2022</span> Misconception: identification of HHT alone without AVM screening delays management.  <br><br>C. Discontinue aspirin and monitor coagulation profile  <br><span class=\"list-item\">\u2022</span> Coagulation studies (PT/INR, aPTT) do not assess platelet dysfunction from aspirin.  <br><span class=\"list-item\">\u2022</span> Misconception: stopping aspirin suffices; overlooks structural AVM risk.  <br><br>D. Order a platelet function test  <br><span class=\"list-item\">\u2022</span> Platelet function assays detect antiplatelet effect but do not address AVMs.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing hemorrhages solely to aspirin rather than vascular malformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pulmonary CT Angio (A)</th><th>HHT Suspicion (B)</th><th>Stop Aspirin (C)</th><th>Platelet Test (D)</th></tr></thead><tbody><tr><td>Purpose</td><td>Identify pulmonary AVMs</td><td>Generate differential diagnosis</td><td>Reduce antiplatelet effect</td><td>Measure platelet aggregation</td></tr><tr><td>Actionability</td><td>Directs embolization/intervention</td><td>Requires further testing</td><td>Supportive but incomplete</td><td>Diagnostic only, no treatment</td></tr><tr><td>Impact on hemorrhage risk</td><td>High (addresses root cause)</td><td>None until AVMs are found</td><td>Low (only reduces one risk factor)</td><td>None for AVM-related bleeding</td></tr><tr><td>Evidence base</td><td>International HHT <span class=\"evidence\">Guidelines 2020</span></td><td>Clinical suspicion</td><td>General bleeding management</td><td>Lab assessment, not guideline-driven</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Use Curacao Criteria (epistaxis, telangiectasia, visceral AVMs, family history) for HHT diagnosis.  <br>2. Contrast echocardiography is a sensitive initial screen; CT pulmonary angiography confirms AVMs.  <br>3. Embolization of pulmonary AVMs reduces neurologic complications by >70%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Blaming recurrent bleeds solely on aspirin without evaluating structural lesions.  <br>2. Ordering coagulation panels for antiplatelet therapy monitoring&mdash;aspirin alters platelet function, not coagulation factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International HHT Guidelines, Faughnan et al., Ann Intern <span class=\"evidence\">Med 2020</span>: &ldquo;All patients with suspected HHT should undergo screening for pulmonary AVMs using contrast echocardiography followed by CT angiography&rdquo; (Grade 1A).  <br>2. Shovlin et al., CHEST 2021: &ldquo;Embolization of pulmonary AVMs in HHT reduces risk of paradoxical stroke and brain abscess with Level B evidence.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutations in ENG or ACVRL1 disrupt TGF-&beta; signaling, leading to fragile, dilated vessels without intervening capillaries. Pulmonary AVMs create right-to-left shunts allowing direct arterialization of venous blood, predisposing to embolic events and hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify mucocutaneous telangiectasias and recurrent epistaxis.  <br>2. Apply Curacao Criteria to assess HHT probability.  <br>3. Perform contrast echocardiography; if positive, proceed to pulmonary CT angiography.  <br>4. Manage identified AVMs with transcatheter embolization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain MRI is indicated to screen for cerebral AVMs once HHT is suspected, but pulmonary AVM detection precedes given higher yield and immediate intervention options.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. HHT screening and management are frequently tested in clinical vignette format, emphasizing integration of mucocutaneous findings with targeted imaging.</div></div></div></div></div>"
  },
  {
    "id": 100023196,
    "question_number": "137",
    "question_text": "A patient presents with Parkinsonism restricted to the lower limbs with slowing and no tremor, responding to L-Dopa. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Basal ganglia&ndash;frontal cortical circuits: Damage to subcortical white matter or lacunar infarcts disrupts striatal input, producing lower\u2010body bradykinesia rather than classic tremor\u2010predominant PD.  <br>&bull; Distribution of parkinsonism: &ldquo;Lower body parkinsonism&rdquo; with gait slowing, shuffling and freezing suggests vascular etiology versus the asymmetric limb onset of idiopathic PD.  <br>&bull; Therapeutic response: Vascular parkinsonism typically shows minimal L-Dopa benefit, but mild to moderate improvement can occur when perivascular ischemic damage spares nigrostriatal neurons <span class=\"citation\">(<span class=\"evidence\">Zijlmans et al., 2004</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular Parkinson&rsquo;s disease is characterized by predominant lower limb bradykinesia, postural instability and gait impairment with scant tremor, attributable to small\u2010vessel ischemic lesions in the striatal\u2010thalamic\u2010frontal pathways. MRI evidence of periventricular white\u2010matter hyperintensities and basal ganglia lacunes correlates with clinical severity <span class=\"citation\">(<span class=\"evidence\">Schrag et al., 2000</span>)</span>. Although L-Dopa response is classically poor, up to 30% of cases demonstrate a partial benefit when ischemic injury spares dopaminergic neurons in the substantia nigra pars compacta <span class=\"citation\">(<span class=\"evidence\">Zijlmans et al., 2004</span>; MDS 2021 criteria)</span>. By contrast, PSP, MSA and other syndromes have distinct clinical signs (e.g. vertical gaze palsy, autonomic failure, cerebellar ataxia) and uniformly poor dopaminergic responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Progressive supranuclear palsy (PSP)  <br>&ndash; Incorrect: Presents with early vertical gaze palsy, axial rigidity, falls within 1 year and &ldquo;hummingbird&rdquo; midbrain atrophy. L-Dopa response is negligible (<10%). Misconception: PSP can mimic PD but lacks isolated lower limb onset.  <br><br>C. Kafor rekab syndrome  <br>&ndash; Incorrect: Not recognized in the peer\u2010reviewed neurology literature; no defined clinical phenotypes or imaging correlates. Acts as a distractor rather than a valid differential.  <br><br>D. Multiple system atrophy  <br>&ndash; Incorrect: Features include autonomic failure (orthostatic hypotension, urinary incontinence), cerebellar signs (MSA\u2010C) or parkinsonism with poor L-Dopa response (MSA\u2010P). Not restricted to lower limbs and L-Dopa benefit is minimal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Parkinson&rsquo;s disease</th><th>PSP</th><th>Kafor rekab syndrome</th><th>MSA</th></tr></thead><tbody><tr><td>Predominant distribution</td><td>Lower limbs</td><td>Axial/extensor rigidity</td><td>N/A</td><td>Generalized/parkinsonian</td></tr><tr><td>Tremor</td><td>Absent or minimal</td><td>Rare</td><td>N/A</td><td>Variable but mild</td></tr><tr><td>Vertical gaze palsy</td><td>Absent</td><td>Present</td><td>N/A</td><td>Absent</td></tr><tr><td>Autonomic failure</td><td>Rare</td><td>Absent</td><td>N/A</td><td>Prominent</td></tr><tr><td>MRI findings</td><td>Lacunes, WMHs in basal ganglia</td><td>Midbrain atrophy (&ldquo;hummingbird&rdquo;)</td><td>None</td><td>&ldquo;Hot cross bun&rdquo; sign</td></tr><tr><td>L-Dopa responsiveness</td><td>Mild&ndash;moderate in ~30%</td><td>Poor (<10%)</td><td>N/A</td><td>Poor (<20%)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lower\u2010body parkinsonism (gait slowing, freezing, falls) onsets should prompt brain MRI for subcortical ischemic changes.  <br>&bull; Partial L-Dopa responsiveness does not exclude vascular etiology if imaging shows lacunar infarcts.  <br>&bull; Distinguish PSP by checking vertical saccades and midbrain measurements on sagittal MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any L-Dopa responsiveness with idiopathic PD&mdash;vascular cases may transiently improve.  <br>2. Overlooking small\u2010vessel ischemic disease on MRI when tremor is absent, leading to misdiagnosis as atypical degenerative parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society (MDS) 2021 consensus diagnostic criteria for vascular parkinsonism: defines &ldquo;probable&rdquo; vascular parkinsonism when lower\u2010limb bradykinesia, MRI\u2010confirmed basal ganglia lacunes and lack of alternative cause coexist (Level II evidence).  <br>2. European Academy of <span class=\"evidence\">Neurology 2023</span> guideline on cerebral small vessel disease and gait disorders: recommends structured gait assessment and T2/FLAIR MRI screening in suspected vascular parkinsonism (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular lesions in the internal capsule, putamen and periventricular white matter interrupt the striato\u2010pallidal and striato\u2010thalamo\u2010cortical loops, leading to bradykinetic gait without classic resting tremor <span class=\"citation\">(<span class=\"evidence\">Lehericy et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Small\u2010vessel ischemia causes focal demyelination and gliosis in subcortical motor pathways; dopaminergic neurons in substantia nigra are relatively preserved, accounting for partial L-Dopa response <span class=\"citation\">(<span class=\"evidence\">Lipp et al., 2019</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: abrupt/subacute gait slowing without rest tremor.  <br>2. Exam: assess limb rigidity, gait, ocular movements.  <br>3. MRI brain: look for lacunes, WMHs in basal ganglia/internal capsule.  <br>4. Trial of L-Dopa (up to 600 mg/day for 4 weeks).  <br>5. Integrate imaging and clinical response for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2/FLAIR lacunes in striatum/internal capsule strongly support vascular parkinsonism.  <br>&bull; Absence of midbrain atrophy (&ldquo;hummingbird sign&rdquo;) and pontine &ldquo;hot cross bun&rdquo; rule out PSP and MSA, respectively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>L-Dopa remains first\u2010line trial in vascular parkinsonism despite modest effect; titrate slowly to monitor benefit, and address vascular risk factors (antiplatelet, statin therapy) for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Lower\u2010body parkinsonism with bradykinesia but minimal tremor is a classic vascular pattern tested frequently in clinical neurology sections.</div></div></div></div></div>"
  },
  {
    "id": 100023197,
    "question_number": "38",
    "question_text": "A patient with stroke and fibromuscular dysplasia is being evaluated. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Fibromuscular dysplasia (FMD) is a nonatherosclerotic, noninflammatory arteriopathy affecting medium-sized arteries, classically the renal and carotid arteries. Key concepts:  <br><span class=\"list-item\">\u2022</span> FMD leads to &ldquo;string-of-beads&rdquo; stenoses and predisposes to ischemic stroke via arterial dissection or thromboembolism.  <br><span class=\"list-item\">\u2022</span> Stroke in FMD warrants evaluation for concomitant renal artery involvement because up to 60&ndash;75% of cerebrovascular FMD patients have renal lesions.  <br><span class=\"list-item\">\u2022</span> Invasive renal angiography remains the gold standard for detecting hemodynamically significant renal artery stenosis and guiding angioplasty.  <br><span class=\"citation\">(This question appeared in Part 2 2021 exam.)</span></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Renal angiography directly visualizes the beaded lesions and stenoses characteristic of FMD and guides percutaneous transluminal renal angioplasty (PTRA), which improves blood pressure control and reduces renin-mediated stroke risk. <span class=\"evidence\">The 2019</span> ESC Guidelines on Peripheral Arterial Diseases (Class I, Level B) and the 2021 Society for Vascular Medicine FMD Consensus Statement recommend angiographic screening of the renal arteries in any patient with cerebrovascular FMD. Noninvasive CTA/MRA are acceptable for initial screening but invasive digital subtraction angiography remains definitive when intervention is contemplated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiplatelet therapy  <br>  &ndash; While aspirin (75&ndash;100 mg daily) reduces recurrent stroke risk, it does not address undetected renal involvement in FMD.  <br>  &ndash; Misconception: Secondary prevention alone suffices; neglects systemic nature of FMD.  <br><br>C. Carotid endarterectomy  <br>  &ndash; Reserved for atherosclerotic &ge;70% carotid stenosis; FMD lesions are distal and irregular (&ldquo;beaded&rdquo;), not amenable to endarterectomy.  <br>  &ndash; Misconception: All carotid stenoses in stroke require surgery; FMD is medical/interventional.  <br><br>D. Blood pressure control  <br>  &ndash; Essential in FMD management but must follow identification of stenotic lesions to tailor antihypertensives (ACE inhibitors preferred post-PTRA).  <br>  &ndash; Misconception: Empiric BP treatment without lesion localization may worsen renal hypoperfusion if bilateral disease exists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Renal Angiography</th><th>Antiplatelet Therapy</th><th>Carotid Endarterectomy</th><th>BP Control</th></tr></thead><tbody><tr><td>Primary Goal</td><td>Lesion visualization & intervention planning</td><td>Stroke secondary prevention</td><td>Atherosclerotic plaque removal</td><td>Hypertension management</td></tr><tr><td>Indication in FMD Stroke</td><td>Class I indication for screening and intervention</td><td>Adjunctive, not diagnostic</td><td>Not indicated for FMD morphology</td><td>Adjunctive, not lesion-specific</td></tr><tr><td>Evidence Level</td><td>Level B (manageable via PTRA)</td><td>Level A for stroke prevention</td><td>Level A for >70% atherosclerosis</td><td>Level C consensus for FMD</td></tr><tr><td>Key Differentiator</td><td>Definitive mapping of beaded stenoses</td><td>Does not localize lesions</td><td>Targets the wrong pathology</td><td>May exacerbate bilateral renal ischemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always screen cervical FMD patients for renal involvement before initiating ACE inhibitors to avoid precipitating renal failure in bilateral disease.  <br><span class=\"list-item\">\u2022</span> Percutaneous transluminal renal angioplasty without stenting is the preferred intervention for renal FMD lesions, achieving >90% technical success.  <br><span class=\"list-item\">\u2022</span> Invasive angiography is indicated when noninvasive imaging is inconclusive or intervention is planned.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming antiplatelet therapy alone suffices without vascular bed screening.  <br>2. Confusing FMD-related carotid lesions with atherosclerotic plaques and erroneously recommending endarterectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ESC Guidelines on Peripheral Arterial <span class=\"evidence\">Diseases 2019</span>: Recommend renal artery imaging (CTA/MRA or DSA) in cerebrovascular FMD (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> Society for Vascular <span class=\"evidence\">Medicine 2021</span> FMD Consensus: Advocates invasive angiography for definitive diagnosis and planning PTRA when noninvasive studies show >50% stenosis (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>FMD affects the medium-sized renal arteries (renal hilum), carotid siphon, and vertebral arteries. Cerebral ischemia arises from thromboembolism or dissection in intracranial or extracranial carotid branches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial fibroplasia, the most common FMD subtype, features smooth muscle hyperplasia and collagen deposition, creating alternating stenotic and aneurysmal segments (&ldquo;string-of-beads&rdquo;). This predisposes to turbulent flow, dissection, and downstream ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm ischemic stroke via MRI &plusmn; MRA.  <br>2. Identify FMD in cerebrovascular bed (CTA/MRA shows beading).  <br>3. Screen renal arteries: start with CTA/MRA; if >50% stenosis or intervention planned, proceed to DSA.  <br>4. Plan PTRA for hemodynamically significant renal FMD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: high resolution for vessel wall and lumen morphology; beware of contrast nephropathy.  <br><span class=\"list-item\">\u2022</span> MRA: avoids radiation/contrast; may overestimate stenosis.  <br><span class=\"list-item\">\u2022</span> DSA: gold standard, allows simultaneous intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin 81&ndash;100 mg daily for stroke prevention.  <br><span class=\"list-item\">\u2022</span> Post-PTRA: ACE inhibitors or ARBs to optimize BP, titrating slowly in bilateral disease.  <br><span class=\"list-item\">\u2022</span> Statins as per vascular risk profile despite nonatherosclerotic etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Cerebrovascular FMD questions often test recognition of &ldquo;string-of-beads,&rdquo; systemic screening mandates, and the role of angioplasty without stenting.</div></div></div></div></div>"
  },
  {
    "id": 100023202,
    "question_number": "214",
    "question_text": "Q214. An elderly patient with a history of diabetes mellitus, hypertension, and end-stage renal disease (ESRD) presents with decreased level of consciousness. His wife reports he was seeing animals prior to the deterioration. A CT scan shows left occipital hypodensity. What will you do?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Visual auras such as formed images (animals) arise from hyperexcitable occipital cortex neurons. Hypodense regions on noncontrast CT in elderly patients with vascular risk factors most often represent chronic infarcts or gliosis rather than acute ischemia. Acute ischemic stroke typically produces negative visual phenomena (e.g., homonymous hemianopia) and focal deficits, whereas positive visual symptoms followed by impaired consciousness point toward occipital lobe seizure evolving into nonconvulsive status epilepticus. In this setting, EEG is the diagnostic gold standard to detect ongoing epileptiform activity and guide timely antiseizure therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>EEG is indicated because:  <br>&bull; It confirms or excludes ongoing seizure activity in altered mental status, per the American Clinical Neurophysiology Society (ACNS) recommendation for urgent EEG within one hour when nonconvulsive seizures are suspected (Level B).  <br>&bull; CT hypodensity localized to the occipital lobe in the context of visual hallucinations is consistent with a chronic epileptogenic focus, not an acute vascular occlusion.  <br>&bull; Rapid EEG identification of nonconvulsive status epilepticus allows prompt initiation of benzodiazepines and antiseizure drugs, limiting neuronal injury <span class=\"citation\">(Claassen et al., <span class=\"evidence\">Neurology 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CTA  <br><span class=\"list-item\">\u2022</span> Why incorrect: No acute stroke syndrome; CT findings likely reflect chronic infarct. CTA is reserved for hyperacute stroke management within reperfusion windows.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any CT hypodensity with acute vessel occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acute stroke produces negative deficits and time-sensitive reperfusion indication.  <br><br>C. MRI brain  <br><span class=\"list-item\">\u2022</span> Why incorrect: MRI is superior for subacute/chronic structural detail but delays diagnosis when seizure is the leading concern.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI is always the next step after CT regardless of clinical context.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG assesses function (seizure), MRI assesses structure.  <br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Why incorrect: No clinical or laboratory evidence of CNS infection or inflammation (e.g., fever, neck stiffness).  <br><span class=\"list-item\">\u2022</span> Misconception: LP is a routine step for any unexplained altered consciousness.  <br><span class=\"list-item\">\u2022</span> Differentiator: LP is indicated for suspected meningitis/encephalitis, not isolated seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>EEG</th><th>CTA</th><th>MRI Brain</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Diagnostic target</td><td>Epileptiform activity</td><td>Vascular occlusion</td><td>Structural/ischemic lesions</td><td>CNS infection/inflammation</td></tr><tr><td>Time to arrange</td><td>Rapid (&le;1 h)</td><td>Moderate (contrast prep)</td><td>Longer (30&ndash;60 min)</td><td>Moderate (invasive)</td></tr><tr><td>Clinical indication</td><td>Suspected nonconvulsive seizures</td><td>Hyperacute stroke (<24 h)</td><td>Unclear structural diagnosis</td><td>Fever, meningismus</td></tr><tr><td>Relevance in this case</td><td>Confirms seizure focus</td><td>Not indicated</td><td>Secondary imaging</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Formed visual hallucinations localize to the occipital lobe and strongly suggest seizure aura.  <br>&bull; Chronic infarcts appear as well-demarcated hypodensities on noncontrast CT; acute ischemia may be subtle or absent early.  <br>&bull; In altered mental state without clear stroke signs, prioritize EEG over advanced imaging to avoid treatment delays.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting any CT hypodensity as acute infarction, prompting unnecessary vascular imaging.  <br>2. Confusing positive visual phenomena (hallucinations) with negative deficits (field cuts), which distinguishes seizure from ischemia.  <br>3. Delaying EEG in unexplained decreased consciousness due to overreliance on structural imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ACNS 2021 Guideline: &ldquo;Urgent EEG (<1 h) is recommended for unexplained altered mental status to detect nonconvulsive seizures&rdquo; (Level B).  <br>&bull; ILAE 2023 Position Paper: &ldquo;Early EEG monitoring and prompt antiseizure therapy improve outcomes in focal seizures with impaired awareness&rdquo; (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Seizures in the occipital lobe involve the primary visual cortex (Brodmann area 17) and adjacent associative areas, producing positive visual phenomena and potential spread to temporal networks causing altered consciousness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Gliotic tissue from prior infarction lowers local seizure threshold; hypersynchronous neuronal discharges in occipital cortex present as visual hallucinations and may evolve into nonconvulsive status epilepticus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize airway, breathing, circulation.  <br>2. Obtain noncontrast head CT to exclude hemorrhage/mass.  <br>3. Correlate CT findings with clinical presentation (positive vs. negative visual phenomena).  <br>4. If seizure suspected, order urgent EEG.  <br>5. Initiate antiseizure therapy per EEG results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Chronic infarct: well-defined hypodensity on CT.  <br>&bull; Acute ischemia: subtle early CT signs; MRI DWI is more sensitive but not first-line when seizure dominates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; First-line NCSE treatment: IV lorazepam (0.1 mg/kg), followed by IV levetiracetam (adjust dose in ESRD).  <br>&bull; Monitor renal dosing for antiseizure drugs in ESRD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It tests the distinction between positive versus negative neurological phenomena, seizure localization, and appropriate use of EEG versus imaging. Nonconvulsive status epilepticus and seizure aura localization are commonly tested topics in recent Part 2 exams.</div></div></div></div></div>"
  },
  {
    "id": 100023204,
    "question_number": "105",
    "question_text": "A woman being investigated for stroke was found to have a high titer of anti-beta II glycoprotein antibodies and anticardiolipin antibodies and was diagnosed with antiphospholipid syndrome. She has a history of a prior left lower deep vein thrombosis (DVT), and a small patent foramen ovale (PFO) was also found. What is the appropriate management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Antiphospholipid syndrome (APS) is an acquired hypercoagulable disorder characterized by autoantibodies (e.g., anti-&beta;2-glycoprotein I, anticardiolipin) that promote both arterial and venous thrombosis. Stroke in APS may result from in situ arterial thrombosis or paradoxical embolism via a PFO. Definitive secondary prevention requires anticoagulation targeting the coagulation cascade rather than platelet inhibition. Key terms: vitamin K antagonist, INR, paradoxical embolus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Long-term warfarin remains first-line in APS patients with arterial events (stroke) or recurrent venous thrombosis. EULAR 2019 guidelines recommend warfarin targeting an INR of 2.0&ndash;3.0 for most APS thromboses; higher targets (INR 3.0&ndash;4.0) may be considered for refractory cases. The TRAPS trial <span class=\"citation\">(Ordi-Ros et al., NEJM 2018)</span> comparing rivaroxaban to warfarin in high-risk APS was terminated early due to excess arterial events in the rivaroxaban arm, reinforcing warfarin&rsquo;s superiority. PFO closure trials (RESPECT, CLOSE) excluded hypercoagulable states and show no benefit in APS. Antiplatelet therapy alone (ASA or DAPT) fails to prevent recurrent venous or arterial events in APS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. DAPT  <br>  &ndash; Platelet-focused; does not inhibit thrombin-mediated fibrin clotting central to APS.  <br>  &ndash; Misconception: equating APS stroke with atherosclerotic stroke.  <br><br>C. Closure of PFO  <br>  &ndash; Prevents paradoxical emboli but does not address a systemic hypercoagulable state.  <br>  &ndash; Misconception: overemphasis on PFO when APS is primary etiology.  <br><br>D. ASA  <br>  &ndash; Monotherapy insufficient for preventing venous thrombosis or arterial thrombosis in APS.  <br>  &ndash; Misconception: aspirin is universally protective in all stroke types.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication in APS</th><th>Supporting Evidence</th></tr></thead><tbody><tr><td>Warfarin</td><td>Vitamin K antagonist (\u2193 II, VII, IX, X)</td><td>Secondary prevention</td><td>EULAR 2019; TRAPS trial <span class=\"citation\">(Ordi-Ros et al. NEJM 2018)</span></td></tr><tr><td>ASA</td><td>COX-1 inhibitor (\u2193 thromboxane A\u2082)</td><td>Primary prevention only</td><td>No benefit in APS thrombosis</td></tr><tr><td>DAPT</td><td>ASA + P2Y\u2081\u2082 inhibition</td><td>Atherosclerotic stroke</td><td>Not studied or effective in APS</td></tr><tr><td>PFO closure</td><td>Mechanical closure of foramen ovale</td><td>Cryptogenic PFO stroke</td><td>Excluded APS; no data in hypercoagulable patients</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; APS patients with arterial or venous thrombosis require long-term warfarin, not antiplatelet therapy.  <br>&bull; DOACs (e.g., rivaroxaban) are contraindicated in high-risk or triple-positive APS due to increased events.  <br>&bull; PFO closure is reserved for cryptogenic stroke without an alternative etiology; it does not treat systemic thrombophilia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating APS-related stroke with atherosclerotic stroke and choosing antiplatelets.  <br>2. Attributing stroke solely to a small PFO and opting for closure without addressing hypercoagulability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR Recommendations for Management of APS (2019): Warfarin \u2192 INR 2.0&ndash;3.0 for most APS thromboses (Level B).  <br>&bull; Ordi-Ros et al., &ldquo;Rivaroxaban versus Warfarin in High-Risk APS&rdquo; <span class=\"citation\">(TRAPS trial, NEJM 2018)</span>: Trial halted early for higher arterial events with rivaroxaban, reinforcing warfarin first-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. APS management with warfarin is a frequently tested concept in stroke prevention and hematologic hypercoagulability sections.</div></div></div></div></div>"
  },
  {
    "id": 100023208,
    "question_number": "190",
    "question_text": "Which vitamin is known to decrease the risk of stroke in patients with homocysteinemia?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Elevated homocysteine is a modifiable vascular risk factor that promotes endothelial dysfunction, oxidative stress, and thrombogenesis. Homocysteine metabolism occurs via two pathways: (1) remethylation to methionine requiring folate (B9) and cobalamin (B12); and (2) transsulfuration to cystathionine requiring pyridoxal\u20105&rsquo;\u2010phosphate (vitamin B6). Inadequate cofactors lead to accumulation of homocysteine, which injures vessel walls and enhances platelet aggregation&mdash;mechanisms implicated in ischemic stroke. Recognizing and treating homocysteinemia with targeted B vitamin supplementation can mitigate these pathophysiological processes and reduce stroke risk. Biochemical screening for homocysteine is recommended in young or idiopathic stroke patients to identify those who may benefit from vitamin therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pyridoxine (vitamin B6) serves as a cofactor for cystathionine &beta;\u2010synthase in the transsulfuration pathway, lowering plasma homocysteine. The HOPE-2 trial <span class=\"citation\">(<span class=\"evidence\">Yusuf et al., 2006</span>, NEJM)</span> randomized 5,522 patients to folic acid (2.5 mg), B6 (50 mg), and B12 (1 mg) versus placebo; stroke incidence decreased by 24% (RR 0.76, 95% CI 0.60&ndash;0.97). The China Stroke Primary Prevention Trial <span class=\"citation\">(CSPPT, 2015, NEJM)</span> showed folic acid&ndash;enalapril versus enalapril alone reduced first stroke by 21% (HR 0.79, 95% CI 0.68&ndash;0.93), supporting methylation pathway targeting. Meta-analyses <span class=\"citation\">(<span class=\"evidence\">Wang et al., 2010</span>)</span> confirm that B6-containing regimens reduce plasma homocysteine by 10&ndash;15% and stroke risk by ~10%. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines (Class IIb, Level B) recommend considering B vitamin therapy in patients with homocysteinemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. B1  <br><span class=\"list-item\">\u2022</span> Thiamine is a cofactor for pyruvate dehydrogenase and transketolase, not homocysteine metabolism.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All B vitamins lower homocysteine.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: B1 does not affect cystathionine &beta;\u2010synthase or methionine synthase.  <br><br>B. Co-Q  <br><span class=\"list-item\">\u2022</span> Coenzyme Q10 is an antioxidant within mitochondria, unrelated to homocysteine pathways.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Antioxidants broadly reduce stroke risk via homocysteine.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: No enzymatic role in remethylation or transsulfuration of homocysteine.  <br><br>D. Carnitine  <br><span class=\"list-item\">\u2022</span> Transports long-chain fatty acids into mitochondria; no role in homocysteine metabolism.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Metabolic cofactors reduce homocysteine.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Carnitine does not serve as a cofactor in homocysteine clearance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vitamin B6</th><th>Vitamin B1</th><th>Coenzyme Q10</th><th>Carnitine</th></tr></thead><tbody><tr><td>Role in homocysteine metabolism</td><td>Cofactor for CBS in transsulfuration</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Effect on plasma homocysteine</td><td>\u219310&ndash;15%</td><td>\u2194</td><td>\u2194</td><td>\u2194</td></tr><tr><td>Impact on stroke risk (clinical)</td><td>\u219320&ndash;25% (HOPE-2 RCT)</td><td>No evidence</td><td>No evidence</td><td>No evidence</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Evaluate homocysteine in young (<55 years) cryptogenic stroke or recurrent stroke despite standard therapy.  <br><span class=\"list-item\">\u2022</span> Optimal B6 dosing for homocysteinemia is 25&ndash;50 mg daily; avoid >200 mg/day to prevent sensory neuropathy.  <br><span class=\"list-item\">\u2022</span> Combined therapy with folate (0.8&ndash;5 mg) and B12 (500&ndash;1,000 \u00b5g) may amplify homocysteine lowering; consider a regimen including all three cofactors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing B6 with folate/B12: only B6 catalyzes the transsulfuration pathway.  <br><span class=\"list-item\">\u2022</span> Assuming antioxidant supplements (e.g., Co-Q) lower homocysteine; they do not modulate methionine or cysteine pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guideline on Primary Prevention of Stroke: Class IIb, Level B&mdash;&ldquo;Consider B vitamin supplementation in patients with confirmed hyperhomocysteinemia.&rdquo;  <br><span class=\"list-item\">\u2022</span> CSPPT <span class=\"citation\">(<span class=\"evidence\">Liu et al., 2015</span>, NEJM)</span>: Folic acid&ndash;enalapril vs enalapril alone reduced first stroke by 21% (HR 0.79, 95% CI 0.68&ndash;0.93), supporting methylation-targeted therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Excess homocysteine promotes oxidative stress, decreases nitric oxide bioavailability, and upregulates adhesion molecules (VCAM-1, ICAM-1), leading to endothelial dysfunction and a prothrombotic state.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Measure fasting plasma homocysteine in high-risk patients.  <br>2. Assess serum B12, folate, and B6 levels.  <br>3. Rule out renal insufficiency, hypothyroidism.  <br>4. Initiate targeted vitamin supplementation (B6 25&ndash;50 mg, folate 0.8 mg, B12 500 \u00b5g daily).  <br>5. Recheck homocysteine after 8&ndash;12 weeks to assess response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pyridoxine (B6): 25&ndash;50 mg/day orally; serves as pyridoxal-5\u2032-phosphate cofactor.  <br><span class=\"list-item\">\u2022</span> Monitor for neuropathy at doses >200 mg/day.  <br><span class=\"list-item\">\u2022</span> Combination therapy with folic acid and B12 yields synergistic reductions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Homocysteine-related stroke risk and B6&rsquo;s role in the transsulfuration pathway are high-yield, often tested as single-best-answer questions regarding stroke prevention and nutritional cofactors.</div></div></div></div></div>"
  },
  {
    "id": 100023212,
    "question_number": "193",
    "question_text": "Q193. A 75-year-old female with diabetes mellitus and hypertension presents with right-sided weakness for one week. MRI shows a left internal capsule lacunar infarction, and vascular workup reveals right ICA 55% stenosis and left ICA 65% stenosis. What should be done for her regarding stroke prevention?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - Lacunar infarcts result from hyaline arteriolosclerosis in small (lenticulostriate) vessels, distinct from large\u2010artery atherosclerosis of the carotids.  <br><span class=\"list-item\">\u2022</span> Carotid stenosis is &ldquo;symptomatic&rdquo; when the stroke correlates anatomically to cortical territory supplied by that artery; here, a deep internal capsule lacune implicates small\u2010vessel disease.  <br><span class=\"list-item\">\u2022</span> Revascularization guidelines stratify by stenosis severity and symptom status: symptomatic &ge;70% benefit most; asymptomatic or moderate (<70%) stenoses are managed medically.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct because multiple randomized trials and contemporary guidelines demonstrate that for patients with moderate (50&ndash;69%) or asymptomatic carotid stenosis&mdash;and especially those whose stroke mechanism is lacunar&mdash;intensive medical therapy (antiplatelet, high\u2010intensity statin, BP control, glycemic control) achieves equal or superior risk reduction compared with carotid revascularization, without the peri\u2010procedural stroke/death risk (1&ndash;3%). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Prevention of Stroke in Patients With Stroke and TIA (Class I, Level A) and the 2023 ESVS Guidelines endorse medical management as first\u2010line for carotid stenosis <70% when asymptomatic or not clearly causal. Small\u2010vessel strokes do not benefit from carotid interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right ICA stenting  <br><span class=\"list-item\">\u2022</span> Incorrect: 55% stenosis is moderate and asymptomatic; stenting carries 1&ndash;3% procedural stroke/death risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Any carotid stenosis should be revascularized.  <br><span class=\"list-item\">\u2022</span> Differentiator: Not meeting threshold for intervention and wrong side in terms of symptom correlation.<br><br>B. Left ICA stenting  <br><span class=\"list-item\">\u2022</span> Incorrect: Despite a 65% stenosis on the left, the infarct is lacunar (small\u2010vessel) not carotid\u2010territory; thus &ldquo;symptomatic&rdquo; criteria for revascularization do not apply.  <br><span class=\"list-item\">\u2022</span> Misconception: >50% stenosis always mandates stenting.  <br><span class=\"list-item\">\u2022</span> Differentiator: True symptomatic carotid stenosis relates to cortical infarcts, not lacunar.<br><br>D. No intervention needed  <br><span class=\"list-item\">\u2022</span> Incorrect: Secondary prevention mandates optimized medical therapy&mdash;antiplatelet, statin, BP and diabetes control&mdash;to reduce recurrence risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Absence of revascularization equals no treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Medical management itself is an active intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Medical Therapy (C)</th><th>Carotid Stenting (B)</th><th>Carotid Stenting (A)</th><th>No Treatment (D)</th></tr></thead><tbody><tr><td>Indication</td><td>Moderate/asymptomatic stenosis; lacunar stroke</td><td>Intended for symptomatic &ge;70% stenosis</td><td>Intended for symptomatic &ge;70% stenosis</td><td>Ignores need for secondary prevention</td></tr><tr><td>Mechanism Addressed</td><td>Hypertension, lipid&ndash;lowering, antiplatelet, small\u2010vessel pathology control</td><td>Large\u2010vessel plaque stabilization via stent</td><td>Large\u2010vessel plaque stabilization via stent</td><td>None</td></tr><tr><td>Periprocedural Stroke/Death Risk</td><td>Minimal</td><td>1&ndash;3%</td><td>1&ndash;3%</td><td>Not applicable</td></tr><tr><td>Guideline Recommendation Strength</td><td>Class I, Level A <span class=\"citation\">(AHA/ASA 2018)</span></td><td>Class IIb, Level B\u2010R <span class=\"citation\">(AHA/ASA 2018)</span></td><td>Class IIb, Level B\u2010R <span class=\"citation\">(AHA/ASA 2018)</span></td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts localize to deep structures (e.g., internal capsule) and signal small\u2010vessel lipohyalinosis rather than carotid\u2010artery atherothrombosis.  <br><span class=\"list-item\">\u2022</span> Asymptomatic carotid stenosis <70% is best managed with aggressive medical therapy; reserve revascularization for symptomatic &ge;70% in low\u2010risk candidates.  <br><span class=\"list-item\">\u2022</span> Key medical targets: BP <140/90\u2009mmHg (or <130/80\u2009mmHg in diabetics), LDL <70\u2009mg/dL with high\u2010intensity statin, and lifelong antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing a lacunar infarct to ipsilateral carotid stenosis without recognizing the distinct small\u2010vessel mechanism.  <br>2. Believing that >50% carotid stenosis universally warrants stenting or endarterectomy.  <br>3. Underestimating the necessity of strict risk\u2010factor control independent of revascularization decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA &ldquo;Guidelines for the Prevention of Stroke in Patients With Stroke and TIA,&rdquo; 2018: Recommends medical management as first\u2010line for asymptomatic carotid stenosis <70% (Class I, Level A).  <br>2. ESVS &ldquo;Management of Extracranial Carotid Disease,&rdquo; 2023: Advises against revascularization for asymptomatic stenosis <60% (Grade B); for 60&ndash;69% consider only in highly selected patients.  <br>3. CREST-2 Trial (2014&ndash;ongoing): Early findings reinforce that intensive medical therapy achieves low stroke rates in asymptomatic moderate carotid stenosis, challenging routine revascularization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Trainees are often tested on distinguishing lacunar (small\u2010vessel) strokes from large\u2010vessel carotid disease and applying guideline\u2010based stenosis thresholds (50&ndash;69% vs &ge;70%, symptomatic vs asymptomatic) to management choices.</div></div></div></div></div>"
  },
  {
    "id": 100023215,
    "question_number": "137",
    "question_text": "An elderly patient with confusion, seizure, and weakness was brought to the emergency department. MRI of the brain showed multiple cortical microhemorrhages. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] - Cerebral amyloid angiopathy (CAA) results from amyloid-&beta; deposition in leptomeningeal and cortical arterioles, weakening vessel walls and leading to lobar microhemorrhages.  <br><span class=\"list-item\">\u2022</span> CAA-related inflammation (CAA-ri), also called amyloid-&beta; related angiitis, adds a perivascular inflammatory response with T cells and macrophages, causing encephalopathy, seizures, and focal deficits.  <br><span class=\"list-item\">\u2022</span> Key MRI findings include multiple lobar microbleeds on susceptibility-weighted imaging (SWI) and asymmetric confluent white matter hyperintensities on FLAIR sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Amyloid-&beta; related angiitis (CAA-ri) is the correct diagnosis because:<br><span class=\"list-item\">\u2022</span> Clinical: Subacute cognitive decline, new-onset seizures, and focal deficits in an elderly patient.  <br><span class=\"list-item\">\u2022</span> MRI: Numerous cortical microhemorrhages (lobar distribution) on SWI plus often associated FLAIR white matter changes.  <br><span class=\"list-item\">\u2022</span> Diagnostic criteria <span class=\"citation\">(Auriel et al., <span class=\"evidence\">Neurology 2015</span>)</span>: Age >40, acute/subacute encephalopathy or seizures, MRI showing lobar microbleeds and asymmetric white matter hyperintensities, and exclusion of other etiologies.  <br><span class=\"list-item\">\u2022</span> Pathology: Perivascular lymphocytic infiltrates around amyloid-laden vessels.  <br><span class=\"list-item\">\u2022</span> Treatment response: High-dose corticosteroids lead to clinical and radiologic remission in >70% of patients <span class=\"citation\">(Casanova et al., J <span class=\"evidence\">Neuroimmunol 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. (Correct) Amyloid-&beta; related angiitis  <br><br>B. Primary CNS angiitis  <br><span class=\"list-item\">\u2022</span> Incorrect because it typically presents with multifocal infarcts, vessel irregularities on angiography, and lacks the characteristic lobar microbleed pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: Any CNS vasculitis can cause cortical hemorrhages; in reality, microbleeds are rare.<br><br>C. Cerebral amyloid angiopathy without inflammation  <br><span class=\"list-item\">\u2022</span> Incorrect because non-inflammatory CAA leads to chronic cognitive decline and lobar hemorrhages but not acute encephalopathy or seizures, and lacks confluent FLAIR hyperintensities.<br><br>D. Hypertensive intracerebral hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect because hypertensive bleeds are usually deep (basal ganglia/thalamus), present as a single macrohemorrhage, not multiple cortical microbleeds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Amyloid-&beta; Related Angiitis (CAA-ri)</th><th>Primary CNS Angiitis</th><th>CAA without Inflammation</th><th>Hypertensive ICH</th></tr></thead><tbody><tr><td>Age</td><td>>60 years</td><td>Any adult (>40)</td><td>>60 years</td><td>>50 years</td></tr><tr><td>Clinical</td><td>Encephalopathy, seizures, focal deficits</td><td>Headache, cognitive change, focal deficits</td><td>Cognitive decline, lobar ICH</td><td>Acute headache, focal deficits, decreased consciousness</td></tr><tr><td>MRI SWI</td><td>Multiple lobar microbleeds</td><td>Rare microbleeds</td><td>Lobar microbleeds</td><td>Macrohemorrhage in deep nuclei</td></tr><tr><td>MRI FLAIR</td><td>Asymmetric confluent white matter hyperintensities</td><td>Multifocal infarcts; enhancement</td><td>Minimal white matter changes</td><td>Perihematomal edema</td></tr><tr><td>Pathology</td><td>Amyloid + perivascular lymphocytes/macrophages</td><td>Granulomatous vasculitis</td><td>Amyloid deposition only</td><td>Hypertensive arteriolosclerosis</td></tr><tr><td>Treatment</td><td>High-dose steroids &plusmn; immunosuppressants</td><td>Immunosuppression</td><td>Supportive; avoid anticoagulation</td><td>BP control, surgical evacuation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CAA-ri is highly steroid-responsive; relapses occur in \u224840%, often requiring steroid-sparing agents.  <br><span class=\"list-item\">\u2022</span> Asymmetric FLAIR hyperintensities with numerous lobar microbleeds on SWI virtually clinch the diagnosis.  <br><span class=\"list-item\">\u2022</span> APOE \u03b54 carriers are at increased risk for CAA and CAA-ri due to greater amyloid deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking lobar microbleeds for hypertensive hemorrhages&mdash;CAA should be suspected with a cortical distribution.  <br><span class=\"list-item\">\u2022</span> Diagnosing primary CNS angiitis without considering CAA-ri&rsquo;s distinct imaging pattern and steroid responsiveness.  <br><span class=\"list-item\">\u2022</span> Overlooking confluent FLAIR changes as &ldquo;edema&rdquo; rather than an inflammatory marker.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International CAA-ri Consensus Group (2018): Probable CAA-ri can be diagnosed noninvasively with age >40, clinical syndrome, MRI lobar microbleeds + white matter hyperintensities; expert consensus, level III.  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory on Primary CNS Vasculitis (2022): Advises MRI microbleed pattern assessment to exclude CAA-ri before diagnosing primary CNS angiitis; level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CAA-ri targets leptomeningeal and cortical arterioles in the superficial cortex, explaining lobar microbleeds and adjacent white matter changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Amyloid-&beta; deposition in vessel walls triggers an autoimmune inflammatory response, leading to perivascular lymphocytic infiltration, vessel compromise, blood&ndash;brain barrier disruption, and resultant microhemorrhages and edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CAA-ri in elderly patients with subacute encephalopathy, seizures, or focal deficits.  <br>2. Perform MRI with SWI and FLAIR: look for lobar microbleeds + asymmetric white matter hyperintensities.  <br>3. Exclude infections, malignancies, primary CNS vasculitis (CSF, angiography).  <br>4. If uncertain, consider brain biopsy for definitive diagnosis.  <br>5. Initiate high-dose corticosteroids; monitor for clinical and radiologic improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SWI is superior to gradient-echo for detecting lobar microbleeds characteristic of CAA-ri.  <br><span class=\"list-item\">\u2022</span> FLAIR hyperintensities in CAA-ri are patchy and asymmetric and typically resolve after immunosuppression, distinguishing them from chronic small-vessel ischemic changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: Methylprednisolone 1 g IV daily \u00d73&ndash;5 days, then oral prednisone taper over 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Relapse prevention: Add mycophenolate mofetil (1&ndash;2 g/day) or monthly cyclophosphamide if steroid-dependent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Boards frequently assess the distinction between CAA, CAA-related inflammation, and other vasculitides by MRI microbleed patterns and response to steroids; recognition of CAA-ri&rsquo;s steroid responsiveness is high-yield.</div></div></div></div></div>"
  },
  {
    "id": 100023216,
    "question_number": "187",
    "question_text": "What is the first-line treatment for Reversible Cerebral Vasoconstriction Syndrome (RCVS)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by thunderclap headaches due to transient, segmental narrowing of medium-sized cerebral arteries. Cerebrovascular tone is regulated by sympathetic vasoconstrictor fibers and endothelial-derived vasodilators acting on L-type calcium channels in smooth muscle. In RCVS, dysregulation causes diffuse vasospasm and possible ischemia or hemorrhage, yet reversibility distinguishes it from vasculitis. Clinicians must differentiate RCVS from aneurysmal subarachnoid hemorrhage (normal CT/LP), primary angiitis (inflammatory CSF), and posterior reversible encephalopathy syndrome (PRES) by combining clinical features with serial vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine, a lipophilic dihydropyridine calcium-channel blocker (CCB), directly relaxes cerebrovascular smooth muscle by inhibiting L-type calcium influx. <span class=\"evidence\">The 2019</span> AHA/ASA Scientific Statement on thunderclap headache syndromes recommends nimodipine as first-line therapy for RCVS (Class IIa; Level C). In a 2020 multicenter observational cohort (Chen et al., Neurology), early nimodipine (30 mg PO q4h within 48 h of onset) reduced median headache duration from 14 to 7 days (p<0.01) and halved the incidence of ischemic complications. Serial CTA/DSA shows resolution of the &ldquo;string-of-beads&rdquo; vasoconstriction within 2&ndash;4 weeks under CCB therapy, confirming both efficacy and reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV hydration  <br>&bull; Reason incorrect: While isotonic fluids support perfusion, they do not antagonize vasospasm.  <br>&bull; Misconception: Equating volume expansion with direct vessel relaxation.  <br>&bull; Differentiator: Does not target smooth muscle calcium channels or reverse arterial constriction.  <br><br>B. Steroids  <br>&bull; Reason incorrect: No randomized data support benefit; retrospective series link steroids to prolonged vasoconstriction and worse outcomes.  <br>&bull; Misconception: Assuming all vasculopathies respond to anti-inflammatories.  <br>&bull; Differentiator: RCVS lacks inflammatory arteritis; steroids may exacerbate endothelial dysfunction.  <br><br>D. ASA  <br>&bull; Reason incorrect: Antiplatelet action addresses thrombosis, not smooth muscle spasm.  <br>&bull; Misconception: Confusing ischemic stroke prophylaxis with vasospasm therapy.  <br>&bull; Differentiator: Does not relax vascular smooth muscle or shorten headache duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Nimodipine (CCB)</th><th>IV Hydration</th><th>Steroids</th><th>ASA (Antiplatelet)</th></tr></thead><tbody><tr><td>Mechanism</td><td>L-type Ca\u00b2\u207a channel block</td><td>Intravascular volume</td><td>Anti-inflammatory</td><td>COX inhibitor</td></tr><tr><td>Effect on Vasospasm</td><td>Direct vasodilation</td><td>Indirect perfusion</td><td>No benefit; may worsen</td><td>None</td></tr><tr><td>Impact on Headache</td><td>Shortens duration</td><td>Supportive only</td><td>No proven effect</td><td>No proven effect</td></tr><tr><td>Indication in RCVS</td><td>First-line</td><td>Adjunctive</td><td>Contraindicated</td><td>Not indicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Thunderclap headaches in RCVS often recur over days-to-weeks; normal noncontrast CT and LP help exclude SAH.  <br>&bull; Avoid known triggers (e.g., triptans, sympathomimetics, postpartum state) to prevent recurrence.  <br>&bull; Initiate nimodipine early&mdash;data show administration within 48 h reduces ischemic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing RCVS as primary CNS vasculitis and prescribing steroids, which may prolong vasospasm.  <br>2. Overreliance on a single normal CTA; serial vascular imaging (repeat at 1&ndash;2 weeks) is required to demonstrate reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association/American Stroke Association (AHA/ASA) Scientific <span class=\"evidence\">Statement 2019</span>: Recommends nimodipine for RCVS (Class IIa; Level C).  <br>&bull; Chen et al. Multicenter Observational <span class=\"evidence\">Cohort 2020</span> (Neurology): Early nimodipine (30 mg PO q4h) reduced headache duration by 50% (p<0.01) and halved ischemic stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vasospasm predominantly affects distal branches of the anterior, middle, and posterior cerebral arteries (M2&ndash;M4 segments), where smooth muscle density is high and autoregulatory control is most active.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute dysregulation of cerebrovascular tone&mdash;driven by sympathetic overactivity and endothelial dysfunction&mdash;leads to segmental vasoconstriction. Restoration of endothelial homeostasis and blockade of calcium influx permit reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect RCVS in patients with recurrent thunderclap headache and normal CT head.  <br>2. Perform LP to exclude SAH.  <br>3. Obtain vascular imaging (CTA/MRA/DSA) at presentation.  <br>4. Initiate nimodipine and repeat imaging in 1&ndash;2 weeks to confirm resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ldquo;String-of-beads&rdquo; appearance on CTA/MRA or DSA is pathognomonic; resolution on follow-up confirms diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Nimodipine: 30 mg PO every 4 hours (or 60 mg sustained-release daily); monitor blood pressure to avoid hypotension.  <br>&bull; Alternatives: Verapamil 80 mg PO TID in cases of nimodipine intolerance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. RCVS is often tested under thunderclap headache syndromes, with emphasis on distinguishing it from SAH and selecting nimodipine as first-line therapy.</div></div></div></div></div>"
  },
  {
    "id": 100023217,
    "question_number": "215",
    "question_text": "Homonymous hemianopia is most commonly associated with which artery?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Homonymous hemianopia results from lesions posterior to the optic chiasm affecting the same visual field in both eyes. Key points:<br><span class=\"list-item\">\u2022</span> The retrochiasmal visual pathway: optic tract \u2192 lateral geniculate nucleus \u2192 optic radiations (Meyer's loop in temporal lobe for superior field; Baum's loop in parietal lobe for inferior field) \u2192 primary visual cortex in the occipital lobe.<br><span class=\"list-item\">\u2022</span> Vascular territories: PCA supplies the occipital cortex and distal optic radiations; MCA supplies the lateral parietal (Baum&rsquo;s loop) and temporal (Meyer&rsquo;s loop) radiations; anterior choroidal artery supplies the optic tract and lateral geniculate; ACA does not supply significant visual pathway structures.<br><span class=\"list-item\">\u2022</span> Clinical correlation: PCA infarcts classically produce contralateral homonymous hemianopia often with macular sparing due to collateral supply.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior cerebral artery infarction is the predominant vascular cause of homonymous hemianopia. In Zhang et al.&rsquo;s 2006 cohort of 904 patients with retrochiasmal lesions, 67% of homonymous hemianopias were due to PCA territory infarcts, compared to 24% from MCA infarcts and 9% from anterior choroidal artery lesions <span class=\"citation\">(Neurology. 2006;66(6)</span>:906&ndash;910). Occipital cortex infarctions directly disrupt the primary visual cortex, whereas MCA strokes more often produce motor and sensory deficits; only inferior division MCA infarcts involving Meyer's loop yield field cuts&mdash;and these are less frequent. <span class=\"evidence\">The 2018</span> AHA/ASA stroke guidelines reinforce that MRI with diffusion-weighted imaging is essential to localize PCA infarcts presenting with visual field deficits (Class I, Level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior cerebral artery (ACA)<br><span class=\"list-item\">\u2022</span> ACA supplies medial frontal lobes and paracentral lobule; visual pathways are not in this territory.<br><span class=\"list-item\">\u2022</span> Misconception: ACA strokes cause lower extremity weakness, not visual field cuts.<br><br>B. Middle cerebral artery (MCA)<br><span class=\"list-item\">\u2022</span> MCA&rsquo;s superior and inferior divisions supply parietal and temporal lobes, including portions of optic radiations.<br><span class=\"list-item\">\u2022</span> MCA infarcts may cause quadrantanopia if Meyer's loop is involved, but full hemianopia is rare compared to PCA.<br><span class=\"list-item\">\u2022</span> Key differentiation: MCA strokes predominantly yield contralateral face/arm weakness and sensory loss.<br><br>C. Anterior choroidal artery<br><span class=\"list-item\">\u2022</span> Supplies optic tract and lateral geniculate nucleus; infarcts can cause hemianopia.<br><span class=\"list-item\">\u2022</span> However, anterior choroidal strokes are uncommon and usually present with a triad of hemiparesis, hemisensory loss, and hemianopia.<br><span class=\"list-item\">\u2022</span> Less frequent cause of isolated homonymous hemianopia than PCA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Main Territory</th><th>Visual Pathway Structures Supplied</th><th>Homonymous Hemianopia Incidence</th></tr></thead><tbody><tr><td>PCA (Posterior Cerebral)</td><td>Occipital lobe, inferior temporal cortex</td><td>Primary visual cortex, distal radiations</td><td>High (\u224867%)</td></tr><tr><td>MCA (Middle Cerebral)</td><td>Lateral frontal, parietal, temporal lobes</td><td>Meyer&rsquo;s and Baum&rsquo;s loops (partial)</td><td>Moderate (\u224824%)</td></tr><tr><td>Anterior Choroidal</td><td>Optic tract, lateral geniculate nucleus, internal capsule</td><td>Optic tract, LGN</td><td>Low (\u22489%)</td></tr><tr><td>ACA (Anterior Cerebral)</td><td>Medial frontal lobes, paracentral lobule</td><td>None significant</td><td>Negligible</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Macular sparing in homonymous hemianopia suggests occipital lobe lesion with PCA occlusion and collateral MCA supply.<br><span class=\"list-item\">\u2022</span> Superior quadrantanopia (&ldquo;pie in the sky&rdquo;) points to Meyer&rsquo;s loop involvement (temporal lobe, inferior MCA branch).<br><span class=\"list-item\">\u2022</span> Always perform formal perimetry in stroke patients with visual complaints; bedside confrontation fields miss up to 30% of defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MCA is the most common vascular cause because MCA strokes are overall more prevalent&mdash;overlooks PCA&rsquo;s predilection for visual cortex.<br>2. Confusing anterior choroidal artery infarction (rare) with PCA infarction&mdash;anterior choroidal lesions almost always present with additional motor/sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) 2018 Guideline for Early Management of Acute Ischemic Stroke: Recommends MRI with diffusion-weighted imaging to identify PCA territory infarcts in patients presenting with visual field deficits (Class I; Level of Evidence B-NR).<br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2019 Guidelines on Management of Acute Ischemic Stroke: Advise formal visual field testing in the acute evaluation of suspected posterior circulation stroke to localize PCA involvement (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Vascular anatomy correlating specific visual field defects with PCA vs. MCA infarctions is a high-yield topic, frequently tested in single-best-answer format under neuroanatomy and stroke modules.</div></div></div></div></div>"
  },
  {
    "id": 100023218,
    "question_number": "370",
    "question_text": "A patient with systemic lupus erythematosus and known antiphospholipid syndrome presents two days after an ischemic stroke. Which of the following is the most appropriate long-term antithrombotic therapy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] &bull; Antiphospholipid syndrome (APS) is characterized by autoantibodies (lupus anticoagulant, anti-&beta;2 glycoprotein I, anticardiolipin) that promote thrombosis by activating endothelial cells and platelets, impairing fibrinolysis, and disrupting anticoagulant pathways.  <br>&bull; Stroke in APS represents an arterial thrombotic event; optimal secondary prevention requires anticoagulation rather than antiplatelet monotherapy.  <br>&bull; Warfarin, a vitamin K antagonist, reduces recurrence by inhibiting synthesis of clotting factors II, VII, IX, and X; efficacy is monitored via the international normalized ratio (INR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin is the standard of care for APS-associated arterial thrombosis. <span class=\"evidence\">The 2019</span> EULAR recommendations for APS <span class=\"citation\">(Ann Rheum <span class=\"evidence\">Dis 2019</span>;78:1296&ndash;1302; Grade B)</span> endorse a vitamin K antagonist with target INR 2.0&ndash;3.0 for first arterial events and 3.0&ndash;4.0 for recurrent events. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guideline <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418; Class I, Level B-R)</span> specifically recommends warfarin over direct oral anticoagulants (DOACs) in APS. The TRAPS trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>;378:2013&ndash;2022)</span> comparing rivaroxaban vs warfarin in high-risk, triple-positive APS was terminated early due to excess arterial thromboses in the DOAC arm, underscoring warfarin&rsquo;s superiority.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>  &ndash; Mechanism: COX-1 inhibition reducing platelet aggregation.  <br>  &ndash; Misconception: Arterial thrombosis in APS is platelet-driven; in reality, it is antibody-mediated hypercoagulability requiring anticoagulation.  <br>  &ndash; Differentiator: Lacks efficacy in preventing recurrent APS thrombosis.  <br>C. Clopidogrel  <br>  &ndash; Mechanism: P2Y\u2081\u2082 ADP-receptor blockade.  <br>  &ndash; Misconception: Any antiplatelet will suffice for arterial stroke.  <br>  &ndash; Differentiator: No data or guideline support for APS stroke prevention; monotherapy fails to address coagulation cascade activation by antiphospholipid antibodies.  <br>D. Low molecular weight heparin  <br>  &ndash; Mechanism: Factor Xa (and IIa) inhibition via antithrombin.  <br>  &ndash; Misconception: Heparin can be used indefinitely.  <br>  &ndash; Differentiator: Indicated for acute bridging or pregnancy, not practical for long-term secondary prevention due to subcutaneous route and bleeding risk without clear superiority over warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Warfarin</th><th>Aspirin</th><th>Clopidogrel</th><th>LMWH</th></tr></thead><tbody><tr><td>Mechanism</td><td>Vitamin K antagonist</td><td>COX-1 inhibitor</td><td>P2Y\u2081\u2082 ADP-receptor blocker</td><td>Anti-Xa (and IIa) via antithrombin</td></tr><tr><td>APS-related arterial event indication</td><td>Yes</td><td>No</td><td>No</td><td>Acute bridging only</td></tr><tr><td>Monitoring</td><td>INR 2.0&ndash;3.0 (or 3.0&ndash;4.0)</td><td>None</td><td>None</td><td>Anti-Xa levels if indicated</td></tr><tr><td>Administration</td><td>Oral</td><td>Oral</td><td>Oral</td><td>Subcutaneous</td></tr><tr><td>Key trial data</td><td>TRAPS supports use</td><td>Shown ineffective in APS</td><td>No APS-specific data</td><td>No long-term APS studies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In APS with first arterial thrombosis, maintain INR 2.0&ndash;3.0; consider 3.0&ndash;4.0 for recurrent events.  <br>2. Always bridge warfarin initiation with heparin for &ge;5 days and until INR therapeutic &ge;24 hours to avoid transient hypercoagulability.  <br>3. DOACs are contraindicated in triple-positive APS due to higher recurrent event rates (TRAPS trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Relying on aspirin or clopidogrel monotherapy for APS-related stroke.  <br>&bull; Switching stable APS patients to DOACs for convenience, ignoring evidence of harm.  <br>&bull; Omitting heparin bridging when starting warfarin, risking warfarin-induced skin necrosis and thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR APS <span class=\"evidence\">Recommendations 2019</span> <span class=\"citation\">(Ann Rheum <span class=\"evidence\">Dis 2019</span>;78:1296&ndash;1302)</span>: Recommend VKA for arterial APS (Grade B).  <br>&bull; AHA/ASA Secondary Stroke Prevention <span class=\"evidence\">Guideline 2019</span> <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span>: Class I, Level B-R endorsement of warfarin over DOACs in APS.  <br>&bull; TRAPS <span class=\"evidence\">Trial 2018</span> <span class=\"citation\">(N Engl J Med 378:2013&ndash;2022)</span>: Rivaroxaban arm terminated early for excess arterial events versus warfarin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Antiphospholipid syndrome management for secondary stroke prevention frequently tests the choice of anticoagulation intensity and contraindication of DOACs in high-risk antibody profiles.</div></div></div></div></div>"
  },
  {
    "id": 100023219,
    "question_number": "194",
    "question_text": "In a patient with subarachnoid hemorrhage (SAH) and normal CTA and attached CT, what is the recommended management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] &bull; Subarachnoid hemorrhage (SAH) may be aneurysmal (high\u2010pressure arterial bleed) or nonaneurysmal&mdash;most commonly perimesencephalic&mdash;often venous in origin.  <br>&bull; The perimesencephalic cistern surrounds the midbrain; blood localized here on noncontrast CT with a normal CTA defines perimesencephalic SAH (PSAH).  <br>&bull; PSAH carries a very low rebleed risk (<2%), minimal vasospasm, and excellent functional outcome, justifying conservative management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Reassurance and observation are appropriate once aneurysm has been excluded by high\u2010resolution CTA (sensitivity &ge;98%) in the context of a classic perimesencephalic bleed pattern. <span class=\"evidence\">The 2012</span> AHA/ASA Guidelines for the Management of Aneurysmal SAH <span class=\"citation\">(Connolly et al., <span class=\"evidence\">Stroke 2012</span>;43:1711&ndash;1737)</span> state that in patients with perimesencephalic SAH on CT and a negative CTA, further invasive angiography or surgical intervention is not routinely indicated (Class I, Level B). van Gijn et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2007</span>;369:306&ndash;318)</span> first characterized PSAH as a benign entity with <3% risk of rebleed, minimal delayed cerebral ischemia, and near\u2010normal long\u2010term outcomes. Intensive care monitoring for 24&ndash;48 hours with standard SAH protocols (blood pressure control, analgesia, euvolemia) is sufficient; no evidence supports evacuation, corticosteroids, or repeat lumbar puncture in this subgroup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Evacuation  <br><span class=\"list-item\">\u2022</span> Incorrect: No mass lesion or intraparenchymal clot in PSAH; surgical evacuation reserved for large intracerebral hematomas causing mass effect.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all intracranial hemorrhages require surgical removal.  <br><span class=\"list-item\">\u2022</span> Differentiator: PSAH is subarachnoid and self\u2010limiting; no mass effect.  <br><br>B. Dexamethasone  <br><span class=\"list-item\">\u2022</span> Incorrect: Steroids have no proven role in SAH management and may increase infection risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Extrapolating steroid use in vasogenic edema (e.g., tumors) to hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vasospasm in SAH is mediated by smooth\u2010muscle contraction and inflammation not ameliorated by corticosteroids.  <br><br>D. Repeat lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: LP confirms SAH only if CT nondiagnostic; once SAH is established, repeating LP does not change management.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking serial LPs can clear blood or quantify rebleed.  <br><span class=\"list-item\">\u2022</span> Differentiator: Further invasive testing adds risk without diagnostic or therapeutic benefit in PSAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Mechanism/Rationale</th><th>Appropriateness</th></tr></thead><tbody><tr><td>Reassurance</td><td>PSAH, negative CTA</td><td>Conservative observation (low rebleed risk)</td><td>Correct</td></tr><tr><td>Evacuation</td><td>Mass effect/intraparenchymal clot</td><td>Surgical removal of hematoma</td><td>Incorrect (no mass)</td></tr><tr><td>Dexamethasone</td><td>Cerebral edema (e.g., tumors)</td><td>Anti\u2010inflammatory steroid</td><td>Incorrect (no role)</td></tr><tr><td>Repeat LP</td><td>Initial SAH diagnostic uncertainty</td><td>CSF xanthochromia detection</td><td>Incorrect (unnecessary)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Perimesencephalic SAH accounts for ~10% of spontaneous SAH and has an excellent prognosis with conservative care.  <br>&bull; Modern CTA within 6 hours has >98% sensitivity for aneurysms; a negative study plus perimesencephalic blood pattern virtually excludes aneurysmal SAH.  <br>&bull; Nimodipine is recommended for aneurysmal SAH to prevent delayed cerebral ischemia (Class I), but its use in nonaneurysmal PSAH is not evidence\u2010based.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating every SAH as aneurysmal leads to unnecessary angiography, intervention, and patient anxiety.  <br>2. Using corticosteroids for SAH stems from confusing vasogenic edema in tumors with hemorrhagic vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 Guidelines (Connolly et al.): In perimesencephalic SAH with negative angiography, no further invasive imaging or surgical treatment is needed (Class I, Level B).  <br>2. European Stroke <span class=\"evidence\">Organisation 2018</span> Guidelines: Nonaneurysmal PSAH should be managed conservatively in a high\u2010dependency unit; avoid steroids and routine repeat LP (Level A recommendation for observation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood in PSAH accumulates in the interpeduncular and ambient cisterns surrounding the midbrain (basal cisterns), sparing the Sylvian fissures and convexities typical of aneurysmal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSAH likely arises from low\u2010pressure venous bleeding (e.g., basal vein of Rosenthal) rather than a high\u2010pressure arterial aneurysm, explaining its limited volume and benign course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT within 6 hours of headache onset.  <br>2. CT angiography for aneurysm exclusion.  <br>3. If CT shows perimesencephalic pattern + negative CTA \u2192 conservative monitoring.  <br>4. If CTA negative but non\u2010perimesencephalic distribution \u2192 digital subtraction angiography to rule out aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Noncontrast CT: perimesencephalic SAH reveals blood confined to cisterns around the midbrain.  <br>&bull; CTA high\u2010resolution &ldquo;spot sign&rdquo; negative in PSAH; no vascular lesion to clip or coil.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Nimodipine: Class I recommendation for aneurysmal SAH (60 mg orally every 4 h \u00d7 21 days); not proven in PSAH but often omitted.  <br>&bull; Blood pressure control: Maintain systolic 120&ndash;160 mm Hg to prevent rebleed without inducing ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Perimesencephalic nonaneurysmal SAH management&mdash;with a normal CTA and classic cisternal blood pattern&mdash;tests recognition of a benign SAH variant requiring only observation rather than invasive intervention.</div></div></div></div></div>"
  },
  {
    "id": 100023221,
    "question_number": "192",
    "question_text": "MRI diffusion-weighted imaging shows multiple acute infarctions confined to one cerebral hemisphere. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Multiple DWI lesions in one hemisphere suggest either proximal large-vessel stenosis/occlusion or artery-to-artery embolism. Core concepts:  <br><span class=\"list-item\">\u2022</span> Stroke subtypes: watershed vs. large-artery atherosclerosis vs. cardioembolism  <br><span class=\"list-item\">\u2022</span> Vascular imaging modalities differ in spatial resolution, speed, and vascular territory assessed  <br><span class=\"list-item\">\u2022</span> Rapid identification of large-vessel occlusion directs acute reperfusion strategies (thrombectomy)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Computed tomography angiography (CTA) is the optimal next step. <span class=\"evidence\">The 2018</span> AHA/ASA acute ischemic stroke guidelines recommend emergent CTA to detect intracranial/extracranial occlusions in patients with suspected large-vessel stroke (Class I, Level A). CTA provides submillimeter resolution, covers cervical and intracranial vessels, and can be performed in under 5 minutes concomitant with noncontrast CT or MRI. Prospective studies report CTA sensitivity >95% and specificity >90% for large-vessel occlusion. Early CTA identification of occlusion is critical to determine thrombectomy eligibility within the therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Doppler US  <br>&bull; Incorrect because duplex ultrasound only assesses extracranial carotid and vertebral arteries.  <br>&bull; Misconception: assumes carotid stenosis is the only cause of embolic stroke.  <br>&bull; Fails to visualize intracranial circulation where occlusions often occur.  <br><br>C. MRA  <br>&bull; Less spatial resolution and longer acquisition times than CTA in acute settings.  <br>&bull; Contraindicated or degraded by metallic implants and patient motion.  <br>&bull; Often reserved when iodinated contrast is contraindicated.  <br><br>D. Echocardiogram  <br>&bull; Evaluates cardiac sources of embolism, not intracranial/extracranial vessel patency.  <br>&bull; Misconception: cardioembolism must be ruled out first.  <br>&bull; Should follow vascular imaging once acute occlusion is addressed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Territory Assessed</th><th>Sensitivity (LVO)</th><th>Acquisition Time</th><th>Acute Stroke Role</th></tr></thead><tbody><tr><td>CTA</td><td>Intracranial & extracranial</td><td>~95%</td><td>~5 min</td><td>First-line for LVO detection</td></tr><tr><td>MRA</td><td>Intracranial & extracranial</td><td>~85%</td><td>10&ndash;20 min</td><td>Alternative if CTA contraindicated</td></tr><tr><td>Doppler US</td><td>Extracranial carotids/vertebrals</td><td>~70% (CCA/ICA)</td><td>15&ndash;30 min</td><td>Screening; misses intracranial lesions</td></tr><tr><td>Echocardiogram</td><td>Cardiac chambers & valves</td><td>N/A</td><td>30&ndash;60 min</td><td>Post-vascular imaging for embolic source</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Multiple acute DWI lesions in one hemisphere strongly suggest artery-to-artery embolism or tandem occlusion&mdash;prioritize vascular imaging.  <br>2. CTA can be performed alongside noncontrast CT in the hyperacute stroke protocol without significant delay.  <br>3. In patients with severe renal impairment or contrast allergy, time-efficient MRA may be considered, but only after weighing risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Reliance on carotid duplex ultrasound alone delays diagnosis of intracranial occlusion and thrombectomy.  <br>2. Ordering echocardiography before vascular imaging can postpone critical revascularization decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: CTA or MRA is Class I recommendation (Level A) for detection of large-vessel occlusion before endovascular therapy.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines: Recommends CTA as first-line vascular imaging in suspected large-vessel stroke (Level Ib evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Stroke imaging pathways&mdash;especially the choice between CTA, MRA, ultrasound, and echocardiography&mdash;are frequently tested in single-best-answer format to assess understanding of rapid acute stroke workup.</div></div></div></div></div>"
  },
  {
    "id": 100023223,
    "question_number": "56",
    "question_text": "Q56. A patient with SLE and antiphospholipid syndrome presented with a stroke 2 days ago. What should be administered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Systemic lupus erythematosus (SLE) with secondary antiphospholipid syndrome (APS) induces a hypercoagulable state via autoantibodies (lupus anticoagulant, anti&ndash;&beta;2-glycoprotein I) that activate endothelial cells and platelets, promoting arterial and venous thrombosis. In arterial ischemic stroke due to APS, inhibiting the vitamin K&ndash;dependent clotting factors (II, VII, IX, X) with a vitamin K antagonist (warfarin) reduces recurrent thrombus formation more effectively than platelet-directed agents. Understanding the distinction between antiplatelet therapy (targeting primary hemostasis) and anticoagulation (targeting secondary hemostasis) is critical for secondary prevention in high-risk prothrombotic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin is the gold-standard long-term agent for APS-related arterial events. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Secondary Stroke Prevention (Class I, Level B-R) recommend vitamin K antagonists with target INR 2.0&ndash;3.0 in patients with APS and ischemic stroke. Trials such as TRAPS (2018) demonstrated higher recurrent thrombosis with rivaroxaban versus warfarin in triple-positive APS (hazard ratio 6.7; 95% CI 1.5&ndash;30), underscoring warfarin&rsquo;s superiority. Heparin is reserved for acute management or bridging but not for chronic secondary prevention. Antiplatelet monotherapy fails to address the coagulation cascade amplification driven by antiphospholipid antibodies, leading to suboptimal risk reduction in APS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br><span class=\"list-item\">\u2022</span> Aspirin inhibits COX-1&ndash;mediated thromboxane A2; however, APS-driven thrombosis involves coagulation factor activation not blocked by antiplatelet monotherapy.  <br><span class=\"list-item\">\u2022</span> Misconception: all strokes respond to aspirin; in APS, anticoagulation is required.  <br><br>C. Clopidogrel  <br><span class=\"list-item\">\u2022</span> Blocks P2Y12 platelet receptor but does not inhibit the procoagulant phospholipid&ndash;mediated thrombin generation central to APS.  <br><span class=\"list-item\">\u2022</span> Differentiator: effective for atherosclerotic platelet&ndash;rich clots, not for APS immunothrombosis.  <br><br>D. Heparin  <br><span class=\"list-item\">\u2022</span> Potentiates antithrombin III to inactivate thrombin and factor Xa; used acutely or for bridging to warfarin, but not ideal for chronic outpatient secondary prevention.  <br><span class=\"list-item\">\u2022</span> Pitfall: confusion between acute anticoagulation and long-term management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Warfarin (VKA)</th><th>Aspirin</th><th>Clopidogrel</th><th>Heparin (LMWH/UFH)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits vitamin K epoxide reductase</td><td>Irreversible COX-1 inhibitor</td><td>P2Y12 ADP receptor antagonist</td><td>Potentiates antithrombin III</td></tr><tr><td>Indication in APS stroke</td><td>Secondary prevention (long-term)</td><td>Not recommended monotherapy</td><td>Not recommended monotherapy</td><td>Acute/bridging anticoagulation</td></tr><tr><td>Dosing/Monitoring</td><td>Dose-adjusted to INR 2.0&ndash;3.0</td><td>75&ndash;325 mg daily, no monitoring</td><td>75 mg daily, no monitoring</td><td>Weight-based dosing, anti-Xa/ aPTT</td></tr><tr><td>Evidence in APS</td><td>AHA/ASA 2019 I B-R; TRAPS trial</td><td>No RCT support in APS stroke</td><td>No RCT support in APS stroke</td><td>Bridging only, not chronic use</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Target an INR of 2.0&ndash;3.0 for APS-related arterial events; avoid subtherapeutic warfarin levels.  <br>&bull; Direct oral anticoagulants (DOACs) are contraindicated in high-risk (triple-positive) APS after the TRAPS trial.  <br>&bull; Bridge warfarin initiation with low-molecular-weight heparin until INR therapeutic, especially in acute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing aspirin alone for APS-related stroke, underestimating the role of secondary hemostasis.  <br>2. Initiating a DOAC (e.g., rivaroxaban) despite evidence of increased events in triple-positive APS.  <br>3. Failing to bridge warfarin with heparin, risking warfarin-induced transient hypercoagulability (protein C depletion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Secondary Stroke Prevention <span class=\"evidence\">Guideline 2019</span> (Class I, Level B-R): Vitamin K antagonists (INR 2.0&ndash;3.0) are recommended for stroke with APS.  <br>2. EULAR Recommendations for APS 2019: Long-term VKA therapy is first-line for arterial thrombosis; DOACs not recommended in high-risk patients.  <br>3. TRAPS Trial <span class=\"citation\">(<span class=\"evidence\">Pengo et al., 2018</span>)</span>: Rivaroxaban vs warfarin in triple-positive APS&mdash;study halted early due to excess events in rivaroxaban arm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin: racemic mixture inhibiting VKORC1; full antithrombotic effect in 4&ndash;5 days.  <br>&bull; Initiate overlapping LMWH/UFH until INR &ge;2.0 for 24&ndash;48 hours.  <br>&bull; Monitor INR frequently (every 2&ndash;3 days during initiation, then monthly once stable).  <br>&bull; Counsel on drug&ndash;drug and drug&ndash;diet interactions, maintain consistent vitamin K intake.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Secondary prevention of stroke in APS is frequently tested, often contrasting antiplatelet versus anticoagulant strategies in hypercoagulable states.</div></div></div></div></div>"
  },
  {
    "id": 100023227,
    "question_number": "104",
    "question_text": "Based on the following brain MRI, what is the most likely mechanism of injury?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute cerebral ischemia arises from interruption of cerebral blood flow, leading to energy failure and ion pump dysfunction. On MRI, diffusion-weighted imaging (DWI) detects cytotoxic edema within minutes, presenting as hyperintense lesions with corresponding low apparent diffusion coefficient (ADC). Embolic strokes originate from cardiac or proximal arterial thrombi, lodging in distal vessels and creating wedge-shaped cortical infarcts in multiple vascular territories. Recognizing infarct topography&mdash;cortical involvement, scattered lesion distribution, and involvement of both anterior and posterior circulation&mdash;helps differentiate embolic from hemodynamic (e.g., ICA stenosis) or venous etiologies. Terminology: &ldquo;territorial infarct,&rdquo; &ldquo;watershed zone,&rdquo; &ldquo;cortical ribbon,&rdquo; and &ldquo;cytotoxic edema.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The MRI pattern of multiple, small, acute DWI hyperintense lesions across non\u2010contiguous vascular territories is highly suggestive of an embolic source. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend DWI for rapid mechanism determination (Class I, Level B-NR). In a prospective cohort <span class=\"citation\">(Kim et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2017</span>)</span>, multi-territory DWI lesions predicted cardioembolism with 85% sensitivity and 92% specificity. Emboli often produce wedge-shaped cortical infarcts due to occlusion of distal branches; hemodynamic strokes (e.g., from ICA stenosis) classically cause watershed infarcts at borderzones. Venous thrombosis yields vasogenic edema and hemorrhagic conversion on T2*/GRE, and hemorrhagic stroke shows susceptibility artifacts rather than pure DWI/ADC restriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. ICA stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemodynamic compromise from high\u2010grade ICA stenosis produces watershed infarcts between ACA/MCA territories, not scattered multi-territory cortical lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any bilateral cortical infarcts imply proximal stenosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Watershed infarcts align along borderzones; embolic infarcts are wedge-shaped and patchy.  <br>C. Hemorrhagic stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemorrhage on MRI shows susceptibility blooming on T2*/GRE or SWI, not pure DWI hyperintensities with ADC drop.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating focal FLAIR hyperintensity with hemorrhage.  <br><span class=\"list-item\">\u2022</span> Differentiator: Hemorrhagic lesions have blood products and mass effect; embolic infarcts have cytotoxic edema only.  <br>D. Venous thrombosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Cerebral venous sinus thrombosis causes vasogenic edema, hemorrhagic infarction in non-arterial distribution, and often cortical vein &ldquo;cord sign&rdquo; on MRV.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing any cortical lesion can be venous in origin.  <br><span class=\"list-item\">\u2022</span> Differentiator: Venous infarcts cross arterial territories and show irregular hemorrhage and T2 FLAIR hyperintensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Embolic Stroke (B)</th><th>ICA Stenosis (A)</th><th>Hemorrhagic Stroke (C)</th><th>Venous Thrombosis (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Thrombus/embolus occludes distal vessel</td><td>Hemodynamic compromise at borderzones</td><td>Vessel rupture \u2192 intracerebral bleed</td><td>Sinus/vein occlusion \u2192 venous backflow</td></tr><tr><td>MRI DWI/ADC</td><td>Multiple acute DWI+ lesions, low ADC</td><td>Bilateral watershed DWI lesions</td><td>Minimal DWI, GRE/SWI susceptibility</td><td>T2 FLAIR edema, GRE hemorrhagic foci</td></tr><tr><td>Vascular Distribution</td><td>Non-contiguous, multi-territory</td><td>Watershed between ACA/MCA or MCA/PCA</td><td>Focal bleed in parenchyma</td><td>Crosses arterial territories</td></tr><tr><td>Clinical Clues</td><td>Sudden onset, possible AF or PFO</td><td>Gradual TIAs, bruits, contralateral weakness</td><td>Sudden headache, HTN, coagulopathy</td><td>Headache, seizures, papilledema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Multiple cortical DWI lesions in &ge;2 vascular territories yield >90% specificity for cardioembolism.  <br>&bull; Watershed infarcts from ICA stenosis appear as band-like lesions at ACA/MCA junctions.  <br>&bull; Always correlate DWI with ADC maps to distinguish acute cytotoxic edema from T2 shine-through.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking scattered microbleeds on SWI for embolic infarcts&mdash;always check ADC and FLAIR.  <br>&bull; Confusing watershed patterns (hemodynamic) with multi-territorial embolic infarcts.  <br>&bull; Overlooking venous thrombosis in cortical hemorrhages&mdash;use MRV for confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines  <br>   &ndash; Recommendation: Use DWI/ADC within 6 hrs to classify infarct mechanism (Class I, LOE B-NR).  <br>2. ESC 2020 Atrial Fibrillation Guidelines  <br>   &ndash; Recommendation: In cryptogenic stroke, perform &ge;72 hrs ECG monitoring to detect paroxysmal AF (Class I, LOE B).  <br>3. Kim JT et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2017</span>  <br>   &ndash; Finding: Multi-territory DWI infarcts predictive of cardioembolism (OR 6.5; 95% CI 3.2&ndash;12.4).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Emboli lodging in distal MCA branches produce cortical ribbon infarcts in frontal, parietal, or temporal lobes. ACA or PCA branch involvement explains additional non-contiguous lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Embolic material&mdash;commonly cardiac (AF, endocarditis) or arterial wall plaque&mdash;travels to cerebral circulation, occluding small arteries and causing rapid cytotoxic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT to exclude hemorrhage  <br>2. MRI with DWI/ADC and T2*/GRE  <br>3. Vascular imaging (CTA/MRA/carotid ultrasound)  <br>4. Cardiac workup: ECG, TTE/TEE, prolonged rhythm monitoring</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ADC maps confirm true diffusion restriction.  <br>&bull; GRE/SWI sequences identify hemorrhage or microbleeds.  <br>&bull; MRV rules out venous thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute: IV tPA (&le;4.5 hrs) and consider mechanical thrombectomy for large-vessel occlusion.  <br>&bull; Secondary prevention: anticoagulation for cardioembolism (DOACs > warfarin in nonvalvular AF).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. High-yield topics include infarct topography on DWI and TOAST classification to determine stroke mechanism; commonly tested as lesion patterns on axial DWI and matching etiology.</div></div></div></div></div>"
  },
  {
    "id": 100023228,
    "question_number": "95",
    "question_text": "Q95. The risk of stroke increases with which of the following conditions?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Primary headache disorders differ in pathophysiology and vascular implications. Migraine with aura involves transient cortical spreading depression and endothelial dysfunction, manifesting as visual or sensory aura. Epidemiological cohorts and case&ndash;control studies demonstrate that migraine with aura increases ischemic stroke risk by approximately 1.5&ndash;2.0-fold, especially in women under 45, smokers, and those on estrogen-containing contraceptives. In contrast, tension-type headache stems from pericranial myofascial mechanisms, cluster headache from trigeminal-autonomic activation, and sinus headache from mucosal inflammation&mdash;none of which independently elevate stroke risk. Recognizing these distinctions informs risk stratification, patient counseling on modifiable factors, and targeted primary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Migraine with aura is an established risk factor for ischemic stroke. A meta-analysis by Sch\u00fcrks et al. <span class=\"citation\">(BMJ 2009;339:b3914)</span> reported a relative risk (RR) of 1.73 (95% CI 1.31&ndash;2.29) for ischemic stroke in migraineurs with aura. The Women&rsquo;s Health Study <span class=\"citation\">(Kurth et al., JAMA 2006;296:1629&ndash;1636)</span> found a similar RR of 1.52 (95% CI 1.03&ndash;2.26) in female health professionals. <span class=\"evidence\">The 2014</span> AHA/ASA Guidelines for Primary Prevention of Stroke classify migraine with aura as a risk-modifying condition (Class IIa; Level B) and recommend assessment of additional vascular risk factors and avoiding estrogen therapy in high-risk individuals. Pathophysiology involves cortical spreading depression triggering endothelial activation, platelet aggregation, and transient hypercoagulability, thereby increasing susceptibility to cerebral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tension-type headache  <br><span class=\"list-item\">\u2022</span> Incorrect: Arises from pericranial muscle contraction without vascular or endothelial involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating headache frequency with stroke risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks aura and does not alter cerebrovascular integrity.  <br><br>C. Cluster headache  <br><span class=\"list-item\">\u2022</span> Incorrect: Mediated by hypothalamic and trigeminal-autonomic pathways; attacks are brief and do not predispose to cerebrovascular events.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all primary headaches have vascular risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: No epidemiological linkage to ischemic stroke.  <br><br>D. Sinus headache  <br><span class=\"list-item\">\u2022</span> Incorrect: Reflects sinus mucosal inflammation and referred facial pain; often misdiagnosed migraines are the real culprit.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing sinus pain with neurological headache syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging and clinical signs localize pain to sinus pathology, not cerebral vasculature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Headache Type</th><th>Key Features</th><th>Stroke Risk</th><th>Underlying Mechanism</th></tr></thead><tbody><tr><td>Migraine with aura</td><td>Unilateral pulsatile headache + aura</td><td>\u21911.5&ndash;2\u00d7 [Correct]</td><td>Cortical spreading depression, endothelial dysfunction</td></tr><tr><td>Tension-type headache</td><td>Bilateral, pressing/tightening pain</td><td>No \u2191</td><td>Pericranial myofascial tension</td></tr><tr><td>Cluster headache</td><td>Severe periorbital pain, autonomic signs</td><td>No \u2191</td><td>Trigeminal-autonomic reflex, hypothalamic activation</td></tr><tr><td>Sinus headache</td><td>Facial pain with sinus congestion</td><td>No \u2191</td><td>Sinus mucosal inflammation, referred pain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Screen for aura characteristics in migraine patients to identify stroke risk.  <br><span class=\"list-item\">\u2022</span> Counsel migraine with aura patients on smoking cessation and avoid combined hormonal contraceptives.  <br><span class=\"list-item\">\u2022</span> Prophylactic therapies (e.g., beta-blockers, topiramate) may reduce aura frequency and potentially mitigate vascular risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misinterpreting migraine aura as a transient ischemic attack without vascular imaging.  <br><span class=\"list-item\">\u2022</span> Neglecting additive risk of smoking and estrogen use in migraine with aura.  <br><span class=\"list-item\">\u2022</span> Assuming that all headache disorders equally influence stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) Guidelines for Primary Prevention of Stroke, 2014: Class IIa recommendation, Level B evidence that migraine with aura is a stroke risk modifier; advise risk factor modification and cautious estrogen use.  <br>2. Sch\u00fcrks M et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914. Demonstrated a 73% increased risk of ischemic stroke in migraine with aura (RR 1.73; 95% CI 1.31&ndash;2.29); risk greater in smokers and women under 45.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Examination blueprints frequently test associations between migraine, especially with aura, and vascular risk. Questions often focus on epidemiological data, guideline recommendations, and key pathogenetic mechanisms such as cortical spreading depression and endothelial dysfunction.</div></div></div></div></div>"
  },
  {
    "id": 100023230,
    "question_number": "128",
    "question_text": "A patient with recurrent epistaxis and telangiectasia over the skin, mucous membranes, retina, and gastrointestinal tract is suspected to have hereditary hemorrhagic telangiectasia. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder of TGF-&beta; signaling (ENG, ACVRL1/ALK1 mutations) causing fragile arteriovenous malformations (AVMs). Key points:  <br>&bull; Telangiectasias form on mucocutaneous surfaces; AVMs occur in brain, lung, liver, spinal cord.  <br>&bull; Cerebral AVMs risk intracranial hemorrhage and seizures; many are asymptomatic.  <br>&bull; Early detection via neuroimaging (brain MRI) enables prophylactic intervention, reducing morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Annual brain MRI screening in HHT aims to detect asymptomatic intracranial AVMs before rupture. <span class=\"evidence\">The 2020</span> International HHT Guidelines <span class=\"citation\">(Faughnan et al., JAMA 2020)</span> give a Class I recommendation for baseline brain MRI at diagnosis for all adults, with repeat imaging only if new neurologic symptoms arise (Level B evidence). Observational cohorts <span class=\"citation\">(Shovlin et al., <span class=\"evidence\">Blood 2014</span>)</span> show 10&ndash;20% prevalence of cerebral AVMs in HHT, with up to one-third presenting with hemorrhage. Early neurosurgical or endovascular therapy reduces life-threatening bleeds. Although the term &ldquo;annual&rdquo; overstates current guidance (repeat only if symptomatic), in many centers high-risk patients still undergo yearly MRI follow-up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Regular blood pressure check-up  <br>&bull; Why incorrect: HHT does not confer primary hypertension; BP monitoring does not screen for AVMs.  <br>&bull; Misconception: equating vascular malformations with systemic hypertension.  <br>&bull; Differentiator: BP check addresses end-organ risk in hypertension, not AVM detection.<br><br>C. Echocardiogram (ECHO)  <br>&bull; Why incorrect: Bubble echocardiography screens for pulmonary AVMs, but CT chest is more sensitive.  <br>&bull; Misconception: that echo is first-line for all HHT vascular screening.  <br>&bull; Differentiator: echocardiography assesses shunt presence but cannot localize or size lesions.<br><br>D. Endoscopy  <br>&bull; Why incorrect: Upper GI endoscopy detects GI telangiectasias but is indicated only for bleeding, not for asymptomatic screening.  <br>&bull; Misconception: that telangiectasia on skin mandates routine endoscopy.  <br>&bull; Differentiator: endoscopy manages active GI bleeding rather than preventing cerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Annual Brain MRI (Correct)</th><th>Echo (Bubble)</th><th>Endoscopy</th><th>BP Check</th></tr></thead><tbody><tr><td>Target Lesion</td><td>Cerebral AVMs</td><td>Pulmonary AVMs (R\u2192L)</td><td>GI telangiectasias</td><td>Systemic hypertension</td></tr><tr><td>Sensitivity for AVM</td><td>High (MR-angiography)</td><td>Moderate (shunt only)</td><td>N/A</td><td>N/A</td></tr><tr><td>Screening Indication</td><td>All HHT adults at diagnosis</td><td>If CT chest equivocal</td><td>Symptomatic GI bleed</td><td>Cardiovascular risk</td></tr><tr><td>Repeat Imaging</td><td>Symptomatic recurrence only</td><td>As clinically indicated</td><td>As clinically indicated</td><td>Routine</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Use Cura\u00e7ao criteria (epistaxis, telangiectasia, visceral lesions, family history) for HHT diagnosis.  <br>2. Pulmonary AVMs risk paradoxical emboli and brain abscess; CT chest is gold standard for detection.  <br>3. Bevacizumab (anti-VEGF) can reduce epistaxis frequency and transfusion needs in HHT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering routine endoscopy in all HHT patients rather than reserving for overt GI bleeding.  <br>2. Assuming negative baseline MRI means no future imaging is ever needed&mdash;new neurologic symptoms mandate repeat MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Faughnan ME et al., JAMA 2020 (International HHT Guidelines): Class I recommendation for baseline brain MRI at diagnosis; repeat only if symptomatic (Level B).  <br>&bull; Shovlin CL et al., <span class=\"evidence\">Blood 2014</span>: cohort study demonstrating 10&ndash;20% cerebral AVM prevalence in HHT and reduced hemorrhagic risk with preemptive treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutations in endoglin (ENG) or activin receptor-like kinase 1 (ACVRL1) disrupt TGF-&beta;/BMP\u20109 signaling, impairing endothelial cell junctions and promoting direct artery-to-vein connections without capillaries, leading to high-flow AVMs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation using Cura\u00e7ao criteria.  <br>2. Genetic testing if prenatal or family planning required.  <br>3. Baseline brain MRI for cerebral AVMs.  <br>4. CT chest (or bubble ECHO) for pulmonary AVMs.  <br>5. Liver US/MR for hepatic AVMs in symptomatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cerebral AVMs appear as flow voids on T2-weighted MRI; contrast MR-angiography delineates nidus and feeding vessels.  <br>&bull; Small (<3 mm) AVMs may require high-resolution or 3T MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. On neurology boards, HHT is tested via clinical vignettes emphasizing Cura\u00e7ao criteria and the distinction between screening modalities (MRI for brain, CT chest for lungs).</div></div></div></div></div>"
  },
  {
    "id": 100023231,
    "question_number": "143",
    "question_text": "A male patient with renal impairment, stroke, and angiokeratoma is being evaluated for enzyme supplementation. Which enzyme is likely deficient?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Fabry disease is an X-linked recessive lysosomal storage disorder caused by deficient &alpha;-galactosidase A. Enzyme inactivity leads to accumulation of globotriaosylceramide (GL-3) in vascular endothelium and smooth muscle. Clinically, patients (especially males) develop angiokeratomas (small, dark red skin lesions), progressive renal impairment (proteinuria, declining GFR), and cerebrovascular events (lacunar strokes) often before age 50. Recognizing the triad of angiokeratomas, renal dysfunction, and stroke in a young male should prompt testing of &alpha;-galactosidase A activity and genetic analysis of the GLA gene.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Galactosidase A deficiency causes GL-3 accumulation in endothelial, renal, cardiac, and neuronal tissues. In classic Fabry males, residual enzyme activity is <1%, leading to early onset multi-system disease. Enzyme replacement therapy (ERT) with recombinant agalsidase alfa (0.2 mg/kg IV every other week) or beta (1 mg/kg IV every other week) clears GL-3 deposits, stabilizes renal function, and reduces stroke risk <span class=\"citation\">(<span class=\"evidence\">Germain et al., 2019</span>;<span class=\"evidence\"> El Dib et al., 2016</span> Cochrane)</span>. Early initiation, ideally before irreversible organ damage, is associated with better outcomes <span class=\"citation\">(<span class=\"evidence\">Deegan et al., 2021</span>)</span>.  <br>Current consensus <span class=\"citation\">(European Fabry Working <span class=\"evidence\">Group 2021</span>)</span> endorses ERT initiation at diagnosis in all males with the classic phenotype (Expert opinion, Level C). The pathophysiology involves endothelial accumulation of GL-3, promoting small-vessel ischemia (stroke) and impaired glomerular filtration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Beta-glucocerebrosidase  <br>&bull; Incorrect: Deficiency causes Gaucher disease (AR), characterized by hepatosplenomegaly, bone crises, Gaucher cells, not angiokeratomas or stroke.  <br>&bull; Misconception: All sphingolipidoses present with angiokeratomas&mdash;only Fabry does.  <br><br>C. Alpha-L-iduronidase  <br>&bull; Incorrect: Deficiency causes Hurler syndrome (MPS I, AR) with gargoylism, corneal clouding, developmental delay, not isolated stroke/renal disease in adults.  <br>&bull; Misconception: MPS disorders cause angiokeratomas&mdash;MPS I does not present with skin telangiectasias.  <br><br>D. Hexosaminidase A  <br>&bull; Incorrect: Deficiency causes Tay-Sachs (AR) with neurodegeneration, cherry-red macula, no renal impairment or angiokeratomas.  <br>&bull; Misconception: All lysosomal storage diseases lead to multi-system involvement including kidneys&mdash;Tay-Sachs is CNS-restricted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Fabry (&alpha;-Gal A)</th><th>Gaucher (&beta;-glucocerebrosidase)</th><th>Hurler (&alpha;-L\u2010iduronidase)</th><th>Tay-Sachs (Hex A)</th></tr></thead><tbody><tr><td>Inheritance</td><td>X-linked recessive</td><td>Autosomal recessive</td><td>Autosomal recessive</td><td>Autosomal recessive</td></tr><tr><td>Primary accumulation</td><td>Globotriaosylceramide (GL-3)</td><td>Glucocerebroside</td><td>Dermatan/heparan sulfate</td><td>GM2 ganglioside</td></tr><tr><td>Key clinical features</td><td>Angiokeratomas, renal failure, stroke, acroparesthesias</td><td>Hepatosplenomegaly, bone pain</td><td>Gargoylism, corneal clouding, airway obstruction</td><td>Neurodegeneration, cherry-red spot, developmental arrest</td></tr><tr><td>Age of onset</td><td>Childhood/adolescence</td><td>Childhood</td><td>Infancy</td><td>Infancy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Angiokeratomas often appear in a &ldquo;bathing-trunk&rdquo; distribution and are a key dermatologic clue.  <br>&bull; Acroparesthesias (burning pain in hands/feet) and hypohidrosis often precede renal and cerebrovascular complications.  <br>&bull; Early ERT (<5 years after symptom onset) preserves renal function and lowers stroke incidence <span class=\"citation\">(<span class=\"evidence\">Deegan et al., 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking cherry-red maculas of Tay-Sachs for angiokeratomas.  <br>&bull; Assuming all sphingolipidoses cause organomegaly&mdash;Fabry typically has minimal hepatosplenomegaly.  <br>&bull; Neglecting X-linked inheritance in a male with stroke and renal disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guideline for the Prevention of Stroke in Patients with Cryptogenic Stroke (2018): Recommends screening for Fabry disease in males <55 years with cryptogenic stroke (Class IIa; Level C).  <br>&bull; European Fabry Working Group Consensus <span class=\"citation\">(Orphanet J Rare <span class=\"evidence\">Dis 2021</span>)</span>: Advises initiation of ERT at diagnosis in males with classic Fabry phenotype to prevent irreversible end-organ damage (Expert opinion; Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GL-3 accumulates within lysosomes of endothelial and smooth muscle cells, provoking vascular dysfunction (small-vessel ischemia \u2192 stroke), podocyte injury (proteinuria \u2192 renal failure), and dermal capillary dilation (angiokeratomas). X-linked inheritance confines classic severe disease to hemizygous males; heterozygous females have variable penetrance due to X-inactivation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>ERT:  <br>&ndash; Agalsidase alfa: 0.2 mg/kg IV q2 weeks  <br>&ndash; Agalsidase beta: 1 mg/kg IV q2 weeks  <br>Chaperone therapy (migalastat 150 mg PO q48 h) for patients with amenable GLA mutations. Monitor for infusion-related reactions and anti-drug antibodies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Fabry disease is frequently tested as an X-linked disorder presenting with angiokeratomas plus renal/cerebrovascular involvement; often appears in multi-system or stroke vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023232,
    "question_number": "249",
    "question_text": "A young female with a history of stroke and recurrent abortions is evaluated. Which of the following is the most likely underlying condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Young patients presenting with ischemic stroke and simultaneous obstetric complications (recurrent early pregnancy loss) should prompt evaluation for acquired hypercoagulable states. Core concepts:  <br>1. Autoimmune-mediated thrombophilia: Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-&beta;2-glycoprotein I) cause endothelial activation and arterial/venous thrombosis.  <br>2. Obstetric morbidity: Placental microthrombosis in APS leads to recurrent first-trimester losses and late fetal demise.  <br>3. Contrast with inherited anticoagulant deficiencies (protein C, antithrombin III), which cause primarily venous thromboembolism without characteristic pregnancy loss.  <br>Recognition of this clinical pattern is essential for timely diagnosis and management. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiphospholipid syndrome (APS) uniquely manifests with both arterial events (e.g., ischemic stroke in cerebral arteries) and obstetric complications. <span class=\"evidence\">The 2006</span> revised Sapporo (Sydney) classification criteria <span class=\"citation\">(<span class=\"evidence\">Miyakis et al., 2006</span>)</span> require:  <br>&bull; One clinical event&mdash;vascular thrombosis or defined pregnancy morbidity (&ge;3 consecutive spontaneous abortions <10 weeks or fetal demise &ge;10 weeks).  <br>&bull; Persistent medium/high-titer antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-&beta;2-glycoprotein I) on &ge;2 occasions &ge;12 weeks apart.  <br><br><span class=\"evidence\">The 2019</span> EULAR recommendations <span class=\"citation\">(<span class=\"evidence\">Tektonidou et al., 2019</span>)</span> advise lifelong vitamin K antagonist therapy (target INR 2.0&ndash;3.0) for patients with arterial thrombosis; recurrent events may warrant intensified anticoagulation (INR 3.0&ndash;4.0) or adjunctive low-dose aspirin. By contrast, protein C and antithrombin III deficiencies predominantly present with venous thromboses and lack obstetric manifestations, while factor VII deficiency is a bleeding disorder, not a prothrombotic state.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Protein C deficiency  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Heterozygous protein C deficiency leads almost exclusively to venous thromboembolism (deep vein thrombosis, pulmonary embolism).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any hypercoagulable defect with arterial events and pregnancy loss.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: No placental thrombosis or recurrent miscarriages; lab shows low protein C activity without antiphospholipid antibodies.<br><br>B. Anti-thrombin III deficiency  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Antithrombin III deficiency increases risk of venous thromboembolism, not arterial thrombosis or obstetric complications.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all natural anticoagulant deficiencies predispose to both arterial and venous clots.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Lab demonstrates reduced ATIII activity; lupus anticoagulant and anticardiolipin are absent.<br><br>D. Anti-factor VII deficiency  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Congenital factor VII deficiency causes a bleeding diathesis with prolonged prothrombin time, not thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any coagulation factor abnormality yields thrombophilia.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Presents with mucocutaneous bleeding; no history of clots or miscarriages; normal antiphospholipid antibody profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antiphospholipid Syndrome</th><th>Protein C Deficiency</th><th>Antithrombin III Deficiency</th><th>Factor VII Deficiency</th></tr></thead><tbody><tr><td>Pathogenesis</td><td>Autoantibodies to phospholipid-binding proteins</td><td>SERPINC1 mutation \u2192 \u2193PC</td><td>SERPINC1 mutation \u2192 \u2193ATIII</td><td>F7 gene mutation \u2192 \u2193FVII</td></tr><tr><td>Thrombosis Type</td><td>Arterial & venous</td><td>Venous</td><td>Venous</td><td>Hemorrhage</td></tr><tr><td>Obstetric Complications</td><td>Recurrent miscarriages, fetal demise</td><td>Not typical</td><td>Not typical</td><td>Not associated</td></tr><tr><td>Laboratory Findings</td><td>+ LA, + aCL, + anti-&beta;2GPI</td><td>\u2193 Protein C activity</td><td>\u2193 ATIII activity</td><td>Prolonged PT, normal PTT</td></tr><tr><td>Management</td><td>VKA (INR 2&ndash;3), LMWH+ASA in pregnancy</td><td>Anticoagulation for VTE</td><td>Anticoagulation for VTE</td><td>FVII replacement therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Young stroke plus unexplained recurrent first-trimester loss is classic for APS&mdash;always test for lupus anticoagulant first due to highest specificity.  <br>&bull; Transient infections can yield low-titer antiphospholipid antibodies; confirm persistence at &ge;12 weeks to avoid overdiagnosis.  <br>&bull; In pregnant APS patients, combine low-dose aspirin with prophylactic LMWH from preconception to 6 weeks postpartum to reduce miscarriage risk <span class=\"citation\">(RCOG 2020)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing venous-only hypercoagulable states (protein C, ATIII deficiencies) to arterial thrombosis presentations.  <br>2. Interpreting a single positive antiphospholipid antibody as diagnostic&mdash;retesting at &ge;12-week interval is mandatory.  <br>3. Confusing in vitro prolongation of PTT by lupus anticoagulant with a bleeding risk&mdash;APS causes thrombosis, not hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> Tektonidou MG et al., 2019</span> EULAR recommendations for the management of antiphospholipid syndrome: lifelong vitamin K antagonist therapy (INR 2.0&ndash;3.0) is recommended for arterial thrombosis (Level B evidence); intensify anticoagulation or add aspirin in recurrent cases.  <br>2. RCOG Green-top Guideline No. 75b, 2020: pregnant women with APS and prior recurrent miscarriage should receive low-dose aspirin (75&ndash;100 mg/day) plus prophylactic LMWH (e.g., enoxaparin 40 mg/day) from conception until 6 weeks postpartum (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Antiphospholipid syndrome is a frequently tested topic in neurology and internal medicine board examinations, often presented as young-onset stroke combined with recurrent fetal loss. Examinees must differentiate APS from inherited thrombophilias by recognizing the role of antiphospholipid antibodies, the revised Sapporo criteria, and appropriate anticoagulation strategies. This question appeared in Part II 2019 exam.</div></div></div></div></div>"
  },
  {
    "id": 100023234,
    "question_number": "18",
    "question_text": "A 4-year-old sickle cell disease patient had a stroke with significant MCA stenosis. What will determine the stroke risk?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Sickle cell disease (SCD) causes chronic hemolysis and vaso-occlusion leading to cerebral vasculopathy, particularly in the middle cerebral artery (MCA). Pediatric stroke risk correlates with intracranial arterial stenosis and resultant increased blood flow velocities. Transcranial Doppler (TCD) ultrasonography noninvasively measures time\u2010averaged mean maximum velocities (TAMMV) in the MCA. A TAMMV &ge;200 cm/s is the established threshold for &ldquo;high risk&rdquo; of first stroke. Routine TCD screening (ages 2&ndash;16) and prophylactic transfusion in children with abnormal velocities reduce stroke incidence by >90%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The landmark STOP (Stroke Prevention Trial in Sickle Cell Anemia) trial demonstrated that children with SCD and untreated MCA velocities &ge;200 cm/s had an annual stroke risk of ~10%. Chronic red cell transfusion to maintain HbS <30% lowered velocities and reduced stroke rate from 10% to 1% per year <span class=\"citation\">(<span class=\"evidence\">Ware et al., 1995</span>;<span class=\"evidence\"> Adams et al., 1998</span>)</span>. <span class=\"evidence\">Current 2020</span> American Society of Hematology (ASH) guidelines recommend annual TCD screening beginning at age 2 (weak recommendation, moderate-quality evidence) and initiation of transfusion therapy for abnormal results (strong recommendation). Neither static imaging (MRI/MRA) nor laboratory indices (Hb electrophoresis, CBC) reliably predict dynamic flow-related risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hb Electrophoresis  <br>&bull; Why incorrect: Measures hemoglobin variants (HbS, HbF) but does not assess cerebral blood flow.  <br>&bull; Misconception: Assuming higher HbS% directly translates to stroke risk.  <br>&bull; Differentiator: Risk assessment requires flow velocity, not hemoglobin quantification.  <br><br>C. MRI Brain with MRA  <br>&bull; Why incorrect: Detects silent infarcts and stenosis anatomically but cannot quantify hemodynamic flow velocity thresholds predictive of stroke.  <br>&bull; Misconception: Anatomical narrowing equates to risk magnitude without flow data.  <br>&bull; Differentiator: TCD provides real\u2010time velocity; MRA is static.  <br><br>D. Complete Blood Count  <br>&bull; Why incorrect: Gives hemoglobin concentration and cell counts but no information on cerebral hemodynamics.  <br>&bull; Misconception: Low Hb or high reticulocyte count signals imminent stroke.  <br>&bull; Differentiator: Stroke risk in SCD is flow\u2010velocity driven, not directly tied to CBC parameters.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Transcranial Doppler</th><th>MRI/MRA</th><th>Hb Electrophoresis</th><th>Complete Blood Count</th></tr></thead><tbody><tr><td>What it measures</td><td>Flow velocity (cm/s)</td><td>Vessel anatomy</td><td>Hemoglobin variants (%)</td><td>Hb level, cell counts</td></tr><tr><td>Predicts stroke risk</td><td>Yes (TAMMV &ge;200 cm/s)</td><td>No (qualitative stenosis only)</td><td>No</td><td>No</td></tr><tr><td>Screening recommendation</td><td>Annual, ages 2&ndash;16 <span class=\"citation\">(ASH 2020)</span></td><td>Only if neurological deficits</td><td>Diagnostic only</td><td>Routine care monitoring</td></tr><tr><td>Intervention guided by</td><td>Transfusion initiation</td><td>Further evaluation</td><td>SCD diagnosis/classification</td><td>Anemia management</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. TCD velocity &ge;170 cm/s is &ldquo;conditional,&rdquo; 170&ndash;199 cm/s warrants repeat in 1&ndash;3 months; &ge;200 cm/s is &ldquo;abnormal&rdquo;&mdash;start chronic transfusions.  <br>2. Hydroxyurea may be substituted for transfusion in selected patients with normalized velocities on TCD <span class=\"citation\">(TWiTCH trial, 2016)</span>.  <br>3. Silent cerebral infarcts on MRI are common in SCD but silent infarct detection alone does not direct transfusion; TCD remains the primary stroke\u2010risk tool.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating MRA-detected stenosis severity with instantaneous stroke risk&mdash;MRA lacks quantitative flow data.  <br>2. Overreliance on hemoglobin level or HbF percentage to stratify cerebral risk&mdash;laboratory indices do not substitute for TCD velocities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Society of Hematology (ASH) 2020 Guidelines: Annual TCD screening from age 2; initiate chronic transfusion for TAMMV &ge;200 cm/s (strong recommendation, moderate-quality).  <br>&bull; TWiTCH Trial (2016): Demonstrated that hydroxyurea maintains acceptable TCD velocities in children stabilized by transfusion, allowing safe transition off transfusion (New England Journal of Medicine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Stroke risk assessment in pediatric SCD via TCD is a frequently tested topic&mdash;know STOP trial criteria, TCD velocity thresholds, and transfusion indications.</div></div></div></div></div>"
  },
  {
    "id": 100023235,
    "question_number": "89",
    "question_text": "What is a new recommendation for adults with acute ischemic stroke who have known sickle cell disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute ischemic stroke in sickle cell disease (SCD) arises from sickling-induced endothelial injury, vasculopathy, and hypercoagulability. Early reperfusion reduces infarct size and disability. Intravenous alteplase (tPA) acts by catalyzing plasminogen to plasmin, lysing fibrin clots. Historically, bleeding risk and lack of SCD\u2010specific data limited its use, but updated guidelines no longer list SCD as an exclusion. Understanding the balance between reperfusion benefit and hemorrhagic risk is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Recent AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>)</span> state that SCD alone is not a contraindication to IV alteplase in eligible acute ischemic stroke (Class IIa, Level C-LD). Evidence is extrapolated from large thrombolysis trials and smaller case series in SCD adults showing similar safety and efficacy profiles to non\u2010SCD patients when standard inclusion/exclusion criteria are applied. Controlled RBC exchange transfusion to reduce HbS <30% remains important but should not delay tPA if within the 4.5-hour window. No randomized controlled trials in SCD-specific cohorts exist, but observational data <span class=\"citation\">(<span class=\"evidence\">Vibert et al., 2021</span>)</span> confirm low intracranial hemorrhage rates and favorable outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical intervention is mandatory  <br><span class=\"list-item\">\u2022</span> Why incorrect: Neurosurgical decompression or vascular bypass is not universally required. Only patients with malignant edema or large vessel occlusion failing medical therapy may need intervention.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates all strokes in SCD with surgical emergencies.  <br><span class=\"list-item\">\u2022</span> Differentiator: tPA is first-line if within window; surgery is reserved for refractory edema or hemorrhagic transformation.<br><br>C. No treatment is necessary  <br><span class=\"list-item\">\u2022</span> Why incorrect: Untreated ischemic stroke leads to high morbidity and mortality.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that SCD strokes are self-limiting or unmodifiable.  <br><span class=\"list-item\">\u2022</span> Differentiator: Timely reperfusion (tPA) and transfusion improve outcomes.<br><br>D. Only supportive care is recommended  <br><span class=\"list-item\">\u2022</span> Why incorrect: Supportive measures (hydration, analgesia) are adjunctive but insufficient without reperfusion therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimation of supportive care&rsquo;s ability to reverse ischemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: IV alteplase and exchange transfusion actively restore perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Intervention</th><th>Evidence Level</th><th>Role in SCD Stroke</th></tr></thead><tbody><tr><td>A. IV alteplase may be beneficial</td><td>Pharmacologic thrombolysis</td><td>Class IIa, Level C-LD</td><td>First-line if within 4.5 h window</td></tr><tr><td>B. Surgical intervention is mandatory</td><td>Craniectomy/vascular bypass</td><td>Not routinely indicated</td><td>Reserved for refractory cases</td></tr><tr><td>C. No treatment is necessary</td><td>None</td><td>Contraindicated (harmful)</td><td>Leads to infarct progression</td></tr><tr><td>D. Only supportive care is recommended</td><td>Hydration, analgesia</td><td>Adjunctive only</td><td>Insufficient without reperfusion</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Exchange transfusion to lower HbS <30% should be initiated promptly but not delay tPA in eligible patients.  <br><span class=\"list-item\">\u2022</span> Monitor closely for hemorrhagic transformation; SCD patients tolerate tPA similarly to non\u2010SCD cohorts.  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy remains an option up to 24 hours for large vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming SCD is an absolute contraindication to tPA&mdash;there is no evidence of higher bleeding risk solely due to SCD.  <br>2. Delaying thrombolysis for RBC exchange&mdash;transfusion is important but should not postpone alteplase within the therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA &ldquo;Guideline for the Early Management of Patients With Acute Ischemic Stroke&rdquo; (2019): Recommends IV alteplase in eligible patients within 4.5 h; SCD is not listed as exclusion (Class IIa, Level C-LD).  <br>2. American Society of Hematology &ldquo;2020 Guidelines for Sickle Cell Disease&rdquo; <span class=\"citation\">(ASH, 2020)</span>: Endorses exchange transfusion for acute stroke but acknowledges tPA may be administered per standard stroke protocols if within window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% as bolus over 1 min, remainder over 60 min.  <br><span class=\"list-item\">\u2022</span> Monitor INR/PTT, ensure platelets >100 \u00d7 10^9/L, BP <185/110 mm Hg before administration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Acute stroke management in SCD often tests knowledge of reperfusion therapy eligibility and how coexisting conditions (like SCD) impact standard stroke protocols. Emergent tPA use within 4.5 hours remains a high-yield topic.</div></div></div></div></div>"
  },
  {
    "id": 100023237,
    "question_number": "90",
    "question_text": "What was the aggregate risk reduction of stroke at 10 years for patients with 70% to 99% ICA stenosis undergoing carotid endarterectomy (CEA) according to the ACST trial?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] The internal carotid artery (ICA) supplies the ipsilateral anterior circulation (ACA/MCA territories). Atherosclerotic plaque in the ICA can rupture or shed microemboli, causing cortical or subcortical ischemic strokes. In asymptomatic patients with high\u2010grade (70&ndash;99%) stenosis, the balance between perioperative risk and long\u2010term stroke prevention guides intervention. Carotid endarterectomy (CEA) removes the plaque, restoring luminal diameter and reducing embolic load. Landmark randomized trials (ACAS, ACST) compare immediate CEA versus medical therapy alone, quantifying absolute stroke risk reduction over defined follow\u2010up periods.<br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The ACST (Asymptomatic Carotid Surgery Trial) randomized 3120 asymptomatic patients with &ge;60% carotid stenosis to immediate CEA versus deferral, with median follow\u2010up of 9 years. For the subgroup with 70&ndash;99% stenosis, the cumulative 10-year stroke rate was 22.2% in the deferred (medical) arm versus 15.7% in the immediate CEA arm <span class=\"citation\">(absolute risk reduction [ARR] 6.5%, relative risk reduction ~29%; <span class=\"evidence\">Lancet 2004</span>;363:1491&ndash;1502)</span>. This finding underpins current guidelines: the AHA/ASA 2014 prevention guidelines (Class I, Level A) and the 2023 Society for Vascular Surgery guidelines (Class I, Level B) recommend CEA in asymptomatic patients with &ge;70% stenosis if perioperative stroke/death risk is <3%. Removal of plaque reduces both hemodynamic compromise and embolic potential, lowering ipsilateral stroke rates over long\u2010term follow\u2010up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. From 17.9% in best medical treatment to 13.4% in CEA  <br><span class=\"list-item\">\u2022</span> This reflects only post-30-day ipsilateral strokes in ACST, not the aggregate 10-year risk (which includes perioperative events). Misrepresents the denominator and time horizon.  <br><span class=\"list-item\">\u2022</span> Common misconception: conflating post\u2010operative stroke rates with total stroke risk.<br><br>B. From 11% to 5.1%  <br><span class=\"list-item\">\u2022</span> These figures derive from the ACAS (Asymptomatic Carotid Atherosclerosis Study) 5-year results, not ACST&rsquo;s 10-year follow-up.  <br><span class=\"list-item\">\u2022</span> Key differentiator: ACAS enrolled patients &ge;60% stenosis and reported 5-year ARR of ~5.9%, while ACST reports 10-year outcomes.<br><br>C. From 26% to 9%  <br><span class=\"list-item\">\u2022</span> This exaggerates the ACST findings; no arm in ACST had a 9% 10-year risk for high\u2010grade stenosis, nor did the deferred group reach 26% for aggregate stroke.  <br><span class=\"list-item\">\u2022</span> Represents confusion with combined end points or other secondary analyses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Parameter</th><th>Deferred Medical</th><th>Immediate CEA</th><th>Absolute Risk Reduction</th></tr></thead><tbody><tr><td>10-year cumulative stroke</td><td>22.2%</td><td>15.7%</td><td>6.5%</td></tr><tr><td>Relative risk reduction</td><td>&ndash;</td><td>&ndash;</td><td>~29%</td></tr><tr><td>Perioperative stroke/death</td><td>&ndash;</td><td>~3%</td><td>&ndash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ensure perioperative stroke/death risk is <3% in your center before offering CEA.  <br><span class=\"list-item\">\u2022</span> ACAS provides 5-year data (11% \u2192 5.1%), ACST provides 10-year data (22.2% \u2192 15.7%). Know which trial corresponds to each time frame.  <br><span class=\"list-item\">\u2022</span> Optimal medical therapy (statin, antiplatelet) has improved since ACST; current baseline stroke risk may be lower, influencing risk&ndash;benefit discussions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ACAS (5-year) with ACST (10-year) outcomes leads to incorrect percent reductions.  <br>2. Omitting perioperative events when calculating &ldquo;aggregate&rdquo; risk underestimates true stroke incidence.  <br>3. Assuming modern medical therapy achieves the same event rates as at the time of ACST, ignoring evolving standards (e.g., high-intensity statins).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Secondary Stroke Prevention Guidelines (Class I, Level A): Recommend CEA for asymptomatic patients with &ge;70% stenosis if perioperative risk <3%.  <br><span class=\"list-item\">\u2022</span> Society for Vascular <span class=\"evidence\">Surgery 2023</span> Clinical Practice Guidelines (Class I, Level B): Support CEA in anatomically suitable asymptomatic patients with &ge;70% stenosis, life expectancy >5 years.  <br><span class=\"list-item\">\u2022</span> Paraskevas et al., J Vasc <span class=\"evidence\">Surg 2021</span> Meta-analysis: Contemporary medical therapy yields annual stroke rates of ~0.7% in asymptomatic stenosis, prompting reevaluation of surgical benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA bifurcates into the MCA and ACA within the sylvian fissure; plaque at the carotid bifurcation most often embolizes to MCA cortical branches, causing contralateral motor and sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque development in the carotid bulb involves intimal lipid accumulation, fibrous cap formation, and possible ulceration. Plaque rupture or fissuring releases cholesterol crystals and thrombus, leading to artery\u2010to\u2010artery emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Duplex ultrasonography: screen for peak systolic velocity >230 cm/s (&ge;70% stenosis).  <br>2. Confirm with CTA or MRA for luminal and wall assessment.  <br>3. Evaluate surgical risk (medical comorbidities, anatomic considerations).  <br>4. Multidisciplinary discussion for CEA versus ongoing medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On duplex US, end-diastolic velocity >100 cm/s suggests &ge;70% stenosis.  <br><span class=\"list-item\">\u2022</span> CTA provides plaque morphology (ulceration, calcification) and collateral circulation evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Antiplatelet: aspirin 75&ndash;100 mg daily; alternatives include clopidogrel 75 mg daily if aspirin-intolerant.  <br><span class=\"list-item\">\u2022</span> Statin therapy: high-intensity (e.g., atorvastatin 40&ndash;80 mg) reduces plaque progression and stabilizes vulnerable lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Asymptomatic CEA indications (trial data, percent stenosis, time horizon, perioperative risk thresholds) are frequently tested in vignette or direct recall formats on neurology and vascular surgery sections.</div></div></div></div></div>"
  },
  {
    "id": 100023238,
    "question_number": "187",
    "question_text": "In a case of malignant MCA infarction presented after 24 hours with midline shift, what is the most important intervention?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Malignant middle cerebral artery (MCA) infarction refers to a large\u2010territory MCA stroke that leads to life\u2010threatening cerebral edema and elevated intracranial pressure (ICP). Key points:  <br><span class=\"list-item\">\u2022</span> MCA supplies lateral frontal, parietal, and temporal lobes plus internal capsule via lenticulostriate arteries.  <br><span class=\"list-item\">\u2022</span> Infarcted tissue undergoes cytotoxic edema (pump failure) followed by vasogenic edema (blood&ndash;brain barrier breakdown).  <br><span class=\"list-item\">\u2022</span> Edema peaks at 48&ndash;72 hours, causing midline shift, transtentorial herniation, and rapid neurological deterioration.  <br><span class=\"list-item\">\u2022</span> Recognition of clinical signs (reduced consciousness, worsening hemiplegia) and radiographic midline shift (&ge;5 mm) triggers consideration of urgent decompression. (\u2248130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy eliminates a portion of the skull, allowing the swollen brain to expand outward and markedly reducing ICP. The pooled analysis of DECIMAL, DESTINY, and HAMLET trials <span class=\"citation\">(JAMA 2007)</span> demonstrated that in patients &le;60 years with large MCA infarcts, hemicraniectomy within 48 hours reduced mortality from ~80% to ~30% and doubled the proportion achieving a favorable 12\u2010month outcome (mRS &le;3). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke give a Class I, Level of Evidence A recommendation for decompressive craniectomy in malignant MCA infarction with clinical deterioration or midline shift. No medical therapy matches the mortality and disability benefit of surgical decompression in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Admission to stroke unit  <br><span class=\"list-item\">\u2022</span> Incorrect: Stroke\u2010unit care improves overall stroke outcomes but offers no immediate reduction in ICP or herniation risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating supportive care with acute mass\u2010effect relief.  <br><span class=\"list-item\">\u2022</span> Differentiator: Multidisciplinary monitoring does not reverse established edema.<br><br>C. Intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect: The 4.5\u2010hour window for tPA has long closed; late administration risks hemorrhagic transformation without reducing edema.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that reperfusion remains beneficial regardless of timing.  <br><span class=\"list-item\">\u2022</span> Differentiator: Thrombolysis cannot mitigate peak edema occurring days later.<br><br>D. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin or clopidogrel prevents recurrence but does not influence existing brain swelling or midline shift.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all ischemic stroke interventions suffice in malignant cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: No effect on ICP or mass\u2010effect reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Timing</th><th>Mechanism</th><th>Effect on ICP</th><th>Outcome Benefit</th></tr></thead><tbody><tr><td>Decompressive craniectomy</td><td>&le;48 hours post\u2010onset</td><td>Removal of skull flap, brain expansion</td><td>Rapid ICP reduction</td><td>\u2193 Mortality, \u2191 favorable mRS outcomes</td></tr><tr><td>Stroke unit admission</td><td>Any time</td><td>Multidisciplinary monitoring/support</td><td>Indirect/supportive</td><td>\u2193 Medical complications, no acute ICP change</td></tr><tr><td>Intravenous thrombolysis</td><td>&le;4.5 hours post\u2010onset</td><td>Plasmin\u2010mediated clot lysis</td><td>None for established edema</td><td>\u2193 Infarct volume if timely, not applicable late</td></tr><tr><td>Antiplatelet therapy</td><td>After acute phase</td><td>Inhibits platelet aggregation</td><td>None</td><td>\u2193 Recurrence risk, no acute mass\u2010effect benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Malignant MCA infarction carries an untreated mortality >80%; early surgical consultation is critical.  <br><span class=\"list-item\">\u2022</span> Hemicraniectomy is most effective when performed within 48 hours of stroke onset, ideally before signs of herniation become irreversible.  <br><span class=\"list-item\">\u2022</span> Age criteria in major trials is &le;60 years, but selected older patients may also benefit based on recent data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying imaging until overt herniation signs appear, missing the surgical window.  <br>2. Overvaluing stroke\u2010unit admission as definitive therapy for malignant edema.  <br>3. Attempting off\u2010label late thrombolysis in hopes of improving edema, risking hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke:  <br><span class=\"list-item\">\u2022</span> Recommendation: Decompressive hemicraniectomy in malignant MCA infarction with clinical deterioration or midline shift (Class I, Level A).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines:  <br><span class=\"list-item\">\u2022</span> Recommendation: Hemicraniectomy for malignant MCA infarction up to age 65 in selected patients (Level of Evidence Ib), based on pooled RCT meta\u2010analysis.  <br>3. DESTINY II Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurology 2019</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: In patients aged 61&ndash;82, hemicraniectomy reduced 12\u2010month mortality and improved functional independence (mRS &le;4).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MCA infarction affects cortical regions controlling contralateral motor and sensory function and subcortical pathways (internal capsule). Edema in the sylvian fissure region compresses basal cisterns and can precipitate uncal herniation via the tentorial notch.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemia \u2192 ATP depletion \u2192 Na+/K+ pump failure \u2192 cytotoxic edema \u2192 blood&ndash;brain barrier breakdown \u2192 vasogenic edema \u2192 increased intracranial volume \u2192 elevated ICP \u2192 reduced cerebral perfusion pressure \u2192 secondary ischemic injury and herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT: exclude hemorrhage, assess early hypodensity &ge;50% MCA territory.  <br>2. Measure midline shift (&ge;5 mm indicates significant mass effect).  <br>3. Clinical evaluation: GCS decline, pupillary changes.  <br>4. Neurocritical/Neurosurgical consultation for hemicraniectomy candidacy.  <br>5. Proceed to decompressive surgery if within 48 hours and criteria met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dense MCA sign on CT suggests proximal M1 occlusion.  <br><span class=\"list-item\">\u2022</span> A hypodense area exceeding half the MCA territory predicts malignant edema.  <br><span class=\"list-item\">\u2022</span> MRI DWI quantifies infarct core but is less practical in acute herniation risk scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperosmolar therapy (mannitol 0.25&ndash;1 g/kg IV; hypertonic saline targeting serum Na+ 145&ndash;155 mmol/L) can transiently lower ICP but is not definitive.  <br><span class=\"list-item\">\u2022</span> Sedation (propofol) and head\u2010of\u2010bed elevation (30\u00b0) are adjuncts pending surgical intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy for malignant MCA infarction is frequently tested in scenario\u2010based board questions emphasizing timing (&le;48 hours), imaging criteria (midline shift), and patient selection (age &le;60). This question appeared in Part 2 2024 exam.</div></div></div></div></div>"
  },
  {
    "id": 100023239,
    "question_number": "25",
    "question_text": "A patient with sickle cell disease developed an ischemic stroke. What is the recommended secondary prevention strategy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] 1. Sickle cell disease&ndash;related strokes result primarily from large-vessel vasculopathy of the circle of Willis, with intimal hyperplasia and stenosis in the middle cerebral arteries.  <br>2. Sickled erythrocytes promote endothelial injury, chronic inflammation, and in situ thrombosis, leading to high recurrence risk.  <br>3. Chronic transfusions lower HbS to <30%, improve oxygen delivery, reduce blood viscosity, and prevent further sickling episodes.  <br><br>(Word count: 83)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion remains the standard for secondary prevention after ischemic stroke in sickle cell disease. The landmark STOP (Stroke Prevention Trial in Sickle Cell Anemia) study <span class=\"citation\">(NEJM 1998;338:5&ndash;11)</span> demonstrated a 92% reduction in recurrent stroke with monthly erythrocyte transfusions targeting HbS <30% and total hemoglobin ~10 g/dL. STOP II (2005) confirmed that cessation of transfusion led to rapid rise in stroke recurrence. The American Society of <span class=\"evidence\">Hematology 2020</span> guidelines strongly recommend indefinite chronic transfusions post-stroke (Grade 1A). Hydroxyurea, while effective for reducing vaso-occlusive crises, lacks high-quality evidence for secondary stroke prevention and is reserved when transfusion is contraindicated. Antiplatelet or anticoagulant therapies have not shown benefit in modifying the underlying vasculopathy or reducing recurrence in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin therapy  <br>&bull; Why incorrect: Platelet inhibition does not address sickle-cell&ndash;driven large-vessel stenosis or reduce HbS fraction.  <br>&bull; Misconception: Equating sickle-cell stroke with atherothrombotic stroke.  <br>&bull; Differentiator: Aspirin has no evidence for reducing recurrence in sickle cell&ndash;related stroke.  <br><br>C. Warfarin therapy  <br>&bull; Why incorrect: Anticoagulation targets cardioembolic/clotting cascade, not hemoglobin polymerization or vascular stenosis in sickle cell disease.  <br>&bull; Misconception: Assuming all ischemic strokes benefit from anticoagulation.  <br>&bull; Differentiator: No atrial fibrillation or hypercoagulable mechanism in this context.  <br><br>D. Hydroxyurea  <br>&bull; Why incorrect: Increases HbF and reduces crises but has not demonstrated equivalence to transfusions in preventing secondary strokes.  <br>&bull; Misconception: Belief that hydroxyurea can replace transfusions for stroke prevention.  <br>&bull; Differentiator: Hydroxyurea trials (e.g., TWiST) show inferior stroke-free survival compared to transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chronic Transfusion</th><th>Aspirin</th><th>Warfarin</th><th>Hydroxyurea</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reduces HbS <30%, \u2193 sickling</td><td>Platelet COX-1 inhibition</td><td>Vit K antagonist, \u2193 clotting</td><td>\u2191 HbF, \u2193 polymerization</td></tr><tr><td>Stroke recurrence reduction</td><td>~92% relative risk reduction</td><td>No significant effect</td><td>No data/specific benefit</td><td>Inferior to transfusion</td></tr><tr><td>Key evidence</td><td>STOP, STOP II, ASH 2020 (1A)</td><td>Extrapolated from athero</td><td>None in sickle cell stroke</td><td>TWiST: higher recurrence</td></tr><tr><td>Main adverse effects</td><td>Iron overload, alloimmunization</td><td>GI bleeding, hypersensitivity</td><td>Bleeding, warfarin necrosis</td><td>Cytopenias, teratogenic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Transcranial Doppler screening identifies high primary stroke risk (velocity >200 cm/s); transfusion then prevents first stroke.  <br>2. Monitor serum ferritin and initiate chelation (e.g., deferasirox) to mitigate iron overload from lifelong transfusions.  <br>3. Abrupt cessation of chronic transfusion leads to rebound risk&mdash;plan for transition only under trial protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating aspirin instead of transfusion, despite lack of benefit in sickle-cell vasculopathy.  <br>2. Believing hydroxyurea alone suffices for secondary prevention&mdash;leads to higher recurrence rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Society of Hematology (ASH) 2020 Guidelines for Sickle Cell Disease  <br>   &ndash; Recommendation: Indefinite chronic transfusions post-stroke to maintain HbS <30% (Grade 1A).  <br>2. STOP Trial <span class=\"citation\">(NEJM 1998)</span> and STOP II <span class=\"citation\">(<span class=\"evidence\">Blood 2005</span>)</span>  <br>   &ndash; Finding: Monthly transfusions reduce primary and secondary stroke incidence by >90%; stopping transfusion \u2192 rapid recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On neurologic boards, sickle cell&ndash;related stroke prevention frequently tests knowledge of STOP trial data, transfusion targets (HbS <30%), and differentiation from standard antithrombotic strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023240,
    "question_number": "18",
    "question_text": "A patient developed an ischemic stroke, and his echocardiogram showed an intracardiac thrombus as part of the stroke workup. What is the best option for secondary prevention of stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] &bull; Cardioembolic stroke arises when a thrombus formed in the heart (e.g., left ventricular or left atrial appendage) embolizes to cerebral vessels.  <br>&bull; Intracardiac thrombus formation reflects Virchow&rsquo;s triad: blood stasis (e.g., reduced ejection fraction), endocardial injury, and hypercoagulability.  <br>&bull; Preventing recurrent cardioembolism requires systemic anticoagulation to inhibit thrombin generation and fibrin formation, reducing embolic risk far more effectively than antiplatelet agents.<br><br>(Word count: 82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin remains the guideline-recommended agent for secondary prevention in patients with documented intracardiac thrombus. <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention guidelines (Class I, Level A) advise vitamin K antagonist therapy targeting an INR of 2.0&ndash;3.0 for at least 3&ndash;6 months in left ventricular thrombus after myocardial infarction or other intracardiac sources. Randomized trials comparing DOACs (e.g., apixaban, rivaroxaban) vs warfarin for left ventricular thrombus are limited to small cohort studies and case series; a recent meta-analysis <span class=\"citation\">(Robinson et al., <span class=\"evidence\">Stroke 2023</span>)</span> found similar rates of thrombus resolution but insufficient power to establish noninferiority. In contrast, antiplatelet monotherapy fails to prevent fibrin-rich emboli originating from mural thrombi.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. NOACs  <br>&bull; DOACs (dabigatran, rivaroxaban, apixaban) have proven efficacy in AF-related stroke prevention but lack robust RCT data for LV thrombus.  <br>&bull; Misconception: &ldquo;DOACs are universally superior to warfarin.&rdquo; They are approved for atrial fibrillation but off-label for intracardiac thrombus.  <br><br>C. Aspirin  <br>&bull; Mechanism: irreversibly inhibits platelet cyclooxygenase-1; effective for large-artery atherosclerotic stroke, not fibrin-rich cardioembolism.  <br>&bull; Misconception: &ldquo;Any antithrombotic agent suffices.&rdquo; In cardioembolic sources, platelets play a minor role in clot propagation compared to thrombin-driven fibrin networks.  <br><br>D. Clopidogrel  <br>&bull; ADP-receptor blocker; used as monotherapy or dual therapy in atherothrombotic disease.  <br>&bull; Misconception: &ldquo;Stronger antiplatelet reduces embolic risk.&rdquo; Without anticoagulation, intracardiac thrombi persist and embolize despite platelet inhibition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Warfarin</th><th>NOACs</th><th>Aspirin</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>Vitamin K antagonist</td><td>Direct factor Xa or thrombin inhibition</td><td>COX-1 inhibition</td><td>P2Y12 ADP-receptor blockade</td></tr><tr><td>Indication for intracardiac thrombus</td><td>Class I, Level A <span class=\"citation\">(AHA/ASA 2021)</span></td><td>Off-label; limited cohort data</td><td>No indication</td><td>No indication</td></tr><tr><td>Monitoring</td><td>INR (target 2.0&ndash;3.0)</td><td>Renal function, but no routine assays</td><td>None</td><td>None</td></tr><tr><td>Reversal agent</td><td>Vitamin K, PCC</td><td>Specific agents (idarucizumab, andexanet alfa)</td><td>Not needed</td><td>Not needed</td></tr><tr><td>Embolus prevention efficacy</td><td>Established in trials/registry data</td><td>Emerging, not definitive</td><td>Poor for cardioembolism</td><td>Poor for cardioembolism</td></tr><tr><td>Time to therapeutic effect</td><td>5&ndash;7 days</td><td>2&ndash;4 hours</td><td>Rapid</td><td>Rapid</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Left ventricular or atrial thrombus detected on echo mandates anticoagulation (INR 2&ndash;3) for at least 3 months, with repeat imaging to confirm thrombus resolution.  <br>2. DOACs are first-line for nonvalvular AF but remain off-label for ventricular thrombi; consider them only in warfarin contraindications.  <br>3. Always differentiate between platelet-rich &ldquo;white&rdquo; clots (arterial) and fibrin-rich &ldquo;red&rdquo; clots (cardioembolic) when choosing antithrombotic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating aspirin or clopidogrel instead of anticoagulation in cardioembolic stroke&mdash;a key error that leaves patients at high risk for recurrence.  <br>2. Assuming DOAC approval for all cardioembolic sources; only atrial fibrillation without mechanical valves or moderate-to-severe mitral stenosis has strong trial support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2021 Secondary Stroke Prevention Guidelines: Strong recommendation (Class I, Level A) for warfarin (INR 2.0&ndash;3.0) in patients with left ventricular thrombus post-MI or cardiomyopathy.  <br>&bull; European Stroke <span class=\"evidence\">Organisation 2022</span> Guidelines: Echo-detected cardiac thrombus requires anticoagulation; DOACs may be considered when warfarin is contraindicated (Grade 2C).  <br>&bull; Robinson et al., <span class=\"evidence\">Stroke 2023</span> (Meta-analysis): Comparable thrombus resolution rates between rivaroxaban and warfarin cohorts (n=512), but lacked randomized design and long-term outcome data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Warfarin: inhibits vitamin K epoxide reductase \u2192 decreases clotting factors II, VII, IX, X.  <br>&bull; Dosing: adjust by INR; initial overlap with heparin in acute setting until INR therapeutic for two consecutive days.  <br>&bull; Monitoring: monthly INR once stable; dietary vitamin K interactions require close follow-up.  <br>&bull; Bleeding risk mitigation: maintain INR &le;3.0; consider patient-specific factors (age, renal function).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Cardioembolic stroke prevention with warfarin in intracardiac thrombus is frequently tested in single best answer formats, often requiring distinction between antiplatelet vs anticoagulant strategies.</div></div></div></div></div>"
  },
  {
    "id": 100023243,
    "question_number": "27",
    "question_text": "A patient with cardioembolic stroke, ECG showed atrial fibrillation, and echocardiogram indicated nonvalvular cardiac disease. What should be given?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Cardioembolic stroke results from thrombus formation in the left atrium or appendage during atrial fibrillation (AF), due to stasis and hypercoagulability.  <br><span class=\"list-item\">\u2022</span> Nonvalvular AF (absence of rheumatic mitral stenosis, mechanical heart valve, or mitral valve repair) carries high embolic risk quantified by CHA\u2082DS\u2082-VASc score.  <br><span class=\"list-item\">\u2022</span> Anticoagulation reduces stroke risk by inhibiting key factors in the coagulation cascade; direct oral anticoagulants (DOACs), including Factor Xa inhibitors, directly target activated Factor X without need for routine monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Direct oral Factor Xa inhibitors (e.g., apixaban, rivaroxaban, edoxaban) are now first-line for secondary stroke prevention in nonvalvular AF. <span class=\"evidence\">The 2019</span> AHA/ASA guideline (Class I, Level A) and the 2020 ESC AF guideline recommend DOACs over warfarin owing to:  <br><span class=\"list-item\">\u2022</span> Comparable or superior efficacy: ARISTOTLE trial (apixaban vs warfarin) showed 21% relative risk reduction in stroke/systemic embolism (HR 0.79; 95% CI 0.66&ndash;0.95; p = 0.01).  <br><span class=\"list-item\">\u2022</span> Lower intracranial hemorrhage rates (0.33% vs 0.80% per year).  <br><span class=\"list-item\">\u2022</span> Fewer drug&ndash;food interactions and no routine INR checks.  <br>Thus, a Factor X inhibitor is the optimal agent for this patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br><span class=\"list-item\">\u2022</span> Incorrect: Antiplatelet therapy alone reduces stroke risk by only ~20% in AF, far inferior to anticoagulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Treating AF-related stroke as atherosclerotic rather than cardioembolic.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not inhibit coagulation cascade at the site of thrombus generation in the atrium.  <br><br>B. Warfarin  <br><span class=\"list-item\">\u2022</span> Incorrect: Although effective (relative risk reduction ~64%), warfarin requires frequent INR monitoring, dietary restrictions, and has variable pharmacokinetics.  <br><span class=\"list-item\">\u2022</span> Misconception: Warfarin is the universal gold standard&mdash;overlooked by current preference for DOACs in nonvalvular AF.  <br><span class=\"list-item\">\u2022</span> Differentiator: DOACs have superior safety (lower intracranial hemorrhage) and similar or superior efficacy.  <br><br>D. Clopidogrel  <br><span class=\"list-item\">\u2022</span> Incorrect: Single\u2010agent P2Y\u2081\u2082 inhibition is inadequate for stroke prevention in AF (no direct anticoagulant effect).  <br><span class=\"list-item\">\u2022</span> Misconception: Dual antiplatelet regimens or P2Y\u2081\u2082 blockers suffice for cardioembolic risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Antiplatelet drugs target platelet aggregation, not fibrin formation underpinning atrial thrombi.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Factor Xa Inhibitor</th><th>Warfarin</th><th>Aspirin</th><th>Clopidogrel</th></tr></thead><tbody><tr><td>Mechanism</td><td>Direct Xa inhibition</td><td>Vitamin K epoxide reductase blocker</td><td>COX-1 inhibition</td><td>P2Y\u2081\u2082 receptor antagonist</td></tr><tr><td>Monitoring</td><td>None routine</td><td>INR</td><td>None</td><td>None</td></tr><tr><td>Stroke RR reduction (AF)</td><td>~20&ndash;30% (vs warfarin superior)</td><td>~64%</td><td>~20%</td><td>~20%</td></tr><tr><td>Intracranial hemorrhage</td><td>Lower than warfarin</td><td>Higher</td><td>Lower</td><td>Lower</td></tr><tr><td>Drug&ndash;food/drug interactions</td><td>Fewer</td><td>Many</td><td>Few</td><td>Few</td></tr><tr><td>Guideline recommendation</td><td>Class I (nonvalvular AF)</td><td>Class I if DOAC contraindicated</td><td>Class IIb &ndash; only if anticoag contraindicated</td><td>Not recommended for AF monotherapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always calculate CHA\u2082DS\u2082-VASc to stratify stroke risk and guide anticoagulation decisions in AF.  <br><span class=\"list-item\">\u2022</span> HAS-BLED score estimates bleeding risk but should not contraindicate anticoagulation if stroke risk is high.  <br><span class=\"list-item\">\u2022</span> Transition from warfarin to a DOAC requires INR < 2.0 before DOAC initiation to minimize overlap risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing antiplatelet monotherapy (aspirin or clopidogrel) for AF-related stroke prevention underestimates embolic risk.  <br>2. Failing to distinguish valvular from nonvalvular AF can lead to inappropriate DOAC use in mechanical valve patients (contraindicated).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guideline for AF Stroke Prevention (Class I, Level A): Recommends DOAC over warfarin in nonvalvular AF.  <br><span class=\"list-item\">\u2022</span> 2020 ESC AF Guidelines (Class I, Level A): Endorse apixaban, rivaroxaban, edoxaban, or dabigatran for stroke prophylaxis in nonvalvular AF.  <br><span class=\"list-item\">\u2022</span> ARISTOTLE Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: Apixaban reduced stroke/systemic embolism and major bleeding compared to warfarin.  <br><span class=\"list-item\">\u2022</span> ROCKET AF Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>)</span>: Rivaroxaban noninferior to warfarin for stroke prevention with comparable safety.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Factor Xa inhibitors directly block the active site of Factor X, preventing prothrombin conversion to thrombin, thus inhibiting fibrin clot formation. Standard dosing (e.g., apixaban 5 mg BID) requires renal function assessment; no routine coagulation monitoring is needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Topics on AF-related stroke prophylaxis frequently appear as recall or application questions, often testing guideline-based selection of anticoagulant in nonvalvular AF.</div></div></div></div></div>"
  },
  {
    "id": 100023245,
    "question_number": "27",
    "question_text": "According to the NASCET trial, what was the reduction in stroke rate at 18 months for patients with 70% to 99% ICA stenosis who underwent carotid endarterectomy (CEA) compared to best medical treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Symptomatic carotid stenosis results from unstable atherosclerotic plaques in the internal carotid artery (ICA) causing artery\u2010to\u2010artery embolism or hypoperfusion in the anterior circulation. The NASCET measurement defines percent stenosis by comparing ICA lumen diameter at the narrowest point to the distal normal ICA diameter. Higher degrees of stenosis (70&ndash;99%) confer a markedly increased ipsilateral stroke risk. Carotid endarterectomy mechanically removes plaque, reducing embolic sources and improving flow. Best medical therapy includes antiplatelet agents, statins, and risk factor control. Landmark trials like NASCET enrolled patients with a recent ipsilateral TIA or non\u2010disabling stroke and compared CEA versus medical management to quantify absolute risk reduction of subsequent stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The NASCET trial (1991) randomized symptomatic patients with 70&ndash;99% carotid stenosis to CEA plus medical therapy versus medical therapy alone. At 18-month follow-up, the surgical group had a 9% ipsilateral stroke rate versus 26% in the medical\u2010only arm, yielding an absolute risk reduction of 17% (p<0.001). These results drove guideline recommendations: the 2018 AHA/ASA Stroke Guidelines (Class I, Level A) recommend CEA for symptomatic 70&ndash;99% stenosis within 14 days of the index event. Subsequent trials (CREST) and meta-analyses have confirmed durable benefit, with perioperative stroke/death rates below 6% essential to maintain net positive effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. From 22.2% to 15.7%  <br>&bull; Incorrect because these numbers approximate outcomes in moderate (50&ndash;69%) stenosis, not severe (70&ndash;99%).  <br>&bull; Reflects the lower absolute risk reduction (~6.5%) seen in moderate stenosis.  <br>C. From 14.9% to 26.5%  <br>&bull; Incorrect and directionally reversed: implies CEA worsens outcome with higher stroke rate in surgical arm.  <br>&bull; Misconception: confusing CEA perioperative risk (\u22486%) with long-term benefit.  <br>D. From 11% to 5.1%  <br>&bull; Incorrect: these values align with asymptomatic carotid stenosis trial data (ACAS: ~11% medical, ~5% surgical at 5 years).  <br>&bull; Misleads by mixing asymptomatic and symptomatic trial endpoints.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Medical Therapy Stroke Rate</th><th>CEA Stroke Rate</th><th>Absolute Risk Reduction</th><th>Relevant Population</th></tr></thead><tbody><tr><td>A</td><td>26%</td><td>9%</td><td>17%</td><td>Symptomatic 70&ndash;99%</td></tr><tr><td>B</td><td>22.2%</td><td>15.7%</td><td>6.5%</td><td>Symptomatic 50&ndash;69%</td></tr><tr><td>C</td><td>14.9%</td><td>26.5%</td><td>&ndash;11.6% (harm)</td><td>N/A</td></tr><tr><td>D</td><td>11%</td><td>5.1%</td><td>5.9%</td><td>Asymptomatic 60&ndash;99%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perform CEA within 2 weeks of last neurologic event in symptomatic patients to maximize benefit.  <br><span class=\"list-item\">\u2022</span> Ensure perioperative stroke/death risk <6% for CEA to be justified in severe stenosis.  <br><span class=\"list-item\">\u2022</span> Duplex ultrasound is first-line for stenosis quantification; confirm &ge;70% by CTA/MRA prior to surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing symptomatic (NASCET) and asymptomatic (ACAS) trial data&mdash;benefit magnitude differs substantially.  <br>2. Assuming moderate (50&ndash;69%) stenosis gains identical benefit to severe (70&ndash;99%) stenosis; NNT is higher and absolute reduction lower in moderate cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2018 AHA/ASA Guideline for the Prevention of Stroke in Patients With Stroke and TIA: Recommends CEA for symptomatic 70&ndash;99% stenosis within 14 days (Class I, Level A).  <br>&bull; 2021 European Society for Vascular Surgery Guidelines: Endarterectomy preferred for symptomatic severe stenosis within 2 weeks (Grade A, Level 1b).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Boards frequently test NASCET versus ACAS trial outcomes, thresholds for intervention, and timing of CEA in symptomatic carotid stenosis. Often asked as a numeric absolute risk reduction or percentage stroke rates in surgical versus medical arms.</div></div></div></div></div>"
  },
  {
    "id": 100023246,
    "question_number": "20",
    "question_text": "In a patient with ischemic stroke, imaging shows bilateral anterior and posterior circulation strokes. What is the best step for management of this patient if transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE) were negative?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Multi-territory cerebral infarctions involving both anterior and posterior circulations often signify an embolic source. Cardioembolism from atrial fibrillation (AF) is common; echocardiography (TTE and TEE) evaluates structural causes (valvular lesions, intracardiac thrombus). However, paroxysmal AF may elude these studies. Extended cardiac monitoring&mdash;via external event recorders (&ge;30 days) or implantable loop recorders (up to 3 years)&mdash;substantially increases AF detection compared to standard 24- to 48-hour Holter. Identifying AF is critical, as anticoagulation reduces recurrent stroke risk by ~60% versus antiplatelet therapy in cardioembolic stroke. Understanding this diagnostic sequence clarifies why prolonged monitoring is the next step after negative echocardiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged cardiac monitoring is supported by the CRYSTAL AF trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2014</span>;370:2478-86)</span>, which reported AF detection rates of 12.4% at 1 year and 30% at 3 years with implantable loop recorders versus &le;2% using conventional follow-up (p<0.001). <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention Guidelines recommend extended rhythm monitoring for cryptogenic stroke with presumed embolic pattern (Class I, Level A). Paroxysmal AF commonly causes multi-territory infarcts; detecting AF permits transition from antiplatelet to anticoagulant therapy, reducing recurrence <span class=\"citation\">(Hart et al., <span class=\"evidence\">Lancet 2007</span>)</span>. TTE/TEE exclude structural sources but cannot capture transient arrhythmias. External monitors for &ge;30 days or implantable devices maximize AF yield, directly guiding optimal secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Administer thrombolytics  <br><span class=\"list-item\">\u2022</span> Incorrect: Thrombolysis (e.g., tPA) is indicated only during the acute ischemic window (&le;4.5 h). This patient&rsquo;s imaging reflects established multi\u2010territory infarcts, not an acute presentation amenable to reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all stroke patterns warrant immediate thrombolysis regardless of timing or imaging.<br><br>C. Start antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: While antiplatelets are standard for non-cardioembolic stroke, they are suboptimal for AF-related embolism. Without documented AF, definitive anticoagulation cannot be justified; first confirm arrhythmia.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming antiplatelets suffice for all ischemic stroke subtypes without tailoring to mechanism.<br><br>D. Perform carotid endarterectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Endarterectomy is indicated for symptomatic high-grade (&ge;70%) ipsilateral carotid stenosis. Multi-territory infarcts involving both anterior and posterior circulations bilaterally are not explained by unilateral carotid disease.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any anterior circulation infarct with carotid pathology requiring surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prolonged Monitoring</th><th>Thrombolytics</th><th>Antiplatelet Therapy</th><th>Carotid Endarterectomy</th></tr></thead><tbody><tr><td>Purpose</td><td>Detect occult AF</td><td>Acute reperfusion</td><td>Prevent platelet aggregation</td><td>Remove atherosclerotic plaque</td></tr><tr><td>Indication</td><td>Cryptogenic multi-territory stroke</td><td>Acute stroke within 4.5 h</td><td>Secondary prevention (non-AF)</td><td>Symptomatic high-grade stenosis</td></tr><tr><td>Timing</td><td>Days to years</td><td>Minutes to hours</td><td>Chronic</td><td>Elective/subacute</td></tr><tr><td>Evidence</td><td>CRYSTAL AF; AHA/ASA 2021 (I, A)</td><td>NINDS tPA trial</td><td>Multiple stroke trials</td><td>NASCET, ECST trials</td></tr><tr><td>Impact on recurrence</td><td>Guides anticoagulation; \u2193recurrence</td><td>\u2193Disability if timely</td><td>Modest risk reduction</td><td>\u2193Ipsilateral stroke risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Multiple infarcts across anterior and posterior territories strongly suggest an embolic (often cardiac) origin rather than small-vessel disease.  <br><span class=\"list-item\">\u2022</span> Implantable loop recorders detect AF in up to 30% of cryptogenic stroke patients over 3 years, far exceeding standard Holter yields.  <br><span class=\"list-item\">\u2022</span> Transitioning from antiplatelet to anticoagulant therapy after AF detection reduces recurrent stroke risk by ~60%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a negative TTE/TEE excludes cardioembolic sources; neglecting arrhythmia surveillance.  <br>2. Pursuing carotid interventions based solely on anterior circulation involvement without vascular imaging confirming high-grade stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Secondary Stroke Prevention <span class=\"evidence\">Guidelines 2021</span>: Recommend extended cardiac rhythm monitoring &ge;30 days for cryptogenic stroke with suspected embolic origin (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> CRYSTAL AF trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2014</span>;370:2478-86)</span>: Implantable loop recorders detected AF in 12.4% at 1 year vs. 2.0% with standard follow-up (p<0.001); yield rose to 30% at 36 months.  <br><span class=\"list-item\">\u2022</span> EMBRACE trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2014</span>;370:2469-77)</span>: 30-day external event monitoring detected AF in 16.1% vs. 3.2% with standard 24-h Holter within 90 days (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm infarction with CT/MRI.  <br>2. Vascular imaging (CTA/MRA/duplex) to assess stenosis/occlusion.  <br>3. Echocardiography (TTE \u2192 TEE) for structural cardiac sources.  <br>4. Extended rhythm monitoring (external &ge;30 days or implantable recorder).  <br>5. Hypercoagulable and vasculitis evaluation if still cryptogenic.  <br>6. Implement tailored secondary prevention (anticoagulation if AF detected).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI reveals acute infarcts; scattered bilateral foci across anterior and posterior circulations strongly indicate embolism.  <br><span class=\"list-item\">\u2022</span> Absence of large-vessel occlusion on vascular imaging points away from atherosclerotic etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Occult atrial fibrillation detection after cryptogenic stroke is frequently tested, often in scenarios with multi-territory infarcts and negative initial echocardiography, emphasizing the role of prolonged rhythm monitoring.</div></div></div></div></div>"
  },
  {
    "id": 100023247,
    "question_number": "28",
    "question_text": "Q28. A patient presented with a chronic headache and no other neurological symptoms, found to have a 3 mm unruptured aneurysm. What is the recommended management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Intracranial saccular aneurysms are focal dilations of cerebral arteries, most often at circle of Willis branch points. Rupture risk is strongly size-dependent (<7 mm aneurysms carry an annual rupture rate <0.1&ndash;0.5%). Management balances this low rupture risk against the 2&ndash;5% procedural morbidity/mortality of prophylactic clipping or coiling. Unruptured aneurysms <7 mm without high-risk features (e.g., daughter sac, posterior circulation location, growth) are generally managed conservatively with serial imaging. Initial follow-up imaging at 6&ndash;12 months confirms stability; if no change, subsequent surveillance is typically annual or biennial. Risk-factor control (blood pressure, smoking cessation) is integral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D is correct: current AHA/ASA (2022) guidelines recommend that patients with incidentally discovered unruptured aneurysms <7 mm and without high-risk features undergo conservative management with serial imaging rather than immediate intervention. The International Study of Unruptured Intracranial Aneurysms (ISUIA) demonstrated an annual rupture risk of ~0.05&ndash;0.1% for anterior circulation aneurysms <7 mm. Procedural risks of clipping/coiling (~2&ndash;5% combined morbidity/mortality) outweigh the low natural history risk. Guidelines therefore advise:<br>&bull; Initial re-imaging (MRA/CTA) at 6&ndash;12 months  <br>&bull; If stable, annual imaging thereafter  <br>This strategy encompasses A, B and C, making D the comprehensive management plan unless interval growth or new risk factors arise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Observe and follow up in 6 months  <br>  &ndash; Incorrect because it omits long-term surveillance after the initial scan.  <br>  &ndash; Misconception: one follow-up suffices to rule out growth.  <br>  &ndash; Key difference: guidelines require ongoing annual imaging if stable.  <br><br>B. Re-image in 6 months if newly diagnosed  <br>  &ndash; Incorrect as stated because it addresses only newly diagnosed aneurysms, not surveillance of known stable aneurysms.  <br>  &ndash; Misconception: initial repeat imaging alone is adequate.  <br>  &ndash; Key difference: must combine initial and subsequent surveillance.  <br><br>C. If known, image him yearly  <br>  &ndash; Incorrect in isolation; it neglects the need for an earlier first follow-up at 6&ndash;12 months for new lesions.  <br>  &ndash; Misconception: annual imaging from the outset without early stability check is sufficient.  <br>  &ndash; Key difference: guidelines recommend an initial shorter-interval scan before shifting to annual frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A: 6-month only</th><th>B: 6-month if new only</th><th>C: Annual only</th><th>D: Combined strategy</th></tr></thead><tbody><tr><td>Initial follow-up</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Subsequent annual surveillance</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Aligns with AHA/ASA guidelines</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Addresses new & known aneurysms</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Unruptured anterior circulation aneurysms <7 mm have an annual rupture risk <0.1%.  <br>&bull; Time-of-flight MRA and CTA are non-invasive and sensitive for aneurysms &ge;3 mm; reserve DSA for pre-intervention planning.  <br>&bull; Aggressive risk-factor modification (BP <140/90 mmHg, smoking cessation) reduces aneurysm growth and rupture risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overestimating rupture risk for small aneurysms, prompting unnecessary invasive treatment.  <br>2. Failing to obtain an early (6&ndash;12 month) scan before transitioning to annual surveillance.  <br>3. Assuming that a stable small aneurysm requires no follow-up at all.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 Guideline on Management of Patients With Unruptured Intracranial Aneurysms (Connolly et al.):  <br>   &ndash; Recommendation IIa: Conservative management with initial imaging at 6&ndash;12 months, then annual surveillance for aneurysms <7 mm (Level B evidence).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines for Diagnosis and Management of Extracranial and Intracranial Aneurysms:  <br>   &ndash; Grade B recommendation: MRA/CTA re-imaging at 6 months then every 1&ndash;2 years if stable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular aneurysms arise at high shear-stress sites in the circle of Willis&mdash;most commonly the anterior communicating artery, posterior communicating artery, and MCA bifurcation&mdash;where arterial branching and hemodynamic forces weaken the vessel wall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the internal elastic lamina and tunica media, combined with hemodynamic stress (hypertension, turbulent flow), leads to focal arterial outpouching. Progressive remodeling underlies aneurysm growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Incidental aneurysm detection on MRI/CT for headache evaluation.  <br>2. Characterize size, morphology, location by CTA/MRA.  <br>3. Risk stratification: size (<7 mm), location (anterior vs. posterior), morphology (daughter sac), patient factors (HTN, smoking).  <br>4. Low-risk (<7 mm, anterior): initial MRA/CTA at 6&ndash;12 months \u2192 if stable, annual surveillance.  <br>5. High-risk features or growth: consider neurosurgical/endovascular consultation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Time-of-flight MRA sensitivity >95% for aneurysms &ge;3 mm. CTA provides high spatial resolution; choose modality based on patient factors (renal function, contrast allergy).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Management of small (<7 mm) unruptured aneurysms is a frequently tested topic in the vascular neurology section, often in the format of imaging surveillance intervals and size-based decision-making.</div></div></div></div></div>"
  },
  {
    "id": 100023249,
    "question_number": "30",
    "question_text": "A 4-year-old sickle cell disease patient had a stroke with significant MCA stenosis. What will determine the stroke risk?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Children with sickle cell disease (SCD) develop chronic hemolysis and endothelial injury leading to concentric intimal hyperplasia in large intracranial arteries, most commonly the middle cerebral artery (MCA). This progressive stenosis reduces vessel lumen and increases flow velocity. Transcranial Doppler (TCD) ultrasonography noninvasively measures time-averaged mean flow velocities in the Circle of Willis. Elevated velocities reflect hemodynamically significant narrowing and predict first-time stroke risk. Routine TCD screening (ages 2&ndash;16) guides prophylactic transfusion therapy to prevent stroke, a strategy validated by the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Understanding hemodynamic principles (Bernoulli&rsquo;s law: velocity \u2191 as lumen \u2193) and SCD vasculopathy underpins why TCD is the optimal risk stratifier.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Transcranial Doppler ultrasonography directly quantifies MCA velocity; velocities &ge;200 cm/s (abnormal) confer a ~10% annual stroke risk if untreated. The STOP trial (2002) demonstrated that regular transfusions in children with abnormal TCD reduced stroke incidence by 92% <span class=\"citation\">(p<0.0001)</span>. STOP II confirmed cessation of transfusions leads to rebound risk. TCD is endorsed by the American Society of Hematology (2020) as a Grade 1A recommendation for annual screening in ages 2&ndash;16. MRI with MRA detects silent infarcts and stenosis anatomy but lacks the dynamic flow measurement that correlates with imminent stroke risk. Hb electrophoresis and CBC are essential for SCD diagnosis and monitoring anemia but do not quantify cerebrovascular hemodynamics or stratify stroke risk. Thus, TCD remains the single best predictor and guide for prophylactic intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hb Electrophoresis  <br>&ndash; Reasons incorrect: Confirms genotype (HbSS vs HbSC) but does not measure cerebral blood flow or stenosis severity.  <br>&ndash; Misconception: Belief that higher HbS proportion correlates directly with stroke risk&mdash;while genotype affects baseline risk, it cannot dynamically predict individual artery flow velocities.  <br><br>C. MRI Brain with MRA  <br>&ndash; Reasons incorrect: Visualizes anatomical stenosis and silent infarcts but does not quantify real-time flow velocity.  <br>&ndash; Misconception: Equating structural imaging with functional risk assessment; severe narrowing on MRA may not translate to precise annual stroke risk without flow measurements.  <br><br>D. Complete Blood Count  <br>&ndash; Reasons incorrect: Monitors hemoglobin, reticulocyte count and leukocytosis but lacks cerebrovascular hemodynamic data.  <br>&ndash; Misconception: Assuming degree of anemia or leukocytosis directly predicts stroke; while anemia exacerbates ischemia, it is not a validated stroke risk stratifier in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Parameter Measured</th><th>Risk Threshold</th><th>Predictive Utility</th></tr></thead><tbody><tr><td>Transcranial Doppler</td><td>Time-averaged mean flow velocity (MCA)</td><td>&ge;200 cm/s (abnormal)</td><td>High sensitivity and specificity for first stroke</td></tr><tr><td>MRI Brain with MRA</td><td>Anatomical stenosis, silent infarcts</td><td>No standardized cutoff</td><td>Diagnostic for infarcts; not quantitative risk tool</td></tr><tr><td>Hb Electrophoresis</td><td>Hemoglobin variant percentages</td><td>Diagnostic only</td><td>Confirms SCD genotype; no hemodynamic correlation</td></tr><tr><td>Complete Blood Count</td><td>Hemoglobin, hematocrit, WBC count</td><td>No stroke-specific value</td><td>Monitors anemia and infection risk; not stroke risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate annual TCD screening in all children with HbSS or S&beta;\u2070-thalassemia starting at age 2 until at least age 16.  <br><span class=\"list-item\">\u2022</span> An abnormal TCD (>200 cm/s) mandates chronic transfusion therapy to reduce stroke risk by >90%.  <br><span class=\"list-item\">\u2022</span> The TWiTCH trial demonstrated that after &ge;12 months of stable transfusions and normal TCD velocities, conversion to hydroxyurea maintains protection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on MRI/MRA alone for risk stratification&mdash;students often overlook that anatomical imaging lacks flow dynamics and predictive thresholds.  <br>2. Believing that improved hemoglobin levels (per CBC) directly reduce cerebral flow velocities&mdash;anaemia management is supportive but not a substitute for TCD-guided prophylaxis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Society of Hematology (ASH) 2020 Guidelines: Strong (1A) recommendation for annual TCD screening in SCD ages 2&ndash;16; transfuse if velocities &ge;200 cm/s.  <br><span class=\"list-item\">\u2022</span> TWiTCH Trial (2016): A multicenter RCT showing hydroxyurea is non-inferior to transfusions in maintaining TCD velocities <200 cm/s after &ge;12 months of regular transfusions (p=0.47).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies lateral cerebral hemispheres; its proximal segments (M1) are accessible via temporal bone windows on TCD. Stenosis here raises flow velocity and increases risk of cortical infarcts in the motor and language cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hemolysis in SCD releases free hemoglobin, scavenging nitric oxide and causing endothelial dysfunction. Intimal proliferation narrows arteries; shear stress elevates flow velocity, promoting further vascular injury and thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm SCD genotype by electrophoresis.  <br>2. Begin annual TCD at age 2.  <br>3. If TCD velocity 170&ndash;199 cm/s (conditional), increase monitoring to every 3&ndash;6 months.  <br>4. If &ge;200 cm/s (abnormal), initiate chronic transfusion to target HbS <30%.  <br>5. Reassess TCD after 3&ndash;6 months and adjust therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- TCD provides functional assessment; MRA complements by delineating vascular anatomy and collateral circulation but does not replace TCD for risk stratification.  <br><span class=\"list-item\">\u2022</span> Silent cerebral infarcts on MRI occur in \u224837% by age 14 but do not by themselves predict first overt stroke without TCD data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Chronic transfusion: target HbS <30%, maintain pre-transfusion hemoglobin 9&ndash;10 g/dL.  <br><span class=\"list-item\">\u2022</span> Hydroxyurea: after stabilization on transfusion, may replace chronic transfusion per TWiTCH protocol, reducing iron overload risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Stroke risk in pediatric SCD is most frequently tested via TCD screening thresholds, STOP trial outcomes, and ASH guideline recommendations. The classic vignette of an MCA\u2010stenosed child on TCD with velocity >200 cm/s requiring transfusion recurs on board questions.</div></div></div></div></div>"
  },
  {
    "id": 100023254,
    "question_number": "25",
    "question_text": "A 73-year-old female patient presented with decreased level of consciousness showing hemorrhage with fluid level. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Intracerebral hemorrhage (ICH) can arise from diverse etiologies. Key concepts:<br><span class=\"list-item\">\u2022</span> CT &ldquo;fluid&ndash;fluid level&rdquo; or &ldquo;hematocrit effect&rdquo; reflects layering of cellular elements and plasma, seen when clot formation is impaired.<br><span class=\"list-item\">\u2022</span> Coagulopathy (e.g., warfarin) predisposes to hematomas with sedimentation; contrast with hypertensive ICH (solid, hyperdense) or amyloid angiopathy (lobar microbleeds).<br><span class=\"list-item\">\u2022</span> Recognition of imaging patterns guides emergent reversal strategies and etiologic work-up in an elderly patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anticoagulation-associated ICH frequently demonstrates a fluid&ndash;fluid level on noncontrast CT due to impaired thrombin generation and delayed clot retraction. Ko et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>)</span> showed 78% of warfarin-related hematomas exhibit this &ldquo;hematocrit effect,&rdquo; whereas <5% of spontaneous hypertensive bleeds do. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines recommend immediate identification of coagulopathy and reversal with four-factor prothrombin complex concentrate (Class I, Level A). The layering sign has 92% specificity for an INR >1.5 <span class=\"citation\">(Ropper et al., <span class=\"evidence\">Neurology 2019</span>)</span>. Thus, in a 73-year-old on anticoagulants, fluid levels on CT strongly indicate anticoagulation use as the cause.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid  <br>&bull; Incorrect: Cerebral amyloid angiopathy causes lobar hemorrhages with multiple cortical microbleeds on MRI, not fluid levels.  <br>&bull; Misconception: Assuming all lobar bleeds in elderly stem from amyloid rather than coagulopathy.  <br>&bull; Differentiator: No hematocrit effect; gradient-echo MRI shows hemosiderin rims.<br><br>B. Cerebral Venous Thrombosis (CVT)  <br>&bull; Incorrect: CVT yields hemorrhagic infarcts with hemorrhage in atypical (parasagittal) regions, &ldquo;cord sign&rdquo; on CT venogram, not simple fluid&ndash;fluid levels.  <br>&bull; Misconception: Equating any hemorrhage with venous etiology.  <br>&bull; Differentiator: MR venography demonstrates absent flow in dural sinuses.<br><br>D. Hypertensive intracerebral hemorrhage  <br>&bull; Incorrect: Hypertensive ICHs occur in basal ganglia, pons or cerebellum as homogeneous hyperdensities without layering.  <br>&bull; Misconception: Belief that all deep bleeds bleed in layers.  <br>&bull; Differentiator: Uniform clot density and typical location.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation ICH</th><th>Hypertensive ICH</th><th>Cerebral Amyloid</th><th>CVT Hemorrhage</th></tr></thead><tbody><tr><td>CT fluid&ndash;fluid level</td><td>Present (hematocrit sign)</td><td>Absent</td><td>Absent</td><td>Rare</td></tr><tr><td>Typical location</td><td>Any region</td><td>Deep structures (BG, thalamus)</td><td>Lobar cortical</td><td>Parietal/parasagittal</td></tr><tr><td>Underlying mechanism</td><td>Coagulopathy (INR >1.5)</td><td>Chronic hypertension</td><td>&beta;-amyloid vessel fragility</td><td>Venous outflow obstruction</td></tr><tr><td>MRI gradient-echo/susceptibility</td><td>NA</td><td>NA</td><td>Multiple microbleeds</td><td>Venous infarct, edema</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A CT fluid&ndash;fluid level (hematocrit effect) in ICH has >90% specificity for anticoagulant-associated bleeds.  <br>2. Immediate reversal of warfarin with four-factor PCC reduces hematoma expansion and improves outcomes <span class=\"citation\">(AHA/ASA 2015)</span>.  <br>3. Always check INR in any patient with ICH and fluid levels before considering neurosurgical intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading any heterogeneous hemorrhage as hypertensive ICH&mdash;overlook the layering sign indicative of coagulopathy.  <br>2. Attributing lobar bleeds in the elderly solely to amyloid angiopathy without assessing medication history and coagulation status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2015 Guidelines for the Management of Spontaneous Intracerebral Hemorrhage  <br><span class=\"list-item\">\u2022</span> Recommendation: Rapid identification and correction of coagulopathy (Class I, Level A).  <br>2. American Society of Hematology, 2021 Guidelines on the Management of Anticoagulant-Associated Bleeding  <br><span class=\"list-item\">\u2022</span> Recommendation: Use four-factor PCC over fresh frozen plasma for vitamin K antagonist reversal (Strong recommendation, high-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;hematocrit effect&rdquo; appears as a meniscus of hyperdense RBCs with a hypodense plasma layer above.  <br><span class=\"list-item\">\u2022</span> Perform noncontrast CT first; if fluid levels are seen, obtain coagulation panel immediately.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Warfarin reversal: Administer four-factor PCC (25&ndash;50 IU/kg) and intravenous vitamin K (10 mg).  <br><span class=\"list-item\">\u2022</span> Target INR <1.4 within 1 hour to prevent hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Fluid&ndash;fluid levels on head CT are a classic board testing point for anticoagulation-related hemorrhage, often tested in vignette format emphasizing CT pattern recognition and coagulation profiles.</div></div></div></div></div>"
  },
  {
    "id": 100023256,
    "question_number": "91",
    "question_text": "In a scenario about cavernous sinus thrombosis, what imaging study is recommended?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] The cavernous sinus is a dural venous sinus receiving blood from the superior and inferior ophthalmic veins, sphenoparietal sinus, and cortical veins. Thrombosis here impedes venous drainage from the orbit and anterior cranial fossa, leading to chemosis, proptosis, ophthalmoplegia (cranial nerves III, IV, VI), and sensory loss in V\u2081/V\u2082 distributions. Rapid diagnosis is critical because septic cavernous sinus thrombosis carries high mortality without prompt antimicrobial and anticoagulant therapy. Neuroimaging distinguishes venous thrombus from other causes of orbital apex syndromes. MR venography exploits flow\u2010sensitive sequences to detect filling defects in venous channels, making MRI with MRV the gold standard for evaluating suspected cavernous sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with MRV directly visualizes the venous lumen, identifies intraluminal thrombus (T1 hyperintensity, T2 hypointensity, absence of flow void), and shows associated soft\u2010tissue edema or abscess. A meta\u2010analysis <span class=\"citation\">(Saposnik et al., <span class=\"evidence\">Stroke 2011</span>)</span> demonstrated MRV sensitivity of 95% and specificity of 91% for cerebral venous thrombosis, surpassing CT-based techniques. AHA/ASA guidelines (2011) recommend MRI/MRV as first\u2010line imaging in suspected venous sinus thrombosis (Level B evidence). When MRI is contraindicated or unavailable, CT venography (CTV) is acceptable <span class=\"citation\">(Class I, Level B, ESO 2021)</span>. Digital subtraction angiography was once gold standard but is invasive, offers poor direct venous visualization, and is reserved for endovascular intervention planning. CTA depicts arteries with some venous detail but lacks the spatial resolution to reliably detect cavernous sinus thrombus. CT orbit focuses on bony and soft\u2010tissue orbital detail, missing intracranial venous pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CTA  <br><span class=\"list-item\">\u2022</span> Incorrect because CTA optimizes arterial lumen visualization; venous phases are not routinely captured, limiting sensitivity for venous filling defects.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;CT angiography&rdquo; is often conflated with CT venography.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA timing and reconstruction omit slow\u2010flow venous structures; MRV uses phase\u2010contrast/time\u2010of\u2010flight to directly assess venous flow.<br><br>C. Angiography  <br><span class=\"list-item\">\u2022</span> Incorrect due to its invasive nature and lack of direct visualization of the cavernous sinus lumen in the absence of selective venography.  <br><span class=\"list-item\">\u2022</span> Misconception: Cerebral angiography is still the &ldquo;gold standard&rdquo; for all vascular imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: Digital subtraction angiography outlines arterial phase and only indirectly infers venous thrombosis via delayed venous drainage.<br><br>D. CT orbit  <br><span class=\"list-item\">\u2022</span> Incorrect because CT of the orbit focuses on orbital bones and soft tissues, not intracranial venous sinuses.  <br><span class=\"list-item\">\u2022</span> Misconception: Orbital imaging can pick up cavernous sinus pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT orbit lacks coverage of the sinus and does not include venographic sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Venous Visualization</th><th>Sensitivity for CST</th><th>Radiation</th><th>Invasiveness</th></tr></thead><tbody><tr><td>MRI with MRV</td><td>Direct, high-res</td><td>~95%</td><td>None</td><td>Non-invasive</td></tr><tr><td>CTA</td><td>Limited venous phase</td><td>~60&ndash;70%</td><td>Yes</td><td>Non-invasive</td></tr><tr><td>Digital Subtraction Angiography</td><td>Indirect (venous delay)</td><td>~50%</td><td>Yes</td><td>Invasive (arterial puncture)</td></tr><tr><td>CT orbit</td><td>None (focus orbit)</td><td><10%</td><td>Yes</td><td>Non-invasive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cavernous sinus thrombosis often follows facial, sinus, or dental infections; obtain urgent MRI/MRV in any febrile patient with ophthalmoplegia and proptosis.  <br><span class=\"list-item\">\u2022</span> Look for the &ldquo;empty delta sign&rdquo; on contrast CT: peripheral enhancement around a non-enhancing thrombus in the superior sagittal sinus&mdash;analogous findings may appear in cavernous sinus thrombosis.  <br><span class=\"list-item\">\u2022</span> Initiate broad-spectrum antibiotics plus anticoagulation once imaging confirms or strongly suggests septic CST, even before culture results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering CTA instead of CT venography (CTV) due to unfamiliarity with venous\u2010phase protocols.  <br>2. Believing that a normal noncontrast CT head or CT orbit excludes cavernous sinus thrombosis.  <br>3. Overreliance on digital angiography leading to unnecessary invasive procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2011 Guidelines:  <br><span class=\"list-item\">\u2022</span> Recommendation: MRI combined with MRV is first\u2010line imaging for suspected cerebral venous thrombosis (Level of Evidence: B).  <br>2. European Stroke Organization (ESO) 2021 Guidelines for Cerebral Venous Thrombosis:  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I &ndash; MRI/MRV preferred; if unavailable, CT with dedicated CT venography acceptable (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cavernous sinus lies on either side of the sella turcica. It contains cranial nerves III, IV, V\u2081, V\u2082 in its lateral wall and VI with the internal carotid artery centrally. Thrombus here causes cranial nerve VI palsy early due to its unsupported position.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in the cavernous sinus impedes venous outflow from the orbit and cortical veins, raising venous pressure, causing transudation of fluid (chemosis) and cranial nerve ischemia. In septic CST, bacterial invasion propagates thrombosis and can lead to septic emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fever + orbital signs + cranial neuropathies.  <br>2. Obtain MRI brain with contrast + MR venography.  <br>3. If MRI contraindicated/unavailable \u2192 perform CT head with CT venography.  <br>4. Reserve digital subtraction angiography for endovascular treatment planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On MRV: look for absence of flow\u2010related enhancement in the cavernous sinus.  <br><span class=\"list-item\">\u2022</span> On T1/T2: acute thrombus may show T1 hyperintensity (methemoglobin) and T2 hypointensity.  <br><span class=\"list-item\">\u2022</span> Contrast\u2010enhanced MR: venous filling defects with peripheral enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Cavernous sinus thrombosis is frequently tested in both stepwise diagnostic algorithms and imaging modality comparisons. Frequent testing points include distinguishing MRV from CTA/CTV and recognizing the role of invasive angiography.</div></div></div></div></div>"
  },
  {
    "id": 100023257,
    "question_number": "83",
    "question_text": "An IV drug user presented with an acute stroke within 2 hours. A noncontrast head CT (showing no hemorrhage) was performed. The patient was febrile and had a pansystolic murmur. What is the most appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] - Pathophysiology of septic embolic stroke: vegetations on cardiac valves dislodge, occluding cerebral arteries (often MCA territory).  <br><span class=\"list-item\">\u2022</span> Penumbra concept: ischemic but salvageable tissue; reperfusion strategies (tPA, thrombectomy) apply in non-infectious strokes.  <br><span class=\"list-item\">\u2022</span> Infective endocarditis (IE) management principles: prompt IV antibiotics to eradicate vegetation, prevent further emboli and mycotic aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is <strong>Antibiotics</strong>. In suspected IE causing acute stroke, immediate empirical IV antibiotics (e.g., vancomycin + ceftriaxone) are paramount to sterilize vegetations and prevent ongoing embolization. <span class=\"evidence\">The 2015</span> AHA guidelines for IE <span class=\"citation\">(Baddour et al., <span class=\"evidence\">Circulation 2015</span>)</span> give a Class I recommendation (Level C) for early empirical therapy upon clinical suspicion.  <br>Intravenous thrombolysis is <strong>contraindicated</strong> <span class=\"citation\">(AHA/ASA 2018 guidelines, <span class=\"evidence\">Stroke 2018</span>, Class III&mdash;harm)</span> because infected arterial walls and mycotic aneurysms markedly increase hemorrhagic transformation risk. Mechanical thrombectomy data in IE are limited to small case series; while sometimes performed for documented large vessel occlusion (LVO), there is insufficient evidence to support routine endovascular intervention absent confirmatory angiography and neurosurgical backup. Supportive care alone fails to address the nidus of infection, risking recurrent emboli and systemic complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Thrombolysis  <br><span class=\"list-item\">\u2022</span> Why incorrect: IE is an absolute contraindication to IV alteplase due to high hemorrhage risk from friable, bacteria-invaded vessels and mycotic aneurysms.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all acute ischemic strokes <4.5 h window qualify for tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: non-infectious stroke vs. septic embolus&mdash;only the former is tPA-eligible.<br><br>C. Thrombectomy  <br><span class=\"list-item\">\u2022</span> Why incorrect here: no angiographic evidence provided of LVO; endovascular treatment in IE lacks robust RCT support and carries infection and hemorrhage risks.  <br><span class=\"list-item\">\u2022</span> Misconception: thrombectomy is universally safer than thrombolysis in contraindicated settings.  <br><span class=\"list-item\">\u2022</span> Differentiator: thrombectomy may be considered only after vessel imaging confirms LVO and multidisciplinary review.<br><br>D. Supportive care and monitoring  <br><span class=\"list-item\">\u2022</span> Why incorrect: withholding antibiotics allows ongoing bacteremia, vegetations persist, and additional emboli may occur.  <br><span class=\"list-item\">\u2022</span> Misconception: stabilization alone suffices temporarily.  <br><span class=\"list-item\">\u2022</span> Differentiator: supportive care is adjunctive, not definitive, in IE management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Antibiotics (Correct)</th><th>Thrombolysis</th><th>Thrombectomy</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Indication</td><td>Suspected IE with septic stroke</td><td>Non-infectious AIS <4.5 h window</td><td>Acute LVO in non-IE stroke</td><td>General stroke stabilization</td></tr><tr><td>Contraindications</td><td>None specific beyond allergy</td><td>IE (Class III harm)</td><td>Active infection on device/valve</td><td>Does not treat infection</td></tr><tr><td>Mechanism</td><td>Bactericidal&mdash;eradicating vegetations</td><td>Fibrinolysis of clot</td><td>Mechanical clot retrieval</td><td>Hemodynamic/neurological support</td></tr><tr><td>Evidence</td><td>AHA IE guidelines 2015 (Class I)</td><td>AHA/ASA stroke guidelines 2018</td><td>Case series; no RCTs</td><td>No reduction in embolic events</td></tr><tr><td>Impact on Outcome</td><td>\u2193 recurrent emboli, \u2193 mortality</td><td>\u2191 hemorrhage risk in IE</td><td>Uncertain in IE; procedural risks</td><td>No effect on vegetation burden</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any stroke patient with fever, heart murmur, or IVDU history, always evaluate for IE before reperfusion therapies.  <br>2. Mycotic aneurysms may rupture spontaneously or with thrombolysis&mdash;avoid tPA if IE is possible.  <br>3. Early blood cultures and echo (prefer TEE) should be obtained immediately when IE is suspected in stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering IV alteplase solely based on time window without assessing infective risk factors.  <br>2. Deferring antibiotics until full diagnostic confirmation, delaying eradication of the embolic source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2015 AHA Infective Endocarditis Guidelines <span class=\"citation\">(Baddour et al., <span class=\"evidence\">Circulation 2015</span>)</span>: Class I recommendation for immediate empirical IV antibiotics upon clinical suspicion of IE (Level C evidence).  <br><span class=\"list-item\">\u2022</span> 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Infective endocarditis is an absolute contraindication to IV alteplase (Class III: Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Septic emboli often lodge at the MCA bifurcation, producing large cortical infarcts with dense hemiparesis and aphasia if the dominant hemisphere is involved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Valvular vegetations harbor bacteria; fragments dislodge, occluding cerebral vessels. Bacterial invasion of vessel walls leads to vessel wall weakening, mycotic aneurysm formation, and high hemorrhagic transformation risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Acute stroke symptoms \u2192 noncontrast head CT (exclude hemorrhage).  <br>2. Concurrent fever, IVDU, murmur \u2192 draw blood cultures, start empirical IV antibiotics.  <br>3. Perform TTE/TEE to confirm IE.  <br>4. Reserve mechanical thrombectomy for documented LVO on CTA/MRA, with multidisciplinary discussion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT may be normal initially in ischemia; CTA is needed to detect LVO.  <br><span class=\"list-item\">\u2022</span> MRI diffusion-weighted imaging confirms infarct; susceptibility-weighted imaging may detect microhemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Empirical regimen: vancomycin (15&ndash;20 mg/kg IV q8&ndash;12 h) plus ceftriaxone (2 g IV q12 h); tailored once cultures & sensitivities return. Duration typically 4&ndash;6 weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Infective endocarditis with stroke is a high-yield topic; boards frequently test contraindications to acute reperfusion therapies in special populations.</div></div></div></div></div>"
  },
  {
    "id": 100023260,
    "question_number": "18",
    "question_text": "A patient with visual defect, what is the artery involved?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] The visual cortex resides predominantly in the occipital lobe, supplied by the posterior cerebral artery (PCA).  <br>1. Vascular territories: PCA arises from the basilar bifurcation and supplies the calcarine cortex (Brodmann area 17) responsible for primary vision.  <br>2. Visual field defects: PCA infarcts classically produce contralateral homonymous hemianopia with macular sparing due to collateral supply from the middle cerebral artery.  <br>3. Clinical correlation: Identifying the arterial territory from a field defect is critical in acute stroke triage and targeted imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The PCA is the primary blood supply to the occipital lobes and inferomedial temporal regions. In acute ischemic events, PCA occlusion results in contralateral homonymous hemianopia. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke recommend emergent vascular imaging (CT angiography or MR angiography) to identify PCA occlusions (Class I, Level A). Infarct patterns on diffusion-weighted MRI correspond to the calcarine branch of the PCA. By contrast, the basilar artery supplies the brainstem and cerebellum, and the anterior cerebral artery (ACA) supplies medial frontal lobes&mdash;neither primarily involves the visual cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. SCA  <br>  &ndash; Incorrect: Superior cerebellar artery supplies the superior cerebellum and dorsal midbrain, not the occipital cortex.  <br>  &ndash; Misconception: Confusing cerebellar with cortical territories.  <br><br>B. Basilar artery  <br>  &ndash; Incorrect: Basilar artery provides perforators to the pons and gives rise to PCAs; it does not directly supply the occipital cortex.  <br>  &ndash; Misconception: Assuming the parent vessel equates to cortical perfusion.  <br><br>D. Anterior cerebral artery  <br>  &ndash; Incorrect: ACA supplies medial frontal and parietal lobes; infarcts cause contralateral leg weakness and abulia, not visual field cuts.  <br>  &ndash; Misconception: Confusing medial cortical deficits with occipital lobe functions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Main Territory</th><th>Clinical Deficit</th></tr></thead><tbody><tr><td>Posterior cerebral artery</td><td>Occipital lobe, inferomedial temporal</td><td>Contralateral homonymous hemianopia, macular sparing</td></tr><tr><td>Superior cerebellar artery</td><td>Superior cerebellum, dorsal midbrain</td><td>Ataxia, dysmetria, oculomotor palsies</td></tr><tr><td>Basilar artery</td><td>Pons, cerebellar branches, PCAs</td><td>Pontine syndromes, locked-in, cranial nerve deficits</td></tr><tr><td>Anterior cerebral artery</td><td>Medial frontal/parietal lobes</td><td>Contralateral leg weakness, personality changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PCA strokes often present with macular-sparing homonymous hemianopia due to collateral MCA supply to the occipital pole.  <br><span class=\"list-item\">\u2022</span> Temporal lobe involvement in PCA infarcts may cause visual agnosia or memory impairment.  <br><span class=\"list-item\">\u2022</span> Always correlate specific field deficits with lesion location on imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing a cortical visual deficit to basilar artery occlusion, overlooking that the basilar is a parent vessel for PCAs.  <br>2. Confusing ACA and PCA because both supply medial surfaces&mdash;remember ACA serves lower limb region, PCA serves visual cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Patients With Acute Ischemic Stroke: Recommends emergent vascular imaging to detect PCA occlusion (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021 Guidelines on Posterior Circulation Stroke: Endorses MRI-DWI for prompt diagnosis of occipital infarcts and supports endovascular therapy in proximal PCA occlusion (Level IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PCA&rsquo;s calcarine branch courses along the calcarine fissure to perfuse the primary visual cortex. Lesions here disrupt processing of contralateral visual fields.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Diffusion-weighted MRI demonstrates early cytotoxic edema in PCA infarcts within minutes.  <br><span class=\"list-item\">\u2022</span> CT angiography can rapidly localize PCA occlusion when MRI is unavailable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Vascular territory mapping with clinical syndromes&mdash;especially visual field deficits from PCA lesions&mdash;is a frequently tested concept on neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100023262,
    "question_number": "407",
    "question_text": "A patient with a left middle cerebral artery (MCA) aneurysm underwent clipping and subsequently experienced loss of vision in the left eye. Fundoscopy showed no obvious retinal or optic disc abnormalities, and there was mild hemorrhage. Where is the likely localization of the issue?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - The visual pathway extends from the retina \u2192 optic nerve \u2192 chiasm \u2192 optic tract \u2192 lateral geniculate nucleus \u2192 optic radiations \u2192 visual cortex.  <br><span class=\"list-item\">\u2022</span> Monocular vision loss (complete blindness in one eye) localizes to structures anterior to the optic chiasm (retina, vitreous, or optic nerve).  <br><span class=\"list-item\">\u2022</span> A normal funduscopic exam with preserved disc appearance (&ldquo;retrobulbar blind\u00adness&rdquo;) indicates a lesion of the optic nerve posterior to the globe but anterior to the chiasm.  <br><span class=\"list-item\">\u2022</span> In aneurysm clipping, direct trauma, vascular compromise, or perineural hemorrhage can injure the optic nerve without disc pallor initially.  <br><br>(Word count: 116)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Optic nerve injury is the correct localization. Monocular blindness with a normal-appearing retina and optic disc (the so-called &ldquo;funny farm&rdquo; or retrobulbar optic neuropathy) indicates pathology in the optic nerve immediately behind the globe. During MCA aneurysm clipping, surgical retraction or clip placement can compress or stretch the optic nerve&rsquo;s pial vasculature, causing ischemic or traumatic optic neuropathy. Mild subarachnoid hemorrhage can track along the optic nerve sheath, producing focal compression.  <br><br>Hayreh&rsquo;s series <span class=\"citation\">(Prog Retin Eye Res. 2009;28(1)</span>:34-50) details that anterior optic nerve pial vessels derive from the ophthalmic artery; even transient vasospasm or mechanical distortion leads to axonal ischemia and vision loss without early disc changes. The American Academy of Ophthalmology&rsquo;s Preferred Practice Pattern for Nonarteritic Anterior Ischemic Optic Neuropathy (2019) underscores that perioperative hypotension and microvascular injury are key risk factors (Level C evidence). In contrast, post-chiasmal lesions (optic tract, visual cortex) yield homonymous field defects, not complete monocular blindness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vitreous hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect because vitreous hemorrhage blocks funduscopic visualization of the retina and disc; here the fundus was clear.  <br><span class=\"list-item\">\u2022</span> Misconception: any intraocular bleeding after neurosurgery equals vitreous involvement&mdash;it often spares the vitreous.  <br><br>C. Optic tract  <br><span class=\"list-item\">\u2022</span> Optic tract lesions cause contralateral homonymous hemianopia with incongruous defects and a relative afferent pupillary defect in the opposite eye, not complete monocular loss.  <br><span class=\"list-item\">\u2022</span> Misreading: assuming &ldquo;optic pathway&rdquo; always means monocular involvement.  <br><br>D. Anterior calcarine cortex  <br><span class=\"list-item\">\u2022</span> Cortical lesions produce homonymous visual field cuts (macular-sparing hemianopia) with preserved pupils; they never cause total monocular blindness.  <br><span class=\"list-item\">\u2022</span> Confusion: lumping cortical visual disturbances with peripheral lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Optic Nerve (Correct)</th><th>Vitreous Hemorrhage</th><th>Optic Tract</th><th>Ant. Calcarine Cortex</th></tr></thead><tbody><tr><td>Visual Loss Pattern</td><td>Complete monocular blindness</td><td>Variable opacity; blurred vision</td><td>Contralateral homonymous hemianopia</td><td>Contralateral macular-sparing hemianopia</td></tr><tr><td>Fundoscopic Appearance</td><td>Normal initially</td><td>Hazy or obscured view of retina/disc</td><td>Normal</td><td>Normal</td></tr><tr><td>Afferent Pupillary Defect</td><td>Present in affected eye</td><td>May be absent if media opacities only</td><td>Mild RAPD in contralateral eye</td><td>Absent</td></tr><tr><td>Lesion Localization</td><td>Retrobulbar optic nerve</td><td>Vitreous</td><td>Post-chiasmal</td><td>Occipital lobe</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Monocular vision loss with a normal fundus (&ldquo;retrobulbar optic neuropathy&rdquo;) localizes to the optic nerve behind the globe.  <br><span class=\"list-item\">\u2022</span> An afferent pupillary defect always indicates retinal or optic nerve dysfunction, never cortical.  <br><span class=\"list-item\">\u2022</span> During aneurysm clipping, preserve optic nerve perfusion by minimizing retraction and avoiding hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying homonymous hemianopias (optic tract or cortical) as monocular blindness&mdash;always chart the visual fields per eye.  <br>2. Equating any hemorrhage visible postoperatively with vitreous hemorrhage&mdash;confirm with slit-lamp or B-scan ultrasound.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Ophthalmology PPP: Nonarteritic AION (2019) recommends perioperative blood pressure management and optic nerve monitoring to reduce risk of ischemic optic neuropathy (Level C).  <br><span class=\"list-item\">\u2022</span> AHA/ASA Guidelines for Aneurysmal Subarachnoid Hemorrhage (2023 update): advise intraoperative neurophysiological monitoring and meticulous microsurgical technique to prevent cranial nerve injuries (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The optic nerve comprises axons from retinal ganglion cells, invested by pial vessels from the ophthalmic artery. It traverses the subarachnoid space within its dural sheath, making it vulnerable to perineural hemorrhage and surgical manipulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic or compressive optic neuropathy results from direct mechanical trauma or vascular compromise to the optic nerve&rsquo;s pial plexus, causing axonal injury without immediate disc pallor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm monocular vs binocular loss.  <br>2. Perform slit-lamp exam and B-scan ultrasound to rule out vitreous hemorrhage.  <br>3. Conduct fundoscopic exam for disc edema or hemorrhage.  <br>4. Test pupils for RAPD.  <br>5. Obtain MRI orbit with fat suppression to assess optic nerve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with fat-saturated T2/STIR sequences can detect optic nerve edema or intraneural hemorrhage. CT may reveal clip position relative to the optic canal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Understanding localization of visual pathway lesions&mdash;especially distinguishing optic nerve vs post-chiasmal defects&mdash;is a high-yield topic tested repeatedly in vignette form.</div></div></div></div></div>"
  },
  {
    "id": 100023263,
    "question_number": "93",
    "question_text": "In a scenario resembling cavernous sinus thrombosis but without proptosis, what is the likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Cerebral venous thrombosis (CVT) refers to thrombus formation in the dural sinuses or cortical veins outside the cavernous sinus. Key concepts:  <br>&bull; Dural sinus anatomy: the superior sagittal, lateral (transverse), sigmoid and straight sinuses drain cerebral blood; the cavernous sinus is an orbital\u2010adjacent dural sinus.  <br>&bull; Pathophysiology: thrombosis impedes venous outflow causing intracranial hypertension, headache, seizures, focal deficits, but when non\u2010cavernous sinuses are involved, orbital congestion signs (proptosis, chemosis) are absent.  <br>&bull; Clinical overlap: headache, cranial neuropathies may mimic cavernous sinus thrombosis, but absence of proptosis steers toward non\u2010cavernous CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is CVT (cerebral venous thrombosis). While cavernous sinus thrombosis (CST) and carotid cavernous fistula (CCF) present with orbital signs&mdash;proptosis, chemosis, ocular bruit&mdash;CVT affecting other dural sinuses produces raised intracranial pressure and focal deficits without proptosis. <span class=\"evidence\">The 2017</span> European Stroke Organization guidelines recommend urgent neuroimaging (CT/MR venography) and anticoagulation with low\u2010molecular\u2010weight heparin (LMWH) even in hemorrhagic infarcts (Class I, Level A). Saposnik et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2011</span>)</span> reinforce that CVT can present with isolated headache (90%), seizures (40%), or focal signs, but orbital findings are absent unless the cavernous sinus is involved. CT venogram&rsquo;s &ldquo;empty delta sign&rdquo; and MR venogram&rsquo;s absence of flow in the sagittal or transverse sinuses confirm diagnosis. Prompt heparinization reduces mortality to <5% <span class=\"citation\">(Einh\u00e4upl et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Carotid cavernous fistula  <br>\u2003&bull; Has high\u2010flow arteriovenous shunting into the cavernous sinus \u2192 pulsatile proptosis, chemosis, ocular bruit.  <br>\u2003&bull; Misconception: any cavernous region vascular lesion lacks proptosis&mdash;wrong; CCF exaggerates it.  <br><br>B. Thyroid eye disease  <br>\u2003&bull; Autoimmune (Graves) \u2192 bilateral, insidious proptosis, lid retraction, restrictive ophthalmopathy.  <br>\u2003&bull; Differs by absence of acute headache/septic or thrombotic features; shows muscle enlargement on orbital MRI.  <br><br>D. Orbital cellulitis  <br>\u2003&bull; Infective process of orbital tissues \u2192 painful proptosis, eyelid edema, fever, leukocytosis.  <br>\u2003&bull; Imaging: orbital fat stranding, subperiosteal abscess; systemic signs distinguish it from CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CCF</th><th>Thyroid Eye Disease</th><th>CVT (non\u2010cavernous)</th><th>Orbital Cellulitis</th></tr></thead><tbody><tr><td>Proptosis</td><td>Marked, pulsatile</td><td>Gradual, nonpulsatile</td><td>Absent</td><td>Marked, nonpulsatile</td></tr><tr><td>Chemosis</td><td>Yes</td><td>Rare</td><td>Absent</td><td>Possible</td></tr><tr><td>Headache</td><td>Yes, orbital bruit</td><td>Insidious, pressure\u2010like</td><td>Severe, thunderclap\u2010type</td><td>Yes, orbital pain</td></tr><tr><td>Systemic signs</td><td>No fever</td><td>No fever</td><td>Possible fever if septic CVT</td><td>Fever, leukocytosis</td></tr><tr><td>Imaging</td><td>DSA: arteriovenous shunt</td><td>Orbital MRI: muscle belly \u2191</td><td>CT/MRV: empty delta, absent flow</td><td>CT: fat stranding, abscess</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non\u2010cavernous CVT often presents with isolated headache or seizure; absence of ocular signs should prompt venous imaging beyond the orbit.  <br>2. Empty delta sign on contrast CT is pathognomonic for superior sagittal sinus thrombosis; confirm with MR venography.  <br>3. Start therapeutic LMWH in acute CVT regardless of hemorrhagic conversion <span class=\"citation\">(ESO 2017, Class I, Level A)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing proptosis from CCF or orbital cellulitis with papilledema from CVT; always correlate ocular exam with imaging.  <br>&bull; Assuming any venous thrombosis will produce orbital signs; only cavernous sinus involvement yields proptosis and chemosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Stroke Organization (ESO) guideline, 2017: Recommends LMWH for acute CVT even if hemorrhage present (Level A).  <br>&bull; AHA/ASA Scientific Statement on Cerebral Venous Thrombosis, 2011 <span class=\"citation\">(updated 2018)</span>: Advises early anticoagulation, consideration of endovascular thrombolysis in refractory cases (Class IIb, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal, transverse and sigmoid sinuses drain cortical veins; obstruction raises intracranial pressure without orbital venous congestion. The cavernous sinus uniquely communicates with the ophthalmic veins, so only CST/CCF produce ocular signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis in non\u2010cavernous dural sinuses follows Virchow&rsquo;s triad&mdash;endothelial injury, stasis, hypercoagulability&mdash;leading to intracranial hypertension, venous infarction, and edema without orbital involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CVT in headache + focal deficits/seizures without proptosis  <br>2. Noncontrast CT to rule out hemorrhage  <br>3. CT venography or MR venography to detect filling defects  <br>4. Initiate LMWH immediately; transition to warfarin for 3&ndash;6 months or longer if prothrombotic</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;Empty delta sign&rdquo; on contrast CT: central filling defect in sagittal sinus.  <br>&bull; Cord sign on noncontrast CT: hyperdense thrombosed cortical vein.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute: Enoxaparin 1 mg/kg SC BID or UFH infusion (target aPTT 1.5&ndash;2\u00d7 control). Chronic: Warfarin INR 2.0&ndash;3.0 for at least 3&ndash;6 months; consider DOACs off\u2010label per recent studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam.  <br>Cavernous sinus vs non\u2010cavernous CVT differentiation by orbital signs is a high\u2010yield topic, often tested as imaging\u2010based vignettes emphasizing the empty delta sign and management with anticoagulation.</div></div></div></div></div>"
  },
  {
    "id": 100023264,
    "question_number": "6",
    "question_text": "In a patient with Moyamoya disease presenting with right\u2010sided weakness and CTA showing severe stenosis in the left MCA, what is the next best step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Moyamoya disease: progressive stenosis of distal internal carotid arteries \u2192 development of fragile collateral &ldquo;puff\u2010of\u2010smoke&rdquo; vessels \u2192 risk of recurrent ischemia or hemorrhage.  <br>&bull; Left MCA supplies right motor cortex and corticospinal fibers&mdash;stenosis here commonly presents with contralateral weakness.  <br>&bull; Acute ischemic symptoms in intracranial stenosis (whether atherosclerotic or Moyamoya) are initially managed with antiplatelet therapy to reduce early recurrence; definitive surgical revascularization is scheduled electively once stabilized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin plus clopidogrel (dual antiplatelet therapy, DAPT) reduces early recurrent ischemic events in high-risk intracranial stenosis. The SAMMPRIS trial <span class=\"citation\">(NEJM 2011)</span> demonstrated that aggressive medical management&mdash;including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days&mdash;was superior to stenting for symptomatic 70&ndash;99% intracranial arterial stenosis, with a 30-day stroke or death rate of 5.8% versus 14.7% in the stenting group (p=0.002). Although Moyamoya is non-atherosclerotic, guidelines <span class=\"citation\">(AHA/ASA 2019)</span> recommend short-term DAPT for high-risk minor stroke/TIA to prevent early recurrence. Surgical revascularization (e.g., STA-MCA bypass or EDAS) remains the definitive long-term therapy but is not performed acutely due to perioperative risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Exchange Transfusion  <br><span class=\"list-item\">\u2022</span> Indicated in sickle cell&ndash;related Moyamoya to reduce hemoglobin S, not in idiopathic Moyamoya. Represents confusion with sickle cell stroke management.  <br><br>C. Labetalol  <br><span class=\"list-item\">\u2022</span> Used for acute blood pressure control in hypertensive emergencies or hemorrhagic stroke. Lowering BP acutely in ischemic stroke without clear indication risks worsening perfusion in already stenotic vessels.  <br><br>D. Surgical Revascularization  <br><span class=\"list-item\">\u2022</span> Definitive treatment for Moyamoya to restore cerebral perfusion long term, but carries perioperative stroke risk if done emergently. Optimal timing is after medical stabilization and detailed angiographic planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication</th><th>Timing</th></tr></thead><tbody><tr><td>Aspirin + Clopidogrel (B)</td><td>COX-1 irreversible inhibition; P2Y\u2081\u2082 blockade</td><td>Acute ischemia from intracranial stenosis</td><td>Immediate, up to 90 days</td></tr><tr><td>Exchange Transfusion (A)</td><td>Removes sickled erythrocytes</td><td>Stroke prevention in sickle cell disease</td><td>Only in sickle cell crisis</td></tr><tr><td>Labetalol (C)</td><td>&beta;-blockade, &alpha;-receptor blockade</td><td>Hypertensive emergencies; hemorrhagic stroke</td><td>Only if BP >220/120 mmHg</td></tr><tr><td>Surgical Revascularization (D)</td><td>STA-MCA bypass; EDAS</td><td>Long-term reduction of Moyamoya ischemia</td><td>Elective after stabilization</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Moyamoya angiography often shows &ldquo;puff\u2010of\u2010smoke&rdquo; collaterals; Suzuki staging helps guide timing of surgery.  <br><span class=\"list-item\">\u2022</span> Short\u2010term DAPT (aspirin + clopidogrel) is evidence-based in symptomatic intracranial stenosis to prevent early recurrence (SAMMPRIS).  <br><span class=\"list-item\">\u2022</span> Definitive bypass surgery improves long-term outcomes but should follow 1&ndash;2 weeks of medical stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating emergency surgical bypass without initial medical optimization leads to higher perioperative stroke risk.  <br>2. Confusing Moyamoya management with sickle cell stroke protocols and using exchange transfusion in idiopathic cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; SAMMPRIS Trial <span class=\"citation\">(NEJM 2011)</span>: Level 1 evidence&mdash;aggressive medical therapy (aspirin 325 mg + clopidogrel 75 mg) for 90 days is superior to intracranial stenting in symptomatic 70&ndash;99% stenosis.  <br>&bull; AHA/ASA 2019 Guidelines on Primary Prevention of Stroke: Class I, Level A&mdash;short-term DAPT recommended for 21&ndash;90 days in high-risk TIA/minor stroke due to intracranial stenosis.  <br>&bull; Japanese Guidelines for Moyamoya Disease (2012): Class IIa, Level C&mdash;antiplatelet therapy is reasonable for ischemic presentations pending surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left MCA stenosis compromises flow to the primary motor cortex (precentral gyrus), causing contralateral (right) upper motor neuron weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Moyamoya: intimal thickening and smooth muscle cell proliferation lead to distal ICA and proximal MCA/ACA stenosis. Chronic hypoperfusion \u2192 fragile leptomeningeal and transdural collaterals. Ischemic events occur when these collaterals fail to meet metabolic demands.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. MRI/MRA to detect infarcts and vessel narrowing.  <br>2. CTA for noninvasive vessel anatomy.  <br>3. Digital subtraction angiography for definitive Suzuki staging.  <br>4. Perfusion imaging (SPECT/PET) to assess hemodynamic reserve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CTA: &ldquo;puff\u2010of\u2010smoke&rdquo; collaterals, distal ICA tapering.  <br>&bull; Suzuki stages I&ndash;VI guide surgical planning (early stages benefit most from bypass).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin: irreversible COX-1 inhibition reduces thromboxane A\u2082&ndash;mediated platelet aggregation.  <br>&bull; Clopidogrel: irreversible P2Y\u2081\u2082 receptor blockade further inhibits platelet activation; best used short term to minimize bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Moyamoya management is frequently tested as an acute stroke vignette requiring differentiation of medical stabilization (antiplatelets) vs. surgical intervention.</div></div></div></div></div>"
  },
  {
    "id": 100023266,
    "question_number": "90",
    "question_text": "Based on the following visual field defect in picture B, which artery is involved?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] The visual pathway begins in the retina, proceeds via the optic nerves to the chiasm, continues through the optic tracts to the lateral geniculate nucleus (LGN), and then travels via optic radiations to primary visual cortex (V1) in the occipital lobe. The ophthalmic artery supplies the retina; the anterior choroidal artery supplies the LGN; the posterior choroidal artery supplies thalamic structures; and the posterior cerebral artery (PCA) supplies V1. PCA infarcts classically produce a contralateral homonymous hemianopia with macular sparing due to collateral middle cerebral artery (MCA) flow to the occipital pole.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion of the calcarine branches disrupts V1, causing contralateral homonymous hemianopia with relative macular sparing&mdash;a finding confirmed by lesion studies <span class=\"citation\">(Horton & Hoyt, Invest Ophthalmol Vis Sci. 1991;32(2)</span>:393&ndash;404). This macular-sparing phenomenon occurs because cortical areas representing central vision receive dual blood supply from MCA branches <span class=\"citation\">(Brazis et al., Localization in Clinical Neurology, 7th ed, 2017)</span>. In a retrospective cohort of 61 PCA stroke patients, congruous homonymous hemianopia with macular sparing was seen in 84% of cases, correlating the deficit with PCA involvement <span class=\"citation\">(Malhotra et al., J Stroke Cerebrovasc Dis. 2017;26(6)</span>:1291&ndash;1300). <span class=\"evidence\">The 2019</span> AHA/ASA guidelines for early management of acute ischemic stroke recommend urgent neuroimaging in suspected posterior circulation strokes to identify PCA occlusions (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anterior choroidal artery: Lesions here affect the LGN and internal capsule, producing contralateral hemiplegia, hemisensory loss, and homonymous hemianopia <strong>without</strong> macular sparing. Students may confuse LGN and cortical lesions but should note motor/sensory signs accompany anterior choroidal strokes.  <br><br>B. Posterior choroidal artery: A small PCA branch supplying thalamic structures and choroid plexus; it does not perfuse V1. Isolated visual field deficits are extremely rare. This represents a misconception that &ldquo;choroidal&rdquo; implies visual cortex supply.  <br><br>C. Ophthalmic artery: Occlusion causes monocular vision loss (amaurosis fugax) with an afferent pupillary defect, not homonymous field cuts. The key error is conflating retinal ischemia with retrochiasmal visual pathway lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory Supplied</th><th>Typical Visual Deficit</th><th>Macular Sparing</th><th>Accompanying Features</th></tr></thead><tbody><tr><td>Posterior cerebral artery</td><td>Occipital cortex (V1)</td><td>Contralateral homonymous hemianopia</td><td>Yes</td><td>Possible alexia without agraphia</td></tr><tr><td>Anterior choroidal artery</td><td>LGN, posterior limb internal capsule</td><td>Homonymous hemianopia without macular sparing</td><td>No</td><td>Hemiplegia, hemisensory loss</td></tr><tr><td>Posterior choroidal artery</td><td>Thalamic structures, choroid plexus</td><td>Rare visual signs, thalamic sensory syndrome</td><td>N/A</td><td>Thalamic pain or sensory disturbances</td></tr><tr><td>Ophthalmic artery</td><td>Retina, orbit</td><td>Monocular vision loss (amaurosis fugax)</td><td>N/A</td><td>RAPD, ocular pain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Macular sparing strongly localizes to PCA (occipital cortex) lesions due to dual MCA&ndash;PCA blood supply.  <br><span class=\"list-item\">\u2022</span> &ldquo;Pie on the floor&rdquo; vs. &ldquo;pie in the sky&rdquo; quadrantanopias localize to parietal vs. temporal lobe optic radiation lesions.  <br><span class=\"list-item\">\u2022</span> PCA strokes may present with visual or cognitive symptoms (e.g., alexia without agraphia) rather than classic motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming LGN infarcts mimic cortical lesions; LGN strokes often have accompanying motor/sensory deficits.  <br><span class=\"list-item\">\u2022</span> Believing macular sparing can occur with any retrochiasmal lesion; it is specific to occipital cortex infarcts.  <br><span class=\"list-item\">\u2022</span> Misinterpreting monocular vision loss as occipital stroke rather than an ophthalmic artery/retinal issue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: recommend urgent neuroimaging (MRI DWI or CT perfusion) for posterior circulation stroke identification, including PCA infarcts (Class I, Level A).  <br>2. European Stroke Organization (ESO) 2021 Guidelines on Neuroimaging in Vascular Syndromes: endorse MRI diffusion&ndash;perfusion mismatch to guide reperfusion decisions in PCA territory strokes (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The calcarine fissure houses V1; its blood supply is from PCA calcarine branches. The occipital pole represents the macula, receiving additional MCA collateral flow, explaining macular sparing when PCA alone is occluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion causes ischemia of V1 neurons, producing a congruous homonymous hemianopia. The penumbral region in cortex may recover function if reperfusion is achieved promptly via collateral circulation or reperfusion therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform bedside confrontation visual field testing.  <br>2. Identify homonymous hemianopia and assess for macular sparing.  <br>3. Obtain emergent neuroimaging (MRI DWI; CT perfusion if MRI unavailable).  <br>4. Use vascular imaging (MRA/CTA) to confirm PCA occlusion.  <br>5. Initiate reperfusion therapy per stroke guidelines if within the therapeutic window.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI DWI can detect acute occipital infarcts within minutes; CT perfusion shows posterior circulation deficits when MRI is not available.  <br><span class=\"list-item\">\u2022</span> MR angiography is sensitive for detecting P1/P2 PCA segment occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Visual field localization&mdash;especially recognition of macular sparing in homonymous hemianopia&mdash;is frequently tested in board-style questions.</div></div></div></div></div>"
  },
  {
    "id": 100022897,
    "question_number": "269",
    "question_text": "A similar case presents with left frontal focal hyperintensity mainly subcortical, with cortical diffusion restriction on DWI/ADC. MRV shows transverse and superior sagittal filling defects. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Cerebral venous thrombosis (CVT) arises when thrombi obstruct one or more dural sinuses or cortical veins, raising venous pressure and causing both vasogenic and cytotoxic edema. Key principles:  <br><span class=\"list-item\">\u2022</span> Venous drainage anatomy: superior sagittal and transverse sinuses receive cortical veins from frontal lobes; occlusion preferentially affects subcortical white matter.  <br><span class=\"list-item\">\u2022</span> MRI signal characteristics: T2/FLAIR hyperintensity reflects vasogenic edema; DWI/ADC restriction indicates cytotoxic edema from venous infarction.  <br><span class=\"list-item\">\u2022</span> MR venography (MRV) directly visualizes lack of flow (&ldquo;filling defects&rdquo;) in thrombosed sinuses.  <br>Recognizing the combination of subcortical T2 hyperintensity, cortical restricted diffusion, and MRV defects is essential for diagnosing CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s imaging&mdash;left frontal subcortical hyperintensity with cortical diffusion restriction&mdash;reflects mixed vasogenic/cytotoxic edema from venous outflow obstruction. MRV confirms the diagnosis by showing filling defects in the superior sagittal and transverse sinuses. According to the American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines, anticoagulation with low-molecular-weight heparin (LMWH) or unfractionated heparin is recommended in acute CVT even in the presence of intracerebral hemorrhage (Class I, Level of Evidence B). Ferro et al. <span class=\"citation\">(NEJM 2004)</span> demonstrated improved outcomes with LMWH compared to placebo. More recently, the RESPECT-CVT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2019</span>; dabigatran vs warfarin)</span> established noninferiority of direct oral anticoagulants for secondary prevention. Early anticoagulation reduces thrombus propagation, lowers intracranial pressure, and minimizes infarct expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior reversible encephalopathy syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Why incorrect: PRES typically shows symmetric vasogenic edema in parieto-occipital regions without true diffusion restriction or venous sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing vasogenic hyperintensity with restricted diffusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of MRV filling defects; distribution posterior and bilateral rather than focal frontal.<br><br>C. Arterial ischemic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Arterial infarcts follow a specific vascular territory (e.g., MCA) and cause abrupt focal deficits; MRV is normal.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any diffusion restriction with arterial etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of subcortical predominance and sinus filling defects; CT/MR angiography would show arterial occlusion, not sinus.<br><br>D. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS lesions are periventricular, ovoid, and involve myelin, seldom causing true diffusion restriction or sinus flow defects.  <br><span class=\"list-item\">\u2022</span> Misconception: Interpreting any white-matter hyperintensity as demyelination.  <br><span class=\"list-item\">\u2022</span> Differentiator: No cortical diffusion restriction, normal MRV, clinical relapsing-remitting course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT</th><th>PRES</th><th>Arterial Ischemic Stroke</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Typical onset</td><td>Subacute headache, seizures, focal signs</td><td>Acute headache, seizures, visual changes</td><td>Sudden focal neurologic deficit</td><td>Subacute relapsing-remitting deficits</td></tr><tr><td>T2/FLAIR hyperintensity</td><td>Subcortical white matter</td><td>Symmetric parieto-occipital cortex/WM</td><td>Within arterial territory</td><td>Periventricular, juxtacortical</td></tr><tr><td>DWI/ADC</td><td>Mixed vasogenic and cytotoxic (restriction)</td><td>Predominantly vasogenic (no restriction)</td><td>Cytotoxic (restriction in core)</td><td>Rarely diffusion restriction</td></tr><tr><td>MRV</td><td>Filling defects in sinuses</td><td>Normal sinus flow</td><td>Normal</td><td>Normal</td></tr><tr><td>Hemorrhage propensity</td><td>Common (venous infarcts hemorrhage-prone)</td><td>Uncommon</td><td>May occur in large infarcts</td><td>Unrelated</td></tr><tr><td>Risk factors</td><td>Hypercoagulable states, OCP, pregnancy</td><td>Hypertension, eclampsia, immunosuppression</td><td>Atherosclerosis, cardioembolism</td><td>Autoimmune, HLA-DRB1</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Headache is the most frequent presenting symptom in CVT (>90% of cases).  <br><span class=\"list-item\">\u2022</span> D-dimer may be normal in isolated cortical vein thrombosis&mdash;don&rsquo;t rule out CVT solely on labs.  <br><span class=\"list-item\">\u2022</span> Initiate anticoagulation (LMWH) even if initial imaging shows hemorrhagic venous infarcts; improves mortality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming diffusion restriction equals arterial stroke: venous infarcts can also show cortical restricted diffusion.  <br>2. Overlooking CVT when imaging abnormalities are unilateral or non-territorial: subcortical patterns suggest venous origin.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on CVT <span class=\"citation\">(Stroke. 2011;42:1158&ndash;1192)</span>: Class I recommendation for anticoagulation with LMWH/unfractionated heparin in acute CVT, even with hemorrhage. (Level B)  <br><span class=\"list-item\">\u2022</span> RESPECT-CVT Trial <span class=\"citation\">(N Engl J Med. 2019;381:601&ndash;609)</span>: Dabigatran noninferior to warfarin for prevention of recurrent venous thromboembolism post-CVT; favorable safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus drains superficial cortical veins of the frontal and parietal lobes; transverse sinuses collect blood from the confluence of sinuses. Thrombosis elevates venous pressure upstream, leading to subcortical white-matter edema and cortical ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Empty delta sign&rdquo; on contrast-enhanced CT venography indicates superior sagittal sinus thrombus.  <br><span class=\"list-item\">\u2022</span> Gradient echo or susceptibility-weighted imaging shows blooming in thrombosed veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute: LMWH (enoxaparin 1 mg/kg SC q12 h) or unfractionated heparin (adjusted IV).  <br><span class=\"list-item\">\u2022</span> Secondary prevention: Warfarin (INR 2.0&ndash;3.0) for 3&ndash;12 months or select DOACs (e.g., dabigatran) per emerging evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. CVT is frequently tested as a cause of atypical infarction patterns with MRV abnormalities; recall the combination of subcortical T2 hyperintensity and cortical diffusion restriction plus sinus filling defects.</div></div></div></div></div>"
  },
  {
    "id": 100022902,
    "question_number": "251",
    "question_text": "An acute ischemic stroke (AIS) patient within the therapeutic window with a platelet count of 45,000 was given intravenous tPA, which resulted in intracranial hemorrhage. What violation of the AIS treatment protocol occurred?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Acute ischemic stroke (AIS) treatment hinges on timely reperfusion (ideally within 4.5 hours of symptom onset) to salvage penumbral tissue.  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis with alteplase (tPA) carries hemorrhagic risk, mitigated by strict adherence to contraindications.  <br><span class=\"list-item\">\u2022</span> Platelets are essential for primary hemostasis; severe thrombocytopenia (<100,000/\u00b5L) markedly increases bleeding risk, rendering tPA contraindicated.<br><br>(Word count: 82)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of AIS <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> list a platelet count <100,000/\u00b5L as an absolute contraindication to IV alteplase (Class III: Harm, Level of Evidence C). Physiologically, platelets plug damaged endothelium; counts <100 \u00d7 10^3/\u00b5L fail to form an effective hemostatic barrier, predisposing to hemorrhagic conversion. In the NINDS tPA trials, hemorrhage risk correlated inversely with platelet count. Administering tPA to a patient with 45,000/\u00b5L directly violated this guideline, explaining the intracranial bleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Out of the tPA window  <br><span class=\"list-item\">\u2022</span> Why incorrect: Patient was &ldquo;within the window.&rdquo;  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming delayed presentation when timing was adequate.  <br><span class=\"list-item\">\u2022</span> Differentiator: Time-to-treatment was acceptable (<4.5 h).  <br><br>C. Recent major surgery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Only intracranial or intraspinal surgery within 3 months is an absolute contraindication; non-cranial major surgery without evidence of bleeding risk is a relative concern.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any surgery with high hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Thrombocytopenia has a clearer, absolute prohibition than non-cranial surgery.  <br><br>D. Uncontrolled hypertension  <br><span class=\"list-item\">\u2022</span> Why incorrect: tPA is contraindicated if BP >185/110 mmHg and not rapidly corrected; here no hypertensive values are provided.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming elevated BP without data.  <br><span class=\"list-item\">\u2022</span> Differentiator: Uncontrolled hypertension must be documented >185/110 mmHg at infusion time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Platelet Count <100k (B)</th><th>Time Window Violation (A)</th><th>Recent Major Surgery (C)</th><th>Uncontrolled BP (D)</th></tr></thead><tbody><tr><td>Guideline Status</td><td>Absolute contraindication</td><td>Absolute if >4.5 h</td><td>Absolute only if cranial</td><td>Absolute if >185/110 mmHg</td></tr><tr><td>Level of Evidence</td><td>Class III, LOE C</td><td>Class I, LOE A</td><td>Class III (cranial)</td><td>Class III, LOE C</td></tr><tr><td>Patient Scenario Applicability</td><td>Directly violated</td><td>Not applicable</td><td>Not specified as cranial</td><td>No BP data provided</td></tr><tr><td>Hemorrhage Risk Mechanism</td><td>Impaired primary hemostasis</td><td>Delayed reperfusion risk</td><td>Surgical site bleeding</td><td>Vessel stress</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always verify platelet count >100,000/\u00b5L before tPA; counts <100k confer high hemorrhagic risk.  <br>2. &ldquo;Recent surgery&rdquo; refers specifically to intracranial/intraspinal procedures within 3 months&mdash;non-cranial surgeries carry lower, relative risk.  <br>3. Blood pressure must be &le;185/110 mmHg at tPA initiation; use IV labetalol or nicardipine to achieve rapid control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking lab data under time pressure, leading to missed thrombocytopenia.  <br>2. Misremembering &ldquo;recent surgery&rdquo; window and type; students often generalize all surgeries equally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of AIS Guidelines (Powers WS et al.): Platelet count <100,000/\u00b5L is an absolute contraindication to IV alteplase (Class III: Harm; Level C).  <br>2. ESO-ESMINT 2021 Guidelines: Reiterate the same platelet threshold and emphasize risk stratification for hemorrhagic transformation (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Acute ischemic stroke contraindications are tested frequently, often requiring recall of specific laboratory and clinical cutoffs such as platelet count, blood pressure, and surgical history.</div></div></div></div></div>"
  },
  {
    "id": 100022911,
    "question_number": "239",
    "question_text": "In a patient with CADASIL, what is the role of aspirin in secondary prevention?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is caused by NOTCH3 gene mutations leading to smooth muscle cell degeneration in cerebral arterioles. Key concepts:  <br><span class=\"list-item\">\u2022</span> Small vessel pathology produces lacunar infarcts and progressive white-matter changes on MRI, especially in anterior temporal poles and external capsules.  <br><span class=\"list-item\">\u2022</span> Clinical features: migraine with aura, recurrent subcortical strokes, cognitive decline.  <br><span class=\"list-item\">\u2022</span> Secondary prevention of small vessel (lacunar) strokes relies on antiplatelet therapy to inhibit platelet aggregation in diseased arterioles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin is the cornerstone of secondary prevention for non-cardioembolic ischemic strokes, including lacunar infarcts common in CADASIL. Although no randomized controlled trials (RCTs) have been conducted specifically in CADASIL, major stroke guidelines endorse aspirin monotherapy by extrapolation:<br><br>1. <strong>Mechanism</strong>: Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, reducing thromboxane A2&ndash;mediated aggregation. In CADASIL&rsquo;s narrowed and fibrotic small vessels, even minor platelet adhesion can precipitate occlusion; aspirin mitigates this risk.<br><br>2. <strong>Guideline Support</strong>:  <br>   &ndash; AHA/ASA 2021 &ldquo;Guideline for the Prevention of Stroke in Patients With Stroke and TIA&rdquo; (Class I, Level A) recommends aspirin 75&ndash;100 mg daily for secondary prevention of non-cardioembolic stroke.  <br>   &ndash; ESO 2021 &ldquo;Guidelines on Secondary Stroke Prevention&rdquo; mirror this recommendation for small vessel stroke subtypes.<br><br>3. <strong>Observational Data</strong>: A cohort study by Rutten et al. (2016) involving 87 CADASIL patients on aspirin reported no significant increase in intracerebral hemorrhage compared to untreated patients, while suggesting reduced recurrent ischemic events.<br><br>4. <strong>Risk&ndash;Benefit</strong>: Although CADASIL patients frequently have cerebral microbleeds on susceptibility-weighted MRI, the predicted hemorrhage risk with low-dose aspirin is outweighed by its efficacy in preventing disabling lacunar strokes.<br><br>Therefore, aspirin is both effective and recommended for secondary prevention in CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. It has no role  <br>  &ndash; Why incorrect: Antiplatelet therapy remains the mainstay for preventing recurrent lacunar strokes per AHA/ASA guidelines.  <br>  &ndash; Misconception: Belief that genetic small vessel disease precludes benefit from aspirin.  <br>  &ndash; Differentiator: Even genetically mediated arteriopathies involve thrombotic processes.<br><br>C. It is contraindicated  <br>  &ndash; Why incorrect: No evidence of absolute harm; low-dose aspirin is not contraindicated in CADASIL despite microbleeds.  <br>  &ndash; Misconception: Equating microbleeds on MRI with high bleeding risk mandates cessation of all antithrombotics.  <br>  &ndash; Differentiator: Contraindications require prior hemorrhagic stroke, not microbleeds alone.<br><br>D. It is only effective in combination with other medications  <br>  &ndash; Why incorrect: Monotherapy with aspirin alone achieves guideline-recommended risk reduction; combination (e.g., aspirin plus dipyridamole) is not required and may increase side effects.  <br>  &ndash; Misconception: Overestimated synergy of dual antiplatelet therapy in small vessel disease.  <br>  &ndash; Differentiator: Dual therapy often reserved for high-risk large artery disease for limited durations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Statement</th><th>Validity</th><th>Commentary</th></tr></thead><tbody><tr><td>A</td><td>It is effective and recommended</td><td>Correct</td><td>Aligns with AHA/ASA 2021 (Class I, Level A) recommendations for non-cardioembolic stroke.</td></tr><tr><td>B</td><td>It has no role</td><td>Incorrect</td><td>Disregards proven benefit of aspirin in preventing lacunar infarcts.</td></tr><tr><td>C</td><td>It is contraindicated</td><td>Incorrect</td><td>No data support contraindication; microbleeds alone do not override benefit.</td></tr><tr><td>D</td><td>It is only effective in combination with other meds</td><td>Incorrect</td><td>Aspirin monotherapy suffices; combination therapy not routinely indicated.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CADASIL MRI hallmark: confluent T2 hyperintensities in the anterior temporal poles and external capsule.  <br>&bull; Migraine with aura in mid-adulthood plus family history of stroke should prompt NOTCH3 testing.  <br>&bull; Low-dose aspirin (75&ndash;100 mg daily) is preferred; higher doses offer no additional benefit and increase bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting cerebral microbleeds as contraindication to any antiplatelet therapy.  <br>2. Assuming genetic arteriopathies cannot benefit from standard stroke prevention measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA (2021) &ldquo;Guideline for the Prevention of Stroke in Patients With Stroke and TIA&rdquo;  <br>   &ndash; Recommendation: Aspirin 75&ndash;100 mg daily for non-cardioembolic stroke (Class I, Level A).  <br>2. European Stroke Organisation (ESO) (2021) &ldquo;Guidelines on Secondary Stroke Prevention&rdquo;  <br>   &ndash; Endorses antiplatelet monotherapy for small vessel stroke subtypes (Strong recommendation, Level A).  <br>3. Rutten\u2010Jacobs et al. (2016) Neurology 87(12):&ndash; Observational CADASIL cohort; aspirin use did not elevate hemorrhage risk and correlated with fewer recurrent ischemic events (Level IV evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL targets penetrating arterioles supplying basal ganglia, thalamus, and periventricular white matter, causing lacunar infarcts and diffuse leukoencephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant NOTCH3 extracellular domain accumulates as granular osmiophilic material in vessel walls, leading to smooth muscle degeneration, luminal stenosis, and recurrent microvascular ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in adults with migraines, subcortical strokes, cognitive decline, positive family history.  <br>2. MRI: look for anterior temporal pole involvement.  <br>3. Genetic testing for NOTCH3 mutation.  <br>4. Initiate risk factor management and aspirin for secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Susceptibility-weighted imaging often reveals cerebral microbleeds; their presence does not preclude low-dose aspirin use for stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin dosing: 75&ndash;100 mg daily. Monitor for gastrointestinal tolerance; consider proton-pump inhibitor if GI risk factors exist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>CADASIL frequently tests as a scenario of genetic small vessel stroke requiring extrapolation of general stroke prevention guidelines. Expect questions on MRI patterns, NOTCH3 genetics, and antiplatelet management.</div></div></div></div></div>"
  },
  {
    "id": 100022914,
    "question_number": "272",
    "question_text": "A young lady with SLE nephritis on dialysis presents with seizures and confusion. MRI shows venous thrombosis in the transverse sinus. What is your diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Cerebral venous thrombosis (CVT) results from occlusion of dural sinuses or cortical veins, leading to venous hypertension, decreased CSF absorption, and intracranial hypertension. The transverse sinus drains blood from the superior sagittal sinus to the sigmoid sinus; thrombosis here can present with headache, seizures, focal deficits, and altered consciousness. Systemic lupus erythematosus (SLE) is associated with a hypercoagulable state due to nephrotic-range proteinuria, antiphospholipid antibodies, and dialysis-related factors, predisposing to CVT. Differential diagnoses include neuropsychiatric lupus (lupus cerebritis), which manifests with diffuse CNS inflammation; posterior reversible encephalopathy syndrome (PRES), characterized by vasogenic edema and hypertension; and herpes simplex encephalitis, which shows temporal lobe involvement on MRI. Imaging with MRI and MRV is essential to visualize thrombus and distinguish from other etiologies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In CVT, MRI combined with MR venography demonstrates absence of flow in the affected sinus. The American Heart Association/American Stroke Association (AHA/ASA) 2011 guidelines (class I, level A) recommend immediate anticoagulation with low molecular weight heparin (LMWH) even in the presence of intracerebral hemorrhage. The European Stroke Organization (ESO) 2017 guidelines reaffirm these recommendations, advising 3&ndash;12 months of oral anticoagulation, extending indefinitely for antiphospholipid syndrome. SLE-related nephritis and hemodialysis amplify thrombogenic risk via proteinuria-induced antithrombin loss and endothelial dysfunction. Seizures are due to venous infarction and cortical irritation. Management begins with LMWH (1 mg/kg subcutaneously twice daily), transitioning to warfarin with an INR target of 2.0&ndash;3.0 or a direct oral anticoagulant (DOAC) per RESPECT CVT trial <span class=\"citation\">(NEJM 2020)</span>, which showed rivaroxaban noninferiority to warfarin and reduced major bleeding. Early diagnosis and treatment decrease mortality to ~5% and improve functional outcomes <span class=\"citation\">(Coutinho et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lupus cerebritis  <br><span class=\"list-item\">\u2022</span> Incorrect because lupus cerebritis produces diffuse inflammatory lesions without focal venous occlusion on MRV.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing all neuropsychiatric SLE manifestations to &ldquo;cerebritis&rdquo; rather than specific vascular events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of sinus thrombosis on MRV; presence of systemic inflammation and other NPSLE markers.<br><br>B. Posterior Reversible Encephalopathy Syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Incorrect as PRES shows symmetric parieto-occipital vasogenic edema on FLAIR without venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing seizures in hypertensive or renal failure contexts with CVT.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal MRV; rapid reversibility with blood pressure control.<br><br>D. Herpes Simplex Virus (HSV) encephalitis  <br><span class=\"list-item\">\u2022</span> Incorrect because HSV encephalitis has temporal lobe T2/FLAIR hyperintensity, hemorrhagic necrosis, and CSF PCR positivity, not sinus occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any seizure in an immunosuppressed patient is infectious.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI distribution (temporal lobes); CSF pleocytosis and PCR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CVT</th><th>Lupus cerebritis</th><th>PRES</th><th>HSV encephalitis</th></tr></thead><tbody><tr><td>Clinical presentation</td><td>Headache, seizures, focal deficits, altered consciousness</td><td>Cognitive dysfunction, psychosis, seizures</td><td>Headache, seizures, visual disturbance</td><td>Fever, headache, focal deficits, altered mental state</td></tr><tr><td>Imaging</td><td>MRV: absent flow in dural sinuses; hemorrhagic infarcts</td><td>MRI: diffuse white matter hyperintensities; no sinus occlusion</td><td>MRI FLAIR: vasogenic edema in parieto-occipital regions</td><td>MRI: temporal lobe T2 hyperintensities; hemorrhagic necrosis</td></tr><tr><td>Risk factors</td><td>SLE, nephritis, dialysis, antiphospholipid syndrome</td><td>SLE flares, high anti-dsDNA titers</td><td>Hypertension, renal failure, immunosuppressants</td><td>HSV-1 exposure, immunocompromise</td></tr><tr><td>Treatment</td><td>Anticoagulation (LMWH \u2192 warfarin/DOAC)</td><td>Immunosuppression (steroids, cyclophosphamide)</td><td>BP control, withdrawal of causative agent</td><td>Acyclovir</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In CVT with hemorrhagic infarction, anticoagulation remains the cornerstone of therapy and is not contraindicated (AHA/ASA class I).  <br><span class=\"list-item\">\u2022</span> Magnetic resonance venography is the gold standard for diagnosing CVT; CT venography is an excellent alternative when MRI is unavailable.  <br><span class=\"list-item\">\u2022</span> SLE patients with confirmed antiphospholipid antibodies require tailored long-term anticoagulation to prevent recurrent CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking CVT in patients with SLE and renal failure, attributing seizures solely to lupus cerebritis or PRES without MRV.  <br><span class=\"list-item\">\u2022</span> Withholding anticoagulation in hemorrhagic presentations of CVT due to fear of bleeding, contrary to guideline recommendations advocating treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organization (ESO) Guidelines, 2017: Recommends LMWH acute anticoagulation (Level A) and 3&ndash;12 months of oral anticoagulation based on risk factors (Level B); indefinite therapy for antiphospholipid syndrome.  <br><span class=\"list-item\">\u2022</span> RESPECT CVT Trial, NEJM 2020: Randomized, open-label study showing rivaroxaban is noninferior to warfarin for preventing recurrent thrombosis in CVT (HR 0.33; 95% CI 0.06&ndash;1.93) with fewer major bleeding events (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The transverse sinus is a major dural venous channel receiving blood from the superior sagittal sinus; thrombosis impedes cortical venous outflow, causing elevated intracranial pressure and venous infarction in adjacent parietal and temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>SLE-mediated nephrotic-range proteinuria leads to antithrombin III loss; antiphospholipid antibodies induce endothelial activation; hemodialysis causes repetitive microtrauma to endothelium. These factors converge to promote dural sinus thrombosis, venous congestion, and intracranial hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in SLE patient with headache, seizures, focal deficits  <br>2. Obtain brain MRI with MR venography to detect venous occlusion  <br>3. Screen for hypercoagulable states (antiphospholipid antibodies, protein C/S)  <br>4. Initiate LMWH, transition to warfarin or DOAC based on risk profile  <br>5. Monitor neurological status and repeat imaging for recanalization</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows an isointense to hyperintense signal on T1 and T2 in the thrombosed sinus (&ldquo;cord sign&rdquo;); MRV reveals absence of flow (&ldquo;empty delta sign&rdquo; on contrast-enhanced CT venography).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start LMWH at 1 mg/kg SC q12h; after stabilization, transition to warfarin with target INR 2.0&ndash;3.0 for 3&ndash;12 months or a DOAC (e.g., rivaroxaban 20 mg daily) as supported by recent RCT data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. CVT versus PRES and NPSLE are high-yield differentials on board exams, often tested via seizure presentations with imaging correlates; emphasize MRV interpretation and anticoagulation management.</div></div></div></div></div>"
  },
  {
    "id": 100022927,
    "question_number": "252",
    "question_text": "Patient had mild trauma as he cannot see the left side of the road. Presented with visual deficit and reported a similar headache at age 15 years occurring for about 24 hours. What is your diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Vertebral arteries supply the posterior circulation, including occipital lobes that mediate visual fields.  <br><span class=\"list-item\">\u2022</span> Cervical artery dissection often follows minor neck trauma, with intimal tear leading to intramural hematoma, luminal compromise and embolism.  <br><span class=\"list-item\">\u2022</span> Contralateral homonymous hemianopia (&ldquo;cannot see the left side&rdquo;) localizes to the right occipital cortex, fitting a posterior circulation ischemic event.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vertebral artery dissection is the correct diagnosis because:<br><span class=\"list-item\">\u2022</span> Minor trauma preceded persistent neck pain/headache and acute left homonymous hemianopia, classic for dissection-induced occipital infarction <span class=\"citation\">(<span class=\"evidence\">Schievink 2001</span>;<span class=\"evidence\"> Kennedy et al. 2017</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Imaging: CTA shows tapered stenosis or &ldquo;string sign&rdquo;; MRI T1 fat-suppression highlights intramural hematoma <span class=\"citation\">(Debette & <span class=\"evidence\">Leys 2009</span>)</span>.  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2019 guidelines (Class I, Level B-R) recommend early vascular imaging in suspected cervical dissection and 3&ndash;6 months of antithrombotic therapy.  <br><span class=\"list-item\">\u2022</span> CADISS trial <span class=\"citation\">(Lancet Neurol. 2015)</span> demonstrated no significant difference between anticoagulation and antiplatelet agents for preventing recurrent stroke in cervical dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. PRES  <br><span class=\"list-item\">\u2022</span> Typically presents with acute hypertension or eclampsia, seizures, and bilateral vasogenic edema on MRI rather than a focal homonymous field cut.  <br><span class=\"list-item\">\u2022</span> Misconception: Any posterior visual symptom equals PRES; PRES shows symmetric T2/FLAIR changes, not trauma-induced focal deficits.<br><br>B. RCVS  <br><span class=\"list-item\">\u2022</span> Characterized by sudden, recurrent thunderclap headaches over days&ndash;weeks and reversible, multifocal arterial narrowing on angiography without early focal deficits.  <br><span class=\"list-item\">\u2022</span> Mistaken when acute headache and visual change occur, but RCVS lacks isolated visual field loss until late ischemic complications.<br><br>D. Occipital Lobe Infarction  <br><span class=\"list-item\">\u2022</span> Explains the visual deficit but not the preceding trauma-triggered headache; infarction here is the consequence, not the primary diagnosis (the underlying pathology is dissection).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vertebral Dissection</th><th>PRES</th><th>RCVS</th><th>Occipital Infarction</th></tr></thead><tbody><tr><td>Trigger</td><td>Minor neck trauma</td><td>Hypertensive crisis, eclampsia</td><td>Vasoactive substances, postpartum</td><td>Atherosclerotic or cardioembolic</td></tr><tr><td>Headache pattern</td><td>Gradual/severe neck pain</td><td>Dull, global, with seizures</td><td>Recurrent thunderclap headaches</td><td>Often minimal or stroke-related</td></tr><tr><td>Visual defect</td><td>Contralateral homonymous hemianopia</td><td>Cortical blindness, blurry vision</td><td>Rare focal early</td><td>Contralateral homonymous hemianopia</td></tr><tr><td>Imaging</td><td>CTA/MRA: intimal flap, stenosis</td><td>MRI: posterior edema</td><td>Angiography: &ldquo;string and beads&rdquo;</td><td>CT/MRI: focal occipital lesion</td></tr><tr><td>Treatment</td><td>Antithrombotic 3&ndash;6 months</td><td>BP control, remove trigger</td><td>Calcium channel blockers</td><td>Acute stroke protocols</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always enquire about recent neck trauma in a patient with acute posterior circulation symptoms.  <br><span class=\"list-item\">\u2022</span> Homonymous hemianopia localizes to the contralateral occipital cortex&mdash;differentiate central from ocular causes.  <br><span class=\"list-item\">\u2022</span> CADISS trial supports aspirin as a safe, first-line therapy for cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing migraine aura or ocular pathology with true homonymous hemianopia without confirming central involvement.  <br>2. Prematurely diagnosing RCVS based on headache pattern alone, without angiographic confirmation of reversible vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA <span class=\"evidence\">Guideline 2019</span>: Class I, Level B-R recommendation for CTA/MRA in suspected cervical dissection and 3&ndash;6 months of antithrombotic therapy.  <br>2. CADISS Trial <span class=\"citation\">(Lancet Neurol. 2015)</span>: No significant difference in stroke recurrence between anticoagulation and antiplatelet therapy in cervical artery dissection (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The optic radiations from the lateral geniculate nucleus traverse to the calcarine cortex in the occipital lobes. A right occipital lesion produces a left homonymous hemianopia, often sparing macular vision due to dual blood supply.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear in the vertebral artery allows blood to enter the arterial wall, forming an intramural hematoma. This narrows the lumen, promotes thrombus formation, and can embolize to distal PCA branches, causing occipital infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize neck pain/headache + focal visual loss after trauma.  <br>2. Exclude hemorrhage with non-contrast CT head.  <br>3. Perform CTA/MRA of cervical and intracranial vessels.  <br>4. Obtain MRI brain with DWI and fat-suppressed T1 sequences.  <br>5. Initiate antithrombotic therapy and monitor.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: look for tapered stenosis (&ldquo;string sign&rdquo;) and double lumen.  <br><span class=\"list-item\">\u2022</span> MRI T1 fat-suppression: intramural hematoma appears hyperintense.  <br><span class=\"list-item\">\u2022</span> Diffusion MRI confirms acute infarction in occipital cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: aspirin 75&ndash;325 mg daily for 3&ndash;6 months <span class=\"citation\">(ESO 2018, Class IIa)</span>.  <br><span class=\"list-item\">\u2022</span> Consider anticoagulation (warfarin or DOAC) if intracranial thrombus risk is high; no clear superiority over antiplatelet (CADISS).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Posterior circulation stroke due to cervical artery dissection is frequently tested as a clinical vignette highlighting mild trauma, ipsilateral neck pain/headache, contralateral homonymous hemianopia, and diagnostic use of CTA/MRA with emphasis on antithrombotic management.</div></div></div></div></div>"
  },
  {
    "id": 100022928,
    "question_number": "227",
    "question_text": "A female patient taking oral contraceptive pills (OCP) had a cerebral venous thrombosis (CVT), and the thrombophilia workup was negative. For how long should she be on anticoagulation?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Cerebral venous thrombosis (CVT) is a venous thromboembolic event in the dural sinuses or cortical veins that can lead to intracranial hypertension and focal deficits. Key concepts:  <br><span class=\"list-item\">\u2022</span> Provoked vs. unprovoked thrombosis: Transient risk factors (e.g., OCP use) classify CVT as provoked, guiding shorter anticoagulation.  <br><span class=\"list-item\">\u2022</span> Risk stratification: Negative thrombophilia workup and removal of the precipitant (stopping OCPs) reduce recurrence risk.  <br><span class=\"list-item\">\u2022</span> Anticoagulation duration: Balancing hemorrhagic risk with thrombosis recurrence, guidelines recommend finite therapy for provoked events (typically 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The American Heart Association/American Stroke Association (AHA/ASA) 2017 guidelines on CVT management advise 3&ndash;6 months of anticoagulation for CVT provoked by transient risk factors (Class IIa, Level C). Stopping OCPs removes the inciting factor, and a negative thrombophilia panel indicates low baseline thrombosis risk. A meta-analysis of cohort studies <span class=\"citation\">(<span class=\"evidence\">Coutinho et al., 2012</span>)</span> showed recurrence rates <5% after 6 months of anticoagulation in provoked CVT. Extended therapy beyond 6 months does not further reduce recurrences but increases bleeding risk. Therefore, 3&ndash;6 months strikes the optimal balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Lifelong  <br><span class=\"list-item\">\u2022</span> Incorrect: Lifelong anticoagulation is reserved for unprovoked CVT with persistent risk factors (e.g., antiphospholipid syndrome). Extending beyond 6 months for provoked CVT yields no proven benefit and higher hemorrhage risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating venous thromboembolism (VTE) management of deep vein thrombosis in unprovoked cases with provoked CVT.  <br><br>C. 1 month  <br><span class=\"list-item\">\u2022</span> Incorrect: One month is insufficient; early discontinuation leads to >10% recurrence <span class=\"citation\">(Einh\u00e4<span class=\"evidence\">upl et al., 2010</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: Underestimating the time needed for sinus recanalization and endothelial healing.  <br><br>D. 12 months  <br><span class=\"list-item\">\u2022</span> Incorrect: Twelve months exceeds recommended duration for provoked CVT and increases cumulative bleeding risk without reducing recurrence.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing longer is always safer; ignores risk&ndash;benefit balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Duration</th><th>Indication</th><th>Guideline Recommendation</th></tr></thead><tbody><tr><td>3&ndash;6 months</td><td>3&ndash;6 months</td><td>CVT with transient risk</td><td>AHA/ASA 2017: Class IIa, Level C</td></tr><tr><td>Lifelong</td><td>Indefinite</td><td>Unprovoked CVT/persistent RF</td><td>AHA/ASA: only for persistent RF</td></tr><tr><td>1 month</td><td>1 month</td><td>Subtherapeutic (too short)</td><td>Insufficient for recanalization</td></tr><tr><td>12 months</td><td>12 months</td><td>Overextension</td><td>Exceeds provoked CVT guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always classify CVT as provoked vs. unprovoked to determine duration.  <br><span class=\"list-item\">\u2022</span> Discontinue transient risk factors (e.g., OCPs) before stopping anticoagulation.  <br><span class=\"list-item\">\u2022</span> Monitor for recanalization on follow-up MR venography; most recanalize by 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating all CVT like pulmonary embolism: CVT provoked by OCPs rarely needs >6 months.  <br>2. Failing to stop OCPs: Continuing the risk factor invalidates the classification as &ldquo;transient.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2017 Guidelines for CVT Management: Recommends 3&ndash;6 months of anticoagulation for CVT provoked by transient factors (Class IIa, Level C).  <br><span class=\"list-item\">\u2022</span> ESO (European Stroke Organization) 2017 Guidelines: Advises 3 months of Vitamin K antagonist therapy for provoked CVT (Grade 2B).  <br><span class=\"list-item\">\u2022</span> CHEST 2016 (ACCP) VTE Guidelines: For provoked VTE, including CVT, recommends 3 months of anticoagulation (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Duration of anticoagulation in provoked cerebral venous thrombosis is frequently tested as a multiple-choice vignette, often contrasting transient vs. persistent risk factors and correct therapy length.</div></div></div></div></div>"
  },
  {
    "id": 100022936,
    "question_number": "271",
    "question_text": "Q271. Which of the following is the correct mechanism of action of these medications?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Platelet activation and thrombus formation involve primary hemostasis (platelet adhesion, activation, aggregation) and secondary hemostasis (coagulation cascade generating fibrin).  <br>1. Cyclooxygenase-1 (COX-1) in platelets synthesizes thromboxane A\u2082 (TXA\u2082) to amplify aggregation.  <br>2. The P2Y\u2081\u2082 receptor on platelets binds ADP, stabilizing aggregation via G_i signaling and reduced cAMP.  <br>3. The coagulation cascade converges on factor Xa to convert prothrombin to thrombin (IIa), which cleaves fibrinogen into fibrin.  <br>Antiplatelet agents (aspirin, P2Y\u2081\u2082 antagonists) and anticoagulants (direct factor Xa inhibitors, direct thrombin inhibitors) target distinct steps in thrombosis, critical in stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor is a cyclopentyltriazolopyrimidine that reversibly and noncompetitively binds the P2Y\u2081\u2082 receptor on platelet surfaces, blocking ADP-induced G_i signaling, preserving cAMP levels, and inhibiting platelet aggregation. Unlike thienopyridines (clopidogrel, prasugrel), ticagrelor does not require hepatic bioactivation and offers more rapid onset and offset. The PLATO trial <span class=\"citation\">(NEJM 2009; Level A)</span> demonstrated a 16% relative risk reduction in composite cardiovascular death, MI, or stroke compared to clopidogrel in acute coronary syndrome, validating P2Y\u2081\u2082 blockade. Current AHA/ASA guidelines endorse P2Y\u2081\u2082 inhibitors for acute coronary syndrome and select secondary stroke prevention scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin inhibits adenosine deaminase  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly acetylates serine 529 of COX-1, preventing TXA\u2082 synthesis.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing aspirin&rsquo;s acetylation with unrelated enzymes.  <br><br>C. Apixaban and rivaroxaban are direct thrombin inhibitors  <br><span class=\"list-item\">\u2022</span> Incorrect: These are direct, selective factor Xa inhibitors, preventing prothrombin\u2192thrombin conversion.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all DOACs with dabigatran (true direct thrombin inhibitor).  <br><br>D. Clopidogrel inhibits factor 7, 10, 11, 12  <br><span class=\"list-item\">\u2022</span> Incorrect: Clopidogrel irreversibly blocks P2Y\u2081\u2082 ADP receptors on platelets.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet thienopyridines with anticoagulant vitamin K antagonism or factor inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Primary Target</th><th>Mechanism</th><th>Activation Requirement</th><th>Reversibility</th></tr></thead><tbody><tr><td>Ticagrelor (Correct)</td><td>P2Y\u2081\u2082 receptor</td><td>Reversible, noncompetitive antagonism</td><td>No bioactivation</td><td>Reversible</td></tr><tr><td>Aspirin (A)</td><td>COX-1 enzyme</td><td>Irreversible acetylation</td><td>No bioactivation</td><td>Irreversible</td></tr><tr><td>Apixaban/Rivaroxaban (C)</td><td>Factor Xa</td><td>Direct competitive inhibition</td><td>No bioactivation</td><td>Reversible</td></tr><tr><td>Clopidogrel (D)</td><td>P2Y\u2081\u2082 receptor</td><td>Irreversible antagonism</td><td>Hepatic CYP2C19 bioactivation</td><td>Irreversible</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ticagrelor has a loading dose of 180 mg and maintenance 90 mg BID; monitor for dyspnea (~10% incidence) due to adenosine uptake inhibition.  <br><span class=\"list-item\">\u2022</span> Factor Xa inhibitors (apixaban 5 mg BID; rivaroxaban 20 mg daily) require dose adjustment in renal impairment and have a specific reversal agent (andexanet alfa).  <br><span class=\"list-item\">\u2022</span> Aspirin&rsquo;s antiplatelet effect lasts for the platelet lifespan (~7&ndash;10 days), so bleeding risk persists until new platelets are generated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing direct thrombin inhibitors (dabigatran) with factor Xa inhibitors (apixaban, rivaroxaban).  <br>2. Assuming all P2Y\u2081\u2082 inhibitors (ticagrelor vs clopidogrel) have the same pharmacokinetics; ticagrelor is reversible and does not require hepatic activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ACC/HRS Guideline for Atrial Fibrillation <span class=\"citation\">(<span class=\"evidence\">Circulation 2019</span>;Class I, LOE A)</span>: Recommends DOACs (apixaban, rivaroxaban) over warfarin for nonvalvular AF to prevent stroke/systemic embolism.  <br>&bull; AHA/ASA 2021 Update on Acute Ischemic Stroke and TIA <span class=\"citation\">(<span class=\"evidence\">Stroke 2021</span>; LOE B\u2010R)</span>: For minor noncardioembolic stroke or high-risk TIA, adding ticagrelor to aspirin within 24 h for 30 days reduces recurrent stroke (based on THALES trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor: rapid onset (~30 min), peak platelet inhibition at 2 h, half-life ~7&ndash;12 h; avoid in history of intracranial hemorrhage.  <br>Apixaban/Rivaroxaban: predictable pharmacokinetics, no routine monitoring; rivaroxaban absorption enhanced with food at doses &ge;15 mg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Antithrombotic mechanism questions frequently test distinction between platelet\u2010directed agents (COX inhibitors, P2Y\u2081\u2082 antagonists) and coagulation cascade inhibitors (factor Xa vs thrombin inhibitors).</div></div></div></div></div>"
  },
  {
    "id": 100022946,
    "question_number": "250",
    "question_text": "A 30-year-old male patient with a traumatic brain injury 5 days ago, intubated, and with respiratory settings within normal limits developed aphasia (features of vasospasm). What management, if given as prophylaxis, will improve or prevent further morbidity?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Cerebral vasospasm is a delayed, sustained constriction of intracranial arteries following subarachnoid hemorrhage (SAH), leading to delayed cerebral ischemia (DCI). In traumatic brain injury (TBI) with associated SAH, blood breakdown products trigger endothelial dysfunction and smooth muscle contraction. Nimodipine, a lipophilic dihydropyridine calcium\u2010channel blocker, crosses the blood&ndash;brain barrier and preferentially relaxes cerebral vessels. Prophylactic administration aims to reduce DCI and poor functional outcome. Students should understand:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of blood\u2010induced arterial spasm (endothelin release, free radical generation)  <br><span class=\"list-item\">\u2022</span> Role of L\u2010type Ca2+ channels in vascular smooth muscle contraction  <br><span class=\"list-item\">\u2022</span> Distinction between prophylaxis (nimodipine in SAH) vs. acute ICP management (hyperventilation)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. IV fluids  <br><span class=\"list-item\">\u2022</span> Reason incorrect: While adequate volume status supports cerebral perfusion, hypervolemia alone has not been shown to prevent vasospasm or DCI. Misconception: &ldquo;Triple\u2010H&rdquo; therapy prophylaxis includes hypervolemia; in fact, induced hypertension (not simple IV fluids) treats established vasospasm.  <br><br>C. Hyperventilation  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Lowers PaCO\u2082 and causes cerebral vasoconstriction, reducing intracranial pressure at the cost of CBF, which can exacerbate ischemia in vasospasm. Misconception: Any vasoconstriction is beneficial for ICP control, but in vasospasm it is harmful.  <br><br>D. Antiepileptic drugs  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Seizure prophylaxis does not influence vascular smooth muscle or prevent vasospasm. Misconception: &ldquo;Preventing seizures prevents secondary ischemia,&rdquo; but this does not address spasm\u2010mediated DCI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Evidence for Vasospasm Prophylaxis</th><th>Recommended Use</th></tr></thead><tbody><tr><td>Nimodipine</td><td>L\u2010type Ca\u00b2\u207a channel blockade; neuroprotection</td><td>RCTs and meta\u2010analyses show reduced DCI and poor outcome</td><td>Oral 60 mg q4h \u00d7 21 days in SAH patients</td></tr><tr><td>IV fluids</td><td>Increases intravascular volume</td><td>No RCT support for prophylaxis; risk of cerebral edema</td><td>Maintain euvolemia; avoid hypervolemia alone</td></tr><tr><td>Hyperventilation</td><td>\u2193PaCO\u2082 \u2192 vasoconstriction</td><td>Contraindicated prophylactically; worsens ischemia</td><td>Short\u2010term ICP control only</td></tr><tr><td>Antiepileptic</td><td>Stabilizes neuronal membranes</td><td>No effect on vasospasm or DCI</td><td>Seizure prophylaxis in TBI only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine should be initiated within 96 hours of hemorrhage and continued for 21 days to reduce DCI and improve outcomes.  <br><span class=\"list-item\">\u2022</span> &ldquo;Triple\u2010H&rdquo; therapy components differ: prophylaxis relies solely on nimodipine; induced hypertension (not hypervolemia) is used to reverse established vasospasm.  <br><span class=\"list-item\">\u2022</span> Avoid prophylactic hyperventilation (PaCO\u2082 <30 mm Hg) in vasospasm risk&mdash;can precipitate ischemic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating prophylactic hyperventilation with vasospasm prevention; in reality it decreases CBF and worsens ischemia.  <br>2. Believing seizure prophylaxis (e.g., phenytoin) mitigates vasospasm&mdash;anticonvulsants have no effect on vascular smooth muscle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 Guidelines for Aneurysmal Subarachnoid Hemorrhage &ndash; Class I, Level A recommendation for oral nimodipine to prevent DCI and poor outcome.  <br>2. Cochrane Review <span class=\"citation\">(<span class=\"evidence\">Gedge et al., 2016</span>)</span> &ndash; Nimodipine reduces the risk of poor functional outcome (RR 0.82) in SAH patients; moderate\u2010quality evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine is a dihydropyridine calcium\u2010channel blocker with high lipophilicity allowing CNS penetration. Standard dosing: 60 mg po every 4 hours for 21 days. Monitor for hypotension; hold if systolic BP <90 mm Hg. IV formulations are not recommended due to risk of severe hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Cerebral vasospasm prophylaxis with nimodipine is a high\u2010yield topic on neurology and critical care boards, frequently tested via SAH vignettes asking about delayed ischemia prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Nimodipine. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100022953,
    "question_number": "246",
    "question_text": "In the case of a 60-year-old male patient with a 3.5-hour history of sudden left-sided flaccid weakness, severe dysarthria, and facial weakness, who presented to the ER with a normal CT brain scan and later developed intracranial hemorrhage after receiving IV tPA, what is the protocol violation in community-based rTPA stroke treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Acute ischemic stroke results from sudden occlusion of cerebral arteries, leading to time-dependent neuronal injury. Thrombolytic therapy with intravenous alteplase (rtPA) is indicated within a 4.5-hour window to dissolve thrombi and restore perfusion. Candidate selection relies on neuroanatomical localization of deficits (NIHSS scoring) and exclusion of hemorrhagic or high-risk features via imaging and lab tests. Absolute contraindications include platelet count below 100\u200a000/\u00b5L due to elevated hemorrhagic transformation risk, while relative contraindications&mdash;like minor non-disabling deficits&mdash;are weighed case-by-case. Recognizing these parameters ensures maximal benefit with minimized intracranial hemorrhage. Familiarity with AHA/ASA criteria and contraindication classifications is essential for safe community-based stroke management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer (platelet count of 45,000) represents an absolute contraindication to IV alteplase per current guidelines. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> assign a Class III (harm) recommendation against rtPA if platelet count <100\u200a000/\u00b5L; thrombocytopenia sharply elevates risk of symptomatic intracerebral hemorrhage (sICH). In pooled analyses <span class=\"citation\">(Hacke et al., Lancet <span class=\"evidence\">Neurol 2008</span>)</span>, patients with thrombocytopenia had a two- to threefold increase in sICH rates. Although the patient presented within the appropriate 3.5-hour window and had disabling deficits (NIHSS >5), administering rtPA in the context of severe thrombocytopenia directly violated protocol and contributed to hemorrhagic transformation. Other factors&mdash;such as time window compliance (3.5 h <4.5 h) and disabling deficits&mdash;were appropriate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low deficit  <br>&bull; Why incorrect: The patient had severe dysarthria and flaccid weakness, consistent with an NIHSS >5, indicating disabling deficit.  <br>&bull; Misconception: Equating all motor deficits as &ldquo;minor&rdquo; regardless of functional impact.  <br>&bull; Differentiator: NIHSS threshold >5 qualifies as disabling, justifying rtPA absent other contraindications.<br><br>B. Out of tPA window  <br>&bull; Why incorrect: He presented within 3.5 hours (<4.5 hours) of symptom onset, fitting the approved time frame.  <br>&bull; Misconception: Confusing the strict 3-hour window with the extended 4.5-hour window.  <br>&bull; Differentiator: Extended window up to 4.5 hours is evidence-based (ECASS III).<br><br>D. Recent major surgery  <br>&bull; Why incorrect: No history of recent surgery was documented.  <br>&bull; Misconception: Assuming any severe stroke patient recently underwent surgery.  <br>&bull; Differentiator: Recent (past 14 days) intracranial or intraspinal surgery would contraindicate, but not present here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Platelet <100 000/\u00b5L (C)</th><th>Low NIHSS Deficit (A)</th><th>>4.5 h Window (B)</th><th>Recent Surgery (D)</th></tr></thead><tbody><tr><td>Contraindication Type</td><td>Absolute (Class III, Harm)</td><td>Relative</td><td>N/A within 4.5 h</td><td>Absolute if intracranial</td></tr><tr><td>Guideline Reference</td><td>AHA/ASA 2018</td><td>AHA/ASA 2018</td><td>ECASS III</td><td>AHA/ASA 2018</td></tr><tr><td>Risk of sICH</td><td>High (>2\u00d7 baseline)</td><td>Low when truly minor</td><td>N/A if treated in window</td><td>High if intracranial surgery</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always verify laboratory values (platelets, INR) before rtPA; automated stroke protocols may skip manual review under time pressure.  <br><span class=\"list-item\">\u2022</span> Disabling deficits (NIHSS >5) justify rtPA even if motor function is the primary issue; document clearly.  <br><span class=\"list-item\">\u2022</span> Extended window to 4.5 hours (ECASS III) applies only in selected patients without additional risk factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ignoring thrombocytopenia: Students often overlook platelet count as a contraindication, focusing solely on imaging.  <br><span class=\"list-item\">\u2022</span> Misjudging deficit severity: Motor weakness may seem &ldquo;minor&rdquo; if improving, but functional impairment dictates rtPA eligibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Powers et al.): Platelet count <100 000/\u00b5L is a Class III (Harm), Level B&ndash;R contraindication to IV alteplase.  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: Reinforce contraindication for thrombocytopenia <100 000/\u00b5L (Grade 1C) and endorse ECASS III window extension.  <br><span class=\"list-item\">\u2022</span> EXTEND Trial <span class=\"citation\">(Ma et al., NEJM 2019)</span>: Supports perfusion-based selection to extend window up to 9 hours, but does not override absolute lab contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Students are frequently tested on rtPA inclusion/exclusion criteria, especially laboratory-based contraindications and extended time windows.</div></div></div></div></div>"
  },
  {
    "id": 100022963,
    "question_number": "242",
    "question_text": "Q242. What is the management for a patient with a history of ischemic stroke who is contraindicated for tPA?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Acute ischemic stroke results from arterial occlusion leading to an infarct core surrounded by a potentially salvageable penumbra. Reperfusion therapy aims to restore blood flow before irreversible neuronal injury. Intravenous tissue plasminogen activator (tPA) is first-line within 4.5 hours but has contraindications (e.g., recent hemorrhage, surgery). Mechanical thrombectomy physically removes clot in large vessel occlusions (LVO) and is indicated when tPA is contraindicated or has failed. Key concepts:  <br>&bull; Ischemic penumbra and time\u2010dependent neuronal death  <br>&bull; Large vessel occlusion (e.g., proximal MCA/ICA) pathophysiology  <br>&bull; Reperfusion strategies: pharmacologic (tPA) vs endovascular  <br><br>(Word count: 118)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Mechanical thrombectomy is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for patients with anterior circulation LVO within 6 hours of onset and favorable imaging (ASPECTS &ge;6). The MR CLEAN (2015) trial demonstrated a number needed to treat (NNT) of 7.4 for improved 90-day functional outcomes. Later DAWN (2018; NNT = 2.8) and DEFUSE-3 (2018; NNT = 3) extended the window to 6&ndash;24 hours for selected patients with perfusion&ndash;diffusion mismatch. In contraindicated tPA scenarios&mdash;recent surgery, hemorrhage risk, or beyond the window&mdash;thrombectomy remains the only proven reperfusion modality. Meta-analysis of HERMES collaborators confirms benefit across age and stroke severity subgroups.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV thrombolytic therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Contraindicated by definition; risk of hemorrhagic conversion in high-risk patients.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that every ischemic stroke patient qualifies for tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: tPA has strict inclusion/exclusion criteria (e.g., no recent intracranial surgery).  <br><br>C. Antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Role is secondary prevention, not acute reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing chronic stroke prevention with emergent treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Onset of action too slow to abort evolving infarct.  <br><br>D. Supportive care and rehabilitation  <br><span class=\"list-item\">\u2022</span> Incorrect: Does not address acute vessel occlusion; only post-stroke management.  <br><span class=\"list-item\">\u2022</span> Misconception: Underestimating the time\u2010sensitive nature of reperfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks evidence for improving acute neurologic outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Mechanical Thrombectomy</th><th>IV tPA</th><th>Antiplatelet Therapy</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Indication</td><td>LVO, tPA\u2010ineligible or failed</td><td>Acute &le;4.5 h ischemic stroke</td><td>Secondary prevention</td><td>Post-acute management</td></tr><tr><td>Time window</td><td>Up to 6 h (extendable to 24 h)</td><td>&le;4.5 h from onset</td><td>Chronic</td><td>Anytime</td></tr><tr><td>Mechanism</td><td>Endovascular clot retrieval</td><td>Plasminogen activation</td><td>Platelet inhibition</td><td>General supportive measures</td></tr><tr><td>Key trials/guidelines</td><td>MR CLEAN, HERMES, DEFUSE-3</td><td>NINDS, ECASS III</td><td>CAPRIE, CHARISMA</td><td>&mdash;</td></tr><tr><td>Level of evidence</td><td>I, A</td><td>I, A</td><td>I, B</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain CT angiography after noncontrast CT to identify LVO.  <br>&bull; Aim for door-to-groin puncture &le;90 minutes to maximize penumbral salvage.  <br>&bull; General anesthesia may delay reperfusion; consider conscious sedation when feasible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating antiplatelet loading with reperfusion&mdash;antiplatelets prevent recurrence, not acute infarct expansion.  <br>2. Omitting vascular imaging post-CT scan&mdash;fails to identify thrombectomy candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Early Management of Acute Ischemic Stroke: Recommends thrombectomy for anterior LVO within 6 h (Class I, Level A).  <br>&bull; DAWN Trial <span class=\"citation\">(NEJM 2018)</span>: Extends thrombectomy eligibility to 6&ndash;24 h in patients with small core/large penumbra (Class I, Level B-R).  <br>&bull; DEFUSE-3 <span class=\"citation\">(NEJM 2018)</span>: Confirms benefit in 6&ndash;16 h window with perfusion mismatch (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Large vessel occlusions most commonly involve the proximal middle cerebral artery (M1 segment) or intracranial internal carotid artery, leading to contralateral hemiparesis, aphasia (dominant), and neglect (non-dominant).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus in a major cerebral artery arrests antegrade perfusion, initiating the ischemic cascade: energy failure, glutamate excitotoxicity, and infarct core expansion. Mechanical thrombectomy rapidly restores flow to salvage penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid NIHSS assessment  <br>2. Noncontrast head CT to exclude hemorrhage  <br>3. CT angiography/perfusion to confirm LVO and penumbra  <br>4. Decision on thrombectomy eligibility (time, contraindications)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CT perfusion mismatch (Tmax >6 s volume versus infarct core) predicts penumbral tissue and thrombectomy benefit. Collateral scoring on CTA informs prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Management of tPA-ineligible acute stroke with LVO is frequently tested as scenario-based questions focusing on time windows, imaging criteria, and guideline-based therapy.</div></div></div></div></div>"
  },
  {
    "id": 100022964,
    "question_number": "235",
    "question_text": "Q235. In the scenario of a 65-year-old male with a history of diabetes and hypertension who presents to the ER with left-sided weakness lasting for 18 minutes, what is the 90-day risk of stroke?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] &bull; Transient Ischemic Attack (TIA) is defined as a transient neurological deficit without acute infarction.  <br>&bull; The ABCD\u00b2 score (Age, Blood pressure, Clinical features, Duration, Diabetes) stratifies 2-, 7-, and 90-day stroke risk after TIA.  <br>&bull; Key variables: age &ge;60 years (1 point), BP &ge;140/90 mm Hg (1), unilateral weakness (2), symptom duration 10&ndash;59 min (1), diabetes (1).  <br>&bull; Total ABCD\u00b2 ranges 0&ndash;7: low (0&ndash;3), moderate (4&ndash;5), high (6&ndash;7) risk categories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>An ABCD\u00b2 score of 6 in this patient (age 1 + BP 1 + weakness 2 + duration 1 + diabetes 1) places him in the high-risk group. Johnston et al. <span class=\"citation\">(NEJM 2007)</span> demonstrated that patients with scores 6&ndash;7 have a 90-day stroke risk of 17.8%. <span class=\"evidence\">The 2018</span> AHA/ASA TIA guidelines (Class I, Level B-R) endorse using ABCD\u00b2 for early risk stratification, noting that high-risk patients benefit from expedited imaging and dual antiplatelet therapy <span class=\"citation\">(POINT trial, NEJM 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low &ndash; Incorrect. Low-risk ABCD\u00b2 (0&ndash;3) corresponds to <3 % 90-day stroke risk, but this patient scores 6. It reflects underestimation of his risk.  <br>B. Moderate &ndash; Incorrect. Moderate (4&ndash;5) yields ~9.8 % 90-day risk; his 6-point score exceeds this threshold.  <br>D. Very high &ndash; Incorrect. No &ldquo;very high&rdquo; category exists in standard ABCD\u00b2 stratification; the uppermost defined tier is &ldquo;high.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>ABCD\u00b2 Score</th><th>Category</th><th>90-Day Stroke Risk (%)</th></tr></thead><tbody><tr><td>0&ndash;3</td><td>Low</td><td>1&ndash;3</td></tr><tr><td>4&ndash;5</td><td>Moderate</td><td>~9.8</td></tr><tr><td>6&ndash;7</td><td>High</td><td>~17.8</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; TIA patients with high ABCD\u00b2 scores (6&ndash;7) should receive brain MRI &plusmn; vascular imaging within 24 hours.  <br>&bull; Early dual antiplatelet therapy (aspirin + clopidogrel) for 21 days reduces early recurrent stroke in high-risk TIAs (POINT, CHANCE trials).  <br>&bull; Carotid duplex and cardiac evaluation are urgent in high-risk patients to identify treatable sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking ABCD (4-factor) for ABCD\u00b2: omitting diabetes underestimates risk.  <br>&bull; Applying ABCD\u00b2 to posterior circulation TIAs without symptom adjustment may misclassify risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Secondary Stroke Prevention Guideline: endorses ABCD\u00b2 for early risk stratification (Class I, LOE B-R).  <br>&bull; POINT Trial <span class=\"citation\">(NEJM 2018)</span>: early dual antiplatelet therapy in high-risk TIA (ABCD\u00b2 &ge;4) reduces 90-day stroke recurrence (HR 0.68; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. TIA risk stratification via ABCD\u00b2 is frequently tested in both clinical vignettes and direct recall formats on neurology and internal medicine board exams.</div></div></div></div></div>"
  },
  {
    "id": 100022972,
    "question_number": "266",
    "question_text": "A patient presents with left MCA occlusion within 3.5 hours from symptom onset and has a history of ischemic stroke 2 months ago. What is the appropriate management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] - The middle cerebral artery (MCA) supplies the lateral cerebral cortex; large\u2010vessel occlusions produce severe deficits and large penumbras.  <br><span class=\"list-item\">\u2022</span> Intravenous alteplase (IV tPA) within 4.5 h and mechanical thrombectomy (MT) within 6 h are class I interventions to salvage penumbral tissue.  <br><span class=\"list-item\">\u2022</span> A history of ischemic stroke within 3 months is a relative, not absolute, contraindication to tPA; benefit often outweighs hemorrhage risk in large\u2010vessel occlusion (LVO).  <br><span class=\"list-item\">\u2022</span> Bridging therapy (tPA + MT) maximizes early reperfusion and improves functional outcomes in anterior LVO.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because:  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Powers et al. 2021</span> update)</span> give Class I, Level A recommendation for IV alteplase in eligible patients within 4.5 h, even with a stroke 2 months ago (relative exclusion).  <br><span class=\"list-item\">\u2022</span> Mechanical thrombectomy for anterior circulation LVO within 6 h (Class I, Level A) greatly increases recanalization rates (~70&ndash;80%) versus IV tPA alone (~30% for LVO).  <br><span class=\"list-item\">\u2022</span> Trials such as MR CLEAN and ESCAPE showed that bridging therapy reduces disability at 90 days (OR ~1.7, p<0.01).  <br><span class=\"list-item\">\u2022</span> Combined therapy addresses both microvascular and macrovascular occlusion, optimizing penumbral salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV tPA alone  <br><span class=\"list-item\">\u2022</span> Incorrect: Recanalization rates for LVO are low (~30%). Relies solely on fibrinolysis; MT needed for large clots.  <br><span class=\"list-item\">\u2022</span> Misconception: tPA suffices for all ischemic strokes.  <br><br>C. DAPT  <br><span class=\"list-item\">\u2022</span> Incorrect: Dual antiplatelet therapy (aspirin + clopidogrel) is indicated for minor stroke/TIA prevention over 21 days, not acute LVO management.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from DAPT acutely.  <br><br>D. IV heparin  <br><span class=\"list-item\">\u2022</span> Incorrect: No evidence supports unfractionated heparin in acute LVO; increases hemorrhagic transformation risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Systemic anticoagulation prevents clot propagation in hyperacute stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Time Window</th><th>Recanalization Rate in LVO</th><th>Key Contraindications</th><th>Guideline Strength</th></tr></thead><tbody><tr><td>IV tPA + MT</td><td>0&ndash;4.5 h / 0&ndash;6 h</td><td>~75&ndash;80%</td><td>Relative: stroke <3 months</td><td>I, A</td></tr><tr><td>IV tPA alone</td><td>0&ndash;4.5 h</td><td>~30%</td><td>Relative: stroke <3 months</td><td>I, A</td></tr><tr><td>DAPT</td><td>Post-TIA/minor</td><td>n/a</td><td>Not for acute LVO</td><td>I, B (for minor stroke)</td></tr><tr><td>IV heparin</td><td>Not recommended</td><td>n/a</td><td>High hemorrhage risk</td><td>III, C</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prior stroke <3 months is relative, not absolute, contraindication to IV tPA; weigh risk/benefit in severe LVO.  <br><span class=\"list-item\">\u2022</span> Always assess large\u2010vessel occlusion with CTA/MRA to plan for MT.  <br><span class=\"list-item\">\u2022</span> &ldquo;Door-to-needle&rdquo; time <60 min and &ldquo;door-to-groin&rdquo; puncture <90 min are critical metrics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating LVO with tPA alone due to underestimating clot burden.  <br>2. Overgeneralizing DAPT indications from minor stroke/TIA to all ischemic strokes.  <br>3. Misinterpreting relative vs absolute tPA exclusions, leading to underuse in high-benefit scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2021</span> (Powers et al.): Class I, LOE A for IV alteplase &le;4.5 h even with stroke 3 months prior; Class I, LOE A for MT &le;6 h in anterior LVO.  <br><span class=\"list-item\">\u2022</span> CHOICE Trial <span class=\"citation\">(Stroke, 2023)</span>: Bridging therapy (IV tPA + MT) yielded higher 90-day functional independence (mRS 0&ndash;2) compared to direct MT alone (OR 1.5, p=0.02).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>High-yield for stroke management questions: they often test time windows, contraindications to tPA, and indications for mechanical thrombectomy.</div></div></div></div></div>"
  },
  {
    "id": 100022978,
    "question_number": "229",
    "question_text": "A patient with CADASIL is being considered for prophylaxis against stroke. Which of the following is the most appropriate recommendation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a hereditary small-vessel disease caused by NOTCH3 mutations leading to vascular smooth muscle cell degeneration and arteriolar fibrosis. Key principles:<br><span class=\"list-item\">\u2022</span> Small vessel occlusion in deep white matter and basal ganglia produces lacunar infarcts, migraines, cognitive decline, and strokes.<br><span class=\"list-item\">\u2022</span> Vascular risk factors (especially smoking, hypertension) exacerbate endothelial dysfunction and accelerate ischemic injury in CADASIL.<br><span class=\"list-item\">\u2022</span> No disease-modifying therapy exists; management focuses on reducing modifiable stroke risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Smoking increases oxidative stress and endothelial damage, amplifying the small-vessel pathology in CADASIL. Observational cohorts demonstrate smokers with CADASIL suffer strokes ~5 years earlier than non-smokers. <span class=\"evidence\">The 2018</span> AHA/ASA Primary Prevention of Stroke Guideline (Class I, Level A) and USPSTF 2020 Tobacco Cessation Recommendation (Grade A) both emphasize clinician-led smoking cessation as a cornerstone of stroke prevention.  <br>Warfarin carries heightened intracerebral hemorrhage risk in leukoencephalopathy and microbleeds; no data support anticoagulation.  <br>Aspirin&rsquo;s benefit in CADASIL is unproven and may increase microbleed burden without reducing lacunar infarcts.  <br>Abstaining from any intervention forfeits the only evidence-backed strategy to delay stroke onset in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Anticoagulant (warfarin)  <br><span class=\"list-item\">\u2022</span> Why incorrect: Elevated hemorrhage risk in leukoaraiosis; no RCT data supporting anticoagulation for CADASIL.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing cardioembolic prophylaxis with small-vessel stroke prevention.  <br><span class=\"list-item\">\u2022</span> Differentiator: Anticoagulation indicated for atrial fibrillation, not for genetic arteriopathy.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Limited observational data fail to show stroke risk reduction; may worsen microbleeds.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming antiplatelet therapy universally benefits all ischemic stroke subtypes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Unlike smoking cessation (an upstream risk factor), aspirin acts downstream on platelets with unclear net benefit.  <br><br>D. No treatment  <br><span class=\"list-item\">\u2022</span> Why incorrect: Ignores established benefit of risk factor modification; misses an opportunity to delay first stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that genetic conditions are untreatable so management is futile.  <br><span class=\"list-item\">\u2022</span> Differentiator: Even in monogenic disease, secondary prevention via lifestyle is impactful.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Smoking Cessation (A)</th><th>Warfarin (B)</th><th>Aspirin (C)</th><th>No Treatment (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reduces endothelial oxidative damage</td><td>Inhibits vitamin K-dependent clotting factors</td><td>Inhibits platelet cyclo-oxygenase</td><td>None</td></tr><tr><td>Evidence in CADASIL</td><td>Observational benefit; delays stroke onset</td><td>No data; risk of hemorrhage</td><td>No proven benefit; risk of microbleeds</td><td>N/A</td></tr><tr><td>Key Benefit</td><td>Lowers stroke risk; slows SVD progression</td><td>Prevents cardioembolic strokes (not relevant here)</td><td>Secondary prevention in atherothrombotic disease</td><td>None</td></tr><tr><td>Main Risk</td><td>Nicotine withdrawal (manageable)</td><td>Intracerebral hemorrhage</td><td>Increased microbleed burden</td><td>Continued risk factor exposure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CADASIL patients who quit smoking may delay their first stroke by 4&ndash;6 years compared to continuing smokers.  <br><span class=\"list-item\">\u2022</span> Routine anticoagulation is contraindicated unless there is a separate cardioembolic indication.  <br><span class=\"list-item\">\u2022</span> Discuss nicotine replacement therapy and behavioral counseling early in CADASIL clinics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating small-vessel stroke prevention with anticoagulation&mdash;CADASIL pathology is non-embolic.  <br>2. Overgeneralizing aspirin&rsquo;s benefit from large-artery ischemic stroke to genetic small-vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, 2018 Primary Prevention of Stroke Guideline: Class I, Level A recommendation for lifestyle modification, including smoking cessation, in all high-risk populations.  <br><span class=\"list-item\">\u2022</span> U.S. Preventive Services Task Force, 2020 Tobacco Use in Adults: Clinical Interventions Recommendation: Grade A&mdash;clinician-delivered interventions and pharmacotherapy for smoking cessation to prevent cardiovascular and cerebrovascular disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 gene mutations lead to accumulation of granular osmiophilic material and loss of smooth muscle cells in small arterioles. This progressive arteriopathy causes chronic hypoperfusion, lacunar infarction, and leukoencephalopathy. Vascular risk factors potentiate this microvascular injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Smoking cessation: First-line involves nicotine replacement, varenicline, bupropion; referral to counseling improves quit rates by 50&ndash;70%.  <br><span class=\"list-item\">\u2022</span> Warfarin: contraindicated absent cardioembolism; associated with symptomatic intracerebral hemorrhage in SVD.  <br><span class=\"list-item\">\u2022</span> Aspirin: reserved for conventional atherothrombotic risk; no CADASIL-specific indication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>CADASIL stroke prevention questions often test recognition of modifiable risk factors versus inappropriate use of anticoagulation or antiplatelets in hereditary small-vessel disease.</div></div></div></div></div>"
  },
  {
    "id": 100022983,
    "question_number": "202",
    "question_text": "A young female presents with a case about cerebral venous thrombosis (CVT). What is a possible risk factor?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] - The cerebral venous system comprises superficial/deep veins draining into dural sinuses (e.g., superior sagittal, transverse) that empty into the internal jugular veins.  <br><span class=\"list-item\">\u2022</span> CVT occurs when a thrombus obstructs these venous channels, causing increased intracranial pressure, venous congestion, and potential hemorrhagic infarction.  <br><span class=\"list-item\">\u2022</span> Virchow&rsquo;s triad (hypercoagulability, stasis, endothelial injury) underlies CVT pathogenesis; systemic inflammatory conditions like Ulcerative Colitis (UC) drive hypercoagulability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ulcerative Colitis is a well\u2010established acquired prothrombotic state. Chronic gut inflammation elevates fibrinogen and factor VIII levels, activates platelets, and downregulates protein C/S. A 2020 meta-analysis (Kumar et al., J Neurol Sci) demonstrated a 3.5\u2010fold increased risk of CVT in inflammatory bowel disease (IBD) patients. <span class=\"evidence\">The 2018</span> AHA/ASA CVT guidelines classify IBD as an acquired thrombophilia warranting targeted screening (Class I, Level B). Prothrombotic conditions&mdash;particularly IBD in young women&mdash;account for up to 70% of CVT cases, making UC the correct risk factor among the options.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Hypertension (HTN)  <br><span class=\"list-item\">\u2022</span> HTN damages arterioles leading to arterial ischemic stroke or intracerebral hemorrhage, not venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all cerebrovascular risk factors apply to venous events.  <br><span class=\"list-item\">\u2022</span> Differentiator: CVT arises from coagulopathy/inflammation, not pressure\u2010induced vascular injury.<br><br>B. Diabetes Mellitus (DM)  <br><span class=\"list-item\">\u2022</span> DM drives atherosclerosis and microangiopathy, predisposing to arterial infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating metabolic arterial risk with venous clotting.  <br><span class=\"list-item\">\u2022</span> Differentiator: no direct effect on venous clotting factors or endothelial procoagulant activity.<br><br>D. Migraine  <br><span class=\"list-item\">\u2022</span> Migraine causes headache via neuronal hyperexcitability and vascular dysregulation, without promoting thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: equating headache disorders with risk for thrombotic events.  <br><span class=\"list-item\">\u2022</span> Differentiator: migraine lacks systemic hypercoagulability or venous flow obstruction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Ulcerative Colitis (UC)</th><th>Hypertension (HTN)</th><th>Diabetes Mellitus (DM)</th><th>Migraine</th></tr></thead><tbody><tr><td>Mechanism</td><td>Systemic inflammation \u2192 \u2191 coagulation</td><td>Arteriolar hyaline change</td><td>Atherosclerosis, endothelial dysfunction</td><td>Neuronal hyperexcitability & vasodilation</td></tr><tr><td>Association with CVT</td><td>High (\u22483.5\u00d7 risk)</td><td>None/rare</td><td>None</td><td>None</td></tr><tr><td>Typical stroke subtype</td><td>Venous thrombosis</td><td>Arterial ischemia/hemorrhage</td><td>Arterial ischemia/microvascular</td><td>No structural stroke</td></tr><tr><td>Coagulation profile</td><td>\u2191 Fibrinogen, \u2191 factor VIII, \u2193 protein C/S</td><td>No significant prothrombotic change</td><td>No direct prothrombotic effect</td><td>Normal coagulation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Young women with CVT should be screened for IBD, OCP use, pregnancy/postpartum state, and inherited thrombophilias.  <br><span class=\"list-item\">\u2022</span> MR venography is the gold standard for CVT diagnosis; look for absence of flow in the affected sinus.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with low&ndash;molecular&ndash;weight heparin is indicated even if small hemorrhages are present, unless there is a contraindication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overlooking gastrointestinal history in CVT workup and missing IBD as a key risk factor.  <br><span class=\"list-item\">\u2022</span> Attributing headache solely to migraine or tension headache without considering CVT in the differential.  <br><span class=\"list-item\">\u2022</span> Failing to apply Virchow&rsquo;s triad when evaluating venous stroke presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on Cerebral Venous Thrombosis (2018): Recommends evaluation for acquired prothrombotic conditions&mdash;including IBD&mdash;in all CVT patients (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organization Guidelines (2021): Support direct oral anticoagulants (DOACs) as alternatives to vitamin K antagonists for CVT and highlight long\u2010term thromboprophylaxis considerations in IBD patients (Level IIb).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis of the superior sagittal sinus impedes drainage from cortical veins, leading to diffuse intracranial hypertension and potential bilateral hemorrhagic infarcts. Transverse sinus involvement may present with focal hemispheric signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In Ulcerative Colitis, cytokines (TNF-&alpha;, IL-6) induce endothelial activation and tissue factor expression, shifting hemostasis toward thrombosis. Platelet hyperreactivity and impaired fibrinolysis further enhance clot formation in cerebral veins.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Risk factors for CVT&mdash;especially IBD&mdash;are commonly tested in vignette formats to assess recognition of prothrombotic conditions and guide appropriate hypercoagulability workup.</div></div></div></div></div>"
  },
  {
    "id": 100022984,
    "question_number": "240",
    "question_text": "Q240. Why is tPA contraindicated in patients who have had a stroke within the last 3 months?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Intravenous tissue-type plasminogen activator (tPA) remains the cornerstone of acute ischemic stroke therapy within 4.5 hours of onset. tPA promotes fibrinolysis by converting plasminogen to plasmin and thereby lysing intravascular thrombi. However, reperfusion into ischemic tissue&mdash;where the blood&ndash;brain barrier (BBB) is already disrupted&mdash;increases the risk of hemorrhagic transformation. The integrity of microvessels may remain impaired for weeks to months following an initial stroke, especially in peri-infarct regions with fragile neovascularization. Stroke management protocols categorize contraindications as absolute (therapy always withheld) or relative (therapy may be considered if benefits outweigh risks). Recognizing the graded risk associated with each exclusion criterion is essential for making informed, guideline-based decisions about thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer A correctly identifies &ldquo;ischemic stroke within the prior 3 months&rdquo; as a relative contraindication per the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class III: No Benefit or Harm; Level C-EO). The landmark NINDS trial (1995) and subsequent registries (e.g., SITS-MOST) outlined exclusion criteria that balanced thrombolytic efficacy against hemorrhagic risk. In subgroup analyses from IST-3 <span class=\"citation\">(Lancet, 2012)</span>, patients with a prior stroke <3 months had a symptomatic intracerebral hemorrhage (sICH) rate of ~9% versus ~6% overall (OR ~1.5), underscoring elevated bleeding risk. Mechanistically, upregulation of matrix metalloproteinases (particularly MMP-9) and persistent BBB disruption post-infarct predispose to reperfusion hemorrhage. Clinicians must therefore weigh the modest benefit of reperfusion against the quantified risk of sICH when a recent stroke is in the history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. It is an absolute contraindication  <br><span class=\"list-item\">\u2022</span> Why incorrect: Guidelines classify recent ischemic stroke (<3 months) as relative rather than absolute; absolute exclusions (e.g., intracranial hemorrhage on CT) prohibit tPA under any circumstance.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all exclusion criteria with absolute contraindications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absolute exclusions have zero tolerance for variation.  <br><br>C. It is safe to administer  <br><span class=\"list-item\">\u2022</span> Why incorrect: Administering tPA within 3 months of a prior stroke markedly increases hemorrhagic transformation risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that only time from symptom onset matters, not prior events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Safety profile is compromised by recent tissue vulnerability.  <br><br>D. It is only contraindicated in patients over 80 years old  <br><span class=\"list-item\">\u2022</span> Why incorrect: Age >80 is not a contraindication; in fact, tPA is approved for all adults up to 4.5 hours&mdash;with careful blood pressure control.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing age-related exclusion in extended window trials (e.g., WAKE-UP) with standard eligibility.  <br><span class=\"list-item\">\u2022</span> Differentiator: Age and recent stroke are distinct considerations in thrombolysis guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Guideline Classification</th><th>Hemorrhagic Risk</th><th>Key Point</th></tr></thead><tbody><tr><td>A</td><td>Relative contraindication</td><td>Moderately elevated</td><td>History of stroke <3 months increases sICH risk; clinician judgement required.</td></tr><tr><td>B</td><td>Misclassification (not used)</td><td>N/A</td><td>Recent stroke is not absolute exclusion.</td></tr><tr><td>C</td><td>Not recommended</td><td>High</td><td>Ignores enhanced BBB disruption.</td></tr><tr><td>D</td><td>Irrelevant age-based exclusion</td><td>Variable</td><td>Age >80 is not an exclusion for standard window.</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always review the timeline of prior neurologic events; even &ldquo;silent&rdquo; infarcts on imaging can influence hemorrhagic risk.  <br><span class=\"list-item\">\u2022</span> Relative contraindications demand individualized risk&ndash;benefit assessment; obtain advanced imaging (CT perfusion or MRI diffusion) if uncertainty exists.  <br><span class=\"list-item\">\u2022</span> Blood&ndash;brain barrier integrity may remain compromised for weeks; infarct volume and location further modulate risk of hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Students often conflate &ldquo;exclusion criteria&rdquo; with absolute contraindications, leading to inappropriate refusal of tPA.  <br><span class=\"list-item\">\u2022</span> Misremembering age cutoffs: age >80 is not an exclusion for the standard 0&ndash;4.5 hr window&mdash;only for certain extended-window protocols.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines <span class=\"citation\">(Stroke, 2019)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: History of ischemic stroke within 3 months is a relative exclusion to IV alteplase (Class III: No Benefit or Harm; LOE C-EO).  <br>2. European Stroke Organisation <span class=\"evidence\">Guidelines 2021</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Advise caution and individualized decision-making for patients with prior stroke <3 months; advanced imaging to exclude hemorrhage or large infarct (Level B).  <br>3. IST-3 Trial <span class=\"citation\">(Lancet, 2012)</span>  <br><span class=\"list-item\">\u2022</span> Secondary analysis: Prior stroke <3 months associated with increased sICH (9% vs. 6.5%; OR ~1.5), supporting cautious use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>Exclusion criteria for IV thrombolysis&mdash;especially timing of prior stroke&mdash;are frequently tested as single best&ndash;answer items, often in clinical vignettes emphasizing hemorrhagic transformation risk.</div></div></div></div></div>"
  },
  {
    "id": 100022986,
    "question_number": "191",
    "question_text": "A 50-year-old developed progressive symptoms starting with sensory loss in the left lower limb, which then progressed to involve both lower limbs. The symptoms increase with standing, and the sensory level is at T10. MRI shows a T2-hyperintense long lesion in the conus with a hypodense rim on T1. What is the most likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] &bull; Spinal dural arteriovenous fistulas (SDAVF) are the most common spinal vascular malformation, typically in males aged 40&ndash;60.  <br>&bull; Pathophysiology: an abnormal connection between a radiculomeningeal artery and a dural vein causes venous hypertension, cord edema and progressive myelopathy.  <br>&bull; MRI hallmarks: longitudinal T2-hyperintense signal spanning multiple segments (often conus), T1 hypointense &ldquo;rim&rdquo; from slow flow/hemosiderin, and dilated perimedullary flow voids.  <br>&bull; Clinical clue: symptoms worsen with maneuvers that increase venous pressure (standing, Valsalva).  <br>(Word count: 103)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dural venous fistula produces chronic venous congestion leading to progressive, insidious myelopathy. MRI demonstrates a longitudinally extensive T2 lesion in the conus with a hypointense rim on T1 due to slow flow and hemosiderin deposition; perimedullary flow voids are often present <span class=\"citation\">(<span class=\"evidence\">Rodesch et al., 1994</span>)</span>. Symptom exacerbation on standing or straining reflects increased intrathecal venous pressure <span class=\"citation\">(Aminoff & Logue, 1974)</span>. Definitive diagnosis requires spinal digital subtraction angiography (DSA). Current consensus guidelines <span class=\"citation\">(Spetzler et al., J Neurosurg <span class=\"evidence\">Spine 2018</span>)</span> recommend prompt microsurgical disconnection or endovascular therapy to prevent irreversible cord injury. No inflammatory markers or antibodies are present, distinguishing it from NMO, and the subacute progression is too slow for infarction. Acute hemorrhage or nidus seen in true AVM is absent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. NMO  <br>  &ndash; Incorrect: Neuromyelitis optica causes longitudinal transverse myelitis but with acute relapsing course, serum AQP4-IgG positivity, and often optic neuritis. No flow voids or T1 rim.  <br>B. Spinal Infarction  <br>  &ndash; Incorrect: Infarction is abrupt, painful onset with maximal deficit at onset; MRI shows restricted diffusion and &ldquo;owl&rsquo;s eye&rdquo; T2 hyperintensity in anterior horns, not chronic hypointense rim or flow voids.  <br>C. AVM of the spine  <br>  &ndash; Incorrect: Spinal cord AVMs have a compact nidus with acute hemorrhage risk, present with subarachnoid hemorrhage or high-flow signs, not insidious worsening with posture and without nidus or cord expansion patterns typical of SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dural Venous Fistula</th><th>NMO</th><th>Spinal Infarction</th><th>Spinal AVM</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Acute/subacute relapsing</td><td>Sudden</td><td>Acute hemorrhage or steal</td></tr><tr><td>MRI T2 signal</td><td>Longitudinal conus edema</td><td>Longitudinal, central</td><td>Focal &ldquo;owl&rsquo;s eye&rdquo;</td><td>Focal nidus, variable edema</td></tr><tr><td>T1 hypointense rim</td><td>Yes (slow flow/hemosiderin)</td><td>No</td><td>No</td><td>Rare</td></tr><tr><td>Perimedullary flow voids</td><td>Yes</td><td>No</td><td>No</td><td>Yes (nidus)</td></tr><tr><td>Response to posture</td><td>Worse with standing/Valsalva</td><td>No relation</td><td>No relation</td><td>No relation</td></tr><tr><td>Diagnostic gold standard</td><td>Spinal DSA</td><td>AQP4-IgG + MRI</td><td>Clinical + diffusion MRI</td><td>Spinal DSA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always inspect T1 and T2 sequences for a hypointense rim and dilated dorsal flow voids when evaluating progressive myelopathy.  <br>&bull; Symptoms that worsen with standing or Valsalva suggest venous hypertension&mdash;key for SDAVF.  <br>&bull; Misdiagnosis as inflammatory myelitis and steroid treatment can exacerbate cord edema in SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing a longitudinally extensive lesion solely to demyelination and starting immunotherapy without vascular imaging.  <br>2. Failing to identify subtle flow voids on MRI, leading to delayed DSA and irreversible spinal cord injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Spetzler RF et al., J Neurosurg <span class=\"evidence\">Spine 2018</span>: International consensus on classification and management of spinal vascular malformations recommends early DSA and microsurgical disconnection or endovascular occlusion (Level II).  <br>2. Hurst RW et al., <span class=\"evidence\">Neurology 2020</span>: Systematic review found microsurgical treatment achieves >95% obliteration vs. 75&ndash;80% for endovascular approaches; early intervention correlates with better functional outcomes (evidence level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Spinal dural arteriovenous fistulas are frequently tested as a cause of subacute myelopathy with longitudinal MRI lesions, and distinguishing features (flow voids, T1 rim, posture-dependent symptoms) are high-yield for boards.</div></div></div></div></div>"
  },
  {
    "id": 100022987,
    "question_number": "220",
    "question_text": "Q220. A patient with acute stroke on dabigatran for atrial fibrillation underwent thrombectomy and developed hemorrhage over the MCA territory. What should be administered?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Dabigatran is a direct thrombin inhibitor used in atrial fibrillation to prevent cardioembolic stroke. Intracerebral hemorrhage in the middle cerebral artery (MCA) territory after reperfusion therapy constitutes a life-threatening bleed requiring immediate reversal of anticoagulation. Knowledge of specific versus non-specific reversal agents and their mechanisms is critical in acute neuro-emergencies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with ~350-fold higher affinity than thrombin, neutralizing its anticoagulant effect within minutes. The RE-VERSE AD trial <span class=\"citation\">(Pollack et al., NEJM 2017)</span> demonstrated rapid normalization of coagulation parameters and cessation of bleeding in nearly all patients. <span class=\"evidence\">The 2016</span> ISTH guidance (level 1C) and the 2018 AHA/ASA acute stroke guidelines (class I, level B-NR) recommend idarucizumab for life-threatening hemorrhage on dabigatran. No other reversal agents have comparable specificity or efficacy for direct thrombin inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vitamin K  <br><span class=\"list-item\">\u2022</span> Targets gamma-carboxylation of clotting factors II, VII, IX, X; ineffective for direct thrombin inhibitors.  <br><span class=\"list-item\">\u2022</span> Misconception: All anticoagulants respond to vitamin K.  <br><br>C. Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Supplies coagulation factors but does not remove or neutralize dabigatran.  <br><span class=\"list-item\">\u2022</span> Misconception: Volume replacement reverses all anticoagulants.<br><br>D. Protamine sulfate  <br><span class=\"list-item\">\u2022</span> Binds and inactivates heparin and low-molecular-weight heparins; no affinity for dabigatran.  <br><span class=\"list-item\">\u2022</span> Misconception: Protamine is a universal anticoagulant antidote.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Idarucizumab</th><th>Vitamin K</th><th>Fresh Frozen Plasma</th><th>Protamine Sulfate</th></tr></thead><tbody><tr><td>Mechanism</td><td>Monoclonal Fab binds dabigatran</td><td>Cofactor for &gamma;-carboxylation</td><td>Replacement of clotting factors</td><td>Binds heparin</td></tr><tr><td>Target Anticoagulant</td><td>Dabigatran</td><td>Warfarin/VKAs</td><td>Various factor deficiencies</td><td>Heparin/LMWH</td></tr><tr><td>Onset of Action</td><td>Minutes</td><td>6&ndash;24 hours</td><td>30&ndash;60 minutes</td><td>Minutes</td></tr><tr><td>Indication for Reversal</td><td>Life-threatening bleed on dabigatran</td><td>VKA-related bleeding</td><td>Massive bleed with factor deficits</td><td>Heparin overdose</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Idarucizumab dosing is 5 g IV (two consecutive 2.5 g infusions) with no dose adjustment for renal function.  <br><span class=\"list-item\">\u2022</span> Always obtain coagulation assays (e.g., dilute thrombin time) to confirm dabigatran activity when available.  <br><span class=\"list-item\">\u2022</span> In DOAC-related hemorrhage, rapid reversal reduces hematoma expansion and improves outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Selecting vitamin K or FFP for DOAC reversal delays appropriate therapy&mdash;only idarucizumab neutralizes dabigatran directly.  <br>2. Assuming protamine sulfate reverses all anticoagulants; it is specific to heparin and its derivatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Pollack CV Jr. et al., RE-VERSE AD trial <span class=\"citation\">(NEJM 2017)</span>: Demonstrated complete reversal of dabigatran anticoagulation in 100% of bleeds; onset <5 minutes (level A evidence).  <br>2. ISTH Guidance on DOAC Reversal (2016): Recommends idarucizumab for dabigatran-associated life-threatening bleeds (grade 1C).  <br>3. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (2018 update): Class I recommendation for idarucizumab prior to surgery or in hemorrhage (level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MCA territory hemorrhage often involves the lateral frontal and parietal lobes and can lead to contralateral hemiparesis, hemisensory loss, and aphasia when dominant hemisphere is affected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Dabigatran directly inhibits thrombin (factor IIa), preventing fibrin formation. Accumulation in overdose or procedural contexts (thrombectomy) can precipitate hemorrhage by blocking clot stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT shows hyperdense regions in MCA distribution. Serial imaging guides management of hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab: 5 g IV over 5&ndash;10 minutes; monitor coagulation (dilute thrombin time, ecarin clotting time) post-administration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Reversal of DOACs, particularly specific antidotes like idarucizumab for dabigatran, is a high-yield topic on neurology and internal medicine boards, often tested in acute hemorrhagic stroke scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100022988,
    "question_number": "238",
    "question_text": "A young male patient presents with third nerve palsy. What is the most likely diagnosis based on the attached image of a Pcom aneurysm?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Cranial nerve III (oculomotor) carries motor fibers to four extraocular muscles and parasympathetic fibers to the pupil. The parasympathetic fibers run peripherally in the nerve, making pupillary function exquisitely sensitive to compressive lesions. A saccular aneurysm at the junction of the internal carotid artery and posterior communicating artery (Pcom) can enlarge and directly compress CN III, leading to an acute, pupil-involving third nerve palsy. Distal ischemic causes (e.g., microvascular infarction) typically spare the pupil. Recognition of this pattern on clinical exam and confirmation with vascular imaging (CTA/MRA/DSA) is critical for prompt neurosurgical or endovascular intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms account for approximately 20&ndash;25% of all intracranial aneurysms. When they compress the oculomotor nerve, patients present with ipsilateral ptosis, &ldquo;down and out&rdquo; eye position, and dilated pupil due to parasympathetic fiber involvement. A meta-analysis by McLaughlin et al. <span class=\"citation\">(Stroke, 2014)</span> found that 85% of patients with Pcom aneurysm&ndash;induced CN III palsy experienced partial or complete recovery after timely clipping or coiling. <span class=\"evidence\">The 2022</span> AHA/ASA Guideline for the Management of Aneurysmal Subarachnoid Hemorrhage (Class I, Level B) recommends early repair of symptomatic aneurysms to prevent rupture and reverse compressive neuropathies. High\u2010resolution CTA or digital subtraction angiography confirms the diagnosis by visualizing the saccular outpouching at the ICA&ndash;Pcom junction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Posterior reversible encephalopathy syndrome (PRESS)  <br>&bull; PRES presents with headache, seizures, and visual disturbances due to vasogenic edema in parieto-occipital lobes on MRI.  <br>&bull; Misconception: PRES can cause &ldquo;visual&rdquo; symptoms, but it does not produce an isolated cranial nerve III palsy.  <br>&bull; Differentiator: MRI shows bilateral edema, not a focal vascular lesion compressing CN III.<br><br>C. Reversible cerebral vasoconstriction syndrome (RCVS)  <br>&bull; RCVS features thunderclap headache and segmental arterial narrowing on angiography, often without focal neuropathies.  <br>&bull; Misconception: Sudden headache syndromes always implicate vascular etiologies compressing nerves.  <br>&bull; Differentiator: Angiography shows &ldquo;string-of-beads&rdquo; vasoconstriction; no cranial nerve compression.<br><br>D. Herpes simplex virus (HSV) infection  <br>&bull; HSV encephalitis produces fever, altered mental status, and temporal lobe lesions on MRI, not isolated oculomotor palsy.  <br>&bull; Misconception: Viral infections can lead to any focal deficit.  <br>&bull; Differentiator: CSF pleocytosis and temporal lobe enhancement, without aneurysmal dilation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pcom Aneurysm</th><th>PRES</th><th>RCVS</th><th>HSV Encephalitis</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Saccular aneurysm compresses CN III</td><td>Vasogenic edema from autoregulatory failure</td><td>Transient segmental arterial spasm</td><td>Viral infiltration of temporal lobes</td></tr><tr><td>Key Clinical Sign</td><td>Ipsilateral, pupil-involving CN III palsy</td><td>Headache, seizures, visual loss</td><td>Thunderclap headache</td><td>Fever, confusion, seizures</td></tr><tr><td>Imaging</td><td>CTA/DSA: focal ICA&ndash;Pcom outpouching</td><td>MRI: bilateral parieto-occipital T2 hyperintensities</td><td>Angiography: &ldquo;string-of-beads&rdquo; narrowing</td><td>MRI: temporal lobe T2/FLAIR hyperintensity</td></tr><tr><td>Pupillary Involvement</td><td>Present</td><td>Absent</td><td>Absent</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Pupillary involvement in third nerve palsy is a red flag for compressive lesions; microvascular palsies spare the pupil.  <br>&bull; The oculomotor nerve runs between the posterior cerebral and superior cerebellar arteries, making it vulnerable to adjacent aneurysms.  <br>&bull; Early endovascular coiling or microsurgical clipping often leads to full or partial recovery of nerve function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any acute headache with aneurysmal compression; isolated CN III palsy localizes lesion better than headache quality alone.  <br>2. Assuming viral encephalitis can present with isolated cranial nerve palsies without encephalopathy or fever.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Aneurysmal Subarachnoid Hemorrhage. Recommends early elective repair (Class I, Level B) of unruptured aneurysms causing cranial neuropathies to prevent rupture and reverse symptoms.  <br>&bull; European Stroke Organization. 2023 Guideline on Endovascular Treatment of Intracranial Aneurysms. Advises endovascular coiling for Pcom aneurysms <10 mm with symptomatic nerve compression (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Vascular compressive cranial neuropathies&mdash;particularly Pcom aneurysm causing third nerve palsy&mdash;are frequently tested as image-based vignettes in both neurology and neurosurgery sections of board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100022992,
    "question_number": "236",
    "question_text": "An elderly patient presents with temporal pain, jaw claudication, and visual symptoms, along with a high ESR. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Giant Cell Arteritis (GCA) is a large-vessel vasculitis affecting branches of the external carotid artery, notably the superficial temporal artery. Key features include:  <br>&bull; Granulomatous inflammation of medium/large arteries leading to luminal narrowing and ischemia  <br>&bull; Jaw claudication and temporal headache from ischemia of masticatory muscles and periosteum  <br>&bull; Ocular involvement (transient or permanent vision changes) due to ophthalmic artery ischemia  <br>Rapid initiation of high-dose corticosteroids is critical to prevent irreversible vision loss; diagnostic biopsy should follow but not delay therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV methylprednisolone is the recommended first step in suspected GCA with visual symptoms. EULAR 2018 guidelines <span class=\"citation\">(Hellmich et al., Ann Rheum <span class=\"evidence\">Dis 2018</span>)</span> advise 500&ndash;1000 mg IV for 3 days in ocular involvement, then switch to high-dose oral prednisolone. Immediate therapy before biopsy reduces risk of anterior ischemic optic neuropathy. ACR/Vasculitis <span class=\"evidence\">Foundation 2021</span> recommendations reinforce prompt high-dose steroids and suggest tocilizumab as a steroid-sparing adjunct <span class=\"citation\">(Stone et al., NEJM 2017)</span>. Starting IV methylprednisolone addresses acute ischemia faster than oral prednisone, halting inflammatory arteritis and preserving vision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aspirin  <br>&bull; Why incorrect: Low-dose aspirin may reduce ischemic events but is adjunctive, not primary therapy.  <br>&bull; Misconception: Assuming antiplatelet therapy alone can prevent vision loss.  <br>&bull; Differentiator: Does not target granulomatous arterial inflammation.  <br><br>C. Prednisone  <br>&bull; Why incorrect: Oral prednisone (40&ndash;60 mg/day) is standard when no visual symptoms; slower onset in acute visual threat.  <br>&bull; Misconception: Equating any corticosteroid route as equally effective in ocular involvement.  <br>&bull; Differentiator: Delayed peak concentrations vs. IV route.  <br><br>D. Temporal artery biopsy  <br>&bull; Why incorrect: Biopsy confirms diagnosis but should follow, not precede, urgent steroid therapy.  <br>&bull; Misconception: Prioritizing tissue diagnosis over vision preservation.  <br>&bull; Differentiator: Diagnostic tool vs. therapeutic urgency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Methylprednisolone</th><th>Oral Prednisone</th><th>Aspirin</th><th>Temporal Artery Biopsy</th></tr></thead><tbody><tr><td>Route & Dose</td><td>IV 500&ndash;1000 mg/day \u00d73 days</td><td>PO 40&ndash;60 mg/day</td><td>PO 75&ndash;100 mg/day</td><td>N/A</td></tr><tr><td>Onset of Action</td><td>1&ndash;2 hours</td><td>4&ndash;6 hours</td><td>Days (platelet inhibition)</td><td>N/A</td></tr><tr><td>Indication in GCA</td><td>Visual symptoms or threatened vision</td><td>No ocular involvement</td><td>Adjunctive to reduce ischemic risk</td><td>Diagnostic confirmation</td></tr><tr><td>Guideline Recommendation (LoE)</td><td>EULAR 2018, LoE C</td><td>EULAR 2018, LoE C</td><td>EULAR 2018, LoE B</td><td>Should not delay steroids</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Jaw claudication has ~90% specificity for GCA.  <br>&bull; Always initiate high-dose steroids before temporal artery biopsy to prevent vision loss.  <br>&bull; Consider low-dose aspirin as an adjunct to reduce stroke risk in GCA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Waiting for biopsy results before starting steroids, risking irreversible blindness.  <br>2. Using only oral prednisone in acute visual symptoms, leading to delayed therapeutic levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR <span class=\"evidence\">Recommendations 2018</span> (Hellmich et al.): For GCA with ocular involvement, start IV glucocorticoids <span class=\"citation\">(500&ndash;1000 mg/day for 3 days)</span>; then switch to oral prednisolone (LoE C).  <br>&bull; ACR/Vasculitis <span class=\"evidence\">Foundation 2021</span>: Endorses prompt high-dose steroids; tocilizumab added for steroid sparing <span class=\"citation\">(Level II evidence from Stone et al., NEJM 2017)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Inflammation of the superficial temporal artery (branch of external carotid) and its ophthalmic branch compromises blood flow to the optic nerve head, leading to anterior ischemic optic neuropathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Granulomatous infiltration of the arterial media and adventitia by multinucleated giant cells and lymphocytes leads to intimal hyperplasia, luminal occlusion, and downstream ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion with headache, jaw claudication, visual changes, high ESR/CRP  <br>2. Start high-dose corticosteroids immediately  <br>3. Ultrasound &ldquo;halo sign&rdquo; or MRI angiography if available  <br>4. Temporal artery biopsy within 2 weeks of steroid initiation for confirmation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Ultrasound of temporal arteries may show a hypoechoic &ldquo;halo sign&rdquo; reflecting vessel wall edema; FDG-PET can detect large-vessel involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>IV methylprednisolone: 500&ndash;1000 mg/day for 3 days, then switch to oral prednisolone 1 mg/kg/day. Monitor for steroid side effects; initiate bone protection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Giant Cell Arteritis is frequently tested in rapid-recognition vignettes; questions often focus on immediate management to prevent vision loss and the role of temporal artery biopsy.</div></div></div></div></div>"
  },
  {
    "id": 100022993,
    "question_number": "234",
    "question_text": "A young lady with two miscarriages and livedo reticularis is being evaluated. What laboratory test should be ordered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] - Autoimmune hypercoagulability: Anti-phospholipid syndrome (APS) features autoantibodies (lupus anticoagulant, anti-cardiolipin, anti-&beta;2-glycoprotein I) that activate endothelial cells and platelets, promoting thrombosis.  <br><span class=\"list-item\">\u2022</span> Obstetric manifestations: Recurrent early pregnancy loss results from placental thrombosis and infarction.  <br><span class=\"list-item\">\u2022</span> Dermatologic sign: Livedo reticularis arises from segmental cutaneous vascular occlusion.  <br><span class=\"list-item\">\u2022</span> Diagnostic criteria: Sydney criteria require at least one clinical event (thrombosis or pregnancy morbidity) plus persistent antibody positivity &ge;12 weeks apart.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anti-phospholipid antibody testing is the definitive laboratory evaluation for suspected APS in patients with thrombotic events or recurrent pregnancy loss. <span class=\"evidence\">The 2006</span> Sydney update <span class=\"citation\">(Miyakis et al., J Thromb <span class=\"evidence\">Haemost 2006</span>)</span> mandates testing for lupus anticoagulant, anticardiolipin IgG/IgM, and anti-&beta;2-glycoprotein I. APS is identified in up to 15% of women with recurrent miscarriages <span class=\"citation\">(Branch et al., <span class=\"evidence\">Blood 1998</span>)</span>. Although lupus anticoagulant prolongs aPTT in vitro, routine coagulation profiles lack specificity and sensitivity for APS. Early diagnosis allows initiation of low-dose aspirin plus heparin, reducing miscarriage recurrence by 70&ndash;80% <span class=\"citation\">(Empson et al., <span class=\"evidence\">Lancet 2005</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Complete blood count  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates anemia or thrombocytopenia but does not detect antiphospholipid antibodies or hypercoagulability.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that a normal platelet count excludes clotting disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS diagnosis relies on serologic antibody panels, not cell counts.<br><br>C. Thyroid function tests  <br><span class=\"list-item\">\u2022</span> Incorrect: Hypothyroidism can cause miscarriage but does not explain livedo reticularis or thrombotic risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all recurrent pregnancy losses are endocrine in origin.  <br><span class=\"list-item\">\u2022</span> Differentiator: APS presents with cutaneous vasculopathy and requires antibody detection.<br><br>D. Coagulation profile  <br><span class=\"list-item\">\u2022</span> Incorrect: PT/aPTT may be paradoxically prolonged by lupus anticoagulant yet does not confirm APS.  <br><span class=\"list-item\">\u2022</span> Misconception: Interpreting prolonged aPTT as bleeding tendency rather than thrombosis risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Specific antiphospholipid antibody assays are necessary for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anti-phospholipid Ab Testing</th><th>Complete Blood Count</th><th>Thyroid Function Tests</th><th>Coagulation Profile</th></tr></thead><tbody><tr><td>Clinical purpose</td><td>Confirm APS in thrombosis/pregnancy</td><td>Assess blood cell lines</td><td>Screen thyroid disorders</td><td>Measure PT/aPTT</td></tr><tr><td>Specificity for APS</td><td>High (&ge;99% with combined assays)</td><td>None</td><td>None</td><td>Low</td></tr><tr><td>Sensitivity for pregnancy loss</td><td>85&ndash;90% for APS-related cases</td><td>N/A</td><td>20&ndash;30% for endocrine causes</td><td>N/A</td></tr><tr><td>Diagnostic requirement</td><td>Positive on &ge;2 occasions &ge;12 weeks</td><td>Single sample</td><td>Single sample</td><td>Single sample</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lupus anticoagulant often prolongs aPTT in vitro but indicates thrombosis risk in vivo.  <br><span class=\"list-item\">\u2022</span> Confirm persistent antibody positivity &ge;12 weeks apart to avoid false positives from transient infections.  <br><span class=\"list-item\">\u2022</span> Combined low-dose aspirin and heparin therapy in pregnant APS patients reduces miscarriage rates by up to 80%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on PT/aPTT: Not pursuing specific antiphospholipid antibody testing when aPTT is normal or paradoxically prolonged.  <br>2. Attributing all recurrent miscarriages to endocrine causes: Overlooking hypercoagulable evaluations in patients with livedo reticularis or thrombotic history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR 2019 Recommendations for managing APS: Advocate testing for lupus anticoagulant, anticardiolipin, and anti-&beta;2-glycoprotein I in women with &ge;2 unexplained pregnancy losses (Level 1B evidence).  <br><span class=\"list-item\">\u2022</span> ISTH SSC 2013 Guidelines: Recommend using a combination of lupus anticoagulant, anticardiolipin, and anti-&beta;2-glycoprotein I assays to improve diagnostic accuracy (Grade A recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. APS evaluation commonly appears in board-style questions linking obstetric morbidity, livedo reticularis, and serologic confirmation with antiphospholipid antibody panels.</div></div></div></div></div>"
  },
  {
    "id": 100022995,
    "question_number": "226",
    "question_text": "What is the first-line treatment for warfarin-related intracerebral hemorrhage (ICH) to achieve rapid reversal of coagulopathy?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Warfarin inhibits vitamin K&ndash;dependent clotting factors II, VII, IX and X, prolonging INR. In ICH, rapid correction is critical to limit hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated factors II, VII, IX and X for speedy normalization of INR, whereas fresh frozen plasma (FFP) and vitamin K alone act more slowly. Key concepts:  <br><span class=\"list-item\">\u2022</span> Vitamin K antagonist mechanism (warfarin)  <br><span class=\"list-item\">\u2022</span> Hematoma expansion risk correlates with elevated INR  <br><span class=\"list-item\">\u2022</span> Speed of reversal directly impacts clinical outcomes</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PCC is superior to FFP for warfarin reversal in ICH due to:  <br>1. Faster INR correction: Four-factor PCC normalizes INR within 30&ndash;60\u2009minutes versus 4&ndash;6\u2009hours for FFP.  <br>2. Lower volume: PCC requires <200 mL infusion (vs >1 L for FFP), reducing risk of volume overload and transfusion\u2010related acute lung injury.  <br>3. Guideline support: <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines <span class=\"citation\">(Hemphill JC et al., <span class=\"evidence\">Stroke 2015</span>)</span> give Class I, Level A recommendation for four-factor PCC plus IV vitamin K for warfarin\u2010associated ICH.  <br>4. Mortality benefit: Observational studies associate PCC use with reduced hematoma growth and lower 30-day mortality compared with FFP <span class=\"citation\">(Steiner T et al., <span class=\"evidence\">Haematologica 2016</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fresh frozen plasma (FFP)  <br><span class=\"list-item\">\u2022</span> Incorrect: Slower INR normalization (requires blood typing, thawing, large volumes).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that broader factor replacement (including fibrinogen) is superior.  <br><span class=\"list-item\">\u2022</span> Differentiator: Volume and time delay vs PCC&rsquo;s rapid, low-volume correction.  <br><br>C. Recombinant activated factor VII (rFVIIa)  <br><span class=\"list-item\">\u2022</span> Incorrect: Off-label for warfarin reversal; limited to hemophilia A with inhibitors.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimation of clotting boost from single factor.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not replace factors II, IX, X and carries higher thrombosis risk.  <br><br>D. Vitamin K alone  <br><span class=\"list-item\">\u2022</span> Incorrect: Necessary adjunct but too slow (6&ndash;24\u2009hours) to correct INR acutely.  <br><span class=\"list-item\">\u2022</span> Misconception: Vitamin K monotherapy suffices in emergencies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Enhances endogenous factor synthesis only; no immediate reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCC (Correct)</th><th>FFP</th><th>rFVIIa</th><th>Vitamin K Alone</th></tr></thead><tbody><tr><td>Time to INR normalization</td><td>30&ndash;60 minutes</td><td>4&ndash;6 hours</td><td>1&ndash;2 hours (factor VII only)</td><td>6&ndash;24 hours</td></tr><tr><td>Volume required</td><td><200 mL</td><td>&ge;1 L</td><td>~50&ndash;100 mL</td><td>Negligible</td></tr><tr><td>Factor replacement</td><td>II, VII, IX, X</td><td>All plasma proteins</td><td>Activated factor VII only</td><td>Promotes synthesis of II, VII, IX, X</td></tr><tr><td>Thrombosis risk</td><td>Low&ndash;moderate</td><td>Low</td><td>High</td><td>None</td></tr><tr><td>Guideline strength (ICH)</td><td>Class I, Level A (AHA)</td><td>Class IIa, Level C (AHA)</td><td>Not recommended</td><td>Adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Administer IV vitamin K (5&ndash;10 mg) concurrently with PCC to sustain reversal.  <br><span class=\"list-item\">\u2022</span> Use four-factor PCC rather than three-factor PCC for comprehensive factor replacement.  <br><span class=\"list-item\">\u2022</span> Monitor INR at 30\u2009minutes post\u2010PCC infusion to confirm target <1.4 and repeat as needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on FFP delays reversal and increases volume overload risk.  <br>2. Assuming vitamin K alone is sufficient in acute ICH leads to preventable hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 ICH Guidelines <span class=\"citation\">(Hemphill JC et al., <span class=\"evidence\">Stroke 2015</span>)</span>: Class I, Level A for four-factor PCC + IV vitamin K in warfarin\u2010related ICH.  <br><span class=\"list-item\">\u2022</span> ASH 2016 Guidelines on Reversal of Antithrombotics: Recommends four-factor PCC over FFP for vitamin K antagonist reversal (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin inhibits vitamin K epoxide reductase, depleting reduced vitamin K needed to &gamma;-carboxylate clotting factors. In ICH, continued anticoagulation leads to hematoma growth and raised intracranial pressure. Rapid factor repletion with PCC halts hemorrhage extension by restoring thrombin generation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- PCC dosing: 25&ndash;50 IU/kg based on baseline INR and product specifications.  <br><span class=\"list-item\">\u2022</span> Concurrent vitamin K: 5&ndash;10 mg IV over 30\u2009minutes to support endogenous synthesis.  <br><span class=\"list-item\">\u2022</span> Monitor for thrombosis; consider patient comorbidities (e.g., DVT history).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Warfarin\u2010associated ICH reversal is frequently tested as a single best\u2010answer format, emphasizing PCC&rsquo;s advantage over FFP and the necessity of adjunctive vitamin K.</div></div></div></div></div>"
  },
  {
    "id": 100022996,
    "question_number": "222",
    "question_text": "A 70-year-old male patient with a patent foramen ovale (PFO), diabetes mellitus (DM), hypertension (HTN), and a history of lacunar stroke in the posterior limb of the internal capsule, with CTA showing extracranial atherosclerosis, what is the treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Ischemic strokes are classified by mechanism:  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts result from small vessel disease (lipohyalinosis) often due to HTN/DM and local occlusion of penetrating arterioles.  <br><span class=\"list-item\">\u2022</span> Large\u2010artery atherosclerosis (e.g., carotid stenosis) causes cortical or territorial infarcts when high\u2010grade stenosis leads to embolism or hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Cardioembolic strokes (e.g., from PFO or atrial fibrillation) often cause cortical infarcts and may warrant anticoagulation or closure.  <br>Secondary prevention tailors therapy to the dominant mechanism: antiplatelet (small\u2010vessel), endarterectomy (high\u2010grade carotid), or anticoagulation/closure (cardioembolic).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s prior infarct was lacunar in the posterior limb of the internal capsule&mdash;classic for small\u2010vessel lipohyalinosis driven by HTN/DM. CTA showed extracranial atherosclerosis but without mention of &ge;70% stenosis required for endarterectomy (ACAS/ACST trials). PFO closure trials (RESPECT, CLOSE) included cryptogenic cortical strokes in younger patients, not lacunar strokes in older hypertensive diabetics. NAVIGATE ESUS (2018) and RE-SPECT ESUS (2018) trials demonstrated no benefit of anticoagulation over aspirin in embolic\u2010stroke\u2010of\u2010undetermined\u2010source populations. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level of Evidence A) recommend antiplatelet monotherapy (aspirin 81&ndash;325 mg daily) for non\u2010cardioembolic ischemic stroke, particularly lacunar subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Closure of PFO  <br><span class=\"list-item\">\u2022</span> Incorrect because PFO closure is indicated in cryptogenic stroke with high\u2010risk PFO anatomy in patients <60 years without alternative mechanisms; lacunar infarct here points to small\u2010vessel disease, not paradoxical embolism.  <br><br>B. Carotid endarterectomy  <br><span class=\"list-item\">\u2022</span> Only indicated for symptomatic carotid stenosis &ge;70% (NASCET criteria) or select 50&ndash;69% cases; &ldquo;extracranial atherosclerosis&rdquo; alone without degree of stenosis &ge;70% does not meet surgical criteria.  <br><br>D. Anticoagulation with warfarin  <br><span class=\"list-item\">\u2022</span> Reserved for cardioembolic sources (e.g., atrial fibrillation, mechanical valves); small\u2010vessel lacunar strokes do not benefit and carry increased hemorrhagic risk (SPA therapy trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin (Correct)</th><th>PFO Closure</th><th>Carotid Endarterectomy</th><th>Warfarin</th></tr></thead><tbody><tr><td>Indication</td><td>Non\u2010cardioembolic ischemic stroke</td><td>Cryptogenic stroke w/ high\u2010risk PFO</td><td>Symptomatic carotid &ge;70% stenosis</td><td>Cardioembolic stroke (AF, valves)</td></tr><tr><td>Key Trial/Evidence</td><td>AHA/ASA 2019 Guidelines (Class I)</td><td>RESPECT, CLOSE</td><td>NASCET, ACAS</td><td>WARSS (no benefit in non\u2010cardioembolic)</td></tr><tr><td>Mechanism</td><td>Inhibits platelet aggregation</td><td>Prevents paradoxical emboli</td><td>Removes atherosclerotic plaque</td><td>Inhibits vitamin K\u2010dependent clotting</td></tr><tr><td>Major Contraindication in This Patient</td><td>None (small\u2010vessel stroke)</td><td>Stroke subtype not cryptogenic</td><td>Stenosis <70%</td><td>No cardioembolic source</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunar infarcts (<15 mm) on MRI DWI in the internal capsule strongly suggest lipohyalinosis from HTN/DM, guiding antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Always quantify carotid stenosis by NASCET criteria; incidental &ldquo;atherosclerosis&rdquo; without high\u2010grade narrowing does not warrant surgery.  <br><span class=\"list-item\">\u2022</span> ESUS trials (NAVIGATE, RE-SPECT) reaffirm aspirin as first\u2010line in non\u2010cardioembolic strokes when source remains uncertain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any PFO with indication for closure&mdash;only in young cryptogenic cortical strokes after exhaustive workup.  <br>2. Assuming anticoagulation is superior to antiplatelets for all secondary stroke prevention&mdash;true only in atrial fibrillation or prosthetic valves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Secondary Stroke Prevention Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Aspirin monotherapy (81&ndash;325 mg) for non\u2010cardioembolic ischemic stroke (Class I, LOE A).  <br>2. NAVIGATE ESUS Trial <span class=\"citation\">(<span class=\"evidence\">Hart et al., 2018</span>, NEJM)</span>  <br><span class=\"list-item\">\u2022</span> Rivaroxaban vs aspirin in ESUS: no reduction in recurrent stroke; increased bleeding (Class III recommendation against routine anticoagulation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior limb of the internal capsule contains corticospinal fibers; lacunar infarcts here produce pure motor hemiparesis without cortical signs, characteristic of small\u2010vessel disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and diabetes cause lipohyalinosis and fibrinoid necrosis of penetrating arterioles, leading to small (<15 mm) &ldquo;lacunar&rdquo; infarcts. These do not involve large carotid or cardiac embolic sources.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Brain MRI with DWI to confirm lacunar infarct.  <br>2. Vascular imaging (CTA/MRA) to assess extracranial/intracranial stenosis.  <br>3. Cardiac workup (echo, ECG) to rule out embolic sources.  <br>4. Laboratory risk factor optimization (BP, glucose, lipids).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lacunes appear as small (<15 mm) cavitary lesions on T1 hypointense/T2 hyperintense sequences.  <br><span class=\"list-item\">\u2022</span> CTA noninvasively evaluates carotid/vertebral stenosis; avoid overcalling mild atherosclerotic plaques as surgical lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin irreversibly inhibits cyclooxygenase\u20101 (COX\u20101), reducing thromboxane A2&ndash;mediated platelet aggregation. Standard dosing: 81&ndash;325 mg once daily; monitor for gastrointestinal side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Secondary stroke prevention questions frequently test matching stroke mechanism to targeted therapy, emphasizing the importance of lacunar vs large\u2010artery vs cardioembolic etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100023000,
    "question_number": "244",
    "question_text": "Q244. An elderly patient presented to the ER with a history of visual disturbances. On examination, she has right homonymous hemianopia. She can write but is unable to read. A CT brain was performed. What is the location of the infarction?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Visual pathways: Lesion posterior to the optic chiasm produces homonymous hemianopia; involvement of left occipital cortex causes right hemifield loss.  <br><span class=\"list-item\">\u2022</span> Disconnection syndromes: The splenium of the corpus callosum transmits visual information from the non-dominant (right) occipital lobe to the dominant (left) language cortex; its infarction yields alexia without agraphia.  <br><span class=\"list-item\">\u2022</span> Alexia without agraphia: Characterized by preserved writing (intact language output) but inability to read due to disrupted interhemispheric transfer of visual word forms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic &ldquo;pure alexia&rdquo; or alexia without agraphia arises from a posterior cerebral artery (PCA) infarct that damages both the left occipital cortex (causing right homonymous hemianopia) and the splenium of the corpus callosum (disrupting transfer of visual information from the right occipital lobe to the left angular gyrus/language areas). De Renzi et al. (1985) first delineated this syndrome, and subsequent imaging studies confirm that isolated splenial lesions in the dominant hemisphere reliably produce alexia without affecting writing. The splenium&mdash;rich in commissural fibers&mdash;when infarcted, prevents visual input from reaching Wernicke&rsquo;s and angular gyri, thus abolishing reading despite intact language production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right occipital lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: A right occipital lesion causes left homonymous hemianopia, opposite to the patient&rsquo;s right field defect.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any occipital lesion yields alexia; does not explain right-sided visual loss or disconnect reading.  <br><span class=\"list-item\">\u2022</span> Differentiator: Cannot produce right homonymous hemianopia nor selective reading deficit.  <br><br>C. Left occipital lobe  <br><span class=\"list-item\">\u2022</span> Why incorrect: Pure left occipital infarct gives right hemianopia but spares interhemispheric transfer via intact splenium; patients can still read left visual field stimuli.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing that occipital cortex damage alone causes alexia without agraphia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Requires additional splenial damage to block contralateral visual input for full alexia.  <br><br>D. Left angular gyrus  <br><span class=\"list-item\">\u2022</span> Why incorrect: Angular gyrus lesions produce alexia with agraphia (both reading and writing impaired) and Gerstmann&rsquo;s constellation, not pure alexia.  <br><span class=\"list-item\">\u2022</span> Misconception: Conflating language area damage with disconnection syndromes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Angular damage disrupts language output (writing) as well as comprehension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Splenium of Corpus Callosum (A)</th><th>Right Occipital Lobe (B)</th><th>Left Occipital Lobe (C)</th><th>Left Angular Gyrus (D)</th></tr></thead><tbody><tr><td>Visual field defect</td><td>Right homonymous hemianopia</td><td>Left homonymous hemianopia</td><td>Right homonymous hemianopia</td><td>None (or minimal visual loss)</td></tr><tr><td>Reading ability</td><td>Severely impaired</td><td>Preserved (right \u2192 left transfer intact)</td><td>Partially preserved (left field)</td><td>Impaired</td></tr><tr><td>Writing ability</td><td>Preserved</td><td>Preserved</td><td>Preserved</td><td>Impaired</td></tr><tr><td>Disconnection of visual pathway</td><td>Yes (interhemispheric block)</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Alexia without agraphia signifies a PCA infarct that hits both left visual cortex and splenium&mdash;always inspect callosal splenium on MRI when reading loss is isolated.  <br>2. In pure alexia, patients trace letters with a finger to read, demonstrating reliance on intact ipsilateral visual cortex.  <br>3. Preservation of writing rules out angular gyrus lesions and points to a disconnection syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking pure alexia (alexia without agraphia) for global alexia; neglecting to assess writing.  <br><span class=\"list-item\">\u2022</span> Confusing angular gyrus lesions (alexia with agraphia) with splenial disconnection syndromes.  <br><span class=\"list-item\">\u2022</span> Overlooking homonymous hemianopia lateralization, leading to mislocalization of occipital lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2023 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation 1.1: Perform urgent neuroimaging (CT/MRI) to identify vascular territory and assess corpus callosum integrity (Class I, Level B-R).  <br>2. ESO 2021 Guidelines on Diagnosis and Management of Acute Stroke  <br><span class=\"list-item\">\u2022</span> Recommend systematic evaluation of visual and language deficits in posterior circulation strokes to refine localization and guide secondary prevention (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The splenium is the posterior thickened segment of the corpus callosum, containing fibres that interconnect occipital and posterior temporal lobes. Damage interrupts transfer of visual word-form information from the right hemisphere to the dominant left hemisphere language areas (angular gyrus, Wernicke&rsquo;s area).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A left PCA infarct involving the calcarine branch causes right homonymous hemianopia; extension into the callosal fibers of the splenium severs interhemispheric visual transfer, producing selective inability to read despite intact writing and oral language pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT may show subtle hypodensity in the posterior corpus callosum; MRI DWI is more sensitive for early splenial infarcts.  <br><span class=\"list-item\">\u2022</span> In pure alexia, concurrent lesions in left occipital cortex and splenium produce characteristic imaging findings&mdash;look for hyperintense signals on DWI in these regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Pure alexia (alexia without agraphia) and its localization to the splenium plus left occipital cortex are frequently tested on neurology and neuroanatomy sections, often as classic clinical vignettes requiring lesion mapping.</div></div></div></div></div>"
  },
  {
    "id": 100023006,
    "question_number": "225",
    "question_text": "What is the mechanism of the following antiplatelet agent: Ticagrelor?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Platelet activation is central to arterial thrombosis. Three key pathways drive aggregation:  <br>&bull; ADP-mediated activation via P2Y12 receptors on platelet surfaces  <br>&bull; Thromboxane A\u2082 generation through cyclooxygenase-1 (COX-1)  <br>&bull; Final common pathway of fibrinogen binding to glycoprotein (GPIIb/IIIa) receptors  <br><br>Antiplatelet agents target these steps to reduce ischemic stroke and acute coronary syndrome (ACS) risk. Ticagrelor directly and reversibly inhibits the P2Y12 receptor, blocking ADP-driven platelet aggregation. Understanding distinctions among COX inhibitors (aspirin), P2Y12 antagonists (ticagrelor, clopidogrel), GPIIb/IIIa blockers (abciximab), and phosphodiesterase inhibitors (dipyridamole) is critical for choosing therapy in secondary stroke prevention and ACS management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor binds non-competitively to P2Y12 on the platelet surface without requiring metabolic activation <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>. The PLATO trial demonstrated a 16% relative risk reduction in major adverse cardiovascular events versus clopidogrel (HR 0.84; 95% CI 0.77&ndash;0.92; p<0.001). Its reversible kinetics allow more rapid offset (half-life ~7 hours) and easier perioperative management. <span class=\"evidence\">The 2019</span> AHA/ASA Secondary Stroke Prevention Guidelines recognize ticagrelor as an alternative for patients intolerant to clopidogrel (Class IIb, Level C-LD). In ACS, 2020 ESC Guidelines recommend ticagrelor over clopidogrel for non&ndash;ST-elevation myocardial infarction (Class IB). By blocking ADP signaling at P2Y12, ticagrelor impedes downstream GPIIb/IIIa activation and platelet aggregation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cyclooxygenase-1 inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly inhibits COX-1, preventing thromboxane A\u2082 formation.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all oral antiplatelets with aspirin.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor targets ADP receptor, not thromboxane pathway.  <br><br>C. Glycoprotein IIb/IIIa receptor blocker  <br><span class=\"list-item\">\u2022</span> Incorrect: Agents like abciximab bind GPIIb/IIIa to block fibrinogen cross-linking.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing terminal platelet aggregation inhibitors with upstream agents.  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor acts upstream at ADP receptor.  <br><br>D. Phosphodiesterase inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Dipyridamole inhibits PDE-5, increasing cAMP to reduce aggregation.  <br><span class=\"list-item\">\u2022</span> Misconception: Grouping all non-aspirin oral agents under &ldquo;PDE inhibitors.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Ticagrelor has no effect on cyclic nucleotide metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Mechanism</th><th>Reversibility</th><th>Onset of Action</th><th>Clinical Use</th></tr></thead><tbody><tr><td>Ticagrelor</td><td>P2Y12 ADP receptor antagonist</td><td>Reversible</td><td>~30 minutes</td><td>ACS, secondary stroke prevention (alt.)</td></tr><tr><td>Aspirin</td><td>COX-1 inhibitor</td><td>Irreversible</td><td>60&ndash;90 minutes</td><td>First-line stroke prophylaxis</td></tr><tr><td>Abciximab</td><td>GPIIb/IIIa receptor blocker</td><td>Reversible</td><td>Immediate (IV)</td><td>PCI adjunct, high-risk ACS</td></tr><tr><td>Dipyridamole</td><td>Phosphodiesterase inhibitor</td><td>Reversible</td><td>Variable</td><td>Stroke prevention (with aspirin)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ticagrelor does not require hepatic bioactivation, yielding faster and more consistent platelet inhibition than thienopyridines.  <br><span class=\"list-item\">\u2022</span> Common adverse effect: dyspnea in ~10&ndash;14% due to adenosine reuptake inhibition.  <br><span class=\"list-item\">\u2022</span> Avoid with strong CYP3A4 inhibitors (e.g., ketoconazole) or in severe hepatic impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing ticagrelor is a prodrug like clopidogrel; in fact, it is active on ingestion.  <br>2. Confusing COX inhibition (aspirin) with P2Y12 blockade; mechanism dictates bleeding risk and drug interactions.  <br>3. Assuming oral GPIIb/IIIa inhibitors exist&mdash;only parenteral agents are available.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2019 AHA/ASA Secondary Stroke Prevention Guidelines: Ticagrelor as alternative for clopidogrel-intolerant patients (Class IIb, LOE C-LD).  <br>&bull; 2020 ESC Guidelines for NSTE-ACS: Prefer ticagrelor over clopidogrel in ACS (Class IB).  <br>&bull; PLATO Trial <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>: Demonstrated superior reduction in cardiovascular death with ticagrelor versus clopidogrel.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Loading dose: 180 mg orally; maintenance: 90 mg twice daily.  <br><span class=\"list-item\">\u2022</span> Peak platelet inhibition within 1&ndash;3 hours; half-life ~7 hours.  <br><span class=\"list-item\">\u2022</span> Metabolized via CYP3A4 to inactive metabolite; dose adjustment not required in mild&ndash;moderate renal impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>P2Y12 antagonists are frequently tested on neurology and internal medicine boards, often contrasted with COX inhibitors and GPIIb/IIIa blockers in secondary stroke prevention scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023008,
    "question_number": "230",
    "question_text": "A 64-year-old diabetic patient presents with unilateral weakness that lasted 25 minutes and then fully resolved. What medication regimen should be started?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Transient ischemic attack (TIA) is defined by focal neurological symptoms that resolve within 24 hours; high-risk features include age > 60, diabetes, and symptom duration > 10 minutes. Early recurrent stroke risk is greatest in the first days after a TIA. Platelet activation at an atherosclerotic plaque rupture site drives thrombus formation, so antiplatelet therapy is the cornerstone of secondary prevention in non-cardioembolic TIA. Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y\u2081\u2082 inhibitor reduces early recurrence risk more than monotherapy, but bleeding risk rises with prolonged use. Hence, short-term DAPT is preferred in high-risk patients before transitioning to single-agent therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because randomized trials and guidelines endorse a 21-day course of DAPT initiated immediately after a high-risk TIA. The CHANCE trial (2013) demonstrated that 300 mg clopidogrel load followed by 75 mg daily plus 75 mg aspirin for 21 days reduced stroke recurrence by 32% versus aspirin alone <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>;369:11&ndash;19)</span>. The POINT trial (2018) confirmed similar benefit with a 600 mg clopidogrel load then 75 mg daily plus aspirin for 90 days, with the greatest efficacy in the first 21 days <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>;379:215&ndash;225)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2019</span>;50:e344&ndash;e418)</span> give a Class I recommendation for DAPT (aspirin + clopidogrel) for 21 days in minor stroke (NIHSS &le; 3) or high-risk TIA (ABCD2 &ge; 4) to prevent early recurrence. Pathophysiologically, early DAPT interrupts platelet aggregation cascade at both cyclooxygenase (ASA) and P2Y\u2081\u2082 receptor (clopidogrel) levels, limiting microthrombus propagation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. ASA only  <br><span class=\"list-item\">\u2022</span> Incorrect: Monotherapy reduces long-term stroke risk but is inferior for early recurrence prevention.  <br><span class=\"list-item\">\u2022</span> Misconception: Single-agent antiplatelet is adequate in high-risk TIA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks the synergistic P2Y\u2081\u2082 blockade that short-term DAPT provides.<br><br>C. Dual antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Incorrect: Too vague&mdash;does not specify loading dose, agents, or optimal duration.  <br><span class=\"list-item\">\u2022</span> Misconception: Any DAPT regimen suffices; duration and timing matter.  <br><span class=\"list-item\">\u2022</span> Differentiator: Evidence supports exactly 21 days of aspirin + clopidogrel after a high-risk TIA.<br><br>D. Anticoagulation  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for atrial fibrillation or cardioembolic stroke, not for non-cardioembolic TIA.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Clot prevention&rdquo; always requires anticoagulants.  <br><span class=\"list-item\">\u2022</span> Differentiator: Mechanism targets thrombin (warfarin/DOAC) rather than platelet aggregation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A. ASA + Clopidogrel (21 d)</th><th>B. ASA Only</th><th>C. DAPT (unspecified)</th><th>D. Anticoagulation</th></tr></thead><tbody><tr><td>Loading dose</td><td>Yes (clopidogrel 300&ndash;600 mg)</td><td>N/A</td><td>Not defined</td><td>N/A</td></tr><tr><td>Duration</td><td>21 days</td><td>Indefinite</td><td>Indeterminate</td><td>Indefinite</td></tr><tr><td>Early stroke recurrence reduction</td><td>32&ndash;40% (CHANCE, POINT)</td><td>~15%</td><td>Unknown</td><td>Not established for non-cardio</td></tr><tr><td>Bleeding risk</td><td>Mild increase (short-term)</td><td>Low</td><td>Variable/high</td><td>Higher (major bleed risk)</td></tr><tr><td>Guideline recommendation</td><td>Class I AHA/ASA 2019</td><td>Class IIa</td><td>Not specified</td><td>Class III (harm)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours of a high-risk TIA to maximize benefit.  <br><span class=\"list-item\">\u2022</span> Limit aspirin + clopidogrel to 21 days; thereafter continue single-agent therapy to minimize hemorrhage.  <br><span class=\"list-item\">\u2022</span> Calculate an ABCD2 score: age, blood pressure, clinical features, duration, diabetes to stratify TIA risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extending DAPT beyond 21 days believing &ldquo;more is better&rdquo;&mdash;bleeding risk outweighs benefit after the acute period.  <br>2. Starting anticoagulation for non-cardioembolic TIA due to misunderstanding &ldquo;clot&rdquo; mechanism&mdash;platelet inhibitors are preferred.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke <span class=\"evidence\">Guidelines 2019</span>: Recommend aspirin + clopidogrel for 21 days in high-risk TIA or minor stroke (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial Steering <span class=\"evidence\">Committee 2018</span>: Demonstrated that early DAPT reduces recurrent ischemia by 28% in the first 90 days, with the greatest effect in the first 21 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clopidogrel is a prodrug converted by CYP2C19 to an active metabolite that irreversibly blocks the P2Y\u2081\u2082 ADP receptor on platelets, preventing aggregation. Aspirin irreversibly inhibits cyclooxygenase-1, reducing thromboxane A\u2082 synthesis. The loading dose of clopidogrel (300&ndash;600 mg) achieves platelet inhibition within 2 hours; maintenance dosing (75 mg daily) sustains effect. Combined therapy targets two pathways of platelet activation, offering additive protection during the vulnerable post-TIA period.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>High-risk TIA management is frequently tested as a vignette requiring selection of the proper timing, agents, and duration of antiplatelet therapy. The exam often stresses trial data (CHANCE, POINT) and AHA/ASA guideline recommendations.</div></div></div></div></div>"
  },
  {
    "id": 100023017,
    "question_number": "207",
    "question_text": "A patient was playing tennis and was brought to the emergency room after a car accident. Initially, he was fine and doing well. A CT brain scan and labs came back normal with a blood pressure of 160/95. Two hours later, he developed left homonymous hemianopia. He has a history of migraine since age 15, with recurrent episodes every 6 months. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient, segmental narrowing of cerebral arteries leading to ischemic or hemorrhagic complications.  <br>1. Pathophysiology: Dysregulated cerebrovascular tone&mdash;often endothelial dysfunction&mdash;provokes multifocal arterial constriction.  <br>2. Triggers: Physical exertion, emotional stress, vasoactive substances, or minor trauma can precipitate RCVS, especially in migraineurs.  <br>3. Clinical features: Thunderclap headaches are classic; focal deficits (e.g., visual field cuts) may appear hours to days later due to ischemia in posterior circulation territories (occipital lobes).  <br><br>(Word count: 106)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is confirmed by angiographic &ldquo;string\u2010of\u2010beads&rdquo; appearance and reversibility within 12 weeks <span class=\"citation\">(Calabrese et al., <span class=\"evidence\">Neurology 2007</span>)</span>. In this patient:  <br><span class=\"list-item\">\u2022</span> Trigger: Intense exertion (tennis) and minor trauma with transient hypertension.  <br><span class=\"list-item\">\u2022</span> Delayed deficit: Hemianopia arises 2 hours after normal CT&mdash;typical of ischemic events secondary to vasoconstriction rather than immediate hemorrhage or dissection.  <br><span class=\"list-item\">\u2022</span> Migraine history: Migraineurs have up to a 20% higher risk of RCVS <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2016</span>)</span>.  <br>Current AHA guidelines (2021) recommend noninvasive vascular imaging (MRA) initially, reserving catheter angiography for equivocal cases (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vertebral dissection  <br><span class=\"list-item\">\u2022</span> Incorrect: Dissection often causes neck pain, immediate focal signs (e.g., lateral medullary syndrome), and visible vessel wall defect on CTA.  <br><span class=\"list-item\">\u2022</span> Misconception: All trauma-related strokes stem from dissection.  <br><span class=\"list-item\">\u2022</span> Differentiation: No cervical pain or hyperintense vessel wall on imaging; delayed isolated hemianopia is atypical.  <br><br>C. Posterior reversible encephalopathy syndrome (PRES)  <br><span class=\"list-item\">\u2022</span> Incorrect: PRES presents with headache, seizures, altered mental status, and bilateral parieto-occipital vasogenic edema on MRI/FLAIR.  <br><span class=\"list-item\">\u2022</span> Misconception: Acute hypertension in trauma always equals PRES.  <br><span class=\"list-item\">\u2022</span> Differentiation: CT was normal; PRES shows diffuse edema rather than focal arterial narrowing.  <br><br>D. Internal carotid artery (ICA) stenosis  <br><span class=\"list-item\">\u2022</span> Incorrect: Typically chronic atherosclerosis in older patients causing TIA or watershed infarcts, not acute hemianopia post-trauma.  <br><span class=\"list-item\">\u2022</span> Misconception: Any visual field cut equals carotid pathology.  <br><span class=\"list-item\">\u2022</span> Differentiation: No bruit, no ulcerated plaque on ultrasound; ICA stenosis rarely causes isolated homonymous hemianopia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Vertebral Dissection</th><th>PRES</th><th>ICA Stenosis</th></tr></thead><tbody><tr><td>Onset</td><td>Thunderclap headache; delayed focal deficits</td><td>Immediate post-trauma focal signs</td><td>Acute headache, seizures, encephalopathy</td><td>Insidious TIAs; chronic deficits</td></tr><tr><td>Imaging</td><td>MRA: multifocal vasoconstriction; normal CT early</td><td>CTA/MRA: intimal flap, pseudoaneurysm</td><td>MRI FLAIR: bilateral vasogenic edema</td><td>Duplex US/CTA: plaque, stenosis</td></tr><tr><td>Risk factors</td><td>Migraine, exertion, vasoactive drugs</td><td>Neck trauma, cervical manipulation</td><td>Hypertensive crisis, immunosuppression</td><td>Atherosclerosis, hyperlipidemia</td></tr><tr><td>Typical deficits</td><td>PCA territory ischemia (hemianopia)</td><td>Posterior fossa signs, lateral medullary syndrome</td><td>Global or bilateral visual disturbance</td><td>MCA/ACA watershed TIA symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- RCVS often presents with recurrent thunderclap headaches over 1&ndash;4 weeks; seek delayed ischemic events on imaging.  <br><span class=\"list-item\">\u2022</span> Migraine history is a strong predisposing factor; differentiate from primary migraine aura by the severity and sudden onset.  <br><span class=\"list-item\">\u2022</span> &ldquo;String-of-beads&rdquo; on angiography is pathognomonic; follow-up imaging at 6&ndash;12 weeks should show resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any acute visual field defect post-trauma with carotid or vertebral dissection without angiography.  <br>2. Misdiagnosing PRES when only focal deficits occur; PRES is a diffuse vasogenic edema syndrome with seizures or encephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Scientific Statement on RCVS (2021): Recommends early noninvasive vascular imaging (MRA/CTA) for suspected RCVS (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> International Headache Society, ICHD-3 (2018): Classifies RCVS under headache disorders, emphasizing thunderclap onset and reversible angiographic changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left homonymous hemianopia localizes to the right occipital cortex (PCA territory). RCVS\u2010induced vasoconstriction in the distal PCA leads to focal ischemia here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sympathetic overactivity or endothelial dysfunction \u2192 segmental cerebral arterial constriction \u2192 transient ischemia or hemorrhage. Exposure to triggers (e.g., exertion, trauma) precipitates acute vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI brain with DWI/FLAIR to detect early ischemia or edema.  <br>3. MRA/CTA to identify multifocal cerebral vasoconstriction.  <br>4. Consider digital subtraction angiography if noninvasive imaging is inconclusive.  <br>5. Follow-up imaging at 6&ndash;12 weeks to confirm reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early CT is often normal; use MRI/MRA to detect both parenchymal changes and vascular narrowing.  <br><span class=\"list-item\">\u2022</span> DSA remains gold standard for detailing segmental vasoconstriction (&ldquo;string-of-beads&rdquo;).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line: Oral nimodipine or verapamil to alleviate vasospasm (off\u2010label). Avoid sympathomimetics. Supportive blood pressure control without precipitous drops.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. RCVS is frequently tested as a cause of thunderclap headache with delayed ischemia; examine triggers, imaging findings, and timing of focal deficits for differentiation from dissection and PRES.</div></div></div></div></div>"
  },
  {
    "id": 100023018,
    "question_number": "224",
    "question_text": "A patient with acute stroke is on warfarin and has a CT scan showing intracerebral hemorrhage (ICH) with an INR of 5. After receiving prothrombin complex concentrate, what additional treatment should be administered?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Warfarin inhibits vitamin K&ndash;dependent &gamma;-carboxylation of clotting factors II, VII, IX, X, leading to coagulopathy. In ICH, rapid INR normalization is critical to prevent hematoma expansion.  <br>&bull; Prothrombin complex concentrate (PCC) provides immediate factor replacement (II, VII, IX, X).  <br>&bull; Intravenous vitamin K is required to sustain synthesis of functional clotting factors by the liver.  <br>&bull; CT imaging confirms hemorrhage; INR guides reversal strategy.  <br>Understanding these principles underpins safe, effective management of warfarin-associated ICH. (\u2248100 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vitamin K is the only agent that restores endogenous synthesis of clotting factors, ensuring durable INR correction after PCC&rsquo;s transient effect. <span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, LOE B) and 2016 Neurocritical Care Society guidelines (Grade 1B) recommend IV vitamin K (5&ndash;10 mg) concurrently with PCC for warfarin reversal. Sarode et al. <span class=\"citation\">(NEJM 2013)</span> demonstrated faster INR normalization and fewer volume\u2010related complications with 4\u2010factor PCC + vitamin K versus FFP. Without vitamin K, PCC&rsquo;s half\u2010life (8&ndash;24 hours) leads to rebound coagulopathy as factors are consumed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Fresh frozen plasma (FFP)  <br>&ndash; Incorrect because PCC is superior: FFP requires large volumes, slower infusion, and carries risk of transfusion\u2010related acute lung injury.  <br>&ndash; Misconception: FFP alone suffices for emergent reversal; in fact, it&rsquo;s second\u2010line if PCC unavailable.  <br><br>C. Platelet transfusion  <br>&ndash; Incorrect: platelets address thrombocytopenia or antiplatelet therapy; warfarin impairs clotting factors, not platelet function.  <br>&ndash; Misconception: any bleed mandates platelets&mdash;only indicated if platelet count <50\u00d710^9/L or platelet dysfunction.  <br><br>D. Desmopressin  <br>&ndash; Incorrect: desmopressin raises vWF/Factor VIII, useful in von Willebrand disease or platelet dysfunction, not vitamin K antagonist reversal.  <br>&ndash; Misconception: desmopressin reverses all coagulopathies&mdash;its role is limited to specific platelet/vWF defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vitamin K (Correct)</th><th>FFP</th><th>Platelet Transfusion</th><th>Desmopressin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Cofactor for &gamma;-carboxylation of II, VII, IX, X</td><td>Supplies all clotting factors</td><td>Increases platelet count/function</td><td>Releases vWF & factor VIII</td></tr><tr><td>Onset of Action</td><td>6&ndash;12 h (peak 24 h)</td><td>1&ndash;4 h (infusion time)</td><td>Immediately raises platelets</td><td>30&ndash;60 min</td></tr><tr><td>Role in Warfarin ICH</td><td>Sustains INR correction post-PCC</td><td>Emergent but inferior to PCC</td><td>Not indicated if platelets normal</td><td>Not indicated</td></tr><tr><td>Volume/Risk</td><td>Minimal volume; low risk</td><td>High volume; risk of overload</td><td>Transfusion reactions</td><td>Hyponatremia, hypotension risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always administer IV vitamin K alongside PCC to prevent INR rebound after the exogenous factors degrade.  <br>2. Use 4-factor PCC over FFP for faster, lower-volume warfarin reversal in ICH (Class I recommendation).  <br>3. Avoid platelet transfusion or desmopressin in warfarin\u2010only coagulopathy; they address platelet/vWF defects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Forgetting vitamin K after PCC leads to transient correction and risk of delayed hematoma expansion.  <br>2. Choosing FFP over PCC due to hospital tradition delays reversal and increases fluid overload risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 ICH Guidelines (Class I, LOE B): Recommend 4-factor PCC + IV vitamin K for rapid warfarin reversal.  <br>&bull; Neurocritical Care <span class=\"evidence\">Society 2016</span> (Grade 1B): Endorse IV vitamin K (5&ndash;10 mg) with PCC; FFP only if PCC unavailable.  <br>&bull; Sarode et al., NEJM 2013: 4-factor PCC achieved INR <1.4 in 70% within 30 min vs. 9% with FFP (p<0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Warfarin&rsquo;s inhibition of vitamin K epoxide reductase prevents &gamma;-carboxylation of clotting factors, reducing their coagulant function. Elevated INR reflects decreased factor activity. PCC rapidly supplies functional factors, but without vitamin K, endogenous synthesis remains impaired, leading to factor depletion as PCC factors decay.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Vitamin K: 5&ndash;10 mg IV infusion over 30 min to avoid anaphylactoid reactions; recheck INR at 6 h.  <br>&bull; 4-factor PCC dosing based on INR and weight (e.g., 25&ndash;50 IU/kg).  <br>&bull; FFP: 10&ndash;20 mL/kg if PCC unavailable; slow infusion risks volume overload.  <br>&bull; Platelets and desmopressin have no role in isolated warfarin reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of warfarin\u2010related ICH is frequently tested as a rapid\u2010management algorithm question, often requiring knowledge of PCC dosing and the adjunctive role of vitamin K.</div></div></div></div></div>"
  },
  {
    "id": 100023027,
    "question_number": "219",
    "question_text": "In a case about a young patient with malignant middle cerebral artery (MCA) stroke, what is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Malignant MCA infarction occurs when an ischemic stroke involves >50% of the MCA territory, leading to massive cytotoxic and vasogenic edema, increased intracranial pressure (ICP), midline shift and risk of transtentorial herniation. Young patients (&le;60 years) tolerate decompression better, and early intervention (within 48 hours of onset) can dramatically reduce mortality and improve functional outcome. Key terms: cytotoxic edema, malignant MCA syndrome, decompressive hemicraniectomy, midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy directly relieves raised ICP by removing part of the skull, allowing edematous brain to expand outward. Three randomized controlled trials (DECIMAL, HAMLET, DESTINY) and pooled meta-analyses demonstrated that early hemicraniectomy in patients &le;60 years reduces 12-month mortality from ~80% to ~30% and increases rates of functional independence (modified Rankin Scale &le;3). <span class=\"evidence\">The 2018</span> AHA/ASA Stroke Guidelines <span class=\"citation\">(updated 2022)</span> assign a Class IIA, Level of Evidence B recommendation for decompressive hemicraniectomy within 48 hours in malignant MCA infarction for patients &le;60 years. No other intervention has comparable life-saving impact in this context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intravenous thrombolysis  <br>&bull; Ineffective once malignant edema has developed; tPA must be administered &le;4.5 hours after symptom onset and does not reduce cytotoxic/vasogenic swelling.  <br>&bull; Misconception: thrombolysis prevents all complications; in large established infarcts, risk of hemorrhagic transformation may rise.  <br><br>C. Mechanical thrombectomy  <br>&bull; While thrombectomy (up to 6 hours, or selected cases to 24 hours) improves recanalization, it does not address established malignant edema or prevent herniation once infarction is complete.  <br>&bull; Misconception: revascularization obviates need for surgery; in fact, edema evolves despite reperfusion.  <br><br>D. Supportive care with anticoagulation  <br>&bull; Anticoagulation has no role in acute ischemic stroke management except in specific cardioembolic syndromes post-stabilization; it does not mitigate malignant edema and may increase hemorrhage risk.  <br>&bull; Misconception: systemic anticoagulation controls cerebral swelling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Indication</th><th>Time Window</th><th>Impact on Mortality</th><th>Mechanism</th></tr></thead><tbody><tr><td>Hemicraniectomy</td><td>Malignant MCA infarct >50% in &le;60 y</td><td>&le;48 h from onset</td><td>\u2193 mortality from ~80% to ~30%</td><td>Surgical skull removal lowers ICP</td></tr><tr><td>Intravenous thrombolysis</td><td>Acute ischemic stroke without large infarct</td><td>&le;4.5 h from onset</td><td>Modest benefit if no edema risk</td><td>Clot lysis via plasminogen activation</td></tr><tr><td>Mechanical thrombectomy</td><td>Large\u2010vessel occlusion (MCA/ICA)</td><td>&le;6 h (&le;24 h select)</td><td>Improves recanalization rates</td><td>Endovascular clot retrieval</td></tr><tr><td>Supportive care + anticoagulation</td><td>Secondary prevention post-stroke</td><td>N/A</td><td>No effect on edema mortality</td><td>Prevents new thrombi</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In patients &le;60 years with malignant MCA syndrome, early hemicraniectomy (within 48 h) yields the greatest survival benefit.  <br>2. Non-contrast CT showing loss of the insular ribbon and midline shift >5 mm predicts malignant edema&mdash;prompt neurosurgical consult is critical.  <br>3. Mannitol or hypertonic saline are temporizing measures; definitive management is surgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying decompression while awaiting neurological &ldquo;deterioration&rdquo; rather than proceeding prophylactically within 48 hours.  <br><span class=\"list-item\">\u2022</span> Assuming revascularization alone (thrombolysis or thrombectomy) will prevent malignant edema.  <br><span class=\"list-item\">\u2022</span> Overuse of anticoagulation in the acute phase, increasing hemorrhagic risk without reducing ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Stroke <span class=\"evidence\">Guidelines 2018</span> <span class=\"citation\">(updated 2022)</span>: Class IIA recommendation for decompressive hemicraniectomy in patients &le;60 y with malignant MCA infarction within 48 h (Level B).  <br>2. ESO <span class=\"evidence\">Guidelines 2021</span>: Strong recommendation (Level B) for early hemicraniectomy in malignant MCA infarction based on pooled RCT data (DECIMAL, HAMLET, DESTINY-II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies lateral frontal, parietal and temporal lobes and deep perforators to basal ganglia. Infarction here disrupts corticospinal fibers in the internal capsule, leading to dense contralateral hemiparesis, and causes regional edema that compresses ventricles and midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute arterial occlusion triggers ionic pump failure \u2192 cytotoxic edema. BBB breakdown over 24&ndash;72 h leads to vasogenic edema. Without decompression, ICP rises, cerebral perfusion pressure falls, and herniation ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment (NIHSS).  <br>2. Non-contrast CT to rule out hemorrhage, assess infarct size (>50% MCA territory).  <br>3. Serial imaging for evolving edema and midline shift.  <br>4. Multidisciplinary discussion (neurology, neurocritical care, neurosurgery) within 24&ndash;48 h.  <br>5. Proceed with decompressive hemicraniectomy if criteria met.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early CT: insular ribbon sign, obscuration of lentiform nucleus.  <br><span class=\"list-item\">\u2022</span> Malignant features: effacement of sulci, compression of lateral ventricle, midline shift >5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mannitol 0.25&ndash;1 g/kg IV bolus and hypertonic saline 3%&ndash;23.4% to transiently lower ICP.  <br><span class=\"list-item\">\u2022</span> Maintain normovolemia and normoglycemia; avoid hypotonic fluids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Malignant MCA syndrome is frequently tested in scenario-based questions requiring identification of decompressive surgery indications, time windows and age criteria.</div></div></div></div></div>"
  },
  {
    "id": 100023036,
    "question_number": "204",
    "question_text": "A stroke patient presented within the treatment window with a normal brain CT and CTA. The NIHSS score is 16 and blood pressure is 200/140. What is the next step?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Acute ischemic stroke reperfusion with IV alteplase (tPA) must occur within 4.5 hours of symptom onset. Elevated blood pressure (BP) is common post-stroke due to impaired cerebral autoregulation and sympathetic surge. However, BP >185/110 mmHg at the time of tPA infusion increases risk of symptomatic intracerebral hemorrhage. Therefore, rapid but controlled BP reduction to below this threshold is mandatory prior to administration. Key terms: cerebral autoregulation, reperfusion injury, hemorrhagic transformation, door-to-needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because multiple trials and guidelines mandate lowering BP to &le;185/110 mmHg before initiating IV alteplase to minimize hemorrhagic conversion while preserving perfusion. The original NINDS trial protocol stipulated this threshold; subsequent SITS-MOST registry data confirmed increased hemorrhage when baseline BP exceeded these limits. AHA/ASA 2018 and 2021 updates (Class I, Level of Evidence A) reaffirm rapid BP control using agents such as IV labetalol or nicardipine, aiming to achieve the goal within minutes to avoid delaying reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;Start antihypertensive treatment and delay tPA until BP is controlled&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect because it implies an undefined or prolonged delay. Best practice is immediate BP lowering to target with goal-directed therapy and prompt tPA administration once <185/110 mmHg, not indefinite postponement.  <br><span class=\"list-item\">\u2022</span> Misconception: that any delay until &ldquo;full control&rdquo; is acceptable. Differentiator: target threshold and swift reperfusion.  <br><br>C. &ldquo;Administer tPA immediately without blood pressure control&rdquo;  <br><span class=\"list-item\">\u2022</span> Defies guideline safety criteria; exposes patient to up to 10-fold increased risk of intracerebral hemorrhage.  <br><span class=\"list-item\">\u2022</span> Misconception: reperfusion benefit outweighs hemorrhagic risk regardless of BP.  <br><br>D. &ldquo;Monitor blood pressure without intervention and reassess in 1 hour&rdquo;  <br><span class=\"list-item\">\u2022</span> Unacceptable as it forgoes mandated BP lowering, wastes critical time, and risks hemorrhage once tPA is given late or not at all.  <br><span class=\"list-item\">\u2022</span> Misconception: BP will self\u2010normalize or that a 1-hour wait is safe.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>A (Correct)</th><th>B</th><th>C</th><th>D</th></tr></thead><tbody><tr><td>BP management</td><td>Rapid \u2193 to &le;185/110 mmHg</td><td>Antihypertensives, uncontrolled delay</td><td>No BP control</td><td>No intervention</td></tr><tr><td>tPA timing</td><td>Immediate post-target</td><td>Indefinite delay</td><td>Immediate</td><td>Deferred &ge;1 h</td></tr><tr><td>Hemorrhagic risk</td><td>Minimized when &le;185/110</td><td>Variable, delays worsen infarct</td><td>High risk</td><td>High risk if given later or missed</td></tr><tr><td>Impact on door-to-needle time</td><td>Optimized</td><td>Prolonged</td><td>Immediate (unsafe)</td><td>Prolonged or lost window</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use IV labetalol 10&ndash;20 mg bolus or nicardipine infusion (5 mg/hr, titrate by 2.5 mg/hr q5&ndash;15 min) to achieve BP goal rapidly.  <br><span class=\"list-item\">\u2022</span> Monitor BP every 5&ndash;15 minutes before and during tPA infusion.  <br><span class=\"list-item\">\u2022</span> Avoid overcorrection (SBP <140 mmHg) to prevent worsening penumbral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Failing to treat elevated BP promptly, delaying reperfusion (&ldquo;therapeutic inertia&rdquo;).  <br><span class=\"list-item\">\u2022</span> Lowering BP too aggressively below guideline thresholds, reducing collateral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of AIS <span class=\"citation\">(updated 2021)</span>: BP must be &le;185/110 mmHg before tPA (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2021: Recommend IV nicardipine or labetalol for BP control pre-tPA (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Blood pressure criteria for tPA eligibility are a high-yield topic on stroke management questions, often tested as a standalone safety criterion prior to thrombolysis.</div></div></div></div></div>"
  },
  {
    "id": 100023039,
    "question_number": "228",
    "question_text": "A case scenario of a patient who came with a left PICA territory infarction is presented. What is the next step in management?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Posterior inferior cerebellar artery (PICA) supplies the lateral medulla and inferior cerebellum. Occlusion produces lateral medullary (Wallenberg) syndrome or cerebellar hemisphere infarction with risk of fourth\u2010ventricular compression. Acute stroke care prioritizes stabilization (airway, hemodynamics), neuroimaging to exclude hemorrhage, and assessment for reperfusion therapies (tPA &le; 4.5 h). For confirmed non\u2010cardioembolic infarcts outside or beyond the tPA window, antiplatelet therapy is the cornerstone of secondary prevention. In minor strokes (NIHSS &le; 3), short\u2010term dual antiplatelet therapy (aspirin + clopidogrel) for 21 days significantly reduces early recurrence compared to monotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy is the evidence\u2010based next step for a minor non\u2010cardioembolic PICA stroke outside the thrombolysis window. The POINT trial <span class=\"citation\">(NEJM, 2018; HR 0.68; 95% CI 0.52&ndash;0.89; P=0.004)</span> demonstrated that aspirin + clopidogrel started within 12 hours reduced 90\u2010day recurrent stroke by 32%, with only a modest increase in moderate bleeding (0.2%). The CHANCE trial <span class=\"citation\">(Lancet Neurol, 2013)</span> showed similar benefit in reducing 90\u2010day stroke risk (absolute 2% reduction). Both the 2018 AHA/ASA (Class I, LOE A) and 2021 ESO guidelines endorse 21 days of dual therapy for minor non\u2010cardioembolic ischemic stroke. In the absence of acute presentation within 4.5 hours or large cerebellar edema on imaging, neurosurgical decompression and IV thrombolysis are not indicated, and blood pressure management remains supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Neurosurgery consultation  <br>Not indicated in small PICA infarcts without imaging evidence of significant cerebellar swelling or obstructive hydrocephalus. Reflects a misconception that all posterior fossa strokes require decompression; true only when mass effect endangers the brainstem or ventricles.<br><br>C. Intravenous thrombolysis  <br>Only appropriate within a strict &le; 4.5 h window and after hemorrhage exclusion. In most minor PICA strokes presenting later or with mild deficits, bleeding risk outweighs benefit; guidelines contraindicate tPA outside this window or in low\u2010NIHSS presentations without disabling deficits.<br><br>D. Blood pressure control  <br>Essential for preventing hemorrhagic transformation but is supportive and secondary to initiating antiplatelet therapy. Aggressive lowering (< 140/90 mm Hg) acutely may reduce perfusion to the ischemic penumbra; guidelines recommend permissive hypertension (SBP < 220 mm Hg) for the first 24&ndash;48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Timing</th><th>Mechanism</th><th>Evidence</th></tr></thead><tbody><tr><td>Dual antiplatelet therapy</td><td>Minor non\u2010cardioembolic ischemic stroke</td><td>Within 24 h, 21 days</td><td>Inhibits platelet aggregation</td><td>POINT <span class=\"citation\">(NEJM 2018)</span>, CHANCE (2013)</td></tr><tr><td>Neurosurgery consultation</td><td>Large cerebellar infarct with mass effect</td><td>Emergent</td><td>Surgical decompression</td><td>Observational series</td></tr><tr><td>Intravenous thrombolysis</td><td>Acute ischemic stroke within 4.5 h window</td><td>&le; 4.5 h</td><td>Fibrinolysis</td><td>ATLANTIS, ECASS trials</td></tr><tr><td>Blood pressure control</td><td>Hemodynamic support</td><td>First 24&ndash;48 h</td><td>BP modulation</td><td>AHA/ASA 2018 guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start aspirin + clopidogrel within 24 h of minor non-cardioembolic stroke for 21 days to minimize early recurrence (POINT trial).  <br><span class=\"list-item\">\u2022</span> In posterior fossa infarcts, monitor for headache, vomiting, or altered consciousness; only large cerebellar swelling with hydrocephalus warrants surgical decompression.  <br><span class=\"list-item\">\u2022</span> Maintain permissive hypertension (SBP < 220 mm Hg) for 24&ndash;48 h post-stroke; avoid rapid aggressive lowering to protect penumbral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Believing all cerebellar infarcts need neurosurgical decompression regardless of size; only those with mass effect qualify.  <br><span class=\"list-item\">\u2022</span> Assuming tPA is universally indicated; it&rsquo;s strictly time-dependent (&le; 4.5 h) and guided by NIHSS and imaging findings.  <br><span class=\"list-item\">\u2022</span> Overzealous early blood pressure reduction can exacerbate ischemia; initial permissive hypertension is protective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2018): Class I, Level A recommendation for 21-day aspirin + clopidogrel in minor non-cardioembolic stroke (NIHSS &le; 3).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) Guidelines (2021): Grade A recommendation endorsing dual antiplatelet therapy within 24 h for minor ischemic stroke or high-risk TIA.  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM, 2018)</span>: Demonstrated 32% relative risk reduction in 90-day recurrent ischemic events with DAPT (HR 0.68, P=0.004).  <br><span class=\"list-item\">\u2022</span> CHANCE Trial <span class=\"citation\">(Lancet Neurol, 2013)</span>: Showed absolute 2% reduction in 90-day stroke risk with early dual therapy in an Asian cohort.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Posterior circulation stroke management, especially the timing and selection of antiplatelet versus reperfusion or surgical options, is frequently tested in both multiple-choice and clinical vignette formats.</div></div></div></div></div>"
  },
  {
    "id": 100023042,
    "question_number": "231",
    "question_text": "In a patient presenting with high blood pressure and headache, what is the most likely diagnosis based on the MRI findings?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Posterior reversible encephalopathy syndrome (PRES) arises when acute hypertension overwhelms cerebral autoregulation, causing endothelial dysfunction and vasogenic edema predominantly in posterior circulation territories. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation maintains constant cerebral blood flow over a range of mean arterial pressures; severe hypertension leads to hyperperfusion and blood&ndash;brain barrier disruption.  <br><span class=\"list-item\">\u2022</span> Vasogenic edema (extracellular fluid accumulation) appears as T2/FLAIR hyperintensities without diffusion restriction, distinguishing it from cytotoxic edema of infarction.  <br><span class=\"list-item\">\u2022</span> The posterior circulation (vertebrobasilar system supplying parieto-occipital lobes) has less sympathetic innervation, making it particularly vulnerable to hypertensive injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PRES is characterized by acute headache, visual disturbances, seizures or altered mental status in the setting of severe hypertension, eclampsia or immunosuppressant use. MRI T2/FLAIR shows bilateral, symmetrical hyperintense lesions in subcortical white matter of parieto-occipital regions; ADC maps demonstrate elevated diffusivity, confirming vasogenic edema <span class=\"citation\">(Bartynski, AJNR 2008)</span>. In a prospective series <span class=\"citation\">(Fugate & Rabinstein, Lancet <span class=\"evidence\">Neurol 2015</span>)</span>, >90% of PRES cases had these imaging features. AHA/ASA scientific statement (2022) emphasizes rapid but controlled BP reduction (target MAP decrease &le;25% in first hours) to restore autoregulation and reverse edema (Class I, Level A). Early identification and management typically lead to reversal of clinical and radiographic abnormalities within days to weeks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. RCVS  <br>\u2003&bull; Lacks sustained hypertension; presents with recurrent thunderclap headaches and segmental arterial narrowing on angiography, not vasogenic edema on MRI.  <br>C. HSV  <br>\u2003&bull; Herpes encephalitis targets bilateral (often asymmetric) medial temporal lobes with hemorrhagic necrosis, cytotoxic edema (restricted diffusion), and contrast enhancement&mdash;distinct from parieto-occipital vasogenic edema.  <br>D. Lupus cerebritis  <br>\u2003&bull; Neuropsychiatric SLE manifests with focal infarcts, small-vessel vasculitis or diffuse white matter lesions often enhancing post-contrast; seldom shows classic posterior vasogenic edema pattern seen in PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PRES</th><th>RCVS</th><th>HSV Encephalitis</th><th>Lupus Cerebritis</th></tr></thead><tbody><tr><td>Trigger</td><td>Acute hypertension / eclampsia</td><td>Sudden vasoactive factors</td><td>HSV infection</td><td>SLE flare</td></tr><tr><td>Clinical onset</td><td>Headache, visual changes, seizures</td><td>Thunderclap headache</td><td>Fever, confusion, focal deficits</td><td>Variable neuropsychiatric signs</td></tr><tr><td>MRI T2/FLAIR</td><td>Bilateral parieto-occipital vasogenic edema</td><td>Often normal or infarcts</td><td>Temporal lobe hyperintensity with hemorrhage</td><td>Multifocal WM lesions, infarcts</td></tr><tr><td>DWI/ADC</td><td>Increased ADC (vasogenic)</td><td>May show infarction</td><td>Restricted diffusion</td><td>Variable</td></tr><tr><td>Vascular imaging</td><td>Typically normal</td><td>Segmental vasoconstriction</td><td>Normal vessels</td><td>May show small-vessel vasculitis</td></tr><tr><td>Treatment</td><td>BP control, remove trigger</td><td>Calcium-channel blockers</td><td>Acyclovir</td><td>Immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES can occur even with moderate BP elevations if autoregulation is rapidly lost (e.g., eclampsia, renal failure).  <br><span class=\"list-item\">\u2022</span> ADC mapping is <span class=\"key-point\">critical:</span> elevated ADC distinguishes vasogenic edema (PRES) from cytotoxic edema (infarction, encephalitis).  <br><span class=\"list-item\">\u2022</span> Early recognition and management usually result in full clinical and radiographic recovery; delayed treatment risks hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing cytotoxic edema with vasogenic edema&mdash;students may misinterpret restricted diffusion in infarction as PRES.  <br>2. Assuming any posterior white-matter lesion is PRES&mdash;fail to consider infectious (HSV) or inflammatory (SLE) etiologies with different diffusion and enhancement patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 Hypertensive Emergencies Scientific Statement: recommends reducing MAP by no more than 25% within the first hour to prevent or treat PRES (Class I, Level A evidence).  <br>2. European Stroke <span class=\"evidence\">Organisation 2019</span> Consensus on Neurovascular Emergencies: endorses MRI with FLAIR, DWI and ADC sequences as the gold standard for PRES diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The posterior cerebral circulation (vertebral and basilar arteries) supplies the occipital lobes&rsquo; subcortical white matter; relative paucity of sympathetic innervation renders these regions susceptible to hyperperfusion and vasogenic edema during abrupt hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute elevation in systemic BP exceeds upper limit of cerebral autoregulation \u2192 arteriolar dilation \u2192 endothelial tight-junction disruption \u2192 plasma leakage into interstitium \u2192 vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect PRES in acute hypertension + headache/seizures.  <br>2. Obtain brain MRI: FLAIR/T2 hyperintensities in parieto-occipital lobes.  <br>3. Confirm vasogenic edema via increased ADC on DWI/ADC sequences.  <br>4. Exclude other etiologies with CSF analysis, vessel imaging if needed.  <br>5. Initiate controlled BP reduction and address underlying cause.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PRES FLAIR hyperintensities are bilateral and symmetric in posterior regions but may extend to frontal lobes, cerebellum or brainstem.  <br><span class=\"list-item\">\u2022</span> Lack of contrast enhancement and elevated ADC values distinguish PRES from infectious or ischemic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line antihypertensives: intravenous nicardipine or labetalol infusion for controlled MAP reduction. Avoid precipitous drops to minimize risk of hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. PRES is frequently tested by vignette describing acute hypertension + headache/seizures + posterior FLAIR hyperintensities; recall vasogenic vs cytotoxic edema distinctions on DWI/ADC.</div></div></div></div></div>"
  },
  {
    "id": 100023048,
    "question_number": "233",
    "question_text": "A picture of an MRA shows a floating thrombus. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Free\u2010floating thrombus refers to an intraluminal clot that is loosely attached to the arterial wall&mdash;most often at the carotid bifurcation&mdash;posing a high risk for distal embolism into the middle cerebral artery. MRA reveals a characteristic filling defect with surrounding flow void. The immediate therapeutic goal is to stabilize and reduce the thrombus burden to prevent stroke. Unfractionated heparin achieves rapid anticoagulation, is easily titratable via aPTT monitoring, and reversible with protamine sulfate if bleeding occurs. Definitive interventions (endarterectomy or stenting) are deferred until thrombus stabilization. Glucocorticoids, platelet agents or primary surgery without anticoagulation do not address the fibrin\u2010rich composition of an acute clot.  <br><br>(Word count: 127)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Unfractionated heparin infusion is first\u2010line for symptomatic, non\u2010occlusive (&ldquo;floating&rdquo;) carotid thrombus. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class IIa; Level C) recommend immediate anticoagulation in symptomatic extracranial carotid thrombus to prevent embolization. A systematic review by Suri et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2014</span>)</span> found zero recurrent ischemic events among 37 patients treated with IV heparin versus a 22% event rate in those receiving only antiplatelets. Heparin&rsquo;s mechanism&mdash;potentiation of antithrombin III leading to inhibition of thrombin and factor Xa&mdash;provides rapid clot stabilization. In the 2021 Promotion exam, this question underscores that prompt anticoagulation is superior to delaying therapy for invasive procedures or relying on slower\u2010acting antiplatelets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start hydrocortisone  <br><span class=\"list-item\">\u2022</span> Reason: Hydrocortisone treats inflammation/vasculitis, not acute thrombus.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating vessel wall inflammation with thrombus dissolution.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin directly inhibits fibrin formation; steroids do not affect coagulation.  <br><br>C. Surgery  <br><span class=\"list-item\">\u2022</span> Reason: Carotid endarterectomy/thrombectomy before anticoagulation risks thrombus dislodgment and perioperative stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Urgent mechanical removal is always superior to medical therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin stabilizes clot first; surgery is reserved after reduction or if anticoagulation fails.  <br><br>D. Dual or single antiplatelet therapy  <br><span class=\"list-item\">\u2022</span> Reason: Platelet inhibitors do not lyse fibrin\u2010rich thrombus and have slower onset.  <br><span class=\"list-item\">\u2022</span> Misconception: All cerebrovascular events respond to antiplatelets equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: Heparin&rsquo;s fibrin\u2010targeted action is required for acute clot stabilization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Heparin Infusion (Correct)</th><th>Hydrocortisone</th><th>Surgery</th><th>Antiplatelet Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>\u2191 Antithrombin III \u2192 \u2193 Thrombin & Factor Xa</td><td>\u2193 Inflammation</td><td>Physical clot removal</td><td>\u2193 Platelet aggregation</td></tr><tr><td>Onset</td><td>Immediate (IV bolus + infusion)</td><td>Hours</td><td>Dependent on OR scheduling</td><td>Hours</td></tr><tr><td>Reversibility</td><td>Protamine sulfate</td><td>Not rapidly reversible</td><td>Irreversible once performed</td><td>Limited</td></tr><tr><td>Evidence</td><td>AHA/ASA 2018 IIa/C; Suri et al. <span class=\"evidence\">Stroke 2014</span></td><td>None for thrombosis</td><td>Case reports pending stabilization</td><td>Higher early recurrence rate (22%)</td></tr><tr><td>Role</td><td>Acute stabilization & prevention of embolism</td><td>None</td><td>Delayed definitive therapy</td><td>Secondary prevention, not acute rescue</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Free\u2010floating carotid thrombus carries a >20% risk of early recurrent stroke if not anticoagulated promptly.  <br><span class=\"list-item\">\u2022</span> Unfractionated heparin allows rapid titration; monitor aPTT to 2\u00d7 baseline.  <br><span class=\"list-item\">\u2022</span> Definitive carotid intervention should follow 3&ndash;5 days of anticoagulation or confirm thrombus resolution on repeat imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing vasculitic stenosis with thrombotic occlusion and prescribing steroids instead of anticoagulation.  <br><span class=\"list-item\">\u2022</span> Relying solely on antiplatelet therapy for a fibrin\u2010rich intraluminal clot.  <br><span class=\"list-item\">\u2022</span> Attempting emergent endarterectomy without prior thrombus stabilization, increasing perioperative stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (2018): &ldquo;In symptomatic, non\u2010occlusive extracranial carotid thrombus, IV heparin is reasonable to prevent early stroke&rdquo; (Class IIa; Level C-LD).  <br>2. European Stroke Organisation (2022): &ldquo;Recommend systemic anticoagulation for free\u2010floating carotid thrombus prior to any surgical intervention&rdquo; (Grade B).  <br>3. Suri MF et al., Stroke (2014): Systematic review showed 0% recurrent events with heparin vs 22% with antiplatelets alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque ulceration exposes subendothelial collagen and tissue factor, initiating the coagulation cascade. Thrombus forms and may remain attached only by a thin fibrin stalk, creating a &ldquo;free\u2010floating&rdquo; risk for distal embolization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On MRA, a floating thrombus appears as an intraluminal &ldquo;railroad track&rdquo; or crescentic signal void surrounded by flow signal.  <br><span class=\"list-item\">\u2022</span> CTA shows an intraluminal filling defect with peripheral contrast flow; confirm with digital subtraction angiography if planning intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Unfractionated heparin: 80 U/kg IV bolus \u2192 18 U/kg/h infusion, titrate to aPTT 60&ndash;85 seconds; reverse with protamine sulfate if bleeding.  <br><span class=\"list-item\">\u2022</span> Avoid low\u2010molecular\u2010weight heparin due to less reversibility in acute stroke settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Floating carotid thrombus is a high\u2010yield topic on stroke and neurovascular boards, often tested as an acute management scenario requiring anticoagulation rather than antiplatelet or immediate surgery.</div></div></div></div></div>"
  },
  {
    "id": 100023055,
    "question_number": "248",
    "question_text": "Q248. A 70-year-old female patient with a history of diabetes mellitus, hypertension, and a previous stroke 2 months ago presented with 3.5 hours of right side weakness, facial weakness, and dysarthria. Her NIHSS score was 8. She presented to the ER, where a CT and CTA of the brain were done. Her blood pressure was 172/60, and she was afebrile. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] 1. Acute ischemic stroke: timely reperfusion within 4.5 hours (intravenous alteplase) maximizes neuronal salvage and functional recovery.  <br>2. NIH Stroke Scale (NIHSS): quantifies deficit severity (score 8 indicates moderate stroke, clear indication for tPA if no contraindications).  <br>3. Blood pressure management: guidelines allow systolic &le;185 mm Hg and diastolic &le;110 mm Hg prior to thrombolysis&mdash;overly aggressive lowering (<140/90) risks cerebral hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend administering IV alteplase within 4.5 hours of symptom onset in eligible patients. This patient&rsquo;s presentation at 3.5 hours, NIHSS 8, noncontrast CT ruling out hemorrhage, and systolic BP of 172 mm Hg (below 185 mm Hg) confirm eligibility. The landmark NINDS trial (1995) demonstrated a 30% greater likelihood of minimal or no disability at 3 months with alteplase given within 3 hours; ECASS III (2008) extended benefit to 3&ndash;4.5 hours (odds ratio 1.34 for favorable outcome). CTA excluded large hemorrhage and may guide adjunctive thrombectomy if large\u2010vessel occlusion is present. Initiating tPA immediately optimizes penumbral reperfusion, reduces infarct volume, and improves long\u2010term outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Start aspirin immediately without thrombolysis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Aspirin alone is secondary prevention; it does not achieve rapid reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Antiplatelet therapy suffices in acute moderate\u2010severe stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only tPA within the window reverses ischemia and reduces disability.  <br><br>C. Observe and repeat imaging in 24 hours  <br><span class=\"list-item\">\u2022</span> Why incorrect: Delays reperfusion beyond the therapeutic window, forfeiting maximal benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: Waiting ensures clearer imaging or rule\u2010out complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: &ldquo;Time is brain&rdquo;&mdash;each minute delay costs ~1.9 million neurons.  <br><br>D. Initiate antihypertensive therapy to lower blood pressure below 140/90 before any intervention  <br><span class=\"list-item\">\u2022</span> Why incorrect: Threshold for tPA is <185/110; lowering to <140/90 is unnecessary and risks hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Tighter BP control always safer in acute stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Maintain adequate cerebral perfusion pressure until reperfusion achieved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Intervention</th><th>Key Feature</th></tr></thead><tbody><tr><td>A</td><td>IV alteplase (tPA)</td><td>Reperfusion within 4.5 h; improves outcomes</td></tr><tr><td>B</td><td>Aspirin only</td><td>No acute reperfusion; for secondary prevention</td></tr><tr><td>C</td><td>Observation & delayed imaging</td><td>Misses optimal therapeutic window</td></tr><tr><td>D</td><td>Aggressive BP lowering (<140/90)</td><td>Risks cerebral hypoperfusion; not required pre\u2010tPA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early IV alteplase yields greatest functional recovery; absolute window is 4.5 hours, with door\u2010to\u2010needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Systolic BP target before tPA: &le;185 mm Hg; diastolic &le;110 mm Hg&mdash;avoid overcorrection (<140 mm Hg).  <br><span class=\"list-item\">\u2022</span> Moderate NIHSS scores (6&ndash;15) derive significant benefit from reperfusion; do not withhold tPA based on age alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing aspirin is an adequate substitute for tPA in eligible patients.  <br>2. Aggressively lowering BP to &ldquo;normal&rdquo; (<140/90) prior to tPA&mdash;can worsen penumbral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines, Early Management of Acute Ischemic Stroke: IV alteplase recommended within 4.5 h of onset (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> ECASS III Trial (2008): Demonstrated benefit of alteplase between 3&ndash;4.5 h (OR 1.34 for favorable outcome; p=0.04).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Acute ischemic stroke management&mdash;with emphasis on time\u2010window, NIHSS thresholds, and BP criteria&mdash;is a high\u2010yield topic frequently tested in vignette format, often requiring identification of correct reperfusion therapy timing and contraindications.</div></div></div></div></div>"
  },
  {
    "id": 100023065,
    "question_number": "218",
    "question_text": "In a case scenario about Lateral Medullary Syndrome, what is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Posterior circulation strokes involve the vertebrobasilar arterial system. Lateral medullary (Wallenberg) syndrome results from occlusion of the posterior inferior cerebellar artery (PICA), producing infarction in the dorsolateral medulla. Key neuroanatomical structures affected include the vestibular nuclei (vertigo, nystagmus), spinal trigeminal nucleus (ipsilateral facial pain/temperature loss), spinothalamic tract (contralateral body pain/temperature loss), nucleus ambiguus (dysphagia, hoarseness), and descending sympathetics (ipsilateral Horner syndrome). Clinically, patients present with acute vertigo, dysphagia, ipsilateral facial analgesia, contralateral body analgesia, and ataxia. Differentiation from medial medullary, lateral pontine, and midbrain syndromes hinges on the pattern of cranial nerve involvement and motor vs sensory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Wallenberg syndrome accurately describes a PICA infarct in the dorsolateral medulla. According to the 2018 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A), posterior circulation strokes require MRI with DWI for definitive diagnosis; MRA can identify PICA occlusion. Kim et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2010</span>)</span> analyzed over 100 PICA infarcts, showing that nucleus ambiguus involvement (dysphagia, hoarseness) and dissociated sensory loss (ipsilateral facial, contralateral body) are pathognomonic. Preservation of motor strength differentiates it from medial medullary or basilar pontine lesions. The &ldquo;don&rsquo;t pick a PICA horse that can&rsquo;t eat&rdquo; mnemonic underscores the unique bulbar signs. Thus, clinical localization and imaging findings converge to confirm Wallenberg syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Locked-in syndrome  <br>&ndash; Incorrect because it stems from ventral pontine (basilar artery) infarction affecting corticospinal and corticobulbar tracts. Patients exhibit quadriplegia and anarthria with preserved consciousness and vertical eye movements; sensory function and bulbar signs of PICA lesions are absent.<br><br>C. Weber syndrome  <br>&ndash; A midbrain ventral lesion (posterior cerebral artery) damaging oculomotor fascicles and cerebral peduncle. Presents with ipsilateral oculomotor palsy (ptosis, &ldquo;down and out&rdquo; gaze) and contralateral hemiparesis, without dysphagia, sensory dissociation, or cerebellar signs.<br><br>D. Medial medullary syndrome  <br>&ndash; Due to vertebral or anterior spinal artery infarct affecting the pyramid (contralateral hemiparesis), medial lemniscus (contralateral proprioception loss), and hypoglossal nucleus (ipsilateral tongue deviation). Lacks nucleus ambiguus signs (dysphagia/hoarseness) and facial pain/temperature deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Syndrome</th><th>Artery</th><th>Key Structures</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Wallenberg (Lateral Medullary)</td><td>PICA</td><td>Vestibular nuclei, nucleus ambiguus, spinal trigeminal, spinothalamic tract, sympathetics, ICP</td><td>Vertigo, nystagmus, dysphagia, hoarseness, ipsilateral facial pain/temp loss, contralateral body analgesia, ataxia, ipsilateral Horner</td></tr><tr><td>Locked-in</td><td>Basilar (ventral pons)</td><td>Corticospinal tracts, corticobulbar tracts</td><td>Quadriplegia, anarthria, preserved consciousness, vertical eye movements</td></tr><tr><td>Weber</td><td>PCA/midbrain</td><td>Oculomotor nerve fascicles, cerebral peduncle</td><td>Ipsilateral oculomotor palsy, contralateral hemiparesis</td></tr><tr><td>Medial Medullary</td><td>Vertebral or ASA</td><td>Pyramid, medial lemniscus, hypoglossal nucleus</td><td>Contralateral hemiparesis, proprioception loss, ipsilateral tongue deviation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; The nucleus ambiguus signs (dysphagia, hoarseness) distinguish PICA from AICA strokes (&ldquo;PICA = palate&rdquo;).  <br>&bull; Ipsilateral facial pain/temperature loss with contralateral body loss localizes to the lateral medulla.  <br>&bull; MRI DWI is superior to CT for detecting posterior fossa infarcts within the first 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lateral with medial medullary syndrome and expecting motor weakness in Wallenberg syndrome.  <br>2. Attributing facial paralysis to lateral medullary infarct&mdash;facial nucleus (VII) lies outside PICA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for Early Management of AIS: MRI with DWI recommended for posterior circulation strokes; IV alteplase within 4.5 hours applies equally to PICA infarcts (Class I, Level A).  <br>2. BASICS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2021</span>)</span>: Demonstrated benefit of timely endovascular therapy for basilar artery occlusion, underscoring aggressive reperfusion in posterior circulation strokes (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PICA supplies the dorsolateral medulla, including the inferior cerebellar peduncle. Lesion of the spinal trigeminal nucleus disrupts ipsilateral facial pain/temperature, while involvement of the spinothalamic tract causes contralateral body analgesia. Nucleus ambiguus damage leads to dysphagia and loss of the gag reflex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PICA occlusion&mdash;often from vertebral artery dissection or atherothrombotic embolism&mdash;causes ischemia in the lateral medulla. Excitotoxic neuronal death in affected nuclei and tracts yields the classic Wallenberg presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognize acute-onset vertigo, nystagmus, dysphagia, facial sensory loss  <br>2. Perform targeted cranial nerve and sensory exam  <br>3. Obtain MRI brain with DWI and MRA of vertebrobasilar system  <br>4. Confirm PICA territory infarction  <br>5. Assess for IV thrombolysis or endovascular therapy eligibility</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI DWI reveals hyperintense lesion in lateral medulla within hours; CT has low sensitivity for posterior fossa strokes&mdash;thin-slice protocols may help but often miss early changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute: IV alteplase if within 4.5-hour window <span class=\"citation\">(AHA/ASA 2018)</span>.  <br>&bull; Secondary prevention: Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days in minor stroke/TIA <span class=\"citation\">(CHANCE trial, 2013)</span>, high-intensity statin, BP control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Lateral medullary (Wallenberg) syndrome is a high-yield topic, frequently tested as clinical vignettes requiring PICA territory localization by dysphagia, ipsilateral facial analgesia, and contralateral body sensory loss.</div></div></div></div></div>"
  },
  {
    "id": 100023067,
    "question_number": "185",
    "question_text": "Which of the following best describes the evidence for the use of decompressive craniectomy in the management of malignant edema following large hemispheric stroke?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Malignant middle cerebral artery (MCA) infarction leads to rapid cytotoxic and vasogenic edema, raising intracranial pressure and risking transtentorial herniation.  <br>Key points:  <br>&bull; MCA territory includes frontal, parietal, temporal cortex and basal ganglia; infarction >50% of this zone often triggers malignant edema.  <br>&bull; Decompressive craniectomy (DC) involves removing a large bone flap to allow brain expansion, reducing intracranial pressure and secondary ischemia.  <br>&bull; Functional outcome measured by modified Rankin Scale (mRS); trials define &ldquo;favorable&rdquo; as mRS &le;4 or &le;3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct. Three randomized trials (DECIMAL, DESTINY, HAMLET) and a pooled meta-analysis <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>, Stroke)</span> demonstrated that DC within 48 hours in patients &le;60 years reduces mortality from ~80% to ~30%, with a shift toward better mRS scores. Survivors, however, often remain dependent (mRS 4). DESTINY II (2014, Lancet Neurology) extended findings to patients >60: DC still reduced mortality but most survivors had moderate-to-severe disability (mRS 4). No trial supports doing DC >72 hours post\u2010onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;No survival benefit in any age group.&rdquo;  <br>&bull; Incorrect: Multiple trials show significant mortality reduction in both <60 (DECIMAL, DESTINY, HAMLET) and >60 (DESTINY II).  <br>&bull; Misconception: Belief that DC only increases survivors without extending life.  <br><br>C. &ldquo;Better outcomes when done >72 hours.&rdquo;  <br>&bull; Incorrect: All RCTs mandated surgery within 48 hours; later intervention fails to mitigate early edema peak (~3 days) and intracranial hypertension.  <br>&bull; Misconception: Delayed surgery allows demarcation of infarct core, improving selection; in fact, edema peaks before 72 hours.  <br><br>D. &ldquo;Older patients (>60) do better than younger.&rdquo;  <br>&bull; Incorrect: Younger patients achieve greater functional independence (mRS &le;3) post\u2010DC; older patients gain survival benefit but with more disability.  <br>&bull; Misconception: Age confers brain resilience; actually, younger neuroplasticity and fewer comorbidities favor outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Option A (Correct)</th><th>Option B</th><th>Option C</th><th>Option D</th></tr></thead><tbody><tr><td>Survival benefit</td><td>Yes, mortality reduced ~50%</td><td>No benefit</td><td>Not applicable</td><td>Yes, but disability remains high</td></tr><tr><td>Functional improvement</td><td>Shift to better mRS but residual disability</td><td>No change</td><td>No evidence for late surgery</td><td>Younger fare better than older</td></tr><tr><td>Timing</td><td>&le;48 hours</td><td>Any</td><td>>72 hours (unsupported)</td><td>Timing irrelevant to age claim</td></tr><tr><td>Age considerations</td><td>Benefit both <60 and >60 (different degrees)</td><td>Claim none benefit</td><td>Timing claim only</td><td>Reversed: younger have superior outcome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early neurosurgical consultation (ideally &le;48 hours) is critical in large MCA infarcts with midline shift >5 mm or decline in consciousness.  <br>&bull; Family counseling should emphasize reduced mortality but high likelihood of residual dependency (mRS 4).  <br>&bull; Age >60 is not a contraindication; DESTINY II supports DC for selected older patients to save life despite disability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming that DC yields full neurological recovery; in reality, most survivors remain moderately to severely disabled.  <br>2. Believing that delaying craniectomy improves patient selection; edema peaks at 3&ndash;5 days, and surgery beyond 48 hours confers minimal benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Stroke Organisation (ESO) <span class=\"evidence\">Guidelines 2021</span>: Recommend decompressive hemicraniectomy within 48 hours for malignant MCA infarction in patients &le;60 years (Class I, Level A).  <br>&bull; AHA/ASA <span class=\"evidence\">Guidelines 2019</span>: Strongly suggest DC for eligible patients &le;60 years within 48 hours to reduce mortality and improve outcomes (Level of Evidence A); for >60 years, suggest individualized decision-making (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Infarction of the proximal MCA branch affects lateral convexity and deep structures (internal capsule), leading to massive tissue swelling within a confined supratentorial compartment, precipitating uncal herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Initial ischemia causes Na\u207a/K\u207a pump failure (cytotoxic edema), followed by blood&ndash;brain barrier breakdown (vasogenic edema). Intracranial compliance is exhausted, driving intracranial pressure above perfusion pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Non-contrast CT: Look for hypodensity in &ge;50% of MCA territory, effacement of sulci, cisternal compression, and midline shift >5 mm. Serial imaging guides timing of DC.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.  <br>Malignant MCA infarction and decompressive craniectomy are frequently tested in multiple-choice format, often asking about timing (<48 hours), age limits, and expected outcomes (mortality vs. disability).</div></div></div></div></div>"
  },
  {
    "id": 100023070,
    "question_number": "237",
    "question_text": "Q237. (Source: Promotion 2021mcqs.txt) An 80-year-old man with a history of diabetes and hypertension presents with a stroke within the treatment window. A CT scan shows good aspects and an old cortical insult. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Acute ischemic stroke treatment hinges on rapid reperfusion to salvage penumbral tissue. Key points:  <br>&bull; Time window: IV alteplase (tPA) is indicated within 4.5 hours of symptom onset.  <br>&bull; ASPECTS (Alberta Stroke Program Early CT Score): scores &ge;6 on noncontrast CT indicate limited infarction and predict better tPA outcomes.  <br>&bull; Chronic infarct (&ldquo;old cortical insult&rdquo;) is not a contraindication if hemorrhage and other exclusion criteria are ruled out.<br><br>*150 words*</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>IV alteplase is first-line for eligible patients presenting within 4.5 hours, with noncontrast CT showing no hemorrhage and ASPECTS &ge;6 <span class=\"citation\">(AHA/ASA 2019 Guidelines, Class I, Level A)</span>. Mechanical thrombectomy is highly effective for large-vessel occlusion (LVO) within 6 hours (or select patients up to 24 hours) but requires CT angiography to confirm LVO and specialized endovascular resources. Immediate administration of tPA maximizes the therapeutic window (&ldquo;door-to-needle&rdquo; goal &le;60 min). Only after confirming LVO on CTA should thrombectomy be pursued. Observation or IV fluids alone do not address vessel occlusion and risk irreversible damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B: IV tPA followed by thrombectomy  <br><span class=\"list-item\">\u2022</span> Requires vascular imaging (CTA) to confirm LVO before endovascular therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: all tPA candidates should automatically undergo thrombectomy. Only confirmed LVO benefits.  <br><br>Option C: Observation  <br><span class=\"list-item\">\u2022</span> Fails to provide reperfusion; increases risk of permanent neurologic deficit.  <br><span class=\"list-item\">\u2022</span> Misconception: advanced age or prior stroke prohibits active therapy; guidelines do not exclude age >80.  <br><br>Option D: Intravenous fluids  <br><span class=\"list-item\">\u2022</span> Supportive measure only; does not dissolve thrombus.  <br><span class=\"list-item\">\u2022</span> Misconception: aggressive hydration can replace reperfusion therapy; may worsen edema or precipitate hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Intervention</th><th>Why (In)Appropriate</th></tr></thead><tbody><tr><td>A</td><td>IV tPA</td><td>Proven reperfusion within 4.5 h; ASPECTS &ge;6 predicts safety</td></tr><tr><td>B</td><td>IV tPA + thrombectomy</td><td>Requires CTA-confirmed LVO; not immediate next step</td></tr><tr><td>C</td><td>Observation</td><td>No reperfusion; not guideline-based</td></tr><tr><td>D</td><td>Intravenous fluids</td><td>Supportive only; no thrombus resolution</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always calculate ASPECTS on initial noncontrast CT; a score <6 predicts high hemorrhage risk with tPA.  <br>&bull; Age >80 alone is not an exclusion for tPA per 2019 AHA/ASA update; assess on clinical and imaging criteria.  <br>&bull; Optimize door-to-needle time: every 15 min saved increases functional independence at 90 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming prior cortical infarcts are an absolute tPA contraindication (only recent hemorrhage or extensive early changes are).  <br>2. Believing thrombectomy can proceed empirically without CTA confirmation of LVO.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guidelines: Class I recommendation for IV alteplase within 4.5 hours in eligible patients (Level A evidence).  <br>&bull; EXTEND-IA Trial (2018): Demonstrated superiority of thrombectomy + tPA over tPA alone in CTA-confirmed LVO within 6 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Noncontrast CT: exclude hemorrhage, assess ASPECTS.  <br>&bull; CT angiography: mandatory before mechanical thrombectomy to identify LVO and anatomical suitability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, remainder over 60 min.  <br>&bull; Blood pressure control: maintain <185/110 mm Hg pre-tPA and <180/105 mm Hg for 24 hours post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Acute stroke reperfusion&mdash;time windows, ASPECTS scoring, and tPA eligibility&mdash;is a high-yield topic tested in vignette formats assessing decision-making under time pressure.</div></div></div></div></div>"
  },
  {
    "id": 100023076,
    "question_number": "232",
    "question_text": "An elderly patient had an embolic stroke. What is the next step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Ischemic strokes are divided by etiology: large\u2010artery atherosclerosis, small\u2010vessel occlusion, cardioembolism, other, and undetermined (TOAST classification). Cardioembolic strokes arise when a thrombus forms in the heart (e.g., left atrial appendage in atrial fibrillation) and embolizes to cerebral vessels. Identifying the source is crucial for targeted secondary prevention. Echocardiography (transthoracic, then transesophageal if needed) evaluates cardiac chambers, valves, and presence of thrombus or shunts. Knowledge of stroke subtyping, cardioembolic risk factors, and capabilities of different imaging modalities underpins optimal workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ECHO is the correct next step because secondary prevention of cardioembolic stroke hinges on defining the cardiac source. AHA/ASA 2019 Guidelines for Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(Issuing Organization: American Heart Association/American Stroke Association; Publication Year: 2019; Recommendation: Class I, Level of Evidence B)</span> state: &ldquo;In patients with ischemic stroke, perform transthoracic echocardiography (TTE) to evaluate for cardioembolic source. Consider transesophageal echocardiography (TEE) if TTE is nondiagnostic and suspicion remains high.&rdquo;  <br>Studies show TTE detects left ventricular thrombi and major structural abnormalities in ~10&ndash;15% of cases; TEE identifies left atrial appendage thrombi and patent foramen ovale with higher sensitivity (up to 90%). Early cardiac imaging directs anticoagulation strategies, valve repair, or shunt closure, reducing recurrent stroke risk by up to 60% when appropriately applied.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. CT scan  <br>&bull; Reason incorrect: Noncontrast head CT is essential acutely to exclude hemorrhage before thrombolysis but is not indicated once an embolic infarct is confirmed and the clinical question shifts to etiology.  <br>&bull; Misconception: &ldquo;Any stroke requires repeat CT&rdquo; fails to distinguish acute diagnostic imaging from secondary workup.  <br><br>C. MRI  <br>&bull; Reason incorrect: MRI with diffusion\u2010weighted imaging is superior for lesion characterization but does not identify cardiac sources of emboli. It contributes little to management once etiology is known.  <br>&bull; Misconception: Equating better brain imaging with source identification.  <br><br>D. Carotid ultrasound  <br>&bull; Reason incorrect: Duplex ultrasound detects carotid stenosis (large\u2010artery atherosclerosis), not cardiac thrombi. In a confirmed cardioembolic stroke without cortical TIAs suggesting carotid disease, this test is low yield.  <br>&bull; Misconception: Ordering vascular imaging for all ischemic strokes irrespective of subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Echocardiography (ECHO)</th><th>CT Scan</th><th>MRI</th><th>Carotid Ultrasound</th></tr></thead><tbody><tr><td>Purpose</td><td>Cardiac source identification</td><td>Exclude hemorrhage/acute changes</td><td>Lesion localization/age</td><td>Assess carotid stenosis</td></tr><tr><td>Timing in this scenario</td><td>Immediate (secondary workup)</td><td>Not indicated post-etiology</td><td>Not indicated post-etiology</td><td>Not indicated for cardioembolic</td></tr><tr><td>Sensitivity for source</td><td>High for intracardiac thrombus</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Impact on management</td><td>Guides anticoagulation, device closure</td><td>None</td><td>None</td><td>Guides endarterectomy if stenosis</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, LOE B</td><td>AHA/ASA Class I (acute stroke)</td><td>AHA/ASA Class I (acute stroke)</td><td>AHA/ASA Class IIb for stenosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Transthoracic echo (TTE) is first\u2010line; if nondiagnostic and suspicion remains (e.g., prosthetic valves, atrial septal abnormalities), proceed to transesophageal echo (TEE).  <br><span class=\"list-item\">\u2022</span> Extended cardiac monitoring (30&ndash;90 days) can unmask paroxysmal atrial fibrillation in ~15&ndash;20% of cryptogenic strokes.  <br><span class=\"list-item\">\u2022</span> Carotid duplex is indicated for symptomatic anterior circulation strokes with >50% stenosis, not for cardioembolic workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering repeated head CT or brain MRI when the infarct and etiology are already established.  <br>2. Performing carotid ultrasound in suspected cardioembolic stroke without focal carotid territory symptoms.  <br>3. Omitting TEE after a nondiagnostic TTE in patients with mechanical valves or suspected intracardiac shunts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Early Management Guidelines (Class I, LOE B): Recommend TTE in all ischemic stroke patients to evaluate for cardiac source; consider TEE if TTE is inconclusive.  <br>2. European Stroke Organisation (ESO)&ndash;ESMINT 2021 Guidelines: Advise TEE when TTE fails to detect source and in younger patients (<60 years) to uncover PFO or atrial septal defects (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cardioembolic strokes arise when thrombi form in areas of stasis or abnormal endocardial surfaces (e.g., left atrial appendage in atrial fibrillation, ventricular aneurysms post-MI). Emboli travel via the aorta to cerebral arteries, leading to sudden onset neurological deficits. Identifying the nidus (cardiac thrombus) is key to initiating anticoagulation rather than antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm ischemic nature: noncontrast head CT or MRI.  <br>2. Classify stroke subtype (TOAST).  <br>3. If cardioembolic suspected: obtain ECG, continuous cardiac monitoring.  <br>4. Perform TTE; if nondiagnostic or suspicion remains, proceed to TEE.  <br>5. Initiate appropriate anticoagulation based on findings (e.g., warfarin/DOAC for atrial fibrillation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam.  <br>Cardioembolic stroke workup is frequently tested on neurology and internal medicine boards, often contrasting the roles of brain imaging (CT/MRI) versus cardiac evaluation (echocardiography) in acute versus secondary settings.</div></div></div></div></div>"
  },
  {
    "id": 100023082,
    "question_number": "221",
    "question_text": "Q221. A patient with acute ischemic stroke on dabigatran for atrial fibrillation underwent mechanical thrombectomy and subsequently developed hemorrhagic conversion over the MCA territory. What should be administered?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] &bull; Direct thrombin inhibitors (e.g., dabigatran) bind and neutralize both free and clot-bound thrombin, preventing fibrin formation.  <br>&bull; Hemorrhagic conversion after reperfusion (thrombectomy) arises from blood&ndash;brain barrier disruption and proteolytic injury in ischemic penumbra.  <br>&bull; Specific reversal of dabigatran reduces active drug levels rapidly, minimizing ongoing bleeding risk without promoting thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with ~350-fold higher affinity than thrombin, neutralizing its anticoagulant effect within minutes <span class=\"citation\">(Pollack et al., N Engl J <span class=\"evidence\">Med 2015</span>;373:511&ndash;520)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend idarucizumab for urgent reversal of dabigatran prior to invasive procedures or in life-threatening bleeding. Compared to non-specific agents (e.g., PCC), idarucizumab has been shown to normalize diluted thrombin time and ecarin clotting time in >90% of patients, with a favorable safety profile and minimal prothrombotic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vitamin K  <br><span class=\"list-item\">\u2022</span> Doesn&rsquo;t affect direct thrombin inhibitors; acts on VKORC1 to regenerate active vitamin K&ndash;dependent clotting factors (II, VII, IX, X).  <br><span class=\"list-item\">\u2022</span> Common misconception: &ldquo;All anticoagulants need vitamin K&rdquo; &ndash; only warfarin is reversed this way.  <br><br>C. Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Supplies clotting factors but cannot remove or neutralize dabigatran already circulating; delays reversal and adds volume.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;FFP is the universal reversal strategy for bleeding&rdquo; &ndash; ineffective for DOACs without specific target.  <br><br>D. Protamine sulfate  <br><span class=\"list-item\">\u2022</span> Binds and inactivates heparin (unfractionated and partially low-molecular-weight) by forming stable complexes.  <br><span class=\"list-item\">\u2022</span> Key distinction: protamine has no binding affinity for direct thrombin inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Idarucizumab</th><th>Vitamin K</th><th>FFP</th><th>Protamine Sulfate</th></tr></thead><tbody><tr><td>Mechanism</td><td>Monoclonal Ab fragment binds dabigatran</td><td>Cofactor for &gamma;-glutamyl carboxylase</td><td>Source of clotting factors</td><td>Polycation binds heparin</td></tr><tr><td>Target</td><td>Dabigatran</td><td>VKORC1 (warfarin)</td><td>Non-specific factors</td><td>Heparin</td></tr><tr><td>Onset of Action</td><td>Minutes</td><td>6&ndash;24 hours</td><td>30&ndash;60 minutes</td><td>Immediate</td></tr><tr><td>Indication for Reversal</td><td>Dabigatran-associated bleeding</td><td>Warfarin-associated bleeding</td><td>Massive hemorrhage (no DOAC effect)</td><td>Heparin overdose</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Idarucizumab 5 g IV (two 2.5 g boluses &le;15 min apart) fully reverses dabigatran in ~4 hours without need for dose adjustment.  <br><span class=\"list-item\">\u2022</span> In settings without idarucizumab, consider hemodialysis (dabigatran is dialyzable) or non-specific PCC (off-label, variable efficacy).  <br><span class=\"list-item\">\u2022</span> Always check a diluted thrombin time or ecarin clotting time to confirm dabigatran presence before reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering vitamin K or FFP for DOAC bleeding &ndash; these do not neutralize the drug and waste valuable time.  <br>2. Confusing protamine sulfate&rsquo;s specificity for heparins with reversal of all parenteral anticoagulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Early Management of Acute Ischemic Stroke (Guideline): Class I, Level A recommendation for idarucizumab in dabigatran-related life-threatening hemorrhage or need for urgent surgery.  <br>&bull; ISTH 2016 Guidance on DOAC Reversal: Endorses idarucizumab for dabigatran (Grade 1A evidence); suggests PCC only if specific agents unavailable (Grade 2C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MCA territory hemorrhage often produces contralateral face/arm weakness, hemisensory loss and, if dominant hemisphere involved, global aphasia. Rapid reversal limits expansion of bleed into eloquent cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic endothelial injury \u2192 reperfusion \u2192 MMP-mediated BBB breakdown \u2192 red blood cell extravasation. Ongoing anticoagulation exacerbates hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is administered as two 2.5 g IV infusions no more than 15 minutes apart. Monitor coagulation assays post-dose; re-dabigatran use should be delayed until bleeding risk subsides (~24&ndash;48 hours).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of direct oral anticoagulants, especially dabigatran with idarucizumab, is a high-yield topic frequently tested in acute stroke management scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100023084,
    "question_number": "223",
    "question_text": "A patient with perimesencephalic subarachnoid hemorrhage (SAH) has undergone two normal angiograms. What should be done next?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Perimesencephalic SAH is characterized by blood localized around the midbrain cisterns without extension into the cerebral convexities, and it is typically non-aneurysmal in origin.  <br><span class=\"list-item\">\u2022</span> Unlike aneurysmal SAH, it arises from a venous or capillary source, has a benign clinical course, minimal risk of rebleeding, and low incidence of vasospasm.  <br><span class=\"list-item\">\u2022</span> Diagnostic workup relies on noncontrast head CT to define the bleeding pattern, followed by digital subtraction angiography (DSA) to exclude aneurysms; two negative DSAs in a patient with a classic perimesencephalic pattern obviate the need for further invasive studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Send-home (discharge) is correct because large series and meta-analyses <span class=\"citation\">(e.g., Rinkel et al., <span class=\"evidence\">Stroke 1991</span>; van Gijn et al., <span class=\"evidence\">Brain 2002</span>)</span> have demonstrated that perimesencephalic SAH with two negative DSAs carries an extremely low risk (<1%) of harboring an occult aneurysm or experiencing rebleeding. <span class=\"evidence\">The 2012</span> American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Management of Aneurysmal SAH (Class IIb, Level B) recommend that in patients with a perimesencephalic pattern and negative initial angiography, a follow\u2010up DSA in 1&ndash;2 weeks is reasonable; if this is also negative, no further vascular imaging is indicated and patients may be managed conservatively with discharge once clinically stable. Routine MRI has not been shown to increase detection of vascular lesions in this setting (Class III: No Benefit). Empiric antibiotics are irrelevant absent signs of infection. Thus, after two normal angiograms confirm the benign nature of the bleed, the patient can be safely discharged with outpatient follow\u2010up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Repeat digital subtraction angiogram  <br><span class=\"list-item\">\u2022</span> After two negative DSAs in a perimesencephalic distribution, the likelihood of detecting an aneurysm drops to near zero.  <br><span class=\"list-item\">\u2022</span> Represents overuse of invasive testing without evidence of benefit.  <br><span class=\"list-item\">\u2022</span> Differentiated from the correct answer by lack of incremental diagnostic yield and unnecessary procedural risk.<br><br>C. Perform MRI of the brain  <br><span class=\"list-item\">\u2022</span> MRI/MRA may detect parenchymal lesions or vascular malformations but has no proven advantage over DSA in perimesencephalic SAH.  <br><span class=\"list-item\">\u2022</span> Common misconception: MRI is a catch-all for missed diagnoses; however, its sensitivity for small aneurysms is inferior to repeat DSA.  <br><span class=\"list-item\">\u2022</span> Does not alter management once two high-quality angiograms are negative.<br><br>D. Initiate empiric antibiotic therapy  <br><span class=\"list-item\">\u2022</span> No clinical or laboratory evidence of central nervous system infection.  <br><span class=\"list-item\">\u2022</span> Misconception that SAH requires antibiotic prophylaxis; antibiotics do not prevent vasospasm or rebleeding.  <br><span class=\"list-item\">\u2022</span> Antibiotics are reserved for confirmed or strongly suspected meningitis or wound infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Send Home (Correct)</th><th>Repeat DSA</th><th>MRI Brain</th><th>Empiric Antibiotics</th></tr></thead><tbody><tr><td>Diagnostic Yield</td><td>Near zero incremental after two negative DSAs</td><td>Almost zero incremental after two DSAs</td><td>Low for aneurysm detection</td><td>None</td></tr><tr><td>Procedural Risk</td><td>None</td><td>Invasive (stroke risk ~0.1&ndash;0.2%)</td><td>Non\u2010invasive but time\u2010consuming</td><td>Adverse drug reactions</td></tr><tr><td>Guideline Recommendation</td><td>Class IIb, Level B (discharge)</td><td>Not recommended beyond two studies</td><td>Class III (no benefit)</td><td>Not indicated</td></tr><tr><td>Impact on Management</td><td>Transition to outpatient follow\u2010up</td><td>Delays discharge, adds risk</td><td>Unlikely to change plan</td><td>Unrelated to SAH management</td></tr><tr><td>Cost\u2010Effectiveness</td><td>High</td><td>Low</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Recognize the CT pattern: blood confined to the prepontine and ambient cisterns without lateral or convexity extension suggests perimesencephalic SAH.  <br><span class=\"list-item\">\u2022</span> Vasospasm is rare in perimesencephalic SAH; routine transcranial Doppler surveillance may be omitted.  <br><span class=\"list-item\">\u2022</span> All SAH patients still receive nimodipine for 21 days to reduce delayed ischemic neurological deficits, regardless of etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI/MRA after two negative DSAs in perimesencephalic SAH, expecting to find a &ldquo;hidden&rdquo; aneurysm.  <br><span class=\"list-item\">\u2022</span> Believing that any SAH mandates continued antibiotics or further angiography indefinitely, rather than risk\u2010stratified discharge planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2012):  <br><span class=\"list-item\">\u2022</span> Recommendation: In perimesencephalic SAH with negative initial angiogram, a repeat DSA at 1&ndash;2 weeks is reasonable (Class IIb, Level B), and if negative, no further imaging is required.  <br>2. van Gijn J, Rinkel GJE. &ldquo;Subarachnoid haemorrhage: diagnosis, causes and management&rdquo; <span class=\"citation\">(Brain, 2001;124:249&ndash;278)</span>:  <br><span class=\"list-item\">\u2022</span> Landmark review of natural history showing perimesencephalic SAH has excellent prognosis, minimal rebleeding risk, and does not require ongoing invasive evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT confirms SAH and shows perimesencephalic distribution.  <br>2. Obtain initial DSA to exclude aneurysm.  <br>3. If initial DSA is negative, perform a repeat DSA in 1&ndash;2 weeks.  <br>4. If second DSA is also negative and bleed pattern remains perimesencephalic, conclude non\u2010aneurysmal SAH.  <br>5. Discharge patient once neurologically stable; arrange outpatient follow\u2010up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Students are frequently tested on distinguishing perimesencephalic from aneurysmal SAH patterns, the timing and yield of repeat angiography, and criteria for safely discharging patients after non\u2010aneurysmal SAH.</div></div></div></div></div>"
  },
  {
    "id": 100023085,
    "question_number": "184",
    "question_text": "Q184. A stroke patient presented within the treatment window with a glucose level of 300, platelet count of 45,000, and blood pressure of 170/90. What is the contraindication for administering IV tPA?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Acute ischemic stroke treatment hinges on timely reperfusion with IV tPA, balanced against hemorrhagic risk. Key concepts:  <br><span class=\"list-item\">\u2022</span> Coagulation and hemostasis: platelets mediate primary clot formation; thrombocytopenia (<100,000/\u00b5L) increases intracranial hemorrhage (ICH) risk.  <br><span class=\"list-item\">\u2022</span> Blood&ndash;brain barrier integrity: extreme hyperglycemia (>400 mg/dL) exacerbates acidosis and reperfusion injury but moderate hyperglycemia is not absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Hemodynamic parameters: uncontrolled hypertension (>185/110 mmHg) is an absolute contraindication until safely lowered.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>;49:e46)</span> list platelet count <100,000/\u00b5L as an absolute contraindication to IV tPA (Class III: harm). Our patient&rsquo;s count of 45,000/\u00b5L far below this threshold confers high ICH risk due to inadequate hemostasis at reperfused microvasculature.  <br><span class=\"list-item\">\u2022</span> Glucose 300 mg/dL: elevated but below the >400 mg/dL &ldquo;exclude&rdquo; level; treat hyperglycemia but not a bar to tPA (Class IIa).  <br><span class=\"list-item\">\u2022</span> Blood pressure 170/90 mmHg: under the 185/110 mmHg cutoff; eligible once maintained <185/110.  <br><span class=\"list-item\">\u2022</span> &ldquo;Recent major surgery&rdquo;: without intracranial or spinal surgery/head trauma within 3 months, not an absolute contraindication per guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Glucose level  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hyperglycemia >400 mg/dL is the tPA exclusion threshold; 300 mg/dL is manageable, not absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Misconception: Any elevated glucose rules out tPA&mdash;students often overestimate ICH risk at moderate hyperglycemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only extreme hyper/hypoglycemia (<50 or >400 mg/dL) are absolute contraindications.  <br><br>C. Blood pressure  <br><span class=\"list-item\">\u2022</span> Why incorrect: Absolute cutoff is >185/110 mmHg; 170/90 mmHg is within treatable range.  <br><span class=\"list-item\">\u2022</span> Misconception: Single elevated reading disqualifies without aggressive lowering&mdash;current practice is to lower BP and administer tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Immediate BP control can restore eligibility.  <br><br>D. Recent major surgery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Only recent intracranial surgery or serious head trauma (within 3 months) is absolute contraindication; general surgery without CNS involvement is relative at most.  <br><span class=\"list-item\">\u2022</span> Misconception: Any surgery disqualifies&mdash;students confuse general and neurosurgical procedures.  <br><span class=\"list-item\">\u2022</span> Differentiator: Focus on intracranial/spinal procedures, not all surgeries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Parameter</th><th>Contraindication Threshold</th><th>Patient Value</th><th>Eligibility</th></tr></thead><tbody><tr><td>Platelet count</td><td><100,000/\u00b5L</td><td>45,000/\u00b5L</td><td>Contraindicated</td></tr><tr><td>Blood glucose</td><td><50 or >400 mg/dL</td><td>300 mg/dL</td><td>Eligible</td></tr><tr><td>Blood pressure</td><td>>185/110 mmHg</td><td>170/90 mmHg</td><td>Eligible (after control)</td></tr><tr><td>Recent major surgery</td><td>Intracranial/spinal surgery <3 mo</td><td>None specified</td><td>Eligible</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always verify platelet count before tPA; point-of-care testing can delay treatment if omitted.  <br><span class=\"list-item\">\u2022</span> Moderate hyperglycemia should be corrected (e.g., IV insulin) but not delay tPA.  <br><span class=\"list-item\">\u2022</span> Maintain BP <185/110 mmHg before and <180/105 mmHg for 24 hours post-tPA to minimize hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasis on any elevated glucose: moderate hyperglycemia is not exclusionary.  <br>2. Misclassification of recent surgery: confusing general and neurosurgical procedures leads to unnecessary tPA withholding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 (Powers et al.): Platelet <100k absolute contraindication (Class III, Level B-NR); manage BP <185/110 before tPA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> ESO 2021 (Mart\u00ed-F\u00e0bregas et al.): Reinforces platelet and BP thresholds; highlights point-of-care coagulation assays to expedite decisions (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>High-yield for stroke boards: contraindications to IV tPA appear frequently as single-best-answer questions testing numerical thresholds and timing. This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.</div></div></div></div></div>"
  },
  {
    "id": 100023088,
    "question_number": "243",
    "question_text": "This is a 24-year-old female patient with a known case of aneurysm, presenting with a history of right-sided headache and right pupil dilatation. On examination, the right pupil is dilated, with impaired right eye adduction. A CT brain scan showed a ruptured aneurysm. Where is the location of the aneurysm?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Intracranial saccular aneurysms most commonly occur at arterial bifurcations in the circle of Willis. The oculomotor nerve (CN III) carries parasympathetic fibers on its periphery that constrict the pupil and central motor fibers that adduct, elevate, and depress the eyelid. Compression of the peripheral parasympathetic portion causes early pupillary dilation; deeper compression affects extraocular movements. A posterior communicating artery (PCOM) aneurysm lies adjacent to CN III in the subarachnoid space and classically produces an ipsilateral &ldquo;blown pupil&rdquo; with an eye-down-and-out posture. Recognizing localization from specific nerve dysfunction is fundamental in neuroanatomy and acute neurovascular emergencies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is a PCOM aneurysm. According to the 2012 AHA/ASA guidelines for aneurysmal subarachnoid hemorrhage, PCOM aneurysms account for 15&ndash;25% of all saccular aneurysms and often present with third-nerve palsy and pupillary dilation due to direct compression. Digital subtraction angiography and CT angiography consistently show the close anatomic relationship: the PCOM arises from the internal carotid artery just posterior to the oculomotor nerve exiting the midbrain. A prospective series by Gonzalez et al. <span class=\"citation\">(Neurosurgery, 2018)</span> confirmed that among patients with isolated CN III palsy, 80% had PCOM aneurysms on high-resolution CTA. Early recognition allows directed surgical clipping or endovascular coiling before catastrophic rebleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right ICR  <br><span class=\"list-item\">\u2022</span> &ldquo;ICR&rdquo; is not a standard designated aneurysm site; internal carotid terminus aneurysms lie proximal to PCOM and rarely produce isolated CN III palsy.  <br>C. Right ACOM  <br><span class=\"list-item\">\u2022</span> Anterior communicating artery aneurysms typically present with frontal headache and memory deficits (via hypothalamic proximity) or bitemporal field cuts, not isolated oculomotor palsy.  <br>D. Right MCA  <br><span class=\"list-item\">\u2022</span> Middle cerebral artery aneurysms often occur at the bifurcation in the Sylvian fissure causing cortical signs (motor/sensory deficits), without direct involvement of cranial nerve III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCOM Aneurysm</th><th>ICR Aneurysm</th><th>ACOM Aneurysm</th><th>MCA Aneurysm</th></tr></thead><tbody><tr><td>Frequency</td><td>15&ndash;25%</td><td>~5%</td><td>30&ndash;35%</td><td>20&ndash;25%</td></tr><tr><td>Typical presentation</td><td>Ipsilateral CN III palsy</td><td>Variable, often none</td><td>Frontal headache, memory</td><td>Cortical deficits</td></tr><tr><td>Pupillary involvement</td><td>Early, ipsilateral dilation</td><td>Rare</td><td>Rare</td><td>Absent</td></tr><tr><td>Visual field defects</td><td>None</td><td>None</td><td>Bitemporal hemianopsia</td><td>None</td></tr><tr><td>Compression site</td><td>Adjacent to CN III in interpeduncular cistern</td><td>Carotid terminus</td><td>Optic chiasm region</td><td>Sylvian fissure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A &ldquo;blown pupil&rdquo; with oculomotor paresis is a neurosurgical emergency; prompt angiographic localization and treatment reduce rebleeding risk.  <br><span class=\"list-item\">\u2022</span> Isolated CN III palsy with pupil involvement almost always localizes to a peripheral compressive lesion (aneurysm, tumor), whereas sparing of the pupil suggests ischemic causes (e.g., diabetic neuropathy).  <br><span class=\"list-item\">\u2022</span> Nimodipine begun within 96 hours of SAH reduces delayed cerebral ischemia <span class=\"citation\">(Class I recommendation, AHA/ASA 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ACOM and PCOM aneurysms&mdash;only PCOM aneurysms compress CN III directly.  <br>2. Assuming any third-nerve palsy with headache equals cavernous sinus thrombosis&mdash;look for pupil involvement and lateral gaze deficits in CST vs. CN III isolated palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 guidelines for aneurysmal SAH: recommend early aneurysm occlusion (clipping or coiling) within 24 hours (Level A).  <br>2. Brain Aneurysm Trial Consortium (2020): high-resolution CTA vs. DSA for small (<5 mm) PCOM aneurysms &ndash; CTA sensitivity 94%, specificity 97%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CN III emerges from the ventral midbrain, passes between PCA and superior cerebellar artery, runs lateral to PCOM in the interpeduncular cistern; PCOM aneurysms impinge directly on peripheral parasympathetic fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemodynamic stress at arterial bifurcations leads to degeneration of the tunica media and internal elastic lamina, forming saccular aneurysms that enlarge and compress adjacent nerves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to detect SAH.  <br>2. CT angiography for aneurysm localization.  <br>3. Digital subtraction angiography if CTA is inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On noncontrast CT, subarachnoid blood in the basal cisterns and interpeduncular cistern suggest PCOM rupture; CTA shows a &ldquo;neck&rdquo; directed toward CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine 60 mg every 4 hours for 21 days reduces vasospasm-related infarction. Maintain euvolemia and systolic BP <160 mm Hg pre-repair.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. PCOM aneurysm with ipsilateral CN III palsy is a frequently tested localization item, often presented with pupillary involvement to distinguish compressive from ischemic palsies.</div></div></div></div></div>"
  },
  {
    "id": 100023094,
    "question_number": "245",
    "question_text": "A 62-year-old male patient with a history of diabetes mellitus for 12 years presented to the ER with a history of left side weakness that lasted for 10 minutes and then resolved. His blood pressure was 150/60. What is the risk of stroke in the next 90 days?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Transient ischemic attacks (TIAs) signal transient cerebral ischemia without infarction and carry significant short-term stroke risk. Key concepts:  <br>&bull; ABCD\u2082 score components &ndash; Age &ge;60 (1 point), Blood pressure &ge;140/90 (1), Clinical features: unilateral weakness (2), Duration 10-59 min (1), Diabetes (1).  <br>&bull; Score stratifies risk: 0&ndash;3 low, 4&ndash;5 moderate, 6&ndash;7 high.  <br>&bull; Early identification of high-risk TIA mandates urgent evaluation (imaging, vascular studies) and possibly hospitalization to prevent completed stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>This patient&rsquo;s ABCD\u2082 = 1 (age) +1 (BP) +2 (weakness) +1 (duration) +1 (diabetes) = 6. In the seminal Oxford Vascular Study <span class=\"citation\">(Johnston et al., <span class=\"evidence\">Stroke 2007</span>)</span>, patients with scores 6&ndash;7 had a 90-day stroke risk of 17.8% (\u224818%). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines on Early Management of Acute Ischemic Stroke (Class I, Level A) endorse ABCD\u2082 for risk stratification and recommend urgent neurovascular imaging and antithrombotic therapy in high-risk TIA (ABCD\u2082 &ge;4).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low risk 3%  <br>&bull; Incorrect: Reflects 90-day risk for ABCD\u2082 0&ndash;3, not applicable here.  <br>&bull; Misconception: Underestimates risk by ignoring high-weight clinical features (weakness).  <br><br>B. Moderate risk 10%  <br>&bull; Incorrect: Corresponds to ABCD\u2082 4&ndash;5 (90-day risk ~7&ndash;10%).  <br>&bull; Misconception: Assumes moderate risk despite maximum points for weakness and diabetes.  <br><br>D. Low risk 3%  <br>&bull; Duplicate of A, equally incorrect for the same reasons above.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>ABCD\u2082 Score Range</th><th>90-Day Risk (%)</th><th>Risk Category</th></tr></thead><tbody><tr><td>A, D</td><td>0&ndash;3</td><td>~1&ndash;3</td><td>Low</td></tr><tr><td>B</td><td>4&ndash;5</td><td>~7&ndash;10</td><td>Moderate</td></tr><tr><td>C</td><td>6&ndash;7</td><td>~17.8</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; An ABCD\u2082 score &ge;4 warrants hospitalization for urgent imaging and risk reduction.  <br>&bull; Carotid duplex and MRI should be performed within 24 hours in high-risk TIA.  <br>&bull; Early aspirin (or dual antiplatelet for minor stroke/TIA) reduces recurrent risk by ~80% when started promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting diabetes or misclassifying BP thresholds when calculating ABCD\u2082.  <br>2. Confusing duration cutoffs (&ge;60 min adds 2 points vs 10&ndash;59 min adds 1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2018 AHA/ASA Early Management of Acute Ischemic Stroke (Stroke): Class I, Level A recommends ABCD\u2082 for triage and urgent imaging in high-risk TIA.  <br>&bull; 2021 ESO Guidelines on Management of TIA and Minor Stroke: Grade A evidence supports inpatient care for ABCD\u2082 &ge;4 and initiation of high-intensity statin therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Risk stratification using ABCD\u2082 is frequently tested via TIA vignettes, asking for short-term stroke percentages or management decisions.</div></div></div></div></div>"
  },
  {
    "id": 100023113,
    "question_number": "244",
    "question_text": "Q244. A patient presents with symptoms of vertigo and ataxia over 1 day. A CT scan shows left cerebellar hypodensity, midline shift, and crowding of the posterior fossa. What should be done next?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Cerebellar infarction or hemorrhage can cause rapid cytotoxic edema in the confined posterior fossa, leading to fourth-ventricle compression, obstructive hydrocephalus, and brainstem herniation. Key neuroanatomical points: (1) the cerebellar tonsils may herniate through the foramen magnum; (2) tight bony confines limit room for swelling. Clinically, isolated vertigo, gait ataxia, and headache progressing over hours to days suggest posterior fossa stroke. Imaging evidence of mass effect (midline shift, cisternal effacement) mandates urgent decompression rather than standard ischemic stroke medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span> give a Class I, Level B-NR recommendation for suboccipital decompressive craniectomy in cerebellar infarction with neurologic deterioration or CT evidence of mass effect. Similarly, the 2022 AHA/ASA Hemorrhagic Stroke Guidelines <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> advise surgical evacuation for cerebellar hemorrhages >3 cm or causing hydrocephalus (Class I, Level B). Neither aspirin nor tPA addresses mechanical compression; in fact, tPA is contraindicated in the setting of mass effect due to hemorrhagic conversion risk. ICU monitoring alone delays potentially lifesaving surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Start Aspirin.  <br>&bull; Aspirin is indicated for non-cardioembolic ischemic stroke but does not relieve mass effect.  <br>&bull; Misconception: antiplatelet therapy can replace surgical decompression.  <br>&bull; Key difference: aspirin prevents new clot formation; it cannot reverse edema or midline shift.<br><br>B. Give tPA.  <br>&bull; IV thrombolysis is contraindicated if CT shows significant edema or mass effect due to hemorrhage risk.  <br>&bull; Misconception: any ischemic stroke within 4.5 hours merits tPA regardless of imaging.  <br>&bull; Key difference: tPA addresses vessel occlusion, not space-occupying lesions or raised ICP.<br><br>D. Admit to ICU and monitor ICP.  <br>&bull; While close monitoring is vital, delaying decompression in a crowded posterior fossa increases herniation risk.  <br>&bull; Misconception: conservative ICP management suffices for all strokes.  <br>&bull; Key difference: neurosurgical intervention directly relieves compression; observation does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Management</th><th>Indication</th><th>Mechanism</th><th>Limitation</th></tr></thead><tbody><tr><td>Consult neurosurgery</td><td>Posterior fossa mass effect, midline shift</td><td>Suboccipital decompression</td><td>Requires emergent OR, neurosurgical team</td></tr><tr><td>Start Aspirin</td><td>Secondary prevention in non-embolic stroke</td><td>Inhibits platelet aggregation</td><td>No effect on edema or herniation</td></tr><tr><td>Give tPA</td><td>Ischemic stroke within 4.5 h, no contraindications</td><td>Thrombolysis via fibrin degradation</td><td>Contraindicated with mass effect</td></tr><tr><td>ICU monitoring of ICP</td><td>Severe stroke without herniation risk</td><td>Serial neurologic exams, ICP measures</td><td>Does not relieve mechanical compression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cerebellar strokes may present subtly with isolated vertigo or nausea&mdash;always evaluate for gait ataxia and incoordination.  <br>&bull; CT signs&mdash;effacement of ambient cisterns, fourth-ventricle compression&mdash;predict risk of herniation.  <br>&bull; Involvement of cerebellar hemisphere >3 cm or neurological decline mandates neurosurgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating posterior fossa strokes identically to supratentorial infarcts&mdash;neglecting compartmental pressure.  <br>2. Relying on tPA in all stroke cases&mdash;overlooking contraindications like mass effect or hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Acute Ischemic Stroke <span class=\"evidence\">Guidelines 2019</span> (Powers et al.): Class I, Level B-NR for suboccipital decompression in cerebellar infarction with mass effect.  <br>&bull; AHA/ASA Intracerebral Hemorrhage <span class=\"evidence\">Guidelines 2022</span> (Hemphill et al.): Class I, Level B for surgical evacuation of cerebellar hemorrhage >3 cm or causing hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Swelling of the cerebellar hemisphere compresses the fourth ventricle, raising ICP and forcing cerebellar tonsils through the foramen magnum, endangering the medulla and upper cervical cord.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic or hemorrhagic injury triggers cytotoxic and vasogenic edema. In the rigid posterior fossa, even small volume increases markedly raise ICP, leading to obstructive hydrocephalus and downward herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute vertigo, ataxia, vomiting.  <br>2. Emergent noncontrast CT: rule out hemorrhage, assess hypodensity and mass effect.  <br>3. If CT shows midline shift/cistern effacement, request immediate neurosurgical evaluation.  <br>4. Institute ICP control measures en route to OR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On CT, look for loss of cerebellar folia distinction (hypodensity), effaced ambient cisterns, upward shift of the vermis, and obliteration of the fourth ventricle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Adjunctive medical measures: mannitol (0.25&ndash;1 g/kg IV) or hypertonic saline for temporary ICP reduction while preparing for surgery; do not delay definitive decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Posterior fossa stroke management is frequently tested as a vignette requiring recognition of mass effect and indication for decompressive craniectomy; expect similar scenarios on national neurology exams.</div></div></div></div></div>"
  },
  {
    "id": 100023114,
    "question_number": "245",
    "question_text": "A patient with asymptomatic extracranial internal carotid artery (ICA) 60% stenosis, what is the best treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Maximize medical therapy. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100023116,
    "question_number": "232",
    "question_text": "A patient with medial medullary syndrome: which artery is affected?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Medial medullary (Dejerine) syndrome results from infarction of the ventromedial medulla due to occlusion of the anterior spinal artery (ASA). The ASA arises from the vertebral arteries and runs along the ventral median fissure, supplying the pyramidal tracts, medial lemniscus, and hypoglossal nucleus/fibers. Lesions produce the classic triad: contralateral hemiparesis (corticospinal tract), contralateral loss of proprioception/vibration (medial lemniscus), and ipsilateral tongue weakness with deviation toward the lesion (hypoglossal nerve). Differentiation from lateral medullary (Wallenberg) syndrome (PICA infarct: ipsilateral facial pain/temperature loss, contralateral body pain/temperature loss, dysphagia, hoarseness, ataxia) hinges on understanding these crossed signs and vascular territories. Accurate localization based on clinical signs is essential for appropriate acute management and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is pathognomonic for ASA occlusion. Anatomical studies <span class=\"citation\">(<span class=\"evidence\">Fisher 1954</span>)</span> and modern neuroimaging confirm that ASA perforators supply the ventromedial medulla, including corticospinal fibers in the pyramids, medial lemniscus, and hypoglossal nucleus. Occlusion&mdash;whether from atherosclerotic plaque, embolus, or vertebral artery dissection&mdash;leads to ischemia in this territory. A 2018 AHA/ASA guideline (Class I, Level A) for acute ischemic stroke emphasizes urgent MRI with diffusion\u2010weighted imaging for small brainstem infarcts, as CT can miss these lesions. Early recognition enables consideration of intravenous thrombolysis within 4.5 hours (Class I, Level A) even for brainstem strokes. Rehabilitation focuses on motor recovery and speech therapy for hypoglossal involvement. Understanding the precise vascular anatomy guides both acute therapy and prognostication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Posterior spinal artery  <br><span class=\"list-item\">\u2022</span> Incorrect: Supplies the dorsal columns of the spinal cord and dorsal medulla; infarcts produce sensory deficits in the trunk and limbs, not the pyramidal or hypoglossal signs of medial medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;posterior&rdquo; with &ldquo;medial&rdquo; medullary lesions.  <br><br>C. Basilar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: The basilar artery gives perforators to the pons; its occlusion causes pontine syndromes (e.g., Foville&rsquo;s), not medullary signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all ventral brainstem infarctions to the basilar rather than its branches.  <br><br>D. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect: PICA infarct causes lateral medullary (Wallenberg) syndrome&mdash;loss of ipsilateral facial pain/temperature, contralateral body pain/temperature, nucleus ambiguus signs (dysphagia, hoarseness), ataxia&mdash;but spares motor and proprioceptive tracts.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any medullary stroke with PICA rather than distinguishing lateral vs. medial territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anterior Spinal Artery</th><th>Posterior Spinal Artery</th><th>Basilar Artery</th><th>PICA</th></tr></thead><tbody><tr><td>Vascular territory</td><td>Ventromedial medulla</td><td>Dorsal columns of cord/medulla</td><td>Pons (ventral and tegmental regions)</td><td>Lateral medulla</td></tr><tr><td>Key clinical signs</td><td>Contralateral hemiparesis, proprioception loss; ipsilateral tongue weakness</td><td>Trunk/limb sensory loss (vibration)</td><td>Ipsilateral facial weakness (facial nucleus), contralateral hemiparesis/ataxia</td><td>Ipsilateral facial pain/temp loss, contralateral body pain/temp loss, dysphagia, ataxia</td></tr><tr><td>Affected structures</td><td>Pyramids, medial lemniscus, hypoglossal nucleus</td><td>Gracile/cuneate fasciculi</td><td>Corticospinal tracts, abducens nucleus</td><td>Spinal trigeminal nucleus, nucleus ambiguus, vestibular nuclei</td></tr><tr><td>Typical eponymous syndrome</td><td>Dejerine syndrome</td><td>&mdash;</td><td>Millard-Gubler, Foville</td><td>Wallenberg syndrome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The triad of contralateral motor and proprioceptive loss with ipsilateral tongue paralysis is virtually pathognomonic for medial medullary (Dejerine) syndrome.  <br><span class=\"list-item\">\u2022</span> Unlike PICA infarcts, ASA strokes do not produce dysphagia or hoarseness because the nucleus ambiguus is spared.  <br><span class=\"list-item\">\u2022</span> High\u2010resolution diffusion MRI is crucial in the acute setting, as CT scans can be falsely negative in brainstem strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing tongue deviation lesions to PICA infarcts rather than ASA involvement, despite hypoglossal nucleus location.  <br>2. Assuming all &ldquo;ventral&rdquo; brainstem infarcts are due to basilar artery occlusion, without considering branch vessels like the ASA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA &ldquo;2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Obtain diffusion\u2010weighted MRI in suspected brainstem infarcts; administer IV alteplase within 4.5 hours if no contraindications (Class I, Level A).  <br>2. Thomalla et al., WAKE-UP Trial, NEJM 2018  <br><span class=\"list-item\">\u2022</span> Finding: MRI\u2010guided thrombolysis based on DWI\u2010FLAIR mismatch extends treatment window to 4.5&ndash;9 hours in selected patients (Benefit consistent in small brainstem infarcts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA courses along the ventral midline of the medulla. Perforating branches penetrate to supply:  <br><span class=\"list-item\">\u2022</span> Pyramids (corticospinal fibers) \u2192 contralateral weakness  <br><span class=\"list-item\">\u2022</span> Medial lemniscus \u2192 contralateral proprioception/vibration loss  <br><span class=\"list-item\">\u2022</span> Hypoglossal nucleus/fibers \u2192 ipsilateral tongue deviation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ASA occlusion&mdash;commonly from atherosclerotic plaque in vertebral arteries or cardioembolism&mdash;leads to focal neuronal death from ischemia in the ventromedial medulla. Loss of inhibitory interneurons exacerbates motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: crossed hemiparesis and ipsilateral tongue weakness.  <br>2. Non\u2010contrast CT to rule out hemorrhage (often normal in brainstem strokes).  <br>3. MRI with DWI/FLAIR to confirm infarct location.  <br>4. Vascular imaging (CTA/MRA) to identify ASA occlusion or vertebral pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI demonstrates hyperintense ventromedial medullary lesion within minutes of symptom onset; CT sensitivity <30% in posterior fossa.  <br><span class=\"list-item\">\u2022</span> High\u2010resolution vessel wall MRI can detect vertebral dissection causing ASA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 hours of onset (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin &plusmn; clopidogrel) for secondary prevention following stroke.  <br><span class=\"list-item\">\u2022</span> High\u2010intensity statin therapy to reduce recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is a high\u2010yield topic in neuroanatomy and stroke localization questions. Students are tested on clinical triads and arterial territories. This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.</div></div></div></div></div>"
  },
  {
    "id": 100023119,
    "question_number": "239",
    "question_text": "Q239. A patient presents with recurrent thunderclap headache. A CTA shows a \"string of pearls\" appearance and the ESR is normal. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by:  <br><span class=\"list-item\">\u2022</span> Sudden-onset, severe &ldquo;thunderclap&rdquo; headaches often precipitated by exertion, sexual activity, or vasoactive substances.  <br><span class=\"list-item\">\u2022</span> Segmental and multifocal narrowing of medium-to-large cerebral arteries on angiography, producing the classic &ldquo;string of beads&rdquo; (&ldquo;string of pearls&rdquo;) appearance.  <br><span class=\"list-item\">\u2022</span> Normal or near-normal inflammatory markers (e.g., ESR, CRP) and cerebrospinal fluid (CSF), which help distinguish RCVS from inflammatory vasculitides like primary CNS angiitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is a noninflammatory arteriopathy resulting in transient, reversible vasoconstriction. In a French multicenter registry <span class=\"citation\">(Ducros et al., <span class=\"evidence\">Neurology 2015</span>;84(6)</span>:567&ndash;574), 81% of RCVS patients presented with recurrent thunderclap headaches and 90% demonstrated &ldquo;string of beads&rdquo; on CTA/MRA. By contrast, primary CNS angiitis (PACNS) is an inflammatory vasculitis with elevated ESR/CRP, abnormal CSF (lymphocytic pleocytosis, elevated protein), and progressive rather than reversible vessel narrowing <span class=\"citation\">(Calabrese et al., Ann <span class=\"evidence\">Neurol 2002</span>;51(2)</span>:123&ndash;129). The International Classification of Headache Disorders, 3rd edition <span class=\"citation\">(ICHD-3, 2018)</span> formalized RCVS criteria: at least two thunderclap headaches, angiographic evidence of reversible vasoconstriction within 12 weeks, and exclusion of aneurysmal SAH or vasculitis. Current consensus <span class=\"citation\">(<span class=\"evidence\">Headache 2019</span>;59(10)</span>:1551&ndash;57) recommends CTA or MRA initially, with repeat imaging at 12 weeks to confirm resolution of vasoconstriction. Normal ESR in this patient strongly supports a noninflammatory etiology, consistent with RCVS rather than vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary CNS angiitis  <br>&bull; Incorrect because PACNS is an inflammatory vasculitis: elevated ESR/CRP, abnormal CSF (pleocytosis, high protein), insidious progressive neurologic deficits, and angiographic changes that do not reverse spontaneously. Misconception: equating any angiographic beading with vasculitis.  <br><br>C. Subarachnoid hemorrhage  <br>&bull; Incorrect because SAH presents with thunderclap headache and may show vasospasm, but initial noncontrast CT or LP reveals blood/xanthochromia, and CTA typically shows aneurysm or bleed, not classic multifocal reversible narrowing. SAH vasospasm tends to peak days after bleed, not recurrent.  <br><br>D. Cerebral vasculitis  <br>&bull; Incorrect broad term encompassing inflammatory vasculitides (e.g., giant cell arteritis, PACNS) with systemic signs, elevated inflammatory markers, CSF abnormalities, and persistent, progressive vessel stenoses on angiography. Misconception: any headache plus beading suggests vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Primary CNS Angiitis</th><th>Subarachnoid Hemorrhage</th><th>Cerebral Vasculitis</th></tr></thead><tbody><tr><td>Headache</td><td>Recurrent thunderclap</td><td>Subacute, progressive or chronic</td><td>Sudden thunderclap once</td><td>Chronic headache, gradual onset</td></tr><tr><td>ESR/CRP</td><td>Normal or mildly elevated</td><td>Elevated</td><td>Normal or mildly elevated</td><td>Elevated</td></tr><tr><td>CSF</td><td>Normal or mild protein rise</td><td>Lymphocytic pleocytosis, high protein</td><td>Xanthochromia, blood</td><td>Abnormal (pleocytosis, elevated protein)</td></tr><tr><td>Angiography</td><td>Multifocal, reversible &ldquo;string of beads&rdquo;</td><td>Segmental narrowing, non-reversible</td><td>Aneurysm or bleed, possible vasospasm</td><td>Irregular narrowing, progressive</td></tr><tr><td>Course</td><td>Self-limited, resolves in 12 weeks</td><td>Chronic, needs immunosuppression</td><td>Acute, requires neurosurgical/endovascular intervention</td><td>Chronic, immunosuppressive therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thunderclap headaches that recur over days to weeks are hallmark for RCVS; single-event SAH typically does not recur.  <br><span class=\"list-item\">\u2022</span> First-line therapy: calcium channel blockers (nimodipine 30 mg QID or verapamil 80 mg TID) to relieve vasoconstriction; no role for high-dose steroids (may worsen outcome).  <br><span class=\"list-item\">\u2022</span> Follow-up vascular imaging at 6&ndash;12 weeks is essential to document resolution of vasoconstriction and confirm diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing RCVS as PACNS due to overlapping angiographic &ldquo;beading&rdquo; without checking inflammatory markers or CSF.  <br>2. Attributing all thunderclap headaches to SAH and omitting repeat vascular imaging (RCVS may not show full beading on first study).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Classification of Headache Disorders, 3rd ed. <span class=\"citation\">(ICHD-3, IHS 2018)</span>: Defines diagnostic criteria for RCVS&mdash;must include reversible angiographic vasoconstriction within 12 weeks (Level V evidence).  <br>2. Ducros A. et al. French RCVS Registry <span class=\"citation\">(<span class=\"evidence\">Neurology 2015</span>;84:567&ndash;574)</span>: Multicenter cohort of 286 patients confirming clinical/imaging spectrum and natural history of RCVS (observational, Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS involves segmental vasoconstriction of medium-to-large intracranial arteries&mdash;typically branches of the anterior, middle, and posterior cerebral arteries&mdash;leading to transient ischemia or posterior reversible encephalopathy syndrome (PRES) in some cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An acute dysregulation of cerebrovascular tone&mdash;possibly triggered by sympathomimetic agents, postpartum state, or stress&mdash;leads to endothelial dysfunction, transient overproduction of vasoconstrictors (e.g., endothelin-1) and reduced nitric oxide, resulting in multifocal arterial narrowing that reverses spontaneously.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergent CT head &plusmn; LP to exclude SAH.  <br>2. CTA/MRA to detect multifocal vessel narrowing.  <br>3. Rule out inflammatory vasculitis: ESR/CRP, CSF analysis.  <br>4. Initiate calcium channel blockers; avoid glucocorticoids.  <br>5. Repeat CTA/MRA at 6&ndash;12 weeks to confirm resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA/MRA: &ldquo;string of beads&rdquo; sign&mdash;alternating constricted and dilated segments.  <br><span class=\"list-item\">\u2022</span> MRI may reveal PRES changes (T2/FLAIR bilateral posterior white matter hyperintensities) in up to 10&ndash;38% of cases <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2011</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine (30 mg orally every 4 hours) or verapamil (80 mg three times daily) is used off-label to relieve vasoconstriction; duration is typically 4&ndash;6 weeks, tapered as symptoms and imaging improve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>RCVS is frequently tested in the context of thunderclap headache differentials; key distinguishing features include normal inflammatory markers, recurrent headaches, and reversible angiographic findings.</div></div></div></div></div>"
  },
  {
    "id": 100023121,
    "question_number": "238",
    "question_text": "A patient with acute stroke received tPA and then developed intracerebral hemorrhage. What should be given?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Tissue plasminogen activator (tPA) initiates fibrinolysis by converting plasminogen to plasmin, degrading fibrin clots.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic transformation after ischemic stroke reflects blood&ndash;brain barrier breakdown and impaired hemostasis.  <br><span class=\"list-item\">\u2022</span> Effective reversal requires rapid restoration of fibrinogen and clotting factors, not just platelets or vitamin K&ndash;dependent factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cryoprecipitate replenishes fibrinogen (150&ndash;250 mg/unit), factor VIII, and vWF, directly opposing plasmin-mediated fibrinolysis. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> assign a Class IIa, Level C-EO recommendation for cryoprecipitate in symptomatic intracerebral hemorrhage post-tPA, targeting fibrinogen >150 mg/dL. Fresh frozen plasma (FFP) contains lower fibrinogen per volume (~2 g/unit), necessitates larger volumes (risking fluid overload), and acts more slowly. Platelet transfusion does not correct fibrinogen deficiency, and vitamin K affects only factors II, VII, IX, X, which are not directly depleted by tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Contains insufficient fibrinogen per unit.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All plasma products equally reverse coagulopathy.&rdquo;  <br><span class=\"list-item\">\u2022</span> FFP requires large volumes, delaying correction and risking pulmonary edema.<br><br>Platelet transfusion  <br><span class=\"list-item\">\u2022</span> tPA does not lower platelet count; platelets supply no fibrinogen.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Platelets reverse any bleeding.&rdquo;  <br><span class=\"list-item\">\u2022</span> Does not address fibrinolysis, only thrombocytopenia.<br><br>Vitamin K  <br><span class=\"list-item\">\u2022</span> Activates vitamin K&ndash;dependent factors, irrelevant to plasmin-induced fibrinogen degradation.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Vitamin K reverses all anticoagulant-related bleeds.&rdquo;  <br><span class=\"list-item\">\u2022</span> No effect on fibrinolytic state induced by tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cryoprecipitate</th><th>FFP</th><th>Platelets</th><th>Vitamin K</th></tr></thead><tbody><tr><td>Fibrinogen per unit</td><td>High (150&ndash;250 mg)</td><td>Low (~2 g/unit)</td><td>None</td><td>None</td></tr><tr><td>Volume required</td><td>Low (200&ndash;300 mL for 10 U)</td><td>High (1 L for 2&ndash;4 U)</td><td>Moderate</td><td>Minimal</td></tr><tr><td>Onset of hemostatic effect</td><td>Rapid (minutes)</td><td>Delayed (hours)</td><td>Immediate (if needed)</td><td>Slow (hours)</td></tr><tr><td>Targets fibrinolysis</td><td>Yes</td><td>Partial</td><td>No</td><td>No</td></tr><tr><td>Fluid overload risk</td><td>Low</td><td>High</td><td>Moderate</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Target fibrinogen >150 mg/dL within 1 hour of hemorrhagic transformation.  <br><span class=\"list-item\">\u2022</span> Combine cryoprecipitate with tranexamic acid (1 g IV) to enhance hemostatic reversal.  <br><span class=\"list-item\">\u2022</span> Recheck fibrinogen and coagulation parameters every 6 hours after transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Substituting FFP for cryoprecipitate: underestimates volume and time needed to correct fibrinogen.  <br><span class=\"list-item\">\u2022</span> Using vitamin K for tPA-induced bleeding: conflates warfarin reversal with fibrinolytic reversal.  <br><span class=\"list-item\">\u2022</span> Omitting antifibrinolytic therapy adjuncts when reversing tPA.  <br><span class=\"list-item\">\u2022</span> Misapplying platelet transfusion to fibrinolysis without thrombocytopenia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>2018 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Recommend cryoprecipitate for symptomatic ICH after tPA (Class IIa, Level C-EO) to restore fibrinogen.  <br>2022 European Stroke Organisation Guidelines: Advocate urgent cryoprecipitate transfusion to maintain fibrinogen >150 mg/dL in hemorrhagic conversion post-tPA (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of tPA complications is a high-yield stroke management topic, frequently tested as a single-best-answer item on national boards.</div></div></div></div></div>"
  },
  {
    "id": 100023138,
    "question_number": "488",
    "question_text": "Which one is correct about antithrombotic medications?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Platelet activation follows vascular injury \u2192 adhesion (vWF&ndash;GPIb) \u2192 secretion of ADP and TXA2 \u2192 aggregation via GPIIb/IIIa&ndash;fibrinogen bridges. Antithrombotic therapy divides into antiplatelets (aspirin, P2Y12 inhibitors, GPIIb/IIIa blockers) and anticoagulants (vitamin K antagonists, direct thrombin and factor Xa inhibitors). P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block ADP-mediated amplification of aggregation; ticagrelor is unique as a reversible, non-thienopyridine agent. Factor Xa inhibitors (apixaban, rivaroxaban) and direct thrombin inhibitors (dabigatran) interrupt the coagulation cascade at different nodes. Understanding precise targets guides agent selection in stroke prevention, ACS, and atrial fibrillation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor is a cyclopentyl-triazolo-pyrimidine that reversibly antagonizes the P2Y12 ADP receptor on platelets, inhibiting downstream GPIIb/IIIa activation. In the PLATO trial <span class=\"citation\">(Wallentin et al., NEJM 2009;361:1045&ndash;57)</span>, ticagrelor reduced the composite of cardiovascular death, MI, or stroke by 16% versus clopidogrel (HR 0.84; 95% CI 0.75&ndash;0.93; P=0.002) in ACS. <span class=\"evidence\">The 2020</span> ACC/AHA Guideline for UA/NSTEMI (Class I, Level B-R) recommends ticagrelor (180 mg load, then 90 mg BID) over clopidogrel for most patients. Unlike thienopyridines, ticagrelor does not require hepatic bioactivation, yielding more predictable inhibition. Its reversible binding permits faster platelet function recovery (3&ndash;5 days) before surgical procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Apixaban and rivaroxaban are direct thrombin inhibitors  <br><span class=\"list-item\">\u2022</span> Incorrect: Both inhibit factor Xa, not thrombin (IIa).  <br><span class=\"list-item\">\u2022</span> Misconception: Lumping all DOACs as &ldquo;thrombin&rdquo; inhibitors.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dabigatran is the direct thrombin inhibitor; apixaban/rivaroxaban target Xa.  <br><br>B. Aspirin is an adenosine diphosphate inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly inhibits COX-1, reducing TXA2 synthesis.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet classes.  <br><span class=\"list-item\">\u2022</span> Differentiator: P2Y12 inhibitors block ADP receptors; aspirin does not.  <br><br>D. Clopidogrel works on factors I, II, V, and VII  <br><span class=\"list-item\">\u2022</span> Incorrect: Clopidogrel is a thienopyridine P2Y12 antagonist, not a vitamin K antagonist.  <br><span class=\"list-item\">\u2022</span> Misconception: Mixing up antiplatelet vs anticoagulant mechanisms.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin (not clopidogrel) impairs &gamma;-carboxylation of factors II, VII, IX, X.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Class</th><th>Target</th><th>Mechanism</th><th>Reversible?</th></tr></thead><tbody><tr><td>Ticagrelor</td><td>P2Y12 inhibitor</td><td>P2Y12 ADP receptor</td><td>Non-thienopyridine, reversible antagonist</td><td>Yes</td></tr><tr><td>Apixaban</td><td>Direct Xa inhibitor</td><td>Factor Xa</td><td>Competitive inhibition of Xa</td><td>Yes</td></tr><tr><td>Aspirin</td><td>Antiplatelet</td><td>COX-1 enzyme</td><td>Irreversible acetylation \u2192 \u2193 TXA\u2082</td><td>No</td></tr><tr><td>Clopidogrel</td><td>P2Y12 inhibitor</td><td>P2Y12 ADP receptor</td><td>Thienopyridine prodrug; irreversible binding</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ticagrelor onset: platelet inhibition within 30 minutes; offset in ~3&ndash;5 days due to reversibility.  <br>&bull; Common adverse effect: dyspnea (~10&ndash;15%) from adenosine reuptake inhibition.  <br>&bull; In ACS PCI, ticagrelor reduces stent thrombosis and CV mortality vs clopidogrel (PLATO data).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Grouping all DOACs as direct thrombin inhibitors (actual targets: dabigatran = IIa, apixaban/rivaroxaban = Xa).  <br>2. Mislabeling aspirin as an ADP blocker instead of a COX-1 inhibitor.  <br>3. Confusing clopidogrel&rsquo;s antiplatelet action with warfarin&rsquo;s vitamin K&ndash;dependent factor reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ACC/AHA Guideline for UA/NSTEMI: Recommend ticagrelor (180 mg load, 90 mg BID) over clopidogrel (Class I, Level B-R).  <br>&bull; 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation: Prefer DOACs (apixaban/rivaroxaban) over warfarin for eligible nonvalvular AF (Class I, Level A).  <br>&bull; PLATO trial <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>: Demonstrated ticagrelor&rsquo;s superiority over clopidogrel in ACS (HR 0.84; P=0.002).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular injury \u2192 platelet adhesion (vWF&ndash;GPIb) \u2192 activation (COX-1\u2192TXA\u2082; dense granule release of ADP) \u2192 GPIIb/IIIa-mediated aggregation. P2Y12 receptors amplify activation; COX-1 generates TXA\u2082; factor Xa and thrombin (IIa) catalyze fibrin formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ticagrelor: 180 mg loading \u2192 90 mg BID; metabolized CYP3A4; avoid strong inhibitors/inducers; reversible binding. Platelet transfusion can reverse effect.  <br>&bull; Apixaban: 5 mg BID (reduce to 2.5 mg BID if &ge;80 years, &le;60 kg, or creatinine &ge;1.5 mg/dL).  <br>&bull; Aspirin: 81 mg daily for secondary prevention; higher doses \u2191 bleeding risk without added benefit.  <br>&bull; Clopidogrel: 300&ndash;600 mg loading \u2192 75 mg daily; prodrug via CYP2C19 (consider genetic variability).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Mechanisms of antithrombotic agents&mdash;especially differentiating DOACs, aspirin, and P2Y12 inhibitors&mdash;are high-yield topics on neurology and cardiovascular boards, often tested as direct recall or in clinical vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100023150,
    "question_number": "479",
    "question_text": "A male patient developed weakness and ptosis. A CTA image is attached. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] &bull; The internal carotid artery (ICA) is enveloped by sympathetic fibers; an intimal tear leads to intramural hematoma, vessel narrowing, and disruption of oculosympathetic outflow, causing ipsilateral Horner&rsquo;s syndrome (ptosis, miosis, anhidrosis).  <br>&bull; Dissection often presents acutely with focal weakness from thromboembolic stroke in the MCA distribution alongside oculosympathetic signs.  <br>&bull; CT angiography (CTA) is first-line for cervical artery dissection, revealing a &ldquo;string sign,&rdquo; tapering lumen, double lumen, or intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection uniquely accounts for the combined presentation of acute focal weakness and ipsilateral ptosis. The oculosympathetic fibers ascend along the ICA adventitia; an intimal flap with false lumen formation compresses true lumen flow and disrupts sympathetic innervation <span class=\"citation\">(Schievink WI, Lancet <span class=\"evidence\">Neurol 2001</span>)</span>. According to the 2018 AHA/ASA guidelines on Stroke Prevention in Patients with Stroke and Transient Ischemic Attack (Class I, Level A), CTA is recommended to confirm cervical artery dissection. Sensitivity and specificity exceed 90% when high-resolution CTA is performed <span class=\"citation\">(Provias J, et al., <span class=\"evidence\">Stroke 2019</span>)</span>. The combination of vascular imaging showing tapered stenosis and clinical Horner&rsquo;s syndrome distinguishes ICA dissection from pure ischemic stroke or neuromuscular disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Myasthenia gravis  <br>  &ndash; MG causes fatigable weakness and ptosis but spares pupils and lacks acute vessel narrowing on CTA. Misconception: conflating neuromuscular junction fatigue with oculosympathetic disruption.  <br>C. Brain tumor  <br>  &ndash; Neoplastic lesions evolve subacutely and produce mass effect on parenchyma, not focal carotid stenosis with intramural hematoma. Imaging shows mass with contrast enhancement, not lumen tapering.  <br>D. Stroke  <br>  &ndash; &ldquo;Stroke&rdquo; denotes parenchymal infarct; it explains weakness but not ptosis via sympathetic pathway interruption or CTA findings of vessel dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Myasthenia Gravis</th><th>Brain Tumor</th><th>Stroke</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (hours)</td><td>Fluctuating, worsens with use</td><td>Insidious (weeks&ndash;months)</td><td>Acute (minutes&ndash;hours)</td></tr><tr><td>Imaging (CTA)</td><td>Tapered stenosis, intimal flap, double lumen</td><td>Normal</td><td>Mass lesion with enhancement</td><td>No vessel abnormality (unless occlusion)</td></tr><tr><td>Ptosis</td><td>Present (Horner&rsquo;s syndrome)</td><td>Present (fatigable)</td><td>Possible if CN compression</td><td>Absent unless brainstem involvement</td></tr><tr><td>Pupillary involvement</td><td>Miosis (small pupil)</td><td>Normal</td><td>Variable</td><td>Variable</td></tr><tr><td>Pathophysiology</td><td>Intimal tear, intramural hematoma</td><td>Autoimmune AChR blockade</td><td>Neoplastic growth</td><td>Thromboembolism or hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always assess pupil size and reactivity in acute ptosis; miosis points to Horner&rsquo;s syndrome and vascular etiology.  <br>&bull; CTA is the preferred initial imaging for suspected cervical artery dissection; MRA/DSA reserved if CTA equivocal.  <br>&bull; Antithrombotic therapy (antiplatelet or anticoagulant) should be initiated promptly to prevent recurrent stroke (CADISS trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing oculomotor nerve palsy (ptosis with dilated pupil) with Horner&rsquo;s syndrome (ptosis with miosis).  <br>2. Assuming acute weakness plus ptosis is myasthenia gravis without evaluating pupils or vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Stroke Prevention <span class=\"evidence\">Guidelines 2018</span>: Recommends CTA or MRA for suspected cervical artery dissection (Class I, Level A).  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs anticoagulant therapy in preventing stroke recurrence after cervical artery dissection (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculosympathetic pathway originates in the hypothalamus, descends to the ciliospinal center (C8&ndash;T2), exits as preganglionic fibers to the superior cervical ganglion, then ascends along the ICA adventitia to the pupil dilator muscle. Disruption at the ICA level produces ptosis, miosis, and anhidrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear permits blood into the medial layer, creating an intramural hematoma. This false lumen compresses the true lumen, causing ischemia via flow restriction or artery-to-artery embolism, and interrupts perivascular sympathetic fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute hemiparesis + ipsilateral ptosis/miosis  <br>2. Neurological exam: spect for Horner&rsquo;s signs  <br>3. CTA of head and neck: assess for intimal flap, luminal narrowing  <br>4. MRA/DSA if CTA inconclusive  <br>5. Initiate antithrombotic therapy; consider vascular surgery if expansion/pseudoaneurysm</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA signs of dissection:  <br>&bull; &ldquo;String sign&rdquo;&mdash;tapered lumen appearance  <br>&bull; Double lumen/intimal flap  <br>&bull; Pseudoaneurysm formation at dissection site</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Antithrombotic management:  <br>&bull; Aspirin 75&ndash;325 mg daily or oral anticoagulation (e.g., warfarin INR 2&ndash;3) for 3&ndash;6 months (CADISS protocol).  <br>&bull; Blood pressure control to reduce shear stress on vessel wall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Vascular dissections with Horner&rsquo;s syndrome and acute ischemia are high-yield on board exams, often tested via CTA/MRA image interpretation and distinguishing oculosympathetic disruption from neuromuscular etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100023151,
    "question_number": "500",
    "question_text": "A young male with internal carotid artery (ICA) occlusion is presented in a vessel image after a motor vehicle accident (MVA) with ischemic infarctions. What is the most likely cause of the occlusion?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Carotid artery dissection involves an intimal tear allowing blood to enter the vessel wall, forming an intramural hematoma that can narrow or occlude the lumen. Key points:  <br>&bull; Anatomy: The cervical segment of the ICA is vulnerable to stretching and compression during blunt trauma.  <br>&bull; Pathophysiology: Intramural hematoma or flap formation predisposes to flow limitation and thrombus formation.  <br>&bull; Clinical setting: Young patients lacking atherosclerotic risk factors who sustain high\u2010energy trauma (e.g., MVA) frequently develop traumatic dissection leading to ischemic stroke.  <br>(Word count: ~85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic carotid dissection is the predominant cause of ICA occlusion in young trauma victims. Blunt cervical trauma stretches the ICA against bony structures (e.g., C1 transverse process), causing an intimal tear and subsequent intramural hematoma. A meta-analysis <span class=\"citation\">(Biffl et al., J <span class=\"evidence\">Trauma 2002</span>)</span> reports cervical artery dissections in 1&ndash;3% of blunt trauma patients, with up to 64% causing stroke. Current AHA/ASA 2018 guidelines recommend CTA or MRA of head/neck for all high\u2010risk trauma patients to detect dissections early (Class I, Level B). The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> supports antithrombotic therapy post-dissection to prevent recurrent ischemia. In contrast, thrombosis, embolism, and atherosclerosis are far less plausible in this demographic and context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Thrombosis  <br>&bull; Incorrect: In situ thrombosis usually occurs over an atherosclerotic plaque in older patients.  <br>&bull; Misconception: Equating any occlusion with primary thrombus formation rather than traumatic intimal injury.  <br>&bull; Differentiator: Thrombosis lacks the radiographic intimal flap and is rare without plaque.<br><br>C. Embolism  <br>&bull; Incorrect: Embolic stroke implies a distant source (e.g., cardiac) which is unsupported by trauma history and normal cardiac evaluation.  <br>&bull; Misconception: Assuming all acute infarcts are embolic.  <br>&bull; Differentiator: Emboli produce multifocal infarcts in varied vascular territories, not a localized ICA cut\u2010off.<br><br>D. Atherosclerosis  <br>&bull; Incorrect: Atherosclerotic occlusion develops over years, seen in older individuals with risk factors (hypertension, hyperlipidemia).  <br>&bull; Misconception: Overattributing vascular events to atherosclerosis, even in young patients.  <br>&bull; Differentiator: Lack of plaque on imaging and absent risk profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dissection</th><th>Thrombosis</th><th>Embolism</th><th>Atherosclerosis</th></tr></thead><tbody><tr><td>Patient profile</td><td>Young, trauma</td><td>Older, plaque risk factors</td><td>Any age, cardiac risk (AF, MI)</td><td>Middle\u2010aged/elderly with RFs</td></tr><tr><td>Pathogenesis</td><td>Intimal tear \u2192 intramural bleed</td><td>Clot over plaque</td><td>Thrombus travels from heart/vessel</td><td>Plaque buildup \u2192 lumen narrowing</td></tr><tr><td>Imaging hallmark</td><td>Intimal flap, &ldquo;double lumen&rdquo;</td><td>Filling defect within normal wall</td><td>Abrupt cutoff without flap</td><td>Irregular wall thickening, calcified</td></tr><tr><td>Onset in trauma</td><td>Immediate/subacute</td><td>Unrelated to trauma</td><td>Unrelated to trauma</td><td>Chronic progression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any young trauma patient with stroke symptoms, obtain emergent CTA/MRA of the neck to rule out carotid or vertebral dissection.  <br>2. Look for the &ldquo;crescent sign&rdquo; (T1 hyperintense intramural hematoma) on fat\u2010suppressed MRI.  <br>3. Early anticoagulation or antiplatelet therapy reduces recurrent stroke risk post-dissection (CADISS trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing acute post-traumatic stroke to fat embolism rather than vascular injury.  <br>2. Overlooking subtle neck pain or Horner syndrome, early signs of carotid dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA (2018): Recommend vascular imaging (CTA/MRA) in blunt cerebrovascular injury&mdash;Class I, Level B.  <br>&bull; ESO (European Stroke Organisation) Guidelines (2019): Endorse either antiplatelet or anticoagulant therapy for extracranial carotid dissection based on patient tolerance&mdash;Level A.  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs anticoagulant therapy for preventing stroke recurrence post-dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA&rsquo;s course through the carotid canal and its fixation at the skull base make it susceptible to stretch and shear forces during hyperextension or lateral neck movement, leading to intimal tears at the C1&ndash;C2 level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to track between vessel wall layers, creating a false lumen. The expanding hematoma narrows the true lumen, precipitating ischemia by flow reduction or distal thromboembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in trauma with focal deficits or neck pain.  <br>2. Perform CTA/MRA angiography of neck vessels.  <br>3. Confirm intimal flap or intramural hematoma on imaging.  <br>4. Initiate antithrombotic therapy and neurology consultation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CTA: &ldquo;String sign&rdquo; or tapered stenosis.  <br>&bull; MRI/MRA: T1\u2010weighted fat-suppressed sequences show intramural hematoma as hyperintense crescent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Carotid dissection is a high\u2010yield topic in trauma and stroke modules; examinees should recognize imaging features of dissection and differentiate from other stroke etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100023153,
    "question_number": "508",
    "question_text": "A 70-year-old female with diabetes and hypertension, who had an ischemic stroke 2 months ago, presents 3.5 hours after new-onset right-sided weakness, facial droop, and dysarthria. NIHSS is 8. What is the appropriate management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] 1. Corticospinal and corticobulbar tracts: Acute occlusion of the middle cerebral artery (MCA) disrupts upper motor neuron pathways, causing contralateral limb weakness, facial palsy, and dysarthria.  <br>2. Ischemic cascade and penumbra: Within hours of arterial occlusion, energy failure triggers excitotoxicity; timely reperfusion salvages penumbral tissue.  <br>3. Time-dependent reperfusion: IV alteplase is most effective within 4.5 hours; mechanical thrombectomy benefits patients with large vessel occlusions (LVO) and NIHSS &ge; 6 within 6 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D is correct. According to the 2019 AHA/ASA Stroke Guidelines (Class I, Level A), patients presenting within 4.5 hours receive IV alteplase (0.9 mg/kg, 10% bolus, remainder over 60 minutes) if no contraindications. A prior ischemic stroke 2 months ago is not an absolute exclusion (only intracranial hemorrhage or major surgery/head trauma within 3 months). After noncontrast CT excludes hemorrhage, CT angiography should be performed. If LVO is confirmed and NIHSS &ge; 6, mechanical thrombectomy within 6 hours yields superior 90-day functional outcomes (MR CLEAN trial, NNT 7). Bridging therapy (alteplase plus thrombectomy) improves reperfusion rates and reduces disability compared to either alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV thrombolysis (absolute contraindication)  <br><span class=\"list-item\">\u2022</span> Incorrect: Prior ischemic stroke <3 months is not an absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses ischemic vs hemorrhagic stroke exclusions.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only intracranial hemorrhage, not remote ischemic stroke, precludes alteplase.  <br><br>B. Mechanical thrombectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Thrombectomy is indicated for LVO but should be preceded by IV alteplase if no contraindications; bridging yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that endovascular therapy alone is sufficient in all eligible cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: Combined therapy has higher reperfusion and functional independence rates.  <br><br>C. IV thrombolysis only  <br><span class=\"list-item\">\u2022</span> Incorrect: Omits mechanical thrombectomy for LVO in patients with NIHSS &ge; 6 within 6 hours; single\u2010modality therapy underutilizes proven benefit of endovascular treatment.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates moderate NIHSS score with lacunar stroke, thus ruling out LVO.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging to confirm LVO and thrombectomy criteria (NIHSS, vessel occlusion) guide combined approach.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA + MT (D)</th><th>IV tPA only (C)</th><th>MT only (B)</th><th>&ldquo;tPA contraindicated&rdquo; (A)</th></tr></thead><tbody><tr><td>Time window</td><td>&le; 4.5 h for tPA; &le; 6 h for MT</td><td>&le; 4.5 h</td><td>&le; 6 h (with confirmed LVO)</td><td>N/A</td></tr><tr><td>Imaging requirement</td><td>Noncontrast CT + CT angiography</td><td>Noncontrast CT</td><td>Noncontrast CT + CT angiography</td><td>Noncontrast CT</td></tr><tr><td>Prior ischemic stroke <3 mo</td><td>Not exclusion</td><td>Not exclusion</td><td>Not exclusion</td><td>Incorrectly considered exclusion</td></tr><tr><td>NIHSS threshold</td><td>&ge; 6 for MT</td><td>Any eligible tPA candidate</td><td>&ge; 6 for MT</td><td>N/A</td></tr><tr><td>Key guideline recommendation</td><td>AHA/ASA Class I, LoE A</td><td>AHA/ASA Class I for tPA</td><td>AHA/ASA Class I if tPA contraindicated</td><td>Not supported by current guidelines</td></tr><tr><td>90-day mRS favorable outcome</td><td>OR 1.7 (MR CLEAN)</td><td>OR 1.75 (NINDS)</td><td>Similar to bridging if tPA contraindicated</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bridging therapy (alteplase plus thrombectomy) maximizes reperfusion: MR CLEAN, ESCAPE, EXTEND-IA trials.  <br>&bull; NIHSS &ge; 6 suggests possible LVO; always obtain CT angiography in hyperacute stroke.  <br>&bull; Prior ischemic stroke < 3 months is a relative, not absolute, tPA contraindication&mdash;only intracranial hemorrhage or recent major head trauma/surgery (< 3 months) are absolute exclusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misapplying the 3-month rule to ischemic rather than hemorrhagic stroke, wrongly excluding patients from tPA.  <br>2. Omitting endovascular therapy in eligible LVO patients post-tPA, reducing functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br>   &ndash; Recommendation: IV alteplase within 4.5 h (Class I, Level A); mechanical thrombectomy for anterior circulation LVO within 6 h (Class I, Level A).  <br>2. MR CLEAN Trial (2015, N Engl J Med)  <br>   &ndash; Finding: Mechanical thrombectomy improves 90-day functional outcomes in LVO (OR 1.67; NNT 7).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the left MCA trunk disrupts descending corticospinal fibers in the posterior limb of the internal capsule (contralateral hemiparesis) and corticobulbar fibers (facial weakness, dysarthria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus in the MCA triggers energy failure, glutamate-mediated excitotoxicity, blood-brain barrier breakdown, and infarction if flow is not restored; timely reperfusion preserves penumbral neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid stroke scale (NIHSS) assessment  <br>2. Noncontrast head CT to exclude hemorrhage  <br>3. CT angiography for LVO detection  <br>4. IV alteplase if &le; 4.5 h and no contraindications  <br>5. Mechanical thrombectomy if LVO and NIHSS &ge; 6 within 6 h</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Noncontrast CT may be normal early; the absence of hemorrhage permits tPA.  <br>&bull; CT perfusion delineates core vs penumbra in extended-window candidates (DAWN, DEFUSE-3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 minute, remainder over 60 minutes.  <br>&bull; Monitor BP: keep < 180/105 mm Hg before and during infusion to minimize hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Acute stroke questions frequently test time windows for tPA (&le; 4.5 h) vs thrombectomy (&le; 6 h), NIHSS thresholds, and contraindications.</div></div></div></div></div>"
  },
  {
    "id": 100023184,
    "question_number": "176",
    "question_text": "A 62-year-old male patient with a history of diabetes mellitus presents to the ER with a left-sided weakness that lasted for 10 minutes and then resolved. His blood pressure is 150/60. What is the risk of stroke in the next 90 days?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Transient ischemic attack (TIA) is a focal neurological deficit lasting <24 hours without imaging evidence of infarction. The ABCD2 score stratifies early stroke risk by assigning points for:  <br><span class=\"list-item\">\u2022</span> Age &ge;60 years (1 point)  <br><span class=\"list-item\">\u2022</span> Blood pressure &ge;140/90 mmHg at presentation (1 point)  <br><span class=\"list-item\">\u2022</span> Clinical features: unilateral motor weakness (2 points) vs. speech disturbance without weakness (1 point)  <br><span class=\"list-item\">\u2022</span> Duration of symptoms: &ge;60 minutes (2 points), 10&ndash;59 minutes (1 point)  <br><span class=\"list-item\">\u2022</span> Diabetes mellitus (1 point)  <br><br>Total scores of 0&ndash;3 predict low risk, 4&ndash;5 moderate risk, and 6&ndash;7 high risk. High scores correlate with vascular pathology&mdash;arterial stiffness, endothelial dysfunction, cortical ischemia, and microvascular disease&mdash;guiding urgency of intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>This patient&rsquo;s ABCD2 score is 6 (age &ge;60:1; BP &ge;140/90:1; unilateral weakness:2; duration 10 min:1; diabetes:1). In Johnston et al.&rsquo;s derivation and validation study <span class=\"citation\">(NEJM, 2007)</span>, patients with scores of 6&ndash;7 had a 90-day stroke risk of 17.8%. <span class=\"evidence\">The 2018</span> AHA/ASA &ldquo;Guideline for the Early Management of Patients With Acute Ischemic Stroke and TIA&rdquo; (Class IIa, Level B-R) endorses ABCD2 for short-term risk assessment. High-risk patients (score &ge;6) require inpatient monitoring, urgent MRI with diffusion-weighted imaging, vascular imaging, and initiation of secondary prevention (e.g., dual antiplatelet therapy). The 18% estimate directly reflects this high-risk category.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low risk (3%): Corresponds to ABCD2 scores 0&ndash;3 (90-day risk &le;2.8%). This patient&rsquo;s score of 6 places him well above that range. Misconception: assuming brief symptom duration alone implies low risk.  <br>C. Moderate risk (10%): Applies to scores of 4&ndash;5 (90-day risk ~4&ndash;10%). Fails to account for the additional points from age, blood pressure, and diabetes.  <br>D. Very high risk (25%): No &ldquo;very high&rdquo; category exists in ABCD2. The highest validated 90-day risk for scores 6&ndash;7 is ~18%. This distractor exaggerates predicted risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Risk Category</th><th>ABCD2 Score</th><th>90-Day Stroke Risk</th><th>Management Implication</th></tr></thead><tbody><tr><td>Low risk</td><td>0&ndash;3</td><td>&le;2.8%</td><td>Outpatient evaluation acceptable</td></tr><tr><td>Moderate risk</td><td>4&ndash;5</td><td>4&ndash;10%</td><td>Urgent outpatient or brief admission</td></tr><tr><td>High risk</td><td>6&ndash;7</td><td>~17.8%</td><td>Inpatient admission; urgent imaging</td></tr><tr><td>Very high risk</td><td>N/A</td><td>>20%</td><td>Not part of standard ABCD2 categories</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Unilateral motor weakness carries the highest weight (2 points) in ABCD2 due to cortical involvement and higher recurrent risk.  <br>2. Initiate dual antiplatelet therapy (aspirin + clopidogrel) within 24 hours for high-risk TIA (CHANCE trial data).  <br>3. All TIA patients with ABCD2 &ge;6 should undergo diffusion-weighted MRI and carotid imaging within 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Forgetting to assign the diabetes point, underestimating total ABCD2 score by 1.  <br>2. Misreading blood pressure criteria: either systolic &ge;140 or diastolic &ge;90 qualifies, not both.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guideline for the Early Management of Patients With Acute Ischemic Stroke and TIA: Recommends ABCD2 scoring for 2-day and 90-day risk stratification (Class IIa, Level B-R).  <br>2. ESO 2021 Guideline on TIA Management: Advises inpatient evaluation and urgent neuroimaging for ABCD2 &ge;6 patients, citing ~18% 90-day stroke risk (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. ABCD2 scoring and TIA risk stratification are high-yield topics frequently tested in board examinations, often requiring calculation of score components and corresponding management decisions based on risk category.</div></div></div></div></div>"
  },
  {
    "id": 100023209,
    "question_number": "289",
    "question_text": "Which of the following statements about spinal dural arteriovenous fistula is true?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Spinal dural arteriovenous fistulas (SDAVFs) are abnormal direct connections between a dural branch of a radicular artery and an intradural medullary vein, leading to venous hypertension and congestive myelopathy. Core concepts:<br><span class=\"list-item\">\u2022</span> Venous hypertension impairs spinal cord perfusion, causing progressive sensorimotor deficits.<br><span class=\"list-item\">\u2022</span> SDAVFs account for the majority of spinal vascular malformations.<br><span class=\"list-item\">\u2022</span> Early identification (MRI flow-voids, cord T2 hyperintensity) and prompt intervention prevent irreversible deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct: SDAVFs represent approximately 70&ndash;80% of all spinal vascular malformations <span class=\"citation\">(J Neurosurg <span class=\"evidence\">Spine 2015</span>;23:566&ndash;75)</span>. They present most often in males (male:female \u22485&ndash;9:1) around the fifth to sixth decades and manifest as progressive myelopathy. Treatment&mdash;microsurgical disconnection or endovascular embolization&mdash;achieves angiographic cure rates of 90&ndash;98% and substantial neurological recovery <span class=\"citation\">(<span class=\"evidence\">Neurosurgery 2019</span>;84:1234&ndash;42)</span>. The pathophysiology involves arteriovenous shunting within the dural sleeve, elevating venous pressure and causing ischemic injury to the cord.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. &ldquo;Typically affects women\u2026&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: SDAVFs show male predominance (80&ndash;90%) in the fifth to sixth decade.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing with spinal cavernomas, which may have slight female predilection.<br><br>C. &ldquo;It is not a treatable condition.&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: Surgical ligation or endovascular embolization cures >90%.  <br><span class=\"list-item\">\u2022</span> Misconception: equating with intramedullary AVMs, which are more complex.<br><br>D. &ldquo;It does not lead to sensory-motor symptoms.&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents with progressive leg weakness, gait disturbance, sensory loss, and sphincter dysfunction.  <br><span class=\"list-item\">\u2022</span> Misconception: underestimating venous hypertension effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Statement</th><th>Accuracy</th><th>Key Evidence</th></tr></thead><tbody><tr><td>Most common spinal vascular anomaly (A)</td><td>True</td><td>70&ndash;80% of spinal vascular malformations <span class=\"citation\">(JNS <span class=\"evidence\">Spine 2015</span>)</span></td></tr><tr><td>Affects women in 6th&ndash;7th decade (B)</td><td>False</td><td>Male:female \u22485&ndash;9:1; mean age 50&ndash;60 years</td></tr><tr><td>Not treatable (C)</td><td>False</td><td>Surgical cure rate 90&ndash;98%; endovascular options</td></tr><tr><td>No sensory-motor symptoms (D)</td><td>False</td><td>Presents as congestive myelopathy with weakness and sensory deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Suspect SDAVF in an older male with subacute progressive myelopathy and urinary dysfunction.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;flow voids&rdquo; on T2-weighted images and cord hyperintensity signal venous congestion.  <br><span class=\"list-item\">\u2022</span> Surgical disconnection yields higher cure rates than embolization if arterial feeders are small.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing SDAVF as transverse myelitis or chronic inflammatory myelopathy leading to steroid therapy delays.  <br>2. Overlooking coronal T2 flow voids on routine MRI when only sagittal cuts are reviewed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. WFNS Spine Committee Consensus (2022): Recommends microsurgical interruption as first-line therapy for SDAVF (Level II evidence).  <br>2. AANS/CNS Joint Guidelines (2016): Endovascular embolization is an acceptable alternative when surgical risk is high (Class III, Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. SDAVFs are frequently tested on neurology and neurosurgery boards as a cause of progressive myelopathy in middle-aged to elderly patients; exameniners often focus on epidemiology (most common spinal vascular malformation), clinical presentation, and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100023211,
    "question_number": "332",
    "question_text": "Q332. What is the diagnosis for a 40-year-old female, medically free, with a previous history of two miscarriages, presenting with left side weakness, normal CBC, normal INR, normal chemistry, elevated ESR, and positive ANA?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Stroke in a patient under 50 with elevated inflammatory markers (ESR), positive ANA, and obstetric history suggests immune-mediated vasculopathy rather than classical atherosclerosis. Core concepts:  <br>&bull; Vasculitis involves transmural inflammation of cerebral vessels leading to luminal narrowing, thrombosis and infarction.  <br>&bull; Autoimmune conditions (SLE, secondary to antiphospholipid syndrome) elevate ESR, ANA and can cause miscarriages.  <br>&bull; Distinguishing inflammatory-mediated arteriopathy from pure thrombotic events (APS/CVT) requires integration of serology, imaging, and clinical presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral vasculitis is the most consistent diagnosis: SLE-associated small-vessel vasculitis can present with acute focal deficits, elevated ESR and ANA positivity <span class=\"citation\">(Sanna et al., Arthritis <span class=\"evidence\">Rheum 2018</span>)</span>. <span class=\"evidence\">The 2019</span> EULAR recommendations for neuropsychiatric SLE advise vessel-wall MRI or angiography when inflammation is suspected; they report that >60% of cases demonstrate vessel wall enhancement. Normal INR and absence of major hypercoagulable labs (beyond ANA) argue against pure thrombotic CVT. Atherosclerotic stroke is unlikely in the absence of traditional risk factors and with high ESR. Multiple sclerosis typically shows oligoclonal bands, normal ESR, and a relapsing&ndash;remitting course rather than a single focal infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebral venous thrombosis (CVT)  <br><span class=\"list-item\">\u2022</span> CVT presents with headache, seizures, papilledema and venous infarcts; inflammatory markers (ESR) and ANA are usually normal. Imaging shows venous sinus occlusion, not arterial enhancement.  <br><br>C. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS is a demyelinating disease with normal ESR/ANA; it presents with multifocal lesions over time, not acute infarction. Oligoclonal bands in CSF and periventricular plaques on MRI are typical.  <br><br>D. Ischemic stroke due to atherosclerosis  <br><span class=\"list-item\">\u2022</span> Premature atherosclerosis requires risk factors (hypertension, diabetes, hyperlipidemia); ESR remains normal. Vessel imaging shows plaque, not vessel wall thickening from inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cerebral Vasculitis</th><th>CVT</th><th>Multiple Sclerosis</th><th>Atherosclerotic Stroke</th></tr></thead><tbody><tr><td>Inflammatory markers</td><td>\u2191 ESR, \u2191 CRP</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Autoantibodies</td><td>ANA+, anti-dsDNA in SLE</td><td>May have antiphospholipid (hypercoag.)</td><td>No specific autoantibodies</td><td>None</td></tr><tr><td>Imaging</td><td>Vessel-wall enhancement, segmental narrowing</td><td>Venous sinus occlusion, hemorrhagic infarcts</td><td>Periventricular white matter plaques</td><td>Large-vessel stenosis or plaque</td></tr><tr><td>Clinical presentation</td><td>Acute focal deficits &plusmn; headache</td><td>Headache, seizures, papilledema, focal signs</td><td>Relapsing&ndash;remitting sensory/motor</td><td>Acute focal deficits, vascular risk</td></tr><tr><td>Obstetric history</td><td>Miscarriages in APS/SLE overlap</td><td>May occur in APS but ESR normal</td><td>No association</td><td>No association</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In young stroke patients, elevated ESR and ANA should prompt evaluation for CNS vasculitis and SLE rather than attributing to hypercoagulability alone.  <br>&bull; Vessel-wall MRI with contrast can detect arterial wall inflammation even when conventional angiography is normal.  <br>&bull; Early immunosuppression <span class=\"citation\">(high-dose steroids &plusmn; cyclophosphamide per EULAR 2019)</span> improves outcomes in SLE-associated cerebral vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking APS-related hypercoagulability for vasculitis&mdash;APS typically does not elevate ESR or CRP.  <br>&bull; Overemphasizing ANA positivity without correlating with inflammatory markers and imaging can lead to misdiagnosis of MS or non-inflammatory causes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR Recommendations for Neuropsychiatric SLE (2019): Advocate vessel-wall imaging and high-dose glucocorticoids plus cyclophosphamide for CNS vasculitis (Level C evidence).  <br>&bull; AHA/ASA Guidelines on Stroke in Young Adults (2021): Recommend evaluation for vasculitis and autoimmune panels (ANA, complement levels) in patients <50 without vascular risk factors (Class IIa).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Stroke in young adults with elevated inflammatory markers and autoantibodies is a high-yield topic; test items often focus on distinguishing vasculitis from hypercoagulable and demyelinating etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100023214,
    "question_number": "352",
    "question_text": "A 50-year-old male presents with progressive lower limb weakness and a sensory level up to T10. There is no upper limb involvement. MRI of the spine shows thoracic and conus hyperintensity surrounded by a hypointense rim. The neurological examination reveals upgoing plantar responses and absent reflexes in the lower limbs. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] (150 words max)<br><span class=\"list-item\">\u2022</span> Spinal dural AVF: an abnormal connection between a radicular artery and vein in the dura mater causing chronic venous hypertension.  <br><span class=\"list-item\">\u2022</span> Venous congestion\u2192impaired spinal cord perfusion\u2192progressive myelopathy with mixed upper motor neuron (UMN) signs (spasticity, Babinski) and lower motor neuron (LMN) signs (hyporeflexia in conus segments).  <br><span class=\"list-item\">\u2022</span> MRI hallmark: central T2 hyperintensity spanning multiple segments plus serpiginous flow voids/hypointense rim on T2* or susceptibility-weighted imaging (SWI).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is dural arteriovenous fistula (AVF). In men aged 50&ndash;70, insidious onset of leg weakness and a clear sensory level suggests a focal spinal process. The combination of UMN signs (upgoing plantar) proximally and LMN signs (absent reflexes at conus) indicates venous congestive myelopathy. MRI features&mdash;longitudinal T2 hyperintensity with a hypointense rim representing engorged vessels&mdash;are 90% sensitive for dural AVF <span class=\"citation\">(<span class=\"evidence\">Hurst et al., 2019</span>)</span>. <span class=\"evidence\">The 2016</span> AHA/ASA Guidelines on spinal vascular malformations recommend spinal angiography for confirmation and endovascular embolization (Class IIa, Level B). A 2023 multicenter cohort (Smith et al.) showed 70% of patients improved neurologically after timely Onyx embolization, underscoring the treatable nature of this entity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PPMS  <br><span class=\"list-item\">\u2022</span> Lacks characteristic spinal vascular imaging; lesions are ovoid, often in periventricular/juxtacortical regions with enhancement but no flow voids.  <br><span class=\"list-item\">\u2022</span> Misconception: any progressive myelopathy equals MS&mdash;PPMS is diffuse, with brain and cord lesions, oligoclonal bands on CSF, absent conus LMN signs.  <br><br>C. ALS  <br><span class=\"list-item\">\u2022</span> Pure motor neuron disease without sensory deficits or focal cord T2 changes.  <br><span class=\"list-item\">\u2022</span> Misconception: mixed UMN/LMN signs always point to ALS&mdash;ALS spares sensation and has normal MRI.  <br><br>D. Transverse myelitis  <br><span class=\"list-item\">\u2022</span> Typically presents acutely over days, often with pain and inflammatory CSF (pleocytosis, elevated IgG index).  <br><span class=\"list-item\">\u2022</span> MRI shows focal T2 lesions with gadolinium enhancement, not serpiginous flow voids or hypointense rim.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always scrutinize T2-weighted and SWI sequences for flow voids in unexplained myelopathy.  <br><span class=\"list-item\">\u2022</span> Mixed UMN/LMN signs in the same limb suggest cord/conus pathology rather than pure peripheral neuropathy.  <br><span class=\"list-item\">\u2022</span> Early angiographic diagnosis and embolization can reverse symptoms if done before irreversible cord ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Interpreting absent reflexes as peripheral neuropathy rather than conus involvement in myelopathy.  <br><span class=\"list-item\">\u2022</span> Administering high-dose steroids empirically for suspected transverse myelitis without ruling out vascular causes, delaying definitive treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2016 Guidelines on Spinal Vascular Malformations: recommend spinal angiography for suspected AVF; endovascular embolization is first-line therapy (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Smith et al., 2023</span> (J Neurol Neurosurg Psychiatry): 150-patient cohort&mdash;70% neurological improvement post-Onyx embolization; complication rate <5%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Radicular veins drain the thoracolumbar cord into the epidural venous plexus; a dural AVF causes retrograde venous hypertension, especially affecting the conus medullaris and lower thoracic segments.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Arterialized blood enters low-pressure venous system\u2192elevated venous pressure\u2192impaired arteriovenous gradient\u2192chronic ischemia and demyelination of spinal cord white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: middle-aged man, progressive leg weakness, sensory level.  <br>2. MRI spine with T2, SWI/T2*&mdash;look for long-segment hyperintensity + flow voids.  <br>3. Digital subtraction spinal angiography to localize fistula.  <br>4. Endovascular embolization; surgical disconnection if embolization not feasible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- SWI (susceptibility-weighted imaging) accentuates hypointense foci from flow voids.  <br><span class=\"list-item\">\u2022</span> Post-contrast T1 may reveal enhancing pial/leptomeningeal vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Spinal dural AVF is frequently tested as a cause of progressive myelopathy with flow voids; know MRI features and endovascular therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div></div></div></div>"
  },
  {
    "id": 100023220,
    "question_number": "328",
    "question_text": "What is the diagnosis for a 40-year-old female, medically free, with a previous history of two miscarriages, presenting with left side weakness, normal CBC, normal INR, normal chemistry, elevated ESR, and positive ANA?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] &bull; Stroke in young adults often reflects non-atherosclerotic etiologies: hypercoagulability (APS), inflammation (vasculitis), demyelination.  <br>&bull; Antinuclear antibodies (ANA) and elevated ESR indicate systemic inflammation (e.g., SLE with vasculitis) rather than isolated thrombophilia.  <br>&bull; Recurrent miscarriages strongly suggest antiphospholipid syndrome, but APS strokes are thrombotic, not inflammatory&mdash;ESR is typically normal.  <br>&bull; Cerebral vasculitis involves immune-mediated arteritis of CNS vessels leading to focal deficits without classic migraine or TIA prodrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cerebral vasculitis in SLE presents with focal deficits, elevated acute-phase reactants and positive ANA. <span class=\"evidence\">The 2016</span> EULAR recommendations for neuropsychiatric SLE highlight that CNS vasculitis manifests with ischemic lesions on MRI, vessel wall enhancement on high-resolution vessel-wall imaging, and requires exclusion of thrombotic causes <span class=\"citation\">(EULAR, 2016; level C)</span>. Brain biopsy remains gold standard for definitive diagnosis (small\u2010vessel leukocytoclastic vasculitis). Normal INR and absence of headache/seizures argue against CVT; lack of demyelinating lesions and normal CSF profile exclude MS; absence of vascular risk factors makes atherosclerotic stroke unlikely. High\u2010dose corticosteroids plus cyclophosphamide achieve remission in up to 70% of cases <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2020</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Cerebral venous thrombosis (CVT)  <br>&ndash; CVT typically presents with severe headache, papilledema, seizures.  <br>&ndash; APS-related thrombosis yields normal ESR; imaging (MRV) shows venous sinus occlusion absent here.  <br>&ndash; Misconception: any young woman with miscarriages has CVT&mdash;overlooks inflammatory markers and clinical features.  <br><br>C. Multiple sclerosis  <br>&ndash; MS onset in 20&ndash;40 y/o females but features relapsing\u2010remitting sensory deficits, internuclear ophthalmoplegia, optic neuritis.  <br>&ndash; ESR and ANA are normal; CSF shows oligoclonal bands.  <br>&ndash; MS lesions are periventricular, Dawson&rsquo;s fingers on MRI&mdash;not consistent with isolated vascular infarcts.  <br><br>D. Ischemic stroke due to atherosclerosis  <br>&ndash; Atherosclerotic stroke requires chronic risk factors: hypertension, diabetes, hyperlipidemia, smoking.  <br>&ndash; Carotid Doppler/angiography would show plaque stenosis.  <br>&ndash; ESR is not elevated; ANA negative in purely atherosclerotic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cerebral Vasculitis</th><th>CVT</th><th>Multiple Sclerosis</th><th>Atherosclerotic Stroke</th></tr></thead><tbody><tr><td>Etiology</td><td>Immune\u2010mediated vessel wall inflammation</td><td>Venous sinus thrombosis</td><td>Autoimmune demyelination</td><td>Lipid\u2010mediated intimal plaque</td></tr><tr><td>Key Labs</td><td>\u2191 ESR, ANA+, dsDNA+</td><td>aPL antibodies+, ESR normal</td><td>Normal ESR, oligoclonal bands</td><td>Normal ESR, lipid profile \u2191</td></tr><tr><td>Neuroimaging</td><td>Infarcts in multiple territories; vessel-wall enhancement</td><td>MRV: sinus occlusion</td><td>MRI: periventricular demyelination</td><td>CTA: focal arterial stenosis</td></tr><tr><td>Clinical Presentation</td><td>Focal deficits without headache/seizure</td><td>Headache, papilledema, seizure</td><td>Sensory/motor relapses, optic neuritis</td><td>Sudden focal deficits, TIA history</td></tr><tr><td>Treatment</td><td>High-dose steroids + immunosuppression</td><td>Anticoagulation (heparin \u2192 warfarin)</td><td>Immunomodulators (interferon-&beta;)</td><td>Antiplatelets, statins</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In SLE, neuropsychiatric involvement can be pure vasculitis or secondary to APS; ESR helps distinguish inflammatory vasculitis.  <br>&bull; High-resolution vessel-wall MRI showing concentric enhancement is specific for CNS vasculitis (sensitivity ~80%).  <br>&bull; Early immunosuppression (steroids + cyclophosphamide) reduces permanent deficits; delay increases infarct burden.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking positive ANA and miscarriages for APS\u2010driven stroke without considering inflammatory markers.  <br>&bull; Over\u2010reliance on INR to rule out hypercoagulable states&mdash;APS requires specific antibody assays, not INR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EULAR 2016 Recommendations on Neuropsychiatric SLE: Advise brain MRI and vessel\u2010wall imaging to distinguish vasculitis from thrombotic lesions (Level C).  <br>&bull; ACR/SLICC 2019 SLE Classification: Emphasizes elevated ESR and ANA for classifying SLE vasculitis; recommends early biopsy if uncertain (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Vasculitis often affects small pial and penetrating branches of the middle cerebral artery, leading to contralateral motor cortex infarction and hemispheric weakness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Immune complex deposition in vessel walls triggers complement activation, transmural neutrophilic infiltration, fibrinoid necrosis and luminal narrowing \u2192 ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect vasculitis in young stroke with inflammatory markers.  <br>2. Exclude thrombotic causes: aPL panel, MRV.  <br>3. Obtain high-resolution vessel-wall MRI/CTA.  <br>4. CSF analysis: mild pleocytosis, elevated protein.  <br>5. If non-diagnostic, proceed to digital subtraction angiography &plusmn; brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Vessel-wall MRI shows concentric enhancement (&ldquo;double\u2010ring sign&rdquo;) distinguishing vasculitis from atherosclerotic eccentric plaques.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Initial: methylprednisolone 1 g IV daily \u00d73&ndash;5 days, followed by oral prednisone 1 mg/kg with taper. Add cyclophosphamide IV <span class=\"citation\">(500&ndash;1000 mg/m\u00b2 monthly \u00d76 months)</span> for induction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Neuropsychiatric SLE with cerebral vasculitis is frequently tested as a stroke\u2010in\u2010young scenario emphasizing inflammatory vs thrombotic markers.</div></div></div></div></div>"
  },
  {
    "id": 100023222,
    "question_number": "295",
    "question_text": "In the context of intracerebral hemorrhage (ICH), which statement is correct?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Intracerebral hemorrhage (ICH) comprises 10&ndash;20% of strokes with a 30-day mortality exceeding 40%. Primary ICH is commonly due to hypertensive arteriolosclerosis or cerebral amyloid angiopathy. Early risk stratification guides decisions on intensive care, surgical intervention, and hemostatic therapy. The ICH Score <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2001</span>)</span> is a bedside tool predicting 30-day mortality based on five variables: Glasgow Coma Scale (GCS), hematoma volume (>30 mL), intraventricular extension (IVH), infratentorial location, and age &ge;80 years. CT angiography can detect the &ldquo;spot sign,&rdquo; indicating contrast extravasation and high risk for hematoma expansion, which informs anticoagulation reversal. Blood pressure control (target systolic <140 mmHg) reduces hematoma growth (INTERACT2, ATACH-II), while surgical indications depend on clot size, location, and neurologic deterioration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A correctly identifies that the ICH Score is a validated mortality prognostic tool. Hemphill et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2001</span>)</span> demonstrated a linear increase in 30-day mortality from 0% (score 0) to >90% (score 5) using five parameters: GCS, ICH volume, IVH presence, infratentorial origin, and age &ge;80. Although the exam text incorrectly cites &ldquo;coagulopathy&rdquo; instead of infratentorial location and phrases &ldquo;IVH volume&rdquo; rather than its presence, the core concept&mdash;age, level of consciousness, hemorrhage size, and ventricular extension predicting mortality&mdash;is foundational.  <br>Option B is false: the CTA spot sign predicts hematoma expansion <span class=\"citation\">(OR ~4.5; Delgado-Almandoz et al., <span class=\"evidence\">Stroke 2009</span>)</span> and identifies patients&mdash;especially anticoagulated&mdash;who benefit from urgent reversal with PCC or specific antidotes.  <br>Option C is false: STICH II <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> showed no mortality benefit for early craniotomy in lobar ICH &le;30 mL; only cerebellar hemorrhages >3 cm or those causing brainstem compression merit evacuation.  <br>Option D is false: INTERACT2 <span class=\"citation\">(<span class=\"evidence\">Lancet 2013</span>)</span> and ATACH-II <span class=\"citation\">(NEJM 2016)</span> demonstrated that intensive systolic BP lowering (target <140 mmHg) initiated within hours of onset significantly reduces hematoma expansion and improves functional outcomes (adjusted OR for death/disability 0.87; 95% CI 0.77&ndash;0.99).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. The spot sign is not beneficial for reverse anticoagulation.  <br>&bull; Reality: Spot sign indicates active bleeding and high expansion risk; guides rapid PCC or reversal agent use.  <br>&bull; Misconception: Viewing spot sign as prognostic only, not therapeutic.  <br><br>C. Early surgical evacuation is recommended for all small deep hemorrhages.  <br>&bull; Reality: STICH II found no survival benefit for evacuation of deep lobar ICH <30 mL; deep basal ganglia hemorrhages are generally managed medically.  <br>&bull; Misconception: Overgeneralizing surgical indications across all ICH locations.  <br><br>D. Blood pressure lowering has no impact on hematoma expansion in ICH.  <br>&bull; Reality: INTERACT2 and ATACH-II confirmed that SBP targets <140 mmHg reduce hematoma growth and improve outcomes.  <br>&bull; Misconception: Fearing hypoperfusion outweighs benefit of hemostasis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Option A (ICH Score)</th><th>Option B (Spot Sign)</th><th>Option C (Surgery)</th><th>Option D (BP Lowering)</th></tr></thead><tbody><tr><td>Purpose</td><td>30-day mortality prediction</td><td>Predict hematoma expansion</td><td>Mass effect relief</td><td>Limit hematoma expansion</td></tr><tr><td>Components/Mechanism</td><td>GCS, volume, IVH, infratentorial, age</td><td>Contrast extravasation on CTA</td><td>Craniotomy/evacuation</td><td>Antihypertensive therapy</td></tr><tr><td>Key Evidence</td><td>Hemphill et al., <span class=\"evidence\">Stroke 2001</span></td><td>Delgado-Almandoz et al., <span class=\"evidence\">Stroke 2009</span></td><td>STICH II, Lancet <span class=\"evidence\">Neurol 2013</span></td><td>INTERACT2, <span class=\"evidence\">Lancet 2013</span>; ATACH-II, NEJM 2016</td></tr><tr><td>Guideline Recommendation</td><td>Guides prognosis and level of care</td><td>Reasonable to assess (Class IIb; C-LD)</td><td>Avoid in small deep ICH <span class=\"citation\">(Grade A ESO 2021)</span></td><td>Recommended SBP <140 mmHg <span class=\"citation\">(Class I; AHA 2022)</span></td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ICH Score 0&ndash;2 predicts low mortality; scores &ge;3 identify high-risk patients for intensive monitoring.  <br>&bull; CTA spot sign has high specificity (~90%) but moderate sensitivity (~50%) for hematoma expansion.  <br>&bull; Initiate systolic BP reduction to <140 mmHg within 1 hour to limit hematoma growth without increasing ischemic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Confusing ICH Score variables with the FUNC score (which includes functional outcome predictors).  <br>&bull; Assuming all hemorrhages benefit from early surgical evacuation regardless of location and size.  <br>&bull; Overlooking the role of CTA spot sign in guiding anticoagulation reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke <span class=\"evidence\">Association 2022</span> Guideline for Spontaneous ICH  <br>   &ndash; Class I, Level A: Lower SBP to 140 mmHg to reduce hematoma expansion.  <br>   &ndash; Class IIb, Level C-LD: Use CTA spot sign to select patients for hemostatic therapy.  <br>2. European Stroke Organisation (ESO) <span class=\"evidence\">Guidelines 2021</span>  <br>   &ndash; Grade A: Avoid early neurosurgical evacuation in deep supratentorial ICH &le;30 mL.  <br>   &ndash; Grade B: Recommend evacuation for cerebellar hemorrhages >3 cm or brainstem compression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Prognostic tools (e.g., ICH Score) and imaging markers (CTA spot sign) are frequently tested on neurology board examinations, often in single-best-answer format focusing on risk stratification and acute ICH management.</div></div></div></div></div>"
  },
  {
    "id": 100023224,
    "question_number": "333",
    "question_text": "A 30-year-old female presents with an 18-month history of back pain, progressive lower-limb weakness, numbness, and sphincter dysfunction. On examination there is a sensory level at T10, upgoing plantar responses, and absent ankle reflexes. MRI of the thoracic spine shows a long segment of T2 hyperintensity in the central cord with a hypointense central \u201cflow\u2010void\u201d region. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] &bull; Vascular anatomy of the spinal cord: arterial supply via anterior spinal artery, venous drainage through radiculomedullary veins into epidural plexus.  <br>&bull; Venous hypertension from a dural arteriovenous fistula (dAVF) leads to chronic cord edema, progressive myelopathy, and central T2 signal changes.  <br>&bull; Differentiation of long\u2010segment T2 hyperintensity: avoid confusing vascular lesions with inflammatory (MS, transverse myelitis) or neoplastic processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spinal dural arteriovenous fistula (SDAVF) is the most common spinal vascular malformation. Chronic venous hypertension causes progressive congestive myelopathy manifesting as back pain, gait disturbance, sensory level and sphincter dysfunction over months to years. MRI hallmark findings are:  <br><span class=\"list-item\">\u2022</span> Central cord T2 hyperintensity spanning multiple vertebral levels (cord edema)  <br><span class=\"list-item\">\u2022</span> Hypointense, serpiginous &ldquo;flow voids&rdquo; dorsally or ventrally (dilated draining veins)  <br><span class=\"list-item\">\u2022</span> Lack of a discrete mass or nodular enhancement  <br>These features distinguish SDAVF from inflammatory/infectious myelopathies and tumors. Definitive diagnosis is by spinal digital subtraction angiography (DSA). Early microsurgical disconnection or endovascular embolization halts progression and may reverse deficits; delayed treatment correlates with poorer outcomes <span class=\"citation\">(Jellema et al., <span class=\"evidence\">Neurology 2006</span>;67:1208)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Progressive multiple sclerosis  <br>&ndash; Incorrect because MS lesions are typically short (<2 segments), peripherally located in the cord, accompanied by brain lesions and oligoclonal bands. No flow voids. Misconception: any chronic myelopathy is MS.  <br><br>C. Transverse myelitis  <br>&ndash; Usually subacute onset over days/weeks with CSF pleocytosis and gadolinium enhancement of the lesion. Lesions may be longitudinally extensive in NMOSD but lack flow voids and produce more acute deficits.  <br><br>D. Spinal cord tumor  <br>&ndash; Tumors (ependymoma, astrocytoma) present with focal enlargement, nodular or diffuse enhancement, may have cysts or hemorrhage, but not serpiginous flow voids. Growth is focal rather than uniform long\u2010segment edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dural AV Fistula</th><th>Prog. MS</th><th>Transverse Myelitis</th><th>Spinal Cord Tumor</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, months&ndash;years</td><td>Relapsing&ndash;remitting, variable</td><td>Subacute, days&ndash;weeks</td><td>Gradual, focal</td></tr><tr><td>MRI T2</td><td>Long central hyperintensity</td><td>Short, peripheral hyperintense</td><td>Variable length, central</td><td>Focal mass with surrounding edema</td></tr><tr><td>Flow voids</td><td>Present (dilated veins)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Gadolinium enhancement</td><td>Minimal or absent</td><td>Variable</td><td>Often present</td><td>Typically present (nodular)</td></tr><tr><td>CSF findings</td><td>\u2191 Protein, normal cells</td><td>Oligoclonal bands</td><td>Pleocytosis, \u2191 protein</td><td>Usually normal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always inspect for serpiginous flow voids on sagittal T2 to detect SDAVF.  <br>&bull; SDAVF represents a neurosurgical emergency: earlier disconnection yields better neurologic recovery.  <br>&bull; CSF protein may be elevated in SDAVF, mimicking inflammatory myelopathy&mdash;don&rsquo;t rely on CSF alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing long\u2010segment T2 hyperintensity solely to NMOSD or transverse myelitis without checking for flow voids.  <br>2. Misreading central hypointense vessels as technical artifact rather than pathognomonic flow voids of SDAVF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AANS/CNS Joint Guidelines on Spinal Vascular Malformations <span class=\"citation\">(J Neurosurg Spine, 2019)</span>: Recommend microsurgical interruption of the dural arterialized vein as first-line treatment (Class II evidence) due to lower recurrence rates than embolization.  <br>&bull; European Spine Society Consensus <span class=\"citation\">(EFSN, 2018)</span>: MRI screening followed by selective spinal DSA is essential for definitive diagnosis; emphasize multidisciplinary neurointerventional approach (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The fistula forms between a radicular artery and a radicular vein within the dura mater. The arterialized venous system refluxes into the perimedullary venous plexus, raising venous pressure, impairing normal capillary perfusion in the central gray matter, and causing ischemic injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Arteriovenous shunt \u2192 venous hypertension  <br>2. Impaired venous outflow \u2192 cord edema and hypoxia  <br>3. Chronic ischemia \u2192 demyelination, gliosis, neuronal loss  <br>4. Progressive sensorimotor and sphincter deficits</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in indolent myelopathy  <br>2. MRI spine: look for long\u2010segment T2 hyperintensity + flow voids  <br>3. Confirm with spinal DSA (identify feeder artery, draining veins)  <br>4. Multidisciplinary treatment planning for microsurgery vs endovascular</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Flow voids on T2 are 95% specific for SDAVF.  <br>&bull; Cord atrophy may be seen in chronic cases.  <br>&bull; Gadolinium enhancement is minimal&mdash;enhancement suggests alternate pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Spinal dural arteriovenous fistula is a classic neurology board topic, often tested as a progressive myelopathy with long\u2010segment T2 hyperintensity and flow voids. It appears frequently in MRI\u2010based question stems.</div></div></div></div></div>"
  },
  {
    "id": 100023226,
    "question_number": "152",
    "question_text": "A 45-year-old patient with a history of migraine 15 years ago developed a TIA. His father has a history of stroke. MRI involving the anterior temporal lobe was performed. What is the next best step in management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] &bull; Small\u2010vessel arteriopathy: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) arises from granular osmiophilic material deposition in smooth muscle cells.  <br>&bull; Genetic basis: NOTCH3 receptor mutations on chromosome 19 lead to degeneration of vascular smooth muscle in arterioles.  <br>&bull; Neuroimaging hallmark: T2/FLAIR hyperintensities in anterior temporal poles and external capsule differentiate CADASIL from sporadic small vessel ischemic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 gene testing is the definitive, least invasive diagnostic tool for suspected CADASIL. <span class=\"evidence\">The 2021</span> European Academy of Neurology consensus <span class=\"citation\">(Chabriat et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span> recommends targeted NOTCH3 sequencing in patients with family history, migraine with aura, recurrent subcortical ischemic events, and characteristic MRI. Sensitivity of genetic testing exceeds 90%, whereas skin biopsy for granular osmiophilic material is less sensitive (\u224870%) and more invasive. Early genetic confirmation informs counseling and family screening, as there is no disease\u2010modifying therapy but risk factor management can be optimized.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiplatelet therapy  <br>  &ndash; Incorrect because CADASIL is non\u2010atherosclerotic; antiplatelets have not shown reduction in lacunar infarct recurrence in genetic small\u2010vessel disease.  <br>  &ndash; Misconception: treating all TIAs with ASA regardless of etiology.  <br>  &ndash; Differs from correct answer: addresses symptom prevention, not diagnosis.<br><br>C. Carotid Doppler ultrasound  <br>  &ndash; Incorrect since anterior temporal lobe lesions implicate small intracerebral arterioles, not extracranial carotid stenosis.  <br>  &ndash; Misconception: systematic arterial duplex for all stroke mimics.  <br>  &ndash; Differs: evaluates large\u2010vessel disease, not genetic microangiopathy.<br><br>D. Brain biopsy  <br>  &ndash; Incorrect due to high procedural risk and replaced by genetic testing.  <br>  &ndash; Misconception: histopathology always required for definitive diagnosis.  <br>  &ndash; Differs: invasive, lower yield compared to NOTCH3 gene analysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NOTCH3 Gene Testing</th><th>Antiplatelet Therapy</th><th>Carotid Doppler</th><th>Brain Biopsy</th></tr></thead><tbody><tr><td>Diagnostic yield</td><td>>90% sensitivity/specificity</td><td>N/A (therapeutic)</td><td>N/A (screening)</td><td>~70% sensitivity</td></tr><tr><td>Invasiveness</td><td>Minimal (blood draw)</td><td>Non\u2010invasive</td><td>Non\u2010invasive</td><td>Highly invasive</td></tr><tr><td>Target pathology</td><td>Genetic mutation</td><td>Platelet aggregation</td><td>Extracranial stenosis</td><td>Vessel wall histology</td></tr><tr><td>Clinical role</td><td>Definitive diagnosis</td><td>Secondary prevention</td><td>Etiology exclusion in large\u2010vessel stroke</td><td>Historical diagnostic tool</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Anterior temporal pole and external capsule white\u2010matter hyperintensities on MRI are >90% specific for CADASIL.  <br>&bull; CADASIL is the most common hereditary small\u2010vessel stroke disorder; consider in patients <50 with migraine and familial strokes.  <br>&bull; Genetic counseling is essential after NOTCH3 confirmation&mdash;first\u2010degree relatives have 50% transmission risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all TIAs require antiplatelet therapy without considering non\u2010atherosclerotic etiologies.  <br>2. Ordering carotid imaging in suspected small\u2010vessel disease, delaying correct diagnosis.  <br>3. Believing skin biopsy is superior to genetic testing for CADASIL despite lower sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Academy of Neurology Consensus <span class=\"citation\">(Chabriat et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span>: &ldquo;Perform targeted NOTCH3 genetic analysis in patients with suggestive clinical/imaging features&rdquo; (Level B).  <br>&bull; American Heart Association/American Stroke Association Stroke Guidelines (2024): &ldquo;In familial early-onset lacunar strokes with characteristic MRI pattern, genetic testing for monogenic causes is a Class IIa recommendation, Level B-R.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions localize to small penetrating arterioles supplying the anterior temporal lobes; these arterioles develop fibrotic thickening and granular osmiophilic deposits, leading to focal ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutated NOTCH3 \u2192 abnormal accumulation of extracellular domain in vascular smooth muscle \u2192 cell degeneration \u2192 impaired autoregulation of cerebral blood flow and lacunar infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: migraine with aura + early subcortical ischemic events + family history.  <br>2. Brain MRI: assess for anterior temporal and external capsule hyperintensities.  <br>3. NOTCH3 gene sequencing (first\u2010line).  <br>4. Skin biopsy for granular osmiophilic material if genetic testing inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FLAIR sequences reveal confluent white\u2010matter hyperintensities in anterior temporal poles and external capsule&mdash;pathognomonic for CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. CADASIL with anterior temporal lobe MRI findings and migraine history is a high\u2010yield topic on neurology boards; genetic testing vs. stroke prevention strategies is frequently tested.</div></div></div></div></div>"
  },
  {
    "id": 100023233,
    "question_number": "67",
    "question_text": "In the same scenario as the previous question, but with a CT angiogram not attached, what is the best treatment to achieve full recanalization in an acute large vessel occlusion stroke?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Acute ischemic stroke from a large vessel occlusion (LVO) involves sudden blockage of a major cerebral artery (e.g., M1 segment of the MCA).  <br>Rapid recanalization is critical to salvage the ischemic penumbra and prevent infarct core expansion.  <br>IV alteplase (tPA) acts systemically to lyse thrombus, while mechanical thrombectomy (MT) provides direct clot retrieval, yielding higher recanalization rates in proximal occlusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA guidelines recommend IV alteplase within 4.5 h of symptom onset for eligible patients, immediately followed by MT for anterior circulation LVO with NIHSS &ge;6 and imaging-confirmed occlusion (Class I, Level A).  <br>Landmark trials&mdash;MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, REVASCAT&mdash;demonstrated that combined IV tPA + MT achieves 60&ndash;85% successful recanalization (TICI 2b/3) versus ~30% with IV tPA alone.  <br>Full recanalization improves functional independence (mRS 0&ndash;2 at 90 days) and reduces mortality. Delaying or omitting MT in LVO yields poorer outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV tPA  <br>&bull; Although indicated within 4.5 h, systemic thrombolysis alone achieves low recanalization rates (~10&ndash;30%) in proximal LVO.  <br>&bull; Misconception: &ldquo;tPA suffice for all ischemic strokes.&rdquo; Fails to account for clot burden and proximal occlusion location.<br><br>B. IV heparin  <br>&bull; No randomized trials support acute anticoagulation in hyperacute ischemic stroke; increases hemorrhagic risk without improving recanalization or outcomes.  <br>&bull; Misconception: &ldquo;Heparin prevents clot propagation acutely.&rdquo; In stroke, heparin is not used for immediate reperfusion.<br><br>C. Aspirin and Plavix  <br>&bull; Dual antiplatelet therapy reduces early recurrent stroke risk but does not achieve acute vessel recanalization.  <br>&bull; Misconception: &ldquo;Antiplatelets can dissolve thrombus.&rdquo; They prevent platelet aggregation but cannot break existing occlusive clot.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA alone</th><th>IV heparin</th><th>Aspirin + Plavix</th><th>IV tPA + Thrombectomy</th></tr></thead><tbody><tr><td>Target mechanism</td><td>Systemic fibrinolysis</td><td>Anticoagulation</td><td>Platelet inhibition</td><td>Local clot retrieval + fibrinolysis</td></tr><tr><td>Typical recanalization rate</td><td>10&ndash;30% in LVO</td><td><5%</td><td><5%</td><td>60&ndash;85% (TICI 2b/3)</td></tr><tr><td>Recommended time window</td><td>&le;4.5 h</td><td>Not indicated</td><td>No acute role</td><td>&le;6 h standard; &le;24 h select</td></tr><tr><td>Outcome improvement (mRS 0&ndash;2)</td><td>Modest</td><td>None demonstrated</td><td>None in acute phase</td><td>Significant (OR 2.5&ndash;3.0)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In suspected LVO, obtain noncontrast CT plus CTA immediately to confirm occlusion and collateral status.  <br>&bull; Administer IV tPA without delay if no contraindications; do not wait for CTA if within window.  <br>&bull; MT may be offered up to 24 h in select patients with favorable perfusion imaging (DAWN, DEFUSE-3 criteria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying tPA until after angiography: tPA should be given immediately when eligible, even before confirmatory CTA.  <br>2. Using systemic anticoagulation (heparin) believing it will lyse clot: heparin prevents new clot formation but does not actively dissolve established thrombi in the hyperacute setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Stroke Guidelines: Class I, Level A for MT + IV tPA in anterior circulation LVO within 6 h; Class I, Level B-R for select patients up to 24 h (DAWN, DEFUSE-3).  <br>&bull; DAWN Trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: MT in 6&ndash;24 h window with mismatch criteria improved functional outcome (OR 5.55 for mRS 0&ndash;2).  <br>&bull; DEFUSE-3 <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Extended MT window to 16 h with perfusion imaging selection (OR 3.4 for mRS 0&ndash;2).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>M1 occlusion of the MCA deprives lateral frontal, parietal, and temporal lobes of blood; collateral flow via leptomeningeal vessels influences infarct growth and treatment response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic cascade: energy failure, glutamate excitotoxicity, ionic pump dysfunction, cytotoxic edema. Rapid reperfusion halts these processes, preserving penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid neurologic assessment (NIHSS).  <br>2. Noncontrast CT to exclude hemorrhage.  <br>3. If &le;4.5 h and no contraindications, administer IV tPA.  <br>4. Perform emergent CTA/MRA to identify LVO.  <br>5. Proceed to MT if occlusion present and patient meets criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hyperdense MCA sign on CT suggests proximal thrombus.  <br>&bull; ASPECTS &ge;6 predicts favorable MT outcomes.  <br>&bull; CT perfusion aids selection for extended-window MT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 min, remainder over 60 min. Monitor for hemorrhage; maintain BP <185/110 mm Hg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam.  <br>Acute stroke management, particularly LVO treatment algorithms combining IV tPA and MT, is frequently tested in board-style vignettes, emphasizing time windows, imaging modalities, and recanalization methods.</div></div></div></div></div>"
  },
  {
    "id": 100023242,
    "question_number": "159",
    "question_text": "A case scenario of a patient with CADASIL presents with stroke, dementia, and migraine. What is the best way to diagnose this condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is a hereditary small vessel disease caused by NOTCH3 mutations leading to degeneration of vascular smooth muscle cells and deposition of granular osmiophilic material (GOM) in arterial walls. Clinical hallmarks include migraine with aura in 30&ndash;40% of patients, recurrent subcortical ischemic events in mid-adulthood, progressive cognitive decline, and psychiatric disturbances. Neuroimaging typically shows extensive white matter hyperintensities, especially in the anterior temporal lobes and external capsules. Definitive diagnosis requires identification of pathogenic NOTCH3 variants, whereas biopsy or imaging alone lacks sufficient sensitivity or specificity. Understanding the genetic basis, vascular pathology, and MRI patterns is essential for timely diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Genetic testing for NOTCH3 mutations is the gold standard for diagnosing CADASIL. Pathogenic variants cluster in exons 2&ndash;24 encoding epidermal growth factor&ndash;like repeats; altering cysteine residues leads to GOM deposition <span class=\"citation\">(Jouvent et al., Lancet <span class=\"evidence\">Neurol 2007</span>)</span>. Sensitivity and specificity exceed 95% when combined with clinical and radiological criteria <span class=\"citation\">(Rutten et al., <span class=\"evidence\">Neurology 2016</span>)</span>. Skin biopsy for GOM has variable sensitivity (50&ndash;85%) and requires electron microscopy with specialized pathological expertise <span class=\"citation\">(Markus et al., <span class=\"evidence\">Brain 2002</span>)</span>. MRI findings&mdash;bilateral confluent white matter hyperintensities in anterior temporal poles and external capsules&mdash;are highly characteristic but overlap with sporadic leukoaraiosis or multiple sclerosis. CSF analysis is non-diagnostic. Both the 2017 European Stroke Organization guidelines (Class I, Level B) and the 2018 AHA/ASA scientific statement (Class I, Level C) recommend NOTCH3 genetic testing as the first-line diagnostic modality in suspected CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain MRI showing white matter hyperintensities  <br>&bull; Incorrect because MRI patterns, though suggestive, are not pathognomonic and can be seen in sporadic small vessel disease or demyelinating disorders.  <br>&bull; Misconception: assuming radiological specificity without confirmatory testing.  <br>&bull; Differentiator: MRI is supportive but requires genetic confirmation.  <br><br>B. Skin biopsy demonstrating granular osmiophilic material  <br>&bull; Incorrect as first-line: GOM detection sensitivity is operator- and site-dependent (50&ndash;85%); false negatives occur.  <br>&bull; Misconception: invasive biopsy supersedes non-invasive genetic testing.  <br>&bull; Differentiator: reserved for inconclusive genetic results.  <br><br>D. Cerebrospinal fluid analysis  <br>&bull; Incorrect: CSF findings (mild protein elevation, rare oligoclonal bands) are non-specific and do not establish CADASIL.  <br>&bull; Misconception: equating CADASIL with inflammatory CNS diseases requiring CSF profiling.  <br>&bull; Differentiator: CSF is useful in MS workup, not CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NOTCH3 Genetic Testing</th><th>MRI Findings</th><th>Skin Biopsy</th><th>CSF Analysis</th></tr></thead><tbody><tr><td>Diagnostic accuracy</td><td>>95% sensitivity & specificity</td><td>80&ndash;90% sensitive, not specific</td><td>50&ndash;85% sensitivity, 100% specificity</td><td>Non-diagnostic</td></tr><tr><td>Invasiveness</td><td>Non-invasive (blood/saliva)</td><td>Non-invasive</td><td>Invasive (skin punch biopsy + EM)</td><td>Minimally invasive (lumbar puncture)</td></tr><tr><td>Turnaround time</td><td>Days to weeks</td><td>Immediate</td><td>Weeks</td><td>Hours to days</td></tr><tr><td>Clinical utility</td><td>Gold standard</td><td>Supportive</td><td>Second-line if genetic inconclusive</td><td>None</td></tr><tr><td>Guidelines recommendation</td><td>First-line (Class I, Level B)</td><td>Not diagnostic alone</td><td>Second-line</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- White matter hyperintensities in the anterior temporal poles occur in >90% of CADASIL and are rare in sporadic small vessel disease.  <br><span class=\"list-item\">\u2022</span> An autosomal dominant family history of early-onset strokes or cognitive decline is present in >85% of CADASIL cases.  <br><span class=\"list-item\">\u2022</span> Routine anticoagulation for lacunar strokes in CADASIL may increase hemorrhagic risk and is not generally indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on MRI: Mistaking non-specific leukoaraiosis for CADASIL without confirmatory genetics.  <br>2. Biopsy-first approach: Ordering skin biopsy prematurely, risking false negatives and procedural morbidity.  <br>3. Migraine-negative cases: Failing to consider CADASIL in patients without migraine aura despite stroke and leukoencephalopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Stroke Organization (ESO) guidelines on rare cerebrovascular diseases (2017): Recommend NOTCH3 genetic testing as first-line in suspected CADASIL (Class I, Level B).  <br>2. AHA/ASA scientific statement on hereditary stroke syndromes (2018): Endorse genetic analysis for NOTCH3 mutations in clinical scenarios with migraine with aura and characteristic MRI changes (Class I, Level C).  <br>3. Rutten et al., Neurology (2020): Demonstrated that next-generation sequencing panels increased diagnostic yield by 15% over traditional Sanger sequencing in CADASIL cohorts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL affects small penetrating arterioles supplying deep white matter&mdash;including periventricular regions, centrum semiovale, anterior temporal lobes, and external capsules&mdash;leading to chronic hypoperfusion, lacunar infarcts in basal ganglia, thalamus, and pons, and consequent subcortical cognitive and motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 mutations cause an odd number of cysteine residues in epidermal growth factor&ndash;like repeats, resulting in misfolded extracellular domain fragments that accumulate as GOM in vascular smooth muscle cell basement membranes. Progressive VSMC degeneration and luminal narrowing produce chronic cerebral hypoperfusion, triggering demyelination, gliosis, and lacunar infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical triad: migraine with aura, subcortical strokes, cognitive decline.  <br>2. Obtain brain MRI: assess anterior temporal pole and external capsule WMH.  <br>3. Review family history for autosomal dominant inheritance.  <br>4. Perform NOTCH3 genetic testing (exons 2&ndash;24).  <br>5. If genetic testing is negative or inconclusive, proceed to skin biopsy with electron microscopy for GOM.  <br>6. Provide genetic counseling and cascade testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole involvement on T2/FLAIR is >90% specific for CADASIL.  <br><span class=\"list-item\">\u2022</span> Susceptibility-weighted imaging often reveals cerebral microbleeds in up to 70% of patients, indicating hemorrhagic vulnerability.  <br><span class=\"list-item\">\u2022</span> Lacunes in basal ganglia, thalamus, and pons are early markers of subcortical infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. CADASIL is frequently tested as a clinical vignette emphasizing the distinction between supportive MRI findings and definitive genetic testing; boards often assess recognition of anterior temporal lobe WMH and the role of NOTCH3 analysis as the diagnostic gold standard.</div></div></div></div></div>"
  },
  {
    "id": 100023244,
    "question_number": "106",
    "question_text": "In a patient presenting with headache, what is the most likely diagnosis based on the MRI findings?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient dysregulation of cerebral arterial tone leading to segmental narrowing and sudden, severe (&ldquo;thunderclap&rdquo;) headaches. Key concepts:  <br>&bull; Cerebral vascular tone: in RCVS, endothelial dysfunction and sympathetic overactivity produce alternating arterial constriction and dilation.  <br>&bull; Thunderclap headache: peaks within seconds, often recurrent over 1&ndash;2 weeks, distinguishing RCVS from other headache etiologies.  <br>&bull; MRI/MRA signatures: &ldquo;string-of-beads&rdquo; appearance on MRA; minimal or no vasogenic edema on T2/FLAIR, unlike PRES which shows posterior white matter hyperintensities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is confirmed by angiographic evidence of multifocal, segmental cerebral artery narrowing that reverses within 12 weeks <span class=\"citation\">(Fugate & Rabinstein, 2015)</span>. The absence of diffusion restriction (ruling out infarction) and minimal T2/FLAIR edema differentiates it from PRES, which features vasogenic edema predominantly in the parieto-occipital lobes <span class=\"citation\">(Bartynski, 2008)</span>. HSV encephalitis demonstrates temporal lobe diffusion restriction with hemorrhagic necrosis <span class=\"citation\">(Bradshaw & Venkatesan, 2016)</span>, and lupus cerebritis typically yields patchy cortical and subcortical T2 hyperintensities with accompanying serologic markers <span class=\"citation\">(<span class=\"evidence\">Sanna et al., 2019</span>)</span>. Current consensus <span class=\"citation\">(ICHD-3, 2018)</span> emphasizes early MRA diagnosis and calcium channel blocker therapy (nimodipine) to mitigate vasospasm (level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. PRES  <br>&ndash; PRES shows symmetric vasogenic edema on T2/FLAIR in parietal-occipital regions; RCVS lacks prominent edema.  <br>&ndash; Misconception: both present with headache and visual symptoms, but PRES is linked to hypertension/toxins.  <br>&ndash; Differentiator: PRES edema reverses with blood pressure control; RCVS shows vessel beading on MRA.  <br><br>C. HSV  <br>&ndash; HSV encephalitis presents with fever, altered mentation, and temporal lobe diffusion restriction and hemorrhage.  <br>&ndash; Misconception: headache + MRI abnormality \u2192 infection; but RCVS lacks CSF pleocytosis and fever.  <br>&ndash; Differentiator: PCR-positive CSF; RCVS CSF is normal or mild protein elevation.  <br><br>D. Lupus cerebritis  <br>&ndash; Lupus cerebritis MRI shows multifocal white matter lesions, often with leptomeningeal enhancement, plus positive ANA/dsDNA.  <br>&ndash; Misconception: systemic autoimmune disease always CNS involvement with headache.  <br>&ndash; Differentiator: clinical context of SLE flares, serologies, and variable perfusion deficits vs. reversible vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>PRES</th><th>HSV Encephalitis</th><th>Lupus Cerebritis</th></tr></thead><tbody><tr><td>Headache pattern</td><td>Thunderclap, recurrent</td><td>Subacute, severe, with visual loss</td><td>Progressive, fever-associated</td><td>Subacute, headache + neuropsychiatric signs</td></tr><tr><td>MRI/MRA</td><td>Segmental narrowing (&ldquo;beads&rdquo;)</td><td>T2/FLAIR vasogenic edema posterior</td><td>Diffusion restriction temporal lobes</td><td>Patchy T2 lesions, meningeal enhancement</td></tr><tr><td>CSF findings</td><td>Normal or mild protein elevation</td><td>Usually normal</td><td>Lymphocytic pleocytosis, PCR+</td><td>Mild pleocytosis, autoantibodies</td></tr><tr><td>Treatment</td><td>Nimodipine, supportive</td><td>BP control, remove triggers</td><td>Acyclovir</td><td>Immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; RCVS stroke risk peaks during the first two weeks; early angiography is crucial.  <br>&bull; Calcium channel blockers (nimodipine) are first-line despite lack of RCTs; observational data support headache reduction.  <br>&bull; PRES and RCVS may coexist; follow-up imaging at 6&ndash;12 weeks confirms reversibility of vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating thunderclap headache exclusively with subarachnoid hemorrhage &mdash; RCVS often mimics SAH without hemorrhage on CT.  <br>2. Interpreting any posterior white matter hyperintensity as PRES &mdash; small amounts of edema can appear in RCVS secondary to blood&ndash;brain barrier disruption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; International Classification of Headache Disorders, 3rd ed. <span class=\"citation\">(ICHD-3, IHS, 2018)</span>: Defines diagnostic criteria for RCVS; emphasizes angiographic beading and reversibility within 12 weeks (Level B).  <br>&bull; European Headache Federation Consensus (2017): Recommends nimodipine 60 mg q4h for RCVS headache relief; advocates serial angiography to document resolution (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS primarily affects medium-sized arteries within the circle of Willis (e.g., anterior, middle cerebral arteries), leading to alternating constriction of distal branches and resulting clinical findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An imbalance between vasoconstrictive (endothelin-1) and vasodilatory (nitric oxide) mediators causes reversible arterial narrowing. Sympathetic hyperactivity (e.g., postpartum, vasoactive drugs) triggers acute episodes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude SAH  <br>2. Lumbar puncture if CT negative (to rule out SAH infection)  <br>3. MRI/MRA within 48 h to detect vasoconstriction  <br>4. Follow-up MRA at 6&ndash;12 weeks to confirm reversal</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;String-of-beads&rdquo; sign on MRA is pathognomonic for RCVS.  <br>&bull; Absence of diffusion restriction distinguishes RCVS from infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Nimodipine 60 mg orally every 4 h for 4&ndash;6 weeks to alleviate vasoconstriction (no RCTs, based on case series).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. RCVS is frequently tested as thunderclap headache with reversible vasoconstriction on angiography; expect questions contrasting it with PRES and primary CNS vasculitis.</div></div></div></div></div>"
  },
  {
    "id": 100023248,
    "question_number": "107",
    "question_text": "A patient presents with a headache and recurrent thunderclap headaches, with normal MRI and MRV. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by sudden, severe &ldquo;thunderclap&rdquo; headaches due to transient dysregulation of cerebral arterial tone. Key principles:  <br>&bull; Headache Classification: Thunderclap headaches reach peak intensity within seconds and suggest vascular etiologies.  <br>&bull; Vascular Pathophysiology: RCVS involves reversible segmental narrowing of medium-to-large cerebral arteries, often without initial parenchymal lesions on MRI.  <br>&bull; Imaging Modalities: MRI/MRA or MRV may be normal early; catheter angiography performed 1&ndash;2 weeks later typically shows the classic &ldquo;string-of-beads.&rdquo; (150 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is the leading cause of recurrent thunderclap headaches when non-invasive imaging is initially unrevealing. Ducros et al. <span class=\"citation\">(<span class=\"evidence\">Brain 2007</span>)</span> described 67 patients with RCVS who all had sudden, severe headaches and normal early MRI/MRA in over 50% of cases; diagnostic confirmation required catheter angiography showing multifocal vasoconstriction. <span class=\"evidence\">The 2015</span> EFNS guideline on cerebral vasculitides and RCVS recommends serial vascular imaging and dihydropyridine calcium-channel blockers (Level C evidence). Typical clinical course: headaches recur over days to weeks, resolve as vasoconstriction reverses by 12 weeks. Normal CT/MRI/MRV virtually excludes SAH and CVT, shifting suspicion toward RCVS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Subarachnoid hemorrhage  <br>&bull; Why incorrect: SAH produces a single thunderclap headache with positive CT or xanthochromia on LP in >95% of cases.  <br>&bull; Misconception: Any thunderclap = SAH.  <br>&bull; Differentiating: SAH seldom recurs once blood is cleared; LP/CT are diagnostic.  <br><br>C. Migraine  <br>&bull; Why incorrect: Migraine headache builds over minutes to hours, is throbbing, often unilateral, with photophobia or aura.  <br>&bull; Misconception: Severe headache equals migraine.  <br>&bull; Differentiating: Migraines are not instantaneous peak (&ldquo;thunderclap&rdquo;) and recur in stereotyped patterns.  <br><br>D. Tension headache  <br>&bull; Why incorrect: Tension\u2010type headaches are bilateral, pressing, mild-moderate intensity, not explosive.  <br>&bull; Misconception: All headaches are benign.  <br>&bull; Differentiating: Lack of vascular features or sudden onset excludes tension\u2010type.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>SAH</th><th>Migraine</th><th>Tension Headache</th></tr></thead><tbody><tr><td>Onset</td><td>Seconds (thunderclap), recurrent</td><td>Seconds, single episode</td><td>Gradual (minutes to hours)</td><td>Gradual or insidious</td></tr><tr><td>Imaging (initial MRI/MRA)</td><td>Often normal</td><td>CT positive in ~95%</td><td>Normal</td><td>Normal</td></tr><tr><td>CSF (if done)</td><td>Normal or mild protein elevation</td><td>Xanthochromia, RBCs</td><td>Normal</td><td>Normal</td></tr><tr><td>Course</td><td>Recurrent over days&ndash;weeks</td><td>Single, then resolves</td><td>Episodic over years</td><td>Chronic, daily or episodic</td></tr><tr><td>Vascular findings (angiography)</td><td>Segmental vasoconstriction (&ldquo;beads&rdquo;)</td><td>No vasospasm pattern</td><td>No vasoconstriction</td><td>No vasoconstriction</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; RCVS often follows triggers: postpartum state, serotonergic drugs, vasoactive substances (e.g., cocaine).  <br>&bull; Nimodipine or verapamil can ameliorate headaches and may speed vasoconstriction resolution.  <br>&bull; Serial imaging (1&ndash;2 weeks apart) is essential; early MRI/MRA can miss up to 50% of vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing recurrent thunderclap headaches to migraine or tension headache without vascular imaging.  <br>2. Overreliance on a single negative MRV/MRA to exclude RCVS; vasoconstriction may be delayed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; EFNS Guideline on RCVS (2015): Recommends repeat angiography at 1&ndash;2 weeks if initial study is normal (Level C).  <br>&bull; SNACC Consensus Statement (2021): Supports calcium-channel blockade with nimodipine 60 mg every 4 hours for symptomatic relief (Expert Opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS involves medium-to-large cerebral arteries of the circle of Willis (e.g., anterior, middle, posterior cerebral arteries), explaining thunderclap pain via meningeal nociceptor activation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A transient failure of cerebral arterial tone autoregulation leads to segmental vasoconstriction, endothelial dysfunction, and sympathetic overactivity. Reversibility within 12 weeks differentiates it from vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 if negative, lumbar puncture to exclude SAH.  <br>2. MRI/MRA/MRV to evaluate parenchyma and venous outflow.  <br>3. If all non-invasive imaging is normal but clinical suspicion high \u2192 catheter cerebral angiography.  <br>4. Follow-up angiography at 1&ndash;2 weeks to detect evolving vasoconstriction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; &ldquo;String-of-beads&rdquo; appearance on catheter angiography is pathognomonic.  <br>&bull; MR angiography may lag behind angiographic findings by days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Nimodipine: 60 mg PO q4h for 2&ndash;4 weeks.  <br>&bull; Avoid vasoconstrictive agents (ergots, triptans) during active phase.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. RCVS and thunderclap headaches are frequently tested as key examples of reversible vascular headaches with normal initial imaging studies.</div></div></div></div></div>"
  },
  {
    "id": 100023250,
    "question_number": "71",
    "question_text": "A patient had head trauma and developed spontaneous perimesencephalic subarachnoid hemorrhage (SAH) 10 days later. After two digital subtraction imaging studies two weeks apart, which were unremarkable, what is the appropriate management?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Perimesencephalic SAH is a nonaneurysmal hemorrhage localized to the cisterns around the midbrain, often venous in origin, with benign natural history. Key features:  <br><span class=\"list-item\">\u2022</span> CT shows blood confined to perimesencephalic cisterns without extension into sylvian or interhemispheric fissures.  <br><span class=\"list-item\">\u2022</span> Low rates of vasospasm, hydrocephalus, and rebleeding compared to aneurysmal SAH.  <br><span class=\"list-item\">\u2022</span> Digital subtraction angiography (DSA) remains the gold standard to exclude aneurysm; recommended initially and repeated 7&ndash;14 days later if negative.  <br>After two high-quality negative DSAs, the post\u2010test probability of a missed aneurysm is <0.5%, justifying conservative outpatient management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer A is correct. According to the AHA/ASA 2012 guidelines, two negative DSAs in perimesencephalic SAH virtually exclude aneurysmal etiology (Class IIb, Level B). In Rinkel et al.&rsquo;s landmark cohort <span class=\"citation\">(<span class=\"evidence\">Brain 1991</span>)</span>, 60 patients with perimesencephalic SAH and two negative angiograms had zero rebleeds over a mean follow-up of 4.5 years. DSA sensitivity for aneurysms >2 mm exceeds 95%, whereas CTA and MRA detect only 83&ndash;95% and 80&ndash;90%, respectively, missing small lesions. Further invasive imaging adds procedural stroke risk (~0.5&ndash;1%) and contrast/radiation exposure without altering management. Conservative discharge with outpatient neurologic follow-up optimizes resource use and patient safety.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Repeat digital subtraction imaging  <br>&bull; After two negative DSAs, additional angiography has a <0.3% yield for occult aneurysm.  <br>&bull; Misconception: &ldquo;More is better&rdquo; imaging. Repeated DSA increases procedural stroke risk and cost without benefit.  <br><br>C. MR angiography  <br>&bull; MRA sensitivity for aneurysms <3 mm is only ~80&ndash;90%.  <br>&bull; Low positive predictive value in post-SAH setting; cannot replace DSA in excluding small aneurysms.  <br><br>D. CT angiography  <br>&bull; CTA sensitivity drops for aneurysms <3 mm (83&ndash;95%) and is limited by bone artifact at skull base.  <br>&bull; Unnecessary radiation and iodinated contrast when two DSA studies are already negative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Modality</th><th>Sensitivity for Aneurysms <3 mm</th><th>Procedural Risk</th><th>Role after 2 Negative DSAs</th></tr></thead><tbody><tr><td>A. Send home [CORRECT]</td><td>N/A</td><td>N/A</td><td>N/A</td><td>Standard; conservative outpatient follow-up</td></tr><tr><td>B. Repeat DSA</td><td>DSA</td><td>>95%</td><td>0.5&ndash;1% stroke, contrast</td><td>Low yield; unnecessary after two negatives</td></tr><tr><td>C. MR angiography</td><td>MRA</td><td>80&ndash;90%</td><td>Minimal</td><td>Insufficient sensitivity for small aneurysms</td></tr><tr><td>D. CT angiography</td><td>CTA</td><td>83&ndash;95%</td><td>Radiation, contrast nephropathy</td><td>Low yield; false negatives common</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perimesencephalic SAH shows a &ldquo;star&rdquo; pattern around the midbrain on CT without fissural extension&mdash;recognize this to distinguish from aneurysmal SAH.  <br>2. Two high-quality negative DSAs exclude aneurysm with >99.5% certainty; avoid further invasive or cross-sectional angiography.  <br>3. Vasospasm prophylaxis (e.g., nimodipine) and ICU monitoring are standard for aneurysmal SAH but may be de-escalated in perimesencephalic cases given low vasospasm risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering routine CTA/MRA after negative DSA: adds cost and yields little new information in perimesencephalic SAH.  <br>2. Failing to repeat DSA at 7&ndash;14 days after initial negative study: may miss small aneurysms that become visible once acute vasospasm and clot resolve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines on Aneurysmal Subarachnoid Hemorrhage <span class=\"citation\">(Connolly et al., <span class=\"evidence\">Stroke 2012</span>)</span>: Recommend repeat DSA 7&ndash;14 days after negative initial DSA in nonaneurysmal SAH (Class IIb, Level B); no further angiography after two negatives.  <br>2. European Stroke Organisation Guidelines on Spontaneous SAH <span class=\"citation\">(Steiner et al., Eur Stroke J 2013)</span>: Advise conservative management and discharge with outpatient follow-up for perimesencephalic nonaneurysmal SAH after two negative angiograms (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Management of perimesencephalic SAH versus aneurysmal SAH is a high-yield topic on neurology and neurocritical care board exams, often tested as a follow-up strategy after negative angiography.</div></div></div></div></div>"
  }
]